All	DT
O	NN

live	JJ
O	NN

births	NNS
O	NN

>	JJR
O	NN

or	CC
O	NN

=	JJ
O	NN

23	CD
O	NN

weeks	NNS
O	NN

at	IN
O	NN

the	DT
O	NN

University	NNP
O	NN

of	IN
O	NN

Vermont	NNP
O	NN

in	IN
O	NN

1995	CD
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

2395	CD
O	NN

)	NN
O	NN

were	VBD
O	NN

retrospectively	RB
O	NN

analyzed	VBN
O	NN

for	IN
O	NN

delivery	NN
O	NN

route	NN
O	NN

,	,
O	NN

indication	NN
O	NN

for	IN
O	NN

cesarean	NN
O	NN

,	,
O	NN

gestational	JJ
O	NN

age	NN
O	NN

,	,
O	NN

parity	NN
O	NN

,	,
O	NN

and	CC
O	NN

practice	NN
O	NN

group	NN
O	NN

(	NN
O	NN

to	TO
O	NN

reflect	VB
O	NN

risk	NN
O	NN

status	NN
O	NN

)	NN
O	NN

The	DT
O	NN

total	JJ
O	NN

cesarean	NN
O	NN

rate	NN
O	NN

was	VBD
O	NN

14.4	CD
O	NN

%	NN
O	NN

(	NN
O	NN

344	CD
O	NN

of	IN
O	NN

2395	CD
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

primary	JJ
O	NN

rate	NN
O	NN

was	VBD
O	NN

11.4	CD
O	NN

%	NN
O	NN

(	NN
O	NN

244	CD
O	NN

of	IN
O	NN

2144	CD
O	NN

)	NN
O	NN

Abnormal	JJ
O	NN

presentation	NN
O	NN

was	VBD
O	NN

the	DT
O	NN

most	JJS
O	NN

common	JJ
O	NN

indication	NN
O	NN

(	NN
O	NN

25.6	CD
O	NN

%	NN
O	NN

,	,
O	NN

88	CD
O	NN

of	IN
O	NN

344	CD
O	NN

)	NN
O	NN

The	DT
O	NN

``	``
O	NN

corrected	VBN
O	NN

''	''
O	NN

cesarean	NN
O	NN

rate	NN
O	NN

(	NN
O	NN

maternal-fetal	JJ
O	NN

medicine	NN
O	NN

and	CC
O	NN

transported	VBN
O	NN

patients	NNS
O	NN

excluded	VBN
O	NN

)	NN
O	NN

was	VBD
O	NN

12.4	CD
O	NN

%	NN
O	NN

(	NN
O	NN

273	CD
O	NN

of	IN
O	NN

2194	CD
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

``	``
O	NN

corrected	VBN
O	NN

''	''
O	NN

primary	JJ
O	NN

rate	NN
O	NN

was	VBD
O	NN

9.6	CD
O	NN

%	NN
O	NN

(	NN
O	NN

190	CD
O	NN

of	IN
O	NN

1975	CD
O	NN

)	NN
O	NN

Furthermore	RB
O	NN

,	,
O	NN

when	WRB
O	NN

all	DT
O	NN

deliveries	NNS
O	NN

were	VBD
O	NN

analyzed	VBN
O	NN

,	,
O	NN

regardless	RB
O	NN

of	IN
O	NN

risk	NN
O	NN

status	NN
O	NN

but	CC
O	NNP

limited	JJ
O	NN

to	TO
O	NN

gestational	JJ
O	NN

age	NN
O	NN

>	JJR
O	NN

or	CC
O	NN

=	JJ
O	NN

36	CD
O	NN

weeks	NNS
O	NN

,	,
O	NN

the	DT
O	NN

rates	NNS
O	VBP

did	VBD
O	NNP

not	RB
O	NN

change	NN
O	NN

(	NN
O	NN

12.6	CD
O	NN

%	NN
O	NN

,	,
O	NN

280	CD
O	NN

of	IN
O	NN

2214	CD
O	NN

;	:
O	NN

primary	JJ
O	NN

9.2	CD
O	NN

%	NN
O	NN

,	,
O	NN

183	CD
O	NN

of	IN
O	NN

1994	CD
O	NNP

)	NN
O	NN

Arrest	NN
O	NN

of	IN
O	NN

dilation	NN
O	NN

was	VBD
O	NN

the	DT
O	NN

most	JJS
O	NN

common	JJ
O	NN

indication	NN
O	NN

in	IN
O	NN

both	DT
O	NN

``	``
O	NN

corrected	VBN
O	NN

''	''
O	NN

subgroups	NNS
O	NN

(	NN
O	NN

23.4	CD
O	NN

and	CC
O	NN

24.6	CD
O	NN

%	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

)	NN
O	NN

Cesarean	JJ
O	NN

rates	NNS
O	VBP

at	IN
O	NN

tertiary	JJ
O	NN

care	NN
O	NN

hospitals	NNS
O	NN

should	MD
O	NNP

be	VB
O	NN

compared	VBN
O	NN

with	IN
O	NN

rates	NNS
O	VBP

at	IN
O	NN

community	NN
O	NN

hospitals	NNS
O	NN

only	RB
O	NN

after	IN
O	NN

correcting	VBG
O	NN

for	IN
O	NN

dissimilar	JJ
O	NN

patient	NN
O	NN

groups	NNS
O	NN

or	CC
O	NN

gestational	JJ
O	NN

age	NN
O	NN

In	IN
O	NN

the	DT
O	NN

third	JJ
O	NN

trimester	NN
O	NN

,	,
O	NN

the	DT
O	NN

amniotic	JJ
O	NN

fluid	NN
O	NN

index	NN
O	NN

(	NN
O	NN

AFI	NN
O	NN

)	NN
O	NN

may	MD
O	NNP

be	VB
O	NN

affected	VBN
O	NN

by	IN
O	NN

maternal	JJ
O	NN

fluid	NN
O	NN

status	NN
O	NN

As	IN
O	NN

the	DT
O	NN

ambient	JJ
O	NN

temperature	NN
O	NN

increases	NNS
O	NN

,	,
O	NN

there	RB
O	NN

is	VBZ
O	NN

an	DT
O	NN

increase	NN
O	NN

in	IN
O	NN

insensible	JJ
O	NN

fluid	NN
O	NN

loss	NN
O	NN

and	CC
O	NN

the	DT
O	NN

potential	JJ
O	NN

for	IN
O	NN

dehydration	NN
O	NN

We	PRP
O	VBP

hypothesize	VB
O	NN

that	IN
O	NN

as	IN
O	NN

temperature	NN
O	NN

increases	NNS
O	NN

there	RB
O	NN

would	MD
O	NNP

be	VB
O	NN

a	DT
O	NN

concomitant	JJ
O	NN

decrease	NN
O	NN

in	IN
O	NN

AFI	NN
O	NN

From	IN
O	NN

June	NNP
O	NN

11	CD
O	NN

to	TO
O	NN

August	NNP
O	NN

16	CD
O	NN

,	,
O	NN

1993	CD
O	NN

,	,
O	NN

during	IN
O	NN

a	DT
O	NN

period	NN
O	NN

of	IN
O	NN

unusual	JJ
O	NN

high	JJ
O	NN

heat	NN
O	NN

,	,
O	NN

42	CD
O	NN

women	NNS
O	VBP

with	IN
O	NN

singleton	NN
O	NN

pregnancies	NNS
O	NN

between	IN
O	NN

27	CD
O	NN

and	CC
O	NN

40	CD
O	NN

weeks	NNS
O	NN

'	POS
O	NN

gestation	JJ
O	NN

undergoing	VBG
O	NN

serial	JJ
O	NN

antenatal	JJ
O	NN

testing	NN
O	NN

had	VBD
O	NN

AFI	NN
O	NN

determinations	NNS
O	VBP

recorded	VBN
O	NN

at	IN
O	NN

least	JJS
O	NN

weekly	JJ
O	NN

The	DT
O	NN

daily	RB
O	NN

high	JJ
O	NN

ambient	JJ
O	NN

temperature	NN
O	NN

in	IN
O	NN

our	PRP$
O	NN

urban	JJ
O	NN

area	NN
O	NN

was	VBD
O	NN

subsequently	RB
O	NN

obtained	VBN
O	NN

A	DT
O	NN

2-	CD
O	NN

,	,
O	NN

3-	CD
O	NN

,	,
O	NN

and	CC
O	NN

4-day	JJ
O	NN

mean	VB
O	NN

temperature	NN
O	NN

prior	RB
O	NN

to	TO
O	NN

the	DT
O	NN

test	NN
O	NN

date	NN
O	NN

was	VBD
O	NN

compared	VBN
O	NN

to	TO
O	NN

AFI	NN
O	NN

using	VBG
O	NN

a	DT
O	NN

Spearman-rank	JJ
O	NN

Correlation	NN
O	NN

The	DT
O	NN

daily	RB
O	NN

high	JJ
O	NN

temperature	NN
O	NN

ranged	VBD
O	NN

from	IN
O	NN

71	CD
O	NN

to	TO
O	NN

104	CD
O	NN

degrees	NNS
O	NN

F	NN
O	NN

and	CC
O	NN

AFI	NN
O	NN

values	NNS
O	VBP

ranged	VBD
O	NN

from	IN
O	NN

1.7	CD
O	NN

to	TO
O	NN

24.7	CD
O	NN

cm	NN
O	NN

during	IN
O	NN

the	DT
O	NN

study	NN
O	NN

period	NN
O	NN

There	EX
O	NN

was	VBD
O	NN

a	DT
O	NN

significant	JJ
O	NN

correlation	NN
O	NN

between	IN
O	NN

the	DT
O	NN

2-	CD
O	NN

,	,
O	NN

3-	CD
O	NN

,	,
O	NN

and	CC
O	NN

4-day	JJ
O	NN

mean	VB
O	NN

temperature	NN
O	NN

and	CC
O	NN

AFI	NN
O	NN

,	,
O	NN

with	IN
O	NN

the	DT
O	NN

4-day	JJ
O	NN

mean	VB
O	NN

being	VBG
O	NN

the	DT
O	NN

most	JJS
O	NN

significant	JJ
O	NN

(	NN
O	NN

r	NN
O	NN

=	JJ
O	NN

0.31	CD
O	NN

,	,
O	NN

p	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.001	CD
O	NN

)	NN
O	NN

Fluctuations	NNS
O	NN

in	IN
O	NN

ambient	JJ
O	NN

temperature	NN
O	NN

are	VBP
O	NN

inversely	RB
O	NN

correlated	VBD
O	NN

to	TO
O	NN

changes	NNS
O	VBP

in	IN
O	NN

AFI	NN
O	NN

This	DT
O	NN

relationship	NN
O	NN

should	MD
O	NNP

be	VB
O	NN

taken	VBN
O	NN

into	IN
O	NN

account	NN
O	NN

when	WRB
O	NN

interpreting	VBG
O	NN

the	DT
O	NN

AFI	NN
O	NN

as	IN
O	NN

a	DT
O	NN

measure	NN
O	NN

of	IN
O	NN

fetal	JJ
O	NN

well-being	NN
O	NN

This	DT
O	NN

study	NN
O	NN

tested	VBN
O	NN

the	DT
O	NN

hypothesis	NN
O	NN

that	IN
O	NN

to	TO
O	NN

reduce	VB
O	NN

the	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

macrosomic	JJ
O	NN

infants	NNS
O	NN

in	IN
O	NN

gestational	JJ
O	NN

diabetes	NN
O	NN

cases	NNS
O	NN

,	,
O	NN

good	JJ
O	NN

glycemic	JJ
O	NN

control	NN
O	NN

should	MD
O	NNP

be	VB
O	NN

initiated	VBN
O	NN

before	IN
O	NN

34	CD
O	NN

completed	VBN
O	NN

gestational	JJ
O	NN

weeks	NNS
O	NN

The	DT
O	NN

study	NN
O	NN

population	NN
O	NN

included	VBN
O	NN

84	CD
O	NN

women	NNS
O	VBP

with	IN
O	NN

gestational	JJ
D	NN

diabetes	NN
D	NN

,	,
O	NN

ascertained	VBN
O	NN

by	IN
O	NN

universal	JJ
O	NN

screening	VBG
O	NN

of	IN
O	NN

all	DT
O	NN

women	NNS
O	VBP

attending	VBG
O	NN

the	DT
O	NN

antenatal	JJ
O	NN

clinic	NN
O	NN

of	IN
O	NN

the	DT
O	NN

Hadassah	NNP
O	NNP

Medical	JJ
O	NN

Center	NNP
O	NNP

,	,
O	NN

over	IN
O	NN

a	DT
O	NN

2-year	JJ
O	NN

period	NN
O	NN

The	DT
O	NN

60	CD
O	NN

women	NNS
O	VBP

(	NN
O	NN

71	CD
O	NN

%	NN
O	NN

)	NN
O	NN

,	,
O	NN

who	WP
O	VBP

initiated	VBN
O	NN

treatment	NN
O	NN

before	IN
O	NN

34	CD
O	NN

completed	VBN
O	NN

weeks	NNS
O	NN

,	,
O	NN

composed	VBN
O	NN

the	DT
O	NN

``	``
O	NN

early	RB
O	NN

''	''
O	NN

group	NN
O	NN

The	DT
O	NN

24	CD
O	NN

women	NNS
O	VBP

(	NN
O	NN

29	CD
O	NN

%	NN
O	NN

)	NN
O	NN

,	,
O	NN

who	WP
O	VBP

initiated	VBN
O	NN

treatment	NN
O	NN

after	IN
O	NN

the	DT
O	NN

34th	JJ
O	NN

week	NN
O	NN

,	,
O	NN

composed	VBN
O	NN

the	DT
O	NN

``	``
O	NN

late	RB
O	NN

''	''
O	NN

group	NN
O	NN

All	DT
O	NN

patients	NNS
O	NN

were	VBD
O	NN

managed	VBN
O	NN

by	IN
O	NN

an	DT
O	NN

intensified	VBN
O	NN

protocol	NN
O	NN

,	,
O	NN

including	VBG
O	NN

stringent	JJ
O	NN

glycemic	JJ
T	NN

control	JJ
T	NN

In	IN
O	NN

the	DT
O	NN

``	``
O	NN

early	RB
O	NN

''	''
O	NN

and	CC
O	NN

``	``
O	NN

late	RB
O	NN

''	''
O	NN

groups	NNS
O	NN

,	,
O	NN

mean	VB
O	NN

gestational	JJ
O	NN

age	NN
O	NN

at	IN
O	NN

the	DT
O	NN

beginning	VBG
O	NN

of	IN
O	NN

treatment	NN
O	NN

was	VBD
O	NN

30.0	CD
O	NN

+/-	CC
O	NN

3.8	CD
O	NN

and	CC
O	NN

36.2	CD
O	NN

+/-	CC
O	NN

1.2	CD
O	NN

weeks	NNS
O	NN

,	,
O	NN

and	CC
O	NN

duration	NN
O	NN

of	IN
O	NN

treatment	NN
O	NN

was	VBD
O	NN

9.6	CD
O	NN

+/-	CC
O	NN

4.1	CD
O	NN

and	CC
O	NN

3.7	CD
O	NN

+/-	CC
O	NN

1.8	CD
O	NN

weeks	NNS
O	NN

,	,
O	NN

respectively	RB
O	NN

Maternal	JJ
O	NN

characteristics	NNS
O	NN

were	VBD
O	NN

similar	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

two	CD
O	NN

groups	NNS
O	NN

The	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

macrosomic	JJ
O	NN

and	CC
O	NN

large-for-gestational-age	JJ
O	NN

infants	NNS
O	NN

were	VBD
O	NN

5	CD
O	NN

and	CC
O	NN

11	CD
O	NN

%	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

,	,
O	NN

in	IN
O	NN

the	DT
O	NN

early	RB
O	NN

group	NN
O	NN

as	IN
O	NN

compared	VBN
O	NN

to	TO
O	NN

25	CD
O	NN

and	CC
O	NN

29	CD
O	NN

%	NN
O	NN

in	IN
O	NN

the	DT
O	NN

``	``
O	NN

late	RB
O	NN

''	''
O	NN

group	NN
O	NN

(	NN
O	NN

p	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

)	NN
O	NN

No	DT
O	NN

significant	JJ
O	NN

differences	NNS
O	NN

were	VBD
O	NN

found	VBN
O	NN

between	IN
O	NN

the	DT
O	NN

two	CD
O	NN

groups	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

mode	NN
O	NN

of	IN
O	NN

delivery	NN
O	NN

or	CC
O	NN

Apgar	NNP
O	NNP

scores	NNS
O	NN

We	PRP
O	VBP

conclude	VBP
O	NN

that	IN
O	NN

to	TO
O	NN

reduce	VB
O	NN

the	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

macrosomic	JJ
D	NN

infants	NNS
D	NN

in	IN
D	NN

gestational	JJ
D	NN

diabetes	NN
D	NN

cases	NNS
D	NN

,	,
O	NN

good	JJ
T	NN

glycemic	JJ
T	NN

control	JJ
T	NN

should	MD
O	NNP

be	VB
O	NN

initiated	VBN
O	NN

before	IN
O	NN

34	CD
O	NN

completed	VBN
O	NN

gestational	JJ
O	NN

weeks	NNS
O	NN

Our	PRP$
O	NN

aim	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

investigate	VB
O	NN

the	DT
O	NN

contribution	NN
O	NN

of	IN
O	NN

certain	JJ
O	NN

antenatally	RB
O	NN

detectable	JJ
O	NN

markers	NNS
O	VBP

leading	VBG
O	NN

to	TO
O	NN

the	DT
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

trisomic	JJ
O	NN

fetuses	NNS
O	NN

we	PRP
O	VBP

observed	VBN
O	NN

over	IN
O	NN

a	DT
O	NN

period	NN
O	NN

of	IN
O	NN

6	CD
O	NN

years	NNS
O	NN

In	IN
O	NN

our	PRP$
O	NN

study	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

specifically	RB
O	NN

analyzed	VBN
O	NN

the	DT
O	NN

role	NN
O	NN

played	VBN
O	NN

by	IN
O	NN

advanced	JJ
O	NN

maternal	JJ
O	NN

age	NN
O	NN

and	CC
O	NN

sonographically	RB
O	NN

discovered	VBN
O	NN

abnormalities	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

detection	NN
O	NN

of	IN
O	NN

autosomal	JJ
D	NN

trisomies	NNS
D	NN

All	DT
O	NN

together	RB
O	NN

,	,
O	NN

27	CD
O	NN

fetuses	NNS
O	NN

had	VBD
O	NN

this	DT
O	NN

disorder	NN
O	NN

,	,
O	NN

representing	VBG
O	NN

28.7	CD
O	NN

%	NN
O	NN

(	NN
O	NN

27	CD
O	NN

of	IN
O	NN

94	CD
O	NN

)	NN
O	NN

of	IN
O	NN

all	DT
O	NN

cytogenetic	JJ
D	NN

aberrations	NNS
D	NN

detected	VBN
O	NN

at	IN
O	NN

our	PRP$
O	NN

center	NN
O	NN

over	IN
O	NN

the	DT
O	NN

same	JJ
O	NN

period	NN
O	NN

Down	NN
D	NN

syndrome	NN
D	NN

(	NN
O	NN

12	CD
O	NN

cases	NNS
O	NN

)	NN
O	NN

and	CC
O	NN

Edward	NNP
D	NNP

syndrome	NN
D	NN

(	NN
O	NN

11	CD
O	NN

cases	NNS
O	NN

)	NN
O	NN

were	VBD
O	NN

the	DT
O	NN

most	JJS
O	NN

common	JJ
O	NN

trisomies	NNS
D	NN

,	,
O	NN

while	IN
O	NN

4	CD
O	NN

cases	NNS
O	NN

of	IN
O	NN

Patau	NN
D	NN

syndrome	NN
D	NN

were	VBD
O	NN

also	RB
O	NN

diagnosed	VBN
O	NN

The	DT
O	NN

most	JJS
O	NN

common	JJ
O	NN

indication	NN
O	NN

leading	VBG
O	NN

to	TO
O	NN

diagnosis	NN
O	NN

was	VBD
O	NN

abnormal	JJ
O	NN

ultrasound	NN
O	NN

finding	VBG
O	NN

(	NN
O	NN

48.2	CD
O	NN

%	NN
O	NN

)	NN
O	NN

,	,
O	NN

followed	VBN
O	NN

by	IN
O	NN

advanced	JJ
O	NN

maternal	JJ
O	NN

age	NN
O	NN

(	NN
O	NN

44.4	CD
O	NN

%	NN
O	NN

)	NN
O	NN

However	RB
O	NN

,	,
O	NN

63	CD
O	NN

%	NN
O	NN

of	IN
O	NN

the	DT
O	NN

trisomic	JJ
O	NN

fetuses	NNS
O	NN

belonged	VBD
O	NN

to	TO
O	NN

mothers	NNS
O	NN

aged	JJ
O	NN

35	CD
O	NN

years	NNS
O	NN

and	CC
O	NN

above	IN
O	NN

Down	NN
D	NN

syndrome	NN
D	NN

fetuses	NNS
O	NN

(	NN
O	NN

41.7	CD
O	NN

%	NN
O	NN

)	NN
O	NN

had	VBD
O	NN

prenatally	RB
O	NN

detected	VBN
O	NN

sonographic	JJ
O	NN

anomalies	NNS
O	VBP

,	,
O	NN

63.6	CD
O	NN

%	NN
O	NN

for	IN
O	NN

Edward	NNP
D	NNP

syndrome	NN
D	NN

,	,
O	NN

and	CC
O	NN

all	DT
O	NN

fetuses	NNS
O	NN

with	IN
O	NN

Patau	NN
D	NN

syndrome	NN
D	NN

(	NN
O	NN

4	CD
O	NN

of	IN
O	NN

4	CD
O	NN

)	NN
O	NN

showed	VBD
O	NN

abnormal	JJ
O	NN

sonographic	JJ
O	NN

signs	NNS
O	IN

Trisomy	NN
D	NN

21	CD
D	NN

presented	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

following	VBG
O	NN

features	NNS
O	VBP

:	:
O	NN

hydramnios	NNS
O	NN

,	,
O	NN

complex	JJ
O	NN

malformations	NNS
O	NN

,	,
O	NN

pyelectasis	NN
D	NN

,	,
O	NN

and	CC
O	NN

duodenal	JJ
D	NN

atresia	NN
D	NN

Trisomy	NN
D	NN

18	CD
D	NN

fetuses	NNS
O	NN

showed	VBD
O	NN

hydramnios	NNS
O	NN

,	,
O	NN

intrauterine	JJ
O	NN

growth	NN
O	NN

retardation	NN
O	NN

,	,
O	NN

microcephaly	NN
D	NN

,	,
O	NN

spina	NN
D	NN

bifida	NN
D	NN

,	,
O	NN

and	CC
O	NN

nonimmune	JJ
D	NN

hydrops	NN
D	NN

fetalis	NN
D	NN

Signs	NNS
O	NN

observed	VBN
O	NN

in	IN
O	NN

fetuses	NNS
O	NN

with	IN
O	NN

trisomy	NN
D	NN

13	CD
D	NN

were	VBD
O	NN

:	:
O	NN

hydrocephalus	NN
O	NN

,	,
O	NN

intrauterine	JJ
O	NN

growth	NN
O	NN

retardation	NN
O	NN

,	,
O	NN

oligoanhydramnios	NNS
O	NN

,	,
O	NN

complex	JJ
O	NN

malformations	NNS
O	NN

,	,
O	NN

severe	JJ
O	NN

fetal	JJ
O	NN

bradycardia	NN
D	NN

and	CC
O	NN

hydronephrosis	NN
D	NN

The	DT
O	NN

objective	JJ
O	NN

of	IN
O	NN

this	DT
O	NN

study	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

determine	VB
O	NN

if	IN
O	NN

the	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

preeclampsia	NN
D	NN

is	VBZ
O	NN

increased	VBN
O	NN

in	IN
O	NN

triplet	NN
O	NN

as	IN
O	NN

compared	VBN
O	NN

to	TO
O	NN

twin	JJ
O	NN

gestations	NNS
O	VBP

Fifty-three	CD
O	NN

triplet	NN
O	NN

pregnancies	NNS
O	NN

between	IN
O	NN

1986	CD
O	NN

and	CC
O	NN

1993	CD
O	NN

at	IN
O	NN

The	DT
O	NN

New	NNP
O	NNP

York	NNP
O	NN

Hospital-Cornell	NNP
O	NNP

Medical	JJ
O	NN

Center	NNP
O	NNP

were	VBD
O	NN

reviewed	VBN
O	NN

These	DT
O	NN

were	VBD
O	NN

matched	VBN
O	NN

for	IN
O	NN

maternal	JJ
O	NN

age	NN
O	NN

,	,
O	NN

parity	NN
O	NN

,	,
O	NN

and	CC
O	NN

race	NN
O	NN

to	TO
O	NN

twin	JJ
O	NN

gestations	NNS
O	VBP

(	NN
O	NN

N	NN
O	NN

=	JJ
O	NN

53	CD
O	NN

)	NN
O	NN

from	IN
O	NN

the	DT
O	NN

same	JJ
O	NN

population	NN
O	NN

Severe	JJ
O	NN

preeclampsia	NN
D	NN

was	VBD
O	NN

defined	VBN
O	NN

by	IN
O	NN

standard	JJ
O	NN

criteria	NNS
O	NN

Student	NN
O	NN

's	POS
O	NN

t-test	NN
O	NN

,	,
O	NN

Fisher	NNP
O	NNP

exact	JJ
O	NN

test	NN
O	NN

,	,
O	NN

and	CC
O	NN

Chi-square	JJ
O	NN

were	VBD
O	NN

used	VBN
O	NN

for	IN
O	NN

statistical	JJ
O	NN

analysis	NN
O	NN

The	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

severe	JJ
O	NN

preeclampsia	NN
D	NN

was	VBD
O	NN

increased	VBN
O	NN

significantly	RB
O	NN

in	IN
O	NN

the	DT
O	NN

triplet	NN
O	NN

group	NN
O	NN

12	CD
O	NN

of	IN
O	NN

53	CD
O	NN

(	NN
O	NN

22.6	CD
O	NN

%	NN
O	NN

)	NN
O	NN

as	IN
O	NN

compared	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

twin	JJ
O	NN

group	NN
O	NN

3	CD
O	NN

of	IN
O	NN

53	CD
O	NN

(	NN
O	NN

5.7	CD
O	NN

%	NN
O	NN

)	NN
O	NN

(	NN
O	NN

OR	NN
O	NN

=	JJ
O	NN

4.9	CD
O	NN

,	,
O	NN

95	CD
O	NN

%	NN
O	NN

CI	NN
O	NN

1.2-23.5	CD
O	NN

,	,
O	NN

p	NN
O	NN

=	JJ
O	NN

0.02	CD
O	NN

)	NN
O	NN

The	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

overall	JJ
O	NN

preeclampsia	NN
D	NN

was	VBD
O	NN

not	RB
O	NN

significantly	RB
O	NN

different	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

triplet	NN
O	NN

18	CD
O	NN

of	IN
O	NN

53	CD
O	NN

(	NN
O	NN

33.96	CD
O	NN

%	NN
O	NN

)	NN
O	NN

or	CC
O	NN

twin	JJ
O	NN

12	CD
O	NN

of	IN
O	NN

53	CD
O	NN

(	NN
O	NN

22.6	CD
O	NN

%	NN
O	NN

)	NN
O	NN

groups	NNS
O	NN

In	IN
O	NN

this	DT
O	NN

retrospective	JJ
O	NN

,	,
O	NN

case-controlled	JJ
O	NN

study	NN
O	NN

,	,
O	NN

the	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

severe	JJ
O	NN

pre-eclampsia	NN
D	NN

was	VBD
O	NN

significantly	RB
O	NN

increased	VBN
O	NN

in	IN
O	NN

triplet	NN
O	NN

gestations	NNS
O	VBP

as	IN
O	NN

compared	VBN
O	NN

to	TO
O	NN

twins	NNS
O	NN

although	IN
O	NN

the	DT
O	NN

overall	JJ
O	NN

rate	NN
O	NN

of	IN
O	NN

preeclampsia	NN
D	NN

was	VBD
O	NN

not	RB
O	NN

This	DT
O	NN

information	NN
O	NN

may	MD
O	NNP

be	VB
O	NN

useful	JJ
O	NN

in	IN
O	NN

counseling	VBG
O	NN

patients	NNS
O	NN

with	IN
O	NN

high	JJ
O	NN

order	NN
O	NN

multifetal	JJ
O	NN

gestations	NNS
O	VBP

We	PRP
O	VBP

conducted	VBN
O	NN

a	DT
O	NN

survey	NN
O	NN

and	CC
O	NN

audit	NN
O	NN

of	IN
O	NN

thermal	JJ
O	NN

equipment	NN
O	NN

use	NN
O	NN

in	IN
O	NN

very	RB
O	NN

low-birth-weight	JJ
O	NN

infants	NNS
O	NN

in	IN
O	NN

five	CD
O	NN

Ohio	NNP
O	NNP

neonatal	JJ
O	NN

intensive	JJ
O	NN

care	NN
O	NN

units	NNS
O	NN

(	NN
O	NN

NICUs	NNS
O	NN

)	NN
O	NN

to	TO
O	NN

document	NN
O	NN

regional	JJ
O	NN

practice	NN
O	NN

The	DT
O	NN

survey	NN
O	NN

indicated	VBD
O	NN

a	DT
O	NN

variety	NN
O	NN

of	IN
O	NN

thermal	JJ
O	NN

care	NN
O	NN

styles	NNS
O	NN

Two	CD
O	NN

NICUs	NNS
O	NN

preferred	VBN
O	NN

to	TO
O	NN

admit	VB
O	NN

infants	NNS
O	NN

to	TO
O	NN

incubators	NNS
O	NN

,	,
O	NN

the	DT
O	NN

other	JJ
O	NN

three	CD
O	NN

favoring	VBG
O	NN

radiant	JJ
O	NN

warmers	NNS
O	NN

These	DT
O	NN

three	CD
O	NN

NICUs	NNS
O	NN

moved	VBN
O	NN

infants	NNS
O	NN

from	IN
O	NN

radiant	JJ
O	NN

warmers	NNS
O	NN

into	IN
O	NN

incubators	NNS
O	NN

at	IN
O	NN

significantly	RB
O	NN

different	JJ
O	NN

mean	VB
O	NN

ages	NNS
O	NN

The	DT
O	NN

audit	NN
O	NN

demonstrated	VBD
O	NN

inconsistent	JJ
O	NN

use	NN
O	NN

of	IN
O	NN

plastic	JJ
O	NN

covers	NNS
O	NN

,	,
O	NN

warming	VBG
O	NN

mattresses	NNS
O	NN

,	,
O	NN

and	CC
O	NN

added	VBN
O	NN

humidity	NN
O	NN

under	IN
O	NN

radiant	JJ
O	NN

warmers	NNS
O	NN

,	,
O	NN

and	CC
O	NN

discrepancies	NNS
O	NN

between	IN
O	NN

survey	NN
O	NN

responses	NNS
O	NN

and	CC
O	NN

actual	JJ
O	NN

use	NN
O	NN

within	IN
O	NN

NICUs	NNS
O	NN

Inter-NICU	JJ
O	NN

variability	NN
O	NN

of	IN
O	NN

thermal	JJ
O	NN

equipment	NN
O	NN

use	NN
O	NN

may	MD
O	NNP

complicate	VB
O	NN

fluid	NN
O	NN

management	NN
O	NN

This	DT
O	NN

report	NN
O	NN

describes	VBZ
O	NN

a	DT
O	NN

full-term	JJ
O	NN

newborn	JJ
O	NN

with	IN
O	NN

massive	JJ
D	NN

fetomaternal	JJ
D	NN

hemorrhage	NN
D	NN

Fetal	JJ
O	NN

movements	NNS
O	VBP

were	VBD
O	NN

decreased	VBN
O	NN

48	CD
O	NN

hr	NN
O	NN

prior	RB
O	NN

to	TO
O	NN

delivery	NN
O	NN

On	IN
O	NN

the	DT
O	NN

day	NN
O	NN

of	IN
O	NN

delivery	NN
O	NN

,	,
O	NN

they	PRP
O	VBP

were	VBD
O	NN

absent	JJ
O	NN

The	DT
O	NN

nonstress	JJ
O	NN

test	NN
O	NN

was	VBD
O	NN

abnormal	JJ
O	NN

with	IN
O	NN

low	JJ
O	NN

biophysical	JJ
O	NN

profile	NN
O	NN

and	CC
O	NN

decreased	VBN
O	NN

beat-to-beat	NN
O	NN

variability	NN
O	NN

The	DT
O	NN

infant	NN
O	NN

presented	VBN
O	NN

with	IN
O	NN

extreme	JJ
O	NN

pallor	NN
O	NN

,	,
O	NN

hypotonia	NN
D	NN

,	,
O	NN

hepatosplenomegaly	RB
D	NN

,	,
O	NN

and	CC
O	NN

ascites	NNS
D	NN

The	DT
O	NN

initial	JJ
O	NN

hemoglobin	NN
O	NN

was	VBD
O	NN

2.2	CD
O	NN

g/dL	NN
O	NN

,	,
O	NN

the	DT
O	NN

Kleihauer-Betke	JJ
O	NN

stain	VB
O	NN

was	VBD
O	NN

27.6	CD
O	NN

%	NN
O	NN

(	NN
O	NN

highest	JJS
O	NN

level	NN
O	NN

ever	RB
O	NN

reported	VBN
O	NN

)	NN
O	NN

Right	RB
O	NN

temporal	JJ
O	NN

and	CC
O	NN

cerebellar	NN
O	NN

hemorrhages	NNS
O	NN

were	VBD
O	NN

present	JJ
O	NN

Sequelae	FW
O	FW

include	VBP
O	NN

severe	JJ
O	NN

developmental	JJ
O	NN

delay	NN
O	NN

and	CC
O	NN

asymmetric	JJ
O	NN

double	JJ
O	NN

hemiplegia	NN
D	NN

Omphalocele-Exstrophy-Imperforate	JJ
D	NN

anus-Spinal	JJ
D	NN

defects	NNS
D	NN

(	NN
D	NN

OEIS	NN
D	NN

complex	NN
D	NN

)	NN
D	NN

,	,
O	NN

a	DT
O	NN

combination	NN
O	NN

of	IN
O	NN

omphalocele	NN
D	NN

,	,
O	NN

exstrophy	NN
D	NN

of	IN
D	NN

the	DT
D	NN

bladder	NN
D	NN

,	,
O	NN

an	DT
O	NN

imperforate	JJ
O	NN

anus	NN
O	NN

and	CC
O	NN

spinal	JJ
D	NN

defects	NNS
D	NN

,	,
O	NN

arises	VBZ
O	NN

from	IN
O	NN

a	DT
O	NN

single	JJ
O	NN

localized	JJ
O	NN

defect	NN
O	NN

in	IN
O	NN

the	DT
O	NN

early	RB
O	NN

development	NN
O	NN

of	IN
O	NN

the	DT
O	NN

mesoderm	NN
O	NN

that	IN
O	NN

will	MD
O	VB

later	RB
O	NN

contribute	VB
O	NN

to	TO
O	NN

infraumbilical	JJ
O	NN

mesenchyme	NN
O	NN

,	,
O	NN

cloacal	JJ
O	NN

septum	NN
O	NN

,	,
O	NN

and	CC
O	NN

caudal	JJ
O	NN

vertebrae	NNS
O	NN

In	IN
O	NN

this	DT
O	NN

report	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

document	NN
O	NN

the	DT
O	NN

perinatal	JJ
O	NN

features	NNS
O	VBP

of	IN
O	NN

two	CD
O	NN

cases	NNS
O	NN

of	IN
O	NN

OEIS	NN
D	NN

complex	NN
D	NN

associated	VBN
O	NN

with	IN
O	NN

meningomyeloceles	NNS
D	NN

and	CC
O	NN

severe	JJ
O	NN

lower	JJR
O	NN

limb	NN
O	NN

defects	NNS
O	NN

,	,
O	NN

and	CC
O	NN

discuss	VB
O	NN

the	DT
O	NN

prenatal	JJ
O	NN

diagnosis	NN
O	NN

,	,
O	NN

inheritance	NN
O	NN

,	,
O	NN

and	CC
O	NN

differential	JJ
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

this	DT
O	NN

association	NN
O	NN

of	IN
O	NN

malformations	NNS
O	NN

Although	IN
O	NN

long-term	JJ
O	NN

survival	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

achieved	VBN
O	NN

by	IN
O	NN

successful	JJ
O	NN

corrective	JJ
T	NN

surgery	NN
T	NN

,	,
O	NN

the	DT
O	NN

associated	VBN
O	NN

structural	JJ
O	NN

defects	NNS
O	NN

such	JJ
O	NN

as	IN
O	NN

large	JJ
D	NN

meningomyelocele	NN
D	NN

and	CC
O	NN

severe	JJ
O	NN

limb	NN
D	NN

aplasia	NN
D	NN

or	CC
O	NN

hypoplasia	NN
D	NN

,	,
O	NN

as	IN
O	NN

seen	VBN
O	NN

in	IN
O	NN

our	PRP$
O	NN

patient	NN
O	NN

,	,
O	NN

can	MD
O	NNP

influence	NN
O	NN

the	DT
O	NN

patient	NN
O	NN

's	POS
O	NN

quality	NN
O	NN

of	IN
O	NN

life	NN
O	NN

.	.
O	NN

We	PRP
O	VBP

would	MD
O	NNP

like	IN
O	NN

to	TO
O	NN

emphasize	VB
O	NN

that	IN
O	NN

an	DT
O	NN

accurate	JJ
O	NN

prenatal	JJ
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

OEIS	NN
D	NN

complex	NN
D	NN

and	CC
O	NN

associated	VBN
O	NN

malformations	NNS
O	NN

is	VBZ
O	NN

important	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

detailed	JJ
O	NN

counseling	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

family	NN
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

appropriate	JJ
O	NN

perinatal	JJ
O	NN

management	NN
O	NN

by	IN
O	NN

the	DT
O	NN

obstetricians	NNS
O	NN

,	,
O	NN

pediatric	JJ
O	NN

surgeons	NNS
O	NN

,	,
O	NN

urologists	NNS
O	NN

,	,
O	NN

neurosurgeons	NNS
O	NN

,	,
O	NN

and	CC
O	NN

neonatologists	NNS
O	NN

Nonimmune	JJ
D	NN

hydrops	NN
D	NN

fetails	NNS
D	NN

diagnosed	VBN
O	NN

at	IN
O	NN

21	CD
O	NN

weeks	NNS
O	NN

'	POS
O	NN

gestation	JJ
O	NN

with	IN
O	NN

profound	JJ
O	NN

ascites	NNS
D	NN

,	,
O	NN

hydrothorax	NN
D	NN

,	,
O	NN

and	CC
O	NN

pericardial	JJ
D	NN

effusion	NN
D	NN

receded	VBD
O	NN

gradually	RB
O	NN

with	IN
O	NN

regression	NN
O	NN

of	IN
O	NN

a	DT
O	NN

subchorial	JJ
O	NN

placental	JJ
O	NN

lucencies	NNS
O	NN

immediately	RB
O	NN

below	IN
O	NN

the	DT
O	NN

umbilical	JJ
O	NN

cord	NN
O	NN

insertion	NN
O	NN

Careful	JJ
O	NN

inspection	NN
O	NN

of	IN
O	NN

the	DT
O	NN

delivered	VBN
O	NN

placenta	NN
O	NN

revealed	VBD
O	NN

that	IN
O	NN

there	RB
O	NN

was	VBD
O	NN

a	DT
O	NN

yellowish	JJ
O	NN

lesion	NN
O	NN

of	IN
O	NN

fibrin	JJ
O	NN

deposits	NNS
O	NN

below	IN
O	NN

the	DT
O	NN

cord	NN
O	NN

insertion	NN
O	NN

site	NN
O	NN

,	,
O	NN

which	WDT
O	NN

resulted	VBD
O	NN

from	IN
O	NN

the	DT
O	NN

absorption	NN
O	NN

of	IN
O	NN

hematoma	NN
O	NN

A	DT
O	NN

subchorial	JJ
O	NN

placental	JJ
O	NN

hematoma	NN
D	NN

,	,
O	NN

which	WDT
O	NN

detected	VBN
O	NN

as	IN
O	NN

a	DT
O	NN

subchorial	JJ
O	NN

placental	JJ
O	NN

lucencies	NNS
D	NN

by	IN
O	NN

ultrasonography	NN
O	NN

,	,
O	NN

can	MD
O	NNP

be	VB
O	NN

a	DT
O	NN

cause	NN
O	NN

of	IN
O	NN

reversible	JJ
O	NN

nonimmune	JJ
D	NN

hydrops	NN
D	NN

fetalis	NN
D	NN

The	DT
O	NN

mitochondrial	JJ
D	NN

diseases	NNS
D	NN

are	VBP
O	NN

uncommon	JJ
O	NN

multisystem	NN
O	NN

disorders	NNS
O	NN

characterized	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

functionally	RB
O	NN

and/or	CC
O	NN

structurally	RB
O	NN

abnormal	JJ
O	NN

mitochondria	NN
O	NN

As	IN
O	NN

there	RB
O	NN

have	VB
O	NN

been	VBN
O	NN

few	JJ
O	NN

reports	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

obstetrical	JJ
O	NN

care	NN
O	NN

of	IN
O	NN

affected	VBN
O	NN

patients	NNS
O	NN

,	,
O	NN

we	PRP
O	VBP

wish	NN
O	NN

to	TO
O	NN

document	NN
O	NN

two	CD
O	NN

pregnancies	NNS
O	NN

in	IN
O	NN

a	DT
O	NN

woman	NN
O	NN

with	IN
O	NN

a	DT
O	NN

Chronic	JJ
D	NN

Progressive	JJ
D	NN

External	JJ
D	NN

Ophthalmoplegia	NN
D	NN

(	NN
D	NN

Kearns-Sayre-like	JJ
D	NN

syndrome	NN
D	NN

)	NN
D	NN

Both	DT
O	NN

pregnancies	NNS
O	NN

were	VBD
O	NN

complicated	JJ
O	NN

by	IN
O	NN

preterm	NN
O	NN

labor	NN
O	NN

and	CC
O	NN

hypertension	NN
D	NN

CONTEXT	NN
O	NN

:	:
O	NN

Four	CD
O	NN

genetic	JJ
O	NN

loci	NNS
O	NN

have	VB
O	NN

been	VBN
O	NN

identified	VBN
O	NN

as	IN
O	NN

contributing	VBG
O	NN

to	TO
O	NN

Alzheimer	NN
D	NN

disease	NN
D	NN

(	NN
D	NN

AD	NN
D	NN

)	NN
D	NN

,	,
O	NN

including	VBG
O	NN

the	DT
O	NN

amyloid	NN
O	NN

precursor	NN
O	NN

protein	NN
O	NN

gene	NN
O	NN

,	,
O	NN

the	DT
O	NN

presenilin	NN
O	NN

1	CD
O	NN

gene	NN
O	NN

,	,
O	NN

the	DT
O	NN

presenilin	NN
O	NN

2	CD
O	NN

gene	NN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

apolipoprotein	NN
O	NN

E	NN
O	NN

gene	NN
O	NN

,	,
O	NN

but	CC
O	NNP

do	VB
O	NNP

not	RB
O	NN

account	NN
O	NN

for	IN
O	NN

all	DT
O	NN

the	DT
O	NN

genetic	JJ
O	NN

risk	NN
O	NN

for	IN
O	NN

AD	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

identify	VB
O	NN

additional	JJ
O	NN

genetic	JJ
O	NN

risk	NN
O	NN

factors	NNS
O	NN

for	IN
O	NN

late-onset	JJ
O	NN

AD	NN
O	NN

DESIGN	NN
O	NN

:	:
O	NN

A	DT
O	NN

complete	JJ
O	NN

genomic	JJ
O	NN

screen	NN
O	NN

was	VBD
O	NN

performed	VBN
O	NN

(	NN
O	NN

N=280	NN
O	NN

markers	NNS
O	VBP

)	NN
O	NN

Critical	JJ
O	NN

values	NNS
O	VBP

for	IN
O	NN

chromosomal	JJ
O	NN

regional	JJ
O	NN

follow-up	JJ
O	NN

were	VBD
O	NN

a	DT
O	NN

P	NN
O	NN

value	NN
O	NN

of	IN
O	NN

.05	CD
O	NN

or	CC
O	NN

less	JJR
O	NN

for	IN
O	NN

affected	VBN
O	NN

relative	JJ
O	NN

pair	NN
O	NN

analysis	NN
O	NN

or	CC
O	NN

sibpair	NN
O	NN

analysis	NN
O	NN

,	,
O	NN

a	DT
O	NN

parametric	JJ
O	NN

lod	NN
O	NN

score	NN
O	NN

of	IN
O	NN

1.0	CD
O	NN

or	CC
O	NN

greater	JJR
O	NN

,	,
O	NN

or	CC
O	NN

both	DT
O	NN

Regional	NNP
O	NNP

follow-up	JJ
O	NN

included	VBN
O	NN

analysis	NN
O	NN

of	IN
O	NN

additional	JJ
O	NN

markers	NNS
O	VBP

and	CC
O	NN

a	DT
O	NN

second	JJ
O	NN

data	NNS
O	NN

set	VBN
O	NN

SETTING	VBG
O	NN

:	:
O	NN

Clinic	NNP
O	NNP

populations	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

continental	JJ
O	NN

United	NNP
O	NNP

States	NNPS
O	NNP

PATIENTS	NNS
O	VBP

:	:
O	NN

>	JJR
O	NN

From	IN
O	NN

a	DT
O	NN

series	NN
O	NN

of	IN
O	NN

multiplex	JJ
O	NN

families	NNS
O	NN

affected	VBN
O	NN

with	IN
O	NN

late-onset	JJ
O	NN

(	NN
O	NN

>	JJR
O	NN

or	CC
O	NN

=60	CD
O	NN

years	NNS
O	NN

)	NN
O	NN

AD	NN
O	NN

ascertained	VBN
O	NN

during	IN
O	NN

the	DT
O	NN

last	JJ
O	NN

14	CD
O	NN

years	NNS
O	NN

(	NN
O	NN

National	NNP
O	NNP

Insititute	JJ
O	NN

of	IN
O	NN

Neurological	JJ
O	NN

Disorders	NNS
O	NN

and	CC
O	NN

Stroke-Alzheimer	NNP
O	NNP

's	POS
O	NN

Disease	NN
O	NN

and	CC
O	NN

Related	JJ
O	NN

Disorders	NNS
O	NN

Association	NNP
O	NN

diagnostic	JJ
O	NN

criteria	NNS
O	NN

)	NN
O	NN

and	CC
O	NN

for	IN
O	NN

which	WDT
O	NN

DNA	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

obtained	VBN
O	NN

,	,
O	NN

a	DT
O	NN

subset	NN
O	NN

of	IN
O	NN

16	CD
O	NN

families	NNS
O	NN

(	NN
O	NN

135	CD
O	NN

total	JJ
O	NN

family	NN
O	NN

members	NNS
O	NN

,	,
O	NN

52	CD
O	NN

of	IN
O	NN

whom	WP
O	NN

were	VBD
O	NN

patients	NNS
O	NN

with	IN
O	NN

AD	NN
O	NN

)	NN
O	NN

was	VBD
O	NN

used	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

genomic	JJ
O	NN

screen	NN
O	NN

A	DT
O	NN

second	JJ
O	NN

subset	NN
O	NN

of	IN
O	NN

38	CD
O	NN

families	NNS
O	NN

(	NN
O	NN

216	CD
O	NN

total	JJ
O	NN

family	NN
O	NN

members	NNS
O	NN

,	,
O	NN

89	CD
O	NN

of	IN
O	NN

whom	WP
O	NN

were	VBD
O	NN

patients	NNS
O	NN

with	IN
O	NN

AD	NN
O	NN

)	NN
O	NN

was	VBD
O	NN

used	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

follow-up	JJ
O	NN

analysis	NN
O	NN

MAIN	JJS
O	NN

OUTCOME	NN
O	NN

MEASURES	NNS
O	VBP

:	:
O	NN

Linkage	NN
O	NN

analysis	NN
O	NN

results	NNS
O	VBP

generated	VBN
O	NN

using	VBG
O	NN

both	DT
O	NN

genetic	JJ
O	NN

model-dependent	JJ
O	NN

(	NN
O	NN

lod	NN
O	NN

score	NN
O	NN

)	NN
O	NN

and	CC
O	NN

model-independent	JJ
O	NN

methods	NNS
O	VBP

RESULTS	NNS
O	VBP

:	:
O	NN

Fifteen	CD
O	NN

chromosomal	JJ
O	NN

regions	NNS
O	NN

warranted	VBN
O	NN

initial	JJ
O	NN

follow-up	JJ
O	NN

Follow-up	JJ
O	NN

analyses	NNS
O	VBP

revealed	VBD
O	NN

4	CD
O	NN

regions	NNS
O	NN

of	IN
O	NN

continued	VBN
O	NN

interest	NN
O	NN

on	IN
O	NN

chromosomes	NNS
O	NN

4	CD
O	NN

,	,
O	NN

6	CD
O	NN

,	,
O	NN

12	CD
O	NN

,	,
O	NN

and	CC
O	NN

20	CD
O	NN

,	,
O	NN

with	IN
O	NN

the	DT
O	NN

strongest	JJS
O	NN

results	NNS
O	VBP

observed	VBN
O	NN

forchromosome	NN
O	NN

12	CD
O	NN

Peak	JJ
O	NN

2-point	JJ
O	NN

affecteds-only	RB
O	NN

lod	NN
O	NN

scores	NNS
O	NN

(	NN
O	NN

n=54	NN
O	NN

)	NN
O	NN

were	VBD
O	NN

1.3	CD
O	NN

,	,
O	NN

1.6	CD
O	NN

,	,
O	NN

2.7	CD
O	NN

,	,
O	NN

and	CC
O	NN

2.2	CD
O	NN

and	CC
O	NN

affected	VBN
O	NN

relative	JJ
O	NN

pairs	NNS
O	NN

P	NN
O	NN

values	NNS
O	VBP

(	NN
O	NN

n=54	NN
O	NN

)	NN
O	NN

were	VBD
O	NN

.04	CD
O	NN

,	,
O	NN

.03	CD
O	NN

,	,
O	NN

.14	CD
O	NN

,	,
O	NN

and	CC
O	NN

.04	CD
O	NN

for	IN
O	NN

D12S373	NN
O	NN

,	,
O	NN

D12S1057	NN
O	NN

,	,
O	NN

D12S1042	NN
O	NN

,	,
O	NN

and	CC
O	NN

D12S390	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

Sibpair	NNP
O	NNP

analysis	NN
O	NN

(	NN
O	NN

n=54	NN
O	NN

)	NN
O	NN

resulted	VBD
O	NN

in	IN
O	NN

maximum	NN
O	NN

lod	NN
O	NN

scores	NNS
O	NN

(	NN
O	NN

MLSs	NNS
O	NN

)	NN
O	NN

of	IN
O	NN

1.5	CD
O	NN

,	,
O	NN

2.6	CD
O	NN

,	,
O	NN

3.2	CD
O	NN

,	,
O	NN

and	CC
O	NN

2.3	CD
O	NN

for	IN
O	NN

these	DT
O	NN

markers	NNS
O	VBP

,	,
O	NN

with	IN
O	NN

a	DT
O	NN

peak	JJ
O	NN

multipoint	JJ
O	NN

MLS	NN
O	NN

of	IN
O	NN

3.5	CD
O	NN

A	DT
O	NN

priori	FW
O	FW

stratification	NN
O	NN

by	IN
O	NN

APOE	NN
O	NN

genotype	NN
O	NN

identified	VBN
O	NN

27	CD
O	NN

families	NNS
O	NN

that	IN
O	NN

had	VBD
O	NN

at	IN
O	NN

least	JJS
O	NN

1	CD
O	NN

member	NN
O	NN

with	IN
O	NN

AD	NN
O	NN

whose	WP$
O	NN

genotype	NN
O	NN

did	VBD
O	NNP

not	RB
O	NN

contain	VB
O	NN

an	DT
O	NN

APOE*4	NN
O	NN

allele	NN
O	NN

Analysis	NN
O	NN

of	IN
O	NN

these	DT
O	NN

27	CD
O	NN

families	NNS
O	NN

resulted	VBD
O	NN

in	IN
O	NN

MLSs	NNS
O	NN

of	IN
O	NN

1.0	CD
O	NN

,	,
O	NN

2.4	CD
O	NN

,	,
O	NN

3.7	CD
O	NN

,	,
O	NN

and	CC
O	NN

3.3	CD
O	NN

and	CC
O	NN

a	DT
O	NN

peak	JJ
O	NN

multipoint	JJ
O	NN

MLS	NN
O	NN

of	IN
O	NN

3.9	CD
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

A	DT
O	NN

complete	JJ
O	NN

genomic	JJ
O	NN

screen	NN
O	NN

in	IN
O	NN

families	NNS
O	NN

affected	VBN
O	NN

with	IN
O	NN

late-onset	JJ
O	NN

AD	NN
O	NN

identified	VBN
O	NN

4	CD
O	NN

regions	NNS
O	NN

of	IN
O	NN

interest	NN
O	NN

after	IN
O	NN

follow-up	JJ
O	NN

Chromosome	NN
O	NN

12	CD
O	NN

gave	VBD
O	NN

the	DT
O	NN

strongest	JJS
O	NN

and	CC
O	NN

most	JJS
O	NN

consistent	JJ
O	NN

results	NNS
O	VBP

with	IN
O	NN

a	DT
O	NN

peak	JJ
O	NN

multipoint	JJ
O	NN

MLS	NN
O	NN

of	IN
O	NN

3.5	CD
O	NN

,	,
O	NN

suggesting	VBG
O	NN

that	IN
O	NN

this	DT
O	NN

region	NN
O	NN

contains	VBZ
O	NN

a	DT
O	NN

new	JJ
O	NN

susceptibility	NN
O	NN

gene	NN
O	NN

for	IN
O	NN

AD	NN
O	NN

Additional	JJ
O	NN

analyses	NNS
O	VBP

are	VBP
O	NN

necessary	JJ
O	NN

to	TO
O	NN

identify	VB
O	NN

the	DT
O	NN

chromosome	NN
O	NN

12	CD
O	NN

susceptibility	NN
O	NN

gene	NN
O	NN

for	IN
O	NN

AD	NN
O	NN

and	CC
O	NN

to	TO
O	NN

follow	VB
O	NNP

up	RB
O	NN

the	DT
O	NN

regions	NNS
O	NN

of	IN
O	NN

interest	NN
O	NN

on	IN
O	NN

chromosomes	NNS
O	NN

4	CD
O	NN

,	,
O	NN

6	CD
O	NN

,	,
O	NN

and	CC
O	NN

20	CD
O	NN

CONTEXT	NN
O	NN

:	:
O	NN

A	DT
O	NN

mutation	NN
O	NN

in	IN
O	NN

the	DT
O	NN

BRCA1	NN
O	NN

gene	NN
O	NN

may	MD
O	NNP

confer	VB
O	NN

substantial	JJ
O	NN

risk	NN
O	NN

for	IN
O	NN

breast	NN
O	NN

and/or	CC
O	NN

ovarian	JJ
O	NN

cancer	NN
D	NN

However	RB
O	NN

,	,
O	NN

knowledge	NN
O	NN

regarding	VBG
O	NN

all	DT
O	NN

possible	JJ
O	NN

mutations	NNS
O	VBP

and	CC
O	NN

the	DT
O	NN

relationship	NN
O	NN

between	IN
O	NN

risk	NN
O	NN

factors	NNS
O	NN

and	CC
O	NN

mutations	NNS
O	VBP

is	VBZ
O	NN

incomplete	JJ
O	NN

OBJECTIVES	NNS
O	VBP

:	:
O	NN

To	TO
O	NN

identify	VB
O	NN

BRCA1	NN
O	NN

mutations	NNS
O	VBP

and	CC
O	NN

to	TO
O	NN

determine	VB
O	NN

factors	NNS
O	NN

that	IN
O	NN

best	RB
O	NN

predict	VB
O	NN

presence	NN
O	NN

of	IN
O	NN

a	DT
O	NN

deleterious	JJ
O	NN

BRCA1	NN
O	NN

mutation	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

breast	NN
O	NN

and/or	CC
O	NN

ovarian	JJ
O	NN

cancer	NN
D	NN

DESIGN	NN
O	NN

:	:
O	NN

A	DT
O	NN

complete	JJ
O	NN

sequence	NN
O	NN

analysis	NN
O	NN

of	IN
O	NN

the	DT
O	NN

BRCA1	NN
O	NN

coding	VBG
O	NN

sequence	NN
O	NN

and	CC
O	NN

flanking	JJ
O	NN

intronic	JJ
O	NN

regions	NNS
O	NN

was	VBD
O	NN

performed	VBN
O	NN

in	IN
O	NN

798	CD
O	NN

women	NNS
O	VBP

in	IN
O	NN

a	DT
O	NN

collaborative	JJ
O	NN

effort	NN
O	NN

involving	VBG
O	NN

institutions	NNS
O	VBP

from	IN
O	NN

the	DT
O	NN

United	NNP
O	NNP

States	NNPS
O	NNP

,	,
O	NN

Italy	NNP
O	NNP

,	,
O	NN

Germany	NNP
O	NNP

,	,
O	NN

Finland	NNP
O	NNP

,	,
O	NN

and	CC
O	NN

Switzerland	NNP
O	NNP

PARTICIPANTS	NNS
O	VBP

:	:
O	NN

Institutions	NNS
O	VBP

selected	VBN
O	NN

798	CD
O	NN

persons	NNS
O	VBP

representing	VBG
O	NN

families	NNS
O	NN

(	NN
O	NN

1	CD
O	NN

person	NN
O	NN

for	IN
O	NN

each	DT
O	NN

family	NN
O	NN

)	NN
O	NN

thought	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

at	IN
O	NN

elevated	JJ
O	NN

a	DT
O	NN

priori	FW
O	FW

risk	NN
O	NN

of	IN
O	NN

BRCA1	NN
O	NN

mutation	NN
O	NN

due	JJ
O	NN

to	TO
O	NN

potential	JJ
O	NN

risk	NN
O	NN

factors	NNS
O	NN

,	,
O	NN

such	JJ
O	NN

as	IN
O	NN

multiple	JJ
O	NN

cases	NNS
O	NN

of	IN
O	NN

breast	NN
D	NN

cancer	NN
D	NN

,	,
O	NN

early	RB
O	NN

age	NN
O	NN

of	IN
O	NN

breast	NN
D	NN

cancer	NN
D	NN

diagnosis	NN
O	NN

,	,
O	NN

and	CC
O	NN

cases	NNS
O	NN

of	IN
O	NN

ovarian	JJ
D	NN

cancer	NN
D	NN

No	DT
O	NN

participant	NN
O	NN

was	VBD
O	NN

from	IN
O	NN

a	DT
O	NN

family	NN
O	NN

in	IN
O	NN

which	WDT
O	NN

genetic	JJ
O	NN

markers	NNS
O	VBP

showed	VBD
O	NN

linkage	NN
O	NN

to	TO
O	NN

the	DT
O	NN

BRCA1	NN
O	NN

locus	NN
O	NN

MAJOR	JJ
O	NN

OUTCOME	NN
O	NN

MEASURES	NNS
O	VBP

:	:
O	NN

Sequence	NN
O	NN

variants	NNS
O	NN

detected	VBN
O	NN

in	IN
O	NN

this	DT
O	NN

sample	NN
O	NN

are	VBP
O	NN

presented	VBN
O	NN

along	IN
O	NN

with	IN
O	NN

analyses	NNS
O	VBP

designed	VBN
O	NN

to	TO
O	NN

determine	VB
O	NN

predictive	JJ
O	NN

characteristics	NNS
O	NN

of	IN
O	NN

those	DT
O	NNP

testing	NN
O	NN

positive	JJ
O	NN

for	IN
O	NN

BRCA1	NN
O	NN

mutations	NNS
O	VBP

RESULTS	NNS
O	VBP

:	:
O	NN

In	IN
O	NN

102	CD
O	NN

women	NNS
O	VBP

(	NN
O	NN

12.8	CD
O	NN

%	NN
O	NN

)	NN
O	NN

,	,
O	NN

clearly	RB
O	NN

deleterious	JJ
O	NN

mutations	NNS
O	VBP

were	VBD
O	NN

detected	VBN
O	NN

Fifty	CD
O	NN

new	JJ
O	NN

genetic	JJ
O	NN

alterations	NNS
O	VBP

were	VBD
O	NN

found	VBN
O	NN

including	VBG
O	NN

24	CD
O	NN

deleterious	JJ
O	NN

mutations	NNS
O	VBP

,	,
O	NN

24	CD
O	NN

variants	NNS
O	NN

of	IN
O	NN

unknown	JJ
O	NN

significance	NN
O	NN

,	,
O	NN

and	CC
O	NN

2	CD
O	NN

rare	JJ
O	NN

polymorphisms	NNS
O	NN

In	IN
O	NN

a	DT
O	NN

subset	NN
O	NN

of	IN
O	NN

71	CD
O	NN

Ashkenazi	JJ
O	NN

Jewish	JJ
O	NN

women	NNS
O	VBP

,	,
O	NN

only	RB
O	NN

2	CD
O	NN

distinct	JJ
O	NN

deleterious	JJ
O	NN

mutations	NNS
O	VBP

were	VBD
O	NN

found	VBN
O	NN

:	:
O	NN

185delAG	NN
O	NN

in	IN
O	NN

17	CD
O	NN

cases	NNS
O	NN

and	CC
O	NN

5382insC	NN
O	NN

in	IN
O	NN

7	CD
O	NN

cases	NNS
O	NN

A	DT
O	NN

bias	NN
O	NN

in	IN
O	NN

prior	RB
O	NN

reports	NNS
O	NN

for	IN
O	NN

mutations	NNS
O	VBP

in	IN
O	NN

exon	NN
O	NN

11	CD
O	NN

was	VBD
O	NN

revealed	VBD
O	NN

Characteristics	NNS
O	NN

of	IN
O	NN

a	DT
O	NN

patient	NN
O	NN

's	POS
O	NN

specific	JJ
O	NN

diagnosis	NN
O	NN

(	NN
O	NN

unilateral	JJ
O	NN

or	CC
O	NN

bilateral	JJ
O	NN

breast	NN
D	NN

cancer	NN
D	NN

,	,
O	NN

with	IN
O	NN

or	CC
O	NN

without	IN
O	NN

ovarian	JJ
D	NN

cancer	NN
D	NN

)	NN
O	NN

,	,
O	NN

early	RB
O	NN

age	NN
O	NN

at	IN
O	NN

diagnosis	NN
O	NN

,	,
O	NN

Ashkenazi	JJ
O	NN

Jewish	JJ
O	NN

ethnicity	NN
O	NN

,	,
O	NN

and	CC
O	NN

family	NN
O	NN

history	NN
O	NN

of	IN
O	NN

cancer	NN
O	NN

were	VBD
O	NN

positively	RB
O	NN

associated	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

probability	NN
O	NN

of	IN
O	NN

her	PRP$
O	NN

carrying	VBG
O	NN

a	DT
O	NN

deleterious	JJ
O	NN

BRCA1	NN
O	NN

mutation	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Using	VBG
O	NN

logistic	JJ
O	NN

regression	NN
O	NN

analysis	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

provide	VB
O	NN

a	DT
O	NN

method	NN
O	NN

for	IN
O	NN

evaluating	VBG
O	NN

the	DT
O	NN

probability	NN
O	NN

of	IN
O	NN

a	DT
O	NN

woman	NN
O	NN

's	POS
O	NN

carrying	VBG
O	NN

a	DT
O	NN

deleterious	JJ
O	NN

BRCA1	NN
O	NN

mutation	NN
O	NN

for	IN
O	NN

a	DT
O	NN

wide	JJ
O	NN

range	NN
O	NN

of	IN
O	NN

cases	NNS
O	NN

,	,
O	NN

which	WDT
O	NN

can	MD
O	NNP

be	VB
O	NN

an	DT
O	NN

important	JJ
O	NN

tool	NN
O	NN

for	IN
O	NN

clinicians	NNS
O	NN

as	IN
O	NN

they	PRP
O	VBP

incorporate	VB
O	NN

genetic	JJ
O	NN

susceptibility	NN
O	NN

testing	NN
O	NN

into	IN
O	NN

their	PRP$
O	NN

medical	JJ
O	NN

practice	NN
O	NN

CONTEXT	NN
O	NN

:	:
O	NN

Approximately	RB
O	NN

9	CD
O	NN

%	NN
O	NN

of	IN
O	NN

prostate	NN
D	NN

cancer	NN
D	NN

cases	NNS
O	NN

have	VB
O	NN

been	VBN
O	NN

estimated	VBN
O	NN

to	TO
O	NN

result	NN
O	NN

from	IN
O	NN

inheritance	NN
O	NN

of	IN
O	NN

mutated	VBN
O	NN

prostate	NN
O	NN

cancer	NN
O	NN

susceptibility	NN
O	NN

genes	NNS
O	NN

Few	JJ
O	NN

data	NNS
O	NN

exist	VB
O	NN

as	IN
O	NN

to	TO
O	NN

whether	IN
O	NN

there	RB
O	NN

are	VBP
O	NN

clinical	JJ
O	NN

differences	NNS
O	NN

between	IN
O	NN

prostate	NN
D	NN

cancers	NNS
D	NN

that	IN
O	NN

are	VBP
O	NN

inherited	VBN
O	NN

and	CC
O	NN

those	DT
O	NNP

that	IN
O	NN

occur	VB
O	NN

in	IN
O	NN

the	DT
O	NN

general	JJ
O	NN

population	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

investigate	VB
O	NN

phenotypic	JJ
O	NN

characteristics	NNS
O	NN

of	IN
O	NN

families	NNS
O	NN

potentially	RB
O	NN

linked	VBN
O	NN

to	TO
O	NN

the	DT
O	NN

hereditary	JJ
O	NN

prostate	NN
O	NN

cancer	NN
O	NN

1	CD
O	NN

(	NN
O	NN

HPC1	NN
O	NN

)	NN
O	NN

locus	NN
O	NN

on	IN
O	NN

chromosome	NN
O	NN

1q24-25	CD
O	NN

DESIGN	NN
O	NN

:	:
O	NN

Retrospective	JJ
O	NN

case	NN
O	NN

study	NN
O	NN

in	IN
O	NN

which	WDT
O	NN

clinical	JJ
O	NN

data	NNS
O	NN

were	VBD
O	NN

extracted	VBN
O	NN

from	IN
O	NN

medical	JJ
O	NN

and	CC
O	NN

pathological	JJ
O	NN

records	NNS
O	NN

FAMILIES	NNS
O	VBP

:	:
O	NN

A	DT
O	NN

total	JJ
O	NN

of	IN
O	NN

74	CD
O	NN

North	NNP
O	NNP

American	JJ
O	NN

families	NNS
O	NN

with	IN
O	NN

hereditary	JJ
O	NN

prostate	NN
D	NN

cancer	NN
D	NN

Prostate	NN
O	NN

cancer	NN
O	NN

cases	NNS
O	NN

from	IN
O	NN

the	DT
O	NN

National	NNP
O	NNP

Cancer	NN
O	NN

Data	NNS
O	NN

Base	NNP
O	NNP

were	VBD
O	NN

used	VBN
O	NN

as	IN
O	NN

a	DT
O	NN

reference	NN
O	NN

population	NN
O	NN

for	IN
O	NN

comparison	NN
O	NN

MAIN	JJS
O	NN

OUTCOME	NN
O	NN

MEASURES	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

families	NNS
O	NN

were	VBD
O	NN

divided	VBN
O	NN

into	IN
O	NN

2	CD
O	NN

groups	NNS
O	NN

:	:
O	NN

either	DT
O	NN

potentially	RB
O	NN

linked	VBN
O	NN

(	NN
O	NN

33	CD
O	NN

families	NNS
O	NN

with	IN
O	NN

133	CD
O	NN

men	NNS
O	NN

with	IN
O	NN

prostate	NN
D	NN

cancer	NN
D	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

thus	RB
O	NN

likely	JJ
O	NN

to	TO
O	NN

be	VB
O	NN

carrying	VBG
O	NN

an	DT
O	NN

altered	JJ
O	NN

HPC1	NN
O	NN

gene	NN
O	NN

,	,
O	NN

or	CC
O	NN

potentially	RB
O	NN

unlinked	JJ
O	NN

(	NN
O	NN

41	CD
O	NN

families	NNS
O	NN

with	IN
O	NN

172	CD
O	NN

men	NNS
O	NN

with	IN
O	NN

prostate	NN
D	NN

cancer	NN
D	NN

)	NN
O	NN

,	,
O	NN

on	IN
O	NN

the	DT
O	NN

basis	NN
O	NN

of	IN
O	NN

haplotype	NN
O	NN

analysis	NN
O	NN

in	IN
O	NN

the	DT
O	NN

region	NN
O	NN

of	IN
O	NN

HPC1	NN
O	NN

The	DT
O	NN

age	NN
O	NN

at	IN
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

prostate	NN
D	NN

cancer	NN
D	NN

,	,
O	NN

serum	NN
O	NN

prostate-specific	JJ
O	NN

antigen	NN
O	NN

levels	NNS
O	VBP

,	,
O	NN

digital	JJ
O	NN

rectal	JJ
O	NN

examination	NN
O	NN

status	NN
O	NN

,	,
O	NN

stage	NN
O	NN

,	,
O	NN

grade	NN
O	NN

,	,
O	NN

primary	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

prostate	NN
D	NN

cancers	NNS
D	NN

,	,
O	NN

and	CC
O	NN

occurrence	NN
O	NN

of	IN
O	NN

other	JJ
O	NN

cancers	NNS
D	NN

were	VBD
O	NN

compared	VBN
O	NN

between	IN
O	NN

the	DT
O	NN

groups	NNS
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

mean	VB
O	NN

age	NN
O	NN

at	IN
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

prostate	NN
D	NN

cancer	NN
D	NN

for	IN
O	NN

men	NNS
O	NN

in	IN
O	NN

potentially	RB
O	NN

linked	VBN
O	NN

families	NNS
O	NN

was	VBD
O	NN

significantly	RB
O	NN

lower	JJR
O	NN

than	IN
O	NN

for	IN
O	NN

men	NNS
O	NN

in	IN
O	NN

potentially	RB
O	NN

unlinked	JJ
O	NN

families	NNS
O	NN

(	NN
O	NN

63.7	CD
O	NN

vs	CC
O	NN

65.9	CD
O	NN

years	NNS
O	NN

,	,
O	NN

respectively	RB
O	NN

,	,
O	NN

P=.01	NN
O	NN

;	:
O	NN

mean	VB
O	NN

age	NN
O	NN

at	IN
O	NN

diagnosis	NN
O	NN

in	IN
O	NN

the	DT
O	NN

reference	NN
O	NN

population	NN
O	NN

was	VBD
O	NN

71.6	CD
O	NN

years	NNS
O	NN

)	NN
O	NN

Higher-grade	JJ
O	NN

cancers	NNS
D	NN

(	NN
O	NN

grade	NN
O	NN

3	CD
O	NN

)	NN
O	NN

were	VBD
O	NN

more	RBR
O	NN

common	JJ
O	NN

in	IN
O	NN

potentially	RB
O	NN

linked	VBN
O	NN

families	NNS
O	NN

,	,
O	NN

and	CC
O	NN

advanced-stage	JJ
O	NN

disease	NN
O	NN

was	VBD
O	NN

found	VBN
O	NN

in	IN
O	NN

41	CD
O	NN

%	NN
O	NN

of	IN
O	NN

the	DT
O	NN

case	NN
O	NN

patients	NNS
O	NN

in	IN
O	NN

potentially	RB
O	NN

linked	VBN
O	NN

families	NNS
O	NN

compared	VBN
O	NN

with	IN
O	NN

31	CD
O	NN

%	NN
O	NN

in	IN
O	NN

both	DT
O	NN

the	DT
O	NN

potentially	RB
O	NN

unlinked	JJ
O	NN

families	NNS
O	NN

and	CC
O	NN

the	DT
O	NN

reference	NN
O	NN

groups	NNS
O	NN

(	NN
O	NN

P=.03	NN
O	NN

for	IN
O	NN

the	DT
O	NN

latter	JJ
O	NN

comparison	NN
O	NN

)	NN
O	NN

In	IN
O	NN

the	DT
O	NN

other	JJ
O	NN

clinical	JJ
O	NN

parameters	NNS
O	VBP

,	,
O	NN

we	PRP
O	VBP

found	VBN
O	NN

no	DT
O	NN

significant	JJ
O	NN

differences	NNS
O	NN

between	IN
O	NN

the	DT
O	NN

groups	NNS
O	NN

A	DT
O	NN

modest	JJ
O	NN

excess	JJ
O	NN

of	IN
O	NN

breast	NN
D	NN

cancer	NN
D	NN

and	CC
O	NN

colon	NN
D	NN

cancer	NN
D	NN

was	VBD
O	NN

found	VBN
O	NN

in	IN
O	NN

potentially	RB
O	NN

linked	VBN
O	NN

families	NNS
O	NN

in	IN
O	NN

comparison	NN
O	NN

with	IN
O	NN

potentially	RB
O	NN

unlinked	JJ
O	NN

families	NNS
O	NN

,	,
O	NN

but	CC
O	NNP

this	DT
O	NN

difference	NN
O	NN

was	VBD
O	NN

not	RB
O	NN

statistically	RB
O	NN

significant	JJ
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Families	NNS
O	NN

that	IN
O	NN

provide	VB
O	NN

evidence	NN
O	NN

for	IN
O	NN

segregation	NN
O	NN

of	IN
O	NN

an	DT
O	NN

altered	JJ
O	NN

HPC1	NN
O	NN

gene	NN
O	NN

are	VBP
O	NN

characterized	VBN
O	NN

by	IN
O	NN

multiple	JJ
O	NN

cases	NNS
O	NN

of	IN
O	NN

prostate	NN
D	NN

cancer	NN
D	NN

that	IN
O	NN

,	,
O	NN

in	IN
O	NN

most	JJS
O	NN

respects	NNS
O	NN

,	,
O	NN

are	VBP
O	NN

indistinguishable	JJ
O	NN

from	IN
O	NN

nonhereditary	JJ
O	NN

cases	NNS
O	NN

However	RB
O	NN

,	,
O	NN

3	CD
O	NN

characteristics	NNS
O	NN

were	VBD
O	NN

observed	VBN
O	NN

:	:
O	NN

younger	JJR
O	NN

age	NN
O	NN

at	IN
O	NN

diagnosis	NN
O	NN

,	,
O	NN

higher-grade	JJ
O	NN

tumors	NNS
D	NN

,	,
O	NN

and	CC
O	NN

more	RBR
O	NN

advanced-stage	JJ
O	NN

disease	NN
O	NN

Our	PRP$
O	NN

study	NN
O	NN

shows	NNS
O	VBP

that	IN
O	NN

a	DT
O	NN

significant	JJ
O	NN

fraction	NN
O	NN

of	IN
O	NN

hereditary	JJ
O	NN

prostate	NN
D	NN

cancers	NNS
D	NN

are	VBP
O	NN

diagnosed	VBN
O	NN

in	IN
O	NN

advanced	JJ
O	NN

stages	NNS
O	NN

,	,
O	NN

emphasizing	VBG
O	NN

the	DT
O	NN

clinical	JJ
O	NN

importance	NN
O	NN

of	IN
O	NN

early	RB
O	NN

detection	NN
O	NN

in	IN
O	NN

men	NNS
O	NN

potentially	RB
O	NN

carrying	VBG
O	NN

prostate	NN
O	NN

cancer	NN
O	NN

susceptibility	NN
O	NN

genes	NNS
O	NN

These	DT
O	NN

findings	NNS
O	VBP

support	NN
O	NN

the	DT
O	NN

current	JJ
O	NN

recommendations	NNS
O	NN

to	TO
O	NN

screen	NN
O	NN

men	NNS
O	NN

with	IN
O	NN

a	DT
O	NN

positive	JJ
O	NN

family	NN
O	NN

history	NN
O	NN

of	IN
O	NN

prostate	NN
D	NN

cancer	NN
D	NN

beginning	VBG
O	NN

at	IN
O	NN

age	NN
O	NN

40	CD
O	NN

years	NNS
O	NN

CONTEXT	NN
O	NN

:	:
O	NN

Susceptibility	NN
O	NN

to	TO
O	NN

multiple	JJ
D	NN

sclerosis	NN
D	NN

(	NN
D	NN

MS	NN
D	NN

)	NN
D	NN

involves	VBZ
O	NN

a	DT
O	NN

genetically	RB
O	NN

complex	JJ
O	NN

autoimmune	JJ
O	NN

component	NN
O	NN

However	RB
O	NN

,	,
O	NN

except	IN
O	NN

for	IN
O	NN

genes	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

HLA	NN
O	NN

system	NN
O	NN

,	,
O	NN

specific	JJ
O	NN

susceptibility	NN
O	NN

loci	NNS
O	NN

are	VBP
O	NN

unknown	JJ
O	NN

or	CC
O	NN

unconfirmed	JJ
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

investigate	VB
O	NN

several	JJ
O	NN

loci	NNS
O	NN

spanning	VBG
O	NN

3	CD
O	NN

candidate	NN
O	NN

regions	NNS
O	NN

for	IN
O	NN

a	DT
O	NN

role	NN
O	NN

in	IN
O	NN

multiple	JJ
D	NN

sclerosis	NN
D	NN

(	NN
D	NN

MS	NN
D	NN

)	NN
D	NN

susceptibility	NN
O	NN

in	IN
O	NN

2	CD
O	NN

ethnic	JJ
O	NN

groups	NNS
O	NN

using	VBG
O	NN

both	DT
O	NN

single-locus	NN
O	NN

and	CC
O	NN

haplotype	NN
O	NN

analyses	NNS
O	VBP

The	DT
O	NN

3	CD
O	NN

regions	NNS
O	NN

include	VBP
O	NN

HLA	NN
O	NN

on	IN
O	NN

chromosome	NN
O	NN

6p21.3	JJ
O	NN

,	,
O	NN

APOE	NN
O	NN

on	IN
O	NN

chromosome	NN
O	NN

19ql	JJ
O	NN

3.2	CD
O	NN

,	,
O	NN

and	CC
O	NN

MBP	NN
O	NN

(	NN
O	NN

myelin	JJ
O	NN

basic	JJ
O	NN

protein	NN
O	NN

)	NN
O	NN

on	IN
O	NN

chromosome	NN
O	NN

18q23	NN
O	NN

DESIGN	NN
O	NN

:	:
O	NN

Case-control	JJ
O	NN

association	NN
O	NN

testing	NN
O	NN

SUBJECTS	NNS
O	NN

:	:
O	NN

A	DT
O	NN

total	JJ
O	NN

of	IN
O	NN

120	CD
O	NN

Caucasian	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

MS	NN
O	NN

and	CC
O	NN

107	CD
O	NN

unrelated	JJ
O	NN

control	NN
O	NN

individuals	NNS
O	VBP

from	IN
O	NN

California	NNP
O	NN

,	,
O	NN

and	CC
O	NN

32	CD
O	NN

patients	NNS
O	NN

and	CC
O	NN

32	CD
O	NN

unrelated	JJ
O	NN

control	NN
O	NN

individuals	NNS
O	VBP

from	IN
O	NN

Beijing	NNP
O	NNP

,	,
O	NN

China	NNP
O	NNP

All	DT
O	NN

patients	NNS
O	NN

with	IN
O	NN

MS	NN
O	NN

were	VBD
O	NN

diagnosed	VBN
O	NN

as	IN
O	NN

having	VBG
O	NN

clinically	RB
O	NN

definite	JJ
O	NN

disease	NN
O	NN

according	VBG
O	NN

to	TO
O	NN

published	VBN
O	NN

criteria	NNS
O	NN

MAIN	JJS
O	NN

OUTCOME	NN
O	NN

MEASURES	NNS
O	VBP

:	:
O	NN

Chi2	NN
O	NN

Testing	VBG
O	NN

of	IN
O	NN

loci	NNS
O	NN

and	CC
O	NN

individual	JJ
O	NN

alleles	NNS
O	NN

and	CC
O	NN

haplotypes	NNS
O	NN

Haplotype	NN
O	NN

frequencies	NNS
O	NN

were	VBD
O	NN

estimated	VBN
O	NN

with	IN
O	NN

standard	JJ
O	NN

maximum	NN
O	NN

likelihood	NN
O	NN

methods	NNS
O	VBP

RESULTS	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

HLA	NN
O	NN

effect	NN
O	NN

is	VBZ
O	NN

due	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

class	NN
O	NN

II	NNP
O	NNP

DR2	NN
O	NN

haplotype	NN
O	NN

,	,
O	NN

DRB1*1501-DQA1*0102-DRB1*0602	NN
O	NN

;	:
O	NN

contributions	NNS
O	NN

to	TO
O	NN

MS	NN
O	NN

susceptibility	NN
O	NN

from	IN
O	NN

additional	JJ
O	NN

DRB1-DQB1	NN
O	NN

alleles	NNS
O	NN

or	CC
O	NN

other	JJ
O	NN

HLA	NN
O	NN

region	NN
O	NN

loci	NNS
O	NN

were	VBD
O	NN

not	RB
O	NN

observed	VBN
O	NN

Variation	NN
O	NN

within	IN
O	NN

the	DT
O	NN

MBP	NN
O	NN

locus	NN
O	NN

on	IN
O	NN

chromosome	NN
O	NN

18q23	NN
O	NN

showed	VBD
O	NN

no	DT
O	NN

effect	NN
O	NN

in	IN
O	NN

MS	NN
O	NN

The	DT
O	NN

distribution	NN
O	NN

of	IN
O	NN

haplotypes	NNS
O	NN

from	IN
O	NN

5	CD
O	NN

loci	NNS
O	NN

within	IN
O	NN

the	DT
O	NN

chromosome	NN
O	NN

19q13.2	NN
O	NN

region	NN
O	NN

,	,
O	NN

including	VBG
O	NN

D19S178	NN
O	NN

,	,
O	NN

D19S574	NN
O	NN

,	,
O	NN

APOE	NN
O	NN

,	,
O	NN

APOC2	NN
O	NN

,	,
O	NN

and	CC
O	NN

D19S219	NN
O	NN

,	,
O	NN

differed	VBN
O	NN

between	IN
O	NN

patient	NN
O	NN

and	CC
O	NN

control	NN
O	NN

samples	NNS
O	NN

D19S574	NN
O	NN

showed	VBD
O	NN

a	DT
O	NN

significant	JJ
O	NN

effect	NN
O	NN

(	NN
O	NN

P=.015	NN
O	NN

)	NN
O	NN

in	IN
O	NN

Caucasian	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

MS	NN
O	NN

due	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

increased	VBN
O	NN

frequency	NN
O	NN

of	IN
O	NN

a	DT
O	NN

single	JJ
O	NN

allele	NN
O	NN

(	NN
O	NN

P=.002	NN
O	NN

)	NN
O	NN

The	DT
O	NN

APOE	NN
O	NN

variation	NN
O	NN

,	,
O	NN

prominent	JJ
O	NN

in	IN
O	NN

other	JJ
O	NN

neurological	JJ
O	NN

diseases	NNS
O	NN

,	,
O	NN

showed	VBD
O	NN

no	DT
O	NN

influence	NN
O	NN

on	IN
O	NN

MS	NN
O	NN

susceptibility	NN
O	NN

,	,
O	NN

despite	IN
O	NN

its	PRP$
O	NN

location	NN
O	NN

within	IN
O	NN

the	DT
O	NN

chromosome	NN
O	NN

19q13.2	NN
O	NN

region	NN
O	NN

Interaction	NN
O	NN

effects	NNS
O	NN

between	IN
O	NN

DR2	NN
O	NN

and	CC
O	NN

chromosome	NN
O	NN

19q13.2	NN
O	NN

or	CC
O	NN

MBP	NN
O	NN

in	IN
O	NN

MS	NN
O	NN

susceptibility	NN
O	NN

were	VBD
O	NN

not	RB
O	NN

apparent	JJ
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

The	DT
O	NN

significant	JJ
O	NN

chromosome	NN
O	NN

19q13.2	NN
O	NN

single-locus	NN
O	NN

and	CC
O	NN

multilocus	NN
O	NN

haplotype	NN
O	NN

associations	NNS
O	NN

with	IN
O	NN

MS	NN
O	NN

in	IN
O	NN

Caucasian	JJ
O	NN

and	CC
O	NN

Chinese	JJ
O	NN

patient	NN
O	NN

samples	NNS
O	NN

indicate	VBP
O	NN

an	DT
O	NN

effect	NN
O	NN

from	IN
O	NN

a	DT
O	NN

nearby	RB
O	NN

disease	NN
O	NN

susceptibility	NN
O	NN

locus	NN
O	NN

These	DT
O	NN

initial	JJ
O	NN

observations	NNS
O	NN

are	VBP
O	NN

an	DT
O	NN

encouraging	JJ
O	NN

step	NN
O	NN

toward	IN
O	NN

the	DT
O	NN

description	NN
O	NN

of	IN
O	NN

non-HLA	JJ
O	NN

genetic	JJ
O	NN

susceptibility	NN
O	NN

to	TO
O	NN

MS	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

CONTEXT	NN
O	NN

:	:
O	NN

There	EX
O	NN

is	VBZ
O	NN

a	DT
O	NN

substantial	JJ
O	NN

risk	NN
O	NN

of	IN
O	NN

a	DT
O	NN

second	JJ
O	NN

cancer	NN
O	NN

for	IN
O	NN

persons	NNS
O	VBP

with	IN
O	NN

hereditary	JJ
O	NN

retinoblastoma	NN
O	NN

,	,
O	NN

which	WDT
O	NN

is	VBZ
O	NN

enhanced	VBN
O	NN

by	IN
O	NN

radiotherapy	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

examine	VB
O	NN

long-term	JJ
O	NN

risk	NN
O	NN

of	IN
O	NN

new	JJ
O	NN

primary	JJ
O	NN

cancers	NNS
O	NN

in	IN
O	NN

survivors	NNS
O	NN

of	IN
O	NN

childhood	NN
O	NN

retinoblastoma	NN
O	NN

and	CC
O	NN

quantify	VB
O	NN

the	DT
O	NN

role	NN
O	NN

of	IN
O	NN

radiotherapy	NN
O	NN

in	IN
O	NN

sarcoma	NN
O	NN

development	NN
O	NN

DESIGN	NN
O	NN

:	:
O	NN

Cohort	NN
O	NN

incidence	NN
O	NN

study	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

retinoblastoma	NN
O	NN

followed	VBN
O	NN

for	IN
O	NN

a	DT
O	NN

median	JJ
O	NN

of	IN
O	NN

20	CD
O	NN

years	NNS
O	NN

,	,
O	NN

and	CC
O	NN

nested	JJ
O	NN

case-control	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

a	DT
O	NN

radiation	NN
O	NN

dose-response	JJ
O	NN

relationship	NN
O	NN

for	IN
O	NN

bone	NN
O	NN

and	CC
O	NN

soft	JJ
O	NN

tissue	NN
O	NN

sarcomas	NNS
O	NN

SETTING/PARTICIPANTS	NN
O	NN

:	:
O	NN

A	DT
O	NN

total	JJ
O	NN

of	IN
O	NN

1604	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

retinoblastoma	NN
D	NN

who	WP
O	VBP

survived	VBD
O	NN

at	IN
O	NN

least	JJS
O	NN

1	CD
O	NN

year	NN
O	NN

after	IN
O	NN

diagnosis	NN
O	NN

,	,
O	NN

identified	VBN
O	NN

from	IN
O	NN

hospital	NN
O	NN

records	NNS
O	NN

in	IN
O	NN

Massachusetts	NNP
O	NN

and	CC
O	NN

New	NNP
O	NNP

York	NNP
O	NN

during	IN
O	NN

1914	CD
O	NN

to	TO
O	NN

1984	CD
O	NNP

RESULTS	NNS
O	VBP

:	:
O	NN

Incidence	NN
O	NN

of	IN
O	NN

subsequent	JJ
O	NN

cancers	NNS
D	NN

was	VBD
O	NN

statistically	RB
O	NN

significantly	RB
O	NN

elevated	JJ
O	NN

only	RB
O	NN

in	IN
O	NN

the	DT
O	NN

961	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

hereditary	JJ
O	NN

retinoblastoma	NN
D	NN

,	,
O	NN

in	IN
O	NN

whom	WP
O	NN

190	CD
O	NN

cancers	NNS
D	NN

were	VBD
O	NN

diagnosed	VBN
O	NN

,	,
O	NN

vs	CC
O	NN

6.3	CD
O	NN

expected	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

general	JJ
O	NN

population	NN
O	NN

(	NN
O	NN

relative	JJ
O	NN

risk	NN
O	NN

(	NN
O	NN

RR	NN
O	NN

)	NN
O	NN

,	,
O	NN

30	CD
O	NN

(	NN
O	NN

95	CD
O	NN

%	NN
O	NN

confidence	NN
O	NN

interval	NN
O	NN

,	,
O	NN

26-47	CD
O	NN

)	NN
O	NN

)	NN
O	NN

Cumulative	JJ
O	NN

incidence	NN
O	NN

(	NN
O	NN

+/-SE	NN
O	NN

)	NN
O	NN

of	IN
O	NN

a	DT
O	NN

second	JJ
O	NN

cancer	NN
D	NN

at	IN
O	NN

50	CD
O	NN

years	NNS
O	NN

after	IN
O	NN

diagnosis	NN
O	NN

was	VBD
O	NN

51.0	CD
O	NN

%	NN
O	NN

(	NN
O	NN

+/-6.2	CD
O	NN

%	NN
O	NN

)	NN
O	NN

for	IN
O	NN

hereditary	JJ
O	NN

retinoblastoma	NN
D	NN

,	,
O	NN

and	CC
O	NN

5.0	CD
O	NN

%	NN
O	NN

(	NN
O	NN

+/-3.0	CD
O	NN

%	NN
O	NN

)	NN
O	NN

for	IN
O	NN

nonhereditary	JJ
O	NN

retinoblastoma	NN
D	NN

All	DT
O	NN

114	CD
O	NN

sarcomas	NNS
D	NN

of	IN
O	NN

diverse	JJ
O	NN

histologic	JJ
O	NN

types	NNS
O	NN

occurred	VBD
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

hereditary	JJ
O	NN

retinoblastoma	NN
D	NN

For	IN
O	NN

soft	JJ
O	NN

tissue	NN
O	NN

sarcomas	NNS
D	NN

,	,
O	NN

the	DT
O	NN

RRs	NNS
O	VBP

showed	VBD
O	NN

a	DT
O	NN

stepwise	JJ
O	NN

increase	NN
O	NN

at	IN
O	NN

all	DT
O	NN

dose	NN
O	NN

categories	NNS
O	VBP

,	,
O	NN

and	CC
O	NN

were	VBD
O	NN

statistically	RB
O	NN

significant	JJ
O	NN

at	IN
O	NN

10	CD
O	NN

to	TO
O	NN

29.9	CD
O	NN

Gy	NN
O	NN

and	CC
O	NN

30	CD
O	NN

to	TO
O	NN

59.9	CD
O	NN

Gy	NN
O	NN

A	DT
O	NN

radiation	NN
O	NN

risk	NN
O	NN

for	IN
O	NN

all	DT
O	NN

sarcomas	NNS
O	NN

combined	JJ
O	NN

was	VBD
O	NN

evident	JJ
O	NN

at	IN
O	NN

doses	NNS
O	NN

above	IN
O	NN

5	CD
O	NN

Gy	NN
O	NN

,	,
O	NN

rising	VBG
O	NN

to	TO
O	NN

10.7-fold	JJ
O	NN

at	IN
O	NN

doses	NNS
O	NN

of	IN
O	NN

60	CD
O	NN

Gy	NN
O	NN

or	CC
O	NN

greater	JJR
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

.05	CD
O	NN

)	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Genetic	JJ
O	NN

predisposition	NN
O	NN

has	VBZ
O	NN

a	DT
O	NN

substantial	JJ
O	NN

impact	NN
O	NN

on	IN
O	NN

risk	NN
O	NN

of	IN
O	NN

subsequent	JJ
D	NN

cancers	NNS
D	NN

in	IN
O	NN

retinoblastoma	NN
D	NN

patients	NNS
O	NN

,	,
O	NN

which	WDT
O	NN

is	VBZ
O	NN

further	RB
O	NN

increased	VBN
O	NN

by	IN
O	NN

radiation	NN
T	NN

treatment	NN
T	NN

A	DT
O	NN

radiation	NN
O	NN

dose-response	JJ
O	NN

relationship	NN
O	NN

is	VBZ
O	NN

demonstrated	VBD
O	NN

for	IN
O	NN

all	DT
O	NN

sarcomas	NNS
O	NN

and	CC
O	NN

,	,
O	NN

for	IN
O	NN

the	DT
O	NN

first	RB
O	NN

time	NN
O	NN

in	IN
O	NN

humans	NNS
O	NN

,	,
O	NN

for	IN
O	NN

soft	JJ
O	NN

tissue	NN
O	NN

sarcomas	NNS
O	NN

Retinoblastoma	NN
D	NN

patients	NNS
O	NN

should	MD
O	NNP

be	VB
O	NN

examined	VBN
O	NN

for	IN
O	NN

new	JJ
O	NN

cancers	NNS
D	NN

and	CC
O	NN

followed	VBN
O	NN

into	IN
O	NN

later	RB
O	NN

life	NN
O	NN

to	TO
O	NN

determine	VB
O	NN

whether	IN
O	NN

their	PRP$
O	NN

extraordinary	JJ
O	NN

cancer	NN
O	NN

risk	NN
O	NN

extends	VBZ
O	NN

to	TO
O	NN

common	JJ
O	NN

cancers	NNS
D	NN

of	IN
O	NN

adulthood	NN
O	NN

The	DT
O	NN

objective	JJ
O	NN

of	IN
O	NN

this	DT
O	NN

study	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

determine	VB
O	NN

the	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

recent	JJ
O	NN

cocaine	NN
O	NN

use	NN
O	NN

among	IN
O	NN

a	DT
O	NN

metropolitan	JJ
O	NN

population	NN
O	NN

of	IN
O	NN

predominantly	RB
O	NN

Hispanic	JJ
O	NN

and	CC
O	NN

African-American	JJ
O	NN

women	NNS
O	VBP

with	IN
O	NN

preterm	NN
O	NN

premature	JJ
D	NN

rupture	NN
D	NN

of	IN
D	NN

the	DT
D	NN

membranes	NNS
D	NN

(	NN
D	NN

PROM	NN
D	NN

)	NN
D	NN

and	CC
O	NN

to	TO
O	NN

ascertain	VB
O	NN

the	DT
O	NN

impact	NN
O	NN

of	IN
O	NN

cocaine	NN
O	NN

on	IN
O	NN

the	DT
O	NN

latency	NN
O	NN

period	NN
O	NN

between	IN
O	NN

rupture	NN
O	NN

of	IN
O	NN

membranes	NNS
O	NN

and	CC
O	NN

delivery	NN
O	NN

Urine	NN
O	NN

toxicology	NN
O	NN

screens	NNS
O	NN

were	VBD
O	NN

prospectively	RB
O	NN

obtained	VBN
O	NN

on	IN
O	NN

147	CD
O	NN

women	NNS
O	VBP

with	IN
O	NN

preterm	NN
D	NN

PROM	NN
D	NN

The	DT
O	NN

urine	NN
O	NN

screen	NN
O	NN

did	VBD
O	NNP

not	RB
O	NN

influence	NN
O	NN

management	NN
O	NN

decisions	NNS
O	VBP

All	DT
O	NN

women	NNS
O	VBP

were	VBD
O	NN

expectantly	RB
O	NN

managed	VBN
O	NN

without	IN
O	NN

tocolytics	NNS
O	NN

until	IN
O	NN

37	CD
O	NN

weeks	NNS
O	NN

'	POS
O	NN

gestation	JJ
O	NN

unless	IN
O	NN

they	PRP
O	VBP

developed	VBN
O	NN

clinical	JJ
O	NN

chorioamnionitis	NN
O	NN

,	,
O	NN

or	CC
O	NN

nonreassuring	JJ
O	NN

fetal	JJ
O	NN

heart	NN
O	NN

rate	NN
O	NN

tracing	VBG
O	NN

or	CC
O	NN

biophysical	JJ
O	NN

profile	NN
O	NN

Demographic	JJ
O	NN

information	NN
O	NN

,	,
O	NN

hours	NNS
O	NN

from	IN
O	NN

rupture	NN
O	NN

of	IN
O	NN

membranes	NNS
O	NN

to	TO
O	NN

delivery	NN
O	NN

,	,
O	NN

gestational	JJ
O	NN

age	NN
O	NN

,	,
O	NN

and	CC
O	NN

birth	NN
O	NN

weight	NN
O	NN

at	IN
O	NN

delivery	NN
O	NN

were	VBD
O	NN

compared	VBN
O	NN

using	VBG
O	NN

Fisher	NNP
O	NNP

's	POS
O	NN

exact	JJ
O	NN

,	,
O	NN

Mann-Whitney	JJ
O	NN

U	NNP
O	NNP

,	,
O	NN

and	CC
O	NN

randomization	NN
O	NN

tests	NNS
O	NN

where	WRB
O	NN

appropriate	JJ
O	NN

The	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

positive	JJ
O	NN

urine	NN
O	NN

drug	NN
O	NN

screens	NNS
O	NN

for	IN
O	NN

cocaine	NN
O	NN

was	VBD
O	NN

8.2	CD
O	NN

%	NN
O	NN

Women	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

cocaine	NN
O	NN

positive	JJ
O	NN

group	NN
O	NN

were	VBD
O	NN

of	IN
O	NN

higher	JJR
O	NN

parity	NN
O	NN

(	NN
O	NN

3	CD
O	NN

,	,
O	NN

(	NN
O	NN

0-7	CD
O	NN

)	NN
O	NN

vs.	CC
O	NN

1	CD
O	NN

,	,
O	NN

(	NN
O	NN

0-6	CD
O	NN

)	NN
O	NN

,	,
O	NN

p	NN
O	NN

=	JJ
O	NN

0.001	CD
O	NN

)	NN
O	NN

and	CC
O	NN

tended	VBD
O	NN

to	TO
O	NN

be	VB
O	NN

older	JJR
O	NN

(	NN
O	NN

27	CD
O	NN

,	,
O	NN

(	NN
O	NN

23-42	CD
O	NN

)	NN
O	NN

vs.	CC
O	NN

25	CD
O	NN

,	,
O	NN

(	NN
O	NN

14-40	CD
O	NN

)	NN
O	NN

)	NN
O	NN

There	EX
O	NN

was	VBD
O	NN

a	DT
O	NN

higher	JJR
O	NN

rate	NN
O	NN

of	IN
O	NN

recent	JJ
O	NN

cocaine	NN
O	NN

use	NN
O	NN

among	IN
O	NN

African-American	JJ
O	NN

women	NNS
O	VBP

(	NN
O	NN

20.4	CD
O	NN

%	NN
O	NN

)	NN
O	NN

as	IN
O	NN

compared	VBN
O	NN

to	TO
O	NN

non-African-Americans	NNS
O	VBP

(	NN
O	NN

1.2	CD
O	NN

%	NN
O	NN

,	,
O	NN

p	NN
O	NN

=	JJ
O	NN

0.0001	CD
O	NN

)	NN
O	NN

Cocaine-positive	JJ
O	NN

women	NNS
O	VBP

presented	VBN
O	NN

at	IN
O	NN

an	DT
O	NN

earlier	JJR
O	NN

gestational	JJ
O	NN

age	NN
O	NN

(	NN
O	NN

32	CD
O	NN

weeks	NNS
O	NN

'	POS
O	NN

,	,
O	NN

(	NN
O	NN

24-34	CD
O	NN

)	NN
O	NN

vs.	CC
O	NN

33	CD
O	NN

weeks	NNS
O	NN

'	POS
O	NN

,	,
O	NN

(	NN
O	NN

23-36	CD
O	NN

)	NN
O	NN

,	,
O	NN

p	NN
O	NN

=	JJ
O	NN

0.02	CD
O	NN

)	NN
O	NN

and	CC
O	NN

had	VBD
O	NN

a	DT
O	NN

significantly	RB
O	NN

longer	RB
O	NN

membrane	NN
O	NN

rupture	NN
O	NN

to	TO
O	NN

delivery	NN
O	NN

interval	NN
O	NN

than	IN
O	NN

women	NNS
O	VBP

with	IN
O	NN

a	DT
O	NN

negative	JJ
O	NN

urine	NN
O	NN

drug	NN
O	NN

screen	NN
O	NN

(	NN
O	NN

174	CD
O	NN

hr	NN
O	NN

,	,
O	NN

(	NN
O	NN

6-475	CD
O	NN

)	NN
O	NN

vs.	CC
O	NN

33	CD
O	NN

hours	NNS
O	NN

(	NN
O	NN

1-833	CD
O	NN

)	NN
O	NN

,	,
O	NN

p	NN
O	NN

=	JJ
O	NN

0.01	CD
O	NN

)	NN
O	NN

There	EX
O	NN

was	VBD
O	NN

no	DT
O	NN

significant	JJ
O	NN

difference	NN
O	NN

in	IN
O	NN

the	DT
O	NN

reason	NN
O	NN

for	IN
O	NN

delivery	NN
O	NN

between	IN
O	NN

the	DT
O	NN

two	CD
O	NN

groups	NNS
O	NN

of	IN
O	NN

patients	NNS
O	NN

Recent	JJ
O	NN

cocaine	NN
O	NN

use	NN
O	NN

among	IN
O	NN

women	NNS
O	VBP

with	IN
O	NN

preterm	NN
D	NN

PROM	NN
D	NN

is	VBZ
O	NN

common	JJ
O	NN

in	IN
O	NN

only	RB
O	NN

some	DT
O	NN

segments	NNS
O	NN

of	IN
O	NN

an	DT
O	NN

urban	JJ
O	NN

population	NN
O	NN

Women	NNS
O	VBP

with	IN
O	NN

recent	JJ
O	NN

cocaine	NN
O	NN

use	NN
O	NN

present	JJ
O	NN

with	IN
O	NN

ruptured	VBN
O	NN

membranes	NNS
O	NN

at	IN
O	NN

an	DT
O	NN

earlier	JJR
O	NN

gestational	JJ
O	NN

age	NN
O	NN

and	CC
O	NN

may	MD
O	NNP

actually	RB
O	NN

have	VB
O	NN

a	DT
O	NN

longer	RB
O	NN

latency	NN
O	NN

period	NN
O	NN

than	IN
O	NN

women	NNS
O	VBP

who	WP
O	VBP

do	VB
O	NNP

not	RB
O	NN

use	NN
O	NN

cocaine	NN
O	NN

The	DT
O	NN

objective	JJ
O	NN

of	IN
O	NN

this	DT
O	NN

article	NN
O	NN

is	VBZ
O	NN

to	TO
O	NN

explore	VB
O	NN

attitudes	NNS
O	NN

of	IN
O	NN

an	DT
O	NN

inner-city	JJ
O	NN

,	,
O	NN

pregnant	JJ
O	NN

cohort	NN
O	NN

about	IN
O	NN

general	JJ
O	NN

and	CC
O	NN

HIV-related	JJ
O	NN

prenatal	JJ
O	NN

care	NN
O	NN

Responses	NNS
O	NN

to	TO
O	NN

an	DT
O	NN

interview	NN
O	NN

at	IN
O	NN

initial	JJ
O	NN

prenatal	JJ
O	NN

care	NN
O	NN

enrollment	NN
O	NN

were	VBD
O	NN

compared	VBN
O	NN

using	VBG
O	NN

Chi-square	JJ
O	NN

and	CC
O	NN

Fisher	NNP
O	NNP

's	POS
O	NN

exact	JJ
O	NN

tests	NNS
O	NN

Of	IN
O	NN

75	CD
O	NN

women	NNS
O	VBP

,	,
O	NN

drug	NN
O	NN

users	NNS
O	VBP

(	NN
O	NN

51	CD
O	NN

%	NN
O	NN

)	NN
O	NN

were	VBD
O	NN

more	RBR
O	NN

likely	JJ
O	NN

to	TO
O	NN

say	VB
O	NN

that	IN
O	NN

they	PRP
O	VBP

would	MD
O	NNP

defer	VB
O	NNP

initiating	VBG
O	NN

prenatal	JJ
O	NN

care	NN
O	NN

(	NN
O	NN

P	NN
O	NN

=	JJ
O	NN

0.03	CD
O	NN

)	NN
O	NN

and	CC
O	NN

to	TO
O	NN

minimize	VB
O	NN

the	DT
O	NN

risk	NN
O	NN

of	IN
O	NN

drug	NN
O	NN

or	CC
O	NN

alcohol	NN
O	NN

use	NN
O	NN

to	TO
O	NN

the	DT
O	NN

fetus	NN
O	NN

(	NN
O	NN

P	NN
O	NN

=	JJ
O	NN

0.04	CD
O	NN

)	NN
O	NN

Most	JJS
O	NN

(	NN
O	NN

85	CD
O	NN

%	NN
O	NN

)	NN
O	NN

viewed	VBN
O	NN

pregnancy	NN
O	NN

as	IN
O	NN

inappropriate	JJ
O	NN

for	IN
O	NN

HIV	NN
D	NN

infected	JJ
O	NN

women	NNS
O	VBP

and	CC
O	NN

primarily	RB
O	NN

drug	NN
O	NN

users	NNS
O	VBP

(	NN
O	NN

P	NN
O	NN

=	JJ
O	NN

0.06	CD
O	NN

)	NN
O	NN

would	MD
O	NNP

abort	VB
O	NN

if	IN
O	NN

HIV	NN
D	NN

infected	JJ
O	NN

Over	IN
O	NN

half	DT
O	NN

thought	VBN
O	NN

HIV	NN
D	NN

transmission	NN
O	NN

occurred	VBD
O	NN

most	JJS
O	NN

times	NNS
O	NN

or	CC
O	NN

always	RB
O	NN

Only	RB
O	NN

20	CD
O	NN

%	NN
O	NN

had	VBD
O	NN

heard	VBN
O	NN

of	IN
O	NN

a	DT
O	NN

drug	NN
O	NN

to	TO
O	NN

reduce	VB
O	NN

this	DT
O	NN

risk	NN
O	NN

,	,
O	NN

but	CC
O	NNP

95	CD
O	NN

%	NN
O	NN

would	MD
O	NNP

take	VB
O	NN

such	JJ
O	NN

a	DT
O	NN

therapy	NN
O	NN

These	DT
O	NN

inner-city	JJ
O	NN

,	,
O	NN

pregnant	JJ
O	NN

women	NNS
O	VBP

disapproved	VBN
O	NN

of	IN
O	NN

pregnancy	NN
O	NN

if	IN
O	NN

HIV	NN
D	NN

infected	JJ
O	NN

and	CC
O	NN

thought	VBN
O	NN

the	DT
O	NN

risk	NN
O	NN

of	IN
O	NN

transmission	NN
O	NN

was	VBD
O	NN

high	JJ
O	NN

They	PRP
O	VBP

knew	VBD
O	NN

little	JJ
O	NN

of	IN
O	NN

how	WRB
O	NN

to	TO
O	NN

reduce	VB
O	NN

this	DT
O	NN

risk	NN
O	NN

but	CC
O	NNP

nearly	RB
O	NN

all	DT
O	NN

would	MD
O	NNP

accept	VB
O	NN

a	DT
O	NN

drug	NN
O	NN

to	TO
O	NN

prevent	VB
O	NN

transmission	NN
O	NN

The	DT
O	NN

association	NN
O	NN

of	IN
O	NN

parvovirus	NN
D	NN

B19	NN
D	NN

infection	NN
D	NN

and	CC
O	NN

hydrops	NN
D	NN

fetalis	NN
D	NN

is	VBZ
O	NN

well	RB
O	NN

known	JJ
O	NN

However	RB
O	NN

,	,
O	NN

the	DT
O	NN

association	NN
O	NN

of	IN
O	NN

parvovirus	NN
D	NN

and	CC
O	NN

fetal	JJ
O	NN

pleural	JJ
O	NN

or	CC
O	NN

pericardial	JJ
D	NN

effusions	NNS
D	NN

has	VBZ
O	NN

not	RB
O	NN

been	VBN
O	NN

reported	VBN
O	NN

We	PRP
O	VBP

present	JJ
O	NN

five	CD
O	NN

cases	NNS
O	NN

of	IN
O	NN

isolated	VBN
O	NN

pleural	JJ
O	NN

or	CC
O	NN

pericardial	JJ
D	NN

effusion	NN
D	NN

with	IN
O	NN

documented	VBN
O	NN

maternal	JJ
O	NN

parvovirus	NN
D	NN

infection	NN
D	NN

in	IN
O	NN

four	CD
O	NN

of	IN
O	NN

these	DT
O	NN

pregnancies	NNS
O	NN

In	IN
O	NN

the	DT
O	NN

absence	NN
O	NN

of	IN
O	NN

structural	JJ
O	NN

or	CC
O	NN

karyotypic	JJ
O	NN

abnormalities	NNS
O	NN

,	,
O	NN

spontaneous	JJ
O	NN

resolution	NN
O	NN

of	IN
O	NN

the	DT
O	NN

effusion	NN
O	NN

portends	VBZ
O	NN

for	IN
O	NN

a	DT
O	NN

successful	JJ
O	NN

pregnancy	NN
O	NN

outcome	NN
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Cochlear	JJ
T	NN

implantation	NN
T	NN

is	VBZ
O	NN

nowadays	RB
O	NN

a	DT
O	NN

reliable	JJ
O	NN

and	CC
O	NN

well-accepted	JJ
O	NN

method	NN
O	NN

of	IN
O	NN

auditory	JJ
O	NN

rehabilitation	NN
O	NN

in	IN
O	NN

selected	VBN
O	NN

adults	NNS
O	NN

and	CC
O	NN

children	NNS
O	VBP

METHODS	NNS
O	VBP

:	:
O	NN

We	PRP
O	VBP

present	JJ
O	NN

rehabilitation	NN
O	NN

data	NNS
O	NN

on	IN
O	NN

21	CD
O	NN

adult	JJ
O	NN

patients	NNS
O	NN

provided	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

Nucleus	NN
O	NN

CI22	NN
O	NN

M	NN
O	NN

cochlear	JJ
O	NN

implant	VB
O	NN

using	VBG
O	NN

the	DT
O	NN

SPEAK	VB
O	NN

strategy	NN
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Results	NNS
O	NN

of	IN
O	NN

first	RB
O	NN

tune-up	NN
O	NN

show	NN
O	NN

an	DT
O	NN

open	JJ
O	NN

set	VBN
O	NN

speech	NN
O	NN

understanding	VBG
O	NN

in	IN
O	NN

approximately	RB
O	NN

50	CD
O	NN

%	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

Long-term	JJ
O	NN

results	NNS
O	VBP

also	RB
O	NN

reveal	VB
O	NN

further	RB
O	NN

improvement	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

who	WP
O	VBP

had	VBD
O	NN

no	DT
O	NN

open	JJ
O	NN

set	VBN
O	NN

speech	NN
O	NN

understanding	VBG
O	NN

Our	PRP$
O	NN

data	NNS
O	NN

seem	VB
O	NN

to	TO
O	NN

indicate	VBP
O	NN

similar	JJ
O	NN

results	NNS
O	VBP

in	IN
O	NN

comparison	NN
O	NN

to	TO
O	NN

other	JJ
O	NN

groups	NNS
O	NN

using	VBG
O	NN

the	DT
O	NN

CIS	NN
O	NN

strategy	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

In	IN
O	NN

adults	NNS
O	NN

,	,
O	NN

open	JJ
O	NN

set	VBN
O	NN

speech	NN
O	NN

understanding	VBG
O	NN

can	MD
O	NNP

be	VB
O	NN

achieved	VBN
O	NN

even	RB
O	NN

at	IN
O	NN

the	DT
O	NN

first	RB
O	NN

tune-up	NN
O	NN

Results	NNS
O	NN

of	IN
O	NN

early	RB
O	NN

rehabilitation	NN
O	NN

seem	VB
O	NN

to	TO
O	NN

be	VB
O	NN

influenced	VBN
O	NN

by	IN
O	NN

duration	NN
O	NN

and	CC
O	NN

etiology	NN
O	NN

of	IN
O	NN

deafness	NN
D	NN

,	,
O	NN

experience	NN
O	NN

with	IN
O	NN

hearing	VBG
O	NN

aids	NNS
O	NN

,	,
O	NN

and	CC
O	NN

other	JJ
O	NN

factors	NNS
O	NN

Adverse	JJ
O	NN

drug	NN
O	NN

effects	NNS
O	NN

are	VBP
O	NN

manifold	NN
O	NN

and	CC
O	NN

heterogenous	JJ
O	NN

Many	JJ
O	NN

situations	NNS
O	VBP

may	MD
O	NNP

hamper	VB
O	NN

the	DT
O	NN

signalling	NN
O	NN

(	NN
O	NN

i.e	NN
O	NN

.	.
O	NN

the	DT
O	NN

detection	NN
O	NN

of	IN
O	NN

early	RB
O	NN

warning	VBG
O	NN

signs	NNS
O	IN

)	NN
O	NN

of	IN
O	NN

adverse	JJ
O	NN

effects	NNS
O	NN

and	CC
O	NN

new	JJ
O	NN

signals	NNS
O	VBP

often	RB
O	NN

differ	VBP
O	NN

from	IN
O	NN

previous	JJ
O	NN

experiences	NNS
O	NN

Signals	NNS
O	NN

have	VB
O	NN

qualitative	JJ
O	NN

and	CC
O	NN

quantitative	JJ
O	NN

aspects	NNS
O	NN

Different	JJ
O	NN

categories	NNS
O	VBP

of	IN
O	NN

adverse	JJ
O	NN

effects	NNS
O	NN

need	NN
O	NN

different	JJ
O	NN

methods	NNS
O	VBP

for	IN
O	NN

detection	NN
O	NN

Current	JJ
O	NN

pharmacovigilance	NN
O	NN

is	VBZ
O	NN

predominantly	RB
O	NN

based	VBN
O	NN

on	IN
O	NN

spontaneous	JJ
O	NN

reporting	VBG
O	NN

and	CC
O	NN

is	VBZ
O	NN

mainly	RB
O	NN

helpful	JJ
O	NN

in	IN
O	NN

detecting	VBG
O	NN

type	NN
O	NN

B	NN
O	NN

effects	NNS
O	NN

(	NN
O	NN

those	DT
O	NNP

effects	NNS
O	NN

that	IN
O	NN

are	VBP
O	NN

often	RB
O	NN

allergic	JJ
O	NN

or	CC
O	NN

idiosyncratic	JJ
O	NN

reactions	NNS
O	NN

,	,
O	NN

characteristically	RB
O	NN

occurring	VBG
O	NN

in	IN
O	NN

only	RB
O	NN

a	DT
O	NN

minority	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

and	CC
O	NN

usually	RB
O	NN

unrelated	JJ
O	NN

to	TO
O	NN

dosage	NN
O	NN

and	CC
O	NN

that	IN
O	NN

are	VBP
O	NN

serious	JJ
O	NN

,	,
O	NN

unexpected	JJ
O	NN

and	CC
O	NN

unpredictable	JJ
O	NN

)	NN
O	NN

and	CC
O	NN

unusual	JJ
O	NN

type	NN
O	NN

A	DT
O	NN

effects	NNS
O	NN

(	NN
O	NN

those	DT
O	NNP

effects	NNS
O	NN

that	IN
O	NN

are	VBP
O	NN

related	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

pharmacological	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

drug	NN
O	NN

and	CC
O	NN

are	VBP
O	NN

dosage-related	JJ
O	NN

)	NN
O	NN

Examples	NNS
O	NN

of	IN
O	NN

other	JJ
O	NN

sources	NNS
O	NN

of	IN
O	NN

signals	NNS
O	VBP

are	VBP
O	NN

prescription	NN
O	NN

event	NN
O	NN

monitoring	VBG
O	NN

,	,
O	NN

large	JJ
O	NN

automated	VBN
O	NN

data	NNS
O	NN

resources	NNS
O	NN

on	IN
O	NN

morbidity	NN
O	NN

and	CC
O	NN

drug	NN
O	NN

use	NN
O	NN

(	NN
O	NN

including	VBG
O	NN

record	NN
O	NN

linkage	NN
O	NN

)	NN
O	NN

,	,
O	NN

case-control	JJ
O	NN

surveillance	NN
O	NN

and	CC
O	NN

follow-up	JJ
O	NN

studies	NNS
O	VBP

Type	NN
O	NN

C	NN
O	NN

effects	NNS
O	NN

(	NN
O	NN

those	DT
O	NNP

effects	NNS
O	NN

related	JJ
O	NN

to	TO
O	NN

an	DT
O	NN

increased	VBN
O	NN

frequency	NN
O	NN

of	IN
O	NN

'spontaneous	JJ
O	NN

'	POS
O	NN

disease	NN
O	NN

)	NN
O	NN

are	VBP
O	NN

difficult	JJ
O	NN

to	TO
O	NN

study	NN
O	NN

,	,
O	NN

however	RB
O	NN

,	,
O	NN

and	CC
O	NN

continue	VB
O	NN

to	TO
O	NN

pose	VB
O	NN

a	DT
O	NN

pharmacoepidemiological	JJ
O	NN

challenge	NN
O	NN

Seven	CD
O	NN

basic	JJ
O	NN

considerations	NNS
O	VBP

can	MD
O	NNP

be	VB
O	NN

identified	VBN
O	NN

that	IN
O	NN

determine	VB
O	NN

the	DT
O	NN

evidence	NN
O	NN

contained	VBN
O	NN

in	IN
O	NN

a	DT
O	NN

signal	NN
O	NN

:	:
O	NN

quantitative	JJ
O	NN

strength	NN
O	NN

of	IN
O	NN

the	DT
O	NN

association	NN
O	NN

,	,
O	NN

consistency	NN
O	NN

of	IN
O	NN

the	DT
O	NN

data	NNS
O	NN

,	,
O	NN

exposure	NN
O	NN

response	NN
O	NN

relationship	NN
O	NN

,	,
O	NN

biological	JJ
O	NN

plausibility	NN
O	NN

,	,
O	NN

experimental	JJ
O	NN

findings	NNS
O	VBP

,	,
O	NN

possible	JJ
O	NN

analogies	NNS
O	NN

and	CC
O	NN

the	DT
O	NN

nature	NN
O	NN

and	CC
O	NN

quality	NN
O	NN

of	IN
O	NN

the	DT
O	NN

data	NNS
O	NN

A	DT
O	NN

proposal	NN
O	NN

is	VBZ
O	NN

made	VBN
O	NN

for	IN
O	NN

a	DT
O	NN

standard	JJ
O	NN

signal	NN
O	NN

management	NN
O	NN

procedure	NN
O	NN

at	IN
O	NN

pharmacovigilance	NN
O	NN

centres	NNS
O	NN

,	,
O	NN

including	VBG
O	NN

the	DT
O	NN

following	VBG
O	NN

steps	NNS
O	NN

:	:
O	NN

signal	NN
O	NN

delineation	NN
O	NN

,	,
O	NN

literature	NN
O	NN

search	NN
O	NN

,	,
O	NN

preliminary	JJ
O	NN

inventory	NN
O	NN

of	IN
O	NN

data	NNS
O	NN

,	,
O	NN

collection	NN
O	NN

of	IN
O	NN

additional	JJ
O	NN

information	NN
O	NN

,	,
O	NN

consultation	NN
O	NN

with	IN
O	NN

the	DT
O	NN

World	NNP
O	NNP

Health	NNP
O	NNP

Organization	NNP
O	NNP

Centre	NNP
O	NNP

for	IN
O	NN

International	NNP
O	NNP

Drug	NN
O	NN

Monitoring	VBG
O	NN

and	CC
O	NN

the	DT
O	NN

relevant	JJ
O	NN

drug	NN
O	NN

companies	NNS
O	VBP

,	,
O	NN

aggregated	JJ
O	NN

data	NNS
O	NN

assessment	NN
O	NN

and	CC
O	NN

a	DT
O	NN

report	NN
O	NN

in	IN
O	NN

writing	VBG
O	NN

A	DT
O	NN

better	JJR
O	NN

understanding	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

conditions	NNS
O	VBP

and	CC
O	NN

mechanisms	NNS
O	VBP

involved	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

detection	NN
O	NN

of	IN
O	NN

adverse	JJ
O	NN

drug	NN
O	NN

effects	NNS
O	NN

may	MD
O	NNP

further	RB
O	NN

improve	VB
O	NN

strategies	NNS
O	VBP

for	IN
O	NN

pharmacovigilance	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

study	NN
O	NN

the	DT
O	NN

safety	NN
O	NN

and	CC
O	NN

efficacy	NN
O	NN

of	IN
O	NN

methylphenidate	NN
T	NN

in	IN
O	NN

children	NNS
O	VBP

with	IN
O	NN

the	DT
O	NN

dual	JJ
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

epilepsy	NN
D	NN

and	CC
O	NN

attention	NN
D	NN

deficit	NN
D	NN

hyperactivity	NN
D	NN

disorder	NN
D	NN

(	NN
D	NN

ADHD	NN
D	NN

)	NN
D	NN

STUDY	NN
O	NN

DESIGN	NN
O	NN

:	:
O	NN

Thirty	CD
O	NN

children	NNS
O	VBP

,	,
O	NN

aged	JJ
O	NN

6.4	CD
O	NN

to	TO
O	NN

16.4	CD
O	NN

years	NNS
O	NN

,	,
O	NN

with	IN
O	NN

epilepsy	NN
D	NN

and	CC
O	NN

ADHD	NN
D	NN

were	VBD
O	NN

studied	VBN
O	NN

during	IN
O	NN

a	DT
O	NN

4-month	JJ
O	NN

period	NN
O	NN

During	IN
O	NN

the	DT
O	NN

initial	JJ
O	NN

2	CD
O	NN

months	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

study	NN
O	NN

,	,
O	NN

the	DT
O	NN

children	NNS
O	VBP

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

antiepileptic	JJ
T	NN

drugs	NNS
T	NN

(	NN
T	NN

AEDs	NNS
T	NN

)	NN
T	NN

only	RB
O	NN

,	,
O	NN

and	CC
O	NN

for	IN
O	NN

the	DT
O	NN

remaining	VBG
O	NN

2	CD
O	NN

months	NNS
O	NN

,	,
O	NN

methylphenidate	NN
T	NN

was	VBD
O	NN

added	VBN
O	NN

at	IN
O	NN

a	DT
O	NN

morning	NN
O	NN

dose	NN
O	NN

of	IN
O	NN

0.3	CD
O	NN

mg/kg	NN
O	NN

They	PRP
O	VBP

underwent	VBD
O	NN

neurologic	JJ
O	NN

assessment	NN
O	NN

,	,
O	NN

brain	NN
O	NN

computed	VBN
O	NN

tomography	NN
O	NN

,	,
O	NN

IQ	NNP
O	NNP

testing	NN
O	NN

,	,
O	NN

and	CC
O	NN

assessment	NN
O	NN

with	IN
O	NN

the	DT
O	NN

Childhood	NN
O	NN

Behavior	NN
O	NN

Checklist	NNP
O	NN

at	IN
O	NN

baseline	NN
O	NN

before	IN
O	NN

methylphenidate	NN
T	NN

therapy	NN
T	NN

Electroencephalography	NN
O	NN

,	,
O	NN

AED	NN
O	NN

determinations	NNS
O	VBP

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

continuous-performance	NN
O	NN

task	NN
O	NN

(	NN
O	NN

CPT	NNP
O	NNP

)	NN
O	NN

test	NN
O	NN

were	VBD
O	NN

done	VBN
O	NN

at	IN
O	NN

baseline	NN
O	NN

and	CC
O	NN

after	IN
O	NN

2	CD
O	NN

months	NNS
O	NN

of	IN
O	NN

methylphenidate	NN
O	NN

therapy	NN
O	NN

A	DT
O	NN

double-blind	JJ
O	NN

,	,
O	NN

crossover	NN
O	NN

design	NN
O	NN

was	VBD
O	NN

used	VBN
O	NN

to	TO
O	NN

compare	VB
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

methylphenidate	NN
T	NN

versus	CC
O	NN

placebo	NN
O	NN

on	IN
O	NN

an	DT
O	NN

electroencephalogram	NN
O	NN

,	,
O	NN

AED	NN
O	NN

levels	NNS
O	VBP

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

CPT	NNP
O	NNP

On	IN
O	NN

the	DT
O	NN

2	CD
O	NN

days	NNS
O	NN

of	IN
O	NN

testing	NN
O	NN

,	,
O	NN

the	DT
O	NN

child	NN
O	NN

received	VBN
O	NN

AEDs	NNS
T	NN

and	CC
O	NN

a	DT
O	NN

capsule	NN
O	NN

containing	VBG
O	NN

either	DT
O	NN

placebo	NN
O	NN

or	CC
O	NN

methylphenidate	NN
T	NN

RESULTS	NNS
O	VBP

:	:
O	NN

None	NN
O	NN

of	IN
O	NN

the	DT
O	NN

25	CD
O	NN

children	NNS
O	VBP

of	IN
O	NN

this	DT
O	NN

sample	NN
O	NN

who	WP
O	VBP

were	VBD
O	NN

seizure	NN
O	NN

free	JJ
O	NN

had	VBD
O	NN

attacks	NNS
O	NN

while	IN
O	NN

taking	VBG
O	NN

methylphenidate	NN
O	NN

Of	IN
O	NN

the	DT
O	NN

5	CD
O	NN

children	NNS
O	VBP

with	IN
O	NN

seizures	NNS
D	NN

,	,
O	NN

3	CD
O	NN

had	VBD
O	NN

an	DT
O	NN

increase	NN
O	NN

in	IN
O	NN

attacks	NNS
O	NN

,	,
O	NN

whereas	IN
O	NN

the	DT
O	NN

other	JJ
O	NN

2	CD
O	NN

showed	VBD
O	NN

no	DT
O	NN

change	NN
O	NN

or	CC
O	NN

a	DT
O	NN

reduction	NN
O	NN

There	EX
O	NN

were	VBD
O	NN

no	DT
O	NN

significant	JJ
O	NN

changes	NNS
O	VBP

in	IN
O	NN

AED	NN
O	NN

levels	NNS
O	VBP

or	CC
O	NN

electroencephalographic	JJ
O	NN

findings	NNS
O	VBP

Methylphenidate	NNP
T	NN

benefited	VBD
O	NN

70	CD
O	NN

%	NN
O	NN

of	IN
O	NN

children	NNS
O	VBP

according	VBG
O	NN

to	TO
O	NN

parental	JJ
O	NN

report	NN
O	NN

;	:
O	NN

methylphenidate	NN
T	NN

also	RB
O	NN

enhanced	VBN
O	NN

performance	NN
O	NN

on	IN
O	NN

the	DT
O	NN

CPT	NNP
O	NNP

Side	NN
O	NN

effects	NNS
O	NN

of	IN
O	NN

methylphenidate	NN
T	NN

were	VBD
O	NN

mild	JJ
O	NN

and	CC
O	NN

transient	JJ
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

Methylphenidate	NNP
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

in	IN
O	NN

treating	VBG
O	NN

children	NNS
O	VBP

with	IN
O	NN

epilepsy	NN
D	NN

and	CC
O	NN

ADHD	NN
D	NN

and	CC
O	NN

safe	JJ
O	NN

in	IN
O	NN

children	NNS
O	VBP

who	WP
O	VBP

are	VBP
O	NN

seizure	NN
O	NN

free	JJ
O	NN

Caution	NN
O	NN

is	VBZ
O	NN

warranted	VBN
O	NN

for	IN
O	NN

those	DT
O	NNP

still	RB
O	NN

having	VBG
O	NN

seizures	NNS
O	NN

while	IN
O	NN

receiving	VBG
O	NN

AED	NN
O	NN

therapy	NN
O	NN

The	DT
O	NN

temporal	JJ
O	NN

properties	NNS
O	NN

of	IN
O	NN

semantic	JJ
O	NN

and	CC
O	NN

phonological	JJ
O	NN

processes	NNS
O	VBP

in	IN
O	NN

speech	NN
O	NN

production	NN
O	NN

were	VBD
O	NN

investigated	VBN
O	NN

in	IN
O	NN

a	DT
O	NN

new	JJ
O	NN

experimental	JJ
O	NN

paradigm	NN
O	NN

using	VBG
O	NN

movement-related	JJ
O	NN

brain	NN
O	NN

potentials	NNS
O	VBP

The	DT
O	NN

main	JJ
O	NN

experimental	JJ
O	NN

task	NN
O	NN

was	VBD
O	NN

picture	NN
O	NN

naming	VBG
O	NN

In	IN
O	NN

addition	NN
O	NN

,	,
O	NN

a	DT
O	NN

2-choice	JJ
O	NN

reaction	NN
O	NN

go/no-go	NN
O	NN

procedure	NN
O	NN

was	VBD
O	NN

included	VBN
O	NN

,	,
O	NN

involving	VBG
O	NN

a	DT
O	NN

semantic	JJ
O	NN

and	CC
O	NN

a	DT
O	NN

phonological	JJ
O	NN

categorization	NN
O	NN

of	IN
O	NN

the	DT
O	NN

picture	NN
O	NN

name	NN
O	NN

Lateralized	VBN
O	NN

readiness	NN
O	NN

potentials	NNS
O	VBP

(	NN
O	NN

LRPs	NNS
O	NN

)	NN
O	NN

were	VBD
O	NN

derived	VBN
O	NN

to	TO
O	NN

test	NN
O	NN

whether	IN
O	NN

semantic	JJ
O	NN

and	CC
O	NN

phonological	JJ
O	NN

information	NN
O	NN

activated	VBN
O	NN

motor	NN
O	NN

processes	NNS
O	VBP

at	IN
O	NN

separate	JJ
O	NN

moments	NNS
O	NN

in	IN
O	NN

time	NN
O	NN

An	DT
O	NN

LRP	NN
O	NN

was	VBD
O	NN

only	RB
O	NN

observed	VBN
O	NN

on	IN
O	NN

no-go	JJ
O	NN

trials	NNS
O	NN

when	WRB
O	NN

the	DT
O	NN

semantic	JJ
O	NN

(	NN
O	NN

not	RB
O	NN

the	DT
O	NN

phonological	JJ
O	NN

)	NN
O	NN

decision	NN
O	NN

determined	VBN
O	NN

the	DT
O	NN

response	NN
O	NN

hand	NN
O	NN

Varying	JJ
O	NN

the	DT
O	NN

position	NN
O	NN

of	IN
O	NN

the	DT
O	NN

critical	JJ
O	NN

phoneme	NN
O	NN

in	IN
O	NN

the	DT
O	NN

picture	NN
O	NN

name	NN
O	NN

did	VBD
O	NNP

not	RB
O	NN

affect	VB
O	NN

the	DT
O	NN

onset	NN
O	NN

of	IN
O	NN

the	DT
O	NN

LRP	NN
O	NN

but	CC
O	NNP

rather	RB
O	NN

influenced	VBN
O	NN

when	WRB
O	NN

the	DT
O	NN

LRP	NN
O	NN

began	VBD
O	NN

to	TO
O	NN

differ	VBP
O	NN

on	IN
O	NN

go	VB
O	NN

and	CC
O	NN

no-go	JJ
O	NN

trials	NNS
O	NN

and	CC
O	NN

allowed	VBN
O	NN

the	DT
O	NN

duration	NN
O	NN

of	IN
O	NN

phonological	JJ
O	NN

encoding	VBG
O	NN

of	IN
O	NN

a	DT
O	NN

word	NN
O	NN

to	TO
O	NN

be	VB
O	NN

estimated	VBN
O	NN

These	DT
O	NN

results	NNS
O	VBP

provide	VB
O	NN

electrophysiological	JJ
O	NN

evidence	NN
O	NN

for	IN
O	NN

early	RB
O	NN

semantic	JJ
O	NN

activation	NN
O	NN

and	CC
O	NN

later	RB
O	NN

phonological	JJ
O	NN

encoding	VBG
O	NN

The	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

alanine	NN
O	NN

and	CC
O	NN

glycine	NN
O	NN

substitution	NN
O	NN

for	IN
O	NN

tryptophan	NN
O	NN

upon	IN
O	NN

the	DT
O	NN

species	NNS
O	NN

heterogeneity	NN
O	NN

of	IN
O	NN

gramicidin	NN
O	NN

A	DT
O	NN

analogs	NNS
O	NN

incorporated	VBN
O	NN

into	IN
O	NN

SDS	NN
O	NN

micelles	NNS
O	NN

have	VB
O	NN

been	VBN
O	NN

investigated	VBN
O	NN

The	DT
O	NN

sequential	JJ
O	NN

replacement	NN
O	NN

of	IN
O	NN

the	DT
O	NN

four	CD
O	NN

tryptophan	NN
O	NN

residues	NNS
O	NN

in	IN
O	NN

gramicidin	NN
O	NN

A	DT
O	NN

at	IN
O	NN

positions	NNS
O	NN

15	CD
O	NN

,	,
O	NN

13	CD
O	NN

,	,
O	NN

11	CD
O	NN

,	,
O	NN

and	CC
O	NN

9	CD
O	NN

with	IN
O	NN

glycine	NN
O	NN

showed	VBD
O	NN

that	IN
O	NN

there	RB
O	NN

was	VBD
O	NN

no	DT
O	NN

detectable	JJ
O	NN

effect	NN
O	NN

at	IN
O	NN

position	NN
O	NN

15	CD
O	NN

but	CC
O	NNP

increasing	VBG
O	NN

heterogeneity	NN
O	NN

of	IN
O	NN

species	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

micelles	NNS
O	NN

proceeding	VBG
O	NN

toward	IN
O	NN

the	DT
O	NN

interior	JJ
O	NN

of	IN
O	NN

the	DT
O	NN

micelle	NN
O	NN

at	IN
O	NN

position	NN
O	NN

9	CD
O	NN

The	DT
O	NN

replacement	NN
O	NN

of	IN
O	NN

tryptophan	NN
O	NN

at	IN
O	NN

positions	NNS
O	NN

15	CD
O	NN

and	CC
O	NN

9	CD
O	NN

with	IN
O	NN

alanine	NN
O	NN

was	VBD
O	NN

found	VBN
O	NN

to	TO
O	NN

produce	VB
O	NN

more	RBR
O	NN

species	NNS
O	NN

heterogeneity	NN
O	NN

than	IN
O	NN

found	VBN
O	NN

with	IN
O	NN

glycine	NN
O	NN

substitution	NN
O	NN

at	IN
O	NN

the	DT
O	NN

same	JJ
O	NN

positions	NNS
O	NN

An	DT
O	NN

increase	NN
O	NN

in	IN
O	NN

the	DT
O	NN

SDS	NN
O	NN

concentration	NN
O	NN

reduces	VBZ
O	NN

the	DT
O	NN

number	NN
O	NN

of	IN
O	NN

different	JJ
O	NN

species	NNS
O	NN

present	JJ
O	NN

in	IN
O	NN

micelles	NNS
O	NN

With	IN
O	NN

the	DT
O	NN

Gly-11	NN
O	NN

,	,
O	NN

Gly-13	NN
O	NN

,	,
O	NN

and	CC
O	NN

Gly-15	NN
O	NN

analogs	NNS
O	NN

,	,
O	NN

the	DT
O	NN

increase	NN
O	NN

in	IN
O	NN

SDS	NN
O	NN

concentration	NN
O	NN

results	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

formation	NN
O	NN

of	IN
O	NN

a	DT
O	NN

single	JJ
O	NN

species	NNS
O	NN

;	:
O	NN

however	RB
O	NN

,	,
O	NN

for	IN
O	NN

the	DT
O	NN

Gly-9	NN
O	NN

,	,
O	NN

Ala-9	NN
O	NN

,	,
O	NN

and	CC
O	NN

Ala-15	NN
O	NN

analogs	NNS
O	NN

,	,
O	NN

heterogeneity	NN
O	NN

remains	VBZ
O	NNP

Molecular	JJ
O	NN

dynamics	NNS
O	NN

in	IN
O	NN

torsion-angle	JJ
O	NN

space	NN
O	NN

was	VBD
O	NN

applied	VBN
O	NN

to	TO
O	NN

nuclear	JJ
O	NN

magnetic	JJ
O	NN

resonance	NN
O	NN

structure	NN
O	NN

calculation	NN
O	NN

using	VBG
O	NN

nuclear	JJ
O	NN

Overhauser	NNP
O	NNP

effect-derived	JJ
O	NN

distances	NNS
O	NN

and	CC
O	NN

J-coupling-constant-derived	JJ
O	NN

dihedral	JJ
O	NN

angle	NN
O	NN

restraints	NNS
O	VBP

Compared	VBN
O	NN

to	TO
O	NN

two	CD
O	NN

other	JJ
O	NN

commonly	RB
O	NN

used	VBN
O	NN

algorithms	NNS
O	NN

,	,
O	NN

molecular	JJ
O	NN

dynamics	NNS
O	NN

in	IN
O	NN

Cartesian	JJ
O	NN

space	NN
O	NN

and	CC
O	NN

metric-matrix	JJ
O	NN

geometry	NN
O	NN

combined	JJ
O	NN

with	IN
O	NN

Cartesian	JJ
O	NN

molecular	JJ
O	NN

dynamics	NNS
O	NN

,	,
O	NN

the	DT
O	NN

method	NN
O	NN

shows	NNS
O	VBP

increased	VBN
O	NN

computational	JJ
O	NN

efficiency	NN
O	NN

and	CC
O	NN

success	NN
O	NN

rate	NN
O	NN

for	IN
O	NN

large	JJ
O	NN

proteins	NNS
O	NN

,	,
O	NN

and	CC
O	NN

it	PRP
O	NN

shows	NNS
O	VBP

a	DT
O	NN

dramatically	RB
O	NN

increased	VBN
O	NN

radius	NN
O	NN

of	IN
O	NN

convergence	NN
O	NN

for	IN
O	NN

DNA	NN
O	NN

The	DT
O	NN

torsion-angle	JJ
O	NN

molecular	JJ
O	NN

dynamics	NNS
O	NN

algorithm	NN
O	NN

starts	NNS
O	NN

from	IN
O	NN

an	DT
O	NN

extended	VBN
O	NN

strand	NN
O	NN

conformation	NN
O	NN

and	CC
O	NN

proceeds	NNS
O	NN

in	IN
O	NN

four	CD
O	NN

stages	NNS
O	NN

:	:
O	NN

high-temperature	JJ
O	NN

torsion-angle	JJ
O	NN

molecular	JJ
O	NN

dynamics	NNS
O	NN

,	,
O	NN

slow-cooling	NN
O	NN

torsion-angle	JJ
O	NN

molecular	JJ
O	NN

dynamics	NNS
O	NN

,	,
O	NN

Cartesian	JJ
O	NN

molecular	JJ
O	NN

dynamics	NNS
O	NN

,	,
O	NN

and	CC
O	NN

minimization	NN
O	NN

Tests	NNS
O	NN

were	VBD
O	NN

carried	VBD
O	NN

out	IN
O	NN

using	VBG
O	NN

experimental	JJ
O	NN

NMR	NN
O	NN

data	NNS
O	NN

for	IN
O	NN

protein	NN
O	NN

G	NN
O	NN

,	,
O	NN

interleukin-8	NN
O	NN

,	,
O	NN

villin	NN
O	NN

14T	CD
O	NN

,	,
O	NN

and	CC
O	NN

a	DT
O	NN

12	CD
O	NN

base-pair	NN
O	NN

duplex	NN
O	NN

of	IN
O	NN

DNA	NN
O	NN

,	,
O	NN

and	CC
O	NN

simulated	JJ
O	NN

NMR	NN
O	NN

data	NNS
O	NN

for	IN
O	NN

bovine	JJ
O	NN

pancreatic	JJ
O	NN

trypsin	NN
O	NN

inhibitor	NN
O	NN

For	IN
O	NN

villin	NN
O	NN

14T	CD
O	NN

,	,
O	NN

a	DT
O	NN

monomer	NN
O	NN

consisting	VBG
O	NN

of	IN
O	NN

126	CD
O	NN

residues	NNS
O	NN

,	,
O	NN

structure	NN
O	NN

determination	NN
O	NN

by	IN
O	NN

torsion-angle	JJ
O	NN

molecular	JJ
O	NN

dynamics	NNS
O	NN

has	VBZ
O	NN

a	DT
O	NN

success	NN
O	NN

rate	NN
O	NN

of	IN
O	NN

85	CD
O	NN

%	NN
O	NN

,	,
O	NN

a	DT
O	NN

more	RBR
O	NN

than	IN
O	NN

twofold	RB
O	NN

improvement	NN
O	NN

over	IN
O	NN

other	JJ
O	NN

methods	NNS
O	VBP

In	IN
O	NN

the	DT
O	NN

case	NN
O	NN

of	IN
O	NN

the	DT
O	NN

12	CD
O	NN

base-pair	NN
O	NN

DNA	NN
O	NN

duplex	NN
O	NN

,	,
O	NN

torsion-angle	JJ
O	NN

molecular	JJ
O	NN

dynamics	NNS
O	NN

had	VBD
O	NN

a	DT
O	NN

success	NN
O	NN

rate	NN
O	NN

of	IN
O	NN

52	CD
O	NN

%	NN
O	NN

while	IN
O	NN

Cartesian	JJ
O	NN

molecular	JJ
O	NN

dynamics	NNS
O	NN

and	CC
O	NN

metric-matrix	JJ
O	NN

distance	NN
O	NN

geometry	NN
O	NN

always	RB
O	NN

failed	VBD
O	NN

The	DT
O	NN

wavelet-transform	JJ
O	NN

method	NN
O	NN

is	VBZ
O	NN

used	VBN
O	NN

to	TO
O	NN

quantify	VB
O	NN

the	DT
O	NN

magnetic	JJ
O	NN

resonance	NN
O	NN

spectroscopy	NN
O	NN

(	NN
O	NN

MRS	NNP
O	NNP

)	NN
O	NN

parameters	NNS
O	VBP

:	:
O	NN

chemical	NN
O	NN

shift	NN
O	NN

,	,
O	NN

apparent	JJ
O	NN

relaxation	NN
O	NN

time	NN
O	NN

T2	NN
O	NN

,	,
O	NN

resonance	NN
O	NN

amplitude	NN
O	NN

,	,
O	NN

and	CC
O	NN

phase	NN
O	NN

Wavelet	NNP
O	NNP

transformation	NN
O	NN

is	VBZ
O	NN

a	DT
O	NN

time-frequency	NN
O	NN

representation	NN
O	NN

which	WDT
O	NN

separates	VBZ
O	NN

each	DT
O	NN

component	NN
O	NN

from	IN
O	NN

the	DT
O	NN

FID	NN
O	NN

,	,
O	NN

then	RB
O	NN

successively	RB
O	NN

quantifies	VBZ
O	NN

it	PRP
O	NN

and	CC
O	NN

subtracts	VBZ
O	NN

it	PRP
O	NN

from	IN
O	NN

the	DT
O	NN

raw	JJ
O	NN

signal	NN
O	NN

Two	CD
O	NN

iterative	JJ
O	NN

procedures	NNS
O	VBP

have	VB
O	NN

been	VBN
O	NN

developed	VBN
O	NN

They	PRP
O	VBP

have	VB
O	NN

been	VBN
O	NN

combined	JJ
O	NN

with	IN
O	NN

a	DT
O	NN

nonlinear	JJ
O	NN

regression	NN
O	NN

analysis	NN
O	NN

method	NN
O	NN

and	CC
O	NN

tested	VBN
O	NN

on	IN
O	NN

both	DT
O	NN

simulated	JJ
O	NN

and	CC
O	NN

real	JJ
O	NN

sets	NNS
O	NN

of	IN
O	NN

biomedical	JJ
O	NN

MRS	NNP
O	NNP

data	NNS
O	NN

selected	VBN
O	NN

with	IN
O	NN

respect	NN
O	NN

to	TO
O	NN

the	DT
O	NN

main	JJ
O	NN

problems	NNS
O	VBP

usually	RB
O	NN

encountered	VBN
O	NN

in	IN
O	NN

quantifying	VBG
O	NN

biomedical	JJ
O	NN

MRS	NNP
O	NNP

,	,
O	NN

specifically	RB
O	NN

``	``
O	NN

chemical	NN
O	NN

noise	NN
O	NN

,	,
O	NN

''	''
O	NN

resulting	VBG
O	NN

from	IN
O	NN

overlapping	VBG
O	NN

resonances	NNS
O	NN

,	,
O	NN

and	CC
O	NN

baseline	NN
O	NN

distortion	NN
O	NN

The	DT
O	NN

results	NNS
O	VBP

indicate	VBP
O	NN

that	IN
O	NN

the	DT
O	NN

wavelet-transform	JJ
O	NN

method	NN
O	NN

can	MD
O	NNP

provide	VB
O	NN

efficient	JJ
O	NN

and	CC
O	NN

accurate	JJ
O	NN

quantification	NN
O	NN

of	IN
O	NN

MRS	NNP
O	NNP

data	NNS
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Antiplatelet	JJ
T	NN

therapy	NN
T	NN

with	IN
T	NN

aspirin	NN
T	NN

and	CC
T	NN

systematic	JJ
T	NN

anticoagulation	NN
T	NN

with	IN
T	NN

warfarin	NN
T	NN

reduce	VB
O	NN

cardiovascular	JJ
D	NN

morbidity	NN
D	NN

and	CC
D	NN

mortality	NN
D	NN

after	IN
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

when	WRB
O	NN

given	VBN
O	NN

alone	RB
O	NN

In	IN
O	NN

the	DT
O	NN

Coumadin	NNP
O	NNP

Aspirin	NN
O	NN

Reinfarction	NN
O	NN

Study	NNP
O	NNP

(	NN
O	NN

CARS	NNS
O	NN

)	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

aimed	VBN
O	NN

to	TO
O	NN

find	VB
O	NN

out	IN
O	NN

whether	IN
O	NN

a	DT
O	NN

combination	NN
O	NN

of	IN
O	NN

low-dose	JJ
O	NN

warfarin	NN
T	NN

and	CC
O	NN

low-dose	JJ
T	NN

aspirin	NN
T	NN

would	MD
O	NNP

give	VB
O	NN

superior	JJ
O	NN

results	NNS
O	VBP

to	TO
O	NN

standard	JJ
O	NN

aspirin	NN
T	NN

monotherapy	JJ
T	NN

without	IN
O	NN

excessive	JJ
O	NN

bleeding	VBG
O	NN

risk	NN
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

We	PRP
O	VBP

used	VBN
O	NN

a	DT
O	NN

randomised	VBN
O	NN

double-blind	JJ
O	NN

study	NN
O	NN

design	NN
O	NN

At	IN
O	NN

293	CD
O	NN

sites	NNS
O	NN

,	,
O	NN

we	PRP
O	VBP

randomly	RB
O	NN

assigned	VBN
O	NN

8803	CD
O	NN

patients	NNS
O	NN

who	WP
O	VBP

had	VBD
O	NN

had	VBD
O	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

,	,
O	NN

treatment	NN
O	NN

with	IN
O	NN

160	CD
T	NN

mg	NN
T	NN

aspirin	NN
T	NN

,	,
O	NN

3	CD
T	NN

mg	NN
T	NN

warfarin	NN
T	NN

with	IN
T	NN

80	CD
T	NN

mg	NN
T	NN

aspirin	NN
T	NN

,	,
O	NN

or	CC
O	NN

1	CD
T	NN

mg	NN
T	NN

warfarin	NN
T	NN

with	IN
T	NN

80	CD
T	NN

mg	NN
T	NN

aspirin	NN
T	NN

Patients	NNS
O	NN

took	VBD
O	NN

a	DT
O	NN

single	JJ
O	NN

tablet	NN
O	NN

daily	RB
O	NN

,	,
O	NN

and	CC
O	NN

attended	VBD
O	NN

for	IN
O	NN

prothrombin	NN
O	NN

time	NN
O	NN

(	NN
O	NN

PT	NN
O	NN

)	NN
O	NN

measurements	NNS
O	NN

at	IN
O	NN

weeks	NNS
O	NN

1	CD
O	NN

,	,
O	NN

2	CD
O	NN

,	,
O	NN

3	CD
O	NN

,	,
O	NN

4	CD
O	NN

,	,
O	NN

6	CD
O	NN

,	,
O	NN

and	CC
O	NN

12	CD
O	NN

,	,
O	NN

and	CC
O	NN

then	RB
O	NN

every	DT
O	NN

3	CD
O	NN

months	NNS
O	NN

Patients	NNS
O	NN

were	VBD
O	NN

followed	VBN
O	NN

up	RB
O	NN

for	IN
O	NN

a	DT
O	NN

maximum	NN
O	NN

of	IN
O	NN

33	CD
O	NN

months	NNS
O	NN

(	NN
O	NN

median	JJ
O	NN

14	CD
O	NN

months	NNS
O	NN

)	NN
O	NN

FINDINGS	NNS
O	NN

:	:
O	NN

The	DT
O	NN

primary	JJ
O	NN

event	NN
O	NN

was	VBD
O	NN

first	RB
O	NN

occurrence	NN
O	NN

of	IN
O	NN

reinfarction	NN
O	NN

,	,
O	NN

non-fatal	JJ
O	NN

ischaemic	JJ
D	NN

stroke	NN
D	NN

,	,
O	NN

or	CC
O	NN

cardiovascular	JJ
O	NN

death	NN
O	NN

1-year	JJ
O	NN

life-table	JJ
O	NN

estimates	NNS
O	NN

for	IN
O	NN

the	DT
O	NN

primary	JJ
O	NN

event	NN
O	NN

were	VBD
O	NN

8.6	CD
O	NN

%	NN
O	NN

(	NN
O	NN

95	CD
O	NN

%	NN
O	NN

CI	NN
O	NN

7.6-9.6	CD
O	NN

)	NN
O	NN

for	IN
O	NN

160	CD
O	NN

mg	NN
O	NN

aspirin	NN
T	NN

,	,
O	NN

8.4	CD
O	NN

%	NN
O	NN

(	NN
O	NN

7.4-9.4	CD
O	NN

)	NN
O	NN

for	IN
O	NN

3	CD
O	NN

mg	NN
O	NN

warfarin	NN
T	NN

with	IN
O	NN

80	CD
O	NN

mg	NN
O	NN

aspirin	NN
T	NN

,	,
O	NN

and	CC
O	NN

8.8	CD
O	NN

%	NN
O	NN

(	NN
O	NN

7.6-10	CD
O	NN

)	NN
O	NN

for	IN
O	NN

1	CD
O	NN

mg	NN
O	NN

warfarin	NN
T	NN

with	IN
O	NN

80	CD
O	NN

mg	NN
O	NN

aspirin	NN
T	NN

Primary	JJ
O	NN

comparisons	NNS
O	NN

were	VBD
O	NN

done	VBN
O	NN

with	IN
O	NN

all	DT
O	NN

follow-up	JJ
O	NN

data	NNS
O	NN

The	DT
O	NN

relative	JJ
O	NN

risk	NN
O	NN

of	IN
O	NN

the	DT
O	NN

primary	JJ
O	NN

event	NN
O	NN

for	IN
O	NN

the	DT
O	NN

160	CD
O	NN

mg	NN
O	NN

aspirin	NN
O	NN

group	NN
O	NN

compared	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

3	CD
O	NN

mg	NN
O	NN

warfarin	NN
O	NN

with	IN
O	NN

80	CD
O	NN

mg	NN
O	NN

aspirin	NN
O	NN

group	NN
O	NN

was	VBD
O	NN

0.95	CD
O	NN

(	NN
O	NN

0.81-1.12	CD
O	NN

,	,
O	NN

p	NN
O	NN

=	JJ
O	NN

0.57	CD
O	NN

)	NN
O	NN

For	IN
O	NN

spontaneous	JJ
O	NN

major	JJ
O	NN

haemorrhage	NN
O	NN

(	NN
O	NN

not	RB
O	NN

procedure	NN
O	NN

related	JJ
O	NN

)	NN
O	NN

,	,
O	NN

1-year	JJ
O	NN

life-table	JJ
O	NN

estimates	NNS
O	NN

were	VBD
O	NN

0.74	CD
O	NN

%	NN
O	NN

(	NN
O	NN

0.43-1.1	CD
O	NN

)	NN
O	NN

in	IN
O	NN

the	DT
O	NN

160	CD
O	NN

mg	NN
O	NN

aspirin	NN
O	NN

group	NN
O	NN

and	CC
O	NN

1.4	CD
O	NN

%	NN
O	NN

(	NN
O	NN

0.94-1.8	CD
O	NN

)	NN
O	NN

in	IN
O	NN

the	DT
O	NN

3	CD
O	NN

mg	NN
O	NN

warfarin	NN
O	NN

with	IN
O	NN

80	CD
O	NN

mg	NN
O	NN

aspirin	NN
O	NN

group	NN
O	NN

(	NN
O	NN

p	NN
O	NN

=	JJ
O	NN

0.014	CD
O	NN

log	NN
O	NN

rank	NN
O	NN

on	IN
O	NN

follow-up	JJ
O	NN

)	NN
O	NN

For	IN
O	NN

the	DT
O	NN

3382	CD
O	NN

patients	NNS
O	NN

assigned	VBN
O	NN

3	CD
O	NN

mg	NN
O	NN

warfarin	NN
T	NN

with	IN
O	NN

80	CD
O	NN

mg	NN
O	NN

aspirin	NN
T	NN

,	,
O	NN

the	DT
O	NN

INR	NN
O	NN

results	NNS
O	VBP

were	VBD
O	NN

:	:
O	NN

at	IN
O	NN

week	NN
O	NN

1	CD
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

2985	CD
O	NN

)	NN
O	NN

median	JJ
O	NN

1.51	CD
O	NN

(	NN
O	NN

IQR	NN
O	NN

1.23-2.13	CD
O	NN

)	NN
O	NN

;	:
O	NN

at	IN
O	NN

week	NN
O	NN

4	CD
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

2701	CD
O	NN

)	NN
O	NN

1.27	CD
O	NN

(	NN
O	NN

1.13-1.64	CD
O	NN

)	NN
O	NN

;	:
O	NN

at	IN
O	NN

month	NN
O	NN

6	CD
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

2145	CD
O	NN

)	NN
O	NN

1.19	CD
O	NN

(	NN
O	NN

1.08-1.44	CD
O	NN

)	NN
O	NN

INTERPRETATION	NN
O	NN

:	:
O	NN

Low	JJ
O	NN

,	,
O	NN

fixed-dose	JJ
O	NN

warfarin	NN
T	NN

(	NN
T	NN

1	CD
T	NN

mg	NN
T	NN

or	CC
T	NN

3	CD
T	NN

mg	NN
T	NN

)	NN
T	NN

combined	VBN
T	NN

with	IN
T	NN

low-dose	JJ
T	NN

aspirin	NN
T	NN

(	NN
T	NN

80	CD
T	NN

mg	NN
T	NN

)	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

who	WP
O	VBP

have	VB
O	NN

had	VBD
O	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

does	VBZ
O	NNP

not	RB
O	NN

provide	VB
O	NN

clinical	JJ
O	NN

benefit	NN
O	NN

beyond	IN
O	NN

that	IN
O	NN

achievable	JJ
O	NN

with	IN
O	NN

160	CD
O	NN

mg	NN
O	NN

aspirin	NN
T	NN

monotherapy	JJ
T	NN

BACKGROUND	NN
O	NN

:	:
O	NN

There	EX
O	NN

is	VBZ
O	NN

serological	JJ
O	NN

evidence	NN
O	NN

for	IN
O	NN

an	DT
O	NN

association	NN
O	NN

between	IN
O	NN

Chlamydia	NN
D	NN

pneumoniae	FW
D	NN

and	CC
O	NN

coronary	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

We	PRP
O	VBP

investigated	VBN
O	NN

the	DT
O	NN

hypothesis	NN
O	NN

that	IN
O	NN

an	DT
T	NN

antichlamydial	JJ
T	NN

macrolide	NN
T	NN

antibiotic	JJ
T	NN

,	,
T	NN

roxithromycin	NN
T	NN

,	,
O	NN

can	MD
O	NNP

prevent	VB
O	NN

or	CC
O	NN

reduce	VB
O	NN

recurrent	JJ
O	NN

major	JJ
O	NN

ischaemic	JJ
O	NN

events	NNS
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

unstable	JJ
D	NN

angina	NN
D	NN

METHODS	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

roxithromycin	NN
T	NN

was	VBD
O	NN

assessed	VBN
O	NN

in	IN
O	NN

a	DT
O	NN

double-blind	JJ
O	NN

,	,
O	NN

randomised	VBN
O	NN

,	,
O	NN

prospective	JJ
O	NN

,	,
O	NN

multicentre	JJ
O	NN

,	,
O	NN

parallel-group	JJ
O	NN

,	,
O	NN

placebo-controlled	JJ
O	NN

pilot	NN
O	NN

study	NN
O	NN

of	IN
O	NN

202	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

unstable	JJ
D	NN

angina	NN
D	NN

or	CC
O	NN

non-Q-wave	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

Patients	NNS
O	NN

were	VBD
O	NN

randomly	RB
O	NN

assigned	VBN
O	NN

either	DT
O	NN

roxithromycin	NN
T	NN

150	CD
O	NN

mg	NN
O	NN

orally	RB
O	NN

twice	RB
O	NN

a	DT
O	NN

day	NN
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

102	CD
O	NN

)	NN
O	NN

or	CC
O	NN

placebo	NN
O	NN

orally	RB
O	NN

twice	RB
O	NN

a	DT
O	NN

day	NN
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

100	CD
O	NN

)	NN
O	NN

The	DT
O	NN

treatment	NN
O	NN

was	VBD
O	NN

for	IN
O	NN

30	CD
O	NN

days	NNS
O	NN

Patients	NNS
O	NN

were	VBD
O	NN

followed	VBN
O	NN

up	RB
O	NN

for	IN
O	NN

6	CD
O	NN

months	NNS
O	NN

We	PRP
O	VBP

report	NN
O	NN

the	DT
O	NN

primary	JJ
O	NN

clinical	JJ
O	NN

endpoints	NNS
O	NN

(	NN
O	NN

cardiac	JJ
D	NN

ischaemic	JJ
D	NN

death	NN
D	NN

,	,
O	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

,	,
O	NN

and	CC
O	NN

severe	JJ
O	NN

recurrent	JJ
O	NN

ischaemia	NN
D	NN

)	NN
O	NN

,	,
O	NN

assessed	VBN
O	NN

at	IN
O	NN

day	NN
O	NN

31	CD
O	NN

,	,
O	NN

in	IN
O	NN

202	CD
O	NN

patients	NNS
O	NN

on	IN
O	NN

an	DT
O	NN

intention-to-treat	NN
O	NN

basis	NN
O	NN

FINDINGS	NNS
O	NN

:	:
O	NN

A	DT
O	NN

statistically	RB
O	NN

significant	JJ
O	NN

reduction	NN
O	NN

in	IN
O	NN

the	DT
O	NN

primary	JJ
O	NN

composite	JJ
O	NN

triple	JJ
O	NN

endpoint	NN
O	NN

rates	NNS
O	VBP

was	VBD
O	NN

observed	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

roxithromycin	NN
O	NN

group	NN
O	NN

:	:
O	NN

p	NN
O	NN

=	JJ
O	NN

0.032	CD
O	NN

The	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

severe	JJ
O	NN

recurrent	JJ
O	NN

ischaemia	NN
O	NN

,	,
O	NN

myocardial	JJ
O	NN

infarction	NN
O	NN

,	,
O	NN

and	CC
O	NN

ischaemic	JJ
O	NN

death	NN
O	NN

was	VBD
O	NN

5.4	CD
O	NN

%	NN
O	NN

,	,
O	NN

2.2	CD
O	NN

%	NN
O	NN

,	,
O	NN

and	CC
O	NN

2.2	CD
O	NN

%	NN
O	NN

in	IN
O	NN

the	DT
O	NN

placebo	NN
O	NN

group	NN
O	NN

and	CC
O	NN

1.1	CD
O	NN

%	NN
O	NN

,	,
O	NN

0	CD
O	NN

%	NN
O	NN

,	,
O	NN

and	CC
O	NN

0	CD
O	NN

%	NN
O	NN

,	,
O	NN

in	IN
O	NN

the	DT
O	NN

roxithromycin	NN
O	NN

group	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

No	DT
O	NN

major	JJ
O	NN

drug-related	JJ
O	NN

adverse	JJ
O	NN

effects	NNS
O	NN

were	VBD
O	NN

observed	VBN
O	NN

INTERPRETATION	NN
O	NN

:	:
O	NN

Antichlamydial	JJ
T	NN

antibiotics	NNS
T	NN

may	MD
O	NNP

be	VB
O	NN

useful	JJ
O	NN

in	IN
O	NN

therapeutic	JJ
O	NN

intervention	NN
O	NN

in	IN
O	NN

addition	NN
O	NN

to	TO
O	NN

standard	JJ
O	NN

medication	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

coronary-artery	NN
D	NN

disease	NN
D	NN

Large-scale	JJ
O	NN

trials	NNS
O	NN

are	VBP
O	NN

needed	VBN
O	NN

to	TO
O	NN

confirm	VBP
O	NN

these	DT
O	NN

preliminary	JJ
O	NN

observations	NNS
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Stage	NN
D	NN

Ib	NN
D	NN

and	CC
D	NN

IIa	NN
D	NN

cervical	JJ
D	NN

carcinoma	NN
D	NN

can	MD
O	NNP

be	VB
O	NN

cured	VBN
O	NN

by	IN
O	NN

radical	JJ
T	NN

surgery	NN
T	NN

or	CC
O	NN

radiotherapy	NN
T	NN

These	DT
O	NN

two	CD
O	NN

procedures	NNS
O	VBP

are	VBP
O	NN

equally	RB
O	NN

effective	JJ
O	NN

,	,
O	NN

but	CC
O	NNP

differ	VBP
O	NN

in	IN
O	NN

associated	VBN
O	NN

morbidity	NN
O	NN

and	CC
O	NN

type	NN
O	NN

of	IN
O	NN

complications	NNS
O	NN

In	IN
O	NN

this	DT
O	NN

prospective	JJ
O	NN

randomised	VBN
O	NN

trial	NN
O	NN

of	IN
O	NN

radiotherapy	NN
T	NN

versus	CC
O	NN

surgery	NN
T	NN

,	,
O	NN

our	PRP$
O	NN

aim	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

assess	VB
O	NN

the	DT
O	NN

5-year	JJ
O	NN

survival	NN
O	NN

and	CC
O	NN

the	DT
O	NN

rate	NN
O	NN

and	CC
O	NN

pattern	NN
O	NN

of	IN
O	NN

complications	NNS
O	NN

and	CC
O	NN

recurrences	NNS
O	NN

associated	VBN
O	NN

with	IN
O	NN

each	DT
O	NN

treatment	NN
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

Between	IN
O	NN

September	NNP
O	NNP

,	,
O	NN

1986	CD
O	NN

,	,
O	NN

and	CC
O	NN

December	NNP
O	NN

,	,
O	NN

1991	CD
O	NN

,	,
O	NN

469	CD
O	NN

women	NNS
O	VBP

with	IN
O	NN

newly	RB
O	NN

diagnosed	VBN
O	NN

stage	NN
O	NN

Ib	NN
O	NN

and	CC
O	NN

IIa	NN
O	NN

cervical	JJ
T	NN

carcinoma	NN
T	NN

were	VBD
O	NN

referred	VBN
O	NN

to	TO
O	NN

our	PRP$
O	NN

institute	NN
O	NN

343	CD
O	NN

eligible	JJ
O	NN

patients	NNS
O	NN

were	VBD
O	NN

randomised	VBN
O	NN

:	:
O	NN

172	CD
O	NN

to	TO
O	NN

surgery	NN
T	NN

and	CC
O	NN

171	CD
O	NN

to	TO
O	NN

radical	JJ
O	NN

radiotherapy	NN
T	NN

Adjuvant	JJ
O	NN

radiotherapy	NN
O	NN

was	VBD
O	NN

delivered	VBN
O	NN

after	IN
O	NN

surgery	NN
O	NN

for	IN
O	NN

women	NNS
O	VBP

with	IN
O	NN

surgical	JJ
O	NN

stage	NN
O	NN

pT2b	NN
O	NN

or	CC
O	NN

greater	JJR
O	NN

,	,
O	NN

less	JJR
O	NN

than	IN
O	NN

3	CD
O	NN

mm	NN
O	NN

of	IN
O	NN

safe	JJ
O	NN

cervical	JJ
O	NN

stroma	NN
O	NN

,	,
O	NN

cut-through	JJ
O	NN

,	,
O	NN

or	CC
O	NN

positive	JJ
O	NN

nodes	NNS
O	NN

The	DT
O	NN

primary	JJ
O	NN

outcome	NN
O	NN

measures	NNS
O	VBP

were	VBD
O	NN

5-year	JJ
O	NN

survival	NN
O	NN

and	CC
O	NN

the	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

complications	NNS
O	NN

The	DT
O	NN

analysis	NN
O	NN

of	IN
O	NN

survival	NN
O	NN

and	CC
O	NN

recurrence	NN
O	NN

was	VBD
O	NN

by	IN
O	NN

intention	NN
O	NN

to	TO
O	NN

treat	VB
O	NNP

and	CC
O	NN

analysis	NN
O	NN

of	IN
O	NN

complications	NNS
O	NN

was	VBD
O	NN

by	IN
O	NN

treatment	NN
O	NN

delivered	VBN
O	NN

FINDINGS	NNS
O	NN

:	:
O	NN

170	CD
O	NN

patients	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

surgery	NN
O	NN

group	NN
O	NN

and	CC
O	NN

167	CD
O	NN

in	IN
O	NN

the	DT
O	NN

radiotherapy	NN
O	NN

group	NN
O	NN

were	VBD
O	NN

included	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

intention-to-treat	NN
O	NN

analysis	NN
O	NN

;	:
O	NN

scheduled	VBN
O	NN

treatment	NN
O	NN

was	VBD
O	NN

delivered	VBN
O	NN

to	TO
O	NN

169	CD
O	NN

and	CC
O	NN

158	CD
O	NN

women	NNS
O	VBP

,	,
O	NN

respectively	RB
O	NN

,	,
O	NN

62	CD
O	NN

of	IN
O	NN

114	CD
O	NN

women	NNS
O	VBP

with	IN
O	NN

cervical	JJ
O	NN

diameters	NNS
O	NN

of	IN
O	NN

4	CD
O	NN

cm	NN
O	NN

or	CC
O	NN

smaller	JJR
O	NN

and	CC
O	NN

46	CD
O	NN

of	IN
O	NN

55	CD
O	NN

with	IN
O	NN

diameters	NNS
O	NN

larger	JJR
O	NN

than	IN
O	NN

4	CD
O	NN

cm	NN
O	NN

received	VBN
O	NN

adjuvant	JJ
O	NN

therapy	NN
O	NN

After	IN
O	NN

a	DT
O	NN

median	JJ
O	NN

follow-up	JJ
O	NN

of	IN
O	NN

87	CD
O	NN

(	NN
O	NN

range	NN
O	NN

57-120	JJ
O	NN

)	NN
O	NN

months	NNS
O	NN

,	,
O	NN

5-year	JJ
O	NN

overall	JJ
O	NN

and	CC
O	NN

disease-free	JJ
O	NN

survival	NN
O	NN

were	VBD
O	NN

identical	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

surgery	NN
O	NN

and	CC
O	NN

radiotherapy	NN
O	NN

groups	NNS
O	NN

(	NN
O	NN

83	CD
O	NN

%	NN
O	NN

and	CC
O	NN

74	CD
O	NN

%	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

,	,
O	NN

for	IN
O	NN

both	DT
O	NN

groups	NNS
O	NN

)	NN
O	NN

,	,
O	NN

86	CD
O	NN

women	NNS
O	VBP

developed	VBN
O	NN

recurrent	JJ
O	NN

disease	NN
O	NN

:	:
O	NN

42	CD
O	NN

(	NN
O	NN

25	CD
O	NN

%	NN
O	NN

)	NN
O	NN

in	IN
O	NN

the	DT
O	NN

surgery	NN
O	NN

group	NN
O	NN

and	CC
O	NN

44	CD
O	NN

(	NN
O	NN

26	CD
O	NN

%	NN
O	NN

)	NN
O	NN

in	IN
O	NN

the	DT
O	NN

radiotherapy	NN
O	NN

group	NN
O	NN

Significant	JJ
O	NN

factors	NNS
O	NN

for	IN
O	NN

survival	NN
O	NN

in	IN
O	NN

univariate	JJ
O	NN

and	CC
O	NN

multivariate	JJ
O	NN

analyses	NNS
O	VBP

were	VBD
O	NN

:	:
O	NN

cervical	JJ
O	NN

diameter	NN
O	NN

,	,
O	NN

positive	JJ
O	NN

lymphangiography	NN
O	NN

,	,
O	NN

and	CC
O	NN

adeno-carcinomatous	JJ
O	NN

histotype	NN
O	NN

48	CD
O	NN

(	NN
O	NN

28	CD
O	NN

%	NN
O	NN

)	NN
O	NN

surgery-group	JJ
O	NN

patients	NNS
O	NN

had	VBD
O	NN

severe	JJ
O	NN

morbidity	NN
O	NN

compared	VBN
O	NN

with	IN
O	NN

19	CD
O	NN

(	NN
O	NN

12	CD
O	NN

%	NN
O	NN

)	NN
O	NN

radiotherapy-group	JJ
O	NN

patients	NNS
O	NN

(	NN
O	NN

p	NN
O	NN

=	JJ
O	NN

0.0004	CD
O	NN

)	NN
O	NN

INTERPRETATION	NN
O	NN

:	:
O	NN

There	EX
O	NN

is	VBZ
O	NN

no	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

choice	NN
O	NN

for	IN
O	NN

early-stage	JJ
O	NN

cervical	JJ
D	NN

carcinoma	NN
D	NN

in	IN
O	NN

terms	NNS
O	NN

of	IN
O	NN

overall	JJ
O	NN

or	CC
O	NN

disease-free	JJ
O	NN

survival	NN
O	NN

The	DT
O	NN

combination	NN
O	NN

of	IN
O	NN

surgery	NN
D	NN

and	CC
O	NN

radiotherapy	NN
D	NN

has	VBZ
O	NN

the	DT
O	NN

worst	JJS
O	NN

morbidity	NN
O	NN

,	,
O	NN

especially	RB
O	NN

urological	JJ
O	NN

complications	NNS
O	NN

The	DT
O	NN

optimum	JJ
O	NN

therapy	NN
O	NN

for	IN
O	NN

each	DT
O	NN

patient	NN
O	NN

should	MD
O	NNP

take	VB
O	NN

account	NN
O	NN

of	IN
O	NN

clinical	JJ
O	NN

factors	NNS
O	NN

such	JJ
O	NN

as	IN
O	NN

menopausal	JJ
O	NN

status	NN
O	NN

,	,
O	NN

age	NN
O	NN

,	,
O	NN

medical	JJ
O	NN

illness	NN
O	NN

,	,
O	NN

histological	JJ
O	NN

type	NN
O	NN

,	,
O	NN

and	CC
O	NN

cervical	JJ
O	NN

diameter	NN
O	NN

to	TO
O	NN

yield	NN
O	NN

the	DT
O	NN

best	RB
O	NN

cure	NN
O	NN

with	IN
O	NN

minimum	JJ
O	NN

complications	NNS
O	NN

Today	NN
O	NN

's	POS
O	NN

technology	NN
O	NN

links	NNS
O	NN

health	NN
O	NN

care	NN
O	NN

providers	NNS
O	NN

and	CC
O	NN

patients	NNS
O	NN

across	IN
O	NN

town	NN
O	NN

,	,
O	NN

in	IN
O	NN

the	DT
O	NN

next	JJ
O	NN

state	NN
O	NN

or	CC
O	NN

even	RB
O	NN

another	DT
O	NN

country	NN
O	NN

Nursing	NNP
O	NNP

across	IN
O	NN

state	NN
O	NN

lines	NNS
O	NN

poses	VBZ
O	NN

complications	NNS
O	NN

:	:
O	NN

state-bound	JJ
O	NN

regulatory	JJ
O	NN

and	CC
O	NN

licensure	NN
O	NN

issues	NNS
O	VBP

This	DT
O	NN

article	NN
O	NN

discusses	VBZ
O	NN

many	JJ
O	NN

of	IN
O	NN

the	DT
O	NN

nutritional	JJ
O	NN

topics	NNS
O	NN

important	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

intensivist	NN
O	NN

Nutritional	NNP
O	NNP

assessment	NN
O	NN

,	,
O	NN

substrate	JJ
O	NN

immunonutrition	NN
O	NN

,	,
O	NN

and	CC
O	NN

disease	NN
O	NN

specific	JJ
O	NN

issues	NNS
O	VBP

are	VBP
O	NN

presented	VBN
O	NN

Early	RB
O	NN

introduction	NN
O	NN

of	IN
O	NN

enteral	JJ
O	NN

feeds	VBZ
O	NN

and	CC
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

nutritional	JJ
O	NN

modulation	NN
O	NN

are	VBP
O	NN

emphasized	VBN
O	NN

PROBLEM	NN
O	NN

:	:
O	NN

To	TO
O	NN

compare	VB
O	NN

the	DT
O	NN

expression	NN
O	NN

by	IN
O	NN

T-lymphocytes	NNS
O	VBP

of	IN
O	NN

an	DT
O	NN

immunomodulatory	JJ
O	NN

protein	NN
O	NN

known	JJ
O	NN

as	IN
O	NN

progesterone-induced	JJ
O	NN

blocking	VBG
O	NN

factor	NN
O	NN

(	NN
O	NN

PIBF	NN
O	NN

)	NN
O	NN

in	IN
O	NN

conception	NN
O	NN

versus	CC
O	NN

non-conception	JJ
O	NN

cycles	NNS
O	VBP

even	RB
O	NN

when	WRB
O	NN

there	RB
O	NN

has	VBZ
O	NN

been	VBN
O	NN

definite	JJ
O	NN

fertilization	NN
O	NN

and	CC
O	NN

embryo	NN
O	NN

formation	NN
O	NN

METHOD	NN
O	NN

:	:
O	NN

PIBF	NN
O	NN

expression	NN
O	NN

on	IN
O	NN

T	NN
O	NN

lymphocytes	NNS
O	NN

was	VBD
O	NN

measured	VBN
O	NN

using	VBG
O	NN

an	DT
O	NN

immunohistochemical	JJ
O	NN

method	NN
O	NN

with	IN
O	NN

a	DT
O	NN

PIBF-specific	JJ
O	NN

polyclonal	JJ
O	NN

antibody	NN
O	NN

These	DT
O	NN

levels	NNS
O	VBP

were	VBD
O	NN

determined	VBN
O	NN

in	IN
O	NN

patients	NNS
O	NN

undergoing	VBG
O	NN

three	CD
O	NN

types	NNS
O	NN

of	IN
O	NN

therapy	NN
O	NN

:	:
O	NN

non-in	JJ
O	NN

vitro	FW
O	FW

fertilization	NN
O	NN

(	NN
O	NN

IVF	NN
O	NN

)	NN
O	NN

,	,
O	NN

IVF-embryo	JJ
O	NN

transfer	NN
O	NN

(	NN
O	NN

ET	NNP
O	NNP

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

frozen	JJ
O	NN

ET	NNP
O	NNP

Sera	NNP
O	NNP

were	VBD
O	NN

drawn	VBN
O	NN

12	CD
O	NN

days	NNS
O	NN

from	IN
O	NN

ovulation	NN
O	NN

in	IN
O	NN

non-IVF	JJ
O	NN

cycles	NNS
O	VBP

or	CC
O	NN

9	CD
O	NN

days	NNS
O	NN

after	IN
O	NN

ET	NNP
O	NNP

and	CC
O	NN

were	VBD
O	NN

assayed	VBN
O	NN

for	IN
O	NN

PIBF	NN
O	NN

and	CC
O	NN

beta	NN
O	NN

human	JJ
O	NN

chorionic	JJ
O	NN

gondotropin	NN
O	NN

Comparison	NN
O	NN

of	IN
O	NN

the	DT
O	NN

frequency	NN
O	NN

of	IN
O	NN

lymphocyte	NN
O	NN

expression	NN
O	NN

of	IN
O	NN

PIBF	NN
O	NN

in	IN
O	NN

pregnant	JJ
O	NN

versus	CC
O	NN

non-pregnant	JJ
O	NN

women	NNS
O	VBP

were	VBD
O	NN

made	VBN
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

PIBF	NN
O	NN

was	VBD
O	NN

detected	VBN
O	NN

in	IN
O	NN

29.5	CD
O	NN

%	NN
O	NN

of	IN
O	NN

non-pregnant	JJ
O	NN

women	NNS
O	VBP

and	CC
O	NN

52.5	CD
O	NN

%	NN
O	NN

of	IN
O	NN

pregnant	JJ
O	NN

women	NNS
O	VBP

There	EX
O	NN

were	VBD
O	NN

no	DT
O	NN

differences	NNS
O	NN

in	IN
O	NN

PIBF	NN
O	NN

levels	NNS
O	VBP

by	IN
O	NN

therapy	NN
O	NN

used	VBN
O	NN

in	IN
O	NN

non-pregnant	JJ
O	NN

cases	NNS
O	NN

or	CC
O	NN

in	IN
O	NN

the	DT
O	NN

pregnant	JJ
O	NN

group	NN
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

These	DT
O	NN

data	NNS
O	NN

are	VBP
O	NN

consistent	JJ
O	NN

with	IN
O	NN

the	DT
O	NN

hypothesis	NN
O	NN

that	IN
O	NN

maternal	JJ
O	NN

expression	NN
O	NN

of	IN
O	NN

PIBF	NN
O	NN

in	IN
O	NN

T-lymphocytes	NNS
O	VBP

soon	RB
O	NN

after	IN
O	NN

trophoblast	NN
O	NN

invasion	NN
O	NN

may	MD
O	NNP

depend	VB
O	NN

on	IN
O	NN

successful	JJ
O	NN

implantation	NN
O	NN

Many	JJ
O	NN

amino	NN
O	NN

acids	NNS
O	NN

contain	VB
O	NN

an	DT
O	NN

asymmetric	JJ
O	NN

centre	NN
O	NN

,	,
O	NN

occurring	VBG
O	NN

as	IN
O	NN

laevorotatory	JJ
O	NN

,	,
O	NN

L	NN
O	NN

,	,
O	NN

or	CC
O	NN

dextrorotatory	JJ
O	NN

,	,
O	NN

D	NN
O	NN

,	,
O	NN

compounds	NNS
O	NN

It	PRP
O	NN

is	VBZ
O	NN

generally	RB
O	NN

assumed	VBN
O	NN

that	IN
O	NN

abiotic	JJ
O	NN

synthesis	NN
O	NN

of	IN
O	NN

amino	NN
O	NN

acids	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

early	RB
O	NN

Earth	NNP
O	NN

resulted	VBD
O	NN

in	IN
O	NN

racemic	JJ
O	NN

mixtures	NNS
O	NN

(	NN
O	NN

L-	JJ
O	NN

and	CC
O	NN

D-enantiomers	NNS
O	NN

in	IN
O	NN

equal	JJ
O	NN

abundance	NN
O	NN

)	NN
O	NN

But	CC
O	NNP

the	DT
O	NN

origin	NN
O	NN

of	IN
O	NN

life	NN
O	NN

required	VBN
O	NN

,	,
O	NN

owing	VBG
O	NN

to	TO
O	NN

conformational	JJ
O	NN

constraints	NNS
O	VBP

,	,
O	NN

the	DT
O	NN

almost	RB
O	NN

exclusive	JJ
O	NN

selection	NN
O	NN

of	IN
O	NN

either	DT
O	NN

L-	JJ
O	NN

or	CC
O	NN

D-enantiomers	NNS
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

question	NN
O	NN

of	IN
O	NN

why	WRB
O	NN

living	VBG
O	NN

systems	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

Earth	NNP
O	NN

consist	VBP
O	NN

of	IN
O	NN

L-enantiomers	NNS
O	NN

rather	RB
O	NN

than	IN
O	NN

D-enantiomers	NNS
O	NN

is	VBZ
O	NN

unresolved	JJ
O	NN

A	DT
O	NN

substantial	JJ
O	NN

fraction	NN
O	NN

of	IN
O	NN

the	DT
O	NN

organic	JJ
O	NN

compounds	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

early	RB
O	NN

Earth	NNP
O	NN

may	MD
O	NNP

have	VB
O	NN

been	VBN
O	NN

derived	VBN
O	NN

from	IN
O	NN

comet	NN
O	NN

and	CC
O	NN

meteorite	NN
O	NN

impacts	NNS
O	VBP

It	PRP
O	NN

has	VBZ
O	NN

been	VBN
O	NN

reported	VBN
O	NN

previously	RB
O	NN

that	IN
O	NN

amino	NN
O	NN

acids	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

Murchison	NNP
O	NNP

meteorite	NN
O	NN

exhibit	NN
O	NN

an	DT
O	NN

excess	JJ
O	NN

of	IN
O	NN

L-enantiomers	NNS
O	NN

,	,
O	NN

raising	VBG
O	NN

the	DT
O	NN

possibility	NN
O	NN

that	IN
O	NN

a	DT
O	NN

similar	JJ
O	NN

excess	JJ
O	NN

was	VBD
O	NN

present	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

initial	JJ
O	NN

inventory	NN
O	NN

of	IN
O	NN

organic	JJ
O	NN

compounds	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

Earth	NNP
O	NN

The	DT
O	NN

stable	JJ
O	NN

carbon	NN
O	NN

isotope	NN
O	NN

compositions	NNS
O	NN

of	IN
O	NN

individual	JJ
O	NN

amino	NN
O	NN

acids	NNS
O	NN

in	IN
O	NN

Murchison	NNP
O	NNP

support	NN
O	NN

an	DT
O	NN

extraterrestrial	JJ
O	NN

origin	NN
O	NN

--	:
O	NN

rather	RB
O	NN

than	IN
O	NN

a	DT
O	NN

terrestrial	JJ
O	NN

overprint	NN
O	NN

of	IN
O	NN

biological	JJ
O	NN

amino	NN
O	NN

acids-although	JJ
O	NN

reservations	NNS
O	NN

have	VB
O	NN

persisted	VBD
O	NN

Here	RB
O	NN

we	PRP
O	VBP

show	NN
O	NN

that	IN
O	NN

individual	JJ
O	NN

amino-acid	JJ
O	NN

enantiomers	NNS
O	NN

from	IN
O	NN

Murchison	NNP
O	NNP

are	VBP
O	NN

enriched	JJ
O	NN

in	IN
O	NN

15N	NN
O	NN

relative	JJ
O	NN

to	TO
O	NN

their	PRP$
O	NN

terrestrial	JJ
O	NN

counterparts	NNS
O	NN

,	,
O	NN

so	RB
O	NN

confirming	VBG
O	NN

an	DT
O	NN

extraterrestrial	JJ
O	NN

source	NN
O	NN

for	IN
O	NN

an	DT
O	NN

L-enantiomer	NN
O	NN

excess	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

Solar	NNP
O	NNP

System	NNP
O	NNP

that	IN
O	NN

may	MD
O	NNP

predate	VB
O	NN

the	DT
O	NN

origin	NN
O	NN

of	IN
O	NN

life	NN
O	NN

on	IN
O	NN

the	DT
O	NN

Earth	NNP
O	NN

Home	NNP
O	NNP

care	NN
O	NN

workers	NNS
O	VBP

face	NN
O	NN

an	DT
O	NN

increasing	VBG
O	NN

risk	NN
O	NN

for	IN
O	NN

workplace	NN
O	NN

violence	NN
O	NN

A	DT
O	NN

proactive	JJ
O	NN

preventive	JJ
O	NN

approach	NN
O	NN

is	VBZ
O	NN

presented	VBN
O	NN

that	IN
O	NN

suggests	VBZ
O	NN

strategies	NNS
O	VBP

to	TO
O	NN

use	NN
O	NN

during	IN
O	NN

the	DT
O	NN

previsit	NN
O	NN

phase	NN
O	NN

,	,
O	NN

the	DT
O	NN

visit	NN
O	NN

experience	NN
O	NN

,	,
O	NN

and	CC
O	NN

on	IN
O	NN

an	DT
O	NN

ongoing	JJ
O	NN

basis	NN
O	NN

The	DT
O	NN

miracidia	NN
O	NN

of	IN
O	NN

Fasciola	JJ
O	NN

hepatica	NN
O	NN

and	CC
O	NN

Trichobilharzia	FW
O	FW

ocellata	NN
O	NN

approach	NN
O	NN

their	PRP$
O	NN

host	NN
O	NN

snails	NNS
O	NN

Lymnaea	NN
O	NN

truncatula	NN
O	NN

and	CC
O	NN

L.	NNP
O	NNP

stagnalis	NN
O	NN

by	IN
O	NN

increasing	VBG
O	NN

their	PRP$
O	NN

rate	NN
O	NN

of	IN
O	NN

change	NN
O	NN

of	IN
O	NN

direction	NN
O	NN

(	NN
O	NN

RCD	NN
O	NN

)	NN
O	NN

in	IN
O	NN

increasing	VBG
O	NN

gradients	NNS
O	NN

of	IN
O	NN

snail-conditioned	JJ
O	NN

water	NN
O	NN

(	NN
O	NN

SCW	NN
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

they	PRP
O	VBP

perform	VB
O	NN

a	DT
O	NN

turnback	NN
O	NN

swimming	VBG
O	NN

in	IN
O	NN

decreasing	VBG
O	NN

gradients	NNS
O	NN

Both	DT
O	NN

hostfinding	VBG
O	NN

responses	NNS
O	NN

in	IN
O	NN

both	DT
O	NN

species	NNS
O	NN

were	VBD
O	NN

induced	VBN
O	NN

by	IN
O	NN

glycoconjugates	NNS
O	NN

with	IN
O	NN

a	DT
O	NN

molecular	JJ
O	NN

weight	NN
O	NN

of	IN
O	NN

>	JJR
O	NN

30	CD
O	NN

kDa	NN
O	NN

that	IN
O	NN

were	VBD
O	NN

sensitive	JJ
O	NN

to	TO
O	NN

hydrolysis	NN
O	NN

with	IN
O	NN

pronase	NN
O	NN

E	NN
O	NN

and	CC
O	NN

oxidation	NN
O	NN

with	IN
O	NN

NaIO4	NN
O	NN

Alkaline	NN
O	NN

cleavage	NN
O	NN

revealed	VBD
O	NN

that	IN
O	NN

they	PRP
O	VBP

contained	VBN
O	NN

carbohydrates	NNS
O	NN

linked	VBN
O	NN

O-glycosidically	RB
O	NN

via	IN
O	NN

serine	NN
O	NN

and	CC
O	NN

N-acetylgalactosamine	NN
O	NN

Miracidia	NNP
O	NNP

clearly	RB
O	NN

preferred	VBN
O	NN

SCW	NN
O	NN

from	IN
O	NN

their	PRP$
O	NN

specific	JJ
O	NN

host	NN
O	NN

snail	NN
O	NN

versus	CC
O	NN

other	JJ
O	NN

sympatric	JJ
O	NN

snail	NN
O	NN

species	NNS
O	NN

and	CC
O	NN

did	VBD
O	NNP

not	RB
O	NN

respond	NN
O	NN

to	TO
O	NN

water	NN
O	NN

conditioned	VBN
O	NN

with	IN
O	NN

fish	NN
O	NN

,	,
O	NN

tadpoles	NNS
O	NN

,	,
O	NN

or	CC
O	NN

leeches	NNS
O	NN

Differences	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

chemical	NN
O	NN

characteristics	NNS
O	NN

of	IN
O	NN

SCW	NN
O	NN

from	IN
O	NN

the	DT
O	NN

intermediate	JJ
O	NN

hosts	NNS
O	VBP

L.	NNP
O	NNP

truncatula	NN
O	NN

and	CC
O	NN

L.	NNP
O	NNP

stagnalis	NN
O	NN

could	MD
O	NNP

be	VB
O	NN

shown	VBN
O	NN

by	IN
O	NN

sodium	NN
O	NN

dodecyl	NN
O	NN

sulfate-polyacrylamide	JJ
O	NN

gel	NN
O	NN

electrophoresis	NN
O	NN

,	,
O	NN

blotting	VBG
O	NN

,	,
O	NN

and	CC
O	NN

subsequent	JJ
O	NN

carbohydrate	NN
O	NN

detection	NN
O	NN

The	DT
O	NN

first	RB
O	NN

step	NN
O	NN

of	IN
O	NN

purification	NN
O	NN

of	IN
O	NN

the	DT
O	NN

effective	JJ
O	NN

signaling	VBG
O	NN

SCW	NN
O	NN

components	NNS
O	NN

from	IN
O	NN

both	DT
O	NN

snail	NN
O	NN

species	NNS
O	NN

was	VBD
O	NN

achieved	VBN
O	NN

by	IN
O	NN

ion-exchange	JJ
O	NN

chromatography	NN
O	NN

Black	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

colon	NN
D	NN

cancer	NN
D	NN

in	IN
O	NN

the	DT
O	NN

Black/White	NN
O	NN

Cancer	NN
O	NN

Survival	NN
O	NN

Study	NNP
O	NNP

were	VBD
O	NN

found	VBN
O	NN

to	TO
O	NN

have	VB
O	NN

a	DT
O	NN

poorer	JJR
O	NN

survival	NN
O	NN

than	IN
O	NN

white	JJ
O	NN

patients	NNS
O	NN

More	RBR
O	NN

advanced-stage	JJ
O	NN

disease	NN
O	NN

at	IN
O	NN

diagnosis	NN
O	NN

was	VBD
O	NN

the	DT
O	NN

primary	JJ
O	NN

determinant	NN
O	NN

,	,
O	NN

accounting	VBG
O	NN

for	IN
O	NN

60	CD
O	NN

%	NN
O	NN

of	IN
O	NN

the	DT
O	NN

excess	JJ
O	NN

mortality	NN
O	NN

After	IN
O	NN

adjusting	VBG
O	NN

for	IN
O	NN

stage	NN
O	NN

,	,
O	NN

factors	NNS
O	NN

such	JJ
O	NN

as	IN
O	NN

poverty	NN
O	NN

,	,
O	NN

other	JJ
O	NN

socioeconomic	JJ
O	NN

conditions	NNS
O	VBP

,	,
O	NN

and	CC
O	NN

treatment	NN
O	NN

did	VBD
O	NNP

not	RB
O	NN

further	RB
O	NN

explain	VB
O	NN

the	DT
O	NN

remaining	VBG
O	NN

survival	NN
O	NN

deficit	NN
O	NN

This	DT
O	NN

study	NN
O	NN

examined	VBN
O	NN

the	DT
O	NN

aggressiveness	NN
O	NN

of	IN
O	NN

colon	NN
D	NN

tumors	NNS
D	NN

in	IN
O	NN

blacks	NNS
O	NN

and	CC
O	NN

whites	NNS
O	NN

to	TO
O	NN

explore	VB
O	NN

its	PRP$
O	NN

role	NN
O	NN

in	IN
O	NN

the	DT
O	NN

racial	JJ
O	NN

survival	NN
O	NN

differences	NNS
O	NN

Tumor	NN
O	NN

characteristics	NNS
O	NN

of	IN
O	NN

703	CD
O	NN

cases	NNS
O	NN

of	IN
O	NN

newly	RB
O	NN

diagnosed	VBN
O	NN

invasive	JJ
O	NN

colon	NN
O	NN

adenocarcinoma	NN
D	NN

were	VBD
O	NN

centrally	RB
O	NN

evaluated	VBN
O	NN

by	IN
O	NN

a	DT
O	NN

gastrointestinal	JJ
O	NN

pathologist	NN
O	NN

,	,
O	NN

blinded	VBN
O	NN

in	IN
O	NN

regard	NN
O	NN

to	TO
O	NN

the	DT
O	NN

age	NN
O	NN

,	,
O	NN

race	NN
O	NN

,	,
O	NN

and	CC
O	NN

sex	NN
O	NN

of	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

Blacks	NNPS
O	NNP

were	VBD
O	NN

less	JJR
O	NN

likely	JJ
O	NN

to	TO
O	NN

have	VB
O	NN

poorly	RB
O	NN

differentiated	VBN
O	NN

(	NN
O	NN

grade	NN
O	NN

3	CD
O	NN

)	NN
O	NN

tumors	NNS
D	NN

(	NN
O	NN

odds	NNS
O	NN

ratio	NN
O	NN

(	NN
O	NN

OR	NN
O	NN

)	NN
O	NN

,	,
O	NN

0.44	CD
O	NN

;	:
O	NN

95	CD
O	NN

%	NN
O	NN

confidence	NN
O	NN

interval	NN
O	NN

,	,
O	NN

0.22-0.88	CD
O	NN

)	NN
O	NN

and	CC
O	NN

lymphoid	JJ
O	NN

reaction	NN
O	NN

(	NN
O	NN

OR	NN
O	NN

,	,
O	NN

0.49	CD
O	NN

;	:
O	NN

95	CD
O	NN

%	NN
O	NN

confidence	NN
O	NN

interval	NN
O	NN

,	,
O	NN

0.26-0.90	CD
O	NN

)	NN
O	NN

when	WRB
O	NN

compared	VBN
O	NN

with	IN
O	NN

whites	NNS
O	NN

These	DT
O	NN

black/white	JJ
O	NN

(	NN
O	NN

B/W	NN
O	NN

)	NN
O	NN

differences	NNS
O	NN

remained	VBD
O	NN

statistically	RB
O	NN

significant	JJ
O	NN

after	IN
O	NN

adjusting	VBG
O	NN

for	IN
O	NN

age	NN
O	NN

,	,
O	NN

sex	NN
O	NN

,	,
O	NN

metropolitan	JJ
O	NN

area	NN
O	NN

,	,
O	NN

summary	NN
O	NN

stage	NN
O	NN

,	,
O	NN

socioeconomic	JJ
O	NN

status	NN
O	NN

,	,
O	NN

body	NN
O	NN

mass	NN
O	NN

index	NN
O	NN

,	,
O	NN

and	CC
O	NN

health	NN
O	NN

care	NN
O	NN

access	NN
O	NN

and	CC
O	NN

utilization	NN
O	NN

In	IN
O	NN

addition	NN
O	NN

,	,
O	NN

blacks	NNS
O	NN

were	VBD
O	NN

less	JJR
O	NN

likely	JJ
O	NN

to	TO
O	NN

have	VB
O	NN

high-grade	JJ
O	NN

(	NN
O	NN

grade	NN
O	NN

3	CD
O	NN

)	NN
O	NN

nuclear	JJ
D	NN

atypia	NN
D	NN

,	,
O	NN

mitotic	JJ
O	NN

activity	NN
O	NN

,	,
O	NN

and	CC
O	NN

tubule	NN
O	NN

formation	NN
O	NN

,	,
O	NN

although	IN
O	NN

these	DT
O	NN

ORs	NNS
O	NN

did	VBD
O	NNP

not	RB
O	NN

reach	VB
O	NNP

a	DT
O	NN

statistical	JJ
O	NN

significance	NN
O	NN

level	NN
O	NN

of	IN
O	NN

0.05	CD
O	NN

Similar	JJ
O	NN

B/W	NN
O	NN

differences	NNS
O	NN

were	VBD
O	NN

observed	VBN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
O	NN

disease	NN
O	NN

but	CC
O	NNP

not	RB
O	NN

with	IN
O	NN

early	RB
O	NN

stage	NN
O	NN

Comparison	NN
O	NN

by	IN
O	NN

anatomical	JJ
O	NN

subsite	JJ
O	NN

showed	VBD
O	NN

that	IN
O	NN

blacks	NNS
O	NN

had	VBD
O	NN

statistically	RB
O	NN

significantly	RB
O	NN

better	JJR
O	NN

differentiated	VBN
O	NN

tumors	NNS
D	NN

for	IN
O	NN

cancers	NNS
D	NN

of	IN
O	NN

the	DT
O	NN

proximal	JJ
O	NN

and	CC
O	NN

transverse	JJ
O	NN

colon	NN
O	NN

but	CC
O	NNP

not	RB
O	NN

for	IN
O	NN

the	DT
O	NN

distal	JJ
O	NN

No	DT
O	NN

racial	JJ
O	NN

differences	NNS
O	NN

were	VBD
O	NN

found	VBN
O	NN

for	IN
O	NN

blood	NN
O	NN

vessel	NN
O	NN

and	CC
O	NN

lymphatic	JJ
D	NN

invasion	NN
D	NN

,	,
O	NN

necrosis	NN
D	NN

,	,
O	NN

fibrosis	NN
D	NN

,	,
O	NN

and	CC
O	NN

mucinous	JJ
O	NN

type	NN
O	NN

of	IN
O	NN

histology	NN
O	NN

The	DT
O	NN

findings	NNS
O	VBP

,	,
O	NN

therefore	RB
O	NN

,	,
O	NN

are	VBP
O	NN

the	DT
O	NN

opposite	JJ
O	NN

of	IN
O	NN

those	DT
O	NNP

hypothesized	VBN
O	NN

After	IN
O	NN

adjusting	VBG
O	NN

for	IN
O	NN

stage	NN
O	NN

,	,
O	NN

more	RBR
O	NN

aggressive	JJ
O	NN

tumor	NN
O	NN

characteristics	NNS
O	NN

do	VB
O	NNP

not	RB
O	NN

explain	VB
O	NN

the	DT
O	NN

adverse	JJ
O	NN

survival	NN
O	NN

differential	JJ
O	NN

in	IN
O	NN

blacks	NNS
O	NN

This	DT
O	NN

suggests	VBZ
O	NN

that	IN
O	NN

there	RB
O	NN

may	MD
O	NNP

be	VB
O	NN

racial	JJ
O	NN

differences	NNS
O	NN

in	IN
O	NN

environmental	JJ
O	NN

exposure	NN
O	NN

,	,
O	NN

and	CC
O	NN

that	IN
O	NN

the	DT
O	NN

intensity	NN
O	NN

and	CC
O	NN

mode	NN
O	NN

of	IN
O	NN

delivery	NN
O	NN

of	IN
O	NN

carcinogen	NN
O	NN

insult	NN
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

host	NN
O	NN

susceptibility	NN
O	NN

may	MD
O	NNP

differ	VBP
O	NN

by	IN
O	NN

race	NN
O	NN

and	CC
O	NN

anatomical	JJ
O	NN

subsite	JJ
O	NN

Future	JJ
O	NN

studies	NNS
O	VBP

should	MD
O	NNP

explore	VB
O	NN

the	DT
O	NN

B/W	NN
O	NN

differences	NNS
O	NN

in	IN
O	NN

tumor	NN
O	NN

biology	NN
O	NN

using	VBG
O	NN

molecular	JJ
O	NN

markers	NNS
O	VBP

that	IN
O	NN

precede	VB
O	NN

the	DT
O	NN

conventional	JJ
O	NN

histological	JJ
O	NN

parameters	NNS
O	VBP

evaluated	VBN
O	NN

here	RB
O	NN

A	DT
O	NN

new	JJ
O	NN

method	NN
O	NN

is	VBZ
O	NN

described	VBN
O	NN

for	IN
O	NN

detection	NN
O	NN

of	IN
O	NN

mutations	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

lysosomal	JJ
O	NN

alpha-glucosidase	NN
O	NN

gene	NN
O	NN

(	NN
O	NN

GAA	NN
O	NN

)	NN
O	NN

leading	VBG
O	NN

to	TO
O	NN

Glycogen	NN
D	NN

Storage	NN
D	NN

Disease	NN
D	NN

type	NN
D	NN

II	NNP
D	NNP

(	NN
D	NN

GSDII	NN
D	NN

)	NN
D	NN

A	DT
O	NN

key	JJ
O	NN

feature	NN
O	NN

of	IN
O	NN

the	DT
O	NN

method	NN
O	NN

is	VBZ
O	NN

isolation	NN
O	NN

and	CC
O	NN

reverse	JJ
O	NN

transcription	NN
O	NN

of	IN
O	NN

mRNA	NN
O	NN

followed	VBN
O	NN

by	IN
O	NN

PCR	NN
O	NN

amplification	NN
O	NN

of	IN
O	NN

lysosomal	JJ
O	NN

alpha-glucosidase	NN
O	NN

cDNA	NN
O	NN

with	IN
O	NN

M13-extended	JJ
O	NN

primers	NNS
O	NN

Dye	VB
O	NN

labeled	VBN
O	NN

primers	NNS
O	NN

are	VBP
O	NN

used	VBN
O	NN

for	IN
O	NN

cycle	NN
O	NN

sequencing	NN
O	NN

and	CC
O	NN

an	DT
O	NN

ABI	NN
O	NN

PRISM	NN
O	NN

377	CD
O	NN

DNA	NN
O	NN

sequencing	NN
O	NN

system	NN
O	NN

for	IN
O	NN

analysis	NN
O	NN

The	DT
O	NN

method	NN
O	NN

is	VBZ
O	NN

rapid	JJ
O	NN

and	CC
O	NN

complementary	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

automated	VBN
O	NN

sequencing	NN
O	NN

of	IN
O	NN

all	DT
O	NN

the	DT
O	NN

19	CD
O	NN

,	,
O	NN

PCR	NN
O	NN

amplified	VBN
O	NN

,	,
O	NN

coding	VBG
O	NN

exons	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

GAA	NN
O	NN

gene	NN
O	NN

The	DT
O	NN

advantages	NNS
O	VBP

and	CC
O	NN

pitfalls	NNS
O	NN

of	IN
O	NN

this	DT
O	NN

new	JJ
O	NN

method	NN
O	NN

are	VBP
O	NN

discussed	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

light	JJ
O	NN

of	IN
O	NN

the	DT
O	NN

results	NNS
O	VBP

obtained	VBN
O	NN

with	IN
O	NN

an	DT
O	NN

infantile	JJ
O	NN

GSDII	CD
O	NN

patient	NN
O	NN

A	DT
O	NN

new	JJ
O	NN

splice	NN
O	NN

site	NN
O	NN

mutation	NN
O	NN

in	IN
O	NN

the	DT
O	NN

GAA	NN
O	NN

gene	NN
O	NN

of	IN
O	NN

this	DT
O	NN

patient	NN
O	NN

was	VBD
O	NN

identified	VBN
O	NN

,	,
O	NN

IVS16	NN
O	NN

(	NN
O	NN

+2T	NN
O	NN

--	:
O	NN

>	JJR
O	NN

C	NN
O	NN

)	NN
O	NN

,	,
O	NN

resulting	VBG
O	NN

in	IN
O	NN

the	DT
O	NN

deletion	NN
O	NN

of	IN
O	NN

16	CD
O	NN

base	NN
O	NN

pairs	NNS
O	NN

of	IN
O	NN

exon	NN
O	NN

16	CD
O	NN

The	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

clinical	JJ
O	NN

autonomic	JJ
D	NN

dysfunction	NN
D	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

neurologic	JJ
D	NN

diseases	NNS
D	NN

,	,
O	NN

such	JJ
O	NN

as	IN
O	NN

multiple	JJ
D	NN

sclerosis	NN
D	NN

,	,
O	NN

Parkinson	NNP
D	NNP

's	POS
D	NN

disease	NN
D	NN

,	,
O	NN

and	CC
O	NN

cerebrovascular	JJ
O	NN

accident	NN
O	NN

,	,
O	NN

has	VBZ
O	NN

become	VBN
O	NN

increasingly	RB
O	NN

recognized	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

past	JJ
O	NN

decade	NN
O	NN

Very	RB
O	NN

few	JJ
O	NN

autonomic	JJ
O	NN

tests	NNS
O	NN

have	VB
O	NN

been	VBN
O	NN

done	VBN
O	NN

on	IN
O	NN

pediatric	JJ
O	NN

patients	NNS
O	NN

thus	RB
O	NN

far	RB
O	NN

The	DT
O	NN

purpose	NN
O	NN

of	IN
O	NN

this	DT
O	NN

study	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

investigate	VB
O	NN

the	DT
O	NN

autonomic	JJ
O	NN

function	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

cerebral	JJ
D	NN

palsy	NN
D	NN

using	VBG
O	NN

two	CD
O	NN

noninvasive	JJ
O	NN

tests	NNS
O	NN

:	:
O	NN

sympathetic	JJ
O	NN

skin	NN
O	NN

response	NN
O	NN

(	NN
O	NN

SSR	NN
O	NN

)	NN
O	NN

and	CC
O	NN

R-R	NN
O	NN

interval	NN
O	NN

variation	NN
O	NN

(	NN
O	NN

RRIV	NN
O	NN

)	NN
O	NN

Twenty-four	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

cerebral	JJ
D	NN

palsy	NN
D	NN

and	CC
O	NN

24	CD
O	NN

control	NN
O	NN

subjects	NNS
O	NN

between	IN
O	NN

the	DT
O	NN

ages	NNS
O	NN

of	IN
O	NN

4	CD
O	NN

and	CC
O	NN

12	CD
O	NN

yr	NN
O	NN

were	VBD
O	NN

enrolled	VBN
O	NN

in	IN
O	NN

this	DT
O	NN

study	NN
O	NN

There	EX
O	NN

was	VBD
O	NN

no	DT
O	NN

significant	JJ
O	NN

difference	NN
O	NN

of	IN
O	NN

mean	VB
O	NN

latency	NN
O	NN

,	,
O	NN

amplitude	NN
O	NN

,	,
O	NN

or	CC
O	NN

amplitude	NN
O	NN

ratio	NN
O	NN

of	IN
O	NN

SSR	NN
O	NN

between	IN
O	NN

the	DT
O	NN

two	CD
O	NN

groups	NNS
O	NN

under	IN
O	NN

electric	JJ
O	NN

stimulus	NN
O	NN

,	,
O	NN

startling	JJ
O	NN

stimulus	NN
O	NN

,	,
O	NN

and	CC
O	NN

deep	JJ
O	NN

breathing	VBG
O	NN

conditions	NNS
O	VBP

No	DT
O	NN

significant	JJ
O	NN

difference	NN
O	NN

in	IN
O	NN

frequency	NN
O	NN

of	IN
O	NN

absent	JJ
O	NN

response	NN
O	NN

and	CC
O	NN

asymmetric	JJ
O	NN

response	NN
O	NN

was	VBD
O	NN

also	RB
O	NN

noted	VBN
O	NN

Mean	NN
O	NN

heart	NN
O	NN

rate	NN
O	NN

under	IN
O	NN

relaxed	VBN
O	NN

sitting	VBG
O	NN

condition	NN
O	NN

was	VBD
O	NN

significantly	RB
O	NN

higher	JJR
O	NN

in	IN
O	NN

the	DT
O	NN

study	NN
O	NN

group	NN
O	NN

Significant	JJ
O	NN

negative	JJ
O	NN

correlation	NN
O	NN

between	IN
O	NN

heart	NN
O	NN

rate	NN
O	NN

and	CC
O	NN

age	NN
O	NN

was	VBD
O	NN

noted	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

control	NN
O	NN

group	NN
O	NN

but	CC
O	NNP

was	VBD
O	NN

not	RB
O	NN

present	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

study	NN
O	NN

group	NN
O	NN

Also	RB
O	NN

,	,
O	NN

there	RB
O	NN

was	VBD
O	NN

no	DT
O	NN

statistical	JJ
O	NN

difference	NN
O	NN

of	IN
O	NN

mean	VB
O	NN

RRIV	NN
O	NN

between	IN
O	NN

the	DT
O	NN

two	CD
O	NN

groups	NNS
O	NN

No	DT
O	NN

objective	JJ
O	NN

evidence	NN
O	NN

of	IN
O	NN

autonomic	JJ
O	NN

disturbance	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

cerebral	JJ
D	NN

palsy	NN
D	NN

was	VBD
O	NN

found	VBN
O	NN

in	IN
O	NN

this	DT
O	NN

study	NN
O	NN

A	DT
O	NN

two-credits	JJ
O	NN

per	IN
O	NN

semester	NN
O	NN

clinical	JJ
O	NN

medicine	NN
O	NN

course	NN
O	NN

was	VBD
O	NN

established	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

Department	NNP
O	NN

of	IN
O	NN

Physical	JJ
O	NN

Medicine	NNP
O	NNP

and	CC
O	NN

Rehabilitation	NNP
O	NNP

(	NN
O	NN

PM	NN
O	NN

&	CC
O	NNP

#	#
O	NN

38	CD
O	NN

;	:
O	NN

R	NN
O	NN

)	NN
O	NN

in	IN
O	NN

cooperation	NN
O	NN

with	IN
O	NN

the	DT
O	NN

Johns	NNP
O	NNP

Hopkins	NNP
O	NNP

University	NNP
O	NN

undergraduate	JJ
O	NN

Human	JJ
O	NN

Biology	NN
O	NN

faculty	NN
O	NN

to	TO
O	NN

present	JJ
O	NN

the	DT
O	NN

variety	NN
O	NN

of	IN
O	NN

inpatient	JJ
O	NN

consultation	NN
O	NN

personnel	NNS
O	NN

,	,
O	NN

units	NNS
O	NN

,	,
O	NN

patient	NN
O	NN

diagnostic	JJ
O	NN

groups	NNS
O	NN

,	,
O	NN

and	CC
O	NN

functional	JJ
O	NN

problems	NNS
O	VBP

College	NNP
O	NNP

students	NNS
O	NN

spend	VB
O	NN

4	CD
O	NN

hr	NN
O	NN

weekly	JJ
O	NN

on	IN
O	NN

the	DT
O	NN

PM	NN
O	NN

&	CC
O	NNP

#	#
O	NN

38	CD
O	NN

;	:
O	NN

R	NN
O	NN

consultation	NN
O	NN

service	NN
O	NN

as	IN
O	NN

team	NN
O	NN

members	NNS
O	NN

under	IN
O	NN

resident	JJ
O	NN

supervision	NN
O	NN

The	DT
O	NN

curriculum	NN
O	NN

emphasizes	VBZ
O	NN

student	NN
O	NN

understanding	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

roles	NNS
O	NN

of	IN
O	NN

rehabilitation	NN
O	NN

team	NN
O	NN

members	NNS
O	NN

Objectives	NNS
O	VBP

include	VBP
O	NN

demonstration	NN
O	NN

of	IN
O	NN

working	VBG
O	NN

knowledge	NN
O	NN

of	IN
O	NN

the	DT
O	NN

Biopsychosocial	JJ
O	NN

Model	NNP
O	NNP

,	,
O	NN

the	DT
O	NN

World	NNP
O	NNP

Health	NNP
O	NNP

Organization	NNP
O	NNP

Model	NNP
O	NNP

of	IN
O	NN

disablement	NN
O	NN

and	CC
O	NN

interdisciplinary	JJ
O	NN

rehabilitation	NN
O	NN

intervention	NN
O	NN

The	DT
O	NN

course	NN
O	NN

includes	VBZ
O	NN

simulations	NNS
O	NN

of	IN
O	NN

physical	JJ
O	NN

impairments	NNS
O	VBP

,	,
O	NN

demonstrations	NNS
O	NN

of	IN
O	NN

adaptive	JJ
O	NN

equipment	NN
O	NN

,	,
O	NN

interactive	JJ
O	NN

chart	NN
O	NN

reviews	NNS
O	VBP

,	,
O	NN

readings	NNS
O	NN

,	,
O	NN

and	CC
O	NN

audio	JJ
O	NN

lectures	VBZ
O	NN

A	DT
O	NN

retrospective	JJ
O	NN

sequential	JJ
O	NN

review	NN
O	NN

was	VBD
O	NN

made	VBN
O	NN

of	IN
O	NN

the	DT
O	NN

last	JJ
O	NN

100	CD
O	NN

physical	JJ
O	NN

medicine	NN
O	NN

and	CC
O	NN

rehabilitation	NN
O	NN

consultations	NNS
O	NN

with	IN
O	NN

student	NN
O	NN

attendance	NN
O	NN

The	DT
O	NN

results	NNS
O	VBP

confirm	VBP
O	NN

student	NN
O	NN

exposure	NN
O	NN

to	TO
O	NN

many	JJ
O	NN

ward	NN
O	NN

settings	NNS
O	VBP

(	NN
O	NN

surgery	NN
O	NN

,	,
O	NN

30	CD
O	NN

%	NN
O	NN

;	:
O	NN

neurology/neurosurgery	NN
O	NN

,	,
O	NN

28	CD
O	NN

%	NN
O	NN

;	:
O	NN

medicine	NN
O	NN

,	,
O	NN

24	CD
O	NN

%	NN
O	NN

;	:
O	NN

intensive	JJ
O	NN

care	NN
O	NN

,	,
O	NN

15	CD
O	NN

%	NN
O	NN

;	:
O	NN

oncology	NN
O	NN

,	,
O	NN

2	CD
O	NN

%	NN
O	NN

;	:
O	NN

and	CC
O	NN

psychiatry	NN
O	NN

,	,
O	NN

1	CD
O	NN

%	NN
O	NN

)	NN
O	NN

,	,
O	NN

patient	NN
O	NN

complexity	NN
O	NN

(	NN
O	NN

averaging	VBG
O	NN

10	CD
O	NN

problems	NNS
O	VBP

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

multiple	JJ
O	NN

ICD-9	NN
O	NN

diagnosis	NN
O	NN

categories	NNS
O	VBP

(	NN
O	NN

circulatory	JJ
O	NN

,	,
O	NN

36	CD
O	NN

%	NN
O	NN

;	:
O	NN

neurologic	JJ
O	NN

,	,
O	NN

22	CD
O	NN

%	NN
O	NN

;	:
O	NN

musculoskeletal	JJ
O	NN

,	,
O	NN

17	CD
O	NN

%	NN
O	NN

;	:
O	NN

neoplasms	NNS
O	NN

,	,
O	NN

10	CD
O	NN

%	NN
O	NN

;	:
O	NN

injury	NN
O	NN

,	,
O	NN

5	CD
O	NN

%	NN
O	NN

;	:
O	NN

endocrine	JJ
O	NN

,	,
O	NN

4	CD
O	NN

%	NN
O	NN

;	:
O	NN

infections	NNS
O	NN

,	,
O	NN

3	CD
O	NN

%	NN
O	NN

;	:
O	NN

and	CC
O	NN

others	NNS
O	VBP

,	,
O	NN

3	CD
O	NN

%	NN
O	NN

)	NN
O	NN

The	DT
O	NN

rehabilitation	NN
O	NN

consultation	NN
O	NN

service	NN
O	NN

is	VBZ
O	NN

particularly	RB
O	NN

effective	JJ
O	NN

as	IN
O	NN

an	DT
O	NN

introduction	NN
O	NN

to	TO
O	NN

hospital-based	JJ
O	NN

medical	JJ
O	NN

practice	NN
O	NN

due	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

diagnostic	JJ
O	NN

variety	NN
O	NN

of	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

,	,
O	NN

the	DT
O	NN

functional	JJ
O	NN

approach	NN
O	NN

of	IN
O	NN

rehabilitation	NN
O	NN

,	,
O	NN

and	CC
O	NN

student	NN
O	NN

exposure	NN
O	NN

to	TO
O	NN

multiple	JJ
O	NN

hospital	NN
O	NN

settings	NNS
O	VBP

The	DT
O	NN

Biopsychosocial	JJ
O	NN

Model	NNP
O	NNP

of	IN
O	NN

medical	JJ
O	NN

practice	NN
O	NN

is	VBZ
O	NN

demonstrated	VBD
O	NN

through	IN
O	NN

multiple	JJ
O	NN

interdisciplinary	JJ
O	NN

perspectives	NNS
O	NN

of	IN
O	NN

needs	NNS
O	VBP

and	CC
O	NN

interventions	NNS
O	VBP

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

obvious	JJ
O	NN

functional	JJ
O	NN

deficits	NNS
O	NN

This	DT
O	NN

process	NN
O	NN

develops	VBZ
O	NN

a	DT
O	NN

rudimentary	JJ
O	NN

understanding	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

illness	NN
O	NN

on	IN
O	NN

the	DT
O	NN

person	NN
O	NN

and	CC
O	NN

the	DT
O	NN

variety	NN
O	NN

of	IN
O	NN

medically	RB
O	NN

effective	JJ
O	NN

therapeutic	JJ
O	NN

modalities	NNS
O	NN

This	DT
O	NN

study	NN
O	NN

is	VBZ
O	NN

designed	VBN
O	NN

to	TO
O	NN

investigate	VB
O	NN

the	DT
O	NN

immediate	JJ
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

electrotherapy	JJ
T	NN

on	IN
O	NN

myofascial	JJ
D	NN

trigger	NN
D	NN

points	NNS
D	NN

of	IN
D	NN

upper	JJ
D	NN

trapezius	NN
D	NN

muscle	NN
D	NN

Sixty	CD
O	NN

patients	NNS
O	NN

(	NN
O	NN

25	CD
O	NN

males	NNS
O	VBP

and	CC
O	NN

35	CD
O	NN

females	NNS
O	NN

)	NN
O	NN

who	WP
O	VBP

had	VBD
O	NN

myofascial	JJ
D	NN

trigger	NN
D	NN

points	NNS
D	NN

in	IN
O	NN

one	CD
O	NN

side	NN
O	NN

of	IN
O	NN

the	DT
O	NN

upper	JJ
O	NN

trapezius	NN
O	NN

muscles	NNS
O	NN

were	VBD
O	NN

studied	VBN
O	NN

The	DT
O	NN

involved	VBN
O	NN

upper	JJ
O	NN

trapezius	NN
O	NN

muscles	NNS
O	NN

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

three	CD
O	NN

different	JJ
O	NN

methods	NNS
O	VBP

according	VBG
O	NN

to	TO
O	NN

a	DT
O	NN

random	JJ
O	NN

assignment	NN
O	NN

:	:
O	NN

group	NN
O	NN

A	DT
O	NN

muscles	NNS
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

18	CD
O	NN

)	NN
O	NN

were	VBD
O	NN

given	VBN
O	NN

placebo	NN
O	NN

treatment	NN
O	NN

(	NN
O	NN

control	NN
O	NN

group	NN
O	NN

)	NN
O	NN

;	:
O	NN

group	NN
O	NN

B	NN
O	NN

muscles	NNS
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

20	CD
O	NN

)	NN
O	NN

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

electrical	JJ
T	NN

nerve	NN
T	NN

stimulation	NN
T	NN

(	NN
T	NN

ENS	NN
T	NN

)	NN
T	NN

therapy	NN
T	NN

;	:
O	NN

and	CC
O	NN

group	NN
O	NN

C	NN
O	NN

muscles	NNS
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

22	CD
O	NN

)	NN
O	NN

were	VBD
O	NN

given	VBN
O	NN

electrical	JJ
T	NN

muscle	NN
T	NN

stimulation	NN
T	NN

(	NN
T	NN

EMS	NNP
T	NN

)	NN
T	NN

therapy	NN
T	NN

The	DT
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

treatment	NN
O	NN

was	VBD
O	NN

assessed	VBN
O	NN

by	IN
O	NN

conducting	VBG
O	NN

three	CD
O	NN

measurements	NNS
O	NN

on	IN
O	NN

each	DT
O	NN

muscle	NN
O	NN

before	IN
O	NN

and	CC
O	NN

immediately	RB
O	NN

after	IN
O	NN

treatment	NN
O	NN

:	:
O	NN

subjective	JJ
O	NN

pain	NN
O	NN

intensity	NN
O	NN

(	NN
O	NN

(	NN
O	NN

PI	NN
O	NN

)	NN
O	NN

with	IN
O	NN

a	DT
O	NN

visual	JJ
O	NN

analog	NN
O	NN

scale	NN
O	NN

)	NN
O	NN

,	,
O	NN

pressure	NN
O	NN

pain	NN
O	NN

threshold	NN
O	NN

(	NN
O	NN

(	NN
O	NN

PT	NN
O	NN

)	NN
O	NN

with	IN
O	NN

algometry	NN
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

range	NN
O	NN

of	IN
O	NN

motion	NN
O	NN

(	NN
O	NN

(	NN
O	NN

ROM	NN
O	NN

)	NN
O	NN

with	IN
O	NN

a	DT
O	NN

goniometer	NN
O	NN

)	NN
O	NN

of	IN
O	NN

upper	JJ
O	NN

trapezius	NN
O	NN

muscle	NN
O	NN

(	NN
O	NN

lateral	JJ
O	NN

bending	VBG
O	NN

of	IN
O	NN

cervical	JJ
O	NN

spine	NN
O	NN

to	TO
O	NN

the	DT
O	NN

opposite	JJ
O	NN

side	NN
O	NN

)	NN
O	NN

When	WRB
O	NN

the	DT
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

treatment	NN
O	NN

was	VBD
O	NN

compared	VBN
O	NN

with	IN
O	NN

that	IN
O	NN

of	IN
O	NN

the	DT
O	NN

placebo	NN
O	NN

group	NN
O	NN

(	NN
O	NN

group	NN
O	NN

A	DT
O	NN

)	NN
O	NN

,	,
O	NN

there	RB
O	NN

was	VBD
O	NN

significant	JJ
O	NN

improvement	NN
O	NN

in	IN
O	NN

PI	NN
O	NN

and	CC
O	NN

PT	NN
O	NN

in	IN
O	NN

group	NN
O	NN

B	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.01	CD
O	NN

)	NN
O	NN

but	CC
O	NNP

not	RB
O	NN

in	IN
O	NN

group	NN
O	NN

C	NN
O	NN

(	NN
O	NN

P	NN
O	NN

>	JJR
O	NN

0.05	CD
O	NN

)	NN
O	NN

The	DT
O	NN

improvement	NN
O	NN

of	IN
O	NN

ROM	NN
O	NN

was	VBD
O	NN

significantly	RB
O	NN

more	RBR
O	NN

in	IN
O	NN

group	NN
O	NN

C	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.01	CD
O	NN

)	NN
O	NN

as	IN
O	NN

compared	VBN
O	NN

with	IN
O	NN

that	IN
O	NN

in	IN
O	NN

group	NN
O	NN

A	DT
O	NN

or	CC
O	NN

group	NN
O	NN

B	NN
O	NN

When	WRB
O	NN

each	DT
O	NN

group	NN
O	NN

was	VBD
O	NN

divided	VBN
O	NN

into	IN
O	NN

two	CD
O	NN

additional	JJ
O	NN

subgroups	NNS
O	NN

based	VBN
O	NN

on	IN
O	NN

the	DT
O	NN

initial	JJ
O	NN

PI	NN
O	NN

,	,
O	NN

it	PRP
O	NN

was	VBD
O	NN

found	VBN
O	NN

that	IN
O	NN

ENS	NN
O	NN

could	MD
O	NNP

reduce	VB
O	NN

PI	NN
O	NN

and	CC
O	NN

increase	NN
O	NN

PT	NN
O	NN

significantly	RB
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

)	NN
O	NN

,	,
O	NN

but	CC
O	NNP

did	VBD
O	NNP

not	RB
O	NN

significantly	RB
O	NN

(	NN
O	NN

P	NN
O	NN

>	JJR
O	NN

0.05	CD
O	NN

)	NN
O	NN

improve	VB
O	NN

ROM	NN
O	NN

,	,
O	NN

as	IN
O	NN

compared	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

placebo	NN
O	NN

group	NN
O	NN

for	IN
O	NN

both	DT
O	NN

subgroups	NNS
O	NN

EMS	NNP
O	NNP

could	MD
O	NNP

significantly	RB
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

)	NN
O	NN

improve	VB
O	NN

ROM	NN
O	NN

,	,
O	NN

but	CC
O	NNP

not	RB
O	NN

PT	NN
O	NN

,	,
O	NN

better	JJR
O	NN

than	IN
O	NN

the	DT
O	NN

placebo	NN
O	NN

groups	NNS
O	NN

,	,
O	NN

for	IN
O	NN

either	DT
O	NN

subgroup	NN
O	NN

It	PRP
O	NN

could	MD
O	NNP

reduce	VB
O	NN

PI	NN
O	NN

significantly	RB
O	NN

more	RBR
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

)	NN
O	NN

than	IN
O	NN

placebo	NN
O	NN

controls	NNS
O	VBP

only	RB
O	NN

for	IN
O	NN

the	DT
O	NN

subgroup	NN
O	NN

with	IN
O	NN

mild	JJ
O	NN

to	TO
O	NN

moderate	JJ
O	NN

pain	NN
O	NN

,	,
O	NN

but	CC
O	NNP

not	RB
O	NN

with	IN
O	NN

severe	JJ
O	NN

pain	NN
O	NN

For	IN
O	NN

pain	NN
O	NN

relief	NN
O	NN

,	,
O	NN

ENS	NN
O	NN

was	VBD
O	NN

significantly	RB
O	NN

better	JJR
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

)	NN
O	NN

than	IN
O	NN

EMS	NNP
O	NNP

;	:
O	NN

but	CC
O	NNP

for	IN
O	NN

the	DT
O	NN

improvement	NN
O	NN

of	IN
O	NN

ROM	NN
O	NN

,	,
O	NN

EMS	NNP
O	NNP

was	VBD
O	NN

significantly	RB
O	NN

better	JJR
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

)	NN
O	NN

than	IN
O	NN

ENS	NN
O	NN

It	PRP
O	NN

is	VBZ
O	NN

concluded	VBD
O	NN

that	IN
O	NN

ENS	NN
T	NN

is	VBZ
O	NN

more	RBR
O	NN

effective	JJ
O	NN

for	IN
O	NN

immediate	JJ
O	NN

relief	NN
O	NN

of	IN
O	NN

myofascial	JJ
D	NN

trigger	NN
D	NN

point	NN
D	NN

pain	NN
D	NN

than	IN
O	NN

EMS	NNP
T	NN

,	,
O	NN

and	CC
O	NN

EMS	NNP
T	NN

has	VBZ
O	NN

a	DT
O	NN

better	JJR
O	NN

effect	NN
O	NN

on	IN
O	NN

immediate	JJ
O	NN

release	NN
O	NN

of	IN
O	NN

muscle	NN
D	NN

tightness	NN
D	NN

than	IN
O	NN

ENS	NN
T	NN

Because	IN
O	NN

activity	NN
O	NN

and	CC
O	NN

regular	JJ
O	NN

exercise	NN
O	NN

are	VBP
O	NN

important	JJ
O	NN

factors	NNS
O	NN

to	TO
O	NN

maintain	VB
O	NN

general	JJ
O	NN

good	JJ
O	NN

health	NN
O	NN

in	IN
O	NN

senior	JJ
O	NN

citizens	NNS
O	VBP

,	,
O	NN

we	PRP
O	VBP

investigated	VBN
O	NN

whether	IN
O	NN

senior	JJ
O	NN

dancing	VBG
O	NN

has	VBZ
O	NN

any	DT
O	NN

effect	NN
O	NN

on	IN
O	NN

peripheral	JJ
O	NN

or	CC
O	NN

lumbar	JJ
O	NN

bone	NN
O	NN

density	NN
O	NN

We	PRP
O	VBP

performed	VBN
O	NN

a	DT
O	NN

prospective	JJ
O	NN

study	NN
O	NN

over	IN
O	NN

a12-mo	JJ
O	NN

period	NN
O	NN

on	IN
O	NN

bone	NN
O	NN

density	NN
O	NN

at	IN
O	NN

a	DT
O	NN

spinal	JJ
O	NN

and	CC
O	NN

peripheral	JJ
O	NN

measuring	VBG
O	NN

site	NN
O	NN

in	IN
O	NN

28	CD
O	NN

female	JJ
O	NN

senior	JJ
O	NN

members	NNS
O	NN

(	NN
O	NN

mean	VB
O	NN

age	NN
O	NN

:	:
O	NN

67	CD
O	NN

+/-	CC
O	NN

2	CD
O	NN

yr	NN
O	NN

)	NN
O	NN

of	IN
O	NN

a	DT
O	NN

dancing	VBG
O	NN

group	NN
O	NN

in	IN
O	NN

Vienna	NNP
O	NNP

Lumbar	JJ
O	NN

bone	NN
O	NN

mineral	NN
O	NN

density	NN
O	NN

was	VBD
O	NN

assessed	VBN
O	NN

by	IN
O	NN

quantitative	JJ
O	NN

computed	VBN
O	NN

tomography	NN
O	NN

(	NN
O	NN

qCT	NN
O	NN

)	NN
O	NN

and	CC
O	NN

radial	JJ
O	NN

bone	NN
O	NN

density	NN
O	NN

by	IN
O	NN

single	JJ
O	NN

photon	NN
O	NN

absorptiometry	NN
O	NN

of	IN
O	NN

the	DT
O	NN

distal	JJ
O	NN

forearm	NN
O	NN

The	DT
O	NN

mean	VB
O	NN

training	NN
O	NN

time	NN
O	NN

per	IN
O	NN

week	NN
O	NN

was	VBD
O	NN

3.2	CD
O	NN

+/-	CC
O	NN

0.8	CD
O	NN

h.	NN
O	NN

In	IN
O	NN

the	DT
O	NN

entire	JJ
O	NN

group	NN
O	NN

of	IN
O	NN

female	JJ
O	NN

dancers	NNS
O	NN

,	,
O	NN

no	DT
O	NN

significant	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

dancing	VBG
O	NN

on	IN
O	NN

radial	JJ
O	NN

or	CC
O	NN

lumbar	JJ
O	NN

bone	NN
O	NN

density	NN
O	NN

could	MD
O	NNP

be	VB
O	NN

observed	VBN
O	NN

Linear	JJ
O	NN

regression	NN
O	NN

analysis	NN
O	NN

showed	VBD
O	NN

that	IN
O	NN

the	DT
O	NN

lower	JJR
O	NN

the	DT
O	NN

qCT	NN
O	NN

at	IN
O	NN

the	DT
O	NN

beginning	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

observation	NN
O	NN

period	NN
O	NN

,	,
O	NN

the	DT
O	NN

higher	JJR
O	NN

was	VBD
O	NN

the	DT
O	NN

percentage	NN
O	NN

increase	NN
O	NN

of	IN
O	NN

spinal	JJ
O	NN

qCT	NN
O	NN

in	IN
O	NN

the	DT
O	NN

entire	JJ
O	NN

group	NN
O	NN

during	IN
O	NN

12	CD
O	NN

mo	NN
O	NN

of	IN
O	NN

dancing	VBG
O	NN

(	NN
O	NN

r	NN
O	NN

=	JJ
O	NN

0.52	CD
O	NN

,	,
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.0001	CD
O	NN

)	NN
O	NN

For	IN
O	NN

additional	JJ
O	NN

evaluation	NN
O	NN

,	,
O	NN

females	NNS
O	NN

were	VBD
O	NN

divided	VBN
O	NN

into	IN
O	NN

two	CD
O	NN

subgroups	NNS
O	NN

,	,
O	NN

osteoporotic	JJ
O	NN

or	CC
O	NN

nonosteoporotic	JJ
O	NN

,	,
O	NN

based	VBN
O	NN

on	IN
O	NN

x-rays	NNPS
O	NN

and	CC
O	NN

lumbar	JJ
O	NN

bone	NN
O	NN

mineral	NN
O	NN

density	NN
O	NN

(	NN
O	NN

BMD	NN
O	NN

)	NN
O	NN

as	IN
O	NN

measured	VBN
O	NN

by	IN
O	NN

qCT	NN
O	NN

The	DT
O	NN

group	NN
O	NN

classified	VBN
O	NN

as	IN
O	NN

dancers	NNS
O	NN

with	IN
O	NN

osteoporosis	NN
O	NN

(	NN
O	NN

group	NN
O	NN

I	PRP
O	VBP

)	NN
O	NN

showed	VBD
O	NN

a	DT
O	NN

significant	JJ
O	NN

increase	NN
O	NN

in	IN
O	NN

lumbar	JJ
O	NN

bone	NN
O	NN

density	NN
O	NN

,	,
O	NN

whereas	IN
O	NN

in	IN
O	NN

the	DT
O	NN

group	NN
O	NN

of	IN
O	NN

dancers	NNS
O	NN

without	IN
O	NN

signs	NNS
O	IN

of	IN
O	NN

osteoporosis	NN
D	NN

(	NN
O	NN

group	NN
O	NN

II	NNP
O	NNP

)	NN
O	NN

,	,
O	NN

BMD	NN
O	NN

remained	VBD
O	NN

unchanged	JJ
O	NN

Additionally	RB
O	NN

,	,
O	NN

radial	JJ
O	NN

bone	NN
O	NN

density	NN
O	NN

did	VBD
O	NNP

not	RB
O	NN

show	NN
O	NN

any	DT
O	NN

changes	NNS
O	VBP

in	IN
O	NN

either	DT
O	NN

group	NN
O	NN

Group	NNP
O	NNP

I	PRP
O	VBP

showed	VBD
O	NN

a	DT
O	NN

significant	JJ
O	NN

correlation	NN
O	NN

between	IN
O	NN

basal	JJ
O	NN

spinal	JJ
O	NN

BMD	NN
O	NN

and	CC
O	NN

the	DT
O	NN

percentage	NN
O	NN

change	NN
O	NN

of	IN
O	NN

BMD	NN
O	NN

during	IN
O	NN

the	DT
O	NN

observation	NN
O	NN

period	NN
O	NN

(	NN
O	NN

r	NN
O	NN

=	JJ
O	NN

0.7	CD
O	NN

,	,
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.001	CD
O	NN

)	NN
O	NN

Changes	NNS
O	VBP

of	IN
O	NN

the	DT
O	NN

biochemical	JJ
O	NN

parameters	NNS
O	VBP

were	VBD
O	NN

observed	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

bone-specific	JJ
O	NN

isoenzyme	NN
O	NN

of	IN
O	NN

alkaline	NN
O	NN

phosphatase	NN
O	NN

,	,
O	NN

a	DT
O	NN

marker	NN
O	NN

of	IN
O	NN

osteoblastic	JJ
O	NN

activity	NN
O	NN

,	,
O	NN

in	IN
O	NN

group	NN
O	NN

I	PRP
O	VBP

giving	VBG
O	NN

additional	JJ
O	NN

evidence	NN
O	NN

of	IN
O	NN

increased	VBN
O	NN

bone	NN
O	NN

formation	NN
O	NN

OBJECTIVES	NNS
O	VBP

:	:
O	NN

To	TO
O	NN

estimate	NN
O	NN

the	DT
O	NN

prevalence	NN
O	NN

of	IN
O	NN

Chlamydia	NN
D	NN

trachomatis	NN
D	NN

in	IN
O	NN

asymptomatic	JJ
O	NN

women	NNS
O	VBP

attending	VBG
O	NN

general	JJ
O	NN

practice	NN
O	NN

:	:
O	NN

to	TO
O	NN

assess	VB
O	NN

the	DT
O	NN

potential	JJ
O	NN

of	IN
O	NN

the	DT
O	NN

ligase	NN
O	NN

chain	NN
O	NN

reaction	NN
O	NN

as	IN
O	NN

a	DT
O	NN

screening	VBG
O	NN

tool	NN
O	NN

;	:
O	NN

and	CC
O	NN

to	TO
O	NN

evaluate	VB
O	NN

selective	JJ
O	NN

screening	VBG
O	NN

criteria	NNS
O	NN

DESIGN	NN
O	NN

:	:
O	NN

Cross	NNP
O	NNP

sectional	JJ
O	NN

survey	NN
O	NN

SETTING	VBG
O	NN

:	:
O	NN

Four	CD
O	NN

general	JJ
O	NN

practices	NNS
O	VBP

in	IN
O	NN

northeast	RB
O	NN

London	NNP
O	NN

SUBJECTS	NNS
O	NN

:	:
O	NN

890	CD
O	NN

women	NNS
O	VBP

aged	JJ
O	NN

18-35	CD
O	NN

years	NNS
O	NN

attending	VBG
O	NN

general	JJ
O	NN

practice	NN
O	NN

for	IN
O	NN

a	DT
O	NN

cervical	JJ
O	NN

smear	JJ
O	NN

or	CC
O	NN

a	DT
O	NN

``	``
O	NN

young	JJ
O	NN

well	RB
O	NN

woman	NN
O	NN

''	''
O	NN

check	NN
O	NN

between	IN
O	NN

October	NNP
O	NN

1994	CD
O	NNP

and	CC
O	NN

January	NNP
O	NNP

1996	CD
O	NN

The	DT
O	NN

women	NNS
O	VBP

were	VBD
O	NN

tested	VBN
O	NN

for	IN
O	NN

C	NN
D	NN

trachomatis	NN
D	NN

with	IN
O	NN

confirmed	VBN
O	NN

enzyme	NN
O	NN

immunoassay	NN
O	NN

(	NN
O	NN

endocervical	JJ
O	NN

specimens	NNS
O	NN

)	NN
O	NN

and	CC
O	NN

ligase	NN
O	NN

chain	NN
O	NN

reaction	NN
O	NN

assay	NN
O	NN

on	IN
O	NN

urine	NN
O	NN

specimens	NNS
O	NN

MAIN	JJS
O	NN

OUTCOME	NN
O	NN

MEASURES	NNS
O	VBP

:	:
O	NN

Prevalence	NN
O	NN

of	IN
O	NN

C	NN
D	NN

trachomatis	NN
D	NN

infection	NN
D	NN

in	IN
O	NN

women	NNS
O	VBP

aged	JJ
O	NN

18-35	CD
O	NN

on	IN
O	NN

the	DT
O	NN

basis	NN
O	NN

of	IN
O	NN

each	DT
O	NN

test	NN
O	NN

;	:
O	NN

sensitivity	NN
O	NN

and	CC
O	NN

specificity	NN
O	NN

of	IN
O	NN

both	DT
O	NN

tests	NNS
O	NN

in	IN
O	NN

this	DT
O	NN

population	NN
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Prevalence	NN
O	NN

of	IN
O	NN

confirmed	VBN
O	NN

infection	NN
O	NN

was	VBD
O	NN

2.6	CD
O	NN

%	NN
O	NN

(	NN
O	NN

95	CD
O	NN

%	NN
O	NN

confidence	NN
O	NN

interval	NN
O	NN

1.6	CD
O	NN

%	NN
O	NN

to	TO
O	NN

3.6	CD
O	NN

%	NN
O	NN

)	NN
O	NN

in	IN
O	NN

all	DT
O	NN

women	NNS
O	VBP

Prevalence	NN
O	NN

on	IN
O	NN

the	DT
O	NN

basis	NN
O	NN

of	IN
O	NN

enzyme	NN
O	NN

immunoassay	NN
O	NN

was	VBD
O	NN

1.6	CD
O	NN

%	NN
O	NN

(	NN
O	NN

0.8	CD
O	NN

%	NN
O	NN

to	TO
O	NN

2.7	CD
O	NN

%	NN
O	NN

)	NN
O	NN

,	,
O	NN

with	IN
O	NN

a	DT
O	NN

sensitivity	NN
O	NN

of	IN
O	NN

60	CD
O	NN

%	NN
O	NN

and	CC
O	NN

a	DT
O	NN

specificity	NN
O	NN

of	IN
O	NN

100	CD
O	NN

%	NN
O	NN

Prevalence	NN
O	NN

on	IN
O	NN

the	DT
O	NN

basis	NN
O	NN

of	IN
O	NN

ligase	NN
O	NN

chain	NN
O	NN

reaction	NN
O	NN

was	VBD
O	NN

2.5	CD
O	NN

%	NN
O	NN

(	NN
O	NN

1.5	CD
O	NN

%	NN
O	NN

to	TO
O	NN

3.9	CD
O	NN

%	NN
O	NN

)	NN
O	NN

,	,
O	NN

with	IN
O	NN

90	CD
O	NN

%	NN
O	NN

sensitivity	NN
O	NN

and	CC
O	NN

99.8	CD
O	NN

%	NN
O	NN

specificity	NN
O	NN

Screening	VBG
O	NN

all	DT
O	NN

women	NNS
O	VBP

aged	JJ
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

or	CC
O	NN

=	JJ
O	NN

25	CD
O	NN

and	CC
O	NN

all	DT
O	NN

women	NNS
O	VBP

who	WP
O	VBP

had	VBD
O	NN

had	VBD
O	NN

two	CD
O	NN

or	CC
O	NN

more	RBR
O	NN

partners	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

past	JJ
O	NN

year	NN
O	NN

would	MD
O	NNP

have	VB
O	NN

detected	VBN
O	NN

87	CD
O	NN

%	NN
O	NN

(	NN
O	NN

20/23	CD
O	NN

)	NN
O	NN

of	IN
O	NN

infections	NNS
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

Ligase	NN
O	NN

chain	NN
O	NN

reaction	NN
O	NN

on	IN
O	NN

urine	NN
O	NN

samples	NNS
O	NN

performs	VBZ
O	NN

at	IN
O	NN

least	JJS
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

enzyme	NN
O	NN

immunoassay	NN
O	NN

on	IN
O	NN

cervical	JJ
O	NN

specimens	NNS
O	NN

in	IN
O	NN

this	DT
O	NN

low	JJ
O	NN

prevalence	NN
O	NN

population	NN
O	NN

It	PRP
O	NN

offers	NNS
O	VBP

potential	JJ
O	NN

as	IN
O	NN

a	DT
O	NN

non-invasive	JJ
O	NN

screening	VBG
O	NN

tool	NN
O	NN

A	DT
O	NN

simple	JJ
O	NN

selective	JJ
O	NN

screening	VBG
O	NN

strategy	NN
O	NN

might	MD
O	NNP

be	VB
O	NN

appropriate	JJ
O	NN

and	CC
O	NN

would	MD
O	NNP

be	VB
O	NN

able	JJ
O	NN

to	TO
O	NN

detect	VB
O	NN

most	JJS
O	NN

cases	NNS
O	NN

of	IN
O	NN

infection	NN
D	NN

However	RB
O	NN

,	,
O	NN

a	DT
O	NN

rigorous	JJ
O	NN

economic	JJ
O	NN

evaluation	NN
O	NN

of	IN
O	NN

possible	JJ
O	NN

screening	VBG
O	NN

strategies	NNS
O	VBP

is	VBZ
O	NN

needed	VBN
O	NN

first	RB
O	NN

Recently	RB
O	NN

,	,
O	NN

many	JJ
O	NN

advances	NNS
O	VBP

have	VB
O	NN

been	VBN
O	NN

made	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

study	NN
O	NN

of	IN
O	NN

sexual	JJ
O	NN

differentiation	NN
O	NN

,	,
O	NN

including	VBG
O	NN

the	DT
O	NN

discoveries	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

gene	NN
O	NN

for	IN
O	NN

antim1/4llerian	JJ
O	NN

hormone	NN
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

the	DT
O	NN

gene	NN
O	NN

for	IN
O	NN

its	PRP$
O	NN

receptor	NN
O	NN

However	RB
O	NN

,	,
O	NN

the	DT
O	NN

etiology	NN
O	NN

of	IN
O	NN

the	DT
O	NN

clinical	JJ
O	NN

syndrome	NN
O	NN

of	IN
O	NN

m1/4llerian	JJ
O	NN

agenesis	NN
O	NN

remains	VBZ
O	NNP

elusive	JJ
O	NN

We	PRP
O	VBP

hypothesize	VB
O	NN

that	IN
O	NN

activating	VBG
O	NN

mutations	NNS
O	VBP

of	IN
O	NN

either	DT
O	NN

the	DT
O	NN

antim1/4llerian	JJ
O	NN

hormone	NN
O	NN

gene	NN
O	NN

or	CC
O	NN

its	PRP$
O	NN

receptor	NN
O	NN

gene	NN
O	NN

may	MD
O	NNP

cause	NN
O	NN

m1/4llerian	JJ
O	NN

duct	NN
O	NN

regression	NN
O	NN

in	IN
O	NN

a	DT
O	NN

genetic	JJ
O	NN

female	JJ
O	NN

during	IN
O	NN

embryogenesis	NN
O	NN

This	DT
O	NN

clinical	JJ
O	NN

commentary	NN
O	NN

discusses	VBZ
O	NN

the	DT
O	NN

current	JJ
O	NN

management	NN
O	NN

of	IN
O	NN

the	DT
O	NN

syndrome	NN
O	NN

including	VBG
O	NN

the	DT
O	NN

Abbe-McIndoe	JJ
T	NN

procedure	NN
T	NN

,	,
O	NN

the	DT
O	NN

most	JJS
O	NN

commonly	RB
O	NN

used	VBN
O	NN

method	NN
O	NN

of	IN
O	NN

surgical	JJ
T	NN

correction	NN
T	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

Frank	NNP
T	NN

vaginal	JJ
T	NN

dilation	NN
T	NN

method	NN
T	NN

,	,
O	NN

the	DT
O	NN

most	JJS
O	NN

common	JJ
O	NN

nonsurgical	JJ
O	NN

method	NN
O	NN

of	IN
O	NN

correction	NN
O	NN

OBJECTIVES	NNS
O	VBP

:	:
O	NN

Obesity	NN
D	NN

is	VBZ
O	NN

an	DT
O	NN

important	JJ
O	NN

clinical	JJ
O	NN

problem	NN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

dexfenfluramine	NN
T	NN

hydrochloride	NN
T	NN

for	IN
O	NN

weight	NN
O	NN

reduction	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

widely	RB
O	NN

publicized	VBN
O	NN

since	IN
O	NN

its	PRP$
O	NN

approval	NN
O	NN

by	IN
O	NN

the	DT
O	NN

Food	NNP
O	NNP

and	CC
O	NN

Drug	NN
O	NN

Administration	NNP
O	NNP

However	RB
O	NN

,	,
O	NN

animal	NN
O	NN

and	CC
O	NN

human	JJ
O	NN

studies	NNS
O	VBP

have	VB
O	NN

demonstrated	VBD
O	NN

toxic	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

fenfluramines	NNS
T	NN

that	IN
O	NN

clinicians	NNS
O	NN

should	MD
O	NNP

be	VB
O	NN

aware	JJ
O	NN

of	IN
O	NN

when	WRB
O	NN

considering	VBG
O	NN

prescribing	VBG
O	NN

the	DT
O	NN

drugs	NNS
O	NN

Our	PRP$
O	NN

purpose	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

systematically	RB
O	NN

review	NN
O	NN

data	NNS
O	NN

on	IN
O	NN

brain	NN
O	NN

serotonin	NN
O	NN

neurotoxicity	NN
O	NN

in	IN
O	NN

animals	NNS
O	NN

treated	VBN
O	NN

with	IN
O	NN

fenfluramines	NNS
T	NN

and	CC
O	NN

the	DT
O	NN

evidence	NN
O	NN

linking	VBG
O	NN

fenfluramines	NNS
T	NN

to	TO
O	NN

primary	JJ
D	NN

pulmonary	JJ
D	NN

hypertension	NN
D	NN

(	NN
D	NN

PPH	NN
D	NN

)	NN
D	NN

DATA	NNP
O	NNP

SOURCES	NNS
O	VBP

:	:
O	NN

Archival	JJ
O	NN

articles	NNS
O	NN

and	CC
O	NN

reviews	NNS
O	VBP

identified	VBN
O	NN

through	IN
O	NN

a	DT
O	NN

computerized	JJ
O	NN

search	NN
O	NN

of	IN
O	NN

MEDLINE	NN
O	NN

from	IN
O	NN

1966	CD
O	NN

to	TO
O	NN

April	NNP
O	NNP

1997	CD
O	NN

using	VBG
O	NN

``	``
O	NN

fenfluramine	NN
O	NN

(	NN
O	NN

s	NNS
O	NN

)	NN
O	NN

,	,
O	NN

''	''
O	NN

``	``
O	NN

serotonin	NN
O	NN

,	,
O	NN

''	''
O	NN

``	``
O	NN

neurotoxicity	NN
O	NN

,	,
O	NN

''	''
O	NN

``	``
O	NN

behavior	NN
O	NN

,	,
O	NN

''	''
O	NN

``	``
O	NN

anorexigens	NNS
O	NN

,	,
O	NN

''	''
O	NN

``	``
O	NN

weight	NN
O	NN

loss	NN
O	NN

,	,
O	NN

''	''
O	NN

and	CC
O	NN

``	``
O	NN

primary	JJ
O	NN

pulmonary	JJ
O	NN

hypertension	NN
O	NN

''	''
O	NN

as	IN
O	NN

index	NN
O	NN

terms	NNS
O	NN

STUDY	NN
O	NN

SELECTION	NN
O	NN

:	:
O	NN

Reports	NNS
O	NN

dealing	VBG
O	NN

with	IN
O	NN

long-term	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

fenfluramines	NNS
T	NN

on	IN
O	NN

brain	NN
O	NN

serotonin	NN
O	NN

neurons	NNS
O	NN

,	,
O	NN

body	NN
O	NN

weight	NN
O	NN

,	,
O	NN

and	CC
O	NN

pulmonary	JJ
O	NN

function	NN
O	NN

in	IN
O	NN

animals	NNS
O	NN

and	CC
O	NN

humans	NNS
O	NN

DATA	NNP
O	NNP

EXTRACTION	NN
O	NN

:	:
O	NN

Reports	NNS
O	NN

were	VBD
O	NN

reviewed	VBN
O	NN

by	IN
O	NN

individuals	NNS
O	VBP

with	IN
O	NN

expertise	NN
O	NN

in	IN
O	NN

serotonin	NN
O	NN

neurobiology	NN
O	NN

,	,
O	NN

neurotoxicity	NN
O	NN

,	,
O	NN

neuropsychiatry	NN
O	NN

,	,
O	NN

and	CC
O	NN

pulmonary	JJ
O	NN

medicine	NN
O	NN

and	CC
O	NN

evaluated	VBN
O	NN

for	IN
O	NN

appropriateness	NN
O	NN

for	IN
O	NN

inclusion	NN
O	NN

in	IN
O	NN

this	DT
O	NN

review	NN
O	NN

DATA	NNP
O	NNP

SYNTHESIS	NN
O	NN

:	:
O	NN

Fenfluramines	NNS
T	NN

cause	NN
O	NN

dose-related	JJ
O	NN

,	,
O	NN

long-lasting	JJ
O	NN

reductions	NNS
O	NN

in	IN
O	NN

serotonin	NN
O	NN

axonal	JJ
O	NN

markers	NNS
O	VBP

in	IN
O	NN

all	DT
O	NN

the	DT
O	NN

animal	NN
O	NN

species	NNS
O	NN

tested	VBN
O	NN

and	CC
O	NN

with	IN
O	NN

all	DT
O	NN

the	DT
O	NN

routes	NNS
O	NN

of	IN
O	NN

drug	NN
O	NN

administration	NN
O	NN

used	VBN
O	NN

Doses	NNS
O	NN

of	IN
O	NN

fenfluramines	NNS
O	NN

that	IN
O	NN

produce	VB
O	NN

signs	NNS
O	IN

of	IN
O	NN

brain	NN
O	NN

serotonin	NN
O	NN

neurotoxicity	NN
O	NN

in	IN
O	NN

animals	NNS
O	NN

are	VBP
O	NN

on	IN
O	NN

the	DT
O	NN

same	JJ
O	NN

order	NN
O	NN

as	IN
O	NN

those	DT
O	NNP

used	VBN
O	NN

to	TO
O	NN

treat	VB
O	NNP

humans	NNS
O	NN

for	IN
O	NN

weight	NN
O	NN

loss	NN
O	NN

when	WRB
O	NN

one	CD
O	NN

takes	VBZ
O	NN

into	IN
O	NN

account	NN
O	NN

known	JJ
O	NN

relations	NNS
O	NN

between	IN
O	NN

body	NN
O	NN

mass	NN
O	NN

and	CC
O	NN

drug	NN
O	NN

clearance	NN
O	NN

However	RB
O	NN

,	,
O	NN

no	DT
O	NN

human	JJ
O	NN

studies	NNS
O	VBP

have	VB
O	NN

been	VBN
O	NN

conducted	VBN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

pathological	JJ
O	NN

and	CC
O	NN

clinical	JJ
O	NN

potential	JJ
O	NN

for	IN
O	NN

neurotoxicity	NN
O	NN

in	IN
O	NN

humans	NNS
O	NN

is	VBZ
O	NN

unknown	JJ
O	NN

Appetite	NN
O	NN

suppressants-most	JJ
O	NN

commonly	RB
O	NN

fenfluramines	NNS
T	NN

-increase	NN
O	NN

the	DT
O	NN

risk	NN
O	NN

of	IN
O	NN

developing	VBG
O	NN

PPH	NN
D	NN

(	NN
O	NN

odds	NNS
O	NN

ratio	NN
O	NN

,	,
O	NN

6.3	CD
O	NN

)	NN
O	NN

,	,
O	NN

particularly	RB
O	NN

when	WRB
O	NN

used	VBN
O	NN

for	IN
O	NN

more	RBR
O	NN

than	IN
O	NN

3	CD
O	NN

months	NNS
O	NN

(	NN
O	NN

odds	NNS
O	NN

ratio	NN
O	NN

,	,
O	NN

>	JJR
O	NN

20	CD
O	NN

)	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Fenfluramine	NN
T	NN

and	CC
O	NN

dexfenfluramine	NN
T	NN

have	VB
O	NN

been	VBN
O	NN

demonstrated	VBD
O	NN

to	TO
O	NN

damage	NN
O	NN

brain	NN
O	NN

serotonin	NN
O	NN

neurons	NNS
O	NN

in	IN
O	NN

animal	NN
O	NN

studies	NNS
O	VBP

It	PRP
O	NN

is	VBZ
O	NN

not	RB
O	NN

known	JJ
O	NN

if	IN
O	NN

such	JJ
O	NN

damage	NN
O	NN

occurs	VBZ
O	NN

in	IN
O	NN

humans	NNS
O	NN

or	CC
O	NN

if	IN
O	NN

there	RB
O	NN

are	VBP
O	NN

clinical	JJ
O	NN

consequences	NNS
O	NN

Use	NNP
O	NNP

of	IN
O	NN

fenfluramines	NNS
T	NN

is	VBZ
O	NN

associated	VBN
O	NN

with	IN
O	NN

an	DT
O	NN

increased	VBN
O	NN

risk	NN
O	NN

of	IN
O	NN

PPH	NN
D	NN

Future	JJ
O	NN

studies	NNS
O	VBP

should	MD
O	NNP

address	NN
O	NN

the	DT
O	NN

long-term	JJ
O	NN

consequences	NNS
O	NN

of	IN
O	NN

prolonged	JJ
O	NN

use	NN
O	NN

of	IN
O	NN

fenfluramines	NNS
T	NN

Moxonidine	NN
T	NN

(	NN
T	NN

Physiotens-Solvay	JJ
T	NN

)	NN
T	NN

was	VBD
O	NN

introduced	VBN
O	NN

last	JJ
O	NN

year	NN
O	NN

as	IN
O	NN

the	DT
O	NN

first	RB
O	NN

of	IN
O	NN

a	DT
O	NN

new	JJ
O	NN

class	NN
O	NN

of	IN
O	NN

centrally-acting	JJ
O	NN

antihypertensive	JJ
T	NN

agents	NNS
T	NN

,	,
O	NN

the	DT
O	NN

selective	JJ
O	NN

imidazoline	NN
O	NN

receptor	NN
O	NN

agonists	NNS
O	NN

The	DT
O	NN

manufacturer	NN
O	NN

claims	NNS
O	IN

that	IN
O	NN

moxonidine	NN
T	NN

``	``
O	NN

accurately	RB
O	NN

targets	NNS
O	VBP

imidazoline	NN
O	NN

receptors	NNS
O	VBP

at	IN
O	NN

the	DT
O	NN

cardiovascular	JJ
O	NN

control	NN
O	NN

centre	NN
O	NN

in	IN
O	NN

the	DT
O	NN

brainstem	NN
O	NN

''	''
O	NN

and	CC
O	NN

is	VBZ
O	NN

``	``
O	NN

as	IN
O	NN

effective	JJ
O	NN

as	IN
O	NN

current	JJ
O	NN

first-line	JJ
O	NN

therapies	NNS
O	NN

for	IN
O	NN

essential	JJ
D	NN

hypertension	NN
D	NN

``	``
O	NN

Other	JJ
O	NN

claims	NNS
O	IN

suggest	VBP
O	NN

that	IN
O	NN

it	PRP
O	NN

causes	NNS
O	VBP

fewer	JJR
O	NN

unwanted	JJ
O	NN

effects	NNS
O	NN

than	IN
O	NN

older	JJR
O	NN

centrally-acting	JJ
O	NN

antihypertensive	JJ
T	NN

drugs	NNS
T	NN

such	JJ
O	NN

as	IN
O	NN

clonidine	NN
T	NN

and	CC
O	NN

methyldopa	NN
T	NN

Is	VBZ
O	NN

moxonidine	NN
T	NN

a	DT
O	NN

useful	JJ
O	NN

addition	NN
O	NN

to	TO
O	NN

the	DT
O	NN

growing	VBG
O	NN

number	NN
O	NN

of	IN
O	NN

antihypertensives	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

market	NN
O	NN

?	.
O	NN

This	DT
O	NN

article	NN
O	NN

discusses	VBZ
O	NN

dental	JJ
O	NN

anxiety	NN
O	NN

and	CC
O	NN

phobia	NN
O	NN

The	DT
O	NN

author	NN
O	NN

presents	NNS
O	NN

background	NN
O	NN

information	NN
O	NN

,	,
O	NN

including	VBG
O	NN

incidence	NN
O	NN

and	CC
O	NN

etiology	NN
O	NN

A	DT
O	NN

discussion	NN
O	NN

of	IN
O	NN

evaluative	JJ
O	NN

techniques	NNS
O	VBP

for	IN
O	NN

assessing	VBG
O	NN

anxiety	NN
O	NN

levels	NNS
O	VBP

follows	VBZ
O	NN

Examination	NN
O	NN

and	CC
O	NN

treatment	NN
O	NN

planning	VBG
O	NN

are	VBP
O	NN

considered	VBN
O	NN

in	IN
O	NN

relation	NN
O	NN

to	TO
O	NN

this	DT
O	NN

patient	NN
O	NN

's	POS
O	NN

special	JJ
O	NN

needs	NNS
O	VBP

The	DT
O	NN

article	NN
O	NN

stresses	NNS
O	VBP

behavioral	JJ
O	NN

treatment	NN
O	NN

modalities	NNS
O	NN

that	IN
O	NN

eliminate	VB
O	NN

the	DT
O	NN

debilitating	VBG
O	NN

phobia	NN
O	NN

In	IN
O	NN

closing	VBG
O	NN

,	,
O	NN

the	DT
O	NN

author	NN
O	NN

presents	NNS
O	NN

practical	JJ
O	NN

information	NN
O	NN

regarding	VBG
O	NN

prevention	NN
O	NN

of	IN
O	NN

dental	JJ
O	NN

phobia	NN
O	NN

and	CC
O	NN

the	DT
O	NN

merits	NNS
O	NN

of	IN
O	NN

incorporating	VBG
O	NN

this	DT
O	NN

type	NN
O	NN

of	IN
O	NN

patient	NN
O	NN

into	IN
O	NN

a	DT
O	NN

dental	JJ
O	NN

practice	NN
O	NN

In	IN
O	NN

order	NN
O	NN

to	TO
O	NN

evaluate	VB
O	NN

the	DT
O	NN

applicability	NN
O	NN

of	IN
O	NN

anthelminthic	JJ
T	NN

treatment	NN
T	NN

of	IN
O	NN

wild	JJ
O	NN

foxes	NNS
O	NN

(	NN
O	NN

Vulpes	NNP
O	NNP

vulpes	NNS
O	NN

)	NN
O	NN

to	TO
O	NN

limit	NN
O	NN

their	PRP$
O	NN

infection	NN
D	NN

with	IN
D	NN

Echinococcus	NN
D	NN

multilocularis	NN
D	NN

,	,
O	NN

bait	NN
O	NN

pellets	NNS
O	NN

,	,
O	NN

each	DT
O	NN

containing	VBG
O	NN

50	CD
O	NN

mg	NN
O	NN

praziquantel	NN
T	NN

,	,
O	NN

were	VBD
O	NN

repeatedly	RB
O	NN

distributed	VBN
O	NN

in	IN
O	NN

an	DT
O	NN

area	NN
O	NN

of	IN
O	NN

566	CD
O	NN

km2	NN
O	NN

where	WRB
O	NN

many	JJ
O	NN

foxes	NNS
O	NN

are	VBP
O	NN

infected	JJ
O	NN

,	,
O	NN

in	IN
O	NN

southern	JJ
O	NN

Germany	NNP
O	NNP

After	IN
O	NN

six	CD
O	NN

baiting	VBG
O	NN

campaigns	NNS
O	VBP

(	NN
O	NN

15-20	CD
O	NN

baits/km2	NN
O	NN

)	NN
O	NN

over	IN
O	NN

a	DT
O	NN

period	NN
O	NN

of	IN
O	NN

14	CD
O	NN

months	NNS
O	NN

,	,
O	NN

the	DT
O	NN

prevalence	NN
O	NN

of	IN
O	NN

the	DT
O	NN

cestode	NN
O	NN

in	IN
O	NN

foxes	NNS
O	NN

,	,
O	NN

initially	RB
O	NN

32	CD
O	NN

%	NN
O	NN

,	,
O	NN

had	VBD
O	NN

fallen	VBN
O	NN

to	TO
O	NN

4	CD
O	NN

%	NN
O	NN

The	DT
O	NN

effect	NN
O	NN

was	VBD
O	NN

most	JJS
O	NN

pronounced	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

central	JJ
O	NN

part	NN
O	NN

of	IN
O	NN

the	DT
O	NN

treated	VBN
O	NN

area	NN
O	NN

,	,
O	NN

where	WRB
O	NN

no	DT
O	NN

positive	JJ
O	NN

fox	NN
O	NN

was	VBD
O	NN

found	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

2	CD
O	NN

months	NNS
O	NN

before	IN
O	NN

the	DT
O	NN

end	NN
O	NN

of	IN
O	NN

the	DT
O	NN

trial	NN
O	NN

The	DT
O	NN

study	NN
O	NN

was	VBD
O	NN

controlled	JJ
O	NN

for	IN
O	NN

other	JJ
O	NN

factors	NNS
O	NN

that	IN
O	NN

could	MD
O	NNP

influence	NN
O	NN

the	DT
O	NN

parasite	NN
O	NN

's	POS
O	NN

prevalence	NN
O	NN

,	,
O	NN

such	JJ
O	NN

as	IN
O	NN

the	DT
O	NN

availability	NN
O	NN

of	IN
O	NN

intermediate	JJ
O	NN

hosts	NNS
O	VBP

While	IN
O	NN

the	DT
O	NN

potential	JJ
O	NN

of	IN
O	NN

this	DT
O	NN

baiting	VBG
O	NN

method	NN
O	NN

to	TO
O	NN

remove	VB
O	NN

E	NN
O	NN

multilocularis	JJ
O	NN

from	IN
O	NN

wild	JJ
O	NN

hosts	NNS
O	VBP

has	VBZ
O	NN

been	VBN
O	NN

demonstrated	VBD
O	NN

,	,
O	NN

the	DT
O	NN

question	NN
O	NN

of	IN
O	NN

its	PRP$
O	NN

long-term	JJ
O	NN

efficacy	NN
O	NN

and	CC
O	NN

other	JJ
O	NN

unresolved	JJ
O	NN

problems	NNS
O	VBP

have	VB
O	NN

to	TO
O	NN

be	VB
O	NN

addressed	VBD
O	NN

by	IN
O	NN

consecutive	JJ
O	NN

studies	NNS
O	VBP

before	IN
O	NN

routine	JJ
O	NN

application	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

recommended	VBN
O	NN

In	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

myeloid	JJ
D	NN

leukemia	NN
D	NN

(	NN
D	NN

CML	NN
D	NN

)	NN
D	NN

,	,
O	NN

the	DT
O	NN

neoplastic	JJ
O	NN

(	NN
O	NN

BCR-ABL+	JJ
O	NN

)	NN
O	NN

progenitor	NN
O	NN

cells	NNS
O	VBP

are	VBP
O	NN

characterized	VBN
O	NN

by	IN
O	NN

an	DT
O	NN

increased	VBN
O	NN

proliferative	JJ
O	NN

activity	NN
O	NN

Whether	IN
O	NN

these	DT
O	NN

cells	NNS
O	VBP

are	VBP
O	NN

also	RB
O	NN

resistant	JJ
O	NN

to	TO
O	NN

apoptosis	NN
O	NN

and	CC
O	NN

if	IN
O	NN

so	RB
O	NN

,	,
O	NN

under	IN
O	NN

what	WDT
O	NN

conditions	NNS
O	VBP

remains	VBZ
O	NNP

controversial	JJ
O	NN

We	PRP
O	VBP

now	RB
O	NN

show	NN
O	NN

that	IN
O	NN

highly	RB
O	NN

purified	VBN
O	NN

populations	NNS
O	NN

of	IN
O	NN

very	RB
O	NN

primitive	JJ
O	NN

neoplastic	JJ
O	NN

progenitor	NN
O	NN

cells	NNS
O	VBP

obtained	VBN
O	NN

directly	RB
O	NN

from	IN
O	NN

CML	NN
O	NN

patients	NNS
O	NN

survive	VB
O	NN

and	CC
O	NN

proliferate	VB
O	NN

in	IN
O	NN

vitro	FW
O	FW

for	IN
O	NN

several	JJ
O	NN

weeks	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

absence	NN
O	NN

of	IN
O	NN

any	DT
O	NN

added	VBN
O	NN

growth	NN
O	NN

factors	NNS
O	NN

(	NN
O	NN

except	IN
O	NN

insulin	NN
O	NN

)	NN
O	NN

In	IN
O	NN

contrast	NN
O	NN

,	,
O	NN

purified	VBN
O	NN

primary	JJ
O	NN

normal	JJ
O	NN

progenitors	NNS
O	NN

maintained	JJ
O	NN

under	IN
O	NN

the	DT
O	NN

same	JJ
O	NN

conditions	NNS
O	VBP

die	VB
O	NN

rapidly	RB
O	NN

Nevertheless	RB
O	NN

,	,
O	NN

both	DT
O	NN

primary	JJ
O	NN

CML	NN
O	NN

cells	NNS
O	VBP

and	CC
O	NN

BCR-ABL+	JJ
O	NN

BAF3	NN
O	NN

cells	NNS
O	VBP

show	NN
O	NN

the	DT
O	NN

same	JJ
O	NN

dose-dependent	JJ
O	NN

sensitivity	NN
O	NN

to	TO
O	NN

TNF-alpha	NN
O	NN

or	CC
O	NN

ceramide-induced	JJ
O	NN

apoptosis	NN
O	NN

as	IN
O	NN

their	PRP$
O	NN

respective	JJ
O	NN

normal	JJ
O	NN

counterparts	NNS
O	NN

In	IN
O	NN

fact	NN
O	NN

,	,
O	NN

time	NN
O	NN

course	NN
O	NN

studies	NNS
O	VBP

demonstrated	VBD
O	NN

an	DT
O	NN

even	RB
O	NN

faster	RBR
O	NN

onset	NN
O	NN

of	IN
O	NN

apoptosis	NN
O	NN

in	IN
O	NN

ceramide-treated	JJ
O	NN

BCR-ABL+	JJ
O	NN

BAF3	NN
O	NN

cells	NNS
O	VBP

as	IN
O	NN

compared	VBN
O	NN

to	TO
O	NN

normal	JJ
O	NN

controls	NNS
O	VBP

BCR-ABL+	JJ
O	NN

cells	NNS
O	VBP

treated	VBN
O	NN

with	IN
O	NN

ceramide	NN
O	NN

also	RB
O	NN

showed	VBD
O	NN

a	DT
O	NN

rapid	JJ
O	NN

and	CC
O	NN

sequential	JJ
O	NN

increase	NN
O	NN

in	IN
O	NN

the	DT
O	NN

tyrosine	NN
O	NN

phosphorylation	NN
O	NN

of	IN
O	NN

p210	NN
O	NN

(	NN
O	NN

BCR-ABL	NN
O	NN

)	NN
O	NN

,	,
O	NN

p46-56SHC	NN
O	NN

and	CC
O	NN

p120Cbl	NN
O	NN

These	DT
O	NN

findings	NNS
O	VBP

suggest	VBP
O	NN

growth	NN
O	NN

factor	NN
O	NN

deprivation	NN
O	NN

and	CC
O	NN

treatment	NN
O	NN

with	IN
O	NN

TNF-alpha	NN
O	NN

or	CC
O	NN

ceramide	NN
O	NN

trigger	NN
O	NN

different	JJ
O	NN

initial	JJ
O	NN

events	NNS
O	NN

both	DT
O	NN

of	IN
O	NN

which	WDT
O	NN

can	MD
O	NNP

lead	JJ
O	NN

to	TO
O	NN

apoptosis	NN
O	NN

in	IN
O	NN

factor-dependent	JJ
O	NN

hematopoietic	JJ
O	NN

cells	NNS
O	VBP

However	RB
O	NN

,	,
O	NN

in	IN
O	NN

the	DT
O	NN

first	RB
O	NN

case	NN
O	NN

,	,
O	NN

activation	NN
O	NN

of	IN
O	NN

apoptosis	NN
O	NN

is	VBZ
O	NN

blocked	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

basal	JJ
O	NN

activity	NN
O	NN

of	IN
O	NN

p210	NN
O	NN

(	NN
O	NN

BCR-ABL	NN
O	NN

)	NN
O	NN

,	,
O	NN

whereas	IN
O	NN

in	IN
O	NN

the	DT
O	NN

second	JJ
O	NN

,	,
O	NN

the	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

p210	NN
O	NN

(	NN
O	NN

BCR-ABL	NN
O	NN

)	NN
O	NN

appears	VBZ
O	NN

to	TO
O	NN

accelerate	VB
O	NN

the	DT
O	NN

onset	NN
O	NN

of	IN
O	NN

apoptosis	NN
O	NN

by	IN
O	NN

a	DT
O	NN

mechanism	NN
O	NN

that	IN
O	NN

may	MD
O	NNP

involve	VB
O	NN

an	DT
O	NN

activation	NN
O	NN

of	IN
O	NN

its	PRP$
O	NN

kinase	NN
O	NN

function	NN
O	NN

Clinically	RB
O	NN

,	,
O	NN

the	DT
O	NN

hallmark	NN
O	NN

of	IN
O	NN

the	DT
O	NN

human	JJ
D	NN

amnesic	JJ
D	NN

syndrome	NN
D	NN

is	VBZ
O	NN

an	DT
O	NN

impaired	JJ
O	NN

ability	NN
O	NN

to	TO
O	NN

consciously	RB
O	NN

recollect	NN
O	NN

or	CC
O	NN

remember	VB
O	NN

daily	RB
O	NN

events	NNS
O	NN

If	IN
O	NN

the	DT
O	NN

medial	JJ
O	NN

region	NN
O	NN

of	IN
O	NN

the	DT
O	NN

temporal	JJ
O	NN

lobes	NNS
O	VBP

,	,
O	NN

including	VBG
O	NN

the	DT
O	NN

hippocampus	NN
O	NN

and	CC
O	NN

related	JJ
O	NN

structures	NNS
O	VBP

,	,
O	NN

is	VBZ
O	NN

critical	JJ
O	NN

for	IN
O	NN

establishing	VBG
O	NN

these	DT
O	NN

new	JJ
O	NN

memories	NNS
O	NN

,	,
O	NN

then	RB
O	NN

this	DT
O	NN

brain	NN
O	NN

region	NN
O	NN

should	MD
O	NNP

be	VB
O	NN

active	JJ
O	NN

whenever	WRB
O	NN

events	NNS
O	NN

are	VBP
O	NN

experienced	JJ
O	NN

,	,
O	NN

regardless	RB
O	NN

of	IN
O	NN

whether	IN
O	NN

subjects	NNS
O	NN

are	VBP
O	NN

asked	VBD
O	NNP

explicitly	RB
O	NN

to	TO
O	NN

learn	VB
O	NN

and	CC
O	NN

remember	VB
O	NN

Here	RB
O	NN

we	PRP
O	VBP

show	NN
O	NN

that	IN
O	NN

the	DT
O	NN

medial	JJ
O	NN

temporal	JJ
O	NN

region	NN
O	NN

is	VBZ
O	NN

active	JJ
O	NN

during	IN
O	NN

encoding	VBG
O	NN

and	CC
O	NN

that	IN
O	NN

the	DT
O	NN

hemisphere	NN
O	NN

activated	VBN
O	NN

and	CC
O	NN

the	DT
O	NN

amount	NN
O	NN

of	IN
O	NN

activation	NN
O	NN

depend	VB
O	NN

on	IN
O	NN

the	DT
O	NN

type	NN
O	NN

of	IN
O	NN

stimulus	NN
O	NN

presented	VBN
O	NN

(	NN
O	NN

objects	NNS
O	NN

or	CC
O	NN

words	NNS
O	NN

)	NN
O	NN

,	,
O	NN

whether	IN
O	NN

the	DT
O	NN

stimulus	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

encoded	VBN
O	NN

for	IN
O	NN

meaning	VBG
O	NN

(	NN
O	NN

real	JJ
O	NN

objects	NNS
O	NN

and	CC
O	NN

words	NNS
O	NN

versus	CC
O	NN

nonsense	NN
O	NN

objects	NNS
O	NN

and	CC
O	NN

words	NNS
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

task	NN
O	NN

experience	NN
O	NN

(	NN
O	NN

first	RB
O	NN

versus	CC
O	NN

the	DT
O	NN

second	JJ
O	NN

time	NN
O	NN

a	DT
O	NN

task	NN
O	NN

is	VBZ
O	NN

performed	VBN
O	NN

)	NN
O	NN

These	DT
O	NN

findings	NNS
O	VBP

demonstrate	VB
O	NN

that	IN
O	NN

the	DT
O	NN

medial	JJ
O	NN

temporal	JJ
O	NN

lobe	NN
O	NN

memory	NN
O	NN

system	NN
O	NN

is	VBZ
O	NN

engaged	VBN
O	NN

automatically	RB
O	NN

when	WRB
O	NN

we	PRP
O	VBP

attend	VB
O	NN

to	TO
O	NN

a	DT
O	NN

perceptual	JJ
O	NN

event	NN
O	NN

and	CC
O	NN

that	IN
O	NN

the	DT
O	NN

location	NN
O	NN

and	CC
O	NN

amount	NN
O	NN

of	IN
O	NN

activation	NN
O	NN

depend	VB
O	NN

on	IN
O	NN

stimulus	NN
O	NN

characteristics	NNS
O	NN

(	NN
O	NN

physical	JJ
O	NN

form	NN
O	NN

,	,
O	NN

meaning	VBG
O	NN

)	NN
O	NN

and	CC
O	NN

experience	NN
O	NN

The	DT
O	NN

involvement	NN
O	NN

of	IN
O	NN

structures	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

medial	JJ
O	NN

temporal	JJ
O	NN

lobe	NN
O	NN

during	IN
O	NN

the	DT
O	NN

encoding	VBG
O	NN

of	IN
O	NN

visual	JJ
O	NN

associations	NNS
O	NN

was	VBD
O	NN

studied	VBN
O	NN

with	IN
O	NN

functional	JJ
O	NN

magnetic	JJ
O	NN

resonance	NN
O	NN

imaging	NN
O	NN

In	IN
O	NN

11	CD
O	NN

out	IN
O	NN

of	IN
O	NN

12	CD
O	NN

normal	JJ
O	NN

healthy	JJ
O	NN

volunteers	NNS
O	NN

this	DT
O	NN

task	NN
O	NN

resulted	VBD
O	NN

in	IN
O	NN

activation	NN
O	NN

in	IN
O	NN

posterior	JJ
O	NN

portions	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

parahippocampal	JJ
O	NN

region	NN
O	NN

,	,
O	NN

close	RB
O	NN

to	TO
O	NN

the	DT
O	NN

collateral	NN
O	NN

sulcus	NN
O	NN

In	IN
O	NN

seven	CD
O	NN

subjects	NNS
O	NN

activation	NN
O	NN

was	VBD
O	NN

encountered	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

hippocampal	JJ
O	NN

formation	NN
O	NN

The	DT
O	NN

visual	JJ
O	NN

association	NN
O	NN

task	NN
O	NN

as	IN
O	NN

adapted	VBN
O	NN

for	IN
O	NN

this	DT
O	NN

study	NN
O	NN

may	MD
O	NNP

provide	VB
O	NN

a	DT
O	NN

sensitive	JJ
O	NN

measure	NN
O	NN

to	TO
O	NN

study	NN
O	NN

anterograde	NN
O	NN

amnesia	NN
O	NN

prevalent	JJ
O	NN

in	IN
O	NN

Alzheimer	NN
O	NN

's	POS
O	NN

disease	NN
O	NN

Therefore	RB
O	NN

,	,
O	NN

the	DT
O	NN

present	JJ
O	NN

paradigm	NN
O	NN

enables	VBZ
O	NN

the	DT
O	NN

study	NN
O	NN

of	IN
O	NN

individual	JJ
O	NN

changes	NNS
O	VBP

in	IN
O	NN

learning	VBG
O	NN

and	CC
O	NN

memory	NN
O	NN

capacities	NNS
O	VBP

over	IN
O	NN

time	NN
O	NN

Altered	JJ
O	NN

calcium	NN
O	NN

(	NN
O	NN

Ca2+	NN
O	NN

)	NN
O	NN

homeostasis	NN
O	NN

is	VBZ
O	NN

thought	VBN
O	NN

to	TO
O	NN

play	VB
O	NN

a	DT
O	NN

key	JJ
O	NN

role	NN
O	NN

in	IN
O	NN

aging	VBG
O	NN

and	CC
O	NN

neuropathology	NN
O	NN

resulting	VBG
O	NN

in	IN
O	NN

memory	NN
O	NN

deficits	NNS
O	NN

Several	JJ
O	NN

forms	NNS
O	NN

of	IN
O	NN

hippocampal	JJ
O	NN

synaptic	JJ
O	NN

plasticity	NN
O	NN

are	VBP
O	NN

dependent	JJ
O	NN

on	IN
O	NN

Ca2+	NN
O	NN

,	,
O	NN

providing	VBG
O	NN

a	DT
O	NN

potential	JJ
O	NN

link	NN
O	NN

between	IN
O	NN

altered	JJ
O	NN

Ca2+	NN
O	NN

homeostasis	NN
O	NN

and	CC
O	NN

memory	NN
O	NN

deficits	NNS
O	NN

associated	VBN
O	NN

with	IN
O	NN

aging	VBG
O	NN

The	DT
O	NN

current	JJ
O	NN

study	NN
O	NN

reviews	NNS
O	VBP

evidence	NN
O	NN

for	IN
O	NN

Ca2+	NN
O	NN

dysregulation	NN
O	NN

during	IN
O	NN

aging	VBG
O	NN

which	WDT
O	NN

could	MD
O	NNP

interact	VBP
O	NN

with	IN
O	NN

Ca	NN
O	NN

(	NN
O	NN

2+	JJ
O	NN

)	NN
O	NN

-dependent	JJ
O	NN

synaptic	JJ
O	NN

plasticity	NN
O	NN

The	DT
O	NN

authors	NNS
O	NN

suggest	VBP
O	NN

that	IN
O	NN

changes	NNS
O	VBP

in	IN
O	NN

Ca2+	NN
O	NN

regulation	NN
O	NN

could	MD
O	NNP

adjust	VBP
O	NN

the	DT
O	NN

thresholds	NNS
O	NN

for	IN
O	NN

synaptic	JJ
O	NN

modification	NN
O	NN

,	,
O	NN

favoring	VBG
O	NN

processes	NNS
O	VBP

for	IN
O	NN

depression	NN
O	NN

of	IN
O	NN

synaptic	JJ
O	NN

strength	NN
O	NN

during	IN
O	NN

aging	VBG
O	NN

Transiently	RB
O	NN

evolked	VBN
O	NN

otoacoustic	JJ
O	NN

emissions	NNS
O	NN

(	NN
O	NN

TEOAE	NN
O	NN

)	NN
O	NN

have	VB
O	NN

been	VBN
O	NN

reported	VBN
O	NN

in	IN
O	NN

several	JJ
O	NN

studies	NNS
O	VBP

as	IN
O	NN

absent	JJ
O	NN

in	IN
O	NN

a	DT
O	NN

small	JJ
O	NN

minority	NN
O	NN

of	IN
O	NN

normal	JJ
O	NN

ears	NNS
O	NN

Other	JJ
O	NN

studies	NNS
O	VBP

have	VB
O	NN

reported	VBN
O	NN

TEOAEs	NNS
O	NN

in	IN
O	NN

all	DT
O	NN

normal	JJ
O	NN

ears	NNS
O	NN

Differences	NNS
O	NN

between	IN
O	NN

studies	NNS
O	VBP

may	MD
O	NNP

arise	VB
O	NN

directly	RB
O	NN

from	IN
O	NN

criteria	NNS
O	NN

for	IN
O	NN

TEOAE	NN
O	NN

identification	NN
O	NN

,	,
O	NN

criteria	NNS
O	NN

for	IN
O	NN

selection	NN
O	NN

of	IN
O	NN

normals	NNS
O	NN

,	,
O	NN

or	CC
O	NN

statistically	RB
O	NN

due	JJ
O	NN

to	TO
O	NN

limited	JJ
O	NN

sample	NN
O	NN

sizes	NNS
O	NN

In	IN
O	NN

order	NN
O	NN

to	TO
O	NN

understand	VB
O	NN

and	CC
O	NN

model	NN
O	NN

cochlear	JJ
O	NN

processes	NNS
O	VBP

involved	VBN
O	NN

in	IN
O	NN

TEOAE	NN
O	NN

generation	NN
O	NN

,	,
O	NN

it	PRP
O	NN

needs	NNS
O	VBP

to	TO
O	NN

be	VB
O	NN

known	JJ
O	NN

whether	IN
O	NN

the	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

normal	JJ
O	NN

hearing	VBG
O	NN

leads	VBZ
O	NN

automatically	RB
O	NN

to	TO
O	NN

generation	NN
O	NN

of	IN
O	NN

TEOAEs	NNS
O	NN

The	DT
O	NN

present	JJ
O	NN

study	NN
O	NN

set	VBN
O	NN

out	IN
O	NN

to	TO
O	NN

establish	VB
O	NN

in	IN
O	NN

a	DT
O	NN

large	JJ
O	NN

sample	NN
O	NN

if	IN
O	NN

any	DT
O	NN

ears	NNS
O	NN

could	MD
O	NNP

be	VB
O	NN

found	VBN
O	NN

that	IN
O	NN

lacked	VBD
O	NN

TEOAEs	NNS
O	NN

despite	IN
O	NN

normal	JJ
O	NN

hearing	VBG
O	NN

threshold	NN
O	NN

levels	NNS
O	VBP

(	NN
O	NN

HTL	NN
O	NN

)	NN
O	NN

A	DT
O	NN

total	JJ
O	NN

of	IN
O	NN

397	CD
O	NN

ears	NNS
O	NN

from	IN
O	NN

highly	RB
O	NN

cooperative	JJ
O	NN

adult	JJ
O	NN

subjects	NNS
O	NN

were	VBD
O	NN

examined	VBN
O	NN

under	IN
O	NN

laboratory	NN
O	NN

conditions	NNS
O	VBP

Using	VBG
O	NN

cross	JJ
O	NN

correlation	NN
O	NN

between	IN
O	NN

replicate	VB
O	NN

nonlinear	JJ
O	NN

waveforms	NNS
O	NN

as	IN
O	NN

the	DT
O	NN

criterion	NN
O	NN

,	,
O	NN

TEOAEs	NNS
O	NN

were	VBD
O	NN

present	JJ
O	NN

in	IN
O	NN

99.2	CD
O	NN

%	NN
O	NN

of	IN
O	NN

the	DT
O	NN

sample	NN
O	NN

(	NN
O	NN

lower	JJR
O	NN

CI	NN
O	NN

98.1	CD
O	NN

%	NN
O	NN

)	NN
O	NN

However	RB
O	NN

,	,
O	NN

careful	JJ
O	NN

visual	JJ
O	NN

assessment	NN
O	NN

of	IN
O	NN

the	DT
O	NN

recorded	VBN
O	NN

waveforms	NNS
O	NN

for	IN
O	NN

the	DT
O	NN

remaining	VBG
O	NN

ears	NNS
O	NN

did	VBD
O	NNP

not	RB
O	NN

unequivocally	RB
O	NN

show	NN
O	NN

absence	NN
O	NN

of	IN
O	NN

TEOAE	NN
O	NN

characteristics	NNS
O	NN

in	IN
O	NN

any	DT
O	NN

ear	NN
O	NN

with	IN
O	NN

normal	JJ
O	NN

HTLs	NNS
O	NN

While	IN
O	NN

TEOAE	NN
O	NN

strength	NN
O	NN

varies	VBZ
O	NN

widely	RB
O	NN

among	IN
O	NN

ears	NNS
O	NN

,	,
O	NN

no	DT
O	NN

clear	JJ
O	NN

evidence	NN
O	NN

was	VBD
O	NN

found	VBN
O	NN

to	TO
O	NN

show	NN
O	NN

that	IN
O	NN

TEOAEs	NNS
O	NN

can	MD
O	NNP

be	VB
O	NN

absent	JJ
O	NN

when	WRB
O	NN

HTLs	NNS
O	NN

are	VBP
O	NN

normal	JJ
O	NN

In	IN
O	NN

addition	NN
O	NN

to	TO
O	NN

a	DT
O	NN

long	RB
O	NN

form	NN
O	NN

of	IN
O	NN

591	CD
O	NN

amino	NN
O	NN

acids	NNS
O	NN

(	NN
O	NN

aa	NN
O	NN

)	NN
O	NN

,	,
O	NN

two	CD
O	NN

other	JJ
O	NN

forms	NNS
O	NN

of	IN
O	NN

PRL	NN
O	NN

receptor	NN
O	NN

(	NN
O	NN

PRLR	NN
O	NN

)	NN
O	NN

,	,
O	NN

differing	VBG
O	NN

in	IN
O	NN

the	DT
O	NN

length	NN
O	NN

of	IN
O	NN

their	PRP$
O	NN

cytoplasmic	JJ
O	NN

domains	NNS
O	NN

,	,
O	NN

have	VB
O	NN

been	VBN
O	NN

identified	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

rat	NN
O	NN

The	DT
O	NN

Nb2	NN
O	NN

form	NN
O	NN

,	,
O	NN

lacking	VBG
O	NN

198	CD
O	NN

aa	NN
O	NN

in	IN
O	NN

the	DT
O	NN

cytoplasmic	JJ
O	NN

domain	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

able	JJ
O	NN

to	TO
O	NN

transmit	VB
O	NN

a	DT
O	NN

lactogenic	JJ
O	NN

signal	NN
O	NN

similar	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

long	RB
O	NN

form	NN
O	NN

,	,
O	NN

whereas	IN
O	NN

the	DT
O	NN

short	JJ
O	NN

form	NN
O	NN

of	IN
O	NN

291	CD
O	NN

aa	NN
O	NN

is	VBZ
O	NN

inactive	JJ
O	NN

The	DT
O	NN

ability	NN
O	NN

of	IN
O	NN

PRL	NN
O	NN

to	TO
O	NN

activate	VB
O	NN

the	DT
O	NN

promoter	NN
O	NN

of	IN
O	NN

the	DT
O	NN

beta-casein	NN
O	NN

gene	NN
O	NN

or	CC
O	NN

the	DT
O	NN

lactogenic	JJ
O	NN

hormone	NN
O	NN

responsive	JJ
O	NN

element	NN
O	NN

fused	VBN
O	NN

to	TO
O	NN

the	DT
O	NN

luciferase	NN
O	NN

reporter	NN
O	NN

was	VBD
O	NN

assessed	VBN
O	NN

in	IN
O	NN

Chinese	JJ
O	NN

hamster	NN
O	NN

ovary	JJ
O	NN

cells	NNS
O	VBP

or	CC
O	NN

293	CD
O	NN

fibroblasts	NNS
O	NN

transiently	RB
O	NN

transfected	VBN
O	NN

with	IN
O	NN

PRLR	NN
O	NN

cDNAs	NNS
O	NN

The	DT
O	NN

function	NN
O	NN

of	IN
O	NN

the	DT
O	NN

short	JJ
O	NN

form	NN
O	NN

was	VBD
O	NN

examined	VBN
O	NN

after	IN
O	NN

cotransfection	NN
O	NN

of	IN
O	NN

both	DT
O	NN

the	DT
O	NN

long	RB
O	NN

and	CC
O	NN

short	JJ
O	NN

forms	NNS
O	NN

These	DT
O	NN

results	NNS
O	VBP

clearly	RB
O	NN

show	NN
O	NN

that	IN
O	NN

the	DT
O	NN

short	JJ
O	NN

form	NN
O	NN

acts	NNS
O	NN

as	IN
O	NN

a	DT
O	NN

dominant	JJ
O	NN

negative	JJ
O	NN

inhibitor	NN
O	NN

through	IN
O	NN

the	DT
O	NN

formation	NN
O	NN

of	IN
O	NN

inactive	JJ
O	NN

heterodimers	NNS
O	NN

,	,
O	NN

resulting	VBG
O	NN

in	IN
O	NN

an	DT
O	NN

inhibition	NN
O	NN

of	IN
O	NN

Janus	NN
O	NN

kinase	NN
O	NN

2	CD
O	NN

(	NN
O	NN

JAK2	NN
O	NN

)	NN
O	NN

activation	NN
O	NN

The	DT
O	NN

present	JJ
O	NN

study	NN
O	NN

also	RB
O	NN

investigates	VBZ
O	NN

the	DT
O	NN

possible	JJ
O	NN

participation	NN
O	NN

of	IN
O	NN

cytoplasmic	JJ
O	NN

receptors	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

signal	NN
O	NN

transduction	NN
O	NN

pathway	NN
O	NN

,	,
O	NN

using	VBG
O	NN

cotransfection	NN
O	NN

experiments	NNS
O	VBP

and	CC
O	NN

a	DT
O	NN

new	JJ
O	NN

approach	NN
O	NN

that	IN
O	NN

selectively	RB
O	NN

determines	VBZ
O	NN

the	DT
O	NN

contribution	NN
O	NN

of	IN
O	NN

cytoplasmic	JJ
O	NN

receptors	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

process	NN
O	NN

of	IN
O	NN

signal	NN
O	NN

transduction	NN
O	NN

We	PRP
O	VBP

cotransfected	VBN
O	NN

Chinese	JJ
O	NN

hamster	NN
O	NN

ovary	JJ
O	NN

cells	NNS
O	VBP

with	IN
O	NN

two	CD
O	NN

cDNA	NN
O	NN

constructs	NNS
O	VBP

:	:
O	NN

a	DT
O	NN

cytoplasmic	JJ
O	NN

(	NN
O	NN

soluble	JJ
O	NN

)	NN
O	NN

form	NN
O	NN

of	IN
O	NN

the	DT
O	NN

receptor	NN
O	NN

with	IN
O	NN

a	DT
O	NN

deleted	VBN
O	NN

signal	NN
O	NN

peptide	NN
O	NN

(	NN
O	NN

delta-19	NN
O	NN

)	NN
O	NN

,	,
O	NN

which	WDT
O	NN

is	VBZ
O	NN

unable	JJ
O	NN

to	TO
O	NN

bind	VB
O	NN

PRL	NN
O	NN

,	,
O	NN

and	CC
O	NN

a	DT
O	NN

functionally	RB
O	NN

inactive	JJ
O	NN

receptor	NN
O	NN

mutant	JJ
O	NN

(	NN
O	NN

lacking	VBG
O	NN

box	NN
O	NN

1	CD
O	NN

)	NN
O	NN

,	,
O	NN

which	WDT
O	NN

is	VBZ
O	NN

anchored	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

plasma	NN
O	NN

membrane	NN
O	NN

and	CC
O	NN

able	JJ
O	NN

to	TO
O	NN

bind	VB
O	NN

PRL	NN
O	NN

This	DT
O	NN

approach	NN
O	NN

has	VBZ
O	NN

allowed	VBN
O	NN

us	PRP
O	VBP

to	TO
O	NN

show	NN
O	NN

that	IN
O	NN

delta-19	NN
O	NN

,	,
O	NN

lacking	VBG
O	NN

expression	NN
O	NN

at	IN
O	NN

the	DT
O	NN

plasma	NN
O	NN

membrane	NN
O	NN

,	,
O	NN

can	MD
O	NNP

transduce	VB
O	NN

the	DT
O	NN

hormonal	JJ
O	NN

message	NN
O	NN

,	,
O	NN

at	IN
O	NN

least	JJS
O	NN

to	TO
O	NN

a	DT
O	NN

limited	JJ
O	NN

extent	NN
O	NN

(	NN
O	NN

up	RB
O	NN

to	TO
O	NN

30	CD
O	NN

%	NN
O	NN

of	IN
O	NN

wild	JJ
O	NN

type	NN
O	NN

efficiency	NN
O	NN

)	NN
O	NN

,	,
O	NN

providing	VBG
O	NN

that	IN
O	NN

association/activation	NN
O	NN

occurs	VBZ
O	NN

with	IN
O	NN

a	DT
O	NN

PRL-PRLR	NN
O	NN

complex	JJ
O	NN

initiated	VBN
O	NN

at	IN
O	NN

the	DT
O	NN

cell	NN
O	NN

surface	NN
O	NN

level	NN
O	NN

;	:
O	NN

box	NN
O	NN

1	CD
O	NN

of	IN
O	NN

the	DT
O	NN

cytoplasmic	JJ
O	NN

form	NN
O	NN

is	VBZ
O	NN

necessary	JJ
O	NN

to	TO
O	NN

rescue	NN
O	NN

this	DT
O	NN

partial	JJ
O	NN

transcriptional	JJ
O	NN

activity	NN
O	NN

of	IN
O	NN

the	DT
O	NN

inactive	JJ
O	NN

mutant	JJ
O	NN

This	DT
O	NN

partial	JJ
O	NN

recovery	NN
O	NN

is	VBZ
O	NN

also	RB
O	NN

parallel	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

partial	JJ
O	NN

activation	NN
O	NN

of	IN
O	NN

JAK2	NN
O	NN

,	,
O	NN

indicating	VBG
O	NN

that	IN
O	NN

the	DT
O	NN

signal	NN
O	NN

transduction	NN
O	NN

pathway	NN
O	NN

implicated	VBN
O	NN

JAK2	NN
O	NN

Our	PRP$
O	NN

results	NNS
O	VBP

provide	VB
O	NN

evidence	NN
O	NN

that	IN
O	NN

heterodimerization	NN
O	NN

of	IN
O	NN

receptors	NNS
O	VBP

can	MD
O	NNP

be	VB
O	NN

implicated	VBN
O	NN

either	DT
O	NN

in	IN
O	NN

the	DT
O	NN

positive	JJ
O	NN

or	CC
O	NN

in	IN
O	NN

negative	JJ
O	NN

activation	NN
O	NN

of	IN
O	NN

gene	NN
O	NN

transcription	NN
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Inadequate	JJ
O	NN

dietary	JJ
O	NN

intake	NN
O	NN

of	IN
O	NN

calcium	NN
O	NN

and	CC
O	NN

vitamin	NN
O	NN

D	NN
O	NN

may	MD
O	NNP

contribute	VB
O	NN

to	TO
O	NN

the	DT
O	NN

high	JJ
O	NN

prevalence	NN
O	NN

of	IN
O	NN

osteoporosis	NN
D	NN

among	IN
O	NN

older	JJR
O	NN

persons	NNS
O	VBP

METHODS	NNS
O	VBP

:	:
O	NN

We	PRP
O	VBP

studied	VBN
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

three	CD
O	NN

years	NNS
O	NN

of	IN
O	NN

dietary	JJ
O	NN

supplementation	NN
O	NN

with	IN
O	NN

calcium	NN
O	NN

and	CC
O	NN

vitamin	NN
O	NN

D	NN
O	NN

on	IN
O	NN

bone	NN
O	NN

mineral	NN
O	NN

density	NN
O	NN

,	,
O	NN

biochemical	JJ
O	NN

measures	NNS
O	VBP

of	IN
O	NN

bone	NN
O	NN

metabolism	NN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

incidence	NN
O	NN

of	IN
O	NN

nonvertebral	JJ
O	NN

fractures	NNS
O	NN

in	IN
O	NN

176	CD
O	NN

men	NNS
O	NN

and	CC
O	NN

213	CD
O	NN

women	NNS
O	VBP

65	CD
O	NN

years	NNS
O	NN

of	IN
O	NN

age	NN
O	NN

or	CC
O	NN

older	JJR
O	NN

who	WP
O	VBP

were	VBD
O	NN

living	VBG
O	NN

at	IN
O	NN

home	NN
O	NN

They	PRP
O	VBP

received	VBN
O	NN

either	DT
O	NN

500	CD
O	NN

mg	NN
O	NN

of	IN
O	NN

calcium	NN
O	NN

plus	CC
O	NN

700	CD
O	NN

IU	NN
O	NN

of	IN
O	NN

vitamin	NN
O	NN

D3	NN
O	NN

(	NN
O	NN

cholecalciferol	NN
O	NN

)	NN
O	NN

per	IN
O	NN

day	NN
O	NN

or	CC
O	NN

placebo	NN
O	NN

Bone	NN
O	NN

mineral	NN
O	NN

density	NN
O	NN

was	VBD
O	NN

measured	VBN
O	NN

by	IN
O	NN

dual-energy	JJ
O	NN

x-ray	NN
O	NN

absorptiometry	NN
O	NN

,	,
O	NN

blood	NN
O	NN

and	CC
O	NN

urine	NN
O	NN

were	VBD
O	NN

analyzed	VBN
O	NN

every	DT
O	NN

six	CD
O	NN

months	NNS
O	NN

,	,
O	NN

and	CC
O	NN

cases	NNS
O	NN

of	IN
O	NN

nonvertebral	JJ
O	NN

fracture	NN
O	NN

were	VBD
O	NN

ascertained	VBN
O	NN

by	IN
O	NN

means	NNS
O	VBP

of	IN
O	NN

interviews	NNS
O	NN

and	CC
O	NN

verified	VBN
O	NN

with	IN
O	NN

use	NN
O	NN

of	IN
O	NN

hospital	NN
O	NN

records	NNS
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

mean	VB
O	NN

(	NN
O	NN

+/-SD	NN
O	NN

)	NN
O	NN

changes	NNS
O	VBP

in	IN
O	NN

bone	NN
O	NN

mineral	NN
O	NN

density	NN
O	NN

in	IN
O	NN

the	DT
O	NN

calcium-vitamin	JJ
O	NN

D	NN
O	NN

and	CC
O	NN

placebo	NN
O	NN

groups	NNS
O	NN

were	VBD
O	NN

as	IN
O	NN

follows	VBZ
O	NN

:	:
O	NN

femoral	JJ
O	NN

neck	NN
O	NN

,	,
O	NN

+0.50+/-4.80	CD
O	NN

and	CC
O	NN

-0.70+/-5.03	CD
O	NN

percent	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

(	NN
O	NN

P=0.02	NN
O	NN

)	NN
O	NN

;	:
O	NN

spine	NN
O	NN

,	,
O	NN

+2.12+/-4.06	CD
O	NN

and	CC
O	NN

+1.22+/-4.25	CD
O	NN

percent	NN
O	NN

(	NN
O	NN

P=0.04	NN
O	NN

)	NN
O	NN

;	:
O	NN

and	CC
O	NN

total	JJ
O	NN

body	NN
O	NN

,	,
O	NN

+0.06+/-1.83	CD
O	NN

and	CC
O	NN

-1.09+/-1.71	CD
O	NN

percent	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.001	CD
O	NN

)	NN
O	NN

The	DT
O	NN

difference	NN
O	NN

between	IN
O	NN

the	DT
O	NN

calcium-vitamin	JJ
O	NN

D	NN
O	NN

and	CC
O	NN

placebo	NN
O	NN

groups	NNS
O	NN

was	VBD
O	NN

significant	JJ
O	NN

at	IN
O	NN

all	DT
O	NN

skeletal	JJ
O	NN

sites	NNS
O	NN

after	IN
O	NN

one	CD
O	NN

year	NN
O	NN

,	,
O	NN

but	CC
O	NNP

it	PRP
O	NN

was	VBD
O	NN

significant	JJ
O	NN

only	RB
O	NN

for	IN
O	NN

total-body	JJ
O	NN

bone	NN
O	NN

mineral	NN
O	NN

density	NN
O	NN

in	IN
O	NN

the	DT
O	NN

second	JJ
O	NN

and	CC
O	NN

third	JJ
O	NN

years	NNS
O	NN

Of	IN
O	NN

37	CD
O	NN

subjects	NNS
O	NN

who	WP
O	VBP

had	VBD
O	NN

nonvertebral	JJ
O	NN

fractures	NNS
O	NN

,	,
O	NN

26	CD
O	NN

were	VBD
O	NN

in	IN
O	NN

the	DT
O	NN

placebo	NN
O	NN

group	NN
O	NN

and	CC
O	NN

11	CD
O	NN

were	VBD
O	NN

in	IN
O	NN

the	DT
O	NN

calcium-vitamin	JJ
O	NN

D	NN
O	NN

group	NN
O	NN

(	NN
O	NN

P=0.02	NN
O	NN

)	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

In	IN
O	NN

men	NNS
O	NN

and	CC
O	NN

women	NNS
O	VBP

65	CD
O	NN

years	NNS
O	NN

of	IN
O	NN

age	NN
O	NN

or	CC
O	NN

older	JJR
O	NN

who	WP
O	VBP

are	VBP
O	NN

living	VBG
O	NN

in	IN
O	NN

the	DT
O	NN

community	NN
O	NN

,	,
O	NN

dietary	JJ
T	NN

supplementation	NN
T	NN

with	IN
T	NN

calcium	NN
T	NN

and	CC
T	NN

vitamin	NN
T	NN

D	NN
T	NN

moderately	RB
O	NN

reduced	VBN
O	NN

bone	NN
D	NN

loss	NN
D	NN

measured	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

femoral	JJ
O	NN

neck	NN
O	NN

,	,
O	NN

spine	NN
O	NN

,	,
O	NN

and	CC
O	NN

total	JJ
O	NN

body	NN
O	NN

over	IN
O	NN

the	DT
O	NN

three-year	JJ
O	NN

study	NN
O	NN

period	NN
O	NN

and	CC
O	NN

reduced	VBN
O	NN

the	DT
O	NN

incidence	NN
O	NN

of	IN
O	NN

nonvertebral	JJ
D	NN

fractures	NNS
D	NN

The	DT
O	NN

sterilization	NN
O	NN

and	CC
O	NN

contaminated	VBN
O	NN

waste	NN
O	NN

disposal	NN
O	NN

practices	NNS
O	VBP

in	IN
O	NN

all	DT
O	NN

14	CD
O	NN

dental	JJ
O	NN

clinics	NNS
O	NN

operated	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

Southern	NNP
O	NNP

Sydney	NNP
O	NNP

Area	NNP
O	NNP

Health	NNP
O	NNP

Service	NNP
O	NNP

were	VBD
O	NN

surveyed	VBN
O	NN

All	DT
O	NN

of	IN
O	NN

the	DT
O	NN

clinics	NNS
O	NN

used	VBN
O	NN

autoclaves	NNS
O	NN

for	IN
O	NN

sterilization	NN
O	NN

All	DT
O	NN

hand	NN
O	NN

instruments	NNS
O	NN

,	,
O	NN

handpieces	NNS
O	NN

and	CC
O	NN

triplex	JJ
O	NN

syringes	NNS
O	NN

were	VBD
O	NN

autoclaved	JJ
O	NN

between	IN
O	NN

patients	NNS
O	NN

Chemical	NNP
O	NNP

disinfection	NN
O	NN

solutions	NNS
O	NN

were	VBD
O	NN

used	VBN
O	NN

in	IN
O	NN

12	CD
O	NN

of	IN
O	NN

the	DT
O	NN

14	CD
O	NN

dental	JJ
O	NN

clinics	NNS
O	NN

,	,
O	NN

mainly	RB
O	NN

for	IN
O	NN

surface	NN
O	NN

decontamination	NN
O	NN

Five	CD
O	NN

dental	JJ
O	NN

clinics	NNS
O	NN

had	VBD
O	NN

separate	JJ
O	NN

storage	NN
O	NN

areas	NNS
O	NN

for	IN
O	NN

contaminated	VBN
O	NN

waste	NN
O	NN

which	WDT
O	NN

compiled	VBN
O	NN

with	IN
O	NN

contaminated	VBN
O	NN

waste	NN
O	NN

separation	NN
O	NN

and	CC
O	NN

disposal	NN
O	NN

guidelines	NNS
O	NN

The	DT
O	NN

practice	NN
O	NN

of	IN
O	NN

recapping	VBG
O	NN

needles	NNS
O	NN

with	IN
O	NN

fingers	NNS
O	VBP

and	CC
O	NN

some	DT
O	NN

inadequate	JJ
O	NN

washing	VBG
O	NN

facilities	NNS
O	NN

are	VBP
O	NN

areas	NNS
O	NN

that	IN
O	NN

require	VB
O	NN

particular	JJ
O	NN

attention	NN
O	NN

Safety	NN
O	NN

and	CC
O	NN

efficacy	NN
O	NN

are	VBP
O	NN

crucial	JJ
O	NN

but	CC
O	NNP

separate	JJ
O	NN

issues	NNS
O	VBP

for	IN
O	NN

vitamin	NN
O	NN

and	CC
O	NN

mineral	NN
O	NN

supplements	NNS
O	VBP

Misinterpretation	NN
O	NN

of	IN
O	NN

``	``
O	NN

safe	JJ
O	NN

and	CC
O	NN

adequate	JJ
O	NN

''	''
O	NN

to	TO
O	NN

mean	VB
O	NN

``	``
O	NN

safety	NN
O	NN

limit	NN
O	NN

''	''
O	NN

would	MD
O	NNP

impose	VB
O	NN

restrictions	NNS
O	NN

on	IN
O	NN

vitamin	NN
O	NN

and	CC
O	NN

mineral	NN
O	NN

intakes	NN
O	NN

that	IN
O	NN

are	VBP
O	NN

not	RB
O	NN

needed	VBN
O	NN

to	TO
O	NN

ensure	VB
O	NN

safety	NN
O	NN

Substantial	JJ
O	NN

evidence	NN
O	NN

indicates	VBZ
O	NN

that	IN
O	NN

intakes	NN
O	NN

greater	JJR
O	NN

than	IN
O	NN

the	DT
O	NN

recommended	VBN
O	NN

dietary	JJ
O	NN

allowances	NNS
O	NN

(	NN
O	NN

RDAs	NNS
O	NN

)	NN
O	NN

of	IN
O	NN

certain	JJ
O	NN

vitamins	NNS
O	NN

and	CC
O	NN

minerals	NNS
O	NN

such	JJ
O	NN

as	IN
O	NN

calcium	NN
O	NN

,	,
O	NN

folic	JJ
O	NN

acid	NN
O	NN

,	,
O	NN

vitamin	NN
O	NN

E	NN
O	NN

,	,
O	NN

selenium	NN
O	NN

,	,
O	NN

and	CC
O	NN

chromium	NN
O	NN

reduce	VB
O	NN

the	DT
O	NN

risk	NN
O	NN

of	IN
O	NN

certain	JJ
O	NN

diseases	NNS
O	NN

for	IN
O	NN

some	DT
O	NN

people	NNS
O	VBP

Limitation	NN
O	NN

of	IN
O	NN

intakes	NN
O	NN

to	TO
O	NN

the	DT
O	NN

RDAs	NNS
O	NN

would	MD
O	NNP

preclude	VB
O	NN

reductions	NNS
O	NN

in	IN
O	NN

disease	NN
O	NN

risk	NN
O	NN

from	IN
O	NN

these	DT
O	NN

nutrients	NNS
O	NN

The	DT
O	NN

margin	NN
O	NN

of	IN
O	NN

safety	NN
O	NN

between	IN
O	NN

the	DT
O	NN

usual	JJ
O	NN

dietary	JJ
O	NN

intake	NN
O	NN

and	CC
O	NN

the	DT
O	NN

intake	NN
O	NN

that	IN
O	NN

would	MD
O	NNP

produce	VB
O	NN

adverse	JJ
O	NN

effects	NNS
O	NN

varies	VBZ
O	NN

greatly	RB
O	NN

among	IN
O	NN

the	DT
O	NN

different	JJ
O	NN

nutrients	NNS
O	NN

Very	RB
O	NN

high	JJ
O	NN

intakes	NN
O	NN

of	IN
O	NN

vitamins	NNS
O	NN

A	DT
O	NN

and	CC
O	NN

D	NN
O	NN

,	,
O	NN

niacin	NN
O	NN

,	,
O	NN

pyridoxine	NN
O	NN

,	,
O	NN

and	CC
O	NN

selenium	NN
O	NN

have	VB
O	NN

produced	VBN
O	NN

adverse	JJ
O	NN

effects	NNS
O	NN

Many	JJ
O	NN

widely	RB
O	NN

discussed	VBN
O	NN

putative	JJ
O	NN

adverse	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

vitamin	NN
O	NN

C	NN
O	NN

,	,
O	NN

vitamin	NN
O	NN

E	NN
O	NN

,	,
O	NN

and	CC
O	NN

trivalent	JJ
O	NN

chromium	NN
O	NN

have	VB
O	NN

little	JJ
O	NN

factual	JJ
O	NN

basis	NN
O	NN

There	EX
O	NN

is	VBZ
O	NN

no	DT
O	NN

evidence	NN
O	NN

of	IN
O	NN

adverse	JJ
O	NN

effects	NNS
O	NN

from	IN
O	NN

beta-carotene	NN
O	NN

supplements	NNS
O	VBP

except	IN
O	NN

in	IN
O	NN

current	JJ
O	NN

heavy	JJ
O	NN

smokers	NNS
O	NN

The	DT
O	NN

mutator	NN
O	NN

hypothesis	NN
O	NN

of	IN
O	NN

tumorigenesis	NN
O	NN

suggests	VBZ
O	NN

that	IN
O	NN

loss	NN
O	NN

of	IN
O	NN

chromosomal	JJ
O	NN

stability	NN
O	NN

or	CC
O	NN

maintenance	NN
O	NN

functions	NNS
O	VBP

results	NNS
O	VBP

in	IN
O	NN

elevated	JJ
O	NN

mutation	NN
O	NN

rates	NNS
O	VBP

,	,
O	NN

leading	VBG
O	NN

to	TO
O	NN

the	DT
O	NN

accumulation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

numerous	JJ
O	NN

mutations	NNS
O	VBP

required	VBN
O	NN

for	IN
O	NN

multistep	JJ
O	NN

carcinogenesis	NN
O	NN

The	DT
O	NN

human	JJ
O	NN

DNA	NN
O	NN

mismatch	NN
O	NN

repair	NN
O	NN

(	NN
O	NN

MMR	NN
O	NN

)	NN
O	NN

genes	NNS
O	NN

are	VBP
O	NN

highly	RB
O	NN

conserved	VBN
O	NN

homologues	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

Escherichia	FW
O	FW

coli	NN
O	NN

MutHLS	NN
O	NN

system	NN
O	NN

,	,
O	NN

which	WDT
O	NN

contribute	VB
O	NN

to	TO
O	NN

genomic	JJ
O	NN

stability	NN
O	NN

by	IN
O	NN

surveillance	NN
O	NN

and	CC
O	NN

repair	NN
O	NN

of	IN
O	NN

replication	NN
O	NN

misincorporation	NN
O	NN

errors	NNS
O	VBP

and	CC
O	NN

exogenous	JJ
O	NN

DNA	NN
O	NN

damage	NN
O	NN

Mutations	NNS
O	VBP

in	IN
O	NN

one	CD
O	NN

of	IN
O	NN

these	DT
O	NN

MMR	NN
O	NN

genes	NNS
O	NN

,	,
O	NN

hMSH2	NN
O	NN

,	,
O	NN

account	NN
O	NN

for	IN
O	NN

about	IN
O	NN

half	DT
O	NN

of	IN
O	NN

all	DT
O	NN

cases	NNS
O	NN

of	IN
O	NN

genetically	RB
O	NN

linked	VBN
O	NN

hereditary	JJ
O	NN

non-polyposis	JJ
O	NN

colorectal	JJ
O	NN

cancer	NN
O	NN

Loss	NN
O	NN

of	IN
O	NN

function	NN
O	NN

of	IN
O	NN

p53	NN
O	NN

has	VBZ
O	NN

also	RB
O	NN

been	VBN
O	NN

proposed	VBN
O	NN

to	TO
O	NN

increase	NN
O	NN

cellular	JJ
O	NN

hypermutability	NN
O	NN

,	,
O	NN

thereby	RB
O	NN

accelerating	VBG
O	NN

carcinogenesis	NN
O	NN

,	,
O	NN

although	IN
O	NN

a	DT
O	NN

clear	JJ
O	NN

role	NN
O	NN

for	IN
O	NN

p53	NN
O	NN

in	IN
O	NN

genomic	JJ
O	NN

instability	NN
O	NN

remains	VBZ
O	NNP

controversial	JJ
O	NN

p53	NN
O	NN

is	VBZ
O	NN

mutated	VBN
O	NN

frequently	RB
O	NN

in	IN
O	NN

a	DT
O	NN

wide	JJ
O	NN

range	NN
O	NN

of	IN
O	NN

human	JJ
O	NN

cancers	NNS
D	NN

,	,
O	NN

including	VBG
O	NN

colonic	JJ
D	NN

tumours	NNS
D	NN

Both	DT
O	NN

Msh2-	NN
O	NN

and	CC
O	NN

p53-targeted	JJ
O	NN

knockout	NN
O	NN

mice	NNS
O	NN

are	VBP
O	NN

viable	JJ
O	NN

and	CC
O	NN

susceptible	JJ
O	NN

to	TO
O	NN

cancer	NN
D	NN

Here	RB
O	NN

we	PRP
O	VBP

demonstrate	VB
O	NN

that	IN
O	NN

combined	JJ
O	NN

Msh2	NN
O	NN

and	CC
O	NN

p53	NN
O	NN

ablation	NN
O	NN

(	NN
O	NN

Msh2-/-p53-/-	JJ
O	NN

)	NN
O	NN

results	NNS
O	VBP

in	IN
O	NN

developmental	JJ
O	NN

arrest	NN
O	NN

of	IN
O	NN

all	DT
O	NN

female	JJ
O	NN

embryos	NNS
O	NN

at	IN
O	NN

9.5	CD
O	NN

days	NNS
O	NN

In	IN
O	NN

contrast	NN
O	NN

,	,
O	NN

male	JJ
O	NN

Msh2-/-p53-/-	JJ
O	NN

mice	NNS
O	NN

are	VBP
O	NN

viable	JJ
O	NN

,	,
O	NN

but	CC
O	NNP

succumb	VB
O	NN

to	TO
O	NN

tumours	NNS
D	NN

significantly	RB
O	NN

earlier	JJR
O	NN

(	NN
O	NN

t1-2	NN
O	NN

is	VBZ
O	NN

73	CD
O	NN

days	NNS
O	NN

)	NN
O	NN

than	IN
O	NN

either	DT
O	NN

Msh2-/-	JJ
O	NN

or	CC
O	NN

p53-/-	JJ
O	NN

littermates	NNS
O	NN

Furthermore	RB
O	NN

,	,
O	NN

the	DT
O	NN

frequency	NN
O	NN

of	IN
O	NN

microsatellite	NN
O	NN

instability	NN
O	NN

(	NN
O	NN

MSI	NN
O	NN

)	NN
O	NN

in	IN
O	NN

tumours	NNS
O	NN

from	IN
O	NN

Msh2-/-p53-/-	JJ
O	NN

mice	NNS
O	NN

is	VBZ
O	NN

not	RB
O	NN

significantly	RB
O	NN

different	JJ
O	NN

than	IN
O	NN

in	IN
O	NN

Msh2-/-	JJ
O	NN

mice	NNS
O	NN

Synergism	NN
O	NN

in	IN
O	NN

tumorigenesis	NN
O	NN

and	CC
O	NN

independent	JJ
O	NN

segregation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

MSI	NN
O	NN

phenotype	NN
O	NN

suggest	VBP
O	NN

that	IN
O	NN

Msh2	NN
O	NN

and	CC
O	NN

p53	NN
O	NN

are	VBP
O	NN

not	RB
O	NN

genetically	RB
O	NN

epistatic	JJ
O	NN

Our	PRP$
O	NN

data	NNS
O	NN

(	NN
O	NN

Reddy	NNP
O	NNP

et	FW
O	FW

al	NNP
O	NNP

.	.
O	NN

,	,
O	NN

Radiat	NN
O	NN

Res	NNP
O	NNP

141	CD
O	NN

,	,
O	NN

252-258	CD
O	NN

,	,
O	NN

1995	CD
O	NN

)	NN
O	NN

on	IN
O	NN

the	DT
O	NN

kinetics	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

repair	NN
O	NN

of	IN
O	NN

potentially	RB
O	NN

lethal	JJ
O	NN

damage	NN
O	NN

in	IN
O	NN

log-phase	JJ
O	NN

Chinese	JJ
O	NN

hamster	NN
O	NN

V79	NN
O	NN

cells	NNS
O	VBP

are	VBP
O	NN

used	VBN
O	NN

to	TO
O	NN

test	NN
O	NN

some	DT
O	NN

predictions	NNS
O	NN

which	WDT
O	NN

arise	VB
O	NN

from	IN
O	NN

the	DT
O	NN

different	JJ
O	NN

assumptions	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

repair-misrepair	JJ
O	NN

(	NN
O	NN

RMR	NN
O	NN

)	NN
O	NN

(	NN
O	NN

C	NN
O	NN

A	DT
O	NN

Tobias	NNP
O	NNP

,	,
O	NN

Radiat	NN
O	NN

Res	NNP
O	NNP

104	CD
O	NN

,	,
O	NN

S77-S95	NN
O	NN

,	,
O	NN

1985	CD
O	NN

)	NN
O	NN

,	,
O	NN

lethal-potentially	RB
O	NN

lethal	JJ
O	NN

(	NN
O	NN

LPL	NN
O	NN

)	NN
O	NN

(	NN
O	NN

S.	NNP
O	NNP

B	NN
O	NN

Curtis	NNP
O	NNP

,	,
O	NN

Radiat	NN
O	NN

Res	NNP
O	NNP

106	CD
O	NN

,	,
O	NN

252-270	CD
O	NN

,	,
O	NN

1986	CD
O	NN

)	NN
O	NN

and	CC
O	NN

double-strand	JJ
O	NN

break	NN
O	NN

(	NN
O	NN

DSB	NN
O	NN

)	NN
O	NN

(	NN
O	NN

J	NN
O	NN

Y	NN
O	NN

Ostashevsky	NNP
O	NNP

,	,
O	NN

Radiat	NN
O	NN

Res	NNP
O	NNP

118	CD
O	NN

,	,
O	NN

437-466	CD
O	NN

,	,
O	NN

1989	CD
O	NNP

)	NN
O	NN

models	NNS
O	NN

The	DT
O	NN

LPL	NN
O	NN

model	NN
O	NN

defines	VBZ
O	NN

the	DT
O	NN

time	NN
O	NN

available	JJ
O	NN

for	IN
O	NN

repair	NN
O	NN

of	IN
O	NN

PLD	NN
O	NN

(	NN
O	NN

t	NN
O	NN

(	NN
O	NN

rep	NN
O	NN

)	NN
O	NN

)	NN
O	NN

as	IN
O	NN

the	DT
O	NN

time	NN
O	NN

taken	VBN
O	NN

to	TO
O	NN

reach	VB
O	NNP

maximal	JJ
O	NN

survival	NN
O	NN

in	IN
O	NN

a	DT
O	NN

delayed-plating	JJ
O	NN

recovery	NN
O	NN

experiment	NN
O	NN

Those	DT
O	NN

data	NNS
O	NN

show	NN
O	NN

that	IN
O	NN

after	IN
O	NN

this	DT
O	NN

time	NN
O	NN

has	VBZ
O	NN

elapsed	VBN
O	NN

,	,
O	NN

contrary	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

expectation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

LPL	NN
O	NN

model	NN
O	NN

,	,
O	NN

survival	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

increased	VBN
O	NN

by	IN
O	NN

changing	VBG
O	NN

the	DT
O	NN

medium	NN
O	NN

used	VBN
O	NN

for	IN
O	NN

delayed	VBN
O	NN

plating	VBG
O	NN

from	IN
O	NN

fresh	JJ
O	NN

growth	NN
O	NN

medium	NN
O	NN

to	TO
O	NN

conditioned	VBN
O	NN

medium	NN
O	NN

According	VBG
O	NN

to	TO
O	NN

the	DT
O	NN

RMR	NN
O	NN

model	NN
O	NN

,	,
O	NN

all	DT
O	NN

potentially	RB
O	NN

lethal	JJ
O	NN

lesions	NNS
O	NN

should	MD
O	NNP

also	RB
O	NN

be	VB
O	NN

committed	JJ
O	NN

by	IN
O	NN

that	IN
O	NN

time	NN
O	NN

and	CC
O	NN

be	VB
O	NN

unavailable	JJ
O	NN

for	IN
O	NN

repair	NN
O	NN

in	IN
O	NN

the	DT
O	NN

new	JJ
O	NN

medium	NN
O	NN

Only	RB
O	NN

the	DT
O	NN

DSB	NN
O	NN

model	NN
O	NN

correctly	RB
O	NN

predicted	VBN
O	NN

that	IN
O	NN

PLD	NN
O	NN

(	NN
O	NN

=	JJ
O	NN

DSBs	NNS
O	NN

)	NN
O	NN

would	MD
O	NNP

still	RB
O	NN

be	VB
O	NN

available	JJ
O	NN

for	IN
O	NN

repair	NN
O	NN

after	IN
O	NN

that	IN
O	NN

time	NN
O	NN

Second	JJ
O	NN

,	,
O	NN

data	NNS
O	NN

for	IN
O	NN

split-dose	NN
O	NN

recovery	NN
O	NN

are	VBP
O	NN

used	VBN
O	NN

to	TO
O	NN

predict	VB
O	NN

the	DT
O	NN

first-order	JJ
O	NN

kinetics	NNS
O	NN

time	NN
O	NN

constant	JJ
O	NN

for	IN
O	NN

DSB	NN
O	NN

repair	NN
O	NN

(	NN
O	NN

tau	NN
O	NN

(	NN
O	NN

DSBR	NN
O	NN

)	NN
O	NN

)	NN
O	NN

using	VBG
O	NN

the	DT
O	NN

DSB	NN
O	NN

model	NN
O	NN

(	NN
O	NN

24	CD
O	NN

+/-	CC
O	NN

1.5	CD
O	NN

min	NN
O	NN

)	NN
O	NN

This	DT
O	NN

value	NN
O	NN

is	VBZ
O	NN

nearly	RB
O	NN

identical	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

value	NN
O	NN

of	IN
O	NN

27	CD
O	NN

+/-	CC
O	NN

1	CD
O	NN

min	NN
O	NN

determined	VBN
O	NN

from	IN
O	NN

the	DT
O	NN

data	NNS
O	NN

obtained	VBN
O	NN

by	IN
O	NN

Cheong	NNP
O	NNP

et	FW
O	FW

al	NNP
O	NNP

.	.
O	NN

using	VBG
O	NN

pulsed-field	JJ
O	NN

gel	NN
O	NN

electrophoresis	NN
O	NN

(	NN
O	NN

PFGE	NN
O	NN

)	NN
O	NN

(	NN
O	NN

Mutat	NN
O	NN

Res	NNP
O	NNP

274	CD
O	NN

,	,
O	NN

111-122	CD
O	NN

,	,
O	NN

1992	CD
O	NN

)	NN
O	NN

The	DT
O	NN

value	NN
O	NN

based	VBN
O	NN

on	IN
O	NN

PFGE	NN
O	NN

is	VBZ
O	NN

used	VBN
O	NN

to	TO
O	NN

calculate	VB
O	NNP

the	DT
O	NN

value	NN
O	NN

of	IN
O	NN

t	NN
O	NN

(	NN
O	NN

rep	NN
O	NN

)	NN
O	NN

predicted	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

DSB	NN
O	NN

model	NN
O	NN

(	NN
O	NN

2.6	CD
O	NN

+/-	CC
O	NN

0.1	CD
O	NN

h	NN
O	NN

)	NN
O	NN

,	,
O	NN

which	WDT
O	NN

agrees	VBZ
O	NN

with	IN
O	NN

the	DT
O	NN

value	NN
O	NN

determined	VBN
O	NN

experimentally	RB
O	NN

as	IN
O	NN

the	DT
O	NN

time	NN
O	NN

when	WRB
O	NN

changing	VBG
O	NN

the	DT
O	NN

delayed-plating	JJ
O	NN

medium	NN
O	NN

from	IN
O	NN

growth	NN
O	NN

medium	NN
O	NN

to	TO
O	NN

conditioned	VBN
O	NN

medium	NN
O	NN

no	DT
O	NN

longer	RB
O	NN

gives	VBZ
O	NN

the	DT
O	NN

full	JJ
O	NN

recovery	NN
O	NN

seen	VBN
O	NN

with	IN
O	NN

delayed	VBN
O	NN

plating	VBG
O	NN

in	IN
O	NN

conditioned	VBN
O	NN

medium	NN
O	NN

(	NN
O	NN

2.5	CD
O	NN

h	NN
O	NN

)	NN
O	NN

However	RB
O	NN

,	,
O	NN

some	DT
O	NN

recovery	NN
O	NN

was	VBD
O	NN

seen	VBN
O	NN

for	IN
O	NN

a	DT
O	NN

change	NN
O	NN

in	IN
O	NN

the	DT
O	NN

medium	NN
O	NN

(	NN
O	NN

growth	NN
O	NN

medium	NN
O	NN

to	TO
O	NN

conditioned	VBN
O	NN

medium	NN
O	NN

)	NN
O	NN

up	RB
O	NN

to	TO
O	NN

5-6	CD
O	NN

h	NN
O	NN

postirradiation	NN
O	NN

Reanalysis	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

original	JJ
O	NN

data	NNS
O	NN

on	IN
O	NN

DSB	NN
O	NN

repair	NN
O	NN

shows	NNS
O	VBP

that	IN
O	NN

they	PRP
O	VBP

are	VBP
O	NN

consistent	JJ
O	NN

with	IN
O	NN

two	CD
O	NN

first-order	JJ
O	NN

repair	NN
O	NN

rates	NNS
O	VBP

(	NN
O	NN

18	CD
O	NN

+/-	CC
O	NN

7	CD
O	NN

min	NN
O	NN

and	CC
O	NN

about	IN
O	NN

52	CD
O	NN

min	NN
O	NN

)	NN
O	NN

These	DT
O	NN

results	NNS
O	VBP

are	VBP
O	NN

consistent	JJ
O	NN

with	IN
O	NN

two	CD
O	NN

pools	NNS
O	NN

of	IN
O	NN

DSBs	NNS
O	NN

(	NN
O	NN

or	CC
O	NN

cells	NNS
O	VBP

)	NN
O	NN

,	,
O	NN

each	DT
O	NN

with	IN
O	NN

their	PRP$
O	NN

own	JJ
O	NN

t	NN
O	NN

(	NN
O	NN

rep	NN
O	NN

)	NN
O	NN

The	DT
O	NN

early	RB
O	NN

t	NN
O	NN

(	NN
O	NN

rep	NN
O	NN

)	NN
O	NN

,	,
O	NN

associated	VBN
O	NN

with	IN
O	NN

tau	NN
O	NN

(	NN
O	NN

fast	RB
O	NN

)	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

predicted	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

1.7	CD
O	NN

+/-	CC
O	NN

0.7	CD
O	NN

h	NN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

late	RB
O	NN

t	NN
O	NN

(	NN
O	NN

rep	NN
O	NN

)	NN
O	NN

,	,
O	NN

associated	VBN
O	NN

with	IN
O	NN

tau	NN
O	NN

(	NN
O	NN

slow	JJ
O	NN

)	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

predicted	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

about	IN
O	NN

5	CD
O	NN

h.	NN
O	NN

Both	DT
O	NN

values	NNS
O	VBP

are	VBP
O	NN

in	IN
O	NN

excellent	JJ
O	NN

agreement	NN
O	NN

with	IN
O	NN

the	DT
O	NN

times	NNS
O	NN

at	IN
O	NN

which	WDT
O	NN

changing	VBG
O	NN

from	IN
O	NN

growth	NN
O	NN

medium	NN
O	NN

to	TO
O	NN

conditioned	VBN
O	NN

medium	NN
O	NN

no	DT
O	NN

longer	RB
O	NN

gives	VBZ
O	NN

the	DT
O	NN

full	JJ
O	NN

recovery	NN
O	NN

seen	VBN
O	NN

in	IN
O	NN

conditioned	VBN
O	NN

medium	NN
O	NN

only	RB
O	NN

(	NN
O	NN

the	DT
O	NN

early	RB
O	NN

t	NN
O	NN

(	NN
O	NN

rep	NN
O	NN

)	NN
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

time	NN
O	NN

when	WRB
O	NN

changing	VBG
O	NN

from	IN
O	NN

growth	NN
O	NN

medium	NN
O	NN

to	TO
O	NN

conditioned	VBN
O	NN

medium	NN
O	NN

produces	VBZ
O	NN

no	DT
O	NN

further	RB
O	NN

increase	NN
O	NN

in	IN
O	NN

survival	NN
O	NN

(	NN
O	NN

the	DT
O	NN

late	RB
O	NN

t	NN
O	NN

(	NN
O	NN

rep	NN
O	NN

)	NN
O	NN

)	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

It	PRP
O	NN

is	VBZ
O	NN

noted	VBN
O	NN

that	IN
O	NN

attempts	NNS
O	NN

to	TO
O	NN

correlate	VB
O	NN

radiosensitivity	NN
O	NN

with	IN
O	NN

the	DT
O	NN

rates	NNS
O	VBP

of	IN
O	NN

DSB	NN
O	NN

repair	NN
O	NN

,	,
O	NN

rather	RB
O	NN

than	IN
O	NN

using	VBG
O	NN

an	DT
O	NN

explicit	JJ
O	NN

model	NN
O	NN

such	JJ
O	NN

as	IN
O	NN

the	DT
O	NN

DSB	NN
O	NN

model	NN
O	NN

,	,
O	NN

are	VBP
O	NN

unlikely	JJ
O	NN

to	TO
O	NN

be	VB
O	NN

productive	JJ
O	NN

since	IN
O	NN

survival	NN
O	NN

depends	VBZ
O	NN

on	IN
O	NN

both	DT
O	NN

tau	NN
O	NN

(	NN
O	NN

DSBR	NN
O	NN

)	NN
O	NN

and	CC
O	NN

t	NN
O	NN

(	NN
O	NN

rep	NN
O	NN

)	NN
O	NN

(	NN
O	NN

as	IN
O	NN

defined	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

DSB	NN
O	NN

model	NN
O	NN

)	NN
O	NN

and	CC
O	NN

the	DT
O	NN

latter	JJ
O	NN

may	MD
O	NNP

be	VB
O	NN

the	DT
O	NN

more	RBR
O	NN

important	JJ
O	NN

determinant	NN
O	NN

of	IN
O	NN

radiosensitivity	NN
O	NN

(	NN
O	NN

as	IN
O	NN

it	PRP
O	NN

appears	VBZ
O	NN

to	TO
O	NN

be	VB
O	NN

for	IN
O	NN

ataxia	NN
O	NN

telangiectasia	NN
O	NN

cells	NNS
O	VBP

compared	VBN
O	NN

to	TO
O	NN

normal	JJ
O	NN

fibroblasts	NNS
O	NN

and	CC
O	NN

for	IN
O	NN

irs	NNS
O	NN

compared	VBN
O	NN

to	TO
O	NN

V79	NN
O	NN

cells	NNS
O	VBP

)	NN
O	NN

CONTEXT	NN
O	NN

:	:
O	NN

Adolescents	NNS
O	NN

'	POS
O	NN

concerns	NNS
O	NN

about	IN
O	NN

privacy	NN
O	NN

in	IN
O	NN

clinical	JJ
O	NN

settings	NNS
O	VBP

decrease	NN
O	NN

their	PRP$
O	NN

willingness	NN
O	NN

to	TO
O	NN

seek	VB
O	NN

health	NN
O	NN

care	NN
O	NN

for	IN
O	NN

sensitive	JJ
O	NN

problems	NNS
O	VBP

and	CC
O	NN

may	MD
O	NNP

inhibit	VB
O	NN

their	PRP$
O	NN

communication	NN
O	NN

with	IN
O	NN

physicians	NNS
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

investigate	VB
O	NN

the	DT
O	NN

influence	NN
O	NN

of	IN
O	NN

physicians	NNS
O	NN

'	POS
O	NN

assurances	NNS
O	NN

of	IN
O	NN

confidentiality	NN
O	NN

on	IN
O	NN

adolescents	NNS
O	NN

'	POS
O	NN

willingness	NN
O	NN

to	TO
O	NN

disclose	VB
O	NN

information	NN
O	NN

and	CC
O	NN

seek	VB
O	NN

future	JJ
O	NN

health	NN
O	NN

care	NN
O	NN

DESIGN	NN
O	NN

:	:
O	NN

Randomized	VBN
O	NN

controlled	JJ
O	NN

trial	NN
O	NN

SETTING	VBG
O	NN

:	:
O	NN

Three	CD
O	NN

suburban	JJ
O	NN

public	JJ
O	NN

high	JJ
O	NN

schools	NNS
O	NN

in	IN
O	NN

California	NNP
O	NN

PARTICIPANTS	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

562	CD
O	NN

participating	VBG
O	NN

adolescents	NNS
O	NN

represented	VBN
O	NN

92	CD
O	NN

%	NN
O	NN

of	IN
O	NN

students	NNS
O	NN

in	IN
O	NN

mandatory	JJ
O	NN

classes	NNS
O	NN

INTERVENTION	NN
O	NN

:	:
O	NN

After	IN
O	NN

random	JJ
O	NN

assignment	NN
O	NN

to	TO
O	NN

1	CD
O	NN

of	IN
O	NN

3	CD
O	NN

groups	NNS
O	NN

,	,
O	NN

the	DT
O	NN

adolescents	NNS
O	NN

listened	VBD
O	NN

to	TO
O	NN

a	DT
O	NN

standardized	JJ
O	NN

audiotape	NN
O	NN

depiction	NN
O	NN

of	IN
O	NN

an	DT
O	NN

office	NN
O	NN

visit	NN
O	NN

during	IN
O	NN

which	WDT
O	NN

they	PRP
O	VBP

heard	VBN
O	NN

a	DT
O	NN

physician	NN
O	NN

who	WP
O	VBP

assured	VBN
O	NN

unconditional	JJ
O	NN

confidentiality	NN
O	NN

,	,
O	NN

a	DT
O	NN

physician	NN
O	NN

who	WP
O	VBP

assured	VBN
O	NN

conditional	JJ
O	NN

confidentiality	NN
O	NN

,	,
O	NN

or	CC
O	NN

a	DT
O	NN

physician	NN
O	NN

who	WP
O	VBP

did	VBD
O	NNP

not	RB
O	NN

mention	NN
O	NN

confidentiality	NN
O	NN

MAIN	JJS
O	NN

OUTCOME	NN
O	NN

MEASURES	NNS
O	VBP

:	:
O	NN

Adolescents	NNS
O	NN

'	POS
O	NN

willingness	NN
O	NN

to	TO
O	NN

disclose	VB
O	NN

general	JJ
O	NN

information	NN
O	NN

,	,
O	NN

willingness	NN
O	NN

to	TO
O	NN

disclose	VB
O	NN

information	NN
O	NN

about	IN
O	NN

sensitive	JJ
O	NN

topics	NNS
O	NN

,	,
O	NN

intended	JJ
O	NN

honesty	NN
O	NN

,	,
O	NN

and	CC
O	NN

likelihood	NN
O	NN

of	IN
O	NN

return	NN
O	NN

visits	NNS
O	VBP

to	TO
O	NN

the	DT
O	NN

physician	NN
O	NN

depicted	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

scenario	NN
O	NN

were	VBD
O	NN

assessed	VBN
O	NN

by	IN
O	NN

anonymous	JJ
O	NN

written	VBN
O	NN

questionnaire	NN
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Assurances	NNP
O	NNP

of	IN
O	NN

confidentiality	NN
O	NN

increased	VBN
O	NN

the	DT
O	NN

number	NN
O	NN

of	IN
O	NN

adolescents	NNS
O	NN

willing	JJ
O	NN

to	TO
O	NN

disclose	VB
O	NN

sensitive	JJ
O	NN

information	NN
O	NN

about	IN
O	NN

sexuality	NN
O	NN

,	,
O	NN

substance	NN
O	NN

use	NN
O	NN

,	,
O	NN

and	CC
O	NN

mental	JJ
O	NN

health	NN
O	NN

from	IN
O	NN

39	CD
O	NN

%	NN
O	NN

(	NN
O	NN

68/175	CD
O	NN

)	NN
O	NN

to	TO
O	NN

46.5	CD
O	NN

%	NN
O	NN

(	NN
O	NN

178/383	CD
O	NN

)	NN
O	NN

(	NN
O	NN

beta=.10	NN
O	NN

,	,
O	NN

P=.02	NN
O	NN

)	NN
O	NN

and	CC
O	NN

increased	VBN
O	NN

the	DT
O	NN

number	NN
O	NN

willing	JJ
O	NN

to	TO
O	NN

seek	VB
O	NN

future	JJ
O	NN

health	NN
O	NN

care	NN
O	NN

from	IN
O	NN

53	CD
O	NN

%	NN
O	NN

(	NN
O	NN

93/175	CD
O	NN

)	NN
O	NN

to	TO
O	NN

67	CD
O	NN

%	NN
O	NN

(	NN
O	NN

259/386	CD
O	NN

)	NN
O	NN

(	NN
O	NN

beta=.17	NN
O	NN

,	,
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

.001	CD
O	NN

)	NN
O	NN

When	WRB
O	NN

comparing	VBG
O	NN

the	DT
O	NN

unconditional	JJ
O	NN

with	IN
O	NN

the	DT
O	NN

conditional	JJ
O	NN

groups	NNS
O	NN

,	,
O	NN

assurances	NNS
O	NN

of	IN
O	NN

unconditional	JJ
O	NN

confidentiality	NN
O	NN

increased	VBN
O	NN

the	DT
O	NN

number	NN
O	NN

of	IN
O	NN

adolescents	NNS
O	NN

willing	JJ
O	NN

to	TO
O	NN

return	NN
O	NN

for	IN
O	NN

a	DT
O	NN

future	JJ
O	NN

visit	NN
O	NN

by	IN
O	NN

10	CD
O	NN

percentage	NN
O	NN

points	NNS
O	NN

,	,
O	NN

from	IN
O	NN

62	CD
O	NN

%	NN
O	NN

(	NN
O	NN

122/196	CD
O	NN

)	NN
O	NN

to	TO
O	NN

72	CD
O	NN

%	NN
O	NN

(	NN
O	NN

137/190	CD
O	NN

)	NN
O	NN

(	NN
O	NN

beta=.14	NN
O	NN

,	,
O	NN

P=.001	NN
O	NN

)	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Adolescents	NNS
O	NN

are	VBP
O	NN

more	RBR
O	NN

willing	JJ
O	NN

to	TO
O	NN

communicate	VBP
O	NN

with	IN
O	NN

and	CC
O	NN

seek	VB
O	NN

health	NN
O	NN

care	NN
O	NN

from	IN
O	NN

physicians	NNS
O	NN

who	WP
O	VBP

assure	VB
O	NN

confidentiality	NN
O	NN

Further	JJ
O	NN

investigation	NN
O	NN

is	VBZ
O	NN

needed	VBN
O	NN

to	TO
O	NN

identify	VB
O	NN

a	DT
O	NN

confidentiality	NN
O	NN

assurance	NN
O	NN

statement	NN
O	NN

that	IN
O	NN

explains	VBZ
O	NN

the	DT
O	NN

legal	JJ
O	NN

and	CC
O	NN

ethical	JJ
O	NN

limitations	NNS
O	NN

of	IN
O	NN

confidentiality	NN
O	NN

without	IN
O	NN

decreasing	VBG
O	NN

adolescents	NNS
O	NN

'	POS
O	NN

likelihood	NN
O	NN

of	IN
O	NN

seeking	VBG
O	NN

future	JJ
O	NN

health	NN
O	NN

care	NN
O	NN

for	IN
O	NN

routine	JJ
O	NN

and	CC
O	NN

nonreportable	JJ
O	NN

sensitive	JJ
O	NN

health	NN
O	NN

concerns	NNS
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Diabetic	NNP
O	NNP

foot	NN
D	NN

infections	NNS
D	NN

cause	NN
O	NN

substantial	JJ
O	NN

morbidity	NN
O	NN

and	CC
O	NN

mortality	NN
O	NN

Neutrophil	NN
O	NN

superoxide	NN
O	NN

generation	NN
O	NN

,	,
O	NN

a	DT
O	NN

crucial	JJ
O	NN

part	NN
O	NN

of	IN
O	NN

neutrophil	NN
O	NN

bactericidal	JJ
O	NN

activity	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

impaired	JJ
O	NN

in	IN
O	NN

diabetes	NN
D	NN

Granulocyte-colony	JJ
O	NN

stimulating	VBG
O	NN

factor	NN
O	NN

(	NN
O	NN

G-CSF	NN
O	NN

)	NN
O	NN

increases	NNS
O	NN

the	DT
O	NN

release	NN
O	NN

of	IN
O	NN

neutrophils	NNS
O	NN

from	IN
O	NN

the	DT
O	NN

bone	NN
O	NN

marrow	NN
O	NN

and	CC
O	NN

improves	VBZ
O	NN

neutrophil	NN
O	NN

function	NN
O	NN

We	PRP
O	VBP

assessed	VBN
O	NN

G-CSF	NN
T	NN

as	IN
O	NN

adjuvant	JJ
O	NN

therapy	NN
O	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

severe	JJ
D	NN

foot	NN
D	NN

infections	NNS
D	NN

in	IN
D	NN

diabetic	JJ
D	NN

patients	NNS
D	NN

METHODS	NNS
O	VBP

:	:
O	NN

40	CD
O	NN

diabetic	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

foot	NN
D	NN

infections	NNS
D	NN

were	VBD
O	NN

enrolled	VBN
O	NN

in	IN
O	NN

a	DT
O	NN

double-blind	JJ
O	NN

placebo-controlled	JJ
O	NN

study	NN
O	NN

On	IN
O	NN

admission	NN
O	NN

,	,
O	NN

patients	NNS
O	NN

were	VBD
O	NN

randomly	RB
O	NN

assigned	VBN
O	NN

G-CSF	NN
T	NN

(	NN
T	NN

filgrastim	NN
T	NN

)	NN
T	NN

therapy	NN
T	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

20	CD
O	NN

)	NN
O	NN

or	CC
O	NN

placebo	NN
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

20	CD
O	NN

)	NN
O	NN

for	IN
O	NN

7	CD
O	NN

days	NNS
O	NN

Both	DT
O	NN

groups	NNS
O	NN

received	VBN
O	NN

similar	JJ
O	NN

antibiotic	JJ
T	NN

and	CC
T	NN

insulin	NN
T	NN

treatment	NN
T	NN

Neutrophils	NNS
O	NN

from	IN
O	NN

the	DT
O	NN

peripheral	JJ
O	NN

blood	NN
O	NN

of	IN
O	NN

these	DT
O	NN

participants	NNS
O	NN

and	CC
O	NN

from	IN
O	NN

healthy	JJ
O	NN

controls	NNS
O	VBP

were	VBD
O	NN

stimulated	VBN
O	NN

with	IN
O	NN

opsonised	VBN
O	NN

zymosan	NN
O	NN

,	,
O	NN

and	CC
O	NN

superoxide	NN
O	NN

production	NN
O	NN

was	VBD
O	NN

measured	VBN
O	NN

by	IN
O	NN

a	DT
O	NN

spectrophotometric	JJ
O	NN

assay	NN
O	NN

(	NN
O	NN

reduction	NN
O	NN

of	IN
O	NN

ferricytochrome	JJ
O	NN

C	NN
O	NN

)	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

FINDINGS	NNS
O	NN

:	:
O	NN

G-CSF	NN
O	NN

therapy	NN
O	NN

was	VBD
O	NN

associated	VBN
O	NN

with	IN
O	NN

earlier	JJR
O	NN

eradication	NN
O	NN

of	IN
O	NN

pathogens	NNS
O	NN

from	IN
O	NN

the	DT
O	NN

infected	JJ
O	NN

ulcer	NN
O	NN

(	NN
O	NN

median	JJ
O	NN

4	CD
O	NN

(	NN
O	NN

range	NN
O	NN

2-10	CD
O	NN

)	NN
O	NN

vs	CC
O	NN

8	CD
O	NN

(	NN
O	NN

2-79	CD
O	NN

)	NN
O	NN

days	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

placebo	NN
O	NN

group	NN
O	NN

;	:
O	NN

p	NN
O	NN

=	JJ
O	NN

0.02	CD
O	NN

)	NN
O	NN

,	,
O	NN

quicker	JJR
O	NN

resolution	NN
O	NN

of	IN
O	NN

cellulitis	NN
O	NN

<	JJR
O	NN

(	NN
O	NN

7	CD
O	NN

(	NN
O	NN

5-20	CD
O	NN

)	NN
O	NN

vs	CC
O	NN

12	CD
O	NN

(	NN
O	NN

5-93	CD
O	NN

)	NN
O	NN

days	NNS
O	NN

;	:
O	NN

p	NN
O	NN

=	JJ
O	NN

0.03	CD
O	NN

)	NN
O	NN

,	,
O	NN

shorter	JJR
O	NN

hospital	NN
O	NN

stay	VB
O	NNP

(	NN
O	NN

10	CD
O	NN

(	NN
O	NN

7-31	CD
O	NN

)	NN
O	NN

vs	CC
O	NN

17.5	CD
O	NN

(	NN
O	NN

9-100	CD
O	NN

)	NN
O	NN

days	NNS
O	NN

;	:
O	NN

p	NN
O	NN

=	JJ
O	NN

0.02	CD
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

a	DT
O	NN

shorter	JJR
O	NN

duration	NN
O	NN

of	IN
O	NN

intravenous	JJ
O	NN

antibiotic	JJ
O	NN

treatment	NN
O	NN

(	NN
O	NN

8.5	CD
O	NN

(	NN
O	NN

5-30	CD
O	NN

)	NN
O	NN

vs	CC
O	NN

14.5	CD
O	NN

(	NN
O	NN

8-63	CD
O	NN

)	NN
O	NN

days	NNS
O	NN

;	:
O	NN

p	NN
O	NN

=	JJ
O	NN

0.02	CD
O	NN

)	NN
O	NN

No	DT
O	NN

G-CSF-treated	JJ
O	NN

patient	NN
O	NN

needed	VBN
O	NN

surgery	NN
T	NN

,	,
O	NN

whereas	IN
O	NN

two	CD
O	NN

placebo	NN
O	NN

recipients	NNS
O	NN

underwent	VBD
O	NN

to	TO
O	NN

amputation	NN
T	NN

and	CC
O	NN

two	CD
O	NN

had	VBD
O	NN

extensive	JJ
O	NN

debridement	NN
T	NN

under	IN
O	NN

anaesthesia	NN
O	NN

After	IN
O	NN

7	CD
O	NN

days	NNS
O	NN

'	POS
O	NN

treatment	NN
O	NN

,	,
O	NN

neutrophil	NN
O	NN

superoxide	NN
O	NN

production	NN
O	NN

was	VBD
O	NN

significantly	RB
O	NN

higher	JJR
O	NN

in	IN
O	NN

the	DT
O	NN

G-CSF	NN
O	NN

group	NN
O	NN

than	IN
O	NN

in	IN
O	NN

the	DT
O	NN

placebo	NN
O	NN

group	NN
O	NN

(	NN
O	NN

16.1	CD
O	NN

(	NN
O	NN

4.2-24.2	CD
O	NN

)	NN
O	NN

vs	CC
O	NN

7.3	CD
O	NN

(	NN
O	NN

2.1-11.5	CD
O	NN

)	NN
O	NN

nmol	NN
O	NN

per	IN
O	NN

10	CD
O	NN

(	NN
O	NN

6	CD
O	NN

)	NN
O	NN

neutrophils	NNS
O	NN

in	IN
O	NN

30	CD
O	NN

min	NN
O	NN

;	:
O	NN

p	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.0001	CD
O	NN

)	NN
O	NN

G-CSF	NN
T	NN

therapy	NN
T	NN

was	VBD
O	NN

generally	RB
O	NN

well	RB
O	NN

tolerated	VBN
O	NN

INTERPRETATION	NN
O	NN

:	:
O	NN

G-CSF	NN
T	NN

treatment	NN
T	NN

was	VBD
O	NN

associated	VBN
O	NN

with	IN
O	NN

improved	VBN
O	NN

clinical	JJ
O	NN

outcome	NN
O	NN

of	IN
O	NN

foot	NN
D	NN

infection	NN
D	NN

in	IN
D	NN

diabetic	JJ
D	NN

patients	NNS
D	NN

This	DT
O	NN

improvement	NN
O	NN

may	MD
O	NNP

be	VB
O	NN

related	JJ
O	NN

to	TO
O	NN

an	DT
O	NN

increase	NN
O	NN

in	IN
O	NN

neutrophil	NN
O	NN

superoxide	NN
O	NN

production	NN
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Accelerated	VBN
T	NN

infusion	NN
T	NN

of	IN
T	NN

alteplase	RB
T	NN

(	NN
T	NN

tissue	NN
T	NN

plasminogen	NN
T	NN

activator	NN
T	NN

)	NN
T	NN

over	IN
O	NN

a	DT
O	NN

period	NN
O	NN

of	IN
O	NN

90	CD
O	NN

minutes	NNS
O	NN

induces	VBZ
O	NN

more	RBR
O	NN

rapid	JJ
O	NN

lysis	NN
O	NN

of	IN
O	NN

coronary-artery	NN
D	NN

thrombi	NN
D	NN

than	IN
O	NN

a	DT
O	NN

3-hour	JJ
O	NN

infusion	NN
O	NN

With	IN
O	NN

two	CD
O	NN

bolus	NN
O	NN

doses	NNS
O	NN

of	IN
O	NN

alteplase	RB
T	NN

,	,
O	NN

further	RB
O	NN

shortening	VBG
O	NN

the	DT
O	NN

duration	NN
O	NN

of	IN
O	NN

administration	NN
O	NN

,	,
O	NN

complete	JJ
O	NN

reperfusion	NN
O	NN

was	VBD
O	NN

achieved	VBN
O	NN

in	IN
O	NN

more	RBR
O	NN

than	IN
O	NN

85	CD
O	NN

percent	NN
O	NN

of	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

in	IN
O	NN

initial	JJ
O	NN

angiographic	JJ
O	NN

studies	NNS
O	VBP

We	PRP
O	VBP

tested	VBN
O	NN

the	DT
O	NN

hypothesis	NN
O	NN

that	IN
O	NN

double-bolus	JJ
T	NN

alteplase	RB
T	NN

is	VBZ
O	NN

at	IN
O	NN

least	JJS
O	NN

as	IN
O	NN

effective	JJ
O	NN

as	IN
O	NN

accelerated	VBN
O	NN

infusion	NN
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

In	IN
O	NN

398	CD
O	NN

hospitals	NNS
O	NN

,	,
O	NN

7169	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

acute	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

were	VBD
O	NN

randomly	RB
O	NN

assigned	VBN
O	NN

to	TO
O	NN

weight-adjusted	JJ
O	NN

,	,
O	NN

accelerated	VBN
O	NN

infusion	NN
O	NN

of	IN
O	NN

100	CD
O	NN

mg	NN
O	NN

of	IN
O	NN

alteplase	RB
T	NN

or	CC
O	NN

to	TO
O	NN

a	DT
O	NN

bolus	NN
O	NN

of	IN
O	NN

50	CD
O	NN

mg	NN
O	NN

of	IN
O	NN

alteplase	RB
T	NN

over	IN
O	NN

a	DT
O	NN

period	NN
O	NN

of	IN
O	NN

1	CD
O	NN

to	TO
O	NN

3	CD
O	NN

minutes	NNS
O	NN

followed	VBN
O	NN

30	CD
O	NN

minutes	NNS
O	NN

later	RB
O	NN

by	IN
O	NN

a	DT
O	NN

second	JJ
O	NN

bolus	NN
O	NN

of	IN
O	NN

50	CD
O	NN

mg	NN
O	NN

(	NN
O	NN

or	CC
O	NN

40	CD
O	NN

mg	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

who	WP
O	VBP

weighed	VBD
O	NN

less	JJR
O	NN

than	IN
O	NN

60	CD
O	NN

kg	NN
O	NN

)	NN
O	NN

The	DT
O	NN

primary	JJ
O	NN

end	NN
O	NN

point	NN
O	NN

was	VBD
O	NN

death	NN
O	NN

from	IN
O	NN

any	DT
O	NN

cause	NN
O	NN

at	IN
O	NN

30	CD
O	NN

days	NNS
O	NN

The	DT
O	NN

trial	NN
O	NN

was	VBD
O	NN

stopped	VBD
O	NN

prematurely	RB
O	NN

because	IN
O	NN

of	IN
O	NN

concern	NN
O	NN

about	IN
O	NN

the	DT
O	NN

safety	NN
O	NN

of	IN
O	NN

the	DT
O	NN

double-bolus	JJ
T	NN

injection	NN
T	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Thirty-day	JJ
O	NN

mortality	NN
O	NN

was	VBD
O	NN

higher	JJR
O	NN

in	IN
O	NN

the	DT
O	NN

double-bolus	JJ
O	NN

group	NN
O	NN

than	IN
O	NN

in	IN
O	NN

the	DT
O	NN

accelerated-infusion	NN
O	NN

group	NN
O	NN

:	:
O	NN

7.98	CD
O	NN

percent	NN
O	NN

as	IN
O	NN

compared	VBN
O	NN

with	IN
O	NN

7.53	CD
O	NN

percent	NN
O	NN

The	DT
O	NN

absolute	JJ
O	NN

difference	NN
O	NN

was	VBD
O	NN

0.44	CD
O	NN

percent	NN
O	NN

,	,
O	NN

with	IN
O	NN

a	DT
O	NN

one-sided	JJ
O	NN

95	CD
O	NN

percent	NN
O	NN

upper	JJ
O	NN

boundary	NN
O	NN

of	IN
O	NN

1.49	CD
O	NN

percent	NN
O	NN

,	,
O	NN

which	WDT
O	NN

exceeded	VBD
O	NN

the	DT
O	NN

prespecified	VBD
O	NN

upper	JJ
O	NN

limit	NN
O	NN

of	IN
O	NN

0.40	CD
O	NN

percent	NN
O	NN

to	TO
O	NN

indicate	VBP
O	NN

equivalence	JJ
O	NN

in	IN
O	NN

30-day	JJ
O	NN

mortality	NN
O	NN

between	IN
O	NN

the	DT
O	NN

two	CD
O	NN

regimens	NNS
O	VBP

The	DT
O	NN

respective	JJ
O	NN

rates	NNS
O	VBP

of	IN
O	NN

any	DT
O	NN

stroke	NN
D	NN

and	CC
O	NN

of	IN
O	NN

hemorrhagic	JJ
D	NN

stroke	NN
D	NN

were	VBD
O	NN

1.92	CD
O	NN

and	CC
O	NN

1.12	CD
O	NN

percent	NN
O	NN

after	IN
O	NN

double-bolus	JJ
O	NN

alteplase	RB
T	NN

,	,
O	NN

as	IN
O	NN

compared	VBN
O	NN

with	IN
O	NN

1.53	CD
O	NN

and	CC
O	NN

0.81	CD
O	NN

percent	NN
O	NN

after	IN
O	NN

an	DT
O	NN

accelerated	VBN
O	NN

infusion	NN
O	NN

of	IN
O	NN

alteplase	RB
T	NN

(	NN
O	NN

P=0.24	NN
O	NN

and	CC
O	NN

P=0.23	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

)	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Double-bolus	JJ
O	NN

alteplase	RB
T	NN

was	VBD
O	NN

not	RB
O	NN

shown	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

equivalent	JJ
O	NN

,	,
O	NN

according	VBG
O	NN

to	TO
O	NN

the	DT
O	NN

prespecified	VBD
O	NN

criteria	NNS
O	NN

,	,
O	NN

to	TO
O	NN

accelerated	VBN
O	NN

infusion	NN
O	NN

with	IN
O	NN

regard	NN
O	NN

to	TO
O	NN

30-day	JJ
O	NN

mortality	NN
O	NN

There	EX
O	NN

was	VBD
O	NN

also	RB
O	NN

a	DT
O	NN

slightly	RB
O	NN

higher	JJR
O	NN

rate	NN
O	NN

of	IN
O	NN

intracranial	JJ
D	NN

hemorrhage	NN
D	NN

with	IN
O	NN

the	DT
O	NN

double-bolus	JJ
T	NN

method	NN
T	NN

Therefore	RB
O	NN

,	,
O	NN

accelerated	VBN
T	NN

infusion	NN
T	NN

of	IN
T	NN

alteplase	RB
T	NN

over	IN
O	NN

a	DT
O	NN

period	NN
O	NN

of	IN
O	NN

90	CD
O	NN

minutes	NNS
O	NN

remains	VBZ
O	NNP

the	DT
O	NN

preferred	VBN
O	NN

regimen	NN
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Fenfluramine	NN
T	NN

and	CC
O	NN

phentermine	NN
T	NN

have	VB
O	NN

been	VBN
O	NN

individually	RB
O	NN

approved	VBN
O	NN

as	IN
O	NN

anorectic	JJ
T	NN

agents	NNS
T	NN

by	IN
O	NN

the	DT
O	NN

Food	NNP
O	NNP

and	CC
O	NN

Drug	NN
O	NN

Administration	NNP
O	NNP

(	NN
O	NN

FDA	NNP
O	NNP

)	NN
O	NN

When	WRB
O	NN

used	VBN
O	NN

in	IN
O	NN

combination	NN
O	NN

the	DT
O	NN

drugs	NNS
O	NN

may	MD
O	NNP

be	VB
O	NN

just	RB
O	NN

as	IN
O	NN

effective	JJ
O	NN

as	IN
O	NN

either	DT
O	NN

drug	NN
O	NN

alone	RB
O	NN

,	,
O	NN

with	IN
O	NN

the	DT
O	NN

added	VBN
O	NN

advantages	NNS
O	VBP

of	IN
O	NN

the	DT
O	NN

need	NN
O	NN

for	IN
O	NN

lower	JJR
O	NN

doses	NNS
O	NN

of	IN
O	NN

each	DT
O	NN

agent	NN
O	NN

and	CC
O	NN

perhaps	RB
O	NN

fewer	JJR
O	NN

side	NN
O	NN

effects	NNS
O	NN

Although	IN
O	NN

the	DT
O	NN

combination	NN
O	NN

has	VBZ
O	NN

not	RB
O	NN

been	VBN
O	NN

approved	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

FDA	NNP
O	NNP

,	,
O	NN

in	IN
O	NN

1996	CD
O	NN

the	DT
O	NN

total	JJ
O	NN

number	NN
O	NN

of	IN
O	NN

prescriptions	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

United	NNP
O	NNP

States	NNPS
O	NNP

for	IN
O	NN

fenfluramine	NN
T	NN

and	CC
O	NN

phentermine	NN
T	NN

exceeded	VBD
O	NN

18	CD
O	NN

million	CD
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

We	PRP
O	VBP

identified	VBN
O	NN

valvular	JJ
O	NN

heart	NN
O	NN

diseasein	NN
O	NN

24	CD
O	NN

women	NNS
O	VBP

treated	VBN
O	NN

with	IN
O	NN

fenfluramine-phentermine	JJ
O	NN

who	WP
O	VBP

had	VBD
O	NN

no	DT
O	NN

history	NN
O	NN

of	IN
O	NN

cardiac	JJ
O	NN

disease	NN
O	NN

The	DT
O	NN

women	NNS
O	VBP

presented	VBN
O	NN

with	IN
O	NN

cardiovascular	JJ
D	NN

symptoms	NNS
D	NN

or	CC
O	NN

a	DT
O	NN

heart	NN
D	NN

murmur	NN
D	NN

As	IN
O	NN

increasing	VBG
O	NN

numbers	NNS
O	NN

of	IN
O	NN

these	DT
O	NN

patients	NNS
O	NN

with	IN
O	NN

similar	JJ
O	NN

clinical	JJ
O	NN

features	NNS
O	VBP

were	VBD
O	NN

identified	VBN
O	NN

,	,
O	NN

there	RB
O	NN

appeared	VBD
O	NN

to	TO
O	NN

be	VB
O	NN

an	DT
O	NN

association	NN
O	NN

between	IN
O	NN

these	DT
O	NN

features	NNS
O	VBP

and	CC
O	NN

fenfluramine-phentermine	JJ
T	NN

therapy	NN
T	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Twenty-four	CD
O	NN

women	NNS
O	VBP

(	NN
O	NN

mean	VB
O	NN

(	NN
O	NN

+/-SD	NN
O	NN

)	NN
O	NN

age	NN
O	NN

,	,
O	NN

44+/-8	CD
O	NN

years	NNS
O	NN

)	NN
O	NN

were	VBD
O	NN

evaluated	VBN
O	NN

12.3+/-7.1	CD
O	NN

months	NNS
O	NN

after	IN
O	NN

the	DT
O	NN

initiation	NN
O	NN

of	IN
O	NN

fenfluramine-phentermine	JJ
T	NN

therapy	NN
T	NN

Echocardiography	NN
O	NN

demonstrated	VBD
O	NN

unusual	JJ
O	NN

valvular	JJ
O	NN

morphology	NN
O	NN

and	CC
O	NN

regurgitation	NN
O	NN

in	IN
O	NN

all	DT
O	NN

patients	NNS
O	NN

Both	DT
O	NN

right-sided	JJ
O	NN

and	CC
O	NN

left-sided	JJ
O	NN

heart	NN
O	NN

valves	NNS
O	NN

were	VBD
O	NN

involved	VBN
O	NN

Eight	CD
O	NN

women	NNS
O	VBP

also	RB
O	NN

had	VBD
O	NN

newly	RB
O	NN

documented	VBN
O	NN

pulmonary	JJ
D	NN

hypertension	NN
D	NN

To	TO
O	NN

date	NN
O	NN

,	,
O	NN

cardiac	JJ
T	NN

surgical	JJ
T	NN

intervention	NN
T	NN

has	VBZ
O	NN

been	VBN
O	NN

required	VBN
O	NN

in	IN
O	NN

five	CD
O	NN

patients	NNS
O	NN

The	DT
O	NN

heart	NN
O	NN

valves	NNS
O	NN

had	VBD
O	NN

a	DT
O	NN

glistening	VBG
O	NN

white	JJ
O	NN

appearance	NN
O	NN

Histopathological	JJ
O	NN

findings	NNS
O	VBP

included	VBN
O	NN

plaque-like	JJ
O	NN

encasement	NN
O	NN

of	IN
O	NN

the	DT
O	NN

leaflets	NNS
O	NN

and	CC
O	NN

chordal	JJ
O	NN

structures	NNS
O	VBP

with	IN
O	NN

intact	JJ
O	NN

valve	NN
O	NN

architecture	NN
O	NN

The	DT
O	NN

histopathological	JJ
O	NN

features	NNS
O	VBP

were	VBD
O	NN

identical	JJ
O	NN

to	TO
O	NN

those	DT
O	NNP

seen	VBN
O	NN

in	IN
O	NN

carcinoid	NN
O	NN

or	CC
O	NN

ergotamine-induced	JJ
O	NN

valve	NN
D	NN

disease	NN
D	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

These	DT
O	NN

cases	NNS
O	NN

arouse	VB
O	NN

concern	NN
O	NN

that	IN
O	NN

fenfluramine-phentermine	JJ
T	NN

therapy	NN
T	NN

may	MD
O	NNP

be	VB
O	NN

associated	VBN
O	NN

with	IN
O	NN

valvular	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

Candidates	NNS
O	NN

for	IN
O	NN

fenfluramine-phentermine	JJ
T	NN

therapy	NN
T	NN

should	MD
O	NNP

be	VB
O	NN

informed	VBN
O	NN

about	IN
O	NN

serious	JJ
O	NN

potential	JJ
O	NN

adverse	JJ
O	NN

effects	NNS
O	NN

,	,
O	NN

including	VBG
O	NN

pulmonary	JJ
D	NN

hypertension	NN
D	NN

and	CC
O	NN

valvular	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Between	IN
O	NN

1987	CD
O	NN

and	CC
O	NN

1992	CD
O	NN

,	,
O	NN

all	DT
O	NN

patients	NNS
O	NN

presenting	VBG
O	NN

to	TO
O	NN

the	DT
O	NN

senior	JJ
O	NN

author	NN
O	NN

with	IN
O	NN

a	DT
O	NN

symptomatic	JJ
O	NN

failed	VBD
O	NN

silicone	NN
O	NN

implant	VB
O	NN

arthroplasty	NN
O	NN

refractory	JJ
O	NN

to	TO
O	NN

conservative	JJ
O	NN

treatment	NN
O	NN

were	VBD
O	NN

converted	VBN
O	NN

to	TO
O	NN

a	DT
O	NN

metatarsophalangeal	NN
O	NN

joint	JJ
O	NN

arthrodesis	NN
O	NN

Internal	JJ
O	NN

fixation	NN
O	NN

was	VBD
O	NN

achieved	VBN
O	NN

with	IN
O	NN

either	DT
O	NN

dual	JJ
O	NN

intrameduilary	JJ
O	NN

threaded	VBN
O	NN

Steinmann	NNP
O	NNP

pins	NNS
O	NN

or	CC
O	NN

an	DT
O	NN

obliquely	RB
O	NN

placed	VBN
O	NN

AO	JJ
O	NN

compression	NN
O	NN

screw	VB
O	NN

and	CC
O	NN

a	DT
O	NN

three-	CD
O	NN

or	CC
O	NN

four-hole	JJ
O	NN

one-third	JJ
O	NN

tubular	JJ
O	NN

dorsal	NN
O	NN

neutralization	NN
O	NN

plate	NN
O	NN

Bone	NN
T	NN

grafting	VBG
T	NN

was	VBD
O	NN

used	VBN
O	NN

to	TO
O	NN

maintain	VB
O	NN

hallux	NN
O	NN

length	NN
O	NN

Successful	JJ
O	NN

arthrodesis	NN
T	NN

was	VBD
O	NN

achieved	VBN
O	NN

in	IN
O	NN

all	DT
O	NN

five	CD
O	NN

feet	NNS
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

rheumatoid	JJ
D	NN

arthritis	NN
D	NN

Subjectively	RB
O	NN

,	,
O	NN

patients	NNS
O	NN

improved	VBN
O	NN

from	IN
O	NN

an	DT
O	NN

average	JJ
O	NN

of	IN
O	NN

0.69	CD
O	NN

before	IN
O	NN

arthrodesis	NN
T	NN

to	TO
O	NN

4.89	CD
O	NN

after	IN
O	NN

arthrodesis	NN
T	NN

The	DT
O	NN

average	JJ
O	NN

walking	VBG
O	NN

tolerance	NN
O	NN

improved	VBN
O	NN

from	IN
O	NN

1.11	CD
O	NN

to	TO
O	NN

4.80	CD
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

overall	JJ
O	NN

level	NN
O	NN

of	IN
O	NN

satisfaction	NN
O	NN

improved	VBN
O	NN

from	IN
O	NN

0.0	CD
O	NN

to	TO
O	NN

4.79	CD
O	NN

The	DT
O	NN

patient	NN
O	NN

's	POS
O	NN

ability	NN
O	NN

to	TO
O	NN

wear	VB
O	NNP

shoes	NNS
O	NN

improved	VBN
O	NN

from	IN
O	NN

0.87	CD
O	NN

to	TO
O	NN

3.1	CD
O	NN

Successful	JJ
O	NN

arthrodesis	NN
T	NN

produces	VBZ
O	NN

a	DT
O	NN

foot	NN
O	NN

that	IN
O	NN

is	VBZ
O	NN

more	RBR
O	NN

functional	JJ
O	NN

and	CC
O	NN

durable	JJ
O	NN

than	IN
O	NN

excisional	JJ
T	NN

arthroplasty	NN
T	NN

Subjectively	RB
O	NN

,	,
O	NN

these	DT
O	NN

patients	NNS
O	NN

stated	VBN
O	NN

that	IN
O	NN

their	PRP$
O	NN

level	NN
O	NN

of	IN
O	NN

pain	NN
O	NN

,	,
O	NN

walking	VBG
O	NN

tolerance	NN
O	NN

,	,
O	NN

and	CC
O	NN

overall	JJ
O	NN

satisfaction	NN
O	NN

improved	VBN
O	NN

significantly	RB
O	NN

after	IN
O	NN

the	DT
O	NN

arthrodesis	NN
T	NN

Clinically	RB
O	NN

,	,
O	NN

there	RB
O	NN

was	VBD
O	NN

no	DT
O	NN

evidence	NN
O	NN

of	IN
O	NN

transfer	NN
D	NN

lesions	NNS
D	NN

,	,
O	NN

tenderness	NN
O	NN

,	,
O	NN

or	CC
O	NN

hallux	NN
D	NN

subluxation	NN
D	NN

Hallux	NNP
O	NNP

length	NN
O	NN

was	VBD
O	NN

well	RB
O	NN

maintained	JJ
O	NN

after	IN
O	NN

surgery	NN
T	NN

with	IN
O	NN

bone	NN
T	NN

grafting	VBG
T	NN

,	,
O	NN

but	CC
O	NNP

it	PRP
O	NN

was	VBD
O	NN

more	RBR
O	NN

difficult	JJ
O	NN

to	TO
O	NN

obtain	VB
O	NN

the	DT
O	NN

alignment	NN
O	NN

goals	NNS
O	NN

The	DT
O	NN

average	JJ
O	NN

postoperative	JJ
O	NN

metatarsophalangeal	NN
O	NN

dorsiflexion	NN
O	NN

angle	NN
O	NN

was	VBD
O	NN

15.6	CD
O	NN

degrees	NNS
O	NN

and	CC
O	NN

the	DT
O	NN

first	RB
O	NN

metatarsophalangeal	NN
O	NN

angle	NN
O	NN

was	VBD
O	NN

3.1	CD
O	NN

degrees	NNS
O	NN

Despite	IN
O	NN

this	DT
O	NN

,	,
O	NN

patient	NN
O	NN

satisfaction	NN
O	NN

was	VBD
O	NN

high	JJ
O	NN

Arthrodesis	FW
T	NN

of	IN
O	NN

the	DT
O	NN

first	RB
O	NN

metatarsophalangeal	NN
O	NN

joint	JJ
O	NN

using	VBG
O	NN

a	DT
O	NN

bone	NN
T	NN

graft	NN
T	NN

to	TO
O	NN

salvage	NN
O	NN

failed	VBD
O	NN

silicone	NN
T	NN

implant	VB
T	NN

arthroplasty	NN
T	NN

produces	VBZ
O	NN

acceptable	JJ
O	NN

subjective	JJ
O	NN

and	CC
O	NN

radiographic	JJ
O	NN

results	NNS
O	VBP

Although	IN
O	NN

technically	RB
O	NN

demanding	VBG
O	NN

,	,
O	NN

it	PRP
O	NN

provides	VBZ
O	NN

long-term	JJ
O	NN

stability	NN
O	NN

to	TO
O	NN

the	DT
O	NN

hallux	NN
O	NN

,	,
O	NN

restores	VBZ
O	NN

weightbearing	VBG
O	NN

,	,
O	NN

and	CC
O	NN

allows	VBZ
O	NN

for	IN
O	NN

maintenance	NN
O	NN

of	IN
O	NN

a	DT
O	NN

propulsive	JJ
O	NN

gait	NN
O	NN

We	PRP
O	VBP

recommend	VB
O	NN

this	DT
O	NN

procedure	NN
O	NN

instead	RB
O	NN

of	IN
O	NN

an	DT
O	NN

excisional	JJ
T	NN

arthroplasty	NN
T	NN

to	TO
O	NN

maintain	VB
O	NN

high	JJ
O	NN

level	NN
O	NN

of	IN
O	NN

function	NN
O	NN

and	CC
O	NN

overall	JJ
O	NN

patient	NN
O	NN

satisfaction	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

estimate	NN
O	NN

the	DT
O	NN

crude	JJ
O	NN

incidence	NN
O	NN

rates	NNS
O	VBP

of	IN
O	NN

cerebrovascular	JJ
D	NN

accidents	NNS
D	NN

among	IN
O	NN

the	DT
O	NN

black	JJ
O	NN

residents	NNS
O	NN

of	IN
O	NN

Harare	NNP
O	NNP

DESIGN	NN
O	NN

:	:
O	NN

Prospective	JJ
O	NN

community-based	JJ
O	NN

study	NN
O	NN

SETTING	VBG
O	NN

:	:
O	NN

Black	JJ
O	NN

residents	NNS
O	NN

of	IN
O	NN

Harare	NNP
O	NNP

,	,
O	NN

Zimbabwe	NNP
O	NNP

PARTICIPANTS	NNS
O	VBP

:	:
O	NN

Two	CD
O	NN

hundred	CD
O	NN

and	CC
O	NN

seventy-three	CD
O	NN

'first-ever	JJ
O	NN

'	POS
O	NN

strokes	NNS
D	NN

prospectively	RB
O	NN

identified	VBN
O	NN

over	IN
O	NN

a	DT
O	NN

12-month	JJ
O	NN

period	NN
O	NN

MAIN	JJS
O	NN

OUTCOME	NN
O	NN

STUDY	NN
O	NN

FACTORS	NNS
O	VBP

:	:
O	NN

Cerebrovascular	JJ
D	NN

accident	NN
D	NN

first-week	JJ
O	NN

fatality	NN
O	NN

rate	NN
O	NN

;	:
O	NN

age-	NN
O	NN

and	CC
O	NN

sex-related	JJ
O	NN

incidence	NN
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

crude	JJ
O	NN

incidence	NN
O	NN

rate	NN
O	NN

was	VBD
O	NN

estimated	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

30.7	CD
O	NN

per	IN
O	NN

100000	CD
O	NN

(	NN
O	NN

95	CD
O	NN

%	NN
O	NN

confidence	NN
O	NN

interval	NN
O	NN

27.1-34.4	CD
O	NN

)	NN
O	NN

and	CC
O	NN

the	DT
O	NN

standardised	JJ
O	NN

rate	NN
O	NN

was	VBD
O	NN

68	CD
O	NN

per	IN
O	NN

100000	CD
O	NN

Fifty-one	CD
O	NN

per	IN
O	NN

cent	NN
O	NN

of	IN
O	NN

stroke	NN
D	NN

victims	NNS
O	NN

were	VBD
O	NN

below	IN
O	NN

the	DT
O	NN

age	NN
O	NN

of	IN
O	NN

54	CD
O	NN

years	NNS
O	NN

Thirty-five	CD
O	NN

per	IN
O	NN

cent	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

died	VBD
O	NN

within	IN
O	NN

1	CD
O	NN

week	NN
O	NN

of	IN
O	NN

the	DT
O	NN

stroke	NN
O	NN

Overall	JJ
O	NN

,	,
O	NN

the	DT
O	NN

age-specific	JJ
O	NN

rates	NNS
O	VBP

for	IN
O	NN

both	DT
O	NN

sexes	NNS
O	NN

rose	VBD
O	NN

with	IN
O	NN

age	NN
O	NN

,	,
O	NN

with	IN
O	NN

the	DT
O	NN

rates	NNS
O	VBP

for	IN
O	NN

women	NNS
O	VBP

being	VBG
O	NN

higher	JJR
O	NN

at	IN
O	NN

all	DT
O	NN

age	NN
O	NN

strata	NN
O	NN

except	IN
O	NN

for	IN
O	NN

the	DT
O	NN

group	NN
O	NN

45-54	CD
O	NN

years	NNS
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

With	IN
O	NN

a	DT
O	NN

standardised	JJ
O	NN

rate	NN
O	NN

of	IN
O	NN

68	CD
O	NN

per	IN
O	NN

100000	CD
O	NN

and	CC
O	NN

a	DT
O	NN

first-week	JJ
O	NN

mortality	NN
O	NN

rate	NN
O	NN

of	IN
O	NN

35	CD
O	NN

%	NN
O	NN

,	,
O	NN

stroke	NN
D	NN

must	MD
O	NNP

now	RB
O	NN

be	VB
O	NN

considered	VBN
O	NN

an	DT
O	NN

important	JJ
O	NN

cause	NN
O	NN

of	IN
O	NN

morbidity	NN
O	NN

and	CC
O	NN

mortality	NN
O	NN

in	IN
O	NN

the	DT
O	NN

population	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

explore	VB
O	NN

the	DT
O	NN

long-term	JJ
O	NN

effect	NN
O	NN

of	IN
O	NN

calcium	NN
T	NN

supplementation	NN
T	NN

during	IN
O	NN

pregnancy	NN
O	NN

on	IN
O	NN

the	DT
O	NN

offspring	NN
O	NN

's	POS
O	NN

blood	NN
O	NN

pressure	NN
O	NN

during	IN
O	NN

childhood	NN
O	NN

DESIGN	NN
O	NN

:	:
O	NN

Follow	VB
O	NN

up	RB
O	NN

of	IN
O	NN

a	DT
O	NN

population	NN
O	NN

enrolled	VBN
O	NN

in	IN
O	NN

a	DT
O	NN

double	JJ
O	NN

blind	JJ
O	NN

,	,
O	NN

randomised	VBN
O	NN

,	,
O	NN

placebo	NN
O	NN

controlled	JJ
O	NN

trial	NN
O	NN

SETTING	VBG
O	NN

:	:
O	NN

Perinatal	JJ
O	NN

research	NN
O	NN

unit	NN
O	NN

,	,
O	NN

World	NNP
O	NNP

Health	NNP
O	NNP

Organisation	NNP
O	NNP

's	POS
O	NN

collaborative	JJ
O	NN

research	NN
O	NN

centre	NN
O	NN

SUBJECTS	NNS
O	NN

:	:
O	NN

591	CD
O	NN

children	NNS
O	VBP

at	IN
O	NN

a	DT
O	NN

mean	VB
O	NN

age	NN
O	NN

of	IN
O	NN

7	CD
O	NN

years	NNS
O	NN

whose	WP$
O	NN

mothers	NNS
O	NN

were	VBD
O	NN

randomly	RB
O	NN

assigned	VBN
O	NN

during	IN
O	NN

pregnancy	NN
O	NN

to	TO
O	NN

receive	VB
O	NN

2	CD
O	NN

g/day	NN
O	NN

of	IN
O	NN

elemental	JJ
O	NN

calcium	NN
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

298	CD
O	NN

)	NN
O	NN

or	CC
O	NN

placebo	NN
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

293	CD
O	NN

)	NN
O	NN

MAIN	JJS
O	NN

OUTCOME	NN
O	NN

MEASURES	NNS
O	VBP

:	:
O	NN

Mean	NN
O	NN

blood	NN
O	NN

pressure	NN
O	NN

and	CC
O	NN

rate	NN
O	NN

of	IN
O	NN

high	JJ
D	NN

blood	NN
D	NN

pressure	NN
D	NN

of	IN
O	NN

children	NNS
O	VBP

RESULTS	NNS
O	VBP

:	:
O	NN

Overall	JJ
O	NN

,	,
O	NN

systolic	JJ
O	NN

blood	NN
O	NN

pressure	NN
O	NN

was	VBD
O	NN

lower	JJR
O	NN

in	IN
O	NN

the	DT
O	NN

calcium	NN
O	NN

group	NN
O	NN

(	NN
O	NN

mean	VB
O	NN

difference	NN
O	NN

-1.4	CD
O	NN

mm	NN
O	NN

Hg	NN
O	NN

;	:
O	NN

95	CD
O	NN

%	NN
O	NN

confidence	NN
O	NN

interval	NN
O	NN

-3.2	CD
O	NN

to	TO
O	NN

0.5	CD
O	NN

)	NN
O	NN

than	IN
O	NN

in	IN
O	NN

the	DT
O	NN

placebo	NN
O	NN

group	NN
O	NN

The	DT
O	NN

effect	NN
O	NN

was	VBD
O	NN

found	VBN
O	NN

predominantly	RB
O	NN

among	IN
O	NN

children	NNS
O	VBP

whose	WP$
O	NN

body	NN
O	NN

mass	NN
O	NN

index	NN
O	NN

at	IN
O	NN

assessment	NN
O	NN

was	VBD
O	NN

above	IN
O	NN

the	DT
O	NN

median	JJ
O	NN

for	IN
O	NN

this	DT
O	NN

population	NN
O	NN

(	NN
O	NN

mean	VB
O	NN

difference	NN
O	NN

in	IN
O	NN

systolic	JJ
O	NN

blood	NN
O	NN

pressure	NN
O	NN

-5.8	CD
O	NN

mm	NN
O	NN

Hg	NN
O	NN

(	NN
O	NN

-9.8	CD
O	NN

mm	NN
O	NN

Hg	NN
O	NN

to	TO
O	NN

-1.7	CD
O	NN

mm	NN
O	NN

Hg	NN
O	NN

)	NN
O	NN

for	IN
O	NN

children	NNS
O	VBP

with	IN
O	NN

an	DT
O	NN

index	NN
O	NN

>	JJR
O	NN

17.5	CD
O	NN

and	CC
O	NN

-3.2	CD
O	NN

mm	NN
O	NN

Hg	NN
O	NN

(	NN
O	NN

-6.3	CD
O	NN

mm	NN
O	NN

Hg	NN
O	NN

to	TO
O	NN

-0.1	CD
O	NN

mm	NN
O	NN

Hg	NN
O	NN

)	NN
O	NN

for	IN
O	NN

those	DT
O	NNP

with	IN
O	NN

an	DT
O	NN

index	NN
O	NN

of	IN
O	NN

>	JJR
O	NN

15.7	CD
O	NN

to	TO
O	NN

17.5	CD
O	NN

)	NN
O	NN

The	DT
O	NN

risk	NN
O	NN

of	IN
O	NN

high	JJ
O	NN

systolic	JJ
O	NN

blood	NN
O	NN

pressure	NN
O	NN

was	VBD
O	NN

also	RB
O	NN

lower	JJR
O	NN

in	IN
O	NN

the	DT
O	NN

calcium	NN
O	NN

group	NN
O	NN

than	IN
O	NN

in	IN
O	NN

the	DT
O	NN

placebo	NN
O	NN

group	NN
O	NN

(	NN
O	NN

relative	JJ
O	NN

risk	NN
O	NN

0.59	CD
O	NN

;	:
O	NN

0.39	CD
O	NN

to	TO
O	NN

0.90	CD
O	NN

)	NN
O	NN

and	CC
O	NN

particularly	RB
O	NN

among	IN
O	NN

children	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

highest	JJS
O	NN

fourth	JJ
O	NN

of	IN
O	NN

body	NN
O	NN

mass	NN
O	NN

index	NN
O	NN

(	NN
O	NN

0.43	CD
O	NN

;	:
O	NN

0.26	CD
O	NN

to	TO
O	NN

0.71	CD
O	NN

)	NN
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

Calcium	NN
T	NN

supplementation	NN
T	NN

during	IN
O	NN

pregnancy	NN
O	NN

is	VBZ
O	NN

associated	VBN
O	NN

with	IN
O	NN

lower	JJR
O	NN

systolic	JJ
O	NN

blood	NN
O	NN

pressure	NN
O	NN

in	IN
O	NN

the	DT
O	NN

offspring	NN
O	NN

,	,
O	NN

particularly	RB
O	NN

among	IN
O	NN

overweight	JJ
O	NN

children	NNS
O	VBP

The	DT
O	NN

fast	RB
O	NN

reaction	NN
O	NN

of	IN
O	NN

peroxynitrite	NN
O	NN

with	IN
O	NN

CO2	NN
O	NN

and	CC
O	NN

the	DT
O	NN

high	JJ
O	NN

concentration	NN
O	NN

of	IN
O	NN

dissolved	VBN
O	NN

CO2	NN
O	NN

in	IN
O	NN

vivo	FW
O	FW

(	NN
O	NN

ca	MD
O	NNP

1	CD
O	NN

mM	NN
O	NN

)	NN
O	NN

suggest	VBP
O	NN

that	IN
O	NN

CO2	NN
O	NN

modulates	VBZ
O	NN

most	JJS
O	NN

of	IN
O	NN

the	DT
O	NN

reactions	NNS
O	NN

of	IN
O	NN

peroxynitrite	NN
O	NN

in	IN
O	NN

biological	JJ
O	NN

systems	NNS
O	NN

The	DT
O	NN

addition	NN
O	NN

of	IN
O	NN

peroxynitrite	NN
O	NN

to	TO
O	NN

CO2	NN
O	NN

produces	VBZ
O	NN

of	IN
O	NN

the	DT
O	NN

adduct	NN
O	NN

ONOO-CO2-	CD
O	NN

(	NN
O	NN

1	CD
O	NN

)	NN
O	NN

The	DT
O	NN

production	NN
O	NN

of	IN
O	NN

1	CD
O	NN

greatly	RB
O	NN

accelerates	VBZ
O	NN

the	DT
O	NN

decomposition	NN
O	NN

of	IN
O	NN

peroxynitrite	NN
O	NN

to	TO
O	NN

give	VB
O	NN

nitrate	JJ
O	NN

We	PRP
O	VBP

now	RB
O	NN

show	NN
O	NN

that	IN
O	NN

the	DT
O	NN

formation	NN
O	NN

of	IN
O	NN

1	CD
O	NN

is	VBZ
O	NN

followed	VBN
O	NN

by	IN
O	NN

reformation	NN
O	NN

of	IN
O	NN

CO2	NN
O	NN

(	NN
O	NN

rather	RB
O	NN

than	IN
O	NN

another	DT
O	NN

carbonate	NN
O	NN

species	NNS
O	NN

such	JJ
O	NN

as	IN
O	NN

CO3	NN
O	NN

=	JJ
O	NN

or	CC
O	NN

HCO3-	JJ
O	NN

)	NN
O	NN

To	TO
O	NN

show	NN
O	NN

this	DT
O	NN

,	,
O	NN

it	PRP
O	NN

is	VBZ
O	NN

necessary	JJ
O	NN

to	TO
O	NN

study	NN
O	NN

systems	NNS
O	NN

with	IN
O	NN

limiting	VBG
O	NN

concentrations	NNS
O	NN

of	IN
O	NN

CO2	NN
O	NN

(	NN
O	NN

When	WRB
O	NN

CO2	NN
O	NN

is	VBZ
O	NN

present	JJ
O	NN

in	IN
O	NN

excess	JJ
O	NN

,	,
O	NN

its	PRP$
O	NN

concentration	NN
O	NN

remains	VBZ
O	NNP

nearly	RB
O	NN

constant	JJ
O	NN

during	IN
O	NN

the	DT
O	NN

decomposition	NN
O	NN

of	IN
O	NN

peroxynitrite	NN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

recycling	VBG
O	NN

of	IN
O	NN

CO2	NN
O	NN

,	,
O	NN

although	IN
O	NN

it	PRP
O	NN

occurs	VBZ
O	NN

,	,
O	NN

can	MD
O	NNP

not	RB
O	NN

be	VB
O	NN

detected	VBN
O	NN

kinetically	RB
O	NN

)	NN
O	NN

We	PRP
O	VBP

find	VB
O	NN

that	IN
O	NN

CO2	NN
O	NN

is	VBZ
O	NN

a	DT
O	NN

true	JJ
O	NN

catalyst	NN
O	NN

of	IN
O	NN

the	DT
O	NN

decomposition	NN
O	NN

of	IN
O	NN

peroxynitrite	NN
O	NN

,	,
O	NN

and	CC
O	NN

this	DT
O	NN

fundamental	JJ
O	NN

insight	NN
O	NN

into	IN
O	NN

its	PRP$
O	NN

action	NN
O	NN

must	MD
O	NNP

be	VB
O	NN

rationalized	VBN
O	NN

by	IN
O	NN

any	DT
O	NN

in	IN
O	NN

vivo	FW
O	FW

or	CC
O	NN

in	IN
O	NN

vitro	FW
O	FW

reaction	NN
O	NN

mechanism	NN
O	NN

that	IN
O	NN

is	VBZ
O	NN

proposed	VBN
O	NN

When	WRB
O	NN

the	DT
O	NN

concentration	NN
O	NN

of	IN
O	NN

CO2	NN
O	NN

is	VBZ
O	NN

lower	JJR
O	NN

than	IN
O	NN

that	IN
O	NN

of	IN
O	NN

peroxynitrite	NN
O	NN

,	,
O	NN

the	DT
O	NN

reformation	NN
O	NN

of	IN
O	NN

CO2	NN
O	NN

amplifies	VBZ
O	NN

the	DT
O	NN

fraction	NN
O	NN

of	IN
O	NN

peroxynitrite	NN
O	NN

that	IN
O	NN

reacts	VBZ
O	NN

with	IN
O	NN

CO2	NN
O	NN

Even	RB
O	NN

low	JJ
O	NN

concentrations	NNS
O	NN

of	IN
O	NN

CO2	NN
O	NN

that	IN
O	NN

result	NN
O	NN

from	IN
O	NN

the	DT
O	NN

dissolution	NN
O	NN

of	IN
O	NN

ambient	JJ
O	NN

CO2	NN
O	NN

can	MD
O	NNP

have	VB
O	NN

pronounced	JJ
O	NN

catalytic	JJ
O	NN

effects	NNS
O	NN

These	DT
O	NN

effects	NNS
O	NN

can	MD
O	NNP

cause	NN
O	NN

deviations	NNS
O	NN

from	IN
O	NN

predicted	VBN
O	NN

kinetic	JJ
O	NN

behavior	NN
O	NN

in	IN
O	NN

studies	NNS
O	VBP

of	IN
O	NN

peroxynitrite	NN
O	NN

in	IN
O	NN

noncarbonate	JJ
O	NN

buffers	NNS
O	VBP

in	IN
O	NN

vitro	FW
O	FW

,	,
O	NN

and	CC
O	NN

since	IN
O	NN

1	CD
O	NN

and	CC
O	NN

other	JJ
O	NN

intermediates	NNS
O	NN

derived	VBN
O	NN

from	IN
O	NN

it	PRP
O	NN

are	VBP
O	NN

oxidants	NNS
O	NN

and/or	CC
O	NN

nitrating	VBG
O	NN

agents	NNS
O	NN

,	,
O	NN

some	DT
O	NN

of	IN
O	NN

the	DT
O	NN

reactions	NNS
O	NN

attributed	VBN
O	NN

to	TO
O	NN

peroxynitrite	NN
O	NN

may	MD
O	NNP

depend	VB
O	NN

on	IN
O	NN

the	DT
O	NN

availability	NN
O	NN

of	IN
O	NN

CO2	NN
O	NN

A	DT
O	NN

prospective	JJ
O	NN

,	,
O	NN

randomized	VBN
O	NN

,	,
O	NN

placebo-controlled	JJ
O	NN

,	,
O	NN

double-blind	JJ
O	NN

,	,
O	NN

parallel-group	JJ
O	NN

,	,
O	NN

6-month	JJ
O	NN

study	NN
O	NN

assessed	VBN
O	NN

the	DT
O	NN

efficacy	NN
O	NN

and	CC
O	NN

safety	NN
O	NN

of	IN
O	NN

ropinirole	NN
T	NN

,	,
T	NN

a	DT
T	NN

nonergoline	JJ
T	NN

D2-dopamine	NN
T	NN

agonist	NN
T	NN

,	,
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

early	RB
D	NN

Parkinson	NNP
D	NNP

's	POS
D	NN

disease	NN
D	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

241	CD
O	NN

;	:
O	NN

Hoehn	NNP
O	NN

&	CC
O	NNP

#	#
O	NN

38	CD
O	NN

;	:
O	NN

Yahr	NN
O	NN

stages	NNS
O	NN

I	PRP
O	VBP

to	TO
O	NN

III	NNP
O	NN

)	NN
O	NN

with	IN
O	NN

limited	JJ
O	NN

or	CC
O	NN

no	DT
O	NN

prior	RB
O	NN

dopaminergic	JJ
T	NN

therapy	NN
T	NN

Patients	NNS
O	NN

(	NN
O	NN

mean	VB
O	NN

age	NN
O	NN

,	,
O	NN

62.8	CD
O	NN

years	NNS
O	NN

)	NN
O	NN

,	,
O	NN

stratified	VBN
O	NN

by	IN
O	NN

concomitant	JJ
O	NN

use	NN
O	NN

of	IN
O	NN

selegiline	NN
T	NN

,	,
O	NN

were	VBD
O	NN

randomized	VBN
O	NN

to	TO
O	NN

ropinirole	NN
T	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

116	CD
O	NN

)	NN
O	NN

or	CC
O	NN

placebo	NN
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

125	CD
O	NN

)	NN
O	NN

The	DT
O	NN

starting	VBG
O	NN

dose	NN
O	NN

of	IN
O	NN

ropinirole	NN
T	NN

was	VBD
O	NN

0.25	CD
O	NN

mg	NN
O	NN

tid	NN
O	NN

with	IN
O	NN

titration	NN
O	NN

to	TO
O	NN

at	IN
O	NN

least	JJS
O	NN

1.5	CD
O	NN

mg	NN
O	NN

tid	NN
O	NN

(	NN
O	NN

maximum	NN
O	NN

dose	NN
O	NN

,	,
O	NN

8	CD
O	NN

mg	NN
O	NN

tid	NN
O	NN

)	NN
O	NN

Primary	JJ
O	NN

efficacy	NN
O	NN

endpoint	NN
O	NN

was	VBD
O	NN

the	DT
O	NN

percentage	NN
O	NN

improvement	NN
O	NN

in	IN
O	NN

Unified	JJ
O	NN

Parkinson	NNP
D	NNP

's	POS
D	NN

Disease	NN
D	NN

Rating	NNP
O	NNP

Scale	NNP
O	NNP

(	NN
O	NN

UPDRS	NN
O	NN

)	NN
O	NN

motor	NN
O	NN

score	NN
O	NN

Ropinirole-treated	JJ
O	NN

patients	NNS
O	NN

had	VBD
O	NN

a	DT
O	NN

significantly	RB
O	NN

greater	JJR
O	NN

percentage	NN
O	NN

improvement	NN
O	NN

in	IN
O	NN

UPDRS	NN
O	NN

motor	NN
O	NN

score	NN
O	NN

than	IN
O	NN

patients	NNS
O	NN

who	WP
O	VBP

received	VBN
O	NN

placebo	NN
O	NN

(	NN
O	NN

+24	CD
O	NN

%	NN
O	NN

vs	CC
O	NN

-3	CD
O	NN

%	NN
O	NN

;	:
O	NN

p	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.001	CD
O	NN

)	NN
O	NN

Ropinirole	NNP
T	NN

was	VBD
O	NN

well	RB
O	NN

tolerated	VBN
O	NN

and	CC
O	NN

patient	NN
O	NN

withdrawals	NNS
O	NN

were	VBD
O	NN

infrequent	JJ
O	NN

Most	JJS
O	NN

adverse	JJ
O	NN

experiences	NNS
O	NN

were	VBD
O	NN

related	JJ
O	NN

to	TO
O	NN

peripheral	JJ
O	NN

dopaminergic	JJ
O	NN

activity	NN
O	NN

Ropinirole	NNP
T	NN

monotherapy	JJ
T	NN

is	VBZ
O	NN

an	DT
O	NN

effective	JJ
O	NN

and	CC
O	NN

well-tolerated	JJ
O	NN

therapeutic	JJ
O	NN

option	NN
O	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

early	RB
D	NN

Parkinson	NNP
D	NNP

's	POS
D	NN

disease	NN
D	NN

Starfish	JJ
O	NN

oocytes	NNS
O	NN

can	MD
O	NNP

be	VB
O	NN

fertilized	VBN
O	NN

after	IN
O	NN

germinal	JJ
O	NN

vesicle	NN
O	NN

breakdown	NN
O	NN

(	NN
O	NN

GVBD	NN
O	NN

)	NN
O	NN

and	CC
O	NN

artificial	JJ
O	NN

parthenogenesis	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

induced	VBN
O	NN

by	IN
O	NN

activating	VBG
O	NN

the	DT
O	NN

oocytes	NNS
O	NN

after	IN
O	NN

GVBD	NN
O	NN

(	NN
O	NN

post-GVBD	JJ
O	NN

activation	NN
O	NN

)	NN
O	NN

In	IN
O	NN

the	DT
O	NN

present	JJ
O	NN

study	NN
O	NN

,	,
O	NN

parthenogenotes	NNS
O	NN

were	VBD
O	NN

obtained	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

activation	NN
O	NN

of	IN
O	NN

immature	JJ
O	NN

oocytes	NNS
O	NN

with	IN
O	NN

caffeine	NN
O	NN

before	IN
O	NN

treatment	NN
O	NN

with	IN
O	NN

1-methyladenine	JJ
T	NN

(	NN
T	NN

1-MeAde	JJ
T	NN

)	NN
T	NN

to	TO
O	NN

induce	VB
O	NN

oocyte	NN
O	NN

maturation	NN
O	NN

Most	JJS
O	NN

of	IN
O	NN

the	DT
O	NN

caffeine-treated	JJ
O	NN

eggs	NNS
O	NN

developed	VBN
O	NN

as	IN
O	NN

tetraploids	NNS
O	NN

,	,
O	NN

as	IN
O	NN

parthenogenotes	NNS
O	NN

produced	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

post-GVBD	JJ
O	NN

activation	NN
O	NN

The	DT
O	NN

parthengenotes	NNS
O	NN

were	VBD
O	NN

derived	VBN
O	NN

only	RB
O	NN

from	IN
O	NN

eggs	NNS
O	NN

that	IN
O	NN

failed	VBD
O	NN

to	TO
O	NN

extrude	VB
O	NN

polar	JJ
O	NN

bodies	NNS
O	NN

,	,
O	NN

mostly	RB
O	NN

from	IN
O	NN

eggs	NNS
O	NN

failing	VBG
O	NN

to	TO
O	NN

extrude	VB
O	NN

a	DT
O	NN

second	JJ
O	NN

polar	JJ
O	NN

body	NN
O	NN

Eggs	NNP
O	NNP

derived	VBN
O	NN

from	IN
O	NN

immature	JJ
O	NN

oocytes	NNS
O	NN

activated	VBN
O	NN

by	IN
O	NN

A23187	NN
O	NN

,	,
O	NN

treated	VBN
O	NN

with	IN
O	NN

1-MeAde	JJ
T	NN

and	CC
O	NN

post-treated	JJ
O	NN

with	IN
O	NN

cytochalasin	NN
T	NN

B	NN
T	NN

failed	VBD
O	NN

to	TO
O	NN

extrude	VB
O	NN

polar	JJ
O	NN

bodies	NNS
O	NN

,	,
O	NN

and	CC
O	NN

eventually	RB
O	NN

developed	VBN
O	NN

into	IN
O	NN

parthenogenetic	JJ
O	NN

embryos	NNS
O	NN

These	DT
O	NN

results	NNS
O	VBP

indicate	VBP
O	NN

that	IN
O	NN

the	DT
O	NN

present	JJ
O	NN

parthenogenesis	NN
O	NN

mechanism	NN
O	NN

shares	NNS
O	VBP

the	DT
O	NN

same	JJ
O	NN

characteristics	NNS
O	NN

as	IN
O	NN

that	IN
O	NN

achieved	VBN
O	NN

by	IN
O	NN

post-GVBD	JJ
O	NN

activation	NN
O	NN

in	IN
O	NN

the	DT
O	NN

suppression	NN
O	NN

of	IN
O	NN

polar	JJ
O	NN

body	NN
O	NN

formation	NN
O	NN

as	IN
O	NN

a	DT
O	NN

key	JJ
O	NN

means	NNS
O	VBP

for	IN
O	NN

successful	JJ
O	NN

starfish	NN
O	NN

parthenogenesis	NN
O	NN

We	PRP
O	VBP

hypothesized	VBN
O	NN

that	IN
O	NN

fluoride	NN
T	NN

partly	RB
O	NN

acts	NNS
O	NN

by	IN
O	NN

changing	VBG
O	NN

the	DT
O	NN

levels	NNS
O	VBP

of	IN
O	NN

circulating	VBG
O	NN

calcium-regulating	JJ
O	NN

hormones	NNS
O	NN

and	CC
O	NN

skeletal	JJ
O	NN

growth	NN
O	NN

factors	NNS
O	NN

The	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

oral	JJ
T	NN

fluoride	NN
T	NN

on	IN
O	NN

24	CD
O	NN

female	JJ
O	NN

,	,
O	NN

Dutch-Belted	JJ
O	NN

,	,
O	NN

young	JJ
O	NN

adult	JJ
O	NN

rabbits	NNS
O	NN

were	VBD
O	NN

studied	VBN
O	NN

The	DT
O	NN

rabbits	NNS
O	NN

were	VBD
O	NN

divided	VBN
O	NN

into	IN
O	NN

two	CD
O	NN

study	NN
O	NN

groups	NNS
O	NN

,	,
O	NN

one	CD
O	NN

control	NN
O	NN

and	CC
O	NN

the	DT
O	NN

other	JJ
O	NN

receiving	VBG
O	NN

about	IN
O	NN

16	CD
O	NN

mg	NN
O	NN

fluoride/rabbit/day	NN
O	NN

in	IN
O	NN

their	PRP$
O	NN

drinking	NN
O	NN

water	NN
O	NN

After	IN
O	NN

6	CD
O	NN

months	NNS
O	NN

of	IN
O	NN

fluoride	NN
T	NN

dosing	NN
T	NN

,	,
O	NN

all	DT
O	NN

rabbits	NNS
O	NN

were	VBD
O	NN

euthanized	VBN
O	NN

and	CC
O	NN

bone	NN
O	NN

and	CC
O	NN

blood	NN
O	NN

samples	NNS
O	NN

were	VBD
O	NN

taken	VBN
O	NN

for	IN
O	NN

analyses	NNS
O	VBP

Fluoride	NN
T	NN

treatment	NN
T	NN

increased	VBN
O	NN

serum	NN
O	NN

and	CC
O	NN

bone	NN
O	NN

fluoride	NN
O	NN

levels	NNS
O	VBP

by	IN
O	NN

over	IN
O	NN

an	DT
O	NN

order	NN
O	NN

of	IN
O	NN

magnitude	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.001	CD
O	NN

)	NN
O	NN

,	,
O	NN

but	CC
O	NNP

did	VBD
O	NNP

not	RB
O	NN

affect	VB
O	NN

body	NN
O	NN

weight	NN
O	NN

or	CC
O	NN

the	DT
O	NN

following	VBG
O	NN

serum	NN
O	NN

biochemical	JJ
O	NN

variables	NNS
O	NN

:	:
O	NN

urea	NN
O	NN

,	,
O	NN

creatinine	NN
O	NN

,	,
O	NN

phosphorus	NN
O	NN

,	,
O	NN

total	JJ
O	NN

protein	NN
O	NN

,	,
O	NN

albumin	NN
O	NN

,	,
O	NN

bilirubin	NN
O	NN

,	,
O	NN

SGOT	NN
O	NN

,	,
O	NN

or	CC
O	NN

total	JJ
O	NN

alkaline	NN
O	NN

phosphatase	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

No	DT
O	NN

skeletal	JJ
D	NN

fluorosis	NN
D	NN

or	CC
O	NN

osteomalacia	NN
D	NN

was	VBD
O	NN

observed	VBN
O	NN

histologically	RB
O	NN

,	,
O	NN

nor	CC
O	NN

did	VBD
O	NNP

fluoride	NN
T	NN

affect	VB
O	NN

serum	NN
O	NN

PTH	NN
O	NN

or	CC
O	NN

Vitamin	NN
O	NN

D	NN
O	NN

metabolites	NNS
O	VBP

(	NN
O	NN

P	NN
O	NN

>	JJR
O	NN

0.4	CD
O	NN

)	NN
O	NN

BAP	NN
O	NN

was	VBD
O	NN

increased	VBN
O	NN

37	CD
O	NN

%	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

)	NN
O	NN

by	IN
O	NN

fluoride	NN
O	NN

;	:
O	NN

serum	NN
O	NN

TRAP	NN
O	NN

was	VBD
O	NN

increased	VBN
O	NN

42	CD
O	NN

%	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

)	NN
O	NN

;	:
O	NN

serum	NN
O	NN

IGF-1	NN
O	NN

was	VBD
O	NN

increased	VBN
O	NN

40	CD
O	NN

%	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

)	NN
O	NN

Fluoride	NN
T	NN

increased	VBN
O	NN

the	DT
O	NN

vertebral	JJ
O	NN

BV/TV	NN
O	NN

by	IN
O	NN

35	CD
O	NN

%	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

)	NN
O	NN

and	CC
O	NN

tibial	JJ
O	NN

ash	JJ
O	NN

weight	NN
O	NN

by	IN
O	NN

10	CD
O	NN

%	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

)	NN
O	NN

However	RB
O	NN

,	,
O	NN

the	DT
O	NN

increases	NNS
O	NN

in	IN
O	NN

bone	NN
O	NN

mass	NN
O	NN

and	CC
O	NN

bone	NN
O	NN

formation	NN
O	NN

were	VBD
O	NN

not	RB
O	NN

reflected	VBN
O	NN

in	IN
O	NN

improved	VBN
O	NN

bone	NN
O	NN

strength	NN
O	NN

Fluoride	NN
O	NN

decreased	VBN
O	NN

bone	NN
O	NN

strength	NN
O	NN

by	IN
O	NN

about	IN
O	NN

19	CD
O	NN

%	NN
O	NN

in	IN
O	NN

the	DT
O	NN

L5	NN
O	NN

vertebra	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.01	CD
O	NN

)	NN
O	NN

and	CC
O	NN

25	CD
O	NN

%	NN
O	NN

in	IN
O	NN

the	DT
O	NN

femoral	JJ
O	NN

neck	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0	CD
O	NN

05	CD
O	NN

)	NN
O	NN

X-ray	NN
O	NN

diffraction	NN
O	NN

showed	VBD
O	NN

altered	JJ
O	NN

mineral	NN
O	NN

crystal	NN
O	NN

thickness	NN
O	NN

in	IN
O	NN

fluoride-treated	JJ
O	NN

bones	NNS
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.001	CD
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

there	RB
O	NN

was	VBD
O	NN

a	DT
O	NN

negative	JJ
O	NN

association	NN
O	NN

between	IN
O	NN

crystal	NN
O	NN

width	NN
O	NN

and	CC
O	NN

fracture	NN
O	NN

stress	NN
O	NN

of	IN
O	NN

the	DT
O	NN

femur	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.02	CD
O	NN

)	NN
O	NN

In	IN
O	NN

conclusion	NN
O	NN

,	,
O	NN

fluoride	NN
O	NN

's	POS
O	NN

effects	NNS
O	NN

on	IN
O	NN

bone	NN
O	NN

mass	NN
O	NN

and	CC
O	NN

bone	NN
O	NN

turnover	NN
O	NN

were	VBD
O	NN

not	RB
O	NN

mediated	VBN
O	NN

by	IN
O	NN

PTH	NN
O	NN

IGF-1	NN
O	NN

was	VBD
O	NN

increased	VBN
O	NN

by	IN
O	NN

fluoride	NN
O	NN

and	CC
O	NN

was	VBD
O	NN

associated	VBN
O	NN

with	IN
O	NN

increased	VBN
O	NN

bone	NN
O	NN

turnover	NN
O	NN

,	,
O	NN

but	CC
O	NNP

was	VBD
O	NN

not	RB
O	NN

correlated	VBD
O	NN

with	IN
O	NN

bone	NN
O	NN

formation	NN
O	NN

markers	NNS
O	VBP

High-dose	JJ
O	NN

fluoride	NN
T	NN

treatment	NN
T	NN

did	VBD
O	NNP

not	RB
O	NN

improve	VB
O	NN

,	,
O	NN

but	CC
O	NNP

decreased	VBN
O	NN

,	,
O	NN

bone	NN
O	NN

strength	NN
O	NN

in	IN
O	NN

rabbits	NNS
O	NN

,	,
O	NN

even	RB
O	NN

in	IN
O	NN

the	DT
O	NN

absence	NN
O	NN

of	IN
O	NN

impaired	JJ
O	NN

mineralization	NN
O	NN

PURPOSE	NN
O	NN

:	:
O	NN

To	TO
O	NN

determine	VB
O	NN

the	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

various	JJ
O	NN

methods	NNS
O	VBP

of	IN
O	NN

managing	VBG
O	NN

the	DT
O	NN

posterior	JJ
O	NN

capsule	NN
O	NN

and	CC
O	NN

anterior	JJ
O	NN

vitreous	JJ
O	NN

on	IN
O	NN

the	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

posterior	NN
D	NN

capsule	NN
D	NN

opacification	NN
D	NN

in	IN
O	NN

pediatric	JJ
O	NN

eyes	NNS
O	VBP

implanted	VBN
O	NN

with	IN
O	NN

posterior	JJ
T	NN

chamber	NN
T	NN

intraocular	JJ
T	NN

lenses	NNS
T	NN

(	NN
T	NN

PC	NN
T	NN

IOLs	NNS
T	NN

)	NN
T	NN

SETTING	VBG
O	NN

:	:
O	NN

Cullen	NNP
O	NNP

Eye	NNP
O	NNP

Institute	NNP
O	NN

,	,
O	NN

Baylor	NNP
O	NNP

College	NNP
O	NNP

of	IN
O	NN

Medicine	NNP
O	NNP

,	,
O	NN

Houston	NNP
O	NNP

,	,
O	NN

Texas	NNP
O	NN

,	,
O	NN

USA	NNP
O	NNP

METHODS	NNS
O	VBP

:	:
O	NN

We	PRP
O	VBP

reviewed	VBN
O	NN

the	DT
O	NN

charts	NNS
O	NN

of	IN
O	NN

20	CD
O	NN

eyes	NNS
O	VBP

of	IN
O	NN

15	CD
O	NN

children	NNS
O	VBP

(	NN
O	NN

aged	JJ
O	NN

1.5	CD
O	NN

to	TO
O	NN

2	CD
O	NN

years	NNS
O	NN

)	NN
O	NN

who	WP
O	VBP

had	VBD
O	NN

primary	JJ
O	NN

cataract	NN
D	NN

surgery	NN
T	NN

with	IN
T	NN

PC	NN
T	NN

IOL	NNP
T	NN

implantation	NN
T	NN

during	IN
O	NN

the	DT
O	NN

past	JJ
O	NN

5	CD
O	NN

years	NNS
O	NN

The	DT
O	NN

posterior	JJ
O	NN

capsule	NN
O	NN

and	CC
O	NN

anterior	JJ
O	NN

vitreous	JJ
O	NN

were	VBD
O	NN

managed	VBN
O	NN

in	IN
O	NN

a	DT
O	NN

variety	NN
O	NN

of	IN
O	NN

ways	NNS
O	NN

:	:
O	NN

In	IN
O	NN

5	CD
O	NN

eyes	NNS
O	VBP

,	,
O	NN

the	DT
O	NN

posterior	JJ
O	NN

capsule	NN
O	NN

was	VBD
O	NN

left	RB
O	NN

intact	JJ
O	NN

;	:
O	NN

in	IN
O	NN

15	CD
O	NN

eyes	NNS
O	VBP

,	,
O	NN

a	DT
O	NN

posterior	JJ
T	NN

continuous	JJ
T	NN

curvilinear	JJ
T	NN

capsulorhexis	NN
T	NN

(	NN
T	NN

PCCC	NN
T	NN

)	NN
T	NN

was	VBD
O	NN

performed	VBN
O	NN

-	:
O	NN

6	CD
O	NN

with	IN
O	NN

and	CC
O	NN

9	CD
O	NN

without	IN
O	NN

anterior	JJ
T	NN

vitrectomy	NN
T	NN

;	:
O	NN

in	IN
O	NN

8	CD
O	NN

eyes	NNS
O	VBP

,	,
O	NN

posterior	JJ
T	NN

optic	JJ
T	NN

capture	NN
T	NN

was	VBD
O	NN

performed	VBN
O	NN

-	:
O	NN

3	CD
O	NN

with	IN
O	NN

and	CC
O	NN

5	CD
O	NN

without	IN
O	NN

vitrectomy	NN
T	NN

The	DT
O	NN

follow-up	JJ
O	NN

ranged	VBD
O	NN

from	IN
O	NN

1	CD
O	NN

to	TO
O	NN

4.5	CD
O	NN

years	NNS
O	NN

(	NN
O	NN

mean	VB
O	NN

2	CD
O	NN

years	NNS
O	NN

)	NN
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Visually	RB
O	NN

significant	JJ
O	NN

secondary	JJ
O	NN

cataract	NN
D	NN

developed	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

five	CD
O	NN

eyes	NNS
O	VBP

with	IN
O	NN

intact	JJ
O	NN

posterior	JJ
O	NN

capsules	NNS
O	NN

and	CC
O	NN

in	IN
O	NN

the	DT
O	NN

four	CD
O	NN

eyes	NNS
O	VBP

that	IN
O	NN

had	VBD
O	NN

PCCC	NN
T	NN

without	IN
O	NN

vitrectomy	NN
T	NN

and	CC
O	NN

without	IN
O	NN

posterior	JJ
T	NN

optic	JJ
T	NN

capture	NN
T	NN

(	NN
O	NN

i.e	NN
O	NN

.	.
O	NN

,	,
O	NN

the	DT
O	NN

optic	JJ
O	NN

was	VBD
O	NN

left	RB
O	NN

in	IN
O	NN

the	DT
O	NN

capsular	JJ
O	NN

bag	NN
O	NN

)	NN
O	NN

The	DT
O	NN

optical	JJ
O	NN

axis	NN
O	NN

remained	VBD
O	NN

clear	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

six	CD
O	NN

eyes	NNS
O	VBP

that	IN
O	NN

had	VBD
O	NN

PC	NN
T	NN

IOL	NNP
T	NN

implantation	NN
T	NN

with	IN
O	NN

vitrectomy	NN
T	NN

(	NN
O	NN

with	IN
O	NN

or	CC
O	NN

without	IN
O	NN

posterior	JJ
T	NN

optic	JJ
T	NN

capture	NN
T	NN

)	NN
O	NN

Initially	RB
O	NN

,	,
O	NN

all	DT
O	NN

eyes	NNS
O	VBP

that	IN
O	NN

had	VBD
O	NN

optic	JJ
T	NN

capture	NN
T	NN

without	IN
O	NN

vitrectomy	NN
T	NN

also	RB
O	NN

remained	VBD
O	NN

clear	JJ
O	NN

,	,
O	NN

but	CC
O	NNP

after	IN
O	NN

6	CD
O	NN

months	NNS
O	NN

,	,
O	NN

four	CD
O	NN

of	IN
O	NN

five	CD
O	NN

developed	VBN
O	NN

opacification	NN
D	NN

CONCLUSION	NN
O	NN

:	:
O	NN

In	IN
O	NN

this	DT
O	NN

series	NN
O	NN

,	,
O	NN

PCCC	NN
T	NN

with	IN
T	NN

anterior	JJ
T	NN

vitrectomy	NN
T	NN

was	VBD
O	NN

the	DT
O	NN

only	RB
O	NN

effective	JJ
O	NN

method	NN
O	NN

of	IN
O	NN

preventing	VBG
O	NN

or	CC
O	NN

delaying	VBG
O	NN

secondary	JJ
D	NN

cataract	NN
D	NN

formation	NN
D	NN

in	IN
O	NN

infants	NNS
O	NN

and	CC
O	NN

children	NNS
O	VBP

Evidence	NN
O	NN

for	IN
O	NN

the	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

a	DT
O	NN

serotonin1A	NN
O	NN

(	NN
O	NN

5-HT1A	NN
O	NN

)	NN
O	NN

receptor	NN
O	NN

subtype	NN
O	NN

in	IN
O	NN

the	DT
O	NN

salmonid	NN
O	NN

fish	NN
O	NN

brain	NN
O	NN

has	VBZ
O	NN

recently	RB
O	NN

been	VBN
O	NN

presented	VBN
O	NN

In	IN
O	NN

the	DT
O	NN

present	JJ
O	NN

study	NN
O	NN

the	DT
O	NN

potent	JJ
O	NN

5-HT1A	NN
O	NN

receptor	NN
O	NN

agonist	NN
O	NN

,	,
O	NN

8-hydroxy-2-	JJ
O	NN

(	NN
O	NN

di-n-propylamino	NN
O	NN

)	NN
O	NN

-tetralin	NN
O	NN

(	NN
O	NN

8-OH-DPAT	NN
O	NN

)	NN
O	NN

was	VBD
O	NN

tested	VBN
O	NN

for	IN
O	NN

its	PRP$
O	NN

effect	NN
O	NN

on	IN
O	NN

plasma	NN
O	NN

cortisol	NN
O	NN

concentrations	NNS
O	NN

in	IN
O	NN

rainbow	NN
O	NN

trout	NNS
O	NN

(	NN
O	NN

Oncorhynchus	NNP
O	NNP

mykiss	JJ
O	NN

)	NN
O	NN

Blood	NN
O	NN

was	VBD
O	NN

sampled	VBN
O	NN

and	CC
O	NN

8-OH-DPAT	NN
O	NN

administered	VBN
O	NN

through	IN
O	NN

a	DT
O	NN

catheter	NN
O	NN

in	IN
O	NN

the	DT
O	NN

dorsal	NN
O	NN

aorta	NN
O	NN

Thirty	CD
O	NN

minutes	NNS
O	NN

after	IN
O	NN

the	DT
O	NN

injection	NN
O	NN

of	IN
O	NN

40	CD
O	NN

microg	NN
O	NN

of	IN
O	NN

8-OH-DPAT/kg	NN
O	NN

,	,
O	NN

plasma	NN
O	NN

cortisol	NN
O	NN

levels	NNS
O	VBP

had	VBD
O	NN

increased	VBN
O	NN

from	IN
O	NN

12	CD
O	NN

to	TO
O	NN

149	CD
O	NN

ng/ml	NN
O	NN

,	,
O	NN

whereupon	NN
O	NN

they	PRP
O	VBP

fell	VBD
O	NN

,	,
O	NN

reaching	VBG
O	NN

baseline	NN
O	NN

levels	NNS
O	VBP

after	IN
O	NN

4	CD
O	NN

h.	NN
O	NN

The	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

1-40	CD
O	NN

microg	NN
O	NN

8-OH-DPAT/kg	NN
O	NN

on	IN
O	NN

plasma	NN
O	NN

cortisol	NN
O	NN

concentrations	NNS
O	NN

was	VBD
O	NN

dose-dependent	JJ
O	NN

The	DT
O	NN

results	NNS
O	VBP

lends	VBZ
O	NN

further	RB
O	NN

support	NN
O	NN

to	TO
O	NN

the	DT
O	NN

hypothesis	NN
O	NN

that	IN
O	NN

the	DT
O	NN

brain	NN
O	NN

serotonergic	JJ
O	NN

system	NN
O	NN

plays	NNS
O	NN

a	DT
O	NN

key	JJ
O	NN

role	NN
O	NN

in	IN
O	NN

integrating	VBG
O	NN

autonomic	JJ
O	NN

,	,
O	NN

behavioral	JJ
O	NN

and	CC
O	NN

neuroendocrine	NN
O	NN

stress-responses	NNS
O	NN

in	IN
O	NN

fish	NN
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

mammals	NNS
O	NN

,	,
O	NN

suggesting	VBG
O	NN

that	IN
O	NN

not	RB
O	NN

only	RB
O	NN

the	DT
O	NN

structural	JJ
O	NN

and	CC
O	NN

biochemical	JJ
O	NN

organization	NN
O	NN

,	,
O	NN

but	CC
O	NNP

also	RB
O	NN

the	DT
O	NN

function	NN
O	NN

of	IN
O	NN

the	DT
O	NN

serotonergic	JJ
O	NN

system	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

conserved	VBN
O	NN

during	IN
O	NN

vertebrate	JJ
O	NN

evolution	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

assess	VB
O	NN

the	DT
O	NN

medicalising	VBG
O	NN

effect	NN
O	NN

of	IN
O	NN

prescribing	VBG
O	NN

antibiotics	NNS
T	NN

for	IN
O	NN

sore	JJ
D	NN

throat	NN
D	NN

SETTING	VBG
O	NN

:	:
O	NN

11	CD
O	NN

general	JJ
O	NN

practices	NNS
O	VBP

in	IN
O	NN

England	NNP
O	NNP

DESIGN	NN
O	NN

:	:
O	NN

Randomised	VBN
O	NN

trial	NN
O	NN

of	IN
O	NN

three	CD
O	NN

approaches	NNS
O	VBP

to	TO
O	NN

sore	JJ
D	NN

throat	NN
D	NN

:	:
O	NN

a	DT
O	NN

10	CD
O	NN

day	NN
O	NN

prescription	NN
O	NN

of	IN
O	NN

antibiotics	NNS
T	NN

,	,
O	NN

no	DT
O	NN

antibiotics	NNS
O	NN

,	,
O	NN

or	CC
O	NN

a	DT
O	NN

delayed	VBN
O	NN

prescription	NN
O	NN

if	IN
O	NN

the	DT
O	NN

sore	JJ
D	NN

throat	NN
D	NN

had	VBD
O	NN

not	RB
O	NN

started	VBD
O	NN

to	TO
O	NN

settle	VB
O	NNP

after	IN
O	NN

three	CD
O	NN

days	NNS
O	NN

PATIENTS	NNS
O	VBP

:	:
O	NN

716	CD
O	NN

patients	NNS
O	NN

aged	JJ
O	NN

4	CD
O	NN

and	CC
O	NN

over	IN
O	NN

with	IN
O	NN

sore	JJ
D	NN

throat	NN
D	NN

and	CC
O	NN

an	DT
O	NN

abnormal	JJ
O	NN

physical	JJ
O	NN

sign	NN
O	NN

:	:
O	NN

84	CD
O	NN

%	NN
O	NN

had	VBD
O	NN

tonsillitis	NN
D	NN

or	CC
O	NN

pharyngitis	NN
D	NN

OUTCOME	NN
O	NN

MEASURES	NNS
O	VBP

:	:
O	NN

Number	NN
O	NN

and	CC
O	NN

rate	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

making	VBG
O	NN

a	DT
O	NN

first	RB
O	NN

return	NN
O	NN

with	IN
O	NN

sore	JJ
D	NN

throat	NN
D	NN

,	,
O	NN

pharyngitis	NN
D	NN

,	,
O	NN

or	CC
O	NN

tonsillitis	NN
D	NN

Early	RB
O	NN

returns	NNS
O	NN

(	NN
O	NN

within	IN
O	NN

two	CD
O	NN

weeks	NNS
O	NN

)	NN
O	NN

and	CC
O	NN

complications	NNS
O	NN

(	NN
O	NN

otitis	NN
D	NN

media	NNS
D	NN

,	,
O	NN

sinusitis	NN
D	NN

,	,
O	NN

quinsy	NN
D	NN

)	NN
O	NN

Outcomes	NNS
O	VBP

were	VBD
O	NN

documented	VBN
O	NN

in	IN
O	NN

675	CD
O	NN

subjects	NNS
O	NN

(	NN
O	NN

94	CD
O	NN

%	NN
O	NN

)	NN
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Mean	NN
O	NN

follow	VB
O	NNP

up	RB
O	NN

time	NN
O	NN

was	VBD
O	NN

similar	JJ
O	NN

(	NN
O	NN

antibiotic	JJ
O	NN

group	NN
O	NN

1.07	CD
O	NN

years	NNS
O	NN

,	,
O	NN

other	JJ
O	NN

two	CD
O	NN

groups	NNS
O	NN

1.03	CD
O	NN

years	NNS
O	NN

)	NN
O	NN

More	RBR
O	NN

of	IN
O	NN

those	DT
O	NNP

initially	RB
O	NN

prescribed	VBN
O	NN

antibiotics	NNS
T	NN

initially	RB
O	NN

returned	VBD
O	NN

to	TO
O	NN

the	DT
O	NN

surgery	NN
O	NN

with	IN
O	NN

sore	JJ
D	NN

throat	NN
D	NN

(	NN
O	NN

38	CD
O	NN

%	NN
O	NN

v	LS
O	NN

27	CD
O	NN

%	NN
O	NN

,	,
O	NN

adjusted	VBN
O	NN

hazard	NN
O	NN

ratio	NN
O	NN

for	IN
O	NN

return	NN
O	NN

1.39	CD
O	NN

%	NN
O	NN

,	,
O	NN

95	CD
O	NN

%	NN
O	NN

confidence	NN
O	NN

interval	NN
O	NN

1.03	CD
O	NN

to	TO
O	NN

1.89	CD
O	NN

)	NN
O	NN

Antibiotics	NNS
T	NN

prescribed	VBN
O	NN

for	IN
O	NN

sore	JJ
D	NN

throat	NN
D	NN

during	IN
O	NN

the	DT
O	NN

previous	JJ
O	NN

year	NN
O	NN

had	VBD
O	NN

an	DT
O	NN

additional	JJ
O	NN

effect	NN
O	NN

(	NN
O	NN

hazard	NN
O	NN

ratio	NN
O	NN

1.69	CD
O	NN

,	,
O	NN

1.20	CD
O	NN

to	TO
O	NN

2.37	CD
O	NN

)	NN
O	NN

Longer	JJR
O	NN

duration	NN
O	NN

of	IN
O	NN

illness	NN
O	NN

(	NN
O	NN

>	JJR
O	NN

5	CD
O	NN

days	NNS
O	NN

)	NN
O	NN

was	VBD
O	NN

associated	VBN
O	NN

with	IN
O	NN

increased	VBN
O	NN

return	NN
O	NN

within	IN
O	NN

six	CD
O	NN

weeks	NNS
O	NN

(	NN
O	NN

hazard	NN
O	NN

ratio	NN
O	NN

2.90	CD
O	NN

,	,
O	NN

1.70	CD
O	NN

to	TO
O	NN

4.92	CD
O	NN

)	NN
O	NN

Prior	RB
O	NN

attendance	NN
O	NN

with	IN
O	NN

upper	JJ
D	NN

respiratory	JJ
D	NN

conditions	NNS
D	NN

was	VBD
O	NN

also	RB
O	NN

associated	VBN
O	NN

with	IN
O	NN

increased	VBN
O	NN

reattendance	NN
O	NN

There	EX
O	NN

was	VBD
O	NN

no	DT
O	NN

difference	NN
O	NN

between	IN
O	NN

groups	NNS
O	NN

in	IN
O	NN

early	RB
O	NN

return	NN
O	NN

(	NN
O	NN

13/238	CD
O	NN

(	NN
O	NN

5.5	CD
O	NN

%	NN
O	NN

)	NN
O	NN

v	LS
O	NN

27/437	CD
O	NN

(	NN
O	NN

6	CD
O	NN

%	NN
O	NN

)	NN
O	NN

)	NN
O	NN

,	,
O	NN

or	CC
O	NN

complications	NNS
O	NN

(	NN
O	NN

2/236	CD
O	NN

(	NN
O	NN

0.8	CD
O	NN

%	NN
O	NN

)	NN
O	NN

v	LS
O	NN

3/434	CD
O	NN

(	NN
O	NN

0.7	CD
O	NN

%	NN
O	NN

)	NN
O	NN

)	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Complications	NNS
O	NN

and	CC
O	NN

early	RB
O	NN

return	NN
O	NN

resulting	VBG
O	NN

from	IN
O	NN

no	DT
O	NN

or	CC
O	NN

delayed	VBN
O	NN

prescribing	VBG
O	NN

of	IN
O	NN

antibiotics	NNS
T	NN

for	IN
O	NN

sore	JJ
D	NN

throat	NN
D	NN

are	VBP
O	NN

rare	JJ
O	NN

Both	DT
O	NN

current	JJ
O	NN

and	CC
O	NN

previous	JJ
O	NN

prescribing	VBG
O	NN

for	IN
O	NN

sore	JJ
D	NN

throat	NN
D	NN

increase	NN
O	NN

reattendance	NN
O	NN

To	TO
O	NN

avoid	VB
O	NN

medicalising	VBG
O	NN

a	DT
O	NN

self	NN
O	NN

limiting	VBG
O	NN

illness	NN
O	NN

doctors	NNS
O	NN

should	MD
O	NNP

avoid	VB
O	NN

antibiotics	NNS
T	NN

or	CC
O	NN

offer	NN
O	NN

a	DT
O	NN

delayed	VBN
O	NN

prescription	NN
O	NN

for	IN
O	NN

most	JJS
O	NN

patients	NNS
O	NN

with	IN
O	NN

sore	JJ
D	NN

throat	NN
D	NN

This	DT
O	NN

study	NN
O	NN

was	VBD
O	NN

designed	VBN
O	NN

to	TO
O	NN

determine	VB
O	NN

and	CC
O	NN

compare	VB
O	NN

the	DT
O	NN

dose-response	JJ
O	NN

characteristics	NNS
O	NN

,	,
O	NN

speed	NN
O	NN

of	IN
O	NN

onset	NN
O	NN

,	,
O	NN

and	CC
O	NN

relative	JJ
O	NN

potency	NN
O	NN

of	IN
O	NN

single-dose	JJ
O	NN

epidural	JJ
T	NN

fentanyl	NN
T	NN

(	NN
T	NN

F	NN
T	NN

)	NN
T	NN

and	CC
O	NN

sufentanil	NN
T	NN

(	NN
T	NN

S	NN
T	NN

)	NN
T	NN

for	IN
O	NN

postoperative	JJ
D	NN

pain	NN
D	NN

relief	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Eighty	CD
O	NN

women	NNS
O	VBP

undergoing	VBG
O	NN

cesarean	NN
O	NN

section	NN
O	NN

(	NN
O	NN

C/S	NN
O	NN

)	NN
O	NN

with	IN
O	NN

epidural	JJ
O	NN

2	CD
O	NN

%	NN
O	NN

lidocaine	NN
O	NN

with	IN
O	NN

epinephrine	NN
O	NN

(	NN
O	NN

1	CD
O	NN

:	:
O	NN

200	CD
O	NN

,	,
O	NN

000	CD
O	NN

)	NN
O	NN

were	VBD
O	NN

randomly	RB
O	NN

assigned	VBN
O	NN

to	TO
O	NN

receive	VB
O	NN

double-blind	JJ
O	NN

epidural	JJ
O	NN

administration	NN
O	NN

of	IN
O	NN

F	NN
O	NN

(	NN
O	NN

25	CD
O	NN

,	,
O	NN

50	CD
O	NN

,	,
O	NN

100	CD
O	NN

,	,
O	NN

or	CC
O	NN

200	CD
O	NN

microg	NN
O	NN

)	NN
O	NN

or	CC
O	NN

S	NN
O	NN

(	NN
O	NN

5	CD
O	NN

,	,
O	NN

10	CD
O	NN

,	,
O	NN

20	CD
O	NN

,	,
O	NN

or	CC
O	NN

30	CD
O	NN

microg	NN
O	NN

)	NN
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

10	CD
O	NN

per	IN
O	NN

group	NN
O	NN

)	NN
O	NN

upon	IN
O	NN

complaint	NN
O	NN

of	IN
O	NN

pain	NN
O	NN

postoperatively	RB
O	NN

Visual	JJ
O	NN

analog	NN
O	NN

scales	NNS
O	NN

(	NN
O	NN

VAS	NNP
O	NNP

,	,
O	NN

0-100	CD
O	NN

mm	NN
O	NN

)	NN
O	NN

were	VBD
O	NN

used	VBN
O	NN

to	TO
O	NN

assess	VB
O	NN

pain	NN
O	NN

and	CC
O	NN

sedation	NN
O	NN

at	IN
O	NN

baseline	NN
O	NN

;	:
O	NN

at	IN
O	NN

3	CD
O	NN

,	,
O	NN

6	CD
O	NN

,	,
O	NN

9	CD
O	NN

,	,
O	NN

12	CD
O	NN

,	,
O	NN

15	CD
O	NN

,	,
O	NN

20	CD
O	NN

,	,
O	NN

25	CD
O	NN

,	,
O	NN

30	CD
O	NN

,	,
O	NN

45	CD
O	NN

,	,
O	NN

and	CC
O	NN

60	CD
O	NN

min	NN
O	NN

;	:
O	NN

and	CC
O	NN

every	DT
O	NN

30	CD
O	NN

min	NN
O	NN

until	IN
O	NN

further	RB
O	NN

analgesia	NN
O	NN

was	VBD
O	NN

requested	VBN
O	NN

The	DT
O	NN

study	NN
O	NN

was	VBD
O	NN

terminated	VBN
O	NN

at	IN
O	NN

30	CD
O	NN

min	NN
O	NN

if	IN
O	NN

satisfactory	JJ
O	NN

analgesia	NN
O	NN

was	VBD
O	NN

not	RB
O	NN

achieved	VBN
O	NN

Side	NN
O	NN

effects	NNS
O	NN

were	VBD
O	NN

recorded	VBN
O	NN

A	DT
O	NN

dose-response	JJ
O	NN

was	VBD
O	NN

demonstrated	VBD
O	NN

for	IN
O	NN

both	DT
O	NN

opioids	NNS
O	NN

F	NN
O	NN

25	CD
O	NN

microg	NN
O	NN

and	CC
O	NN

S	NN
O	NN

5	CD
O	NN

microg	NN
O	NN

were	VBD
O	NN

ineffective	JJ
O	NN

,	,
O	NN

with	IN
O	NN

significantly	RB
O	NN

fewer	JJR
O	NN

women	NNS
O	VBP

achieving	VBG
O	NN

VAS	NNP
O	NNP

scores	NNS
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

10	CD
O	NN

mm	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

compared	VBN
O	NN

with	IN
O	NN

F	NN
O	NN

100	CD
O	NN

or	CC
O	NN

200	CD
O	NN

microg	NN
O	NN

and	CC
O	NN

S	NN
O	NN

20	CD
O	NN

or	CC
O	NN

30	CD
O	NN

microg	NN
O	NN

)	NN
O	NN

F	NN
O	NN

100	CD
O	NN

and	CC
O	NN

200	CD
O	NN

microg	NN
O	NN

and	CC
O	NN

S	NN
O	NN

20	CD
O	NN

and	CC
O	NN

30	CD
O	NN

microg	NN
O	NN

all	DT
O	NN

achieved	VBN
O	NN

VAS	NNP
O	NNP

scores	NNS
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

10	CD
O	NN

mm	NN
O	NN

in	IN
O	NN

all	DT
O	NN

women	NNS
O	VBP

with	IN
O	NN

no	DT
O	NN

differences	NNS
O	NN

in	IN
O	NN

time	NN
O	NN

to	TO
O	NN

50	CD
O	NN

%	NN
O	NN

reduction	NN
O	NN

in	IN
O	NN

VAS	NNP
O	NNP

(	NN
O	NN

mean	VB
O	NN

11-16	CD
O	NN

min	NN
O	NN

)	NN
O	NN

and	CC
O	NN

no	DT
O	NN

differences	NNS
O	NN

in	IN
O	NN

duration	NN
O	NN

of	IN
O	NN

analgesia	NN
O	NN

(	NN
O	NN

mean	VB
O	NN

117-138	CD
O	NN

min	NN
O	NN

)	NN
O	NN

The	DT
O	NN

50	CD
O	NN

%	NN
O	NN

and	CC
O	NN

95	CD
O	NN

%	NN
O	NN

effective	JJ
O	NN

dose	NN
O	NN

values	NNS
O	VBP

for	IN
O	NN

each	DT
O	NN

opioid	JJ
O	NN

to	TO
O	NN

achieve	VB
O	NN

a	DT
O	NN

VAS	NNP
O	NNP

score	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

10	CD
O	NN

mm	NN
O	NN

were	VBD
O	NN

F	NN
O	NN

33	CD
O	NN

microg	NN
O	NN

and	CC
O	NN

92	CD
O	NN

microg	NN
O	NN

and	CC
O	NN

S	NN
O	NN

6.7	CD
O	NN

microg	NN
O	NN

and	CC
O	NN

17.5	CD
O	NN

microg	NN
O	NN

There	EX
O	NN

were	VBD
O	NN

no	DT
O	NN

differences	NNS
O	NN

among	IN
O	NN

groups	NNS
O	NN

in	IN
O	NN

sedation	NN
O	NN

scores	NNS
O	NN

or	CC
O	NN

side	NN
O	NN

effects	NNS
O	NN

Our	PRP$
O	NN

data	NNS
O	NN

suggest	VBP
O	NN

that	IN
O	NN

the	DT
O	NN

relative	JJ
O	NN

analgesic	JJ
O	NN

potency	NN
O	NN

of	IN
O	NN

epidural	JJ
O	NN

S	NN
O	NN

:	:
O	NN

F	NN
O	NN

is	VBZ
O	NN

approximately	RB
O	NN

5	CD
O	NN

and	CC
O	NN

that	IN
O	NN

there	RB
O	NN

are	VBP
O	NN

no	DT
O	NN

differences	NNS
O	NN

between	IN
O	NN

the	DT
O	NN

opioids	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

onset	NN
O	NN

,	,
O	NN

duration	NN
O	NN

,	,
O	NN

and	CC
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

analgesia	NN
O	NN

when	WRB
O	NN

equianalgesic	JJ
O	NN

doses	NNS
O	NN

are	VBP
O	NN

administered	VBN
O	NN

postoperatively	RB
O	NN

after	IN
O	NN

lidocaine	NN
O	NN

anesthesia	NN
O	NN

for	IN
O	NN

C/S	NN
O	NN

We	PRP
O	VBP

describe	VBP
O	NN

2	CD
O	NN

cases	NNS
O	NN

in	IN
O	NN

which	WDT
O	NN

intraoperative	JJ
O	NN

transesophageal	NN
O	NN

echocardiography	NN
O	NN

detected	VBN
O	NN

complications	NNS
O	NN

related	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

proximal	JJ
O	NN

coronary	JJ
O	NN

arteries	NNS
O	NN

during	IN
O	NN

homograft	NN
T	NN

aortic	JJ
T	NN

valve	NN
T	NN

and	CC
T	NN

root	NN
T	NN

replacement	NN
T	NN

In	IN
O	NN

both	DT
O	NN

cases	NNS
O	NN

,	,
O	NN

cardiopulmonary	JJ
T	NN

bypass	NN
T	NN

could	MD
O	NNP

not	RB
O	NN

be	VB
O	NN

discontinued	VBN
O	NN

despite	IN
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

large	JJ
O	NN

doses	NNS
O	NN

of	IN
O	NN

inotropic	JJ
T	NN

drugs	NNS
T	NN

Transesophageal	JJ
O	NN

echocardiography	NN
O	NN

demonstrated	VBD
O	NN

aliasing	VBG
O	NN

on	IN
O	NN

color	NN
O	NN

flow	NN
O	NN

mapping	VBG
O	NN

in	IN
O	NN

the	DT
O	NN

left	RB
O	NN

main	JJ
O	NN

coronary	JJ
O	NN

artery	NN
O	NN

in	IN
O	NN

1	CD
O	NN

case	NN
O	NN

and	CC
O	NN

proximal	JJ
O	NN

right	RB
O	NN

coronary	JJ
O	NN

artery	NN
O	NN

in	IN
O	NN

the	DT
O	NN

other	JJ
O	NN

,	,
O	NN

along	IN
O	NN

with	IN
O	NN

severely	RB
O	NN

depressed	JJ
O	NN

left	RB
O	NN

ventricular	JJ
O	NN

anterior	JJ
O	NN

wall	NN
O	NN

and	CC
O	NN

right	RB
O	NN

ventricular	JJ
O	NN

function	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

Coronary	JJ
T	NN

artery	NN
T	NN

bypass	NN
T	NN

grafting	VBG
T	NN

was	VBD
O	NN

performed	VBN
O	NN

in	IN
O	NN

both	DT
O	NN

cases	NNS
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

outcome	NN
O	NN

was	VBD
O	NN

successful	JJ
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Granulocyte	NN
O	NN

colony-stimulating	JJ
O	NN

factor	NN
O	NN

(	NN
O	NN

G-CSF	NN
O	NN

)	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

used	VBN
O	NN

to	TO
O	NN

improve	VB
O	NN

granulocyte	NN
O	NN

count	NN
O	NN

in	IN
O	NN

chronic	JJ
O	NN

neutropenia	NN
O	NN

and	CC
O	NN

myelodysplasia	NN
O	NN

,	,
O	NN

to	TO
O	NN

minimize	VB
O	NN

the	DT
O	NN

incidence	NN
O	NN

and	CC
O	NN

duration	NN
O	NN

of	IN
O	NN

neutropenia	NN
O	NN

during	IN
O	NN

conventional	JJ
O	NN

chemotherapy	NN
O	NN

,	,
O	NN

and	CC
O	NN

to	TO
O	NN

mobilize	VB
O	NN

peripheral	JJ
O	NN

blood	NN
O	NN

stem	NN
O	NN

cells	NNS
O	VBP

prior	RB
O	NN

to	TO
O	NN

leukapheresis	NN
O	NN

for	IN
O	NN

use	NN
O	NN

in	IN
O	NN

autologous	JJ
O	NN

and	CC
O	NN

allogeneic	JJ
O	NN

marrow	NN
O	NN

transplantation	NN
O	NN

The	DT
O	NN

most	JJS
O	NN

common	JJ
O	NN

toxicity	NN
O	NN

is	VBZ
O	NN

bone	NN
D	NN

pain	NN
D	NN

,	,
O	NN

and	CC
O	NN

other	JJ
O	NN

reactions	NNS
O	NN

such	JJ
O	NN

as	IN
O	NN

inflammation	NN
D	NN

at	IN
O	NN

the	DT
O	NN

site	NN
O	NN

of	IN
O	NN

injection	NN
T	NN

have	VB
O	NN

also	RB
O	NN

occurred	VBD
O	NN

In	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

neutropenia	NN
D	NN

,	,
O	NN

splenomegaly	NN
D	NN

has	VBZ
O	NN

been	VBN
O	NN

described	VBN
O	NN

with	IN
O	NN

long-term	JJ
O	NN

use	NN
O	NN

,	,
O	NN

and	CC
O	NN

extramedullary	JJ
D	NN

hematopoiesis	NN
D	NN

has	VBZ
O	NN

also	RB
O	NN

been	VBN
O	NN

reported	VBN
O	NN

However	RB
O	NN

,	,
O	NN

thus	RB
O	NN

far	RB
O	NN

,	,
O	NN

no	DT
O	NN

life-threatening	JJ
O	NN

sequelae	NN
O	NN

of	IN
O	NN

these	DT
O	NN

effects	NNS
O	NN

are	VBP
O	NN

found	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

literature	NN
O	NN

We	PRP
O	VBP

now	RB
O	NN

describe	VBP
O	NN

a	DT
O	NN

case	NN
O	NN

of	IN
O	NN

spontaneous	JJ
O	NN

splenic	JJ
D	NN

rupture	NN
D	NN

four	CD
O	NN

days	NNS
O	NN

following	VBG
O	NN

a	DT
O	NN

six-day	JJ
O	NN

course	NN
O	NN

of	IN
O	NN

G-CSF	NN
T	NN

therapy	NN
T	NN

in	IN
O	NN

an	DT
O	NN

allogeneic	JJ
O	NN

donor	NN
O	NN

of	IN
O	NN

peripheral	JJ
O	NN

blood	NN
O	NN

stem	NN
O	NN

cells	NNS
O	VBP

Evidence-based	JJ
O	NN

medicine	NN
O	NN

(	NN
O	NN

EBM	NN
O	NN

)	NN
O	NN

aids	NNS
O	NN

clinical	JJ
O	NN

decision	NN
O	NN

making	VBG
O	NN

in	IN
O	NN

all	DT
O	NN

fields	NNS
O	NN

of	IN
O	NN

medicine	NN
O	NN

,	,
O	NN

including	VBG
O	NN

primary	JJ
O	NN

care	NN
O	NN

General	NNP
O	NNP

practice	NN
O	NN

is	VBZ
O	NN

characterized	VBN
O	NN

by	IN
O	NN

particular	JJ
O	NN

emphasis	NN
O	NN

on	IN
O	NN

the	DT
O	NN

doctor-patient	JJ
O	NN

relationship	NN
O	NN

and	CC
O	NN

on	IN
O	NN

biomedical	JJ
O	NN

,	,
O	NN

personal	JJ
O	NN

and	CC
O	NN

contextual	JJ
O	NN

perspectives	NNS
O	NN

in	IN
O	NN

diagnosis	NN
O	NN

Most	JJS
O	NN

evidence	NN
O	NN

available	JJ
O	NN

to	TO
O	NN

general	JJ
O	NN

practitioners	NNS
O	VBP

(	NN
O	NN

GPs	NNS
O	NN

)	NN
O	NN

addresses	NNS
O	VBP

only	RB
O	NN

the	DT
O	NN

bio-medical	JJ
O	NN

perspective	NN
O	NN

and	CC
O	NN

is	VBZ
O	NN

often	RB
O	NN

not	RB
O	NN

directly	RB
O	NN

applicable	JJ
O	NN

to	TO
O	NN

primary	JJ
O	NN

care	NN
O	NN

,	,
O	NN

as	IN
O	NN

it	PRP
O	NN

derives	VBZ
O	NN

from	IN
O	NN

secondary	JJ
O	NN

or	CC
O	NN

tertiary	JJ
O	NN

care	NN
O	NN

Emphasis	NN
O	NN

on	IN
O	NN

the	DT
O	NN

biomedical	JJ
O	NN

domain	NN
O	NN

and	CC
O	NN

the	DT
O	NN

randomized	VBN
O	NN

controlled	JJ
O	NN

trial	NN
O	NN

(	NN
O	NN

RCT	NN
O	NN

)	NN
O	NN

alone	RB
O	NN

reflects	VBZ
O	NN

a	DT
O	NN

reductionist	JJ
O	NN

approach	NN
O	NN

that	IN
O	NN

fails	VBZ
O	NN

to	TO
O	NN

do	VB
O	NNP

justice	NN
O	NN

to	TO
O	NN

the	DT
O	NN

philosophy	NN
O	NN

of	IN
O	NN

general	JJ
O	NN

practice	NN
O	NN

The	DT
O	NN

art	NN
O	NN

of	IN
O	NN

medicine	NN
O	NN

is	VBZ
O	NN

founded	VBN
O	NN

on	IN
O	NN

context	NN
O	NN

,	,
O	NN

anecdote	NN
O	NN

,	,
O	NN

patient	NN
O	NN

stories	NNS
O	NN

of	IN
O	NN

illness	NN
O	NN

and	CC
O	NN

personal	JJ
O	NN

experience	NN
O	NN

,	,
O	NN

and	CC
O	NN

we	PRP
O	VBP

should	MD
O	NNP

continue	VB
O	NN

to	TO
O	NN

blend	VB
O	NN

this	DT
O	NN

with	IN
O	NN

good	JJ
O	NN

quality	NN
O	NN

and	CC
O	NN

appropriate	JJ
O	NN

research	NN
O	NN

findings	NNS
O	VBP

in	IN
O	NN

patient	NN
O	NN

care	NN
O	NN

Abdominal	JJ
D	NN

tuberculosis	NN
D	NN

is	VBZ
O	NN

not	RB
O	NN

uncommon	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

UK	NNP
O	NNP

,	,
O	NN

especially	RB
O	NN

in	IN
O	NN

Asian	JJ
O	NN

immigrants	NNS
O	NN

It	PRP
O	NN

resembles	VBZ
O	NN

Crohn	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

clinically	RB
O	NN

and	CC
O	NN

radiologically	RB
O	NN

,	,
O	NN

and	CC
O	NN

it	PRP
O	NN

may	MD
O	NNP

be	VB
O	NN

difficult	JJ
O	NN

to	TO
O	NN

differentiate	VB
O	NN

between	IN
O	NN

them	PRP
O	VBP

,	,
O	NN

even	RB
O	NN

at	IN
O	NN

laparotomy	NN
O	NN

or	CC
O	NN

histology	NN
O	NN

The	DT
O	NN

distinction	NN
O	NN

is	VBZ
O	NN

important	JJ
O	NN

,	,
O	NN

however	RB
O	NN

,	,
O	NN

for	IN
O	NN

proper	JJ
O	NN

management	NN
O	NN

of	IN
O	NN

the	DT
O	NN

two	CD
O	NN

conditions	NNS
O	VBP

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Every	DT
O	NN

effort	NN
O	NN

must	MD
O	NNP

be	VB
O	NN

made	VBN
O	NN

to	TO
O	NN

exclude	VB
O	NN

abdominal	JJ
D	NN

tuberculosis	NN
D	NN

before	IN
O	NN

the	DT
O	NN

patient	NN
O	NN

is	VBZ
O	NN

diagnosed	VBN
O	NN

as	IN
O	NN

having	VBG
O	NN

Crohn	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

and	CC
O	NN

is	VBZ
O	NN

treated	VBN
O	NN

with	IN
O	NN

steroids	NNS
T	NN

PURPOSE	NN
O	NN

:	:
O	NN

The	DT
O	NN

American	JJ
O	NN

Urological	JJ
O	NN

Association	NNP
O	NN

convened	VBN
O	NN

the	DT
O	NN

Female	JJ
D	NN

Stress	NN
D	NN

Urinary	JJ
D	NN

Incontinence	NN
D	NN

Clinical	JJ
O	NN

Guidelines	NNS
O	NN

Panel	NN
O	NN

to	TO
O	NN

analyze	VB
O	NN

the	DT
O	NN

literature	NN
O	NN

regarding	VBG
O	NN

surgical	JJ
T	NN

procedures	NNS
T	NN

for	IN
O	NN

treating	VBG
O	NN

stress	NN
D	NN

urinary	JJ
D	NN

incontinence	NN
D	NN

in	IN
O	NN

the	DT
O	NN

otherwise	RB
O	NN

healthy	JJ
O	NN

female	JJ
O	NN

subject	JJ
O	NN

and	CC
O	NN

to	TO
O	NN

make	VB
O	NN

practice	NN
O	NN

recommendations	NNS
O	NN

based	VBN
O	NN

on	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

outcomes	NNS
O	VBP

data	NNS
O	NN

MATERIALS	NNS
O	VBP

AND	CC
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

panel	NN
O	NN

searched	VBD
O	NN

the	DT
O	NN

MEDLINE	NN
O	NN

data	NNS
O	NN

base	NN
O	NN

for	IN
O	NN

all	DT
O	NN

articles	NNS
O	NN

through	IN
O	NN

1993	CD
O	NN

on	IN
O	NN

surgical	JJ
T	NN

treatment	NN
T	NN

of	IN
O	NN

female	JJ
D	NN

stress	NN
D	NN

urinary	JJ
D	NN

incontinence	NN
D	NN

Outcomes	NNS
O	VBP

data	NNS
O	NN

were	VBD
O	NN

extracted	VBN
O	NN

from	IN
O	NN

articles	NNS
O	NN

accepted	VBN
O	NN

after	IN
O	NN

panel	NN
O	NN

review	NN
O	NN

The	DT
O	NN

data	NNS
O	NN

were	VBD
O	NN

then	RB
O	NN

meta-analyzed	JJ
O	NN

to	TO
O	NN

produce	VB
O	NN

outcome	NN
O	NN

estimates	NNS
O	NN

for	IN
O	NN

alternative	JJ
O	NN

surgical	JJ
T	NN

procedures	NNS
T	NN

RESULTS	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

data	NNS
O	NN

indicate	VBP
O	NN

that	IN
O	NN

after	IN
O	NN

48	CD
O	NN

months	NNS
O	NN

retropubic	JJ
T	NN

suspensions	NNS
T	NN

and	CC
O	NN

slings	NNS
T	NN

appear	VB
O	NN

to	TO
O	NN

be	VB
O	NN

more	RBR
O	NN

efficacious	JJ
O	NN

than	IN
O	NN

transvaginal	JJ
T	NN

suspensions	NNS
T	NN

,	,
O	NN

and	CC
O	NN

also	RB
O	NN

more	RBR
O	NN

efficacious	JJ
O	NN

than	IN
O	NN

anterior	JJ
T	NN

repairs	NNS
T	NN

The	DT
O	NN

literature	NN
O	NN

suggests	VBZ
O	NN

higher	JJR
O	NN

complication	NN
O	NN

rates	NNS
O	VBP

when	WRB
O	NN

synthetic	JJ
O	NN

materials	NNS
O	NN

are	VBP
O	NN

used	VBN
O	NN

for	IN
O	NN

slings	NNS
T	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

The	DT
O	NN

panel	NN
O	NN

found	VBN
O	NN

sufficient	JJ
O	NN

acceptable	JJ
O	NN

long-term	JJ
O	NN

outcomes	NNS
O	VBP

data	NNS
O	NN

(	NN
O	NN

longer	RB
O	NN

than	IN
O	NN

48	CD
O	NN

months	NNS
O	NN

)	NN
O	NN

to	TO
O	NN

conclude	VBP
O	NN

that	IN
O	NN

surgical	JJ
T	NN

treatment	NN
T	NN

of	IN
O	NN

female	JJ
D	NN

stress	NN
D	NN

urinary	JJ
D	NN

incontinence	NN
D	NN

is	VBZ
O	NN

effective	JJ
O	NN

,	,
O	NN

offering	VBG
O	NN

a	DT
O	NN

long-term	JJ
O	NN

cure	NN
O	NN

in	IN
O	NN

a	DT
O	NN

significant	JJ
O	NN

percentage	NN
O	NN

of	IN
O	NN

women	NNS
O	VBP

The	DT
O	NN

evidence	NN
O	NN

supports	VBZ
O	NN

surgery	NN
T	NN

as	IN
O	NN

initial	JJ
O	NN

therapy	NN
O	NN

and	CC
O	NN

as	IN
O	NN

a	DT
O	NN

secondary	JJ
O	NN

form	NN
O	NN

of	IN
O	NN

therapy	NN
O	NN

after	IN
O	NN

failure	NN
O	NN

of	IN
O	NN

other	JJ
O	NN

treatments	NNS
O	VBP

for	IN
O	NN

stress	NN
D	NN

urinary	JJ
D	NN

incontinence	NN
D	NN

Retropubic	JJ
T	NN

suspensions	NNS
T	NN

and	CC
O	NN

slings	NNS
T	NN

are	VBP
O	NN

the	DT
O	NN

most	JJS
O	NN

efficacious	JJ
O	NN

procedures	NNS
O	VBP

for	IN
O	NN

long-term	JJ
O	NN

success	NN
O	NN

(	NN
O	NN

based	VBN
O	NN

on	IN
O	NN

cure/dry	NN
O	NN

rates	NNS
O	VBP

)	NN
O	NN

However	RB
O	NN

,	,
O	NN

in	IN
O	NN

the	DT
O	NN

panel	NN
O	NN

's	POS
O	NN

opinion	NN
O	NN

retropubic	JJ
T	NN

suspensions	NNS
T	NN

and	CC
O	NN

sling	NN
T	NN

procedures	NNS
T	NN

are	VBP
O	NN

associated	VBN
O	NN

with	IN
O	NN

slightly	RB
O	NN

higher	JJR
O	NN

complication	NN
O	NN

rates	NNS
O	VBP

,	,
O	NN

including	VBG
O	NN

longer	RB
O	NN

convalescence	NN
O	NN

and	CC
O	NN

postoperative	JJ
D	NN

voiding	VBG
D	NN

dysfunction	NN
D	NN

A	DT
O	NN

55-year-old	JJ
O	NN

lady	NN
O	NN

underwent	VBD
O	NN

repeat	NN
O	NN

aortic	JJ
T	NN

valve	NN
T	NN

replacement	NN
T	NN

using	VBG
O	NN

a	DT
O	NN

16-mm	JJ
O	NN

Carbomedics	NNS
O	NN

prosthesis	NN
O	NN

She	PRP
O	VBP

made	VBN
O	NN

an	DT
O	NN

uneventful	JJ
O	NN

postoperative	JJ
O	NN

recovery	NN
O	NN

and	CC
O	NN

now	RB
O	NN

leads	VBZ
O	NN

an	DT
O	NN

unrestricted	JJ
O	NN

life	NN
O	NN

Doppler	NNP
O	NNP

echocardiography	NN
O	NN

reveals	VBZ
O	NN

a	DT
O	NN

21-mm	JJ
O	NN

Hg	NN
O	NN

gradient	NN
O	NN

across	IN
O	NN

the	DT
O	NN

valve	NN
O	NN

at	IN
O	NN

rest	NN
O	NN

This	DT
O	NN

did	VBD
O	NNP

not	RB
O	NN

increase	NN
O	NN

with	IN
O	NN

an	DT
O	NN

infusion	NN
O	NN

of	IN
O	NN

30	CD
O	NN

mcg/kg	NN
O	NN

per	IN
O	NN

min	NN
O	NN

of	IN
O	NN

dobutamine	NN
O	NN

,	,
O	NN

which	WDT
O	NN

resulted	VBD
O	NN

in	IN
O	NN

an	DT
O	NN

increase	NN
O	NN

in	IN
O	NN

the	DT
O	NN

cardiac	JJ
O	NN

output	NN
O	NN

from	IN
O	NN

1.96	CD
O	NN

to	TO
O	NN

5.46	CD
O	NN

l/min	JJ
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

For	IN
O	NN

more	RBR
O	NN

than	IN
O	NN

30	CD
O	NN

years	NNS
O	NN

it	PRP
O	NN

has	VBZ
O	NN

been	VBN
O	NN

known	JJ
O	NN

that	IN
O	NN

gastric	JJ
O	NN

acid	NN
O	NN

secretion	NN
O	NN

is	VBZ
O	NN

inversely	RB
O	NN

related	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

extent	NN
O	NN

and	CC
O	NN

severity	NN
O	NN

of	IN
O	NN

corpal	NN
D	NN

gastritis	NN
D	NN

We	PRP
O	VBP

therefore	RB
O	NN

evaluated	VBN
O	NN

the	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

cure	NN
O	NN

of	IN
O	NN

Helicobacter	NN
D	NN

pylori	NN
D	NN

infection	NN
D	NN

on	IN
O	NN

basal	JJ
O	NN

and	CC
O	NN

pentagastrin-stimulated	JJ
O	NN

acid	NN
O	NN

secretion	NN
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

Basal	JJ
O	NN

acid	NN
O	NN

output	NN
O	NN

(	NN
O	NN

BAO	NNP
O	NNP

)	NN
O	NN

and	CC
O	NN

maximal	JJ
O	NN

acid	NN
O	NN

output	NN
O	NN

(	NN
O	NN

MAO	NNP
O	NN

)	NN
O	NN

were	VBD
O	NN

assessed	VBN
O	NN

in	IN
O	NN

11	CD
O	NN

H.	NNP
O	NNP

pylori-infected	JJ
O	NN

dyspeptic	JJ
O	NN

patients	NNS
O	NN

(	NN
O	NN

8	CD
O	NN

women	NNS
O	VBP

and	CC
O	NN

3	CD
O	NN

men	NNS
O	NN

;	:
O	NN

mean	VB
O	NN

age	NN
O	NN

,	,
O	NN

28	CD
O	NN

years	NNS
O	NN

)	NN
O	NN

before	IN
O	NN

and	CC
O	NN

after	IN
O	NN

successful	JJ
O	NN

anti-H	JJ
O	NN

pylori	NN
O	NN

therapy	NN
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

gastritis	NN
O	NN

index	NN
O	NN

was	VBD
O	NN

significantly	RB
O	NN

lower	JJR
O	NN

after	IN
O	NN

therapy	NN
O	NN

and	CC
O	NN

was	VBD
O	NN

associated	VBN
O	NN

with	IN
O	NN

an	DT
O	NN

increase	NN
O	NN

in	IN
O	NN

both	DT
O	NN

BAO	NNP
O	NNP

and	CC
O	NN

MAO	NNP
O	NN

after	IN
O	NN

cure	NN
O	NN

of	IN
O	NN

the	DT
O	NN

H.	NN
D	NN

pylori	NN
D	NN

infection	NN
D	NN

(	NN
O	NN

BAO	NNP
O	NNP

from	IN
O	NN

0.3	CD
O	NN

mmol/h	JJ
O	NN

and	CC
O	NN

MAO	NNP
O	NN

from	IN
O	NN

4.8	CD
O	NN

mmol/h	JJ
O	NN

to	TO
O	NN

19	CD
O	NN

mmol/	NN
O	NN

h	NN
O	NN

)	NN
O	NN

Basal	JJ
O	NN

and	CC
O	NN

stimulated	VBN
O	NN

acid	NN
O	NN

concentrations	NNS
O	NN

also	RB
O	NN

increased	VBN
O	NN

(	NN
O	NN

29.1	CD
O	NN

+/-	CC
O	NN

36.6	CD
O	NN

to	TO
O	NN

54	CD
O	NN

+/-	CC
O	NN

31	CD
O	NN

mmol/l	NN
O	NN

and	CC
O	NN

72.5	CD
O	NN

+/-	CC
O	NN

46	CD
O	NN

to	TO
O	NN

120.1	CD
O	NN

+/-	CC
O	NN

30	CD
O	NN

mmol/l	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

,	,
O	NN

for	IN
O	NN

basal	JJ
O	NN

and	CC
O	NN

stimulated	VBN
O	NN

acid	NN
O	NN

concentrations	NNS
O	NN

;	:
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

for	IN
O	NN

peak	JJ
O	NN

and	CC
O	NN

MAO	NNP
O	NN

,	,
O	NN

P	NN
O	NN

=	JJ
O	NN

0.07	CD
O	NN

for	IN
O	NN

BAO	NNP
O	NNP

)	NN
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

Gastric	JJ
O	NN

acid	NN
O	NN

secretion	NN
O	NN

increased	VBN
O	NN

into	IN
O	NN

the	DT
O	NN

normal	JJ
O	NN

range	NN
O	NN

after	IN
O	NN

successful	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

H.	NN
D	NN

pylori	NN
D	NN

infection	NN
D	NN

,	,
O	NN

suggesting	VBG
O	NN

that	IN
O	NN

gastric	JJ
O	NN

function	NN
O	NN

can	MD
O	NNP

recover	VB
O	NNP

to	TO
O	NN

normal	JJ
O	NN

or	CC
O	NN

almost	RB
O	NN

normal	JJ
O	NN

after	IN
O	NN

cure	NN
O	NN

of	IN
O	NN

H.	NN
D	NN

pylori	NN
D	NN

infection	NN
D	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

Reports	NNS
O	NN

suggest	VBP
O	NN

that	IN
O	NN

there	RB
O	NN

is	VBZ
O	NN

an	DT
O	NN

increased	VBN
O	NN

incidence	NN
O	NN

of	IN
O	NN

preeclampsia	NN
D	NN

after	IN
O	NN

a	DT
O	NN

previously	RB
O	NN

normal	JJ
O	NN

pregnancy	NN
O	NN

if	IN
O	NN

there	RB
O	NN

is	VBZ
O	NN

a	DT
O	NN

change	NN
O	NN

in	IN
O	NN

paternity	NN
O	NN

We	PRP
O	VBP

hypothesize	VB
O	NN

that	IN
O	NN

there	RB
O	NN

is	VBZ
O	NN

a	DT
O	NN

higher	JJR
O	NN

incidence	NN
O	NN

of	IN
O	NN

preeclampsia	NN
D	NN

(	NN
D	NN

proteinuric	JJ
D	NN

hypertension	NN
D	NN

)	NN
D	NN

in	IN
O	NN

women	NNS
O	VBP

conceiving	VBG
O	NN

by	IN
O	NN

intrauterine	JJ
O	NN

insemination	NN
O	NN

with	IN
O	NN

donor	NN
O	NN

sperm	NN
O	NN

versus	CC
O	NN

intrauterine	JJ
O	NN

insemination	NN
O	NN

with	IN
O	NN

partner	NN
O	NN

sperm	NN
O	NN

STUDY	NN
O	NN

DESIGN	NN
O	NN

:	:
O	NN

This	DT
O	NN

was	VBD
O	NN

a	DT
O	NN

retrospective	JJ
O	NN

cohort	NN
O	NN

study	NN
O	NN

In	IN
O	NN

women	NNS
O	VBP

with	IN
O	NN

primary	JJ
O	NN

infertility	NN
D	NN

all	DT
O	NN

pregnancies	NNS
O	NN

achieved	VBN
O	NN

by	IN
O	NN

either	DT
O	NN

partner	NN
O	NN

or	CC
O	NN

donor	NN
O	NN

intrauterine	JJ
T	NN

insemination	NN
T	NN

carried	VBD
O	NN

to	TO
O	NN

birth	NN
O	NN

of	IN
O	NN

a	DT
O	NN

fetus	NN
O	NN

(	NN
O	NN

>	JJR
O	NN

20	CD
O	NN

weeks	NNS
O	NN

)	NN
O	NN

were	VBD
O	NN

identified	VBN
O	NN

The	DT
O	NN

medical	JJ
O	NN

records	NNS
O	NN

were	VBD
O	NN

examined	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

maternal	JJ
O	NN

and	CC
O	NN

pregnancy	NN
O	NN

outcome	NN
O	NN

data	NNS
O	NN

The	DT
O	NN

relative	JJ
O	NN

risk	NN
O	NN

and	CC
O	NN

95	CD
O	NN

%	NN
O	NN

confidence	NN
O	NN

interval	NN
O	NN

were	VBD
O	NN

calculated	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

risk	NN
O	NN

of	IN
O	NN

preeclampsia	NN
D	NN

The	DT
O	NN

baseline	NN
O	NN

data	NNS
O	NN

were	VBD
O	NN

compared	VBN
O	NN

with	IN
O	NN

t	NN
O	NN

tests	NNS
O	NN

,	,
O	NN

chi	NN
O	NN

2	CD
O	NN

analysis	NN
O	NN

and	CC
O	NN

Fisher	NNP
O	NNP

's	POS
O	NN

exact	JJ
O	NN

test	NN
O	NN

where	WRB
O	NN

appropriate	JJ
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Forty-four	CD
O	NN

patients	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

partner	NN
O	NN

intrauterine	JJ
T	NN

insemination	NN
T	NN

group	NN
O	NN

and	CC
O	NN

37	CD
O	NN

in	IN
O	NN

the	DT
O	NN

donor	NN
T	NN

insemination	NN
T	NN

group	NN
O	NN

were	VBD
O	NN

identified	VBN
O	NN

as	IN
O	NN

having	VBG
O	NN

primary	JJ
O	NN

infertility	NN
D	NN

Three	CD
O	NN

cases	NNS
O	NN

of	IN
O	NN

mild	JJ
O	NN

preeclampsia	NN
D	NN

were	VBD
O	NN

found	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

partner	NN
T	NN

insemination	NN
T	NN

program	NN
O	NN

and	CC
O	NN

nine	CD
O	NN

cases	NNS
O	NN

of	IN
O	NN

preeclampsia	NN
D	NN

(	NN
O	NN

five	CD
O	NN

severe	JJ
O	NN

,	,
O	NN

four	CD
O	NN

mild	JJ
O	NN

)	NN
O	NN

in	IN
O	NN

the	DT
O	NN

donor	NN
T	NN

insemination	NN
T	NN

program	NN
O	NN

(	NN
O	NN

relative	JJ
O	NN

risk	NN
O	NN

1.85	CD
O	NN

,	,
O	NN

95	CD
O	NN

%	NN
O	NN

confidence	NN
O	NN

interval	NN
O	NN

1.20	CD
O	NN

to	TO
O	NN

2.85	CD
O	NN

)	NN
O	NN

.	.
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

There	EX
O	NN

is	VBZ
O	NN

a	DT
O	NN

higher	JJR
O	NN

incidence	NN
O	NN

of	IN
O	NN

preeclampsia	NN
D	NN

in	IN
O	NN

women	NNS
O	VBP

conceiving	VBG
O	NN

by	IN
O	NN

intrauterine	JJ
T	NN

insemination	NN
T	NN

with	IN
O	NN

washed	VBN
O	NN

donor	NN
O	NN

sperm	NN
O	NN

compared	VBN
O	NN

with	IN
O	NN

intrauterine	JJ
T	NN

insemination	NN
T	NN

with	IN
O	NN

washed	VBN
O	NN

partner	NN
O	NN

sperm	NN
O	NN

.	.
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

There	EX
O	NN

is	VBZ
O	NN

a	DT
O	NN

higher	JJR
O	NN

incidence	NN
O	NN

of	IN
O	NN

preeclampsia	NN
D	NN

in	IN
O	NN

women	NNS
O	VBP

conceiving	VBG
O	NN

by	IN
O	NN

intrauterine	JJ
T	NN

insemination	NN
T	NN

with	IN
O	NN

washed	VBN
O	NN

donor	NN
O	NN

sperm	NN
O	NN

compared	VBN
O	NN

with	IN
O	NN

intrauterine	JJ
T	NN

insemination	NN
T	NN

with	IN
O	NN

washed	VBN
O	NN

partner	NN
O	NN

sperm	NN
O	NN

.	.
O	NN

This	DT
O	NN

supports	VBZ
O	NN

,	,
O	NN

indirectly	RB
O	NN

,	,
O	NN

an	DT
O	NN

immunologic	JJ
O	NN

basis	NN
O	NN

for	IN
O	NN

preeclampsia	NN
D	NN

The	DT
O	NN

antigenic	JJ
O	NN

factor	NN
O	NN

would	MD
O	NNP

appear	VB
O	NN

to	TO
O	NN

be	VB
O	NN

located	JJ
O	NN

on	IN
O	NN

the	DT
O	NN

sperm	NN
O	NN

as	IN
O	NN

opposed	VBN
O	NN

to	TO
O	NN

the	DT
O	NN

seminal	JJ
O	NN

fluid	NN
O	NN

itself	PRP
O	NN

After	IN
O	NN

a	DT
O	NN

rapid	JJ
O	NN

examination	NN
O	NN

of	IN
O	NN

a	DT
O	NN

few	JJ
O	NN

basic	JJ
O	NN

concepts	NNS
O	NN

concerning	VBG
O	NN

cellular	JJ
O	NN

aging	VBG
O	NN

and	CC
O	NN

programmed	VBN
O	NN

cell	NN
O	NN

death	NN
O	NN

,	,
O	NN

the	DT
O	NN

aging	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

tissues	NNS
O	NN

and	CC
O	NN

organs	NNS
O	VBP

,	,
O	NN

the	DT
O	NN

authors	NNS
O	NN

discuss	VB
O	NN

the	DT
O	NN

principal	JJ
O	NN

theories	NNS
O	NN

on	IN
O	NN

senescence	NN
O	NN

They	PRP
O	VBP

underline	VB
O	NN

that	IN
O	NN

it	PRP
O	NN

is	VBZ
O	NN

necessary	JJ
O	NN

to	TO
O	NN

agree	VB
O	NN

in	IN
O	NN

considering	VBG
O	NN

the	DT
O	NN

various	JJ
O	NN

genetic	JJ
O	NN

and	CC
O	NN

epigenetic	JJ
O	NN

,	,
O	NN

endogenous	JJ
O	NN

and	CC
O	NN

exogenous	JJ
O	NN

mechanisms	NNS
O	VBP

that	IN
O	NN

lead	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

complex	JJ
O	NN

aging	VBG
O	NN

phenomenon	NN
O	NN

multiple	JJ
O	NN

and	CC
O	NN

interrelated	JJ
O	NN

In	IN
O	NN

particular	JJ
O	NN

they	PRP
O	VBP

stress	NN
O	NN

the	DT
O	NN

hypothesis	NN
O	NN

that	IN
O	NN

senescence	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

due	JJ
O	NN

to	TO
O	NN

a	DT
O	NN

sum	NN
O	NN

of	IN
O	NN

molecular	JJ
O	NN

damages	NNS
O	NN

caused	VBN
O	NN

by	IN
O	NN

free	JJ
O	NN

radicals	NNS
O	NN

,	,
O	NN

and	CC
O	NN

to	TO
O	NN

the	DT
O	NN

loss	NN
O	NN

of	IN
O	NN

telomeric	JJ
O	NN

DNA	NN
O	NN

Radical	NNP
O	NNP

reactions	NNS
O	NN

can	MD
O	NNP

cause	NN
O	NN

mutations	NNS
O	VBP

,	,
O	NN

inactivation	NN
O	NN

or	CC
O	NN

a	DT
O	NN

decrease	NN
O	NN

in	IN
O	NN

the	DT
O	NN

turnover	NN
O	NN

of	IN
O	NN

mitochondrial	JJ
O	NN

DNA	NN
O	NN

which	WDT
O	NN

is	VBZ
O	NN

more	RBR
O	NN

vulnerable	JJ
O	NN

than	IN
O	NN

the	DT
O	NN

nuclear	JJ
O	NN

genoma	NN
O	NN

to	TO
O	NN

the	DT
O	NN

attack	NN
O	NN

of	IN
O	NN

mutagenic	JJ
O	NN

agents	NNS
O	NN

,	,
O	NN

acting	VBG
O	NN

also	RB
O	NN

as	IN
O	NN

a	DT
O	NN

continuous	JJ
O	NN

source	NN
O	NN

of	IN
O	NN

initial	JJ
O	NN

and/or	CC
O	NN

promoting	VBG
O	NN

factors	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

carcinogenetic	JJ
O	NN

process	NN
O	NN

The	DT
O	NN

somatic	JJ
O	NN

cells	NNS
O	VBP

become	VBN
O	NN

senescent	JJ
O	NN

because	IN
O	NN

during	IN
O	NN

cell	NN
O	NN

division	NN
O	NN

,	,
O	NN

they	PRP
O	VBP

lose	VB
O	NN

the	DT
O	NN

mechanisms	NNS
O	VBP

for	IN
O	NN

the	DT
O	NN

lengthening	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

telomere	NN
O	NN

The	DT
O	NN

telomerase	NN
O	NN

prevents	VBZ
O	NN

the	DT
O	NN

shortening	VBG
O	NN

of	IN
O	NN

telomeres	NNS
O	NN

in	IN
O	NN

neoplastic	JJ
O	NN

cells	NNS
O	VBP

and	CC
O	NN

therefore	RB
O	NN

renders	VBZ
O	NN

them	PRP
O	VBP

immortal	JJ
O	NN

Paradoxically	RB
O	NN

the	DT
O	NN

protection	NN
O	NN

of	IN
O	NN

the	DT
O	NN

telomere	NN
O	NN

is	VBZ
O	NN

exactly	RB
O	NN

what	WDT
O	NN

must	MD
O	NNP

be	VB
O	NN

avoided	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

case	NN
O	NN

of	IN
O	NN

tumor	NN
O	NN

cells	NNS
O	VBP

Recently	RB
O	NN

the	DT
O	NN

demonstration	NN
O	NN

that	IN
O	NN

telomerase	NN
O	NN

is	VBZ
O	NN

not	RB
O	NN

always	RB
O	NN

involved	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

restoration	NN
O	NN

of	IN
O	NN

telomere	NN
O	NN

length	NN
O	NN

shows	NNS
O	VBP

the	DT
O	NN

complexity	NN
O	NN

of	IN
O	NN

the	DT
O	NN

problems	NNS
O	VBP

connected	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

cause	NN
O	NN

of	IN
O	NN

senescence	NN
O	NN

Chromosomally	RB
O	NN

integrated	VBN
O	NN

retroviral	JJ
O	NN

switch	NN
O	NN

(	NN
O	NN

S	NN
O	NN

)	NN
O	NN

substrates	NNS
O	NN

have	VB
O	NN

been	VBN
O	NN

developed	VBN
O	NN

to	TO
O	NN

reveal	VB
O	NN

switch	NN
O	NN

recombinase-like	JJ
O	NN

activities	NNS
O	VBP

(	NN
O	NN

SRLA	NN
O	NN

)	NN
O	NN

in	IN
O	NN

pre-B	JJ
O	NN

and	CC
O	NN

mature	JJ
O	NN

B	NN
O	NN

cell	NN
O	NN

lines	NNS
O	NN

Switch	VB
O	NN

substrate	JJ
O	NN

retrovectors	NNS
O	NN

(	NN
O	NN

SSR	NN
O	NN

)	NN
O	NN

contain	VB
O	NN

a	DT
O	NN

long-terminal	JJ
O	NN

repeat-driven	JJ
O	NN

neomycin	NN
O	NN

(	NN
O	NN

Neo	NN
O	NN

)	NN
O	NN

gene	NN
O	NN

for	IN
O	NN

proviral	JJ
O	NN

chromosomal	JJ
O	NN

maintenance	NN
O	NN

(	NN
O	NN

pre-	JJ
O	NN

and	CC
O	NN

post-S	JJ
O	NN

recombination	NN
O	NN

)	NN
O	NN

and	CC
O	NN

a	DT
O	NN

CMV	NN
O	NN

promoter-driven	JJ
O	NN

,	,
O	NN

chimeric	JJ
O	NN

hygromycin-thymidine	NN
O	NN

kinase	NN
O	NN

(	NN
O	NN

Hytk	NN
O	NN

)	NN
O	NN

gene	NN
O	NN

(	NN
O	NN

flanked	VBN
O	NN

by	IN
O	NN

S	NN
O	NN

mu	NN
O	NN

and	CC
O	NN

S	NN
O	NN

gamma	NN
O	NN

2b	JJ
O	NN

recombination	NN
O	NN

targets	NNS
O	VBP

)	NN
O	NN

to	TO
O	NN

select	JJ
O	NN

for	IN
O	NN

(	NN
O	NN

ganciclovir	NN
O	NN

)	NN
O	NN

and	CC
O	NN

against	IN
O	NN

(	NN
O	NN

hygromycin	NN
O	NN

B	NN
O	NN

)	NN
O	NN

S	NN
O	NN

region	NN
O	NN

recombination	NN
O	NN

The	DT
O	NN

retro-substrates	JJ
O	NN

'	POS
O	NN

strong	JJ
O	NN

,	,
O	NN

constitutive	JJ
O	NN

promoters	NNS
O	NN

ensure	VB
O	NN

that	IN
O	NN

variations	NNS
O	NN

in	IN
O	NN

cellular	JJ
O	NN

switch	NN
O	NN

recombinase	NN
O	NN

activities	NNS
O	VBP

are	VBP
O	NN

independent	JJ
O	NN

of	IN
O	NN

S	NN
O	NN

region	NN
O	NN

accessibility	NN
O	NN

control	NN
O	NN

By	IN
O	NN

initially	RB
O	NN

selecting	VBG
O	NN

for	IN
O	NN

proviral	JJ
O	NN

integrants	NNS
O	NN

in	IN
O	NN

hygromycin	NN
O	NN

followed	VBN
O	NN

by	IN
O	NN

shifting	VBG
O	NN

into	IN
O	NN

neomycin	NN
O	NN

+	CC
O	NN

ganciclovir	NN
O	NN

to	TO
O	NN

select	JJ
O	NN

for	IN
O	NN

S	NN
O	NN

sequence-mediated	JJ
O	NN

deletions	NNS
O	VBP

,	,
O	NN

switch	NN
O	NN

recombinations	NNS
O	NN

can	MD
O	NNP

be	VB
O	NN

specifically	RB
O	NN

forestalled	VBN
O	NN

in	IN
O	NN

B	NN
O	NN

cell	NN
O	NN

lines	NNS
O	NN

whilst	IN
O	NN

most	JJS
O	NN

switch-incompetent	JJ
O	NN

cells	NNS
O	VBP

do	VB
O	NNP

not	RB
O	NN

survive	VB
O	NN

secondary	JJ
O	NN

selection	NN
O	NN

A	DT
O	NN

qualitative	JJ
O	NN

,	,
O	NN

direct	JJ
O	NN

PCR	NN
O	NN

assay	NN
O	NN

reveals	VBZ
O	NN

that	IN
O	NN

SSR	NN
O	NN

recombinations	NNS
O	NN

are	VBP
O	NN

stochastic	JJ
O	NN

in	IN
O	NN

B	NN
O	NN

cell	NN
O	NN

lines	NNS
O	NN

generating	VBG
O	NN

a	DT
O	NN

product	NN
O	NN

array	NN
O	NN

akin	JJ
O	NN

to	TO
O	NN

natural	JJ
O	NN

GH	NN
O	NN

class	NN
O	NN

switching	VBG
O	NN

A	DT
O	NN

semi-quantitative	JJ
O	NN

DC-PCR	NN
O	NN

assay	NN
O	NN

detects	VBZ
O	NN

a	DT
O	NN

significant	JJ
O	NN

recombinase	NN
O	NN

activity	NN
O	NN

only	RB
O	NN

in	IN
O	NN

a	DT
O	NN

restricted	JJ
O	NN

set	VBN
O	NN

of	IN
O	NN

late	RB
O	NN

stage	NN
O	NN

pre-B	JJ
O	NN

and	CC
O	NN

mature	JJ
O	NN

B	NN
O	NN

cell	NN
O	NN

lines	NNS
O	NN

BCL1B1	NN
O	NN

mature	JJ
O	NN

B	NN
O	NN

cells	NNS
O	VBP

have	VB
O	NN

the	DT
O	NN

highest	JJS
O	NN

level	NN
O	NN

of	IN
O	NN

recombinase	NN
O	NN

activity	NN
O	NN

with	IN
O	NN

25	CD
O	NN

%	NN
O	NN

or	CC
O	NN

more	RBR
O	NN

of	IN
O	NN

proviral	JJ
O	NN

integrants	NNS
O	NN

accumulating	VBG
O	NN

S	NN
O	NN

mu/S	NN
O	NN

gamma	NN
O	NN

2b	JJ
O	NN

substrate	JJ
O	NN

recombinations	NNS
O	NN

within	IN
O	NN

10-14	CD
O	NN

cell	NN
O	NN

generations	NNS
O	NN

The	DT
O	NN

SSR	NN
O	NN

recombinase	NN
O	NN

assay	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

performed	VBN
O	NN

in	IN
O	NN

a	DT
O	NN

transient	JJ
O	NN

fashion	NN
O	NN

wherein	WRB
O	NN

extensive	JJ
O	NN

,	,
O	NN

B	NN
O	NN

cell-specific	JJ
O	NN

recombination	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

visualized	VBN
O	NN

within	IN
O	NN

only	RB
O	NN

a	DT
O	NN

few	JJ
O	NN

cell	NN
O	NN

divisions	NNS
O	VBP

post	NN
O	NN

proviral	JJ
O	NN

integration	NN
O	NN

We	PRP
O	VBP

propose	VBP
O	NN

that	IN
O	NN

switch	NN
O	NN

recombinase	NN
O	NN

activity	NN
O	NN

becomes	VBZ
O	NN

activated	VBN
O	NN

during	IN
O	NN

B	NN
O	NN

cell	NN
O	NN

ontogeny	NN
O	NN

independent	JJ
O	NN

of	IN
O	NN

or	CC
O	NN

prior	RB
O	NN

to	TO
O	NN

the	DT
O	NN

acquisition	NN
O	NN

of	IN
O	NN

CH	NN
O	NN

locus	NN
O	NN

accessibility	NN
O	NN

and	CC
O	NN

that	IN
O	NN

endogenous	JJ
O	NN

S	NN
O	NN

segment	NN
O	NN

targeting	VBG
O	NN

to	TO
O	NN

pre-existing	JJ
O	NN

recombinase	NN
O	NN

requires	VBZ
O	NN

a	DT
O	NN

level	NN
O	NN

of	IN
O	NN

accessibility	NN
O	NN

beyond	IN
O	NN

transcriptional	JJ
O	NN

activation	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

determine	VB
O	NN

the	DT
O	NN

prevalence	NN
O	NN

of	IN
O	NN

illicit	JJ
O	NN

drug	NN
O	NN

abuse	NN
O	NN

and	CC
O	NN

alcohol	NN
O	NN

use	NN
O	NN

in	IN
O	NN

an	DT
O	NN

obstetric	JJ
O	NN

population	NN
O	NN

based	VBN
O	NN

in	IN
O	NN

an	DT
O	NN

urban	JJ
O	NN

maternity	NN
O	NN

hospital	NN
O	NN

SETTING	VBG
O	NN

:	:
O	NN

A	DT
O	NN

collaborative	JJ
O	NN

study	NN
O	NN

between	IN
O	NN

the	DT
O	NN

Rotunda	NN
O	NN

Hospital	NNP
O	NNP

,	,
O	NN

Dublin	NNP
O	NNP

and	CC
O	NN

the	DT
O	NN

Irish	JJ
O	NN

National	NNP
O	NNP

Drug	NN
O	NN

Advisory	NNP
O	NNP

&	CC
O	NNP

#	#
O	NN

38	CD
O	NN

;	:
O	NN

Treatment	NN
O	NN

Centre	NNP
O	NNP

DESIGN	NN
O	NN

:	:
O	NN

A	DT
O	NN

prospective	JJ
O	NN

study	NN
O	NN

consisting	VBG
O	NN

of	IN
O	NN

anonymous	JJ
O	NN

,	,
O	NN

unlinked	JJ
O	NN

urine	NN
O	NN

testing	NN
O	NN

of	IN
O	NN

504	CD
O	NN

'first	JJ
O	NN

visit	NN
O	NN

'	POS
O	NN

antenatal	JJ
O	NN

patients	NNS
O	NN

and	CC
O	NN

a	DT
O	NN

separate	JJ
O	NN

group	NN
O	NN

of	IN
O	NN

515	CD
O	NN

patients	NNS
O	NN

six	CD
O	NN

weeks	NNS
O	NN

after	IN
O	NN

delivery	NN
O	NN

METHODS	NNS
O	VBP

&	CC
O	NNP

#	#
O	NN

38	CD
O	NN

;	:
O	NN

OUTCOME	NN
O	NN

MEASURES	NNS
O	VBP

:	:
O	NN

Toxicological	JJ
O	NN

screening	VBG
O	NN

using	VBG
O	NN

enzyme-linked	JJ
O	NN

immunoassay	NN
O	NN

techniques	NNS
O	VBP

,	,
O	NN

with	IN
O	NN

all	DT
O	NN

positive	JJ
O	NN

samples	NNS
O	NN

being	VBG
O	NN

reanalysed	VBN
O	NN

Drug	NN
O	NN

histories	NNS
O	VBP

were	VBD
O	NN

taken	VBN
O	NN

and	CC
O	NN

samples	NNS
O	NN

were	VBD
O	NN

tested	VBN
O	NN

for	IN
O	NN

alcohol	NN
O	NN

and	CC
O	NN

six	CD
O	NN

of	IN
O	NN

the	DT
O	NN

most	JJS
O	NN

commonly	RB
O	NN

abused	JJ
O	NN

drugs	NNS
O	NN

The	DT
O	NN

pre-	JJ
O	NN

and	CC
O	NN

postnatal	JJ
O	NN

prevalence	NN
O	NN

of	IN
O	NN

abuse	NN
O	NN

was	VBD
O	NN

matched	VBN
O	NN

with	IN
O	NN

demographic	JJ
O	NN

data	NNS
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

prevalence	NN
O	NN

of	IN
O	NN

chemical	NN
O	NN

substance	NN
O	NN

misuse	NN
O	NN

in	IN
O	NN

the	DT
O	NN

antenatal	JJ
O	NN

population	NN
O	NN

was	VBD
O	NN

2.8	CD
O	NN

%	NN
O	NN

and	CC
O	NN

5.6	CD
O	NN

%	NN
O	NN

in	IN
O	NN

the	DT
O	NN

postnatal	JJ
O	NN

population	NN
O	NN

Substances	NNS
O	NN

identified	VBN
O	NN

included	VBN
O	NN

benzodiazepines	NNS
O	NN

,	,
O	NN

cannabis	NN
O	NN

,	,
O	NN

amphetamines	NNS
O	NN

,	,
O	NN

opiates	NNS
O	NN

and	CC
O	NN

cocaine	NN
O	NN

Less	RBR
O	NN

than	IN
O	NN

2	CD
O	NN

%	NN
O	NN

of	IN
O	NN

samples	NNS
O	NN

tested	VBN
O	NN

positive	JJ
O	NN

for	IN
O	NN

alcohol	NN
O	NN

None	NN
O	NN

of	IN
O	NN

the	DT
O	NN

women	NNS
O	VBP

yielding	VBG
O	NN

positive	JJ
O	NN

samples	NNS
O	NN

had	VBD
O	NN

been	VBN
O	NN

pre-identified	JJ
O	NN

on	IN
O	NN

the	DT
O	NN

basis	NN
O	NN

of	IN
O	NN

history	NN
O	NN

A	DT
O	NN

significant	JJ
O	NN

proportion	NN
O	NN

of	IN
O	NN

the	DT
O	NN

women	NNS
O	VBP

were	VBD
O	NN

in	IN
O	NN

the	DT
O	NN

high	JJ
O	NN

risk	NN
O	NN

categories	NNS
O	VBP

with	IN
O	NN

regard	NN
O	NN

to	TO
O	NN

age	NN
O	NN

and	CC
O	NN

socio-economic	JJ
O	NN

status	NN
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

The	DT
O	NN

prevalence	NN
O	NN

of	IN
O	NN

drug	NN
O	NN

misuse	NN
O	NN

antenatally	RB
O	NN

was	VBD
O	NN

nearly	RB
O	NN

3	CD
O	NN

%	NN
O	NN

and	CC
O	NN

postnatally	RB
O	NN

almost	RB
O	NN

6	CD
O	NN

%	NN
O	NN

Substance	NN
O	NN

abusers	NNS
O	NN

in	IN
O	NN

pregnancy	NN
O	NN

are	VBP
O	NN

more	RBR
O	NN

likely	JJ
O	NN

to	TO
O	NN

be	VB
O	NN

single	JJ
O	NN

,	,
O	NN

unemployed	JJ
O	NN

,	,
O	NN

and	CC
O	NN

to	TO
O	NN

have	VB
O	NN

had	VBD
O	NN

a	DT
O	NN

previous	JJ
O	NN

pregnancy	NN
O	NN

Schizophrenic	JJ
D	NN

illnesses	NNS
D	NN

occur	VB
O	NN

with	IN
O	NN

approximately	RB
O	NN

the	DT
O	NN

same	JJ
O	NN

incidence	NN
O	NN

in	IN
O	NN

all	DT
O	NN

human	JJ
O	NN

populations	NNS
O	NN

with	IN
O	NN

a	DT
O	NN

characteristic	JJ
O	NN

distribution	NN
O	NN

(	NN
O	NN

slightly	RB
O	NN

earlier	JJR
O	NN

in	IN
O	NN

males	NNS
O	VBP

)	NN
O	NN

of	IN
O	NN

ages	NNS
O	NN

of	IN
O	NN

onset	NN
O	NN

Given	VBN
O	NN

that	IN
O	NN

the	DT
O	NN

predisposition	NN
O	NN

(	NN
O	NN

which	WDT
O	NN

presumably	RB
O	NN

is	VBZ
O	NN

genetic	JJ
O	NN

)	NN
O	NN

is	VBZ
O	NN

associated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

procreative	JJ
O	NN

disadvantage	NN
O	NN

why	WRB
O	NN

do	VB
O	NNP

such	JJ
O	NN

illnesses	NNS
O	NN

persist	VB
O	NN

?	.
O	NN

Here	RB
O	NN

it	PRP
O	NN

is	VBZ
O	NN

suggested	VBN
O	NN

that	IN
O	NN

these	DT
O	NN

conditions	NNS
O	VBP

are	VBP
O	NN

a	DT
O	NN

manifestation	NN
O	NN

of	IN
O	NN

genetic	JJ
O	NN

diversity	NN
O	NN

in	IN
O	NN

the	DT
O	NN

evolution	NN
O	NN

of	IN
O	NN

the	DT
O	NN

specifically	RB
O	NN

human	JJ
O	NN

characteristic	JJ
O	NN

of	IN
O	NN

language	NN
O	NN

,	,
O	NN

an	DT
O	NN

innovation	NN
O	NN

that	IN
O	NN

has	VBZ
O	NN

occurred	VBD
O	NN

by	IN
O	NN

a	DT
O	NN

process	NN
O	NN

of	IN
O	NN

progressive	JJ
O	NN

hemispheric	JJ
O	NN

specialization-the	JJ
O	NN

establishment	NN
O	NN

of	IN
O	NN

dominance	NN
O	NN

for	IN
O	NN

some	DT
O	NN

critical	JJ
O	NN

component	NN
O	NN

of	IN
O	NN

language	NN
O	NN

in	IN
O	NN

one	CD
O	NN

or	CC
O	NN

the	DT
O	NN

other	JJ
O	NN

hemisphere	NN
O	NN

Individuals	NNS
O	NN

who	WP
O	VBP

develop	VB
O	NN

schizophrenic	JJ
D	NN

symptoms	NNS
D	NN

show	NN
O	NN

lesser	JJR
O	NN

anatomical	JJ
O	NN

and	CC
O	NN

functional	JJ
O	NN

asymmetries	NNS
O	NN

than	IN
O	NN

the	DT
O	NN

population	NN
O	NN

as	IN
O	NN

a	DT
O	NN

whole	JJ
O	NN

;	:
O	NN

such	JJ
O	NN

symptoms	NNS
O	NN

may	MD
O	NNP

reflect	VB
O	NN

'dominance	NN
O	NN

failure	NN
O	NN

'	POS
O	NN

for	IN
O	NN

language	NN
O	NN

Cloacal	JJ
D	NN

anomalies	NNS
D	NN

are	VBP
O	NN

extremely	RB
O	NN

rare	JJ
O	NN

and	CC
O	NN

have	VB
O	NN

variable	JJ
O	NN

presentations	NNS
O	NN

Prenatal	JJ
O	NN

diagnosis	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

difficult	JJ
O	NN

especially	RB
O	NN

if	IN
O	NN

they	PRP
O	VBP

present	JJ
O	NN

in	IN
O	NN

late	RB
O	NN

gestation	JJ
O	NN

Here	RB
O	NN

we	PRP
O	VBP

present	JJ
O	NN

two	CD
O	NN

cases	NNS
O	NN

diagnosed	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

late	RB
O	NN

third	JJ
O	NN

trimester	NN
O	NN

and	CC
O	NN

review	NN
O	NN

the	DT
O	NN

literature	NN
O	NN

regarding	VBG
O	NN

prenatal	JJ
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

cloacal	JJ
D	NN

anomalies	NNS
D	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

determine	VB
O	NN

whether	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

myocardial	JJ
D	NN

amyloidosis	NN
D	NN

due	JJ
O	NN

either	DT
O	NN

to	TO
O	NN

AL	NNP
O	NNP

(	NN
O	NN

primary	JJ
O	NN

)	NN
O	NN

amyloid	NN
O	NN

or	CC
O	NN

familial	JJ
O	NN

amyloid	NN
O	NN

have	VB
O	NN

distinguishing	VBG
O	NN

echocardiographic	JJ
O	NN

or	CC
O	NN

electrocardiographic	JJ
O	NN

features	NNS
O	VBP

;	:
O	NN

and	CC
O	NN

to	TO
O	NN

compare	VB
O	NN

the	DT
O	NN

prevalence	NN
O	NN

of	IN
O	NN

heart	NN
D	NN

failure	NN
D	NN

and	CC
O	NN

survival	NN
O	NN

in	IN
O	NN

the	DT
O	NN

two	CD
O	NN

types	NNS
O	NN

of	IN
O	NN

amyloidosis	NN
D	NN

in	IN
O	NN

relation	NN
O	NN

to	TO
O	NN

echocardiographic	JJ
O	NN

findings	NNS
O	VBP

DESIGN	NN
O	NN

:	:
O	NN

Blinded	VBN
O	NN

group	NN
O	NN

comparison	NN
O	NN

of	IN
O	NN

randomly	RB
O	NN

selected	VBN
O	NN

cases	NNS
O	NN

of	IN
O	NN

cardiac	JJ
D	NN

amyloidosis	NN
D	NN

SETTING	VBG
O	NN

:	:
O	NN

International	NNP
O	NNP

referral	NN
O	NN

centre	NN
O	NN

for	IN
O	NN

amyloid	NN
O	NN

research	NN
O	NN

and	CC
O	NN

treatment	NN
O	NN

PATIENTS	NNS
O	VBP

:	:
O	NN

36	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

cardiac	JJ
D	NN

amyloid	NN
D	NN

heart	NN
D	NN

disease	NN
D	NN

,	,
O	NN

of	IN
O	NN

whom	WP
O	NN

12	CD
O	NN

had	VBD
O	NN

familial	JJ
O	NN

and	CC
O	NN

24	CD
O	NN

had	VBD
O	NN

primary	JJ
O	NN

AL	NNP
O	NNP

amyloidosis	NN
D	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Familial	JJ
O	NN

and	CC
O	NN

AL	NNP
O	NNP

echocardiograms	NNS
O	NN

were	VBD
O	NN

morphologically	RB
O	NN

indistinguishable	JJ
O	NN

,	,
O	NN

with	IN
O	NN

similar	JJ
O	NN

left	RB
O	NN

ventricular	JJ
O	NN

wall	NN
O	NN

thickness	NN
O	NN

,	,
O	NN

mean	VB
O	NN

(	NN
O	NN

SD	NN
O	NN

)	NN
O	NN

15.4	CD
O	NN

(	NN
O	NN

2.3	CD
O	NN

)	NN
O	NN

nu	NN
O	NN

15.8	CD
O	NN

(	NN
O	NN

2.5	CD
O	NN

)	NN
O	NN

mm	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

;	:
O	NN

right	RB
O	NN

ventricular	JJ
O	NN

wall	NN
O	NN

thickness	NN
O	NN

was	VBD
O	NN

also	RB
O	NN

similar	JJ
O	NN

between	IN
O	NN

amyloid	NN
O	NN

types	NNS
O	NN

:	:
O	NN

9.6	CD
O	NN

(	NN
O	NN

2.8	CD
O	NN

)	NN
O	NN

nu	NN
O	NN

9.7	CD
O	NN

(	NN
O	NN

6.5	CD
O	NN

)	NN
O	NN

mm	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

Doppler	NNP
O	NNP

indices	NNS
O	NN

of	IN
O	NN

left	RB
O	NN

and	CC
O	NN

right	RB
O	NN

ventricular	JJ
O	NN

function	NN
O	NN

,	,
O	NN

left	RB
O	NN

ventricular	JJ
O	NN

volume	NN
O	NN

,	,
O	NN

and	CC
O	NN

ejection	NN
O	NN

fraction	NN
O	NN

were	VBD
O	NN

also	RB
O	NN

similar	JJ
O	NN

Low	JJ
O	NN

voltage	NN
O	NN

electrocardiograms	NN
O	NN

(	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.5	CD
O	NN

mV	NN
O	NN

)	NN
O	NN

were	VBD
O	NN

more	RBR
O	NN

common	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

AL	NNP
O	NNP

(	NN
O	NN

16/24	CD
O	NN

,	,
O	NN

67	CD
O	NN

%	NN
O	NN

)	NN
O	NN

than	IN
O	NN

in	IN
O	NN

the	DT
O	NN

familial	JJ
O	NN

group	NN
O	NN

(	NN
O	NN

4/12	CD
O	NN

,	,
O	NN

25	CD
O	NN

%	NN
O	NN

)	NN
O	NN

,	,
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

The	DT
O	NN

one	CD
O	NN

year	NN
O	NN

survival	NN
O	NN

for	IN
O	NN

familial	JJ
O	NN

and	CC
O	NN

AL	NNP
O	NNP

forms	NNS
O	NN

was	VBD
O	NN

92	CD
O	NN

%	NN
O	NN

(	NN
O	NN

11/12	CD
O	NN

)	NN
O	NN

nu	NN
O	NN

38	CD
O	NN

%	NN
O	NN

(	NN
O	NN

6/24	CD
O	NN

)	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

,	,
O	NN

with	IN
O	NN

virtually	RB
O	NN

all	DT
O	NN

deaths	NNS
O	NN

due	JJ
O	NN

to	TO
O	NN

cardiac	JJ
O	NN

causes	NNS
O	VBP

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Although	IN
O	NN

cardiac	JJ
O	NN

involvement	NN
O	NN

is	VBZ
O	NN

echocardiographically	RB
O	NN

indistinguishable	JJ
O	NN

,	,
O	NN

cardiac	JJ
O	NN

mortality	NN
O	NN

is	VBZ
O	NN

very	RB
O	NN

different	JJ
O	NN

between	IN
O	NN

the	DT
O	NN

two	CD
O	NN

forms	NNS
O	NN

of	IN
O	NN

amyloidosis	NN
D	NN

Preservation	NN
O	NN

of	IN
O	NN

electrocardiographic	JJ
O	NN

voltage	NN
O	NN

in	IN
O	NN

familial	JJ
O	NN

amyloidosis	NN
D	NN

suggests	VBZ
O	NN

that	IN
O	NN

the	DT
O	NN

particular	JJ
O	NN

biochemical	JJ
O	NN

characteristics	NNS
O	NN

of	IN
O	NN

distinct	JJ
O	NN

types	NNS
O	NN

of	IN
O	NN

amyloid	NN
O	NN

fibril	NN
O	NN

have	VB
O	NN

different	JJ
O	NN

pathological	JJ
O	NN

effects	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

myocardium	NN
O	NN

This	DT
O	NN

distinction	NN
O	NN

becomes	VBZ
O	NN

critical	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

evaluation	NN
O	NN

,	,
O	NN

treatment	NN
O	NN

,	,
O	NN

and	CC
O	NN

management	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

who	WP
O	VBP

have	VB
O	NN

a	DT
O	NN

diagnosis	NN
O	NN

within	IN
O	NN

the	DT
O	NN

spectrum	NN
O	NN

of	IN
O	NN

the	DT
O	NN

protein	NN
D	NN

deposition	NN
D	NN

diseases	NNS
D	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

examine	VB
O	NN

the	DT
O	NN

relationship	NN
O	NN

between	IN
O	NN

plasma	NN
O	NN

plasminogen	NN
O	NN

activator	NN
O	NN

inhibitor	NN
O	NN

1	CD
O	NN

(	NN
O	NN

PAI-1	NN
O	NN

)	NN
O	NN

activity	NN
O	NN

and	CC
O	NN

PAI-1	NN
O	NN

gene	NN
O	NN

(	NN
O	NN

4G/5G	NN
O	NN

)	NN
O	NN

polymorphism	NN
O	NN

and	CC
O	NN

diabetic	JJ
D	NN

retinopathy	NN
D	NN

in	IN
O	NN

Pima	NNP
O	NNP

Indians	NNPS
O	NNP

with	IN
O	NN

type	NN
O	NN

2	CD
O	NN

diabetes	NN
D	NN

RESEARCH	NN
O	NN

DESIGN	NN
O	NN

AND	CC
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

We	PRP
O	VBP

studied	VBN
O	NN

171	CD
O	NN

Pima	NNP
O	NNP

Indians	NNPS
O	NNP

with	IN
O	NN

type	NN
O	NN

2	CD
O	NN

diabetes	NN
D	NN

between	IN
O	NN

the	DT
O	NN

ages	NNS
O	NN

of	IN
O	NN

30-70	CD
O	NN

years	NNS
O	NN

in	IN
O	NN

a	DT
O	NN

population-based	JJ
O	NN

epidemiological	JJ
O	NN

survey	NN
O	NN

Plasma	NN
O	NN

PAI-1	NN
O	NN

activity	NN
O	NN

was	VBD
O	NN

measured	VBN
O	NN

by	IN
O	NN

a	DT
O	NN

spectrophotometric	JJ
O	NN

assay	NN
O	NN

and	CC
O	NN

PAI-1	NN
O	NN

4G/5G	NN
O	NN

promoter	NN
O	NN

genotype	NN
O	NN

by	IN
O	NN

the	DT
O	NN

polymerase	NN
O	NN

chain	NN
O	NN

reaction	NN
O	NN

(	NN
O	NN

PCR	NN
O	NN

)	NN
O	NN

using	VBG
O	NN

allele-specific	JJ
O	NN

primers	NNS
O	NN

Retinopathy	NN
D	NN

was	VBD
O	NN

assessed	VBN
O	NN

by	IN
O	NN

ophthalmoscopy	JJ
O	NN

after	IN
O	NN

pupillary	JJ
O	NN

dilation	NN
O	NN

and	CC
O	NN

classified	VBN
O	NN

as	IN
O	NN

any	DT
O	NN

retinopathy	NN
D	NN

or	CC
O	NN

as	IN
O	NN

nonproliferative	JJ
O	NN

and	CC
O	NN

proliferative	JJ
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Retinopathy	NN
D	NN

was	VBD
O	NN

present	JJ
O	NN

in	IN
O	NN

70	CD
O	NN

(	NN
O	NN

41	CD
O	NN

%	NN
O	NN

)	NN
O	NN

subjects	NNS
O	NN

,	,
O	NN

and	CC
O	NN

4	CD
O	NN

(	NN
O	NN

2.3	CD
O	NN

%	NN
O	NN

)	NN
O	NN

subjects	NNS
O	NN

had	VBD
O	NN

proliferative	JJ
O	NN

retinopathy	NN
D	NN

Plasma	NN
O	NN

PAI-1	NN
O	NN

activity	NN
O	NN

was	VBD
O	NN

not	RB
O	NN

significantly	RB
O	NN

different	JJ
O	NN

among	IN
O	NN

subjects	NNS
O	NN

with	IN
O	NN

and	CC
O	NN

without	IN
O	NN

retinopathy	NN
D	NN

(	NN
O	NN

17.1	CD
O	NN

+/-	CC
O	NN

vs.	CC
O	NN

19.7	CD
O	NN

+/-	CC
O	NN

9.1	CD
O	NN

arbitrary	JJ
O	NN

units	NNS
O	NN

(	NN
O	NN

AU	NN
O	NN

)	NN
O	NN

/ml	NN
O	NN

,	,
O	NN

P	NN
O	NN

=	JJ
O	NN

0.09	CD
O	NN

)	NN
O	NN

PAI-1	NN
O	NN

activity	NN
O	NN

was	VBD
O	NN

negatively	RB
O	NN

correlated	VBD
O	NN

with	IN
O	NN

duration	NN
O	NN

of	IN
O	NN

diabetes	NN
D	NN

(	NN
O	NN

rs	NNS
O	NN

=	JJ
O	NN

-0.18	CD
O	NN

,	,
O	NN

P	NN
O	NN

=	JJ
O	NN

0.02	CD
O	NN

)	NN
O	NN

In	IN
O	NN

a	DT
O	NN

logistic	JJ
O	NN

regression	NN
O	NN

analysis	NN
O	NN

controlled	JJ
O	NN

for	IN
O	NN

age	NN
O	NN

,	,
O	NN

sex	NN
O	NN

,	,
O	NN

BMI	NN
O	NN

,	,
O	NN

and	CC
O	NN

duration	NN
O	NN

of	IN
O	NN

diabetes	NN
D	NN

,	,
O	NN

any	DT
O	NN

retinopathy	NN
D	NN

was	VBD
O	NN

significantly	RB
O	NN

associated	VBN
O	NN

with	IN
O	NN

fasting	VBG
O	NN

plasma	NN
O	NN

glucose	NN
O	NN

concentrations	NNS
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.05	CD
O	NN

)	NN
O	NN

,	,
O	NN

2-h	JJ
O	NN

postload	NN
O	NN

glucose	NN
O	NN

(	NN
O	NN

P	NN
O	NN

=	JJ
O	NN

0.02	CD
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

HbA1c	NN
O	NN

(	NN
O	NN

P	NN
O	NN

=	JJ
O	NN

0.008	CD
O	NN

)	NN
O	NN

,	,
O	NN

but	CC
O	NNP

not	RB
O	NN

with	IN
O	NN

PAI-1	NN
O	NN

activity	NN
O	NN

(	NN
O	NN

P	NN
O	NN

=	JJ
O	NN

0.48	CD
O	NN

)	NN
O	NN

The	DT
O	NN

prevalence	NN
O	NN

of	IN
O	NN

retinopathy	NN
D	NN

in	IN
O	NN

the	DT
O	NN

three	CD
O	NN

genotype	NN
O	NN

groups	NNS
O	NN

differed	VBN
O	NN

significantly	RB
O	NN

(	NN
O	NN

4G/4G	NN
O	NN

,	,
O	NN

4G/5G	NN
O	NN

,	,
O	NN

and	CC
O	NN

5G/5G	NN
O	NN

were	VBD
O	NN

44	CD
O	NN

,	,
O	NN

49	CD
O	NN

,	,
O	NN

and	CC
O	NN

24	CD
O	NN

%	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

;	:
O	NN

chi	NN
O	NN

2	CD
O	NN

=	JJ
O	NN

8.22	CD
O	NN

,	,
O	NN

df	NN
O	NN

=	JJ
O	NN

2	CD
O	NN

,	,
O	NN

P	NN
O	NN

=	JJ
O	NN

0.016	CD
O	NN

)	NN
O	NN

and	CC
O	NN

remained	VBD
O	NN

significant	JJ
O	NN

after	IN
O	NN

controlling	VBG
O	NN

for	IN
O	NN

age	NN
O	NN

,	,
O	NN

sex	NN
O	NN

,	,
O	NN

BMI	NN
O	NN

,	,
O	NN

duration	NN
O	NN

of	IN
O	NN

diabetes	NN
D	NN

,	,
O	NN

glycated	VBN
O	NN

hemoglobin	NN
O	NN

,	,
O	NN

and	CC
O	NN

urine	NN
O	NN

albumin-to-creatine	JJ
O	NN

ratio	NN
O	NN

in	IN
O	NN

a	DT
O	NN

logistic	JJ
O	NN

regression	NN
O	NN

analysis	NN
O	NN

The	DT
O	NN

odds	NNS
O	NN

ratios	NNS
O	NN

for	IN
O	NN

retinopathy	NN
D	NN

in	IN
O	NN

subjects	NNS
O	NN

with	IN
O	NN

4G/4G	NN
O	NN

and	CC
O	NN

4G/5G	NN
O	NN

,	,
O	NN

compared	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

5G/5G	NN
O	NN

genotype	NN
O	NN

,	,
O	NN

were	VBD
O	NN

2.0	CD
O	NN

and	CC
O	NN

3.1	CD
O	NN

,	,
O	NN

respectively	RB
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Although	IN
O	NN

diabetic	JJ
D	NN

retinopathy	NN
D	NN

in	IN
O	NN

Pima	NNP
O	NNP

Indians	NNPS
O	NNP

with	IN
O	NN

type	NN
O	NN

2	CD
O	NN

diabetes	NN
D	NN

is	VBZ
O	NN

not	RB
O	NN

associated	VBN
O	NN

with	IN
O	NN

PAI-1	NN
O	NN

activity	NN
O	NN

,	,
O	NN

subjects	NNS
O	NN

with	IN
O	NN

the	DT
O	NN

4G/4G	NN
O	NN

and	CC
O	NN

4G/5G	NN
O	NN

genotype	NN
O	NN

had	VBD
O	NN

a	DT
O	NN

higher	JJR
O	NN

prevalence	NN
O	NN

of	IN
O	NN

retinopathy	NN
D	NN

compared	VBN
O	NN

with	IN
O	NN

5G/5G	NN
O	NN

PAI-1genotype	JJ
O	NN

These	DT
O	NN

preliminary	JJ
O	NN

findings	NNS
O	VBP

indicate	VBP
O	NN

that	IN
O	NN

in	IN
O	NN

Pima	NNP
O	NNP

Indians	NNPS
O	NNP

with	IN
O	NN

type	NN
O	NN

2	CD
O	NN

diabetes	NN
D	NN

,	,
O	NN

presence	NN
O	NN

of	IN
O	NN

the	DT
O	NN

4G	NN
O	NN

allele	NN
O	NN

of	IN
O	NN

the	DT
O	NN

PAI-1	NN
O	NN

gene	NN
O	NN

was	VBD
O	NN

associated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

higher	JJR
O	NN

risk	NN
O	NN

of	IN
O	NN

diabetic	JJ
D	NN

retinopathy	NN
D	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Diagnostic	JJ
O	NN

peritoneal	JJ
O	NN

lavage	NN
O	NN

(	NN
O	NN

DPL	NNP
O	NNP

)	NN
O	NN

is	VBZ
O	NN

used	VBN
O	NN

to	TO
O	NN

diagnose	VB
O	NN

intra-abdominal	JJ
D	NN

injury	NN
D	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

stab	NN
D	NN

wounds	NNS
D	NN

and	CC
O	NN

blunt	JJ
D	NN

trauma	NN
D	NN

Because	IN
O	NN

exploratory	JJ
T	NN

celiotomy	JJ
T	NN

is	VBZ
O	NN

routinely	RB
O	NN

performed	VBN
O	NN

on	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

gunshot	NN
D	NN

wounds	NNS
D	NN

to	TO
D	NN

the	DT
D	NN

abdomen	NN
D	NN

,	,
O	NN

DPL	NNP
O	NNP

is	VBZ
O	NN

rarely	RB
O	NN

employed	VBN
O	NN

However	RB
O	NN

,	,
O	NN

several	JJ
O	NN

studies	NNS
O	VBP

have	VB
O	NN

questioned	VBD
O	NN

routine	JJ
O	NN

exploration	NN
O	NN

and	CC
O	NN

have	VB
O	NN

drawn	VBN
O	NN

attention	NN
O	NN

to	TO
O	NN

the	DT
O	NN

associated	VBN
O	NN

morbidity	NN
O	NN

of	IN
O	NN

negative	JJ
O	NN

celiotomy	NN
O	NN

Diagnostic	JJ
O	NN

peritoneal	JJ
O	NN

lavage	NN
O	NN

is	VBZ
O	NN

an	DT
O	NN

easily	RB
O	NN

performed	VBN
O	NN

and	CC
O	NN

inexpensive	JJ
O	NN

test	NN
O	NN

that	IN
O	NN

may	MD
O	NNP

be	VB
O	NN

useful	JJ
O	NN

in	IN
O	NN

this	DT
O	NN

situation	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

evaluate	VB
O	NN

the	DT
O	NN

performance	NN
O	NN

of	IN
O	NN

DPL	NNP
O	NNP

in	IN
O	NN

the	DT
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

intra-abdominal	JJ
D	NN

injury	NN
D	NN

in	IN
O	NN

hemodynamically	RB
O	NN

stable	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

gunshot	NN
D	NN

wounds	NNS
D	NN

to	TO
O	NN

the	DT
O	NN

abdomen	NN
O	NN

DESIGN	NN
O	NN

:	:
O	NN

A	DT
O	NN

prospective	JJ
O	NN

clinical	JJ
O	NN

trial	NN
O	NN

SETTING	VBG
O	NN

:	:
O	NN

Two	CD
O	NN

urban	JJ
O	NN

trauma	NN
O	NN

centers	NNS
O	NN

PATIENTS	NNS
O	VBP

:	:
O	NN

Patients	NNS
O	NN

with	IN
O	NN

gunshot	NN
D	NN

wounds	NNS
D	NN

to	TO
O	NN

the	DT
O	NN

abdomen	NN
O	NN

and	CC
O	NN

a	DT
O	NN

systolic	JJ
O	NN

blood	NN
O	NN

pressure	NN
O	NN

of	IN
O	NN

at	IN
O	NN

least	JJS
O	NN

90	CD
O	NN

mm	NN
O	NN

Hg	NN
O	NN

INTERVENTIONS	NNS
O	VBP

:	:
O	NN

Clinical	JJ
O	NN

predication	NN
O	NN

of	IN
O	NN

intra-abdominal	JJ
D	NN

injury	NN
D	NN

in	IN
O	NN

the	DT
O	NN

emergency	NN
O	NN

department	NN
O	NN

and	CC
O	NN

DPL	NNP
O	NNP

performed	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

operating	VBG
O	NN

room	NN
O	NN

before	IN
O	NN

the	DT
O	NN

initiation	NN
O	NN

of	IN
O	NN

celiotomy	NN
O	NN

Injuries	NNS
O	NN

found	VBN
O	NN

during	IN
O	NN

the	DT
O	NN

celiotomy	NN
O	NN

were	VBD
O	NN

recorded	VBN
O	NN

MAIN	JJS
O	NN

OUTCOME	NN
O	NN

MEASURES	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

results	NNS
O	VBP

of	IN
O	NN

the	DT
O	NN

clinical	JJ
O	NN

evaluation	NN
O	NN

and	CC
O	NN

DPL	NNP
O	NNP

were	VBD
O	NN

compared	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

findings	NNS
O	VBP

of	IN
O	NN

the	DT
O	NN

celiotomy	NN
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Forty-four	CD
O	NN

patients	NNS
O	NN

were	VBD
O	NN

enrolled	VBN
O	NN

into	IN
O	NN

the	DT
O	NN

study	NN
O	NN

Intra-abdominal	JJ
D	NN

injury	NN
D	NN

was	VBD
O	NN

present	JJ
O	NN

in	IN
O	NN

32	CD
O	NN

(	NN
O	NN

73	CD
O	NN

%	NN
O	NN

)	NN
O	NN

of	IN
O	NN

these	DT
O	NN

patients	NNS
O	NN

The	DT
O	NN

senior	JJ
O	NN

surgery	NN
O	NN

resident	JJ
O	NN

correctly	RB
O	NN

predicted	VBN
O	NN

the	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

intra-abdominal	JJ
D	NN

injury	NN
D	NN

in	IN
O	NN

36	CD
O	NN

(	NN
O	NN

82	CD
O	NN

%	NN
O	NN

)	NN
O	NN

of	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

(	NN
O	NN

sensitivity	NN
O	NN

=	JJ
O	NN

90.0	CD
O	NN

%	NN
O	NN

,	,
O	NN

specificity	NN
O	NN

=	JJ
O	NN

58.3	CD
O	NN

%	NN
O	NN

,	,
O	NN

positive	JJ
O	NN

predictive	JJ
O	NN

value	NN
O	NN

=	JJ
O	NN

85.3	CD
O	NN

%	NN
O	NN

,	,
O	NN

negative	JJ
O	NN

predictive	JJ
O	NN

value	NN
O	NN

=	JJ
O	NN

63.6	CD
O	NN

%	NN
O	NN

,	,
O	NN

phi	NN
O	NN

=	JJ
O	NN

0.52	CD
O	NN

,	,
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

.01	CD
O	NN

)	NN
O	NN

in	IN
O	NN

the	DT
O	NN

emergency	NN
O	NN

department	NN
O	NN

before	IN
O	NN

DPL	NNP
O	NNP

and	CC
O	NN

celiotomy	NN
O	NN

were	VBD
O	NN

performed	VBN
O	NN

Diagnostic	JJ
O	NN

peritoneal	JJ
O	NN

lavage	NN
O	NN

correctly	RB
O	NN

identified	VBN
O	NN

the	DT
O	NN

presence	NN
O	NN

or	CC
O	NN

absence	NN
O	NN

of	IN
O	NN

intra-abdominal	JJ
D	NN

injury	NN
D	NN

in	IN
O	NN

40	CD
O	NN

(	NN
O	NN

91	CD
O	NN

%	NN
O	NN

)	NN
O	NN

of	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

(	NN
O	NN

positive	JJ
O	NN

predictive	JJ
O	NN

value	NN
O	NN

=	JJ
O	NN

96.7	CD
O	NN

%	NN
O	NN

,	,
O	NN

negative	JJ
O	NN

predictive	JJ
O	NN

value	NN
O	NN

=	JJ
O	NN

78.6	CD
O	NN

%	NN
O	NN

,	,
O	NN

phi	NN
O	NN

=	JJ
O	NN

0.79	CD
O	NN

,	,
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

.01	CD
O	NN

)	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Clinical	JJ
O	NN

judgment	NN
O	NN

is	VBZ
O	NN

highly	RB
O	NN

accurate	JJ
O	NN

in	IN
O	NN

separating	VBG
O	NN

patients	NNS
O	NN

with	IN
O	NN

tangential	JJ
O	NN

gunshot	NN
D	NN

wounds	NNS
D	NN

to	TO
O	NN

the	DT
O	NN

abdomen	NN
O	NN

from	IN
O	NN

those	DT
O	NNP

with	IN
O	NN

intra-abdominal	JJ
D	NN

injury	NN
D	NN

but	CC
O	NNP

may	MD
O	NNP

miss	VB
O	NN

patients	NNS
O	NN

with	IN
O	NN

intra-abdominal	JJ
D	NN

hemorrhage	NN
D	NN

Diagnostic	JJ
O	NN

peritoneal	JJ
O	NN

lavage	NN
O	NN

is	VBZ
O	NN

highly	RB
O	NN

predictive	JJ
O	NN

of	IN
O	NN

the	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

intra-abdominal	JJ
D	NN

injury	NN
D	NN

The	DT
O	NN

return	NN
O	NN

of	IN
O	NN

gross	JJ
O	NN

blood	NN
O	NN

on	IN
O	NN

aspiration	NN
O	NN

or	CC
O	NN

a	DT
O	NN

lavage	NN
O	NN

red	JJ
O	NN

blood	NN
O	NN

cell	NN
O	NN

count	NN
O	NN

greater	JJR
O	NN

than	IN
O	NN

10	CD
O	NN

x	CC
O	NN

10	CD
O	NN

(	NN
O	NN

9	CD
O	NN

)	NN
O	NN

/L	NN
O	NN

should	MD
O	NNP

prompt	JJ
O	NN

an	DT
O	NN

urgent	JJ
O	NN

celiotomy	NN
O	NN

Missed	VBN
O	NN

injuries	NNS
O	NN

are	VBP
O	NN

rare	JJ
O	NN

and	CC
O	NN

most	JJS
O	NN

likely	JJ
O	NN

to	TO
O	NN

be	VB
O	NN

bowel	NN
D	NN

perforations	NNS
D	NN

Diagnostic	JJ
O	NN

peritoneal	JJ
O	NN

lavage	NN
O	NN

is	VBZ
O	NN

an	DT
O	NN

objective	JJ
O	NN

test	NN
O	NN

that	IN
O	NN

may	MD
O	NNP

augment	VBP
O	NN

clinical	JJ
O	NN

judgment	NN
O	NN

in	IN
O	NN

selecting	VBG
O	NN

hemodynamically	RB
O	NN

stable	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

potential	JJ
O	NN

tangential	JJ
O	NN

gunshot	NN
D	NN

wounds	NNS
D	NN

for	IN
O	NN

observation	NN
O	NN

and	CC
O	NN

is	VBZ
O	NN

especially	RB
O	NN

useful	JJ
O	NN

in	IN
O	NN

identifying	VBG
O	NN

intra-abdominal	JJ
D	NN

hemorrhage	NN
D	NN

BACKGROUND	NN
O	NN

:	:
O	NN

To	TO
O	NN

evaluate	VB
O	NN

the	DT
O	NN

frequency	NN
O	NN

of	IN
O	NN

Blastocystis	NN
D	NN

hominis	NN
D	NN

parasitation	NN
D	NN

and	CC
O	NN

to	TO
O	NN

ascertain	VB
O	NN

its	PRP$
O	NN

role	NN
O	NN

as	IN
O	NN

an	DT
O	NN

intestinal	JJ
O	NN

a	DT
O	NN

prospective	JJ
O	NN

study	NN
O	NN

during	IN
O	NN

18	CD
O	NN

months	NNS
O	NN

pathogen	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

carried	VBD
O	NN

out	IN
O	NN

SUBJECTS	NNS
O	NN

AND	CC
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

study	NN
O	NN

included	VBN
O	NN

2	CD
O	NN

,	,
O	NN

039	CD
O	NN

patients	NNS
O	NN

,	,
O	NN

which	WDT
O	NN

were	VBD
O	NN

classified	VBN
O	NN

in	IN
O	NN

three	CD
O	NN

groups	NNS
O	NN

(	NN
O	NN

asymptomatic	JJ
O	NN

(	NN
O	NN

group	NN
O	NN

A	DT
O	NN

)	NN
O	NN

,	,
O	NN

with	IN
O	NN

suspicion	NN
O	NN

of	IN
O	NN

parasitosis	NN
D	NN

(	NN
O	NN

group	NN
O	NN

B	NN
O	NN

)	NN
O	NN

,	,
O	NN

with	IN
O	NN

diarrhoea	NN
D	NN

(	NN
O	NN

group	NN
O	NN

C	NN
O	NN

)	NN
O	NN

)	NN
O	NN

In	IN
O	NN

all	DT
O	NN

cases	NNS
O	NN

a	DT
O	NN

coproparasitological	JJ
O	NN

study	NN
O	NN

was	VBD
O	NN

performed	VBN
O	NN

In	IN
O	NN

the	DT
O	NN

group	NN
O	NN

C	NN
O	NN

the	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

non-parasitic	JJ
O	NN

enteropathogens	NNS
O	NN

was	VBD
O	NN

also	RB
O	NN

investigated	VBN
O	NN

In	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

B	NN
O	NN

hominis	NN
O	NN

in	IN
O	NN

the	DT
O	NN

absence	NN
O	NN

of	IN
O	NN

other	JJ
O	NN

pathogens	NNS
O	NN

clinical	JJ
O	NN

and	CC
O	NN

epidemiological	JJ
O	NN

characteristics	NNS
O	NN

were	VBD
O	NN

evaluated	VBN
O	NN

Also	RB
O	NN

,	,
O	NN

its	PRP$
O	NN

was	VBD
O	NN

determined	VBN
O	NN

the	DT
O	NN

morphology	NN
O	NN

and	CC
O	NN

quantification	NN
O	NN

of	IN
O	NN

parasites	NNS
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Parasites	NNS
O	NN

were	VBD
O	NN

identified	VBN
O	NN

in	IN
O	NN

26.2	CD
O	NN

%	NN
O	NN

of	IN
O	NN

population	NN
O	NN

B	NN
O	NN

hominis	NN
O	NN

was	VBD
O	NN

identified	VBN
O	NN

in	IN
O	NN

336	CD
O	NN

patients	NNS
O	NN

(	NN
O	NN

16.5	CD
O	NN

%	NN
O	NN

)	NN
O	NN

The	DT
O	NN

frequency	NN
O	NN

of	IN
O	NN

parasitation	NN
D	NN

was	VBD
O	NN

superior	JJ
O	NN

in	IN
O	NN

adults	NNS
O	NN

(	NN
O	NN

p	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.0001	CD
O	NN

)	NN
O	NN

,	,
O	NN

with	IN
O	NN

a	DT
O	NN

slight	JJ
O	NN

predominance	NN
O	NN

in	IN
O	NN

the	DT
O	NN

female	JJ
O	NN

sex	NN
O	NN

The	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

asymptomatic	JJ
O	NN

carriers	NNS
O	VBP

was	VBD
O	NN

3.3	CD
O	NN

%	NN
O	NN

In	IN
O	NN

21	CD
O	NN

patients	NNS
O	NN

B	NN
O	NN

hominis	NN
O	NN

(	NN
O	NN

group	NN
O	NN

C	NN
O	NN

)	NN
O	NN

was	VBD
O	NN

observed	VBN
O	NN

in	IN
O	NN

absence	NN
O	NN

of	IN
O	NN

other	JJ
O	NN

enteropathogens	NNS
O	NN

Statistical	JJ
O	NN

significant	JJ
O	NN

association	NN
O	NN

was	VBD
O	NN

found	VBN
O	NN

between	IN
O	NN

B	NN
O	NN

hominis	NN
O	NN

,	,
O	NN

in	IN
O	NN

absence	NN
O	NN

of	IN
O	NN

other	JJ
O	NN

pathogens	NNS
O	NN

and	CC
O	NN

the	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

clinical	JJ
O	NN

manifestations	NNS
O	NN

(	NN
O	NN

p	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

0.0001	CD
O	NN

)	NN
O	NN

,	,
O	NN

the	DT
O	NN

most	JJS
O	NN

common	JJ
O	NN

of	IN
O	NN

which	WDT
O	NN

were	VBD
O	NN

diarrhoea	NN
D	NN

and	CC
O	NN

abdominal	JJ
D	NN

pain	NN
D	NN

We	PRP
O	VBP

did	VBD
O	NNP

not	RB
O	NN

find	VB
O	NN

a	DT
O	NN

statistically	RB
O	NN

significant	JJ
O	NN

association	NN
O	NN

between	IN
O	NN

the	DT
O	NN

number	NN
O	NN

of	IN
O	NN

B	NN
O	NN

hominis	NN
O	NN

present	JJ
O	NN

and	CC
O	NN

stool	NN
O	NN

characteristics	NNS
O	NN

The	DT
O	NN

vacuolar	JJ
O	NN

form	NN
O	NN

was	VBD
O	NN

the	DT
O	NN

predominant	JJ
O	NN

morphological	JJ
O	NN

type	NN
O	NN

The	DT
O	NN

ameboid	JJ
O	NN

form	NN
O	NN

was	VBD
O	NN

observed	VBN
O	NN

only	RB
O	NN

in	IN
O	NN

diarrhoeal	NN
O	NN

stools	NNS
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

B	NN
O	NN

hominis	NN
O	NN

is	VBZ
O	NN

the	DT
O	NN

most	JJS
O	NN

frequent	JJ
O	NN

parasite	NN
O	NN

found	VBN
O	NN

in	IN
O	NN

faecal	JJ
O	NN

parasitological	JJ
O	NN

investigation	NN
O	NN

In	IN
O	NN

absence	NN
O	NN

of	IN
O	NN

other	JJ
O	NN

causes	NNS
O	VBP

,	,
O	NN

B	NN
O	NN

hominis	NN
O	NN

must	MD
O	NNP

be	VB
O	NN

considered	VBN
O	NN

as	IN
O	NN

a	DT
O	NN

pathogen	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

The	DT
O	NN

cause	NN
O	NN

of	IN
O	NN

severe	JJ
O	NN

acquired	VBN
O	NN

hyperammonemia	NN
O	NN

,	,
O	NN

an	DT
O	NN

uncommon	JJ
O	NN

but	CC
O	NNP

often	RB
O	NN

fatal	JJ
O	NN

complication	NN
O	NN

of	IN
O	NN

organ	NN
O	NN

transplantation	NN
O	NN

and	CC
O	NN

chemotherapy	NN
O	NN

for	IN
O	NN

cancer	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

obscure	JJ
O	NN

<	JJR
O	NN

/TO_SEES	NN
O	NN

>	JJR
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

test	NN
O	NN

the	DT
O	NN

hypothesis	NN
O	NN

that	IN
O	NN

liver	NN
O	NN

glutamine	NN
O	NN

synthetase	NN
O	NN

deficiency	NN
O	NN

may	MD
O	NNP

explain	VB
O	NN

hyperammonemia	NN
D	NN

in	IN
O	NN

patients	NNS
O	NN

who	WP
O	VBP

have	VB
O	NN

had	VBD
O	NN

organ	NN
T	NN

transplantation	NN
T	NN

or	CC
O	NN

are	VBP
O	NN

receiving	VBG
O	NN

chemotherapy	NN
T	NN

DESIGN	NN
O	NN

:	:
O	NN

Case	NNP
O	NNP

report	NN
O	NN

PATIENTS	NNS
O	VBP

:	:
O	NN

Two	CD
O	NN

patients	NNS
O	NN

who	WP
O	VBP

had	VBD
O	NN

fatal	JJ
O	NN

hyperammonemia	NN
D	NN

after	IN
O	NN

orthotopic	JJ
O	NN

lung	NN
T	NN

transplantation	NN
T	NN

.	.
O	NN

MEASUREMENTS	NNS
O	NN

:	:
O	NN

Liver	NN
O	NN

tissue	NN
O	NN

was	VBD
O	NN

analyzed	VBN
O	NN

to	TO
O	NN

determine	VB
O	NN

the	DT
O	NN

activities	NNS
O	VBP

of	IN
O	NN

two	CD
O	NN

urea	NN
O	NN

cycle	NN
O	NN

enzymes	NNS
O	NN

and	CC
O	NN

glutamine	NN
O	NN

synthetase	NN
O	NN

Western	JJ
O	NN

blot	NN
O	NN

assays	NNS
O	NN

for	IN
O	NN

hepatic	JJ
O	NN

glutamine	NN
O	NN

synthetase	NN
O	NN

were	VBD
O	NN

performed	VBN
O	NN

to	TO
O	NN

determine	VB
O	NN

whether	IN
O	NN

glutamine	NN
O	NN

synthetase	NN
O	NN

deficiency	NN
O	NN

resulted	VBD
O	NN

from	IN
O	NN

reduced	VBN
O	NN

enzyme	NN
O	NN

levels	NNS
O	VBP

RESULTS	NNS
O	VBP

:	:
O	NN

Activities	NNS
O	VBP

of	IN
O	NN

carbamoyl	NN
O	NN

phosphate	NN
O	NN

synthetase	NN
O	NN

I	PRP
O	VBP

and	CC
O	NN

ornithine	NN
O	NN

carbamoyltransferase	NN
O	NN

in	IN
O	NN

the	DT
O	NN

liver	NN
O	NN

were	VBD
O	NN

normal	JJ
O	NN

The	DT
O	NN

activity	NN
O	NN

of	IN
O	NN

hepatic	JJ
O	NN

glutamine	NN
O	NN

synthetase	NN
O	NN

was	VBD
O	NN

markedly	RB
O	NN

reduced	VBN
O	NN

(	NN
O	NN

in	IN
O	NN

patient	NN
O	NN

1	CD
O	NN

,	,
O	NN

12	CD
O	NN

%	NN
O	NN

of	IN
O	NN

the	DT
O	NN

mean	VB
O	NN

value	NN
O	NN

in	IN
O	NN

controls	NNS
O	VBP

;	:
O	NN

in	IN
O	NN

patient	NN
O	NN

2	CD
O	NN

,	,
O	NN

28	CD
O	NN

%	NN
O	NN

of	IN
O	NN

the	DT
O	NN

mean	VB
O	NN

value	NN
O	NN

in	IN
O	NN

controls	NNS
O	VBP

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

a	DT
O	NN

concomitant	JJ
O	NN

reduction	NN
O	NN

in	IN
O	NN

the	DT
O	NN

amount	NN
O	NN

of	IN
O	NN

glutamine	NN
O	NN

synthetase	NN
O	NN

protein	NN
O	NN

was	VBD
O	NN

observed	VBN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

Hyperammonemia	NN
O	NN

after	IN
O	NN

transplantation	NN
O	NN

was	VBD
O	NN

associated	VBN
O	NN

with	IN
O	NN

hepatic	JJ
O	NN

glutamine	NN
O	NN

synthetase	NN
O	NN

deficiency	NN
O	NN

in	IN
O	NN

two	CD
O	NN

patients	NNS
O	NN

,	,
O	NN

but	CC
O	NNP

the	DT
O	NN

causal	JJ
O	NN

relation	NN
O	NN

between	IN
O	NN

these	DT
O	NN

two	CD
O	NN

conditions	NNS
O	VBP

must	MD
O	NNP

be	VB
O	NN

further	RB
O	NN

studied	VBN
O	NN

Postnatal	JJ
O	NN

growth	NN
O	NN

was	VBD
O	NN

prospectively	RB
O	NN

measured	VBN
O	NN

from	IN
O	NN

birth	NN
O	NN

to	TO
O	NN

1	CD
O	NN

y	NN
O	NN

in	IN
O	NN

54	CD
O	NN

term	NN
O	NN

infants	NNS
O	NN

born	VBN
O	NN

small	JJ
O	NN

for	IN
O	NN

gestational	JJ
O	NN

age	NN
O	NN

(	NN
O	NN

SGA	NNP
O	NNP

)	NN
O	NN

,	,
O	NN

fed	VBN
O	NN

either	DT
O	NN

breast	NN
O	NN

milk	NN
O	NN

or	CC
O	NN

a	DT
O	NN

standard	JJ
O	NN

term	NN
O	NN

infant	NN
O	NN

formula	NN
O	NN

Breastfeeding	VBG
O	NN

was	VBD
O	NN

associated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

0.36	CD
O	NN

and	CC
O	NN

0.64	CD
O	NN

standard	JJ
O	NN

deviation	NN
O	NN

(	NN
O	NN

SD	NN
O	NN

)	NN
O	NN

increase	NN
O	NN

in	IN
O	NN

weight	NN
O	NN

at	IN
O	NN

2	CD
O	NN

weeks	NNS
O	NN

and	CC
O	NN

3	CD
O	NN

months	NNS
O	NN

of	IN
O	NN

age	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

,	,
O	NN

which	WDT
O	NN

persisted	VBD
O	NN

beyond	IN
O	NN

the	DT
O	NN

breastfeeding	VBG
O	NN

period	NN
O	NN

(	NN
O	NN

0.64	CD
O	NN

SD	NN
O	NN

at	IN
O	NN

1	CD
O	NN

y	NN
O	NN

)	NN
O	NN

Breastfed	VBN
O	NN

infants	NNS
O	NN

also	RB
O	NN

showed	VBD
O	NN

greater	JJR
O	NN

catch-up	NN
O	NN

growth	NN
O	NN

in	IN
O	NN

head	NN
O	NN

circumference	NN
O	NN

(	NN
O	NN

SD	NN
O	NN

score	NN
O	NN

(	NN
O	NN

SDS	NN
O	NN

)	NN
O	NN

0.53	CD
O	NN

higher	JJR
O	NN

at	IN
O	NN

3	CD
O	NN

months	NNS
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

greater	JJR
O	NN

body	NN
O	NN

length	NN
O	NN

gain	NN
O	NN

(	NN
O	NN

SDS	NN
O	NN

0.68	CD
O	NN

higher	JJR
O	NN

at	IN
O	NN

6	CD
O	NN

months	NNS
O	NN

)	NN
O	NN

This	DT
O	NN

increased	VBN
O	NN

growth	NN
O	NN

was	VBD
O	NN

independent	JJ
O	NN

of	IN
O	NN

potentially	RB
O	NN

confounding	VBG
O	NN

obstetric	JJ
O	NN

,	,
O	NN

social	JJ
O	NN

and	CC
O	NN

demographic	JJ
O	NN

factors	NNS
O	NN

Our	PRP$
O	NN

findings	NNS
O	VBP

suggest	VBP
O	NN

that	IN
O	NN

breastfeeding	VBG
O	NN

may	MD
O	NNP

promote	VB
O	NN

faster	RBR
O	NN

growth	NN
O	NN

in	IN
O	NN

infants	NNS
O	NN

compromised	VBN
O	NN

by	IN
O	NN

poor	JJ
O	NN

growth	NN
O	NN

in	IN
O	NN

utero	NN
O	NN

SGA	NNP
O	NNP

infants	NNS
O	NN

may	MD
O	NNP

be	VB
O	NN

programmed	VBN
O	NN

for	IN
O	NN

a	DT
O	NN

number	NN
O	NN

of	IN
O	NN

adverse	JJ
O	NN

outcomes	NNS
O	VBP

;	:
O	NN

the	DT
O	NN

possibility	NN
O	NN

that	IN
O	NN

such	JJ
O	NN

events	NNS
O	NN

are	VBP
O	NN

altered	JJ
O	NN

by	IN
O	NN

choice	NN
O	NN

of	IN
O	NN

postnatal	JJ
O	NN

diet	NN
O	NN

is	VBZ
O	NN

a	DT
O	NN

key	JJ
O	NN

issue	NN
O	NN

for	IN
O	NN

future	JJ
O	NN

research	NN
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Few	JJ
O	NN

studies	NNS
O	VBP

have	VB
O	NN

explored	VBN
O	NN

the	DT
O	NN

health	NN
O	NN

practices	NNS
O	VBP

of	IN
O	NN

critical	JJ
O	NN

care	NN
O	NN

nurses	NNS
O	NN

Critical	JJ
O	NN

care	NN
O	NN

nurses	NNS
O	NN

routinely	RB
O	NN

teach	VB
O	NN

patients	NNS
O	NN

about	IN
O	NN

using	VBG
O	NN

healthy	JJ
O	NN

practices	NNS
O	VBP

such	JJ
O	NN

as	IN
O	NN

low-fat	JJ
O	NN

diets	NNS
O	NN

,	,
O	NN

exercise	NN
O	NN

,	,
O	NN

and	CC
O	NN

routine	JJ
O	NN

screening	VBG
O	NN

examinations	NNS
O	VBP

However	RB
O	NN

,	,
O	NN

it	PRP
O	NN

may	MD
O	NNP

be	VB
O	NN

even	RB
O	NN

more	RBR
O	NN

important	JJ
O	NN

that	IN
O	NN

the	DT
O	NN

nurses	NNS
O	NN

themselves	PRP
O	VBP

have	VB
O	NN

a	DT
O	NN

healthy	JJ
O	NN

lifestyle	NN
O	NN

,	,
O	NN

thus	RB
O	NN

serving	VBG
O	NN

as	IN
O	NN

role	NN
O	NN

models	NNS
O	NN

for	IN
O	NN

patients	NNS
O	NN

Nurses	NNS
O	NN

are	VBP
O	NN

selling	VBG
O	NN

a	DT
O	NN

product	NN
O	NN

,	,
O	NN

and	CC
O	NN

that	IN
O	NN

product	NN
O	NN

is	VBZ
O	NN

health	NN
O	NN

The	DT
O	NN

best	RB
O	NN

salespersons	NNS
O	NN

are	VBP
O	NN

those	DT
O	NNP

who	WP
O	VBP

are	VBP
O	NN

genuinely	RB
O	NN

committed	JJ
O	NN

to	TO
O	NN

their	PRP$
O	NN

product	NN
O	NN

and	CC
O	NN

model	NN
O	NN

its	PRP$
O	NN

benefits	NNS
O	NN

Therefore	RB
O	NN

,	,
O	NN

critical	JJ
O	NN

care	NN
O	NN

nurses	NNS
O	NN

'	POS
O	NN

healthful	JJ
O	NN

practices	NNS
O	VBP

can	MD
O	NNP

have	VB
O	NN

a	DT
O	NN

profound	JJ
O	NN

effect	NN
O	NN

on	IN
O	NN

their	PRP$
O	NN

patients	NNS
O	NN

OBJECTIVES	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

purpose	NN
O	NN

of	IN
O	NN

this	DT
O	NN

descriptive	JJ
O	NN

exploratory	JJ
O	NN

study	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

examine	VB
O	NN

critical	JJ
O	NN

care	NN
O	NN

nurses	NNS
O	NN

'	POS
O	NN

responses	NNS
O	NN

to	TO
O	NN

three	CD
O	NN

questions	NNS
O	NN

about	IN
O	NN

health	NN
O	NN

practices	NNS
O	VBP

in	IN
O	NN

their	PRP$
O	NN

daily	RB
O	NN

lives	NNS
O	NN

:	:
O	NN

(	NN
O	NN

1	CD
O	NN

)	NN
O	NN

What	WDT
O	NN

are	VBP
O	NN

critical	JJ
O	NN

care	NN
O	NN

nurses	NNS
O	NN

doing	VBG
O	NN

currently	RB
O	NN

to	TO
O	NN

stay	VB
O	NNP

healthy	JJ
O	NN

?	.
O	NN

(	NN
O	NN

2	CD
O	NN

)	NN
O	NN

Do	VB
O	NN

they	PRP
O	VBP

anticipate	VB
O	NN

making	VBG
O	NN

any	DT
O	NN

changes	NNS
O	VBP

in	IN
O	NN

their	PRP$
O	NN

lifestyle	NN
O	NN

in	IN
O	NN

the	DT
O	NN

future	JJ
O	NN

?	.
O	NN

(	NN
O	NN

3	CD
O	NN

)	NN
O	NN

Would	MD
O	NNP

they	PRP
O	VBP

recommend	VB
O	NN

their	PRP$
O	NN

lifestyle	NN
O	NN

to	TO
O	NN

their	PRP$
O	NN

patients	NNS
O	NN

?	.
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

One	CD
O	NN

hundred	CD
O	NN

twenty-seven	CD
O	NN

critical	JJ
O	NN

care	NN
O	NN

nurses	NNS
O	NN

attending	VBG
O	NN

a	DT
O	NN

midwestern	JJ
O	NN

critical	JJ
O	NN

care	NN
O	NN

conference	NN
O	NN

completed	VBN
O	NN

a	DT
O	NN

two-part	JJ
O	NN

questionnaire	NN
O	NN

designed	VBN
O	NN

to	TO
O	NN

produce	VB
O	NN

a	DT
O	NN

health	NN
O	NN

profile	NN
O	NN

In	IN
O	NN

a	DT
O	NN

man-on-the-street	JJ
O	NN

approach	NN
O	NN

,	,
O	NN

23	CD
O	NN

nurses	NNS
O	NN

participated	VBD
O	NN

in	IN
O	NN

an	DT
O	NN

interview	NN
O	NN

via	IN
O	NN

video	NN
O	NN

camera	NN
O	NN

Descriptive	JJ
O	NN

statistics	NNS
O	NN

were	VBD
O	NN

used	VBN
O	NN

to	TO
O	NN

analyze	VB
O	NN

the	DT
O	NN

data	NNS
O	NN

retrieved	VBN
O	NN

from	IN
O	NN

the	DT
O	NN

questionnaires	NNS
O	NN

Interviews	NNS
O	NN

were	VBD
O	NN

transcribed	VBN
O	NN

verbatim	JJ
O	NN

and	CC
O	NN

analyzed	VBN
O	NN

for	IN
O	NN

themes	NNS
O	NN

with	IN
O	NN

a	DT
O	NN

constant	JJ
O	NN

comparative	JJ
O	NN

method	NN
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

More	RBR
O	NN

than	IN
O	NN

70	CD
O	NN

%	NN
O	NN

of	IN
O	NN

the	DT
O	NN

critical	JJ
O	NN

care	NN
O	NN

nurses	NNS
O	NN

who	WP
O	VBP

responded	VBD
O	NN

engage	VB
O	NN

in	IN
O	NN

exercise	NN
O	NN

and	CC
O	NN

follow	VB
O	NNP

a	DT
O	NN

healthy	JJ
O	NN

,	,
O	NN

low-fat	JJ
O	NN

diet	NN
O	NN

Seventy-one	CD
O	NN

percent	NN
O	NN

said	VBD
O	NN

that	IN
O	NN

they	PRP
O	VBP

anticipate	VB
O	NN

making	VBG
O	NN

a	DT
O	NN

change	NN
O	NN

in	IN
O	NN

their	PRP$
O	NN

lifestyle	NN
O	NN

in	IN
O	NN

the	DT
O	NN

future	JJ
O	NN

,	,
O	NN

and	CC
O	NN

70	CD
O	NN

%	NN
O	NN

said	VBD
O	NN

that	IN
O	NN

they	PRP
O	VBP

would	MD
O	NNP

recommend	VB
O	NN

their	PRP$
O	NN

lifestyle	NN
O	NN

to	TO
O	NN

their	PRP$
O	NN

patients	NNS
O	NN

Five	CD
O	NN

themes	NNS
O	NN

emerged	VBD
O	NN

from	IN
O	NN

the	DT
O	NN

videotaped	JJ
O	NN

interviews	NNS
O	NN

:	:
O	NN

(	NN
O	NN

1	CD
O	NN

)	NN
O	NN

Heart-healthy	JJ
O	NN

practices	NNS
O	VBP

predominated	VBD
O	NN

the	DT
O	NN

responses	NNS
O	NN

(	NN
O	NN

2	CD
O	NN

)	NN
O	NN

Incorporating	VBG
O	NN

a	DT
O	NN

healthy	JJ
O	NN

lifestyle	NN
O	NN

was	VBD
O	NN

easy	JJ
O	NN

for	IN
O	NN

some	DT
O	NN

and	CC
O	NN

a	DT
O	NN

struggle	NN
O	NN

for	IN
O	NN

others	NNS
O	VBP

(	NN
O	NN

3	CD
O	NN

)	NN
O	NN

Critical	JJ
O	NN

care	NN
O	NN

nurses	NNS
O	NN

readily	RB
O	NN

listed	VBN
O	NN

barriers	NNS
O	VBP

to	TO
O	NN

healthy	JJ
O	NN

living	VBG
O	NN

(	NN
O	NN

4	CD
O	NN

)	NN
O	NN

The	DT
O	NN

nurses	NNS
O	NN

had	VBD
O	NN

a	DT
O	NN

positive	JJ
O	NN

attitude	NN
O	NN

about	IN
O	NN

their	PRP$
O	NN

healthy	JJ
O	NN

lifestyles	NNS
O	NN

and	CC
O	NN

felt	VBD
O	NN

optimistic	JJ
O	NN

about	IN
O	NN

being	VBG
O	NN

role	NN
O	NN

models	NNS
O	NN

for	IN
O	NN

their	PRP$
O	NN

patients	NNS
O	NN

(	NN
O	NN

5	CD
O	NN

)	NN
O	NN

Future	JJ
O	NN

plans	NNS
O	NN

were	VBD
O	NN

either	DT
O	NN

singular	JJ
O	NN

in	IN
O	NN

focus	NN
O	NN

or	CC
O	NN

limited	JJ
O	NN

to	TO
O	NN

maintenance	NN
O	NN

of	IN
O	NN

current	JJ
O	NN

health	NN
O	NN

habits	NNS
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

The	DT
O	NN

majority	NN
O	NN

of	IN
O	NN

the	DT
O	NN

nurses	NNS
O	NN

reported	VBN
O	NN

practicing	VBG
O	NN

a	DT
O	NN

healthy	JJ
O	NN

lifestyle	NN
O	NN

and	CC
O	NN

thought	VBN
O	NN

that	IN
O	NN

they	PRP
O	VBP

were	VBD
O	NN

good	JJ
O	NN

role	NN
O	NN

models	NNS
O	NN

for	IN
O	NN

patients	NNS
O	NN

Cytochrome	NN
O	NN

P450	NN
O	NN

1A1	NN
O	NN

(	NN
O	NN

CYP1A1	NN
O	NN

)	NN
O	NN

and	CC
O	NN

glutathione	NN
O	NN

S-transferase	NN
O	NN

M1	NN
O	NN

(	NN
O	NN

GSTM1	NN
O	NN

)	NN
O	NN

genetic	JJ
O	NN

polymorphisms	NNS
O	NN

are	VBP
O	NN

involved	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

activation	NN
O	NN

and	CC
O	NN

detoxification	NN
O	NN

of	IN
O	NN

chemical	NN
O	NN

carcinogens	NNS
O	NN

found	VBN
O	NN

in	IN
O	NN

tobacco	NN
O	NN

smoke	NN
O	NN

;	:
O	NN

thus	RB
O	NN

they	PRP
O	VBP

may	MD
O	NNP

influence	NN
O	NN

host	NN
O	NN

susceptibility	NN
O	NN

to	TO
O	NN

lung	NN
D	NN

cancer	NN
D	NN

In	IN
O	NN

this	DT
O	NN

study	NN
O	NN

at	IN
O	NN

Massachusetts	NNP
O	NN

General	NNP
O	NNP

Hospital	NNP
O	NNP

(	NN
O	NN

Boston	NNP
O	NNP

,	,
O	NN

MA	NNP
O	NNP

,	,
O	NN

USA	NNP
O	NNP

)	NN
O	NN

of	IN
O	NN

416	CD
O	NN

cases	NNS
O	NN

and	CC
O	NN

446	CD
O	NN

controls	NNS
O	VBP

(	NN
O	NN

mostly	RB
O	NN

White	NNP
O	NNP

)	NN
O	NN

we	PRP
O	VBP

evaluated	VBN
O	NN

the	DT
O	NN

association	NN
O	NN

between	IN
O	NN

the	DT
O	NN

CYP1A1	NN
O	NN

MspI	NN
O	NN

and	CC
O	NN

GSTM1	NN
O	NN

polymorphisms	NNS
O	NN

and	CC
O	NN

lung	NN
D	NN

cancer	NN
D	NN

risk	NN
O	NN

,	,
O	NN

and	CC
O	NN

their	PRP$
O	NN

interaction	NN
O	NN

with	IN
O	NN

cigarette	NN
O	NN

smoke	NN
O	NN

The	DT
O	NN

CYP1A1	NN
O	NN

MspI	NN
O	NN

heterozygous	JJ
O	NN

genotype	NN
O	NN

was	VBD
O	NN

present	JJ
O	NN

in	IN
O	NN

18	CD
O	NN

percent	NN
O	NN

of	IN
O	NN

cases	NNS
O	NN

and	CC
O	NN

16	CD
O	NN

percent	NN
O	NN

of	IN
O	NN

controls	NNS
O	VBP

,	,
O	NN

and	CC
O	NN

one	CD
O	NN

percent	NN
O	NN

of	IN
O	NN

cases	NNS
O	NN

and	CC
O	NN

controls	NNS
O	VBP

were	VBD
O	NN

CYP1A1	NN
O	NN

MspI	NN
O	NN

homozygous	JJ
O	NN

variant	JJ
O	NN

The	DT
O	NN

GSTM1	NN
O	NN

null	JJ
O	NN

genotype	NN
O	NN

was	VBD
O	NN

detected	VBN
O	NN

in	IN
O	NN

54	CD
O	NN

percent	NN
O	NN

of	IN
O	NN

cases	NNS
O	NN

and	CC
O	NN

52	CD
O	NN

percent	NN
O	NN

of	IN
O	NN

controls	NNS
O	VBP

After	IN
O	NN

adjusting	VBG
O	NN

for	IN
O	NN

age	NN
O	NN

,	,
O	NN

gender	NN
O	NN

,	,
O	NN

pack-years	NNS
O	NN

of	IN
O	NN

smoking	NN
O	NN

,	,
O	NN

and	CC
O	NN

years	NNS
O	NN

since	IN
O	NN

quitting	VBG
O	NN

smoking	NN
O	NN

,	,
O	NN

while	IN
O	NN

neither	DT
O	NN

the	DT
O	NN

CYP1A1	NN
O	NN

MspI	NN
O	NN

heterozygous	JJ
O	NN

genotype	NN
O	NN

alone	RB
O	NN

nor	CC
O	NN

the	DT
O	NN

GSTM1	NN
O	NN

null	JJ
O	NN

genotype	NN
O	NN

alone	RB
O	NN

were	VBD
O	NN

associated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

significant	JJ
O	NN

increase	NN
O	NN

in	IN
O	NN

lung	NN
D	NN

cancer	NN
D	NN

risk	NN
O	NN

,	,
O	NN

having	VBG
O	NN

both	DT
O	NN

genetic	JJ
O	NN

traits	NNS
O	NN

was	VBD
O	NN

associated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

twofold	RB
O	NN

increase	NN
O	NN

in	IN
O	NN

risk	NN
O	NN

(	NN
O	NN

95	CD
O	NN

percent	NN
O	NN

confidence	NN
O	NN

interval	NN
O	NN

(	NN
O	NN

CI	NN
O	NN

)	NN
O	NN

=	JJ
O	NN

1.0-3.4	CD
O	NN

)	NN
O	NN

Our	PRP$
O	NN

data	NNS
O	NN

did	VBD
O	NNP

not	RB
O	NN

provide	VB
O	NN

enough	RB
O	NN

evidence	NN
O	NN

for	IN
O	NN

a	DT
O	NN

substantial	JJ
O	NN

modification	NN
O	NN

of	IN
O	NN

the	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

pack-years	NNS
O	NN

on	IN
O	NN

lung	NN
D	NN

cancer	NN
D	NN

risk	NN
O	NN

by	IN
O	NN

the	DT
O	NN

CYP1A1	NN
O	NN

MspI	NN
O	NN

and	CC
O	NN

GSTM1	NN
O	NN

genotypes	NNS
O	NN

However	RB
O	NN

,	,
O	NN

limitations	NNS
O	NN

of	IN
O	NN

our	PRP$
O	NN

study	NN
O	NN

preclude	VB
O	NN

a	DT
O	NN

conclusion	NN
O	NN

about	IN
O	NN

this	DT
O	NN

potential	JJ
O	NN

interaction	NN
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Thrombolytic	JJ
T	NN

treatment	NN
T	NN

has	VBZ
O	NN

been	VBN
O	NN

shown	VBN
O	NN

to	TO
O	NN

accelerate	VB
O	NN

resolution	NN
O	NN

of	IN
O	NN

major	JJ
D	NN

pulmonary	JJ
D	NN

embolism	NN
D	NN

and	CC
O	NN

lead	JJ
O	NN

to	TO
O	NN

a	DT
O	NN

rapid	JJ
O	NN

improvement	NN
O	NN

of	IN
O	NN

right-side	JJ
O	NN

hemodynamics	NNS
O	NN

However	RB
O	NN

,	,
O	NN

the	DT
O	NN

association	NN
O	NN

between	IN
O	NN

these	DT
O	NN

favorable	JJ
O	NN

effects	NNS
O	NN

and	CC
O	NN

the	DT
O	NN

clinical	JJ
O	NN

outcome	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

who	WP
O	VBP

have	VB
O	NN

no	DT
O	NN

severe	JJ
O	NN

hemodynamic	JJ
D	NN

compromise	NN
D	NN

at	IN
O	NN

presentation	NN
O	NN

remains	VBZ
O	NNP

unknown	JJ
O	NN

METHODS	NNS
O	VBP

AND	CC
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

present	JJ
O	NN

multicenter	JJ
O	NN

registry	NN
O	NN

included	VBN
O	NN

719	CD
O	NN

consecutive	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

major	JJ
D	NN

pulmonary	JJ
D	NN

embolism	NN
D	NN

according	VBG
O	NN

to	TO
O	NN

clinical	JJ
O	NN

,	,
O	NN

echocardiographic	JJ
O	NN

,	,
O	NN

scintigraphic	JJ
O	NN

,	,
O	NN

and	CC
O	NN

cardiac	JJ
O	NN

catheterization	NN
O	NN

criteria	NNS
O	NN

Symptom	NN
O	NN

onset	NN
O	NN

was	VBD
O	NN

acute	JJ
O	NN

(	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

48	CD
O	NN

hours	NNS
O	NN

)	NN
O	NN

in	IN
O	NN

63	CD
O	NN

%	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

All	DT
O	NN

patients	NNS
O	NN

were	VBD
O	NN

hemodynamically	RB
O	NN

stable	JJ
O	NN

(	NN
O	NN

ie	FW
O	FW

,	,
O	NN

without	IN
O	NN

evidence	NN
O	NN

of	IN
O	NN

cardiogenic	JJ
D	NN

shock	NN
D	NN

)	NN
O	NN

at	IN
O	NN

presentation	NN
O	NN

treatment	NN
T	NN

(	NN
O	NN

within	IN
O	NN

24	CD
O	NN

hours	NNS
O	NN

of	IN
O	NN

diagnosis	NN
O	NN

)	NN
O	NN

was	VBD
O	NN

given	VBN
O	NN

to	TO
O	NN

169	CD
O	NN

patients	NNS
O	NN

(	NN
O	NN

23.5	CD
O	NN

%	NN
O	NN

)	NN
O	NN

,	,
O	NN

whereas	IN
O	NN

the	DT
O	NN

remaining	VBG
O	NN

550	CD
O	NN

patients	NNS
O	NN

were	VBD
O	NN

initially	RB
O	NN

treated	VBN
O	NN

with	IN
O	NN

heparin	NN
T	NN

alone	RB
O	NN

Overall	JJ
O	NN

30-day	JJ
O	NN

mortality	NN
O	NN

was	VBD
O	NN

significantly	RB
O	NN

lower	JJR
O	NN

in	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

who	WP
O	VBP

received	VBN
O	NN

thrombolytic	JJ
T	NN

agents	NNS
T	NN

(	NN
O	NN

4.7	CD
O	NN

versus	CC
O	NN

11.1	CD
O	NN

%	NN
O	NN

,	,
O	NN

P=.016	NN
O	NN

)	NN
O	NN

Clinical	JJ
O	NN

factors	NNS
O	NN

associated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

higher	JJR
O	NN

death	NN
O	NN

rate	NN
O	NN

were	VBD
O	NN

syncope	NN
D	NN

(	NN
O	NN

P=.012	NN
O	NN

)	NN
O	NN

,	,
O	NN

arterial	JJ
D	NN

hypotension	NN
D	NN

(	NN
O	NN

P=.021	NN
O	NN

)	NN
O	NN

,	,
O	NN

history	NN
O	NN

of	IN
O	NN

congestive	JJ
D	NN

heart	NN
D	NN

failure	NN
D	NN

(	NN
O	NN

P=.013	NN
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

chronic	JJ
D	NN

pulmonary	JJ
D	NN

disease	NN
D	NN

(	NN
O	NN

P=.032	NN
O	NN

)	NN
O	NN

However	RB
O	NN

,	,
O	NN

only	RB
O	NN

primary	JJ
D	NN

thrombolysis	NN
D	NN

was	VBD
O	NN

found	VBN
O	NN

by	IN
O	NN

multivariate	JJ
O	NN

analysis	NN
O	NN

to	TO
O	NN

be	VB
O	NN

an	DT
O	NN

independent	JJ
O	NN

predictor	NN
O	NN

of	IN
O	NN

survival	NN
O	NN

(	NN
O	NN

odds	NNS
O	NN

ratio	NN
O	NN

for	IN
O	NN

in-hospital	JJ
O	NN

death	NN
O	NN

,	,
O	NN

0.46	CD
O	NN

;	:
O	NN

95	CD
O	NN

%	NN
O	NN

confidence	NN
O	NN

interval	NN
O	NN

,	,
O	NN

0.21	CD
O	NN

to	TO
O	NN

1.00	CD
O	NN

)	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Patients	NNS
O	NN

who	WP
O	VBP

underwent	VBD
O	NN

early	RB
O	NN

thrombolytic	JJ
O	NN

treatment	NN
O	NN

had	VBD
O	NN

a	DT
O	NN

reduced	VBN
O	NN

rate	NN
O	NN

of	IN
O	NN

recurrent	JJ
O	NN

pulmonary	JJ
O	NN

embolism	NN
O	NN

(	NN
O	NN

7.7	CD
O	NN

versus	CC
O	NN

18.7	CD
O	NN

%	NN
O	NN

,	,
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

.001	CD
O	NN

)	NN
O	NN

but	CC
O	NNP

also	RB
O	NN

a	DT
O	NN

higher	JJR
O	NN

frequency	NN
O	NN

of	IN
O	NN

major	JJ
O	NN

bleeding	VBG
O	NN

episodes	NNS
O	NN

(	NN
O	NN

21.9	CD
O	NN

%	NN
O	NN

versus	CC
O	NN

7.8	CD
O	NN

%	NN
O	NN

,	,
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

.001	CD
O	NN

)	NN
O	NN

Cerebral	JJ
D	NN

bleeding	NN
D	NN

occurred	VBD
O	NN

in	IN
O	NN

2	CD
O	NN

patients	NNS
O	NN

in	IN
O	NN

each	DT
O	NN

treatment	NN
O	NN

group	NN
O	NN

,	,
O	NN

and	CC
O	NN

1	CD
O	NN

patient	NN
O	NN

in	IN
O	NN

each	DT
O	NN

group	NN
O	NN

died	VBD
O	NN

of	IN
O	NN

a	DT
O	NN

bleeding	NN
D	NN

complication	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

The	DT
O	NN

results	NNS
O	VBP

of	IN
O	NN

our	PRP$
O	NN

study	NN
O	NN

suggest	VBP
O	NN

that	IN
O	NN

thrombolysis	NN
T	NN

may	MD
O	NNP

favorably	RB
O	NN

affect	VB
O	NN

the	DT
O	NN

clinical	JJ
O	NN

outcome	NN
O	NN

of	IN
O	NN

hemodynamically	RB
O	NN

stable	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

major	JJ
D	NN

pulmonary	JJ
D	NN

embolism	NN
D	NN

A	DT
O	NN

66-year-old	JJ
O	NN

male	JJ
O	NN

engineer	NN
O	NN

diagnosed	VBN
O	NN

with	IN
O	NN

malignant	JJ
D	NN

pleural	JJ
D	NN

mesothelioma	NN
D	NN

4	CD
O	NN

years	NNS
O	NN

previously	RB
O	NN

had	VBD
O	NN

thoracotomy	NN
T	NN

,	,
T	NN

radiotherapy	NN
T	NN

,	,
T	NN

and	CC
T	NN

chemotherapy	NN
T	NN

He	PRP
O	VBP

was	VBD
O	NN

followed	VBN
O	NN

regularly	RB
O	NN

with	IN
O	NN

chest	NN
O	NN

computed	VBN
O	NN

tomography	NN
O	NN

(	NN
O	NN

CT	NN
O	NN

)	NN
O	NN

scan	VB
O	NN

and	CC
O	NN

had	VBD
O	NN

been	VBN
O	NN

asymptomatic	JJ
O	NN

During	IN
O	NN

one	CD
O	NN

of	IN
O	NN

his	PRP$
O	NN

physical	JJ
O	NN

examinations	NNS
O	VBP

,	,
O	NN

routine	JJ
O	NN

sigmoidoscopy	NN
O	NN

showed	VBD
O	NN

incidental	JJ
O	NN

colonic	JJ
D	NN

polyps	NNS
D	NN

which	WDT
O	NN

were	VBD
O	NN

biopsied	VBN
O	NN

Subsequently	RB
O	NN

,	,
O	NN

recurrence	NN
O	NN

of	IN
O	NN

pleural	JJ
D	NN

mesothelioma	NN
D	NN

and	CC
O	NN

peritoneal	JJ
O	NN

involvement	NN
O	NN

by	IN
O	NN

mesothelioma	NN
D	NN

was	VBD
O	NN

documented	VBN
O	NN

Two	CD
O	NN

of	IN
O	NN

the	DT
O	NN

polyps	NNS
O	NN

showed	VBD
O	NN

metastatic	JJ
D	NN

malignant	JJ
D	NN

mesothelioma	NN
D	NN

in	IN
O	NN

the	DT
O	NN

lamina	NN
O	NN

propia	NN
O	NN

which	WDT
O	NN

strongly	RB
O	NN

resembled	VBD
O	NN

adenocarcinoma	NN
D	NN

histologically	RB
O	NN

causing	VBG
O	NN

difficulty	NN
O	NN

in	IN
O	NN

making	VBG
O	NN

definitive	JJ
O	NN

diagnosis	NN
O	NN

Review	NN
O	NN

of	IN
O	NN

the	DT
O	NN

literature	NN
O	NN

disclosed	VBN
O	NN

no	DT
O	NN

previously	RB
O	NN

documented	VBN
O	NN

similar	JJ
O	NN

occurrence	NN
O	NN

This	DT
O	NN

case	NN
O	NN

shows	NNS
O	VBP

the	DT
O	NN

importance	NN
O	NN

of	IN
O	NN

clinical	JJ
O	NN

history	NN
O	NN

and	CC
O	NN

ancillary	JJ
O	NN

laboratory	NN
O	NN

procedures	NNS
O	VBP

such	JJ
O	NN

as	IN
O	NN

immunohistochemistry	NN
O	NN

and	CC
O	NN

electron	NN
O	NN

microscopy	NN
O	NN

to	TO
O	NN

avoid	VB
O	NN

diagnostic	JJ
O	NN

pitfalls	NNS
O	NN

The	DT
O	NN

authors	NNS
O	NN

report	NN
O	NN

the	DT
O	NN

postoperative	JJ
O	NN

magnetic	JJ
O	NN

resonance	NN
O	NN

(	NN
O	NN

MR	NN
O	NN

)	NN
O	NN

imaging	NN
O	NN

findings	NNS
O	VBP

in	IN
O	NN

36	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

Parkinson	NNP
D	NNP

's	POS
D	NN

disease	NN
D	NN

who	WP
O	VBP

underwent	VBD
O	NN

unilateral	JJ
T	NN

microelectrode-guided	JJ
T	NN

posteroventral	JJ
T	NN

pallidotomy	NN
T	NN

The	DT
O	NN

lesions	NNS
O	NN

were	VBD
O	NN

placed	VBN
O	NN

within	IN
O	NN

1	CD
O	NN

mm	NN
O	NN

of	IN
O	NN

the	DT
O	NN

ventral	JJ
O	NN

border	NN
O	NN

of	IN
O	NN

the	DT
O	NN

globus	NN
O	NN

pallidus	NN
O	NN

internus	NN
O	NN

(	NN
O	NN

GPi	NN
O	NN

)	NN
O	NN

to	TO
O	NN

include	VBP
O	NN

pallidothalamic	JJ
O	NN

outflow	NN
O	NN

pathways	NNS
O	VBP

Sequential	JJ
O	NN

MR	NN
O	NN

studies	NNS
O	VBP

were	VBD
O	NN

obtained	VBN
O	NN

within	IN
O	NN

1	CD
O	NN

to	TO
O	NN

3	CD
O	NN

days	NNS
O	NN

postoperatively	RB
O	NN

and	CC
O	NN

at	IN
O	NN

6-month	JJ
O	NN

follow-up	JJ
O	NN

examination	NN
O	NN

Thirty-four	CD
O	NN

(	NN
O	NN

94	CD
O	NN

%	NN
O	NN

)	NN
O	NN

of	IN
O	NN

the	DT
O	NN

36	CD
O	NN

patients	NNS
O	NN

enjoyed	VBN
O	NN

sustained	JJ
O	NN

moderate	JJ
O	NN

or	CC
O	NN

marked	JJ
O	NN

improvement	NN
O	NN

of	IN
O	NN

their	PRP$
O	NN

parkinsonian	NN
D	NN

symptoms	NNS
D	NN

6	CD
O	NN

months	NNS
O	NN

postoperatively	RB
O	NN

Transient	JJ
O	NN

side	NN
O	NN

effects	NNS
O	NN

occurred	VBD
O	NN

in	IN
O	NN

five	CD
O	NN

patients	NNS
O	NN

(	NN
O	NN

14	CD
O	NN

%	NN
O	NN

)	NN
O	NN

,	,
O	NN

but	CC
O	NNP

there	RB
O	NN

were	VBD
O	NN

no	DT
O	NN

persistent	JJ
O	NN

complications	NNS
O	NN

The	DT
O	NN

pallidal	JJ
O	NN

radiofrequency	NN
O	NN

lesions	NNS
O	NN

were	VBD
O	NN

prolate	JJ
O	NN

spheroid	NN
O	NN

shaped	JJ
O	NN

and	CC
O	NN

were	VBD
O	NN

composed	VBN
O	NN

of	IN
O	NN

three	CD
O	NN

concentric	JJ
O	NN

zones	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

early	RB
O	NN

postoperative	JJ
O	NN

studies	NNS
O	VBP

The	DT
O	NN

mean	VB
O	NN

volume	NN
O	NN

of	IN
O	NN

the	DT
O	NN

middle	JJ
O	NN

zone	NN
O	NN

,	,
O	NN

corresponding	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

area	NN
O	NN

of	IN
O	NN

hemorrhagic	JJ
D	NN

coagulation	NN
D	NN

necrosis	NN
D	NN

,	,
O	NN

was	VBD
O	NN

44.4	CD
O	NN

+/-	CC
O	NN

17.6	CD
O	NN

mm3	NN
O	NN

;	:
O	NN

the	DT
O	NN

mean	VB
O	NN

lesion	NN
O	NN

volume	NN
O	NN

as	IN
O	NN

defined	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

outer	JJ
O	NN

zone	NN
O	NN

,	,
O	NN

corresponding	JJ
O	NN

to	TO
O	NN

perilesional	JJ
D	NN

edema	NN
D	NN

,	,
O	NN

was	VBD
O	NN

262.2	CD
O	NN

+/-	CC
O	NN

111.6	CD
O	NN

mm3	NN
O	NN

Additional	JJ
O	NN

edema	NN
D	NN

spreading	VBG
O	NN

to	TO
O	NN

the	DT
O	NN

internal	JJ
O	NN

capsule	NN
O	NN

was	VBD
O	NN

noted	VBN
O	NN

in	IN
O	NN

32	CD
O	NN

of	IN
O	NN

34	CD
O	NN

cases	NNS
O	NN

and	CC
O	NN

to	TO
O	NN

the	DT
O	NN

optic	JJ
O	NN

tract	NN
O	NN

in	IN
O	NN

11	CD
O	NN

of	IN
O	NN

34	CD
O	NN

cases	NNS
O	NN

In	IN
O	NN

two	CD
O	NN

patients	NNS
O	NN

small	JJ
O	NN

ischemic	JJ
D	NN

infarctions	NNS
D	NN

involving	VBG
O	NN

the	DT
O	NN

corona	NN
O	NN

radiata	NN
O	NN

were	VBD
O	NN

found	VBN
O	NN

,	,
O	NN

and	CC
O	NN

in	IN
O	NN

one	CD
O	NN

a	DT
O	NN

venous	JJ
D	NN

infarction	NN
D	NN

was	VBD
O	NN

detected	VBN
O	NN

Ischemic	JJ
D	NN

infarction	NN
D	NN

resulted	VBD
O	NN

in	IN
O	NN

mild	JJ
O	NN

transient	JJ
O	NN

Broca	NN
D	NN

's	POS
D	NN

aphasia	NN
D	NN

in	IN
O	NN

one	CD
O	NN

patient	NN
O	NN

,	,
O	NN

but	CC
O	NNP

there	RB
O	NN

was	VBD
O	NN

no	DT
O	NN

detectable	JJ
O	NN

neurological	JJ
O	NN

deficit	NN
O	NN

in	IN
O	NN

the	DT
O	NN

other	JJ
O	NN

two	CD
O	NN

The	DT
O	NN

mean	VB
O	NN

volume	NN
O	NN

of	IN
O	NN

late-phase	JJ
O	NN

(	NN
O	NN

6	CD
O	NN

months	NNS
O	NN

)	NN
O	NN

lesions	NNS
O	NN

was	VBD
O	NN

22	CD
O	NN

+/-	CC
O	NN

28.8	CD
O	NN

mm3	NN
O	NN

In	IN
O	NN

three	CD
O	NN

patients	NNS
O	NN

no	DT
O	NN

lesion	NN
O	NN

was	VBD
O	NN

identified	VBN
O	NN

despite	IN
O	NN

sustained	JJ
O	NN

clinical	JJ
O	NN

improvement	NN
O	NN

The	DT
O	NN

lesion	NN
O	NN

was	VBD
O	NN

located	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

posteroventral	JJ
O	NN

GPi	NN
O	NN

in	IN
O	NN

all	DT
O	NN

cases	NNS
O	NN

except	IN
O	NN

in	IN
O	NN

one	CD
O	NN

patient	NN
O	NN

in	IN
O	NN

whom	WP
O	NN

it	PRP
O	NN

was	VBD
O	NN

confined	VBN
O	NN

to	TO
O	NN

the	DT
O	NN

GP	NN
O	NN

externus	NN
O	NN

(	NN
O	NN

GPe	NNP
O	NNP

)	NN
O	NN

This	DT
O	NN

49-year-old	JJ
O	NN

woman	NN
O	NN

did	VBD
O	NNP

not	RB
O	NN

experience	NN
O	NN

sustained	JJ
O	NN

benefit	NN
O	NN

The	DT
O	NN

authors	NNS
O	NN

found	VBN
O	NN

no	DT
O	NN

consistent	JJ
O	NN

correlations	NNS
O	NN

between	IN
O	NN

lesion	NN
O	NN

size	NN
O	NN

and	CC
O	NN

location	NN
O	NN

and	CC
O	NN

clinical	JJ
O	NN

outcome	NN
O	NN

as	IN
O	NN

measured	VBN
O	NN

by	IN
O	NN

a	DT
O	NN

global	JJ
O	NN

outcome	NN
O	NN

score	NN
O	NN

,	,
O	NN

the	DT
O	NN

Unified	JJ
O	NN

Parkinson	NNP
O	NNP

's	POS
O	NN

Disease	NN
O	NN

Rating	NNP
O	NNP

Scale	NNP
O	NNP

motor	NN
O	NN

,	,
O	NN

activities	NNS
O	VBP

of	IN
O	NN

daily	RB
O	NN

living	VBG
O	NN

,	,
O	NN

and	CC
O	NN

bradykinesia	NN
O	NN

``	``
O	NN

off	IN
O	NN

''	''
O	NN

scores	NNS
O	NN

or	CC
O	NN

rating	NN
O	NN

of	IN
O	NN

dyskinesias	NN
O	NN

Lesioning	VBG
O	NN

of	IN
O	NN

pallidal	JJ
O	NN

and	CC
O	NN

subpallidal	JJ
O	NN

pathways	NNS
O	VBP

may	MD
O	NNP

contribute	VB
O	NN

to	TO
O	NN

the	DT
O	NN

sustained	JJ
O	NN

clinical	JJ
O	NN

benefit	NN
O	NN

in	IN
O	NN

this	DT
O	NN

series	NN
O	NN

Magnetic	JJ
O	NN

resonance	NN
O	NN

imaging	NN
O	NN

analysis	NN
O	NN

showed	VBD
O	NN

that	IN
O	NN

intraoperative	JJ
O	NN

microelectrode	NN
O	NN

recording	VBG
O	NN

facilitated	VBN
O	NN

accurate	JJ
O	NN

placement	NN
O	NN

of	IN
O	NN

the	DT
O	NN

lesion	NN
O	NN

in	IN
O	NN

this	DT
O	NN

critical	JJ
O	NN

area	NN
O	NN

A	DT
O	NN

commercially	RB
O	NN

available	JJ
O	NN

health	NN
O	NN

food	NN
O	NN

product	NN
O	NN

of	IN
O	NN

cold-pressed	JJ
O	NN

hemp	NN
O	NN

seed	NN
O	NN

oil	NN
O	NN

ingested	VBN
O	NN

by	IN
O	NN

one	CD
O	NN

volunteer	NN
O	NN

twice	RB
O	NN

a	DT
O	NN

day	NN
O	NN

for	IN
O	NN

4	CD
O	NN

1/2	CD
O	NN

days	NNS
O	NN

(	NN
O	NN

135	CD
O	NN

mL	NN
O	NN

total	JJ
O	NN

)	NN
O	NN

Urine	NN
O	NN

specimens	NNS
O	NN

collected	VBN
O	NN

from	IN
O	NN

the	DT
O	NN

volunteer	NN
O	NN

were	VBD
O	NN

subjected	VBN
O	NN

to	TO
O	NN

standard	JJ
O	NN

workplace	NN
O	NN

urine	NN
O	NN

drug	NN
O	NN

testing	NN
O	NN

procedures	NNS
O	VBP

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

following	VBG
O	NN

concentrations	NNS
O	NN

of	IN
O	NN

11-nor-delta9-	JJ
O	NN

tetrahydrocannabinol	NN
O	NN

carboxylic	JJ
O	NN

acid	NN
O	NN

(	NN
O	NN

9-THCA	NN
O	NN

)	NN
O	NN

were	VBD
O	NN

detected	VBN
O	NN

:	:
O	NN

41	CD
O	NN

ng/mL	NN
O	NN

9-THCA	NN
O	NN

at	IN
O	NN

45	CD
O	NN

h	NN
O	NN

,	,
O	NN

49	CD
O	NN

ng/mL	NN
O	NN

at	IN
O	NN

69	CD
O	NN

h	NN
O	NN

,	,
O	NN

and	CC
O	NN

55	CD
O	NN

ng/mL	NN
O	NN

at	IN
O	NN

93	CD
O	NN

h.	NN
O	NN

Ingestion	NN
O	NN

was	VBD
O	NN

discontinued	VBN
O	NN

after	IN
O	NN

93	CD
O	NN

h	NN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

following	VBG
O	NN

concentrations	NNS
O	NN

were	VBD
O	NN

detected	VBN
O	NN

:	:
O	NN

68	CD
O	NN

ng/mL	NN
O	NN

at	IN
O	NN

108	CD
O	NN

h	NN
O	NN

,	,
O	NN

57	CD
O	NN

ng/mL	NN
O	NN

at	IN
O	NN

117	CD
O	NN

h	NN
O	NN

,	,
O	NN

31	CD
O	NN

ng/mL	NN
O	NN

at	IN
O	NN

126	CD
O	NN

h	NN
O	NN

,	,
O	NN

and	CC
O	NN

20	CD
O	NN

ng/mL	NN
O	NN

at	IN
O	NN

142	CD
O	NN

h.	NN
O	NN

The	DT
O	NN

first	RB
O	NN

specimen	NN
O	NN

that	IN
O	NN

tested	VBN
O	NN

negative	JJ
O	NN

(	NN
O	NN

50	CD
O	NN

ng/mL	NN
O	NN

initial	JJ
O	NN

immunoassay	NN
O	NN

test	NN
O	NN

,	,
O	NN

15	CD
O	NN

ng/mL	NN
O	NN

confirmatory	JJ
O	NN

gas	NN
O	NN

chromatographic-mass	JJ
O	NN

spectrometric	JJ
O	NN

test	NN
O	NN

)	NN
O	NN

was	VBD
O	NN

at	IN
O	NN

146	CD
O	NN

h	NN
O	NN

,	,
O	NN

which	WDT
O	NN

was	VBD
O	NN

53	CD
O	NN

h	NN
O	NN

after	IN
O	NN

the	DT
O	NN

last	JJ
O	NN

hemp	NN
O	NN

seed	NN
O	NN

oil	NN
O	NN

ingestion	NN
O	NN

Four	CD
O	NN

subsequent	JJ
O	NN

specimens	NNS
O	NN

taken	VBN
O	NN

to	TO
O	NN

177	CD
O	NN

h	NN
O	NN

were	VBD
O	NN

also	RB
O	NN

negative	JJ
O	NN

This	DT
O	NN

study	NN
O	NN

indicates	VBZ
O	NN

that	IN
O	NN

a	DT
O	NN

workplace	NN
O	NN

urine	NN
O	NN

drug	NN
O	NN

test	NN
O	NN

positive	JJ
O	NN

for	IN
O	NN

cannabinoids	NNS
O	NN

may	MD
O	NNP

arise	VB
O	NN

from	IN
O	NN

the	DT
O	NN

consumption	NN
O	NN

of	IN
O	NN

commercially	RB
O	NN

available	JJ
O	NN

cold-pressed	JJ
O	NN

hemp	NN
O	NN

seed	NN
O	NN

oil	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

We	PRP
O	VBP

determined	VBN
O	NN

the	DT
O	NN

sensitivity	NN
O	NN

and	CC
O	NN

specificity	NN
O	NN

of	IN
O	NN

neonatal	JJ
O	NN

brain-stem	NN
O	NN

auditory	JJ
O	NN

evoked	VBN
O	NN

potentials	NNS
O	VBP

(	NN
O	NN

BAEP	NN
O	NN

)	NN
O	NN

as	IN
O	NN

markers	NNS
O	VBP

for	IN
O	NN

subsequent	JJ
O	NN

hearing	NN
D	NN

impairment	NN
D	NN

and	CC
O	NN

for	IN
O	NN

developmental	JJ
D	NN

problems	NNS
D	NN

found	VBN
O	NN

later	RB
O	NN

in	IN
O	NN

infancy	NN
O	NN

and	CC
O	NN

childhood	NN
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

BAEP	NN
O	NN

studies	NNS
O	VBP

were	VBD
O	NN

performed	VBN
O	NN

before	IN
O	NN

discharge	NN
O	NN

in	IN
O	NN

infants	NNS
O	NN

treated	VBN
O	NN

with	IN
O	NN

extracorporeal	JJ
T	NN

membrane	NN
T	NN

oxygenation	NN
T	NN

(	NN
T	NN

ECMO	NN
T	NN

)	NN
T	NN

,	,
O	NN

and	CC
O	NN

two	CD
O	NN

specific	JJ
O	NN

abnormalities	NNS
O	NN

were	VBD
O	NN

analyzed	VBN
O	NN

:	:
O	NN

elevated	JJ
O	NN

threshold	NN
O	NN

and	CC
O	NN

delayed	VBN
O	NN

central	JJ
O	NN

auditory	JJ
O	NN

conduction	NN
O	NN

Behavioral	JJ
O	NN

audiometry	NN
O	NN

was	VBD
O	NN

repeated	VBN
O	NN

during	IN
O	NN

periodic	JJ
O	NN

follow-up	JJ
O	NN

until	IN
O	NN

reliable	JJ
O	NN

responses	NNS
O	NN

were	VBD
O	NN

obtained	VBN
O	NN

for	IN
O	NN

all	DT
O	NN

frequencies	NNS
O	NN

,	,
O	NN

and	CC
O	NN

standardized	JJ
O	NN

developmental	JJ
O	NN

testing	NN
O	NN

was	VBD
O	NN

also	RB
O	NN

conducted	VBN
O	NN

The	DT
O	NN

sensitivity	NN
O	NN

and	CC
O	NN

specificity	NN
O	NN

of	IN
O	NN

an	DT
O	NN

elevated	JJ
O	NN

threshold	NN
O	NN

on	IN
O	NN

the	DT
O	NN

neonatal	JJ
O	NN

BAEP	NN
O	NN

for	IN
O	NN

detecting	VBG
O	NN

subsequent	JJ
O	NN

hearing	VBG
O	NN

loss	NN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

relationship	NN
O	NN

of	IN
O	NN

any	DT
O	NN

neonatal	JJ
O	NN

BAEP	NN
O	NN

abnormality	NN
O	NN

to	TO
O	NN

language	NN
O	NN

or	CC
O	NN

developmental	JJ
O	NN

disorders	NNS
O	NN

in	IN
O	NN

infancy	NN
O	NN

,	,
O	NN

were	VBD
O	NN

calculated	VBN
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Test	NN
O	NN

results	NNS
O	VBP

for	IN
O	NN

46	CD
O	NN

ECMO-treated	JJ
O	NN

infants	NNS
O	NN

(	NN
O	NN

57.5	CD
O	NN

%	NN
O	NN

)	NN
O	NN

were	VBD
O	NN

normal	JJ
O	NN

,	,
O	NN

and	CC
O	NN

those	DT
O	NNP

for	IN
O	NN

34	CD
O	NN

infants	NNS
O	NN

(	NN
O	NN

42.5	CD
O	NN

%	NN
O	NN

)	NN
O	NN

were	VBD
O	NN

abnormal	JJ
O	NN

,	,
O	NN

with	IN
O	NN

either	DT
O	NN

elevated	JJ
O	NN

wave	NN
O	NN

V	NN
O	NN

threshold	NN
O	NN

,	,
O	NN

prolonged	JJ
O	NN

wave	NN
O	NN

I-V	NN
O	NN

interval	NN
O	NN

,	,
O	NN

or	CC
O	NN

both	DT
O	NN

on	IN
O	NN

neonatal	JJ
O	NN

BAEP	NN
O	NN

recordings	NNS
O	NN

Most	JJS
O	NN

significantly	RB
O	NN

,	,
O	NN

7	CD
O	NN

(	NN
O	NN

58	CD
O	NN

%	NN
O	NN

)	NN
O	NN

of	IN
O	NN

the	DT
O	NN

12	CD
O	NN

children	NNS
O	VBP

with	IN
O	NN

subsequent	JJ
O	NN

sensorineural	NN
D	NN

hearing	NN
D	NN

loss	NN
D	NN

had	VBD
O	NN

left	RB
O	NN

the	DT
O	NN

hospital	NN
O	NN

after	IN
O	NN

showing	VBG
O	NN

normal	JJ
O	NN

results	NNS
O	VBP

on	IN
O	NN

threshold	NN
O	NN

tests	NNS
O	NN

There	EX
O	NN

was	VBD
O	NN

no	DT
O	NN

significant	JJ
O	NN

difference	NN
O	NN

in	IN
O	NN

the	DT
O	NN

frequency	NN
O	NN

of	IN
O	NN

hearing	NN
D	NN

loss	NN
D	NN

between	IN
O	NN

subjects	NNS
O	NN

with	IN
O	NN

abnormal	JJ
O	NN

(	NN
O	NN

5/21	CD
O	NN

,	,
O	NN

or	CC
O	NN

24	CD
O	NN

%	NN
O	NN

)	NN
O	NN

and	CC
O	NN

those	DT
O	NNP

with	IN
O	NN

normal	JJ
O	NN

BAEP	NN
O	NN

thresholds	NNS
O	NN

(	NN
O	NN

7/59	CD
O	NN

,	,
O	NN

or	CC
O	NN

12	CD
O	NN

%	NN
O	NN

;	:
O	NN

Fisher	NNP
O	NNP

Exact	JJ
O	NN

Test	NN
O	NN

,	,
O	NN

p	NN
O	NN

=	JJ
O	NN

0.28	CD
O	NN

)	NN
O	NN

Therefore	RB
O	NN

the	DT
O	NN

sensitivity	NN
O	NN

of	IN
O	NN

neonatal	JJ
O	NN

BAEP	NN
O	NN

testing	NN
O	NN

for	IN
O	NN

predicting	VBG
O	NN

subsequent	JJ
O	NN

hearing	NN
D	NN

loss	NN
D	NN

was	VBD
O	NN

only	RB
O	NN

42	CD
O	NN

%	NN
O	NN

Neonatal	JJ
O	NN

BAEP	NN
O	NN

specificity	NN
O	NN

for	IN
O	NN

excluding	VBG
O	NN

subsequent	JJ
O	NN

hearing	NN
D	NN

loss	NN
D	NN

was	VBD
O	NN

76	CD
O	NN

%	NN
O	NN

In	IN
O	NN

contrast	NN
O	NN

,	,
O	NN

on	IN
O	NN

language	NN
O	NN

development	NN
O	NN

testing	NN
O	NN

,	,
O	NN

19	CD
O	NN

children	NNS
O	VBP

demonstrated	VBD
O	NN

receptive	JJ
O	NN

language	NN
O	NN

delay	NN
O	NN

Of	IN
O	NN

these	DT
O	NN

children	NNS
O	VBP

,	,
O	NN

12	CD
O	NN

(	NN
O	NN

63	CD
O	NN

%	NN
O	NN

)	NN
O	NN

had	VBD
O	NN

abnormal	JJ
O	NN

neonatal	JJ
O	NN

BAEP	NN
O	NN

recordings	NNS
O	NN

and	CC
O	NN

7	CD
O	NN

(	NN
O	NN

37	CD
O	NN

%	NN
O	NN

)	NN
O	NN

had	VBD
O	NN

a	DT
O	NN

normal	JJ
O	NN

BAEP	NN
O	NN

threshold	NN
O	NN

,	,
O	NN

normal	JJ
O	NN

central	JJ
O	NN

auditory	JJ
O	NN

conduction	NN
O	NN

test	NN
O	NN

results	NNS
O	VBP

,	,
O	NN

or	CC
O	NN

both	DT
O	NN

(	NN
O	NN

p	NN
O	NN

=	JJ
O	NN

0.04	CD
O	NN

)	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Neonatal	JJ
O	NN

BAEP	NN
O	NN

threshold	NN
O	NN

recordings	NNS
O	NN

were	VBD
O	NN

of	IN
O	NN

limited	JJ
O	NN

value	NN
O	NN

for	IN
O	NN

predicting	VBG
O	NN

subsequent	JJ
O	NN

hearing	NN
D	NN

loss	NN
D	NN

common	JJ
O	NN

in	IN
O	NN

ECMO	NN
T	NN

-treated	JJ
O	NN

survivors	NNS
O	NN

However	RB
O	NN

,	,
O	NN

an	DT
O	NN

abnormal	JJ
O	NN

neonatal	JJ
O	NN

BAEP	NN
O	NN

significantly	RB
O	NN

increased	VBN
O	NN

the	DT
O	NN

probability	NN
O	NN

of	IN
O	NN

finding	VBG
O	NN

a	DT
O	NN

receptive	JJ
O	NN

language	NN
O	NN

delay	NN
O	NN

during	IN
O	NN

early	RB
O	NN

childhood	NN
O	NN

,	,
O	NN

even	RB
O	NN

in	IN
O	NN

those	DT
O	NNP

with	IN
O	NN

subsequently	RB
O	NN

normal	JJ
O	NN

audiometry	NN
O	NN

findings	NNS
O	VBP

Because	IN
O	NN

neonatal	JJ
O	NN

ECMO	NN
T	NN

is	VBZ
O	NN

associated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

high	JJ
O	NN

risk	NN
O	NN

of	IN
O	NN

hearing	NN
D	NN

and	CC
D	NN

receptive	JJ
D	NN

language	NN
D	NN

disorders	NNS
D	NN

,	,
O	NN

parents	NNS
O	NN

should	MD
O	NNP

be	VB
O	NN

counseled	VBN
O	NN

that	IN
O	NN

audiologic	JJ
O	NN

and	CC
O	NN

developmental	JJ
O	NN

follow-up	JJ
O	NN

evaluations	NNS
O	VBP

in	IN
O	NN

surviving	VBG
O	NN

children	NNS
O	VBP

are	VBP
O	NN

essential	JJ
O	NN

regardless	RB
O	NN

of	IN
O	NN

the	DT
O	NN

results	NNS
O	VBP

of	IN
O	NN

neonatal	JJ
O	NN

BAEP	NN
O	NN

testing	NN
O	NN

The	DT
O	NN

Federated	NNP
O	NNP

Council	NNP
O	NNP

of	IN
O	NN

Internal	JJ
O	NN

Medicine	NNP
O	NNP

has	VBZ
O	NN

developed	VBN
O	NN

a	DT
O	NN

resource	NN
O	NN

guide	NN
O	NN

to	TO
O	NN

help	NN
O	NN

internal	JJ
O	NN

medicine	NN
O	NN

residency	NN
O	NN

programs	NNS
O	NN

produce	VB
O	NN

internists	NNS
O	NN

who	WP
O	VBP

are	VBP
O	NN

prepared	JJ
O	NN

for	IN
O	NN

today	NN
O	NN

's	POS
O	NN

practice	NN
O	NN

of	IN
O	NN

internal	JJ
O	NN

medicine	NN
O	NN

and	CC
O	NN

the	DT
O	NN

challenges	NNS
O	IN

of	IN
O	NN

practice	NN
O	NN

in	IN
O	NN

the	DT
O	NN

future	JJ
O	NN

The	DT
O	NN

guide	NN
O	NN

situates	VBZ
O	NN

general	JJ
O	NN

internal	JJ
O	NN

medicine	NN
O	NN

as	IN
O	NN

the	DT
O	NN

primary	JJ
O	NN

care	NN
O	NN

profession	NN
O	NN

that	IN
O	NN

focuses	VBZ
O	NN

on	IN
O	NN

preventive	JJ
O	NN

,	,
O	NN

short-term	JJ
O	NN

,	,
O	NN

and	CC
O	NN

long-term	JJ
O	NN

care	NN
O	NN

of	IN
O	NN

adult	JJ
O	NN

patients	NNS
O	NN

It	PRP
O	NN

assumes	VBZ
O	NN

that	IN
O	NN

a	DT
O	NN

single	JJ
O	NN

pathway	NN
O	NN

is	VBZ
O	NN

sufficient	JJ
O	NN

for	IN
O	NN

educating	VBG
O	NN

general	JJ
O	NN

internists	NNS
O	NN

and	CC
O	NN

subspecialty-bound	JJ
O	NN

trainees	NNS
O	NN

It	PRP
O	NN

identifies	VBZ
O	NN

the	DT
O	NN

learning	VBG
O	NN

experiences	NNS
O	NN

that	IN
O	NN

should	MD
O	NNP

be	VB
O	NN

part	NN
O	NN

of	IN
O	NN

general	JJ
O	NN

internal	JJ
O	NN

medicine	NN
O	NN

residency	NN
O	NN

training	NN
O	NN

,	,
O	NN

lists	NNS
O	VBP

the	DT
O	NN

clinical	JJ
O	NN

competencies	NNS
O	NN

that	IN
O	NN

are	VBP
O	NN

important	JJ
O	NN

for	IN
O	NN

primary	JJ
O	NN

care	NN
O	NN

practice	NN
O	NN

,	,
O	NN

and	CC
O	NN

describes	VBZ
O	NN

the	DT
O	NN

role	NN
O	NN

of	IN
O	NN

the	DT
O	NN

integrative	JJ
O	NN

disciplines	NNS
O	NN

that	IN
O	NN

should	MD
O	NNP

inform	VB
O	NN

the	DT
O	NN

care	NN
O	NN

of	IN
O	NN

every	DT
O	NN

patient	NN
O	NN

It	PRP
O	NN

also	RB
O	NN

describes	VBZ
O	NN

a	DT
O	NN

process	NN
O	NN

that	IN
O	NN

program	NN
O	NN

directors	NNS
O	VBP

and	CC
O	NN

local	JJ
O	NN

program	NN
O	NN

committees	NNS
O	VBP

can	MD
O	NNP

use	NN
O	NN

to	TO
O	NN

develop	VB
O	NN

competency-based	JJ
O	NN

curricula	NN
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Darier	NN
D	NN

disease	NN
D	NN

is	VBZ
O	NN

an	DT
O	NN

uncommon	JJ
O	NN

genodermatosis	NN
D	NN

characterized	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

symmetrical	JJ
O	NN

eruption	NN
O	NN

of	IN
O	NN

keratotic	JJ
O	NN

reddish-brown	JJ
O	NN

papules	NNS
O	NN

occurring	VBG
O	NN

in	IN
O	NN

the	DT
O	NN

seborrheic	JJ
O	NN

areas	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

body	NN
O	NN

A	DT
O	NN

unilateral	JJ
O	NN

,	,
O	NN

or	CC
O	NN

localized	JJ
O	NN

,	,
O	NN

variant	JJ
O	NN

has	VBZ
O	NN

been	VBN
O	NN

identified	VBN
O	NN

We	PRP
O	VBP

report	NN
O	NN

4	CD
O	NN

new	JJ
O	NN

cases	NNS
O	NN

of	IN
O	NN

localized	JJ
O	NN

Darier	NN
D	NN

disease	NN
D	NN

and	CC
O	NN

review	NN
O	NN

the	DT
O	NN

English-language	JJ
O	NN

literature	NN
O	NN

The	DT
O	NN

implications	NNS
O	VBP

of	IN
O	NN

these	DT
O	NN

cases	NNS
O	NN

on	IN
O	NN

future	JJ
O	NN

genetic	JJ
O	NN

studies	NNS
O	VBP

are	VBP
O	NN

also	RB
O	NN

discussed	VBN
O	NN

OBSERVATIONS	NNS
O	NN

:	:
O	NN

Localized	JJ
O	NN

Darier	NN
D	NN

disease	NN
D	NN

occurred	VBD
O	NN

with	IN
O	NN

equal	JJ
O	NN

frequency	NN
O	NN

in	IN
O	NN

males	NNS
O	VBP

and	CC
O	NN

females	NNS
O	NN

The	DT
O	NN

average	JJ
O	NN

age	NN
O	NN

at	IN
O	NN

onset	NN
O	NN

was	VBD
O	NN

27	CD
O	NN

years	NNS
O	NN

The	DT
O	NN

most	JJS
O	NN

frequent	JJ
O	NN

site	NN
O	NN

of	IN
O	NN

involvement	NN
O	NN

was	VBD
O	NN

the	DT
O	NN

trunk	NN
O	NN

(	NN
O	NN

40	CD
O	NN

%	NN
O	NN

(	NN
O	NN

16/40	CD
O	NN

)	NN
O	NN

)	NN
O	NN

This	DT
O	NN

condition	NN
O	NN

was	VBD
O	NN

aggravated	VBN
O	NN

by	IN
O	NN

sunlight	NN
O	NN

,	,
O	NN

heat	NN
O	NN

,	,
O	NN

or	CC
O	NN

sweating	NN
O	NN

in	IN
O	NN

42	CD
O	NN

%	NN
O	NN

(	NN
O	NN

19/40	CD
O	NN

)	NN
O	NN

of	IN
O	NN

reported	VBN
O	NN

cases	NNS
O	NN

,	,
O	NN

and	CC
O	NN

38	CD
O	NN

%	NN
O	NN

(	NN
O	NN

15/40	CD
O	NN

)	NN
O	NN

of	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

responded	VBD
O	NN

to	TO
O	NN

treatment	NN
O	NN

with	IN
O	NN

topical	JJ
O	NN

tretinoin	NN
T	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Many	JJ
O	NN

of	IN
O	NN

the	DT
O	NN

clinical	JJ
O	NN

features	NNS
O	VBP

of	IN
O	NN

localized	JJ
O	NN

Darier	NN
D	NN

disease	NN
D	NN

suggest	VBP
O	NN

that	IN
O	NN

it	PRP
O	NN

is	VBZ
O	NN

a	DT
O	NN

genetic	JJ
O	NN

mosaic	JJ
O	NN

of	IN
O	NN

generalized	VBN
O	NN

Darier	NN
D	NN

disease	NN
D	NN

Further	JJ
O	NN

studies	NNS
O	VBP

of	IN
O	NN

localized	JJ
O	NN

Darier	NN
D	NN

disease	NN
D	NN

may	MD
O	NNP

therefore	RB
O	NN

prove	VB
O	NN

to	TO
O	NN

be	VB
O	NN

instrumental	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

search	NN
O	NN

for	IN
O	NN

the	DT
O	NN

Darier	NN
D	NN

disease	NN
D	NN

gene	NN
O	NN

UV	NN
O	NN

radiation	NN
O	NN

induces	VBZ
O	NN

two	CD
O	NN

major	JJ
O	NN

DNA	NN
O	NN

damage	NN
O	NN

products	NNS
O	NN

,	,
O	NN

the	DT
O	NN

cyclobutane	NN
O	NN

pyrimidine	NN
O	NN

dimer	NN
O	NN

(	NN
O	NN

CPD	NN
O	NN

)	NN
O	NN

and	CC
O	NN

,	,
O	NN

at	IN
O	NN

a	DT
O	NN

lower	JJR
O	NN

frequency	NN
O	NN

,	,
O	NN

the	DT
O	NN

pyrimidine	NN
O	NN

(	NN
O	NN

6-4	CD
O	NN

)	NN
O	NN

pyrimidinone	NN
O	NN

dimer	NN
O	NN

(	NN
O	NN

6-4	CD
O	NN

product	NN
O	NN

)	NN
O	NN

Although	IN
O	NN

Escherichia	FW
O	FW

coli	NN
O	NN

and	CC
O	NN

Saccharomyes	NNS
O	NN

cerevisiae	FW
O	FW

produce	VB
O	NN

a	DT
O	NN

CPD-specific	JJ
O	NN

photolyase	NN
O	NN

that	IN
O	NN

eliminates	VBZ
O	NN

only	RB
O	NN

this	DT
O	NN

class	NN
O	NN

of	IN
O	NN

dimer	NN
O	NN

,	,
O	NN

Arabidopsis	NNP
O	NN

thaliana	NN
O	NN

,	,
O	NN

Drosphila	NN
O	NN

melanogaster	FW
O	FW

,	,
O	NN

Crotalus	NNP
O	NNP

atrox	NN
O	NN

,	,
O	NN

and	CC
O	NN

Xenopus	NN
O	NN

laevis	NN
O	NN

have	VB
O	NN

recently	RB
O	NN

been	VBN
O	NN

shown	VBN
O	NN

to	TO
O	NN

photoreactivate	NN
O	NN

both	DT
O	NN

CPDs	NNS
O	NN

and	CC
O	NN

6-4	CD
O	NN

products	NNS
O	NN

We	PRP
O	VBP

describe	VBP
O	NN

the	DT
O	NN

isolation	NN
O	NN

and	CC
O	NN

characterization	NN
O	NN

of	IN
O	NN

two	CD
O	NN

new	JJ
O	NN

classes	NNS
O	NN

of	IN
O	NN

mutants	NNS
O	NN

of	IN
O	NN

Arabidopsis	NNP
O	NN

,	,
O	NN

termed	VBN
O	NN

uvr2	NN
O	NN

and	CC
O	NN

uvr3	NN
O	NN

,	,
O	NN

that	IN
O	NN

are	VBP
O	NN

defective	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

photoreactivation	NN
O	NN

of	IN
O	NN

CPDs	NNS
O	NN

and	CC
O	NN

6-4	CD
O	NN

products	NNS
O	NN

,	,
O	NN

respectively	RB
O	NN

We	PRP
O	VBP

demonstrate	VB
O	NN

that	IN
O	NN

the	DT
O	NN

CPD	NN
O	NN

photolyase	NN
O	NN

mutation	NN
O	NN

is	VBZ
O	NN

genetically	RB
O	NN

linked	VBN
O	NN

to	TO
O	NN

a	DT
O	NN

DNA	NN
O	NN

sequence	NN
O	NN

encoding	VBG
O	NN

a	DT
O	NN

type	NN
O	NN

II	NNP
O	NNP

(	NN
O	NN

metazoan	NN
O	NN

)	NN
O	NN

CPD	NN
O	NN

photolyase	NN
O	NN

In	IN
O	NN

addition	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

are	VBP
O	NN

able	JJ
O	NN

to	TO
O	NN

generate	VB
O	NN

plants	NNS
O	NN

in	IN
O	NN

which	WDT
O	NN

only	RB
O	NN

CPDs	NNS
O	NN

or	CC
O	NN

6-4	CD
O	NN

products	NNS
O	NN

are	VBP
O	NN

photoreactivated	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

nuclear	JJ
O	NN

genome	NN
O	NN

by	IN
O	NN

exposing	VBG
O	NN

these	DT
O	NN

mutants	NNS
O	NN

to	TO
O	NN

UV	NN
O	NN

light	JJ
O	NN

and	CC
O	NN

then	RB
O	NN

allowing	VBG
O	NN

them	PRP
O	VBP

to	TO
O	NN

repair	NN
O	NN

one	CD
O	NN

or	CC
O	NN

the	DT
O	NN

other	JJ
O	NN

class	NN
O	NN

of	IN
O	NN

dimers	NNS
O	NN

This	DT
O	NN

provides	VBZ
O	NN

us	PRP
O	VBP

with	IN
O	NN

a	DT
O	NN

unique	JJ
O	NN

opportunity	NN
O	NN

to	TO
O	NN

study	NN
O	NN

the	DT
O	NN

biological	JJ
O	NN

consequences	NNS
O	NN

of	IN
O	NN

each	DT
O	NN

of	IN
O	NN

these	DT
O	NN

two	CD
O	NN

major	JJ
O	NN

UV-induced	JJ
O	NN

photoproducts	NNS
O	NN

in	IN
O	NN

an	DT
O	NN

intact	JJ
O	NN

living	VBG
O	NN

system	NN
O	NN

A	DT
O	NN

diffuse	JJ
O	NN

macular	JJ
D	NN

erythroderma	NN
D	NN

and	CC
O	NN

subsequent	JJ
O	NN

desquamation	NN
D	NN

after	IN
O	NN

1	CD
O	NN

to	TO
O	NN

2	CD
O	NN

weeks	NNS
O	NN

are	VBP
O	NN

two	CD
O	NN

of	IN
O	NN

the	DT
O	NN

five	CD
O	NN

major	JJ
O	NN

diagnostic	JJ
O	NN

criteria	NNS
O	NN

of	IN
O	NN

toxic	JJ
D	NN

shock	NN
D	NN

syndrome	NN
D	NN

(	NN
D	NN

TSS	NN
D	NN

)	NN
D	NN

We	PRP
O	VBP

present	JJ
O	NN

the	DT
O	NN

case	NN
O	NN

of	IN
O	NN

a	DT
O	NN

15-month-old	JJ
O	NN

girl	NN
O	NN

with	IN
O	NN

TSS	NN
D	NN

,	,
O	NN

but	CC
O	NNP

without	IN
O	NN

erythroderma	NN
D	NN

or	CC
O	NN

desquamation	NN
D	NN

She	PRP
O	VBP

was	VBD
O	NN

admitted	VBN
O	NN

with	IN
O	NN

high	JJ
D	NN

fever	NN
D	NN

,	,
O	NN

shock	NN
D	NN

,	,
O	NN

and	CC
O	NN

multiorgan	JJ
O	NN

involvement	NN
O	NN

Minimal	JJ
O	NN

or	CC
O	NN

no	DT
O	NN

cutaneous	JJ
O	NN

signs	NNS
O	IN

were	VBD
O	NN

present	JJ
O	NN

Initially	RB
O	NN

the	DT
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

the	DT
O	NN

syndrome	NN
O	NN

of	IN
O	NN

hemorrhagic	JJ
D	NN

shock	NN
D	NN

and	CC
O	NN

encephalopathy	NN
D	NN

was	VBD
O	NN

made	VBN
O	NN

After	IN
O	NN

7	CD
O	NN

days	NNS
O	NN

,	,
O	NN

a	DT
O	NN

TSS	NN
D	NN

toxin	NN
O	NN

1-producing	JJ
O	NN

strain	NN
O	NN

of	IN
O	NN

Staphylococcus	FW
O	FW

aureus	NN
O	NN

was	VBD
O	NN

cultured	VBN
O	NN

from	IN
O	NN

an	DT
O	NN

inguinal	JJ
O	NN

lymph	NN
O	NN

node	NN
O	NN

,	,
O	NN

where	WRB
O	NN

inflammation	NN
D	NN

had	VBD
O	NN

already	RB
O	NN

been	VBN
O	NN

noticed	VBN
O	NN

on	IN
O	NN

admission	NN
O	NN

Moreover	RB
O	NN

,	,
O	NN

the	DT
O	NN

girl	NN
O	NN

had	VBD
O	NN

no	DT
O	NN

antibodies	NNS
O	NN

against	IN
O	NN

this	DT
O	NN

toxin	NN
O	NN

The	DT
O	NN

serum	NN
O	NN

cytokine	NN
O	NN

profile	NN
O	NN

during	IN
O	NN

the	DT
O	NN

acute	JJ
O	NN

phase	NN
O	NN

of	IN
O	NN

her	PRP$
O	NN

illness	NN
O	NN

showed	VBD
O	NN

high	JJ
O	NN

levels	NNS
O	VBP

of	IN
O	NN

tumor	NN
O	NN

necrosis	NN
O	NN

factor-alpha	NN
O	NN

,	,
O	NN

interleukin-6	NN
O	NN

and	CC
O	NN

interferon-gamma	NN
O	NN

,	,
O	NN

as	IN
O	NN

is	VBZ
O	NN

seen	VBN
O	NN

during	IN
O	NN

activation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

immune	JJ
O	NN

system	NN
O	NN

by	IN
O	NN

TSS	NN
D	NN

toxin	NN
O	NN

1	CD
O	NN

Other	JJ
O	NN

possible	JJ
O	NN

causes	NNS
O	VBP

for	IN
O	NN

the	DT
O	NN

patient	NN
O	NN

's	POS
O	NN

illness	NN
O	NN

were	VBD
O	NN

excluded	VBN
O	NN

We	PRP
O	VBP

conclude	VBP
O	NN

that	IN
O	NN

the	DT
O	NN

patient	NN
O	NN

had	VBD
O	NN

TSS	NN
D	NN

without	IN
O	NN

rash	NN
D	NN

Without	IN
O	NN

the	DT
O	NN

evidence	NN
O	NN

implicating	VBG
O	NN

a	DT
O	NN

TSS	NN
D	NN

toxin	NN
O	NN

1-producing	JJ
O	NN

strain	NN
O	NN

of	IN
O	NN

S.	NNP
O	NNP

aureus	NN
O	NN

as	IN
O	NN

the	DT
O	NN

cause	NN
O	NN

of	IN
O	NN

her	PRP$
O	NN

disease	NN
O	NN

,	,
O	NN

a	DT
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

syndrome	NN
O	NN

of	IN
O	NN

hemorrhagic	JJ
D	NN

shock	NN
D	NN

and	CC
O	NN

encephalopathy	NN
D	NN

would	MD
O	NNP

have	VB
O	NN

been	VBN
O	NN

made	VBN
O	NN

It	PRP
O	NN

is	VBZ
O	NN

possible	JJ
O	NN

that	IN
O	NN

some	DT
O	NN

cases	NNS
O	NN

of	IN
O	NN

syndrome	NN
O	NN

of	IN
O	NN

hemorrhagic	JJ
D	NN

shock	NN
D	NN

and	CC
O	NN

encephalopathy	NN
D	NN

represent	VB
O	NN

a	DT
O	NN

variant	JJ
O	NN

of	IN
O	NN

TSS	NN
D	NN

in	IN
O	NN

small	JJ
O	NN

children	NNS
O	VBP

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

The	DT
O	NN

growing	VBG
O	NN

teratoma	NN
O	NN

syndrome	NN
O	NN

refers	VBZ
O	NN

to	TO
O	NN

the	DT
O	NN

phenomenon	NN
O	NN

whereby	WRB
O	NN

germ	NN
O	NN

cell	NN
O	NN

tumors	NNS
O	NN

enlarge	VB
O	NN

after	IN
O	NN

chemotherapy	NN
O	NN

despite	IN
O	NN

complete	JJ
O	NN

eradication	NN
O	NN

of	IN
O	NN

malignant	JJ
O	NN

cells	NNS
O	VBP

and	CC
O	NN

normalization	NN
O	NN

of	IN
O	NN

serum	NN
O	NN

tumor	NN
O	NN

markers	NNS
O	VBP

This	DT
O	NN

clinical	JJ
O	NN

scenario	NN
O	NN

must	MD
O	NNP

be	VB
O	NN

differentiated	VBN
O	NN

from	IN
O	NN

that	IN
O	NN

in	IN
O	NN

which	WDT
O	NN

germ	NN
D	NN

cell	NN
D	NN

tumors	NNS
D	NN

maintain	VB
O	NN

their	PRP$
O	NN

malignant	JJ
O	NN

characteristics	NNS
O	NN

with	IN
O	NN

elevated	JJ
O	NN

levels	NNS
O	VBP

of	IN
O	NN

serum	NN
O	NN

tumor	NN
O	NN

markers	NNS
O	VBP

METHODS	NNS
O	VBP

:	:
O	NN

Hospital	NNP
O	NNP

record	NN
O	NN

review	NN
O	NN

was	VBD
O	NN

conducted	VBN
O	NN

of	IN
O	NN

2	CD
O	NN

cases	NNS
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Two	CD
O	NN

male	JJ
O	NN

patients	NNS
O	NN

are	VBP
O	NN

presented	VBN
O	NN

,	,
O	NN

1	CD
O	NN

with	IN
O	NN

a	DT
O	NN

metastatic	JJ
D	NN

germ	NN
D	NN

cell	NN
D	NN

tumor	NN
D	NN

of	IN
O	NN

both	DT
O	NN

the	DT
O	NN

retroperitoneum	NN
O	NN

and	CC
O	NN

mediastinum	NN
O	NN

(	NN
O	NN

with	IN
O	NN

elevated	JJ
O	NN

alpha-fetoprotein	NN
O	NN

level	NN
O	NN

)	NN
O	NN

and	CC
O	NN

1	CD
O	NN

with	IN
O	NN

a	DT
O	NN

primary	JJ
D	NN

germ	NN
D	NN

cell	NN
D	NN

tumor	NN
D	NN

of	IN
O	NN

the	DT
O	NN

mediastinum	NN
O	NN

(	NN
O	NN

with	IN
O	NN

elevated	JJ
O	NN

alpha-fetoprotein	NN
O	NN

and	CC
O	NN

beta-human	NN
O	NN

chorionic	JJ
O	NN

gonadotropin	NN
O	NN

levels	NNS
O	VBP

)	NN
O	NN

After	IN
O	NN

completion	NN
O	NN

of	IN
O	NN

chemotherapy	NN
T	NN

and	CC
O	NN

normalization	NN
O	NN

of	IN
O	NN

tumor	NN
O	NN

markers	NNS
O	VBP

,	,
O	NN

both	DT
O	NN

patients	NNS
O	NN

presented	VBN
O	NN

with	IN
O	NN

pulmonary	JJ
D	NN

symptoms	NNS
D	NN

attributable	JJ
O	NN

to	TO
O	NN

their	PRP$
O	NN

massively	RB
O	NN

enlarging	VBG
O	NN

mediastinal	JJ
D	NN

teratomas	NNS
D	NN

.	.
O	NN

The	DT
O	NN

clinical	JJ
O	NN

and	CC
O	NN

roentgenographic	JJ
O	NN

features	NNS
O	VBP

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

thoracic	JJ
O	NN

manifestations	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

growing	VBG
O	NN

teratoma	NN
D	NN

syndrome	NN
D	NN

,	,
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

its	PRP$
O	NN

management	NN
O	NN

,	,
O	NN

are	VBP
O	NN

reviewed	VBN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

After	IN
O	NN

chemotherapy	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

primary	JJ
D	NN

or	CC
D	NN

metastatic	JJ
D	NN

mediastinal	JJ
D	NN

germ	NN
D	NN

cell	NN
D	NN

tumors	NNS
D	NN

whose	WP$
O	NN

tumor	NN
O	NN

markers	NNS
O	VBP

normalize	VB
O	NN

,	,
O	NN

a	DT
O	NN

growing	VBG
O	NN

mass	NN
O	NN

in	IN
O	NN

the	DT
O	NN

mediastinum	NN
O	NN

may	MD
O	NNP

represent	VB
O	NN

the	DT
O	NN

growing	VBG
O	NN

teratoma	NN
D	NN

syndrome	NN
D	NN

The	DT
O	NN

chicken	NN
O	NN

calmodulin	NN
O	NN

I	PRP
O	VBP

(	NN
O	NN

CaMI	NN
O	NN

)	NN
O	NN

gene	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

isolated	VBN
O	NN

and	CC
O	NN

characterized	VBN
O	NN

on	IN
O	NN

the	DT
O	NN

level	NN
O	NN

of	IN
O	NN

cDNA	NN
O	NN

and	CC
O	NN

genomic	JJ
O	NN

DNA	NN
O	NN

The	DT
O	NN

deduced	VBN
O	NN

amino	NN
O	NN

acid	NN
O	NN

(	NN
O	NN

aa	NN
O	NN

)	NN
O	NN

sequence	NN
O	NN

is	VBZ
O	NN

identical	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

one	CD
O	NN

of	IN
O	NN

chicken	NN
O	NN

CaMII	NN
O	NN

which	WDT
O	NN

consists	VBZ
O	NN

of	IN
O	NN

148	CD
O	NN

aa	NN
O	NN

The	DT
O	NN

CaMI	NN
O	NN

gene	NN
O	NN

contains	VBZ
O	NN

six	CD
O	NN

exons	NNS
O	NN

Its	PRP$
O	NN

intron/exon	NN
O	NN

organization	NN
O	NN

is	VBZ
O	NN

identical	JJ
O	NN

to	TO
O	NN

that	IN
O	NN

of	IN
O	NN

the	DT
O	NN

chicken	NN
O	NN

CaMII	NN
O	NN

and	CC
O	NN

the	DT
O	NN

CaMI	NN
O	NN

and	CC
O	NN

CaMIII	NN
O	NN

genes	NNS
O	NN

of	IN
O	NN

rat	NN
O	NN

and	CC
O	NN

human	JJ
O	NN

Expression	NN
O	NN

of	IN
O	NN

the	DT
O	NN

CaMI	NN
O	NN

gene	NN
O	NN

was	VBD
O	NN

detected	VBN
O	NN

in	IN
O	NN

all	DT
O	NN

chicken	NN
O	NN

tissues	NNS
O	NN

examined	VBN
O	NN

,	,
O	NN

although	IN
O	NN

at	IN
O	NN

varying	VBG
O	NN

levels	NNS
O	VBP

The	DT
O	NN

gene	NN
O	NN

is	VBZ
O	NN

transcribed	VBN
O	NN

into	IN
O	NN

four	CD
O	NN

mRNAs	NNS
O	NN

of	IN
O	NN

0.8	CD
O	NN

,	,
O	NN

1.4	CD
O	NN

,	,
O	NN

1.7	CD
O	NN

and	CC
O	NN

4.4	CD
O	NN

kb	NN
O	NN

as	IN
O	NN

determined	VBN
O	NN

by	IN
O	NN

Northern	JJ
O	NN

blot	NN
O	NN

analysis	NN
O	NN

Our	PRP$
O	NN

results	NNS
O	VBP

demonstrate	VB
O	NN

that	IN
O	NN

the	DT
O	NN

``	``
O	NN

multigene-one-protein	JJ
O	NN

''	''
O	NN

principle	NN
O	NN

of	IN
O	NN

CaM	NN
O	NN

synthesis	NN
O	NN

is	VBZ
O	NN

not	RB
O	NN

only	RB
O	NN

applicable	JJ
O	NN

to	TO
O	NN

mammals	NNS
O	NN

whose	WP$
O	NN

CaM	NN
O	NN

is	VBZ
O	NN

encoded	VBN
O	NN

by	IN
O	NN

three	CD
O	NN

different	JJ
O	NN

genes	NNS
O	NN

,	,
O	NN

but	CC
O	NNP

also	RB
O	NN

to	TO
O	NN

chickens	NNS
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

We	PRP
O	VBP

assessed	VBN
O	NN

the	DT
O	NN

accuracy	NN
O	NN

of	IN
O	NN

two	CD
O	NN

electron	NN
O	NN

beam	NN
O	NN

computed	VBN
O	NN

tomography	NN
O	NN

(	NN
O	NN

EBCT	NN
O	NN

)	NN
O	NN

protocols	NNS
O	VBP

for	IN
O	NN

predicting	VBG
O	NN

coronary	JJ
D	NN

events	NNS
D	NN

METHODS	NNS
O	VBP

AND	CC
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

In	IN
O	NN

1994	CD
O	NNP

,	,
O	NN

24	CD
O	NN

months	NNS
O	NN

after	IN
O	NN

enrollment	NN
O	NN

in	IN
O	NN

a	DT
O	NN

longitudinal	JJ
O	NN

study	NN
O	NN

,	,
O	NN

326	CD
O	NN

high-risk	JJ
O	NN

adults	NNS
O	NN

underwent	VBD
O	NN

both	DT
O	NN

3-	CD
O	NN

and	CC
O	NN

6-mm	JJ
O	NN

image-slice	JJ
O	NN

thickness	NN
O	NN

EBCT	NN
O	NN

scanning	NN
O	NN

and	CC
O	NN

were	VBD
O	NN

followed	VBN
O	NN

up	RB
O	NN

for	IN
O	NN

32.0+/-4.0	CD
O	NN

additional	JJ
O	NN

months	NNS
O	NN

Events	NNS
O	NN

were	VBD
O	NN

defined	VBN
O	NN

as	IN
O	NN

either	DT
O	NN

coronary	JJ
O	NN

death	NN
O	NN

,	,
O	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

,	,
O	NN

or	CC
O	NN

revascularization	NN
D	NN

We	PRP
O	VBP

monitored	VBN
O	NN

these	DT
O	NN

subjects	NNS
O	NN

for	IN
O	NN

the	DT
O	NN

32-month	JJ
O	NN

postscanning	VBG
O	NN

period	NN
O	NN

with	IN
O	NN

yearly	JJ
O	NN

phone	NN
O	NN

calls	NNS
O	NN

and	CC
O	NN

acquisition	NN
O	NN

of	IN
O	NN

records	NNS
O	NN

for	IN
O	NN

all	DT
O	NN

hospital	NN
O	NN

admissions	NNS
O	NN

At	IN
O	NN

the	DT
O	NN

time	NN
O	NN

of	IN
O	NN

scanning	NN
O	NN

,	,
O	NN

11	CD
O	NN

subjects	NNS
O	NN

(	NN
O	NN

3	CD
O	NN

%	NN
O	NN

)	NN
O	NN

had	VBD
O	NN

already	RB
O	NN

suffered	VBN
O	NN

12	CD
O	NN

events	NNS
O	NN

(	NN
O	NN

5	CD
O	NN

infarctions	NNS
D	NN

and	CC
O	NN

7	CD
O	NN

revascularizations	NNS
D	NN

)	NN
O	NN

during	IN
O	NN

the	DT
O	NN

24-month	JJ
O	NN

prescanning	VBG
O	NN

period	NN
O	NN

During	IN
O	NN

the	DT
O	NN

postscanning	VBG
O	NN

period	NN
O	NN

,	,
O	NN

18	CD
O	NN

subjects	NNS
O	NN

(	NN
O	NN

6	CD
O	NN

%	NN
O	NN

)	NN
O	NN

suffered	VBN
O	NN

23	CD
O	NN

events	NNS
O	NN

(	NN
O	NN

5	CD
O	NN

coronary	JJ
O	NN

deaths	NNS
O	NN

,	,
O	NN

6	CD
O	NN

infarctions	NNS
D	NN

,	,
O	NN

and	CC
O	NN

12	CD
O	NN

revascularizations	NNS
D	NN

)	NN
O	NN

Thus	RB
O	NN

,	,
O	NN

28	CD
O	NN

subjects	NNS
O	NN

(	NN
O	NN

9	CD
O	NN

%	NN
O	NN

)	NN
O	NN

suffered	VBN
O	NN

35	CD
O	NN

events	NNS
O	NN

Calcium	NN
O	NN

quantities	NNS
O	NN

calculated	VBN
O	NN

for	IN
O	NN

both	DT
O	NN

protocols	NNS
O	VBP

,	,
O	NN

performed	VBN
O	NN

on	IN
O	NN

the	DT
O	NN

same	JJ
O	NN

subjects	NNS
O	NN

,	,
O	NN

were	VBD
O	NN

sorted	VBN
O	NN

in	IN
O	NN

ascending	VBG
O	NN

order	NN
O	NN

and	CC
O	NN

divided	VBN
O	NN

into	IN
O	NN

equal	JJ
O	NN

quartiles	NNS
O	NN

When	WRB
O	NN

revascularizations	NNS
D	NN

were	VBD
O	NN

included	VBN
O	NN

,	,
O	NN

there	RB
O	NN

was	VBD
O	NN

a	DT
O	NN

significant	JJ
O	NN

trend	NN
O	NN

toward	IN
O	NN

higher	JJR
O	NN

frequencies	NNS
O	NN

of	IN
O	NN

events	NNS
O	NN

with	IN
O	NN

increasing	VBG
O	NN

calcium	NN
O	NN

quantity	NN
O	NN

(	NN
O	NN

P	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

.01	CD
O	NN

)	NN
O	NN

However	RB
O	NN

,	,
O	NN

coronary	JJ
O	NN

death	NN
O	NN

and	CC
O	NN

infarction	NN
D	NN

were	VBD
O	NN

not	RB
O	NN

significantly	RB
O	NN

more	RBR
O	NN

frequent	JJ
O	NN

in	IN
O	NN

higher	JJR
O	NN

quartiles	NNS
O	NN

These	DT
O	NN

relationships	NNS
O	NN

were	VBD
O	NN

preserved	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

subjects	NNS
O	NN

without	IN
O	NN

prior	RB
O	NN

events	NNS
O	NN

at	IN
O	NN

the	DT
O	NN

time	NN
O	NN

of	IN
O	NN

scanning	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Calcium	NN
O	NN

quantities	NNS
O	NN

from	IN
O	NN

the	DT
O	NN

3-mm	JJ
O	NN

and	CC
O	NN

the	DT
O	NN

more	RBR
O	NN

reproducible	JJ
O	NN

6-mm	JJ
O	NN

scanning	NN
O	NN

are	VBP
O	NN

equally	RB
O	NN

accurate	JJ
O	NN

for	IN
O	NN

predicting	VBG
O	NN

events	NNS
O	NN

Coronary	JJ
O	NN

calcium	NN
O	NN

amount	NN
O	NN

appears	VBZ
O	NN

to	TO
O	NN

be	VB
O	NN

a	DT
O	NN

weak	JJ
O	NN

predictor	NN
O	NN

of	IN
O	NN

coronary	JJ
O	NN

death	NN
O	NN

and	CC
O	NN

infarction	NN
D	NN

Its	PRP$
O	NN

predictive	JJ
O	NN

accuracy	NN
O	NN

is	VBZ
O	NN

superior	JJ
O	NN

for	IN
O	NN

predicting	VBG
O	NN

revascularization	NN
D	NN

Research	NNP
O	NNP

into	IN
O	NN

the	DT
O	NN

genetic	JJ
O	NN

component	NN
O	NN

of	IN
O	NN

some	DT
O	NN

complex	JJ
O	NN

behaviors	NNS
O	NN

often	RB
O	NN

causes	NNS
O	VBP

controversy	NN
O	NN

,	,
O	NN

depending	VBG
O	NN

on	IN
O	NN

the	DT
O	NN

social	JJ
O	NN

meaning	VBG
O	NN

and	CC
O	NN

significance	NN
O	NN

of	IN
O	NN

the	DT
O	NN

behavior	NN
O	NN

under	IN
O	NN

study	NN
O	NN

Research	NNP
O	NNP

into	IN
O	NN

sexual	JJ
O	NN

orientation-simplistically	RB
O	NN

referred	VBN
O	NN

to	TO
O	NN

as	IN
O	NN

``	``
O	NN

gay	JJ
O	NN

gene	NN
O	NN

''	''
O	NN

research-is	JJ
O	NN

an	DT
O	NN

example	NN
O	NN

of	IN
O	NN

research	NN
O	NN

that	IN
O	NN

provokes	VBZ
O	NN

intense	JJ
O	NN

controversy	NN
O	NN

This	DT
O	NN

research	NN
O	NN

is	VBZ
O	NN

worrisome	JJ
O	NN

for	IN
O	NN

many	JJ
O	NN

reasons	NNS
O	VBP

,	,
O	NN

including	VBG
O	NN

the	DT
O	NN

fact	NN
O	NN

that	IN
O	NN

it	PRP
O	NN

has	VBZ
O	NN

been	VBN
O	NN

used	VBN
O	NN

to	TO
O	NN

harm	NN
O	NN

lesbians	NNS
O	NN

and	CC
O	NN

gay	JJ
O	NN

men	NNS
O	NN

Many	JJ
O	NN

homosexual	JJ
O	NN

people	NNS
O	VBP

have	VB
O	NN

been	VBN
O	NN

forced	VBN
O	NN

to	TO
O	NN

undergo	VB
O	NN

``	``
O	NN

treatments	NNS
O	VBP

''	''
O	NN

to	TO
O	NN

change	NN
O	NN

their	PRP$
O	NN

sexual	JJ
O	NN

orientation	NN
O	NN

Other	JJ
O	NN

chose	VBD
O	NN

to	TO
O	NN

undergo	VB
O	NN

them	PRP
O	VBP

to	TO
O	NN

escape	NN
O	NN

discrimination	NN
O	NN

and	CC
O	NN

social	JJ
O	NN

disapprobation	NN
O	NN

But	CC
O	NNP

there	RB
O	NN

are	VBP
O	NN

other	JJ
O	NN

reasons	NNS
O	VBP

to	TO
O	NN

worry	NN
O	NN

about	IN
O	NN

such	JJ
O	NN

research	NN
O	NN

The	DT
O	NN

very	RB
O	NN

motivation	NN
O	NN

for	IN
O	NN

seeking	VBG
O	NN

an	DT
O	NN

``	``
O	NN

origin	NN
O	NN

''	''
O	NN

of	IN
O	NN

homosexuality	NN
O	NN

reveals	VBZ
O	NN

homophobia	NN
O	NN

Moreover	RB
O	NN

,	,
O	NN

such	JJ
O	NN

research	NN
O	NN

may	MD
O	NNP

lead	JJ
O	NN

to	TO
O	NN

prenatal	JJ
O	NN

tests	NNS
O	NN

that	IN
O	NN

claim	NN
O	NN

to	TO
O	NN

predict	VB
O	NN

for	IN
O	NN

homosexuality	NN
O	NN

For	IN
O	NN

homosexual	JJ
O	NN

people	NNS
O	VBP

who	WP
O	VBP

live	JJ
O	NN

in	IN
O	NN

countries	NNS
O	NN

with	IN
O	NN

no	DT
O	NN

legal	JJ
O	NN

protections	NNS
O	VBP

these	DT
O	NN

dangers	NNS
O	NN

are	VBP
O	NN

particularly	RB
O	NN

serious	JJ
O	NN

The	DT
O	NN

efficiency	NN
O	NN

of	IN
O	NN

testicular	JJ
T	NN

sperm	NN
T	NN

retrieval	NN
T	NN

by	IN
T	NN

testicular	JJ
T	NN

fine	JJ
T	NN

needle	NN
T	NN

aspiration	NN
T	NN

(	NN
T	NN

TEFNA	NN
T	NN

)	NN
T	NN

was	VBD
O	NN

compared	VBN
O	NN

with	IN
O	NN

open	JJ
T	NN

biopsy	NN
T	NN

and	CC
T	NN

testicular	JJ
T	NN

sperm	NN
T	NN

extraction	NN
T	NN

(	NN
T	NN

TESE	NN
T	NN

)	NN
T	NN

,	,
O	NN

in	IN
O	NN

37	CD
O	NN

rigorously	RB
O	NN

selected	VBN
O	NN

patients	NNS
O	NN

with	IN
O	NN

non-obstructive	JJ
D	NN

azoospermia	NN
D	NN

All	DT
O	NN

patients	NNS
O	NN

underwent	VBD
O	NN

TEFNA	NN
T	NN

and	CC
O	NN

TESE	NN
T	NN

consecutively	RB
O	NN

Thus	RB
O	NN

,	,
O	NN

each	DT
O	NN

patient	NN
O	NN

served	VBD
O	NN

as	IN
O	NN

his	PRP$
O	NN

own	JJ
O	NN

control	NN
O	NN

The	DT
O	NN

case	NN
O	NN

was	VBD
O	NN

regarded	VBN
O	NN

as	IN
O	NN

successful	JJ
O	NN

if	IN
O	NN

at	IN
O	NN

least	JJS
O	NN

one	CD
O	NN

testicular	JJ
O	NN

spermatozoon	NN
O	NN

was	VBD
O	NN

found	VBN
O	NN

allowing	VBG
O	NN

intracytoplasmic	JJ
O	NN

sperm	NN
O	NN

injection	NN
O	NN

(	NN
O	NN

ICSI	NN
O	NN

)	NN
O	NN

of	IN
O	NN

at	IN
O	NN

least	JJS
O	NN

one	CD
O	NN

oocyte	NN
O	NN

The	DT
O	NN

mean	VB
O	NN

age	NN
O	NN

of	IN
O	NN

the	DT
O	NN

male	JJ
O	NN

patients	NNS
O	NN

was	VBD
O	NN

32.7	CD
O	NN

years	NNS
O	NN

(	NN
O	NN

range	NN
O	NN

24-47	CD
O	NN

)	NN
O	NN

Whereas	IN
O	NN

by	IN
O	NN

TEFNA	NN
T	NN

spermatozoa	NN
O	NN

enabling	VBG
O	NN

performance	NN
O	NN

of	IN
O	NN

ICSI	NN
O	NN

were	VBD
O	NN

found	VBN
O	NN

in	IN
O	NN

only	RB
O	NN

four	CD
O	NN

patients	NNS
O	NN

out	IN
O	NN

of	IN
O	NN

37	CD
O	NN

(	NN
O	NN

11	CD
O	NN

%	NN
O	NN

)	NN
O	NN

,	,
O	NN

open	JJ
T	NN

biopsy	NN
T	NN

and	CC
T	NN

TESE	NN
T	NN

yielded	VBD
O	NN

spermatozoa	NN
O	NN

in	IN
O	NN

16	CD
O	NN

cases	NNS
O	NN

(	NN
O	NN

43	CD
O	NN

%	NN
O	NN

)	NN
O	NN

The	DT
O	NN

negative	JJ
O	NN

predictive	JJ
O	NN

value	NN
O	NN

of	IN
O	NN

high	JJ
O	NN

serum	NN
O	NN

follicle	NN
O	NN

stimulating	VBG
O	NN

hormone	NN
O	NN

(	NN
O	NN

FSH	NN
O	NN

)	NN
O	NN

concentrations	NNS
O	NN

(	NN
O	NN

>	JJR
O	NN

or	CC
O	NN

=10	CD
O	NN

IU/l	NN
O	NN

)	NN
O	NN

(	NN
O	NN

predicting	VBG
O	NN

failure	NN
O	NN

to	TO
O	NN

find	VB
O	NN

spermatozoa	NN
O	NN

for	IN
O	NN

ICSI	NN
O	NN

)	NN
O	NN

was	VBD
O	NN

low	JJ
O	NN

(	NN
O	NN

38.4	CD
O	NN

%	NN
O	NN

)	NN
O	NN

The	DT
O	NN

positive	JJ
O	NN

predictive	JJ
O	NN

value	NN
O	NN

(	NN
O	NN

predicting	VBG
O	NN

the	DT
O	NN

chance	NN
O	NN

to	TO
O	NN

find	VB
O	NN

spermatozoa	NN
O	NN

for	IN
O	NN

ICSI	NN
O	NN

)	NN
O	NN

of	IN
O	NN

normal-sized	JJ
O	NN

testicle	NN
O	NN

was	VBD
O	NN

not	RB
O	NN

different	JJ
O	NN

from	IN
O	NN

that	IN
O	NN

of	IN
O	NN

small-sized	JJ
O	NN

(	NN
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

15	CD
O	NN

ml	NN
O	NN

)	NN
O	NN

testicle	NN
O	NN

(	NN
O	NN

50	CD
O	NN

%	NN
O	NN

)	NN
O	NN

Complications	NNS
O	NN

included	VBN
O	NN

one	CD
O	NN

case	NN
O	NN

of	IN
O	NN

testicular	JJ
D	NN

bleeding	NN
D	NN

following	VBG
O	NN

fine	JJ
T	NN

needle	NN
T	NN

aspiration	NN
T	NN

,	,
O	NN

treated	VBN
O	NN

locally	RB
O	NN

,	,
O	NN

and	CC
O	NN

two	CD
O	NN

cases	NNS
O	NN

of	IN
O	NN

extratunical	JJ
D	NN

haematomata	NN
D	NN

following	VBG
O	NN

TESE	NN
O	NN

requiring	VBG
O	NN

no	DT
O	NN

intervention	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

In	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

non-obstructive	JJ
O	NN

azoospermia	NN
O	NN

,	,
O	NN

TEFNA	NN
O	NN

has	VBZ
O	NN

a	DT
O	NN

significantly	RB
O	NN

lower	JJR
O	NN

yield	NN
O	NN

compared	VBN
O	NN

to	TO
O	NN

TESE	NN
O	NN

Performance	NNP
O	NNP

of	IN
O	NN

ICSI	NN
O	NN

with	IN
O	NN

testicular	JJ
O	NN

sperm	NN
O	NN

in	IN
O	NN

these	DT
O	NN

cases	NNS
O	NN

resulted	VBD
O	NN

in	IN
O	NN

satisfactory	JJ
O	NN

fertilization	NN
O	NN

and	CC
O	NN

high	JJ
O	NN

embryo	NN
O	NN

transfer	NN
O	NN

rates	NNS
O	VBP

The	DT
O	NN

implantation	NN
O	NN

and	CC
O	NN

pregnancy	NN
O	NN

rates	NNS
O	VBP

per	IN
O	NN

embryo	NN
O	NN

transfer	NN
O	NN

were	VBD
O	NN

13	CD
O	NN

and	CC
O	NN

29	CD
O	NN

%	NN
O	NN

respectively	RB
O	NN

Neither	DT
O	NN

serum	NN
O	NN

FSH	NN
O	NN

values	NNS
O	VBP

nor	CC
O	NN

testicular	JJ
O	NN

size	NN
O	NN

were	VBD
O	NN

predictive	JJ
O	NN

of	IN
O	NN

the	DT
O	NN

chances	NNS
O	NN

to	TO
O	NN

find	VB
O	NN

spermatozoa	NN
O	NN

for	IN
O	NN

ICSI	NN
O	NN

Some	DT
O	NN

complications	NNS
O	NN

may	MD
O	NNP

occur	VB
O	NN

even	RB
O	NN

following	VBG
O	NN

TEFNA	NN
T	NN

Cyclin	NN
O	NN

D1	NN
O	NN

,	,
O	NN

the	DT
O	NN

regulatory	JJ
O	NN

subunit	NN
O	NN

of	IN
O	NN

certain	JJ
O	NN

protein	NN
O	NN

kinases	NNS
O	NN

thought	VBN
O	NN

to	TO
O	NN

advance	NN
O	NN

the	DT
O	NN

G1	NN
O	NN

phase	NN
O	NN

of	IN
O	NN

the	DT
O	NN

cell	NN
O	NN

cycle	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

now	RB
O	NN

established	VBN
O	NN

as	IN
O	NN

a	DT
O	NN

proto-oncogene	NN
O	NN

,	,
O	NN

with	IN
O	NN

evidence	NN
O	NN

indicating	VBG
O	NN

that	IN
O	NN

its	PRP$
O	NN

derangement	NN
O	NN

may	MD
O	NNP

contribute	VB
O	NN

to	TO
O	NN

the	DT
O	NN

uncontrolled	JJ
O	NN

cell	NN
O	NN

growth	NN
O	NN

characteristic	JJ
O	NN

of	IN
O	NN

tumors	NNS
D	NN

The	DT
O	NN

chromosomal	JJ
O	NN

translocation	NN
O	NN

t	NN
O	NN

(	NN
O	NN

11	CD
O	NN

;	:
O	NN

14	CD
O	NN

)	NN
O	NN

(	NN
O	NN

q13	NN
O	NN

:	:
O	NN

q32	NN
O	NN

)	NN
O	NN

,	,
O	NN

involving	VBG
O	NN

rearrangement	NN
O	NN

of	IN
O	NN

the	DT
O	NN

BCL-1	NN
O	NN

locus	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

closely	RB
O	NN

associated	VBN
O	NN

with	IN
O	NN

human	JJ
D	NN

lymphoid	JJ
D	NN

neoplasia	NN
D	NN

affecting	VBG
O	NN

mantle	NN
D	NN

cell	NN
D	NN

lymphomas	NNS
D	NN

(	NN
D	NN

MCL	NN
D	NN

)	NN
D	NN

Recently	RB
O	NN

,	,
O	NN

the	DT
O	NN

putative	JJ
O	NN

BCL-1	NN
O	NN

proto-oncogene	NN
O	NN

turned	VBD
O	NN

out	IN
O	NN

to	TO
O	NN

be	VB
O	NN

none	NN
O	NN

other	JJ
O	NN

than	IN
O	NN

the	DT
O	NN

cyclin	NN
O	NN

D1	NN
O	NN

gene	NN
O	NN

Although	IN
O	NN

the	DT
O	NN

observed	VBN
O	NN

break	NN
O	NN

points	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

BCL-1	NN
O	NN

locus	NN
O	NN

are	VBP
O	NN

not	RB
O	NN

tightly	RB
O	NN

clustered	VBN
O	NN

,	,
O	NN

its	PRP$
O	NN

rearrangement	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

documented	VBN
O	NN

in	IN
O	NN

40-70	CD
O	NN

%	NN
O	NN

of	IN
O	NN

cases	NNS
O	NN

of	IN
O	NN

mantle	NN
D	NN

cell	NN
D	NN

lymphoma	NN
D	NN

,	,
O	NN

whereas	IN
O	NN

it	PRP
O	NN

only	RB
O	NN

rarely	RB
O	NN

occurs	VBZ
O	NN

in	IN
O	NN

other	JJ
O	NN

B	NN
D	NN

cell	NN
D	NN

lymphomas	NNS
D	NN

Of	IN
O	NN

note	NN
O	NN

,	,
O	NN

all	DT
O	NN

of	IN
O	NN

the	DT
O	NN

known	JJ
O	NN

break	NN
O	NN

points	NNS
O	NN

leave	VB
O	NNP

the	DT
O	NN

cyclin	NN
O	NN

D1	NN
O	NN

coding	VBG
O	NN

region	NN
O	NN

structurally	RB
O	NN

intact	JJ
O	NN

and	CC
O	NN

result	NN
O	NN

in	IN
O	NN

increased	VBN
O	NN

protein	NN
O	NN

expression	NN
O	NN

,	,
O	NN

implying	VBG
O	NN

that	IN
O	NN

this	DT
O	NN

may	MD
O	NNP

provide	VB
O	NN

a	DT
O	NN

highly	RB
O	NN

sensitive	JJ
O	NN

and	CC
O	NN

specific	JJ
O	NN

marker	NN
O	NN

for	IN
O	NN

MCL	NN
D	NN

Recent	JJ
O	NN

studies	NNS
O	VBP

demonstrated	VBD
O	NN

that	IN
O	NN

immunohistochemical	JJ
O	NN

detection	NN
O	NN

in	IN
O	NN

paraffin-embedded	JJ
O	NN

material	NN
O	NN

,	,
O	NN

using	VBG
O	NN

a	DT
O	NN

monoclonal	JJ
O	NN

antibody	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

very	RB
O	NN

useful	JJ
O	NN

for	IN
O	NN

routine	JJ
O	NN

diagnosis	NN
O	NN

Current	JJ
O	NN

knowledge	NN
O	NN

of	IN
O	NN

cyclin	NN
O	NN

D1	NN
O	NN

overexpression	NN
O	NN

in	IN
O	NN

malignant	JJ
D	NN

lymphomas	NNS
D	NN

,	,
O	NN

with	IN
O	NN

emphasis	NN
O	NN

on	IN
O	NN

its	PRP$
O	NN

clinicopathologic	JJ
O	NN

significance	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

reviewed	VBN
O	NN

In	IN
O	NN

the	DT
O	NN

mammalian	JJ
O	NN

central	JJ
O	NN

nervous	JJ
O	NN

system	NN
O	NN

,	,
O	NN

a	DT
O	NN

diverse	JJ
O	NN

group	NN
O	NN

of	IN
O	NN

basic	JJ
O	NN

helix-loop-helix	JJ
O	NN

(	NN
O	NN

bHLH	JJ
O	NN

)	NN
O	NN

proteins	NNS
O	NN

is	VBZ
O	NN

involved	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

determination	NN
O	NN

of	IN
O	NN

progenitor	NN
O	NN

cells	NNS
O	VBP

and	CC
O	NN

,	,
O	NN

subsequently	RB
O	NN

,	,
O	NN

in	IN
O	NN

regulating	VBG
O	NN

neuronal	JJ
O	NN

differentiation	NN
O	NN

Here	RB
O	NN

we	PRP
O	VBP

report	NN
O	NN

the	DT
O	NN

identification	NN
O	NN

of	IN
O	NN

a	DT
O	NN

novel	JJ
O	NN

subfamily	NN
O	NN

of	IN
O	NN

bHLH	JJ
O	NN

proteins	NNS
O	NN

,	,
O	NN

defined	VBN
O	NN

by	IN
O	NN

two	CD
O	NN

mammalian	JJ
O	NN

enhancer-of-split-	JJ
O	NN

and	CC
O	NN

hairy-related	JJ
O	NN

proteins	NNS
O	NN

,	,
O	NN

termed	VBN
O	NN

SHARP-1	NN
O	NN

and	CC
O	NN

SHARP-2	NN
O	NN

In	IN
O	NN

contrast	NN
O	NN

to	TO
O	NN

known	JJ
O	NN

bHLH	JJ
O	NN

genes	NNS
O	NN

,	,
O	NN

detectable	JJ
O	NN

transcription	NN
O	NN

of	IN
O	NN

SHARP	JJ
O	NN

genes	NNS
O	NN

begins	VBZ
O	NN

at	IN
O	NN

the	DT
O	NN

end	NN
O	NN

of	IN
O	NN

embryonic	JJ
O	NN

development	NN
O	NN

marking	VBG
O	NN

differentiated	VBN
O	NN

neurons	NNS
O	NN

that	IN
O	NN

have	VB
O	NN

reached	VBN
O	NN

a	DT
O	NN

final	JJ
O	NN

position	NN
O	NN

,	,
O	NN

and	CC
O	NN

increases	NNS
O	NN

as	IN
O	NN

postnatal	JJ
O	NN

development	NN
O	NN

proceeds	NNS
O	NN

In	IN
O	NN

the	DT
O	NN

adult	JJ
O	NN

,	,
O	NN

SHARP	JJ
O	NN

genes	NNS
O	NN

are	VBP
O	NN

expressed	VBN
O	NN

in	IN
O	NN

subregions	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

CNS	NN
O	NN

that	IN
O	NN

have	VB
O	NN

been	VBN
O	NN

associated	VBN
O	NN

with	IN
O	NN

adult	JJ
O	NN

plasticity	NN
O	NN

In	IN
O	NN

PC12	NN
O	NN

cells	NNS
O	VBP

,	,
O	NN

a	DT
O	NN

model	NN
O	NN

system	NN
O	NN

to	TO
O	NN

study	NN
O	NN

neurite	NN
O	NN

outgrowth	NN
O	NN

,	,
O	NN

SHARP	JJ
O	NN

genes	NNS
O	NN

can	MD
O	NNP

be	VB
O	NN

induced	VBN
O	NN

by	IN
O	NN

NGF	NN
O	NN

with	IN
O	NN

the	DT
O	NN

kinetics	NNS
O	NN

of	IN
O	NN

an	DT
O	NN

immediate-early	JJ
O	NN

gene	NN
O	NN

Similarly	RB
O	NN

,	,
O	NN

within	IN
O	NN

1	CD
O	NN

h	NN
O	NN

after	IN
O	NN

the	DT
O	NN

administration	NN
O	NN

of	IN
O	NN

kainic	JJ
O	NN

acid	NN
O	NN

in	IN
O	NN

vivo	FW
O	FW

,	,
O	NN

SHARP-2	NN
O	NN

is	VBZ
O	NN

induced	VBN
O	NN

in	IN
O	NN

neurons	NNS
O	NN

throughout	IN
O	NN

the	DT
O	NN

rat	NN
O	NN

cerebral	JJ
O	NN

cortex	NN
O	NN

This	DT
O	NN

suggests	VBZ
O	NN

that	IN
O	NN

neuronal	JJ
O	NN

bHLH	JJ
O	NN

proteins	NNS
O	NN

are	VBP
O	NN

also	RB
O	NN

involved	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

``	``
O	NN

adaptive	JJ
O	NN

''	''
O	NN

changes	NNS
O	VBP

of	IN
O	NN

mature	JJ
O	NN

CNS	NN
O	NN

neurons	NNS
O	NN

which	WDT
O	NN

are	VBP
O	NN

coupled	VBN
O	NN

to	TO
O	NN

glutamatergic	JJ
O	NN

stimulation	NN
O	NN

The	DT
O	NN

embryonic	JJ
O	NN

development	NN
O	NN

of	IN
O	NN

the	DT
O	NN

face	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

studied	VBN
O	NN

in	IN
O	NN

many	JJ
O	NN

reviews	NNS
O	VBP

,	,
O	NN

this	DT
O	NN

work	NN
O	NN

purposes	NNS
O	VBP

only	RB
O	NN

to	TO
O	NN

clear	JJ
O	NN

up	RB
O	NN

some	DT
O	NN

points	NNS
O	NN

which	WDT
O	NN

remain	VBP
O	NN

obscure	JJ
O	NN

concerning	VBG
O	NN

cervico-facial	JJ
O	NN

morphogenesis	NN
O	NN

In	IN
O	NN

the	DT
O	NN

first	RB
O	NN

part	NN
O	NN

of	IN
O	NN

this	DT
O	NN

study	NN
O	NN

only	RB
O	NN

the	DT
O	NN

facial	JJ
O	NN

development	NN
O	NN

,	,
O	NN

properly	RB
O	NN

speaking	VBG
O	NN

,	,
O	NN

is	VBZ
O	NN

considered	VBN
O	NN

,	,
O	NN

although	IN
O	NN

it	PRP
O	NN

can	MD
O	NNP

not	RB
O	NN

be	VB
O	NN

separate	JJ
O	NN

of	IN
O	NN

cervical	JJ
O	NN

development	NN
O	NN

to	TO
O	NN

which	WDT
O	NN

a	DT
O	NN

second	JJ
O	NN

study	NN
O	NN

will	MD
O	VB

be	VB
O	NN

reserved	VBN
O	NN

In	IN
O	NN

the	DT
O	NN

present	JJ
O	NN

study	NN
O	NN

we	PRP
O	VBP

recall	NN
O	NN

the	DT
O	NN

particular	JJ
O	NN

aspects	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

neurulation	NN
O	NN

in	IN
O	NN

the	DT
O	NN

cephalic	JJ
O	NN

area	NN
O	NN

,	,
O	NN

then	RB
O	NN

the	DT
O	NN

establishment	NN
O	NN

of	IN
O	NN

the	DT
O	NN

facial	JJ
O	NN

processes	NNS
O	VBP

Then	RB
O	NN

we	PRP
O	VBP

approach	NN
O	NN

among	IN
O	NN

other	JJ
O	NN

things	NNS
O	NN

the	DT
O	NN

way	NN
O	NN

to	TO
O	NN

consider	VB
O	NN

the	DT
O	NN

maxillary	JJ
O	NN

process	NN
O	NN

with	IN
O	NN

regard	NN
O	NN

to	TO
O	NN

the	DT
O	NN

other	JJ
O	NN

facial	JJ
O	NN

processes	NNS
O	VBP

After	IN
O	NN

is	VBZ
O	NN

considered	VBN
O	NN

constitution	NN
O	NN

and	CC
O	NN

natured	JJ
O	NN

of	IN
O	NN

the	DT
O	NN

prechordal	JJ
O	NN

plate	NN
O	NN

which	WDT
O	NN

has	VBZ
O	NN

been	VBN
O	NN

diversely	RB
O	NN

explained	VBN
O	NN

Finally	RB
O	NN

,	,
O	NN

the	DT
O	NN

modelling	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

face	NN
O	NN

is	VBZ
O	NN

evocated	VBN
O	NN

,	,
O	NN

in	IN
O	NN

which	WDT
O	NN

the	DT
O	NN

dissociation	NN
O	NN

between	IN
O	NN

the	DT
O	NN

olfactive	JJ
O	NN

and	CC
O	NN

buccal	JJ
O	NN

spheres	NNS
O	NN

is	VBZ
O	NN

pointed	JJ
O	NN

out	IN
O	NN

,	,
O	NN

with	IN
O	NN

the	DT
O	NN

disparition	NN
O	NN

of	IN
O	NN

the	DT
O	NN

muzzle	NN
O	NN

,	,
O	NN

as	IN
O	NN

it	PRP
O	NN

is	VBZ
O	NN

established	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

haplorhinae	NN
O	NN

,	,
O	NN

a	DT
O	NN

class	NN
O	NN

of	IN
O	NN

primates	NNS
O	NN

in	IN
O	NN

which	WDT
O	NN

the	DT
O	NN

human	JJ
O	NN

being	VBG
O	NN

is	VBZ
O	NN

involved	VBN
O	NN

This	DT
O	NN

phenomenon	NN
O	NN

raises	VBZ
O	NN

different	JJ
O	NN

questions	NNS
O	NN

,	,
O	NN

in	IN
O	NN

particular	JJ
O	NN

about	IN
O	NN

the	DT
O	NN

relation	NN
O	NN

of	IN
O	NN

this	DT
O	NN

disposition	NN
O	NN

with	IN
O	NN

the	DT
O	NN

nasoseptal	JJ
O	NN

center	NN
O	NN

,	,
O	NN

the	DT
O	NN

medial	JJ
O	NN

part	NN
O	NN

of	IN
O	NN

the	DT
O	NN

nasodorsal	JJ
O	NN

center	NN
O	NN

A	DT
O	NN

case-control	JJ
O	NN

study	NN
O	NN

was	VBD
O	NN

performed	VBN
O	NN

in	IN
O	NN

eight	CD
O	NN

pairs	NNS
O	NN

of	IN
O	NN

women	NNS
O	VBP

to	TO
O	NN

determine	VB
O	NN

whether	IN
O	NN

preeclamptic	JJ
O	NN

women	NNS
O	VBP

developed	VBN
O	NN

abnormalities	NNS
O	NN

in	IN
O	NN

minor	JJ
O	NN

hemoglobins	NNS
O	NN

,	,
O	NN

glycolytic	JJ
O	NN

enzymes	NNS
O	NN

,	,
O	NN

or	CC
O	NN

other	JJ
O	NN

blood	NN
O	NN

components	NNS
O	NN

that	IN
O	NN

might	MD
O	NNP

provide	VB
O	NN

insight	NN
O	NN

into	IN
O	NN

the	DT
O	NN

pathophysiology	NN
O	NN

of	IN
O	NN

preeclampsia	NN
D	NN

,	,
O	NN

or	CC
O	NN

that	IN
O	NN

in	IN
O	NN

combination	NN
O	NN

might	MD
O	NNP

be	VB
O	NN

used	VBN
O	NN

as	IN
O	NN

a	DT
O	NN

marker	NN
O	NN

for	IN
O	NN

the	DT
O	NN

condition	NN
O	NN

These	DT
O	NN

variables	NNS
O	NN

and	CC
O	NN

standard	JJ
O	NN

clinical	JJ
O	NN

tests	NNS
O	NN

were	VBD
O	NN

analyzed	VBN
O	NN

as	IN
O	NN

discriminators	NNS
O	NN

between	IN
O	NN

preeclamptic	JJ
O	NN

and	CC
O	NN

control	NN
O	NN

women	NNS
O	VBP

The	DT
O	NN

subjects	NNS
O	NN

were	VBD
O	NN

matched	VBN
O	NN

for	IN
O	NN

age	NN
O	NN

,	,
O	NN

ethnicity	NN
O	NN

,	,
O	NN

parity	NN
O	NN

,	,
O	NN

and	CC
O	NN

gestational	JJ
O	NN

age	NN
O	NN

Blood	NN
O	NN

samples	NNS
O	NN

were	VBD
O	NN

taken	VBN
O	NN

at	IN
O	NN

the	DT
O	NN

time	NN
O	NN

of	IN
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

preeclampsia	NN
D	NN

and	CC
O	NN

at	IN
O	NN

comparable	JJ
O	NN

gestational	JJ
O	NN

ages	NNS
O	NN

for	IN
O	NN

matched	VBN
O	NN

normal	JJ
O	NN

controls	NNS
O	VBP

Variables	NNS
O	NN

differing	VBG
O	NN

significantly	RB
O	NN

between	IN
O	NN

groups	NNS
O	NN

included	VBN
O	NN

increases	NNS
O	NN

in	IN
O	NN

uric	JJ
O	NN

acid	NN
O	NN

(	NN
O	NN

UA	NNP
O	NNP

)	NN
O	NN

,	,
O	NN

low-density	JJ
O	NN

lipoproteins	NNS
O	NN

(	NN
O	NN

LDL	NN
O	NN

)	NN
O	NN

,	,
O	NN

phosphoglycerate	NN
O	NN

kinase	NN
O	NN

(	NN
O	NN

PGK	NN
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

mean	VB
O	NN

platelet	NN
O	NN

volume	NN
O	NN

(	NN
O	NN

MPV	NN
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

decreases	NNS
O	NN

in	IN
O	NN

glyceraldehyde	NN
O	NN

phosphate	NN
O	NN

dehydrogenase	NN
O	NN

(	NN
O	NN

G3PD	NN
O	NN

)	NN
O	NN

in	IN
O	NN

preeclamptic	JJ
O	NN

women	NNS
O	VBP

compared	VBN
O	NN

to	TO
O	NN

normal	JJ
O	NN

controls	NNS
O	VBP

Discriminant	JJ
O	NN

analysis	NN
O	NN

revealed	VBD
O	NN

the	DT
O	NN

following	VBG
O	NN

function	NN
O	NN

to	TO
O	NN

separate	JJ
O	NN

the	DT
O	NN

groups	NNS
O	NN

:	:
O	NN

0.7764	CD
O	NN

(	NN
O	NN

UA	NNP
O	NNP

)	NN
O	NN

+	CC
O	NN

0.8086	CD
O	NN

(	NN
O	NN

PGK	NN
O	NN

)	NN
O	NN

-0.7032	CD
O	NN

(	NN
O	NN

G3PD	NN
O	NN

)	NN
O	NN

+	CC
O	NN

0.1399	CD
O	NN

(	NN
O	NN

LDL	NN
O	NN

)	NN
O	NN

-0.2386	CD
O	NN

(	NN
O	NN

MPV	NN
O	NN

)	NN
O	NN

A	DT
O	NN

discriminant	JJ
O	NN

score	NN
O	NN

of	IN
O	NN

>	JJR
O	NN

or	CC
O	NN

=	JJ
O	NN

275	CD
O	NN

indicated	VBD
O	NN

a	DT
O	NN

>	JJR
O	NN

or	CC
O	NN

=	JJ
O	NN

90	CD
O	NN

%	NN
O	NN

probability	NN
O	NN

of	IN
O	NN

preeclampsia	NN
D	NN

The	DT
O	NN

results	NNS
O	VBP

are	VBP
O	NN

consistent	JJ
O	NN

with	IN
O	NN

perturbations	NNS
O	NN

in	IN
O	NN

red	JJ
O	NN

cell	NN
O	NN

glycolysis	NN
O	NN

in	IN
O	NN

preeclampsia	NN
D	NN

Further	JJ
O	NN

prospective	JJ
O	NN

studies	NNS
O	VBP

are	VBP
O	NN

warranted	VBN
O	NN

to	TO
O	NN

test	NN
O	NN

the	DT
O	NN

efficacy	NN
O	NN

of	IN
O	NN

this	DT
O	NN

discriminant	JJ
O	NN

function	NN
O	NN

in	IN
O	NN

predicting	VBG
O	NN

preeclampsia	NN
D	NN

A	DT
O	NN

novel	JJ
O	NN

technique	NN
O	NN

for	IN
O	NN

patterning	NN
O	NN

immobilized	VBN
O	NN

antibody	NN
O	NN

layers	NNS
O	NN

based	VBN
O	NN

upon	IN
O	NN

photolithography	NN
O	NN

and	CC
O	NN

oxygen	NN
O	NN

plasma	NN
O	NN

exposure	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

developed	VBN
O	NN

Mouse	NN
O	NN

monoclonal	JJ
O	NN

antibodies	NNS
O	NN

specific	JJ
O	NN

for	IN
O	NN

thiabendazole	JJ
T	NN

(	NN
O	NN

a	DT
O	NN

post-harvest	JJ
O	NN

fungicide	NN
O	NN

and	CC
O	NN

veterinary	JJ
O	NN

anthelmintic	JJ
O	NN

)	NN
O	NN

were	VBD
O	NN

covalently	RB
O	NN

linked	VBN
O	NN

through	IN
O	NN

free	JJ
O	NN

amine	NN
O	NN

groups	NNS
O	NN

to	TO
O	NN

aminosilanized	VBN
O	NN

silicon	NN
O	NN

dioxide	NN
O	NN

films	NNS
O	NN

using	VBG
O	NN

glutaraldehyde	NN
O	NN

Immobilized	VBN
O	NN

antibody	NN
O	NN

layers	NNS
O	NN

were	VBD
O	NN

stabilized	VBN
O	NN

with	IN
O	NN

sucrose	NN
O	NN

,	,
O	NN

dehydrated	JJ
O	NN

,	,
O	NN

and	CC
O	NN

stored	VBN
O	NN

refrigerated	VBN
O	NN

with	IN
O	NN

desiccant	JJ
O	NN

Photolithographic	JJ
O	NN

patterning	NN
O	NN

was	VBD
O	NN

performed	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

positive	JJ
O	NN

photoresist	NN
O	NN

with	IN
O	NN

modified	VBN
O	NN

bake	VB
O	NN

temperatures	NNS
O	NN

and	CC
O	NN

times	NNS
O	NN

,	,
O	NN

selective	JJ
O	NN

UV	NN
O	NN

exposure	NN
O	NN

with	IN
O	NN

a	DT
O	NN

contact	NN
O	NN

mask	NN
O	NN

,	,
O	NN

and	CC
O	NN

aqueous	JJ
O	NN

alkaline	NN
O	NN

solubilization	NN
O	NN

of	IN
O	NN

exposed	VBN
O	NN

resist	VB
O	NN

Exposed	VBN
O	NN

regions	NNS
O	NN

of	IN
O	NN

immobilized	VBN
O	NN

antibody	NN
O	NN

were	VBD
O	NN

then	RB
O	NN

removed	VBN
O	NN

by	IN
O	NN

exposure	NN
O	NN

to	TO
O	NN

a	DT
O	NN

low	JJ
O	NN

power	NN
O	NN

,	,
O	NN

radio	NN
O	NN

frequency	NN
O	NN

oxygen	NN
O	NN

discharge	NN
O	NN

Residual	JJ
O	NN

resist	VB
O	NN

was	VBD
O	NN

stripped	VBN
O	NN

with	IN
O	NN

acetone	NN
O	NN

Successful	JJ
O	NN

patterning	NN
O	NN

was	VBD
O	NN

demonstrated	VBD
O	NN

by	IN
O	NN

challenging	VBG
O	NN

surfaces	NNS
O	NN

with	IN
O	NN

goat	NN
O	NN

anti-mouse	JJ
O	NN

antibody	NN
O	NN

conjugated	VBN
O	NN

to	TO
O	NN

tetramethylrhodamine	NN
O	NN

isothiocyanate	NN
O	NN

Sucrose	NN
O	NN

stabilization	NN
O	NN

was	VBD
O	NN

necessary	JJ
O	NN

for	IN
O	NN

antibody	NN
O	NN

to	TO
O	NN

undergo	VB
O	NN

photoresist	NN
O	NN

processing	VBG
O	NN

without	IN
O	NN

loss	NN
O	NN

of	IN
O	NN

binding	VBG
O	NN

activity	NN
O	NN

Challenge	NN
O	NN

with	IN
O	NN

enzyme	NN
O	NN

linked	VBN
O	NN

antigen	NN
O	NN

of	IN
O	NN

oxygen	NN
O	NN

plasma	NN
O	NN

exposed	VBN
O	NN

antibody	NN
O	NN

layers	NNS
O	NN

demonstrated	VBD
O	NN

that	IN
O	NN

plasma	NN
O	NN

treatment	NN
O	NN

completely	RB
O	NN

neutralized	VBD
O	NN

antibody	NN
O	NN

capture	NN
O	NN

ability	NN
O	NN

Ellipsometry	NN
O	NN

measurements	NNS
O	NN

of	IN
O	NN

oxygen	NN
O	NN

plasma	NN
O	NN

exposed	VBN
O	NN

antibody	NN
O	NN

layers	NNS
O	NN

indicated	VBD
O	NN

complete	JJ
O	NN

removal	NN
O	NN

of	IN
O	NN

immobilized	VBN
O	NN

antibodies	NNS
O	NN

Fluorescent	JJ
O	NN

imaging	NN
O	NN

demonstrated	VBD
O	NN

smallest	JJS
O	NN

line	NN
O	NN

widths	NNS
O	NN

of	IN
O	NN

2-3	CD
O	NN

microns	NNS
O	NN

Immune	JJ
O	NN

cells	NNS
O	VBP

in	IN
O	NN

vivo	FW
O	FW

routinely	RB
O	NN

perform	VB
O	NN

highly	RB
O	NN

selective	JJ
O	NN

immunosensing	NN
O	NN

in	IN
O	NN

blood	NN
O	NN

and	CC
O	NN

tissues	NNS
O	NN

as	IN
O	NN

part	NN
O	NN

of	IN
O	NN

their	PRP$
O	NN

normal	JJ
O	NN

immune	JJ
O	NN

surveillance	NN
O	NN

functions	NNS
O	VBP

We	PRP
O	VBP

have	VB
O	NN

been	VBN
O	NN

investigating	VBG
O	NN

the	DT
O	NN

potential	JJ
O	NN

of	IN
O	NN

exploiting	VBG
O	NN

the	DT
O	NN

immunosensing	NN
O	NN

detection	NN
O	NN

abilities	NNS
O	NN

of	IN
O	NN

excitable	JJ
O	NN

immune	JJ
O	NN

cells	NNS
O	VBP

(	NN
O	NN

i.e	NN
O	NN

.	.
O	NN

the	DT
O	NN

mast	NN
O	NN

cell	NN
O	NN

)	NN
O	NN

for	IN
O	NN

the	DT
O	NN

development	NN
O	NN

of	IN
O	NN

whole	JJ
O	NN

cell	NN
O	NN

immunobiosensors	NNS
O	NN

A	DT
O	NN

key	JJ
O	NN

feature	NN
O	NN

is	VBZ
O	NN

that	IN
O	NN

these	DT
O	NN

immune	JJ
O	NN

cells	NNS
O	VBP

can	MD
O	NNP

be	VB
O	NN

selectively	RB
O	NN

engineered	VBN
O	NN

to	TO
O	NN

recognize	VB
O	NNP

specific	JJ
O	NN

antigens	NNS
O	NN

in	IN
O	NN

vitro	FW
O	FW

In	IN
O	NN

the	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

antigen	NN
O	NN

,	,
O	NN

these	DT
O	NN

cells	NNS
O	VBP

undergo	VB
O	NN

excitable	JJ
O	NN

activation	NN
O	NN

responses	NNS
O	NN

which	WDT
O	NN

result	NN
O	NN

in	IN
O	NN

increased	VBN
O	NN

metabolism	NN
O	NN

and	CC
O	NN

the	DT
O	NN

exocytosis	NN
O	NN

of	IN
O	NN

stored	VBN
O	NN

intracellular	JJ
O	NN

mediators	NNS
O	NN

We	PRP
O	VBP

have	VB
O	NN

previously	RB
O	NN

determined	VBN
O	NN

that	IN
O	NN

mast	NN
O	NN

cell	NN
O	NN

metabolic	JJ
O	NN

responses	NNS
O	NN

can	MD
O	NNP

be	VB
O	NN

thermally	RB
O	NN

transduced	VBN
O	NN

in	IN
O	NN

real	JJ
O	NN

time	NN
O	NN

,	,
O	NN

thus	RB
O	NN

indicating	VBG
O	NN

the	DT
O	NN

possibility	NN
O	NN

of	IN
O	NN

whole	JJ
O	NN

cell	NN
O	NN

thermoelectric	JJ
O	NN

immunobiosensing	NN
O	NN

In	IN
O	NN

this	DT
O	NN

work	NN
O	NN

we	PRP
O	VBP

investigated	VBN
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

enzyme	NN
O	NN

amplification	NN
O	NN

systems	NNS
O	NN

to	TO
O	NN

enhance	VB
O	NN

the	DT
O	NN

direct	JJ
O	NN

transduction	NN
O	NN

of	IN
O	NN

immune	JJ
O	NN

cell	NN
O	NN

responses	NNS
O	NN

to	TO
O	NN

analyte	NN
O	NN

It	PRP
O	NN

was	VBD
O	NN

found	VBN
O	NN

that	IN
O	NN

with	IN
O	NN

appropriate	JJ
O	NN

enzymes	NNS
O	NN

,	,
O	NN

peak	JJ
O	NN

outputs	NNS
O	NN

occurred	VBD
O	NN

within	IN
O	NN

approximately	RB
O	NN

5	CD
O	NN

min	NN
O	NN

(	NN
O	NN

4-20	CD
O	NN

times	NNS
O	NN

faster	RBR
O	NN

than	IN
O	NN

without	IN
O	NN

enzymes	NNS
O	NN

)	NN
O	NN

and	CC
O	NN

peak	JJ
O	NN

response	NN
O	NN

magnitudes	NNS
O	NN

were	VBD
O	NN

up	RB
O	NN

to	TO
O	NN

nine-fold	JJ
O	NN

greater	JJR
O	NN

than	IN
O	NN

without	IN
O	NN

enzymes	NNS
O	NN

An	DT
O	NN

easy-to-use	JJ
O	NN

technique	NN
O	NN

for	IN
O	NN

detection	NN
O	NN

of	IN
O	NN

antibodies	NNS
O	NN

specific	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

parasite	NN
O	NN

L.	NNP
O	NNP

donovani	JJ
O	NN

in	IN
O	NN

human	JJ
O	NN

serum	NN
O	NN

sample	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

developed	VBN
O	NN

The	DT
O	NN

method	NN
O	NN

is	VBZ
O	NN

based	VBN
O	NN

on	IN
O	NN

an	DT
O	NN

evanescent	JJ
O	NN

wave	NN
O	NN

generated	VBN
O	NN

from	IN
O	NN

a	DT
O	NN

tapered	VBN
O	NN

configuration	NN
O	NN

of	IN
O	NN

decladded	VBN
O	NN

optical	JJ
O	NN

fibre	NN
O	NN

and	CC
O	NN

does	VBZ
O	NNP

not	RB
O	NN

require	VB
O	NN

any	DT
O	NN

volumetric	JJ
O	NN

measurement	NN
O	NN

Tapered	VBN
O	NN

fibres	NNS
O	NN

are	VBP
O	NN

immobilized	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

purified	VBN
O	NN

cell	NN
O	NN

surface	NN
O	NN

protein	NN
O	NN

of	IN
O	NN

L.	NNP
O	NNP

donovani	JJ
O	NN

by	IN
O	NN

covalent	JJ
O	NN

bonding	NN
O	NN

Treated	VBN
O	NN

fibres	NNS
O	NN

are	VBP
O	NN

incubated	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

patient	NN
O	NN

serum	NN
O	NN

for	IN
O	NN

10	CD
O	NN

min	NN
O	NN

followed	VBN
O	NN

by	IN
O	NN

incubation	NN
O	NN

with	IN
O	NN

goat	NN
O	NN

anti	JJ
O	NN

human	JJ
O	NN

IgG	NN
O	NN

tagged	VBN
O	NN

FITC	NN
O	NN

Fluorescent	JJ
O	NN

intensity	NN
O	NN

from	IN
O	NN

the	DT
O	NN

fibre	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

shown	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

proportional	JJ
O	NN

to	TO
O	NN

L.	NNP
O	NNP

donovani	JJ
O	NN

specific	JJ
O	NN

antibodies	NNS
O	NN

present	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

test	NN
O	NN

sera	NNS
O	VBP

Direct	JJ
O	NN

readings	NNS
O	NN

can	MD
O	NNP

be	VB
O	NN

obtained	VBN
O	NN

after	IN
O	NN

signal	NN
O	NN

enhancement	NN
O	NN

through	IN
O	NN

a	DT
O	NN

photomultiplier	NN
O	NN

tube	NN
O	NN

within	IN
O	NN

5	CD
O	NN

min	NN
O	NN

The	DT
O	NN

system	NN
O	NN

,	,
O	NN

when	WRB
O	NN

tested	VBN
O	NN

on	IN
O	NN

12	CD
O	NN

positive	JJ
O	NN

sera	NNS
O	VBP

,	,
O	NN

did	VBD
O	NNP

not	RB
O	NN

show	NN
O	NN

any	DT
O	NN

false	JJ
O	NN

negative	JJ
O	NN

result	NN
O	NN

Also	RB
O	NN

,	,
O	NN

no	DT
O	NN

false	JJ
O	NN

positive	JJ
O	NN

result	NN
O	NN

was	VBD
O	NN

obtained	VBN
O	NN

with	IN
O	NN

serum	NN
O	NN

samples	NNS
O	NN

of	IN
O	NN

patients	NNS
O	NN

infected	JJ
O	NN

with	IN
O	NN

leprosy	NNP
D	NNP

,	,
O	NN

tuberculosis	NN
D	NN

,	,
O	NN

typhoid	NN
D	NN

and	CC
O	NN

malaria	NN
D	NN

,	,
O	NN

showing	VBG
O	NN

the	DT
O	NN

specificity	NN
O	NN

of	IN
O	NN

the	DT
O	NN

sensor	NN
O	NN

and	CC
O	NN

efficacy	NN
O	NN

of	IN
O	NN

the	DT
O	NN

technique	NN
O	NN

We	PRP
O	VBP

present	JJ
O	NN

an	DT
O	NN

optical	JJ
O	NN

biosensor	NN
O	NN

design	NN
O	NN

that	IN
O	NN

expands	NNS
O	NN

the	DT
O	NN

utility	NN
O	NN

of	IN
O	NN

enzyme	NN
O	NN

biosensors	NNS
O	NN

These	DT
O	NN

biosensors	NNS
O	NN

are	VBP
O	NN

fabricated	VBN
O	NN

by	IN
O	NN

site-selective	JJ
O	NN

photodeposition	NN
O	NN

of	IN
O	NN

analyte-sensitive	JJ
O	NN

polymer	NN
O	NN

matrices	NNS
O	NN

on	IN
O	NN

optical	JJ
O	NN

imaging	NN
O	NN

fibres	NNS
O	NN

These	DT
O	NN

dual-analyte	JJ
O	NN

arrays	NNS
O	NN

allow	VB
O	NN

for	IN
O	NN

the	DT
O	NN

simultaneous	JJ
O	NN

,	,
O	NN

independent	JJ
O	NN

measurement	NN
O	NN

of	IN
O	NN

the	DT
O	NN

analyte	NN
O	NN

of	IN
O	NN

interest	NN
O	NN

and	CC
O	NN

the	DT
O	NN

transducing	VBG
O	NN

analyte	NN
O	NN

The	DT
O	NN

first	RB
O	NN

integrated	VBN
O	NN

optical-biosensors	NNS
O	NN

using	VBG
O	NN

this	DT
O	NN

design	NN
O	NN

have	VB
O	NN

been	VBN
O	NN

prepared	JJ
O	NN

that	IN
O	NN

allow	VB
O	NN

both	DT
O	NN

the	DT
O	NN

dependent	JJ
O	NN

and	CC
O	NN

independent	JJ
O	NN

analytes	NNS
O	NN

to	TO
O	NN

be	VB
O	NN

measured	VBN
O	NN

simultaneously	RB
O	NN

,	,
O	NN

for	IN
O	NN

example	NN
O	NN

penicillin	NN
O	NN

and	CC
O	NN

pH	NN
O	NN

(	NN
O	NN

Healey	NNP
O	NNP

&	CC
O	NNP

#	#
O	NN

38	CD
O	NN

;	:
O	NN

Walt	NNP
O	NNP

,	,
O	NN

1995	CD
O	NN

)	NN
O	NN

or	CC
O	NN

glucose	NN
O	NN

and	CC
O	NN

O2	CD
O	NN

(	NN
O	NN

Li	NNP
O	NNP

&	CC
O	NNP

#	#
O	NN

38	CD
O	NN

;	:
O	NN

Walt	NNP
O	NNP

,	,
O	NN

1995	CD
O	NN

)	NN
O	NN

Independent	NNP
O	NNP

measurement	NN
O	NN

of	IN
O	NN

the	DT
O	NN

transducing	VBG
O	NN

analyte	NN
O	NN

allows	VBZ
O	NN

penicillin	NN
T	NN

or	CC
O	NN

glucose	NN
O	NN

to	TO
O	NN

be	VB
O	NN

quantitated	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

a	DT
O	NN

concurrent	JJ
O	NN

pH	NN
O	NN

or	CC
O	NN

O2	CD
O	NN

change	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

Penicillin	NN
T	NN

can	MD
O	NNP

be	VB
O	NN

measured	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

range	NN
O	NN

0.25-10.0	CD
O	NN

mM	NN
O	NN

in	IN
O	NN

the	DT
O	NN

pH	NN
O	NN

range	NN
O	NN

6.2-7.5	CD
O	NN

Glucose	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

measured	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

range	NN
O	NN

0.6-20.0	CD
O	NN

mM	NN
O	NN

in	IN
O	NN

the	DT
O	NN

O2	CD
O	NN

range	NN
O	NN

20-100	CD
O	NN

%	NN
O	NN

The	DT
O	NN

utility	NN
O	NN

of	IN
O	NN

the	DT
O	NN

sensor	NN
O	NN

design	NN
O	NN

was	VBD
O	NN

demonstrated	VBD
O	NN

by	IN
O	NN

using	VBG
O	NN

the	DT
O	NN

penicillin-dual-analyte	JJ
O	NN

biosensor	NN
O	NN

to	TO
O	NN

quantitate	VB
O	NN

penicillin	NN
T	NN

produced	VBN
O	NN

during	IN
O	NN

a	DT
O	NN

Penicillium	NNP
O	NNP

chrysogenum	NN
O	NN

fermentation	NN
O	NN

The	DT
O	NN

characterization	NN
O	NN

of	IN
O	NN

low	JJ
O	NN

molecular	JJ
O	NN

weight	NN
O	NN

ligand	NN
O	NN

interaction	NN
O	NN

with	IN
O	NN

receptor	NN
O	NN

molecules	NNS
O	NN

is	VBZ
O	NN

of	IN
O	NN

importance	NN
O	NN

for	IN
O	NN

the	DT
O	NN

investigation	NN
O	NN

of	IN
O	NN

biological	JJ
O	NN

processes	NNS
O	VBP

and	CC
O	NN

for	IN
O	NN

drug	NN
O	NN

research	NN
O	NN

We	PRP
O	VBP

report	NN
O	NN

on	IN
O	NN

the	DT
O	NN

investigation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

binding	VBG
O	NN

of	IN
O	NN

low	JJ
O	NN

molecular	JJ
O	NN

weight	NN
O	NN

ligands	NNS
O	NN

to	TO
O	NN

immobilized	VBN
O	NN

receptors	NNS
O	VBP

by	IN
O	NN

label-free	JJ
O	NN

detection	NN
O	NN

Reflectometric	JJ
O	NN

interference	NN
O	NN

spectroscopy	NN
O	NN

,	,
O	NN

an	DT
O	NN

optical	JJ
O	NN

transducer	NN
O	NN

which	WDT
O	NN

allows	VBZ
O	NN

the	DT
O	NN

monitoring	VBG
O	NN

of	IN
O	NN

a	DT
O	NN

few	JJ
O	NN

picograms	NN
O	NN

per	IN
O	NN

square	JJ
O	NN

millimetre	JJ
O	NN

changes	NNS
O	VBP

in	IN
O	NN

surface	NN
O	NN

coverage	NN
O	NN

,	,
O	NN

was	VBD
O	NN

used	VBN
O	NN

to	TO
O	NN

study	NN
O	NN

two	CD
O	NN

model	NN
O	NN

systems	NNS
O	NN

In	IN
O	NN

both	DT
O	NN

cases	NNS
O	NN

detection	NN
O	NN

of	IN
O	NN

the	DT
O	NN

binding	VBG
O	NN

event	NN
O	NN

was	VBD
O	NN

successful	JJ
O	NN

High	JJ
O	NN

affinity	NN
O	NN

binding	VBG
O	NN

of	IN
O	NN

biotin	NN
O	NN

to	TO
O	NN

immobilized	VBN
O	NN

streptavidin	NN
O	NN

was	VBD
O	NN

clearly	RB
O	NN

detectable	JJ
O	NN

at	IN
O	NN

receptor	NN
O	NN

surface	NN
O	NN

concentrations	NNS
O	NN

as	IN
O	NN

low	JJ
O	NN

as	IN
O	NN

1-2	CD
O	NN

x	CC
O	NN

10	CD
O	NN

(	NN
O	NN

10	CD
O	NN

)	NN
O	NN

binding	VBG
O	NN

sites/mm2	NN
O	NN

Linear	JJ
O	NN

correlation	NN
O	NN

between	IN
O	NN

the	DT
O	NN

receptor	NN
O	NN

surface	NN
O	NN

concentration	NN
O	NN

and	CC
O	NN

the	DT
O	NN

response	NN
O	NN

to	TO
O	NN

biotin	NN
O	NN

binding	VBG
O	NN

was	VBD
O	NN

observed	VBN
O	NN

Using	VBG
O	NN

immobilized	VBN
O	NN

DNA	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

investigated	VBN
O	NN

the	DT
O	NN

binding	VBG
O	NN

of	IN
O	NN

common	JJ
O	NN

intercalators	NNS
O	NN

with	IN
O	NN

respect	NN
O	NN

to	TO
O	NN

kinetics	NNS
O	NN

and	CC
O	NN

thermodynamics	NNS
O	NN

by	IN
O	NN

evaluation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

association	NN
O	NN

and	CC
O	NN

the	DT
O	NN

dissociation	NN
O	NN

part	NN
O	NN

of	IN
O	NN

the	DT
O	NN

binding	VBG
O	NN

curve	NN
O	NN

Bi-exponential	JJ
O	NN

increase	NN
O	NN

and	CC
O	NN

decrease	NN
O	NN

of	IN
O	NN

intercalator	NN
O	NN

loading	VBG
O	NN

was	VBD
O	NN

observed	VBN
O	NN

,	,
O	NN

indicating	VBG
O	NN

complex	JJ
O	NN

interaction	NN
O	NN

kinetics	NNS
O	NN

The	DT
O	NN

four	CD
O	NN

structurally	RB
O	NN

different	JJ
O	NN

intercalators	NNS
O	NN

showed	VBD
O	NN

significant	JJ
O	NN

distinction	NN
O	NN

in	IN
O	NN

binding	VBG
O	NN

kinetics	NNS
O	NN

and	CC
O	NN

equilibrium	NN
O	NN

signals	NNS
O	VBP

Improvement	NN
O	NN

of	IN
O	NN

experimental	JJ
O	NN

parameters	NNS
O	VBP

is	VBZ
O	NN

required	VBN
O	NN

to	TO
O	NN

obtain	VB
O	NN

more	RBR
O	NN

reliable	JJ
O	NN

kinetic	JJ
O	NN

data	NNS
O	NN

An	DT
O	NN

amperometric	JJ
O	NN

lactate	NN
O	NN

oxidase	NN
O	NN

catheter	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

developed	VBN
O	NN

for	IN
O	NN

in	IN
O	NN

vivo	FW
O	FW

application	NN
O	NN

to	TO
O	NN

real-time	JJ
O	NN

lactate	NN
O	NN

monitoring	VBG
O	NN

The	DT
O	NN

electrochemical	JJ
O	NN

behaviour	NN
O	NN

of	IN
O	NN

the	DT
O	NN

1	CD
O	NN

x	CC
O	NN

3	CD
O	NN

mm	NN
O	NN

Pt-Ag/AgCl	NN
O	NN

thin	JJ
O	NN

film	NN
O	NN

electrode	NN
O	NN

is	VBZ
O	NN

not	RB
O	NN

significantly	RB
O	NN

influenced	VBN
O	NN

by	IN
O	NN

lactate	NN
O	NN

oxidase-polyurethane	NN
O	NN

covering	VBG
O	NN

Gamma-irradiation	NN
O	NN

(	NN
O	NN

25	CD
O	NN

kGy	NN
O	NN

)	NN
O	NN

is	VBZ
O	NN

suitable	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

sterilization	NN
O	NN

procedure	NN
O	NN

The	DT
O	NN

final	JJ
O	NN

lactate	NN
O	NN

catheter	NN
O	NN

is	VBZ
O	NN

characterized	VBN
O	NN

by	IN
O	NN

a	DT
O	NN

linear	JJ
O	NN

concentration	NN
O	NN

range	NN
O	NN

between	IN
O	NN

0.5	CD
O	NN

and	CC
O	NN

20	CD
O	NN

mmol/l	NN
O	NN

lactate	NN
O	NN

with	IN
O	NN

a	DT
O	NN

sensitivity	NN
O	NN

around	IN
O	NN

2	CD
O	NN

nA	NN
O	NN

mmol-1	NN
O	NN

l-1	NN
O	NN

lactate	NN
O	NN

The	DT
O	NN

accuracy	NN
O	NN

is	VBZ
O	NN

demonstrated	VBD
O	NN

by	IN
O	NN

the	DT
O	NN

measurement	NN
O	NN

of	IN
O	NN

control	NN
O	NN

sera	NNS
O	VBP

Both	DT
O	NN

physiological	JJ
O	NN

and	CC
O	NN

pathological	JJ
O	NN

materials	NNS
O	NN

correlate	VB
O	NN

well	RB
O	NN

with	IN
O	NN

the	DT
O	NN

declared	VBD
O	NN

values	NNS
O	VBP

The	DT
O	NN

dry	JJ
O	NN

stored	VBN
O	NN

lactate	NN
O	NN

catheter	NN
O	NN

needs	NNS
O	VBP

about	IN
O	NN

10	CD
O	NN

min	NN
O	NN

for	IN
O	NN

hydration	NN
O	NN

and	CC
O	NN

is	VBZ
O	NN

characterized	VBN
O	NN

by	IN
O	NN

response	NN
O	NN

times	NNS
O	NN

t98	NN
O	NN

%	NN
O	NN

of	IN
O	NN

less	JJR
O	NN

than	IN
O	NN

2	CD
O	NN

min	NN
O	NN

Ex	FW
O	FW

vivo	FW
O	FW

whole	JJ
O	NN

blood	NN
O	NN

measurements	NNS
O	NN

using	VBG
O	NN

the	DT
O	NN

lactate	NN
O	NN

catheter	NN
O	NN

(	NN
O	NN

y	NN
O	NN

)	NN
O	NN

give	VB
O	NN

a	DT
O	NN

correlation	NN
O	NN

with	IN
O	NN

the	DT
O	NN

BIOSEN	NN
O	NN

Med	VBN
O	NN

L	NN
O	NN

(	NN
O	NN

x	CC
O	NN

)	NN
O	NN

of	IN
O	NN

y	NN
O	NN

=	JJ
O	NN

(	NN
O	NN

1.010x	NN
O	NN

+	CC
O	NN

0.513	CD
O	NN

)	NN
O	NN

mmol/l	NN
O	NN

(	NN
O	NN

r	NN
O	NN

=	JJ
O	NN

0.9748	CD
O	NN

)	NN
O	NN

Lactate	NN
O	NN

values	NNS
O	VBP

obtained	VBN
O	NN

by	IN
O	NN

continuous	JJ
O	NN

catheter	NN
O	NN

operation	NN
O	NN

ex	FW
O	FW

vivo	FW
O	FW

correlate	VB
O	NN

well	RB
O	NN

with	IN
O	NN

those	DT
O	NNP

obtained	VBN
O	NN

by	IN
O	NN

BIOSEN	NN
O	NN

Med	VBN
O	NN

L.	NNP
O	NNP

First	NNP
O	NNP

subcutaneous	JJ
O	NN

implantation	NN
O	NN

(	NN
O	NN

dog	NN
O	NN

)	NN
O	NN

underlines	VBZ
O	NN

the	DT
O	NN

characteristics	NNS
O	NN

obtained	VBN
O	NN

ex	FW
O	FW

vivo	FW
O	FW

:	:
O	NN

after	IN
O	NN

30	CD
O	NN

min	NN
O	NN

hydration	NN
O	NN

the	DT
O	NN

lactate	NN
O	NN

catheter	NN
O	NN

follows	VBZ
O	NN

the	DT
O	NN

lactate	NN
O	NN

concentration	NN
O	NN

measured	VBN
O	NN

ex	FW
O	FW

vivo	FW
O	FW

with	IN
O	NN

samples	NNS
O	NN

from	IN
O	NN

the	DT
O	NN

leg	NN
O	NN

vein	NN
O	NN

by	IN
O	NN

BIOSEN	NN
O	NN

Med	VBN
O	NN

L.	NNP
O	NNP

The	DT
O	NN

diffusion-limited	JJ
O	NN

binding	VBG
O	NN

kinetics	NNS
O	NN

of	IN
O	NN

antigen	NN
O	NN

(	NN
O	NN

or	CC
O	NN

antibody	NN
O	NN

)	NN
O	NN

in	IN
O	NN

solution	NN
O	NN

to	TO
O	NN

antibody	NN
O	NN

(	NN
O	NN

or	CC
O	NN

antigen	NN
O	NN

)	NN
O	NN

immobilized	VBN
O	NN

on	IN
O	NN

a	DT
O	NN

biosensor	NN
O	NN

and	CC
O	NN

other	JJ
O	NN

surfaces	NNS
O	NN

is	VBZ
O	NN

analyzed	VBN
O	NN

within	IN
O	NN

a	DT
O	NN

fractal	JJ
O	NN

framework	NN
O	NN

Often	RB
O	NN

,	,
O	NN

the	DT
O	NN

binding	VBG
O	NN

kinetics	NNS
O	NN

may	MD
O	NNP

be	VB
O	NN

described	VBN
O	NN

by	IN
O	NN

a	DT
O	NN

single-fractal	JJ
O	NN

analysis	NN
O	NN

In	IN
O	NN

some	DT
O	NN

cases	NNS
O	NN

,	,
O	NN

the	DT
O	NN

binding	VBG
O	NN

curve	NN
O	NN

exhibits	VBZ
O	NN

complexities	NNS
O	NN

Then	RB
O	NN

,	,
O	NN

for	IN
O	NN

these	DT
O	NN

cases	NNS
O	NN

,	,
O	NN

the	DT
O	NN

dual-fractal	JJ
O	NN

analysis	NN
O	NN

provides	VBZ
O	NN

an	DT
O	NN

improved	VBN
O	NN

fit	JJ
O	NN

when	WRB
O	NN

compared	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

single-fractal	JJ
O	NN

analysis	NN
O	NN

This	DT
O	NN

indicates	VBZ
O	NN

a	DT
O	NN

change	NN
O	NN

in	IN
O	NN

the	DT
O	NN

reaction	NN
O	NN

mechanism	NN
O	NN

on	IN
O	NN

the	DT
O	NN

surface	NN
O	NN

It	PRP
O	NN

is	VBZ
O	NN

of	IN
O	NN

interest	NN
O	NN

to	TO
O	NN

note	NN
O	NN

that	IN
O	NN

the	DT
O	NN

state	NN
O	NN

of	IN
O	NN

disorder	NN
O	NN

(	NN
O	NN

or	CC
O	NN

the	DT
O	NN

fractal	JJ
O	NN

dimension	NN
O	NN

)	NN
O	NN

and	CC
O	NN

the	DT
O	NN

binding	VBG
O	NN

rate	NN
O	NN

coefficient	NN
O	NN

both	DT
O	NN

increase	NN
O	NN

as	IN
O	NN

the	DT
O	NN

reaction	NN
O	NN

progresses	VBZ
O	NN

on	IN
O	NN

the	DT
O	NN

biosensor	NN
O	NN

surface	NN
O	NN

For	IN
O	NN

example	NN
O	NN

,	,
O	NN

for	IN
O	NN

the	DT
O	NN

binding	VBG
O	NN

of	IN
O	NN

10	CD
O	NN

nM	NN
O	NN

insulin	NN
O	NN

growth	NN
O	NN

factor-1	NN
O	NN

in	IN
O	NN

solution	NN
O	NN

to	TO
O	NN

insulin	NN
O	NN

growth	NN
O	NN

factor	NN
O	NN

binding	VBG
O	NN

protein-1	NN
O	NN

immobilized	VBN
O	NN

on	IN
O	NN

a	DT
O	NN

biosensor	NN
O	NN

surface	NN
O	NN

,	,
O	NN

a	DT
O	NN

64	CD
O	NN

%	NN
O	NN

increase	NN
O	NN

in	IN
O	NN

the	DT
O	NN

fractal	JJ
O	NN

dimension	NN
O	NN

from	IN
O	NN

1.73	CD
O	NN

(	NN
O	NN

Df1	NN
O	NN

)	NN
O	NN

to	TO
O	NN

2.85	CD
O	NN

(	NN
O	NN

Df2	NN
O	NN

)	NN
O	NN

leads	VBZ
O	NN

to	TO
O	NN

an	DT
O	NN

increase	NN
O	NN

in	IN
O	NN

the	DT
O	NN

binding	VBG
O	NN

rate	NN
O	NN

coefficient	NN
O	NN

by	IN
O	NN

a	DT
O	NN

factor	NN
O	NN

of	IN
O	NN

31.8	CD
O	NN

from	IN
O	NN

3.92	CD
O	NN

(	NN
O	NN

k1	NN
O	NN

)	NN
O	NN

to	TO
O	NN

125	CD
O	NN

(	NN
O	NN

k2	NN
O	NN

)	NN
O	NN

Furthermore	RB
O	NN

,	,
O	NN

as	IN
O	NN

the	DT
O	NN

IGF-1	NN
O	NN

concentration	NN
O	NN

in	IN
O	NN

solution	NN
O	NN

increases	NNS
O	NN

from	IN
O	NN

10	CD
O	NN

to	TO
O	NN

80	CD
O	NN

nM	NN
O	NN

in	IN
O	NN

solution	NN
O	NN

,	,
O	NN

k2	NN
O	NN

and	CC
O	NN

Df2	NN
O	NN

exhibit	NN
O	NN

a	DT
O	NN

linear	JJ
O	NN

increase	NN
O	NN

k1	NN
O	NN

and	CC
O	NN

Df1	NN
O	NN

exhibit	NN
O	NN

a	DT
O	NN

linear	JJ
O	NN

increase	NN
O	NN

with	IN
O	NN

the	DT
O	NN

reciprocal	JJ
O	NN

of	IN
O	NN

the	DT
O	NN

IGF-1	NN
O	NN

concentration	NN
O	NN

in	IN
O	NN

solution	NN
O	NN

The	DT
O	NN

different	JJ
O	NN

examples	NNS
O	NN

analyzed	VBN
O	NN

and	CC
O	NN

presented	VBN
O	NN

together	RB
O	NN

provide	VB
O	NN

a	DT
O	NN

means	NNS
O	VBP

by	IN
O	NN

which	WDT
O	NN

the	DT
O	NN

antigen-antibody	JJ
O	NN

reactions	NNS
O	NN

may	MD
O	NNP

be	VB
O	NN

better	JJR
O	NN

controlled	JJ
O	NN

by	IN
O	NN

noting	VBG
O	NN

the	DT
O	NN

magnitude	NN
O	NN

of	IN
O	NN

the	DT
O	NN

changes	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

fractal	JJ
O	NN

dimension	NN
O	NN

and	CC
O	NN

in	IN
O	NN

the	DT
O	NN

binding	VBG
O	NN

rate	NN
O	NN

coefficient	NN
O	NN

as	IN
O	NN

the	DT
O	NN

reaction	NN
O	NN

progresses	VBZ
O	NN

on	IN
O	NN

the	DT
O	NN

biosensor	NN
O	NN

surface	NN
O	NN

Also	RB
O	NN

,	,
O	NN

the	DT
O	NN

magnitude	NN
O	NN

of	IN
O	NN

the	DT
O	NN

changes	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

binding	VBG
O	NN

rate	NN
O	NN

coefficients	NNS
O	VBP

(	NN
O	NN

k1	NN
O	NN

and	CC
O	NN

k2	NN
O	NN

)	NN
O	NN

and	CC
O	NN

in	IN
O	NN

the	DT
O	NN

fractal	JJ
O	NN

dimensions	NNS
O	NN

(	NN
O	NN

Df1	NN
O	NN

and	CC
O	NN

Df2	NN
O	NN

)	NN
O	NN

as	IN
O	NN

different	JJ
O	NN

parameters	NNS
O	VBP

are	VBP
O	NN

changed	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

different	JJ
O	NN

biosensor	NN
O	NN

applications	NNS
O	NN

are	VBP
O	NN

of	IN
O	NN

particular	JJ
O	NN

value	NN
O	NN

,	,
O	NN

since	IN
O	NN

they	PRP
O	VBP

provide	VB
O	NN

us	PRP
O	VBP

with	IN
O	NN

a	DT
O	NN

measure	NN
O	NN

or	CC
O	NN

extent	NN
O	NN

of	IN
O	NN

changes	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

binding	VBG
O	NN

rate	NN
O	NN

coefficient	NN
O	NN

on	IN
O	NN

changing	VBG
O	NN

different	JJ
O	NN

experimental	JJ
O	NN

parameter	NN
O	NN

values	NNS
O	VBP

It	PRP
O	NN

is	VBZ
O	NN

of	IN
O	NN

interest	NN
O	NN

to	TO
O	NN

note	NN
O	NN

the	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

different	JJ
O	NN

parameters	NNS
O	VBP

on	IN
O	NN

the	DT
O	NN

extent	NN
O	NN

or	CC
O	NN

heterogeneity	NN
O	NN

that	IN
O	NN

exists	VBZ
O	NN

on	IN
O	NN

the	DT
O	NN

surface	NN
O	NN

and	CC
O	NN

how	WRB
O	NN

this	DT
O	NN

influences	VBZ
O	NNP

the	DT
O	NN

binding	VBG
O	NN

rate	NN
O	NN

coefficients	NNS
O	VBP

This	DT
O	NN

may	MD
O	NNP

be	VB
O	NN

one	CD
O	NN

method	NN
O	NN

to	TO
O	NN

help	NN
O	NN

manipulate	VB
O	NN

or	CC
O	NN

control	NN
O	NN

the	DT
O	NN

binding	VBG
O	NN

rate	NN
O	NN

coefficients	NNS
O	VBP

on	IN
O	NN

the	DT
O	NN

reaction	NN
O	NN

surface	NN
O	NN

To	TO
O	NN

determine	VB
O	NN

if	IN
O	NN

microscopic	JJ
O	NN

urinalysis	NN
O	NN

is	VBZ
O	NN

needed	VBN
O	NN

in	IN
O	NN

all	DT
O	NN

pediatric	JJ
O	NN

emergency	NN
O	NN

room	NN
O	NN

patients	NNS
O	NN

screened	VBN
O	NN

for	IN
O	NN

urinary	JJ
D	NN

tract	NN
D	NN

infections	NNS
D	NN

(	NN
D	NN

UTI	NN
D	NN

)	NN
D	NN

,	,
O	NN

we	PRP
O	VBP

compared	VBN
O	NN

the	DT
O	NN

dipstick	NN
O	NN

urinalysis	NN
O	NN

and	CC
O	NN

complete	JJ
O	NN

urinalysis	NN
O	NN

(	NN
O	NN

dipstick	NN
O	NN

and	CC
O	NN

microscopy	NN
O	NN

)	NN
O	NN

with	IN
O	NN

urine	NN
O	NN

cultures	NNS
O	NN

in	IN
O	NN

236	CD
O	NN

children	NNS
O	VBP

,	,
O	NN

aged	JJ
O	NN

3	CD
O	NN

weeks	NNS
O	NN

to	TO
O	NN

21	CD
O	NN

years	NNS
O	NN

The	DT
O	NN

ability	NN
O	NN

to	TO
O	NN

detect	VB
O	NN

UTI	NN
D	NN

by	IN
O	NN

dipstick	NN
O	NN

only	RB
O	NN

and	CC
O	NN

by	IN
O	NN

complete	JJ
O	NN

urinalysis	NN
O	NN

was	VBD
O	NN

the	DT
O	NN

same	JJ
O	NN

,	,
O	NN

however	RB
O	NN

microscopic	JJ
O	NN

evaluation	NN
O	NN

added	VBN
O	NN

many	JJ
O	NN

false-positive	JJ
O	NN

results	NNS
O	VBP

without	IN
O	NN

detecting	VBG
O	NN

additional	JJ
O	NN

UTIs	NNS
D	NN

Because	IN
O	NN

the	DT
O	NN

ability	NN
O	NN

to	TO
O	NN

detect	VB
O	NN

UTI	NN
D	NN

(	NN
O	NN

sensitivity	NN
O	NN

)	NN
O	NN

is	VBZ
O	NN

maintained	JJ
O	NN

,	,
O	NN

we	PRP
O	VBP

now	RB
O	NN

offer	NN
O	NN

a	DT
O	NN

dipstick	NN
O	NN

only	RB
O	NN

urinalysis	NN
O	NN

to	TO
O	NN

our	PRP$
O	NN

emergency	NN
O	NN

room	NN
O	NN

for	IN
O	NN

children	NNS
O	VBP

2	CD
O	NN

years	NNS
O	NN

of	IN
O	NN

age	NN
O	NN

or	CC
O	NN

older	JJR
O	NN

,	,
O	NN

with	IN
O	NN

a	DT
O	NN

microscopic	JJ
O	NN

analysis	NN
O	NN

performed	VBN
O	NN

automatically	RB
O	NN

if	IN
O	NN

dipstick	NN
O	NN

results	NNS
O	VBP

are	VBP
O	NN

positive	JJ
O	NN

If	IN
O	NN

no	DT
O	NN

microscopic	JJ
O	NN

urinalysis	NN
O	NN

is	VBZ
O	NN

required	VBN
O	NN

,	,
O	NN

testing	NN
O	NN

turn-around	NN
O	NN

time	NN
O	NN

is	VBZ
O	NN

reduced	VBN
O	NN

by	IN
O	NN

12.3	CD
O	NN

min/test	JJS
O	NN

and	CC
O	NN

the	DT
O	NN

hospital	NN
O	NN

charge	NN
O	NN

is	VBZ
O	NN

reduced	VBN
O	NN

from	IN
O	NN

U.S	JJ
O	NN

$	$
O	CD

32	CD
O	NN

to	TO
O	NN

U.S	JJ
O	NN

$	$
O	CD

12	CD
O	NN

Using	VBG
O	NN

video-intensified	JJ
O	NN

fluorescence	NN
O	NN

microscopy	NN
O	NN

and	CC
O	NN

a	DT
O	NN

pseudocolor	NN
O	NN

display	NN
O	NN

of	IN
O	NN

fluorescence	NN
O	NN

intensity	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

analyzed	VBN
O	NN

the	DT
O	NN

distribution	NN
O	NN

of	IN
O	NN

microinjected	VBN
O	NN

molecules	NNS
O	NN

within	IN
O	NN

the	DT
O	NN

nurse-cell/oocyte	JJ
O	NN

syncytium	NN
O	NN

of	IN
O	NN

Drosophila	FW
O	FW

ovarian	JJ
O	NN

follicles	NNS
O	NN

We	PRP
O	VBP

varied	JJ
O	NN

the	DT
O	NN

composition	NN
O	NN

and	CC
O	NN

the	DT
O	NN

osmolarity	NN
O	NN

of	IN
O	NN

the	DT
O	NN

culture	NN
O	NN

solution	NN
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

the	DT
O	NN

electrical	JJ
O	NN

charge	NN
O	NN

and	CC
O	NN

the	DT
O	NN

molecular	JJ
O	NN

mass	NN
O	NN

of	IN
O	NN

the	DT
O	NN

microinjected	VBN
O	NN

fluorescent	JJ
O	NN

probe	NN
O	NN

As	IN
O	NN

culture	NN
O	NN

solutions	NNS
O	NN

,	,
O	NN

we	PRP
O	VBP

used	VBN
O	NN

four	CD
O	NN

simple	JJ
O	NN

salines	NNS
O	VBP

(	NN
O	NN

IMADS	NN
O	NN

)	NN
O	NN

and	CC
O	NN

a	DT
O	NN

complex	JJ
O	NN

tissue-culture	NN
O	NN

medium	NN
O	NN

(	NN
O	NN

R-14	NN
O	NN

)	NN
O	NN

that	IN
O	NN

matched	VBN
O	NN

the	DT
O	NN

osmolarity	NN
O	NN

of	IN
O	NN

adult	JJ
O	NN

hemolymph	NN
O	NN

Small	JJ
O	NN

amounts	NNS
O	NN

of	IN
O	NN

two	CD
O	NN

anionic	JJ
O	NN

dyes	NNS
O	NN

(	NN
O	NN

Lucifer	NN
O	NN

Yellow	JJ
O	NN

CH	NN
O	NN

and	CC
O	NN

Lucifer	NN
O	NN

Yellow	JJ
O	NN

dextran	NN
O	NN

)	NN
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

of	IN
O	NN

two	CD
O	NN

cationic	JJ
O	NN

dyes	NNS
O	NN

(	NN
O	NN

rhodamine	NN
O	NN

6G	NN
O	NN

and	CC
O	NN

tetramethylrhodamine	NN
O	NN

dextran-lysine	JJ
O	NN

)	NN
O	NN

were	VBD
O	NN

iontophoretically	RB
O	NN

microinjected	VBN
O	NN

either	DT
O	NN

into	IN
O	NN

a	DT
O	NN

nurse	NN
O	NN

cell	NN
O	NN

or	CC
O	NN

into	IN
O	NN

the	DT
O	NN

oocyte	NN
O	NN

of	IN
O	NN

stage-10	JJ
O	NN

follicles	NNS
O	NN

In	IN
O	NN

the	DT
O	NN

tissue-culture	NN
O	NN

medium	NN
O	NN

,	,
O	NN

within	IN
O	NN

a	DT
O	NN

few	JJ
O	NN

seconds	NNS
O	NN

following	VBG
O	NN

microinjection	NN
O	NN

,	,
O	NN

all	DT
O	NN

tested	VBN
O	NN

dyes	NNS
O	NN

passed	VBN
O	NN

through	IN
O	NN

the	DT
O	NN

intercellular	JJ
O	NN

bridges	NNS
O	NN

in	IN
O	NN

both	DT
O	NN

the	DT
O	NN

anterior	JJ
O	NN

direction	NN
O	NN

(	NN
O	NN

to	TO
O	NN

the	DT
O	NN

nurse	NN
O	NN

cells	NNS
O	VBP

)	NN
O	NN

and	CC
O	NN

the	DT
O	NN

posterior	JJ
O	NN

direction	NN
O	NN

(	NN
O	NN

to	TO
O	NN

the	DT
O	NN

oocyte	NN
O	NN

)	NN
O	NN

,	,
O	NN

independent	JJ
O	NN

of	IN
O	NN

their	PRP$
O	NN

electrical	JJ
O	NN

charge	NN
O	NN

or	CC
O	NN

molecular	JJ
O	NN

mass	NN
O	NN

In	IN
O	NN

all	DT
O	NN

simple	JJ
O	NN

salines	NNS
O	VBP

,	,
O	NN

irrespective	RB
O	NN

of	IN
O	NN

their	PRP$
O	NN

osmolarity	NN
O	NN

,	,
O	NN

Lucifer	NN
O	NN

Yellow	JJ
O	NN

CH	NN
O	NN

was	VBD
O	NN

found	VBN
O	NN

to	TO
O	NN

preferentially	RB
O	NN

migrate	VB
O	NN

in	IN
O	NN

the	DT
O	NN

posterior	JJ
O	NN

direction	NN
O	NN

and	CC
O	NN

to	TO
O	NN

accumulate	VB
O	NN

in	IN
O	NN

the	DT
O	NN

oocyte	NN
O	NN

due	JJ
O	NN

to	TO
O	NN

progressive	JJ
O	NN

binding	VBG
O	NN

to	TO
O	NN

yolk	NN
O	NN

spheres	NNS
O	NN

Thus	RB
O	NN

,	,
O	NN

with	IN
O	NN

this	DT
O	NN

sensitive	JJ
O	NN

method	NN
O	NN

,	,
O	NN

no	DT
O	NN

correlation	NN
O	NN

was	VBD
O	NN

detectable	JJ
O	NN

between	IN
O	NN

the	DT
O	NN

external	JJ
O	NN

osmolarity	NN
O	NN

,	,
O	NN

the	DT
O	NN

electrical	JJ
O	NN

charge	NN
O	NN

and	CC
O	NN

the	DT
O	NN

preferential	JJ
O	NN

direction	NN
O	NN

of	IN
O	NN

migration	NN
O	NN

of	IN
O	NN

a	DT
O	NN

microinjected	VBN
O	NN

probe	NN
O	NN

Our	PRP$
O	NN

results	NNS
O	VBP

indicate	VBP
O	NN

that	IN
O	NN

the	DT
O	NN

electrical	JJ
O	NN

gradient	NN
O	NN

described	VBN
O	NN

by	IN
O	NN

other	JJ
O	NN

authors	NNS
O	NN

does	VBZ
O	NNP

not	RB
O	NN

exert	VB
O	NN

significant	JJ
O	NN

influence	NN
O	NN

on	IN
O	NN

the	DT
O	NN

migration	NN
O	NN

of	IN
O	NN

charged	VBN
O	NN

molecules	NNS
O	NN

through	IN
O	NN

intercellular	JJ
O	NN

bridges	NNS
O	NN

in	IN
O	NN

situ	FW
O	FW

The	DT
O	NN

AF-4	NN
O	NN

gene	NN
O	NN

on	IN
O	NN

human	JJ
O	NN

chromosome	NN
O	NN

4q21	NN
O	NN

is	VBZ
O	NN

involved	VBN
O	NN

in	IN
O	NN

reciprocal	JJ
O	NN

translocations	NNS
O	NN

to	TO
O	NN

the	DT
O	NN

ALL-1	NN
O	NN

gene	NN
O	NN

on	IN
O	NN

chromosome	NN
O	NN

11q23	NN
O	NN

,	,
O	NN

which	WDT
O	NN

are	VBP
O	NN

associated	VBN
O	NN

with	IN
O	NN

acute	JJ
D	NN

lymphoblastic	JJ
D	NN

leukaemias	NNS
D	NN

A	DT
O	NN

set	VBN
O	NN

of	IN
O	NN

recombinant	JJ
O	NN

phage	NN
O	NN

carrying	VBG
O	NN

genomic	JJ
O	NN

fragments	NNS
O	NN

for	IN
O	NN

the	DT
O	NN

coding	VBG
O	NN

region	NN
O	NN

and	CC
O	NN

flanking	JJ
O	NN

sequences	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

AF-4	NN
O	NN

gene	NN
O	NN

were	VBD
O	NN

isolated	VBN
O	NN

Phage	NN
O	NN

inserts	NNS
O	VBP

were	VBD
O	NN

assembled	VBN
O	NN

into	IN
O	NN

four	CD
O	NN

contigs	NNS
O	NN

with	IN
O	NN

21	CD
O	NN

exons	NNS
O	NN

,	,
O	NN

and	CC
O	NN

an	DT
O	NN

intron	NN
O	NN

phase	NN
O	NN

map	NN
O	NN

was	VBD
O	NN

produced	VBN
O	NN

enabling	VBG
O	NN

the	DT
O	NN

interpretation	NN
O	NN

of	IN
O	NN

translocation-generated	JJ
O	NN

fusion	NN
O	NN

proteins	NNS
O	NN

The	DT
O	NN

gene	NN
O	NN

contains	VBZ
O	NN

two	CD
O	NN

alternative	JJ
O	NN

first	RB
O	NN

exons	NNS
O	NN

,	,
O	NN

1a	NN
O	NN

and	CC
O	NN

1b	NN
O	NN

,	,
O	NN

both	DT
O	NN

including	VBG
O	NN

a	DT
O	NN

translation	NN
O	NN

initiation	NN
O	NN

codon	NN
O	NN

The	DT
O	NN

translocation	NN
O	NN

breakpoint	NN
O	NN

cluster	NN
O	NN

region	NN
O	NN

is	VBZ
O	NN

flanked	VBN
O	NN

by	IN
O	NN

exons	NNS
O	NN

3	CD
O	NN

and	CC
O	NN

6	CD
O	NN

and	CC
O	NN

two	CD
O	NN

different	JJ
O	NN

polyadenylation	NN
O	NN

signals	NNS
O	VBP

were	VBD
O	NN

identified	VBN
O	NN

Polyclonal	JJ
O	NN

antisera	NNS
O	NN

directed	VBN
O	NN

against	IN
O	NN

three	CD
O	NN

different	JJ
O	NN

portions	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

AF-4	NN
O	NN

protein	NN
O	NN

were	VBD
O	NN

produced	VBN
O	NN

and	CC
O	NN

used	VBN
O	NN

to	TO
O	NN

detect	VB
O	NN

a	DT
O	NN

116	CD
O	NN

kD	NN
O	NN

protein	NN
O	NN

in	IN
O	NN

cellular	JJ
O	NN

extracts	NNS
O	VBP

of	IN
O	NN

human	JJ
O	NN

B-lymphoblastoid	JJ
O	NN

and	CC
O	NN

proB	NN
O	NN

cell	NN
O	NN

lines	NNS
O	NN

In	IN
O	NN

mitogen-stimulated	JJ
O	NN

human	JJ
O	NN

peripheral	JJ
O	NN

blood	NN
O	NN

mononuclear	JJ
O	NN

cells	NNS
O	VBP

the	DT
O	NN

AF-4	NN
O	NN

antigen	NN
O	NN

was	VBD
O	NN

predominantly	RB
O	NN

located	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

nucleus	NN
O	NN

The	DT
O	NN

AF-4	NN
O	NN

gene	NN
O	NN

is	VBZ
O	NN

a	DT
O	NN

member	NN
O	NN

of	IN
O	NN

the	DT
O	NN

AF-4	NN
O	NN

,	,
O	NN

LAF-4	NN
O	NN

and	CC
O	NN

FMR-2	NN
O	NN

gene	NN
O	NN

family	NN
O	NN

The	DT
O	NN

members	NNS
O	NN

of	IN
O	NN

this	DT
O	NN

family	NN
O	NN

encode	VBP
O	NN

serine-proline-rich	JJ
O	NN

proteins	NNS
O	NN

with	IN
O	NN

properties	NNS
O	NN

of	IN
O	NN

nuclear	JJ
O	NN

transcription	NN
O	NN

factors	NNS
O	NN

Comparison	NN
O	NN

of	IN
O	NN

AF-4	NN
O	NN

protein	NN
O	NN

coding	VBG
O	NN

sequences	NNS
O	NN

with	IN
O	NN

the	DT
O	NN

LAF-4	NN
O	NN

and	CC
O	NN

FMR-2	NN
O	NN

sequences	NNS
O	NN

revealed	VBD
O	NN

five	CD
O	NN

highly	RB
O	NN

conserved	VBN
O	NN

domains	NNS
O	NN

of	IN
O	NN

potential	JJ
O	NN

functional	JJ
O	NN

relevance	NN
O	NN

Immunoglobulin	NN
O	NN

superfamily	NN
O	NN

molecules	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

brain	NN
O	NN

are	VBP
O	NN

involved	VBN
O	NN

in	IN
O	NN

distinct	JJ
O	NN

aspects	NNS
O	NN

of	IN
O	NN

nervous	JJ
O	NN

system	NN
O	NN

histogenesis	NN
O	NN

,	,
O	NN

for	IN
O	NN

example	NN
O	NN

neuronal	JJ
O	NN

migration	NN
O	NN

and	CC
O	NN

axonal	JJ
O	NN

growth	NN
O	NN

To	TO
O	NN

identify	VB
O	NN

novel	JJ
O	NN

members	NNS
O	NN

of	IN
O	NN

this	DT
O	NN

superfamily	NN
O	NN

in	IN
O	NN

the	DT
O	NN

chick	NN
O	NN

nervous	JJ
O	NN

system	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

developed	VBN
O	NN

a	DT
O	NN

polymerase	NN
O	NN

chain	NN
O	NN

reaction-based	JJ
O	NN

approach	NN
O	NN

making	VBG
O	NN

use	NN
O	NN

of	IN
O	NN

sequence	NN
O	NN

motifs	NNS
O	NN

of	IN
O	NN

immunoglobulin-like	JJ
O	NN

domains	NNS
O	NN

In	IN
O	NN

the	DT
O	NN

present	JJ
O	NN

study	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

report	NN
O	NN

the	DT
O	NN

molecular	JJ
O	NN

cloning	VBG
O	NN

of	IN
O	NN

three	CD
O	NN

isoforms	NNS
O	NN

,	,
O	NN

the	DT
O	NN

biochemical	JJ
O	NN

analysis	NN
O	NN

and	CC
O	NN

the	DT
O	NN

immunohistochemical	JJ
O	NN

characterization	NN
O	NN

of	IN
O	NN

one	CD
O	NN

of	IN
O	NN

the	DT
O	NN

proteins	NNS
O	NN

identified	VBN
O	NN

in	IN
O	NN

this	DT
O	NN

screen	NN
O	NN

This	DT
O	NN

molecule	NN
O	NN

has	VBZ
O	NN

91	CD
O	NN

%	NN
O	NN

sequence	NN
O	NN

identity	NN
O	NN

with	IN
O	NN

the	DT
O	NN

limbic	JJ
O	NN

system-associated	JJ
O	NN

membrane	NN
O	NN

protein	NN
O	NN

(	NN
O	NN

LAMP	NN
O	NN

)	NN
O	NN

characterized	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

rat	NN
O	NN

and	CC
O	NN

is	VBZ
O	NN

therefore	RB
O	NN

referred	VBN
O	NN

to	TO
O	NN

as	IN
O	NN

the	DT
O	NN

chicken	NN
O	NN

homologue	NN
O	NN

of	IN
O	NN

the	DT
O	NN

latter	JJ
O	NN

(	NN
O	NN

chLAMP	NN
O	NN

)	NN
O	NN

The	DT
O	NN

molecule	NN
O	NN

is	VBZ
O	NN

a	DT
O	NN

glycosylphosphatidyl-inositol-anchored	JJ
O	NN

60	CD
O	NN

kDa	NN
O	NN

protein	NN
O	NN

with	IN
O	NN

three	CD
O	NN

immunoglobulin-like	JJ
O	NN

domains	NNS
O	NN

and	CC
O	NN

contains	VBZ
O	NN

40	CD
O	NN

%	NN
O	NN

N-linked	JJ
O	NN

carbohydrate	NN
O	NN

We	PRP
O	VBP

identify	VB
O	NN

three	CD
O	NN

different	JJ
O	NN

mRNA	NN
O	NN

forms	NNS
O	NN

of	IN
O	NN

chLAMP	NN
O	NN

and	CC
O	NN

show	NN
O	NN

that	IN
O	NN

two	CD
O	NN

forms	NNS
O	NN

with	IN
O	NN

distinct	JJ
O	NN

5'-termini	JJ
O	NN

are	VBP
O	NN

differentially	RB
O	NN

transcribed	VBN
O	NN

in	IN
O	NN

neural	JJ
O	NN

development	NN
O	NN

In	IN
O	NN

addition	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

demonstrate	VB
O	NN

using	VBG
O	NN

a	DT
O	NN

fusion	NN
O	NN

protein	NN
O	NN

expressed	VBN
O	NN

in	IN
O	NN

eukaryotic	JJ
O	NN

cells	NNS
O	VBP

that	IN
O	NN

chLAMP	NN
O	NN

has	VBZ
O	NN

homophilic	JJ
O	NN

binding	VBG
O	NN

activity	NN
O	NN

The	DT
O	NN

protein	NN
O	NN

was	VBD
O	NN

found	VBN
O	NN

on	IN
O	NN

a	DT
O	NN

subset	NN
O	NN

of	IN
O	NN

axons	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

central	JJ
O	NN

and	CC
O	NN

peripheral	JJ
O	NN

nervous	JJ
O	NN

system	NN
O	NN

and	CC
O	NN

is	VBZ
O	NN

likely	JJ
O	NN

to	TO
O	NN

be	VB
O	NN

involved	VBN
O	NN

in	IN
O	NN

specific	JJ
O	NN

cell-cell	JJ
O	NN

interactions	NNS
O	NN

in	IN
O	NN

neurohistogenesis	NN
O	NN

Two	CD
O	NN

novel	JJ
O	NN

cDNAs	NNS
O	NN

,	,
O	NN

DNAS1L2	NN
O	NN

and	CC
O	NN

DNAS1L3	NN
O	NN

,	,
O	NN

are	VBP
O	NN

predicted	VBN
O	NN

to	TO
O	NN

encode	VBP
O	NN

proteins	NNS
O	NN

of	IN
O	NN

299	CD
O	NN

and	CC
O	NN

305	CD
O	NN

amino	NN
O	NN

acids	NNS
O	NN

with	IN
O	NN

56	CD
O	NN

and	CC
O	NN

46	CD
O	NN

%	NN
O	NN

residue	NN
O	NN

identity	NN
O	NN

(	NN
O	NN

71	CD
O	NN

and	CC
O	NN

63	CD
O	NN

%	NN
O	NN

similarity	NN
O	NN

)	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

,	,
O	NN

to	TO
O	NN

deoxyribonuclease	NN
O	NN

I	PRP
O	VBP

(	NN
O	NN

DNase	NN
O	NN

I	PRP
O	VBP

)	NN
O	NN

DNAS1L2	NN
O	NN

is	VBZ
O	NN

located	JJ
O	NN

on	IN
O	NN

a	DT
O	NN

16p13.3	NN
O	NN

cosmid	NN
O	NN

,	,
O	NN

while	IN
O	NN

DNAS1L3	NN
O	NN

maps	NNS
O	NN

to	TO
O	NN

3p14.3-p21.1	NN
O	NN

by	IN
O	NN

fluorescence	NN
O	NN

in	IN
O	NN

situ	FW
O	FW

hybridization	NN
O	NN

and	CC
O	NN

by	IN
O	NN

PCR	NN
O	NN

analysis	NN
O	NN

of	IN
O	NN

a	DT
O	NN

radiation	NN
O	NN

hybrid	NN
O	NN

panel	NN
O	NN

Northern	JJ
O	NN

analysis	NN
O	NN

revealed	VBD
O	NN

DNAS1L3	NN
O	NN

expression	NN
O	NN

nearly	RB
O	NN

exclusively	RB
O	NN

in	IN
O	NN

liver	NN
O	NN

,	,
O	NN

while	IN
O	NN

DNAS1L2	NN
O	NN

expression	NN
O	NN

was	VBD
O	NN

detected	VBN
O	NN

in	IN
O	NN

brain	NN
O	NN

by	IN
O	NN

RT-PCR	NN
O	NN

The	DT
O	NN

previously	RB
O	NN

defined	VBN
O	NN

DNL1L	NN
O	NN

or	CC
O	NN

DNAS1L1	NN
O	NN

is	VBZ
O	NN

expressed	VBN
O	NN

highest	JJS
O	NN

in	IN
O	NN

heart	NN
O	NN

and	CC
O	NN

skeletal	JJ
O	NN

muscle	NN
O	NN

,	,
O	NN

while	IN
O	NN

DNase	NN
O	NN

I	PRP
O	VBP

is	VBZ
O	NN

expressed	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

pancreas	NN
O	NN

,	,
O	NN

parotid	NN
O	NN

gland	NN
O	NN

,	,
O	NN

and	CC
O	NN

kidney	NN
O	NN

Thus	RB
O	NN

,	,
O	NN

to	TO
O	NN

date	NN
O	NN

,	,
O	NN

four	CD
O	NN

DNase	NN
O	NN

I-like	JJ
O	NN

genes	NNS
O	NN

that	IN
O	NN

show	NN
O	NN

different	JJ
O	NN

tissue	NN
O	NN

expression	NN
O	NN

patterns	NNS
O	VBP

are	VBP
O	NN

known	JJ
O	NN

A	DT
O	NN

comparison	NN
O	NN

of	IN
O	NN

DNAS1L1	NN
O	NN

,	,
O	NN

DNAS1L2	NN
O	NN

,	,
O	NN

and	CC
O	NN

DNAS1L3	NN
O	NN

with	IN
O	NN

the	DT
O	NN

well-characterized	JJ
O	NN

DNase	NN
O	NN

I	PRP
O	VBP

suggests	VBZ
O	NN

that	IN
O	NN

the	DT
O	NN

DNAS1L	NN
O	NN

proteins	NNS
O	NN

are	VBP
O	NN

unlikely	JJ
O	NN

to	TO
O	NN

be	VB
O	NN

glycosylated	VBN
O	NN

or	CC
O	NN

bind	VB
O	NN

actin	NN
O	NN

;	:
O	NN

however	RB
O	NN

,	,
O	NN

catalytic	JJ
O	NN

and	CC
O	NN

calcium-	NN
O	NN

and	CC
O	NN

DNA-binding	JJ
O	NN

residues	NNS
O	NN

are	VBP
O	NN

conserved	VBN
O	NN

,	,
O	NN

and	CC
O	NN

potentially	RB
O	NN

cleavable	JJ
O	NN

signal	NN
O	NN

peptides	NNS
O	NN

are	VBP
O	NN

present	JJ
O	NN

among	IN
O	NN

all	DT
O	NN

these	DT
O	NN

proteins	NNS
O	NN

This	DT
O	NN

analysis	NN
O	NN

also	RB
O	NN

identifies	VBZ
O	NN

regions	NNS
O	NN

of	IN
O	NN

high	JJ
O	NN

conservation	NN
O	NN

among	IN
O	NN

these	DT
O	NN

proteins	NNS
O	NN

with	IN
O	NN

no	DT
O	NN

currently	RB
O	NN

assigned	VBN
O	NN

function	NN
O	NN

Two	CD
O	NN

different	JJ
O	NN

responses	NNS
O	NN

to	TO
O	NN

the	DT
O	NN

therapy	NN
O	NN

were	VBD
O	NN

observed	VBN
O	NN

in	IN
O	NN

a	DT
O	NN

group	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

receiving	VBG
O	NN

the	DT
O	NN

protease	NN
T	NN

inhibitor	NN
T	NN

indinavir	NN
T	NN

In	IN
O	NN

one	CD
O	NN

,	,
O	NN

suppression	NN
O	NN

of	IN
O	NN

virus	NN
O	NN

replication	NN
O	NN

occurred	VBD
O	NN

and	CC
O	NN

has	VBZ
O	NN

persisted	VBD
O	NN

for	IN
O	NN

90	CD
O	NN

weeks	NNS
O	NN

(	NN
O	NN

bDNA	NN
O	NN

,	,
O	NN

&	CC
O	NNP

#	#
O	NN

60	CD
O	NN

;	:
O	NN

500	CD
O	NN

human	JJ
O	NN

immunodeficiency	NN
O	NN

virus	NN
O	NN

type	NN
O	NN

1	CD
O	NN

(	NN
O	NN

HIV-1	NN
O	NN

)	NN
O	NN

RNA	NN
O	NN

copies/ml	NN
O	NN

)	NN
O	NN

In	IN
O	NN

the	DT
O	NN

second	JJ
O	NN

group	NN
O	NN

,	,
O	NN

a	DT
O	NN

rebound	VB
O	NN

in	IN
O	NN

virus	NN
O	NN

levels	NNS
O	VBP

in	IN
O	NN

plasma	NN
O	NN

followed	VBN
O	NN

the	DT
O	NN

initial	JJ
O	NN

sharp	JJ
O	NN

decline	NN
O	NN

observed	VBN
O	NN

at	IN
O	NN

the	DT
O	NN

start	VB
O	NN

of	IN
O	NN

therapy	NN
O	NN

This	DT
O	NN

was	VBD
O	NN

associated	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

emergence	NN
O	NN

of	IN
O	NN

drug-resistant	JJ
O	NN

variants	NNS
O	NN

Sequence	NN
O	NN

analysis	NN
O	NN

of	IN
O	NN

the	DT
O	NN

protease	NN
O	NN

gene	NN
O	NN

during	IN
O	NN

the	DT
O	NN

course	NN
O	NN

of	IN
O	NN

therapy	NN
O	NN

revealed	VBD
O	NN

that	IN
O	NN

in	IN
O	NN

this	DT
O	NN

second	JJ
O	NN

group	NN
O	NN

there	RB
O	NN

was	VBD
O	NN

a	DT
O	NN

sequential	JJ
O	NN

acquisition	NN
O	NN

of	IN
O	NN

protease	NN
O	NN

mutations	NNS
O	VBP

at	IN
O	NN

amino	NN
O	NN

acids	NNS
O	NN

46	CD
O	NN

,	,
O	NN

82	CD
O	NN

,	,
O	NN

54	CD
O	NN

,	,
O	NN

71	CD
O	NN

,	,
O	NN

89	CD
O	NN

,	,
O	NN

and	CC
O	NN

90	CD
O	NN

In	IN
O	NN

the	DT
O	NN

six	CD
O	NN

patients	NNS
O	NN

in	IN
O	NN

this	DT
O	NN

group	NN
O	NN

,	,
O	NN

there	RB
O	NN

was	VBD
O	NN

also	RB
O	NN

an	DT
O	NN

identical	JJ
O	NN

mutation	NN
O	NN

in	IN
O	NN

the	DT
O	NN

gag	NN
O	NN

p7/p1	NN
O	NN

gag	NN
O	NN

protease	NN
O	NN

cleavage	NN
O	NN

site	NN
O	NN

In	IN
O	NN

three	CD
O	NN

of	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

,	,
O	NN

this	DT
O	NN

change	NN
O	NN

was	VBD
O	NN

seen	VBN
O	NN

as	IN
O	NN

early	RB
O	NN

as	IN
O	NN

6	CD
O	NN

to	TO
O	NN

10	CD
O	NN

weeks	NNS
O	NN

after	IN
O	NN

the	DT
O	NN

start	VB
O	NN

of	IN
O	NN

therapy	NN
O	NN

In	IN
O	NN

one	CD
O	NN

patient	NN
O	NN

,	,
O	NN

a	DT
O	NN

second	JJ
O	NN

mutation	NN
O	NN

occurred	VBD
O	NN

at	IN
O	NN

the	DT
O	NN

gag	NN
O	NN

p1/p6	NN
O	NN

cleavage	NN
O	NN

site	NN
O	NN

,	,
O	NN

but	CC
O	NNP

it	PRP
O	NN

appeared	VBD
O	NN

18	CD
O	NN

weeks	NNS
O	NN

after	IN
O	NN

the	DT
O	NN

time	NN
O	NN

of	IN
O	NN

appearance	NN
O	NN

of	IN
O	NN

the	DT
O	NN

p7/p1	NN
O	NN

mutation	NN
O	NN

Recombinant	JJ
O	NN

HIV-1	NN
O	NN

variants	NNS
O	NN

containing	VBG
O	NN

two	CD
O	NN

or	CC
O	NN

three	CD
O	NN

mutations	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

protease	NN
O	NN

gene	NN
O	NN

were	VBD
O	NN

constructed	VBN
O	NN

either	DT
O	NN

with	IN
O	NN

mutations	NNS
O	VBP

at	IN
O	NN

the	DT
O	NN

p7/p1	NN
O	NN

cleavage	NN
O	NN

site	NN
O	NN

or	CC
O	NN

with	IN
O	NN

wild-type	JJ
O	NN

(	NN
O	NN

WT	JJ
O	NN

)	NN
O	NN

gag	NN
O	NN

sequences	NNS
O	NN

When	WRB
O	NN

recombinant	JJ
O	NN

HIV-1-containing	JJ
O	NN

protease	NN
O	NN

mutations	NNS
O	VBP

at	IN
O	NN

46	CD
O	NN

and	CC
O	NN

82	CD
O	NN

was	VBD
O	NN

grown	VBN
O	NN

in	IN
O	NN

MT2	NN
O	NN

cells	NNS
O	VBP

,	,
O	NN

there	RB
O	NN

was	VBD
O	NN

a	DT
O	NN

68	CD
O	NN

%	NN
O	NN

reduction	NN
O	NN

in	IN
O	NN

its	PRP$
O	NN

rate	NN
O	NN

of	IN
O	NN

replication	NN
O	NN

compared	VBN
O	NN

to	TO
O	NN

the	DT
O	NN

WT	JJ
O	NN

virus	NN
O	NN

Introduction	NN
O	NN

of	IN
O	NN

an	DT
O	NN

additional	JJ
O	NN

mutation	NN
O	NN

at	IN
O	NN

the	DT
O	NN

gag	NN
O	NN

p7/p1	NN
O	NN

protease	NN
O	NN

cleavage	NN
O	NN

site	NN
O	NN

compensated	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

partially	RB
O	NN

defective	JJ
O	NN

protease	NN
O	NN

gene	NN
O	NN

Similarly	RB
O	NN

,	,
O	NN

rates	NNS
O	VBP

of	IN
O	NN

replication	NN
O	NN

of	IN
O	NN

viruses	NNS
O	NN

with	IN
O	NN

mutations	NNS
O	VBP

M46L/I	NN
O	NN

,	,
O	NN

I54V	NN
O	NN

,	,
O	NN

and	CC
O	NN

V82A	NN
O	NN

in	IN
O	NN

protease	NN
O	NN

were	VBD
O	NN

enhanced	VBN
O	NN

both	DT
O	NN

in	IN
O	NN

the	DT
O	NN

presence	NN
O	NN

and	CC
O	NN

in	IN
O	NN

the	DT
O	NN

absence	NN
O	NN

of	IN
O	NN

Indinavir	NNP
O	NNP

when	WRB
O	NN

combined	JJ
O	NN

with	IN
O	NN

mutations	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

gag	NN
O	NN

p7/p1	NN
O	NN

and	CC
O	NN

the	DT
O	NN

gag	NN
O	NN

p1/p6	NN
O	NN

cleavage	NN
O	NN

sites	NNS
O	NN

Optimal	JJ
O	NN

rates	NNS
O	VBP

of	IN
O	NN

virus	NN
O	NN

replication	NN
O	NN

require	VB
O	NN

protease	NN
O	NN

cleavage	NN
O	NN

of	IN
O	NN

precursor	NN
O	NN

polyproteins	NNS
O	NN

A	DT
O	NN

mutation	NN
O	NN

in	IN
O	NN

the	DT
O	NN

cleavage	NN
O	NN

site	NN
O	NN

that	IN
O	NN

enhanced	VBN
O	NN

the	DT
O	NN

availability	NN
O	NN

of	IN
O	NN

a	DT
O	NN

protein	NN
O	NN

that	IN
O	NN

was	VBD
O	NN

rate	NN
O	NN

limiting	VBG
O	NN

for	IN
O	NN

virus	NN
O	NN

maturation	NN
O	NN

would	MD
O	NNP

confer	VB
O	NN

on	IN
O	NN

that	IN
O	NN

virus	NN
O	NN

a	DT
O	NN

significant	JJ
O	NN

growth	NN
O	NN

advantage	NN
O	NN

and	CC
O	NN

may	MD
O	NNP

explain	VB
O	NN

the	DT
O	NN

uniform	JJ
O	NN

emergence	NN
O	NN

of	IN
O	NN

viruses	NNS
O	NN

with	IN
O	NN

alterations	NNS
O	VBP

at	IN
O	NN

the	DT
O	NN

p7/p1	NN
O	NN

cleavage	NN
O	NN

site	NN
O	NN

This	DT
O	NN

is	VBZ
O	NN

the	DT
O	NN

first	RB
O	NN

report	NN
O	NN

of	IN
O	NN

the	DT
O	NN

emergence	NN
O	NN

of	IN
O	NN

mutations	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

gag	NN
O	NN

p7/p1	NN
O	NN

protease	NN
O	NN

cleavage	NN
O	NN

sites	NNS
O	NN

in	IN
O	NN

patients	NNS
O	NN

receiving	VBG
O	NN

protease	NN
T	NN

therapy	NN
T	NN

and	CC
O	NN

identifies	VBZ
O	NN

this	DT
O	NN

change	NN
O	NN

as	IN
O	NN

an	DT
O	NN

important	JJ
O	NN

determinant	NN
O	NN

of	IN
O	NN

HIV-1	NN
O	NN

resistance	NN
O	NN

to	TO
O	NN

protease	NN
O	NN

inhibitors	NNS
O	NN

in	IN
O	NN

patient	NN
O	NN

populations	NNS
O	NN

A	DT
O	NN

novel	JJ
O	NN

intracellular	JJ
O	NN

calcium-binding	JJ
O	NN

protein	NN
O	NN

from	IN
O	NN

Echinococcus	NN
O	NN

granulosus	NN
O	NN

is	VBZ
O	NN

described	VBN
O	NN

in	IN
O	NN

this	DT
O	NN

work	NN
O	NN

A	DT
O	NN

cDNA	NN
O	NN

was	VBD
O	NN

isolated	VBN
O	NN

from	IN
O	NN

a	DT
O	NN

lambdagt11	NN
O	NN

protoscolex	NN
O	NN

expression	NN
O	NN

library	NN
O	NN

and	CC
O	NN

the	DT
O	NN

deduced	VBN
O	NN

amino	NN
O	NN

acid	NN
O	NN

sequence	NN
O	NN

has	VBZ
O	NN

at	IN
O	NN

least	JJS
O	NN

fifteen	CD
O	NN

sequentially	RB
O	NN

repeated	VBN
O	NN

twelve-residue	JJ
O	NN

repeats	NNS
O	VBP

that	IN
O	NN

resemble	VB
O	NN

the	DT
O	NN

calcium-binding	JJ
O	NN

loop	NN
O	NN

of	IN
O	NN

EF-hands	NNS
O	NN

;	:
O	NN

however	RB
O	NN

,	,
O	NN

the	DT
O	NN

dodecamer	NN
O	NN

motif	NN
O	NN

has	VBZ
O	NN

no	DT
O	NN

flanking	JJ
O	NN

helices	NNS
O	NN

The	DT
O	NN

cDNA	NN
O	NN

was	VBD
O	NN

expressed	VBN
O	NN

in	IN
O	NN

Escherichia	FW
O	FW

coli	NN
O	NN

using	VBG
O	NN

the	DT
O	NN

pGEX	NN
O	NN

vector	NN
O	NN

,	,
O	NN

and	CC
O	NN

a	DT
O	NN

recombinant	JJ
O	NN

fusion	NN
O	NN

protein	NN
O	NN

(	NN
O	NN

EgCaBP1-GST	NN
O	NN

)	NN
O	NN

was	VBD
O	NN

obtained	VBN
O	NN

The	DT
O	NN

recombinant	JJ
O	NN

fusion	NN
O	NN

protein	NN
O	NN

binds	VBZ
O	NN

calcium	NN
O	NN

when	WRB
O	NN

assayed	VBN
O	NN

with	IN
O	NN

45Ca	NN
O	NN

It	PRP
O	NN

is	VBZ
O	NN

possible	JJ
O	NN

that	IN
O	NN

the	DT
O	NN

calcium-binding	JJ
O	NN

motifs	NNS
O	NN

present	JJ
O	NN

a	DT
O	NN

secondary	JJ
O	NN

structure	NN
O	NN

similar	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

parallel	JJ
O	NN

beta	NN
O	NN

roll	NN
O	NN

structure	NN
O	NN

described	VBN
O	NN

for	IN
O	NN

an	DT
O	NN

alkaline	NN
O	NN

protease	NN
O	NN

from	IN
O	NN

Pseudomonas	FW
O	FW

aeruginosa	FW
O	FW

A	DT
O	NN

native	JJ
O	NN

protein	NN
O	NN

of	IN
O	NN

more	RBR
O	NN

than	IN
O	NN

300	CD
O	NN

kDa	NN
O	NN

was	VBD
O	NN

recognized	VBN
O	NN

by	IN
O	NN

an	DT
O	NN

anti-EgCaBP1	JJ
O	NN

monoclonal	JJ
O	NN

antibody	NN
O	NN

by	IN
O	NN

Western-blot	JJ
O	NN

analysis	NN
O	NN

Immunohistochemistry	NN
O	NN

using	VBG
O	NN

a	DT
O	NN

pool	NN
O	NN

of	IN
O	NN

anti-EgCaBP1-GST	JJ
O	NN

mouse	NN
O	NN

sera	NNS
O	VBP

demonstrated	VBD
O	NN

a	DT
O	NN

strong	JJ
O	NN

association	NN
O	NN

of	IN
O	NN

the	DT
O	NN

protein	NN
O	NN

with	IN
O	NN

calcareous	JJ
O	NN

corpuscles	NNS
O	NN

The	DT
O	NN

possible	JJ
O	NN

role	NN
O	NN

of	IN
O	NN

this	DT
O	NN

protein	NN
O	NN

and	CC
O	NN

that	IN
O	NN

of	IN
O	NN

the	DT
O	NN

calcareous	JJ
O	NN

corpuscles	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

protoscolex	NN
O	NN

are	VBP
O	NN

discussed	VBN
O	NN

The	DT
O	NN

enzyme	NN
O	NN

activity	NN
O	NN

of	IN
O	NN

mitogen-activated	JJ
O	NN

protein	NN
O	NN

kinase	NN
O	NN

(	NN
O	NN

MAP	NN
O	NN

kinase	NN
O	NN

)	NN
O	NN

increases	NNS
O	NN

in	IN
O	NN

response	NN
O	NN

to	TO
O	NN

agents	NNS
O	NN

acting	VBG
O	NN

on	IN
O	NN

a	DT
O	NN

variety	NN
O	NN

of	IN
O	NN

cell	NN
O	NN

surface	NN
O	NN

receptors	NNS
O	VBP

,	,
O	NN

including	VBG
O	NN

receptors	NNS
O	VBP

linked	VBN
O	NN

to	TO
O	NN

heterotrimeric	JJ
O	NN

G	NN
O	NN

proteins	NNS
O	NN

In	IN
O	NN

this	DT
O	NN

report	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

demonstrated	VBD
O	NN

that	IN
O	NN

Raf-1	NN
O	NN

protein	NN
O	NN

kinase	NN
O	NN

activity	NN
O	NN

in	IN
O	NN

the	DT
O	NN

mouse	NN
O	NN

parotid	NN
O	NN

glands	NNS
O	NN

was	VBD
O	NN

induced	VBN
O	NN

by	IN
O	NN

chronic	JJ
O	NN

isoproterenol	NN
O	NN

administration	NN
O	NN

in	IN
O	NN

whole	JJ
O	NN

animals	NNS
O	NN

To	TO
O	NN

investigate	VB
O	NN

the	DT
O	NN

molecular	JJ
O	NN

nature	NN
O	NN

underlying	VBG
O	NN

cellular	JJ
O	NN

responses	NNS
O	NN

to	TO
O	NN

Raf-1	NN
O	NN

activation	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

have	VB
O	NN

stably	RB
O	NN

transfected	VBN
O	NN

rat	NN
O	NN

salivary	JJ
O	NN

epithelial	JJ
O	NN

Pa-4	NN
O	NN

cells	NNS
O	VBP

with	IN
O	NN

human	JJ
O	NN

Raf-1-estrogen	JJ
O	NN

receptor	NN
O	NN

fusion	NN
O	NN

gene	NN
O	NN

(	NN
O	NN

DeltaRaf-1	NN
O	NN

:	:
O	NN

ER	NN
O	NN

)	NN
O	NN

and	CC
O	NN

used	VBN
O	NN

mRNA	NN
O	NN

differential	JJ
O	NN

display	NN
O	NN

in	IN
O	NN

search	NN
O	NN

of	IN
O	NN

messages	NNS
O	NN

induced	VBN
O	NN

by	IN
O	NN

DeltaRaf-1	NN
O	NN

:	:
O	NN

ER	NN
O	NN

activation	NN
O	NN

Through	IN
O	NN

this	DT
O	NN

approach	NN
O	NN

,	,
O	NN

the	DT
O	NN

gene	NN
O	NN

encoding	VBG
O	NN

non-histone	JJ
O	NN

chromosomal	JJ
O	NN

protein	NN
O	NN

HMGI-C	NN
O	NN

was	VBD
O	NN

identified	VBN
O	NN

as	IN
O	NN

one	CD
O	NN

of	IN
O	NN

the	DT
O	NN

target	NN
O	NN

genes	NNS
O	NN

activated	VBN
O	NN

by	IN
O	NN

oncogenic	JJ
O	NN

Raf-1	NN
O	NN

kinase	NN
O	NN

Activation	NN
O	NN

of	IN
O	NN

Raf-1	NN
O	NN

kinase	NN
O	NN

resulted	VBD
O	NN

in	IN
O	NN

a	DT
O	NN

delayed	VBN
O	NN

and	CC
O	NN

sustained	JJ
O	NN

increase	NN
O	NN

of	IN
O	NN

HMGI-C	NN
O	NN

expression	NN
O	NN

in	IN
O	NN

the	DT
O	NN

Pa-4	NN
O	NN

cells	NNS
O	VBP

The	DT
O	NN

induction	NN
O	NN

of	IN
O	NN

HMGI-C	NN
O	NN

mRNA	NN
O	NN

level	NN
O	NN

is	VBZ
O	NN

sensitive	JJ
O	NN

to	TO
O	NN

both	DT
O	NN

the	DT
O	NN

protein	NN
O	NN

synthesis	NN
O	NN

inhibitor	NN
O	NN

cycloheximide	NN
O	NN

and	CC
O	NN

transcription	NN
O	NN

inhibitor	NN
O	NN

actinomycin	JJ
O	NN

D	NN
O	NN

The	DT
O	NN

role	NN
O	NN

of	IN
O	NN

the	DT
O	NN

extracellular	JJ
O	NN

signal-related	JJ
O	NN

kinase	NN
O	NN

(	NN
O	NN

ERK	NN
O	NN

)	NN
O	NN

signaling	VBG
O	NN

pathway	NN
O	NN

in	IN
O	NN

the	DT
O	NN

HMGI-C	NN
O	NN

induction	NN
O	NN

was	VBD
O	NN

highlighted	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

result	NN
O	NN

that	IN
O	NN

the	DT
O	NN

MAP	NN
O	NN

kinase	NN
O	NN

kinase	NN
O	NN

(	NN
O	NN

MEK	NN
O	NN

)	NN
O	NN

inhibitor	NN
O	NN

,	,
O	NN

PD	NN
O	NN

98059	CD
O	NN

,	,
O	NN

blocked	VBN
O	NN

DeltaRaf-1	NN
O	NN

:	:
O	NN

ER-	JJ
O	NN

and	CC
O	NN

12-O-tetradecanoylphorbol-13-acetate-stimulated	JJ
O	NN

HMGI-C	NN
O	NN

induction	NN
O	NN

Altogether	RB
O	NN

,	,
O	NN

these	DT
O	NN

findings	NNS
O	VBP

support	NN
O	NN

the	DT
O	NN

notion	NN
O	NN

that	IN
O	NN

the	DT
O	NN

Raf/MEK/ERK	NN
O	NN

signaling	VBG
O	NN

module	NN
O	NN

,	,
O	NN

at	IN
O	NN

least	JJS
O	NN

in	IN
O	NN

part	NN
O	NN

,	,
O	NN

regulates	VBZ
O	NN

transcriptional	JJ
O	NN

activation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

chromosomal	JJ
O	NN

architectural	JJ
O	NN

protein	NN
O	NN

HMGI-C	NN
O	NN

Pendred	VBN
D	NN

syndrome	NN
D	NN

is	VBZ
O	NN

a	DT
O	NN

recessively	RB
O	NN

inherited	VBN
O	NN

disorder	NN
O	NN

with	IN
O	NN

the	DT
O	NN

hallmark	NN
O	NN

features	NNS
O	VBP

of	IN
O	NN

congenital	JJ
D	NN

deafness	NN
D	NN

and	CC
O	NN

thyroid	NN
D	NN

goitre	NN
D	NN

By	IN
O	NN

some	DT
O	NN

estimates	NNS
O	NN

,	,
O	NN

the	DT
O	NN

disorder	NN
O	NN

may	MD
O	NNP

account	NN
O	NN

for	IN
O	NN

upwards	NNS
O	NN

of	IN
O	NN

10	CD
O	NN

%	NN
O	NN

of	IN
O	NN

hereditary	JJ
D	NN

deafness	NN
D	NN

Previous	JJ
O	NN

genetic	JJ
O	NN

linkage	NN
O	NN

studies	NNS
O	VBP

localized	JJ
O	NN

the	DT
O	NN

gene	NN
O	NN

to	TO
O	NN

a	DT
O	NN

broad	JJ
O	NN

interval	NN
O	NN

on	IN
O	NN

human	JJ
O	NN

chromosome	NN
O	NN

7q22-31.1	JJ
O	NN

Using	VBG
O	NN

a	DT
O	NN

positional	JJ
O	NN

cloning	VBG
O	NN

strategy	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

have	VB
O	NN

identified	VBN
O	NN

the	DT
O	NN

gene	NN
O	NN

(	NN
O	NN

PDS	NN
O	NN

)	NN
O	NN

mutated	VBN
O	NN

in	IN
O	NN

Pendred	VBN
D	NN

syndrome	NN
D	NN

and	CC
O	NN

found	VBN
O	NN

three	CD
O	NN

apparently	RB
O	NN

deleterious	JJ
O	NN

mutations	NNS
O	VBP

,	,
O	NN

each	DT
O	NN

segregating	VBG
O	NN

with	IN
O	NN

the	DT
O	NN

disease	NN
O	NN

in	IN
O	NN

the	DT
O	NN

respective	JJ
O	NN

families	NNS
O	NN

in	IN
O	NN

which	WDT
O	NN

they	PRP
O	VBP

occur	VB
O	NN

PDS	NN
O	NN

produces	VBZ
O	NN

a	DT
O	NN

transcript	NN
O	NN

of	IN
O	NN

approximately	RB
O	NN

5	CD
O	NN

kb	NN
O	NN

that	IN
O	NN

was	VBD
O	NN

found	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

expressed	VBN
O	NN

at	IN
O	NN

significant	JJ
O	NN

levels	NNS
O	VBP

only	RB
O	NN

in	IN
O	NN

the	DT
O	NN

thyroid	NN
O	NN

The	DT
O	NN

predicted	VBN
O	NN

protein	NN
O	NN

,	,
O	NN

pendrin	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

closely	RB
O	NN

related	JJ
O	NN

to	TO
O	NN

a	DT
O	NN

number	NN
O	NN

of	IN
O	NN

known	JJ
O	NN

sulphate	NN
O	NN

transporters	NNS
O	VBP

These	DT
O	NN

studies	NNS
O	VBP

provide	VB
O	NN

compelling	JJ
O	NN

evidence	NN
O	NN

that	IN
O	NN

defects	NNS
O	NN

in	IN
O	NN

pendrin	NN
O	NN

cause	NN
O	NN

Pendred	VBN
D	NN

syndrome	NN
D	NN

thereby	RB
O	NN

launching	VBG
O	NN

a	DT
O	NN

new	JJ
O	NN

area	NN
O	NN

of	IN
O	NN

investigation	NN
O	NN

into	IN
O	NN

thyroid	NN
O	NN

physiology	NN
O	NN

,	,
O	NN

the	DT
O	NN

pathogenesis	NN
O	NN

of	IN
O	NN

congenital	JJ
D	NN

deafness	NN
D	NN

and	CC
O	NN

the	DT
O	NN

role	NN
O	NN

of	IN
O	NN

altered	JJ
O	NN

sulphate	NN
O	NN

transport	NN
O	NN

in	IN
O	NN

human	JJ
O	NN

disease	NN
O	NN

We	PRP
O	VBP

report	NN
O	NN

the	DT
O	NN

cDNA	NN
O	NN

cloning	VBG
O	NN

,	,
O	NN

partial	JJ
O	NN

genomic	JJ
O	NN

organization	NN
O	NN

,	,
O	NN

and	CC
O	NN

expression	NN
O	NN

pattern	NN
O	NN

of	IN
O	NN

Stra10	NN
O	NN

,	,
O	NN

a	DT
O	NN

novel	JJ
O	NN

retinoic	JJ
O	NN

acid-inducible	JJ
O	NN

gene	NN
O	NN

in	IN
O	NN

P19	NN
O	NN

embryonal	JJ
D	NN

carcinoma	NN
D	NN

cells	NNS
O	VBP

Four	CD
O	NN

murine	JJ
O	NN

cDNA	NN
O	NN

isoforms	NNS
O	NN

have	VB
O	NN

been	VBN
O	NN

isolated	VBN
O	NN

,	,
O	NN

which	WDT
O	NN

are	VBP
O	NN

likely	JJ
O	NN

to	TO
O	NN

result	NN
O	NN

from	IN
O	NN

alternative	JJ
O	NN

splicing	NN
O	NN

The	DT
O	NN

predicted	VBN
O	NN

protein	NN
O	NN

sequences	NNS
O	NN

exhibit	NN
O	NN

approximately	RB
O	NN

85	CD
O	NN

%	NN
O	NN

identity	NN
O	NN

with	IN
O	NN

the	DT
O	NN

Pbx-related	JJ
O	NN

Meis1	NN
O	NN

homeobox	NN
O	NN

gene	NN
O	NN

products	NNS
O	NN

,	,
O	NN

which	WDT
O	NN

are	VBP
O	NN

involved	VBN
O	NN

in	IN
O	NN

myeloid	JJ
D	NN

leukemia	NN
D	NN

in	IN
O	NN

BXH-2	NN
O	NN

mice	NNS
O	NN

,	,
O	NN

and	CC
O	NN

one	CD
O	NN

of	IN
O	NN

the	DT
O	NN

Stra10	NN
O	NN

isoforms	NNS
O	NN

corresponds	VBZ
O	NN

to	TO
O	NN

the	DT
O	NN

recently	RB
O	NN

published	VBN
O	NN

Meis2	NN
O	NN

sequence	NN
O	NN

(	NN
O	NN

Nakamura	NNP
O	NNP

et	FW
O	FW

al	NNP
O	NNP

.	.
O	NN

(	NN
O	NN

1996	CD
O	NN

)	NN
O	NN

Oncogene	NN
O	NN

13	CD
O	NN

:	:
O	NN

2235-2242	CD
O	NN

)	NN
O	NN

The	DT
O	NN

Meis2	NN
O	NN

homeodomain	NN
O	NN

is	VBZ
O	NN

identical	JJ
O	NN

to	TO
O	NN

that	IN
O	NN

of	IN
O	NN

Meis1	NN
O	NN

,	,
O	NN

and	CC
O	NN

is	VBZ
O	NN

most	JJS
O	NN

closely	RB
O	NN

related	JJ
O	NN

to	TO
O	NN

those	DT
O	NNP

of	IN
O	NN

the	DT
O	NN

Pbx/TGIF	NN
O	NN

homeobox	NN
O	NN

gene	NN
O	NN

products	NNS
O	NN

By	IN
O	NN

in	IN
O	NN

situ	FW
O	FW

hybridization	NN
O	NN

analysis	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

show	NN
O	NN

that	IN
O	NN

the	DT
O	NN

Meis2	NN
O	NN

gene	NN
O	NN

displays	NNS
O	VBP

spatially	RB
O	NN

restricted	JJ
O	NN

expression	NN
O	NN

patterns	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

developing	VBG
O	NN

nervous	JJ
O	NN

system	NN
O	NN

,	,
O	NN

limbs	NNS
O	NN

,	,
O	NN

face	NN
O	NN

,	,
O	NN

and	CC
O	NN

in	IN
O	NN

various	JJ
O	NN

viscera	NN
O	NN

In	IN
O	NN

adult	JJ
O	NN

mice	NNS
O	NN

,	,
O	NN

Meis2	NN
O	NN

is	VBZ
O	NN

mainly	RB
O	NN

expressed	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

brain	NN
O	NN

and	CC
O	NN

female	JJ
O	NN

genital	JJ
O	NN

tract	NN
O	NN

,	,
O	NN

with	IN
O	NN

a	DT
O	NN

different	JJ
O	NN

distribution	NN
O	NN

of	IN
O	NN

the	DT
O	NN

alternative	JJ
O	NN

splice	NN
O	NN

forms	NNS
O	NN

in	IN
O	NN

these	DT
O	NN

organs	NNS
O	VBP

A	DT
O	NN

methodical	JJ
O	NN

strategy	NN
O	NN

for	IN
O	NN

the	DT
O	NN

isolation	NN
O	NN

of	IN
O	NN

microsatellite	NN
O	NN

markers	NNS
O	VBP

specific	JJ
O	NN

for	IN
O	NN

targeted	VBN
O	NN

regions	NNS
O	NN

of	IN
O	NN

bovine	JJ
O	NN

chromosomes	NNS
O	NN

is	VBZ
O	NN

presented	VBN
O	NN

The	DT
O	NN

procedure	NN
O	NN

involves	VBZ
O	NN

directed	VBN
O	NN

microdissection	NN
O	NN

of	IN
O	NN

one	CD
O	NN

defined	VBN
O	NN

subchromosomal	JJ
O	NN

area	NN
O	NN

,	,
O	NN

its	PRP$
O	NN

DOP-PCR-amplification	NN
O	NN

and	CC
O	NN

cloning	VBG
O	NN

With	IN
O	NN

this	DT
O	NN

approach	NN
O	NN

,	,
O	NN

a	DT
O	NN

library	NN
O	NN

specific	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

BTA	NN
O	NN

6q21-31	JJ
O	NN

chromosomal	JJ
O	NN

region	NN
O	NN

was	VBD
O	NN

constructed	VBN
O	NN

Eleven	CD
O	NN

unique	JJ
O	NN

microsatellite-containing	JJ
O	NN

sequences	NNS
O	NN

were	VBD
O	NN

isolated	VBN
O	NN

,	,
O	NN

converted	VBN
O	NN

into	IN
O	NN

sequence-tagged	JJ
O	NN

microsatellite	NN
O	NN

sites	NNS
O	NN

,	,
O	NN

and	CC
O	NN

characterized	VBN
O	NN

concerning	VBG
O	NN

their	PRP$
O	NN

species-specific	JJ
O	NN

origin	NN
O	NN

Seven	CD
O	NN

primer	NN
O	NN

pairs	NNS
O	NN

generated	VBN
O	NN

bovine-specific	JJ
O	NN

PCR	NN
O	NN

products	NNS
O	NN

and	CC
O	NN

provided	VBN
O	NN

a	DT
O	NN

set	VBN
O	NN

of	IN
O	NN

microsatellite	NN
O	NN

markers	NNS
O	VBP

that	IN
O	NN

generally	RB
O	NN

revealed	VBD
O	NN

high	JJ
O	NN

informativity	NN
O	NN

in	IN
O	NN

the	DT
O	NN

HF	NN
O	NN

breed	NN
O	NN

Linkage	NN
O	NN

analysis	NN
O	NN

assigned	VBN
O	NN

six	CD
O	NN

of	IN
O	NN

them	PRP
O	VBP

to	TO
O	NN

their	PRP$
O	NN

predefined	VBN
O	NN

subchromosomal	JJ
O	NN

origin	NN
O	NN

on	IN
O	NN

BTA	NN
O	NN

6	CD
O	NN

corresponding	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

specific	JJ
O	NN

rehybridization	NN
O	NN

signal	NN
O	NN

of	IN
O	NN

the	DT
O	NN

DOP-PCR	NN
O	NN

product	NN
O	NN

generated	VBN
O	NN

from	IN
O	NN

the	DT
O	NN

microdissected	VBN
O	NN

chromosome	NN
O	NN

area	NN
O	NN

6q21-31	JJ
O	NN

The	DT
O	NN

results	NNS
O	VBP

underline	VB
O	NN

the	DT
O	NN

usefulness	NN
O	NN

of	IN
O	NN

the	DT
O	NN

BTA	NN
O	NN

6q21-31	JJ
O	NN

library	NN
O	NN

for	IN
O	NN

targeted	VBN
O	NN

isolation	NN
O	NN

of	IN
O	NN

unique	JJ
O	NN

sequences	NNS
O	NN

that	IN
O	NN

are	VBP
O	NN

specific	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

dissected	VBN
O	NN

chromosomal	JJ
O	NN

region	NN
O	NN

as	IN
O	NN

demonstrated	VBD
O	NN

here	RB
O	NN

by	IN
O	NN

the	DT
O	NN

isolation	NN
O	NN

of	IN
O	NN

microsatellite	NN
O	NN

markers	NNS
O	VBP

Phylogeographic	JJ
O	NN

structure	NN
O	NN

was	VBD
O	NN

determined	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

yellow	JJ
O	NN

mongoose	NN
O	NN

,	,
O	NN

Cynictis	NN
O	NN

penicillata	NN
O	NN

,	,
O	NN

using	VBG
O	NN

mtDNA	NN
O	NN

RFLPs	NNS
O	NN

and	CC
O	NN

control	NN
O	NN

region	NN
O	NN

sequences	NNS
O	NN

The	DT
O	NN

RFLP	NN
O	NN

analysis	NN
O	NN

revealed	VBD
O	NN

13	CD
O	NN

haplotypes	NNS
O	NN

which	WDT
O	NN

showed	VBD
O	NN

weak	JJ
O	NN

geographical	JJ
O	NN

patterning	NN
O	NN

consistent	JJ
O	NN

with	IN
O	NN

a	DT
O	NN

recent	JJ
O	NN

range	NN
O	NN

expansion	NN
O	NN

from	IN
O	NN

a	DT
O	NN

refugial	JJ
O	NN

population	NN
O	NN

(	NN
O	NN

s	NNS
O	NN

)	NN
O	NN

An	DT
O	NN

analysis	NN
O	NN

of	IN
O	NN

molecular	JJ
O	NN

variance	NN
O	NN

(	NN
O	NN

AMOVA	NNP
O	NN

)	NN
O	NN

revealed	VBD
O	NN

no	DT
O	NN

correspondence	NN
O	NN

between	IN
O	NN

mtDNA	NN
O	NN

phylogeography	NN
O	NN

and	CC
O	NN

subspecies	NNS
O	NN

delimitation	NN
O	NN

,	,
O	NN

nor	CC
O	NN

between	IN
O	NN

matrilines	NNS
O	NN

and	CC
O	NN

areas	NNS
O	NN

characterized	VBN
O	NN

by	IN
O	NN

a	DT
O	NN

high	JJ
O	NN

incidence	NN
O	NN

of	IN
O	NN

the	DT
O	NN

viverrid-type	JJ
D	NN

rabies	NNP
D	NNP

,	,
O	NN

of	IN
O	NN

which	WDT
O	NN

the	DT
O	NN

yellow	JJ
O	NN

mongoose	NN
O	NN

is	VBZ
O	NN

the	DT
O	NN

principal	JJ
O	NN

vector	NN
O	NN

The	DT
O	NN

lack	NN
O	NN

of	IN
O	NN

structure	NN
O	NN

was	VBD
O	NN

also	RB
O	NN

shown	VBN
O	NN

by	IN
O	NN

control	NN
O	NN

region	NN
O	NN

sequences	NNS
O	NN

although	IN
O	NN

four	CD
O	NN

of	IN
O	NN

the	DT
O	NN

maternal	JJ
O	NN

lineages	NNS
O	NN

shared	VBN
O	NN

a	DT
O	NN

near-perfect	JJ
O	NN

81	CD
O	NN

bp	NN
O	NN

repeat	NN
O	NN

We	PRP
O	VBP

speculate	VBP
O	NN

that	IN
O	NN

regional	JJ
O	NN

hot	JJ
O	NN

spots	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

viverrid	NN
D	NN

rabies	NNP
D	NNP

biotype	NN
O	NN

reflect	VB
O	NN

population	NN
O	NN

density	NN
O	NN

differences	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

yellow	JJ
O	NN

mongoose	NN
O	NN

that	IN
O	NN

are	VBP
O	NN

not	RB
O	NN

underscored	VBN
O	NN

by	IN
O	NN

genetic	JJ
O	NN

partitioning	VBG
O	NN

,	,
O	NN

at	IN
O	NN

least	JJS
O	NN

at	IN
O	NN

the	DT
O	NN

level	NN
O	NN

of	IN
O	NN

resolution	NN
O	NN

provided	VBN
O	NN

by	IN
O	NN

our	PRP$
O	NN

analyses	NNS
O	VBP

The	DT
O	NN

indoor	JJ
O	NN

pollution	NN
O	NN

,	,
O	NN

where	WRB
O	NN

the	DT
O	NN

patients	NNS
O	NN

pass	NN
O	NN

in	IN
O	NN

general	JJ
O	NN

close	RB
O	NN

to	TO
O	NN

90	CD
O	NN

%	NN
O	NN

of	IN
O	NN

their	PRP$
O	NN

time	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

an	DT
O	NN

important	JJ
O	NN

factor	NN
O	NN

to	TO
O	NN

take	VB
O	NN

in	IN
O	NN

consideration	NN
O	NN

if	IN
O	NN

one	CD
O	NN

wants	VBZ
O	NN

to	TO
O	NN

evaluate	VB
O	NN

suitably	RB
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

air	NN
O	NN

pollution	NN
O	NN

on	IN
O	NN

the	DT
O	NN

health	NN
O	NN

Causes	VBZ
O	NN

of	IN
O	NN

this	DT
O	NN

kind	RB
O	NN

of	IN
O	NN

pollution	NN
O	NN

are	VBP
O	NN

partially	RB
O	NN

linked	VBN
O	NN

to	TO
O	NN

the	DT
O	NN

external	JJ
O	NN

pollution	NN
O	NN

and	CC
O	NN

the	DT
O	NN

outdoor	JJ
O	NN

environment	NN
O	NN

and	CC
O	NN

also	RB
O	NN

are	VBP
O	NN

function	NN
O	NN

of	IN
O	NN

human	JJ
O	NN

activities	NNS
O	VBP

and	CC
O	NN

introduced	VBN
O	NN

products	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

habitat	NN
O	NN

(	NN
O	NN

heating	NN
O	NN

,	,
O	NN

tabagisme	NN
O	NN

,	,
O	NN

handywork	NN
O	NN

,	,
O	NN

products	NNS
O	NN

of	IN
O	NN

maintenance	NN
O	NN

,	,
O	NN

coatings	NNS
O	NN

,	,
O	NN

materials	NNS
O	NN

of	IN
O	NN

construction	NN
O	NN

,	,
O	NN

etc	FW
O	FW

)	NN
O	NN

The	DT
O	NN

effects	NNS
O	NN

on	IN
O	NN

health	NN
O	NN

are	VBP
O	NN

as	IN
O	NN

various	JJ
O	NN

as	IN
O	NN

the	DT
O	NN

pollutants	NNS
O	NN

,	,
O	NN

going	VBG
O	NN

from	IN
O	NN

sharp	JJ
O	NN

intoxication	NN
O	NN

to	TO
O	NN

irritations	NNS
O	NN

or	CC
O	NN

simply	RB
O	NN

desagreements	NNS
O	NN

In	IN
O	NN

this	DT
O	NN

problem	NN
O	NN

of	IN
O	NN

public	JJ
O	NN

health	NN
O	NN

we	PRP
O	VBP

may	MD
O	NNP

not	RB
O	NN

underestimated	VBD
O	NN

sensitive	JJ
O	NN

persons	NNS
O	VBP

and	CC
O	NN

risky	JJ
O	NN

group	NN
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

long	RB
O	NN

terme	NN
O	NN

effects	NNS
O	NN

,	,
O	NN

and	CC
O	NN

chronic	JJ
O	NN

exposition	NN
O	NN

effects	NNS
O	NN

The	DT
O	NN

search	NN
O	NN

of	IN
O	NN

solutions	NNS
O	NN

needs	NNS
O	VBP

multiple	JJ
O	NN

competences	NNS
O	NN

from	IN
O	NN

the	DT
O	NN

physician	NN
O	NN

,	,
O	NN

who	WP
O	VBP

has	VBZ
O	NN

to	TO
O	NN

play	VB
O	NN

an	DT
O	NN

essential	JJ
O	NN

role	NN
O	NN

Dioxins	NNS
O	NN

are	VBP
O	NN

a	DT
O	NN

family	NN
O	NN

of	IN
O	NN

chlorinated	VBN
O	NN

aromatic	JJ
O	NN

hydrocarbons	NNS
O	NN

that	IN
O	NN

are	VBP
O	NN

produced	VBN
O	NN

during	IN
O	NN

combustion	NN
O	NN

processes	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

a	DT
O	NN

chlorine	NN
O	NN

donor	NN
O	NN

and	CC
O	NN

as	IN
O	NN

by-products	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

chlorine-processing	JJ
O	NN

chemical	NN
O	NN

industries	NNS
O	NN

Several	JJ
O	NN

dioxins	NNS
O	NN

are	VBP
O	NN

extremely	RB
O	NN

stable	JJ
O	NN

compounds	NNS
O	NN

and	CC
O	NN

persist	VB
O	NN

for	IN
O	NN

years	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

environment	NN
O	NN

Exposure	NN
O	NN

to	TO
O	NN

dioxins	NNS
O	NN

occurs	VBZ
O	NN

mainly	RB
O	NN

via	IN
O	NN

the	DT
O	NN

ingestion	NN
O	NN

of	IN
O	NN

contaminated	VBN
O	NN

food	NN
O	NN

The	DT
O	NN

lipophilic	JJ
O	NN

character	NN
O	NN

of	IN
O	NN

dioxins	NNS
O	NN

prevents	VBZ
O	NN

their	PRP$
O	NN

excretion	NN
O	NN

in	IN
O	NN

the	DT
O	NN

urine	NN
O	NN

and	CC
O	NN

causes	NNS
O	VBP

their	PRP$
O	NN

accumulation	NN
O	NN

in	IN
O	NN

body	NN
O	NN

fat	JJ
O	NN

The	DT
O	NN

mechanisms	NNS
O	VBP

of	IN
O	NN

dioxin	NN
O	NN

action	NN
O	NN

are	VBP
O	NN

similar	JJ
O	NN

to	TO
O	NN

those	DT
O	NNP

of	IN
O	NN

a	DT
O	NN

hormone	NN
O	NN

Dioxins	NNS
O	NN

bind	VB
O	NN

to	TO
O	NN

a	DT
O	NN

specific	JJ
O	NN

intracellular	JJ
O	NN

receptor	NN
O	NN

and	CC
O	NN

the	DT
O	NN

complex	JJ
O	NN

acts	NNS
O	NN

as	IN
O	NN

a	DT
O	NN

transcription	NN
O	NN

factor	NN
O	NN

that	IN
O	NN

induces	VBZ
O	NN

the	DT
O	NN

production	NN
O	NN

of	IN
O	NN

a	DT
O	NN

great	JJ
O	NN

number	NN
O	NN

of	IN
O	NN

proteins	NNS
O	NN

Certain	JJ
O	NN

dioxins	NNS
O	NN

,	,
O	NN

particularly	RB
O	NN

2	CD
O	NN

,	,
O	NN

3	CD
O	NN

,	,
O	NN

7	CD
O	NN

,	,
O	NN

8-tetrachlorodibenzo-p-dioxin	NN
O	NN

,	,
O	NN

are	VBP
O	NN

very	RB
O	NN

toxic	JJ
O	NN

and	CC
O	NN

able	JJ
O	NN

to	TO
O	NN

induce	VB
O	NN

numerous	JJ
O	NN

clinical	JJ
O	NN

conditions	NNS
O	VBP

The	DT
O	NN

carcinogenicity	NN
O	NN

of	IN
O	NN

dioxins	NNS
O	NN

is	VBZ
O	NN

well	RB
O	NN

documented	VBN
O	NN

in	IN
O	NN

animal	NN
O	NN

models	NNS
O	NN

and	CC
O	NN

has	VBZ
O	NN

been	VBN
O	NN

described	VBN
O	NN

in	IN
O	NN

humans	NNS
O	NN

after	IN
O	NN

professional	JJ
O	NN

and	CC
O	NN

accidental	JJ
O	NN

exposures	NNS
O	VBP

Recent	JJ
O	NN

experimental	JJ
O	NN

data	NNS
O	NN

also	RB
O	NN

indicate	VBP
O	NN

that	IN
O	NN

dioxins	NNS
O	NN

can	MD
O	NNP

cause	NN
O	NN

dysfunction	NN
D	NN

of	IN
D	NN

the	DT
D	NN

sexual	JJ
D	NN

and	CC
D	NN

thyroid	NN
D	NN

hormone	NN
D	NN

systems	NNS
D	NN

and	CC
O	NN

that	IN
O	NN

the	DT
O	NN

administration	NN
O	NN

of	IN
O	NN

dioxins	NNS
O	NN

induces	VBZ
O	NN

several	JJ
O	NN

conditions	NNS
O	VBP

related	JJ
O	NN

to	TO
O	NN

hormonal	JJ
D	NN

dysfunction	NN
D	NN

Chronic	JJ
O	NN

exposure	NN
O	NN

of	IN
O	NN

female	JJ
O	NN

Rhesus	NN
O	NN

monkeys	NNS
O	NN

increases	NNS
O	NN

the	DT
O	NN

incidence	NN
O	NN

and	CC
O	NN

severity	NN
O	NN

of	IN
O	NN

endometriosis	NN
D	NN

The	DT
O	NN

administration	NN
O	NN

of	IN
O	NN

dioxins	NNS
O	NN

during	IN
O	NN

pregnancy	NN
O	NN

and	CC
O	NN

nursing	NN
O	NN

causes	NNS
O	VBP

altered	JJ
O	NN

development	NN
O	NN

of	IN
O	NN

the	DT
O	NN

reproductive	JJ
O	NN

system	NN
O	NN

,	,
O	NN

decreased	VBN
O	NN

spermatogenesis	NN
O	NN

,	,
O	NN

hypothyroidism	NN
D	NN

and	CC
O	NN

disturbed	JJ
O	NN

psychomotor	NN
O	NN

development	NN
O	NN

in	IN
O	NN

the	DT
O	NN

offspring	NN
O	NN

The	DT
O	NN

particular	JJ
O	NN

sensibility	NN
O	NN

of	IN
O	NN

the	DT
O	NN

fetus	NN
O	NN

and	CC
O	NN

newborn	JJ
O	NN

is	VBZ
O	NN

of	IN
O	NN

concern	NN
O	NN

because	IN
O	NN

the	DT
O	NN

exposition	NN
O	NN

to	TO
O	NN

dioxins	NNS
O	NN

is	VBZ
O	NN

particularly	RB
O	NN

important	JJ
O	NN

during	IN
O	NN

those	DT
O	NNP

periods	NNS
O	NN

of	IN
O	NN

life	NN
O	NN

In	IN
O	NN

humans	NNS
O	NN

a	DT
O	NN

series	NN
O	NN

of	IN
O	NN

conditions	NNS
O	VBP

related	JJ
O	NN

to	TO
O	NN

hormonal	JJ
D	NN

dysfunction	NN
D	NN

as	IN
O	NN

undescended	JJ
O	NN

testis	NN
O	NN

,	,
O	NN

decreased	VBN
O	NN

spermatogenesis	NN
O	NN

,	,
O	NN

testicular	JJ
D	NN

cancer	NN
D	NN

and	CC
O	NN

endometriosis	NN
D	NN

have	VB
O	NN

increased	VBN
O	NN

in	IN
O	NN

incidence	NN
O	NN

during	IN
O	NN

the	DT
O	NN

last	JJ
O	NN

decades	NNS
O	NN

The	DT
O	NN

chronological	JJ
O	NN

parallelism	NN
O	NN

with	IN
O	NN

the	DT
O	NN

appearance	NN
O	NN

of	IN
O	NN

dioxins	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

environment	NN
O	NN

suggests	VBZ
O	NN

that	IN
O	NN

these	DT
O	NN

might	MD
O	NNP

exert	VB
O	NN

biological	JJ
O	NN

effects	NNS
O	NN

at	IN
O	NN

the	DT
O	NN

prevailing	VBG
O	NN

level	NN
O	NN

of	IN
O	NN

exposure	NN
O	NN

Nevertheless	RB
O	NN

this	DT
O	NN

hypothesis	NN
O	NN

is	VBZ
O	NN

currently	RB
O	NN

unconfirmed	JJ
O	NN

by	IN
O	NN

epidemiological	JJ
O	NN

studies	NNS
O	VBP

The	DT
O	NN

implications	NNS
O	VBP

of	IN
O	NN

this	DT
O	NN

scientific	JJ
O	NN

incertitude	NN
O	NN

for	IN
O	NN

the	DT
O	NN

implementation	NN
O	NN

of	IN
O	NN

preventive	JJ
O	NN

measures	NNS
O	VBP

are	VBP
O	NN

briefly	RB
O	NN

discussed	VBN
O	NN

This	DT
O	NN

presentation	NN
O	NN

summarizes	VBZ
O	NN

the	DT
O	NN

debate	NN
O	NN

on	IN
O	NN

the	DT
O	NN

suggested	VBN
O	NN

progressive	JJ
O	NN

impairment	NN
O	NN

of	IN
O	NN

semen	NN
O	NN

quality	NN
O	NN

(	NN
O	NN

the	DT
O	NN

``	``
O	NN

sperm	NN
O	NN

fall	NN
O	NN

''	''
O	NN

)	NN
O	NN

in	IN
O	NN

the	DT
O	NN

last	JJ
O	NN

forty	CD
O	NN

years	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

developed	VBN
O	NN

countries	NNS
O	NN

The	DT
O	NN

various	JJ
O	NN

available	JJ
O	NN

data	NNS
O	NN

strongly	RB
O	NN

suggesting	VBG
O	NN

an	DT
O	NN

environmental	JJ
O	NN

toxic	JJ
O	NN

origin	NN
O	NN

for	IN
O	NN

the	DT
O	NN

``	``
O	NN

sperm	NN
O	NN

fall	NN
O	NN

''	''
O	NN

will	MD
O	VB

be	VB
O	NN

presented	VBN
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

the	DT
O	NN

most	JJS
O	NN

frequently	RB
O	NN

suspected	VBN
O	NN

class	NN
O	NN

of	IN
O	NN

substances	NNS
O	NN

,	,
O	NN

the	DT
O	NN

xenoestrogens	NNS
O	NN

Diabetes	NNP
D	NNP

mellitus	NN
D	NN

is	VBZ
O	NN

a	DT
O	NN

still	RB
O	NN

growing	VBG
O	NN

disease	NN
O	NN

New	NNP
O	NNP

diagnostic	JJ
O	NN

criteria	NNS
O	NN

lowered	JJ
O	NN

the	DT
O	NN

cut	NN
O	NN

off	IN
O	NN

value	NN
O	NN

to	TO
O	NN

126	CD
O	NN

mg/dl	NN
O	NN

,	,
O	NN

in	IN
O	NN

order	NN
O	NN

to	TO
O	NN

detect	VB
O	NN

more	RBR
O	NN

rapidly	RB
O	NN

diabetes	NN
D	NN

and	CC
O	NN

its	PRP$
O	NN

complications	NNS
O	NN

The	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

diabetes	NN
D	NN

2	LS
D	NN

by	IN
O	NN

the	DT
O	NN

classic	JJ
T	NN

oral	JJ
T	NN

antidiabetic	JJ
T	NN

drugs	NNS
T	NN

(	NN
T	NN

sulfamides	NNS
T	NN

and	CC
T	NN

biguanides	NNS
T	NN

)	NN
T	NN

is	VBZ
O	NN

completed	VBN
O	NN

by	IN
O	NN

intestinal	JJ
T	NN

glycosidases	NNS
T	NN

inhibitors	NNS
T	NN

and	CC
O	NN

thiazolidendiones	NNS
T	NN

These	DT
O	NN

last	JJ
O	NN

drugs	NNS
O	NN

seem	VB
O	NN

very	RB
O	NN

attractive	JJ
O	NN

because	IN
O	NN

they	PRP
O	VBP

decrease	NN
O	NN

insulin	NN
O	NN

resistance	NN
O	NN

in	IN
O	NN

obese	JJ
O	NN

,	,
O	NN

diabetics	NNS
O	NN

Their	PRP$
O	NN

hepatic	JJ
O	NN

side	NN
O	NN

effects	NNS
O	NN

must	MD
O	NNP

be	VB
O	NN

however	RB
O	NN

under	IN
O	NN

control	NN
O	NN

Better	RBR
O	NN

knowledge	NN
O	NN

of	IN
O	NN

non	JJ
O	NN

lipidic	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

statins	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

arterial	JJ
O	NN

wall	NN
O	NN

and	CC
O	NN

the	DT
O	NN

discovery	NN
O	NN

of	IN
O	NN

the	DT
O	NN

action	NN
O	NN

of	IN
O	NN

fibrates	NNS
O	NN

on	IN
O	NN

PPAR	NN
O	NN

(	NN
O	NN

Peroxisome	NN
O	NN

Proliferator	NN
O	NN

Activated	VBN
O	NN

Receptors	NNS
O	NN

)	NN
O	NN

improved	VBN
O	NN

strongly	RB
O	NN

the	DT
O	NN

therapeutic	JJ
O	NN

management	NN
O	NN

of	IN
O	NN

hyperlipidemias	NN
D	NN

Recent	JJ
O	NN

intervention	NN
O	NN

studies	NNS
O	VBP

have	VB
O	NN

demonstrated	VBD
O	NN

the	DT
O	NN

necessity	NN
O	NN

to	TO
O	NN

treat	VB
O	NNP

vigorously	RB
O	NN

dysipidemias	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Despite	IN
O	NN

Beta-blockade	JJ
T	NN

therapy	NN
T	NN

has	VBZ
O	NN

been	VBN
O	NN

considered	VBN
O	NN

as	IN
O	NN

an	DT
O	NN

absolute	JJ
O	NN

contraindication	NN
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

heart	NN
D	NN

failure	NN
D	NN

,	,
O	NN

it	PRP
O	NN

has	VBZ
O	NN

been	VBN
O	NN

shown	VBN
O	NN

that	IN
O	NN

they	PRP
O	VBP

could	MD
O	NNP

have	VB
O	NN

a	DT
O	NN

beneficial	JJ
O	NN

effect	NN
O	NN

,	,
O	NN

provided	VBN
O	NN

that	IN
O	NN

they	PRP
O	VBP

were	VBD
O	NN

introduced	VBN
O	NN

at	IN
O	NN

very	RB
O	NN

low	JJ
O	NN

dose	NN
O	NN

,	,
O	NN

and	CC
O	NN

very	RB
O	NN

progressively	RB
O	NN

in	IN
O	NN

addition	NN
O	NN

of	IN
O	NN

the	DT
O	NN

traditional	JJ
O	NN

treatment	NN
O	NN

The	DT
O	NN

advances	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

understanding	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

neuro-hormonal	JJ
O	NN

mechanisms	NNS
O	VBP

of	IN
O	NN

heart	NN
O	NN

failure	NN
O	NN

have	VB
O	NN

modified	VBN
O	NN

the	DT
O	NN

therapeutic	JJ
O	NN

strategy	NN
O	NN

:	:
O	NN

the	DT
O	NN

deleterious	JJ
O	NN

effect	NN
O	NN

of	IN
O	NN

the	DT
O	NN

activation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

sympathetic	JJ
O	NN

nervous	JJ
O	NN

system	NN
O	NN

on	IN
O	NN

the	DT
O	NN

myocardium	NN
O	NN

has	VBZ
O	NN

served	VBD
O	NN

as	IN
O	NN

the	DT
O	NN

rationale	NN
O	NN

for	IN
O	NN

randomized	VBN
O	NN

clinical	JJ
O	NN

trials	NNS
O	NN

comparing	VBG
O	NN

beta-blockade	NN
O	NN

to	TO
O	NN

placebo	NN
O	NN

:	:
O	NN

the	DT
O	NN

current	JJ
O	NN

data	NNS
O	NN

are	VBP
O	NN

promising	JJ
O	NN

,	,
O	NN

suggesting	VBG
O	NN

a	DT
O	NN

beneficial	JJ
O	NN

effect	NN
O	NN

on	IN
O	NN

survival	NN
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

on	IN
O	NN

quality	NN
O	NN

of	IN
O	NN

life	NN
O	NN

However	RB
O	NN

,	,
O	NN

these	DT
O	NN

results	NNS
O	VBP

have	VB
O	NN

to	TO
O	NN

be	VB
O	NN

confirmed	VBN
O	NN

by	IN
O	NN

larger	JJR
O	NN

trials	NNS
O	NN

,	,
O	NN

currently	RB
O	NN

underway	NN
O	NN

,	,
O	NN

before	IN
O	NN

to	TO
O	NN

consider	VB
O	NN

that	IN
O	NN

beta-blockade	NN
O	NN

should	MD
O	NNP

definitely	RB
O	NN

be	VB
O	NN

incorporated	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

heart	NN
O	NN

failure	NN
O	NN

Calcium	NN
T	NN

antagonists	NNS
T	NN

have	VB
O	NN

been	VBN
O	NN

used	VBN
O	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

cardiovascular	JJ
D	NN

diseases	NNS
D	NN

for	IN
O	NN

more	RBR
O	NN

than	IN
O	NN

25	CD
O	NN

years	NNS
O	NN

Several	JJ
O	NN

recent	JJ
O	NN

retrospective	JJ
O	NN

studies	NNS
O	VBP

have	VB
O	NN

suggested	VBN
O	NN

that	IN
O	NN

chronic	JJ
O	NN

treatment	NN
O	NN

with	IN
O	NN

short-acting	JJ
T	NN

dihydropyridines	NNS
T	NN

increased	VBN
O	NN

the	DT
O	NN

incidence	NN
O	NN

of	IN
O	NN

cardiac	JJ
D	NN

events	NNS
D	NN

,	,
O	NN

cancer	NN
D	NN

and	CC
O	NN

gastrointestinal	JJ
D	NN

bleedings	NNS
D	NN

Randomized	VBN
O	NN

prospective	JJ
O	NN

studies	NNS
O	VBP

have	VB
O	NN

,	,
O	NN

however	RB
O	NN

,	,
O	NN

never	RB
O	NN

been	VBN
O	NN

able	JJ
O	NN

to	TO
O	NN

confirm	VBP
O	NN

these	DT
O	NN

observations	NNS
O	NN

In	IN
O	NN

addition	NN
O	NN

,	,
O	NN

well-conducted	JJ
O	NN

studies	NNS
O	VBP

using	VBG
O	NN

verapamil	NN
T	NN

and	CC
O	NN

diltiazem	NN
T	NN

have	VB
O	NN

suggested	VBN
O	NN

that	IN
O	NN

these	DT
O	NN

calcium	NN
T	NN

antagonists	NNS
T	NN

may	MD
O	NNP

even	RB
O	NN

improve	VB
O	NN

cardiovascular	JJ
D	NN

mortality	NN
D	NN

and	CC
D	NN

morbidity	NN
D	NN

of	IN
O	NN

the	DT
O	NN

hypertensive	JJ
O	NN

patient	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

There	EX
O	NN

is	VBZ
O	NN

therefore	RB
O	NN

no	DT
O	NN

reason	NN
O	NN

to	TO
O	NN

believe	VB
O	NN

that	IN
O	NN

the	DT
O	NN

questionable	JJ
O	NN

results	NNS
O	VBP

derived	VBN
O	NN

from	IN
O	NN

retrospective	JJ
O	NN

studies	NNS
O	VBP

of	IN
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

short-acting	JJ
O	NN

calcium	NN
O	NN

antagonists	NNS
O	NN

on	IN
O	NN

cardiac	JJ
O	NN

and	CC
O	NN

noncardiac	JJ
O	NN

events	NNS
O	NN

may	MD
O	NNP

apply	VB
O	NN

to	TO
O	NN

the	DT
O	NN

newer	JJR
O	NN

generation	NN
O	NN

of	IN
O	NN

long-acting	JJ
O	NN

calcium	NN
O	NN

antagonists	NNS
O	NN

Sumatriptan	NNP
T	NN

and	CC
O	NN

other	JJ
O	NN

selective	JJ
O	NN

serotonin	NN
T	NN

agonists	NNS
T	NN

represent	VB
O	NN

a	DT
O	NN

major	JJ
O	NN

breakthrough	NN
O	NN

in	IN
O	NN

acute	JJ
D	NN

migraine	NN
D	NN

treatment	NN
O	NN

These	DT
O	NN

drugs	NNS
O	NN

are	VBP
O	NN

very	RB
O	NN

efficacious	JJ
O	NN

and	CC
O	NN

generally	RB
O	NN

devoided	VBN
O	NN

of	IN
O	NN

important	JJ
O	NN

side	NN
O	NN

effects	NNS
O	NN

,	,
O	NN

but	CC
O	NNP

they	PRP
O	VBP

are	VBP
O	NN

expensive	JJ
O	NN

and	CC
O	NN

therefore	RB
O	NN

have	VB
O	NN

to	TO
O	NN

be	VB
O	NN

compared	VBN
O	NN

with	IN
O	NN

other	JJ
O	NN

,	,
O	NN

more	RBR
O	NN

conventional	JJ
O	NN

drugs	NNS
O	NN

with	IN
O	NN

established	VBN
O	NN

or	CC
O	NN

assumed	VBN
O	NN

efficacy	NN
O	NN

We	PRP
O	VBP

summarize	VB
O	NN

the	DT
O	NN

pharmacologic	JJ
O	NN

characteristics	NNS
O	NN

of	IN
O	NN

Sumatriptan	NNP
T	NN

and	CC
O	NN

give	VB
O	NN

recommendations	NNS
O	NN

about	IN
O	NN

its	PRP$
O	NN

use	NN
O	NN

in	IN
O	NN

clinical	JJ
O	NN

practice	NN
O	NN

Fiercer	JJR
O	NN

competition	NN
O	NN

between	IN
O	NN

athletes	NNS
O	NN

and	CC
O	NN

a	DT
O	NN

wider	JJR
O	NN

knowledge	NN
O	NN

of	IN
O	NN

optimal	JJ
O	NN

training	NN
O	NN

regimens	NNS
O	VBP

dramatically	RB
O	NN

influence	NN
O	NN

current	JJ
O	NN

training	NN
O	NN

methods	NNS
O	VBP

A	DT
O	NN

single	JJ
O	NN

training	NN
O	NN

bout	NN
O	NN

per	IN
O	NN

day	NN
O	NN

was	VBD
O	NN

previously	RB
O	NN

considered	VBN
O	NN

sufficient	JJ
O	NN

,	,
O	NN

whereas	IN
O	NN

today	NN
O	NN

athletes	NNS
O	NN

regularly	RB
O	NN

train	NN
O	NN

twice	RB
O	NN

a	DT
O	NN

day	NN
O	NN

or	CC
O	NN

more	RBR
O	NN

Consequently	RB
O	NN

,	,
O	NN

the	DT
O	NN

number	NN
O	NN

of	IN
O	NN

athletes	NNS
O	NN

who	WP
O	VBP

are	VBP
O	NN

overtraining	VBG
O	NN

and	CC
O	NN

have	VB
O	NN

insufficient	JJ
O	NN

rest	NN
O	NN

is	VBZ
O	NN

increasing	VBG
O	NN

Positive	JJ
O	NN

overtraining	VBG
O	NN

can	MD
O	NNP

be	VB
O	NN

regarded	VBN
O	NN

as	IN
O	NN

a	DT
O	NN

natural	JJ
O	NN

process	NN
O	NN

when	WRB
O	NN

the	DT
O	NN

end	NN
O	NN

result	NN
O	NN

is	VBZ
O	NN

adaptation	NN
O	NN

and	CC
O	NN

improved	VBN
O	NN

performance	NN
O	NN

:	:
O	NN

the	DT
O	NN

supercompensation	NN
O	NN

principle	NN
O	NN

--	:
O	NN

which	WDT
O	NN

includes	VBZ
O	NN

the	DT
O	NN

breakdown	NN
O	NN

process	NN
O	NN

(	NN
O	NN

training	NN
O	NN

)	NN
O	NN

followed	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

recovery	NN
O	NN

process	NN
O	NN

(	NN
O	NN

rest	NN
O	NN

)	NN
O	NN

--	:
O	NN

is	VBZ
O	NN

well	RB
O	NN

known	JJ
O	NN

in	IN
O	NN

sports	NNS
O	NN

However	RB
O	NN

,	,
O	NN

negative	JJ
O	NN

overtraining	VBG
O	NN

,	,
O	NN

causing	VBG
O	NN

maladaptation	NN
O	NN

and	CC
O	NN

other	JJ
O	NN

negative	JJ
O	NN

consequences	NNS
O	NN

such	JJ
O	NN

as	IN
O	NN

staleness	NN
O	NN

,	,
O	NN

can	MD
O	NNP

occur	VB
O	NN

Physiological	JJ
O	NN

,	,
O	NN

psychological	JJ
O	NN

,	,
O	NN

biochemical	JJ
O	NN

and	CC
O	NN

immunological	JJ
O	NN

symptoms	NNS
O	NN

must	MD
O	NNP

be	VB
O	NN

considered	VBN
O	NN

,	,
O	NN

both	DT
O	NN

independently	RB
O	NN

and	CC
O	NN

together	RB
O	NN

,	,
O	NN

to	TO
O	NN

fully	RB
O	NN

understand	VB
O	NN

the	DT
O	NN

'staleness	NN
O	NN

'	POS
O	NN

syndrome	NN
O	NN

However	RB
O	NN

,	,
O	NN

psychological	JJ
O	NN

testing	NN
O	NN

may	MD
O	NNP

reveal	VB
O	NN

early-warning	JJ
O	NN

signs	NNS
O	IN

more	RBR
O	NN

readily	RB
O	NN

than	IN
O	NN

the	DT
O	NN

various	JJ
O	NN

physiological	JJ
O	NN

or	CC
O	NN

immunological	JJ
O	NN

markers	NNS
O	VBP

The	DT
O	NN

time	NN
O	NN

frame	NN
O	NN

of	IN
O	NN

training	NN
O	NN

and	CC
O	NN

recovery	NN
O	NN

is	VBZ
O	NN

also	RB
O	NN

important	JJ
O	NN

since	IN
O	NN

the	DT
O	NN

consequences	NNS
O	NN

of	IN
O	NN

negative	JJ
O	NN

overtraining	VBG
O	NN

comprise	VBP
O	NN

an	DT
O	NN

overtraining-response	JJ
O	NN

continuum	NN
O	NN

from	IN
O	NN

short	JJ
O	NN

to	TO
O	NN

long	RB
O	NN

term	NN
O	NN

effects	NNS
O	NN

An	DT
O	NN

athlete	NN
O	NN

failing	VBG
O	NN

to	TO
O	NN

recover	VB
O	NNP

within	IN
O	NN

72	CD
O	NN

hours	NNS
O	NN

has	VBZ
O	NN

presumably	RB
O	NN

negatively	RB
O	NN

overtrained	VBN
O	NN

and	CC
O	NN

is	VBZ
O	NN

in	IN
O	NN

an	DT
O	NN

overreached	VBD
O	NN

state	NN
O	NN

For	IN
O	NN

an	DT
O	NN

elite	NN
O	NN

athlete	NN
O	NN

to	TO
O	NN

refrain	NN
O	NN

from	IN
O	NN

training	NN
O	NN

for	IN
O	NN

>	JJR
O	NN

72	CD
O	NN

hours	NNS
O	NN

is	VBZ
O	NN

extremely	RB
O	NN

undesirable	JJ
O	NN

,	,
O	NN

highlighting	VBG
O	NN

the	DT
O	NN

importance	NN
O	NN

of	IN
O	NN

a	DT
O	NN

carefully	RB
O	NN

monitored	VBN
O	NN

recovery	NN
O	NN

process	NN
O	NN

There	EX
O	NN

are	VBP
O	NN

many	JJ
O	NN

methods	NNS
O	VBP

used	VBN
O	NN

to	TO
O	NN

measure	NN
O	NN

the	DT
O	NN

training	NN
O	NN

process	NN
O	NN

but	CC
O	NNP

few	JJ
O	NN

with	IN
O	NN

which	WDT
O	NN

to	TO
O	NN

match	NN
O	NN

the	DT
O	NN

recovery	NN
O	NN

process	NN
O	NN

against	IN
O	NN

it	PRP
O	NN

One	CD
O	NN

such	JJ
O	NN

framework	NN
O	NN

for	IN
O	NN

this	DT
O	NN

is	VBZ
O	NN

referred	VBN
O	NN

to	TO
O	NN

as	IN
O	NN

the	DT
O	NN

total	JJ
O	NN

quality	NN
O	NN

recovery	NN
O	NN

(	NN
O	NN

TQR	NN
O	NN

)	NN
O	NN

process	NN
O	NN

By	IN
O	NN

using	VBG
O	NN

a	DT
O	NN

TQR	NN
O	NN

scale	NN
O	NN

,	,
O	NN

structured	JJ
O	NN

around	IN
O	NN

the	DT
O	NN

scale	NN
O	NN

developed	VBN
O	NN

for	IN
O	NN

ratings	NNS
O	NN

of	IN
O	NN

perceived	VBN
O	NN

exertion	NN
O	NN

(	NN
O	NN

RPE	NN
O	NN

)	NN
O	NN

,	,
O	NN

the	DT
O	NN

recovery	NN
O	NN

process	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

monitored	VBN
O	NN

and	CC
O	NN

matched	VBN
O	NN

against	IN
O	NN

the	DT
O	NN

breakdown	NN
O	NN

(	NN
O	NN

training	NN
O	NN

)	NN
O	NN

process	NN
O	NN

(	NN
O	NN

TQR	NN
O	NN

versus	CC
O	NN

RPE	NN
O	NN

)	NN
O	NN

The	DT
O	NN

TQR	NN
O	NN

scale	NN
O	NN

emphasises	VBZ
O	NN

both	DT
O	NN

the	DT
O	NN

athlete	NN
O	NN

's	POS
O	NN

perception	NN
O	NN

of	IN
O	NN

recovery	NN
O	NN

and	CC
O	NN

the	DT
O	NN

importance	NN
O	NN

of	IN
O	NN

active	JJ
O	NN

measures	NNS
O	VBP

to	TO
O	NN

improve	VB
O	NN

the	DT
O	NN

recovery	NN
O	NN

process	NN
O	NN

Furthermore	RB
O	NN

,	,
O	NN

directing	VBG
O	NN

attention	NN
O	NN

to	TO
O	NN

psychophysiological	JJ
O	NN

cues	NNS
O	NN

serves	VBZ
O	NN

the	DT
O	NN

same	JJ
O	NN

purpose	NN
O	NN

as	IN
O	NN

in	IN
O	NN

RPE	NN
O	NN

,	,
O	NN

i.e	NN
O	NN

.	.
O	NN

increasing	VBG
O	NN

self-awareness	NN
O	NN

This	DT
O	NN

article	NN
O	NN

reviews	NNS
O	VBP

and	CC
O	NN

conceptualises	NNS
O	NN

the	DT
O	NN

whole	JJ
O	NN

overtraining	VBG
O	NN

process	NN
O	NN

In	IN
O	NN

doing	VBG
O	NN

so	RB
O	NN

,	,
O	NN

it	PRP
O	NN

(	NN
O	NN

i	LS
O	NN

)	NN
O	NN

aims	NNS
O	NN

to	TO
O	NN

differentiate	VB
O	NN

between	IN
O	NN

the	DT
O	NN

types	NNS
O	NN

of	IN
O	NN

stress	NN
O	NN

affecting	VBG
O	NN

an	DT
O	NN

athlete	NN
O	NN

's	POS
O	NN

performance	NN
O	NN

:	:
O	NN

(	NN
O	NN

ii	LS
O	NN

)	NN
O	NN

identifies	VBZ
O	NN

factors	NNS
O	NN

influencing	VBG
O	NN

an	DT
O	NN

athlete	NN
O	NN

's	POS
O	NN

ability	NN
O	NN

to	TO
O	NN

adapt	VB
O	NN

to	TO
O	NN

physical	JJ
O	NN

training	NN
O	NN

:	:
O	NN

(	NN
O	NN

iii	LS
O	NN

)	NN
O	NN

structures	NNS
O	VBP

the	DT
O	NN

recovery	NN
O	NN

process	NN
O	NN

The	DT
O	NN

TQR	NN
O	NN

method	NN
O	NN

to	TO
O	NN

facilitate	VB
O	NN

monitoring	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

recovery	NN
O	NN

process	NN
O	NN

is	VBZ
O	NN

then	RB
O	NN

suggested	VBN
O	NN

and	CC
O	NN

a	DT
O	NN

conceptual	JJ
O	NN

model	NN
O	NN

that	IN
O	NN

incorporates	VBZ
O	NN

all	DT
O	NN

of	IN
O	NN

the	DT
O	NN

important	JJ
O	NN

parameters	NNS
O	VBP

for	IN
O	NN

performance	NN
O	NN

gain	NN
O	NN

(	NN
O	NN

adaptation	NN
O	NN

)	NN
O	NN

and	CC
O	NN

loss	NN
O	NN

(	NN
O	NN

maladaptation	NN
O	NN

)	NN
O	NN

Little	JJ
O	NN

attention	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

directed	VBN
O	NN

toward	IN
O	NN

identifying	VBG
O	NN

the	DT
O	NN

changes	NNS
O	VBP

which	WDT
O	NN

occur	VB
O	NN

in	IN
O	NN

salivary	JJ
O	NN

composition	NN
O	NN

in	IN
O	NN

response	NN
O	NN

to	TO
O	NN

exercise	NN
O	NN

To	TO
O	NN

address	NN
O	NN

this	DT
O	NN

,	,
O	NN

our	PRP$
O	NN

article	NN
O	NN

first	RB
O	NN

refers	VBZ
O	NN

to	TO
O	NN

the	DT
O	NN

main	JJ
O	NN

aspects	NNS
O	NN

of	IN
O	NN

salivary	JJ
O	NN

gland	NN
O	NN

physiology	NN
O	NN

A	DT
O	NN

knowledge	NN
O	NN

of	IN
O	NN

the	DT
O	NN

neural	JJ
O	NN

control	NN
O	NN

of	IN
O	NN

salivary	JJ
O	NN

secretion	NN
O	NN

is	VBZ
O	NN

especially	RB
O	NN

important	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

understanding	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

exertion	NN
O	NN

on	IN
O	NN

salivary	JJ
O	NN

secretion	NN
O	NN

Both	DT
O	NN

salivary	JJ
O	NN

output	NN
O	NN

and	CC
O	NN

composition	NN
O	NN

depend	VB
O	NN

on	IN
O	NN

the	DT
O	NN

activity	NN
O	NN

of	IN
O	NN

the	DT
O	NN

autonomic	JJ
O	NN

nervous	JJ
O	NN

system	NN
O	NN

and	CC
O	NN

any	DT
O	NN

modification	NN
O	NN

of	IN
O	NN

this	DT
O	NN

activity	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

observed	VBN
O	NN

indirectly	RB
O	NN

by	IN
O	NN

alternations	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

salivary	JJ
O	NN

excretion	NN
O	NN

The	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

physical	JJ
O	NN

activity	NN
O	NN

(	NN
O	NN

with	IN
O	NN

reference	NN
O	NN

to	TO
O	NN

factors	NNS
O	NN

such	JJ
O	NN

as	IN
O	NN

exercise	NN
O	NN

intensity	NN
O	NN

and	CC
O	NN

duration	NN
O	NN

,	,
O	NN

or	CC
O	NN

type	NN
O	NN

of	IN
O	NN

exercise	NN
O	NN

protocol	NN
O	NN

)	NN
O	NN

on	IN
O	NN

salivary	JJ
O	NN

composition	NN
O	NN

are	VBP
O	NN

then	RB
O	NN

considered	VBN
O	NN

Exercise	NN
O	NN

might	MD
O	NNP

indeed	RB
O	NN

induce	VB
O	NN

changes	NNS
O	VBP

in	IN
O	NN

several	JJ
O	NN

salivary	JJ
O	NN

components	NNS
O	NN

such	JJ
O	NN

as	IN
O	NN

immunoglobulins	NNS
O	NN

,	,
O	NN

hormones	NNS
O	NN

,	,
O	NN

lactate	NN
O	NN

,	,
O	NN

proteins	NNS
O	NN

and	CC
O	NN

electrolytes	NNS
O	NN

Saliva	FW
O	FW

composition	NN
O	NN

might	MD
O	NNP

therefore	RB
O	NN

be	VB
O	NN

used	VBN
O	NN

as	IN
O	NN

an	DT
O	NN

alternative	JJ
O	NN

noninvasive	JJ
O	NN

indicator	NN
O	NN

of	IN
O	NN

the	DT
O	NN

response	NN
O	NN

of	IN
O	NN

the	DT
O	NN

different	JJ
O	NN

body	NN
O	NN

tissues	NNS
O	NN

and	CC
O	NN

systems	NNS
O	NN

to	TO
O	NN

physical	JJ
O	NN

exertion	NN
O	NN

In	IN
O	NN

this	DT
O	NN

respect	NN
O	NN

,	,
O	NN

the	DT
O	NN

response	NN
O	NN

of	IN
O	NN

salivary	JJ
O	NN

amylase	NN
O	NN

and	CC
O	NN

salivary	JJ
O	NN

electrolytes	NNS
O	NN

to	TO
O	NN

incremental	JJ
O	NN

levels	NNS
O	VBP

of	IN
O	NN

exercise	NN
O	NN

is	VBZ
O	NN

of	IN
O	NN

particular	JJ
O	NN

interest	NN
O	NN

Beyond	IN
O	NN

a	DT
O	NN

certain	JJ
O	NN

intensity	NN
O	NN

of	IN
O	NN

exercise	NN
O	NN

,	,
O	NN

and	CC
O	NN

coinciding	VBG
O	NN

with	IN
O	NN

the	DT
O	NN

accumulation	NN
O	NN

of	IN
O	NN

blood	NN
O	NN

lactate	NN
O	NN

(	NN
O	NN

anaerobic	JJ
O	NN

threshold	NN
O	NN

or	CC
O	NN

AT	IN
O	NN

)	NN
O	NN

,	,
O	NN

a	DT
O	NN

'saliva	NN
O	NN

threshold	NN
O	NN

'	POS
O	NN

(	NN
O	NN

Tsa	NN
O	NN

)	NN
O	NN

does	VBZ
O	NNP

indeed	RB
O	NN

exist	VB
O	NN

Tsa	NN
O	NN

is	VBZ
O	NN

the	DT
O	NN

point	NN
O	NN

during	IN
O	NN

exercise	NN
O	NN

at	IN
O	NN

which	WDT
O	NN

the	DT
O	NN

levels	NNS
O	VBP

of	IN
O	NN

salivary	JJ
O	NN

alpha-amylase	NN
O	NN

and	CC
O	NN

electrolytes	NNS
O	NN

(	NN
O	NN

especially	RB
O	NN

Na+	NN
O	NN

)	NN
O	NN

also	RB
O	NN

begin	VB
O	NN

to	TO
O	NN

rise	NN
O	NN

above	IN
O	NN

baseline	NN
O	NN

levels	NNS
O	VBP

The	DT
O	NN

occurrence	NN
O	NN

of	IN
O	NN

the	DT
O	NN

2	CD
O	NN

thresholds	NNS
O	NN

(	NN
O	NN

AT	IN
O	NN

and	CC
O	NN

Tsa	NN
O	NN

)	NN
O	NN

might	MD
O	NNP

,	,
O	NN

in	IN
O	NN

turn	VB
O	NNP

,	,
O	NN

be	VB
O	NN

attributable	JJ
O	NN

to	TO
O	NN

the	DT
O	NN

same	JJ
O	NN

underlying	VBG
O	NN

mechanism	NN
O	NN

,	,
O	NN

that	IN
O	NN

of	IN
O	NN

increased	VBN
O	NN

adrenal	JJ
O	NN

sympathetic	JJ
O	NN

activity	NN
O	NN

at	IN
O	NN

high	JJ
O	NN

exercise	NN
O	NN

intensities	NNS
O	NN

Fat	NNP
O	NNP

is	VBZ
O	NN

an	DT
O	NN

extremely	RB
O	NN

important	JJ
O	NN

substrate	JJ
O	NN

for	IN
O	NN

muscle	NN
O	NN

contraction	NN
O	NN

,	,
O	NN

both	DT
O	NN

at	IN
O	NN

rest	NN
O	NN

and	CC
O	NN

during	IN
O	NN

exercise	NN
O	NN

Triglycerides	NNS
O	NN

(	NN
O	NN

TGs	NNS
O	NN

)	NN
O	NN

,	,
O	NN

stored	VBN
O	NN

in	IN
O	NN

adipose	NN
O	NN

tissue	NN
O	NN

and	CC
O	NN

within	IN
O	NN

muscle	NN
O	NN

fibres	NNS
O	NN

,	,
O	NN

are	VBP
O	NN

considered	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

the	DT
O	NN

main	JJ
O	NN

source	NN
O	NN

of	IN
O	NN

the	DT
O	NN

free	JJ
O	NN

fatty	JJ
O	NN

acids	NNS
O	NN

(	NN
O	NN

FFAs	NNS
O	NN

)	NN
O	NN

oxidised	VBN
O	NN

during	IN
O	NN

exercise	NN
O	NN

It	PRP
O	NN

is	VBZ
O	NN

still	RB
O	NN

unclear	JJ
O	NN

,	,
O	NN

however	RB
O	NN

,	,
O	NN

how	WRB
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

these	DT
O	NN

substrates	NNS
O	NN

is	VBZ
O	NN

regulated	VBN
O	NN

during	IN
O	NN

exercise	NN
O	NN

The	DT
O	NN

regulation	NN
O	NN

seems	VBZ
O	NNP

to	TO
O	NN

be	VB
O	NN

multifactorial	JJ
O	NN

and	CC
O	NN

includes	VBZ
O	NN

:	:
O	NN

(	NN
O	NN

i	LS
O	NN

)	NN
O	NN

dietary	JJ
O	NN

and	CC
O	NN

nutritional	JJ
O	NN

status	NN
O	NN

;	:
O	NN

(	NN
O	NN

ii	LS
O	NN

)	NN
O	NN

hormonal	JJ
O	NN

milieu	NN
O	NN

;	:
O	NN

(	NN
O	NN

iii	LS
O	NN

)	NN
O	NN

exercise	NN
O	NN

mode	NN
O	NN

,	,
O	NN

intensity	NN
O	NN

and	CC
O	NN

duration	NN
O	NN

;	:
O	NN

and	CC
O	NN

(	NN
O	NN

iv	NN
O	NN

)	NN
O	NN

training	NN
O	NN

status	NN
O	NN

On	IN
O	NN

the	DT
O	NN

other	JJ
O	NN

hand	NN
O	NN

,	,
O	NN

the	DT
O	NN

mechanism	NN
O	NN

for	IN
O	NN

FFA	NN
O	NN

transport	NN
O	NN

from	IN
O	NN

its	PRP$
O	NN

storage	NN
O	NN

as	IN
O	NN

triglycerides	NNS
O	NN

in	IN
O	NN

adipose	NN
O	NN

tissue	NN
O	NN

and	CC
O	NN

muscle	NN
O	NN

to	TO
O	NN

its	PRP$
O	NN

place	NN
O	NN

of	IN
O	NN

utilisation	NN
O	NN

in	IN
O	NN

heart	NN
O	NN

,	,
O	NN

skeletal	JJ
O	NN

muscle	NN
O	NN

,	,
O	NN

kidney	NN
O	NN

and	CC
O	NN

liver	NN
O	NN

is	VBZ
O	NN

more	RBR
O	NN

clearly	RB
O	NN

understood	VBN
O	NN

It	PRP
O	NN

has	VBZ
O	NN

been	VBN
O	NN

determined	VBN
O	NN

that	IN
O	NN

the	DT
O	NN

plasma	NN
O	NN

FFA	NN
O	NN

turnover	NN
O	NN

rate	NN
O	NN

is	VBZ
O	NN

sufficiently	RB
O	NN

rapid	JJ
O	NN

to	TO
O	NN

account	NN
O	NN

for	IN
O	NN

most	JJS
O	NN

of	IN
O	NN

the	DT
O	NN

fat	JJ
O	NN

metabolised	VBN
O	NN

during	IN
O	NN

low	JJ
O	NN

intensity	NN
O	NN

exercise	NN
O	NN

(	NN
O	NN

25	CD
O	NN

to	TO
O	NN

40	CD
O	NN

%	NN
O	NN

VO2max	NN
O	NN

)	NN
O	NN

However	RB
O	NN

,	,
O	NN

an	DT
O	NN

exercise	NN
O	NN

intensity	NN
O	NN

of	IN
O	NN

65	CD
O	NN

%	NN
O	NN

VO2max	NN
O	NN

results	NNS
O	VBP

in	IN
O	NN

a	DT
O	NN

slight	JJ
O	NN

decrease	NN
O	NN

in	IN
O	NN

the	DT
O	NN

amount	NN
O	NN

of	IN
O	NN

plasma	NN
O	NN

FFA	NN
O	NN

uptake	NN
O	NN

by	IN
O	NN

muscle	NN
O	NN

tissue	NN
O	NN

Other	JJ
O	NN

studies	NNS
O	VBP

have	VB
O	NN

found	VBN
O	NN

that	IN
O	NN

during	IN
O	NN

prolonged	JJ
O	NN

exercise	NN
O	NN

,	,
O	NN

muscle	NN
O	NN

TGs	NNS
O	NN

become	VBN
O	NN

the	DT
O	NN

predominant	JJ
O	NN

source	NN
O	NN

of	IN
O	NN

energy	NN
O	NN

obtained	VBN
O	NN

from	IN
O	NN

fat	JJ
O	NN

Furthermore	RB
O	NN

,	,
O	NN

it	PRP
O	NN

is	VBZ
O	NN

widely	RB
O	NN

documented	VBN
O	NN

that	IN
O	NN

endurance	JJ
O	NN

activities	NNS
O	VBP

increase	NN
O	NN

the	DT
O	NN

energy	NN
O	NN

utilisation	NN
O	NN

from	IN
O	NN

fat	JJ
O	NN

while	IN
O	NN

sparing	VBG
O	NN

carbohydrate	NN
O	NN

sources	NNS
O	NN

For	IN
O	NN

example	NN
O	NN

,	,
O	NN

during	IN
O	NN

exercise	NN
O	NN

on	IN
O	NN

a	DT
O	NN

cycle	NN
O	NN

ergometer	NN
O	NN

,	,
O	NN

nonplasma	JJ
O	NN

FFAs	NNS
O	NN

and	CC
O	NN

plasma	NN
O	NN

FFAs	NNS
O	NN

contribute	VB
O	NN

40	CD
O	NN

%	NN
O	NN

,	,
O	NN

and	CC
O	NN

carbohydrates	NNS
O	NN

60	CD
O	NN

%	NN
O	NN

,	,
O	NN

of	IN
O	NN

the	DT
O	NN

total	JJ
O	NN

calculated	VBN
O	NN

amount	NN
O	NN

of	IN
O	NN

energy	NN
O	NN

expenditure	NN
O	NN

before	IN
O	NN

exercise	NN
O	NN

and	CC
O	NN

vice	NN
O	NN

versa	RB
O	NN

after	IN
O	NN

exercise	NN
O	NN

(	NN
O	NN

60	CD
O	NN

%	NN
O	NN

nonplasma	JJ
O	NN

and	CC
O	NN

plasma	NN
O	NN

FFAs	NNS
O	NN

and	CC
O	NN

40	CD
O	NN

%	NN
O	NN

carbohydrates	NNS
O	NN

)	NN
O	NN

Although	IN
O	NN

it	PRP
O	NN

was	VBD
O	NN

many	JJ
O	NN

years	NNS
O	NN

before	IN
O	NN

it	PRP
O	NN

was	VBD
O	NN

fully	RB
O	NN

demonstrated	VBD
O	NN

,	,
O	NN

fat	JJ
O	NN

is	VBZ
O	NN

now	RB
O	NN

known	JJ
O	NN

to	TO
O	NN

be	VB
O	NN

transported	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

blood	NN
O	NN

as	IN
O	NN

FFA	NN
O	NN

bound	VBN
O	NN

to	TO
O	NN

the	DT
O	NN

protein	NN
O	NN

carrier	NN
O	NN

albumin	NN
O	NN

The	DT
O	NN

mobilisation	NN
O	NN

of	IN
O	NN

FFA	NN
O	NN

is	VBZ
O	NN

primarily	RB
O	NN

a	DT
O	NN

function	NN
O	NN

of	IN
O	NN

sympathetic	JJ
O	NN

nervous	JJ
O	NN

activity	NN
O	NN

directed	VBN
O	NN

towards	IN
O	NN

the	DT
O	NN

adipocytes	NNS
O	NN

,	,
O	NN

or	CC
O	NN

the	DT
O	NN

'fat	NN
O	NN

pad	NN
O	NN

'	POS
O	NN

.	.
O	NN

This	DT
O	NN

nervous	JJ
O	NN

activity	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

direct	JJ
O	NN

or	CC
O	NN

may	MD
O	NNP

be	VB
O	NN

an	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

circulating	VBG
O	NN

catecholamines	NNS
O	NN

such	JJ
O	NN

as	IN
O	NN

adrenaline	NN
O	NN

(	NN
O	NN

epinephrine	NN
O	NN

)	NN
O	NN

This	DT
O	NN

article	NN
O	NN

summarises	VBZ
O	NN

the	DT
O	NN

role	NN
O	NN

of	IN
O	NN

fat	JJ
O	NN

metabolism	NN
O	NN

during	IN
O	NN

exercise	NN
O	NN

As	IN
O	NN

the	DT
O	NN

clinical	JJ
O	NN

availability	NN
O	NN

of	IN
O	NN

glycohaemoglobin/GHb	NN
O	NN

measurement	NN
O	NN

increases	NNS
O	NN

,	,
O	NN

so	RB
O	NN

does	VBZ
O	NNP

the	DT
O	NN

need	NN
O	NN

for	IN
O	NN

comparable	JJ
O	NN

and	CC
O	NN

accurate	JJ
O	NN

values	NNS
O	VBP

among	IN
O	NN

different	JJ
O	NN

laboratories	NNS
O	NN

and	CC
O	NN

different	JJ
O	NN

methods	NNS
O	VBP

At	IN
O	NN

least	JJS
O	NN

there	RB
O	NN

should	MD
O	NNP

be	VB
O	NN

comparability	NN
O	NN

,	,
O	NN

i.e	NN
O	NN

.	.
O	NN

,	,
O	NN

commutability	NN
O	NN

or	CC
O	NN

feasibility	NN
O	NN

of	IN
O	NN

providing	VBG
O	NN

comparable	JJ
O	NN

results	NNS
O	VBP

from	IN
O	NN

different	JJ
O	NN

assays	NNS
O	NN

in	IN
O	NN

different	JJ
O	NN

laboratories	NNS
O	NN

A	DT
O	NN

clinical	JJ
O	NN

joint	JJ
O	NN

study	NN
O	NN

on	IN
O	NN

insulin	NN
T	NN

therapy	NN
T	NN

,	,
O	NN

a	DT
O	NN

survey	NN
O	NN

of	IN
O	NN

the	DT
O	NN

actual	JJ
O	NN

inter-laboratory	JJ
O	NN

differences	NNS
O	NN

in	IN
O	NN

GHb	NN
O	NN

measurement	NN
O	NN

among	IN
O	NN

41	CD
O	NN

institutions	NNS
O	VBP

and	CC
O	NN

an	DT
O	NN

assessment	NN
O	NN

of	IN
O	NN

11	CD
O	NN

assay	NN
O	NN

methods	NNS
O	VBP

for	IN
O	NN

the	DT
O	NN

determination	NN
O	NN

of	IN
O	NN

GHb	NN
O	NN

were	VBD
O	NN

performed	VBN
O	NN

using	VBG
O	NN

commercial	JJ
O	NN

calibrators	NNS
O	NN

and	CC
O	NN

fresh	JJ
O	NN

blood	NN
O	NN

samples	NNS
O	NN

Data	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

actual	JJ
O	NN

state	NN
O	NN

of	IN
O	NN

inter-laboratory	JJ
O	NN

and	CC
O	NN

inter-assay	JJ
O	NN

differences	NNS
O	NN

of	IN
O	NN

observed	VBN
O	NN

values	NNS
O	VBP

were	VBD
O	NN

useful	JJ
O	NN

for	IN
O	NN

comparing	VBG
O	NN

results	NNS
O	VBP

among	IN
O	NN

facilities	NNS
O	NN

The	DT
O	NN

recommendation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

Japan	NNP
O	NNP

Diabetes	NNP
O	NNP

Society	NNP
O	NNP

to	TO
O	NN

measure	NN
O	NN

only	RB
O	NN

the	DT
O	NN

stable	JJ
O	NN

GHb	NN
O	NN

component	NN
O	NN

and	CC
O	NN

to	TO
O	NN

correct	JJ
O	NN

the	DT
O	NN

GHb	NN
O	NN

percentage	NN
O	NN

by	IN
O	NN

two-point	JJ
O	NN

calibration	NN
O	NN

with	IN
O	NN

assigned	VBN
O	NN

values	NNS
O	VBP

,	,
O	NN

was	VBD
O	NN

effective	JJ
O	NN

but	CC
O	NNP

not	RB
O	NN

sufficient	JJ
O	NN

Even	RB
O	NN

after	IN
O	NN

correction	NN
O	NN

,	,
O	NN

8	CD
O	NN

out	IN
O	NN

of	IN
O	NN

11	CD
O	NN

methods	NNS
O	VBP

still	RB
O	NN

remained	VBD
O	NN

of	IN
O	NN

little	JJ
O	NN

practical	JJ
O	NN

use	NN
O	NN

because	IN
O	NN

of	IN
O	NN

their	PRP$
O	NN

large	JJ
O	NN

relative	JJ
O	NN

errors	NNS
O	VBP

Inter-method	JJ
O	NN

differences	NNS
O	NN

among	IN
O	NN

11	CD
O	NN

available	JJ
O	NN

assay	NN
O	NN

methods	NNS
O	VBP

were	VBD
O	NN

great	JJ
O	NN

even	RB
O	NN

after	IN
O	NN

correction	NN
O	NN

and	CC
O	NN

depended	VBD
O	NN

on	IN
O	NN

not	RB
O	NN

only	RB
O	NN

the	DT
O	NN

methods	NNS
O	VBP

but	CC
O	NNP

the	DT
O	NN

samples	NNS
O	NN

used	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

determination	NN
O	NN

The	DT
O	NN

performance	NN
O	NN

of	IN
O	NN

some	DT
O	NN

methods	NNS
O	VBP

or	CC
O	NN

instruments	NNS
O	NN

used	VBN
O	NN

are	VBP
O	NN

only	RB
O	NN

poor	JJ
O	NN

at	IN
O	NN

distinguishing	VBG
O	NN

the	DT
O	NN

stable	JJ
O	NN

glycated	VBN
O	NN

haemoglobin	NN
O	NN

itself	PRP
O	NN

Some	DT
O	NN

alternative	JJ
O	NN

measurement	NN
O	NN

system	NN
O	NN

with	IN
O	NN

comparability	NN
O	NN

,	,
O	NN

commutability	NN
O	NN

and	CC
O	NN

precision	NN
O	NN

should	MD
O	NNP

be	VB
O	NN

established	VBN
O	NN

An	DT
O	NN

urgent	JJ
O	NN

and	CC
O	NN

worldwide	JJ
O	NN

problem	NN
O	NN

to	TO
O	NN

remove	VB
O	NN

inter-laboratory	JJ
O	NN

differences	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

measurement	NN
O	NN

of	IN
O	NN

GHb	NN
O	NN

needs	NNS
O	VBP

to	TO
O	NN

be	VB
O	NN

solved	VBD
O	NN

Users	NNS
O	VBP

in	IN
O	NN

clinical	JJ
O	NN

practice	NN
O	NN

must	MD
O	NNP

recognize	VB
O	NNP

these	DT
O	NN

problems	NNS
O	VBP

,	,
O	NN

and	CC
O	NN

,	,
O	NN

before	IN
O	NN

supply	NN
O	NN

,	,
O	NN

the	DT
O	NN

providers	NNS
O	NN

should	MD
O	NNP

check	NN
O	NN

their	PRP$
O	NN

method	NN
O	NN

and	CC
O	NN

keep	VB
O	NN

records	NNS
O	NN

that	IN
O	NN

are	VBP
O	NN

readily	RB
O	NN

traceable	JJ
O	NN

A	DT
O	NN

postal	JJ
O	NN

survey	NN
O	NN

was	VBD
O	NN

performed	VBN
O	NN

to	TO
O	NN

determine	VB
O	NN

the	DT
O	NN

current	JJ
O	NN

practices	NNS
O	VBP

and	CC
O	NN

attitudes	NNS
O	NN

of	IN
O	NN

radiologists	NNS
O	NN

towards	IN
O	NN

the	DT
O	NN

imaging	NN
O	NN

of	IN
O	NN

suspected	VBN
O	NN

lower	JJR
O	NN

limb	NN
O	NN

deep	JJ
D	NN

vein	NN
D	NN

thrombosis	NN
D	NN

(	NN
D	NN

DVT	NN
D	NN

)	NN
D	NN

One	CD
O	NN

hundred	CD
O	NN

and	CC
O	NN

twenty-seven	CD
O	NN

departments	NNS
O	NN

responded	VBD
O	NN

to	TO
O	NN

a	DT
O	NN

questionnaire	NN
O	NN

sent	VBN
O	NN

in	IN
O	NN

March	NNP
O	NNP

1996	CD
O	NN

The	DT
O	NN

results	NNS
O	VBP

show	NN
O	NN

that	IN
O	NN

87	CD
O	NN

%	NN
O	NN

of	IN
O	NN

hospitals	NNS
O	NN

possess	VB
O	NN

colour	NN
O	NN

Doppler	NNP
O	NNP

ultrasound	NN
O	NN

(	NN
O	NN

CDUS	NN
O	NN

)	NN
O	NN

machines	NNS
O	NN

and	CC
O	NN

that	IN
O	NN

46	CD
O	NN

%	NN
O	NN

of	IN
O	NN

departments	NNS
O	NN

perform	VB
O	NN

ultrasound	NN
O	NN

as	IN
O	NN

the	DT
O	NN

first	RB
O	NN

line	NN
O	NN

investigation	NN
O	NN

in	IN
O	NN

over	IN
O	NN

90	CD
O	NN

%	NN
O	NN

of	IN
O	NN

cases	NNS
O	NN

Thirty	CD
O	NN

per	IN
O	NN

cent	NN
O	NN

of	IN
O	NN

departments	NNS
O	NN

considered	VBN
O	NN

calf	NN
O	NN

vein	NN
O	NN

visualization	NN
O	NN

to	TO
O	NN

be	VB
O	NN

generally	RB
O	NN

adequate	JJ
O	NN

and	CC
O	NN

34	CD
O	NN

%	NN
O	NN

thought	VBN
O	NN

that	IN
O	NN

clinicians	NNS
O	NN

in	IN
O	NN

their	PRP$
O	NN

hospitals	NNS
O	NN

invariably	RB
O	NN

anticoagulated	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

isolated	VBN
T	NN

calf	NN
T	NN

thrombus	NN
T	NN

In	IN
O	NN

hospitals	NNS
O	NN

where	WRB
O	NN

venography	NN
O	NN

was	VBD
O	NN

routinely	RB
O	NN

used	VBN
O	NN

as	IN
O	NN

the	DT
O	NN

first	RB
O	NN

line	NN
O	NN

investigation	NN
O	NN

,	,
O	NN

the	DT
O	NN

most	JJS
O	NN

common	JJ
O	NN

reasons	NNS
O	VBP

were	VBD
O	NN

:	:
O	NN

the	DT
O	NN

perceived	VBN
O	NN

inferiority	NN
O	NN

of	IN
O	NN

ultrasound	NN
O	NN

(	NN
O	NN

US	NNP
O	NN

)	NN
O	NN

in	IN
O	NN

demonstrating	VBG
O	NN

below-knee	JJ
O	NN

clot	NN
D	NN

,	,
O	NN

its	PRP$
O	NN

time-consuming	JJ
O	NN

nature	NN
O	NN

and	CC
O	NN

the	DT
O	NN

limited	JJ
O	NN

access	NN
O	NN

to	TO
O	NN

suitable	JJ
O	NN

ultrasound	NN
O	NN

machines	NNS
O	NN

The	DT
O	NN

widespread	JJ
O	NN

use	NN
O	NN

of	IN
O	NN

ultrasound	NN
O	NN

is	VBZ
O	NN

encouraging	JJ
O	NN

,	,
O	NN

however	RB
O	NN

,	,
O	NN

there	RB
O	NN

are	VBP
O	NN

clearly	RB
O	NN

diverse	JJ
O	NN

views	NNS
O	NN

A	DT
O	NN

significant	JJ
O	NN

minority	NN
O	NN

of	IN
O	NN

departments	NNS
O	NN

depend	VB
O	NN

principally	RB
O	NN

upon	IN
O	NN

venography	NN
O	NN

in	IN
O	NN

the	DT
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

DVT	NN
D	NN

Existential	JJ
O	NN

phenomenology	NN
O	NN

and	CC
O	NN

the	DT
O	NN

sociological	JJ
O	NN

tradition	NN
O	NN

Dual	JJ
O	NN

leadership	NN
O	NN

in	IN
O	NN

complex	JJ
O	NN

organizations	NNS
O	VBP

Scientists	NNS
O	NN

at	IN
O	NN

major	JJ
O	NN

and	CC
O	NN

minor	JJ
O	NN

universities	NNS
O	NN

:	:
O	NN

a	DT
O	NN

study	NN
O	NN

of	IN
O	NN

productivity	NN
O	NN

and	CC
O	NN

recognition	NN
O	NN

Demotion	NN
O	NN

in	IN
O	NN

industrial	JJ
O	NN

management	NN
O	NN

Career	NNP
O	NNP

anchorage	NN
O	NN

:	:
O	NN

managerial	JJ
O	NN

mobility	NN
O	NN

motivations	NNS
O	NN

Social	NNP
O	NNP

class	NN
O	NN

and	CC
O	NN

premarital	JJ
O	NN

sexual	JJ
O	NN

permissiveness	NN
O	NN

:	:
O	NN

a	DT
O	NN

re-examination	NN
O	NN

A	DT
O	NN

comment	NN
O	NN

on	IN
O	NN

``	``
O	NN

anomy	NN
O	NN

''	''
O	NN

A	DT
O	NN

factor	NN
O	NN

analytic	JJ
O	NN

exploration	NN
O	NN

of	IN
O	NN

the	DT
O	NN

alienation	NN
O	NN

,	,
O	NN

anomia	NN
O	NN

and	CC
O	NN

authoritarianism	NN
O	NN

domain	NN
O	NN

Technical	NNP
O	NNP

note	NN
O	NN

on	IN
O	NN

two	CD
O	NN

rates	NNS
O	VBP

of	IN
O	NN

mixed	JJ
O	NN

marriage	NN
O	NN

Some	DT
O	NN

comments	NNS
O	NN

on	IN
O	NN

awareness	NN
O	NN

On	IN
O	NN

experimental	JJ
O	NN

design	NN
O	NN

Observations	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

incidence	NN
O	NN

of	IN
O	NN

following	VBG
O	NN

of	IN
O	NN

visual	JJ
O	NN

and	CC
O	NN

auditory	JJ
O	NN

stimuli	NNS
O	VBP

in	IN
O	NN

naive	JJ
O	NN

mallard	NN
O	NN

ducklings	NNS
O	NN

(	NN
O	NN

Anas	NNP
O	NNP

platyrhynchos	NNS
O	NN

)	NN
O	NN

The	DT
O	NN

comfort	NN
O	NN

movements	NNS
O	VBP

of	IN
O	NN

Anatidae	FW
O	FW

Potential	JJ
O	NN

ethological	JJ
O	NN

isolating	VBG
O	NN

mechanisms	NNS
O	VBP

and	CC
O	NN

assortative	JJ
O	NN

mating	VBG
O	NN

in	IN
O	NN

the	DT
O	NN

domestic	JJ
O	NN

fowl	NN
O	NN

An	DT
O	NN

experimental	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

conflict	NN
O	NN

and	CC
O	NN

fear	NN
O	NN

:	:
O	NN

an	DT
O	NN

analysis	NN
O	NN

of	IN
O	NN

behavior	NN
O	NN

of	IN
O	NN

young	JJ
O	NN

chicks	NNS
O	NN

toward	IN
O	NN

a	DT
O	NN

mealworm	NN
O	NN

I	PRP
O	VBP

.	.
O	NN

The	DT
O	NN

behavior	NN
O	NN

of	IN
O	NN

chicks	NNS
O	NN

which	WDT
O	NN

do	VB
O	NNP

not	RB
O	NN

eat	VB
O	NNP

the	DT
O	NN

mealworm	NN
O	NN

The	DT
O	NN

measuring	VBG
O	NN

function	NN
O	NN

of	IN
O	NN

the	DT
O	NN

first	RB
O	NN

legs	NNS
O	VBP

of	IN
O	NN

Araneus	FW
O	FW

diadematus	NN
O	NN

Cl	NN
O	NN

The	DT
O	NN

transport	NN
O	NN

of	IN
O	NN

prey	NN
O	NN

by	IN
O	NN

ants	NNS
O	NN

Courtship	NN
O	NN

behaviour	NN
O	NN

in	IN
O	NN

the	DT
O	NN

Drosophila	FW
O	FW

obscura	NN
O	NN

group	NN
O	NN

II	NNP
O	NNP

Comparative	JJ
O	NN

studies	NNS
O	VBP

Vision	NNP
O	NNP

versus	CC
O	NN

touch	NN
O	NN

in	IN
O	NN

form	NN
O	NN

discrimination	NN
O	NN

Short-term	JJ
O	NN

retention	NN
O	NN

as	IN
O	NN

a	DT
O	NN

function	NN
O	NN

of	IN
O	NN

method	NN
O	NN

of	IN
O	NN

measurement	NN
O	NN

,	,
O	NN

recording	VBG
O	NN

time	NN
O	NN

,	,
O	NN

and	CC
O	NN

meaningfulness	NN
O	NN

of	IN
O	NN

the	DT
O	NN

material	NN
O	NN

The	DT
O	NN

conservation	NN
O	NN

of	IN
O	NN

a	DT
O	NN

shape	NN
O	NN

property	NN
O	NN

and	CC
O	NN

a	DT
O	NN

proposal	NN
O	NN

about	IN
O	NN

the	DT
O	NN

origin	NN
O	NN

of	IN
O	NN

the	DT
O	NN

conservations	NNS
O	NN

Persisting	VBG
O	NN

odours	VBZ
O	NN

as	IN
O	NN

a	DT
O	NN

biasing	VBG
O	NN

factor	NN
O	NN

in	IN
O	NN

open-field	JJ
O	NN

research	NN
O	NN

with	IN
O	NN

mice	NNS
O	NN

The	DT
O	NN

display	NN
O	NN

of	IN
O	NN

information	NN
O	NN

and	CC
O	NN

the	DT
O	NN

judgment	NN
O	NN

of	IN
O	NN

contingency	NN
O	NN

Vividness	NN
O	NN

of	IN
O	NN

words	NNS
O	NN

and	CC
O	NN

learning	VBG
O	NN

to	TO
O	NN

learn	VB
O	NN

in	IN
O	NN

free-recall	JJ
O	NN

learning	VBG
O	NN

Genetic	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

the	DT
O	NN

memorization	NN
O	NN

of	IN
O	NN

words	NNS
O	NN

and	CC
O	NN

pictures	NNS
O	NN

Amylase	NN
O	NN

production	NN
O	NN

by	IN
O	NN

Streptomyces	FW
O	FW

species	NNS
O	NN

Physico-chemical	JJ
O	NN

studies	NNS
O	VBP

on	IN
O	NN

the	DT
O	NN

stability	NN
O	NN

of	IN
O	NN

penicillin	NN
T	NN

salts	NNS
T	NN

IV	CD
O	NN

A	DT
O	NN

statistical	JJ
O	NN

evaluation	NN
O	NN

Studies	NNS
O	VBP

on	IN
O	NN

nitrogen	NN
O	NN

metabolism	NN
O	NN

of	IN
O	NN

Penicillium	NNP
O	NNP

chrysogenum	NN
O	NN

Thom	NNP
O	NNP

.	.
O	NN

I	PRP
O	VBP

.	.
O	NN

Effects	NNS
O	NN

of	IN
O	NN

lactose	NN
O	NN

and	CC
O	NN

sucrose	NN
O	NN

additions	NNS
O	NN

on	IN
O	NN

nitrogen	NN
O	NN

metabolism	NN
O	NN

Studies	NNS
O	VBP

on	IN
O	NN

nitrogen	NN
O	NN

metabolism	NN
O	NN

of	IN
O	NN

Penicillium	NNP
O	NNP

chrysogenum	NN
O	NN

Thom	NNP
O	NNP

.	.
O	NN

II	NNP
O	NNP

Amino	NN
O	NN

acid	NN
O	NN

metabolism	NN
O	NN

and	CC
O	NN

its	PRP$
O	NN

relation	NN
O	NN

to	TO
O	NN

the	DT
O	NN

biosynthesis	NN
O	NN

of	IN
O	NN

penicillin	NN
T	NN

The	DT
O	NN

contribution	NN
O	NN

of	IN
O	NN

thoracic	JJ
T	NN

surgery	NN
T	NN

to	TO
O	NN

our	PRP$
O	NN

discipline	NN
O	NN

Research	NNP
O	NNP

past	JJ
O	NN

and	CC
O	NN

present	JJ
O	NN

,	,
O	NN

with	IN
O	NN

particular	JJ
O	NN

reference	NN
O	NN

to	TO
O	NN

the	DT
O	NN

application	NN
O	NN

of	IN
O	NN

the	DT
O	NN

techniques	NNS
O	VBP

of	IN
O	NN

basic	JJ
O	NN

science	NN
O	NN

to	TO
O	NN

the	DT
O	NN

problems	NNS
O	VBP

of	IN
O	NN

adrenal	JJ
O	NN

pathology	NN
O	NN

Some	DT
O	NN

inflammatory	JJ
D	NN

disorders	NNS
D	NN

of	IN
O	NN

the	DT
O	NN

large	JJ
O	NN

intestine	NN
O	NN

Coexistence	NN
O	NN

of	IN
O	NN

subdural	JJ
O	NN

and	CC
O	NN

archnoidal	JJ
O	NN

collections	NNS
O	NN

of	IN
O	NN

fluid	NN
O	NN

:	:
O	NN

an	DT
O	NN

unusual	JJ
O	NN

case	NN
O	NN

The	DT
O	NN

scope	NN
O	NN

of	IN
O	NN

sphincterotomy	NN
T	NN

in	IN
O	NN

biliary	JJ
T	NN

and	CC
T	NN

pancreatic	JJ
T	NN

surgery	NN
T	NN

Sarcoidosis	NN
T	NN

involving	VBG
O	NN

the	DT
O	NN

veriform	NN
O	NN

appendix	NN
O	NN

``	``
O	NN

Chronic	JJ
D	NN

pancreatitis	NN
D	NN

``	``
O	NN

and	CC
O	NN

carcinoma	NN
D	NN

of	IN
D	NN

the	DT
D	NN

pancreas	NN
D	NN

A	DT
O	NN

method	NN
O	NN

to	TO
O	NN

aid	NN
O	NN

correct	JJ
O	NN

diagnosis	NN
O	NN

Control	NN
O	NN

of	IN
O	NN

post-haemorrhoidectomy	JJ
D	NN

bleeding	NN
D	NN

with	IN
O	NN

a	DT
T	NN

Foley	NNP
T	NN

catheter	NN
T	NN

and	CC
T	NN

a	DT
T	NN

pack	NN
T	NN

Diagnosis	NN
O	NN

and	CC
O	NN

therapy	NN
O	NN

of	IN
O	NN

chronic	JJ
D	NN

aspecific	JJ
D	NN

pancreatitis	NN
D	NN

Behavior	NN
O	NN

of	IN
O	NN

the	DT
O	NN

tetanus	NN
D	NN

patient	NN
O	NN

subjected	VBN
O	NN

to	TO
O	NN

resuscitation	NN
T	NN

treatment	NN
T	NN

Further	JJ
O	NN

data	NNS
O	NN

on	IN
O	NN

mediastinal	JJ
D	NN

and	CC
D	NN

pulmonary	JJ
D	NN

tumors	NNS
D	NN

of	IN
O	NN

the	DT
O	NN

child	NN
O	NN

Review	NN
O	NN

and	CC
O	NN

personal	JJ
O	NN

cases	NNS
O	NN

Dextran	NN
O	NN

of	IN
O	NN

low	JJ
O	NN

molecular	JJ
O	NN

weight	NN
O	NN

in	IN
O	NN

peripheral	JJ
D	NN

arterial	JJ
D	NN

insufficiency	NN
D	NN

Clinico-statistical	JJ
O	NN

considerations	NNS
O	VBP

on	IN
O	NN

vescicular	JJ
D	NN

mole	NN
D	NN

On	IN
O	NN

the	DT
O	NN

significance	NN
O	NN

of	IN
O	NN

histologic	JJ
O	NN

findings	NNS
O	VBP

in	IN
O	NN

neoplasms	NNS
D	NN

of	IN
O	NN

the	DT
O	NN

trophoblast	NN
O	NN

(	NN
O	NN

case	NN
O	NN

contributions	NNS
O	NN

)	NN
O	NN

Diagnostic	JJ
O	NN

evaluation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

patient	NN
O	NN

with	IN
O	NN

high	JJ
D	NN

blood	NN
D	NN

pressure	NN
D	NN

Epidemiology	NNP
O	NNP

of	IN
O	NN

hypertension	NN
D	NN

Renal	JJ
D	NN

vascular	JJ
D	NN

hypertension	NN
D	NN

;	:
O	NN

diagnosis	NN
O	NN

and	CC
O	NN

treatment	NN
O	NN

The	DT
O	NN

use	NN
O	NN

of	IN
O	NN

radioactive	JJ
O	NN

isotopes	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

hypertension	NN
D	NN

The	DT
O	NN

angiogram	NN
O	NN

in	IN
O	NN

the	DT
O	NN

study	NN
O	NN

of	IN
O	NN

hypertension	NN
D	NN

Guanethidine	NN
O	NN

Hepatocerebral	JJ
D	NN

degeneration	NN
D	NN

(	NN
D	NN

portal	NN
D	NN

systemic	JJ
D	NN

encephalopathy	NN
D	NN

)	NN
D	NN

The	DT
O	NN

relationship	NN
O	NN

to	TO
O	NN

fatty	JJ
O	NN

acids	NNS
O	NN

Oviposition	NN
O	NN

and	CC
O	NN

its	PRP$
O	NN

regulation	NN
O	NN

in	IN
O	NN

the	DT
O	NN

polygynous	JJ
O	NN

society	NN
O	NN

of	IN
O	NN

Polistes	NNS
O	NN

gallicus	NN
O	NN

L.	NNP
O	NNP

Interaction	NN
O	NN

of	IN
O	NN

aggressive	JJ
O	NN

and	CC
O	NN

sexual	JJ
O	NN

behavior	NN
O	NN

in	IN
O	NN

male	JJ
O	NN

mice	NNS
O	NN

Conflict	NN
O	NN

and	CC
O	NN

conditioned	VBN
O	NN

aversive	JJ
O	NN

stimuli	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

development	NN
O	NN

of	IN
O	NN

experimental	JJ
O	NN

neuroses	NNS
O	NN

Study	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

newer	JJR
O	NN

analeptic	JJ
O	NN

(	NN
O	NN

Micoren	JJ
O	NN

)	NN
O	NN

in	IN
O	NN

hypoventilation	NN
O	NN

syndrome	NN
O	NN

Treatment	NN
O	NN

of	IN
O	NN

a	DT
D	NN

disorder	NN
D	NN

of	IN
D	NN

perception	NN
D	NN

and	CC
D	NN

concept	NN
D	NN

formation	NN
D	NN

in	IN
O	NN

a	DT
O	NN

case	NN
O	NN

of	IN
O	NN

school	NN
O	NN

failure	NN
O	NN

Rorschach	JJ
O	NN

correlates	VBZ
O	NN

of	IN
O	NN

time	NN
O	NN

estimation	NN
O	NN

Use	NNP
O	NNP

of	IN
O	NN

food	NN
O	NN

in	IN
O	NN

child	NN
T	NN

psychotherapy	NN
T	NN

About	IN
O	NN

genital	JJ
O	NN

discharge	NN
O	NN

with	IN
O	NN

special	JJ
O	NN

consideration	NN
O	NN

of	IN
O	NN

its	PRP$
O	NN

cervical	JJ
O	NN

manifestation	NN
O	NN

Auto-uro	NN
T	NN

therapy	NN
T	NN

:	:
O	NN

status	NN
O	NN

and	CC
O	NN

future	JJ
O	NN

prospects	NNS
O	NN

Clinical	JJ
O	NN

experience	NN
O	NN

with	IN
O	NN

the	DT
O	NN

surface	NN
T	NN

anesthetic	JJ
T	NN

xylocaine	NN
T	NN

in	IN
O	NN

obstetrics	NNS
O	NN

The	DT
O	NN

problem	NN
O	NN

of	IN
O	NN

medicinal	JJ
O	NN

management	NN
O	NN

of	IN
O	NN

labor	NN
O	NN

Conglutination	NN
O	NN

of	IN
O	NN

the	DT
O	NN

labia	NN
O	NN

minora	NN
O	NN

The	DT
O	NN

fight	NN
O	NN

against	IN
O	NN

hemolytic	JJ
D	NN

disease	NN
D	NN

of	IN
O	NN

the	DT
O	NN

newborn	JJ
O	NN

in	IN
O	NN

general	JJ
O	NN

practice	NN
O	NN

Long	JJ
O	NN

term	NN
O	NN

results	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

300	CD
O	NN

most	JJS
O	NN

grave	JJ
O	NN

cases	NNS
O	NN

out	IN
O	NN

of	IN
O	NN

4000	CD
O	NN

hyperthyroid	JJ
D	NN

patients	NNS
D	NN

treated	VBN
O	NN

with	IN
O	NN

iodine	NN
T	NN

I-131	NN
T	NN

at	IN
O	NN

the	DT
O	NN

center	NN
O	NN

of	IN
O	NN

Ancona	NNP
O	NNP

On	IN
O	NN

socalled	JJ
O	NN

nervous	JJ
O	NN

exhaustion	NN
O	NN

Examination	NN
O	NN

of	IN
O	NN

neonatal	JJ
O	NN

archaic	JJ
O	NN

(	NN
O	NN

primitive	JJ
O	NN

)	NN
O	NN

reflexes	NNS
O	NN

in	IN
O	NN

icterus	NN
D	NN

gravis	NN
D	NN

Urologic	JJ
O	NN

complications	NNS
O	NN

in	IN
O	NN

non-recurrent	JJ
D	NN

cancer	NN
D	NN

of	IN
O	NN

the	DT
O	NN

cervix	NN
O	NN

Prolonged	JJ
T	NN

cortisone	NN
T	NN

therapy	NN
T	NN

in	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

allergic	JJ
D	NN

diseases	NNS
D	NN

The	DT
O	NN

complexing	VBG
O	NN

of	IN
O	NN

calcium	NN
O	NN

by	IN
O	NN

citrate	NN
O	NN

,	,
O	NN

ortho-	JJ
O	NN

and	CC
O	NN

polyphosphates	NNS
O	NN

A	DT
O	NN

method	NN
O	NN

of	IN
O	NN

determining	VBG
O	NN

the	DT
O	NN

patency	NN
O	NN

of	IN
O	NN

the	DT
O	NN

nasolacrimal	JJ
O	NN

apparatus	NN
O	NN

Intra-arterial	JJ
O	NN

infusion	NN
O	NN

of	IN
O	NN

the	DT
O	NN

head	NN
O	NN

and	CC
O	NN

neck	NN
O	NN

Anatomic	JJ
O	NN

and	CC
O	NN

distributional	JJ
O	NN

problems	NNS
O	VBP

Lymphatics	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

mouth	NN
O	NN

and	CC
O	NN

neck	NN
O	NN

Effect	NN
O	NN

of	IN
O	NN

sodium	NN
O	NN

ions	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

behavior	NN
O	NN

of	IN
O	NN

rest	NN
O	NN

and	CC
O	NN

action	NN
O	NN

potentials	NNS
O	VBP

of	IN
O	NN

the	DT
O	NN

cell	NN
O	NN

membrane	NN
O	NN

of	IN
O	NN

the	DT
O	NN

rat	NN
O	NN

myometrium	NN
O	NN

Studies	NNS
O	VBP

on	IN
O	NN

contractile	NN
O	NN

properties	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

blood	NN
O	NN

serum	NN
O	NN

Twin	JJ
O	NN

pregnancy	NN
O	NN

and	CC
O	NN

fetal	JJ
O	NN

and	CC
O	NN

infantile	JJ
O	NN

perinatal	JJ
D	NN

mortality	NN
D	NN

Fate	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

2d	JJ
O	NN

twin	JJ
O	NN

Differential	JJ
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

infectious	JJ
D	NN

hepatitis	NN
D	NN

in	IN
O	NN

pregnancy	NN
O	NN

Epithelial	JJ
O	NN

metaplasia	NN
D	NN

of	IN
O	NN

the	DT
O	NN

endometrium	NN
O	NN

Leukoplakia	NN
D	NN

of	IN
O	NN

the	DT
O	NN

vaginal	JJ
O	NN

portion	NN
O	NN

of	IN
O	NN

the	DT
O	NN

uterus	NN
O	NN

and	CC
O	NN

its	PRP$
O	NN

clinical	JJ
O	NN

evaluation	NN
O	NN

Blood	NN
O	NN

loss	NN
O	NN

in	IN
O	NN

artificial	JJ
O	NN

interruption	NN
O	NN

of	IN
O	NN

pregnancy	NN
O	NN

Modified	VBN
T	NN

bra	NN
T	NN

in	IN
O	NN

the	DT
O	NN

prevention	NN
O	NN

of	IN
O	NN

mastitis	NN
D	NN

in	IN
O	NN

nursing	NN
O	NN

mothers	NNS
O	NN

Hormonal	JJ
O	NN

phenomenon	NN
O	NN

after	IN
O	NN

the	DT
O	NN

excision	NN
O	NN

of	IN
O	NN

hydatiform	NN
O	NN

mole	NN
O	NN

Fetal	JJ
O	NN

chondrodystrophy	NN
O	NN

Malignant	JJ
D	NN

mesodermal	JJ
D	NN

mixed	JJ
D	NN

tumor	NN
D	NN

of	IN
O	NN

the	DT
O	NN

uterus	NN
O	NN

following	VBG
O	NN

irradiation	NN
T	NN

Supportive	JJ
O	NN

role	NN
O	NN

of	IN
O	NN

nurse	NN
O	NN

in	IN
O	NN

first	RB
O	NN

stage	NN
O	NN

of	IN
O	NN

labor	NN
O	NN

``	``
O	NN

can	MD
O	NNP

not	RB
O	NN

be	VB
O	NN

emphasized	VBN
O	NN

enough	RB
O	NN

''	''
O	NN

,	,
O	NN

according	VBG
O	NN

to	TO
O	NN

patient	NN
O	NN

Toxemia	NN
D	NN

of	IN
O	NN

pregnancy	NN
O	NN

Outpatient	NN
O	NN

care	NN
O	NN

--	:
O	NN

the	DT
O	NN

role	NN
O	NN

of	IN
O	NN

the	DT
O	NN

nurse	NN
O	NN

Abandonment	NN
O	NN

:	:
O	NN

deepest	JJS
O	NN

fear	NN
O	NN

of	IN
O	NN

hospitalized	VBN
O	NN

children	NNS
O	VBP

Support	NN
O	NN

in	IN
O	NN

first	RB
O	NN

stage	NN
O	NN

of	IN
O	NN

labor	NN
O	NN

The	DT
O	NN

family	NN
O	NN

physician	NN
O	NN

and	CC
O	NN

cervical	JJ
D	NN

carcinoma	NN
D	NN

--	:
O	NN

challenge	NN
O	NN

and	CC
O	NN

opportunity	NN
O	NN

Purposeful	JJ
O	NN

``	``
O	NN

heroic	JJ
O	NN

''	''
O	NN

heart	NN
O	NN

treatment	NN
O	NN

Skilled	JJ
O	NN

workers	NNS
O	VBP

are	VBP
O	NN

vital	JJ
O	NN

to	TO
O	NN

maintenance	NN
O	NN

cost	NN
O	NN

cuts	NNS
O	NN

Karen	NNP
O	NNP

:	:
O	NN

the	DT
O	NN

other	JJ
O	NN

side	NN
O	NN

of	IN
O	NN

the	DT
O	NN

picture	NN
O	NN

Rhesus	NN
D	NN

haemolytic	JJ
D	NN

disease	NN
D	NN

;	:
O	NN

an	DT
O	NN

approach	NN
O	NN

to	TO
O	NN

prevention	NN
O	NN

Tumours	NNP
D	NNP

of	IN
O	NN

the	DT
O	NN

uterus	NN
O	NN

2	CD
O	NN

Malignancy	NN
O	NN

Cancer	NN
D	NN

of	IN
O	NN

the	DT
O	NN

vulva	NN
O	NN

Effects	NNS
O	NN

of	IN
O	NN

smoking	NN
O	NN

on	IN
O	NN

selected	VBN
O	NN

clinical	JJ
O	NN

obstetric	JJ
O	NN

factors	NNS
O	NN

Amniotic	JJ
D	NN

fluid	NN
D	NN

embolism	NN
D	NN

A	DT
O	NN

review	NN
O	NN

of	IN
O	NN

the	DT
O	NN

syndrome	NN
O	NN

with	IN
O	NN

a	DT
O	NN

report	NN
O	NN

of	IN
O	NN

4	CD
O	NN

cases	NNS
O	NN

Chronic	JJ
D	NN

histiocytosis	NN
D	NN

X	NN
D	NN

associated	VBN
O	NN

with	IN
O	NN

pregnancy	NN
O	NN

Disseminated	VBN
D	NN

lupus	NN
D	NN

erythematosus	NN
D	NN

in	IN
O	NN

pregnancy	NN
O	NN

Intralesional	JJ
T	NN

therapy	NN
T	NN

with	IN
T	NN

betamethasone	NN
T	NN

Strucutre	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

influenza	NN
D	NN

virus	NN
D	NN

2	CD
O	NN

students	NNS
O	NN

at	IN
O	NN

Quo	NN
O	NN

Vadis	NNP
O	NN

Double	JJ
O	NN

aortic	JJ
O	NN

arch	JJ
O	NN

associated	VBN
O	NN

with	IN
O	NN

tetralogy	NN
O	NN

of	IN
O	NN

Fallot	NNP
O	NNP

in	IN
O	NN

infants	NNS
O	NN

;	:
O	NN

report	NN
O	NN

of	IN
O	NN

two	CD
O	NN

cases	NNS
O	NN

Tested	VBN
O	NN

questionnaires	NNS
O	NN

help	NN
O	NN

administration	NN
O	NN

learn	VB
O	NN

if	IN
O	NN

programs	NNS
O	NN

are	VBP
O	NN

a	DT
O	NN

success	NN
O	NN

,	,
O	NN

and	CC
O	NN

why	WRB
O	NN

Dumping	VBG
D	NN

syndrome	NN
D	NN

following	VBG
O	NN

pyloroplasty	JJ
T	NN

.	.
O	NN

Measured	VBN
O	NN

subtotal	JJ
O	NN

gastrectomy	NN
O	NN

for	IN
O	NN

duodenal	JJ
O	NN

ulcer	NN
O	NN

The	DT
O	NN

lesions	NNS
O	NN

in	IN
O	NN

bovine	JJ
O	NN

udders	NNS
O	NN

shedding	VBG
O	NN

nonhemolytic	JJ
O	NN

coagulase-negative	JJ
O	NN

staphylococci	NNS
O	NN

Repository	JJ
O	NN

vitamin	NN
O	NN

B	NN
O	NN

12	CD
O	NN

preparations	NNS
O	NN

Mass	JJ
O	NN

spectrometry	NN
O	NN

in	IN
O	NN

structural	JJ
O	NN

and	CC
O	NN

stereochemical	JJ
O	NN

problems	NNS
O	VBP

93	CD
O	NN

Further	JJ
O	NN

observations	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

importance	NN
O	NN

of	IN
O	NN

interatomic	JJ
O	NN

distance	NN
O	NN

in	IN
O	NN

the	DT
O	NN

McLafferty	NN
O	NN

rearrangement	NN
O	NN

Synthesis	NN
O	NN

and	CC
O	NN

fragmentation	NN
O	NN

behavior	NN
O	NN

of	IN
O	NN

deuterium-labeled	JJ
O	NN

12-keto	JJ
O	NN

steroids	NNS
O	NN

Treatment	NN
O	NN

of	IN
O	NN

childhood	NN
D	NN

schizophrenia	NN
D	NN

A	DT
O	NN

three-year	JJ
O	NN

comparison	NN
O	NN

of	IN
O	NN

day	NN
O	NN

and	CC
O	NN

residental	JJ
O	NN

treatment	NN
O	NN

Polycystic	JJ
O	NN

ovaries	NNS
O	NN

associated	VBN
O	NN

with	IN
O	NN

congenital	JJ
D	NN

adrenal	JJ
D	NN

hyperplasia	NN
D	NN

Beta-propiolactone	JJ
T	NN

as	IN
O	NN

used	VBN
O	NN

in	IN
O	NN

sterilization	NN
O	NN

of	IN
O	NN

homografts	NNS
O	NN

not	RB
O	NN

carcinogenic	JJ
O	NN

for	IN
O	NN

mice	NNS
O	NN

New	NNP
O	NNP

operations	NNS
O	NN

in	IN
O	NN

children	NNS
O	VBP

's	POS
O	NN

cardiac	JJ
O	NN

disease	NN
O	NN

Effect	NN
O	NN

of	IN
O	NN

diabetes	NN
D	NN

and	CC
O	NN

starvation	NN
O	NN

on	IN
O	NN

myocardial	JJ
O	NN

triglyceride	NN
O	NN

and	CC
O	NN

free	JJ
O	NN

fatty	JJ
O	NN

acid	NN
O	NN

utilization	NN
O	NN

Effect	NN
O	NN

of	IN
O	NN

epinephrine	NN
O	NN

on	IN
O	NN

myocardial	JJ
O	NN

triglyceride	NN
O	NN

and	CC
O	NN

free	JJ
O	NN

fatty	JJ
O	NN

acid	NN
O	NN

utilization	NN
O	NN

Diurnal	JJ
O	NN

periodicity	NN
O	NN

in	IN
O	NN

the	DT
O	NN

metabolic	JJ
O	NN

activity	NN
O	NN

of	IN
O	NN

bone	NN
O	NN

tissue	NN
O	NN

Fine	JJ
O	NN

structure	NN
O	NN

of	IN
O	NN

desmosomes	NNS
O	NN

,	,
O	NN

hemidesmosomes	NNS
O	NN

,	,
O	NN

and	CC
O	NN

an	DT
O	NN

adepidermal	JJ
O	NN

globular	JJ
O	NN

layer	NN
O	NN

in	IN
O	NN

developing	VBG
O	NN

newt	NN
O	NN

epidermis	NN
O	NN

Redundant	JJ
O	NN

myelin	JJ
O	NN

sheaths	NNS
O	NN

and	CC
O	NN

other	JJ
O	NN

ultrastructural	JJ
O	NN

features	NNS
O	VBP

of	IN
O	NN

the	DT
O	NN

toad	NN
O	NN

cerebellum	NN
O	NN

A	DT
O	NN

radioautographic	JJ
O	NN

study	NN
O	NN

with	IN
O	NN

H3-thymidine	NN
O	NN

on	IN
O	NN

adrenal	JJ
O	NN

medulla	NN
O	NN

nuclei	NNS
O	NN

of	IN
O	NN

rats	NNS
O	NN

intermittently	RB
O	NN

exposed	VBN
O	NN

to	TO
O	NN

cold	JJ
O	NN

A	DT
O	NN

fine	JJ
O	NN

structural	JJ
O	NN

analysis	NN
O	NN

of	IN
O	NN

the	DT
O	NN

epidermis	NN
O	NN

of	IN
O	NN

the	DT
O	NN

earthworm	NN
O	NN

,	,
O	NN

Lumbricus	NN
O	NN

terrestris	NN
O	NN

L.	NNP
O	NNP

Effect	NN
O	NN

of	IN
O	NN

thoracic	JJ
O	NN

cava	NN
O	NN

obstruction	NN
O	NN

on	IN
O	NN

response	NN
O	NN

of	IN
O	NN

proximal	JJ
O	NN

tubule	NN
O	NN

sodium	NN
O	NN

reabsorption	NN
O	NN

to	TO
O	NN

saline	NN
O	NN

infusion	NN
O	NN

The	DT
O	NN

metabolism	NN
O	NN

of	IN
O	NN

intravenously	RB
O	NN

injected	VBN
O	NN

isotopic	JJ
O	NN

cholic	JJ
O	NN

acid	NN
O	NN

in	IN
O	NN

Laennec	NNP
D	NNP

's	POS
D	NN

cirrhosis	NN
D	NN

The	DT
O	NN

origin	NN
O	NN

and	CC
O	NN

glyceride	NN
O	NN

distribution	NN
O	NN

of	IN
O	NN

fatty	JJ
O	NN

acids	NNS
O	NN

in	IN
O	NN

rat	NN
O	NN

adipose	NN
O	NN

tissue	NN
O	NN

Absorption	NN
O	NN

of	IN
O	NN

medium	NN
O	NN

and	CC
O	NN

long	RB
O	NN

chain	NN
O	NN

triglycerides	NNS
O	NN

:	:
O	NN

factors	NNS
O	NN

influencing	VBG
O	NN

their	PRP$
O	NN

hydrolysis	NN
O	NN

and	CC
O	NN

transport	NN
O	NN

The	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

epinephrine	NN
O	NN

on	IN
O	NN

immunoreactive	JJ
O	NN

insulin	NN
O	NN

levels	NNS
O	VBP

in	IN
O	NN

man	NN
O	NN

The	DT
O	NN

role	NN
O	NN

of	IN
O	NN

the	DT
O	NN

liver	NN
O	NN

in	IN
O	NN

serum-induced	JJ
O	NN

hypercoagulability	NN
D	NN

Comparative	JJ
O	NN

fates	NNS
O	NN

of	IN
O	NN

intravenously	RB
O	NN

and	CC
O	NN

orally	RB
O	NN

administered	VBN
O	NN

aldosterone	NN
O	NN

:	:
O	NN

evidence	NN
O	NN

for	IN
O	NN

extrahepatic	JJ
O	NN

formation	NN
O	NN

of	IN
O	NN

acid-hydrolyzable	JJ
O	NN

conjugate	NN
O	NN

in	IN
O	NN

man	NN
O	NN

Binding	NN
O	NN

of	IN
O	NN

sulfobromophthalein	NN
O	NN

(	NN
O	NN

BSP	NN
O	NN

)	NN
O	NN

sodium	NN
O	NN

by	IN
O	NN

plasma	NN
O	NN

albumin	NN
O	NN

Its	PRP$
O	NN

role	NN
O	NN

in	IN
O	NN

hepatic	JJ
O	NN

BSP	NN
O	NN

extraction	NN
O	NN

The	DT
O	NN

rationale	NN
O	NN

of	IN
O	NN

extended	VBN
T	NN

resection	NN
T	NN

for	IN
O	NN

complicated	JJ
D	NN

cancer	NN
D	NN

of	IN
D	NN

the	DT
D	NN

large	JJ
D	NN

bowel	NN
D	NN

Etiology	NN
O	NN

and	CC
O	NN

incidence	NN
O	NN

of	IN
O	NN

renal	JJ
D	NN

stones	NNS
D	NN

Diagnosis	NN
O	NN

of	IN
O	NN

stone	NN
D	NN

disease	NN
D	NN

Medical	JJ
T	NN

treatment	NN
T	NN

of	IN
O	NN

stone	NN
D	NN

disease	NN
D	NN

Surgical	NNP
T	NN

treatment	NN
T	NN

of	IN
O	NN

urinary	JJ
D	NN

stones	NNS
D	NN

Prevention	NNP
O	NNP

of	IN
O	NN

stone	NN
D	NN

formation	NN
D	NN

Urinary	JJ
O	NN

calculi	JJ
O	NN

Is	VBZ
O	NN

the	DT
O	NN

task	NN
O	NN

hopeless	JJ
O	NN

?	.
O	NN

The	DT
O	NN

family	NN
O	NN

medicine	NN
O	NN

program	NN
O	NN

of	IN
O	NN

the	DT
O	NN

University	NNP
O	NN

of	IN
O	NN

Miami	NNP
O	NNP

Electron	NN
O	NN

microscopic	JJ
O	NN

studies	NNS
O	VBP

of	IN
O	NN

Mycoplasma	NN
O	NN

(	NN
O	NN

PPLO	NN
O	NN

strain	NN
O	NN

880	CD
O	NN

)	NN
O	NN

in	IN
O	NN

artificial	JJ
O	NN

medium	NN
O	NN

and	CC
O	NN

in	IN
O	NN

tissue	NN
O	NN

culture	NN
O	NN

Chemotherapeutic	JJ
O	NN

effects	NNS
O	NN

on	IN
O	NN

mammalian	JJ
D	NN

tumor	NN
D	NN

cells	NNS
D	NN

3	CD
O	NN

Modification	NN
O	NN

of	IN
O	NN

leukemia	NN
O	NN

L1210	NN
O	NN

growth	NN
O	NN

kinetics	NNS
O	NN

with	IN
O	NN

an	DT
O	NN

antimetabolite	JJ
O	NN

Comparison	NN
O	NN

of	IN
O	NN

the	DT
O	NN

sensitivity	NN
O	NN

of	IN
O	NN

normal	JJ
O	NN

hematopoietic	JJ
O	NN

and	CC
O	NN

transplanted	VBN
O	NN

lymphoma	NN
O	NN

colony-forming	JJ
O	NN

cells	NNS
O	VBP

of	IN
O	NN

mice	NNS
O	NN

to	TO
O	NN

vinblastine	NN
O	NN

administered	VBN
O	NN

in	IN
O	NN

vivo	FW
O	FW

Evidence	NN
O	NN

for	IN
O	NN

an	DT
O	NN

immunological	JJ
O	NN

reaction	NN
O	NN

of	IN
O	NN

the	DT
O	NN

host	NN
O	NN

directed	VBN
O	NN

against	IN
O	NN

its	PRP$
O	NN

own	JJ
O	NN

actively	RB
O	NN

growing	VBG
O	NN

primary	JJ
D	NN

tumor	NN
D	NN

Hyperbaric	JJ
T	NN

oxygen	NN
T	NN

,	,
T	NN

whole-body	JJ
T	NN

X	NN
T	NN

irradiation	NN
T	NN

,	,
T	NN

and	CC
T	NN

cyclophosphamide	NN
T	NN

combination	NN
T	NN

therapy	NN
T	NN

in	IN
O	NN

mouse	NN
D	NN

leukemia	NN
D	NN

L1210	NN
D	NN

Clinical	JJ
O	NN

staging	NN
O	NN

in	IN
O	NN

cancer	NN
D	NN

of	IN
D	NN

the	DT
D	NN

larynx	NN
D	NN

:	:
O	NN

a	DT
O	NN

report	NN
O	NN

on	IN
O	NN

788	CD
O	NN

cases	NNS
O	NN

using	VBG
O	NN

the	DT
O	NN

American	JJ
O	NN

Joint	NNP
O	NNP

Committee	NNP
O	NNP

's	POS
O	NN

method	NN
O	NN

of	IN
O	NN

stage	NN
O	NN

classification	NN
O	NN

Comparison	NN
O	NN

of	IN
O	NN

the	DT
O	NN

international	JJ
O	NN

and	CC
O	NN

American	JJ
O	NN

systems	NNS
O	NN

for	IN
O	NN

the	DT
O	NN

staging	NN
O	NN

of	IN
O	NN

breast	NN
D	NN

cancer	NN
D	NN

Effects	NNS
O	NN

of	IN
O	NN

tryptophan	NN
O	NN

mustard	NN
O	NN

on	IN
O	NN

incorporation	NN
O	NN

of	IN
O	NN

amino	NN
O	NN

acids	NNS
O	NN

into	IN
O	NN

proteins	NNS
O	NN

in	IN
O	NN

tumor-bearing	JJ
O	NN

rats	NNS
O	NN

An	DT
O	NN

electron	NN
O	NN

microscope	NN
O	NN

study	NN
O	NN

of	IN
O	NN

plant	NN
D	NN

neoplasia	NN
D	NN

induced	VBN
O	NN

by	IN
O	NN

wound	NN
D	NN

tumor	NN
D	NN

virus	NN
D	NN

Possibilities	NNS
O	NN

of	IN
O	NN

surgical	JJ
T	NN

correction	NN
T	NN

of	IN
O	NN

malformations	NNS
D	NN

of	IN
D	NN

the	DT
D	NN

bones	NNS
D	NN

of	IN
D	NN

the	DT
D	NN

foot	NN
D	NN

The	DT
O	NN

postprandial	JJ
O	NN

period	NN
O	NN

of	IN
O	NN

the	DT
O	NN

gastrectomized	VBN
O	NN

patient	NN
O	NN

Radiocinematographic	JJ
O	NN

and	CC
O	NN

clinical	JJ
O	NN

correlation	NN
O	NN

Muscle	NN
O	NN

pathology	NN
O	NN

;	:
O	NN

contribution	NN
O	NN

of	IN
O	NN

experimentation	NN
O	NN

Origin	NN
O	NN

of	IN
O	NN

milk	NN
O	NN

cholesterol	NN
O	NN

in	IN
O	NN

the	DT
O	NN

rat	NN
O	NN

:	:
O	NN

dietary	JJ
O	NN

versus	CC
O	NN

endogenous	JJ
O	NN

sources	NNS
O	NN

Comparative	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

two	CD
O	NN

benzodiazepine	NN
O	NN

compounds	NNS
O	NN

on	IN
O	NN

isolated	VBN
O	NN

human	JJ
O	NN

myometrium	NN
O	NN

Histochemistry	NN
O	NN

of	IN
O	NN

hydrolytic	JJ
O	NN

and	CC
O	NN

oxidative	JJ
O	NN

enzymes	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

human	JJ
O	NN

and	CC
O	NN

experimentally	RB
O	NN

induced	VBN
O	NN

adenocarcinoma	NN
D	NN

of	IN
O	NN

the	DT
O	NN

endometrium	NN
O	NN

Cardiac	JJ
O	NN

monitors	NNS
O	NN

work	NN
O	NN

--	:
O	NN

but	CC
O	NNP

they	PRP
O	VBP

should	MD
O	NNP

report	NN
O	NN

more	RBR
O	NN

than	IN
O	NN

they	PRP
O	VBP

do	VB
O	NNP

Delivery	NN
O	NN

room	NN
O	NN

pediatrics	NNS
O	NN

The	DT
O	NN

responsibilities	NNS
O	VBP

of	IN
O	NN

the	DT
O	NN

obstetrician	NN
O	NN

A	DT
O	NN

pediatrician	NN
O	NN

's	POS
O	NN

checklist	NN
O	NN

for	IN
O	NN

adolescents	NNS
O	NN

Community	NNP
O	NNP

clinic	NN
O	NN

treatment	NN
O	NN

for	IN
O	NN

back-ward	JJ
O	NN

patients	NNS
O	NN

Studies	NNS
O	VBP

in	IN
O	NN

infantile	JJ
D	NN

malnutrition	NN
D	NN

V	NN
O	NN

The	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

dietary	JJ
O	NN

protein	NN
O	NN

source	NN
O	NN

on	IN
O	NN

serum	NN
O	NN

proteins	NNS
O	NN

Fish	NN
T	NN

protein	NN
T	NN

concentrates	VBZ
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

kwashiorkor	NN
D	NN

athyrism	NN
D	NN

in	IN
O	NN

the	DT
O	NN

fetal	JJ
O	NN

rat	NN
O	NN

Evidence	NN
O	NN

for	IN
O	NN

impairment	NN
O	NN

of	IN
O	NN

elastin	NN
O	NN

formation	NN
O	NN

Familial	JJ
D	NN

vitamin	NN
D	NN

D	NN
D	NN

resistant	JJ
D	NN

rickets	NN
D	NN

in	IN
O	NN

untreated	JJ
O	NN

adult	JJ
O	NN

Bony	JJ
O	NN

proliferation	NN
O	NN

of	IN
O	NN

neural	JJ
O	NN

arches	NNS
O	NN

with	IN
O	NN

cord	NN
O	NN

compression	NN
O	NN

Amyloidosis	NN
D	NN

of	IN
O	NN

the	DT
O	NN

cornea	NN
O	NN

Report	NNP
O	NNP

of	IN
O	NN

a	DT
O	NN

case	NN
O	NN

without	IN
O	NN

conjunctival	JJ
O	NN

involvement	NN
O	NN

Effect	NN
O	NN

of	IN
O	NN

tranquilizing	VBG
T	NN

drugs	NNS
T	NN

on	IN
O	NN

postnatal	JJ
O	NN

behavior	NN
O	NN

Fathers	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

delivery	NN
O	NN

room	NN
O	NN

--	:
O	NN

an	DT
O	NN

opposition	NN
O	NN

standpoint	NN
O	NN

Fathers	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

delivery	NN
O	NN

--	:
O	NN

''	''
O	NN

helpful	JJ
O	NN

and	CC
O	NN

supportive	JJ
O	NN

''	''
O	NN

``	``
O	NN

Return	NN
O	NN

the	DT
O	NN

joy	NN
O	NN

of	IN
O	NN

home	NN
O	NN

delivery	NN
O	NN

''	''
O	NN

with	IN
O	NN

fathers	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

delivery	NN
O	NN

room	NN
O	NN

Fathers	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

delivery	NN
O	NN

room	NN
O	NN

--	:
O	NN

long	RB
O	NN

experience	NN
O	NN

molds	NNS
O	NN

one	CD
O	NN

viewpoint	NN
O	NN

Doctors	NNS
O	NN

--	:
O	NN

we	PRP
O	VBP

need	NN
O	NN

you	PRP
O	VBP

Pharmacological	JJ
O	NN

blockade	NN
O	NN

of	IN
O	NN

ovulation	NN
O	NN

in	IN
O	NN

the	DT
O	NN

ewe	NN
O	NN

Some	DT
O	NN

factors	NNS
O	NN

affecting	VBG
O	NN

the	DT
O	NN

response	NN
O	NN

of	IN
O	NN

the	DT
O	NN

immature	JJ
O	NN

mouse	NN
O	NN

to	TO
O	NN

pregnant	JJ
O	NN

mare	NN
O	NN

serum	NN
O	NN

gonadotrophin	NN
O	NN

and	CC
O	NN

human	JJ
O	NN

chorionic	JJ
O	NN

gonadotrophin	NN
O	NN

The	DT
O	NN

metabolism	NN
O	NN

of	IN
O	NN

cortisol	NN
O	NN

by	IN
O	NN

human	JJ
O	NN

extra-hepatic	JJ
O	NN

tissues	NNS
O	NN

Aromatization	NN
O	NN

of	IN
O	NN

7-alpha-hydroxydehydroepiandrosterone	NN
O	NN

and	CC
O	NN

of	IN
O	NN

its	PRP$
O	NN

3-sulphate	JJ
O	NN

by	IN
O	NN

ovarian	JJ
O	NN

and	CC
O	NN

placental	JJ
O	NN

tissue	NN
O	NN

cultures	NNS
O	NN

Metabolic	JJ
O	NN

and	CC
O	NN

endocrine	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

lysergic	JJ
O	NN

acid	NN
O	NN

diethylamide	NN
O	NN

(	NN
O	NN

LSD-25	CD
O	NN

)	NN
O	NN

on	IN
O	NN

male	JJ
O	NN

rats	NNS
O	NN

Mutation	NN
O	NN

frequencies	NNS
O	NN

detected	VBN
O	NN

following	VBG
O	NN

irradiation	NN
T	NN

of	IN
O	NN

virgin	JJ
O	NN

and	CC
O	NN

inseminated	VBN
O	NN

Drosophila	FW
O	FW

melanogaster	FW
O	FW

females	NNS
O	NN

Relationship	NN
O	NN

of	IN
O	NN

fractons	NNS
O	NN

of	IN
O	NN

soybeans	NNS
O	NN

and	CC
O	NN

a	DT
O	NN

crystalline	JJ
O	NN

soybean	NN
O	NN

trypsin	NN
O	NN

inhibitor	NN
O	NN

to	TO
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

feeding	VBG
O	NN

unheated	JJ
O	NN

soybean	NN
O	NN

meal	NN
O	NN

to	TO
O	NN

chicks	NNS
O	NN

Metabolism	NN
O	NN

of	IN
O	NN

polyunsaturated	JJ
O	NN

fatty	JJ
O	NN

acids	NNS
O	NN

and	CC
O	NN

serum	NN
O	NN

cholesterol	NN
O	NN

levels	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

rat	NN
O	NN

Comparison	NN
O	NN

of	IN
O	NN

neutral	JJ
O	NN

fat	JJ
O	NN

and	CC
O	NN

free	JJ
O	NN

fatty	JJ
O	NN

acids	NNS
O	NN

in	IN
O	NN

high	JJ
O	NN

lipid-low	JJ
O	NN

carbohydrate	NN
O	NN

diets	NNS
O	NN

for	IN
O	NN

the	DT
O	NN

growing	VBG
O	NN

chicken	NN
O	NN

An	DT
O	NN

approach	NN
O	NN

to	TO
O	NN

quantitative	JJ
O	NN

analysis	NN
O	NN

of	IN
O	NN

intrauterine	JJ
O	NN

pressure	NN
O	NN

data	NNS
O	NN

Intracranial	JJ
D	NN

teratomas	NNS
D	NN

in	IN
O	NN

fetal	JJ
O	NN

life	NN
O	NN

and	CC
O	NN

infancy	NN
O	NN

Twinning	VBG
O	NN

in	IN
O	NN

relation	NN
O	NN

to	TO
O	NN

birth	NN
O	NN

weight	NN
O	NN

,	,
O	NN

mortality	NN
O	NN

,	,
O	NN

and	CC
O	NN

congenital	JJ
D	NN

anomalies	NNS
D	NN

Breast	NN
O	NN

engorgement	NN
O	NN

and	CC
O	NN

postpartum	NN
D	NN

fever	NN
D	NN

Evolution	NN
O	NN

of	IN
O	NN

a	DT
O	NN

placenta	NN
O	NN

circumvallata	NN
O	NN

Sequential	JJ
O	NN

estrogen-progestogen	JJ
T	NN

therapy	NN
T	NN

in	IN
O	NN

gynecology	NN
O	NN

Ovarian	JJ
D	NN

carcinoma	NN
D	NN

The	DT
O	NN

problems	NNS
O	VBP

of	IN
O	NN

staging	NN
O	NN

and	CC
O	NN

grading	VBG
O	NN

Oxytocin	NN
O	NN

induction	NN
O	NN

in	IN
O	NN

pregnant	JJ
O	NN

rabbits	NNS
O	NN

,	,
O	NN

with	IN
O	NN

special	JJ
O	NN

reference	NN
O	NN

to	TO
O	NN

the	DT
O	NN

stillbirth	NN
O	NN

rate	NN
O	NN

Significance	NN
O	NN

of	IN
O	NN

a	DT
O	NN

single	JJ
O	NN

umbilical	JJ
O	NN

artery	NN
O	NN

Report	NNP
O	NNP

from	IN
O	NN

the	DT
O	NN

collaborative	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

cerebral	JJ
O	NN

palsy	NN
O	NN

Perforated	JJ
D	NN

peptic	JJ
D	NN

ulcer	NN
D	NN

in	IN
O	NN

pregnancy	NN
O	NN

Poverty	NN
O	NN

as	IN
O	NN

an	DT
O	NN

isolated	VBN
O	NN

factor	NN
O	NN

in	IN
O	NN

relation	NN
O	NN

to	TO
O	NN

perinatal	JJ
D	NN

asphyxia	NN
D	NN

Perforation	NN
D	NN

of	IN
D	NN

the	DT
D	NN

postpartum	NN
D	NN

uterus	NN
D	NN

with	IN
O	NN

an	DT
O	NN

intrauterine	JJ
O	NN

contraceptive	JJ
O	NN

device	NN
O	NN

Congenital	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

,	,
O	NN

deaf-mutism	NN
D	NN

and	CC
O	NN

associated	VBN
D	NN

somatic	JJ
D	NN

malformations	NNS
D	NN

occurring	VBG
O	NN

in	IN
O	NN

several	JJ
O	NN

members	NNS
O	NN

of	IN
O	NN

one	CD
O	NN

family	NN
O	NN

Toward	IN
O	NN

a	DT
O	NN

community	NN
O	NN

alcoholism	NN
O	NN

program	NN
O	NN

Cases	NNS
O	NN

8	CD
O	NN

and	CC
O	NN

9	CD
O	NN

Anesthesia	NNP
T	NN

accidents	NNS
O	NN

Gynaecological	JJ
O	NN

pain	NN
O	NN

Profileplasty	JJ
T	NN

Hypertrophic	JJ
O	NN

obstructive	JJ
O	NN

cardiomyopathy	NN
D	NN

Oral	JJ
T	NN

contraceptives	NNS
T	NN

,	,
O	NN

thrombosis	NN
D	NN

,	,
O	NN

and	CC
O	NN

cyclical	JJ
O	NN

factors	NNS
O	NN

affecting	VBG
O	NN

veins	NNS
O	VBP

.	.
O	NN

On	IN
O	NN

the	DT
O	NN

influence	NN
O	NN

of	IN
O	NN

cytostatic	JJ
O	NN

agents	NNS
O	NN

and	CC
O	NN

immune	JJ
O	NN

bodies	NNS
O	NN

on	IN
O	NN

choriocarcinoma	NN
O	NN

cells	NNS
O	VBP

in	IN
O	NN

tissue	NN
O	NN

culture	NN
O	NN

Fat	NNP
O	NNP

absorption	NN
O	NN

:	:
O	NN

a	DT
O	NN

transport	NN
O	NN

problem	NN
O	NN

Corpora	NNP
D	NNP

lutea	NN
D	NN

in	IN
O	NN

proven	JJ
O	NN

mules	NNS
O	NN

Reconstructive	JJ
O	NN

tubal	JJ
T	NN

surgery	NN
T	NN

Studies	NNS
O	VBP

on	IN
O	NN

the	DT
O	NN

natural	JJ
O	NN

posterior	JJ
O	NN

pituitary	JJ
O	NN

hormones	NNS
O	NN

II	NNP
O	NNP

On	IN
O	NN

the	DT
O	NN

official	JJ
O	NN

inspection	NN
O	NN

of	IN
O	NN

coal-tar	JJ
O	NN

dyes	NNS
O	NN

in	IN
O	NN

1969	CD
O	NN

3	CD
O	NN

Analysis	NN
O	NN

of	IN
O	NN

Cr	NN
O	NN

,	,
O	NN

Zn	NN
O	NN

,	,
O	NN

Fe	NNP
O	NNP

and	CC
O	NN

Pb	NN
O	NN

contaminants	NNS
O	NN

in	IN
O	NN

food	NN
O	NN

coal-tar	JJ
O	NN

dyes	NNS
O	NN

and	CC
O	NN

their	PRP$
O	NN

aluminium	NN
O	NN

lakes	NN
O	NN

by	IN
O	NN

atomic	JJ
O	NN

absorption	NN
O	NN

spectrophotometry	NN
O	NN

Radiosterilization	NN
O	NN

of	IN
O	NN

medical	JJ
O	NN

products	NNS
O	NN

I	PRP
O	VBP

.	.
O	NN

Effects	NNS
O	NN

of	IN
O	NN

radiation	NN
O	NN

on	IN
O	NN

physical	JJ
O	NN

and	CC
O	NN

chemical	NN
O	NN

properties	NNS
O	NN

of	IN
O	NN

injection	NN
O	NN

needles	NNS
O	NN

Screening	VBG
O	NN

tests	NNS
O	NN

of	IN
O	NN

microorganisms	NNS
O	NN

for	IN
O	NN

the	DT
O	NN

microbial	JJ
O	NN

transformation	NN
O	NN

of	IN
O	NN

griseophenone	NN
O	NN

A	DT
O	NN

,	,
O	NN

N-methylcoclaurine	NN
O	NN

and	CC
O	NN

sparteine	NN
O	NN

Gas	NN
O	NN

chromatographic	JJ
O	NN

studies	NNS
O	VBP

on	IN
O	NN

organic	JJ
O	NN

mercurials	NNS
O	NN

Application	NN
O	NN

of	IN
O	NN

infra-red	JJ
O	NN

absorption	NN
O	NN

spectroscopy	NN
O	NN

to	TO
O	NN

examination	NN
O	NN

of	IN
O	NN

drugs	NNS
O	NN

and	CC
O	NN

their	PRP$
O	NN

preparation	NN
O	NN

XIX	NNP
O	NNP

Determination	NN
O	NN

of	IN
O	NN

silicone	NN
O	NN

oil	NN
O	NN

in	IN
O	NN

disposable	JJ
O	NN

plastic	JJ
O	NN

syringes	NNS
O	NN

Observation	NN
O	NN

of	IN
O	NN

air	NN
O	NN

pollution	NN
O	NN

with	IN
O	NN

the	DT
O	NN

aid	NN
O	NN

of	IN
O	NN

continuous	JJ
O	NN

analysers	NNS
O	NN

3	CD
O	NN

Correlation	NN
O	NN

between	IN
O	NN

the	DT
O	NN

concentration	NN
O	NN

of	IN
O	NN

various	JJ
O	NN

kinds	NNS
O	NN

of	IN
O	NN

pollutants	NNS
O	NN

in	IN
O	NN

atmosphere	NN
O	NN

and	CC
O	NN

wind	NN
O	NN

direction	NN
O	NN

and	CC
O	NN

velocity	NN
O	NN

at	IN
O	NN

Kasumigaseki	NNP
O	NNP

,	,
O	NN

central	JJ
O	NN

district	NN
O	NN

of	IN
O	NN

Tokyo	NNP
O	NNP

Ultramicro-analysis	JJ
O	NN

of	IN
O	NN

cyclohexylamine	NN
O	NN

and	CC
O	NN

low	JJ
O	NN

fatty	JJ
O	NN

amines	NNS
O	NN

by	IN
O	NN

gas	NN
O	NN

chromatography	NN
O	NN

Some	DT
O	NN

knowledges	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

potency	NN
O	NN

of	IN
O	NN

heparin	NN
O	NN

fractions	NNS
O	NN

obtained	VBN
O	NN

by	IN
O	NN

gel	NN
O	NN

filtration	NN
O	NN

On	IN
O	NN

the	DT
O	NN

peripheral	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

endotoxin	NN
O	NN

and	CC
O	NN

leucocyte	NN
O	NN

pyrogen	NN
O	NN

in	IN
O	NN

rabbit	NN
O	NN

A	DT
O	NN

tentative	JJ
O	NN

draft	NN
O	NN

of	IN
O	NN

qualitative	JJ
O	NN

test	NN
O	NN

of	IN
O	NN

fluoride	NN
O	NN

for	IN
O	NN

adoption	NN
O	NN

to	TO
O	NN

the	DT
O	NN

general	JJ
O	NN

tests	NNS
O	NN

of	IN
O	NN

eighth	JJ
O	NN

revised	VBN
O	NN

edition	NN
O	NN

of	IN
O	NN

the	DT
O	NN

Pharmacopoeia	NNP
O	NNP

of	IN
O	NN

Japan	NNP
O	NNP

Identification	NN
O	NN

of	IN
O	NN

tranquillizers	NNS
T	NN

by	IN
O	NN

thin-layer	JJ
O	NN

chromatography	NN
O	NN

Analysis	NN
O	NN

of	IN
O	NN

steroids	NNS
O	NN

II	NNP
O	NNP

A	DT
O	NN

note	NN
O	NN

on	IN
O	NN

the	DT
O	NN

assay	NN
O	NN

of	IN
O	NN

corticoid	NN
O	NN

preparations	NNS
O	NN

by	IN
O	NN

tetrazolium	NN
O	NN

salt	NN
O	NN

Analysis	NN
O	NN

of	IN
O	NN

steroids	NNS
O	NN

3	CD
O	NN

Colorimetric	JJ
O	NN

assay	NN
O	NN

of	IN
O	NN

thiomesterone	NN
O	NN

Studies	NNS
O	VBP

on	IN
O	NN

the	DT
O	NN

radioimmunoassay	NN
O	NN

of	IN
O	NN

insulin	NN
T	NN

I	PRP
O	VBP

.	.
O	NN

The	DT
O	NN

production	NN
O	NN

and	CC
O	NN

detection	NN
O	NN

of	IN
O	NN

anti-insulin	JJ
O	NN

serum	NN
O	NN

and	CC
O	NN

anti-guinea-pig	JJ
O	NN

globulin	NN
O	NN

rabbit	NN
O	NN

serum	NN
O	NN

Synthesis	NN
O	NN

of	IN
O	NN

lysergic	JJ
O	NN

acid	NN
O	NN

diethylamide	NN
O	NN

(	NN
O	NN

LSD	NN
O	NN

)	NN
O	NN

Studies	NNS
O	VBP

on	IN
O	NN

the	DT
O	NN

anti-microbial	JJ
O	NN

activity	NN
O	NN

of	IN
O	NN

nonionic	JJ
O	NN

and	CC
O	NN

anionic	JJ
O	NN

surfactants	NNS
O	NN

On	IN
O	NN

the	DT
O	NN

National	NNP
O	NNP

Institute	NNP
O	NN

of	IN
O	NN

Hygienic	JJ
O	NN

Sciences	NNPS
O	NNP

Standard	JJ
O	NN

``	``
O	NN

lysozyme	NN
O	NN

standard	JJ
O	NN

''	''
O	NN

On	IN
O	NN

the	DT
O	NN

examination	NN
O	NN

of	IN
O	NN

ginseng	NN
O	NN

and	CC
O	NN

powdered	JJ
O	NN

ginseng	NN
O	NN

in	IN
O	NN

1969	CD
O	NN

On	IN
O	NN

the	DT
O	NN

standardization	NN
O	NN

of	IN
O	NN

plastic	JJ
T	NN

suture	NN
T	NN

Undergraduate	JJ
O	NN

research	NN
O	NN

assistants	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

Faculty	NN
O	NN

of	IN
O	NN

Medicine	NNP
O	NNP

University	NNP
O	NN

College	NNP
O	NNP

of	IN
O	NN

Rhodesia	NNP
O	NNP

Congenital	JJ
D	NN

aortic	JJ
D	NN

stenosis	NN
D	NN

Sodium	NN
O	NN

in	IN
O	NN

heart	NN
D	NN

failure	NN
D	NN

Potassium	NN
O	NN

in	IN
O	NN

heart	NN
D	NN

failure	NN
D	NN

Hydrogen	NN
O	NN

ion	NN
O	NN

equilibrium	NN
O	NN

in	IN
O	NN

heart	NN
D	NN

failure	NN
D	NN

Various	JJ
O	NN

aspects	NNS
O	NN

of	IN
O	NN

water-salt	JJ
O	NN

metabolism	NN
O	NN

in	IN
O	NN

heart	NN
D	NN

congestive	JJ
D	NN

failure	NN
D	NN

Clinical	JJ
O	NN

physiopathology	NN
O	NN

of	IN
O	NN

the	DT
O	NN

patency	NN
O	NN

of	IN
O	NN

the	DT
O	NN

interatrial	JJ
O	NN

septum	NN
O	NN

Various	JJ
O	NN

aspects	NNS
O	NN

of	IN
O	NN

diuresis	NN
D	NN

in	IN
O	NN

heart	NN
D	NN

congestive	JJ
D	NN

failure	NN
D	NN

Changes	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

mechanism	NN
O	NN

of	IN
O	NN

renal	JJ
O	NN

acidification	NN
O	NN

in	IN
O	NN

congestive	JJ
D	NN

heart	NN
D	NN

failure	NN
D	NN

:	:
O	NN

effects	NNS
O	NN

of	IN
O	NN

diuretic	JJ
T	NN

treatment	NN
T	NN

on	IN
O	NN

the	DT
O	NN

acid-base	NN
O	NN

equilibrium	NN
O	NN

Defects	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

interventricular	JJ
O	NN

septum	NN
O	NN

not	RB
O	NN

associated	VBN
O	NN

with	IN
O	NN

other	JJ
O	NN

malformations	NNS
O	NN

Clinical	JJ
O	NN

physiopathology	NN
O	NN

of	IN
O	NN

the	DT
O	NN

patency	NN
O	NN

of	IN
O	NN

Botallo	NN
D	NN

's	POS
D	NN

ductus	NN
D	NN

arteriosus	NN
D	NN

Clinical	JJ
O	NN

physiopathology	NN
O	NN

of	IN
O	NN

congenital	JJ
D	NN

cyanogenic	JJ
D	NN

cardiopathies	NNS
D	NN

Electronic	JJ
O	NN

computers	NNS
O	NN

in	IN
O	NN

medical	JJ
O	NN

education	NN
O	NN

of	IN
O	NN

the	DT
O	NN

future	JJ
O	NN

Anesthesiology	NNP
O	NNP

and	CC
O	NN

computers	NNS
O	NN

Immediate	NNP
O	NNP

outcome	NN
O	NN

and	CC
O	NN

long-term	JJ
O	NN

results	NNS
O	VBP

of	IN
O	NN

108	CD
O	NN

sphincterotomies	NNS
O	NN

of	IN
O	NN

Oddi	NNP
O	NNP

's	POS
O	NN

sphincter	NN
O	NN

of	IN
O	NN

biliary	JJ
O	NN

indication	NN
O	NN

Neuraminic	JJ
O	NN

acid-containing	JJ
O	NN

oligosaccharides	NNS
O	NN

of	IN
O	NN

human	JJ
O	NN

urine	NN
O	NN

:	:
O	NN

isolation	NN
O	NN

and	CC
O	NN

identification	NN
O	NN

of	IN
O	NN

di-N-acetylneuraminyl-3-galactosyl-N-acetylgalactosamine	NN
O	NN

,	,
O	NN

6-2-Nacetylneuraminyl-lactose	JJ
O	NN

,	,
O	NN

6-2-N-acetylneuraminyl-N-acetyllactosamine	JJ
O	NN

and	CC
O	NN

3-2-N-acetylneuraminyl-lactose	JJ
O	NN

Determination	NN
O	NN

of	IN
O	NN

serum	NN
O	NN

oxytocinase	NN
O	NN

(	NN
O	NN

1-cystine-aminopeptidase	JJ
O	NN

)	NN
O	NN

activity	NN
O	NN

Intolerance	NN
O	NN

to	TO
O	NN

milk	NN
O	NN

in	IN
O	NN

ulcerative	JJ
D	NN

colitis	NN
D	NN

A	DT
O	NN

preliminary	JJ
O	NN

report	NN
O	NN

Rhinitis	NN
D	NN

in	IN
O	NN

herds	NNS
O	NN

with	IN
O	NN

piglet	NN
D	NN

influenza	NN
D	NN

Research	NNP
O	NNP

on	IN
O	NN

breeding	VBG
O	NN

hygiene	NN
O	NN

in	IN
O	NN

pigs	NNS
O	NN

and	CC
O	NN

piglets	NNS
O	NN

free	JJ
O	NN

from	IN
O	NN

epidemic	JJ
D	NN

diseases	NNS
D	NN

The	DT
O	NN

stimulatory	JJ
O	NN

effect	NN
O	NN

of	IN
O	NN

luteinizing	VBG
O	NN

hormone	NN
O	NN

on	IN
O	NN

adenosine	NN
O	NN

3	CD
O	NN

'	POS
O	NN

,	,
O	NN

5'-monophosphate	JJ
O	NN

accumulation	NN
O	NN

in	IN
O	NN

corpus	NN
O	NN

luteum	NN
O	NN

slices	NNS
O	NN

Electrolyte	NN
O	NN

and	CC
O	NN

acid-base	NN
O	NN

balance	NN
O	NN

in	IN
O	NN

fetal	JJ
O	NN

and	CC
O	NN

maternal	JJ
O	NN

blood	NN
O	NN

An	DT
O	NN

experimental	JJ
O	NN

and	CC
O	NN

a	DT
O	NN

clinical	JJ
O	NN

study	NN
O	NN

Q	NNP
D	NNP

fever	NN
D	NN

at	IN
O	NN

a	DT
O	NN

combined	JJ
O	NN

meat	NN
O	NN

and	CC
O	NN

poultry	NN
O	NN

abattoir	NN
O	NN

Some	DT
O	NN

functional	JJ
O	NN

and	CC
O	NN

morphological	JJ
O	NN

alterations	NNS
O	VBP

occurring	VBG
O	NN

during	IN
O	NN

and	CC
O	NN

after	IN
O	NN

the	DT
O	NN

adaptation	NN
O	NN

of	IN
O	NN

BHK	NNP
O	NNP

21	CD
O	NN

clone	NN
O	NN

13	CD
O	NN

cells	NNS
O	VBP

to	TO
O	NN

suspension	NN
O	NN

culture	NN
O	NN

Asbestos	NN
O	NN

as	IN
O	NN

an	DT
O	NN

urban	JJ
O	NN

air	NN
O	NN

contaminant	NN
O	NN

Gas	NN
O	NN

permeability	NN
O	NN

of	IN
O	NN

plastic	JJ
O	NN

membranes	NNS
O	NN

for	IN
O	NN

artificial	JJ
T	NN

lungs	NNS
T	NN

Technoogy	JJ
O	NN

,	,
O	NN

automation	NN
O	NN

and	CC
O	NN

human	JJ
O	NN

welfare	NN
O	NN

A	DT
O	NN

radium	NN
O	NN

accident	NN
O	NN

in	IN
O	NN

a	DT
O	NN

hospital	NN
O	NN

High	JJ
O	NN

energy	NN
O	NN

roentgen	NN
O	NN

ray	NN
O	NN

contamination	NN
O	NN

of	IN
O	NN

the	DT
O	NN

electron	NN
O	NN

beam	NN
O	NN

from	IN
O	NN

a	DT
O	NN

medical	JJ
O	NN

betatron	NN
O	NN

The	DT
O	NN

genetically	RB
O	NN

significant	JJ
O	NN

dose	NN
O	NN

from	IN
O	NN

roentgen	NN
O	NN

examinations	NNS
O	VBP

in	IN
O	NN

Finland	NNP
O	NNP

in	IN
O	NN

1963	CD
O	NN

Differential	JJ
O	NN

expression	NN
O	NN

of	IN
O	NN

fibroblast	NN
O	NN

growth	NN
O	NN

factor-2	NN
O	NN

and	CC
O	NN

receptor	NN
O	NN

by	IN
O	NN

glial	JJ
O	NN

cells	NNS
O	VBP

in	IN
O	NN

experimental	JJ
O	NN

autoimmune	JJ
D	NN

encephalomelitis	NN
D	NN

(	NN
D	NN

EAE	NN
D	NN

)	NN
D	NN

Cesarean	JJ
O	NN

deliveries	NNS
O	NN

at	IN
O	NN

a	DT
O	NN

university	NN
O	NN

hospital	NN
O	NN

:	:
O	NN

analysis	NN
O	NN

of	IN
O	NN

rates	NNS
O	VBP

and	CC
O	NN

indications	NNS
O	NN

Increase	NN
O	NN

in	IN
O	NN

ambient	JJ
O	NN

temperature	NN
O	NN

may	MD
O	NNP

explain	VB
O	NN

decrease	NN
O	NN

in	IN
O	NN

amniotic	JJ
O	NN

fluid	NN
O	NN

index	NN
O	NN

Early	RB
O	NN

treatment	NN
O	NN

of	IN
O	NN

gestational	JJ
D	NN

diabetes	NN
D	NN

reduces	VBZ
O	NN

the	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

fetal	JJ
D	NN

macrosomia	NN
D	NN

Antenatally	RB
O	NN

detectable	JJ
O	NN

markers	NNS
O	VBP

for	IN
O	NN

the	DT
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

autosomally	RB
D	NN

trisomic	JJ
D	NN

fetuses	NNS
D	NN

in	IN
O	NN

at-risk	JJ
O	NN

pregnancies	NNS
O	NN

The	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

severe	JJ
O	NN

preeclampsia	NN
D	NN

is	VBZ
O	NN

increased	VBN
O	NN

in	IN
O	NN

triplet	NN
O	NN

as	IN
O	NN

compared	VBN
O	NN

to	TO
O	NN

twin	JJ
O	NN

gestations	NNS
O	VBP

Thermal	JJ
O	NN

equipment	NN
O	NN

usage	NN
O	NN

patterns	NNS
O	VBP

in	IN
O	NN

neonatal	JJ
O	NN

intensive	JJ
O	NN

care	NN
O	NN

units	NNS
O	NN

:	:
O	NN

interunit	NN
O	NN

variability	NN
O	NN

and	CC
O	NN

intraunit	JJ
O	NN

consistency	NN
O	NN

Massive	JJ
O	NN

fetomaternal	JJ
D	NN

hemorrhage	NN
D	NN

Perinatal	JJ
O	NN

features	NNS
O	VBP

of	IN
O	NN

omphalocele-exstrophy-imperforate	JJ
D	NN

anus-spinal	JJ
D	NN

defects	NNS
D	NN

(	NN
D	NN

OEIS	NN
D	NN

complex	NN
D	NN

)	NN
D	NN

associated	VBN
O	NN

with	IN
O	NN

large	JJ
O	NN

meningomyeloceles	NNS
D	NN

and	CC
O	NN

severe	JJ
D	NN

limb	NN
D	NN

defects	NNS
D	NN

Subchorial	JJ
D	NN

hematoma	NN
D	NN

:	:
O	NN

a	DT
O	NN

probable	JJ
O	NN

cause	NN
O	NN

of	IN
O	NN

reversible	JJ
O	NN

nonimmune	JJ
O	NN

hydrops	NNS
O	NN

fetalis	NN
D	NN

Pregnancy	NN
O	NN

in	IN
O	NN

chronic	JJ
O	NN

progressive	JJ
O	NN

external	JJ
O	NN

ophthalmoplegia	NN
D	NN

:	:
O	NN

a	DT
O	NN

case	NN
O	NN

report	NN
O	NN

Effect	NN
O	NN

of	IN
O	NN

magnesium	NN
O	NN

sulfate	NN
O	NN

on	IN
O	NN

the	DT
O	NN

development	NN
O	NN

of	IN
O	NN

cystic	JJ
O	NN

periventricular	JJ
O	NN

leukomalacia	NN
D	NN

in	IN
O	NN

preterm	NN
O	NN

infants	NNS
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Repeated	JJ
O	NN

courses	NNS
O	NN

of	IN
O	NN

steroids	NNS
O	NN

in	IN
O	NN

preterm	NN
O	NN

membrane	NN
O	NN

rupture	NN
O	NN

do	VB
O	NNP

not	RB
O	NN

increase	NN
O	NN

the	DT
O	NN

risk	NN
O	NN

of	IN
O	NN

histologic	JJ
O	NN

chorioamnionitis	NN
O	NN

Intrapartum	NNP
O	NNP

sonography	NN
O	NN

of	IN
O	NN

the	DT
O	NN

lower	JJR
O	NN

uterine	JJ
O	NN

segment	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

breech-presenting	JJ
O	NN

fetuses	NNS
O	NN

Isolated	VBN
O	NN

persistent	JJ
O	NN

fetal	JJ
O	NN

bradycardia	NN
O	NN

in	IN
O	NN

complete	JJ
O	NN

A-V	NN
O	NN

block	NN
O	NN

:	:
O	NN

a	DT
O	NN

conservative	JJ
O	NN

approach	NN
O	NN

is	VBZ
O	NN

appropriate	JJ
O	NN

A	DT
O	NN

case	NN
O	NN

report	NN
O	NN

and	CC
O	NN

a	DT
O	NN

review	NN
O	NN

of	IN
O	NN

the	DT
O	NN

literature	NN
O	NN

Spontaneous	JJ
O	NN

rectus	NN
D	NN

sheath	NN
D	NN

hematoma	NN
D	NN

during	IN
O	NN

pregnancy	NN
O	NN

mimicking	VBG
O	NN

abruptio	NN
D	NN

placenta	NN
D	NN

Amnioinfusion	NN
T	NN

for	IN
O	NN

prevention	NN
O	NN

of	IN
O	NN

pulmonary	JJ
D	NN

hypoplasia	NN
D	NN

in	IN
O	NN

second-trimester	NN
O	NN

rupture	NN
O	NN

of	IN
O	NN

membranes	NNS
O	NN

Trauma	FW
O	FW

and	CC
O	NN

pregnancy	NN
O	NN

Fetal	JJ
O	NN

breathing	VBG
O	NN

movements	NNS
O	VBP

within	IN
O	NN

24	CD
O	NN

hours	NNS
O	NN

of	IN
O	NN

delivery	NN
O	NN

in	IN
O	NN

prematurity	NN
O	NN

are	VBP
O	NN

related	JJ
O	NN

to	TO
O	NN

histologic	JJ
O	NN

and	CC
O	NN

clinical	JJ
O	NN

evidence	NN
O	NN

of	IN
O	NN

amnionitis	NN
D	NN

Laerdal	JJ
O	NN

infant	NN
O	NN

resuscitators	NNS
O	NN

are	VBP
O	NN

unreliable	JJ
O	NN

as	IN
O	NN

free-flow	JJ
O	NN

oxygen	NN
O	NN

delivery	NN
O	NN

devices	NNS
O	NN

Laryngeal	NN
D	NN

obstruction	NN
D	NN

caused	VBN
O	NN

by	IN
O	NN

lingual	NN
D	NN

thyroglossal	NN
D	NN

duct	NN
D	NN

cyst	NN
D	NN

presenting	VBG
O	NN

at	IN
O	NN

birth	NN
O	NN

Oligohydramnios	JJ
O	NN

and	CC
O	NN

the	DT
O	NN

appropriately	RB
O	NN

grown	VBN
O	NN

fetus	NN
O	NN

Ultrastructure	NN
O	NN

of	IN
O	NN

human	JJ
O	NN

colostral	JJ
O	NN

cells	NNS
O	VBP

Dubowitz	NNP
O	NNP

assessment	NN
O	NN

of	IN
O	NN

gestational	JJ
O	NN

age	NN
O	NN

and	CC
O	NN

agreement	NN
O	NN

with	IN
O	NN

prenatal	JJ
O	NN

methods	NNS
O	VBP

Low	JJ
O	NN

prenatal	JJ
O	NN

weight	NN
O	NN

gain	NN
O	NN

among	IN
O	NN

low-income	JJ
O	NN

women	NNS
O	VBP

:	:
O	NN

what	WDT
O	NN

are	VBP
O	NN

the	DT
O	NN

risk	NN
O	NN

factors	NNS
O	NN

?	.
O	NN

Depression	NN
D	NN

after	IN
O	NN

childbirth	NN
O	NN

:	:
O	NN

the	DT
O	NN

views	NNS
O	NN

of	IN
O	NN

medical	JJ
O	NN

students	NNS
O	NN

and	CC
O	NN

women	NNS
O	VBP

compared	VBN
O	NN

Breastfeeding	VBG
O	NN

and	CC
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

pacifiers	NNS
O	NN

Care	NNP
O	NNP

in	IN
O	NN

normal	JJ
O	NN

birth	NN
O	NN

:	:
O	NN

a	DT
O	NN

practical	JJ
O	NN

guide	NN
O	NN

Technical	NNP
O	NNP

Working	VBG
O	NN

Group	NNP
O	NNP

,	,
O	NN

World	NNP
O	NNP

Health	NNP
O	NNP

Organization	NNP
O	NNP

Cesarean	JJ
O	NN

sections	NNS
O	NN

:	:
O	NN

women	NNS
O	VBP

's	POS
O	NN

choice	NN
O	NN

for	IN
O	NN

giving	VBG
O	NN

birth	NN
O	NN

?	.
O	NN

Epidurals	NNS
T	NN

and	CC
O	NN

breastfeeding	VBG
O	NN

Lamaze	NN
O	NN

and	CC
O	NN

Bradley	NNP
O	NNP

childbirth	NN
O	NN

classes	NNS
O	NN

Concerns	NNS
O	NN

about	IN
O	NN

the	DT
O	NN

institutionalization	NN
O	NN

of	IN
O	NN

childbirth	NN
O	NN

education	NN
O	NN

Index	NNP
O	NNP

to	TO
O	NN

current	JJ
O	NN

literature	NN
O	NN

A	DT
O	NN

randomized	VBN
O	NN

trial	NN
O	NN

of	IN
O	NN

one-to-one	JJ
O	NN

nurse	NN
O	NN

support	NN
O	NN

of	IN
O	NN

women	NNS
O	VBP

in	IN
O	NN

labor	NN
O	NN

Commentary	JJ
O	NN

:	:
O	NN

are	VBP
O	NN

nurses	NNS
O	NN

effective	JJ
O	NN

providers	NNS
O	NN

of	IN
O	NN

labor	NN
O	NN

support	NN
O	NN

?	.
O	NN

Should	MD
O	NNP

they	PRP
O	VBP

be	VB
O	NN

?	.
O	NN

Can	MD
O	NNP

they	PRP
O	VBP

be	VB
O	NN

?	.
O	NN

Women	NNS
O	VBP

's	POS
O	NN

views	NNS
O	NN

of	IN
O	NN

different	JJ
O	NN

models	NNS
O	NN

of	IN
O	NN

antenatal	JJ
O	NN

care	NN
O	NN

in	IN
O	NN

Victoria	NNP
O	NNP

,	,
O	NN

Australia	NNP
O	NN

The	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

discharge	NN
O	NN

pack	NN
O	NN

formula	NN
O	NN

and	CC
O	NN

breast	NN
O	NN

pumps	NNS
O	NN

on	IN
O	NN

breastfeeding	VBG
O	NN

duration	NN
O	NN

and	CC
O	NN

choice	NN
O	NN

of	IN
O	NN

infant	NN
O	NN

feeding	VBG
O	NN

method	NN
O	NN

Commentary	JJ
O	NN

:	:
O	NN

discharge	NN
O	NN

packs	NNS
O	VBP

:	:
O	NN

how	WRB
O	NN

much	RB
O	NN

do	VB
O	NNP

they	PRP
O	VBP

matter	NN
O	NN

?	.
O	NN

Quality	JJ
O	NN

framework	NN
O	NN

for	IN
O	NN

force	NN
O	NN

plate	NN
O	NN

testing	NN
O	NN

Bone	NN
O	NN

registration	NN
O	NN

method	NN
O	NN

for	IN
O	NN

robot	NN
T	NN

assisted	VBN
T	NN

surgery	NN
T	NN

:	:
O	NN

pedicle	NN
O	NN

screw	VB
O	NN

insertion	NN
O	NN

Parameter	NN
O	NN

sensitivity	NN
O	NN

of	IN
O	NN

a	DT
O	NN

mathematical	JJ
O	NN

model	NN
O	NN

of	IN
O	NN

the	DT
O	NN

anterior	JJ
O	NN

cruciate	JJ
O	NN

ligament	NN
O	NN

Simultaneous	JJ
O	NN

measurement	NN
O	NN

of	IN
O	NN

stiffness	NN
O	NN

and	CC
O	NN

energy	NN
O	NN

absorptive	JJ
O	NN

properties	NNS
O	NN

of	IN
O	NN

articular	JJ
O	NN

cartilage	NN
O	NN

and	CC
O	NN

subchondral	JJ
O	NN

trabecular	JJ
O	NN

bone	NN
O	NN

Estimation	NN
O	NN

of	IN
O	NN

loads	NNS
O	NN

and	CC
O	NN

stresses	NNS
O	VBP

in	IN
O	NN

abdominal	JJ
O	NN

muscles	NNS
O	NN

during	IN
O	NN

slow	JJ
O	NN

lifts	NNS
O	VBP

Contralateral	JJ
O	NN

modification	NN
O	NN

of	IN
O	NN

transitory	JJ
O	NN

evoked	VBN
O	NN

otoacoustic	JJ
O	NN

emissions	NNS
O	NN

Treatment	NN
O	NN

of	IN
O	NN

cavernous	JJ
D	NN

hemangiomas	NN
D	NN

with	IN
O	NN

the	DT
O	NN

neodymium	NN
T	NN

:	:
T	NN

YAG	NN
T	NN

laser	NN
T	NN

Mucous	JJ
D	NN

membrane	NN
D	NN

melanomas	NNS
D	NN

of	IN
O	NN

the	DT
O	NN

upper	JJ
O	NN

aerodigestive	JJ
O	NN

tract	NN
O	NN

An	DT
O	NN

analysis	NN
O	NN

of	IN
O	NN

34	CD
O	NN

cases	NNS
O	NN

Are	VBP
O	NN

the	DT
O	NN

products	NNS
O	NN

of	IN
O	NN

CD44	NN
O	NN

exons	NNS
O	NN

v5	NN
O	NN

and	CC
O	NN

v6	NN
O	NN

markers	NNS
O	VBP

for	IN
O	NN

metastasis	NN
O	NN

of	IN
O	NN

laryngeal	NN
D	NN

carcinomas	NNS
D	NN

?	.
O	NN

Detection	NN
O	NN

of	IN
O	NN

differentially	RB
O	NN

expressed	VBN
O	NN

genes	NNS
O	NN

in	IN
O	NN

head-neck	NN
D	NN

carcinomas	NNS
D	NN

Tuberculosis	NN
D	NN

of	IN
O	NN

the	DT
O	NN

parotid	NN
O	NN

gland	NN
O	NN

:	:
O	NN

a	DT
O	NN

rare	JJ
O	NN

differential	JJ
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

parotid	NN
D	NN

tumor	NN
D	NN

A	DT
O	NN

case	NN
O	NN

of	IN
O	NN

sarcoidosis	NN
D	NN

of	IN
O	NN

the	DT
O	NN

mastoid	JJ
O	NN

Genomic	JJ
O	NN

medicine	NN
O	NN

Internet	NN
O	NN

resources	NNS
O	NN

for	IN
O	NN

medical	JJ
O	NN

genetics	NNS
O	NN

Genetics	NNP
O	NNP

A	DT
O	NN

piece	NN
O	NN

of	IN
O	NN

my	PRP$
O	NN

mind	NN
O	NN

A	DT
O	NN

'normal	JJ
O	NN

'	POS
O	NN

practice	NN
O	NN

Predisposition	NN
O	NN

genetic	JJ
O	NN

testing	NN
O	NN

for	IN
O	NN

late-onset	NN
D	NN

disorders	NNS
D	NN

in	IN
O	NN

adults	NNS
O	NN

A	DT
O	NN

position	NN
O	NN

paper	NN
O	NN

of	IN
O	NN

the	DT
O	NN

National	NNP
O	NNP

Society	NNP
O	NNP

of	IN
O	NN

Genetic	JJ
O	NN

Counselors	NNS
O	VBP

Scientists	NNS
O	NN

revel	VB
O	NN

in	IN
O	NN

new	JJ
O	NN

research	NN
O	NN

tool	NN
O	NN

:	:
O	NN

an	DT
O	NN

online	JJ
O	NN

index	NN
O	NN

of	IN
O	NN

cancer	NN
O	NN

genes	NNS
O	NN

Center	NNP
O	NNP

for	IN
O	NN

genetic	JJ
O	NN

research	NN
O	NN

on	IN
O	NN

scleroderma	NN
D	NN

As	IN
O	NN

discoveries	NNS
O	NN

unfold	VB
O	NN

,	,
O	NN

a	DT
O	NN

new	JJ
O	NN

urgency	NN
O	NN

to	TO
O	NN

bring	VB
O	NN

genetic	JJ
O	NN

literacy	NN
O	NN

to	TO
O	NN

physicians	NNS
O	NN

>	JJR
O	NN

From	IN
O	NN

the	DT
O	NN

Centers	NNPS
O	NNP

for	IN
O	NN

Disease	NN
O	NN

Control	NN
O	NN

and	CC
O	NN

Prevention	NNP
O	NNP

Gonorrhea	NN
D	NN

among	IN
O	NN

men	NNS
O	NN

who	WP
O	VBP

have	VB
O	NN

sex	NN
O	NN

with	IN
O	NN

men	NNS
O	NN

--	:
O	NN

selected	VBN
O	NN

sexually	RB
O	NN

transmitted	JJ
O	NN

diseases	NNS
O	NN

clinics	NNS
O	NN

,	,
O	NN

1993-1996	CD
O	NN

>	JJR
O	NN

From	IN
O	NN

the	DT
O	NN

Centers	NNPS
O	NNP

for	IN
O	NN

Disease	NN
O	NN

Control	NN
O	NN

and	CC
O	NN

Prevention	NNP
O	NNP

Chlamydia	NN
D	NN

screening	VBG
O	NN

practices	NNS
O	VBP

of	IN
O	NN

primary-care	JJ
O	NN

providers	NNS
O	NN

--	:
O	NN

Wake	VB
O	NN

County	NNP
O	NNP

,	,
O	NN

North	NNP
O	NNP

Carolina	NNP
O	NNP

,	,
O	NN

1996	CD
O	NN

Social	NNP
O	NNP

ties	NNS
O	NN

and	CC
O	NN

susceptibility	NN
O	NN

to	TO
O	NN

the	DT
O	NN

common	JJ
D	NN

cold	JJ
D	NN

Prevention	NNP
O	NNP

of	IN
O	NN

bacterial	JJ
D	NN

endocarditis	NN
D	NN

:	:
O	NN

American	JJ
O	NN

Heart	NNP
O	NNP

Association	NNP
O	NN

recommendations	NNS
O	NN

Issues	NNS
O	VBP

regarding	VBG
O	NN

antiretroviral	JJ
T	NN

treatment	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

HIV-1	NN
D	NN

infection	NN
D	NN

Prescribing	VBG
O	NN

protease	NN
T	NN

inhibitors	NNS
T	NN

for	IN
O	NN

the	DT
O	NN

homeless	JJ
O	NN

Treatment	NN
O	NN

of	IN
O	NN

verruca	NN
D	NN

vulgaris	NN
D	NN

with	IN
O	NN

topical	JJ
T	NN

cidofovir	NN
T	NN

Complete	JJ
O	NN

genomic	JJ
O	NN

screen	NN
O	NN

in	IN
O	NN

late-onset	JJ
O	NN

familial	JJ
O	NN

Alzheimer	NN
D	NN

disease	NN
D	NN

Evidence	NN
O	NN

for	IN
O	NN

a	DT
O	NN

new	JJ
O	NN

locus	NN
O	NN

on	IN
O	NN

chromosome	NN
O	NN

12	CD
O	NN

BRCA1	NN
O	NN

sequence	NN
O	NN

analysis	NN
O	NN

in	IN
O	NN

women	NNS
O	VBP

at	IN
O	NN

high	JJ
O	NN

risk	NN
O	NN

for	IN
O	NN

susceptibility	NN
O	NN

mutations	NNS
O	VBP

Risk	NN
O	NN

factor	NN
O	NN

analysis	NN
O	NN

and	CC
O	NN

implications	NNS
O	VBP

for	IN
O	NN

genetic	JJ
O	NN

testing	NN
O	NN

Characteristics	NNS
O	NN

of	IN
O	NN

prostate	NN
D	NN

cancer	NN
D	NN

in	IN
O	NN

families	NNS
O	NN

potentially	RB
O	NN

linked	VBN
O	NN

to	TO
O	NN

the	DT
O	NN

hereditary	JJ
O	NN

prostate	NN
O	NN

cancer	NN
O	NN

1	CD
O	NN

(	NN
O	NN

HPC1	NN
O	NN

)	NN
O	NN

locus	NN
O	NN

Chromosome	NN
O	NN

19	CD
O	NN

single-locus	NN
O	NN

and	CC
O	NN

multilocus	NN
O	NN

haplotype	NN
O	NN

associations	NNS
O	NN

with	IN
O	NN

multiple	JJ
D	NN

sclerosis	NN
D	NN

Evidence	NN
O	NN

of	IN
O	NN

a	DT
O	NN

new	JJ
O	NN

susceptibility	NN
O	NN

locus	NN
O	NN

in	IN
O	NN

Caucasian	JJ
O	NN

and	CC
O	NN

Chinese	JJ
O	NN

patients	NNS
O	NN

Cancer	NN
D	NN

incidence	NN
O	NN

after	IN
O	NN

retinoblastoma	NN
D	NN

Radiation	NNP
O	NN

dose	NN
O	NN

and	CC
O	NN

sarcoma	NN
O	NN

risk	NN
O	NN

Genetic	JJ
O	NN

testing	NN
O	NN

in	IN
O	NN

hereditary	JJ
O	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

Molecular	JJ
O	NN

neurogenetics	NNS
O	NN

:	:
O	NN

the	DT
O	NN

genome	NN
O	NN

is	VBZ
O	NN

settling	VBG
O	NN

the	DT
O	NN

issue	NN
O	NN

Family	NNP
O	NNP

history	NN
O	NN

and	CC
O	NN

genetic	JJ
O	NN

risk	NN
O	NN

factors	NNS
O	NN

:	:
O	NN

forward	RB
O	NN

to	TO
O	NN

the	DT
O	NN

future	JJ
O	NN

Preparing	VBG
O	NN

health	NN
O	NN

professionals	NNS
O	VBP

for	IN
O	NN

the	DT
O	NN

genetic	JJ
O	NN

revolution	NN
O	NN

Preterm	NNP
O	NNP

premature	JJ
O	NN

rupture	NN
D	NN

of	IN
D	NN

the	DT
D	NN

membranes	NNS
D	NN

associated	VBN
O	NN

with	IN
O	NN

recent	JJ
O	NN

cocaine	NN
O	NN

use	NN
O	NN

Attitudes	NNS
O	NN

toward	IN
O	NN

health-care	NN
O	NN

,	,
O	NN

HIV	NN
D	NN

infection	NN
D	NN

,	,
O	NN

and	CC
O	NN

perinatal	JJ
O	NN

transmission	NN
O	NN

interventions	NNS
O	VBP

in	IN
O	NN

a	DT
O	NN

cohort	NN
O	NN

of	IN
O	NN

inner-city	JJ
O	NN

,	,
O	NN

pregnant	JJ
O	NN

women	NNS
O	VBP

Association	NNP
O	NN

of	IN
O	NN

parvovirus	NN
D	NN

infection	NN
D	NN

with	IN
O	NN

isolated	VBN
O	NN

fetal	JJ
O	NN

effusions	NNS
O	NN

Early	RB
O	NN

and	CC
O	NN

long-term	JJ
O	NN

results	NNS
O	VBP

of	IN
O	NN

rehabilitation	NN
O	NN

of	IN
O	NN

cochlear	JJ
T	NN

implant	VB
T	NN

patients	NNS
O	NN

)	NN
O	NN

Principles	NNS
O	VBP

of	IN
O	NN

signal	NN
O	NN

detection	NN
O	NN

in	IN
O	NN

pharmacovigilance	NN
O	NN

Homology	NN
O	NN

modeling	NN
O	NN

of	IN
O	NN

adenylosuccinate	JJ
O	NN

synthetase	NN
O	NN

from	IN
O	NN

Saccharomyces	FW
O	FW

cerevisiae	FW
O	FW

reveals	VBZ
O	NN

a	DT
O	NN

possible	JJ
O	NN

binding	VBG
O	NN

region	NN
O	NN

for	IN
O	NN

single-stranded	JJ
O	NN

ARS	NN
O	NN

sequences	NNS
O	NN

Deletion	NN
O	NN

analysis	NN
O	NN

of	IN
O	NN

the	DT
O	NN

p16/CDKN2	NN
O	NN

gene	NN
O	NN

in	IN
O	NN

head	NN
O	NN

and	CC
O	NN

neck	NN
O	NN

squamous	JJ
O	NN

cell	NN
O	NN

carcinoma	NN
D	NN

using	VBG
O	NN

quantitative	JJ
O	NN

polymerase	NN
O	NN

chain	NN
O	NN

reaction	NN
O	NN

method	NN
O	NN

Ribosomal	JJ
O	NN

S6	NN
O	NN

kinase	NN
O	NN

p90rsk	NN
O	NN

and	CC
O	NN

mRNA	NN
O	NN

cap-binding	JJ
O	NN

protein	NN
O	NN

eIF4E	NN
O	NN

phosphorylations	NNS
O	NN

correlate	VB
O	NN

with	IN
O	NN

MAP	NN
O	NN

kinase	NN
O	NN

activation	NN
O	NN

during	IN
O	NN

meiotic	JJ
O	NN

reinitiation	NN
O	NN

of	IN
O	NN

mouse	NN
O	NN

oocytes	NNS
O	NN

Hyaluronidase	NN
O	NN

activity	NN
O	NN

of	IN
O	NN

macaque	JJ
O	NN

sperm	NN
O	NN

assessed	VBN
O	NN

by	IN
O	NN

an	DT
O	NN

in	IN
O	NN

vitro	FW
O	FW

cumulus	JJ
O	NN

penetration	NN
O	NN

assay	NN
O	NN

The	DT
O	NN

comparison	NN
O	NN

of	IN
O	NN

the	DT
O	NN

responsiveness	NN
O	NN

of	IN
O	NN

human	JJ
O	NN

isolated	VBN
O	NN

internal	JJ
O	NN

mammary	JJ
O	NN

and	CC
O	NN

gastroepiploic	JJ
O	NN

arteries	NNS
O	NN

to	TO
O	NN

levcromakalim	NN
O	NN

:	:
O	NN

an	DT
O	NN

alternative	JJ
O	NN

approach	NN
O	NN

to	TO
O	NN

the	DT
O	NN

management	NN
O	NN

of	IN
O	NN

graft	NN
O	NN

spasm	NN
O	NN

Single-dose	JJ
O	NN

pharmacokinetics	NNS
O	NN

of	IN
O	NN

felbamate	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

renal	JJ
O	NN

dysfunction	NN
O	NN

Reporting	NNP
O	NNP

of	IN
O	NN

adverse	JJ
O	NN

drug	NN
O	NN

reactions	NNS
O	NN

by	IN
O	NN

hospital	NN
O	NN

doctors	NNS
O	NN

and	CC
O	NN

the	DT
O	NN

response	NN
O	NN

to	TO
O	NN

intervention	NN
O	NN

Glutamate	JJ
O	NN

receptors	NNS
O	VBP

and	CC
O	NN

gene	NN
O	NN

induction	NN
O	NN

:	:
O	NN

signalling	NN
O	NN

from	IN
O	NN

receptor	NN
O	NN

to	TO
O	NN

nucleus	NN
O	NN

Role	NN
O	NN

of	IN
O	NN

phosphatidylinositol	NN
O	NN

3-kinase	NN
O	NN

in	IN
O	NN

degranulation	NN
O	NN

induced	VBN
O	NN

by	IN
O	NN

IgE-dependent	JJ
O	NN

and	CC
O	NN

-independent	JJ
O	NN

mechanisms	NNS
O	VBP

in	IN
O	NN

rat	NN
O	NN

basophilic	JJ
O	NN

RBL-2H3	NN
O	NN

(	NN
O	NN

ml	NN
O	NN

)	NN
O	NN

cells	NNS
O	VBP

Platelet-derived	JJ
O	NN

growth	NN
O	NN

factor	NN
O	NN

activates	VBZ
O	NN

a	DT
O	NN

mammalian	JJ
O	NN

Ste20	NN
O	NN

coupled	VBN
O	NN

mitogen-activated	JJ
O	NN

protein	NN
O	NN

kinase	NN
O	NN

in	IN
O	NN

airway	NN
O	NN

smooth	JJ
O	NN

muscle	NN
O	NN

Cyclic	JJ
O	NN

AMP	NN
O	NN

inhibitors	NNS
O	NN

inhibits	VBZ
O	NN

PDGF-stimulated	JJ
O	NN

mitogen-activated	JJ
O	NN

protein	NN
O	NN

kinase	NN
O	NN

activity	NN
O	NN

in	IN
O	NN

rat	NN
O	NN

aortic	JJ
O	NN

smooth	JJ
O	NN

muscle	NN
O	NN

cells	NNS
O	VBP

via	IN
O	NN

inactivation	NN
O	NN

of	IN
O	NN

c-Raf-1	NN
O	NN

kinase	NN
O	NN

and	CC
O	NN

induction	NN
O	NN

of	IN
O	NN

MAP	NN
O	NN

kinase	NN
O	NN

phosphatase-1	NN
O	NN

Mitochondrial	JJ
O	NN

cytopathies	NNS
O	NN

and	CC
O	NN

renal	JJ
D	NN

tubular	JJ
D	NN

acidosis	NN
D	NN

Elective	JJ
T	NN

surgery	NN
T	NN

for	IN
O	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

in	IN
O	NN

the	DT
O	NN

aged	JJ
O	NN

:	:
O	NN

a	DT
O	NN

clinical-economical	JJ
O	NN

evaluation	NN
O	NN

Leukaemia	NN
D	NN

and	CC
O	NN

non-Hodgkin	JJ
D	NN

's	POS
D	NN

lymphoma	NN
D	NN

in	IN
O	NN

children	NNS
O	VBP

and	CC
O	NN

young	JJ
O	NN

adults	NNS
O	NN

:	:
O	NN

are	VBP
O	NN

prenatal	JJ
O	NN

and	CC
O	NN

neonatal	JJ
O	NN

factors	NNS
O	NN

important	JJ
O	NN

determinants	NNS
O	NN

of	IN
O	NN

disease	NN
O	NN

?	.
O	NN

Inverse	JJ
O	NN

correlation	NN
O	NN

between	IN
O	NN

loss	NN
O	NN

of	IN
O	NN

heterozygosity	NN
O	NN

of	IN
O	NN

the	DT
O	NN

short	JJ
O	NN

arm	NN
O	NN

of	IN
O	NN

chromosome	NN
O	NN

12	CD
O	NN

and	CC
O	NN

p15ink4B/p16ink4	NN
O	NN

gene	NN
O	NN

inactivation	NN
O	NN

in	IN
O	NN

childhood	NN
D	NN

acute	JJ
D	NN

lymphoblastic	JJ
D	NN

leukaemia	NN
D	NN

Drug	NN
O	NN

resistance	NN
O	NN

markers	NNS
O	VBP

:	:
O	NN

are	VBP
O	NN

they	PRP
O	VBP

bad	JJ
O	NN

or	CC
O	NN

good	JJ
O	NN

?	.
O	NN

Elective	JJ
T	NN

surgery	NN
T	NN

for	IN
O	NN

gastrointestinal	JJ
D	NN

tumours	NNS
D	NN

in	IN
O	NN

the	DT
O	NN

elderly	JJ
O	NN

Folate	NNP
T	NN

and	CC
O	NN

heart	NN
D	NN

disease	NN
D	NN

:	:
O	NN

theoretical	JJ
O	NN

link	NN
O	NN

needs	NNS
O	VBP

study	NN
O	NN

.	.
O	NN

A	DT
O	NN

call	NN
O	NN

for	IN
O	NN

stepped-up	JJ
O	NN

melanoma	NN
D	NN

screening	VBG
O	NN

New	NNP
O	NNP

approaches	NNS
O	VBP

to	TO
O	NN

stroke	NN
D	NN

require	VB
O	NN

immediate	JJ
O	NN

action	NN
O	NN

The	DT
O	NN

focus	NN
O	NN

is	VBZ
O	NN

now	RB
O	NN

on	IN
O	NN

standards	NNS
O	NN

and	CC
O	NN

privacy	NN
O	NN

in	IN
O	NN

electronic	JJ
O	NN

patient	NN
O	NN

records	NNS
O	NN

Osteopathic	JJ
O	NN

manifesto	NN
O	NN

I	PRP
O	VBP

.	.
O	NN

Introduction	NN
O	NN

II	NNP
O	NNP

The	DT
O	NN

roots	NNS
O	NN

1981	CD
O	NN

Treatment	NN
O	NN

uncertainties	NNS
O	NN

surround	VB
O	NN

early	RB
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

breast	NN
D	NN

cancer	NN
D	NN

Depression	NN
D	NN

in	IN
O	NN

the	DT
O	NN

chronically	RB
O	NN

ill	RB
O	NN

needs	NNS
O	VBP

separate	JJ
O	NN

treatment	NN
O	NN

Medical	JJ
O	NN

centers	NNS
O	NN

tackle	VB
O	NN

delays	NNS
O	VBP

,	,
O	NN

reduce	VB
O	NN

wait	VB
O	NN

times	NNS
O	NN

Epilepsy	NNP
O	NN

and	CC
O	NN

attention	NN
O	NN

deficit	NN
O	NN

hyperactivity	NN
O	NN

disorder	NN
O	NN

:	:
O	NN

is	VBZ
O	NN

methylphenidate	NN
O	NN

safe	JJ
O	NN

and	CC
O	NN

effective	JJ
O	NN

?	.
O	NN

Applying	VBG
O	NN

the	DT
O	NN

AIDS	NN
D	NN

paradigm	NN
O	NN

to	TO
O	NN

hepatitis	NN
D	NN

New	NNP
O	NNP

asthma	NN
D	NN

guidelines	NNS
O	NN

emphasize	VB
O	NN

better	JJR
O	NN

diagnosis	NN
O	NN

,	,
O	NN

stricter	JJR
O	NN

control	NN
O	NN

Osteopathic	JJ
O	NN

manifesto	NN
O	NN

IV	CD
O	NN

The	DT
O	NN

search	NN
O	NN

1981	CD
O	NN

Researchers	NNP
O	NNP

puzzle	NN
O	NN

over	IN
O	NN

origin	NN
O	NN

of	IN
O	NN

type	NN
O	NN

2	CD
O	NN

diabetes	NN
D	NN

Ovarian	JJ
D	NN

cancer	NN
D	NN

:	:
O	NN

diagnostic	JJ
O	NN

limitations	NNS
O	NN

,	,
O	NN

treatment	NN
O	NN

obstacles	NNS
O	NN

Osteopathic	JJ
O	NN

manifesto	NN
O	NN

V	NN
O	NN

Legislative	JJ
O	NN

and	CC
O	NN

legal	JJ
O	NN

vigilance	NN
O	NN

1981	CD
O	NN

Osteopathic	JJ
O	NN

manifesto	NN
O	NN

VI	NNP
O	NNP

The	DT
O	NN

light	JJ
O	NN

of	IN
O	NN

the	DT
O	NN

profession	NN
O	NN

1981	CD
O	NN

Electrophysiological	JJ
O	NN

evidence	NN
O	NN

on	IN
O	NN

the	DT
O	NN

time	NN
O	NN

course	NN
O	NN

of	IN
O	NN

semantic	JJ
O	NN

and	CC
O	NN

phonological	JJ
O	NN

processes	NNS
O	VBP

in	IN
O	NN

speech	NN
O	NN

production	NN
O	NN

Effects	NNS
O	NN

of	IN
O	NN

alanine	NN
O	NN

and	CC
O	NN

glycine	NN
O	NN

substitution	NN
O	NN

for	IN
O	NN

tryptophan	NN
O	NN

on	IN
O	NN

the	DT
O	NN

heterogeneity	NN
O	NN

of	IN
O	NN

gramicidin	NN
O	NN

A	DT
O	NN

analogs	NNS
O	NN

in	IN
O	NN

micelles	NNS
O	NN

Torsion-angle	JJ
O	NN

molecular	JJ
O	NN

dynamics	NNS
O	NN

as	IN
O	NN

a	DT
O	NN

new	JJ
O	NN

efficient	JJ
O	NN

tool	NN
O	NN

for	IN
O	NN

NMR	NN
O	NN

structure	NN
O	NN

calculation	NN
O	NN

Time-domain	JJ
O	NN

quanification	NN
O	NN

of	IN
O	NN

amplitude	NN
O	NN

,	,
O	NN

chemical	NN
O	NN

shift	NN
O	NN

,	,
O	NN

apparent	JJ
O	NN

relaxation	NN
O	NN

time	NN
O	NN

T2	NN
O	NN

,	,
O	NN

and	CC
O	NN

phase	NN
O	NN

by	IN
O	NN

wavelet-transform	JJ
O	NN

analysis	NN
O	NN

Application	NN
O	NN

to	TO
O	NN

biomedical	JJ
O	NN

magnetic	JJ
O	NN

resonance	NN
O	NN

spectroscopy	NN
O	NN

Investigation	NNP
O	NNP

of	IN
O	NN

uncertainties	NNS
O	NN

in	IN
O	NN

relaxation	NN
O	NN

analysis	NN
O	NN

of	IN
O	NN

2D	NN
O	NN

NOE	NNP
O	NNP

which	WDT
O	NN

arise	VB
O	NN

from	IN
O	NN

spectral	JJ
O	NN

noise	NN
O	NN

An	DT
O	NN

efficient	JJ
O	NN

HN	NN
O	NN

(	NN
O	NN

CA	NNP
O	NNP

)	NN
O	NN

NH	NNP
O	NNP

pluse	NN
O	NN

scheme	NN
O	NN

for	IN
O	NN

triple-resonance	JJ
O	NN

4D	NN
O	NN

correlation	NN
O	NN

of	IN
O	NN

sequential	JJ
O	NN

amide	NN
O	NN

protons	NNS
O	NN

and	CC
O	NN

nitrogens-15	JJ
O	NN

in	IN
O	NN

deuterated	VBN
O	NN

proteins	NNS
O	NN

Optimal	JJ
O	NN

detection	NN
O	NN

of	IN
O	NN

weak	JJ
O	NN

nJ	NN
O	NN

(	NN
O	NN

1H-	CD
O	NN

119Sn	NN
O	NN

)	NN
O	NN

couplings	NNS
O	NN

by	IN
O	NN

gradient-enhanced	JJ
O	NN

1D	NN
O	NN

and	CC
O	NN

2D	NN
O	NN

heteronuclear	JJ
O	NN

multiple-quantum	JJ
O	NN

correlation	NN
O	NN

spectroscopy	NN
O	NN

Application	NN
O	NN

to	TO
O	NN

a	DT
O	NN

novel	JJ
O	NN

tin	NN
O	NN

derivative	JJ
O	NN

of	IN
O	NN

erythromycin	NN
O	NN

A	DT
O	NN

Thermoelectric	NNP
O	NNP

cooling	VBG
O	NN

for	IN
O	NN

NMR	NN
O	NN

sample	NN
O	NN

temperature	NN
O	NN

control	NN
O	NN

H2NCO-E.COSY	NN
O	NN

,	,
O	NN

a	DT
O	NN

simple	JJ
O	NN

method	NN
O	NN

for	IN
O	NN

the	DT
O	NN

sterospecific	JJ
O	NN

assignment	NN
O	NN

of	IN
O	NN

side-chain	JJ
O	NN

amide	NN
O	NN

protons	NNS
O	NN

in	IN
O	NN

proteins	NNS
O	NN

Applying	VBG
O	NN

excitation	NN
O	NN

sculpting	VBG
O	NN

to	TO
O	NN

construct	NN
O	NN

singly	RB
O	NN

and	CC
O	NN

doubly	RB
O	NN

selective	JJ
O	NN

1D	NN
O	NN

NMR	NN
O	NN

experiments	NNS
O	VBP

Radiation	NNP
O	NN

dosimetry	NN
O	NN

by	IN
O	NN

localized	JJ
O	NN

magnetic	JJ
O	NN

resonance	NN
O	NN

spectroscopy	NN
O	NN

The	DT
O	NN

2D	NN
O	NN

NMR	NN
O	NN

experiments	NNS
O	VBP

H	NN
O	NN

(	NN
O	NN

C	NN
O	NN

)	NN
O	NN

CO2	NN
O	NN

and	CC
O	NN

HCCO2	NN
O	NN

for	IN
O	NN

assignment	NN
O	NN

and	CC
O	NN

pH	NN
O	NN

titration	NN
O	NN

of	IN
O	NN

carboxylate	NN
O	NN

groups	NNS
O	NN

in	IN
O	NN

uniformly	RB
O	NN

15N/13C-labeled	JJ
O	NN

proteins	NNS
O	NN

Post-acquisition	NN
O	NN

solvent	JJ
O	NN

suppression	NN
O	NN

by	IN
O	NN

singular-value	JJ
O	NN

decomposition	NN
O	NN

Osteopathic	JJ
O	NN

manifesto	NN
O	NN

IX	CD
O	NN

What	WDT
O	NN

about	IN
O	NN

our	PRP$
O	NN

distinctiveness	NN
O	NN

?	.
O	NN

1981	CD
O	NN

Preparing	VBG
O	NN

for	IN
O	NN

thalidomide	NN
T	NN

's	POS
T	NN

comeback	NN
O	NN

Heart	NNP
D	NNP

disease	NN
D	NN

:	:
O	NN

women	NNS
O	VBP

's	POS
O	NN

unique	JJ
O	NN

risks	NNS
O	VBP

demand	NN
O	NN

attention	NN
O	NN

Resolution	NNP
O	NNP

due	JJ
O	NN

in	IN
O	NN

medical	JJ
O	NN

software	NN
O	NN

regulation	NN
O	NN

Osteopathic	JJ
O	NN

manifesto	NN
O	NN

VII	NN
O	NN

Shadows	NNS
O	NN

and	CC
O	NN

images	NNS
O	NN

1981	CD
O	NN

The	DT
O	NN

practical	JJ
O	NN

use	NN
O	NN

of	IN
O	NN

PCR	NN
O	NN

for	IN
O	NN

rapid	JJ
O	NN

detection	NN
O	NN

of	IN
O	NN

methicillin	NN
T	NN

resistance	NN
O	NN

among	IN
O	NN

staphylococcal	JJ
O	NN

clinical	JJ
O	NN

isolates	NNS
O	NN

from	IN
O	NN

Turkish	JJ
O	NN

hospitals	NNS
O	NN

Randomised	VBN
O	NN

double-blind	JJ
O	NN

trial	NN
O	NN

of	IN
O	NN

fixed	VBN
O	NN

low-dose	JJ
O	NN

warfarin	NN
T	NN

with	IN
T	NN

aspirin	NN
T	NN

after	IN
O	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

Coumadin	NNP
O	NNP

Aspirin	NN
O	NN

Reinfarction	NN
O	NN

Study	NNP
O	NNP

(	NN
O	NN

CARS	NNS
O	NN

)	NN
O	NN

Investigators	NNS
O	NN

Randomised	VBN
O	NN

trial	NN
O	NN

of	IN
O	NN

roxithromycin	NN
T	NN

in	IN
O	NN

non-Q-wave	JJ
D	NN

coronary	JJ
D	NN

syndromes	NNS
D	NN

:	:
O	NN

ROXIS	NN
O	NN

Pilot	NN
O	NN

Study	NNP
O	NNP

ROXIS	NN
O	NN

Study	NNP
O	NNP

Group	NNP
O	NNP

Association	NNP
O	NN

between	IN
O	NN

5-HT2A	NN
O	NN

gene	NN
O	NN

promoter	NN
O	NN

polymorphism	NN
O	NN

and	CC
O	NN

anorexia	NN
D	NN

nervosa	NN
D	NN

Randomised	VBN
O	NN

study	NN
O	NN

of	IN
O	NN

radical	JJ
T	NN

surgery	NN
T	NN

versus	CC
T	NN

radiotherapy	NN
T	NN

for	IN
O	NN

stage	NN
D	NN

Ib-IIa	NN
D	NN

cervical	JJ
D	NN

cancer	NN
D	NN

State	NNP
O	NNP

regulation	NN
O	NN

in	IN
O	NN

a	DT
O	NN

world	NN
O	NN

of	IN
O	NN

``	``
O	NN

boundary-less	JJ
O	NN

''	''
O	NN

technology	NN
O	NN

Screening	VBG
O	NN

for	IN
O	NN

Chlamydia	NN
D	NN

trachomatis	NN
D	NN

?	.
O	NN

Physician-assisted	JJ
O	NN

suicide	NN
O	NN

in	IN
O	NN

Oregon	NNP
O	NN

Common	JJ
O	NN

nutritional	JJ
O	NN

issues	NNS
O	VBP

in	IN
O	NN

pediatric	JJ
O	NN

and	CC
O	NN

adult	JJ
O	NN

critical	JJ
O	NN

care	NN
O	NN

medicine	NN
O	NN

A	DT
O	NN

multifactorial	JJ
O	NN

analysis	NN
O	NN

of	IN
O	NN

facial	JJ
O	NN

nerve	NN
O	NN

results	NNS
O	VBP

in	IN
O	NN

surgery	NN
O	NN

for	IN
O	NN

cerebellopontine	NN
O	NN

angle	NN
O	NN

tumors	NNS
O	NN

Osteopathic	JJ
O	NN

manifesto	NN
O	NN

VIII	CD
O	NN

Our	PRP$
O	NN

distinct	JJ
O	NN

image	NN
O	NN

1981	CD
O	NN

Quality	JJ
O	NN

in	IN
O	NN

general	JJ
O	NN

practice	NN
O	NN

Winning	VBG
O	NN

the	DT
O	NN

war	NN
O	NN

on	IN
O	NN

cancer	NN
D	NN

Clinical	JJ
O	NN

problem-solving	JJ
O	NN

--	:
O	NN

where	WRB
O	NN

did	VBD
O	NNP

good	JJ
O	NN

old	JJ
O	NN

clinical	JJ
O	NN

diagnosis	NN
O	NN

go	VB
O	NN

?	.
O	NN

The	DT
O	NN

named	VBN
O	NN

nurse	NN
O	NN

:	:
O	NN

patient	NN
O	NN

and	CC
O	NN

nurse	NN
O	NN

expectations	NNS
O	IN

Genetic	JJ
O	NN

testing	NN
O	NN

opens	VBZ
O	NN

brave	VB
O	NN

new	JJ
O	NN

world	NN
O	NN

Heterologous	JJ
O	NN

vaccines	NNS
T	NN

:	:
O	NN

proponent	NN
O	NN

sparks	VBZ
O	NN

some	DT
O	NN

interest	NN
O	NN

Steps	NNS
O	NN

still	RB
O	NN

being	VBG
O	NN

taken	VBN
O	NN

to	TO
O	NN

undo	VB
O	NN

damage	NN
O	NN

of	IN
O	NN

``	``
O	NN

America	NNP
O	NNP

's	POS
O	NN

Nuremberg	NNP
O	NN

''	''
O	NN

Patient-centered	JJ
O	NN

ethics	NNS
O	NN

reclaiming	VBG
O	NN

center	NN
O	NN

stage	NN
O	NN

Social	NNP
O	NNP

ties	NNS
O	NN

and	CC
O	NN

susceptibility	NN
O	NN

to	TO
O	NN

the	DT
O	NN

common	JJ
D	NN

cold	JJ
D	NN

Connecting	VBG
O	NN

peptide	NN
O	NN

,	,
O	NN

correcting	VBG
O	NN

peptide	NN
O	NN

?	.
O	NN

Winning	VBG
O	NN

health	NN
O	NN

victories	NNS
O	NN

with	IN
O	NN

community	NN
O	NN

commitment	NN
O	NN

Telemedicine	NN
O	NN

gets	VBZ
O	NN

a	DT
O	NN

chance	NN
O	NN

to	TO
O	NN

prove	VB
O	NN

itself	PRP
O	NN

Additional	JJ
O	NN

opinions	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

mortality	NN
O	NN

of	IN
O	NN

animal	NN
O	NN

research	NN
O	NN

Recurrent	JJ
D	NN

strokes	NNS
D	NN

in	IN
O	NN

a	DT
O	NN

34-year-old	JJ
O	NN

man	NN
O	NN

A	DT
O	NN

plan	NN
O	NN

for	IN
O	NN

improving	VBG
O	NN

outcomes	NNS
O	VBP

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

renal	JJ
D	NN

failure	NN
D	NN

Scientific	NNP
O	NNP

evidence	NN
O	NN

in	IN
O	NN

family	NN
O	NN

and	CC
O	NN

community	NN
O	NN

medicine	NN
O	NN

Evidence	NN
O	NN

that	IN
O	NN

the	DT
O	NN

expression	NN
O	NN

of	IN
O	NN

progesterone-induced	JJ
O	NN

blocking	VBG
O	NN

factor	NN
O	NN

by	IN
O	NN

maternal	JJ
O	NN

T-lymphocytes	NNS
O	VBP

is	VBZ
O	NN

positively	RB
O	NN

correlated	VBD
O	NN

with	IN
O	NN

conception	NN
O	NN

Another	DT
O	NN

use	NN
O	NN

of	IN
O	NN

androgens	NNS
T	NN

:	:
O	NN

treatment	NN
O	NN

of	IN
O	NN

anemia	NN
D	NN

of	IN
D	NN

end-stage	NN
D	NN

renal	JJ
D	NN

disease	NN
D	NN

Isotopic	JJ
O	NN

evidence	NN
O	NN

for	IN
O	NN

extraterrestrial	JJ
O	NN

non-racemic	JJ
O	NN

amino	NN
O	NN

acids	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

Murchison	NNP
O	NNP

meteorite	NN
O	NN

The	DT
O	NN

American	JJ
O	NN

Medical	JJ
O	NN

Association	NNP
O	NN

Guidelines	NNS
O	NN

for	IN
O	NN

Adolescent	JJ
O	NN

Preventive	JJ
O	NN

Services	NNP
O	NNP

Classification	NN
O	NN

of	IN
O	NN

malignant	JJ
D	NN

lymphomas	NNS
D	NN

:	:
O	NN

the	DT
O	NN

updated	VBN
O	NN

Kiel	NNP
O	NNP

classification	NN
O	NN

Rethink	VB
O	NN

on	IN
O	NN

screening	VBG
O	NN

for	IN
O	NN

breast	NN
D	NN

cancer	NN
D	NN

Sports-related	JJ
O	NN

ocular	JJ
D	NN

injuries	NNS
D	NN

Fruit	NNP
O	NNP

juice	NN
O	NN

consumption	NN
O	NN

The	DT
O	NN

case	NN
O	NN

of	IN
O	NN

the	DT
O	NN

missing	VBG
O	NN

methylphenidate	NN
T	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Intensive	JJ
T	NN

insulin	NN
T	NN

treatment	NN
T	NN

after	IN
O	NN

acute	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

in	IN
O	NN

diabetes	NN
D	NN

mellitus	NN
D	NN

Intensive	JJ
O	NN

insulin	NN
O	NN

regimens	NNS
O	VBP

in	IN
O	NN

primary	JJ
O	NN

prevention	NN
O	NN

should	MD
O	NNP

be	VB
O	NN

assessed	VBN
O	NN

GPs	NNS
O	NN

'	POS
O	NN

perceptions	NNS
O	NN

of	IN
O	NN

tolerability	NN
O	NN

of	IN
O	NN

selective	JJ
O	NN

serotonin	NN
O	NN

reuptake	NN
O	NN

inhibitors	NNS
O	NN

and	CC
O	NN

tricyclic	JJ
O	NN

antidepressants	NNS
T	NN

Research	NNP
O	NNP

into	IN
O	NN

long	RB
O	NN

term	NN
O	NN

use	NN
O	NN

is	VBZ
O	NN

needed	VBN
O	NN

Diagnosing	VBG
O	NN

and	CC
O	NN

managing	VBG
O	NN

polymyalgia	NN
D	NN

rheumatica	NN
D	NN

and	CC
O	NN

temporal	JJ
D	NN

arteritis	NN
D	NN

Sensitivity	NN
O	NN

of	IN
O	NN

temporal	JJ
O	NN

artery	NN
O	NN

biopsy	NN
O	NN

varies	VBZ
O	NN

with	IN
O	NN

biopsy	NN
O	NN

length	NN
O	NN

and	CC
O	NN

sectioning	NN
O	NN

strategy	NN
O	NN

Obstructive	JJ
O	NN

sleep	NN
D	NN

apnoea	NN
D	NN

Authors	NNS
O	NN

'	POS
O	NN

reply	NN
O	NN

Impact	NN
O	NN

of	IN
O	NN

postmenopausal	JJ
O	NN

hormone	NN
T	NN

therapy	NN
T	NN

on	IN
O	NN

cardiovascular	JJ
O	NN

events	NNS
O	NN

and	CC
O	NN

cancer	NN
D	NN

.	.
O	NN

Search	VB
O	NN

for	IN
O	NN

studies	NNS
O	VBP

was	VBD
O	NN

limited	JJ
O	NN

Treating	VBG
O	NN

shoulder	NN
O	NN

complaints	NNS
O	NN

in	IN
O	NN

general	JJ
O	NN

practice	NN
O	NN

Diagnostic	JJ
O	NN

criteria	NNS
O	NN

must	MD
O	NNP

be	VB
O	NN

used	VBN
O	NN

and	CC
O	NN

therapeutic	JJ
O	NN

regimens	NNS
O	VBP

standardised	JJ
O	NN

Authorship	NN
O	NN

System	NNP
O	NNP

acknowledging	VBG
O	NN

roles	NNS
O	NN

of	IN
O	NN

contributors	NNS
O	VBP

is	VBZ
O	NN

best	RB
O	NN

Authorship	NN
O	NN

New	NNP
O	NNP

authorship	NN
O	NN

practices	NNS
O	VBP

are	VBP
O	NN

needed	VBN
O	NN

in	IN
O	NN

developing	VBG
O	NN

countries	NNS
O	NN

Authorship	NN
O	NN

Researchers	NNP
O	NNP

'	POS
O	NN

objective	JJ
O	NN

is	VBZ
O	NN

to	TO
O	NN

get	VB
O	NNP

the	DT
O	NN

job	NN
O	NN

done	VBN
O	NN

Quality	JJ
O	NN

and	CC
O	NN

clinical	JJ
O	NN

audit	NN
O	NN

Transurethral	JJ
T	NN

microwave	NN
T	NN

thermotherapy	JJ
T	NN

Management	NNP
O	NNP

of	IN
O	NN

ileosigmoid	NN
D	NN

knotting	VBG
D	NN

Epitome	NNP
O	NNP

of	IN
O	NN

myocarditis	NN
D	NN

Producing	NNP
O	NNP

consistent	JJ
O	NN

estimates	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

power	NN
O	NN

spectral	JJ
O	NN

density	NN
O	NN

of	IN
O	NN

NN	NNP
O	NNP

sequences	NNS
O	NN

Environmental	JJ
O	NN

tobacco	NN
O	NN

smoke	NN
O	NN

and	CC
O	NN

coronary	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

Long-term	JJ
O	NN

benefit	NN
O	NN

of	IN
O	NN

one	CD
O	NN

thrombolytic	JJ
T	NN

over	IN
O	NN

another	DT
O	NN

Coupling	NN
O	NN

of	IN
O	NN

hemodynamic	JJ
O	NN

measurements	NNS
O	NN

with	IN
O	NN

oxygen	NN
O	NN

during	IN
O	NN

exercise	NN
O	NN

does	VBZ
O	NNP

not	RB
O	NN

improve	VB
O	NN

risk	NN
O	NN

stratification	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

heart	NN
D	NN

failure	NN
D	NN

Smoking	NN
O	NN

--	:
O	NN

good	JJ
O	NN

or	CC
O	NN

bad	JJ
O	NN

for	IN
O	NN

semen	NN
O	NN

?	.
O	NN

The	DT
O	NN

pruning	NN
O	NN

of	IN
O	NN

Doctor	NN
O	NN

McDonough	NNP
O	NNP

and	CC
O	NN

the	DT
O	NN

``	``
O	NN

humanizing	VBG
O	NN

''	''
O	NN

of	IN
O	NN

statistics	NNS
O	NN

Violence	NN
O	NN

Prevention	NNP
O	NNP

in	IN
O	NN

the	DT
O	NN

home	NN
O	NN

health	NN
O	NN

setting	VBG
O	NN

Contempo	NNP
O	NN

1997	CD
O	NN

:	:
O	NN

obstetrics	NNS
O	NN

and	CC
O	NN

gynecology	NN
O	NN

Mortality	NN
O	NN

and	CC
O	NN

refusal	NN
O	NN

of	IN
O	NN

ICU	NN
O	NN

admission	NN
O	NN

Extracorporeal	JJ
O	NN

photopheresis	NN
O	NN

in	IN
O	NN

S	NN
O	NN

(	NN
O	NN

c	NN
O	NN

)	NN
O	NN

zary	JJ
O	NN

syndrome	NN
O	NN

Attacks	NNS
O	NN

on	IN
O	NN

tobacco	NN
O	NN

industry	NN
O	NN

Does	VBZ
O	NNP

blinding	VBG
O	NN

of	IN
O	NN

readers	NNS
O	NN

affect	VB
O	NN

results	NNS
O	VBP

of	IN
O	NN

meta-analyses	NNS
O	NN

?	.
O	NN

Consumption	NN
O	NN

of	IN
O	NN

alcohol	NN
O	NN

and	CC
O	NN

mortality	NN
O	NN

in	IN
O	NN

Russia	NNP
O	NNP

Presenilin	NNP
O	NNP

polymorphisms	NNS
O	NN

in	IN
O	NN

Alzheimer	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

Autoimmune	NN
D	NN

enteropathy	NN
D	NN

in	IN
O	NN

adults	NNS
O	NN

Cyclosporiasis	NN
D	NN

and	CC
O	NN

raspberries	NNS
O	NN

Protean	JJ
O	NN

agonists	NNS
O	NN

Keys	NNP
O	NNP

to	TO
O	NN

receptor	NN
O	NN

active	JJ
O	NN

states	NNS
O	NN

?	.
O	NN

Kinetic	JJ
O	NN

models	NNS
O	NN

of	IN
O	NN

ion	NN
O	NN

channels	NNS
O	NN

Agonist	NN
O	NN

efficacy	NN
O	NN

and	CC
O	NN

allosteric	JJ
O	NN

models	NNS
O	NN

of	IN
O	NN

receptor	NN
O	NN

action	NN
O	NN

Receptor	NN
O	NN

Classification	NN
O	NN

:	:
O	NN

The	DT
O	NN

Integration	NN
O	NN

of	IN
O	NN

Operational	JJ
O	NN

,	,
O	NN

Structural	JJ
O	NN

,	,
O	NN

and	CC
O	NN

Transductional	JJ
O	NN

Information	NN
O	NN

Conference	NN
O	NN

proceedings	NNS
O	NN

Verona	NNP
O	NNP

,	,
O	NN

Italy	NNP
O	NNP

,	,
O	NN

September	NNP
O	NNP

21-22	CD
O	NN

,	,
O	NN

1995	CD
O	NN

Policies	NNS
O	VBP

for	IN
O	NN

posting	VBG
O	NN

biomedical	JJ
O	NN

journal	NN
O	NN

information	NN
O	NN

on	IN
O	NN

the	DT
O	NN

Internet	NN
O	NN

International	NNP
O	NNP

Committee	NNP
O	NNP

of	IN
O	NN

Medical	JJ
O	NN

Journal	NNP
O	NNP

Editors	NNS
O	NN

Who	WP
O	NN

understands	VBZ
O	NNP

the	DT
O	NN

menopause	NN
O	NN

?	.
O	NN

Comparison	NN
O	NN

of	IN
O	NN

two	CD
O	NN

methods	NNS
O	VBP

of	IN
O	NN

screening	VBG
O	NN

for	IN
O	NN

genital	JJ
O	NN

chlamydial	JJ
D	NN

infection	NN
D	NN

in	IN
O	NN

women	NNS
O	VBP

attending	VBG
O	NN

in	IN
O	NN

general	JJ
O	NN

practice	NN
O	NN

:	:
O	NN

cross	JJ
O	NN

sectional	JJ
O	NN

survey	NN
O	NN

Antimicrobial	JJ
T	NN

therapy	NN
T	NN

in	IN
O	NN

neutropenia	NN
D	NN

M1/4llerian	NN
O	NN

agenesis	NN
O	NN

:	:
O	NN

an	DT
O	NN

update	VB
O	NN

The	DT
O	NN

US	NNP
O	NN

attack	NN
O	NN

on	IN
O	NN

Cuba	NNP
O	NNP

's	POS
O	NN

health	NN
O	NN

Patient	NN
O	NN

consent	NN
O	NN

for	IN
O	NN

publication	NN
O	NN

and	CC
O	NN

the	DT
O	NN

health	NN
O	NN

of	IN
O	NN

the	DT
O	NN

public	JJ
O	NN

Brain	NN
D	NN

serotonin	NN
D	NN

neurotoxicity	NN
D	NN

and	CC
O	NN

primary	JJ
D	NN

pulmonary	JJ
D	NN

hypertension	NN
D	NN

from	IN
O	NN

fenfluramine	NN
T	NN

and	CC
O	NN

dexfenfluramine	NN
T	NN

Battling	VBG
O	NN

HI	NN
D	NN

on	IN
O	NN

many	JJ
O	NN

fronts	NNS
O	NN

Medical	JJ
O	NN

Injury	NNP
O	NN

Compensation	NNP
O	NNP

Reform	NNP
O	NNP

Act	NNP
O	NNP

:	:
O	NN

good	JJ
O	NN

or	CC
O	NN

bad	JJ
O	NN

?	.
O	NN

Fever	NN
O	NN

of	IN
O	NN

unknown	JJ
O	NN

origin	NN
O	NN

Moxonidine	NN
T	NN

for	IN
O	NN

hypertension	NN
D	NN

Researchers	NNP
O	NNP

make	VB
O	NN

slow	JJ
O	NN

headway	NN
O	NN

in	IN
O	NN

managing	VBG
O	NN

dry	JJ
D	NN

mouth	NN
D	NN

A	DT
O	NN

kinder	JJR
O	NN

,	,
O	NN

gentler	JJR
O	NN

approach	NN
O	NN

Putting	VBG
O	NN

patients	NNS
O	NN

first	RB
O	NN

?	.
O	NN

Managing	VBG
O	NN

the	DT
O	NN

anxious	JJ
O	NN

and	CC
O	NN

phobic	JJ
O	NN

dental	JJ
O	NN

patient	NN
O	NN

Do	VB
O	NN

it	PRP
O	NN

or	CC
O	NN

lose	VB
O	NN

it	PRP
O	NN

Assessment	NNP
O	NNP

of	IN
O	NN

fetal	JJ
O	NN

nuchal	JJ
O	NN

translucency	NN
O	NN

test	NN
O	NN

for	IN
O	NN

Down	NN
D	NN

's	POS
D	NN

syndrome	NN
D	NN

Amiodarone	NNP
T	NN

and	CC
O	NN

thyroid	NN
O	NN

function	NN
O	NN

Chemotherapy	NN
T	NN

with	IN
T	NN

praziquantel	NN
T	NN

has	VBZ
O	NN

the	DT
O	NN

potential	JJ
O	NN

to	TO
O	NN

reduce	VB
O	NN

the	DT
O	NN

prevalence	NN
O	NN

of	IN
O	NN

Echinococcus	NN
D	NN

multilocularis	NN
D	NN

in	IN
O	NN

wild	JJ
O	NN

foxes	NNS
O	NN

(	NN
O	NN

Vulpes	NNP
O	NNP

vulpes	NNS
O	NN

)	NN
O	NN

Death	NN
O	NN

rates	NNS
O	VBP

from	IN
O	NN

childhood	NN
D	NN

leukaemia	NN
D	NN

near	IN
O	NN

nuclear	JJ
O	NN

sites	NNS
O	NN

Other	JJ
O	NN

studies	NNS
O	VBP

showed	VBD
O	NN

that	IN
O	NN

radiation	NN
O	NN

levels	NNS
O	VBP

in	IN
O	NN

Newbury	NNP
O	NN

area	NN
O	NN

were	VBD
O	NN

low	JJ
O	NN

Haemoptysis	NN
D	NN

:	:
O	NN

a	DT
O	NN

rare	JJ
O	NN

cause	NN
O	NN

Human	JJ
D	NN

papillomavirus	NN
D	NN

types	NNS
O	NN

52	CD
O	NN

and	CC
O	NN

58	CD
O	NN

are	VBP
O	NN

prevalent	JJ
O	NN

in	IN
O	NN

cervical	JJ
D	NN

cancer	NN
D	NN

from	IN
O	NN

Chinese	JJ
O	NN

women	NNS
O	VBP

Breastfeeding	VBG
O	NN

after	IN
O	NN

early	RB
O	NN

discharge	NN
O	NN

Malnutrition	NN
D	NN

and	CC
O	NN

microcephaly	NN
D	NN

in	IN
O	NN

Australian	JJ
O	NN

aboriginal	JJ
O	NN

children	NNS
O	VBP

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Probucol	NN
T	NN

and	CC
T	NN

multivitamins	NNS
T	NN

in	IN
O	NN

the	DT
O	NN

prevention	NN
O	NN

of	IN
O	NN

restenosis	NN
D	NN

after	IN
O	NN

coronary	JJ
O	NN

angioplasty	NN
O	NN

Generalised	JJ
O	NN

caseous	JJ
D	NN

lymphadenitis	NN
D	NN

Public	NNP
O	NNP

health	NN
O	NN

approach	NN
O	NN

to	TO
O	NN

activated	VBN
O	NN

protein	NN
O	NN

C	NN
O	NN

resistance	NN
O	NN

assay	NN
O	NN

Hormone	NN
T	NN

replacement	NN
T	NN

therapy	NN
T	NN

Dose-volume	JJ
O	NN

histograms	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

interpreted	VBN
O	NN

in	IN
O	NN

different	JJ
O	NN

ways	NNS
O	NN

Addressing	VBG
O	NN

needle-stick	JJ
O	NN

concerns	NNS
O	NN

Cervical	JJ
D	NN

cancer	NN
D	NN

screening	VBG
O	NN

CyberCHEST	NN
O	NN

An	DT
O	NN

open	JJ
O	NN

future	JJ
O	NN

Keeping	VBG
O	NN

us	PRP
O	VBP

on	IN
O	NN

our	PRP$
O	NN

toes	NNS
O	VBP

!	.
O	NN

Thalidomide	NNP
O	NNP

in	IN
O	NN

oral	JJ
O	NN

Crohn	NN
O	NN

's	POS
O	NN

disease	NN
O	NN

refractory	JJ
O	NN

to	TO
O	NN

conventional	JJ
O	NN

medical	JJ
O	NN

treatment	NN
O	NN

Mortality	NN
O	NN

and	CC
O	NN

length	NN
O	NN

of	IN
O	NN

stay	VB
O	NNP

in	IN
O	NN

teaching	NN
O	NN

vs	CC
O	NN

nonteaching	JJ
O	NN

hospitals	NNS
O	NN

Early	RB
O	NN

discharge	NN
O	NN

of	IN
O	NN

newborns	NNS
O	NN

Patient	NN
O	NN

consent	NN
O	NN

for	IN
O	NN

publication	NN
O	NN

Flucticasone	NN
T	NN

propionate	NN
T	NN

is	VBZ
O	NN

safe	JJ
O	NN

in	IN
O	NN

recommended	VBN
O	NN

doses	NNS
O	NN

Fetal	JJ
O	NN

nuchal	JJ
O	NN

translucency	NN
O	NN

test	NN
O	NN

for	IN
O	NN

Down	NN
D	NN

's	POS
D	NN

syndrome	NN
D	NN

Treatment	NN
O	NN

of	IN
O	NN

hypertension	NN
D	NN

in	IN
O	NN

elderly	JJ
O	NN

patients	NNS
O	NN

Meta-analyses	NNS
O	VBP

and	CC
O	NN

large	JJ
O	NN

randomized	VBN
O	NN

,	,
O	NN

controlled	JJ
O	NN

trials	NNS
O	NN

Low-fat	JJ
O	NN

diets	NNS
O	NN

Ultrasonographic	JJ
O	NN

evaluation	NN
O	NN

of	IN
O	NN

parathyroid	JJ
D	NN

hyperplasia	NN
D	NN

Misconceptions	NNS
O	NN

about	IN
O	NN

mosaicism	NN
D	NN

Are	VBP
O	NN

normal	JJ
O	NN

hearing	VBG
O	NN

thresholds	NNS
O	NN

a	DT
O	NN

sufficient	JJ
O	NN

condition	NN
O	NN

for	IN
O	NN

click-evoked	JJ
O	NN

otoacoustic	JJ
O	NN

emissions	NNS
O	NN

?	.
O	NN

Structure	NN
O	NN

and	CC
O	NN

in	IN
O	NN

vitro	FW
O	FW

substrate	JJ
O	NN

specificity	NN
O	NN

of	IN
O	NN

the	DT
O	NN

murine	JJ
O	NN

multidrug	JJ
O	NN

resistance-associated	JJ
O	NN

protein	NN
O	NN

ATP-dependent	JJ
O	NN

transport	NN
O	NN

of	IN
O	NN

lipophilic	JJ
O	NN

cytotoxic	JJ
O	NN

drugs	NNS
O	NN

by	IN
O	NN

membrane	NN
O	NN

vesicles	NNS
O	NN

prepared	JJ
O	NN

from	IN
O	NN

MRP-overexpressing	JJ
O	NN

HL60/ADR	NN
O	NN

cells	NNS
O	VBP

Cellular	JJ
O	NN

and	CC
O	NN

in	IN
O	NN

vitro	FW
O	FW

transport	NN
O	NN

of	IN
O	NN

glutathione	NN
O	NN

conjugates	NNS
O	NN

by	IN
O	NN

MRP	NN
O	NN

Dominant	JJ
O	NN

negative	JJ
O	NN

and	CC
O	NN

cooperative	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

mutant	JJ
O	NN

forms	NNS
O	NN

of	IN
O	NN

prolactin	NN
O	NN

receptor	NN
O	NN

Effect	NN
O	NN

of	IN
O	NN

calcium	NN
O	NN

and	CC
O	NN

vitamin	NN
O	NN

D	NN
O	NN

supplementation	NN
O	NN

on	IN
O	NN

bone	NN
O	NN

density	NN
O	NN

in	IN
O	NN

men	NNS
O	NN

and	CC
O	NN

women	NNS
O	VBP

65	CD
O	NN

years	NNS
O	NN

of	IN
O	NN

age	NN
O	NN

or	CC
O	NN

older	JJR
O	NN

Infection	NN
O	NN

control	NN
O	NN

and	CC
O	NN

contaminated	VBN
O	NN

waste	NN
O	NN

disposal	NN
O	NN

practices	NNS
O	VBP

in	IN
O	NN

Southern	NNP
O	NNP

Sydney	NNP
O	NNP

Area	NNP
O	NNP

Health	NNP
O	NNP

Service	NNP
O	NNP

Dental	JJ
O	NN

Clinics	NNS
O	NN

Vitamins	NNS
O	NN

and	CC
O	NN

minerals	NNS
O	NN

:	:
O	NN

efficacy	NN
O	NN

and	CC
O	NN

safety	NN
O	NN

Joint	NNP
O	NNP

Commission	NNP
O	NN

on	IN
O	NN

Accreditation	NN
O	NN

of	IN
O	NN

Healthcare	NNP
O	NNP

Organizations	NNP
O	NNP

'	POS
O	NN

infection	NN
O	NN

control	NN
O	NN

requirements	NNS
O	VBP

:	:
O	NN

fact	NN
O	NN

or	CC
O	NN

fiction	NN
O	NN

?	.
O	NN

Poppy	NNP
O	NNP

tea	NN
O	NN

and	CC
O	NN

the	DT
O	NN

baker	NN
O	NN

's	POS
O	NN

first	RB
O	NN

seizure	NN
D	NN

ABC	NNP
O	NN

of	IN
O	NN

mental	JJ
O	NN

health	NN
O	NN

Mental	JJ
O	NN

health	NN
O	NN

and	CC
O	NN

the	DT
O	NN

law	NN
O	NN

Female	JJ
O	NN

embryonic	JJ
O	NN

lethality	NN
O	NN

in	IN
O	NN

mice	NNS
O	NN

nullizygous	JJ
O	NN

for	IN
O	NN

both	DT
O	NN

Msh2	NN
O	NN

and	CC
O	NN

p53	NN
O	NN

Tests	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

double-strand	JJ
O	NN

break	NN
O	NN

,	,
O	NN

lethal-potentially	RB
O	NN

lethal	JJ
O	NN

and	CC
O	NN

repair-misrepair	JJ
O	NN

models	NNS
O	NN

for	IN
O	NN

mammalian	JJ
O	NN

cell	NN
O	NN

survival	NN
O	NN

using	VBG
O	NN

data	NNS
O	NN

for	IN
O	NN

survival	NN
O	NN

as	IN
O	NN

a	DT
O	NN

function	NN
O	NN

of	IN
O	NN

delayed-plating	JJ
O	NN

interval	NN
O	NN

for	IN
O	NN

log-phase	JJ
O	NN

Chinese	JJ
O	NN

hamster	NN
O	NN

V79	NN
O	NN

cells	NNS
O	VBP

Influence	NN
O	NN

of	IN
O	NN

physician	NN
O	NN

confidentiality	NN
O	NN

assurances	NNS
O	NN

on	IN
O	NN

adolescents	NNS
O	NN

'	POS
O	NN

willingness	NN
O	NN

to	TO
O	NN

disclose	VB
O	NN

information	NN
O	NN

and	CC
O	NN

seek	VB
O	NN

future	JJ
O	NN

health	NN
O	NN

care	NN
O	NN

A	DT
O	NN

randomized	VBN
O	NN

controlled	JJ
O	NN

trial	NN
O	NN

Fever	NN
D	NN

in	IN
O	NN

Africa	NNP
O	NNP

:	:
O	NN

do	VB
O	NNP

patients	NNS
O	NN

know	VB
O	NN

when	WRB
O	NN

they	PRP
O	VBP

are	VBP
O	NN

hot	JJ
O	NN

?	.
O	NN

Randomised	VBN
O	NN

placebo-controlled	JJ
O	NN

trial	NN
O	NN

of	IN
O	NN

granulocyte-colony	JJ
T	NN

stimulating	VBG
T	NN

factor	NN
T	NN

in	IN
O	NN

diabetic	JJ
D	NN

foot	NN
D	NN

infection	NN
D	NN

Systemic	JJ
O	NN

absorption	NN
O	NN

of	IN
O	NN

sunscreen	NN
O	NN

after	IN
O	NN

topical	JJ
O	NN

application	NN
O	NN

A	DT
O	NN

comparison	NN
O	NN

of	IN
O	NN

continuous	JJ
T	NN

infusion	NN
T	NN

of	IN
T	NN

alteplase	RB
T	NN

with	IN
T	NN

double-bolus	JJ
T	NN

administration	NN
T	NN

for	IN
O	NN

acute	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

The	DT
O	NN

Continuous	JJ
O	NN

Infusion	NN
O	NN

versus	CC
O	NN

Double-Bolus	JJ
O	NN

Administration	NNP
O	NNP

of	IN
O	NN

Alteplase	RB
O	NN

(	NN
O	NN

COBALT	NNP
O	NNP

)	NN
O	NN

Investigators	NNS
O	NN

Evaluation	NN
O	NN

and	CC
O	NN

management	NN
O	NN

of	IN
O	NN

traumatic	JJ
D	NN

lacerations	NNS
D	NN

Atrial	JJ
D	NN

fibrillation	NN
D	NN

begets	VBZ
O	NN

trouble	NN
O	NN

Ethics	NNS
O	NN

of	IN
O	NN

HIV	NN
O	NN

trials	NNS
O	NN

The	DT
O	NN

ethics	NNS
O	NN

industry	NN
O	NN

Fever	NN
D	NN

in	IN
O	NN

Africa	NNP
O	NNP

and	CC
O	NN

WHO	WP
O	VBP

recommendation	NN
O	NN

``	``
D	NN

Whiplash	NN
D	NN

''	''
D	NN

injury	NN
D	NN

of	IN
O	NN

the	DT
O	NN

cervical	JJ
O	NN

spine	NN
O	NN

:	:
O	NN

value	NN
O	NN

of	IN
O	NN

modern	JJ
O	NN

diagnostic	JJ
O	NN

imaging	NN
O	NN

Guidelines	NNS
O	NN

and	CC
O	NN

cardiac	JJ
O	NN

anaesthetists	NNS
O	NN

Antibiotic	JJ
T	NN

management	NN
T	NN

of	IN
O	NN

sore	JJ
D	NN

throat	NN
D	NN

Lansoprazole	JJ
T	NN

,	,
O	NN

H.	NNP
O	NNP

pylori	NN
O	NN

,	,
O	NN

and	CC
O	NN

atrophic	JJ
D	NN

gastritis	NN
D	NN

.	.
O	NN

Help	VB
O	NN

wanted	VBD
O	NN

:	:
O	NN

ultrasonographers	NNS
O	NN

``	``
O	NN

Children	NNS
O	VBP

are	VBP
O	NN

not	RB
O	NN

supposed	VBN
O	NN

to	TO
O	NN

die	VB
O	NN

''	''
O	NN

Combined	VBN
O	NN

pediatric	JJ
O	NN

and	CC
O	NN

radiation	NN
O	NN

oncology	NN
O	NN

grand	JJ
O	NN

rounds	NNS
O	NN

addresses	NNS
O	VBP

severe	JJ
O	NN

illness	NN
O	NN

and	CC
O	NN

death	NN
O	NN

Structure-activity	JJ
O	NN

and	CC
O	NN

mechanism	NN
O	NN

studies	NNS
O	VBP

on	IN
O	NN

silicon	NN
O	NN

phthalocyanines	NNS
O	NN

with	IN
O	NN

Plasmodium	NN
O	NN

falciparum	NN
O	NN

in	IN
O	NN

the	DT
O	NN

dark	JJ
O	NN

and	CC
O	NN

under	IN
O	NN

red	JJ
O	NN

light	JJ
O	NN

The	DT
O	NN

importance	NN
O	NN

of	IN
O	NN

being	VBG
O	NN

where	WRB
O	NN

?	.
O	NN

Balancing	VBG
O	NN

the	DT
O	NN

perspective	NN
O	NN

on	IN
O	NN

practice	NN
O	NN

coverage	NN
O	NN

Effects	NNS
O	NN

of	IN
O	NN

dobutamine	NN
T	NN

at	IN
O	NN

maximally	RB
O	NN

tolerated	VBN
O	NN

dose	NN
O	NN

on	IN
O	NN

myocardial	JJ
O	NN

blood	NN
O	NN

flow	NN
O	NN

in	IN
O	NN

humans	NNS
O	NN

with	IN
O	NN

ischemic	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

.	.
O	NN

Cholesterol-lowering	JJ
T	NN

therapy	NN
T	NN

Ion	NN
O	NN

composition	NN
O	NN

of	IN
O	NN

airway	NN
O	NN

surface	NN
O	NN

liquid	JJ
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

cystic	JJ
D	NN

fibrosis	NN
D	NN

as	IN
O	NN

compared	VBN
O	NN

with	IN
O	NN

normal	JJ
O	NN

and	CC
O	NN

disease-control	JJ
O	NN

subjects	NNS
O	NN

Research	NNP
O	NNP

in	IN
O	NN

Copenhagen	NNP
O	NNP

hospitals	NNS
O	NN

--	:
O	NN

a	DT
O	NN

bibliometric	JJ
O	NN

evaluation	NN
O	NN

More	RBR
O	NN

on	IN
O	NN

infertility	NN
D	NN

Dermatobia	NN
O	NN

--	:
O	NN

tropical	JJ
D	NN

myiasis	NN
D	NN

Progressive	JJ
O	NN

sensorineural	JJ
O	NN

hearing	NN
D	NN

loss	NN
D	NN

,	,
O	NN

subjective	JJ
O	NN

tinnitus	NN
D	NN

and	CC
O	NN

vertigo	NN
D	NN

caused	VBN
O	NN

by	IN
O	NN

elevated	JJ
O	NN

blood	NN
O	NN

lipids	NNS
O	NN

Chronic	JJ
O	NN

telogen	NN
D	NN

effluvium	NN
D	NN

:	:
O	NN

potential	JJ
O	NN

complication	NN
O	NN

for	IN
O	NN

clinical	JJ
O	NN

trials	NNS
O	NN

in	IN
O	NN

female	JJ
O	NN

androgenetic	JJ
D	NN

alopecia	NN
D	NN

?	.
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Measles	NNP
D	NNP

vaccination	NN
T	NN

and	CC
O	NN

inflammatory	JJ
O	NN

bowel	NN
O	NN

disease	NN
O	NN

Treatment	NN
O	NN

of	IN
O	NN

suicidal	JJ
O	NN

patients	NNS
O	NN

The	DT
O	NN

systemic	JJ
O	NN

amyloidoses	NNS
T	NN

Cancer	NN
D	NN

therapy	NN
T	NN

and	CC
O	NN

tumor	NN
O	NN

physiology	NN
O	NN

Mutual	JJ
O	NN

relationships	NNS
O	NN

based	VBN
O	NN

on	IN
O	NN

equality	NN
O	NN

Specialists	NNS
O	NN

and	CC
O	NN

nurses	NNS
O	NN

:	:
O	NN

the	DT
O	NN

pillars	NNS
O	NN

of	IN
O	NN

hospital	NN
O	NN

care	NN
O	NN

Disability	NN
O	NN

models	NNS
O	NN

in	IN
O	NN

geriatrics	NNS
O	NN

:	:
O	NN

comprehensive	JJ
O	NN

rather	RB
O	NN

than	IN
O	NN

competing	VBG
O	NN

models	NNS
O	NN

should	MD
O	NNP

be	VB
O	NN

promoted	VBN
O	NN

Ethical	JJ
O	NN

issues	NNS
O	VBP

in	IN
O	NN

interventional	JJ
T	NN

radiology	NN
T	NN

Taking	VBG
O	NN

issue	NN
O	NN

with	IN
O	NN

UK	NNP
O	NNP

funding	VBG
O	NN

priorities	NNS
O	VBP

Phototherapeutic	JJ
T	NN

keratectomy	NN
T	NN

in	IN
O	NN

recurrent	JJ
D	NN

corneal	NN
D	NN

erosions	NNS
D	NN

refractory	JJ
O	NN

to	TO
O	NN

other	JJ
O	NN

forms	NNS
O	NN

of	IN
O	NN

treatment	NN
O	NN

Wegener	NNP
D	NNP

's	POS
D	NN

granulomatosis	NN
D	NN

from	IN
O	NN

infancy	NN
O	NN

to	TO
O	NN

adolescence	NN
O	NN

Hormonal	JJ
O	NN

responses	NNS
O	NN

to	TO
O	NN

restraint	NN
O	NN

in	IN
O	NN

rhesus	NN
O	NN

monkeys	NNS
O	NN

Planned	NNP
O	NNP

parenthood	NN
O	NN

and	CC
O	NN

artifical	JJ
O	NN

selection	NN
O	NN

Valvular	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

associated	VBN
O	NN

with	IN
O	NN

fenfluramine-phentermine	JJ
T	NN

The	DT
O	NN

role	NN
O	NN

of	IN
O	NN

procedures	NNS
O	VBP

in	IN
O	NN

family	NN
O	NN

practice	NN
O	NN

:	:
O	NN

is	VBZ
O	NN

there	RB
O	NN

a	DT
O	NN

right	RB
O	NN

answer	NN
O	NN

?	.
O	NN

Arthrodesis	FW
T	NN

of	IN
T	NN

the	DT
T	NN

first	RB
T	NN

metatarsophalangeal	JJ
T	NN

joint	JJ
T	NN

to	TO
O	NN

salvage	NN
O	NN

failed	VBD
D	NN

silicone	NN
D	NN

implant	VB
D	NN

arthroplasty	NN
D	NN

Methadone	NNP
T	NN

maintenance	NN
T	NN

treatment	NN
T	NN

:	:
O	NN

a	DT
O	NN

Canadian	JJ
O	NN

perspective	NN
O	NN

Survey	NN
O	NN

on	IN
O	NN

rotavirus	NN
D	NN

infections	NNS
D	NN

in	IN
O	NN

a	DT
O	NN

German	JJ
O	NN

pediatric	JJ
O	NN

hospital	NN
O	NN

Stroke	NN
D	NN

incidence	NN
O	NN

rates	NNS
O	VBP

among	IN
O	NN

black	JJ
O	NN

residents	NNS
O	NN

of	IN
O	NN

Harare	NNP
O	NNP

--	:
O	NN

a	DT
O	NN

prospective	JJ
O	NN

community-based	JJ
O	NN

study	NN
O	NN

Long-term	JJ
O	NN

effect	NN
O	NN

of	IN
O	NN

calcium	NN
O	NN

supplementation	NN
O	NN

during	IN
O	NN

pregnancy	NN
O	NN

on	IN
O	NN

the	DT
O	NN

blood	NN
O	NN

pressure	NN
O	NN

of	IN
O	NN

offspring	NN
O	NN

:	:
O	NN

follow	VB
O	NNP

up	RB
O	NN

of	IN
O	NN

a	DT
O	NN

randomised	VBN
O	NN

controlled	JJ
O	NN

trial	NN
O	NN

The	DT
O	NN

catalytic	JJ
O	NN

role	NN
O	NN

of	IN
O	NN

carbon	NN
O	NN

dioxide	NN
O	NN

in	IN
O	NN

the	DT
O	NN

decomposition	NN
O	NN

of	IN
O	NN

peroxynitrite	NN
O	NN

Unethical	JJ
O	NN

trials	NNS
O	NN

of	IN
O	NN

interventions	NNS
O	VBP

to	TO
O	NN

reduce	VB
O	NN

perinatal	JJ
O	NN

transmission	NN
O	NN

of	IN
O	NN

the	DT
O	NN

human	JJ
O	NN

immunodeficiency	NN
O	NN

virus	NN
O	NN

in	IN
O	NN

developing	VBG
O	NN

countries	NNS
O	NN

Ropinirole	NNP
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

early	RB
D	NN

Parkinson	NNP
D	NNP

's	POS
D	NN

disease	NN
D	NN

The	DT
O	NN

Ropinirole	NNP
O	NNP

Study	NNP
O	NNP

Group	NNP
O	NNP

DOTS	NNS
O	NN

--	:
O	NN

are	VBP
O	NN

we	PRP
O	VBP

over-optimistic	JJ
O	NN

?	.
O	NN

Activation	NN
O	NN

at	IN
O	NN

the	DT
O	NN

germinal	JJ
O	NN

vesicle	NN
O	NN

stage	NN
O	NN

of	IN
O	NN

starfish	NN
O	NN

oocytes	NNS
O	NN

produces	VBZ
O	NN

parthenogenetic	JJ
O	NN

development	NN
O	NN

through	IN
O	NN

the	DT
O	NN

failure	NN
O	NN

of	IN
O	NN

polar	JJ
O	NN

body	NN
O	NN

extrusion	NN
O	NN

Female	JJ
O	NN

genital	JJ
O	NN

mutilation	NN
O	NN

:	:
O	NN

a	DT
O	NN

contemporary	JJ
O	NN

issue	NN
O	NN

,	,
O	NN

and	CC
O	NN

a	DT
O	NN

Victorian	JJ
O	NN

obsession	NN
O	NN

Early	RB
O	NN

death	NN
O	NN

amongst	IN
O	NN

anaesthetists	NNS
O	NN

Fluoride	NN
T	NN

treatment	NN
T	NN

increased	VBN
O	NN

serum	NN
O	NN

IGF-1	NN
O	NN

,	,
O	NN

bone	NN
O	NN

turnover	NN
O	NN

,	,
O	NN

and	CC
O	NN

bone	NN
O	NN

mass	NN
O	NN

,	,
O	NN

but	CC
O	NNP

not	RB
O	NN

bone	NN
O	NN

strength	NN
O	NN

,	,
O	NN

in	IN
O	NN

rabbits	NNS
O	NN

Retrospective	JJ
O	NN

comparison	NN
O	NN

of	IN
O	NN

techniques	NNS
O	VBP

to	TO
O	NN

prevent	VB
O	NN

secondary	JJ
D	NN

cataract	NN
D	NN

formation	NN
D	NN

after	IN
O	NN

posterior	JJ
O	NN

chamber	NN
O	NN

intraocular	JJ
O	NN

lens	NN
T	NN

implantation	NN
T	NN

in	IN
O	NN

infants	NNS
O	NN

and	CC
O	NN

children	NNS
O	VBP

Serotonin	NN
O	NN

as	IN
O	NN

a	DT
O	NN

regulator	NN
O	NN

of	IN
O	NN

hypothalamic-pituitary-interrenal	JJ
O	NN

activity	NN
O	NN

in	IN
O	NN

teleost	NN
O	NN

fish	NN
O	NN

Predicting	VBG
O	NN

functional	JJ
O	NN

appliance	NN
O	NN

treatment	NN
O	NN

outcome	NN
O	NN

in	IN
O	NN

Class	NNP
O	NNP

II	NNP
O	NNP

malocclusions	NNS
D	NN

--	:
O	NN

a	DT
O	NN

review	NN
O	NN

Effect	NN
O	NN

of	IN
O	NN

cereal	NN
O	NN

fibre	NN
O	NN

source	NN
O	NN

and	CC
O	NN

processing	VBG
O	NN

on	IN
O	NN

rectal	JJ
O	NN

epithelial	JJ
O	NN

cell	NN
O	NN

proliferation	NN
O	NN

Update	NNP
O	NNP

:	:
O	NN

influenza	NN
D	NN

activity	NN
O	NN

--	:
O	NN

worldwide	JJ
O	NN

,	,
O	NN

March-August	NNP
O	NNP

1997	CD
O	NN

A	DT
O	NN

drop	NN
O	NN

in	IN
O	NN

pediatric	JJ
O	NN

subject	JJ
O	NN

examination	NN
O	NN

scores	NNS
O	NN

after	IN
O	NN

curriculum	NN
O	NN

changes	NNS
O	VBP

that	IN
O	NN

emphasize	VB
O	NN

general	JJ
O	NN

pediatric	JJ
O	NN

topics	NNS
O	NN

Paradigms	NNPS
O	NNP

and	CC
O	NN

the	DT
O	NN

rise	NN
O	NN

(	NN
O	NN

or	CC
O	NN

fall	NN
O	NN

?	.
O	NN

)	NN
O	NN

of	IN
O	NN

molecular	JJ
O	NN

biology	NN
O	NN

Water	NN
O	NN

fluoridation	NN
O	NN

,	,
O	NN

tooth	NN
D	NN

decay	NN
D	NN

in	IN
O	NN

5	CD
O	NN

year	NN
O	NN

olds	NNS
O	NN

,	,
O	NN

and	CC
O	NN

social	JJ
O	NN

deprivation	NN
O	NN

measured	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

Jarman	NNP
O	NNP

score	NN
O	NN

:	:
O	NN

analysis	NN
O	NN

of	IN
O	NN

data	NNS
O	NN

from	IN
O	NN

British	JJ
O	NN

dental	JJ
O	NN

surveys	NNS
O	NN

The	DT
O	NN

diabetes	NN
D	NN

audit	NN
O	NN

and	CC
O	NN

research	NN
O	NN

in	IN
O	NN

Tayside	NN
O	NN

Scotland	NNP
O	NNP

(	NN
O	NN

DARTS	NN
O	NN

)	NN
O	NN

study	NN
O	NN

:	:
O	NN

electronic	JJ
O	NN

record	NN
O	NN

linkage	NN
O	NN

to	TO
O	NN

create	VB
O	NN

a	DT
O	NN

diabetes	NN
O	NN

register	NN
O	NN

DARTS/MEMO	NN
O	NN

Collaboration	NN
O	NN

Pharmaceutical	NNP
O	NNP

industry	NN
O	NN

is	VBZ
O	NN

invited	VBN
O	NN

to	TO
O	NN

respond	NN
O	NN

to	TO
O	NN

amnesty	NN
O	NN

for	IN
O	NN

unreported	JJ
O	NN

trials	NNS
O	NN

Should	MD
O	NNP

we	PRP
O	VBP

screen	NN
O	NN

for	IN
O	NN

gestational	JJ
D	NN

diabetes	NN
D	NN

?	.
O	NN

Vesico-uterine	JJ
D	NN

fistula	NN
D	NN

--	:
O	NN

a	DT
O	NN

rare	JJ
O	NN

complication	NN
O	NN

of	IN
O	NN

vacuum	NN
T	NN

extraction	NN
T	NN

in	IN
O	NN

a	DT
O	NN

patient	NN
O	NN

with	IN
O	NN

previous	JJ
O	NN

caesarean	NN
T	NN

section	NN
T	NN

Managing	VBG
O	NN

endophthalmitis	NN
D	NN

The	DT
O	NN

plug	NN
O	NN

and	CC
O	NN

patch	NN
O	NN

repair	NN
O	NN

for	IN
O	NN

managing	VBG
O	NN

the	DT
O	NN

inguinal	JJ
O	NN

hernia	NN
O	NN

of	IN
O	NN

the	DT
O	NN

adult	JJ
O	NN

Human	JJ
O	NN

herpesvirus	NN
O	NN

8	CD
O	NN

variants	NNS
O	NN

in	IN
O	NN

sarcoid	NN
O	NN

tissues	NNS
O	NN

Practice	NN
O	NN

parameters	NNS
O	VBP

for	IN
O	NN

the	DT
O	NN

assessment	NN
O	NN

and	CC
O	NN

treatment	NN
O	NN

of	IN
O	NN

children	NNS
O	VBP

and	CC
O	NN

adolescents	NNS
O	NN

with	IN
O	NN

schizophrenia	NN
D	NN

American	JJ
O	NN

Academy	NNP
O	NNP

of	IN
O	NN

Child	NN
O	NN

and	CC
O	NN

Adolescent	JJ
O	NN

Psychiatry	NNP
O	NNP

Practice	NN
O	NN

parameters	NNS
O	VBP

for	IN
O	NN

the	DT
O	NN

psychiatric	JJ
O	NN

assessment	NN
O	NN

of	IN
O	NN

infants	NNS
O	NN

and	CC
O	NN

toddlers	NNS
O	NN

(	NN
O	NN

0-36	CD
O	NN

months	NNS
O	NN

)	NN
O	NN

American	JJ
O	NN

Academy	NNP
O	NNP

of	IN
O	NN

Child	NN
O	NN

and	CC
O	NN

Adolescent	JJ
O	NN

Psychiatry	NNP
O	NNP

Practice	NN
O	NN

parameters	NNS
O	VBP

for	IN
O	NN

the	DT
O	NN

forensic	JJ
O	NN

evaluation	NN
O	NN

of	IN
O	NN

children	NNS
O	VBP

and	CC
O	NN

adolescents	NNS
O	NN

who	WP
O	VBP

may	MD
O	NNP

have	VB
O	NN

been	VBN
O	NN

physically	RB
O	NN

or	CC
O	NN

sexually	RB
O	NN

abused	JJ
O	NN

American	JJ
O	NN

Academy	NNP
O	NNP

of	IN
O	NN

Child	NN
O	NN

and	CC
O	NN

Adolescent	JJ
O	NN

Psychiatry	NNP
O	NNP

Practice	NN
O	NN

parameters	NNS
O	VBP

for	IN
O	NN

the	DT
O	NN

psychiatric	JJ
O	NN

assessment	NN
O	NN

of	IN
O	NN

children	NNS
O	VBP

and	CC
O	NN

adolescents	NNS
O	NN

American	JJ
O	NN

Academy	NNP
O	NNP

of	IN
O	NN

Child	NN
O	NN

and	CC
O	NN

Adolescent	JJ
O	NN

Psychiatry	NNP
O	NNP

Alternative	JJ
O	NN

medicine	NN
O	NN

Leprosy	NN
D	NN

beyond	IN
O	NN

the	DT
O	NN

year	NN
O	NN

2000	CD
O	NN

Effect	NN
O	NN

of	IN
O	NN

danaparoid	JJ
T	NN

sodium	NN
T	NN

on	IN
O	NN

hard	RB
O	NN

exudates	VBZ
O	NN

in	IN
O	NN

diabetic	JJ
D	NN

retinopathy	NN
D	NN

.	.
O	NN

Lead	JJ
O	NN

based	VBN
O	NN

paint	NN
O	NN

hazards	NNS
O	VBP

in	IN
O	NN

early	RB
O	NN

childhood	NN
O	NN

centres	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

Wellington	NNP
O	NNP

region	NN
O	NN

Gene	NNP
O	NNP

technology	NN
O	NN

and	CC
O	NN

democracy	NN
O	NN

Use	NNP
O	NNP

of	IN
O	NN

statins	NNS
T	NN

Adequacy	NN
O	NN

of	IN
O	NN

SMAC	NN
O	NN

's	POS
O	NN

statement	NN
O	NN

should	MD
O	NNP

be	VB
O	NN

judged	VBN
O	NN

by	IN
O	NN

clinicians	NNS
O	NN

,	,
O	NN

not	RB
O	NN

health	NN
O	NN

economists	NNS
O	NN

Glasgow	NNP
O	NNP

has	VBZ
O	NN

already	RB
O	NN

produced	VBN
O	NN

strategy	NN
O	NN

for	IN
O	NN

treatment	NN
O	NN

Evidence	NN
O	NN

on	IN
O	NN

effectiveness	NN
O	NN

is	VBZ
O	NN

stronger	JJR
O	NN

for	IN
O	NN

statins	NNS
T	NN

than	IN
O	NN

for	IN
O	NN

other	JJ
O	NN

treatments	NNS
O	VBP

Evidence	NN
O	NN

based	VBN
O	NN

advertising	NN
O	NN

?	.
O	NN

Half	NN
O	NN

of	IN
O	NN

drug	NN
O	NN

advertisements	NNS
O	NN

in	IN
O	NN

BMJ	NNP
O	NN

over	IN
O	NN

six	CD
O	NN

months	NNS
O	NN

cited	VBN
O	NN

no	DT
O	NN

supporting	VBG
O	NN

evidence	NN
O	NN

Non-steroidal	JJ
T	NN

anti-inflammatory	JJ
T	NN

therapy	NN
T	NN

for	IN
O	NN

bronchial	JJ
D	NN

asthma	NN
D	NN

Drugs	NNS
O	NN

for	IN
O	NN

the	DT
O	NN

Third	JJ
O	NN

World	NNP
O	NNP

Getting	VBG
O	NN

a	DT
O	NN

handle	VB
O	NNP

on	IN
O	NN

the	DT
O	NN

molecules	NNS
O	NN

that	IN
O	NN

guide	NN
O	NN

axons	NNS
O	NN

The	DT
O	NN

functional	JJ
O	NN

neuroanatomy	NN
O	NN

of	IN
O	NN

episodic	JJ
O	NN

memory	NN
O	NN

retrieval	NN
O	NN

Re	NNP
O	NNP

:	:
O	NN

``	``
O	NN

Biologic	JJ
O	NN

synergism	NN
O	NN

and	CC
O	NN

parallelism	NN
O	NN

''	''
O	NN

Shifting	VBG
O	NN

medical	JJ
O	NN

education	NN
O	NN

from	IN
O	NN

the	DT
O	NN

icebox	NN
O	NN

to	TO
O	NN

the	DT
O	NN

refrigerator	NN
O	NN

Reattendance	NN
O	NN

and	CC
O	NN

complications	NNS
O	NN

in	IN
O	NN

a	DT
O	NN

randomised	VBN
O	NN

trial	NN
O	NN

of	IN
O	NN

prescribing	VBG
O	NN

strategies	NNS
O	VBP

for	IN
O	NN

sore	JJ
O	NN

throat	NN
O	NN

:	:
O	NN

the	DT
O	NN

medicalising	VBG
O	NN

effect	NN
O	NN

of	IN
O	NN

prescribing	VBG
O	NN

antibiotics	NNS
O	NN

Pure	JJ
D	NN

alexia	NN
D	NN

could	MD
O	NNP

not	RB
O	NN

be	VB
O	NN

a	DT
O	NN

disconnection	NN
O	NN

syndrome	NN
O	NN

A	DT
O	NN

randomized	VBN
O	NN

,	,
O	NN

double-blind	JJ
O	NN

,	,
O	NN

dose-response	JJ
O	NN

comparison	NN
O	NN

of	IN
O	NN

epidural	JJ
T	NN

fentanyl	NN
T	NN

versus	CC
O	NN

sufentanil	NN
T	NN

analgesia	NN
T	NN

after	IN
O	NN

cesarean	NN
T	NN

section	NN
T	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Coronary	JJ
O	NN

artery	NN
O	NN

problems	NNS
O	VBP

during	IN
O	NN

homograft	NN
O	NN

aortic	JJ
O	NN

valve	NN
O	NN

replacement	NN
O	NN

:	:
O	NN

role	NN
O	NN

of	IN
O	NN

transesophageal	NN
O	NN

echocardiography	NN
O	NN

Spontaneous	JJ
O	NN

splenic	JJ
D	NN

rupture	NN
D	NN

following	VBG
O	NN

administration	NN
O	NN

of	IN
O	NN

granulocyte	NN
T	NN

colony-stimulating	JJ
T	NN

factor	NN
T	NN

(	NN
T	NN

G-CSF	NN
T	NN

)	NN
T	NN

:	:
O	NN

occurrence	NN
O	NN

in	IN
O	NN

an	DT
O	NN

allogeneic	JJ
O	NN

donor	NN
O	NN

of	IN
O	NN

peripheral	JJ
O	NN

blood	NN
O	NN

stem	NN
O	NN

cells	NNS
O	VBP

Evidence-based	JJ
O	NN

medicine	NN
O	NN

and	CC
O	NN

general	JJ
O	NN

practice	NN
O	NN

Koch	NNP
O	NNP

's	POS
O	NN

or	CC
O	NN

Crohn	NN
O	NN

's	POS
O	NN

?	.
O	NN

Female	JJ
O	NN

Stress	NN
O	NN

Urinary	JJ
O	NN

Incontinence	NN
O	NN

Clinical	JJ
O	NN

Guidelines	NNS
O	NN

Panel	NN
O	NN

summary	NN
O	NN

report	NN
O	NN

on	IN
O	NN

surgical	JJ
T	NN

management	NN
T	NN

of	IN
O	NN

female	JJ
D	NN

stress	NN
D	NN

urinary	JJ
D	NN

incontinence	NN
D	NN

The	DT
O	NN

American	JJ
O	NN

Urological	JJ
O	NN

Association	NNP
O	NN

Haemodynamic	JJ
O	NN

performance	NN
O	NN

of	IN
O	NN

a	DT
O	NN

16-mm	JJ
O	NN

Carbomedics	NNS
O	NN

aortic	JJ
O	NN

prosthesis	NN
O	NN

Case	NNP
O	NNP

records	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

Massachusetts	NNP
O	NN

General	NNP
O	NNP

Hospital	NNP
O	NNP

Weekly	NNP
O	NNP

clinicopathological	JJ
O	NN

exercises	NNS
O	NN

Case	NNP
O	NNP

30-1997	CD
O	NN

A	DT
O	NN

preterm	NN
O	NN

newborn	JJ
O	NN

female	JJ
O	NN

triplet	NN
O	NN

with	IN
O	NN

diffuse	JJ
O	NN

cystic	JJ
O	NN

changes	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

left	RB
O	NN

lung	NN
O	NN

Cure	VB
O	NN

of	IN
O	NN

Helicobacter	NN
D	NN

pylori	NN
D	NN

infection	NN
D	NN

improves	VBZ
O	NN

gastric	JJ
O	NN

acid	NN
O	NN

secretion	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

corpus	NN
D	NN

gastritis	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Increased	VBN
O	NN

incidence	NN
O	NN

of	IN
O	NN

preeclampsia	NN
D	NN

in	IN
O	NN

women	NNS
O	VBP

conceiving	VBG
O	NN

by	IN
O	NN

intrauterine	JJ
T	NN

insemination	NN
T	NN

with	IN
T	NN

donor	NN
T	NN

versus	CC
T	NN

partner	NN
T	NN

sperm	NN
T	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

primary	JJ
D	NN

infertility	NN
D	NN

Pediatric	NNP
D	NNP

cervical	JJ
D	NN

spine	NN
D	NN

injury	NN
D	NN

sustained	JJ
O	NN

in	IN
O	NN

falls	VBZ
O	NN

from	IN
O	NN

low	JJ
O	NN

heights	NNS
O	NN

Prophylaxis	NNP
O	NN

after	IN
O	NN

occupational	JJ
O	NN

exposure	NN
O	NN

to	TO
O	NN

HIV	NN
O	NN

How	WRB
O	NN

critical	JJ
O	NN

are	VBP
O	NN

critical	JJ
O	NN

values	NNS
O	VBP

?	.
O	NN

Back	RB
O	NN

from	IN
O	NN

the	DT
O	NN

dead	JJ
O	NN

:	:
O	NN

extracorporeal	JJ
T	NN

rewarming	VBG
T	NN

of	IN
O	NN

severe	JJ
D	NN

accidental	JJ
D	NN

hypothermia	NN
D	NN

victims	NNS
O	NN

in	IN
O	NN

accident	NN
O	NN

and	CC
O	NN

emergency	NN
O	NN

A	DT
O	NN

classification	NN
O	NN

of	IN
O	NN

nucleotide-diphospho-sugar	JJ
O	NN

glycosyltransferases	NNS
O	NN

based	VBN
O	NN

on	IN
O	NN

amino	NN
O	NN

acid	NN
O	NN

sequence	NN
O	NN

similarities	NNS
O	NN

EU	NNP
O	NNP

directive	NN
O	NN

on	IN
O	NN

bovine	JJ
D	NN

spongiform	NN
D	NN

encephalopathy	NN
D	NN

will	MD
O	VB

not	RB
O	NN

affect	VB
O	NN

drugs	NNS
O	NN

Management	NNP
O	NNP

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

HIV/AIDS	NN
D	NN

Who	WP
O	NN

should	MD
O	NNP

care	NN
O	NN

?	.
O	NN

Anesthesiology	NNP
O	NNP

Second	JJ
O	NN

of	IN
O	NN

two	CD
O	NN

parts	NNS
O	NN

Overdrugging	VBG
O	NN

and	CC
O	NN

undertreatment	NN
O	NN

in	IN
O	NN

primary	JJ
O	NN

health	NN
O	NN

care	NN
O	NN

Transesophageal	JJ
O	NN

echocardiography	NN
O	NN

probe	NN
O	NN

holder	NN
O	NN

Pregnancy	NN
O	NN

outcomes	NNS
O	VBP

in	IN
O	NN

women	NNS
O	VBP

with	IN
O	NN

gestational	JJ
D	NN

diabetes	NN
D	NN

compared	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

general	JJ
O	NN

obstetric	JJ
O	NN

population	NN
O	NN

Confidentiality	NN
O	NN

as	IN
O	NN

a	DT
O	NN

barrier	NN
O	NN

to	TO
O	NN

treatment	NN
O	NN

Recombinant	JJ
O	NN

human	JJ
O	NN

DNase	NN
O	NN

(	NN
O	NN

rhDNase	NN
O	NN

)	NN
O	NN

influences	VBZ
O	NNP

phospholipid	JJ
O	NN

composition	NN
O	NN

,	,
O	NN

surface	NN
O	NN

activity	NN
O	NN

,	,
O	NN

rheology	NN
O	NN

and	CC
O	NN

consecutively	RB
O	NN

clearance	NN
O	NN

indices	NNS
O	NN

of	IN
O	NN

cystic	JJ
D	NN

fibrosis	NN
D	NN

sputum	NN
O	NN

Palliative	JJ
O	NN

options	NNS
O	NN

of	IN
O	NN

last	JJ
O	NN

resort	NN
O	NN

:	:
O	NN

a	DT
O	NN

comparison	NN
O	NN

of	IN
O	NN

voluntarily	RB
O	NN

stopping	VBG
O	NN

eating	VBG
O	NN

and	CC
O	NN

drinking	NN
O	NN

,	,
O	NN

terminal	JJ
O	NN

sedation	NN
O	NN

,	,
O	NN

physician-assisted	JJ
O	NN

suicide	NN
O	NN

,	,
O	NN

and	CC
O	NN

voluntary	JJ
O	NN

active	JJ
O	NN

euthanasia	NN
O	NN

Automation	NN
O	NN

in	IN
O	NN

cervical	JJ
O	NN

cytology	NN
O	NN

:	:
O	NN

whose	WP$
O	NN

cost	NN
O	NN

and	CC
O	NN

whose	WP$
O	NN

benefit	NN
O	NN

?	.
O	NN

Losing	VBG
O	NN

weight	NN
O	NN

--	:
O	NN

an	DT
O	NN

ill-fated	JJ
O	NN

New	NNP
O	NNP

Year	NN
O	NN

's	POS
O	NN

resolution	NN
O	NN

Lumbar	JJ
D	NN

puncture	NN
D	NN

need	NN
O	NN

n't	RB
O	NN

be	VB
O	NN

a	DT
O	NN

headache	NN
O	NN

Profiting	VBG
O	NN

from	IN
O	NN

closure	NN
O	NN

:	:
O	NN

the	DT
O	NN

private	JJ
O	NN

finance	NN
O	NN

initiative	NN
O	NN

and	CC
O	NN

the	DT
O	NN

NHS	NN
O	NN

Incidence	NN
O	NN

of	IN
O	NN

dog	NN
D	NN

bite	NN
D	NN

injuries	NNS
D	NN

treated	VBN
O	NN

in	IN
O	NN

emergency	NN
O	NN

departments	NNS
O	NN

Use	NNP
O	NNP

of	IN
O	NN

rotational	JJ
O	NN

movements	NNS
O	VBP

to	TO
O	NN

remove	VB
O	NN

mandibular	JJ
O	NN

molars	NNS
O	NN

Comparison	NN
O	NN

of	IN
O	NN

three	CD
O	NN

methods	NNS
O	VBP

used	VBN
O	NN

for	IN
O	NN

assessment	NN
O	NN

of	IN
O	NN

pain	NN
D	NN

in	IN
O	NN

dogs	NNS
O	NN

Randomised	VBN
O	NN

controlled	JJ
O	NN

trial	NN
O	NN

of	IN
O	NN

magnetic-resonance	JJ
T	NN

pelvimetry	NN
T	NN

in	IN
O	NN

breech	NN
D	NN

presentation	NN
D	NN

at	IN
D	NN

term	NN
D	NN

Single-breath	JJ
O	NN

diffusing	VBG
O	NN

capacities	NNS
O	VBP

for	IN
O	NN

NO	NN
O	NN

,	,
O	NN

CO	NNP
O	NNP

and	CC
O	NN

C18O2	NN
O	NN

in	IN
O	NN

rabbits	NNS
O	NN

Improved	VBN
O	NN

control	NN
O	NN

will	MD
O	VB

provide	VB
O	NN

better	JJR
O	NN

quality	NN
O	NN

Interview	NN
O	NN

by	IN
O	NN

Tom	NNP
O	NNP

Heinemann	NNP
O	NNP

Case	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

month	NN
O	NN

Autopsy	NN
O	NN

Committee	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

College	NNP
O	NNP

of	IN
O	NN

American	JJ
O	NN

Pathologists	NNPS
O	NNP

Cor	NNP
O	NNP

pulmonale	JJ
O	NN

Human	JJ
O	NN

papillomavirus	NN
O	NN

in	IN
O	NN

the	DT
O	NN

woman	NN
O	NN

with	IN
O	NN

HIV	NN
O	NN

Reducing	VBG
O	NN

risk	NN
O	NN

is	VBZ
O	NN

best	RB
O	NN

strategy	NN
O	NN

The	DT
O	NN

realpolitik	NN
O	NN

of	IN
O	NN

a	DT
O	NN

new	JJ
O	NN

National	NNP
O	NNP

Health	NNP
O	NNP

Service	NNP
O	NNP

for	IN
O	NN

the	DT
O	NN

UK	NNP
O	NNP

What	WDT
O	NN

is	VBZ
O	NN

your	PRP$
O	NN

diagnosis	NN
O	NN

?	.
O	NN

Foreign	JJ
O	NN

body	NN
O	NN

in	IN
O	NN

the	DT
O	NN

abdomen	NN
O	NN

Septic	JJ
D	NN

arthritis	NN
D	NN

Brain	NN
D	NN

tumours	NNS
D	NN

and	CC
O	NN

mobile	JJ
O	NN

phones	NNS
O	NN

?	.
O	NN

Lung	NN
D	NN

cancer	NN
D	NN

,	,
O	NN

tobacco	NN
O	NN

smoking	NN
O	NN

and	CC
O	NN

environmental	JJ
O	NN

factors	NNS
O	NN

in	IN
O	NN

Denmark	NNP
O	NNP

Emergency	NN
O	NN

department	NN
O	NN

use	NN
O	NN

as	IN
O	NN

a	DT
O	NN

component	NN
O	NN

of	IN
O	NN

total	JJ
O	NN

ambulatory	JJ
O	NN

care	NN
O	NN

:	:
O	NN

a	DT
O	NN

population	NN
O	NN

perspective	NN
O	NN

Occupational	JJ
T	NN

therapy	NN
T	NN

and	CC
O	NN

outcomes	NNS
O	VBP

for	IN
O	NN

older	JJR
O	NN

adults	NNS
O	NN

Anesthesiology	NNP
O	NNP

Low-molecular-weight	JJ
O	NN

heparins	NNS
O	NN

Case	NNP
O	NNP

30-1997	CD
O	NN

:	:
O	NN

pulmonary	JJ
D	NN

interstitial	JJ
D	NN

emphysema	NN
D	NN

in	IN
O	NN

infancy	NN
O	NN

The	DT
O	NN

tobacco	NN
O	NN

settlement	NN
O	NN

Two	CD
O	NN

actions	NNS
O	VBP

are	VBP
O	NN

possible	JJ
O	NN

for	IN
O	NN

doctors	NNS
O	NN

wanting	VBG
O	NN

to	TO
O	NN

promote	VB
O	NN

human	JJ
O	NN

welfare	NN
O	NN

in	IN
O	NN

Africa	NNP
O	NNP

Carcinogenesis	NN
O	NN

in	IN
O	NN

transgenic	JJ
O	NN

mouse	NN
O	NN

models	NNS
O	NN

Trouble	NN
O	NN

in	IN
O	NN

paradise	NN
O	NN

Atomic	JJ
O	NN

legacy	NN
O	NN

in	IN
O	NN

the	DT
O	NN

Marshall	NNP
O	NNP

Islands	NNP
O	NNP

The	DT
O	NN

road	NN
O	NN

to	TO
O	NN

justice	NN
O	NN

Solvent	JJ
O	NN

solution	NN
O	NN

Role	NN
O	NN

of	IN
O	NN

free	JJ
O	NN

radicals	NNS
O	NN

,	,
O	NN

telomeres	NNS
O	NN

,	,
O	NN

and	CC
O	NN

telomerases	NNS
O	NN

in	IN
O	NN

aging	VBG
O	NN

and	CC
O	NN

cancerogenesis	NN
O	NN

The	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

ephedrine	NN
O	NN

on	IN
O	NN

the	DT
O	NN

onset	NN
O	NN

time	NN
O	NN

of	IN
O	NN

rocuronium	NN
O	NN

Antibody	NN
O	NN

class	NN
O	NN

switch	NN
O	NN

recombinase	NN
O	NN

activity	NN
O	NN

is	VBZ
O	NN

B	NN
O	NN

cell	NN
O	NN

stage	NN
O	NN

specific	JJ
O	NN

and	CC
O	NN

functions	NNS
O	VBP

stochastically	RB
O	NN

in	IN
O	NN

the	DT
O	NN

absence	NN
O	NN

of	IN
O	NN

'targeted	VBN
O	NN

accessibility	NN
O	NN

'	POS
O	NN

control	NN
O	NN

Systematic	JJ
O	NN

review	NN
O	NN

of	IN
O	NN

prophylactic	NN
O	NN

vs	CC
O	NN

rescue	NN
O	NN

surfactant	JJ
O	NN

The	DT
O	NN

safety-net	NN
O	NN

role	NN
O	NN

of	IN
O	NN

international	JJ
O	NN

medical	JJ
O	NN

graduates	NNS
O	NN

The	DT
O	NN

prevalence	NN
O	NN

of	IN
O	NN

chemical	NN
O	NN

substance	NN
O	NN

and	CC
O	NN

alcohol	NN
O	NN

abuse	NN
O	NN

in	IN
O	NN

an	DT
O	NN

obstetric	JJ
O	NN

population	NN
O	NN

in	IN
O	NN

Dublin	NNP
O	NNP

schizophrenia	NN
D	NN

as	IN
O	NN

failure	NN
O	NN

of	IN
O	NN

hemispheric	JJ
O	NN

dominance	NN
O	NN

for	IN
O	NN

language	NN
O	NN

Late	RB
O	NN

prenatal	JJ
O	NN

ultrasound	NN
O	NN

features	NNS
O	VBP

of	IN
O	NN

hydrometrocolpos	NNS
O	NN

secondary	JJ
O	NN

to	TO
O	NN

cloacal	JJ
D	NN

anomaly	NN
D	NN

:	:
O	NN

case	NN
O	NN

reports	NNS
O	NN

and	CC
O	NN

review	NN
O	NN

of	IN
O	NN

the	DT
O	NN

literature	NN
O	NN

Familial	JJ
O	NN

and	CC
O	NN

primary	JJ
O	NN

(	NN
O	NN

AL	NNP
O	NNP

)	NN
O	NN

cardiac	JJ
D	NN

amyloidosis	NN
D	NN

:	:
O	NN

echocardiographically	RB
O	NN

similar	JJ
O	NN

diseases	NNS
O	NN

with	IN
O	NN

distinctly	RB
O	NN

different	JJ
O	NN

clinical	JJ
O	NN

outcomes	NNS
O	VBP

Diabetic	NNP
O	NNP

retinopathy	NN
O	NN

,	,
O	NN

promoter	NN
O	NN

(	NN
O	NN

4G/5G	NN
O	NN

)	NN
O	NN

polymorphism	NN
O	NN

of	IN
O	NN

PAI-1	NN
O	NN

gene	NN
O	NN

,	,
O	NN

and	CC
O	NN

PAI-1	NN
O	NN

activity	NN
O	NN

in	IN
O	NN

Pima	NNP
O	NNP

Indians	NNPS
O	NNP

with	IN
O	NN

type	NN
O	NN

2	CD
O	NN

diabetes	NN
D	NN

Evaluation	NN
O	NN

of	IN
O	NN

diagnostic	JJ
O	NN

peritoneal	JJ
O	NN

lavage	NN
O	NN

in	IN
O	NN

stable	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

gunshot	NN
D	NN

wounds	NNS
D	NN

to	TO
O	NN

the	DT
O	NN

abdomen	NN
O	NN

Cerebral	JJ
D	NN

abscesses	NNS
D	NN

in	IN
O	NN

a	DT
O	NN

patient	NN
O	NN

with	IN
O	NN

AIDS	NN
D	NN

caused	VBN
O	NN

by	IN
O	NN

methicillin-resistant	JJ
O	NN

Staphylococcus	FW
O	FW

aureus	NN
O	NN

(	NN
O	NN

MRSA	NNP
O	NN

)	NN
O	NN

A	DT
O	NN

randomised	VBN
O	NN

comparison	NN
O	NN

of	IN
O	NN

the	DT
O	NN

EuroQol	NN
O	NN

and	CC
O	NN

Short	JJ
O	NN

Form-36	NN
O	NN

after	IN
O	NN

stroke	NN
D	NN

United	NNP
O	NNP

Kingdom	NNP
O	NNP

collaborators	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

International	NNP
O	NNP

Stroke	NN
O	NN

Trial	NN
O	NN

Clinical	JJ
O	NN

significance	NN
O	NN

of	IN
O	NN

Blastocystis	NN
D	NN

hominis	NN
D	NN

infection	NN
D	NN

:	:
O	NN

epidemiologic	JJ
O	NN

study	NN
O	NN

Karolinska	FW
O	FW

Institute	NNP
O	NN

rocked	VBD
O	NN

by	IN
O	NN

research	NN
O	NN

misconduct	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Hepatic	JJ
O	NN

glutamine	NN
O	NN

synthetase	NN
O	NN

deficiency	NN
O	NN

in	IN
O	NN

fatal	JJ
O	NN

hyperammonemia	NN
O	NN

after	IN
O	NN

lung	NN
O	NN

transplantation	NN
O	NN

Where	WRB
O	NN

next	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

rectal	JJ
D	NN

cancer	NN
D	NN

?	.
O	NN

GAPS	NNS
O	VBP

(	NN
O	NN

AMA	NNP
O	NNP

Guidelines	NNS
O	NN

for	IN
O	NN

Adolescent	JJ
O	NN

Preventive	JJ
O	NN

Services	NNP
O	NNP

)	NN
O	NN

Protocols	NNS
O	VBP

for	IN
O	NN

wound	NN
O	NN

management	NN
O	NN

Chronic	JJ
O	NN

leg	NN
D	NN

ulcers	NNS
D	NN

:	:
O	NN

beware	NN
O	NN

the	DT
O	NN

'wolf	NN
O	NN

in	IN
O	NN

sheep	NN
O	NN

's	POS
O	NN

clothing	NN
O	NN

!	.
O	NN

'	POS
O	NN

.	.
O	NN

Role	NN
O	NN

of	IN
O	NN

fine	JJ
T	NN

needle	NN
T	NN

aspiration	NN
T	NN

cytology	NN
T	NN

in	IN
O	NN

the	DT
O	NN

management	NN
O	NN

of	IN
O	NN

the	DT
O	NN

discrete	JJ
D	NN

parotid	NN
D	NN

lump	NN
D	NN

More	RBR
O	NN

than	IN
O	NN

20	CD
O	NN

years	NNS
O	NN

second-look	JJ
O	NN

surgery	NN
T	NN

in	IN
O	NN

advanced	JJ
D	NN

epithelial	JJ
D	NN

ovarian	JJ
D	NN

cancer	NN
D	NN

:	:
O	NN

what	WDT
O	NN

did	VBD
O	NNP

we	PRP
O	VBP

learn	VB
O	NN

?	.
O	NN

Evaluating	VBG
O	NN

prostate	NN
T	NN

needle	NN
T	NN

biopsy	NN
T	NN

:	:
O	NN

therapeutic	JJ
O	NN

and	CC
O	NN

prognostic	JJ
O	NN

importance	NN
O	NN

Sudden	JJ
O	NN

cryptococcal	JJ
D	NN

deafness	NN
D	NN

Methicillin-resistant	JJ
O	NN

Staphylococcus	FW
O	FW

aureus	NN
O	NN

clinical	JJ
O	NN

strain	NN
O	NN

with	IN
O	NN

reduced	VBN
O	NN

vancomycin	NN
T	NN

susceptibility	NN
O	NN

HIV	NN
O	NN

and	CC
O	NN

AIDS	NN
D	NN

awareness	NN
O	NN

:	:
O	NN

an	DT
O	NN

evaluation	NN
O	NN

of	IN
O	NN

a	DT
O	NN

short	JJ
O	NN

training	NN
O	NN

programme	NN
O	NN

for	IN
O	NN

midwives	NNS
O	NN

What	WDT
O	NN

investigations	NNS
O	NN

and	CC
O	NN

procedures	NNS
O	VBP

do	VB
O	NNP

patients	NNS
O	NN

in	IN
O	NN

hospices	NNS
O	NN

want	VB
O	NN

?	.
O	NN

Interview	NN
O	NN

based	VBN
O	NN

survey	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

and	CC
O	NN

their	PRP$
O	NN

nurses	NNS
O	NN

Occupational	JJ
O	NN

asthma	NN
D	NN

due	JJ
O	NN

to	TO
O	NN

porcine	NN
O	NN

pancreatic	JJ
O	NN

amylase	NN
O	NN

Double-blind	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

pulsing	VBG
T	NN

magnetic	JJ
T	NN

field	NN
T	NN

effects	NNS
O	NN

on	IN
O	NN

multiple	JJ
D	NN

sclerosis	NN
D	NN

.	.
O	NN

CDA	NNP
O	NNP

opposes	VBZ
O	NN

proposed	VBN
O	NN

HBV	NN
O	NN

recommendations	NNS
O	NN

The	DT
O	NN

influence	NN
O	NN

of	IN
O	NN

allergy	NN
D	NN

and	CC
O	NN

smoking	NN
O	NN

on	IN
O	NN

the	DT
O	NN

sulphation	NN
O	NN

of	IN
O	NN

nasal	JJ
O	NN

mucins	NNS
O	NN

Clinical	JJ
O	NN

problem-solving	JJ
O	NN

A	DT
O	NN

hidden	JJ
O	NN

agenda	NN
O	NN

A	DT
O	NN

comparison	NN
O	NN

of	IN
O	NN

the	DT
O	NN

early	RB
O	NN

outcome	NN
O	NN

of	IN
O	NN

acute	JJ
O	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

in	IN
O	NN

women	NNS
O	VBP

and	CC
O	NN

men	NNS
O	NN

The	DT
O	NN

Third	JJ
O	NN

International	NNP
O	NNP

Study	NNP
O	NNP

of	IN
O	NN

Infarct	JJ
O	NN

Survival	NN
O	NN

Collaborative	JJ
O	NN

Group	NNP
O	NNP

Management	NNP
O	NNP

of	IN
O	NN

life-threatening	JJ
O	NN

acid-base	NN
D	NN

disorders	NNS
D	NN

Second	JJ
O	NN

of	IN
O	NN

two	CD
O	NN

parts	NNS
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Freeze-dried	JJ
O	NN

cortical	JJ
O	NN

allograft	NN
O	NN

in	IN
O	NN

posterior	JJ
O	NN

spinal	JJ
O	NN

arthrodesis	NN
O	NN

:	:
O	NN

use	NN
O	NN

with	IN
O	NN

segmental	JJ
O	NN

instrumentation	NN
O	NN

for	IN
O	NN

idiopathic	JJ
O	NN

adolescent	JJ
O	NN

scoliosis	NN
O	NN

Removal	NN
O	NN

of	IN
O	NN

a	DT
O	NN

broken	JJ
O	NN

solid-core	NN
O	NN

intramedullary	JJ
O	NN

femoral	JJ
O	NN

nail	NN
O	NN

using	VBG
O	NN

both	DT
O	NN

antegrade	NN
O	NN

and	CC
O	NN

retrograde	JJ
O	NN

starting	VBG
O	NN

points	NNS
O	NN

Do	VB
O	NN

no	DT
O	NN

harm	NN
O	NN

Thalidomide	NNP
T	NN

,	,
O	NN

laser	NN
O	NN

cavity	NN
O	NN

preparation	NN
O	NN

and	CC
O	NN

oral	JJ
O	NN

hydrogen	NN
O	NN

peroxide	NN
O	NN

Emergency	NN
O	NN

!	.
O	NN

Meningococcal	JJ
D	NN

disease	NN
D	NN

First	NNP
O	NNP

the	DT
O	NN

bad	JJ
O	NN

news	NN
O	NN

...	:
O	NN

Does	VBZ
O	NNP

hyperglycemia	NN
D	NN

really	RB
O	NN

cause	NN
O	NN

coronary	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

?	.
O	NN

Diagnosis	NN
O	NN

and	CC
O	NN

therapy	NN
O	NN

of	IN
O	NN

primary	JJ
O	NN

stomach	NN
D	NN

lymphoma	NN
D	NN

Consensus	NN
O	NN

of	IN
O	NN

the	DT
O	NN

Surgical	NNP
O	NNP

Working	VBG
O	NN

Group	NNP
O	NNP

for	IN
O	NN

Oncology	NNP
O	NNP

,	,
O	NN

the	DT
O	NN

Working	VBG
O	NN

Group	NNP
O	NNP

for	IN
O	NN

Medical	JJ
O	NN

Oncology	NNP
O	NNP

and	CC
O	NN

the	DT
O	NN

Working	VBG
O	NN

Group	NNP
O	NNP

for	IN
O	NN

Radiologic	JJ
O	NN

Oncology	NNP
O	NNP

Rate	NN
O	NN

of	IN
O	NN

RhD	NN
O	NN

sensitisation	NN
O	NN

before	IN
O	NN

and	CC
O	NN

after	IN
O	NN

implementation	NN
O	NN

of	IN
O	NN

a	DT
O	NN

community	NN
O	NN

based	VBN
O	NN

antenatal	JJ
O	NN

prophylaxis	NN
O	NN

programme	NN
O	NN

Ovine	JJ
D	NN

Johne	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

Effect	NN
O	NN

of	IN
O	NN

HAART	JJ
O	NN

on	IN
O	NN

natural	JJ
O	NN

history	NN
O	NN

of	IN
O	NN

AIDS-related	JJ
D	NN

opportunistic	JJ
D	NN

disorders	NNS
D	NN

Psoas	NN
D	NN

abscess	NN
D	NN

Diagnosed	VBN
O	NN

if	IN
O	NN

suspected	VBN
O	NN

Breastfeeding	VBG
O	NN

and	CC
O	NN

catch-up	NN
O	NN

growth	NN
O	NN

in	IN
O	NN

infants	NNS
O	NN

born	VBN
O	NN

small	JJ
O	NN

for	IN
O	NN

gestational	JJ
O	NN

age	NN
O	NN

Health	NNP
O	NNP

practices	NNS
O	VBP

of	IN
O	NN

critical	JJ
O	NN

care	NN
O	NN

nurses	NNS
O	NN

:	:
O	NN

are	VBP
O	NN

these	DT
O	NN

nurses	NNS
O	NN

good	JJ
O	NN

role	NN
O	NN

models	NNS
O	NN

for	IN
O	NN

patients	NNS
O	NN

?	.
O	NN

Testing	VBG
O	NN

for	IN
O	NN

Helicobacter	NN
D	NN

pylori	NN
D	NN

infection	NN
D	NN

after	IN
O	NN

antibiotic	JJ
T	NN

treatment	NN
T	NN

.	.
O	NN

Bullous	JJ
O	NN

eruption	NN
O	NN

in	IN
O	NN

a	DT
O	NN

patient	NN
O	NN

with	IN
O	NN

systemic	JJ
D	NN

lupus	NN
D	NN

erythematosus	NN
D	NN

:	:
O	NN

mite	JJ
D	NN

dermatitis	NN
D	NN

caused	VBN
O	NN

by	IN
O	NN

Cheyletiella	NN
O	NN

blakei	FW
O	FW

A	DT
O	NN

case-control	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

cytochrome	NN
O	NN

P450	NN
O	NN

1A1	NN
O	NN

,	,
O	NN

glutathione	NN
O	NN

S-transferase	NN
O	NN

M1	NN
O	NN

,	,
O	NN

cigarette	NN
O	NN

smoking	NN
O	NN

and	CC
O	NN

lung	NN
O	NN

cancer	NN
O	NN

susceptibility	NN
O	NN

(	NN
O	NN

Massachusetts	NNP
O	NN

,	,
O	NN

United	NNP
O	NNP

States	NNPS
O	NNP

)	NN
O	NN

Association	NNP
O	NN

between	IN
O	NN

thrombolytic	JJ
T	NN

treatment	NN
T	NN

and	CC
O	NN

the	DT
O	NN

prognosis	NN
O	NN

of	IN
O	NN

hemodynamically	RB
O	NN

stable	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

major	JJ
D	NN

pulmonary	JJ
D	NN

embolism	NN
D	NN

:	:
O	NN

results	NNS
O	VBP

of	IN
O	NN

a	DT
O	NN

multicenter	JJ
O	NN

registry	NN
O	NN

.	.
O	NN

Metastatic	JJ
D	NN

malignant	JJ
D	NN

mesothelioma	NN
D	NN

presenting	VBG
O	NN

as	IN
O	NN

colonic	JJ
O	NN

polyps	NNS
O	NN

Microelectrode-guided	JJ
T	NN

posteroventral	JJ
T	NN

pallidotomy	NN
T	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

Parkinson	NNP
D	NNP

's	POS
D	NN

disease	NN
D	NN

:	:
O	NN

postoperative	JJ
O	NN

magnetic	JJ
O	NN

resonance	NN
O	NN

imaging	NN
O	NN

analysis	NN
O	NN

A	DT
O	NN

positive	JJ
O	NN

cannabinoids	NNS
O	NN

workplace	NN
O	NN

drug	NN
O	NN

test	NN
O	NN

following	VBG
O	NN

the	DT
O	NN

ingestion	NN
O	NN

of	IN
O	NN

commercially	RB
O	NN

available	JJ
O	NN

hemp	NN
O	NN

seed	NN
O	NN

oil	NN
O	NN

Congenital	JJ
D	NN

diaphragmatic	NN
D	NN

hernia	NN
D	NN

:	:
O	NN

what	WDT
O	NN

happens	VBZ
O	NN

after	IN
O	NN

discharge	NN
O	NN

?	.
O	NN

Goldilocks	NNP
O	NN

and	CC
O	NN

Mrs	NNP
O	NNP

Ilych	NN
O	NN

:	:
O	NN

a	DT
O	NN

critical	JJ
O	NN

look	NN
O	NN

at	IN
O	NN

the	DT
O	NN

``	``
O	NN

philosophy	NN
O	NN

of	IN
O	NN

hospice	NN
O	NN

''	''
O	NN

Sensitivity	NN
O	NN

and	CC
O	NN

specificity	NN
O	NN

of	IN
O	NN

the	DT
O	NN

neonatal	JJ
O	NN

brain-stem	NN
O	NN

auditory	JJ
O	NN

evoked	VBN
O	NN

potential	JJ
O	NN

for	IN
O	NN

hearing	VBG
O	NN

and	CC
O	NN

language	NN
O	NN

deficits	NNS
O	NN

in	IN
O	NN

survivors	NNS
O	NN

of	IN
O	NN

extracorporeal	JJ
O	NN

membrane	NN
O	NN

oxygenation	NN
O	NN

The	DT
O	NN

Federated	NNP
O	NNP

Council	NNP
O	NNP

of	IN
O	NN

Internal	JJ
O	NN

Medicine	NNP
O	NNP

's	POS
O	NN

resource	NN
O	NN

guide	NN
O	NN

for	IN
O	NN

residency	NN
O	NN

education	NN
O	NN

:	:
O	NN

an	DT
O	NN

instrument	NN
O	NN

for	IN
O	NN

curricular	JJ
O	NN

change	NN
O	NN

A	DT
O	NN

reluctant	JJ
O	NN

doctor	NN
O	NN

shopper	NN
O	NN

Frequent	JJ
O	NN

users	NNS
O	VBP

of	IN
O	NN

emergency	NN
O	NN

services	NNS
O	NN

Localized	JJ
O	NN

Darier	NN
D	NN

disease	NN
D	NN

Implications	NNS
O	VBP

for	IN
O	NN

genetic	JJ
O	NN

studies	NNS
O	VBP

Follow	VB
O	NN

up	RB
O	NN

after	IN
O	NN

potential	JJ
O	NN

curative	JJ
O	NN

surgery	NN
T	NN

of	IN
O	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

Guidelines	NNS
O	NN

from	IN
O	NN

the	DT
O	NN

Norwegian	JJ
O	NN

Gastrointestinal	JJ
O	NN

Cancer	NN
O	NN

Group	NNP
O	NNP

The	DT
O	NN

prison	NN
O	NN

patient	NN
O	NN

Fulminant	JJ
O	NN

hepatic	JJ
D	NN

failure	NN
D	NN

in	IN
O	NN

murine	JJ
D	NN

hepatitis	NN
D	NN

virus	NN
D	NN

strain	NN
D	NN

3	LS
D	NN

infection	NN
D	NN

:	:
O	NN

tissue-specific	JJ
O	NN

expression	NN
O	NN

of	IN
O	NN

a	DT
O	NN

novel	JJ
O	NN

fgl2	NN
O	NN

prothrombinase	NN
O	NN

Lung	NN
T	NN

volume	NN
T	NN

reduction	NN
T	NN

surgery	NN
T	NN

for	IN
O	NN

emphysema	NN
D	NN

The	DT
O	NN

use	NN
O	NN

and	CC
O	NN

effects	NNS
O	NN

of	IN
O	NN

postcoital	JJ
O	NN

contraception	NN
O	NN

Vancomycin-resistant	JJ
O	NN

Staphylococcus	FW
O	FW

aureus	NN
O	NN

:	:
O	NN

apocalypse	NN
O	NN

now	RB
O	NN

?	.
O	NN

Reflex	NN
D	NN

sympathetic	JJ
D	NN

dystrophy	NN
D	NN

:	:
O	NN

fact	NN
O	NN

and	CC
O	NN

fiction	NN
O	NN

Acute	JJ
D	NN

hydrocephalus	NN
D	NN

and	CC
O	NN

brain	NN
D	NN

abscess	NN
D	NN

in	IN
O	NN

Listeria	NN
D	NN

monocytogenes	NNS
D	NN

meningitis	NN
D	NN

Antisense	JJ
O	NN

suppression	NN
O	NN

of	IN
O	NN

4-coumarate	JJ
O	NN

:	:
O	NN

coenzyme	NN
O	NN

A	DT
O	NN

ligase	NN
O	NN

activity	NN
O	NN

in	IN
O	NN

Arabidopsis	NNP
O	NN

leads	VBZ
O	NN

to	TO
O	NN

altered	JJ
O	NN

lignin	NN
O	NN

subunit	NN
O	NN

composition	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Alopecia	NNP
O	NNP

as	IN
O	NN

a	DT
O	NN

consequence	NN
O	NN

of	IN
O	NN

tacrolimus	NN
O	NN

therapy	NN
O	NN

in	IN
O	NN

renal	JJ
O	NN

transplantation	NN
O	NN

?	.
O	NN

Implementation	NN
O	NN

of	IN
O	NN

pharmaceutical	JJ
O	NN

practice	NN
O	NN

guidelines	NNS
O	NN

In	IN
O	NN

vitro	FW
O	FW

interactions	NNS
O	NN

of	IN
O	NN

oxidatively	RB
O	NN

modified	VBN
O	NN

LDL	NN
O	NN

with	IN
O	NN

type	NN
O	NN

I	PRP
O	VBP

,	,
O	NN

II	NNP
O	NNP

,	,
O	NN

III	NNP
O	NN

,	,
O	NN

IV	CD
O	NN

,	,
O	NN

and	CC
O	NN

V	NN
O	NN

collagen	NN
O	NN

,	,
O	NN

laminin	NN
O	NN

,	,
O	NN

fibronectin	NN
O	NN

,	,
O	NN

and	CC
O	NN

poly-D-lysine	JJ
O	NN

Factors	NNS
O	NN

influencing	VBG
O	NN

blood	NN
O	NN

flow	NN
O	NN

in	IN
O	NN

the	DT
O	NN

optic	JJ
O	NN

nerve	NN
O	NN

head	NN
O	NN

Mutations	NNS
O	VBP

of	IN
O	NN

the	DT
O	NN

Drosophila	FW
O	FW

dDP	NN
O	NN

,	,
O	NN

dE2F	NN
O	NN

,	,
O	NN

and	CC
O	NN

cyclin	NN
O	NN

E	NN
O	NN

genes	NNS
O	NN

reveal	VB
O	NN

distinct	JJ
O	NN

roles	NNS
O	NN

for	IN
O	NN

the	DT
O	NN

E2F-DP	NN
O	NN

transcription	NN
O	NN

factor	NN
O	NN

and	CC
O	NN

cyclin	NN
O	NN

E	NN
O	NN

during	IN
O	NN

the	DT
O	NN

G1-S	NN
O	NN

transition	NN
O	NN

SYT-SSX	NN
O	NN

gene	NN
O	NN

fusion	NN
O	NN

as	IN
O	NN

a	DT
O	NN

determinant	NN
O	NN

of	IN
O	NN

morphology	NN
O	NN

and	CC
O	NN

prognosis	NN
O	NN

in	IN
O	NN

synovial	JJ
O	NN

sarcoma	NN
O	NN

A	DT
O	NN

rapid	JJ
O	NN

molecular	JJ
O	NN

method	NN
O	NN

(	NN
O	NN

polymerase	NN
O	NN

chain	NN
O	NN

reaction	NN
O	NN

with	IN
O	NN

sequence-specific	JJ
O	NN

primers	NNS
O	NN

)	NN
O	NN

to	TO
O	NN

genotype	NN
O	NN

for	IN
O	NN

ABO	NN
O	NN

blood	NN
O	NN

group	NN
O	NN

and	CC
O	NN

secretor	NN
O	NN

status	NN
O	NN

and	CC
O	NN

its	PRP$
O	NN

potential	JJ
O	NN

for	IN
O	NN

organ	NN
T	NN

transplants	NNS
T	NN

A	DT
O	NN

population-based	JJ
O	NN

registry	NN
O	NN

on	IN
O	NN

paraproteinaemia	NN
D	NN

in	IN
O	NN

The	DT
O	NN

Netherlands	NNP
O	NNP

Comprehensive	NNP
O	NNP

Cancer	NN
O	NN

Centre	NNP
O	NNP

West	NNP
O	NNP

,	,
O	NN

Leiden	JJ
O	NN

,	,
O	NN

The	DT
O	NN

Netherlands	NNP
O	NNP

Intra-	JJ
O	NN

and	CC
O	NN

inter-individual	JJ
O	NN

biological	JJ
O	NN

variability	NN
O	NN

data	NNS
O	NN

bank	NN
O	NN

Genetic	JJ
O	NN

testing	NN
O	NN

for	IN
O	NN

cancer	NN
D	NN

risk	NN
O	NN

:	:
O	NN

how	WRB
O	NN

to	TO
O	NN

reconcile	VB
O	NN

the	DT
O	NN

conflicts	NNS
O	VBP

Run-in	NN
O	NN

periods	NNS
O	NN

in	IN
O	NN

randomized	VBN
O	NN

trials	NNS
O	NN

:	:
O	NN

implications	NNS
O	VBP

for	IN
O	NN

the	DT
O	NN

application	NN
O	NN

of	IN
O	NN

results	NNS
O	VBP

in	IN
O	NN

clinical	JJ
O	NN

practice	NN
O	NN

Rapid	JJ
O	NN

and	CC
O	NN

ultrarapid	NN
O	NN

opioid	JJ
T	NN

detoxification	NN
T	NN

techniques	NNS
O	VBP

Fulminant	JJ
O	NN

hepatitis	NN
T	NN

associated	VBN
O	NN

with	IN
O	NN

hepatitis	NN
T	NN

A	DT
T	NN

virus	NN
T	NN

superinfection	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
O	NN

hepatitis	NN
T	NN

C	NN
T	NN

The	DT
O	NN

Overactive	JJ
T	NN

Bladder	NN
T	NN

:	:
O	NN

From	IN
O	NN

Basic	JJ
O	NN

Science	NNP
O	NNP

to	TO
O	NN

Clinical	JJ
O	NN

Management	NNP
O	NNP

Consensus	NN
O	NN

Conference	NN
O	NN

Proceedings	NNP
O	NNP

London	NNP
O	NN

,	,
O	NN

England	NNP
O	NNP

,	,
O	NN

June	NNP
O	NN

29	CD
O	NN

,	,
O	NN

1997	CD
O	NN

Techniques	NNS
O	VBP

for	IN
O	NN

erbium	NN
T	NN

:	:
T	NN

YAG	NN
T	NN

laser	NN
T	NN

skin	NN
T	NN

resurfacing	VBG
T	NN

:	:
O	NN

initial	JJ
O	NN

pearls	NNS
O	NN

from	IN
O	NN

the	DT
O	NN

first	RB
O	NN

100	CD
O	NN

patients	NNS
O	NN

Predicting	VBG
O	NN

changes	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

distribution	NN
O	NN

of	IN
O	NN

sweating	NN
D	NN

following	VBG
O	NN

thoracoscopic	JJ
T	NN

sympathectomy	NN
T	NN

.	.
O	NN

The	DT
O	NN

AACC	NN
O	NN

Lectureship	NN
O	NN

Award	NN
O	NN

Address	NN
O	NN

The	DT
O	NN

market	NN
O	NN

for	IN
O	NN

health	NN
O	NN

care	NN
O	NN

:	:
O	NN

where	WRB
O	NN

is	VBZ
O	NN

the	DT
O	NN

patient	NN
O	NN

?	.
O	NN

Human	JJ
O	NN

fetal	JJ
O	NN

pituitary	JJ
O	NN

expresses	VBZ
O	NN

functional	JJ
O	NN

growth	NN
O	NN

hormone-releasing	NN
O	NN

peptide	NN
O	NN

receptors	NNS
O	VBP

The	DT
O	NN

Bizarro	NNP
O	NNP

world	NN
O	NN

of	IN
O	NN

osteodistraction	NN
T	NN

A	DT
O	NN

piece	NN
O	NN

of	IN
O	NN

my	PRP$
O	NN

mind	NN
O	NN

Leaders	NNS
O	VBP

or	CC
O	NN

lemmings	NNS
O	NN

?	.
O	NN

Sales	NNS
O	NN

of	IN
O	NN

food	NN
O	NN

aid	NN
O	NN

as	IN
O	NN

sign	NN
O	NN

of	IN
O	NN

distress	NN
O	NN

,	,
O	NN

not	RB
O	NN

excess	JJ
O	NN

Gastrointestinal	JJ
O	NN

absorption	NN
O	NN

of	IN
O	NN

metals	NNS
O	NN

Embryonic	JJ
O	NN

stem	NN
O	NN

cells	NNS
O	VBP

and	CC
O	NN

hematopoietic	JJ
O	NN

stem	NN
O	NN

cell	NN
O	NN

biology	NN
O	NN

Shark	NN
T	NN

cartilage	NN
T	NN

for	IN
O	NN

cancer	NN
D	NN

?	.
O	NN

The	DT
O	NN

role	NN
O	NN

of	IN
O	NN

the	DT
O	NN

school	NN
O	NN

in	IN
O	NN

the	DT
O	NN

management	NN
O	NN

of	IN
O	NN

attention	NN
D	NN

deficit	NN
D	NN

hyperactivity	NN
D	NN

disorder	NN
D	NN

Photorepair	NN
O	NN

mutants	NNS
O	NN

of	IN
O	NN

Arabidopsis	NNP
O	NN

Toxic	JJ
D	NN

shock	NN
D	NN

syndrome	NN
D	NN

without	IN
O	NN

rash	NN
D	NN

in	IN
O	NN

a	DT
O	NN

young	JJ
O	NN

child	NN
O	NN

:	:
O	NN

link	NN
O	NN

with	IN
O	NN

syndrome	NN
O	NN

of	IN
O	NN

hemorrhagic	JJ
D	NN

shock	NN
D	NN

and	CC
O	NN

encephalopathy	NN
D	NN

?	.
O	NN

Mediastinal	JJ
O	NN

growing	VBG
O	NN

teratoma	NN
D	NN

syndrome	NN
D	NN

Structure	NN
O	NN

and	CC
O	NN

expression	NN
O	NN

of	IN
O	NN

the	DT
O	NN

chicken	NN
O	NN

calmodulin	NN
O	NN

I	PRP
O	VBP

gene	NN
O	NN

Fibromyalgia	NN
D	NN

--	:
O	NN

out	IN
O	NN

of	IN
O	NN

control	NN
O	NN

?	.
O	NN

Fibromyalgia	NN
D	NN

:	:
O	NN

La	NNP
O	NNP

Maladie	NNP
O	NNP

est	NN
O	NN

Morte	NNP
O	NNP

Vive	JJ
O	NN

le	DT
O	NN

Malade	VB
O	NN

!	.
O	NN

Electron	NN
O	NN

beam	NN
O	NN

computed	VBN
O	NN

tomographic	JJ
O	NN

coronary	JJ
O	NN

calcium	NN
O	NN

as	IN
O	NN

a	DT
O	NN

predictor	NN
O	NN

of	IN
O	NN

coronary	JJ
O	NN

events	NNS
O	NN

:	:
O	NN

comparison	NN
O	NN

of	IN
O	NN

two	CD
O	NN

protocols	NNS
O	VBP

The	DT
O	NN

ethics	NNS
O	NN

of	IN
O	NN

genetic	JJ
O	NN

research	NN
O	NN

on	IN
O	NN

sexual	JJ
O	NN

orientation	NN
O	NN

Testicular	JJ
T	NN

sperm	NN
T	NN

retrieval	NN
T	NN

by	IN
T	NN

percutaneous	JJ
T	NN

fine	JJ
T	NN

needle	NN
T	NN

sperm	NN
T	NN

aspiration	NN
T	NN

compared	VBN
O	NN

with	IN
O	NN

testicular	JJ
T	NN

sperm	NN
T	NN

extraction	NN
T	NN

by	IN
T	NN

open	JJ
T	NN

biopsy	NN
T	NN

in	IN
O	NN

men	NNS
O	NN

with	IN
O	NN

non-obstructive	JJ
D	NN

azoospermia	NN
D	NN

Cyclin	NN
O	NN

D1	NN
O	NN

overexpression	NN
O	NN

in	IN
O	NN

malignant	JJ
D	NN

lymphomas	NNS
D	NN

Patient	NN
O	NN

safety	NN
O	NN

and	CC
O	NN

scented	JJ
O	NN

pediatric	JJ
O	NN

anesthesia	NN
O	NN

facemasks	NNS
O	NN

Ion	NN
O	NN

channels	NNS
O	NN

SHARPs	NNS
O	NN

:	:
O	NN

mammalian	JJ
O	NN

enhancer-of-split-	JJ
O	NN

and	CC
O	NN

hairy-related	JJ
O	NN

proteins	NNS
O	NN

coupled	VBN
O	NN

to	TO
O	NN

neuronal	JJ
O	NN

stimulation	NN
O	NN

Complementary	JJ
O	NN

and	CC
O	NN

alternative	JJ
O	NN

medicine	NN
O	NN

:	:
O	NN

friend	NN
O	NN

,	,
O	NN

foe	NN
O	NN

,	,
O	NN

or	CC
O	NN

OWA	NNP
O	NNP

?	.
O	NN

Ondansetron	NN
T	NN

is	VBZ
O	NN

not	RB
O	NN

a	DT
O	NN

panacea	NN
O	NN

Masking	VBG
O	NN

,	,
O	NN

blinding	VBG
O	NN

,	,
O	NN

and	CC
O	NN

peer	VB
O	NN

review	NN
O	NN

:	:
O	NN

the	DT
O	NN

blind	JJ
O	NN

leading	VBG
O	NN

the	DT
O	NN

blinded	VBN
O	NN

Human	JJ
O	NN

cervico-facial	JJ
O	NN

morphogenesis	NN
O	NN

Evaluation	NN
O	NN

of	IN
O	NN

acquired	VBN
O	NN

data	NNS
O	NN

and	CC
O	NN

current	JJ
O	NN

outlook	NN
O	NN

(	NN
O	NN

Part	NNP
O	NNP

1	CD
O	NN

:	:
O	NN

facial	JJ
O	NN

morphogenesis	NN
O	NN

)	NN
O	NN

The	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

TRK-530	NN
T	NN

on	IN
O	NN

experimental	JJ
O	NN

arthritis	NN
D	NN

in	IN
O	NN

mice	NNS
O	NN

Spontaneous	JJ
O	NN

exfoliation	NN
O	NN

of	IN
O	NN

teeth	NNS
O	VBP

following	VBG
O	NN

severe	JJ
O	NN

elemental	JJ
O	NN

mercury	NN
D	NN

poisoning	NN
D	NN

:	:
O	NN

case	NN
O	NN

report	NN
O	NN

and	CC
O	NN

histological	JJ
O	NN

investigation	NN
O	NN

for	IN
O	NN

mechanism	NN
O	NN

Small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

can	MD
O	NNP

express	VB
O	NN

CD34	NN
O	NN

antigen	NN
O	NN

X	NN
O	NN

inactivation	NN
O	NN

in	IN
O	NN

females	NNS
O	NN

with	IN
O	NN

X-linked	JJ
D	NN

disease	NN
D	NN

Report	NNP
O	NNP

of	IN
O	NN

spores	NNS
O	NN

of	IN
O	NN

Henneguya	NN
O	NN

salminicola	NN
O	NN

(	NN
O	NN

Myxozoa	NN
O	NN

)	NN
O	NN

in	IN
O	NN

human	JJ
O	NN

stool	NN
O	NN

specimens	NNS
O	NN

:	:
O	NN

possible	JJ
O	NN

source	NN
O	NN

of	IN
O	NN

confusion	NN
O	NN

with	IN
O	NN

human	JJ
O	NN

spermatozoa	NN
O	NN

Evaluation	NN
O	NN

of	IN
O	NN

a	DT
O	NN

ventilation	NN
T	NN

strategy	NN
T	NN

to	TO
O	NN

prevent	VB
O	NN

barotrauma	NN
D	NN

in	IN
O	NN

patients	NNS
O	NN

at	IN
O	NN

high	JJ
O	NN

risk	NN
O	NN

for	IN
O	NN

acute	JJ
D	NN

respiratory	JJ
D	NN

distress	NN
D	NN

syndrome	NN
D	NN

Pressure-	NN
O	NN

and	CC
O	NN

Volume-Limited	JJ
O	NN

Ventilation	NN
O	NN

Strategy	NN
O	NN

Group	NNP
O	NNP

Audit	NNP
O	NNP

commission	NN
O	NN

tackles	VBZ
O	NN

anaesthetic	JJ
O	NN

services	NNS
O	NN

Abdominal	JJ
D	NN

tuberculosis	NN
D	NN

involving	VBG
O	NN

hepatic	JJ
O	NN

hilar	JJ
O	NN

lymph	NN
O	NN

nodes	NNS
O	NN

A	DT
O	NN

cause	NN
O	NN

of	IN
O	NN

portal	NN
D	NN

vein	NN
D	NN

thrombosis	NN
D	NN

and	CC
O	NN

portal	NN
D	NN

hypertension	NN
D	NN

Treatment	NN
O	NN

of	IN
O	NN

men	NNS
O	NN

with	IN
O	NN

paraphilia	NN
D	NN

with	IN
O	NN

a	DT
O	NN

long-acting	JJ
O	NN

analogue	NN
T	NN

of	IN
T	NN

gonadotropin-releasing	JJ
T	NN

hormone	NN
T	NN

Analgesic	JJ
D	NN

nephropathy	NN
D	NN

Translocations	NNS
O	NN

of	IN
O	NN

11q13	NN
O	NN

in	IN
O	NN

mantle	NN
D	NN

cell	NN
D	NN

lymphoma	NN
D	NN

fail	VB
O	NN

to	TO
O	NN

disrupt	VB
O	NN

the	DT
O	NN

S	NN
O	NN

mu	NN
O	NN

bp-2	NN
O	NN

gene	NN
O	NN

Variation	NN
O	NN

in	IN
O	NN

proficiency	NN
O	NN

testing	NN
O	NN

performance	NN
O	NN

by	IN
O	NN

testing	NN
O	NN

site	NN
O	NN

The	DT
T	NN

``	``
T	NN

H	NN
T	NN

''	''
T	NN

graft	NN
T	NN

:	:
O	NN

an	DT
O	NN

alternative	JJ
O	NN

approach	NN
O	NN

for	IN
O	NN

performing	VBG
O	NN

minimally	RB
O	NN

invasive	JJ
O	NN

direct	JJ
T	NN

coronary	JJ
T	NN

artery	NN
T	NN

bypass	NN
T	NN

Effect	NN
O	NN

of	IN
O	NN

interferon	NN
T	NN

on	IN
O	NN

hepatitis	NN
D	NN

B	NN
D	NN

.	.
O	NN

Health	NNP
O	NNP

insurance	NN
O	NN

for	IN
O	NN

children	NNS
O	VBP

--	:
O	NN

a	DT
O	NN

model	NN
O	NN

for	IN
O	NN

incremental	JJ
O	NN

health	NN
O	NN

reform	NN
O	NN

?	.
O	NN

Distinction	NN
O	NN

awards	NNS
O	NN

and	CC
O	NN

racial	JJ
O	NN

discrimination	NN
O	NN

Potential	JJ
O	NN

biases	NNS
O	VBP

were	VBD
O	NN

not	RB
O	NN

taken	VBN
O	NN

into	IN
O	NN

account	NN
O	NN

in	IN
O	NN

study	NN
O	NN

of	IN
O	NN

waiting	VBG
O	NN

times	NNS
O	NN

Factors	NNS
O	NN

affecting	VBG
O	NN

uptake	NN
O	NN

of	IN
O	NN

antenatal	JJ
O	NN

HIV	NN
O	NN

testing	NN
O	NN

in	IN
O	NN

London	NNP
O	NN

:	:
O	NN

results	NNS
O	VBP

of	IN
O	NN

a	DT
O	NN

multicentre	JJ
O	NN

study	NN
O	NN

Coronary	JJ
O	NN

arterioluminal	JJ
O	NN

communications	NNS
O	NN

in	IN
O	NN

routine	JJ
O	NN

angiography	NN
O	NN

Peptide	NN
O	NN

nucleic	JJ
O	NN

acid	NN
O	NN

(	NN
O	NN

PNA	NN
O	NN

)	NN
O	NN

from	IN
O	NN

DNA	NN
O	NN

recognition	NN
O	NN

to	TO
O	NN

antisense	JJ
O	NN

and	CC
O	NN

DNA	NN
O	NN

structure	NN
O	NN

Homeopathy	NNP
T	NN

for	IN
O	NN

postoperative	JJ
D	NN

ileus	NN
D	NN

?	.
O	NN

A	DT
O	NN

meta-analysis	NN
O	NN

Treatment	NN
O	NN

of	IN
O	NN

postmenopausal	JJ
D	NN

osteoporosis	NN
D	NN

Fascioloidiasis	NN
D	NN

in	IN
O	NN

game-ranched	JJ
O	NN

elk	NN
O	NN

from	IN
O	NN

Montana	NNP
O	NN

Connexin-26	NN
O	NN

mutations	NNS
O	VBP

in	IN
O	NN

sporadic	JJ
O	NN

non-syndromal	JJ
D	NN

sensorineural	NN
D	NN

deafness	NN
D	NN

Lyme	NN
D	NN

disease	NN
D	NN

presenting	VBG
O	NN

as	IN
O	NN

Tourette	NN
D	NN

's	POS
D	NN

syndrome	NN
D	NN

The	DT
O	NN

screening	VBG
O	NN

muddle	VB
O	NN

Treatment	NN
O	NN

of	IN
O	NN

hypertensive	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

diabetes	NN
D	NN

China	NNP
O	NNP

's	POS
O	NN

human-organ	JJ
O	NN

trade	NN
O	NN

highlighted	VBN
O	NN

by	IN
O	NN

US	NNP
O	NN

arrest	NN
O	NN

of	IN
O	NN

``	``
O	NN

salesman	NN
O	NN

''	''
O	NN

Dimension	NN
O	NN

in	IN
O	NN

defining	VBG
O	NN

tumor	NN
D	NN

response	NN
O	NN

Administration	NNP
O	NNP

of	IN
O	NN

dexamethasone	NN
T	NN

induces	VBZ
O	NN

proteinuria	NN
D	NN

of	IN
O	NN

glomerular	JJ
O	NN

origin	NN
O	NN

in	IN
O	NN

mice	NNS
O	NN

Preoperative	JJ
O	NN

thromboxane	NN
O	NN

A2/prostaglandin	NN
O	NN

H2	NN
O	NN

receptor	NN
O	NN

activity	NN
O	NN

predicts	VBZ
O	NN

early	RB
O	NN

graft	NN
D	NN

thrombosis	NN
D	NN

Hypertension	NN
D	NN

treatment	NN
O	NN

and	CC
O	NN

control	NN
O	NN

in	IN
O	NN

sub-Saharan	JJ
O	NN

Africa	NNP
O	NNP

:	:
O	NN

the	DT
O	NN

epidemiological	JJ
O	NN

basis	NN
O	NN

for	IN
O	NN

policy	NN
O	NN

Needle-exchange	JJ
O	NN

programmes	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

USA	NNP
O	NNP

A	DT
O	NN

discriminant	JJ
O	NN

function	NN
O	NN

for	IN
O	NN

preeclampsia	NN
D	NN

:	:
O	NN

case-control	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

minor	JJ
O	NN

hemoglobins	NNS
O	NN

,	,
O	NN

red	JJ
O	NN

cell	NN
O	NN

enzymes	NNS
O	NN

,	,
O	NN

and	CC
O	NN

clinical	JJ
O	NN

laboratory	NN
O	NN

values	NNS
O	VBP

Patterning	NN
O	NN

of	IN
O	NN

immobilized	VBN
O	NN

antibody	NN
O	NN

layers	NNS
O	NN

via	IN
O	NN

photolithography	NN
O	NN

and	CC
O	NN

oxygen	NN
O	NN

plasma	NN
O	NN

exposure	NN
O	NN

A	DT
O	NN

cell-based	JJ
O	NN

immunobiosensor	NN
O	NN

with	IN
O	NN

engineered	VBN
O	NN

molecular	JJ
O	NN

recognition	NN
O	NN

--	:
O	NN

Part	NNP
O	NNP

II	NNP
O	NNP

:	:
O	NN

Enzyme	NN
O	NN

amplification	NN
O	NN

systems	NNS
O	NN

Evanescent	JJ
O	NN

wave	NN
O	NN

fibre	NN
O	NN

optic	JJ
O	NN

sensor	NN
O	NN

for	IN
O	NN

detection	NN
O	NN

of	IN
O	NN

L.	NNP
O	NNP

donovani	JJ
O	NN

specific	JJ
O	NN

antibodies	NNS
O	NN

in	IN
O	NN

sera	NNS
O	VBP

of	IN
O	NN

kala	FW
O	FW

azar	NN
O	NN

patients	NNS
O	NN

Multianalyte	JJ
O	NN

biosensors	NNS
O	NN

on	IN
O	NN

optical	JJ
O	NN

imaging	NN
O	NN

bundles	NNS
O	NN

Specific	JJ
O	NN

binding	VBG
O	NN

of	IN
O	NN

low	JJ
O	NN

molecular	JJ
O	NN

weight	NN
O	NN

ligands	NNS
O	NN

with	IN
O	NN

direct	JJ
O	NN

optical	JJ
O	NN

detection	NN
O	NN

Amperometric	JJ
O	NN

lactate	NN
O	NN

oxidase	NN
O	NN

catheter	NN
O	NN

for	IN
O	NN

real-time	JJ
O	NN

lactate	NN
O	NN

monitoring	VBG
O	NN

based	VBN
O	NN

on	IN
O	NN

thin	JJ
O	NN

film	NN
O	NN

technology	NN
O	NN

Dual-fractal	JJ
O	NN

analysis	NN
O	NN

for	IN
O	NN

antigen	NN
O	NN

--	:
O	NN

antibody	NN
O	NN

binding	VBG
O	NN

kinetics	NNS
O	NN

for	IN
O	NN

biosensor	NN
O	NN

applications	NNS
O	NN

Dipstick	NN
O	NN

only	RB
O	NN

urinalysis	NN
O	NN

screen	NN
O	NN

for	IN
O	NN

the	DT
O	NN

pediatric	JJ
O	NN

emergency	NN
O	NN

room	NN
O	NN

Cytoplasmic	JJ
O	NN

transport	NN
O	NN

in	IN
O	NN

Drosophila	FW
O	FW

ovarian	JJ
O	NN

follicles	NNS
O	NN

:	:
O	NN

the	DT
O	NN

migration	NN
O	NN

of	IN
O	NN

microinjected	VBN
O	NN

fluorescent	JJ
O	NN

probes	NNS
O	VBP

through	IN
O	NN

intercellular	JJ
O	NN

bridges	NNS
O	NN

depends	VBZ
O	NN

neither	DT
O	NN

on	IN
O	NN

electrical	JJ
O	NN

charge	NN
O	NN

nor	CC
O	NN

on	IN
O	NN

external	JJ
O	NN

osmolarity	NN
O	NN

Further	JJ
O	NN

evidence	NN
O	NN

for	IN
O	NN

the	DT
O	NN

importance	NN
O	NN

of	IN
O	NN

an	DT
O	NN

androgen	NN
O	NN

response	NN
O	NN

element	NN
O	NN

in	IN
O	NN

the	DT
O	NN

factor	NN
O	NN

IX	CD
O	NN

promoter	NN
O	NN

The	DT
O	NN

obstetric	JJ
O	NN

experience	NN
O	NN

of	IN
O	NN

carriers	NNS
O	VBP

of	IN
O	NN

haemophilia	NN
D	NN

Acquired	VBN
O	NN

haemophilia	NN
D	NN

,	,
O	NN

an	DT
O	NN

unusual	JJ
O	NN

cause	NN
O	NN

of	IN
O	NN

severe	JJ
O	NN

postpartum	NN
D	NN

haemorrhage	NN
D	NN

Zoonotic	JJ
O	NN

and	CC
O	NN

viral	JJ
D	NN

infection	NN
D	NN

in	IN
O	NN

fetal	JJ
O	NN

loss	NN
O	NN

after	IN
O	NN

12	CD
O	NN

weeks	NNS
O	NN

High-affinity	JJ
O	NN

binding	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

neonatal	JJ
O	NN

Fc	NN
O	NN

receptor	NN
O	NN

to	TO
O	NN

its	PRP$
O	NN

IgG	NN
O	NN

ligand	NN
O	NN

requires	VBZ
O	NN

receptor	NN
O	NN

immobilization	NN
O	NN

Molecular	JJ
O	NN

distances	NNS
O	NN

from	IN
O	NN

dipolar	JJ
O	NN

coupled	VBN
O	NN

spin-labels	NNS
O	NN

:	:
O	NN

the	DT
O	NN

global	JJ
O	NN

analysis	NN
O	NN

of	IN
O	NN

multifrequency	NN
O	NN

continuous	JJ
O	NN

wave	NN
O	NN

electron	NN
O	NN

paramagnetic	JJ
O	NN

resonance	NN
O	NN

data	NNS
O	NN

Computer	NN
O	NN

science	NN
O	NN

and	CC
O	NN

biology	NN
O	NN

--	:
O	NN

the	DT
O	NN

German	JJ
O	NN

Conference	NN
O	NN

on	IN
O	NN

Bioinformatics	NNS
O	NN

(	NN
O	NN

GCB'96	NN
O	NN

)	NN
O	NN

Surface	NN
O	NN

plasmon	NN
O	NN

resonance	NN
O	NN

analysis	NN
O	NN

of	IN
O	NN

topoisomerase	NN
O	NN

I-DNA	JJ
O	NN

binding	VBG
O	NN

:	:
O	NN

effect	NN
O	NN

of	IN
O	NN

Mg2+	NN
O	NN

and	CC
O	NN

DNA	NN
O	NN

sequence	NN
O	NN

The	DT
O	NN

1996	CD
O	NN

list	NN
O	NN

Proposed	VBN
O	NN

new	JJ
O	NN

bacterial	JJ
O	NN

taxa	NN
O	NN

and	CC
O	NN

proposed	VBN
O	NN

changes	NNS
O	VBP

of	IN
O	NN

bacterial	JJ
O	NN

names	NNS
O	NN

published	VBN
O	NN

during	IN
O	NN

1996	CD
O	NN

and	CC
O	NN

considered	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

of	IN
O	NN

interest	NN
O	NN

to	TO
O	NN

medical	JJ
O	NN

or	CC
O	NN

veterinary	JJ
O	NN

bacteriology	NN
O	NN

An	DT
O	NN

informational	JJ
O	NN

note	NN
O	NN

The	DT
O	NN

1995	CD
O	NN

list	NN
O	NN

Proposed	VBN
O	NN

new	JJ
O	NN

bacterial	JJ
O	NN

taxa	NN
O	NN

and	CC
O	NN

proposed	VBN
O	NN

changes	NNS
O	VBP

of	IN
O	NN

bacterial	JJ
O	NN

names	NNS
O	NN

published	VBN
O	NN

during	IN
O	NN

1995	CD
O	NN

and	CC
O	NN

considered	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

of	IN
O	NN

interest	NN
O	NN

to	TO
O	NN

medical	JJ
O	NN

or	CC
O	NN

veterinary	JJ
O	NN

bacteriology	NN
O	NN

An	DT
O	NN

informational	JJ
O	NN

note	NN
O	NN

Biobehavioral	JJ
O	NN

pain	NN
D	NN

research	NN
O	NN

:	:
O	NN

a	DT
O	NN

multi-institute	JJ
O	NN

assessment	NN
O	NN

of	IN
O	NN

cross-cutting	NN
O	NN

issues	NNS
O	VBP

and	CC
O	NN

research	NN
O	NN

needs	NNS
O	VBP

Use	NNP
O	NNP

of	IN
O	NN

surface	NN
O	NN

plasmon	NN
O	NN

resonance	NN
O	NN

to	TO
O	NN

probe	NN
O	NN

the	DT
O	NN

equilibrium	NN
O	NN

and	CC
O	NN

dynamic	JJ
O	NN

aspects	NNS
O	NN

of	IN
O	NN

interactions	NNS
O	NN

between	IN
O	NN

biological	JJ
O	NN

macromolecules	NNS
O	NN

ABC	NNP
O	NN

of	IN
O	NN

mental	JJ
O	NN

health	NN
O	NN

Psychosexual	JJ
D	NN

problems	NNS
D	NN

Hazards	NNS
O	VBP

of	IN
O	NN

running	VBG
O	NN

a	DT
O	NN

marathon	NN
O	NN

Troponin-T	JJ
O	NN

concentrations	NNS
O	NN

should	MD
O	NNP

be	VB
O	NN

measured	VBN
O	NN

Second	JJ
O	NN

Strang	NNP
O	NNP

International	NNP
O	NNP

Cancer	NN
O	NN

Conference	NN
O	NN

:	:
O	NN

genetics	NNS
O	NN

and	CC
O	NN

the	DT
O	NN

environment	NN
O	NN

New	NNP
O	NNP

York	NNP
O	NN

,	,
O	NN

USA	NNP
O	NNP

,	,
O	NN

15-16	CD
O	NN

November	NNP
O	NN

1996	CD
O	NN

Use	NNP
O	NNP

of	IN
O	NN

a	DT
O	NN

modified	VBN
O	NN

version	NN
O	NN

of	IN
O	NN

the	DT
O	NN

Overt	JJ
O	NN

Aggression	NNP
O	NNP

Scale	NNP
O	NNP

in	IN
O	NN

the	DT
O	NN

measurement	NN
O	NN

and	CC
O	NN

assessment	NN
O	NN

of	IN
O	NN

aggressive	JJ
O	NN

behaviours	NNS
O	NN

following	VBG
O	NN

brain	NN
D	NN

injury	NN
D	NN

Ectopic	JJ
D	NN

pregnancy	NN
D	NN

recurrence	NN
O	NN

:	:
O	NN

role	NN
O	NN

of	IN
O	NN

gynecologic	JJ
O	NN

,	,
O	NN

obstetric	JJ
O	NN

,	,
O	NN

contraceptive	JJ
O	NN

and	CC
O	NN

smoking	NN
O	NN

history	NN
O	NN

AIDS	NNP
O	NN

:	:
O	NN

a	DT
O	NN

world	NN
O	NN

,	,
O	NN

a	DT
O	NN

desire	NN
O	NN

Urogynaecology	NN
O	NN

proceedings	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

joint	JJ
O	NN

RCOG/BAUS	NN
O	NN

urogynaecology	NN
O	NN

meeting	NN
O	NN

19	CD
O	NN

September	NNP
O	NNP

1996	CD
O	NN

The	DT
O	NN

naming	VBG
O	NN

of	IN
O	NN

a	DT
O	NN

syndrome	NN
O	NN

The	DT
O	NN

use	NN
O	NN

of	IN
O	NN

implantable	JJ
O	NN

venous	JJ
O	NN

access	NN
O	NN

devices	NNS
O	NN

(	NN
O	NN

IVADs	NNS
O	NN

)	NN
O	NN

in	IN
O	NN

children	NNS
O	VBP

with	IN
O	NN

hemophilia	NN
D	NN

Nephrotic	JJ
D	NN

syndrome	NN
D	NN

associated	VBN
O	NN

with	IN
O	NN

hypocomplementemia	NN
D	NN

in	IN
O	NN

a	DT
O	NN

4-year-old	JJ
O	NN

boy	NN
O	NN

with	IN
O	NN

hemophilia	NN
D	NN

B	NN
D	NN

Growth	NN
O	NN

hormone	NN
O	NN

secretion	NN
O	NN

in	IN
O	NN

HIV-positive	JJ
O	NN

versus	CC
O	NN

HIV-negative	JJ
O	NN

hemophilic	JJ
O	NN

males	NNS
O	VBP

with	IN
O	NN

abnormal	JJ
O	NN

growth	NN
O	NN

and	CC
O	NN

pubertal	JJ
O	NN

development	NN
O	NN

The	DT
O	NN

Hemophilia	NNP
O	NN

Growth	NN
O	NN

and	CC
O	NN

Development	NNP
O	NNP

Study	NNP
O	NNP

Trends	NNS
O	VBP

in	IN
O	NN

HIV	NN
O	NN

counseling	VBG
O	NN

and	CC
O	NN

testing	NN
O	NN

of	IN
O	NN

clients	NNS
O	NN

attending	VBG
O	NN

a	DT
O	NN

public	JJ
O	NN

sexually	RB
O	NN

transmitted	JJ
O	NN

disease	NN
O	NN

clinic	NN
O	NN

in	IN
O	NN

Portland	NNP
O	NNP

,	,
O	NN

Oregon	NNP
O	NN

,	,
O	NN

1989-1995	CD
O	NN

Risk	NN
O	NN

factors	NNS
O	NN

for	IN
O	NN

HIV-1	NN
D	NN

infection	NN
D	NN

among	IN
O	NN

pregnant	JJ
O	NN

women	NNS
O	VBP

in	IN
O	NN

French	JJ
O	NN

Guiana	NNP
O	NNP

Angiogenesis	NN
O	NN

in	IN
O	NN

inflammatory	JJ
D	NN

disease	NN
D	NN

Epidemiology	NNP
O	NNP

and	CC
O	NN

association	NN
O	NN

with	IN
O	NN

extra-gastrointestinal	JJ
D	NN

diseases	NNS
D	NN

Extra-gastrointestinal	JJ
D	NN

diseases	NNS
D	NN

and	CC
O	NN

Helicobacter	NNP
O	NNP

pylori	NN
O	NN

Update	NNP
O	NNP

on	IN
O	NN

Helicobacter	NNP
O	NNP

pylori	NN
O	NN

research	NN
O	NN

Diagnosis	NN
O	NN

Uptake	NN
O	NN

on	IN
O	NN

Helicobacter	NNP
O	NNP

pylori	NN
O	NN

research	NN
O	NN

Pathogenesis	NN
O	NN

and	CC
O	NN

host	NN
O	NN

response	NN
O	NN

Update	NNP
O	NNP

on	IN
O	NN

Helicobacter	NNP
O	NNP

pylori	NN
O	NN

research	NN
O	NN

Malignancies	NNS
O	NN

Update	NNP
O	NNP

on	IN
O	NN

Helicobacter	NNP
O	NNP

pylori	NN
O	NN

research	NN
O	NN

Dyspepsia	NN
D	NN

Update	NNP
O	NNP

on	IN
O	NN

Helicobacter	NNP
O	NNP

pylori	NN
O	NN

research	NN
O	NN

Eradication	NN
O	NN

Sequence	NN
O	NN

analysis	NN
O	NN

of	IN
O	NN

the	DT
O	NN

36-kb	JJ
O	NN

region	NN
O	NN

between	IN
O	NN

gntZ	NN
O	NN

and	CC
O	NN

trnY	NN
O	NN

genes	NNS
O	NN

of	IN
O	NN

Bacillus	NN
O	NN

subtilis	NNS
O	NN

genome	NN
O	NN

A	DT
O	NN

review	NN
O	NN

of	IN
O	NN

interferon	NN
O	NN

immunogenicity	NN
O	NN

Based	VBN
O	NN

on	IN
O	NN

a	DT
O	NN

roundtable	JJ
O	NN

workshop	NN
O	NN

held	VBN
O	NN

in	IN
O	NN

London	NNP
O	NN

,	,
O	NN

United	NNP
O	NNP

Kingdom	NNP
O	NNP

,	,
O	NN

9	CD
O	NN

February	NNP
O	NNP

1996	CD
O	NN

Histologic	JJ
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

chronic	JJ
D	NN

hepatitis	NN
D	NN

,	,
O	NN

grading	VBG
O	NN

and	CC
O	NN

staging	NN
O	NN

Inositol	NN
T	NN

treatment	NN
O	NN

of	IN
O	NN

autism	NN
D	NN

Current	JJ
O	NN

progress	NN
O	NN

in	IN
O	NN

early	RB
O	NN

pregnancy	NN
O	NN

investigation	NN
O	NN

Truncated-gene	JJ
O	NN

reporter	NN
O	NN

system	NN
O	NN

for	IN
O	NN

studying	VBG
O	NN

the	DT
O	NN

regulation	NN
O	NN

of	IN
O	NN

manganese	NN
O	NN

peroxidase	NN
O	NN

expression	NN
O	NN

Disparate	JJ
O	NN

sequence	NN
O	NN

characteristics	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

Erysiphe	NN
O	NN

graminis	NN
O	NN

f.sp	NN
O	NN

hordei	NN
O	NN

glyceraldehyde-3-phosphate	NN
O	NN

dehydrogenase	NN
O	NN

gene	NN
O	NN

The	DT
O	NN

Integrative	JJ
O	NN

Neurobiology	NNP
O	NNP

of	IN
O	NN

Affiliation	NN
O	NN

Proceedings	NNP
O	NNP

of	IN
O	NN

a	DT
O	NN

conference	NN
O	NN

Washington	NNP
O	NNP

,	,
O	NN

DC	NN
O	NN

,	,
O	NN

USA	NNP
O	NNP

March	NNP
O	NNP

14-17	CD
O	NN

,	,
O	NN

1996	CD
O	NN

Proceedings	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

10th	JJ
O	NN

International	NNP
O	NNP

Symposium	NNP
O	NNP

on	IN
O	NN

the	DT
O	NN

Pharmacology	NN
O	NN

of	IN
O	NN

Thermoregulation	NN
O	NN

Memphis	NNP
O	NNP

,	,
O	NN

Tennessee	NNP
O	NN

,	,
O	NN

USA	NNP
O	NNP

August	NNP
O	NN

17-22	CD
O	NN

,	,
O	NN

1996	CD
O	NN

Neuropeptides	NNS
O	NN

in	IN
O	NN

Development	NNP
O	NNP

and	CC
O	NN

Aging	NN
O	NN

Proceedings	NNP
O	NNP

of	IN
O	NN

a	DT
O	NN

conference	NN
O	NN

Breckenridge	NNP
O	NNP

,	,
O	NN

Colorado	NNP
O	NN

,	,
O	NN

USA	NNP
O	NNP

February	NNP
O	NNP

3-6	CD
O	NN

,	,
O	NN

1996	CD
O	NN

Receptor	NN
O	NN

Classification	NN
O	NN

:	:
O	NN

The	DT
O	NN

Integration	NN
O	NN

of	IN
O	NN

Operational	JJ
O	NN

,	,
O	NN

Structural	JJ
O	NN

,	,
O	NN

and	CC
O	NN

Transductional	JJ
O	NN

Information	NN
O	NN

Proceedings	NNP
O	NNP

of	IN
O	NN

a	DT
O	NN

conference	NN
O	NN

Verona	NNP
O	NNP

,	,
O	NN

Italy	NNP
O	NNP

,	,
O	NN

September	NNP
O	NNP

21-22	CD
O	NN

,	,
O	NN

1995	CD
O	NN

Psychobiology	NN
O	NN

of	IN
O	NN

Postraumatic	JJ
D	NN

Stress	NN
D	NN

Disorder	NN
D	NN

Proceedings	NNP
O	NNP

of	IN
O	NN

a	DT
O	NN

conference	NN
O	NN

New	NNP
O	NNP

York	NNP
O	NN

,	,
O	NN

New	NNP
O	NNP

York	NNP
O	NN

,	,
O	NN

USA	NNP
O	NNP

September	NNP
O	NNP

7-10	CD
O	NN

,	,
O	NN

1996	CD
O	NN

Adolescent	JJ
O	NN

Gynecology	NNP
O	NNP

and	CC
O	NN

Endocrinology	NNP
O	NNP

:	:
O	NN

Basic	JJ
O	NN

and	CC
O	NN

Clinical	JJ
O	NN

Aspects	NNS
O	NN

Proceedings	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

3rd	JJ
O	NN

International	NNP
O	NNP

Congress	NNP
O	NN

Athens	NNP
O	NNP

,	,
O	NN

Greece	NNP
O	NNP

,	,
O	NN

December	NNP
O	NN

6-9	CD
O	NN

,	,
O	NN

1995	CD
O	NN

Proceedings	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

3rd	JJ
O	NN

International	NNP
O	NNP

Conference	NN
O	NN

on	IN
O	NN

Neuroprotective	JJ
O	NN

Agents	NNS
O	NN

:	:
O	NN

Clinical	JJ
O	NN

and	CC
O	NN

Experimental	JJ
O	NN

Aspects	NNS
O	NN

Lake	NNP
O	NNP

Como	NN
O	NN

,	,
O	NN

Italy	NNP
O	NNP

,	,
O	NN

September	NNP
O	NNP

9-12	CD
O	NN

,	,
O	NN

1996	CD
O	NN

Exon/intron	NN
O	NN

structure	NN
O	NN

of	IN
O	NN

the	DT
O	NN

human	JJ
O	NN

AF-4	NN
O	NN

gene	NN
O	NN

,	,
O	NN

a	DT
O	NN

member	NN
O	NN

of	IN
O	NN

the	DT
O	NN

AF-4/LAF-4/FMR-2	NN
O	NN

gene	NN
O	NN

family	NN
O	NN

coding	VBG
O	NN

for	IN
O	NN

a	DT
O	NN

nuclear	JJ
O	NN

protein	NN
O	NN

with	IN
O	NN

structural	JJ
O	NN

alterations	NNS
O	VBP

in	IN
O	NN

acute	JJ
O	NN

leukaemia	NN
D	NN

Cloning	NN
O	NN

and	CC
O	NN

characterization	NN
O	NN

of	IN
O	NN

a	DT
O	NN

neural	JJ
O	NN

cell	NN
O	NN

recognition	NN
O	NN

molecule	NN
O	NN

on	IN
O	NN

axons	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

retinotectal	JJ
O	NN

system	NN
O	NN

and	CC
O	NN

spinal	JJ
O	NN

cord	NN
O	NN

Identification	NN
O	NN

,	,
O	NN

localization	NN
O	NN

,	,
O	NN

and	CC
O	NN

expression	NN
O	NN

of	IN
O	NN

two	CD
O	NN

novel	JJ
O	NN

human	JJ
O	NN

genes	NNS
O	NN

similar	JJ
O	NN

to	TO
O	NN

deoxyribonuclease	NN
O	NN

I	PRP
O	VBP

.	.
O	NN

Drug	NN
O	NN

resistance	NN
O	NN

during	IN
O	NN

indinavir	NN
T	NN

therapy	NN
T	NN

is	VBZ
O	NN

caused	VBN
O	NN

by	IN
O	NN

mutations	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

protease	NN
O	NN

gene	NN
O	NN

and	CC
O	NN

in	IN
O	NN

its	PRP$
O	NN

Gag	NN
O	NN

substrate	JJ
O	NN

cleavage	NN
O	NN

sites	NNS
O	NN

A	DT
O	NN

protein	NN
O	NN

with	IN
O	NN

a	DT
O	NN

novel	JJ
O	NN

calcium-binding	JJ
O	NN

domain	NN
O	NN

associated	VBN
O	NN

with	IN
O	NN

calcareous	JJ
O	NN

corpuscles	NNS
O	NN

in	IN
O	NN

Echinococcus	NN
D	NN

granulosus	NN
D	NN

Oncogenic	JJ
O	NN

raf-1	NN
O	NN

induces	VBZ
O	NN

the	DT
O	NN

expression	NN
O	NN

of	IN
O	NN

non-histone	JJ
O	NN

chromosomal	JJ
O	NN

architectural	JJ
O	NN

protein	NN
O	NN

HMGI-C	NN
O	NN

via	IN
O	NN

a	DT
O	NN

p44/p42	NN
O	NN

mitogen-activated	JJ
O	NN

protein	NN
O	NN

kinase-dependent	JJ
O	NN

pathway	NN
O	NN

in	IN
O	NN

salivary	JJ
O	NN

epithelial	JJ
O	NN

cells	NNS
O	VBP

Pendred	VBN
D	NN

syndrome	NN
D	NN

is	VBZ
O	NN

caused	VBN
O	NN

by	IN
O	NN

mutations	NNS
O	VBP

in	IN
O	NN

a	DT
O	NN

putative	JJ
O	NN

sulphate	NN
O	NN

transporter	NN
O	NN

gene	NN
O	NN

(	NN
O	NN

PDS	NN
O	NN

)	NN
O	NN

Meis2	NN
O	NN

,	,
O	NN

a	DT
O	NN

novel	JJ
O	NN

mouse	NN
O	NN

Pbx-related	JJ
O	NN

homeobox	NN
O	NN

gene	NN
O	NN

induced	VBN
O	NN

by	IN
O	NN

retinoic	JJ
O	NN

acid	NN
O	NN

during	IN
O	NN

differentiation	NN
O	NN

of	IN
O	NN

P19	NN
O	NN

embryonal	JJ
O	NN

carcinoma	NN
O	NN

cells	NNS
O	VBP

Proceedings	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

VIIIth	NN
O	NN

International	NNP
O	NNP

Conference	NN
O	NN

on	IN
O	NN

the	DT
O	NN

Na/K-ATPase	NN
O	NN

and	CC
O	NN

Related	JJ
O	NN

Transport	NN
O	NN

ATPases	NNS
O	NN

Mar	NNP
O	NNP

del	DT
O	NN

Plata	NNP
O	NNP

,	,
O	NN

Argentina	NNP
O	NNP

,	,
O	NN

August	NNP
O	NN

26-30	CD
O	NN

,	,
O	NN

1996	CD
O	NN

Targeted	VBN
O	NN

development	NN
O	NN

of	IN
O	NN

microsatellite	NN
O	NN

markers	NNS
O	VBP

from	IN
O	NN

the	DT
O	NN

defined	VBN
O	NN

region	NN
O	NN

of	IN
O	NN

bovine	JJ
O	NN

chromosome	NN
O	NN

6q21-31	JJ
O	NN

Genetic	JJ
O	NN

population	NN
O	NN

structure	NN
O	NN

in	IN
O	NN

the	DT
O	NN

yellow	JJ
O	NN

mongoose	NN
O	NN

,	,
O	NN

Cynictis	NN
O	NN

penicillata	NN
O	NN

ETTIN	NN
O	NN

patterns	NNS
O	VBP

the	DT
O	NN

Arabidopsis	NNP
O	NN

floral	JJ
O	NN

meristem	NN
O	NN

and	CC
O	NN

reproductive	JJ
O	NN

organs	NNS
O	VBP

Ancient	JJ
O	NN

DNA	NN
O	NN

from	IN
O	NN

amber	NN
O	NN

fossil	JJ
O	NN

bees	NNS
O	NN

?	.
O	NN

The	DT
O	NN

histone	NN
O	NN

H1	NN
O	NN

genes	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

dipteran	NN
O	NN

insect	NN
O	NN

,	,
O	NN

Chironomus	NNP
O	NNP

thummi	NN
O	NN

,	,
O	NN

fall	NN
O	NN

under	IN
O	NN

two	CD
O	NN

divergent	JJ
O	NN

classes	NNS
O	NN

and	CC
O	NN

encode	VBP
O	NN

proteins	NNS
O	NN

with	IN
O	NN

distinct	JJ
O	NN

intranuclear	JJ
O	NN

distribution	NN
O	NN

and	CC
O	NN

potentially	RB
O	NN

different	JJ
O	NN

functions	NNS
O	VBP

Characterization	NN
O	NN

of	IN
O	NN

the	DT
O	NN

orf31-petG	NN
O	NN

gene	NN
O	NN

cluster	NN
O	NN

from	IN
O	NN

the	DT
O	NN

plastid	NN
O	NN

genome	NN
O	NN

of	IN
O	NN

Populus	JJ
O	NN

deltoides	NNS
O	NN

Xenopus	NN
O	NN

Pax-2	NN
O	NN

displays	NNS
O	VBP

multiple	JJ
O	NN

splice	NN
O	NN

forms	NNS
O	NN

during	IN
O	NN

embryogenesis	NN
O	NN

and	CC
O	NN

pronephric	JJ
O	NN

kidney	NN
O	NN

development	NN
O	NN

International	NNP
O	NNP

Workshop	NNP
O	NNP

on	IN
O	NN

Bone	NN
O	NN

Research	NNP
O	NNP

in	IN
O	NN

Space	NN
O	NN

Tokyo	NNP
O	NNP

,	,
O	NN

Japan	NNP
O	NNP

,	,
O	NN

November	NNP
O	NN

11-13	CD
O	NN

,	,
O	NN

1996	CD
O	NN

Proceedings	NNP
O	NNP

Joint	NNP
O	NNP

meeting	NN
O	NN

of	IN
O	NN

the	DT
O	NN

Benelux	NNP
O	NNP

Society	NNP
O	NNP

for	IN
O	NN

Microcirculation	NN
O	NN

and	CC
O	NN

the	DT
O	NN

Gesellschaft	NN
O	NN

f1/4r	NN
O	NN

Mikrozirkulation	NN
O	NN

e.V	NN
O	NN

Mainz	NNP
O	NNP

,	,
O	NN

Germany	NNP
O	NNP

,	,
O	NN

October	NNP
O	NN

23-25	CD
O	NN

,	,
O	NN

1997	CD
O	NN

Abstracts	NNS
O	NN

3rd	JJ
O	NN

Congress	NNP
O	NN

of	IN
O	NN

the	DT
O	NN

French	JJ
O	NN

Society	NNP
O	NNP

of	IN
O	NN

Blood	NN
T	NN

Transfusion	NN
T	NN

Marseille	NNP
O	NNP

,	,
O	NN

France	NNP
O	NNP

,	,
O	NN

28-30	CD
O	NN

April	NNP
O	NNP

1998	CD
O	NN

Central	NNP
O	NNP

and	CC
O	NN

East	NNP
O	NNP

European	JJ
O	NN

Regional	NNP
O	NNP

INTERASMA	NN
O	NN

Conference	NN
O	NN

Budapest	NNP
O	NNP

,	,
O	NN

Hungary	NNP
O	NNP

,	,
O	NN

August	NNP
O	NN

24-27	CD
O	NN

,	,
O	NN

1997	CD
O	NN

Summary	NN
O	NN

of	IN
O	NN

symposium	NN
O	NN

,	,
O	NN

antisense	JJ
O	NN

oligonucleotides	NNS
O	NN

:	:
O	NN

strategies	NNS
O	VBP

and	CC
O	NN

successes	NNS
O	VBP

Sarasota	NNP
O	NNP

,	,
O	NN

Florida	NNP
O	NN

,	,
O	NN

USA	NNP
O	NNP

April	NNP
O	NNP

21	CD
O	NN

,	,
O	NN

1995	CD
O	NN

International	NNP
O	NNP

forensic	JJ
O	NN

science	NN
O	NN

and	CC
O	NN

justice	NN
O	NN

Proceedings	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

6th	JJ
O	NN

Congress	NNP
O	NN

of	IN
O	NN

the	DT
O	NN

Soci	NN
O	NN

(	NN
O	NN

c	NN
O	NN

)	NN
O	NN

t	NN
O	NN

(	NN
O	NN

c	NN
O	NN

)	NN
O	NN

de	IN
O	NNP

Pharmaco-Toxicologie	NN
O	NN

Cellulaire	JJ
O	NN

and	CC
O	NN

the	DT
O	NN

Soci	NN
O	NN

(	NN
O	NN

c	NN
O	NN

)	NN
O	NN

t	NN
O	NN

(	NN
O	NN

c	NN
O	NN

)	NN
O	NN

Franaise	JJ
O	NN

de	IN
O	NNP

Toxicologie	NN
O	NN

G	NN
O	NN

(	NN
O	NN

c	NN
O	NN

)	NN
O	NN

n	NN
O	NN

(	NN
O	NN

c	NN
O	NN

)	NN
O	NN

tique	NN
O	NN

Paris	NNP
O	NNP

,	,
O	NN

France	NNP
O	NNP

,	,
O	NN

March	NNP
O	NNP

6-7	CD
O	NN

,	,
O	NN

1997	CD
O	NN

The	DT
O	NN

Italian	JJ
O	NN

Association	NNP
O	NN

for	IN
O	NN

the	DT
O	NN

Study	NNP
O	NNP

of	IN
O	NN

Glaucoma	NN
D	NN

Proceedings	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

12th	JJ
O	NN

annual	JJ
O	NN

general	JJ
O	NN

meeting	NN
O	NN

Rapallo	NNP
O	NNP

,	,
O	NN

Italy	NNP
O	NNP

,	,
O	NN

14-15	CD
O	NN

March	NNP
O	NNP

1997	CD
O	NN

Report	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

61st	JJ
O	NN

National	NNP
O	NNP

Scientific	NNP
O	NNP

Meeting	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

American	JJ
O	NN

College	NNP
O	NNP

of	IN
O	NN

Rheumatology	NNP
O	NNP

,	,
O	NN

Washington	NNP
O	NNP

DC	NN
O	NN

,	,
O	NN

8-12	CD
O	NN

November	NNP
O	NN

1997	CD
O	NN

Topical	JJ
O	NN

dictionary	NN
O	NN

USAN	NNP
O	NNP

Council	NNP
O	NNP

List	NN
O	NN

No	DT
O	NN

404	CD
O	NN

New	NNP
O	NNP

names	NNS
O	NN

Nagrestipen	NN
O	NN

Proposed	VBN
O	NN

genetic	JJ
O	NN

nomenclature	NN
O	NN

rules	NNS
O	VBP

for	IN
O	NN

Tetrahymena	NNP
O	NNP

thermophila	NN
O	NN

,	,
O	NN

Paramecium	NN
O	NN

primaurelia	NN
O	NN

and	CC
O	NN

Paramecium	NN
O	NN

tetraurelia	NN
O	NN

The	DT
O	NN

Seventh	NNP
O	NNP

International	NNP
O	NNP

Meeting	VBG
O	NN

on	IN
O	NN

Ciliate	VB
O	NN

Molecular	JJ
O	NN

Biology	NN
O	NN

Genetics	NNP
O	NNP

Nomenclature	JJ
O	NN

Joint	NNP
O	NNP

annual	JJ
O	NN

session	NN
O	NN

of	IN
O	NN

the	DT
O	NN

North	NNP
O	NNP

German	JJ
O	NN

Society	NNP
O	NNP

of	IN
O	NN

Radiology	NN
O	NN

and	CC
O	NN

the	DT
O	NN

Radiology	NN
O	NN

Society	NNP
O	NNP

of	IN
O	NN

Lower	JJR
O	NN

Saxony	NNP
O	NNP

and	CC
O	NN

Sachsen	FW
O	FW

Anhalt	NNP
O	NNP

Kiel	NNP
O	NNP

,	,
O	NN

20-21	NN
O	NN

February	NNP
O	NNP

1998	CD
O	NN

Abstracts	NNS
O	NN

Neurone	NN
O	NN

development	NN
O	NN

and	CC
O	NN

death	NN
O	NN

,	,
O	NN

from	IN
O	NN

a	DT
O	NN

cell	NN
O	NN

biologist	NN
O	NN

's	POS
O	NN

perspective	NN
O	NN

3rd	JJ
O	NN

Neurotrauma/Polytrauma	NN
O	NN

Symposium	NNP
O	NNP

Cologne	NNP
O	NNP

,	,
O	NN

Germany	NNP
O	NNP

,	,
O	NN

March	NNP
O	NNP

14-15	CD
O	NN

,	,
O	NN

1998	CD
O	NN

Abstracts	NNS
O	NN

Neuroimmunomodulation	NN
O	NN

:	:
O	NN

Molecular	JJ
O	NN

Aspects	NNS
O	NN

,	,
O	NN

Integrative	JJ
O	NN

Systems	NNP
O	NNP

,	,
O	NN

and	CC
O	NN

Clinical	JJ
O	NN

Advances	NNS
O	VBP

Proceedings	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

3rd	JJ
O	NN

Congress	NNP
O	NN

of	IN
O	NN

the	DT
O	NN

International	NNP
O	NNP

Society	NNP
O	NNP

of	IN
O	NN

NeuroImmunoModulation	NN
O	NN

(	NN
O	NN

ISNIM	NN
O	NN

)	NN
O	NN

Bethesda	NNP
O	NNP

,	,
O	NN

Maryland	NNP
O	NN

,	,
O	NN

USA	NNP
O	NNP

November	NNP
O	NN

13-15	CD
O	NN

,	,
O	NN

1996	CD
O	NN

8th	JJ
O	NN

European	JJ
O	NN

Meeting	VBG
O	NN

on	IN
O	NN

Dysmorphology	NN
O	NN

Strasbourg	NNP
O	NNP

,	,
O	NN

France	NNP
O	NNP

,	,
O	NN

3-6	CD
O	NN

September	NNP
O	NNP

1997	CD
O	NN

Abstracts	NNS
O	NN

EU	NNP
O	NNP

Working	VBG
O	NN

Group	NNP
O	NNP

on	IN
O	NN

Tobacco	NN
O	NN

and	CC
O	NN

Oral	JJ
O	NN

Health	NNP
O	NNP

Consensus	NN
O	NN

Meeting	VBG
O	NN

Copenhagen	NNP
O	NNP

,	,
O	NN

23-26	CD
O	NN

October	NNP
O	NN

1997	CD
O	NN

Abstracts	NNS
O	NN

Presentations	NNS
O	NN

from	IN
O	NN

the	DT
O	NN

2nd	JJ
O	NN

NIH	NNP
O	NN

Symposium	NNP
O	NNP

on	IN
O	NN

Therapeutic	JJ
O	NN

Oligonucleotides	NNS
O	NN

:	:
O	NN

Targeting	NN
O	NN

Transcription	NN
O	NN

Factors	NNS
O	NN

and	CC
O	NN

Signaling	NN
O	NN

Pathways	NNS
O	NN

Bethesda	NNP
O	NNP

,	,
O	NN

Maryland	NNP
O	NN

,	,
O	NN

USA	NNP
O	NNP

December	NNP
O	NN

5	CD
O	NN

,	,
O	NN

1997	CD
O	NN

Infectious	JJ
D	NN

diseases	NNS
D	NN

:	:
O	NN

their	PRP$
O	NN

impact	NN
O	NN

on	IN
O	NN

dentistry	NN
O	NN

What	WDT
O	NN

's	POS
O	NN

new	JJ
O	NN

in	IN
O	NN

protein	NN
O	NN

folding	JJ
O	NN

?	.
O	NN

EMBO	NNP
O	NN

workshop	NN
O	NN

:	:
O	NN

protein	NN
O	NN

folding	JJ
O	NN

and	CC
O	NN

misfolding	VBG
O	NN

inside	IN
O	NN

and	CC
O	NN

outside	IN
O	NN

the	DT
O	NN

cell	NN
O	NN

Meeting	VBG
O	NN

of	IN
O	NN

the	DT
O	NN

European	JJ
O	NN

forum	NN
O	NN

of	IN
O	NN

nurses	NNS
O	NN

17th	JJ
O	NN

European	JJ
O	NN

Workshop	NNP
O	NNP

on	IN
O	NN

the	DT
O	NN

Cell	NN
O	NN

Biology	NN
O	NN

of	IN
O	NN

Phagocytes	NNS
O	NN

Catania	NNP
O	NNP

,	,
O	NN

Italy	NNP
O	NNP

,	,
O	NN

May	NNP
O	NNP

27-31	CD
O	NN

,	,
O	NN

1998	CD
O	NN

Abstracts	NNS
O	NN

Onset	NN
O	NN

of	IN
O	NN

the	DT
O	NN

preovulatory	JJ
O	NN

luteinizing	VBG
O	NN

hormone	NN
O	NN

surge	NN
O	NN

:	:
O	NN

diurnal	JJ
O	NN

timing	VBG
O	NN

and	CC
O	NN

critical	JJ
O	NN

follicular	JJ
O	NN

prerequisites	NNS
O	VBP

Municipal	JJ
O	NN

animal	NN
O	NN

control	NN
O	NN

ordinances	NNS
O	VBP

--	:
O	NN

some	DT
O	NN

legal	JJ
O	NN

issues	NNS
O	VBP

Psychosexual	JJ
O	NN

care	NN
O	NN

in	IN
O	NN

a	DT
O	NN

multi-ethnic	JJ
O	NN

society	NN
O	NN

Serologic	JJ
O	NN

evidence	NN
O	NN

for	IN
O	NN

mother-to-child	JJ
O	NN

transmission	NN
O	NN

of	IN
O	NN

Kaposi	NN
D	NN

sarcoma-associated	JJ
D	NN

herpesvirus	NN
D	NN

infection	NN
D	NN

Brandon/Hill	NNP
O	NNP

selected	VBN
O	NN

list	NN
O	NN

of	IN
O	NN

nursing	NN
O	NN

books	NNS
O	VBP

and	CC
O	NN

journals	NNS
O	VBP

Retraction	NN
O	NN

The	DT
O	NN

TSG101	NN
O	NN

tumor	NN
O	NN

susceptibility	NN
O	NN

gene	NN
O	NN

is	VBZ
O	NN

located	JJ
O	NN

in	IN
O	NN

chromosome	NN
O	NN

11	CD
O	NN

band	NN
O	NN

p15	NN
O	NN

and	CC
O	NN

is	VBZ
O	NN

mutated	VBN
O	NN

in	IN
O	NN

human	JJ
O	NN

breast	NN
D	NN

cancer	NN
D	NN

An	DT
O	NN

omission	NN
O	NN

Indoor	JJ
O	NN

pollution	NN
O	NN

and	CC
O	NN

health	NN
O	NN

Dioxins	NNS
O	NN

:	:
O	NN

current	JJ
O	NN

knowledge	NN
O	NN

about	IN
O	NN

health	NN
O	NN

effects	NNS
O	NN

Influence	NN
O	NN

of	IN
O	NN

environmental	JJ
O	NN

factors	NNS
O	NN

on	IN
O	NN

fertility	NN
O	NN

:	:
O	NN

example	NN
O	NN

of	IN
O	NN

the	DT
O	NN

diminution	NN
O	NN

of	IN
O	NN

sperm	NN
O	NN

quality	NN
O	NN

New	NNP
O	NNP

developments	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

diabetes	NN
D	NN

and	CC
O	NN

hyperlipidemias	NN
D	NN

Role	NN
O	NN

of	IN
O	NN

beta-blockers	NNS
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

cardiac	JJ
D	NN

insufficiency	NN
D	NN

Which	WDT
O	NN

calcium	NN
T	NN

antagonists	NNS
T	NN

for	IN
O	NN

hypertension	NN
D	NN

?	.
O	NN

Correct	JJ
O	NN

use	NN
O	NN

of	IN
O	NN

serotonin	NN
T	NN

agonists	NNS
T	NN

in	IN
O	NN

migraine	NN
D	NN

:	:
O	NN

oral	JJ
O	NN

or	CC
O	NN

injectable	JJ
O	NN

form	NN
O	NN

?	.
O	NN

Overtraining	VBG
O	NN

and	CC
O	NN

recovery	NN
O	NN

A	DT
O	NN

conceptual	JJ
O	NN

model	NN
O	NN

Saliva	FW
O	FW

composition	NN
O	NN

and	CC
O	NN

exercise	NN
O	NN

Lipid	NN
O	NN

metabolism	NN
O	NN

during	IN
O	NN

exercise	NN
O	NN

Golf	NNP
D	NNP

injuries	NNS
D	NN

An	DT
O	NN

overview	NN
O	NN

Prevention	NNP
O	NNP

of	IN
O	NN

ankle	NN
D	NN

injuries	NNS
D	NN

Academic	NNP
O	NNP

medicine	NN
O	NN

--	:
O	NN

alternative	JJ
O	NN

medicine	NN
O	NN

from	IN
O	NN

the	DT
O	NN

viewpoint	NN
O	NN

of	IN
O	NN

public	JJ
O	NN

health	NN
O	NN

public	JJ
O	NN

health	NN
O	NN

directors	NNS
O	VBP

Academic	NNP
O	NNP

medicine	NN
O	NN

and	CC
O	NN

complementary	JJ
O	NN

medicine	NN
O	NN

--	:
O	NN

campaign	NN
O	NN

for	IN
O	NN

the	DT
O	NN

truth	NN
O	NN

in	IN
O	NN

medical	JJ
O	NN

theories	NNS
O	NN

The	DT
O	NN

academic	JJ
O	NN

medicine	NN
O	NN

--	:
O	NN

alternative	JJ
O	NN

medicine	NN
O	NN

tension	NN
O	NN

field	NN
O	NN

Are	VBP
O	NN

academic	JJ
O	NN

medicine-alternative	JJ
O	NN

medicine	NN
O	NN

incompatible	JJ
O	NN

,	,
O	NN

compatible	JJ
O	NN

,	,
O	NN

complementary	JJ
O	NN

?	.
O	NN

Research	NNP
O	NNP

in	IN
O	NN

complementary	JJ
O	NN

medicine	NN
O	NN

:	:
O	NN

results	NNS
O	VBP

and	CC
O	NN

problems	NNS
O	VBP

Subcutaneous	JJ
D	NN

hematomas	NNS
D	NN

,	,
O	NN

reduced	VBN
O	NN

Quick	RB
O	NN

value	NN
O	NN

Factor	NN
D	NN

VII	NN
D	NN

deficiency	NN
D	NN

Mononucleosis	NN
D	NN

infectiosa	NN
D	NN

(	NN
O	NN

Epstein-Barr	JJ
D	NN

virus	NN
D	NN

infection	NN
D	NN

Morphology	NN
O	NN

and	CC
O	NN

molecular	JJ
O	NN

biology	NN
O	NN

of	IN
O	NN

malignant	JJ
O	NN

soft	JJ
D	NN

tissue	NN
D	NN

sarcomas	NNS
D	NN

Surgical	NNP
O	NNP

aspects	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

multidisciplinary	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

soft	JJ
D	NN

tissue	NN
D	NN

sarcomas	NNS
D	NN

Surgical	NNP
T	NN

management	NN
T	NN

of	IN
O	NN

soft	JJ
D	NN

tissue	NN
D	NN

sarcomas	NNS
D	NN

:	:
O	NN

principles	NNS
O	VBP

of	IN
O	NN

resection	NN
T	NN

and	CC
O	NN

reconstructive	JJ
O	NN

plastic	JJ
O	NN

procedures	NNS
O	VBP

Adjuvant	JJ
T	NN

chemotherapy	NN
T	NN

in	IN
O	NN

early	RB
O	NN

soft	JJ
D	NN

tissue	NN
D	NN

sarcoma	NN
D	NN

and	CC
O	NN

palliative	JJ
T	NN

chemotherapy	NN
T	NN

in	IN
O	NN

advanced	JJ
O	NN

soft	JJ
D	NN

tissue	NN
D	NN

sarcoma	NN
D	NN

in	IN
O	NN

adults	NNS
O	NN

Radiotherapy	NN
T	NN

of	IN
O	NN

soft	JJ
D	NN

tissue	NN
D	NN

sarcomas	NNS
D	NN

Spinal	JJ
D	NN

muscular	JJ
D	NN

atrophy	NN
D	NN

:	:
O	NN

where	WRB
O	NN

are	VBP
O	NN

we	PRP
O	VBP

in	IN
O	NN

1998	CD
O	NN

?	.
O	NN

Diseases	NNS
O	NN

transmitted	JJ
O	NN

by	IN
O	NN

non-conventional	JJ
O	NN

agents	NNS
O	NN

(	NN
O	NN

``	``
O	NN

prions	NNS
O	NN

''	''
O	NN

)	NN
O	NN

:	:
O	NN

nosology	JJ
O	NN

and	CC
O	NN

diagnosis	NN
O	NN

A	DT
O	NN

note	NN
O	NN

on	IN
O	NN

the	DT
O	NN

epidemiology	NN
O	NN

of	IN
O	NN

Creutzfeldt-Jakob	NN
D	NN

syndrome	NN
D	NN

Biology	NN
O	NN

of	IN
O	NN

non-conventional	JJ
O	NN

transmissible	JJ
O	NN

agents	NNS
O	NN

or	CC
O	NN

prions	NNS
O	NN

Cerebral	JJ
D	NN

hemosiderosis	NN
D	NN

related	JJ
O	NN

to	TO
O	NN

hereditary	JJ
O	NN

ceruloplasmin	NN
D	NN

deficiency	NN
D	NN

Clinical	JJ
O	NN

familial	JJ
O	NN

case	NN
O	NN

study	NN
O	NN

Intramedullary	JJ
O	NN

metastases	NNS
O	NN

of	IN
O	NN

bronchogenic	JJ
D	NN

carcinoma	NN
D	NN

Two	CD
O	NN

cases	NNS
O	NN

Nervous	JJ
D	NN

system	NN
D	NN

borreliosis	NN
D	NN

with	IN
O	NN

pseudo-lymphoma	NN
O	NN

cells	NNS
O	VBP

in	IN
O	NN

cerebrospinal	JJ
O	NN

fluid	NN
O	NN

Epidural	JJ
O	NN

and	CC
O	NN

intramedullary	JJ
O	NN

abscess	NN
O	NN

of	IN
O	NN

acute	JJ
O	NN

onset	NN
O	NN

Cranial	JJ
D	NN

nerve	NN
D	NN

injuries	NNS
D	NN

during	IN
O	NN

multifocal	JJ
O	NN

neuropathies	NNS
O	NN

with	IN
O	NN

persistent	JJ
O	NN

conduction	NN
O	NN

blocks	NNS
O	NN

Cytokines	NNS
O	NN

and	CC
O	NN

peripheral	JJ
O	NN

neuropathies	NNS
O	NN

Clinical	JJ
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

frontotemporal	NN
D	NN

dementia	NN
D	NN

Study	NNP
O	NNP

of	IN
O	NN

cortical	JJ
D	NN

atrophy	NN
D	NN

with	IN
O	NN

magnetic	JJ
O	NN

resonance	NN
O	NN

imaging	NN
O	NN

in	IN
O	NN

corticobasal	NN
D	NN

degeneration	NN
D	NN

Autosomal	JJ
O	NN

dominant	JJ
O	NN

nocturnal	JJ
O	NN

frontal	JJ
O	NN

lobe	NN
O	NN

epilepsy	NN
D	NN

Eosinophilic	JJ
D	NN

meningitis	NN
D	NN

due	JJ
O	NN

to	TO
O	NN

Angiostrongylus	JJ
O	NN

cantonensis	NN
O	NN

Case	NNP
O	NNP

of	IN
O	NN

superficial	JJ
D	NN

hemosiderosis	NN
D	NN

of	IN
D	NN

the	DT
D	NN

central	JJ
D	NN

nervous	JJ
D	NN

system	NN
D	NN

treated	VBN
O	NN

with	IN
O	NN

trientine	NN
T	NN

Germinal	JJ
D	NN

tumor	NN
D	NN

metastases	NNS
D	NN

Case	NNP
O	NNP

report	NN
O	NN

Bradycardia	NN
D	NN

:	:
O	NN

an	DT
O	NN

unrecognized	JJ
O	NN

complication	NN
O	NN

of	IN
O	NN

some	DT
O	NN

epileptic	JJ
O	NN

crises	NNS
O	VBP

Facial	JJ
D	NN

palsy	NN
O	NN

relevant	JJ
O	NN

to	TO
O	NN

HIV	NN
O	NN

seropositivity	NN
O	NN

Pneumosinus	NN
O	NN

dilatans	NNS
O	NN

:	:
O	NN

a	DT
O	NN

little-known	JJ
O	NN

diagnostic	JJ
O	NN

tool	NN
O	NN

Current	JJ
O	NN

status	NN
O	NN

of	IN
O	NN

mitochondrial	JJ
D	NN

diseases	NNS
D	NN

Vascular	JJ
D	NN

Parkinson	NNP
D	NNP

syndromes	NNS
D	NN

:	:
O	NN

a	DT
O	NN

controversial	JJ
O	NN

concept	NN
O	NN

Epilepsy	NNP
D	NNP

and	CC
O	NN

psychiatric	JJ
D	NN

disorders	NNS
D	NN

:	:
O	NN

epidemiological	JJ
O	NN

data	NNS
O	NN

Auditory	JJ
D	NN

perception	NN
D	NN

disorders	NNS
D	NN

due	JJ
O	NN

to	TO
O	NN

bilateral	JJ
D	NN

cortical	JJ
D	NN

lesions	NNS
D	NN

An	DT
O	NN

electrophysiology	NN
O	NN

study	NN
O	NN

Zinc	NN
T	NN

gluconate	NN
T	NN

lozenges	NNS
T	NN

for	IN
O	NN

treating	VBG
O	NN

the	DT
O	NN

common	JJ
D	NN

cold	JJ
D	NN

Body	NN
O	NN

weight	NN
O	NN

and	CC
O	NN

mortality	NN
O	NN

among	IN
O	NN

women	NNS
O	VBP

Survey	NN
O	NN

and	CC
O	NN

assessment	NN
O	NN

of	IN
O	NN

the	DT
O	NN

actual	JJ
O	NN

state	NN
O	NN

of	IN
O	NN

routine	JJ
O	NN

measurement	NN
O	NN

of	IN
O	NN

glycohaemoglobin/GHb	NN
O	NN

by	IN
O	NN

commercial	JJ
O	NN

methods	NNS
O	VBP

:	:
O	NN

warning	VBG
O	NN

to	TO
O	NN

the	DT
O	NN

users	NNS
O	VBP

and	CC
O	NN

the	DT
O	NN

providers	NNS
O	NN

The	DT
O	NN

radiological	JJ
O	NN

investigation	NN
O	NN

of	IN
O	NN

suspected	VBN
O	NN

lower	JJR
O	NN

limb	NN
O	NN

deep	JJ
D	NN

vein	NN
D	NN

thrombosis	NN
D	NN

p53	NN
O	NN

mutations	NNS
O	VBP

in	IN
O	NN

BRCA1-associated	JJ
O	NN

familial	JJ
O	NN

breast	NN
D	NN

cancer	NN
D	NN

Metronidazole	NNP
T	NN

(	NN
O	NN

Flagyl	NNP
O	NNP

)	NN
O	NN

The	DT
O	NN

Preterm	NNP
O	NNP

Prediction	NN
O	NN

Study	NNP
O	NNP

:	:
O	NN

association	NN
O	NN

of	IN
O	NN

cesarean	NN
T	NN

delivery	NN
T	NN

with	IN
O	NN

increases	NNS
O	NN

in	IN
O	NN

maternal	JJ
O	NN

weight	NN
O	NN

and	CC
O	NN

body	NN
O	NN

mass	NN
O	NN

index	NN
O	NN

Controversies	NNS
O	VBP

in	IN
O	NN

hydrating	VBG
O	NN

the	DT
O	NN

terminally	RB
O	NN

ill	RB
O	NN

patient	NN
O	NN

Frequency	NN
O	NN

and	CC
O	NN

significance	NN
O	NN

of	IN
O	NN

antinuclear	JJ
O	NN

antibodies	NNS
O	NN

in	IN
O	NN

multiple	JJ
D	NN

sclerosis	NN
D	NN

Magnetic	JJ
O	NN

resonance	NN
O	NN

imaging	NN
O	NN

of	IN
O	NN

the	DT
O	NN

bone	NN
O	NN

marrow	NN
O	NN

in	IN
O	NN

hematologic	JJ
D	NN

malignancies	NNS
D	NN

Generation	NN
O	NN

of	IN
O	NN

diversity	NN
O	NN

in	IN
O	NN

mammalian	JJ
O	NN

gut-associated	JJ
O	NN

lymphoid	JJ
O	NN

tissues	NNS
O	NN

:	:
O	NN

restricted	JJ
O	NN

V	NN
O	NN

gene	NN
O	NN

usage	NN
O	NN

does	VBZ
O	NNP

not	RB
O	NN

preclude	VB
O	NN

complex	JJ
O	NN

V	NN
O	NN

gene	NN
O	NN

organization	NN
O	NN

A	DT
O	NN

major	JJ
O	NN

non-LTR	JJ
O	NN

retrotransposon	NN
O	NN

of	IN
O	NN

Bombyx	NN
O	NN

mori	NN
O	NN

,	,
O	NN

L1Bm	NN
O	NN

Algae	NNP
O	NNP

or	CC
O	NN

protozoa	NN
O	NN

:	:
O	NN

phylogenetic	JJ
O	NN

position	NN
O	NN

of	IN
O	NN

euglenophytes	NNS
O	NN

and	CC
O	NN

dinoflagellates	NNS
O	NN

as	IN
O	NN

inferred	VBN
O	NN

from	IN
O	NN

mitochondrial	JJ
O	NN

sequences	NNS
O	NN

Structure	NN
O	NN

and	CC
O	NN

function	NN
O	NN

of	IN
O	NN

the	DT
O	NN

long	RB
O	NN

terminal	JJ
O	NN

repeats	NNS
O	VBP

of	IN
O	NN

feline	JJ
O	NN

leukemia	NN
O	NN

viruses	NNS
O	NN

derived	VBN
O	NN

from	IN
O	NN

naturally	RB
O	NN

occurring	VBG
O	NN

acute	JJ
D	NN

myeloid	JJ
D	NN

leukemias	NNS
D	NN

in	IN
O	NN

cats	NNS
O	NN

Use	NNP
O	NNP

of	IN
O	NN

protein-C	JJ
T	NN

concentrate	NN
T	NN

,	,
T	NN

heparin	NN
T	NN

,	,
T	NN

and	CC
T	NN

haemodiafiltration	NN
T	NN

in	IN
O	NN

meningococcus-induced	JJ
D	NN

purpura	NN
D	NN

fulminans	NNS
D	NN

Satellite	NNP
O	NNP

DNA	NN
O	NN

repeat	NN
O	NN

sequence	NN
O	NN

variation	NN
O	NN

is	VBZ
O	NN

low	JJ
O	NN

in	IN
O	NN

three	CD
O	NN

species	NNS
O	NN

of	IN
O	NN

burying	VBG
O	NN

beetles	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

genus	NN
O	NN

Nicrophorus	NN
O	NN

(	NN
O	NN

Coleoptera	NNP
O	NNP

:	:
O	NN

Silphidae	FW
O	FW

)	NN
O	NN

The	DT
O	NN

importance	NN
O	NN

of	IN
O	NN

patient	NN
O	NN

registration	NN
O	NN

and	CC
O	NN

processing	VBG
O	NN

Dose-dependent	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

recombinant	JJ
O	NN

human	JJ
O	NN

interleukin-6	NN
O	NN

on	IN
O	NN

glucose	NN
O	NN

regulation	NN
O	NN

Genomic	JJ
O	NN

sequence	NN
O	NN

of	IN
O	NN

a	DT
O	NN

Lyme	NN
D	NN

disease	NN
D	NN

spirochaete	NN
O	NN

,	,
O	NN

Borrelia	FW
O	FW

burgdorferi	FW
O	FW

Interaction	NN
O	NN

between	IN
O	NN

electronic	JJ
O	NN

article	NN
O	NN

surveillance	NN
O	NN

systems	NNS
O	NN

and	CC
O	NN

implantable	JJ
O	NN

defibrillators	NNS
O	NN

:	:
O	NN

insights	NNS
O	NN

from	IN
O	NN

a	DT
O	NN

fourth	JJ
O	NN

generation	NN
O	NN

ICD	NN
O	NN

Human	JJ
O	NN

bodily	JJ
O	NN

health	NN
O	NN

and	CC
O	NN

the	DT
O	NN

common	JJ
O	NN

good	JJ
O	NN

Proposals	NNS
O	VBP

for	IN
O	NN

action	NN
O	NN

by	IN
O	NN

individuals	NNS
O	VBP

and	CC
O	NN

the	DT
O	NN

Catholic	JJ
O	NN

Church	NNP
O	NNP

Invited	VBN
O	NN

commentary	NN
O	NN

:	:
O	NN

le	DT
O	NN

mystre	NN
O	NN

de	IN
O	NNP

Montr	NN
O	NN

(	NN
O	NN

c	NN
O	NN

)	NN
O	NN

al	NNP
O	NNP

.	.
O	NN

Why	WRB
O	NN

Oedipus	NNP
O	NN

and	CC
O	NN

not	RB
O	NN

Christ	NNP
O	NN

?	.
O	NN

:	:
O	NN

a	DT
O	NN

psychoanalytic	JJ
O	NN

inquiry	NN
O	NN

into	IN
O	NN

innocence	NN
O	NN

,	,
O	NN

human	JJ
O	NN

sacrifice	NN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

sacred	JJ
O	NN

--	:
O	NN

Part	NNP
O	NNP

I	PRP
O	VBP

:	:
O	NN

Innocence	NN
O	NN

,	,
O	NN

spirituality	NN
O	NN

,	,
O	NN

and	CC
O	NN

human	JJ
O	NN

sacrifice	NN
O	NN

Equine	NN
O	NN

dinucleotide	NN
O	NN

repeat	NN
O	NN

loci	NNS
O	NN

LEX049-LEX063	NN
O	NN

Molecular	JJ
O	NN

systematics	NNS
O	NN

of	IN
O	NN

tanagers	NNS
O	NN

(	NN
O	NN

Thraupinae	FW
O	FW

)	NN
O	NN

:	:
O	NN

evolution	NN
O	NN

and	CC
O	NN

biogeography	NN
O	NN

of	IN
O	NN

a	DT
O	NN

diverse	JJ
O	NN

radiation	NN
O	NN

of	IN
O	NN

neotropical	JJ
O	NN

birds	NNS
O	NN

Expression	NN
O	NN

of	IN
O	NN

cytokeratin	NN
O	NN

20	CD
O	NN

in	IN
O	NN

urinary	JJ
O	NN

cytology	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

bladder	NN
D	NN

carcinoma	NN
D	NN

A	DT
O	NN

family	NN
O	NN

of	IN
O	NN

highly	RB
O	NN

repetitive	JJ
O	NN

DNAs	NNS
O	NN

from	IN
O	NN

``	``
O	NN

ginbuna	NN
O	NN

''	''
O	NN

(	NN
O	NN

Carassius	NNP
O	NNP

auratus	NN
O	NN

langsdorfi	NN
O	NN

)	NN
O	NN

genome	NN
O	NN

common	JJ
O	NN

to	TO
O	NN

Carassius	NNP
O	NNP

auratus	NN
O	NN

populations	NNS
O	NN

Characterization	NN
O	NN

of	IN
O	NN

cDNA	NN
O	NN

clones	NNS
O	NN

in	IN
O	NN

size-fractionated	JJ
O	NN

cDNA	NN
O	NN

libraries	NNS
O	NN

from	IN
O	NN

human	JJ
O	NN

brain	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Respiratory	JJ
O	NN

arrest	NN
O	NN

following	VBG
O	NN

peribulbar	JJ
O	NN

anesthesia	NN
O	NN

for	IN
O	NN

cataract	NN
O	NN

surgery	NN
O	NN

:	:
O	NN

case	NN
O	NN

report	NN
O	NN

and	CC
O	NN

review	NN
O	NN

of	IN
O	NN

the	DT
O	NN

literature	NN
O	NN

Mouse	NN
O	NN

LIM-kinase	NN
O	NN

2	CD
O	NN

gene	NN
O	NN

:	:
O	NN

cDNA	NN
O	NN

cloning	VBG
O	NN

,	,
O	NN

genomic	JJ
O	NN

organization	NN
O	NN

,	,
O	NN

and	CC
O	NN

tissue-specific	JJ
O	NN

expression	NN
O	NN

of	IN
O	NN

two	CD
O	NN

alternatively	RB
O	NN

initiated	VBN
O	NN

transcripts	NNS
O	NN

A	DT
O	NN

gross	JJ
O	NN

and	CC
O	NN

microscopic	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

cerebral	JJ
D	NN

injuries	NNS
D	NN

accompanying	VBG
O	NN

maxillofacial	JJ
O	NN

high-velocity	JJ
O	NN

projectile	NN
D	NN

wounding	VBG
D	NN

in	IN
O	NN

dogs	NNS
O	NN

Does	VBZ
O	NNP

this	DT
O	NN

patient	NN
O	NN

have	VB
O	NN

a	DT
O	NN

mole	NN
O	NN

or	CC
O	NN

a	DT
O	NN

melanoma	NN
D	NN

?	.
O	NN

Methotrexate	NNP
T	NN

and	CC
O	NN

trimethoprim	NN
T	NN

:	:
O	NN

a	DT
O	NN

fatal	JJ
O	NN

interaction	NN
O	NN

Pellagra	NN
D	NN

and	CC
O	NN

the	DT
O	NN

origin	NN
O	NN

of	IN
O	NN

a	DT
O	NN

myth	NN
O	NN

:	:
O	NN

evidence	NN
O	NN

from	IN
O	NN

European	JJ
O	NN

literature	NN
O	NN

and	CC
O	NN

folklore	NN
O	NN

Absorbable	JJ
T	NN

suture	NN
T	NN

technique	NN
T	NN

:	:
O	NN

solution	NN
O	NN

to	TO
O	NN

the	DT
O	NN

growth	NN
O	NN

problem	NN
O	NN

in	IN
O	NN

pediatric	JJ
O	NN

pacing	NN
O	NN

with	IN
O	NN

endocardial	JJ
O	NN

leads	VBZ
O	NN

Undergraduate	JJ
O	NN

orthodontic	JJ
O	NN

education	NN
O	NN

:	:
O	NN

what	WDT
O	NN

should	MD
O	NNP

we	PRP
O	VBP

teach	VB
O	NN

rather	RB
O	NN

than	IN
O	NN

what	WDT
O	NN

can	MD
O	NNP

we	PRP
O	VBP

teach	VB
O	NN

?	.
O	NN

Genetic	JJ
O	NN

variation	NN
O	NN

in	IN
O	NN

the	DT
O	NN

dimorphic	JJ
O	NN

regions	NNS
O	NN

of	IN
O	NN

RAP-1	NN
O	NN

genes	NNS
O	NN

and	CC
O	NN

rap-1	NN
O	NN

loci	NNS
O	NN

of	IN
O	NN

Babesia	NN
D	NN

bigemina	NN
D	NN

History	NN
O	NN

--	:
O	NN

a	DT
O	NN

living	VBG
O	NN

museum	NN
O	NN

Interview	NN
O	NN

by	IN
O	NN

Grethe	NNP
O	NNP

Kjaergaard	NNP
O	NNP

Gastric	JJ
O	NN

site	NN
O	NN

of	IN
O	NN

epidermoid	NN
D	NN

carcinoma	NN
D	NN

Hypodermic	JJ
O	NN

needles	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

neuropathic	JJ
O	NN

foot	NN
O	NN

of	IN
O	NN

a	DT
O	NN

patient	NN
O	NN

with	IN
O	NN

diabetes	NN
D	NN

Helicobacter	NNP
O	NNP

pylori	NN
O	NN

--	:
O	NN

more	RBR
O	NN

light	JJ
O	NN

,	,
O	NN

less	JJR
O	NN

heat	NN
O	NN

A	DT
O	NN

national	JJ
O	NN

survey	NN
O	NN

of	IN
O	NN

physician-assisted	JJ
O	NN

suicide	NN
O	NN

and	CC
O	NN

euthanasia	NN
O	NN

in	IN
O	NN

the	DT
O	NN

United	NNP
O	NNP

States	NNPS
O	NNP

Death	NN
O	NN

is	VBZ
O	NN

a	DT
O	NN

journey	NN
O	NN

to	TO
O	NN

be	VB
O	NN

undertaken	VBN
O	NN

Replicated	VBN
O	NN

declines	NNS
O	NN

in	IN
O	NN

assault	NN
O	NN

rates	NNS
O	VBP

after	IN
O	NN

implementation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

Assaulted	VBN
O	NN

Staff	NNP
O	NNP

Action	NNP
O	NNP

Program	NN
O	NN

Positive	JJ
O	NN

patch	NN
O	NN

test	NN
O	NN

to	TO
O	NN

cocamidopropyl	NN
O	NN

betaine	NN
O	NN

in	IN
O	NN

a	DT
O	NN

hairdresser	NN
O	NN

Management	NNP
O	NNP

of	IN
O	NN

dyslipidemia	NN
D	NN

in	IN
O	NN

adults	NNS
O	NN

with	IN
O	NN

diabetes	NN
D	NN

American	JJ
O	NN

Diabetes	NNP
O	NNP

Association	NNP
O	NN

Acute	JJ
D	NN

diverticulitis	NN
D	NN

Investigation	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

yeast	NN
O	NN

mitochondrial	JJ
O	NN

unselective	JJ
O	NN

channel	NN
O	NN

in	IN
O	NN

intact	JJ
O	NN

and	CC
O	NN

permeabilized	JJ
O	NN

spheroplasts	NNS
O	NN

Acute	JJ
D	NN

sciatica	NN
D	NN

with	IN
O	NN

an	DT
O	NN

infective	JJ
O	NN

cause	NN
O	NN

An	DT
O	NN

ecologic	JJ
O	NN

analysis	NN
O	NN

of	IN
O	NN

psychosocial	JJ
D	NN

stress	NN
D	NN

and	CC
O	NN

heart	NN
D	NN

disease	NN
D	NN

in	IN
O	NN

British	JJ
O	NN

Columbia	NNP
O	NNP

Human	JJ
O	NN

leukocyte	NN
O	NN

antigen	NN
O	NN

frequencies	NNS
O	NN

in	IN
O	NN

a	DT
O	NN

selected	VBN
O	NN

group	NN
O	NN

of	IN
O	NN

Lebanese	JJ
O	NN

Greek	JJ
O	NN

Orthodox	JJ
O	NN

Alcohol	NN
O	NN

and	CC
O	NN

the	DT
O	NN

heart	NN
O	NN

Spontaneous	JJ
D	NN

ovarian	JJ
D	NN

hyperstimulation	NN
D	NN

syndrome	NN
D	NN

with	IN
O	NN

pregnancy	NN
O	NN

Will	MD
O	NNP

the	DT
O	NN

real	JJ
O	NN

plastic	JJ
O	NN

surgeon	NN
O	NN

please	VB
O	NN

stand	VB
O	NN

up	RB
O	NN

?	.
O	NN

Modulation	NN
O	NN

of	IN
O	NN

ultraviolet	JJ
O	NN

light-induced	JJ
O	NN

epidermal	JJ
D	NN

damage	NN
D	NN

:	:
O	NN

beneficial	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

tocopherol	NN
T	NN

A	DT
O	NN

survey	NN
O	NN

of	IN
O	NN

the	DT
O	NN

attitudes	NNS
O	NN

of	IN
O	NN

chronic	JJ
O	NN

psychiatric	JJ
O	NN

patients	NNS
O	NN

living	VBG
O	NN

in	IN
O	NN

the	DT
O	NN

community	NN
O	NN

toward	IN
O	NN

their	PRP$
O	NN

medication	NN
O	NN

Alterations	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

developing	VBG
O	NN

immune	JJ
O	NN

system	NN
O	NN

of	IN
O	NN

the	DT
O	NN

F344	NN
O	NN

rat	NN
O	NN

after	IN
O	NN

perinatal	JJ
O	NN

exposure	NN
O	NN

to	TO
O	NN

2	CD
O	NN

,	,
O	NN

3	CD
O	NN

,	,
O	NN

7	CD
O	NN

,	,
O	NN

8-tetrachlorodibenzo-p-dioxin	NN
O	NN

:	:
O	NN

II	NNP
O	NNP

Effects	NNS
O	NN

on	IN
O	NN

the	DT
O	NN

pup	NN
O	NN

and	CC
O	NN

the	DT
O	NN

adult	JJ
O	NN

Renal	JJ
O	NN

ultrasonography	NN
O	NN

:	:
O	NN

a	DT
O	NN

procedure	NN
O	NN

for	IN
O	NN

nephrologists	NNS
O	NN

Use	NNP
O	NNP

of	IN
O	NN

cisapride	NN
T	NN

in	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

constipation	NN
D	NN

in	IN
O	NN

children	NNS
O	VBP

Bilateral	JJ
O	NN

sampling	NN
O	NN

of	IN
O	NN

the	DT
O	NN

internal	JJ
O	NN

jugular	JJ
O	NN

vein	NN
O	NN

to	TO
O	NN

distinguish	VB
O	NN

between	IN
O	NN

mechanisms	NNS
O	VBP

of	IN
O	NN

adrenocorticotropic	JJ
O	NN

hormone-dependent	JJ
O	NN

Cushing	NN
D	NN

syndrome	NN
D	NN

The	DT
O	NN

influence	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

'	POS
O	NN

hopes	NNS
O	VBP

of	IN
O	NN

receiving	VBG
O	NN

a	DT
O	NN

prescription	NN
O	NN

on	IN
O	NN

doctors	NNS
O	NN

'	POS
O	NN

perceptions	NNS
O	NN

and	CC
O	NN

the	DT
O	NN

decision	NN
O	NN

to	TO
O	NN

prescribe	VB
O	NN

:	:
O	NN

a	DT
O	NN

questionnaire	NN
O	NN

survey	NN
O	NN

Coronary	JJ
D	NN

endothelial	JJ
D	NN

dysfunction	NN
D	NN

in	IN
O	NN

humans	NNS
O	NN

is	VBZ
O	NN

associated	VBN
O	NN

with	IN
O	NN

myocardial	JJ
D	NN

perfusion	NN
D	NN

defects	NNS
D	NN

Medical	JJ
O	NN

devices	NNS
O	NN

and	CC
O	NN

the	DT
O	NN

year	NN
O	NN

2000	CD
O	NN

problem	NN
O	NN

Internists	NNPS
O	NNP

'	POS
O	NN

and	CC
O	NN

surgeons	NNS
O	NN

'	POS
O	NN

attitudes	NNS
O	NN

toward	IN
O	NN

guns	NNS
O	NN

and	CC
O	NN

firearm	NN
O	NN

injury	NN
O	NN

prevention	NN
O	NN

Firearm	NN
O	NN

injury	NN
O	NN

prevention	NN
O	NN

American	JJ
O	NN

College	NNP
O	NNP

of	IN
O	NN

Physicians	NNP
O	NNP

Management	NNP
O	NNP

of	IN
O	NN

vaginal	JJ
D	NN

vault	NN
D	NN

prolapse	NN
D	NN

Death	NN
O	NN

rates	NNS
O	VBP

of	IN
O	NN

characters	NNS
O	NN

in	IN
O	NN

soap	NN
O	NN

operas	NNS
O	NN

on	IN
O	NN

British	JJ
O	NN

television	NN
O	NN

:	:
O	NN

is	VBZ
O	NN

a	DT
O	NN

government	NN
O	NN

health	NN
O	NN

warning	VBG
O	NN

required	VBN
O	NN

?	.
O	NN

Child	NN
O	NN

sexual	JJ
O	NN

abuse	NN
O	NN

:	:
O	NN

when	WRB
O	NN

a	DT
O	NN

doctor	NN
O	NN

's	POS
O	NN

duty	NN
O	NN

to	TO
O	NN

report	NN
O	NN

abuse	NN
O	NN

conflicts	NNS
O	VBP

with	IN
O	NN

a	DT
O	NN

duty	NN
O	NN

of	IN
O	NN

confidentiality	NN
O	NN

to	TO
O	NN

the	DT
O	NN

victim	NN
O	NN

Tissue	NN
O	NN

adhesives	NNS
O	NN

--	:
O	NN

revisited	VBN
O	NN

Racial	JJ
O	NN

discrimination	NN
O	NN

in	IN
O	NN

the	DT
O	NN

allocation	NN
O	NN

of	IN
O	NN

distinction	NN
O	NN

awards	NNS
O	NN

?	.
O	NN

Analysis	NN
O	NN

of	IN
O	NN

list	NN
O	NN

of	IN
O	NN

award	NN
O	NN

holders	NNS
O	VBP

by	IN
O	NN

type	NN
O	NN

of	IN
O	NN

award	NN
O	NN

,	,
O	NN

specialty	NN
O	NN

and	CC
O	NN

region	NN
O	NN

Multicenter	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

surfactant	JJ
T	NN

(	NN
T	NN

beractant	JJ
T	NN

)	NN
T	NN

use	NN
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

term	NN
O	NN

infants	NNS
O	NN

with	IN
O	NN

severe	JJ
D	NN

respiratory	JJ
D	NN

failure	NN
D	NN

Survanta	NN
O	NN

in	IN
O	NN

Term	NN
O	NN

Infants	NNS
O	NN

Study	NNP
O	NNP

Group	NNP
O	NNP

Consultation	NN
O	NN

section	NN
O	NN

Cataract	NN
D	NN

surgical	JJ
O	NN

problem	NN
O	NN

Changing	VBG
O	NN

the	DT
O	NN

law	NN
O	NN

on	IN
O	NN

decision	NN
O	NN

making	VBG
O	NN

for	IN
O	NN

mentally	RB
O	NN

incapacitated	JJ
O	NN

adults	NNS
O	NN

The	DT
O	NN

coding	VBG
O	NN

audit	NN
O	NN

Providing	VBG
O	NN

primary	JJ
O	NN

care	NN
O	NN

in	IN
O	NN

the	DT
O	NN

accident	NN
O	NN

and	CC
O	NN

emergency	NN
O	NN

department	NN
O	NN

Challenges	NNS
O	VBP

to	TO
O	NN

Native	JJ
O	NN

American	JJ
O	NN

health	NN
O	NN

care	NN
O	NN

Federal	NNP
O	NNP

programs	NNS
O	NN

and	CC
O	NN

Indian	JJ
O	NN

country	NN
O	NN

:	:
O	NN

a	DT
O	NN

time	NN
O	NN

for	IN
O	NN

reinvention	NN
O	NN

Chicago	NNP
O	NNP

report	NN
O	NN

profiles	NNS
O	NN

Big	JJ
O	NN

city	NN
O	NN

health	NN
O	NN

College-age	JJ
O	NN

drinking	NN
O	NN

problems	NNS
O	VBP

Using	VBG
O	NN

YPLL	NN
O	NN

in	IN
O	NN

health	NN
O	NN

planning	VBG
O	NN

WHO	WP
O	VBP

decides	VBZ
O	NN

:	:
O	NN

food	NN
O	NN

irradiation	NN
O	NN

safe	JJ
O	NN

at	IN
O	NN

any	DT
O	NN

level	NN
O	NN

Genetic	JJ
O	NN

sampling	NN
O	NN

:	:
O	NN

big	JJ
O	NN

brother	NN
O	NN

or	CC
O	NN

big	JJ
O	NN

science	NN
O	NN

?	.
O	NN

Physician	NN
O	NN

assistants	NNS
O	NN

and	CC
O	NN

nurse	NN
O	NN

practitioners	NNS
O	VBP

in	IN
O	NN

hospital	NN
O	NN

outpatient	NN
O	NN

departments	NNS
O	NN

,	,
O	NN

1993-1994	CD
O	NN

Laying	VBG
O	NN

the	DT
O	NN

foundation	NN
O	NN

for	IN
O	NN

Healthy	JJ
O	NN

People	NNS
O	VBP

2010	CD
O	NN

The	DT
O	NN

first	RB
O	NN

year	NN
O	NN

of	IN
O	NN

consultation	NN
O	NN

The	DT
O	NN

veracious	JJ
O	NN

etiology	NN
O	NN

of	IN
O	NN

ectopic	JJ
D	NN

pregnancy	NN
D	NN

Is	VBZ
O	NN

dietary	JJ
O	NN

fat	JJ
O	NN

a	DT
O	NN

major	JJ
O	NN

determinant	NN
O	NN

of	IN
O	NN

body	NN
O	NN

fat	JJ
O	NN

?	.
O	NN

Factors	NNS
O	NN

involved	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

fall	NN
O	NN

of	IN
O	NN

thyroid	NN
O	NN

stimulating	VBG
O	NN

hormone	NN
O	NN

in	IN
O	NN

treated	VBN
O	NN

hypothyroidism	NN
D	NN

Case	NNP
O	NNP

complexity	NN
O	NN

Imaging	NNP
O	NNP

pulmonary	JJ
D	NN

embolism	NN
D	NN

Early	RB
O	NN

inpatient	JJ
O	NN

rehabilitation	NN
O	NN

after	IN
O	NN

elective	JJ
O	NN

hip	NN
O	NN

and	CC
O	NN

knee	NN
O	NN

arthroplasty	NN
T	NN

Inpatient	JJ
O	NN

rehabilitation	NN
O	NN

after	IN
O	NN

total	JJ
O	NN

joint	JJ
T	NN

replacement	NN
T	NN

Delayed	VBN
O	NN

healing	NN
O	NN

of	IN
O	NN

rhytidectomy	NN
T	NN

flap	NN
O	NN

resurfaced	VBD
O	NN

with	IN
O	NN

CO2	NN
O	NN

laser	NN
O	NN

The	DT
O	NN

SAPHO	NN
D	NN

syndrome	NN
D	NN

:	:
O	NN

an	DT
O	NN

evolving	VBG
O	NN

concept	NN
O	NN

for	IN
O	NN

unifying	JJ
O	NN

several	JJ
O	NN

idiopathic	JJ
O	NN

disorders	NNS
O	NN

of	IN
O	NN

bone	NN
O	NN

and	CC
O	NN

skin	NN
O	NN

Beverage	NNP
O	NNP

use	NN
O	NN

and	CC
O	NN

risk	NN
O	NN

for	IN
O	NN

kidney	NN
D	NN

stones	NNS
D	NN

in	IN
O	NN

women	NNS
O	VBP

Use	NNP
O	NNP

of	IN
O	NN

a	DT
O	NN

Foley	NNP
O	NNP

catheter	NN
O	NN

in	IN
O	NN

the	DT
O	NN

removal	NN
O	NN

of	IN
O	NN

a	DT
O	NN

substernal	JJ
D	NN

goiter	NN
D	NN

Early	RB
O	NN

identification	NN
O	NN

of	IN
O	NN

variant	JJ
O	NN

Creutzfeldt-Jakob	NN
D	NN

disease	NN
D	NN

Slater	NNP
O	NNP

revisited	VBN
O	NN

:	:
O	NN

6	CD
O	NN

year	NN
O	NN

follow	VB
O	NNP

up	RB
O	NN

study	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

medically	RB
O	NN

unexplained	JJ
O	NN

motor	NN
D	NN

symptoms	NNS
D	NN

Re	NNP
O	NNP

:	:
O	NN

Intermediate	NNP
O	NNP

term	NN
O	NN

assessment	NN
O	NN

of	IN
O	NN

the	DT
O	NN

reliability	NN
O	NN

,	,
O	NN

function	NN
O	NN

and	CC
O	NN

patient	NN
O	NN

satisfaction	NN
O	NN

with	IN
O	NN

the	DT
O	NN

AMS700	NN
O	NN

ultrex	NN
O	NN

penile	NN
O	NN

prosthesis	NN
O	NN

Reduced	VBN
O	NN

ratio	NN
O	NN

of	IN
O	NN

male	JJ
O	NN

to	TO
O	NN

female	JJ
O	NN

births	NNS
O	NN

in	IN
O	NN

several	JJ
O	NN

industrial	JJ
O	NN

countries	NNS
O	NN

:	:
O	NN

a	DT
O	NN

sentinel	NN
O	NN

health	NN
O	NN

indicator	NN
O	NN

?	.
O	NN

Should	MD
O	NNP

we	PRP
O	VBP

accept	VB
O	NN

mediocrity	NN
O	NN

?	.
O	NN

Resolution	NNP
O	NNP

of	IN
O	NN

recalcitrant	JJ
D	NN

molluscum	NN
D	NN

contagiosum	NN
D	NN

virus	NN
D	NN

lesions	NNS
D	NN

in	IN
O	NN

human	JJ
O	NN

immunodeficiency	NN
O	NN

virus-infected	JJ
O	NN

patients	NNS
O	NN

treated	VBN
O	NN

with	IN
O	NN

cidofovir	NN
T	NN

Colonoscopic	JJ
O	NN

removal	NN
O	NN

of	IN
O	NN

chicken	NN
O	NN

bones	NNS
O	NN

impacted	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

sigmoid	NN
O	NN

in	IN
O	NN

two	CD
O	NN

patients	NNS
O	NN

``	``
O	NN

Pull	VB
O	NN

''	''
O	NN

or	CC
O	NN

``	``
O	NN

push	NN
O	NN

''	''
O	NN

PEG	NN
O	NN

:	:
O	NN

the	DT
O	NN

reinsertion	NN
O	NN

of	IN
O	NN

the	DT
O	NN

gastroscope	NN
O	NN

is	VBZ
O	NN

often	RB
O	NN

unnecessary	JJ
O	NN

Clear	JJ
D	NN

cell	NN
D	NN

papulosis	NN
D	NN

:	:
O	NN

case	NN
O	NN

report	NN
O	NN

and	CC
O	NN

literature	NN
O	NN

review	NN
O	NN

Malignant	JJ
D	NN

melanoma	NN
D	NN

in	IN
O	NN

situ	FW
O	FW

:	:
O	NN

an	DT
O	NN

oxymoron	NN
O	NN

whose	WP$
O	NN

time	NN
O	NN

has	VBZ
O	NN

come	VBN
O	NN

External	JJ
T	NN

beam	NN
T	NN

radiation	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

choroidal	NN
D	NN

neovascularization	NN
D	NN

Somatic	JJ
O	NN

mesoderm	NN
O	NN

differentiation	NN
O	NN

and	CC
O	NN

the	DT
O	NN

development	NN
O	NN

of	IN
O	NN

a	DT
O	NN

subset	NN
O	NN

of	IN
O	NN

pericardial	JJ
O	NN

cells	NNS
O	VBP

depend	VB
O	NN

on	IN
O	NN

the	DT
O	NN

not	RB
O	NN

enough	RB
O	NN

muscles	NNS
O	NN

(	NN
O	NN

nem	NN
O	NN

)	NN
O	NN

locus	NN
O	NN

,	,
O	NN

which	WDT
O	NN

contains	VBZ
O	NN

the	DT
O	NN

inscuteable	JJ
O	NN

gene	NN
O	NN

and	CC
O	NN

the	DT
O	NN

intron	NN
O	NN

located	JJ
O	NN

gene	NN
O	NN

,	,
O	NN

skittles	NNS
O	NN

Hemodynamic	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

acute	JJ
O	NN

tetrandrine	NN
O	NN

and	CC
O	NN

terlipressin	NN
O	NN

administration	NN
O	NN

on	IN
O	NN

portal	JJ
O	NN

hypertensive	JJ
O	NN

rats	NNS
O	NN

Nonneoplastic	JJ
D	NN

disorders	NNS
D	NN

of	IN
D	NN

the	DT
D	NN

eccrine	NN
D	NN

glands	NNS
D	NN

Cerebrospinal	JJ
O	NN

fluid	NN
O	NN

and	CC
O	NN

plasma	NN
O	NN

insulin	NN
O	NN

levels	NNS
O	VBP

in	IN
O	NN

Alzheimer	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

:	:
O	NN

relationship	NN
O	NN

to	TO
O	NN

severity	NN
O	NN

of	IN
O	NN

dementia	NN
D	NN

and	CC
O	NN

apolipoprotein	NN
O	NN

E	NN
O	NN

genotype	NN
O	NN

Isolated	VBN
O	NN

internal	JJ
D	NN

ophthalmoplegia	NN
D	NN

associated	VBN
O	NN

with	IN
O	NN

IgG	NN
O	NN

anti-GQ1b	JJ
O	NN

antibody	NN
O	NN

Bolus	NN
T	NN

thrombolytic	JJ
T	NN

infusions	NNS
T	NN

during	IN
O	NN

CPR	NNP
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

refractory	JJ
D	NN

arrest	NN
D	NN

rhythms	NNS
D	NN

:	:
O	NN

outcome	NN
O	NN

of	IN
O	NN

a	DT
O	NN

case	NN
O	NN

series	NN
O	NN

Enthesopathy	NN
D	NN

in	IN
O	NN

a	DT
O	NN

case	NN
O	NN

of	IN
O	NN

primary	JJ
D	NN

biliary	JJ
D	NN

cirrhosis	NN
D	NN

with	IN
O	NN

positive	JJ
O	NN

HLA-B27	NN
O	NN

Remifentanil	NN
T	NN

in	IN
O	NN

the	DT
O	NN

critically	RB
O	NN

ill	RB
O	NN

Hyponatremia	NN
D	NN

with	IN
O	NN

venlafaxine	NN
T	NN

.	.
O	NN

Use	NNP
O	NNP

of	IN
O	NN

a	DT
O	NN

nerve	NN
T	NN

stimulator	NN
T	NN

for	IN
O	NN

phrenic	JJ
D	NN

nerve	NN
D	NN

block	NN
D	NN

in	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

hiccups	NNS
D	NN

Anaesthesia	NNP
O	NNP

for	IN
O	NN

laparoscopic	JJ
T	NN

cholecystectomy	NN
T	NN

in	IN
O	NN

a	DT
O	NN

patient	NN
O	NN

with	IN
O	NN

Eisenmenger	NN
D	NN

's	POS
D	NN

syndrome	NN
D	NN

Micronutrients	NNS
T	NN

and	CC
O	NN

human	JJ
O	NN

cancer	NN
D	NN

risks	NNS
D	NN

--	:
O	NN

prospects	NNS
O	NN

for	IN
O	NN

prevention	NN
O	NN

Joint	NNP
O	NNP

International	NNP
O	NNP

Symposium	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

Danish	JJ
O	NN

Cancer	NN
O	NN

Society	NNP
O	NNP

,	,
O	NN

European	JJ
O	NN

Cancer	NN
O	NN

Prevention	NNP
O	NNP

Organization	NNP
O	NNP

and	CC
O	NN

National	NNP
O	NNP

Food	NNP
O	NNP

Agency	NNP
O	NNP

of	IN
O	NN

Denmark	NNP
O	NNP

Aarhus	NNP
O	NNP

,	,
O	NN

Denmark	NNP
O	NNP

,	,
O	NN

21-24	CD
O	NN

May	NNP
O	NNP

1997	CD
O	NN

Abstracts	NNS
O	NN

Vitamin	NN
O	NN

K2	NN
O	NN

and	CC
O	NN

serum	NN
O	NN

cholesterol	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

on	IN
O	NN

continuous	JJ
O	NN

ambulatory	JJ
O	NN

peritoneal	JJ
T	NN

dialysis	NN
T	NN

Income	NN
O	NN

inequality	NN
O	NN

and	CC
O	NN

population	NN
O	NN

health	NN
O	NN

Naloxone	NN
T	NN

-precipitated	JJ
O	NN

acute	JJ
D	NN

opioid	NN
D	NN

withdrawal	NN
D	NN

syndrome	NN
D	NN

after	IN
O	NN

epidural	JJ
T	NN

morphine	NN
T	NN

Idiopathic	JJ
D	NN

atrial	NN
D	NN

flutter	NN
D	NN

Munchausen	NN
D	NN

's	POS
D	NN

syndrome	NN
D	NN

Clinical	JJ
O	NN

evaluation	NN
O	NN

of	IN
O	NN

adjuvant	JJ
T	NN

chemoradiotherapy	JJ
T	NN

with	IN
T	NN

CDDP	JJ
T	NN

,	,
T	NN

5-FU	JJ
T	NN

,	,
T	NN

and	CC
T	NN

VP-16	NN
T	NN

for	IN
O	NN

advanced	JJ
D	NN

esophageal	NN
D	NN

cancer	NN
D	NN

New	JJ
T	NN

drug	NN
T	NN

treatment	NN
T	NN

for	IN
O	NN

Alzheimer	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

:	:
O	NN

lessons	NNS
O	NN

for	IN
O	NN

healthcare	NN
O	NN

policy	NN
O	NN

Development	NNP
O	NNP

of	IN
O	NN

neurosurgery	NN
T	NN

in	IN
O	NN

Greece	NNP
O	NNP

:	:
O	NN

past	JJ
O	NN

,	,
O	NN

present	JJ
O	NN

,	,
O	NN

and	CC
O	NN

future	JJ
O	NN

Intravascular-catheter-related	JJ
D	NN

infections	NNS
D	NN

The	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

a	DT
O	NN

social	JJ
O	NN

support	NN
O	NN

boosting	VBG
O	NN

intervention	NN
O	NN

on	IN
O	NN

stress	NN
O	NN

,	,
O	NN

coping	VBG
O	NN

,	,
O	NN

and	CC
O	NN

social	JJ
O	NN

support	NN
O	NN

in	IN
O	NN

caregivers	NNS
O	NN

of	IN
O	NN

children	NNS
O	VBP

with	IN
O	NN

HIV/AIDS	NN
D	NN

Point-counterpoint	JJ
O	NN

Mass	JJ
O	NN

population	NN
O	NN

skin	NN
D	NN

cancer	NN
D	NN

screening	VBG
O	NN

is	VBZ
O	NN

not	RB
O	NN

worthwhile	JJ
O	NN

Persons	NNS
O	VBP

successful	JJ
O	NN

at	IN
O	NN

long-term	JJ
O	NN

weight	NN
O	NN

loss	NN
O	NN

and	CC
O	NN

maintenance	NN
O	NN

continue	VB
O	NN

to	TO
O	NN

consume	VB
O	NN

a	DT
O	NN

low-energy	JJ
O	NN

,	,
O	NN

low-fat	JJ
O	NN

diet	NN
O	NN

Ultrasound	NN
O	NN

measurements	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

newborn	JJ
O	NN

hip	NN
O	NN

Comparison	NN
O	NN

of	IN
O	NN

two	CD
O	NN

methods	NNS
O	VBP

in	IN
O	NN

657	CD
O	NN

newborns	NNS
O	NN

Inferences	NNS
O	NN

from	IN
O	NN

symphysiotomy	NN
T	NN

experience	NN
O	NN

1995	CD
O	NN

coronary	JJ
T	NN

artery	NN
T	NN

bypass	NN
T	NN

risk	NN
O	NN

model	NN
O	NN

:	:
O	NN

The	DT
O	NN

Society	NNP
O	NNP

of	IN
O	NN

Thoracic	JJ
O	NN

Surgeons	NNPS
O	NNP

Adult	JJ
O	NN

Cardiac	JJ
O	NN

National	NNP
O	NNP

Database	NN
O	NN

Informed	JJ
O	NN

consent	NN
O	NN

:	:
O	NN

edging	VBG
O	NN

forwards	RB
O	NN

(	NN
O	NN

and	CC
O	NN

backwards	RB
O	NN

)	NN
O	NN

Online	JJ
O	NN

medical	JJ
O	NN

surveys	NNS
O	NN

:	:
O	NN

using	VBG
O	NN

the	DT
O	NN

Internet	NN
O	NN

as	IN
O	NN

a	DT
O	NN

research	NN
O	NN

tool	NN
O	NN

US-guided	JJ
O	NN

puncture	NN
O	NN

of	IN
O	NN

the	DT
O	NN

internal	JJ
O	NN

jugular	JJ
O	NN

vein	NN
O	NN

:	:
O	NN

complications	NNS
O	NN

and	CC
O	NN

anatomic	JJ
O	NN

considerations	NNS
O	VBP

Mouth	NN
O	NN

care	NN
O	NN

and	CC
O	NN

skin	NN
O	NN

care	NN
O	NN

in	IN
O	NN

palliative	JJ
O	NN

medicine	NN
O	NN

Simple	JJ
O	NN

antiseptic	JJ
T	NN

mouthwashes	NNS
T	NN

are	VBP
O	NN

best	RB
O	NN

for	IN
O	NN

infection	NN
D	NN

The	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

melatonin	NN
O	NN

administration	NN
O	NN

on	IN
O	NN

ethanol-induced	JJ
O	NN

lipid	NN
O	NN

peroxidation	NN
O	NN

in	IN
O	NN

rats	NNS
O	NN

A	DT
O	NN

comparison	NN
O	NN

of	IN
O	NN

aspirin	NN
T	NN

plus	CC
T	NN

tirofiban	JJ
T	NN

with	IN
O	NN

aspirin	NN
T	NN

plus	CC
T	NN

heparin	NN
T	NN

for	IN
O	NN

unstable	JJ
D	NN

angina	NN
D	NN

Platelet	NN
O	NN

Receptor	NN
O	NN

Inhibition	NN
O	NN

in	IN
O	NN

Ischemic	JJ
O	NN

Syndrome	NN
O	NN

Management	NNP
O	NNP

(	NN
O	NN

PRISM	NN
O	NN

)	NN
O	NN

Study	NNP
O	NNP

Investigators	NNS
O	NN

Mike	NNP
O	NNP

Grace	NNP
O	NNP

talks	NNS
O	NN

to	TO
O	NN

Mike	NNP
O	NNP

Joy	NNP
O	NNP

Interview	NN
O	NN

by	IN
O	NN

Mike	NNP
O	NNP

Grace	NNP
O	NNP

Multivalent	JJ
O	NN

cations	NNS
O	NN

depress	VB
O	NN

ligand	NN
O	NN

affinity	NN
O	NN

of	IN
O	NN

insulin-like	JJ
O	NN

growth	NN
O	NN

factor-binding	JJ
O	NN

proteins-3	NN
O	NN

and	CC
O	NN

-5	CD
O	NN

on	IN
O	NN

human	JJ
O	NN

GM-10	NN
O	NN

fibroblast	NN
O	NN

cell	NN
O	NN

surfaces	NNS
O	NN

Effect	NN
O	NN

of	IN
O	NN

continuous	JJ
O	NN

spinal	JJ
O	NN

remifentanil	NN
O	NN

infusion	NN
O	NN

on	IN
O	NN

behaviour	NN
O	NN

and	CC
O	NN

spinal	JJ
O	NN

glutamate	NN
O	NN

release	NN
O	NN

evoked	VBN
O	NN

by	IN
O	NN

subcutaneous	JJ
O	NN

formalin	NN
O	NN

in	IN
O	NN

the	DT
O	NN

rat	NN
O	NN

How	WRB
O	NN

long	RB
O	NN

should	MD
O	NNP

suction	NN
O	NN

drains	VBZ
O	NN

stay	VB
O	NNP

in	IN
O	NN

after	IN
O	NN

breast	NN
T	NN

surgery	NN
T	NN

with	IN
O	NN

axillary	JJ
T	NN

dissection	NN
T	NN

?	.
O	NN

Physicians	NNP
O	NNP

disciplined	JJ
O	NN

for	IN
O	NN

sex-related	JJ
O	NN

offenses	NNS
O	NN

Something	NN
O	NN

from	IN
O	NN

nothing	NN
O	NN

:	:
O	NN

the	DT
O	NN

evolution	NN
O	NN

and	CC
O	NN

utility	NN
O	NN

of	IN
O	NN

satellite	NN
O	NN

repeats	NNS
O	VBP

Sudden	JJ
O	NN

death	NN
O	NN

in	IN
O	NN

young	JJ
O	NN

athletes	NNS
O	NN

:	:
O	NN

screening	VBG
O	NN

for	IN
O	NN

the	DT
O	NN

needle	NN
O	NN

in	IN
O	NN

a	DT
O	NN

haystack	NN
O	NN

Chemotherapy	NN
T	NN

alone	RB
T	NN

compared	VBN
O	NN

with	IN
O	NN

chemotherapy	NN
T	NN

plus	CC
T	NN

radiotherapy	NN
T	NN

for	IN
O	NN

localized	JJ
O	NN

intermediate-	NN
O	NN

and	CC
O	NN

high-grade	JJ
O	NN

non-Hodgkin	JJ
D	NN

's	POS
D	NN

lymphoma	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Prevention	NNP
O	NNP

of	IN
O	NN

a	DT
O	NN

first	RB
O	NN

stroke	NN
D	NN

by	IN
O	NN

transfusions	NNS
T	NN

in	IN
O	NN

children	NNS
O	VBP

with	IN
O	NN

sickle	JJ
O	NN

cell	NN
O	NN

anemia	NN
O	NN

and	CC
O	NN

abnormal	JJ
O	NN

results	NNS
O	VBP

on	IN
O	NN

transcranial	JJ
O	NN

Doppler	NNP
O	NNP

ultrasonography	NN
O	NN

HIV	NN
T	NN

vaccines	NNS
T	NN

:	:
O	NN

prospects	NNS
O	NN

and	CC
O	NN

challenges	NNS
O	IN

Occupation	NN
O	NN

:	:
O	NN

the	DT
O	NN

keystone	NN
O	NN

of	IN
O	NN

a	DT
O	NN

curriculum	NN
O	NN

for	IN
O	NN

a	DT
O	NN

self-defined	JJ
O	NN

profession	NN
O	NN

Touch	VB
O	NN

sensibility	NN
O	NN

in	IN
O	NN

the	DT
O	NN

breast	NN
O	NN

after	IN
O	NN

subcutaneous	JJ
T	NN

mastectomy	NN
T	NN

and	CC
O	NN

immediate	JJ
O	NN

reconstruction	NN
O	NN

with	IN
O	NN

a	DT
O	NN

prosthesis	NN
O	NN

Iatrogenic	JJ
T	NN

ruptures	NNS
T	NN

of	IN
O	NN

the	DT
O	NN

tracheobronchial	JJ
O	NN

tree	NN
O	NN

Endoscopic	JJ
T	NN

hemostasis	NN
T	NN

of	IN
O	NN

bleeding	NN
D	NN

duodenal	JJ
D	NN

ulcer	NN
D	NN

in	IN
O	NN

a	DT
O	NN

child	NN
O	NN

with	IN
O	NN

Henoch-Schnlein	NN
D	NN

purpura	NN
D	NN

Classification	NN
O	NN

of	IN
O	NN

primary	JJ
O	NN

gastric	JJ
D	NN

lymphomas	NNS
D	NN

according	VBG
O	NN

to	TO
O	NN

histologic	JJ
O	NN

features	NNS
O	VBP

SCIM	NN
O	NN

--	:
O	NN

spinal	JJ
O	NN

cord	NN
O	NN

independence	NN
O	NN

measure	NN
O	NN

:	:
O	NN

a	DT
O	NN

new	JJ
O	NN

disability	NN
O	NN

scale	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

spinal	JJ
D	NN

cord	NN
D	NN

lesions	NNS
D	NN

Molecular	JJ
O	NN

analysis	NN
O	NN

of	IN
O	NN

cellulose	NN
O	NN

biosynthesis	NN
O	NN

in	IN
O	NN

Arabidopsis	NNP
O	NN

Users	NNS
O	VBP

'	POS
O	NN

guides	NNS
O	NN

to	TO
O	NN

the	DT
O	NN

medical	JJ
O	NN

literature	NN
O	NN

:	:
O	NN

XIV	NNP
O	NN

How	WRB
O	NN

to	TO
O	NN

decide	VB
O	NN

on	IN
O	NN

the	DT
O	NN

applicability	NN
O	NN

of	IN
O	NN

clinical	JJ
O	NN

trial	NN
O	NN

results	NNS
O	VBP

to	TO
O	NN

your	PRP$
O	NN

patient	NN
O	NN

Evidence-Based	JJ
O	NN

Medicine	NNP
O	NNP

Working	VBG
O	NN

Group	NNP
O	NNP

Hemispheric	NNP
O	NNP

difference	NN
O	NN

in	IN
O	NN

human	JJ
O	NN

skin	NN
O	NN

color	NN
O	NN

Limitations	NNPS
O	NNP

of	IN
O	NN

diagnostic	JJ
O	NN

criteria	NNS
O	NN

and	CC
O	NN

assessment	NN
O	NN

instruments	NNS
O	NN

for	IN
O	NN

mental	JJ
D	NN

disorders	NNS
D	NN

Implications	NNS
O	VBP

for	IN
O	NN

research	NN
O	NN

and	CC
O	NN

policy	NN
O	NN

Causing	VBG
O	NN

death	NN
O	NN

or	CC
O	NN

allowing	VBG
O	NN

to	TO
O	NN

die	VB
O	NN

?	.
O	NN

Developments	NNP
O	NNP

in	IN
O	NN

the	DT
O	NN

law	NN
O	NN

Albumin	NN
O	NN

synthesis	NN
O	NN

rates	NNS
O	VBP

are	VBP
O	NN

not	RB
O	NN

decreased	VBN
O	NN

in	IN
O	NN

hypoalbuminemic	JJ
D	NN

cachectic	NN
D	NN

cancer	NN
D	NN

patients	NNS
O	NN

with	IN
O	NN

an	DT
O	NN

ongoing	JJ
O	NN

acute-phase	NN
O	NN

protein	NN
O	NN

response	NN
O	NN

Brain-gut	JJ
O	NN

axis	NN
O	NN

in	IN
O	NN

health	NN
O	NN

and	CC
O	NN

disease	NN
O	NN

Pins	NNS
O	NN

and	CC
O	NN

Rubbers	NNS
O	NN

Traction	NN
O	NN

System	NNP
O	NNP

A	DT
O	NN

specialist	NN
O	NN

nurse	NN
O	NN

can	MD
O	NNP

replace	VB
O	NN

pre-registration	JJ
O	NN

house	NN
O	NN

officers	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

surgical	JJ
O	NN

pre-admission	JJ
O	NN

clinic	NN
O	NN

Voluntary	JJ
O	NN

death	NN
O	NN

:	:
O	NN

a	DT
O	NN

comparison	NN
O	NN

of	IN
O	NN

terminal	JJ
O	NN

dehydration	NN
D	NN

and	CC
O	NN

physician-assisted	JJ
O	NN

suicide	NN
O	NN

Ionized	VBN
O	NN

magnesium	NN
O	NN

in	IN
O	NN

serum	NN
O	NN

and	CC
O	NN

ultrafiltrate	JJ
O	NN

:	:
O	NN

pH	NN
O	NN

and	CC
O	NN

bicarbonate	NN
O	NN

effect	NN
O	NN

on	IN
O	NN

measurements	NNS
O	NN

with	IN
O	NN

the	DT
O	NN

AVL	NN
O	NN

988-4	CD
O	NN

electrolyte	NN
O	NN

analyzer	NN
O	NN

Anterior	NNP
D	NNP

glenohumeral	NN
D	NN

dislocations	NNS
D	NN

:	:
O	NN

what	WDT
O	NN

to	TO
O	NN

do	VB
O	NNP

and	CC
O	NN

how	WRB
O	NN

to	TO
O	NN

do	VB
O	NNP

it	PRP
O	NN

Relationship	NN
O	NN

between	IN
O	NN

topotecan	NN
T	NN

systemic	JJ
O	NN

exposure	NN
O	NN

and	CC
O	NN

tumor	NN
O	NN

response	NN
O	NN

in	IN
O	NN

human	JJ
O	NN

neuroblastoma	NN
D	NN

xenografts	NNS
D	NN

Cerebral	JJ
D	NN

infarct	NN
D	NN

following	VBG
O	NN

central	JJ
T	NN

venous	JJ
T	NN

cannulation	NN
T	NN

The	DT
O	NN

Gram	NN
O	NN

stain	VB
O	NN

Heavy	JJ
O	NN

caffeine	NN
O	NN

intake	NN
O	NN

in	IN
O	NN

pregnancy	NN
O	NN

and	CC
O	NN

sudden	JJ
D	NN

infant	NN
D	NN

death	NN
D	NN

syndrome	NN
D	NN

New	NNP
O	NNP

Zealand	NNP
O	NN

Cot	NN
O	NN

Death	NN
O	NN

Study	NNP
O	NNP

Group	NNP
O	NNP

When	WRB
O	NN

can	MD
O	NNP

odds	NNS
O	NN

ratios	NNS
O	NN

mislead	NN
O	NN

?	.
O	NN

Treatment	NN
O	NN

of	IN
O	NN

renal	JJ
D	NN

failure	NN
D	NN

in	IN
O	NN

idiopathic	JJ
D	NN

membranous	JJ
D	NN

nephropathy	NN
D	NN

with	IN
O	NN

azathioprine	NN
T	NN

and	CC
T	NN

prednisolone	JJ
T	NN

Enzyme	NN
O	NN

structure	NN
O	NN

with	IN
O	NN

two	CD
O	NN

catalytic	JJ
O	NN

sites	NNS
O	NN

for	IN
O	NN

double-sieve	JJ
O	NN

selection	NN
O	NN

of	IN
O	NN

substrate	JJ
O	NN

Role	NN
O	NN

of	IN
O	NN

the	DT
O	NN

ketogenic	JJ
T	NN

diet	NN
T	NN

in	IN
O	NN

children	NNS
O	VBP

with	IN
O	NN

intractable	JJ
D	NN

seizures	NNS
D	NN

.	.
O	NN

Building-associated	JJ
O	NN

pulmonary	JJ
D	NN

disease	NN
D	NN

from	IN
O	NN

exposure	NN
O	NN

to	TO
O	NN

Stachybotrys	NNP
O	NNP

chartarum	NN
O	NN

and	CC
O	NN

Aspergillus	JJ
O	NN

versicolor	NN
O	NN

Interleukin-8	NN
O	NN

participates	VBZ
O	NN

in	IN
O	NN

angiogenesis	NN
O	NN

in	IN
O	NN

non-small	JJ
O	NN

cell	NN
O	NN

,	,
O	NN

but	CC
O	NNP

not	RB
O	NN

small	JJ
O	NN

cell	NN
O	NN

carcinoma	NN
D	NN

of	IN
O	NN

the	DT
O	NN

lung	NN
O	NN

Antenatal	JJ
T	NN

indomethacin	NN
T	NN

--	:
O	NN

adverse	JJ
O	NN

fetal	JJ
O	NN

effects	NNS
O	NN

confirmed	VBN
O	NN

Evaluation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

microparticle	NN
O	NN

enzyme	NN
O	NN

immunoassay	NN
O	NN

Abbott	NNP
O	NNP

IMx	NN
O	NN

Select	NNP
O	NNP

Chlamydia	NN
O	NN

and	CC
O	NN

the	DT
O	NN

importance	NN
O	NN

of	IN
O	NN

urethral	JJ
O	NN

site	NN
O	NN

sampling	NN
O	NN

to	TO
O	NN

detect	VB
O	NN

Chlamydia	NN
D	NN

trachomatis	NN
D	NN

in	IN
O	NN

women	NNS
O	VBP

The	DT
O	NN

persistent	JJ
O	NN

vegetative	JJ
O	NN

state	NN
O	NN

after	IN
O	NN

closed	JJ
D	NN

head	NN
D	NN

injury	NN
D	NN

:	:
O	NN

clinical	JJ
O	NN

and	CC
O	NN

magnetic	JJ
O	NN

resonance	NN
O	NN

imaging	NN
O	NN

findings	NNS
O	VBP

in	IN
O	NN

42	CD
O	NN

patients	NNS
O	NN

Wegener	NNP
D	NNP

's	POS
D	NN

granulomatosis	NN
D	NN

of	IN
O	NN

the	DT
O	NN

head	NN
O	NN

and	CC
O	NN

neck	NN
O	NN

Chromosomal	JJ
O	NN

abnormalities	NNS
O	NN

of	IN
O	NN

a	DT
O	NN

new	JJ
O	NN

nasopharyngeal	NN
D	NN

carcinoma	NN
D	NN

cell	NN
O	NN

line	NN
O	NN

(	NN
O	NN

NPC-BM1	NN
O	NN

)	NN
O	NN

derived	VBN
O	NN

from	IN
O	NN

a	DT
O	NN

bone	NN
D	NN

marrow	NN
D	NN

metastatic	JJ
D	NN

lesion	NN
D	NN

Relation	NN
O	NN

between	IN
O	NN

intellectual	JJ
D	NN

dysfunctioning	VBG
D	NN

and	CC
O	NN

mortality	NN
O	NN

in	IN
O	NN

community-residing	JJ
O	NN

older	JJR
O	NN

people	NNS
O	VBP

Anxiety	NN
O	NN

and	CC
O	NN

autonomic	JJ
O	NN

flexibility	NN
O	NN

:	:
O	NN

a	DT
O	NN

cardiovascular	JJ
O	NN

approach	NN
O	NN

Cross-reactivity	NN
O	NN

of	IN
O	NN

specific	JJ
O	NN

antibodies	NNS
O	NN

directed	VBN
O	NN

to	TO
O	NN

heat	NN
O	NN

shock	NN
O	NN

proteins	NNS
O	NN

from	IN
O	NN

periodontopathogenic	JJ
O	NN

bacteria	NNS
O	NN

and	CC
O	NN

of	IN
O	NN

human	JJ
O	NN

origin	NN
O	NN

(	NN
O	NN

corrected	VBN
O	NN

)	NN
O	NN

Immunogenicity	NN
O	NN

of	IN
O	NN

hepatitis	NN
D	NN

B	NN
D	NN

vaccine	NN
T	NN

in	IN
O	NN

term	NN
O	NN

and	CC
O	NN

preterm	NN
O	NN

infants	NNS
O	NN

Secondary	JJ
O	NN

prevention	NN
O	NN

for	IN
O	NN

stroke	NN
D	NN

after	IN
O	NN

CAPRIE	JJ
T	NN

and	CC
T	NN

ESPS-2	NN
T	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

New-onset	JJ
O	NN

angina	NN
O	NN

preceding	VBG
O	NN

acute	JJ
O	NN

myocardial	JJ
O	NN

infarction	NN
O	NN

is	VBZ
O	NN

associated	VBN
O	NN

with	IN
O	NN

improved	VBN
O	NN

contractile	NN
O	NN

recovery	NN
O	NN

after	IN
O	NN

thrombolysis	NN
O	NN

Magnetic	JJ
O	NN

resonance	NN
O	NN

imaging	NN
O	NN

in	IN
O	NN

focal	JJ
D	NN

myositis	NN
D	NN

Concomitant	JJ
D	NN

alveolitis	NN
D	NN

and	CC
O	NN

asthma	NN
D	NN

following	VBG
O	NN

exposure	NN
O	NN

to	TO
O	NN

triphenylmethane	NN
O	NN

triisocyanate	NN
O	NN

Gorlin	NNP
D	NNP

syndrome	NN
D	NN

:	:
O	NN

identification	NN
O	NN

of	IN
O	NN

4	CD
O	NN

novel	JJ
O	NN

germ-line	NN
O	NN

mutations	NNS
O	VBP

of	IN
O	NN

the	DT
O	NN

human	JJ
O	NN

patched	VBN
O	NN

(	NN
O	NN

PTCH	NN
O	NN

)	NN
O	NN

gene	NN
O	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

137	CD
O	NN

Online	JJ
O	NN

Genetic	JJ
O	NN

findings	NNS
O	VBP

in	IN
O	NN

congenital	JJ
D	NN

bilateral	JJ
D	NN

aplasia	NN
D	NN

of	IN
O	NN

vas	FW
O	FW

deferens	NNS
O	VBP

patients	NNS
O	NN

and	CC
O	NN

identification	NN
O	NN

of	IN
O	NN

six	CD
O	NN

novel	JJ
O	NN

mutatations	NNS
O	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

138	CD
O	NN

Online	JJ
O	NN

A	DT
O	NN

novel	JJ
O	NN

point	NN
O	NN

mutation	NN
O	NN

in	IN
O	NN

a	DT
O	NN

splice	NN
O	NN

acceptor	NN
O	NN

site	NN
O	NN

of	IN
O	NN

intron	NN
O	NN

1	CD
O	NN

of	IN
O	NN

the	DT
O	NN

human	JJ
O	NN

low	JJ
O	NN

density	NN
O	NN

lipoprotein	NN
O	NN

receptor	NN
O	NN

gene	NN
O	NN

which	WDT
O	NN

causes	NNS
O	VBP

severe	JJ
O	NN

hypercholesterolemia	NN
D	NN

:	:
O	NN

an	DT
O	NN

unexpected	JJ
O	NN

absence	NN
O	NN

of	IN
O	NN

exon	NN
O	NN

skipping	VBG
O	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

139	CD
O	NN

Online	JJ
O	NN

A	DT
O	NN

de	IN
O	NNP

novo	FW
O	FW

missense	NN
O	NN

mutation	NN
O	NN

(	NN
O	NN

R1623Q	NN
O	NN

)	NN
O	NN

of	IN
O	NN

the	DT
O	NN

SCN5A	NN
O	NN

gene	NN
O	NN

in	IN
O	NN

a	DT
O	NN

Japanese	JJ
O	NN

girl	NN
O	NN

with	IN
O	NN

sporadic	JJ
D	NN

long	RB
D	NN

QT	NN
D	NN

sydrome	NN
D	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

140	CD
O	NN

Online	JJ
O	NN

Missense	NN
O	NN

mutation	NN
O	NN

in	IN
O	NN

exon	NN
O	NN

11	CD
O	NN

(	NN
O	NN

Codon	NN
O	NN

378	CD
O	NN

)	NN
O	NN

of	IN
O	NN

the	DT
O	NN

presenilin-1	NN
O	NN

gene	NN
O	NN

in	IN
O	NN

a	DT
O	NN

French	JJ
O	NN

family	NN
O	NN

with	IN
O	NN

early-onset	JJ
O	NN

Alzheimer	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

and	CC
O	NN

transmission	NN
O	NN

study	NN
O	NN

by	IN
O	NN

mismatch	NN
O	NN

enhanced	VBN
O	NN

allele	NN
O	NN

specific	JJ
O	NN

amplification	NN
O	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

141	CD
O	NN

Online	JJ
O	NN

besancon	NN
O	NN

@	IN
O	NN

rockefeller1.univ.lyon1.fr	NN
O	NN

Mutation	NN
O	NN

sharing	VBG
O	NN

,	,
O	NN

predominant	JJ
O	NN

involvement	NN
O	NN

of	IN
O	NN

the	DT
O	NN

MLH1	NN
O	NN

gene	NN
O	NN

and	CC
O	NN

description	NN
O	NN

of	IN
O	NN

four	CD
O	NN

novel	JJ
O	NN

mutations	NNS
O	VBP

in	IN
O	NN

hereditary	JJ
D	NN

nonpolyposis	NN
D	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

144	CD
O	NN

Online	JJ
O	NN

A	DT
O	NN

new	JJ
O	NN

informative	JJ
O	NN

Alw	NN
O	NN

26	CD
O	NN

I	PRP
O	VBP

polymorphism	NN
O	NN

in	IN
O	NN

exon	NN
O	NN

10	CD
O	NN

of	IN
O	NN

the	DT
O	NN

human	JJ
O	NN

low	JJ
O	NN

density	NN
O	NN

lipoprotein	NN
O	NN

receptor	NN
O	NN

gene	NN
O	NN

Application	NN
O	NN

to	TO
O	NN

prenatal	JJ
O	NN

diagnosis	NN
O	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

145	CD
O	NN

Online	JJ
O	NN

Novel	JJ
O	NN

acceptor	NN
O	NN

splice	NN
O	NN

site	NN
O	NN

mutation	NN
O	NN

in	IN
O	NN

the	DT
O	NN

invariant	JJ
O	NN

AG	NNP
O	NNP

of	IN
O	NN

intron	NN
O	NN

6	CD
O	NN

of	IN
O	NN

alpha-galactosidase	NN
O	NN

A	DT
O	NN

gene	NN
O	NN

,	,
O	NN

causing	VBG
O	NN

Fabry	NN
D	NN

disease	NN
D	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

146	CD
O	NN

Online	JJ
O	NN

Meta-analysis	NN
O	NN

of	IN
O	NN

trials	NNS
O	NN

comparing	VBG
O	NN

antidepressants	NNS
T	NN

with	IN
O	NN

active	JJ
O	NN

placebos	NNS
O	NN

Evidence-based	JJ
O	NN

guidelines	NNS
O	NN

for	IN
O	NN

universal	JJ
O	NN

counselling	VBG
O	NN

and	CC
O	NN

offering	VBG
O	NN

of	IN
O	NN

HIV	NN
O	NN

testing	NN
O	NN

in	IN
O	NN

pregnancy	NN
O	NN

in	IN
O	NN

Canada	NNP
O	NNP

Chelation	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

peripheral	JJ
D	NN

arterial	JJ
D	NN

occlusive	NN
D	NN

disease	NN
D	NN

:	:
O	NN

a	DT
O	NN

systematic	JJ
O	NN

review	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Sodium	NN
T	NN

channel	NN
T	NN

block	NN
T	NN

with	IN
T	NN

mexiletine	NN
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

in	IN
O	NN

reducing	VBG
O	NN

dispersion	NN
O	NN

of	IN
O	NN

repolarization	NN
O	NN

and	CC
O	NN

preventing	VBG
O	NN

torsade	NN
D	NN

des	FW
D	NN

pointes	NNS
D	NN

in	IN
O	NN

LQT2	NN
O	NN

and	CC
O	NN

LQT3	NN
O	NN

models	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

long-QT	JJ
O	NN

syndrome	NN
O	NN

Simultaneous	JJ
O	NN

microsurgical	JJ
T	NN

vasal	JJ
T	NN

reconstruction	NN
T	NN

and	CC
O	NN

varicocele	NN
T	NN

ligation	NN
T	NN

:	:
O	NN

safety	NN
O	NN

profile	NN
O	NN

and	CC
O	NN

outcomes	NNS
O	VBP

A	DT
O	NN

predetermined	VBN
O	NN

design	NN
O	NN

for	IN
O	NN

easier	JJR
O	NN

aesthetic	JJ
T	NN

abdominoplasty	JJ
T	NN

Significance	NN
O	NN

of	IN
O	NN

revision	NN
O	NN

of	IN
O	NN

the	DT
O	NN

occupational	JJ
O	NN

illness	NN
O	NN

legislation	NN
O	NN

for	IN
O	NN

evaluating	VBG
O	NN

intervertebral	NN
D	NN

disk	NN
D	NN

damage	NN
D	NN

Serum	NN
O	NN

urate	NN
O	NN

during	IN
O	NN

bouts	NNS
O	NN

of	IN
O	NN

acute	JJ
D	NN

gouty	JJ
D	NN

arthritis	NN
D	NN

Isolated	VBN
O	NN

axial	JJ
O	NN

lateral	JJ
O	NN

pulse	NN
O	NN

as	IN
O	NN

a	DT
O	NN

sign	NN
O	NN

of	IN
O	NN

latero-bulbar	JJ
D	NN

ischemia	NN
D	NN

:	:
O	NN

clinical	JJ
O	NN

topographic	JJ
O	NN

correlation	NN
O	NN

Microalbuminuria	NN
D	NN

is	VBZ
O	NN

positively	RB
O	NN

associated	VBN
O	NN

with	IN
O	NN

usual	JJ
O	NN

dietary	JJ
O	NN

saturated	JJ
O	NN

fat	JJ
O	NN

intake	NN
O	NN

and	CC
O	NN

negatively	RB
O	NN

associated	VBN
O	NN

with	IN
O	NN

usual	JJ
O	NN

dietary	JJ
O	NN

protein	NN
O	NN

intake	NN
O	NN

in	IN
O	NN

people	NNS
O	VBP

with	IN
O	NN

insulin-dependent	JJ
D	NN

diabetes	NN
D	NN

mellitus	NN
D	NN

Endoscopic	JJ
T	NN

ultrasound	NN
T	NN

miniprobe-guided	JJ
T	NN

steroid	NN
T	NN

injection	NN
T	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

refractory	JJ
D	NN

esophageal	NN
D	NN

strictures	NNS
D	NN

Purification	NN
O	NN

and	CC
O	NN

characterization	NN
O	NN

of	IN
O	NN

an	DT
O	NN

acetyl	NN
O	NN

xylan	NN
O	NN

esterase	NN
O	NN

from	IN
O	NN

Bacillus	NN
O	NN

pumilus	NN
O	NN

The	DT
O	NN

Stresst'er	NN
O	NN

ergometer	NN
O	NN

as	IN
O	NN

an	DT
O	NN

alternative	JJ
O	NN

to	TO
O	NN

treadmill	NN
O	NN

testing	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

claudication	NN
D	NN

Renal	JJ
D	NN

trauma	NN
D	NN

and	CC
O	NN

the	DT
O	NN

risk	NN
O	NN

of	IN
O	NN

long-term	JJ
O	NN

complications	NNS
O	NN

in	IN
O	NN

shock	NN
T	NN

wave	NN
T	NN

lithotripsy	NN
T	NN

Current	JJ
O	NN

management	NN
O	NN

of	IN
O	NN

corneal	NN
D	NN

abrasions	NNS
D	NN

:	:
O	NN

evidence	NN
O	NN

based	VBN
O	NN

practice	NN
O	NN

?	.
O	NN

Placebo	NN
O	NN

in	IN
O	NN

drug	NN
O	NN

clinical	JJ
O	NN

trials	NNS
O	NN

Chromosome	NN
O	NN

22qII	NN
O	NN

deletions	NNS
O	VBP

An	DT
O	NN

under-recognised	JJ
O	NN

cause	NN
O	NN

of	IN
O	NN

idiopathic	JJ
D	NN

learning	VBG
D	NN

disability	NN
D	NN

Serial	JJ
O	NN

magnetic	JJ
O	NN

resonance	NN
O	NN

imaging	NN
O	NN

findings	NNS
O	VBP

for	IN
O	NN

a	DT
O	NN

spontaneously	RB
O	NN

resolving	VBG
O	NN

spinal	JJ
D	NN

subdural	JJ
D	NN

hematoma	NN
D	NN

:	:
O	NN

case	NN
O	NN

report	NN
O	NN

A	DT
O	NN

simple	JJ
O	NN

technique	NN
O	NN

for	IN
O	NN

correction	NN
O	NN

of	IN
O	NN

mucosal	JJ
D	NN

irregularities	NNS
D	NN

of	IN
D	NN

the	DT
D	NN

lip	NN
D	NN

Cancer	NN
D	NN

risk	NN
O	NN

in	IN
O	NN

the	DT
O	NN

rubber	NN
O	NN

industry	NN
O	NN

:	:
O	NN

a	DT
O	NN

review	NN
O	NN

of	IN
O	NN

the	DT
O	NN

recent	JJ
O	NN

epidemiological	JJ
O	NN

evidence	NN
O	NN

HIV	NN
O	NN

treatment	NN
O	NN

strategies	NNS
O	VBP

:	:
O	NN

planning	VBG
O	NN

for	IN
O	NN

the	DT
O	NN

long	RB
O	NN

term	NN
O	NN

The	DT
O	NN

project	NN
O	NN

of	IN
O	NN

a	DT
O	NN

national	JJ
O	NN

control	NN
O	NN

program	NN
O	NN

for	IN
O	NN

tuberculosis	NN
D	NN

in	IN
O	NN

Spain	NNP
O	NNP

Decrease	NN
O	NN

in	IN
O	NN

antibiotic	JJ
O	NN

susceptibility	NN
O	NN

or	CC
O	NN

increase	NN
O	NN

in	IN
O	NN

resistance	NN
O	NN

?	.
O	NN

Helicobacter	NNP
O	NNP

pylori	NN
O	NN

and	CC
O	NN

abdominal	JJ
O	NN

symptoms	NNS
O	NN

:	:
O	NN

a	DT
O	NN

population-based	JJ
O	NN

study	NN
O	NN

among	IN
O	NN

preschool	JJ
O	NN

children	NNS
O	VBP

in	IN
O	NN

southern	JJ
O	NN

Germany	NNP
O	NNP

Have	VBP
O	NN

we	PRP
O	VBP

treated	VBN
O	NN

AIDS	NN
D	NN

too	RB
O	NN

well	RB
O	NN

?	.
O	NN

Rationing	VBG
O	NN

and	CC
O	NN

the	DT
O	NN

future	JJ
O	NN

of	IN
O	NN

AIDS	NNP
O	NN

exceptionalism	NN
O	NN

Recommendations	NNS
O	NN

on	IN
O	NN

antiretroviral	JJ
T	NN

treatment	NN
T	NN

The	DT
O	NN

AIDS	NNP
O	NN

Study	NNP
O	NNP

Group	NNP
O	NNP

of	IN
O	NN

the	DT
O	NN

Spanish	JJ
O	NN

Society	NNP
O	NNP

of	IN
O	NN

Infectious	JJ
O	NN

Diseases	NNS
O	NN

and	CC
O	NN

Clinical	JJ
O	NN

Microbiology	NNP
O	NNP

Requirements	NNS
O	VBP

for	IN
O	NN

training	NN
O	NN

to	TO
O	NN

ensure	VB
O	NN

competence	NN
O	NN

of	IN
O	NN

endoscopists	NNS
O	NN

performing	VBG
O	NN

invasive	JJ
O	NN

procedures	NNS
O	VBP

in	IN
O	NN

children	NNS
O	VBP

Safe	NN
O	NN

motherhood	NN
O	NN

:	:
O	NN

can	MD
O	NNP

we	PRP
O	VBP

make	VB
O	NN

a	DT
O	NN

difference	NN
O	NN

?	.
O	NN

Lumbar	JJ
D	NN

spine	NN
D	NN

stenosis	NN
D	NN

:	:
O	NN

a	DT
O	NN

common	JJ
O	NN

cause	NN
O	NN

of	IN
O	NN

back	RB
O	NN

and	CC
O	NN

leg	NN
O	NN

pain	NN
D	NN

Myoepithelial	JJ
D	NN

carcinoma	NN
D	NN

with	IN
O	NN

predominance	NN
O	NN

of	IN
O	NN

plasmacytoid	NN
O	NN

cells	NNS
O	VBP

arising	VBG
O	NN

in	IN
O	NN

a	DT
O	NN

pleomorphic	JJ
D	NN

adenoma	NN
D	NN

of	IN
O	NN

the	DT
O	NN

parotid	NN
O	NN

gland	NN
O	NN

Lonomia	NN
O	NN

obliqua	NN
O	NN

caterpillar	NN
O	NN

spicules	NNS
O	NN

trigger	NN
O	NN

human	JJ
O	NN

blood	NN
O	NN

coagulation	NN
O	NN

via	IN
O	NN

activation	NN
O	NN

of	IN
O	NN

factor	NN
O	NN

X	NN
O	NN

and	CC
O	NN

prothrombin	NN
O	NN

Doing	VBG
O	NN

everything	NN
O	NN

Successful	JJ
O	NN

replantation	NN
O	NN

of	IN
O	NN

an	DT
O	NN

amputated	VBN
O	NN

tongue	NN
O	NN

Morbidity	NN
O	NN

and	CC
O	NN

healthcare	NN
O	NN

utilisation	NN
O	NN

of	IN
O	NN

children	NNS
O	VBP

in	IN
O	NN

households	NNS
O	NN

with	IN
O	NN

one	CD
O	NN

adult	JJ
O	NN

:	:
O	NN

comparative	JJ
O	NN

observational	JJ
O	NN

study	NN
O	NN

A	DT
O	NN

novel	JJ
O	NN

frameshift	NN
O	NN

mutation	NN
O	NN

840delA	NN
O	NN

and	CC
O	NN

a	DT
O	NN

novel	JJ
O	NN

polymorphism	NN
O	NN

D203A	NN
O	NN

in	IN
O	NN

the	DT
O	NN

steroidogenic	JJ
O	NN

acute	JJ
O	NN

regulatory	JJ
O	NN

protein	NN
O	NN

gene	NN
O	NN

in	IN
O	NN

a	DT
O	NN

Japanese	JJ
O	NN

patient	NN
O	NN

with	IN
O	NN

congenital	JJ
D	NN

lipoid	NN
D	NN

adrenal	JJ
D	NN

hyperplasia	NN
D	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

117	CD
O	NN

Online	JJ
O	NN

Identification	NN
O	NN

of	IN
O	NN

five	CD
O	NN

new	JJ
O	NN

mutations	NNS
O	VBP

and	CC
O	NN

three	CD
O	NN

novel	JJ
O	NN

polymorphisms	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

muscle	NN
O	NN

chloride	NN
O	NN

channel	NN
O	NN

gene	NN
O	NN

(	NN
O	NN

CLCN1	NN
O	NN

)	NN
O	NN

in	IN
O	NN

20	CD
O	NN

Italian	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

dominant	JJ
O	NN

and	CC
O	NN

recessive	JJ
O	NN

myotonia	NN
D	NN

congenita	NN
D	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

118	CD
O	NN

Online	JJ
O	NN

Identification	NN
O	NN

of	IN
O	NN

a	DT
O	NN

large	JJ
O	NN

insertion	NN
O	NN

and	CC
O	NN

two	CD
O	NN

novel	JJ
O	NN

point	NN
O	NN

mutations	NNS
O	VBP

(	NN
O	NN

3671del8	NN
O	NN

and	CC
O	NN

S1221X	NN
O	NN

)	NN
O	NN

in	IN
O	NN

tuberous	JJ
D	NN

sclerosis	NN
D	NN

complex	NN
D	NN

(	NN
D	NN

TSC	NN
D	NN

)	NN
D	NN

patients	NNS
O	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

119	CD
O	NN

Online	JJ
O	NN

Mutational	JJ
O	NN

analysis	NN
O	NN

of	IN
O	NN

the	DT
O	NN

cystathionine	NN
O	NN

beta-synthase	NN
O	NN

gene	NN
O	NN

:	:
O	NN

a	DT
O	NN

splicing	NN
O	NN

mutation	NN
O	NN

,	,
O	NN

two	CD
O	NN

missense	NN
O	NN

mutations	NNS
O	VBP

and	CC
O	NN

an	DT
O	NN

insertion	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

homocystinuria	NN
D	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

120	CD
O	NN

Online	JJ
O	NN

Analysis	NN
O	NN

of	IN
O	NN

five	CD
O	NN

mutations	NNS
O	VBP

in	IN
O	NN

20	CD
O	NN

mucopolysaccharidois	NN
D	NN

type	NN
O	NN

1	CD
O	NN

patients	NNS
O	NN

:	:
O	NN

high	JJ
O	NN

prevalence	NN
O	NN

of	IN
O	NN

the	DT
O	NN

W402X	NN
O	NN

mutation	NN
O	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

121	CD
O	NN

Online	JJ
O	NN

A	DT
O	NN

novel	JJ
O	NN

missense	NN
O	NN

mutation	NN
O	NN

Ile538Val	NN
O	NN

in	IN
O	NN

the	DT
O	NN

fibroblast	NN
O	NN

growth	NN
O	NN

factor	NN
O	NN

receptor	NN
O	NN

3	CD
O	NN

in	IN
O	NN

hypochondroplasia	NN
D	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

122	CD
O	NN

Online	JJ
O	NN

Detection	NN
O	NN

of	IN
O	NN

four	CD
O	NN

novel	JJ
O	NN

mutations	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

iduronate-2-sulfatase	NN
O	NN

gene	NN
O	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

123	CD
O	NN

Online	JJ
O	NN

Polymorphisms	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

coding	VBG
O	NN

exons	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

human	JJ
O	NN

luteinizing	VBG
O	NN

hormone	NN
O	NN

receptor	NN
O	NN

gene	NN
O	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

124	CD
O	NN

Online	JJ
O	NN

Independent	NNP
O	NNP

occurrence	NN
O	NN

of	IN
O	NN

the	DT
O	NN

novel	JJ
O	NN

Arg2163	NN
O	NN

to	TO
O	NN

His	PRP$
O	NN

mutation	NN
O	NN

in	IN
O	NN

the	DT
O	NN

factor	NN
O	NN

VIII	CD
O	NN

gene	NN
O	NN

in	IN
O	NN

three	CD
O	NN

unrelated	JJ
O	NN

families	NNS
O	NN

with	IN
O	NN

haemophila	NN
D	NN

A	DT
D	NN

with	IN
O	NN

different	JJ
O	NN

phenotypes	NNS
O	NN

Mutations	NNS
O	VBP

in	IN
O	NN

brief	JJ
O	NN

no	DT
O	NN

126	CD
O	NN

Online	JJ
O	NN

Are	VBP
O	NN

Japanese	JJ
O	NN

researchers	NNS
O	NN

exploiting	VBG
O	NN

Thai	NNP
O	NNP

HIV	NN
O	NN

patients	NNS
O	NN

?	.
O	NN

Underutilization	NN
O	NN

of	IN
O	NN

aspirin	NN
T	NN

in	IN
O	NN

older	JJR
O	NN

patients	NNS
O	NN

with	IN
O	NN

prior	RB
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

at	IN
O	NN

the	DT
O	NN

time	NN
O	NN

of	IN
O	NN

admission	NN
O	NN

to	TO
O	NN

a	DT
O	NN

nursing	NN
O	NN

home	NN
O	NN

.	.
O	NN

Distinguishing	VBG
O	NN

silent	JJ
D	NN

lacunar	NN
D	NN

infarction	NN
D	NN

from	IN
O	NN

enlarged	JJ
D	NN

Virchow-Robin	NN
D	NN

spaces	NNS
D	NN

:	:
O	NN

a	DT
O	NN

magnetic	JJ
O	NN

resonance	NN
O	NN

imaging	NN
O	NN

and	CC
O	NN

pathological	JJ
O	NN

study	NN
O	NN

Correlation	NN
O	NN

is	VBZ
O	NN

not	RB
O	NN

causation	NN
O	NN

Inhalation	NN
O	NN

of	IN
O	NN

ammonium	NN
O	NN

nitrate	JJ
O	NN

fuel	NN
O	NN

oil	NN
O	NN

explosive	JJ
O	NN

(	NN
O	NN

ANFO	NNP
O	NN

)	NN
O	NN

Management	NNP
O	NNP

of	IN
O	NN

polycythaemia	NN
D	NN

in	IN
O	NN

adults	NNS
O	NN

with	IN
O	NN

cyanotic	JJ
D	NN

congenital	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

Bolstering	VBG
O	NN

Sisyphus	NNP
O	NNP

Use	NNP
O	NNP

of	IN
O	NN

public	JJ
O	NN

performance	NN
O	NN

reports	NNS
O	NN

:	:
O	NN

a	DT
O	NN

survey	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

undergoing	VBG
O	NN

cardiac	JJ
T	NN

surgery	NN
T	NN

Role	NN
O	NN

of	IN
O	NN

a	DT
O	NN

p53	NN
O	NN

polymorphism	NN
O	NN

in	IN
O	NN

the	DT
O	NN

development	NN
O	NN

of	IN
O	NN

human	JJ
D	NN

papillomavirus-associated	JJ
D	NN

cancer	NN
D	NN

The	DT
O	NN

use	NN
O	NN

of	IN
O	NN

nurses	NNS
O	NN

in	IN
O	NN

alternative	JJ
O	NN

dispute	NN
O	NN

resolution	NN
O	NN

Re	NNP
O	NNP

:	:
O	NN

Friday	NNP
O	NNP

afternoon	NN
O	NN

pulmonary	JJ
T	NN

arteriography	NN
T	NN

(	NN
T	NN

FAPA	NN
T	NN

)	NN
T	NN

:	:
O	NN

are	VBP
O	NN

Fridays	NNS
O	NN

good	JJ
O	NN

for	IN
O	NN

your	PRP$
O	NN

health	NN
O	NN

?	.
O	NN

Hormone	NN
T	NN

replacement	NN
T	NN

therapy	NN
T	NN

and	CC
O	NN

breast	NN
D	NN

cancer	NN
D	NN

.	.
O	NN

Physician	NN
O	NN

heal	VB
O	NNP

thyself	RB
O	NN

:	:
O	NN

are	VBP
O	NN

antibiotics	NNS
T	NN

the	DT
O	NN

cure	NN
O	NN

or	CC
O	NN

the	DT
O	NN

disease	NN
O	NN

?	.
O	NN

Primary	JJ
D	NN

biliary	JJ
D	NN

cirrhosis	NN
D	NN

Polymorphism	NN
O	NN

in	IN
O	NN

promoter	NN
O	NN

region	NN
O	NN

of	IN
O	NN

inducible	JJ
O	NN

nitric	JJ
O	NN

oxide	NN
O	NN

synthase	NN
O	NN

gene	NN
O	NN

and	CC
O	NN

protection	NN
O	NN

against	IN
O	NN

malaria	NN
D	NN

Ventilatory	JJ
O	NN

responses	NNS
O	NN

to	TO
O	NN

acute	JJ
O	NN

and	CC
O	NN

sustained	JJ
O	NN

hypoxia	NN
O	NN

during	IN
O	NN

isoflurane	NN
O	NN

anesthesia	NN
O	NN

Leprosy	NN
D	NN

type	NN
D	NN

1	LS
D	NN

reaction	NN
O	NN

as	IN
O	NN

the	DT
O	NN

first	RB
O	NN

manifestation	NN
O	NN

of	IN
O	NN

borderline	JJ
O	NN

lepromatous	JJ
D	NN

leprosy	NNP
D	NNP

in	IN
O	NN

a	DT
O	NN

young	JJ
O	NN

native	JJ
O	NN

German	JJ
O	NN

A	DT
O	NN

systematic	JJ
O	NN

review	NN
O	NN

of	IN
O	NN

five	CD
O	NN

systemic	JJ
T	NN

treatments	NNS
T	NN

for	IN
O	NN

severe	JJ
D	NN

psoriasis	NN
D	NN

Trisomy	NNP
O	NNP

10	CD
O	NN

in	IN
O	NN

leukemia	NN
D	NN

Receptive	JJ
O	NN

properties	NNS
O	NN

of	IN
O	NN

primary	JJ
O	NN

afferent	JJ
O	NN

fibres	NNS
O	NN

from	IN
O	NN

rabbit	NN
O	NN

pleura	NN
O	NN

,	,
O	NN

in	IN
O	NN

vitro	FW
O	FW

Congenital	JJ
D	NN

anomalies	NNS
D	NN

of	IN
D	NN

tracheobronchial	JJ
D	NN

branching	VBG
D	NN

patterns	NNS
D	NN

:	:
O	NN

spiral	NN
O	NN

CT	NN
O	NN

aspects	NNS
O	NN

in	IN
O	NN

adults	NNS
O	NN

American	JJ
O	NN

Heart	NNP
O	NNP

Association	NNP
O	NN

urges	VBZ
O	NN

caution	NN
O	NN

on	IN
O	NN

new	JJ
O	NN

diet	NN
O	NN

drug	NN
O	NN

Absence	NN
O	NN

of	IN
O	NN

renal	JJ
O	NN

and	CC
O	NN

hepatic	JJ
O	NN

toxicity	NN
O	NN

after	IN
O	NN

four	CD
O	NN

hours	NNS
O	NN

of	IN
O	NN

1.25	CD
O	NN

minimum	JJ
O	NN

alveolar	JJ
O	NN

anesthetic	JJ
O	NN

concentration	NN
O	NN

sevoflurane	NN
O	NN

anesthesia	NN
O	NN

in	IN
O	NN

volunteers	NNS
O	NN

Linear	JJ
D	NN

lichen	NN
D	NN

planopilaris	NN
D	NN

of	IN
O	NN

the	DT
O	NN

face	NN
O	NN

Electrolyte	NN
O	NN

abnormalities	NNS
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

renal	JJ
D	NN

failure	NN
D	NN

receiving	VBG
O	NN

parenteral	JJ
O	NN

nutrition	NN
O	NN

Risk	NN
O	NN

factors	NNS
O	NN

for	IN
O	NN

hemiretinal	JJ
D	NN

vein	NN
D	NN

occlusion	NN
D	NN

:	:
O	NN

comparison	NN
O	NN

with	IN
O	NN

risk	NN
O	NN

factors	NNS
O	NN

for	IN
O	NN

central	JJ
D	NN

and	CC
D	NN

branch	NN
D	NN

retinal	JJ
D	NN

vein	NN
D	NN

occlusion	NN
D	NN

:	:
O	NN

the	DT
O	NN

eye	NN
O	NN

disease	NN
O	NN

case-control	JJ
O	NN

study	NN
O	NN

The	DT
O	NN

psychological	JJ
O	NN

profiles	NNS
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

whiplash-associated	JJ
D	NN

headache	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Fatal	JJ
O	NN

spontaneous	JJ
O	NN

spinal	JJ
O	NN

epidural	JJ
O	NN

hematoma	NN
O	NN

following	VBG
O	NN

thrombolysis	NN
O	NN

for	IN
O	NN

myocardial	JJ
O	NN

infarction	NN
O	NN

Bifid	JJ
O	NN

T	NN
O	NN

waves	NNS
O	NN

induced	VBN
O	NN

by	IN
O	NN

isoprenaline	NN
T	NN

in	IN
O	NN

a	DT
O	NN

patient	NN
O	NN

with	IN
O	NN

Brugada	NN
D	NN

syndrome	NN
D	NN

.	.
O	NN

Quo	NN
O	NN

vadis	NN
O	NN

``	``
O	NN

suprema	NN
O	NN

lex	NN
O	NN

''	''
O	NN

?	.
O	NN

Death	NN
O	NN

in	IN
O	NN

springtime	NN
O	NN

Clinical	JJ
T	NN

management	NN
T	NN

and	CC
O	NN

treatment	NN
O	NN

outcomes	NNS
O	VBP

of	IN
O	NN

Merkel	NN
D	NN

cell	NN
D	NN

carcinoma	NN
D	NN

Relatives	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

resuscitation	NN
O	NN

room	NN
O	NN

:	:
O	NN

their	PRP$
O	NN

point	NN
O	NN

of	IN
O	NN

view	NN
O	NN

Large	JJ
D	NN

airway	NN
D	NN

disease	NN
D	NN

associated	VBN
O	NN

with	IN
O	NN

inflammatory	JJ
D	NN

bowel	NN
D	NN

disease	NN
D	NN

Autonomy	NN
O	NN

in	IN
O	NN

the	DT
O	NN

face	NN
O	NN

of	IN
O	NN

a	DT
O	NN

devastating	VBG
O	NN

diagnosis	NN
O	NN

Advanced	NNP
O	NNP

practice	NN
O	NN

nursing	NN
O	NN

:	:
O	NN

is	VBZ
O	NN

the	DT
O	NN

physician	NN
O	NN

's	POS
O	NN

assistant	JJ
O	NN

an	DT
O	NN

accident	NN
O	NN

of	IN
O	NN

history	NN
O	NN

or	CC
O	NN

a	DT
O	NN

failure	NN
O	NN

to	TO
O	NN

act	NN
O	NN

?	.
O	NN

Acute	JJ
D	NN

obstructive	JJ
D	NN

hydrocephalus	NN
D	NN

complicating	VBG
O	NN

bacterial	JJ
D	NN

meningitis	NN
D	NN

in	IN
O	NN

childhood	NN
O	NN

Subcutaneous	JJ
O	NN

autologous	JJ
O	NN

ovarian	JJ
O	NN

transplantation	NN
O	NN

in	IN
O	NN

Wistar	JJ
O	NN

rats	NNS
O	NN

maintains	VBZ
O	NN

hormone	NN
O	NN

secretion	NN
O	NN

Teaching	VBG
O	NN

irritable	JJ
D	NN

bowel	NN
D	NN

syndrome	NN
D	NN

patients	NNS
O	NN

to	TO
O	NN

care	NN
O	NN

for	IN
O	NN

themselves	PRP
O	VBP

Nonanesthetic	JJ
O	NN

volatile	JJ
O	NN

drugs	NNS
O	NN

obey	VB
O	NNP

the	DT
O	NN

Meyer-Overton	NNP
O	NNP

correlation	NN
O	NN

in	IN
O	NN

two	CD
O	NN

molecular	JJ
O	NN

protein	NN
O	NN

site	NN
O	NN

models	NNS
O	NN

Inhaled	VBN
T	NN

sodium	NN
T	NN

cromoglycate	NN
T	NN

in	IN
O	NN

young	JJ
O	NN

children	NNS
O	VBP

with	IN
O	NN

moderate	JJ
O	NN

asthma	NN
D	NN

Directly	RB
O	NN

observed	VBN
O	NN

therapy	NN
O	NN

and	CC
O	NN

treatment	NN
O	NN

completion	NN
O	NN

for	IN
O	NN

tuberculosis	NN
D	NN

in	IN
O	NN

the	DT
O	NN

United	NNP
O	NNP

States	NNPS
O	NNP

:	:
O	NN

is	VBZ
O	NN

universal	JJ
O	NN

supervised	VBN
O	NN

therapy	NN
O	NN

necessary	JJ
O	NN

?	.
O	NN

Investigation	NNP
O	NNP

of	IN
O	NN

antibiotic	JJ
T	NN

prophylaxis	NN
T	NN

usage	NN
O	NN

for	IN
O	NN

vascular	JJ
O	NN

and	CC
O	NN

nonvascular	JJ
O	NN

interventional	JJ
O	NN

procedures	NNS
O	VBP

Effect	NN
O	NN

of	IN
O	NN

protein	NN
O	NN

kinase	NN
O	NN

C	NN
O	NN

inhibitors	NNS
O	NN

on	IN
O	NN

cardioprotection	NN
O	NN

by	IN
O	NN

ischemic	JJ
O	NN

preconditioning	VBG
O	NN

depends	VBZ
O	NN

on	IN
O	NN

the	DT
O	NN

number	NN
O	NN

of	IN
O	NN

preconditioning	VBG
O	NN

episodes	NNS
O	NN

How	WRB
O	NN

do	VB
O	NNP

you	PRP
O	VBP

treat	VB
O	NNP

refractory	JJ
D	NN

pouchitis	NN
D	NN

and	CC
O	NN

when	WRB
O	NN

do	VB
O	NNP

you	PRP
O	VBP

decide	VB
O	NN

to	TO
O	NN

remove	VB
O	NN

the	DT
O	NN

pouch	NN
O	NN

?	.
O	NN

Filter	NNP
O	NNP

paper	NN
O	NN

blood	NN
O	NN

spot	NN
O	NN

assay	NN
O	NN

of	IN
O	NN

human	JJ
O	NN

insulin-like	JJ
O	NN

growth	NN
O	NN

factor	NN
O	NN

I	PRP
O	VBP

(	NN
O	NN

IGF-I	NN
O	NN

)	NN
O	NN

and	CC
O	NN

IGF-binding	JJ
O	NN

protein-3	JJ
O	NN

and	CC
O	NN

preliminary	JJ
O	NN

application	NN
O	NN

in	IN
O	NN

the	DT
O	NN

evaluation	NN
O	NN

of	IN
O	NN

growth	NN
O	NN

hormone	NN
O	NN

status	NN
O	NN

Effect	NN
O	NN

of	IN
O	NN

iodixanol	NN
D	NN

on	IN
O	NN

renal	JJ
O	NN

function	NN
O	NN

immediately	RB
O	NN

after	IN
O	NN

abdominal	JJ
T	NN

angiography	NN
T	NN

.	.
O	NN

Clinical	JJ
O	NN

comparison	NN
O	NN

with	IN
O	NN

iomeprol	NN
D	NN

and	CC
O	NN

ioxaglate	NN
D	NN

A	DT
O	NN

new	JJ
O	NN

modified	VBN
O	NN

technique	NN
O	NN

for	IN
O	NN

harvest	NN
O	NN

of	IN
O	NN

calcaneal	NN
O	NN

bone	NN
O	NN

grafts	NNS
O	NN

in	IN
O	NN

surgery	NN
T	NN

on	IN
O	NN

the	DT
O	NN

foot	NN
O	NN

and	CC
O	NN

ankle	NN
O	NN

Is	VBZ
O	NN

prevaccination	NN
O	NN

screening	VBG
O	NN

for	IN
O	NN

hepatitis	NN
D	NN

B	NN
D	NN

among	IN
O	NN

sexually	RB
O	NN

active	JJ
O	NN

adolescents	NNS
O	NN

cost-effective	JJ
O	NN

?	.
O	NN

Epilepsy	NNP
D	NNP

--	:
O	NN

a	DT
O	NN

guide	NN
O	NN

to	TO
O	NN

medical	JJ
O	NN

treatment	NN
O	NN

1	CD
O	NN

:	:
O	NN

Antiepileptic	JJ
T	NN

drugs	NNS
T	NN

Adolescent	JJ
O	NN

pregnancy	NN
O	NN

and	CC
O	NN

sexual	JJ
O	NN

abuse	NN
O	NN

Normoxic	JJ
T	NN

cardiopulmonary	JJ
T	NN

bypass	NN
T	NN

reduces	VBZ
O	NN

oxidative	JJ
D	NN

myocardial	JJ
D	NN

damage	NN
D	NN

and	CC
D	NN

nitric	JJ
D	NN

oxide	NN
D	NN

during	IN
O	NN

cardiac	JJ
O	NN

operations	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

adult	JJ
O	NN

A	DT
O	NN

multidimensional	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

preference	NN
O	NN

judgements	NNS
O	NN

for	IN
O	NN

excerpts	NNS
O	NN

of	IN
O	NN

music	NN
O	NN

Extending	VBG
O	NN

the	DT
O	NN

benefits	NNS
O	NN

of	IN
O	NN

breast	NN
D	NN

cancer	NN
D	NN

screening	VBG
O	NN

Still	RB
O	NN

hard	RB
O	NN

to	TO
O	NN

know	VB
O	NN

how	WRB
O	NN

large	JJ
O	NN

the	DT
O	NN

benefits	NNS
O	NN

will	MD
O	VB

really	RB
O	NN

be	VB
O	NN

Rhabdomyolysis	NNP
D	NNP

and	CC
O	NN

carbon	NN
D	NN

monoxide	NN
D	NN

poisoning	NN
D	NN

Effect	NN
O	NN

of	IN
O	NN

dental	JJ
T	NN

treatment	NN
T	NN

on	IN
O	NN

the	DT
O	NN

lung	NN
O	NN

function	NN
O	NN

of	IN
O	NN

children	NNS
O	VBP

with	IN
O	NN

asthma	NN
D	NN

.	.
O	NN

conclusions	NNS
O	NN

:	:
O	NN

apc	NN
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

endoluminal	JJ
D	NN

hemoptysis	NN
D	NN

and	CC
O	NN

airway	NN
D	NN

obstruction	NN
D	NN

induction	NN
T	NN

chemotherapy	NN
T	NN

(	NN
T	NN

cisplatin	NN
T	NN

+	CC
T	NN

vinorelbine	NN
T	NN

)	NN
T	NN

is	VBZ
O	NN

found	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

markedly	RB
O	NN

effective	JJ
O	NN

for	IN
O	NN

squamous	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

carcinoma	NN
D	NN

with	IN
D	NN

sarcoidosis	NN
D	NN

--	:
O	NN

a	DT
O	NN

case	NN
O	NN

report	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

in	IN
O	NN

conclusion	NN
O	NN

,	,
O	NN

3d	NN
O	NN

computer-assisted	JJ
O	NN

analysis	NN
O	NN

of	IN
O	NN

the	DT
O	NN

internal	JJ
O	NN

structure	NN
O	NN

of	IN
O	NN

small	JJ
O	NN

pulmonary	JJ
O	NN

nodules	NNS
O	NN

using	VBG
O	NN

contrast-enhanced	JJ
O	NN

dh-ct	JJ
O	NN

was	VBD
O	NN

found	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

effective	JJ
O	NN

for	IN
O	NN

differentiating	VBG
O	NN

between	IN
O	NN

benign	JJ
O	NN

and	CC
O	NN

malignant	JJ
O	NN

nodules	NNS
O	NN

the	DT
O	NN

patient	NN
O	NN

was	VBD
O	NN

a	DT
O	NN

62-year-old	JJ
O	NN

man	NN
O	NN

with	IN
O	NN

squamous	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

,	,
O	NN

which	WDT
O	NN

was	VBD
O	NN

first	RB
O	NN

successfully	RB
O	NN

treated	VBN
O	NN

by	IN
O	NN

a	DT
O	NN

combination	NN
T	NN

of	IN
T	NN

radiation	NN
T	NN

therapy	NN
T	NN

and	CC
T	NN

chemotherapy	NN
T	NN

,	,
O	NN

but	CC
O	NNP

showed	VBD
O	NN

local	JJ
O	NN

recurrence	NN
O	NN

after	IN
O	NN

8	CD
O	NN

months	NNS
O	NN

the	DT
O	NN

combination	NN
T	NN

of	IN
T	NN

txt	NN
T	NN

,	,
T	NN

gem	NN
T	NN

and	CC
T	NN

cddp	NN
T	NN

may	MD
O	NNP

be	VB
O	NN

effective	JJ
O	NN

for	IN
O	NN

recurrent	JJ
D	NN

non-small-cell	JJ
D	NN

lung	NN
D	NN

carcinoma	NN
D	NN

,	,
O	NN

even	RB
O	NN

in	IN
O	NN

patients	NNS
O	NN

that	IN
O	NN

have	VB
O	NN

failed	VBD
O	NN

to	TO
O	NN

respond	NN
O	NN

to	TO
O	NN

more	RBR
O	NN

than	IN
O	NN

one	CD
O	NN

chemotherapy	NN
O	NN

regimen	NN
O	NN

the	DT
O	NN

aim	NN
O	NN

of	IN
O	NN

the	DT
O	NN

current	JJ
O	NN

study	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

compare	VB
O	NN

the	DT
O	NN

objective	JJ
O	NN

response	NN
O	NN

and	CC
O	NN

survival	NN
O	NN

rates	NNS
O	VBP

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

mrcc	NN
D	NN

treated	VBN
O	NN

with	IN
O	NN

il-2	JJ
T	NN

administered	VBN
O	NN

either	DT
O	NN

systemically	RB
O	NN

(	NN
O	NN

syst	NN
O	NN

,	,
O	NN

subcutaneously	RB
O	NN

)	NN
O	NN

or	CC
O	NN

via	IN
O	NN

inhalation	NN
O	NN

(	NN
O	NN

inh	NN
O	NN

)	NN
O	NN

,	,
O	NN

using	VBG
O	NN

relatively	RB
O	NN

large	JJ
O	NN

sample	NN
O	NN

sizes	NNS
O	NN

to	TO
O	NN

afford	VB
O	NN

a	DT
O	NN

more	RBR
O	NN

meaningful	JJ
O	NN

comparison	NN
O	NN

conclusion	NN
O	NN

:	:
O	NN

as	IN
O	NN

expected	VBN
O	NN

,	,
O	NN

the	DT
O	NN

type	NN
O	NN

of	IN
O	NN

chemotherapy	NN
T	NN

we	PRP
O	VBP

used	VBN
O	NN

,	,
O	NN

to	TO
O	NN

treat	VB
O	NNP

non-seminomatous	JJ
D	NN

germ-cell	NN
D	NN

tumors	NNS
D	NN

proved	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

highly	RB
O	NN

effective	JJ
O	NN

for	IN
O	NN

seminomatous	JJ
D	NN

types	NNS
D	NN

,	,
O	NN

as	IN
O	NN

well	RB
O	NN

carboplatin	NN
T	NN

and	CC
T	NN

ifosfamide	NN
T	NN

performed	VBN
O	NN

well	RB
O	NN

and	CC
O	NN

safe	JJ
O	NN

,	,
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

non-bulky	JJ
D	NN

metastatic	JJ
D	NN

seminoma	NN
D	NN

these	DT
O	NN

results	NNS
O	VBP

suggested	VBN
O	NN

that	IN
O	NN

the	DT
O	NN

sp1	NN
T	NN

decoy	NN
T	NN

strategy	NN
T	NN

would	MD
O	NNP

be	VB
O	NN

effective	JJ
O	NN

for	IN
O	NN

regulating	VBG
O	NN

tumor	NN
D	NN

growth	NN
D	NN

by	IN
O	NN

simultaneously	RB
O	NN

reducing	VBG
O	NN

cancer	NN
O	NN

cell	NN
O	NN

(	NN
O	NN

a	DT
O	NN

)	NN
O	NN

angiogenic	JJ
O	NN

growth	NN
O	NN

factor	NN
O	NN

expression	NN
O	NN

,	,
O	NN

(	NN
O	NN

b	NN
O	NN

)	NN
O	NN

proliferation	NN
O	NN

,	,
O	NN

and	CC
O	NN

(	NN
O	NN

c	NN
O	NN

)	NN
O	NN

invasiveness	NN
O	NN

considering	VBG
O	NN

that	IN
O	NN

hamsters	NNS
O	NN

had	VBD
O	NN

a	DT
O	NN

lung	NN
O	NN

metastasis	NN
O	NN

rate	NN
O	NN

of	IN
O	NN

50	CD
O	NN

%	NN
O	NN

before	IN
O	NN

mdp-lys	JJ
O	NN

treatment	NN
O	NN

,	,
O	NN

liposomal	JJ
T	NN

mdp-lys	JJ
T	NN

given	VBN
O	NN

at	IN
O	NN

a	DT
O	NN

dose	NN
O	NN

of	IN
O	NN

20	CD
O	NN

microg	NN
O	NN

twice/week	NN
O	NN

was	VBD
O	NN

effective	JJ
O	NN

for	IN
O	NN

inhibiting	VBG
O	NN

lung	NN
D	NN

metastasis	NN
D	NN

at	IN
O	NN

a	DT
O	NN

far	RB
O	NN

lower	JJR
O	NN

dose	NN
O	NN

of	IN
O	NN

mdp-lys	JJ
O	NN

than	IN
O	NN

that	IN
O	NN

given	VBN
O	NN

as	IN
O	NN

a	DT
O	NN

solution	NN
O	NN

(	NN
O	NN

40	CD
O	NN

microg	NN
O	NN

vs.	CC
O	NN

350	CD
O	NN

microg	NN
O	NN

per	IN
O	NN

week	NN
O	NN

)	NN
O	NN

we	PRP
O	VBP

have	VB
O	NN

documented	VBN
O	NN

previously	RB
O	NN

that	IN
O	NN

adenovirus-mediated	JJ
T	NN

interleukin	NN
T	NN

12	CD
T	NN

(	NN
T	NN

il-12	JJ
T	NN

)	NN
T	NN

gene	NN
T	NN

therapy	NN
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

for	IN
O	NN

orthotopic	JJ
D	NN

tumor	NN
D	NN

control	NN
O	NN

and	CC
O	NN

suppression	NN
O	NN

of	IN
O	NN

pre-established	JJ
D	NN

metastases	NNS
D	NN

in	IN
D	NN

a	DT
D	NN

preclinical	JJ
D	NN

prostate	NN
D	NN

cancer	NN
D	NN

model	NN
D	NN

(	NN
O	NN

y.	NN
O	NN

nasu	NN
O	NN

et	FW
O	FW

al	NNP
O	NNP

.	.
O	NN

,	,
O	NN

gene	NN
O	NN

ther	IN
O	NN

we	PRP
O	VBP

further	RB
O	NN

developed	VBN
O	NN

a	DT
O	NN

vaccine	NN
O	NN

model	NN
O	NN

based	VBN
O	NN

on	IN
O	NN

s.c.injection	NN
O	NN

of	IN
O	NN

infected	JJ
O	NN

,	,
O	NN

irradiated	JJ
O	NN

rm-9	NN
O	NN

cells	NNS
O	VBP

and	CC
O	NN

found	VBN
O	NN

that	IN
O	NN

both	DT
O	NN

admil-12	JJ
T	NN

and	CC
T	NN

admil-12/b7	JJ
T	NN

are	VBP
O	NN

effective	JJ
O	NN

at	IN
O	NN

suppressing	VBG
O	NN

the	DT
O	NN

development	NN
O	NN

and	CC
O	NN

growth	NN
O	NN

of	IN
O	NN

challenge	NN
D	NN

orthotopic	JJ
D	NN

tumors	NNS
D	NN

using	VBG
O	NN

this	DT
O	NN

protocol	NN
O	NN

despite	IN
O	NN

the	DT
O	NN

marked	JJ
O	NN

toxicity	NN
O	NN

of	IN
O	NN

the	DT
O	NN

initial	JJ
O	NN

intensive	JJ
T	NN

chemotherapy	NN
T	NN

,	,
O	NN

the	DT
O	NN

treatments	NNS
O	VBP

are	VBP
O	NN

tolerable	JJ
O	NN

and	CC
O	NN

effective	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

control	NN
O	NN

of	IN
O	NN

extra-thoracic	JJ
D	NN

micrometastases	NNS
D	NN

,	,
O	NN

whereas	IN
O	NN

they	PRP
O	VBP

are	VBP
O	NN

less	JJR
O	NN

effective	JJ
O	NN

for	IN
O	NN

thoracic	JJ
O	NN

primary	JJ
O	NN

tumor	NN
O	NN

radiotherapy	NN
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

for	IN
O	NN

palliation	NN
O	NN

of	IN
O	NN

symptoms	NNS
D	NN

associated	VBN
D	NN

with	IN
D	NN

sblc	NN
D	NN

clinically	RB
O	NN

,	,
O	NN

oral	JJ
T	NN

administration	NN
T	NN

of	IN
T	NN

uft	NN
T	NN

has	VBZ
O	NN

proved	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

effective	JJ
O	NN

as	IN
O	NN

an	DT
O	NN

adjuvant	JJ
T	NN

therapy	NN
T	NN

after	IN
O	NN

surgery	NN
O	NN

for	IN
O	NN

some	DT
O	NN

malignant	JJ
D	NN

tumors	NNS
D	NN

such	JJ
D	NN

as	IN
D	NN

non-small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

moreover	RB
O	NN

,	,
O	NN

uft	NN
T	NN

has	VBZ
O	NN

proved	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

effective	JJ
O	NN

for	IN
O	NN

inoperable	JJ
D	NN

advanced	JJ
D	NN

malignancies	NNS
D	NN

such	JJ
D	NN

as	IN
D	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

,	,
O	NN

especially	RB
O	NN

in	IN
O	NN

combination	NN
O	NN

with	IN
O	NN

leucovorin	NN
T	NN

or	CC
T	NN

cisplatin	NN
T	NN

a	DT
O	NN

phase	NN
O	NN

ii	LS
O	NN

study	NN
O	NN

of	IN
O	NN

fractionated	VBN
O	NN

administration	NN
O	NN

of	IN
O	NN

irinotecan	JJ
T	NN

(	NN
T	NN

cpt-11	NN
T	NN

)	NN
T	NN

and	CC
T	NN

cisplatin	NN
T	NN

(	NN
T	NN

cddp	NN
T	NN

)	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

non-small-cell	JJ
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

nsclc	NN
D	NN

)	NN
D	NN

was	VBD
O	NN

conducted	VBN
O	NN

in	IN
O	NN

conclusion	NN
O	NN

,	,
O	NN

fractionated	VBN
O	NN

administration	NN
O	NN

of	IN
O	NN

cpt-11	NN
T	NN

and	CC
T	NN

cddp	NN
T	NN

was	VBD
O	NN

highly	RB
O	NN

effective	JJ
O	NN

for	IN
O	NN

advanced	JJ
D	NN

nsclc	NN
D	NN

with	IN
O	NN

manageable	JJ
O	NN

toxicities	NNS
O	NN

we	PRP
O	VBP

report	NN
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

paclitaxel	NN
T	NN

in	IN
O	NN

the	DT
O	NN

successful	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

a	DT
O	NN

patient	NN
O	NN

with	IN
O	NN

recurrent	JJ
D	NN

adenocarcinoma	NN
D	NN

of	IN
D	NN

the	DT
D	NN

cervix	NN
D	NN

weekly	JJ
O	NN

paclitaxel	NN
T	NN

was	VBD
O	NN

very	RB
O	NN

well	RB
O	NN

tolerated	VBN
O	NN

,	,
O	NN

yet	RB
O	NN

was	VBD
O	NN

effective	JJ
O	NN

for	IN
O	NN

recurrent	JJ
D	NN

cervical	JJ
D	NN

adenocarcinoma	NN
D	NN

conclusion	NN
O	NN

:	:
O	NN

our	PRP$
O	NN

results	NNS
O	VBP

suggest	VBP
O	NN

that	IN
O	NN

pseudoephedrine	NN
T	NN

plus	CC
T	NN

acetaminophen	NN
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

for	IN
O	NN

relief	NN
O	NN

of	IN
O	NN

symptoms	NNS
D	NN

attributable	JJ
D	NN

to	TO
D	NN

the	DT
D	NN

paranasal	NN
D	NN

sinuses	NNS
D	NN

that	IN
O	NN

may	MD
O	NNP

develop	VB
O	NN

early	RB
O	NN

in	IN
O	NN

the	DT
O	NN

course	NN
O	NN

of	IN
O	NN

a	DT
O	NN

cold	JJ
O	NN

reviewer	NN
O	NN

's	POS
O	NN

conclusions	NNS
O	NN

:	:
O	NN

a	DT
O	NN

single	JJ
O	NN

dose	NN
O	NN

of	IN
O	NN

nasal	JJ
T	NN

decongestant	NN
T	NN

in	IN
O	NN

the	DT
O	NN

common	JJ
O	NN

cold	JJ
O	NN

is	VBZ
O	NN

moderately	RB
O	NN

effective	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

short	JJ
O	NN

term	NN
O	NN

relief	NN
O	NN

of	IN
O	NN

congestion	NN
D	NN

in	IN
O	NN

adults	NNS
O	NN

,	,
O	NN

while	IN
O	NN

there	RB
O	NN

is	VBZ
O	NN

no	DT
O	NN

evidence	NN
O	NN

available	JJ
O	NN

to	TO
O	NN

show	NN
O	NN

benefit	NN
O	NN

after	IN
O	NN

repeated	VBN
O	NN

use	NN
O	NN

over	IN
O	NN

several	JJ
O	NN

days	NNS
O	NN

conclusions	NNS
O	NN

:	:
O	NN

members	NNS
O	NN

of	IN
O	NN

an	DT
O	NN

ethnically	RB
O	NN

diverse	JJ
O	NN

community	NN
O	NN

believe	VB
O	NN

antibiotics	NNS
T	NN

are	VBP
O	NN

effective	JJ
O	NN

for	IN
O	NN

colds	NNS
D	NN

,	,
O	NN

are	VBP
O	NN

very	RB
O	NN

likely	JJ
O	NN

to	TO
O	NN

seek	VB
O	NN

care	NN
O	NN

for	IN
O	NN

colds	NNS
O	NN

,	,
O	NN

and	CC
O	NN

often	RB
O	NN

obtain	VB
O	NN

antibiotics	NNS
O	NN

without	IN
O	NN

a	DT
O	NN

prescription	NN
O	NN

the	DT
O	NN

available	JJ
O	NN

inactivated	VBN
O	NN

vaccine	NN
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

for	IN
O	NN

preventing	VBG
O	NN

influenza	NN
D	NN

and	CC
O	NN

the	DT
O	NN

serious	JJ
O	NN

disease	NN
O	NN

and	CC
O	NN

death	NN
O	NN

that	IN
O	NN

can	MD
O	NNP

accompany	VB
O	NN

it	PRP
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

amantadine	NN
T	NN

,	,
O	NN

rimantadine	NN
T	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

newly	RB
O	NN

available	JJ
O	NN

drugs	NNS
O	NN

zanamivir	NN
T	NN

and	CC
O	NN

oseltamivir	NN
T	NN

are	VBP
O	NN

effective	JJ
O	NN

for	IN
O	NN

influenza	NN
D	NN

prevention	NN
D	NN

and	CC
D	NN

treatment	NN
D	NN

(	NN
O	NN

the	DT
O	NN

former	JJ
O	NN

two	CD
O	NN

for	IN
O	NN

influenza	NN
O	NN

a	DT
O	NN

only	RB
O	NN

)	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

the	DT
O	NN

availability	NN
O	NN

of	IN
O	NN

four	CD
O	NN

antiviral	JJ
T	NN

agents	NNS
T	NN

that	IN
O	NN

effectively	RB
O	NN

prevent	VB
O	NN

and	CC
O	NN

treat	VB
O	NNP

influenza	NN
D	NN

provides	VBZ
O	NN

the	DT
O	NN

physician	NN
O	NN

with	IN
O	NN

considerable	JJ
O	NN

flexibility	NN
O	NN

for	IN
O	NN

their	PRP$
O	NN

use	NN
O	NN

in	IN
O	NN

influenza	NN
O	NN

control	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

thus	RB
O	NN

influenza	NN
D	NN

vaccination	NN
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

for	IN
O	NN

preventing	VBG
O	NN

influenza	NN
D	NN

disease	NN
D	NN

in	IN
O	NN

persons	NNS
O	VBP

aged	JJ
O	NN

65	CD
O	NN

years	NNS
O	NN

and	CC
O	NN

over	IN
O	NN

,	,
O	NN

and	CC
O	NN

should	MD
O	NNP

be	VB
O	NN

an	DT
O	NN

integral	JJ
O	NN

part	NN
O	NN

of	IN
O	NN

the	DT
O	NN

care	NN
O	NN

of	IN
O	NN

this	DT
O	NN

population	NN
O	NN

residing	VBG
O	NN

in	IN
O	NN

nursing	NN
O	NN

homes	NNS
O	NN

intravenous	JJ
T	NN

injection	NN
T	NN

of	IN
T	NN

pb2-as	JJ
T	NN

,	,
T	NN

as	IN
T	NN

a	DT
T	NN

complex	JJ
T	NN

with	IN
T	NN

dmrie-c	JJ
T	NN

,	,
T	NN

a	DT
T	NN

cationic	JJ
T	NN

liposome	JJ
T	NN

,	,
O	NN

was	VBD
O	NN

most	JJS
O	NN

effective	JJ
O	NN

for	IN
O	NN

prolonging	VBG
O	NN

the	DT
O	NN

mean	VB
O	NN

survival	NN
O	NN

time	NN
O	NN

in	IN
O	NN

days	NNS
O	NN

(	NN
O	NN

msds	NNS
O	NN

)	NN
O	NN

and	CC
O	NN

increasing	VBG
O	NN

the	DT
O	NN

survival	NN
O	NN

rates	NNS
O	VBP

of	IN
O	NN

mice	NNS
O	NN

infected	JJ
O	NN

with	IN
O	NN

the	DT
O	NN

influenza	NN
D	NN

a	DT
D	NN

virus	NN
D	NN

background	NN
O	NN

and	CC
O	NN

objectives	NNS
O	VBP

:	:
O	NN

thoracic	JJ
T	NN

paravertebral	JJ
T	NN

block	NN
T	NN

(	NN
T	NN

tpvb	NN
T	NN

)	NN
T	NN

is	VBZ
O	NN

a	DT
O	NN

unilateral	JJ
O	NN

analgesic	JJ
O	NN

technique	NN
O	NN

that	IN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

advocated	VBN
O	NN

in	IN
O	NN

both	DT
O	NN

acute	JJ
D	NN

and	CC
D	NN

chronic	JJ
D	NN

thoracic	JJ
D	NN

and	CC
D	NN

abdominal	JJ
D	NN

pain	NN
D	NN

other	JJ
T	NN

blocks	NNS
T	NN

such	JJ
T	NN

as	IN
T	NN

interpleural	JJ
T	NN

and	CC
T	NN

epidural	JJ
T	NN

can	MD
O	NNP

be	VB
O	NN

effectively	RB
O	NN

used	VBN
O	NN

in	IN
O	NN

pleuritic	JJ
D	NN

pain	NN
D	NN

this	DT
O	NN

report	NN
O	NN

illustrates	VBZ
O	NN

that	IN
O	NN

tpvb	NN
T	NN

could	MD
O	NNP

also	RB
O	NN

be	VB
O	NN

effective	JJ
O	NN

for	IN
O	NN

this	DT
O	NN

kind	RB
O	NN

of	IN
O	NN

pain	NN
D	NN

conclusions	NNS
O	NN

:	:
O	NN

this	DT
O	NN

case	NN
O	NN

report	NN
O	NN

supports	VBZ
O	NN

the	DT
O	NN

notion	NN
O	NN

that	IN
O	NN

,	,
O	NN

in	IN
O	NN

practice	NN
O	NN

,	,
O	NN

the	DT
T	NN

paravertebral	JJ
T	NN

block	NN
T	NN

could	MD
O	NNP

be	VB
O	NN

an	DT
O	NN

effective	JJ
O	NN

and	CC
O	NN

safe	JJ
O	NN

alternative	JJ
O	NN

to	TO
O	NN

relief	NN
O	NN

of	IN
O	NN

pleuritic	JJ
D	NN

pain	NN
D	NN

conclusion	NN
O	NN

:	:
O	NN

mr-guided	JJ
T	NN

rfa	NN
T	NN

using	VBG
T	NN

single	JJ
T	NN

cooled	VBN
T	NN

tip	NN
T	NN

electrodes	NNS
T	NN

is	VBZ
O	NN

safe	JJ
O	NN

and	CC
O	NN

technically	RB
O	NN

effective	JJ
O	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

hepatic	JJ
D	NN

neoplasms	NNS
D	NN

up	RB
O	NN

to	TO
O	NN

3	CD
O	NN

cm	NN
O	NN

in	IN
O	NN

size	NN
O	NN

,	,
O	NN

however	RB
O	NN

further	RB
O	NN

improvements	NNS
O	VBP

are	VBP
O	NN

necessary	JJ
O	NN

a	DT
O	NN

68-year-old	JJ
O	NN

man	NN
O	NN

underwent	VBD
O	NN

curative	JJ
T	NN

pancreaticoduodenectomy	NN
T	NN

for	IN
O	NN

bile	NN
D	NN

duct	NN
D	NN

cancer	NN
D	NN

one	CD
O	NN

course	NN
O	NN

of	IN
O	NN

chronochemotherapy	JJ
T	NN

was	VBD
O	NN

effective	JJ
O	NN

for	IN
O	NN

lymph	NN
D	NN

node	NN
D	NN

and	CC
D	NN

peritoneum	NN
D	NN

metastases	NNS
D	NN

the	DT
O	NN

only	RB
O	NN

specific	JJ
O	NN

antidote	NN
O	NN

for	IN
O	NN

dosage-dependent	JJ
D	NN

hepatotoxicity	NN
D	NN

is	VBZ
O	NN

n-acetylcysteine	NN
T	NN

(	NN
T	NN

and	CC
T	NN

some	DT
T	NN

other	JJ
T	NN

sulfhydryl	NN
T	NN

donors	NNS
T	NN

)	NN
T	NN

,	,
O	NN

which	WDT
O	NN

is	VBZ
O	NN

highly	RB
O	NN

effective	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

prevention	NN
O	NN

of	IN
O	NN

significant	JJ
O	NN

hepatotoxicity	NN
O	NN

after	IN
O	NN

acetaminophen	NN
O	NN

overdose	NN
O	NN

corticosteroids	NNS
T	NN

can	MD
O	NNP

be	VB
O	NN

considered	VBN
O	NN

for	IN
O	NN

cases	NNS
O	NN

of	IN
O	NN

drug-induced	JJ
D	NN

hepatitis	NN
D	NN

,	,
O	NN

especially	RB
O	NN

those	DT
O	NNP

with	IN
O	NN

evidence	NN
O	NN

of	IN
O	NN

immune	JJ
O	NN

hypersensitivity	NN
O	NN

,	,
O	NN

if	IN
O	NN

no	DT
O	NN

improvement	NN
O	NN

is	VBZ
O	NN

seen	VBN
O	NN

in	IN
O	NN

8	CD
O	NN

to	TO
O	NN

12	CD
O	NN

weeks	NNS
O	NN

our	PRP$
O	NN

conclusion	NN
O	NN

was	VBD
O	NN

that	IN
O	NN

the	DT
O	NN

covered-ems	JJ
T	NN

can	MD
O	NNP

be	VB
O	NN

effective	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

palliation	NN
O	NN

of	IN
O	NN

esophagorespiratory	JJ
D	NN

fistulas	NN
D	NN

the	DT
O	NN

food	NN
O	NN

and	CC
O	NN

drug	NN
O	NN

administration	NN
O	NN

(	NN
O	NN

fda	NN
O	NN

)	NN
O	NN

recently	RB
O	NN

approved	VBN
O	NN

the	DT
O	NN

first	RB
O	NN

protein-polysaccharide	JJ
T	NN

conjugate	NN
T	NN

vaccine	NN
T	NN

to	TO
O	NN

prevent	VB
O	NN

invasive	JJ
D	NN

pneumococcal	JJ
D	NN

diseases	NNS
D	NN

in	IN
O	NN

infants	NNS
O	NN

and	CC
O	NN

toddlers	NNS
O	NN

<	JJR
O	NN

2	CD
O	NN

years	NNS
O	NN

of	IN
O	NN

age	NN
O	NN

this	DT
O	NN

conjugated	VBN
T	NN

vaccine	NN
T	NN

against	IN
O	NN

pneumococcus	NN
D	NN

uses	NNS
O	NN

the	DT
O	NN

same	JJ
O	NN

technology	NN
O	NN

as	IN
O	NN

the	DT
O	NN

successful	JJ
O	NN

vaccine	NN
T	NN

against	IN
O	NN

haemophilus	NN
D	NN

influenzae	NN
D	NN

type	NN
D	NN

b	NN
D	NN

the	DT
O	NN

most	JJS
O	NN

recent	JJ
O	NN

study	NN
O	NN

,	,
O	NN

involving	VBG
O	NN

over	IN
O	NN

37	CD
O	NN

,	,
O	NN

000	CD
O	NN

young	JJ
O	NN

children	NNS
O	VBP

,	,
O	NN

also	RB
O	NN

evaluated	VBN
O	NN

the	DT
O	NN

vaccine	NN
O	NN

's	POS
O	NN

efficacy	NN
O	NN

,	,
O	NN

and	CC
O	NN

reported	VBN
O	NN

that	IN
O	NN

the	DT
O	NN

vaccine	NN
T	NN

is	VBZ
O	NN

highly	RB
O	NN

effective	JJ
O	NN

in	IN
O	NN

preventing	VBG
O	NN

invasive	JJ
D	NN

disease	NN
D	NN

and	CC
O	NN

has	VBZ
O	NN

had	VBD
O	NN

an	DT
O	NN

impact	NN
O	NN

on	IN
O	NN

otitis	NN
D	NN

media	NNS
D	NN

conclusions	NNS
O	NN

:	:
O	NN

the	DT
O	NN

heptavalent	JJ
T	NN

pneumococcal	JJ
T	NN

conjugate	NN
T	NN

vaccine	NN
T	NN

is	VBZ
O	NN

safe	JJ
O	NN

and	CC
O	NN

highly	RB
O	NN

effective	JJ
O	NN

in	IN
O	NN

preventing	VBG
O	NN

pneumococcal	JJ
D	NN

meningitis	NN
D	NN

and	CC
D	NN

bacteremic	JJ
D	NN

pneumonia	NN
D	NN

in	IN
O	NN

young	JJ
O	NN

children	NNS
O	VBP

<	JJR
O	NN

2	CD
O	NN

years	NNS
O	NN

of	IN
O	NN

age	NN
O	NN

;	:
O	NN

it	PRP
O	NN

is	VBZ
O	NN

less	JJR
O	NN

effective	JJ
O	NN

in	IN
O	NN

preventing	VBG
O	NN

otitis	NN
O	NN

media	NNS
O	NN

based	VBN
O	NN

on	IN
O	NN

the	DT
O	NN

results	NNS
O	VBP

of	IN
O	NN

three	CD
O	NN

well-designed	JJ
O	NN

studies	NNS
O	VBP

demonstrating	VBG
O	NN

the	DT
O	NN

vaccine	NN
O	NN

's	POS
O	NN

safety	NN
O	NN

,	,
O	NN

immunogenicity	NN
O	NN

,	,
O	NN

and	CC
O	NN

efficacy	NN
O	NN

,	,
O	NN

the	DT
O	NN

vaccine	NN
T	NN

is	VBZ
O	NN

safe	JJ
O	NN

and	CC
O	NN

effective	JJ
O	NN

for	IN
O	NN

active	JJ
O	NN

immunization	NN
O	NN

of	IN
O	NN

children	NNS
O	VBP

<	JJR
O	NN

2	CD
O	NN

years	NNS
O	NN

of	IN
O	NN

age	NN
O	NN

against	IN
O	NN

invasive	JJ
D	NN

disease	NN
D	NN

caused	VBN
D	NN

by	IN
D	NN

seven	CD
D	NN

streptococcus	NN
D	NN

pneumoniae	FW
D	NN

serotypes	NNS
D	NN

included	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

vaccine	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

i	LS
O	NN

concluded	VBD
O	NN

that	IN
O	NN

6-month	JJ
O	NN

regimen	NN
O	NN

containing	VBG
O	NN

pyrazinamide	NN
T	NN

was	VBD
O	NN

effective	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

with	IN
O	NN

isoniazid-rifampicin	NN
D	NN

susceptible	JJ
D	NN

tuberculosis	NN
D	NN

patients	NNS
O	NN

except	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

complicated	JJ
O	NN

with	IN
O	NN

diabetes	NN
D	NN

mellitus	NN
D	NN

only	RB
O	NN

the	DT
O	NN

combination	NN
T	NN

of	IN
T	NN

a	DT
T	NN

cell	NN
T	NN

wall-active	JJ
T	NN

antibiotic	JJ
T	NN

to	TO
T	NN

which	WDT
T	NN

the	DT
T	NN

enterococcus	NN
T	NN

is	VBZ
T	NN

susceptible	JJ
T	NN

(	NN
T	NN

ie	FW
T	NN

,	,
T	NN

certain	JJ
T	NN

beta-lactams	JJ
T	NN

or	CC
T	NN

vancomycin	NN
T	NN

)	NN
T	NN

plus	CC
T	NN

an	DT
T	NN

aminoglycoside	NN
T	NN

(	NN
T	NN

ie	FW
T	NN

,	,
T	NN

gentamicin	NN
T	NN

or	CC
T	NN

streptomycin	NN
T	NN

)	NN
T	NN

is	VBZ
O	NN

bactericidal	JJ
O	NN

,	,
O	NN

and	CC
O	NN

is	VBZ
O	NN

required	VBN
O	NN

for	IN
O	NN

cure	NN
O	NN

of	IN
O	NN

endocarditis	NN
D	NN

,	,
D	NN

meningitis	NN
D	NN

and	CC
D	NN

probably	RB
D	NN

infection	NN
D	NN

in	IN
D	NN

neutropenic	NN
D	NN

patients	NNS
D	NN

;	:
O	NN

bacteriostatic	JJ
O	NN

activity	NN
O	NN

is	VBZ
O	NN

sufficient	JJ
O	NN

to	TO
O	NN

treat	VB
O	NNP

most	JJS
O	NN

other	JJ
O	NN

infections	NNS
O	NN

two	CD
T	NN

triazole	NN
T	NN

antifungal	JJ
T	NN

agents	NNS
T	NN

,	,
T	NN

fluconazole	NN
T	NN

and	CC
T	NN

itraconazole	NN
T	NN

,	,
O	NN

were	VBD
O	NN

introduced	VBN
O	NN

over	IN
O	NN

a	DT
O	NN

decade	NN
O	NN

ago	IN
O	NN

and	CC
O	NN

since	IN
O	NN

then	RB
O	NN

have	VB
O	NN

been	VBN
O	NN

used	VBN
O	NN

extensively	RB
O	NN

for	IN
O	NN

the	DT
O	NN

prophylaxis	NN
O	NN

and	CC
O	NN

treatment	NN
O	NN

of	IN
O	NN

a	DT
O	NN

variety	NN
O	NN

of	IN
O	NN

fungal	JJ
D	NN

infections	NNS
D	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

topical	JJ
T	NN

corticosteroids	NNS
T	NN

has	VBZ
O	NN

revolutionised	VBN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

inflammatory	JJ
D	NN

skin	NN
D	NN

diseases	NNS
D	NN

in	IN
O	NN

particular	JJ
O	NN

,	,
O	NN

tacrolimus	NN
T	NN

and	CC
T	NN

ascomycin	NN
T	NN

derivatives	NNS
T	NN

have	VB
O	NN

been	VBN
O	NN

shown	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

effective	JJ
O	NN

for	IN
O	NN

treating	VBG
O	NN

atopic	JJ
D	NN

dermatitism	NN
D	NN

with	IN
O	NN

a	DT
O	NN

surprising	JJ
O	NN

lack	NN
O	NN

of	IN
O	NN

side	NN
O	NN

effects	NNS
O	NN

cyclophosphamide	NN
T	NN

therapy	NN
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

for	IN
O	NN

bronchiolitis	NN
D	NN

obliterans	NNS
D	NN

occurring	VBG
D	NN

as	IN
D	NN

a	DT
D	NN

late	RB
D	NN

manifestation	NN
D	NN

of	IN
D	NN

lupus	NN
D	NN

erythematosus	NN
D	NN

(	NN
O	NN

letter	NN
O	NNP

)	NN
O	NN

in	IN
O	NN

summary	NN
O	NN

,	,
O	NN

gemifloxacin	NN
T	NN

was	VBD
O	NN

found	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

well	RB
O	NN

tolerated	VBN
O	NN

and	CC
O	NN

effective	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

aecb	NN
D	NN

,	,
O	NN

suggesting	VBG
O	NN

it	PRP
O	NN

is	VBZ
O	NN

well	RB
O	NN

suited	VBN
O	NN

for	IN
O	NN

empirical	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

this	DT
O	NN

common	JJ
O	NN

respiratory	JJ
O	NN

condition	NN
O	NN

in	IN
O	NN

the	DT
O	NN

current	JJ
O	NN

clinical	JJ
O	NN

environment	NN
O	NN

d-penicillamine	NN
T	NN

(	NN
T	NN

2-amino-3-mercapto-3-methylbutanoic	JJ
T	NN

acid	NN
T	NN

)	NN
T	NN

,	,
T	NN

a	DT
T	NN

well-known	JJ
T	NN

heavy	JJ
T	NN

metal	NN
T	NN

chelator	NN
T	NN

,	,
O	NN

is	VBZ
O	NN

the	DT
O	NN

drug	NN
O	NN

of	IN
O	NN

choice	NN
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

wilson	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

and	CC
O	NN

is	VBZ
O	NN

also	RB
O	NN

effective	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

several	JJ
D	NN

disorders	NNS
D	NN

including	VBG
D	NN

rheumatoid	JJ
D	NN

arthritis	NN
D	NN

,	,
D	NN

primary	JJ
D	NN

biliary	JJ
D	NN

cirrhosis	NN
D	NN

,	,
D	NN

scleroderma	NN
D	NN

,	,
D	NN

fibrotic	JJ
D	NN

lung	NN
D	NN

diseases	NNS
D	NN

and	CC
D	NN

progressive	JJ
D	NN

systemic	JJ
D	NN

sclerosis	NN
D	NN

stages	NNS
O	NN

of	IN
O	NN

non-small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

nsclc	NN
D	NN

)	NN
D	NN

that	IN
O	NN

are	VBP
O	NN

potential	JJ
O	NN

candidates	NNS
O	NN

for	IN
O	NN

surgical	JJ
T	NN

resection	NN
T	NN

have	VB
O	NN

been	VBN
O	NN

treated	VBN
O	NN

in	IN
O	NN

several	JJ
O	NN

ways	NNS
O	NN

:	:
O	NN

surgery	NN
T	NN

alone	RB
O	NN

is	VBZ
O	NN

curative	JJ
O	NN

in	IN
O	NN

only	RB
O	NN

two-thirds	NNS
O	NN

of	IN
O	NN

cases	NNS
O	NN

and	CC
O	NN

post-operative	JJ
T	NN

radiotherapy	NN
T	NN

(	NN
T	NN

rt	NN
T	NN

)	NN
T	NN

provides	VBZ
O	NN

only	RB
O	NN

weak	JJ
O	NN

control	NN
O	NN

of	IN
O	NN

advanced-stage	JJ
O	NN

disease	NN
O	NN

among	IN
O	NN

these	DT
O	NN

,	,
O	NN

the	DT
O	NN

gemcitabine/cisplatin	NN
T	NN

study	NN
O	NN

protocol	NN
O	NN

(	NN
O	NN

gc	NN
O	NN

)	NN
O	NN

,	,
O	NN

set	VBN
O	NN

up	RB
O	NN

in	IN
O	NN

a	DT
O	NN

phase	NN
O	NN

ii	LS
O	NN

study	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

stage	NN
D	NN

iiia	NN
D	NN

n2	NN
D	NN

nsclc	NN
D	NN

,	,
O	NN

was	VBD
O	NN

very	RB
O	NN

effective	JJ
O	NN

(	NN
O	NN

objective	JJ
O	NN

response	NN
O	NN

(	NN
O	NN

or	CC
O	NN

)	NN
O	NN

:	:
O	NN

70.2	CD
O	NN

%	NN
O	NN

;	:
O	NN

median	JJ
O	NN

survival	NN
O	NN

:	:
O	NN

19	CD
O	NN

months	NNS
O	NN

)	NN
O	NN

and	CC
O	NN

should	MD
O	NNP

be	VB
O	NN

promising	JJ
O	NN

for	IN
O	NN

stages	NNS
O	NN

ib	NN
O	NN

and	CC
O	NN

ii	LS
O	NN

several	JJ
O	NN

studies	NNS
O	VBP

have	VB
O	NN

suggested	VBN
O	NN

that	IN
O	NN

non-small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

nsclc	NN
D	NN

)	NN
D	NN

patients	NNS
O	NN

whose	WP$
O	NN

tumors	NNS
O	NN

have	VB
O	NN

neuroendocrine	NN
O	NN

(	NN
O	NN

ne	NN
O	NN

)	NN
O	NN

features	NNS
O	VBP

may	MD
O	NNP

be	VB
O	NN

more	RBR
O	NN

responsive	JJ
O	NN

to	TO
O	NN

chemotherapy	NN
T	NN

in	IN
O	NN

addition	NN
O	NN

,	,
O	NN

increased	VBN
O	NN

expression	NN
O	NN

of	IN
O	NN

p53	NN
O	NN

and	CC
O	NN

her2	NN
O	NN

may	MD
O	NNP

confer	VB
O	NN

relative	JJ
O	NN

chemotherapy	NN
O	NN

resistance	NN
O	NN

and	CC
O	NN

shortened	VBD
O	NN

survival	NN
O	NN

the	DT
O	NN

cancer	NN
O	NN

and	CC
O	NN

leukemia	NN
O	NN

group	NN
O	NN

b	NN
O	NN

performed	VBN
O	NN

a	DT
O	NN

series	NN
O	NN

of	IN
O	NN

studies	NNS
O	VBP

involving	VBG
O	NN

sequential	JJ
T	NN

chemotherapy	NN
T	NN

followed	VBN
T	NN

by	IN
T	NN

radiation	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

unresectable	JJ
D	NN

stage	NN
D	NN

iii	LS
D	NN

nsclc	NN
D	NN

this	DT
O	NN

london	NN
O	NN

lung	NN
O	NN

cancer	NN
O	NN

group	NN
O	NN

trial	NN
O	NN

of	IN
O	NN

gemcitabine/carboplatin	NN
T	NN

may	MD
O	NNP

define	VB
O	NN

an	DT
O	NN

active	JJ
O	NN

,	,
O	NN

safe	JJ
O	NN

,	,
O	NN

and	CC
O	NN

acceptable	JJ
O	NN

treatment	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

extensive-stage	JJ
O	NN

and	CC
O	NN

poor-prognosis	NN
O	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

gemcitabine	NN
T	NN

and	CC
T	NN

carboplatin	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

non-small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

an	DT
T	NN

aggressive	JJ
T	NN

surgical	JJ
T	NN

approach	NN
T	NN

is	VBZ
O	NN

justified	JJ
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

mplc	NN
D	NN

and	CC
O	NN

offers	NNS
O	VBP

the	DT
O	NN

greatest	JJS
O	NN

chance	NN
O	NN

for	IN
O	NN

long-term	JJ
O	NN

survival	NN
O	NN

even	RB
O	NN

in	IN
O	NN

the	DT
O	NN

case	NN
O	NN

of	IN
O	NN

limited	JJ
O	NN

resection	NN
O	NN

methods	NNS
O	VBP

and	CC
O	NN

materials	NNS
O	NN

:	:
O	NN

eleven	NNS
O	NN

patients	NNS
O	NN

with	IN
O	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

sclc	NN
D	NN

)	NN
D	NN

,	,
O	NN

who	WP
O	VBP

had	VBD
O	NN

presented	VBN
O	NN

complete	JJ
O	NN

response	NN
O	NN

of	IN
O	NN

disease	NN
O	NN

after	IN
O	NN

chemotherapy	NN
T	NN

and	CC
O	NN

radical	JJ
T	NN

radiotherapy	NN
T	NN

in	IN
T	NN

the	DT
T	NN

lung	NN
T	NN

,	,
O	NN

were	VBD
O	NN

prescribed	VBN
O	NN

to	TO
O	NN

receive	VB
O	NN

a	DT
O	NN

prophylacting	VBG
O	NN

cranial	JJ
O	NN

irradiation	NN
O	NN

(	NN
O	NN

pci	NN
O	NN

)	NN
O	NN

with	IN
O	NN

a	DT
O	NN

6	CD
O	NN

mev	NN
O	NN

linear	JJ
O	NN

accelerator	NN
O	NN

only	RB
O	NN

22	CD
O	NN

patients	NNS
O	NN

(	NN
O	NN

10	CD
O	NN

%	NN
O	NN

)	NN
O	NN

were	VBD
O	NN

alive	JJ
O	NN

at	IN
O	NN

five	CD
O	NN

years	NNS
O	NN

:	:
O	NN

19	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

nsclc	NN
D	NN

who	WP
O	VBP

had	VBD
O	NN

got	VBD
O	NN

surgical	JJ
T	NN

treatment	NN
T	NN

,	,
O	NN

one	CD
O	NN

patient	NN
O	NN

with	IN
O	NN

nsclc	NN
D	NN

(	NN
D	NN

stage	NN
D	NN

iiib	NN
D	NN

)	NN
D	NN

who	WP
O	VBP

had	VBD
O	NN

recieved	VBN
O	NN

radiotherapy	NN
T	NN

,	,
O	NN

and	CC
O	NN

two	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

sclc	NN
D	NN

,	,
D	NN

limited	JJ
D	NN

disease	NN
D	NN

,	,
O	NN

treated	VBN
O	NN

with	IN
O	NN

chemo-	JJ
T	NN

and	CC
T	NN

radiotherapy	NN
T	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

the	DT
O	NN

standard	JJ
O	NN

care	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

non-small-cell	JJ
D	NN

lung	NN
D	NN

cancer	NN
D	NN

is	VBZ
O	NN

chemotherapy	NN
T	NN

of	IN
T	NN

supportive	JJ
T	NN

care	NN
T	NN

,	,
O	NN

with	IN
O	NN

surgery	NN
T	NN

being	VBG
O	NN

reserved	VBN
O	NN

for	IN
O	NN

palliation	NN
O	NN

of	IN
O	NN

symptoms	NNS
O	NN

;	:
O	NN

however	RB
O	NN

,	,
O	NN

there	RB
O	NN

is	VBZ
O	NN

a	DT
O	NN

small	JJ
O	NN

group	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

a	DT
O	NN

finite	JJ
O	NN

number	NN
O	NN

of	IN
O	NN

extrathoracic	JJ
D	NN

metastases	NNS
D	NN

(	NN
D	NN

oligometastases	NNS
D	NN

)	NN
D	NN

who	WP
O	VBP

may	MD
O	NNP

experience	NN
O	NN

improved	VBN
O	NN

survival	NN
O	NN

by	IN
O	NN

resection	NN
T	NN

of	IN
T	NN

their	PRP$
T	NN

metastases	NNS
T	NN

and	CC
T	NN

the	DT
T	NN

primary	JJ
T	NN

site	NN
T	NN

,	,
O	NN

with	IN
O	NN

or	CC
O	NN

without	IN
O	NN

systemic	JJ
O	NN

treatment	NN
O	NN

five	CD
O	NN

new	JJ
O	NN

agents	NNS
O	NN

,	,
O	NN

paclitaxel	NN
T	NN

,	,
O	NN

docetaxel	NN
T	NN

,	,
O	NN

vinorelbine	NN
T	NN

,	,
O	NN

gemcitabine	NN
T	NN

and	CC
O	NN

irinotecan	JJ
T	NN

,	,
O	NN

have	VB
O	NN

been	VBN
O	NN

introduced	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

nsclc	NN
D	NN

and	CC
O	NN

investigated	VBN
O	NN

extensively	RB
O	NN

both	DT
O	NN

preclinically	RB
O	NN

and	CC
O	NN

clinically	RB
O	NN

whether	IN
O	NN

the	DT
O	NN

era	NN
O	NN

of	IN
O	NN

platinum-based	JJ
T	NN

chemotherapy	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

nsclc	NN
D	NN

should	MD
O	NNP

continue	VB
O	NN

or	CC
O	NN

not	RB
O	NN

must	MD
O	NNP

be	VB
O	NN

determined	VBN
O	NN

by	IN
O	NN

phase	NN
O	NN

iii	LS
O	NN

trials	NNS
O	NN

,	,
O	NN

evaluating	VBG
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

a	DT
O	NN

platinum	NN
O	NN

agent	NN
O	NN

with	IN
O	NN

one	CD
O	NN

of	IN
O	NN

the	DT
O	NN

new	JJ
O	NN

agent	NN
O	NN

combinations	NNS
O	NN

these	DT
O	NN

aggressive	JJ
T	NN

chemotherapeutic	JJ
T	NN

combinations	NNS
T	NN

will	MD
O	VB

hopefully	RB
O	NN

improve	VB
O	NN

survival	NN
O	NN

and	CC
O	NN

quality	NN
O	NN

of	IN
O	NN

life	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

nsclc	NN
D	NN

results	NNS
O	VBP

:	:
O	NN

we	PRP
O	VBP

have	VB
O	NN

performed	VBN
O	NN

60	CD
O	NN

carinal	JJ
T	NN

resections	NNS
T	NN

for	IN
O	NN

bronchogenic	JJ
D	NN

carcinoma	NN
D	NN

:	:
O	NN

18	CD
O	NN

isolated	VBN
T	NN

carinal	JJ
T	NN

resections	NNS
T	NN

for	IN
O	NN

tumor	NN
D	NN

confined	VBN
D	NN

to	TO
D	NN

the	DT
D	NN

carinal	NN
D	NN

or	CC
D	NN

proximal	JJ
D	NN

main	JJ
D	NN

stem	NN
D	NN

bronchus	NN
D	NN

;	:
O	NN

35	CD
O	NN

carinal	JJ
T	NN

pneumonectomies	NNS
T	NN

;	:
O	NN

5	CD
O	NN

carinal	JJ
T	NN

plus	CC
T	NN

lobar	JJ
T	NN

resections	NNS
T	NN

,	,
O	NN

and	CC
O	NN

2	CD
O	NN

carinal	JJ
T	NN

resections	NNS
T	NN

for	IN
O	NN

stump	NN
D	NN

recurrence	NN
D	NN

after	IN
D	NN

prior	RB
D	NN

pneumonectomy	NN
D	NN

conclusions	NNS
O	NN

:	:
O	NN

this	DT
O	NN

constitutes	VBZ
O	NN

one	CD
O	NN

of	IN
O	NN

the	DT
O	NN

largest	JJS
O	NN

single-institution	JJ
O	NN

reports	NNS
O	NN

on	IN
O	NN

carinal	JJ
T	NN

resection	NN
T	NN

for	IN
O	NN

bronchogenic	JJ
D	NN

carcinoma	NN
D	NN

involving	VBG
D	NN

the	DT
D	NN

carina	NN
D	NN

extracorporeal	JJ
T	NN

photopheresis	NN
T	NN

has	VBZ
O	NN

evolved	VBD
O	NN

as	IN
O	NN

a	DT
O	NN

possible	JJ
O	NN

therapy	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

acute	JJ
D	NN

nd	NN
D	NN

chronic	JJ
D	NN

lung	NN
D	NN

allograft	NN
D	NN

rejection	NN
D	NN

methods	NNS
O	VBP

:	:
O	NN

we	PRP
O	VBP

retrospectively	RB
O	NN

reviewed	VBN
O	NN

14	CD
O	NN

patients	NNS
O	NN

diagnosed	VBN
O	NN

with	IN
O	NN

bos	NN
D	NN

who	WP
O	VBP

underwent	VBD
O	NN

therapy	NN
T	NN

with	IN
T	NN

extracorporeal	JJ
T	NN

photopheresis	NN
T	NN

in	IN
O	NN

three	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

bos	NN
D	NN

and	CC
D	NN

concurrent	JJ
D	NN

acute	JJ
D	NN

rejection	NN
D	NN

,	,
O	NN

therapy	NN
T	NN

with	IN
T	NN

extracorporeal	JJ
T	NN

photopheresis	NN
T	NN

led	VBD
O	NN

to	TO
O	NN

the	DT
O	NN

resolution	NN
O	NN

of	IN
O	NN

the	DT
O	NN

acute	JJ
O	NN

rejection	NN
O	NN

episode	NN
O	NN

conclusion	NN
O	NN

:	:
O	NN

extracorporeal	JJ
T	NN

photopheresis	NN
T	NN

appears	VBZ
O	NN

to	TO
O	NN

be	VB
O	NN

a	DT
O	NN

promising	JJ
O	NN

therapy	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

early	RB
D	NN

bos	NN
D	NN

purpose	NN
O	NN

:	:
O	NN

many	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

locally	RB
D	NN

advanced	JJ
D	NN

non-small-cell	JJ
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

la-nsclc	NN
D	NN

)	NN
D	NN

are	VBP
O	NN

eligible	JJ
O	NN

for	IN
O	NN

combined-modality	JJ
T	NN

therapy	NN
T	NN

(	NN
T	NN

cmt	NN
T	NN

;	:
T	NN

chemotherapy	NN
T	NN

and	CC
T	NN

radiotherapy	NN
T	NN

)	NN
T	NN

over	IN
O	NN

the	DT
O	NN

past	JJ
O	NN

twenty	CD
O	NN

years	NNS
O	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

has	VBZ
O	NN

continued	VBN
O	NN

to	TO
O	NN

produce	VB
O	NN

small	JJ
O	NN

survival	NN
O	NN

gains	NNS
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

sclc	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

purpose	NN
O	NN

:	:
O	NN

the	DT
O	NN

benefit	NN
O	NN

of	IN
O	NN

whole-lung	JJ
T	NN

irradiation	NN
T	NN

(	NN
T	NN

wli	NN
T	NN

)	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

who	WP
O	VBP

have	VB
O	NN

pulmonary	JJ
D	NN

metastases	NNS
D	NN

(	NN
D	NN

pm	NN
D	NN

)	NN
D	NN

of	IN
D	NN

ewing	NN
D	NN

sarcoma	NN
D	NN

family	NN
D	NN

tumors	NNS
D	NN

(	NN
D	NN

esft	NN
D	NN

)	NN
D	NN

is	VBZ
O	NN

unclear	JJ
O	NN

extent	NN
O	NN

of	IN
O	NN

pulmonary	JJ
O	NN

involvement	NN
O	NN

at	IN
O	NN

diagnosis	NN
O	NN

,	,
O	NN

response	NN
O	NN

of	IN
O	NN

pm	NN
D	NN

after	IN
O	NN

induction	NN
T	NN

chemotherapy	NN
T	NN

,	,
O	NN

local	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

pm	NN
O	NN

thereafter	RB
O	NN

,	,
O	NN

and	CC
O	NN

clinical	JJ
O	NN

outcome	NN
O	NN

were	VBD
O	NN

recorded	VBN
O	NN

conclusions	NNS
O	NN

:	:
O	NN

the	DT
O	NN

comparable	JJ
O	NN

survival	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

poor	JJ
O	NN

and	CC
O	NN

good	JJ
O	NN

response	NN
O	NN

of	IN
O	NN

pm	NN
D	NN

to	TO
O	NN

induction	NN
T	NN

chemotherapy	NN
T	NN

suggests	VBZ
O	NN

that	IN
O	NN

wli	NN
T	NN

may	MD
O	NNP

benefit	NN
O	NN

poor	JJ
O	NN

responders	NNS
O	NN

objective	JJ
O	NN

:	:
O	NN

to	TO
O	NN

report	NN
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

heparin	NN
T	NN

and	CC
O	NN

enoxaparin	NN
T	NN

for	IN
O	NN

radiation-induced	JJ
D	NN

myelopathy	NN
D	NN

therefore	RB
O	NN

,	,
O	NN

patients	NNS
O	NN

with	IN
O	NN

radiation-induced	JJ
D	NN

spinal	JJ
D	NN

cord	NN
D	NN

injury	NN
D	NN

may	MD
O	NNP

benefit	NN
O	NN

from	IN
O	NN

anticoagulant	JJ
T	NN

therapy	NN
T	NN

conclusions	NNS
O	NN

:	:
O	NN

heparin	NN
T	NN

and/or	CC
T	NN

enoxaparin	NN
T	NN

may	MD
O	NNP

be	VB
O	NN

considered	VBN
O	NN

as	IN
O	NN

potential	JJ
O	NN

treatments	NNS
O	VBP

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

radiation-induced	JJ
D	NN

myelopathy	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

tracheal	NN
O	NN

stent	NN
O	NN

insertion	NN
O	NN

is	VBZ
O	NN

a	DT
O	NN

useful	JJ
O	NN

method	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

malignant	JJ
O	NN

tracheal	NN
O	NN

stenosis	NN
O	NN

expandable	JJ
T	NN

metal	NN
T	NN

stents	NNS
T	NN

were	VBD
O	NN

inserted	VBN
O	NN

in	IN
O	NN

two	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

severe	JJ
D	NN

dyspnea	NN
D	NN

due	JJ
D	NN

to	TO
D	NN

tracheal	NN
D	NN

stenosis	NN
D	NN

caused	VBN
D	NN

by	IN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

and	CC
D	NN

esophageal	NN
D	NN

cancer	NN
D	NN

thus	RB
O	NN

,	,
O	NN

we	PRP
O	VBP

should	MD
O	NNP

recognize	VB
O	NNP

this	DT
O	NN

immanent	JJ
O	NN

risk	NN
O	NN

and	CC
O	NN

perform	VB
O	NN

peri-	JJ
T	NN

and	CC
T	NN

postoperative	JJ
T	NN

management	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

gh-producing	JJ
D	NN

tumors	NNS
D	NN

background	NN
O	NN

:	:
O	NN

at	IN
O	NN

present	JJ
O	NN

the	DT
O	NN

addition	NN
T	NN

of	IN
T	NN

thoracic	JJ
T	NN

irradiation	NN
T	NN

to	TO
T	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

is	VBZ
O	NN

a	DT
O	NN

standard	JJ
O	NN

treatment	NN
O	NN

for	IN
O	NN

limited	JJ
D	NN

staged	VBD
D	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

we	PRP
O	VBP

conducted	VBN
O	NN

a	DT
O	NN

phase	NN
O	NN

ii	LS
O	NN

study	NN
O	NN

of	IN
O	NN

etoposide	NN
T	NN

(	NN
T	NN

vp-16	JJ
T	NN

)	NN
T	NN

-ifosfamide-cisplatin	JJ
T	NN

(	NN
T	NN

vip	NN
T	NN

)	NN
T	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

plus	CC
T	NN

early	JJ
T	NN

concurrent	JJ
T	NN

thoracic	JJ
T	NN

irradiation	NN
T	NN

for	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

with	IN
O	NN

previously	RB
O	NN

untreated	JJ
D	NN

limited	JJ
D	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

in	IN
O	NN

order	NN
O	NN

to	TO
O	NN

assess	VB
O	NN

if	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

modality	NN
O	NN

could	MD
O	NNP

improve	VB
O	NN

the	DT
O	NN

response	NN
O	NN

rate	NN
O	NN

and	CC
O	NN

the	DT
O	NN

toxicity	NN
O	NN

methods	NNS
O	VBP

:	:
O	NN

forty-four	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

limited	JJ
D	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

etoposide-ifosfamide-cisplatin	NN
T	NN

and	CC
T	NN

concurrent	JJ
T	NN

thoracic	JJ
T	NN

irradiation	NN
T	NN

conclusion	NN
O	NN

:	:
O	NN

vip	NN
T	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

and	CC
T	NN

early	JJ
T	NN

concurrent	JJ
T	NN

thoracic	JJ
T	NN

irradiation	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

limited	JJ
D	NN

stage	NN
D	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

revealed	VBD
O	NN

excellent	JJ
O	NN

antitumor	JJ
O	NN

response	NN
O	NN

with	IN
O	NN

tolerable	JJ
O	NN

toxicity	NN
O	NN

in	IN
O	NN

this	DT
O	NN

study	NN
O	NN

we	PRP
O	VBP

analyzed	VBN
O	NN

33	CD
O	NN

cases	NNS
O	NN

which	WDT
O	NN

underwent	VBD
O	NN

complete	JJ
T	NN

surgical	JJ
T	NN

resection	NN
T	NN

to	TO
O	NN

assess	VB
O	NN

the	DT
O	NN

role	NN
O	NN

of	IN
O	NN

surgery	NN
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

n	NN
D	NN

2	LS
D	NN

nsclc	NN
D	NN

we	PRP
O	VBP

thereby	RB
O	NN

recommend	VB
O	NN

that	IN
O	NN

surgery	NN
T	NN

should	MD
O	NNP

only	RB
O	NN

be	VB
O	NN

performed	VBN
O	NN

for	IN
O	NN

those	DT
O	NNP

n	NN
D	NN

2	LS
D	NN

nsclc	NN
D	NN

patients	NNS
O	NN

diagnosed	VBN
O	NN

as	IN
O	NN

t	NN
O	NN

1	CD
O	NN

or	CC
O	NN

t	NN
O	NN

2	CD
O	NN

with	IN
O	NN

a	DT
O	NN

classification	NN
O	NN

of	IN
O	NN

p1	NN
O	NN

or	CC
O	NN

less	JJR
O	NN

inhaled	VBN
T	NN

corticosteroid	NN
T	NN

therapy	NN
T	NN

is	VBZ
O	NN

recommended	VBN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

persistent	JJ
D	NN

disease	NN
D	NN

,	,
O	NN

and	CC
O	NN

careful	JJ
O	NN

instruction	NN
O	NN

in	IN
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

metered-dose	JJ
O	NN

inhalers	NNS
O	NN

is	VBZ
O	NN

particularly	RB
O	NN

important	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

elderly	JJ
O	NN

background	NN
O	NN

:	:
O	NN

the	DT
O	NN

role	NN
O	NN

of	IN
O	NN

surgical	JJ
T	NN

staging	VBG
T	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

non-small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

nsclc	NN
D	NN

)	NN
D	NN

continues	VBZ
O	NN

to	TO
O	NN

evolve	VB
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

this	DT
O	NN

report	NN
O	NN

describes	VBZ
O	NN

our	PRP$
O	NN

findings	NNS
O	VBP

utilizing	VBG
O	NN

routine	JJ
O	NN

cervical	JJ
O	NN

mediastinoscopy	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

evaluation	NN
O	NN

of	IN
O	NN

peripheral	JJ
O	NN

t1	NN
O	NN

(	NN
O	NN

<	JJR
O	NN

3	CD
O	NN

cm	NN
O	NN

)	NN
O	NN

lung	NN
O	NN

tumors	NNS
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

mediastinoscopy	JJ
O	NN

facilitates	VBZ
O	NN

identification	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

regionally	RB
D	NN

advanced	JJ
D	NN

disease	NN
D	NN

prior	RB
D	NN

to	TO
D	NN

resection	NN
D	NN

,	,
O	NN

allowing	VBG
O	NN

neoadjuvant	JJ
T	NN

therapy	NN
T	NN

and	CC
O	NN

avoiding	VBG
O	NN

unnecessary	JJ
O	NN

resections	NNS
O	NN

purpose	NN
O	NN

:	:
O	NN

given	VBN
O	NN

the	DT
O	NN

cisplatin-related	JJ
O	NN

myelotoxicity	NN
O	NN

and	CC
O	NN

nonhematologic	JJ
O	NN

toxicities	NNS
O	NN

,	,
O	NN

we	PRP
O	VBP

were	VBD
O	NN

prompted	VBD
O	NN

to	TO
O	NN

undertake	VB
O	NN

a	DT
O	NN

study	NN
O	NN

of	IN
O	NN

the	DT
O	NN

noncisplatin	JJ
T	NN

combination	NN
T	NN

of	IN
T	NN

paclitaxel	NN
T	NN

plus	CC
T	NN

gemcitabine	NN
T	NN

to	TO
O	NN

evaluate	VB
O	NN

the	DT
O	NN

efficacy	NN
O	NN

,	,
O	NN

tolerance	NN
O	NN

,	,
O	NN

and	CC
O	NN

survival	NN
O	NN

of	IN
O	NN

this	DT
O	NN

combination	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

locally	RB
D	NN

advanced	JJ
D	NN

and	CC
D	NN

metastatic	JJ
D	NN

non-small-cell	JJ
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

nsclc	NN
D	NN

)	NN
D	NN

we	PRP
O	VBP

evaluated	VBN
O	NN

the	DT
O	NN

role	NN
O	NN

of	IN
O	NN

systemic	JJ
T	NN

chemotherapy	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

malignant	JJ
D	NN

pleural	JJ
D	NN

effusions	NNS
D	NN

from	IN
D	NN

nsclc	NN
D	NN

methods	NNS
O	VBP

:	:
O	NN

we	PRP
O	VBP

analyzed	VBN
O	NN

34	CD
O	NN

patients	NNS
O	NN

who	WP
O	VBP

were	VBD
O	NN

found	VBN
O	NN

to	TO
O	NN

have	VB
O	NN

malignant	JJ
D	NN

pleural	JJ
D	NN

effusions	NNS
D	NN

in	IN
O	NN

the	DT
O	NN

course	NN
O	NN

of	IN
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

118	CD
O	NN

patients	NNS
O	NN

enrolled	VBN
O	NN

in	IN
O	NN

three	CD
O	NN

consecutive	JJ
O	NN

clinical	JJ
O	NN

trials	NNS
O	NN

on	IN
O	NN

advanced	JJ
O	NN

nsclc	NN
D	NN

assessing	VBG
O	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

of	IN
T	NN

cisplatin	NN
T	NN

,	,
T	NN

ifosfamide	NN
T	NN

,	,
T	NN

and	CC
T	NN

irinotecan	JJ
T	NN

with	IN
T	NN

recombinant	JJ
T	NN

human	JJ
T	NN

granulocyte	NN
T	NN

colony-stimulating	JJ
T	NN

factor	NN
T	NN

support	NN
T	NN

conclusions	NNS
O	NN

:	:
O	NN

both	DT
O	NN

the	DT
O	NN

response	NN
O	NN

rate	NN
O	NN

and	CC
O	NN

survival	NN
O	NN

data	NNS
O	NN

in	IN
O	NN

this	DT
O	NN

retrospective	JJ
O	NN

study	NN
O	NN

suggest	VBP
O	NN

a	DT
O	NN

high	JJ
O	NN

degree	NN
O	NN

of	IN
O	NN

activity	NN
O	NN

of	IN
O	NN

this	DT
O	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

malignant	JJ
D	NN

pleural	JJ
D	NN

effusions	NNS
D	NN

from	IN
D	NN

nsclc	NN
D	NN

in	IN
O	NN

contrast	NN
O	NN

,	,
O	NN

the	DT
O	NN

introduction	NN
O	NN

and	CC
O	NN

improvement	NN
O	NN

of	IN
O	NN

chemotherapy	NN
T	NN

since	IN
O	NN

the	DT
O	NN

1970s	NNS
O	NN

gave	VBD
O	NN

rise	NN
O	NN

to	TO
O	NN

an	DT
O	NN

improvement	NN
O	NN

in	IN
O	NN

-	:
O	NN

only	RB
O	NN

short-term	JJ
O	NN

(	NN
O	NN

<	JJR
O	NN

2	CD
O	NN

years	NNS
O	NN

)	NN
O	NN

-	:
O	NN

survival	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

small-cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

between	IN
O	NN

july	NNP
O	NNP

1992	CD
O	NN

and	CC
O	NN

december	NNP
O	NN

1997	CD
O	NN

,	,
O	NN

1799	CD
O	NN

patients	NNS
O	NN

were	VBD
O	NN

diagnosed	VBN
O	NN

as	IN
O	NN

having	VBG
O	NN

lung	NN
D	NN

cancer	NN
D	NN

in	IN
O	NN

our	PRP$
O	NN

hospital	NN
O	NN

and	CC
O	NN

926	CD
O	NN

patients	NNS
O	NN

received	VBN
O	NN

chemotherapy	NN
T	NN

and/or	CC
T	NN

thoracic	JJ
T	NN

radiotherapy	NN
T	NN

the	DT
O	NN

administration	NN
O	NN

of	IN
O	NN

mitomycin	NN
T	NN

c	NN
T	NN

in	IN
O	NN

addition	NN
O	NN

to	TO
O	NN

cisplatin-based	JJ
T	NN

regimens	NNS
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

lung	NN
D	NN

cancer	NN
D	NN

should	MD
O	NNP

be	VB
O	NN

carefully	RB
O	NN

considered	VBN
O	NN

570	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

osteosarcoma	NN
D	NN

of	IN
D	NN

the	DT
D	NN

extremities	NNS
D	NN

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

five	CD
O	NN

different	JJ
O	NN

protocols	NNS
O	VBP

of	IN
O	NN

neoadjuvant	JJ
T	NN

chemotherapy	NN
T	NN

at	IN
O	NN

rizzoli	JJ
O	NN

institute	NN
O	NN

between	IN
O	NN

1983	CD
O	NN

and	CC
O	NN

1995	CD
O	NN

we	PRP
O	VBP

conclude	VBP
O	NN

that	IN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

osteosarcoma	NN
D	NN

of	IN
D	NN

the	DT
D	NN

extremities	NNS
D	NN

treated	VBN
O	NN

with	IN
O	NN

neoadjuvant	JJ
T	NN

chemotherapy	NN
T	NN

:	:
O	NN

(	NN
O	NN

a	DT
O	NN

)	NN
O	NN

the	DT
O	NN

pattern	NN
O	NN

of	IN
O	NN

systemic	JJ
O	NN

relapse	NN
O	NN

changes	NNS
O	VBP

according	VBG
O	NN

to	TO
O	NN

the	DT
O	NN

efficacy	NN
O	NN

of	IN
O	NN

the	DT
O	NN

protocol	NN
O	NN

of	IN
O	NN

chemotherapy	NN
O	NN

used	VBN
O	NN

the	DT
O	NN

degree	NN
O	NN

of	IN
O	NN

healing	NN
O	NN

and	CC
O	NN

damage	NN
O	NN

of	IN
O	NN

the	DT
O	NN

bronchial	JJ
O	NN

wall	NN
O	NN

after	IN
O	NN

photodynamic	JJ
T	NN

therapy	NN
T	NN

,	,
T	NN

nd-yag	NN
T	NN

laser	NN
T	NN

and	CC
T	NN

electrocautery	JJ
T	NN

for	IN
O	NN

intraluminal	JJ
D	NN

early-stage	JJ
D	NN

cancer	NN
D	NN

have	VB
O	NN

been	VBN
O	NN

analysed	VBN
O	NN

to	TO
O	NN

examine	VB
O	NN

whether	IN
O	NN

efficacy	NN
O	NN

of	IN
O	NN

postoperative	JJ
O	NN

oral	JJ
O	NN

administration	NN
O	NN

of	IN
O	NN

uft	NN
T	NN

,	,
T	NN

a	DT
T	NN

5-fluorouracil	NN
T	NN

derivative	JJ
T	NN

chemotherapeutic	JJ
T	NN

agent	NN
T	NN

,	,
O	NN

may	MD
O	NNP

be	VB
O	NN

influenced	VBN
O	NN

by	IN
O	NN

incidence	NN
O	NN

of	IN
O	NN

apoptosis	NN
O	NN

(	NN
O	NN

apoptosis	NN
O	NN

index	NN
O	NN

)	NN
O	NN

or	CC
O	NN

apoptosis-related	JJ
O	NN

gene	NN
O	NN

status	NN
O	NN

(	NN
O	NN

p53	NN
O	NN

and	CC
O	NN

bcl-2	NN
O	NN

)	NN
O	NN

of	IN
O	NN

the	DT
O	NN

tumour	NN
O	NN

,	,
O	NN

a	DT
O	NN

total	JJ
O	NN

of	IN
O	NN

162	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

pathologic	JJ
D	NN

stage	NN
D	NN

i	LS
D	NN

non-small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

were	VBD
O	NN

retrospectively	RB
O	NN

reviewed	VBN
O	NN

objectives	NNS
O	VBP

:	:
O	NN

the	DT
O	NN

purpose	NN
O	NN

of	IN
O	NN

this	DT
O	NN

study	NN
O	NN

is	VBZ
O	NN

to	TO
O	NN

review	NN
O	NN

our	PRP$
O	NN

experience	NN
O	NN

with	IN
O	NN

the	DT
O	NN

spectrum	NN
O	NN

of	IN
O	NN

neuroendocrine	NN
D	NN

neoplasms	NNS
D	NN

of	IN
D	NN

the	DT
D	NN

lung	NN
D	NN

with	IN
O	NN

emphasis	NN
O	NN

on	IN
O	NN

the	DT
O	NN

histopathologic	JJ
O	NN

classification	NN
O	NN

and	CC
O	NN

surgical	JJ
T	NN

therapy	NN
T	NN

of	IN
O	NN

each	DT
O	NN

class	NN
O	NN

of	IN
O	NN

neoplasm	NN
O	NN

patients	NNS
O	NN

:	:
O	NN

during	IN
O	NN

this	DT
O	NN

period	NN
O	NN

,	,
O	NN

a	DT
O	NN

total	JJ
O	NN

of	IN
O	NN

77	CD
O	NN

patients	NNS
O	NN

underwent	VBD
O	NN

lung	NN
T	NN

resection	NN
T	NN

for	IN
O	NN

the	DT
O	NN

following	VBG
O	NN

neuroendocrine	NN
D	NN

neoplasms	NNS
D	NN

:	:
O	NN

typical	JJ
D	NN

carcinoid	NN
D	NN

(	NN
D	NN

tc	NN
D	NN

)	NN
D	NN

,	,
O	NN

50	CD
O	NN

patients	NNS
O	NN

;	:
O	NN

atypical	JJ
D	NN

carcinoid	NN
D	NN

(	NN
D	NN

ac	NN
D	NN

)	NN
D	NN

,	,
O	NN

5	CD
O	NN

patients	NNS
O	NN

;	:
O	NN

large	JJ
D	NN

cell	NN
D	NN

neuroendocrine	NN
D	NN

carcinoma	NN
D	NN

(	NN
D	NN

lcnec	NN
D	NN

)	NN
D	NN

,	,
O	NN

9	CD
O	NN

patients	NNS
O	NN

;	:
O	NN

mixed	JJ
D	NN

large-small	NN
D	NN

cell	NN
D	NN

neuroendocrine	NN
D	NN

carcinoma	NN
D	NN

(	NN
D	NN

lsnec	NN
D	NN

)	NN
D	NN

,	,
O	NN

4	CD
O	NN

patients	NNS
O	NN

;	:
O	NN

or	CC
O	NN

small	JJ
D	NN

cell	NN
D	NN

neuroendocrine	NN
D	NN

carcinoma	NN
D	NN

(	NN
D	NN

scc	NN
D	NN

)	NN
D	NN

,	,
O	NN

9	CD
O	NN

patients	NNS
O	NN

despite	IN
O	NN

the	DT
O	NN

poor	JJ
O	NN

overall	JJ
O	NN

prognosis	NN
O	NN

in	IN
O	NN

high-grade	JJ
O	NN

neuroendocrine	NN
D	NN

tumors	NNS
D	NN

of	IN
D	NN

the	DT
D	NN

lung	NN
D	NN

,	,
O	NN

surgery	NN
T	NN

remains	VBZ
O	NNP

a	DT
O	NN

viable	JJ
O	NN

adjunct	NN
O	NN

in	IN
O	NN

the	DT
O	NN

early	RB
O	NN

stages	NNS
O	NN

of	IN
O	NN

this	DT
O	NN

disease	NN
O	NN

urpose	NN
O	NN

:	:
O	NN

to	TO
O	NN

assess	VB
O	NN

results	NNS
O	VBP

with	IN
O	NN

twice-daily	JJ
O	NN

high-dose	JJ
O	NN

radiotherapy	NN
T	NN

(	NN
T	NN

rt	NN
T	NN

)	NN
T	NN

for	IN
O	NN

non-small-cell	JJ
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

nsclc	NN
D	NN

)	NN
D	NN

is	VBZ
O	NN

prolonged	JJ
O	NN

survival	NN
O	NN

possible	JJ
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

supraclavicular	JJ
D	NN

node	NN
D	NN

metastases	NNS
D	NN

in	IN
D	NN

nsclc	NN
D	NN

treated	VBN
O	NN

with	IN
O	NN

chemoradiotherapy	JJ
T	NN

?	.
O	NN

ijrobp	NN
O	NN

1999	CD
O	NN

;	:
O	NN

44	CD
O	NN

(	NN
O	NN

4	CD
O	NN

)	NN
O	NN

:	:
O	NN

847-853	CD
O	NN

we	PRP
O	VBP

aimed	VBN
O	NN

to	TO
O	NN

investigate	VB
O	NN

whether	IN
O	NN

biological	JJ
O	NN

factors	NNS
O	NN

related	JJ
O	NN

to	TO
O	NN

radiosensitivity	NN
O	NN

and	CC
O	NN

chemosensitivity	NN
O	NN

have	VB
O	NN

prognostic	JJ
O	NN

significance	NN
O	NN

in	IN
O	NN

non-small-cell-lung-cancer	JJ
D	NN

(	NN
D	NN

nsclc	NN
D	NN

)	NN
D	NN

patients	NNS
O	NN

treated	VBN
O	NN

with	IN
O	NN

daily	RB
O	NN

low	JJ
O	NN

doses	NNS
O	NN

of	IN
O	NN

cisplatin	NN
T	NN

and	CC
T	NN

radiotherapy	NN
T	NN

we	PRP
O	VBP

treated	VBN
O	NN

27	CD
O	NN

nsclcm	NN
D	NN

patients	NNS
O	NN

with	IN
O	NN

concomitant	JJ
O	NN

daily	RB
O	NN

low-dose	JJ
O	NN

cisplatin	NN
T	NN

and	CC
T	NN

radiotherapy	NN
T	NN

between	IN
O	NN

1993	CD
O	NN

and	CC
O	NN

1995	CD
O	NN

background	NN
O	NN

:	:
O	NN

we	PRP
O	VBP

examined	VBN
O	NN

the	DT
O	NN

complications	NNS
O	NN

and	CC
O	NN

outcomes	NNS
O	VBP

of	IN
O	NN

placing	VBG
O	NN

stents	NNS
T	NN

for	IN
O	NN

both	DT
O	NN

esophageal	NN
D	NN

and	CC
D	NN

tracheobronchial	JJ
D	NN

stenoses	NNS
D	NN

methods	NNS
O	VBP

:	:
O	NN

we	PRP
O	VBP

placed	VBN
O	NN

stents	NNS
T	NN

for	IN
O	NN

both	DT
O	NN

esophageal	NN
D	NN

and	CC
D	NN

tracheobronchial	JJ
D	NN

stenoses	NNS
D	NN

in	IN
O	NN

8	CD
O	NN

patients	NNS
O	NN

(	NN
O	NN

7	CD
O	NN

with	IN
O	NN

esophageal	NN
O	NN

cancer	NN
O	NN

and	CC
O	NN

1	CD
O	NN

with	IN
O	NN

lung	NN
O	NN

cancer	NN
O	NN

)	NN
O	NN

covered	VBN
O	NN

or	CC
O	NN

noncovered	JJ
O	NN

metallic	JJ
T	NN

stents	NNS
T	NN

were	VBD
O	NN

used	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

esophageal	NN
D	NN

stenoses	NNS
D	NN

,	,
O	NN

except	IN
O	NN

in	IN
O	NN

1	CD
O	NN

patient	NN
O	NN

treated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

silicone	NN
O	NN

stent	NN
O	NN

silicone	NN
T	NN

stents	NNS
T	NN

were	VBD
O	NN

used	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

tracheobronchial	JJ
D	NN

stenoses	NNS
D	NN

results	NNS
O	VBP

:	:
O	NN

all	DT
O	NN

patients	NNS
O	NN

experienced	JJ
O	NN

improvement	NN
O	NN

of	IN
O	NN

grades	NNS
O	NN

of	IN
O	NN

both	DT
O	NN

dysphagia	NN
D	NN

and	CC
D	NN

respiratory	JJ
D	NN

symptoms	NNS
D	NN

after	IN
O	NN

stent	JJ
T	NN

therapy	NN
T	NN

conclusions	NNS
O	NN

:	:
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

both	DT
O	NN

esophageal	NN
D	NN

and	CC
D	NN

tracheobronchial	JJ
D	NN

stenoses	NNS
D	NN

,	,
O	NN

a	DT
O	NN

stent	JJ
T	NN

should	MD
O	NNP

be	VB
O	NN

introduced	VBN
O	NN

into	IN
O	NN

the	DT
O	NN

tracheobronchus	NN
O	NN

first	RB
O	NN

because	IN
O	NN

placement	NN
O	NN

of	IN
O	NN

stents	NNS
O	NN

in	IN
O	NN

both	DT
O	NN

the	DT
O	NN

esophagus	NN
O	NN

and	CC
O	NN

tracheobronchus	NN
O	NN

has	VBZ
O	NN

a	DT
O	NN

high	JJ
O	NN

risk	NN
O	NN

of	IN
O	NN

enlargement	NN
O	NN

of	IN
O	NN

the	DT
O	NN

fistula	NN
O	NN

,	,
O	NN

a	DT
O	NN

covered	VBN
T	NN

metallic	JJ
T	NN

stent	JJ
T	NN

is	VBZ
O	NN

preferable	JJ
O	NN

for	IN
O	NN

esophageal	NN
D	NN

cancer	NN
D	NN

involving	VBG
D	NN

the	DT
D	NN

tracheobronchus	NN
D	NN

a	DT
O	NN

retrospective	JJ
O	NN

immunohistochemical	JJ
O	NN

study	NN
O	NN

was	VBD
O	NN

performed	VBN
O	NN

on	IN
O	NN

material	NN
O	NN

from	IN
O	NN

patients	NNS
O	NN

who	WP
O	VBP

were	VBD
O	NN

newly	RB
O	NN

diagnosed	VBN
O	NN

with	IN
O	NN

osteogenic	JJ
D	NN

sarcoma	NN
D	NN

who	WP
O	VBP

were	VBD
O	NN

treated	VBN
O	NN

according	VBG
O	NN

to	TO
O	NN

the	DT
O	NN

t12	NN
T	NN

protocol	NN
T	NN

from	IN
O	NN

the	DT
O	NN

authors	NNS
O	NN

'	POS
O	NN

institution	NN
O	NN

between	IN
O	NN

1986	CD
O	NN

to	TO
O	NN

1993	CD
O	NN

these	DT
O	NN

data	NNS
O	NN

suggest	VBP
O	NN

that	IN
O	NN

her2/erbb-2	NN
O	NN

should	MD
O	NNP

be	VB
O	NN

evaluated	VBN
O	NN

prospectively	RB
O	NN

as	IN
O	NN

a	DT
O	NN

prognostic	JJ
O	NN

indicator	NN
O	NN

and	CC
O	NN

clinical	JJ
O	NN

trials	NNS
O	NN

using	VBG
O	NN

antibodies	NNS
T	NN

that	IN
O	NN

target	NN
O	NN

this	DT
O	NN

receptor	NN
O	NN

should	MD
O	NNP

be	VB
O	NN

considered	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

osteogenic	JJ
D	NN

sarcoma	NN
D	NN

objective	JJ
O	NN

:	:
O	NN

to	TO
O	NN

examine	VB
O	NN

the	DT
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

ninjin	JJ
T	NN

yoei	NN
T	NN

to	TO
T	NN

(	NN
T	NN

nyt	NN
T	NN

;	:
T	NN

ren-shen-yang-rong-tang	JJ
T	NN

in	IN
T	NN

chinese	JJ
T	NN

medicine	NN
T	NN

;	:
T	NN

kotaro	NN
T	NN

pharmaceutical	JJ
T	NN

co.	NN
T	NN

,	,
T	NN

ltd.	NN
T	NN

,	,
T	NN

osaka	NN
T	NN

,	,
T	NN

japan	NN
T	NN

)	NN
T	NN

,	,
T	NN

one	CD
T	NN

of	IN
T	NN

the	DT
T	NN

traditional	JJ
T	NN

herbal	JJ
T	NN

medicines	NNS
T	NN

,	,
O	NN

against	IN
O	NN

lung	NN
D	NN

carcinoma	NN
D	NN

setting	VBG
O	NN

:	:
O	NN

the	DT
O	NN

nursing	NN
O	NN

center	NN
O	NN

himawari	NN
O	NN

design	NN
O	NN

,	,
O	NN

patient	NN
O	NN

,	,
O	NN

and	CC
O	NN

preparation	NN
O	NN

:	:
O	NN

the	DT
O	NN

regular	JJ
O	NN

dosage	NN
O	NN

of	IN
O	NN

nyt	NN
T	NN

(	NN
O	NN

15	CD
O	NN

g/d	NN
O	NN

)	NN
O	NN

was	VBD
O	NN

prescribed	VBN
O	NN

for	IN
O	NN

7	CD
O	NN

weeks	NNS
O	NN

to	TO
O	NN

one	CD
O	NN

elderly	JJ
O	NN

patient	NN
O	NN

with	IN
O	NN

lung	NN
D	NN

carcinoma	NN
D	NN

conclusion	NN
O	NN

:	:
O	NN

nyt	NN
T	NN

has	VBZ
O	NN

a	DT
O	NN

positive	JJ
O	NN

effect	NN
O	NN

on	IN
O	NN

life	NN
O	NN

expectancy	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

malignancy	NN
D	NN

background	NN
O	NN

:	:
O	NN

the	DT
O	NN

costs	NNS
O	NN

of	IN
O	NN

videothoracoscopic	JJ
T	NN

procedures	NNS
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

lung	NN
D	NN

carcinoma	NN
D	NN

were	VBD
O	NN

compared	VBN
O	NN

with	IN
O	NN

those	DT
O	NNP

of	IN
O	NN

patients	NNS
O	NN

who	WP
O	VBP

underwent	VBD
O	NN

open	JJ
T	NN

thoracotomy	NN
T	NN

in	IN
O	NN

japan	NN
O	NN

methods	NNS
O	VBP

:	:
O	NN

the	DT
O	NN

cost	NN
O	NN

of	IN
O	NN

surgical	JJ
T	NN

treatment	NN
T	NN

in	IN
O	NN

1997	CD
O	NN

and	CC
O	NN

1998	CD
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

resectable	JJ
D	NN

primary	JJ
D	NN

or	CC
D	NN

metastatic	JJ
D	NN

lung	NN
D	NN

carcinoma	NN
D	NN

was	VBD
O	NN

analyzed	VBN
O	NN

from	IN
O	NN

itemized	VBN
O	NN

statements	NNS
O	NN

of	IN
O	NN

hospital	NN
O	NN

charges	NNS
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

lung	NN
D	NN

carcinoma	NN
D	NN

who	WP
O	VBP

are	VBP
O	NN

in	IN
O	NN

relatively	RB
O	NN

poor	JJ
O	NN

health	NN
O	NN

,	,
O	NN

the	DT
O	NN

authors	NNS
O	NN

chose	VBD
O	NN

videothoracoscopic	JJ
T	NN

lobectomy	JJ
T	NN

or	CC
T	NN

partial	JJ
T	NN

resection	NN
T	NN

of	IN
T	NN

the	DT
T	NN

lung	NN
T	NN

instead	RB
O	NN

of	IN
O	NN

an	DT
O	NN

open	JJ
O	NN

thoracotomy	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

solitary	JJ
D	NN

pulmonary	JJ
D	NN

metastasis	NN
D	NN

,	,
O	NN

the	DT
O	NN

authors	NNS
O	NN

routinely	RB
O	NN

performed	VBN
O	NN

thoracoscopic	JJ
T	NN

partial	JJ
T	NN

resection	NN
T	NN

of	IN
T	NN

the	DT
T	NN

lung	NN
T	NN

background	NN
O	NN

:	:
O	NN

curative	JJ
T	NN

therapy	NN
T	NN

is	VBZ
O	NN

available	JJ
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

stage	NN
D	NN

0	CD
D	NN

lung	NN
D	NN

carcinoma	NN
D	NN

,	,
O	NN

with	IN
O	NN

a	DT
O	NN

>	JJR
O	NN

90	CD
O	NN

%	NN
O	NN

5-year	JJ
O	NN

survival	NN
O	NN

rate	NN
O	NN

promising	JJ
O	NN

chemopreventive	JJ
T	NN

agents	NNS
T	NN

also	RB
O	NN

are	VBP
O	NN

under	IN
O	NN

investigation	NN
O	NN

currently	RB
O	NN

to	TO
O	NN

reduce	VB
O	NN

the	DT
O	NN

risk	NN
O	NN

of	IN
O	NN

lung	NN
D	NN

carcinoma	NN
D	NN

in	IN
O	NN

high	JJ
O	NN

risk	NN
O	NN

populations	NNS
O	NN

object	NN
O	NN

:	:
O	NN

the	DT
O	NN

purpose	NN
O	NN

of	IN
O	NN

this	DT
O	NN

retrospective	JJ
O	NN

study	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

compare	VB
O	NN

the	DT
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

gamma	NN
T	NN

knife	NN
T	NN

radiosurgery	NN
T	NN

(	NN
T	NN

gks	NNS
T	NN

)	NN
T	NN

for	IN
O	NN

multiple	JJ
D	NN

cerebral	JJ
D	NN

metastases	NNS
D	NN

with	IN
O	NN

that	IN
O	NN

of	IN
O	NN

whole-brain	JJ
T	NN

radiation	NN
T	NN

therapy	NN
T	NN

(	NN
T	NN

wbrt	NN
T	NN

)	NN
T	NN

in	IN
O	NN

the	DT
O	NN

gks	NNS
O	NN

group	NN
O	NN

,	,
O	NN

large	JJ
O	NN

lesions	NNS
O	NN

(	NN
O	NN

>	JJR
O	NN

30	CD
O	NN

mm	NN
O	NN

)	NN
O	NN

were	VBD
O	NN

removed	VBN
O	NN

surgically	RB
O	NN

and	CC
O	NN

all	DT
O	NN

other	JJ
O	NN

small	JJ
D	NN

lesions	NNS
D	NN

(	NN
O	NN

<	JJR
O	NN

or	CC
O	NN

=	JJ
O	NN

30	CD
O	NN

mm	NN
O	NN

)	NN
O	NN

were	VBD
O	NN

treated	VBN
O	NN

by	IN
O	NN

gks	NNS
T	NN

new	JJ
O	NN

distant	JJ
D	NN

lesions	NNS
D	NN

were	VBD
O	NN

treated	VBN
O	NN

by	IN
O	NN

repeated	VBN
O	NN

gks	NNS
T	NN

without	IN
O	NN

prophylactic	NN
O	NN

wbrt	NN
O	NN

conclusions	NNS
O	NN

:	:
O	NN

gamma	NN
T	NN

knife	NN
T	NN

radiosurgery	NN
T	NN

without	IN
O	NN

prophylactic	NN
O	NN

wbrt	NN
O	NN

could	MD
O	NNP

be	VB
O	NN

a	DT
O	NN

primary	JJ
O	NN

choice	NN
O	NN

of	IN
O	NN

treatment	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

as	IN
O	NN

many	JJ
O	NN

as	IN
O	NN

10	CD
O	NN

cerebral	JJ
D	NN

metastases	NNS
D	NN

from	IN
D	NN

nonsmall	NN
D	NN

cell	NN
D	NN

cancer	NN
D	NN

the	DT
O	NN

notable	JJ
O	NN

exception	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

docetaxel	NN
T	NN

,	,
O	NN

which	WDT
O	NN

has	VBZ
O	NN

been	VBN
O	NN

extensively	RB
O	NN

studied	VBN
O	NN

as	IN
O	NN

a	DT
O	NN

second-line	JJ
O	NN

therapy	NN
O	NN

for	IN
O	NN

nsclc	NN
D	NN

object	NN
O	NN

:	:
O	NN

the	DT
O	NN

purpose	NN
O	NN

of	IN
O	NN

this	DT
O	NN

retrospective	JJ
O	NN

study	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

compare	VB
O	NN

the	DT
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

gamma	NN
T	NN

knife	NN
T	NN

radiosurgery	NN
T	NN

(	NN
T	NN

gks	NNS
T	NN

)	NN
T	NN

for	IN
O	NN

multiple	JJ
D	NN

cerebral	JJ
D	NN

metastases	NNS
D	NN

with	IN
O	NN

that	IN
O	NN

of	IN
O	NN

whole-brain	JJ
T	NN

radiation	NN
T	NN

therapy	NN
T	NN

(	NN
T	NN

wbrt	NN
T	NN

)	NN
T	NN

patients	NNS
O	NN

with	IN
O	NN

a	DT
O	NN

single	JJ
D	NN

non-sclc	JJ
D	NN

,	,
D	NN

breast	NN
D	NN

,	,
D	NN

melanoma	NN
D	NN

,	,
D	NN

renal	JJ
D	NN

cell	NN
D	NN

,	,
D	NN

and	CC
D	NN

ovarian	JJ
D	NN

carcinoma	NN
D	NN

brain	NN
D	NN

metastasis	NN
D	NN

have	VB
O	NN

the	DT
O	NN

best	RB
O	NN

chance	NN
O	NN

for	IN
O	NN

long-term	JJ
O	NN

survival	NN
O	NN

if	IN
O	NN

treated	VBN
O	NN

with	IN
O	NN

surgical	JJ
T	NN

resection	NN
T	NN

and	CC
T	NN

wbrt	NN
T	NN

objective	JJ
O	NN

:	:
O	NN

careful	JJ
O	NN

patient	NN
O	NN

selection	NN
O	NN

is	VBZ
O	NN

vital	JJ
O	NN

when	WRB
O	NN

video-assisted	JJ
T	NN

thoracoscopic	JJ
T	NN

surgical	JJ
T	NN

(	NN
T	NN

vats	NNS
T	NN

)	NN
T	NN

therapeutic	JJ
T	NN

pulmonary	JJ
T	NN

metastasectomy	NN
T	NN

of	IN
O	NN

colorectal	JJ
D	NN

carcinoma	NN
D	NN

is	VBZ
O	NN

considered	VBN
O	NN

we	PRP
O	VBP

reviewed	VBN
O	NN

our	PRP$
O	NN

vats	NNS
O	NN

experience	NN
O	NN

for	IN
O	NN

therapeutic	JJ
T	NN

metastasectomy	NN
T	NN

of	IN
O	NN

peripheral	JJ
D	NN

colorectal	JJ
D	NN

pulmonary	JJ
D	NN

metastases	NNS
D	NN

methods	NNS
O	VBP

:	:
O	NN

over	IN
O	NN

90	CD
O	NN

months	NNS
O	NN

,	,
O	NN

therapeutic	JJ
T	NN

vats	NNS
T	NN

metastasectomy	NN
T	NN

was	VBD
O	NN

accomplished	JJ
O	NN

upon	IN
O	NN

80	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

colorectal	JJ
D	NN

metastases	NNS
D	NN

conclusions	NNS
O	NN

:	:
O	NN

therapeutic	JJ
T	NN

vats	NNS
T	NN

resection	NN
T	NN

of	IN
O	NN

colorectal	JJ
D	NN

metastases	NNS
D	NN

appears	VBZ
O	NN

efficacious	JJ
O	NN

objectives	NNS
O	VBP

:	:
O	NN

to	TO
O	NN

review	NN
O	NN

the	DT
O	NN

spectrum	NN
O	NN

of	IN
O	NN

presentation	NN
O	NN

and	CC
O	NN

the	DT
O	NN

surgical	JJ
T	NN

management	NN
T	NN

of	IN
O	NN

non	JJ
D	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

nsclc	NN
D	NN

)	NN
D	NN

and	CC
O	NN

the	DT
O	NN

role	NN
O	NN

of	IN
O	NN

various	JJ
O	NN

diagnostic	JJ
O	NN

modalities	NNS
O	NN

in	IN
O	NN

predicting	VBG
O	NN

the	DT
O	NN

post-operative	JJ
O	NN

stage	NN
O	NN

and	CC
O	NN

the	DT
O	NN

correlation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

post-operative	JJ
O	NN

stage	NN
O	NN

with	IN
O	NN

the	DT
O	NN

chances	NNS
O	NN

of	IN
O	NN

recurrence	NN
O	NN

patients	NNS
O	NN

with	IN
O	NN

limited-stage	NN
D	NN

small-cell	NN
D	NN

carcinoma	NN
D	NN

of	IN
D	NN

the	DT
D	NN

lung	NN
D	NN

are	VBP
O	NN

treated	VBN
O	NN

with	IN
O	NN

combined-modality	JJ
T	NN

therapy	NN
T	NN

with	IN
O	NN

the	DT
O	NN

intent	NN
O	NN

to	TO
O	NN

cure	NN
O	NN

in	IN
O	NN

the	DT
O	NN

past	JJ
O	NN

several	JJ
O	NN

years	NNS
O	NN

,	,
O	NN

new	JJ
T	NN

chemotherapeutic	JJ
T	NN

agents	NNS
T	NN

,	,
T	NN

including	VBG
T	NN

the	DT
T	NN

taxanes	NNS
T	NN

and	CC
T	NN

the	DT
T	NN

topoisomerase	NN
T	NN

i	LS
T	NN

inhibitors	NNS
T	NN

,	,
O	NN

have	VB
O	NN

demonstrated	VBD
O	NN

substantial	JJ
O	NN

activity	NN
O	NN

against	IN
O	NN

small-cell	NN
D	NN

carcinoma	NN
D	NN

we	PRP
O	VBP

evaluated	VBN
O	NN

the	DT
O	NN

role	NN
O	NN

of	IN
O	NN

chemotherapy	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

brain	NN
D	NN

metastases	NNS
D	NN

from	IN
D	NN

nsclc	NN
D	NN

methods	NNS
O	VBP

:	:
O	NN

we	PRP
O	VBP

analyzed	VBN
O	NN

30	CD
O	NN

patients	NNS
O	NN

who	WP
O	VBP

were	VBD
O	NN

discovered	VBN
O	NN

to	TO
O	NN

have	VB
O	NN

brain	NN
O	NN

metastases	NNS
O	NN

during	IN
O	NN

the	DT
O	NN

diagnosis	NN
O	NN

of	IN
O	NN

121	CD
O	NN

patients	NNS
O	NN

enrolled	VBN
O	NN

in	IN
O	NN

three	CD
O	NN

consecutive	JJ
O	NN

clinical	JJ
O	NN

trials	NNS
O	NN

on	IN
O	NN

advanced	JJ
D	NN

nsclc	NN
D	NN

assessing	VBG
O	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

of	IN
T	NN

cisplatin	NN
T	NN

,	,
T	NN

ifosfamide	NN
T	NN

and	CC
T	NN

irinotecan	JJ
T	NN

with	IN
T	NN

rhg-csf	JJ
T	NN

support	NN
T	NN

conclusions	NNS
O	NN

:	:
O	NN

both	DT
O	NN

the	DT
O	NN

response	NN
O	NN

rate	NN
O	NN

and	CC
O	NN

survival	NN
O	NN

data	NNS
O	NN

in	IN
O	NN

this	DT
O	NN

retrospective	JJ
O	NN

study	NN
O	NN

suggest	VBP
O	NN

a	DT
O	NN

high	JJ
O	NN

degree	NN
O	NN

of	IN
O	NN

activity	NN
O	NN

of	IN
O	NN

this	DT
O	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

brain	NN
D	NN

metastases	NNS
D	NN

from	IN
D	NN

nsclc	NN
D	NN

the	DT
O	NN

aim	NN
O	NN

of	IN
O	NN

this	DT
O	NN

study	NN
O	NN

was	VBD
O	NN

the	DT
O	NN

evaluation	NN
O	NN

of	IN
O	NN

both	DT
O	NN

the	DT
O	NN

antitumour	JJ
O	NN

activity	NN
O	NN

and	CC
O	NN

toxicity	NN
O	NN

of	IN
O	NN

an	DT
O	NN

immunochemotherapeutic	JJ
T	NN

regimen	NN
T	NN

consisting	VBG
T	NN

of	IN
T	NN

interferon-alpha2b	JJ
T	NN

and	CC
T	NN

interleukin-2	NN
T	NN

in	IN
T	NN

combination	NN
T	NN

with	IN
T	NN

fotemustine	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

metastatic	JJ
D	NN

melanoma	NN
D	NN

to	TO
O	NN

explore	VB
O	NN

the	DT
O	NN

induction	NN
O	NN

of	IN
O	NN

chemotherapy	NN
T	NN

(	NN
T	NN

ct	NN
T	NN

)	NN
T	NN

dna	NN
O	NN

damage	NN
O	NN

and	CC
O	NN

its	PRP$
O	NN

correlation	NN
O	NN

with	IN
O	NN

tumor	NN
O	NN

response	NN
O	NN

and	CC
O	NN

patient	NN
O	NN

survival	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

undertook	VBD
O	NN

the	DT
O	NN

present	JJ
O	NN

study	NN
O	NN

in	IN
O	NN

20	CD
O	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

sclc	NN
D	NN

)	NN
D	NN

patients	NNS
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

metastatic	JJ
D	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

,	,
O	NN

intravenous	JJ
T	NN

oxaliplatin	NN
T	NN

has	VBZ
O	NN

been	VBN
O	NN

trialled	VBN
O	NN

as	IN
O	NN

a	DT
O	NN

monotherapy	NN
O	NN

and	CC
O	NN

in	IN
O	NN

combination	NN
O	NN

with	IN
O	NN

other	JJ
O	NN

agents	NNS
O	NN

neoadjuvant	JJ
T	NN

therapy	NN
T	NN

with	IN
T	NN

oxaliplatin/fluorouracil/folinic	JJ
T	NN

acid	NN
T	NN

has	VBZ
O	NN

proven	JJ
O	NN

beneficial	JJ
O	NN

in	IN
O	NN

enabling	VBG
O	NN

surgical	JJ
O	NN

removal	NN
O	NN

of	IN
O	NN

previously	RB
O	NN

unresectable	JJ
D	NN

liver	NN
D	NN

metastases	NNS
D	NN

in	IN
O	NN

2	CD
O	NN

studies	NNS
O	VBP

,	,
O	NN

surgery	NN
T	NN

with	IN
O	NN

curative	JJ
O	NN

intent	NN
O	NN

was	VBD
O	NN

performed	VBN
O	NN

in	IN
O	NN

16	CD
O	NN

and	CC
O	NN

51	CD
O	NN

%	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

initially	RB
O	NN

unresectable	JJ
D	NN

liver	NN
D	NN

metastases	NNS
D	NN

following	VBG
O	NN

oxaliplatin/fluorouracil/folinic	JJ
T	NN

acid	NN
T	NN

therapy	NN
T	NN

;	:
O	NN

the	DT
O	NN

5-year	JJ
O	NN

survival	NN
O	NN

rates	NNS
O	VBP

were	VBD
O	NN

40	CD
O	NN

and	CC
O	NN

50	CD
O	NN

%	NN
O	NN

,	,
O	NN

respectively	RB
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

ovarian	JJ
D	NN

cancer	NN
D	NN

,	,
O	NN

first-line	JJ
O	NN

therapy	NN
O	NN

with	IN
O	NN

oxaliplatin/cyclophosphamide	NN
T	NN

achieved	VBN
O	NN

an	DT
O	NN

objective	JJ
O	NN

response	NN
O	NN

rate	NN
O	NN

which	WDT
O	NN

did	VBD
O	NNP

not	RB
O	NN

differ	VBP
O	NN

significantly	RB
O	NN

from	IN
O	NN

that	IN
O	NN

of	IN
O	NN

cisplatin/cyclophosphamide	NN
T	NN

(	NN
O	NN

33	CD
O	NN

vs	CC
O	NN

42	CD
O	NN

%	NN
O	NN

)	NN
O	NN

in	IN
O	NN

addition	NN
O	NN

,	,
O	NN

oxaliplatin	NN
T	NN

has	VBZ
O	NN

shown	VBN
O	NN

efficacy	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

platinum-pretreated	JJ
D	NN

ovarian	JJ
D	NN

cancer	NN
D	NN

and	CC
O	NN

achieved	VBN
O	NN

objective	JJ
O	NN

response	NN
O	NN

rates	NNS
O	VBP

similar	JJ
O	NN

to	TO
O	NN

paclitaxel	NN
O	NN

in	IN
O	NN

this	DT
O	NN

setting	VBG
O	NN

(	NN
O	NN

16	CD
O	NN

vs	CC
O	NN

17	CD
O	NN

%	NN
O	NN

)	NN
O	NN

promising	JJ
O	NN

results	NNS
O	VBP

have	VB
O	NN

also	RB
O	NN

been	VBN
O	NN

found	VBN
O	NN

with	IN
O	NN

oxaliplatin	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

non-hodgkin	JJ
D	NN

's	POS
D	NN

lymphoma	NN
D	NN

,	,
D	NN

breast	NN
D	NN

cancer	NN
D	NN

,	,
D	NN

mesothelioma	NN
D	NN

and	CC
D	NN

non-small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

conclusion	NN
O	NN

:	:
O	NN

oxaliplatin	NN
T	NN

in	IN
T	NN

combination	NN
T	NN

with	IN
T	NN

fluorouracil/folinic	JJ
T	NN

acid	NN
T	NN

is	VBZ
O	NN

an	DT
O	NN

effective	JJ
O	NN

treatment	NN
O	NN

option	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

metastatic	JJ
D	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

,	,
O	NN

both	DT
O	NN

as	IN
O	NN

a	DT
O	NN

first-line	JJ
O	NN

therapy	NN
O	NN

and	CC
O	NN

in	IN
O	NN

patients	NNS
O	NN

refractory	JJ
O	NN

to	TO
O	NN

previous	JJ
O	NN

chemotherapy	NN
O	NN

additional	JJ
O	NN

clinical	JJ
O	NN

investigation	NN
O	NN

of	IN
O	NN

oxaliplatin	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

other	JJ
O	NN

cancers	NNS
D	NN

is	VBZ
O	NN

warranted	VBN
O	NN

given	VBN
O	NN

the	DT
O	NN

promising	JJ
O	NN

results	NNS
O	VBP

achieved	VBN
O	NN

in	IN
O	NN

early	RB
O	NN

trials	NNS
O	NN

,	,
O	NN

most	JJS
O	NN

notably	RB
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

platinum-pretreated	JJ
O	NN

ovarian	JJ
O	NN

cancer	NN
O	NN

combined	VBN
T	NN

modality	NN
T	NN

treatment	NN
T	NN

has	VBZ
O	NN

'come	NN
O	NN

out	IN
O	NN

of	IN
O	NN

age	NN
O	NN

'	POS
O	NN

and	CC
O	NN

increasingly	RB
O	NN

represents	VBZ
O	NN

standard	JJ
O	NN

of	IN
O	NN

care	NN
O	NN

for	IN
O	NN

a	DT
O	NN

rapidly	RB
O	NN

growing	VBG
O	NN

number	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

in	IN
O	NN

locally	RB
O	NN

advanced	JJ
O	NN

stages	NNS
O	NN

of	IN
O	NN

nsclc	NN
D	NN

the	DT
O	NN

current	JJ
O	NN

study	NN
O	NN

was	VBD
O	NN

designed	VBN
O	NN

to	TO
O	NN

assess	VB
O	NN

the	DT
O	NN

prognostic	JJ
O	NN

value	NN
O	NN

of	IN
O	NN

immunomorphologic	JJ
O	NN

changes	NNS
O	VBP

in	IN
O	NN

locoregional	JJ
O	NN

lymph	NN
O	NN

nodes	NNS
O	NN

and	CC
O	NN

lymphocytic	JJ
O	NN

infiltration	NN
O	NN

of	IN
O	NN

primary	JJ
O	NN

tumor	NN
O	NN

(	NN
O	NN

li	NN
O	NN

)	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

who	WP
O	VBP

undergo	VB
O	NN

resection	NN
T	NN

for	IN
O	NN

bronchogenic	JJ
D	NN

carcinoma	NN
D	NN

conclusions	NNS
O	NN

:	:
O	NN

lymph	NN
O	NN

node	NN
O	NN

immunoreactivity	NN
O	NN

and	CC
O	NN

li	NN
O	NN

significantly	RB
O	NN

influence	NN
O	NN

long	RB
O	NN

term	NN
O	NN

survival	NN
O	NN

after	IN
O	NN

curative	JJ
T	NN

surgery	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

carcinoma	NN
D	NN

of	IN
D	NN

the	DT
D	NN

lung	NN
D	NN

and	CC
O	NN

may	MD
O	NNP

be	VB
O	NN

useful	JJ
O	NN

in	IN
O	NN

stratifying	VBG
O	NN

patients	NNS
O	NN

for	IN
O	NN

prospective	JJ
O	NN

trials	NNS
O	NN

of	IN
O	NN

adjuvant	JJ
O	NN

treatment	NN
O	NN

,	,
O	NN

including	VBG
O	NN

immunotherapy	NN
O	NN

the	DT
O	NN

drug	NN
O	NN

is	VBZ
O	NN

currently	RB
O	NN

in	IN
O	NN

phase	NN
O	NN

iii	LS
O	NN

clinical	JJ
O	NN

trials	NNS
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

non-small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

in	IN
O	NN

combination	NN
O	NN

with	IN
O	NN

paclitaxel	NN
T	NN

and	CC
T	NN

carboplatin	NN
T	NN

,	,
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

in	IN
O	NN

advanced	JJ
D	NN

hormone	NN
D	NN

refractory	JJ
D	NN

prostate	NN
D	NN

cancer	NN
D	NN

in	IN
O	NN

combination	NN
O	NN

with	IN
O	NN

mitoxantrone	NN
T	NN

standard	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

sclc	NN
D	NN

consists	VBZ
O	NN

of	IN
O	NN

platinum-based	JJ
T	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

,	,
O	NN

with	IN
O	NN

thoracic	JJ
O	NN

irradiation	NN
O	NN

added	VBN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

limited-stage	JJ
O	NN

disease	NN
O	NN

several	JJ
O	NN

newer	JJR
O	NN

chemotherapeutic	JJ
T	NN

drugs	NNS
T	NN

have	VB
O	NN

recently	RB
O	NN

been	VBN
O	NN

shown	VBN
O	NN

to	TO
O	NN

have	VB
O	NN

significant	JJ
O	NN

activity	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

untreated	JJ
D	NN

or	CC
D	NN

relapsed	VBD
D	NN

sclc	NN
D	NN

we	PRP
O	VBP

recently	RB
O	NN

performed	VBN
O	NN

completion	NN
T	NN

pneumonectomy	NN
T	NN

of	IN
T	NN

the	DT
T	NN

left	VBN
T	NN

lung	NN
T	NN

in	IN
O	NN

a	DT
O	NN

70-year-old	JJ
O	NN

man	NN
O	NN

with	IN
O	NN

hemophilia	NN
O	NN

a	DT
O	NN

,	,
O	NN

for	IN
O	NN

squamous	JJ
D	NN

cell	NN
D	NN

carcinoma	NN
D	NN

in	IN
O	NN

the	DT
O	NN

residual	JJ
O	NN

left	RB
O	NN

lung	NN
O	NN

objective	JJ
O	NN

:	:
O	NN

several	JJ
O	NN

reports	NNS
O	NN

emphasize	VB
O	NN

the	DT
O	NN

importance	NN
O	NN

of	IN
O	NN

en-bloc	JJ
T	NN

resection	NN
T	NN

as	IN
O	NN

the	DT
O	NN

optimal	JJ
O	NN

surgical	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

lung	NN
D	NN

cancer	NN
D	NN

with	IN
O	NN

chest	NN
O	NN

wall	NN
O	NN

invasion	NN
O	NN

methods	NNS
O	VBP

:	:
O	NN

between	IN
O	NN

1981	CD
O	NN

and	CC
O	NN

1998	CD
O	NN

,	,
O	NN

100	CD
O	NN

patients	NNS
O	NN

(	NN
O	NN

90	CD
O	NN

male	JJ
O	NN

;	:
O	NN

ten	CD
O	NN

female	JJ
O	NN

)	NN
O	NN

,	,
O	NN

with	IN
O	NN

a	DT
O	NN

median	JJ
O	NN

age	NN
O	NN

of	IN
O	NN

60	CD
O	NN

years	NNS
O	NN

(	NN
O	NN

36-84	CD
O	NN

)	NN
O	NN

,	,
O	NN

underwent	VBD
O	NN

radical	JJ
T	NN

en-bloc	JJ
T	NN

resection	NN
T	NN

of	IN
O	NN

non-small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

nsclc	NN
D	NN

)	NN
D	NN

with	IN
O	NN

chest	NN
O	NN

wall	NN
O	NN

involvement	NN
O	NN

over	IN
O	NN

the	DT
O	NN

past	JJ
O	NN

17	CD
O	NN

years	NNS
O	NN

(	NN
O	NN

1981	CD
O	NN

to	TO
O	NN

1997	CD
O	NN

)	NN
O	NN

,	,
O	NN

29	CD
O	NN

patients	NNS
O	NN

underwent	VBD
O	NN

complete	JJ
T	NN

pulmonary	JJ
T	NN

resection	NN
T	NN

for	IN
O	NN

primary	JJ
D	NN

lung	NN
D	NN

cancer	NN
D	NN

accompanied	VBN
O	NN

by	IN
O	NN

satellite	NN
O	NN

nodules	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

same	JJ
O	NN

lobe	NN
O	NN

as	IN
O	NN

the	DT
O	NN

primary	JJ
O	NN

of	IN
O	NN

1	CD
O	NN

,	,
O	NN

042	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

primary	JJ
D	NN

lung	NN
D	NN

cancer	NN
D	NN

who	WP
O	VBP

underwent	VBD
O	NN

resection	NN
T	NN

from	IN
O	NN

1982	CD
O	NN

to	TO
O	NN

1995	CD
O	NN

,	,
O	NN

549	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

adenocarcinoma	NN
O	NN

(	NN
O	NN

ad	NN
O	NN

)	NN
O	NN

and	CC
O	NN

363	CD
O	NN

with	IN
O	NN

squamous	JJ
O	NN

cell	NN
O	NN

carcinoma	NN
O	NN

(	NN
O	NN

sq	NN
O	NN

)	NN
O	NN

were	VBD
O	NN

included	VBN
O	NN

in	IN
O	NN

this	DT
O	NN

study	NN
O	NN

for	IN
O	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

sclc	NN
D	NN

)	NN
D	NN

,	,
O	NN

which	WDT
O	NN

accounts	NNS
O	NN

for	IN
O	NN

approximately	RB
O	NN

20	CD
O	NN

%	NN
O	NN

of	IN
O	NN

cases	NNS
O	NN

of	IN
O	NN

lung	NN
O	NN

cancer	NN
O	NN

,	,
O	NN

the	DT
O	NN

primary	JJ
O	NN

treatment	NN
O	NN

is	VBZ
O	NN

chemotherapy	NN
T	NN

and	CC
O	NN

in	IN
O	NN

the	DT
O	NN

majority	NN
O	NN

of	IN
O	NN

cases	NNS
O	NN

the	DT
O	NN

primary	JJ
O	NN

aim	NN
O	NN

is	VBZ
O	NN

to	TO
O	NN

control	NN
O	NN

the	DT
O	NN

disease	NN
O	NN

which	WDT
O	NN

generally	RB
O	NN

would	MD
O	NNP

have	VB
O	NN

spread	NN
O	NN

beyond	IN
O	NN

the	DT
O	NN

lungs	NNS
O	VBP

at	IN
O	NN

the	DT
O	NN

time	NN
O	NN

of	IN
O	NN

presentation	NN
O	NN

a	DT
O	NN

growing	VBG
O	NN

body	NN
O	NN

of	IN
O	NN

evidence	NN
O	NN

suggests	VBZ
O	NN

that	IN
O	NN

postoperative	JJ
T	NN

irradiation	NN
T	NN

for	IN
O	NN

non-small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

may	MD
O	NNP

cause	NN
O	NN

life-threatening	JJ
O	NN

toxicity	NN
O	NN

and	CC
O	NN

,	,
O	NN

when	WRB
O	NN

the	DT
O	NN

risk	NN
O	NN

of	IN
O	NN

local-regional	JJ
O	NN

recurrence	NN
O	NN

is	VBZ
O	NN

low	JJ
O	NN

,	,
O	NN

the	DT
O	NN

toxicity	NN
O	NN

of	IN
O	NN

irradiation	NN
O	NN

may	MD
O	NNP

outweight	VB
O	NN

the	DT
O	NN

benefit	NN
O	NN

as	IN
O	NN

a	DT
O	NN

best-case	JJ
O	NN

scenario	NN
O	NN

,	,
O	NN

postoperative	JJ
T	NN

irradiation	NN
T	NN

may	MD
O	NNP

improve	VB
O	NN

the	DT
O	NN

chance	NN
O	NN

for	IN
O	NN

long-term	JJ
O	NN

survival	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

n2	NN
D	NN

tumors	NNS
D	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

stage	NN
D	NN

i	LS
D	NN

or	CC
D	NN

ii	LS
D	NN

non-small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

nsclc	NN
D	NN

)	NN
D	NN

,	,
O	NN

surgical	JJ
T	NN

resection	NN
T	NN

is	VBZ
O	NN

considered	VBN
O	NN

the	DT
O	NN

standard	JJ
O	NN

of	IN
O	NN

care	NN
O	NN

efforts	NNS
O	NN

at	IN
O	NN

improving	VBG
O	NN

survival	NN
O	NN

for	IN
O	NN

early-stage	JJ
D	NN

nsclc	NN
D	NN

patients	NNS
O	NN

have	VB
O	NN

focused	VBN
O	NN

on	IN
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

chemotherapy	NN
T	NN

administered	VBN
O	NN

postoperatively	RB
O	NN

(	NN
O	NN

adjuvant	JJ
O	NN

)	NN
O	NN

or	CC
O	NN

preoperatively	RB
O	NN

(	NN
O	NN

neoadjuvant	JJ
O	NN

or	CC
O	NN

induction	NN
O	NN

)	NN
O	NN

to	TO
O	NN

eradicate	VB
O	NN

micrometastatic	JJ
D	NN

disease	NN
D	NN

chemotherapy	NN
T	NN

administered	VBN
O	NN

before	IN
O	NN

surgery	NN
O	NN

or	CC
O	NN

definitive	JJ
O	NN

irradiation	NN
O	NN

has	VBZ
O	NN

improved	VBN
O	NN

survival	NN
O	NN

rates	NNS
O	VBP

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

stage	NN
D	NN

iii	LS
D	NN

nsclc	NN
D	NN

patients	NNS
O	NN

:	:
O	NN

patients	NNS
O	NN

with	IN
O	NN

a	DT
O	NN

single	JJ
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

2	CD
O	NN

,	,
O	NN

764	CD
O	NN

)	NN
O	NN

and	CC
O	NN

synchronous	JJ
O	NN

nsclc	NN
D	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

85	CD
O	NN

)	NN
O	NN

who	WP
O	VBP

underwent	VBD
O	NN

pulmonary	JJ
T	NN

resection	NN
T	NN

background	NN
O	NN

:	:
O	NN

prophylactic	NN
T	NN

cranial	JJ
T	NN

irradiation	NN
T	NN

halves	NNS
O	NN

the	DT
O	NN

rate	NN
O	NN

of	IN
O	NN

brain	NN
O	NN

metastases	NNS
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

objectives	NNS
O	VBP

:	:
O	NN

this	DT
O	NN

study	NN
O	NN

aims	NNS
O	NN

to	TO
O	NN

test	NN
O	NN

whether	IN
O	NN

prophylactic	NN
T	NN

cranial	JJ
T	NN

irradiation	NN
T	NN

prolongs	VBZ
O	NN

survival	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

in	IN
O	NN

complete	JJ
O	NN

remission	NN
O	NN

reviewer	NN
O	NN

's	POS
O	NN

conclusions	NNS
O	NN

:	:
O	NN

prophylactic	NN
T	NN

cranial	JJ
T	NN

irradiation	NN
T	NN

significantly	RB
O	NN

improves	VBZ
O	NN

survival	NN
O	NN

and	CC
O	NN

disease-free	JJ
O	NN

survival	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

in	IN
O	NN

complete	JJ
O	NN

remission	NN
O	NN

methods	NNS
O	VBP

:	:
O	NN

non-small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

cells	NNS
O	VBP

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

gemcitabine	NN
T	NN

,	,
O	NN

harvested	VBN
O	NN

,	,
O	NN

and	CC
O	NN

nuclear	JJ
O	NN

extracts	NNS
O	VBP

analyzed	VBN
O	NN

for	IN
O	NN

nf-kappab	JJ
O	NN

dna	NN
O	NN

binding	VBG
O	NN

by	IN
O	NN

electrophoretic	JJ
O	NN

mobility	NN
O	NN

shift	NN
O	NN

assays	NNS
O	NN

novel	JJ
O	NN

treatment	NN
O	NN

strategies	NNS
O	VBP

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

nsclc	NN
D	NN

may	MD
O	NNP

involve	VB
O	NN

chemotherapy	NN
T	NN

combined	JJ
O	NN

with	IN
O	NN

inhibition	NN
O	NN

of	IN
O	NN

nf-kappab-dependent	JJ
O	NN

cell-survival	JJ
O	NN

pathways	NNS
O	VBP

combination	NN
T	NN

chemotherapy	NN
T	NN

is	VBZ
O	NN

the	DT
O	NN

cornerstone	NN
O	NN

of	IN
O	NN

treatment	NN
O	NN

that	IN
O	NN

confers	VBZ
O	NN

a	DT
O	NN

meaningful	JJ
O	NN

survival	NN
O	NN

benefit	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

small-cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

in	IN
O	NN

single-agent	JJ
O	NN

phase	NN
O	NN

ii	LS
O	NN

studies	NNS
O	VBP

,	,
O	NN

irinotecan	JJ
T	NN

yielded	VBD
O	NN

response	NN
O	NN

rates	NNS
O	VBP

between	IN
O	NN

16	CD
O	NN

%	NN
O	NN

and	CC
O	NN

47	CD
O	NN

%	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

previously	RB
O	NN

treated	VBN
O	NN

small-cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

a	DT
O	NN

phase	NN
O	NN

ii	LS
O	NN

study	NN
O	NN

of	IN
O	NN

irinotecan	JJ
T	NN

in	IN
T	NN

combination	NN
T	NN

with	IN
T	NN

cisplatin	NN
T	NN

(	NN
T	NN

platinol	NN
T	NN

)	NN
T	NN

resulted	VBD
O	NN

in	IN
O	NN

a	DT
O	NN

response	NN
O	NN

rate	NN
O	NN

of	IN
O	NN

86	CD
O	NN

%	NN
O	NN

and	CC
O	NN

a	DT
O	NN

median	JJ
O	NN

survival	NN
O	NN

of	IN
O	NN

13.0	CD
O	NN

months	NNS
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

extensive-disease	NN
D	NN

small-cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

based	VBN
O	NN

on	IN
O	NN

these	DT
O	NN

results	NNS
O	VBP

,	,
O	NN

the	DT
O	NN

irinotecan	JJ
T	NN

and	CC
T	NN

cisplatin	NN
T	NN

combination	NN
T	NN

is	VBZ
O	NN

a	DT
O	NN

new	JJ
O	NN

standard	JJ
O	NN

regimen	NN
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

extensive-disease	NN
D	NN

small-cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

background	NN
O	NN

:	:
O	NN

both	DT
O	NN

gemcitabine	NN
T	NN

and	CC
T	NN

etoposide	NN
T	NN

are	VBP
O	NN

active	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

small-cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

sclc	NN
D	NN

)	NN
D	NN

,	,
O	NN

and	CC
O	NN

are	VBP
O	NN

characterised	VBN
O	NN

by	IN
O	NN

mild	JJ
O	NN

toxicity	NN
O	NN

profiles	NNS
O	NN

patients	NNS
O	NN

and	CC
O	NN

methods	NNS
O	VBP

:	:
O	NN

forty-two	CD
O	NN

chemo-naive	JJ
O	NN

extensive	JJ
O	NN

disease	NN
O	NN

sclc	NN
D	NN

patients	NNS
O	NN

were	VBD
O	NN

enrolled	VBN
O	NN

to	TO
O	NN

receive	VB
O	NN

gemcitabine	NN
T	NN

1000	CD
O	NN

mg/m2	NN
O	NN

,	,
O	NN

days	NNS
O	NN

1	CD
O	NN

,	,
O	NN

8	CD
O	NN

and	CC
O	NN

15	CD
O	NN

,	,
O	NN

and	CC
O	NN

etoposide	NN
T	NN

80	CD
O	NN

mg/m2	NN
O	NN

,	,
O	NN

days	NNS
O	NN

8	CD
O	NN

,	,
O	NN

9	CD
O	NN

and	CC
O	NN

10	CD
O	NN

of	IN
O	NN

a	DT
O	NN

28-day	JJ
O	NN

cycle	NN
O	NN

background	NN
O	NN

:	:
O	NN

to	TO
O	NN

find	VB
O	NN

the	DT
O	NN

maximum	NN
O	NN

tolerated	VBN
O	NN

dose	NN
O	NN

for	IN
O	NN

ifosfamide	NN
T	NN

in	IN
T	NN

combination	NN
T	NN

with	IN
T	NN

paclitaxel	NN
T	NN

and	CC
T	NN

carboplatin	NN
T	NN

in	IN
O	NN

small-cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

patients	NNS
O	NN

(	NN
O	NN

sclc	NN
O	NN

)	NN
O	NN

,	,
O	NN

who	WP
O	VBP

are	VBP
O	NN

resistant	JJ
O	NN

to	TO
O	NN

cyclophosphamide	NN
O	NN

,	,
O	NN

doxorubicin	NN
O	NN

and	CC
O	NN

etoposide	NN
O	NN

(	NN
O	NN

cde	NN
O	NN

)	NN
O	NN

conclusions	NNS
O	NN

:	:
O	NN

the	DT
O	NN

maximum	NN
O	NN

tolerated	VBN
O	NN

dose	NN
O	NN

of	IN
O	NN

this	DT
O	NN

combination	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

resistant	JJ
D	NN

sclc	NN
D	NN

is	VBZ
O	NN

ifosfamide	NN
T	NN

2000	CD
O	NN

mg/m2	NN
O	NN

in	IN
O	NN

combination	NN
O	NN

with	IN
O	NN

paclitaxel	NN
T	NN

175	CD
O	NN

mg/m2	NN
O	NN

and	CC
O	NN

carboplatin	NN
T	NN

auc	NN
O	NN

6	CD
O	NN

mg/ml	NN
O	NN

min	NN
O	NN

administered	VBN
O	NN

on	IN
O	NN

the	DT
O	NN

first	RB
O	NN

day	NN
O	NN

of	IN
O	NN

a	DT
O	NN

21-day	JJ
O	NN

cycle	NN
O	NN

many	JJ
O	NN

endobronchial	JJ
T	NN

treatment	NN
T	NN

modalities	NNS
T	NN

are	VBP
O	NN

available	JJ
O	NN

to	TO
O	NN

supplement	NN
O	NN

traditional	JJ
O	NN

therapies	NNS
O	NN

for	IN
O	NN

advanced	JJ
D	NN

lung	NN
D	NN

cancer	NN
D	NN

methods	NNS
O	VBP

:	:
O	NN

the	DT
O	NN

author	NN
O	NN

reviews	NNS
O	VBP

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

several	JJ
O	NN

endobronchial	JJ
T	NN

treatment	NN
T	NN

modalities	NNS
T	NN

that	IN
T	NN

can	MD
T	NN

augment	VBP
T	NN

standard	JJ
T	NN

antitumor	JJ
T	NN

therapies	NNS
T	NN

for	IN
O	NN

advanced	JJ
O	NN

lung	NN
D	NN

cancer	NN
D	NN

,	,
O	NN

including	VBG
O	NN

rigid	JJ
O	NN

and	CC
O	NN

flexible	JJ
O	NN

bronchoscopy	NN
O	NN

,	,
O	NN

laser	NN
O	NN

therapy	NN
O	NN

,	,
O	NN

endobronchial	JJ
O	NN

prosthesis	NN
O	NN

,	,
O	NN

and	CC
O	NN

photodynamic	JJ
O	NN

therapy	NN
O	NN

conclusions	NNS
O	NN

:	:
O	NN

endobronchial	JJ
T	NN

interventions	NNS
T	NN

are	VBP
O	NN

important	JJ
O	NN

adjuncts	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

multimodality	NN
O	NN

management	NN
O	NN

of	IN
O	NN

lung	NN
D	NN

cancer	NN
D	NN

and	CC
O	NN

should	MD
O	NNP

become	VBN
O	NN

standard	JJ
O	NN

considerations	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

management	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
O	NN

lung	NN
O	NN

cancer	NN
O	NN

standard	JJ
O	NN

operations	NNS
O	NN

for	IN
O	NN

lung	NN
D	NN

cancer	NN
D	NN

patients	NNS
O	NN

are	VBP
O	NN

generally	RB
O	NN

accepted	VBN
O	NN

as	IN
O	NN

performing	VBG
O	NN

lobectomy	JJ
T	NN

or	CC
T	NN

pneumonectomy	NN
T	NN

on	IN
O	NN

the	DT
O	NN

tumor	NN
O	NN

baring	VBG
O	NN

lung	NN
O	NN

and	CC
O	NN

ipsilateral	JJ
O	NN

hilar	JJ
O	NN

and	CC
O	NN

mediastinal	JJ
O	NN

lymphadenectomy	NN
O	NN

including	VBG
O	NN

subcarinal	JJ
O	NN

lymph	NN
O	NN

nodes	NNS
O	NN

small	JJ
D	NN

cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

is	VBZ
O	NN

a	DT
O	NN

frequently	RB
O	NN

relapsing	VBG
O	NN

tumor	NN
O	NN

despite	IN
O	NN

a	DT
O	NN

high	JJ
O	NN

rate	NN
O	NN

of	IN
O	NN

response	NN
O	NN

after	IN
O	NN

first-line	JJ
O	NN

chemotherapy	NN
T	NN

for	IN
O	NN

symptomatic	JJ
D	NN

metastases	NNS
D	NN

in	IN
D	NN

bone	NN
D	NN

or	CC
D	NN

brain	NN
D	NN

,	,
O	NN

radiotherapy	NN
T	NN

usually	RB
O	NN

gives	VBZ
O	NN

temporary	JJ
O	NN

palliation	NN
O	NN

for	IN
O	NN

intrathoracic	JJ
D	NN

relapse	NN
D	NN

and	CC
D	NN

severe	JJ
D	NN

obstruction	NN
D	NN

of	IN
D	NN

main	JJ
D	NN

bronchus	NN
D	NN

and/or	CC
D	NN

superior	JJ
D	NN

caval	NN
D	NN

vein	NN
D	NN

,	,
O	NN

radiotherapy	NN
T	NN

is	VBZ
O	NN

a	DT
O	NN

possibility	NN
O	NN

if	IN
O	NN

not	RB
O	NN

given	VBN
O	NN

as	IN
O	NN

part	NN
O	NN

of	IN
O	NN

first-line	JJ
O	NN

treatment	NN
O	NN

tumor	NN
T	NN

vaccines	NNS
T	NN

against	IN
O	NN

gangliosides	NNS
O	NN

that	IN
O	NN

are	VBP
O	NN

expressed	VBN
O	NN

on	IN
O	NN

almost	RB
O	NN

all	DT
O	NN

human	JJ
O	NN

sclc	NN
D	NN

cells	NNS
O	VBP

have	VB
O	NN

been	VBN
O	NN

recently	RB
O	NN

developed	VBN
O	NN

an	DT
O	NN

anti-idiotypic	JJ
T	NN

monoclonal	JJ
T	NN

antibody	NN
T	NN

against	IN
O	NN

the	DT
O	NN

gd3	NN
O	NN

ganglioside	NN
O	NN

,	,
O	NN

bec-2	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

being	VBG
O	NN

evaluated	VBN
O	NN

after	IN
O	NN

chemotherapy	NN
O	NN

in	IN
O	NN

sclc	NN
D	NN

patients	NNS
O	NN

in	IN
O	NN

a	DT
O	NN

european	JJ
O	NN

study	NN
O	NN

the	DT
O	NN

matrix	NN
T	NN

metalloproteinase	NN
T	NN

inhibitors	NNS
T	NN

marimastat	NN
T	NN

and	CC
T	NN

bms-275291	NN
T	NN

are	VBP
O	NN

under	IN
O	NN

evaluation	NN
O	NN

in	IN
O	NN

sclc	NN
D	NN

we	PRP
O	VBP

attempted	VBN
O	NN

a	DT
O	NN

new	JJ
O	NN

regimen	NN
O	NN

of	IN
O	NN

intermittent	JJ
O	NN

administration	NN
O	NN

of	IN
O	NN

5-fu	JJ
T	NN

and	CC
T	NN

low-dose	JJ
T	NN

isovorin	NN
T	NN

(	NN
T	NN

f.i	JJ
T	NN

)	NN
T	NN

to	TO
O	NN

four	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
O	NN

and	CC
O	NN

recurrent	JJ
O	NN

colon	NN
D	NN

cancer	NN
D	NN

purpose/objectives	NNS
O	NN

:	:
O	NN

to	TO
O	NN

describe	VBP
O	NN

the	DT
O	NN

relationship	NN
O	NN

between	IN
O	NN

fatigue	NN
O	NN

and	CC
O	NN

nutritional	JJ
O	NN

status	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

receiving	VBG
O	NN

radiation	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

lung	NN
D	NN

cancer	NN
D	NN

sample	NN
O	NN

:	:
O	NN

45	CD
O	NN

adults	NNS
O	NN

with	IN
O	NN

primary	JJ
O	NN

cancer	NN
D	NN

of	IN
D	NN

the	DT
D	NN

lung	NN
D	NN

receiving	VBG
O	NN

<	JJR
O	NN

outpatient	NN
O	NN

primary	JJ
O	NN

or	CC
O	NN

adjuvant	JJ
O	NN

radiation	NN
T	NN

therapy	NN
T	NN

we	PRP
O	VBP

present	JJ
O	NN

the	DT
O	NN

case	NN
O	NN

of	IN
O	NN

a	DT
O	NN

patient	NN
O	NN

with	IN
O	NN

metastatic	JJ
D	NN

transitional	JJ
D	NN

cell	NN
D	NN

carcinoma	NN
D	NN

of	IN
D	NN

the	DT
D	NN

bladder	NN
D	NN

and	CC
D	NN

renal	JJ
D	NN

failure	NN
D	NN

who	WP
O	VBP

underwent	VBD
O	NN

successful	JJ
O	NN

systemic	JJ
T	NN

chemotherapy	NN
T	NN

with	IN
T	NN

paclitaxel	NN
T	NN

and	CC
T	NN

carboplatin	NN
T	NN

background	NN
O	NN

:	:
O	NN

the	DT
O	NN

objective	JJ
O	NN

of	IN
O	NN

this	DT
O	NN

phase	NN
O	NN

ii	LS
O	NN

study	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

evaluate	VB
O	NN

the	DT
O	NN

concept	NN
O	NN

of	IN
O	NN

sequential	JJ
T	NN

chemotherapy	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

nonsmall	NN
D	NN

cell	NN
D	NN

lung	NN
D	NN

carcinoma	NN
D	NN

(	NN
D	NN

nsclc	NN
D	NN

)	NN
D	NN

by	IN
O	NN

the	DT
O	NN

administration	NN
O	NN

of	IN
O	NN

carboplatin	NN
T	NN

plus	CC
T	NN

gemcitabine	NN
T	NN

followed	VBN
T	NN

by	IN
T	NN

of	IN
T	NN

paclitaxel	NN
T	NN

conclusions	NNS
O	NN

:	:
O	NN

this	DT
O	NN

study	NN
O	NN

is	VBZ
O	NN

the	DT
O	NN

first	RB
O	NN

to	TO
O	NN

evaluate	VB
O	NN

planned	VBN
T	NN

sequential	JJ
T	NN

chemotherapy	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

nsclc	NN
D	NN

patients	NNS
O	NN

who	WP
O	VBP

benefit	NN
O	NN

from	IN
O	NN

a	DT
O	NN

surgical	JJ
T	NN

resection	NN
T	NN

for	IN
O	NN

non-small-cell	JJ
D	NN

lung	NN
D	NN

cancer	NN
D	NN

with	IN
O	NN

aneuploid	NN
O	NN

dna	NN
O	NN

content	JJ
O	NN

prove	VB
O	NN

to	TO
O	NN

have	VB
O	NN

a	DT
O	NN

higher	JJR
O	NN

risk	NN
O	NN

of	IN
O	NN

death	NN
O	NN

purpose	NN
O	NN

:	:
O	NN

this	DT
O	NN

randomized	VBN
O	NN

trial	NN
O	NN

was	VBD
O	NN

designed	VBN
O	NN

to	TO
O	NN

determine	VB
O	NN

whether	IN
O	NN

paclitaxel	NN
T	NN

plus	CC
T	NN

carboplatin	NN
T	NN

(	NN
T	NN

pc	NN
T	NN

)	NN
T	NN

offered	VBN
O	NN

a	DT
O	NN

survival	NN
O	NN

advantage	NN
O	NN

over	IN
O	NN

vinorelbine	NN
T	NN

plus	CC
T	NN

cisplatin	NN
T	NN

(	NN
T	NN

vc	NN
T	NN

)	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

non	JJ
D	NN

--	:
D	NN

small-cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

conclusion	NN
O	NN

:	:
O	NN

pc	NN
T	NN

is	VBZ
O	NN

equally	RB
O	NN

efficacious	JJ
O	NN

as	IN
O	NN

vc	NN
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

advanced	JJ
D	NN

non	JJ
D	NN

--	:
D	NN

small-cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

purpose	NN
O	NN

:	:
O	NN

a	DT
O	NN

prospective	JJ
O	NN

randomized	VBN
O	NN

trial	NN
O	NN

in	IN
O	NN

small-cell	NN
O	NN

lung	NN
O	NN

cancer	NN
O	NN

(	NN
O	NN

sclc	NN
O	NN

)	NN
O	NN

was	VBD
O	NN

performed	VBN
O	NN

to	TO
O	NN

determine	VB
O	NN

if	IN
O	NN

intensification	NN
O	NN

of	IN
O	NN

the	DT
O	NN

platinum	NN
O	NN

dose	NN
O	NN

by	IN
O	NN

giving	VBG
O	NN

cisplatin	NN
T	NN

and	CC
T	NN

carboplatin	NN
T	NN

in	IN
O	NN

combination	NN
O	NN

to	TO
O	NN

patients	NNS
O	NN

with	IN
O	NN

sclc	NN
D	NN

yields	NNS
O	VBP

higher	JJR
O	NN

response	NN
O	NN

rates	NNS
O	VBP

and	CC
O	NN

survival	NN
O	NN

,	,
O	NN

than	IN
O	NN

carboplatin	NN
T	NN

alone	RB
T	NN

in	IN
T	NN

a	DT
T	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

regimen	NN
T	NN

conclusions	NNS
O	NN

:	:
O	NN

the	DT
O	NN

intensification	NN
T	NN

of	IN
T	NN

platinum	NN
T	NN

dose	NN
T	NN

(	NN
T	NN

cisplatin	NN
T	NN

plus	CC
T	NN

carboplatin	NN
T	NN

)	NN
T	NN

in	IN
T	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

significantly	RB
O	NN

increased	VBN
O	NN

the	DT
O	NN

complete	JJ
O	NN

response	NN
O	NN

rate	NN
O	NN

,	,
O	NN

overall	JJ
O	NN

survival	NN
O	NN

and	CC
O	NN

number	NN
O	NN

of	IN
O	NN

two-year	JJ
O	NN

survivors	NNS
O	NN

among	IN
O	NN

sclc	NN
D	NN

patients	NNS
O	NN

with	IN
O	NN

limited	JJ
O	NN

disease	NN
O	NN

compared	VBN
O	NN

to	TO
O	NN

combination	NN
T	NN

therapy	NN
T	NN

with	IN
T	NN

carboplatin	NN
T	NN

alone	RB
T	NN

,	,
O	NN

suggesting	VBG
O	NN

that	IN
O	NN

a	DT
O	NN

more	RBR
O	NN

aggressive	JJ
O	NN

treatment	NN
O	NN

to	TO
O	NN

this	DT
O	NN

category	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

is	VBZ
O	NN

worthwhile	JJ
O	NN

,	,
O	NN

while	IN
O	NN

no	DT
O	NN

difference	NN
O	NN

in	IN
O	NN

treatment	NN
O	NN

outcome	NN
O	NN

was	VBD
O	NN

observed	VBN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

extensive	JJ
O	NN

disease	NN
O	NN

the	DT
O	NN

aim	NN
O	NN

of	IN
O	NN

this	DT
O	NN

study	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

investigate	VB
O	NN

the	DT
O	NN

relationships	NNS
O	NN

among	IN
O	NN

technetium-99m	NN
O	NN

tetrofosmin	JJ
O	NN

(	NN
O	NN

tc-tf	JJ
O	NN

)	NN
O	NN

accumulation	NN
O	NN

in	IN
O	NN

untreated	JJ
O	NN

small	JJ
O	NN

cell	NN
O	NN

lung	NN
O	NN

cancer	NN
O	NN

(	NN
O	NN

sclc	NN
O	NN

)	NN
O	NN

,	,
O	NN

the	DT
O	NN

expression	NN
O	NN

of	IN
O	NN

p-glycoprotein	NN
O	NN

(	NN
O	NN

pgp	NN
O	NN

)	NN
O	NN

and	CC
O	NN

multidrug	JJ
O	NN

resistance	NN
O	NN

related	JJ
O	NN

protein-1	NN
O	NN

(	NN
O	NN

mrp1	NN
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

the	DT
O	NN

response	NN
O	NN

to	TO
O	NN

chemotherapy	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

untreated	JJ
D	NN

sclc	NN
D	NN

tc-tf	JJ
O	NN

chest	NN
O	NN

scintigraphy	NN
O	NN

correlated	VBD
O	NN

well	RB
O	NN

with	IN
O	NN

pgp	NN
O	NN

or	CC
O	NN

mrp1	NN
O	NN

expression	NN
O	NN

and	CC
O	NN

accurately	RB
O	NN

predicted	VBN
O	NN

the	DT
O	NN

response	NN
O	NN

to	TO
O	NN

chemotherapy	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

sclc	NN
D	NN

exploratory	JJ
T	NN

interventions	NNS
T	NN

,	,
T	NN

partial	JJ
T	NN

tumor	NN
T	NN

resections	NNS
T	NN

and	CC
T	NN

lung	NN
T	NN

resections	NNS
T	NN

for	IN
O	NN

metastasis	NN
D	NN

were	VBD
O	NN

more	RBR
O	NN

frequently	RB
O	NN

performed	VBN
O	NN

in	IN
O	NN

young	JJ
O	NN

patients	NNS
O	NN

than	IN
O	NN

in	IN
O	NN

older	JJR
O	NN

patients	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

present	JJ
O	NN

report	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

reviewed	VBN
O	NN

articles	NNS
O	NN

on	IN
O	NN

pulmonary	JJ
T	NN

angiography	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

pulmonary	JJ
D	NN

hypertension	NN
D	NN

prophylactic	NN
T	NN

cranial	JJ
T	NN

irradiation	NN
T	NN

(	NN
T	NN

pci	NN
T	NN

)	NN
T	NN

has	VBZ
O	NN

been	VBN
O	NN

demonstrated	VBD
O	NN

to	TO
O	NN

significantly	RB
O	NN

reduce	VB
O	NN

the	DT
O	NN

incidence	NN
O	NN

of	IN
O	NN

brain	NN
O	NN

relapse	NN
O	NN

from	IN
O	NN

limited	JJ
D	NN

disease	NN
D	NN

small-cell	NN
D	NN

lung	NN
D	NN

cancer	NN
D	NN

(	NN
D	NN

ld	NN
D	NN

sclc	NN
D	NN

)	NN
D	NN

,	,
O	NN

but	CC
O	NNP

concerns	NNS
O	NN

about	IN
O	NN

neurologic	JJ
O	NN

toxicity	NN
O	NN

remain	VBP
O	NN

thus	RB
O	NN

,	,
O	NN

twice-daily	JJ
O	NN

pci	NN
T	NN

should	MD
O	NNP

be	VB
O	NN

considered	VBN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

ld	NN
D	NN

sclc	NN
D	NN

who	WP
O	VBP

achieve	VB
O	NN

a	DT
O	NN

complete	JJ
O	NN

response	NN
O	NN

to	TO
O	NN

chemoirradiation	NN
O	NN

animal	NN
O	NN

studies	NNS
O	VBP

suggest	VBP
O	NN

that	IN
O	NN

the	DT
O	NN

kidney	NN
O	NN

is	VBZ
O	NN

involved	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

elimination	NN
O	NN

of	IN
O	NN

recombinant	JJ
T	NN

human	JJ
T	NN

granulocyte	NN
T	NN

colony-stimulating	JJ
T	NN

factor	NN
T	NN

(	NN
T	NN

rhg-csf	JJ
T	NN

)	NN
T	NN

,	,
O	NN

which	WDT
O	NN

is	VBZ
O	NN

used	VBN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

neutropenia	NN
D	NN

during	IN
O	NN

cancer	NN
D	NN

chemotherapy	NN
T	NN

amifostine	NN
T	NN

(	NN
T	NN

wr-2721	NN
T	NN

)	NN
T	NN

is	VBZ
O	NN

a	DT
O	NN

cytoprotective	JJ
O	NN

agent	NN
O	NN

that	IN
O	NN

protects	VBZ
O	NN

a	DT
O	NN

broad	JJ
O	NN

range	NN
O	NN

of	IN
O	NN

normal	JJ
O	NN

tissues	NNS
O	NN

from	IN
O	NN

the	DT
O	NN

toxic	JJ
D	NN

effects	NNS
D	NN

of	IN
D	NN

chemotherapy	NN
D	NN

and	CC
D	NN

radiotherapy	NN
D	NN

without	IN
O	NN

attenuating	VBG
O	NN

tumour	NN
O	NN

response	NN
O	NN

in	IN
O	NN

a	DT
O	NN

pivotal	JJ
O	NN

phase	NN
O	NN

iii	LS
O	NN

trial	NN
O	NN

,	,
O	NN

242	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

ovarian	JJ
D	NN

cancer	NN
D	NN

were	VBD
O	NN

randomised	VBN
O	NN

to	TO
O	NN

receive	VB
O	NN

treatment	NN
O	NN

with	IN
O	NN

cisplatin	NN
T	NN

100	CD
O	NN

mg/m2	NN
O	NN

and	CC
O	NN

cyclophosphamide	NN
T	NN

1000	CD
O	NN

mg/m2	NN
O	NN

every	DT
O	NN

3	CD
O	NN

weeks	NNS
O	NN

with	IN
O	NN

or	CC
O	NN

without	IN
O	NN

pretreatment	NN
O	NN

with	IN
O	NN

intravenous	JJ
O	NN

amifostine	NN
O	NN

910	CD
O	NN

mg/m2	NN
O	NN

over	IN
O	NN

6	CD
O	NN

cycles	NNS
O	VBP

of	IN
O	NN

therapy	NN
O	NN

,	,
O	NN

amifostine	NN
T	NN

significantly	RB
O	NN

reduced	VBN
O	NN

haematological	JJ
D	NN

,	,
D	NN

renal	JJ
D	NN

and	CC
D	NN

neurological	JJ
D	NN

toxicities	NNS
D	NN

:	:
O	NN

treatment	NN
O	NN

delays	NNS
O	VBP

,	,
O	NN

treatment	NN
O	NN

discontinuation	NN
O	NN

and	CC
O	NN

days	NNS
O	NN

in	IN
O	NN

hospital	NN
O	NN

related	JJ
O	NN

to	TO
O	NN

these	DT
O	NN

adverse	JJ
O	NN

events	NNS
O	NN

were	VBD
O	NN

also	RB
O	NN

significantly	RB
O	NN

reduced	VBN
O	NN

in	IN
O	NN

patients	NNS
O	NN

receiving	VBG
O	NN

amifostine	NN
O	NN

versus	CC
O	NN

patients	NNS
O	NN

receiving	VBG
O	NN

chemotherapy	NN
O	NN

alone	RB
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

in	IN
O	NN

another	DT
O	NN

randomised	VBN
O	NN

phase	NN
O	NN

iii	LS
O	NN

trial	NN
O	NN

in	IN
O	NN

303	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

head	NN
D	NN

and	CC
D	NN

neck	NN
D	NN

cancer	NN
D	NN

undergoing	VBG
O	NN

irradiation	NN
T	NN

therapy	NN
T	NN

(	NN
O	NN

total	JJ
O	NN

dose	NN
O	NN

50	CD
O	NN

to	TO
O	NN

70gy	JJ
O	NN

)	NN
O	NN

,	,
O	NN

pretreatment	NN
O	NN

with	IN
O	NN

intravenous	JJ
O	NN

amifostine	NN
T	NN

200	CD
O	NN

mg/m2	NN
O	NN

significantly	RB
O	NN

reduced	VBN
O	NN

the	DT
O	NN

incidence	NN
O	NN

of	IN
O	NN

acute	JJ
O	NN

and	CC
O	NN

late	RB
O	NN

grade	NN
O	NN

>	JJR
O	NN

or	CC
O	NN

=2	NN
O	NN

xerostomia	NN
D	NN

amifostine	NN
T	NN

(	NN
O	NN

340	CD
O	NN

mg/m2	NN
O	NN

)	NN
O	NN

also	RB
O	NN

provided	VBN
O	NN

significant	JJ
O	NN

protection	NN
O	NN

against	IN
O	NN

pneumonitis	NN
D	NN

and	CC
D	NN

oesophagitis	NN
D	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

lung	NN
D	NN

cancer	NN
D	NN

receiving	VBG
O	NN

thoracic	JJ
T	NN

irradiation	NN
T	NN

in	IN
O	NN

a	DT
O	NN

preliminary	JJ
O	NN

report	NN
O	NN

from	IN
O	NN

a	DT
O	NN

phase	NN
O	NN

iii	LS
O	NN

trial	NN
O	NN

(	NN
O	NN

n	NN
O	NN

=	JJ
O	NN

144	CD
O	NN

)	NN
O	NN

amifostine	NN
T	NN

has	VBZ
O	NN

also	RB
O	NN

been	VBN
O	NN

shown	VBN
O	NN

to	TO
O	NN

stimulate	VB
O	NN

haematopoietic	JJ
O	NN

stem	NN
O	NN

cells	NNS
O	VBP

and	CC
O	NN

has	VBZ
O	NN

been	VBN
O	NN

investigated	VBN
O	NN

as	IN
O	NN

a	DT
O	NN

therapy	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

myelodysplastic	JJ
D	NN

syndrome	NN
D	NN

in	IN
O	NN

number	NN
O	NN

of	IN
O	NN

small	JJ
O	NN

preliminary	JJ
O	NN

studies	NNS
O	VBP

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

conclusion	NN
O	NN

:	:
O	NN

the	DT
O	NN

results	NNS
O	VBP

of	IN
O	NN

phase	NN
O	NN

iii	LS
O	NN

trials	NNS
O	NN

have	VB
O	NN

confirmed	VBN
O	NN

the	DT
O	NN

safety	NN
O	NN

and	CC
O	NN

efficacy	NN
O	NN

of	IN
O	NN

amifostine	NN
T	NN

as	IN
O	NN

a	DT
O	NN

cytoprotectant	JJ
O	NN

to	TO
O	NN

ameliorate	VB
O	NN

cisplatin-induced	JJ
D	NN

cumulative	JJ
D	NN

renal	JJ
D	NN

toxicity	NN
D	NN

,	,
O	NN

for	IN
O	NN

which	WDT
O	NN

it	PRP
O	NN

is	VBZ
O	NN

the	DT
O	NN

only	RB
O	NN

agent	NN
O	NN

proven	JJ
O	NN

to	TO
O	NN

be	VB
O	NN

effective	JJ
O	NN

,	,
O	NN

and	CC
O	NN

neutropenia	NN
D	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
O	NN

ovarian	JJ
O	NN

cancer	NN
O	NN

,	,
O	NN

and	CC
O	NN

to	TO
O	NN

reduce	VB
O	NN

xerostomia	NN
D	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

head	NN
D	NN

and	CC
D	NN

neck	NN
D	NN

cancer	NN
D	NN

receiving	VBG
O	NN

irradiation	NN
T	NN

therapy	NN
T	NN

depending	VBG
O	NN

on	IN
O	NN

the	DT
O	NN

outcome	NN
O	NN

of	IN
O	NN

numerous	JJ
O	NN

ongoing	JJ
O	NN

clinical	JJ
O	NN

trials	NNS
O	NN

,	,
O	NN

amifostine	NN
T	NN

may	MD
O	NNP

eventually	RB
O	NN

find	VB
O	NN

broader	JJR
O	NN

clinical	JJ
O	NN

applications	NNS
O	NN

,	,
O	NN

both	DT
O	NN

as	IN
O	NN

a	DT
O	NN

cytoprotectant	JJ
O	NN

and	CC
O	NN

as	IN
O	NN

a	DT
O	NN

potential	JJ
O	NN

therapy	NN
O	NN

in	IN
O	NN

myelodysplastic	JJ
D	NN

syndrome	NN
D	NN

to	TO
O	NN

perform	VB
O	NN

a	DT
O	NN

curative	JJ
O	NN

operation	NN
O	NN

for	IN
O	NN

the	DT
O	NN

lung	NN
D	NN

cancer	NN
D	NN

without	IN
O	NN

myocardial	JJ
O	NN

infarction	NN
O	NN

,	,
O	NN

minimally	RB
T	NN

invasive	JJ
T	NN

direct	JJ
T	NN

coronary	JJ
T	NN

artery	NN
T	NN

bypass	NN
T	NN

and	CC
T	NN

left	VBN
T	NN

lower	JJR
T	NN

lobectomy	JJ
T	NN

with	IN
T	NN

video-endoscopic	JJ
T	NN

assistance	NN
T	NN

were	VBD
O	NN

performed	VBN
O	NN

simultaneously	RB
O	NN

A	DT
O	NN

review	NN
O	NN

of	IN
O	NN

the	DT
O	NN

fetal-maternal	JJ
O	NN

carboxyhemoglobin	NN
O	NN

relationships	NNS
O	NN

and	CC
O	NN

the	DT
O	NN

differences	NNS
O	NN

in	IN
O	NN

fetal	JJ
O	NN

oxyhemoglobin	NN
O	NN

physiology	NN
O	NN

are	VBP
O	NN

used	VBN
O	NN

to	TO
O	NN

explain	VB
O	NN

the	DT
O	NN

recommendation	NN
O	NN

that	IN
O	NN

pregnant	JJ
O	NN

women	NNS
O	VBP

with	IN
O	NN

carbon	NN
D	NN

monoxide	NN
D	NN

poisoning	NN
D	NN

should	MD
O	NNP

receive	VB
O	NN

100	CD
O	NN

%	NN
O	NN

oxygen	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

up	RB
O	NN

to	TO
O	NN

five	CD
O	NN

times	NNS
O	NN

longer	RB
O	NN

than	IN
O	NN

is	VBZ
O	NN

otherwise	RB
O	NN

necessary	JJ
O	NN

The	DT
O	NN

authors	NNS
O	NN

describe	VBP
O	NN

the	DT
O	NN

case	NN
O	NN

of	IN
O	NN

a	DT
O	NN

child	NN
O	NN

with	IN
O	NN

status	NN
D	NN

epilepticus	NN
D	NN

in	IN
O	NN

whom	WP
O	NN

phenytoin	NN
T	NN

was	VBD
O	NN

administered	VBN
O	NN

via	IN
O	NN

the	DT
O	NN

intraosseous	JJ
O	NN

route	NN
O	NN

,	,
O	NN

and	CC
O	NN

seizure	NN
O	NN

resolution	NN
O	NN

and	CC
O	NN

therapeutic	JJ
O	NN

serum	NN
O	NN

levels	NNS
O	VBP

were	VBD
O	NN

achieved	VBN
O	NN

A	DT
O	NN

patient	NN
O	NN

suffering	VBG
O	NN

baclofen	NN
D	NN

overdose	NN
D	NN

successfully	RB
O	NN

treated	VBN
O	NN

with	IN
O	NN

atropine	NN
T	NN

is	VBZ
O	NN

reported	VBN
O	NN

Atropine	NNP
T	NN

appears	VBZ
O	NN

to	TO
O	NN

be	VB
O	NN

useful	JJ
O	NN

in	IN
O	NN

treating	VBG
O	NN

cases	NNS
O	NN

of	IN
O	NN

baclofen	NN
D	NN

overdose	NN
D	NN

complicated	JJ
O	NN

by	IN
O	NN

bradycardia	NN
O	NN

and	CC
O	NN

hypotension	NN
O	NN

Therapeutic	JJ
O	NN

effect	NN
O	NN

of	IN
O	NN

a	DT
O	NN

left	VBN
T	NN

ventricular	JJ
T	NN

assist	VB
T	NN

device	NN
T	NN

on	IN
O	NN

acute	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

evaluated	VBN
O	NN

by	IN
O	NN

magnetic	JJ
O	NN

resonance	NN
O	NN

imaging	NN
O	NN

Continuous	JJ
T	NN

arteriovenous	JJ
T	NN

hemofiltration	NN
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

anasarca	NN
D	NN

and	CC
D	NN

acute	JJ
D	NN

renal	JJ
D	NN

failure	NN
D	NN

in	IN
O	NN

severely	RB
O	NN

burned	VBN
O	NN

patients	NNS
O	NN

Continuous	JJ
T	NN

renal	JJ
T	NN

replacement	NN
T	NN

therapy	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

acute	JJ
D	NN

renal	JJ
D	NN

dysfunction	NN
D	NN

undergoing	VBG
O	NN

intraaortic	JJ
O	NN

balloon	NN
O	NN

pump	NN
O	NN

and/or	CC
O	NN

left	RB
O	NN

ventricular	JJ
O	NN

device	NN
O	NN

support	NN
O	NN

Continuous	JJ
T	NN

arterio-venous	JJ
T	NN

hemofiltration	NN
T	NN

in	IN
O	NN

a	DT
O	NN

wearable	JJ
O	NN

device	NN
O	NN

to	TO
O	NN

treat	VB
O	NNP

end-stage	NN
D	NN

renal	JJ
D	NN

disease	NN
D	NN

The	DT
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

neostigmine	NN
T	NN

0.07	CD
T	NN

mg	NN
T	NN

kg-1	NN
T	NN

and	CC
T	NN

edrophonium	NN
T	NN

0.8	CD
O	NN

mg	NN
O	NN

kg-1	NN
O	NN

as	IN
O	NN

antagonists	NNS
O	NN

of	IN
O	NN

profound	JJ
D	NN

neuromuscular	JJ
D	NN

blockade	NN
D	NN

induced	VBN
O	NN

by	IN
O	NN

vecuronium	NN
O	NN

0.1	CD
O	NN

mg	NN
O	NN

kg-1	NN
O	NN

or	CC
O	NN

atracurium	NN
O	NN

0.5	CD
O	NN

mg	NN
O	NN

kg-1	NN
O	NN

was	VBD
O	NN

studied	VBN
O	NN

in	IN
O	NN

59	CD
O	NN

healthy	JJ
O	NN

patients	NNS
O	NN

Antagonism	NN
O	NN

of	IN
O	NN

atracurium-induced	JJ
O	NN

neuromuscular	JJ
D	NN

blockade	NN
D	NN

by	IN
O	NN

neostigmine	NN
T	NN

or	CC
T	NN

edrophonium	NN
T	NN

has	VBZ
O	NN

been	VBN
O	NN

studied	VBN
O	NN

using	VBG
O	NN

the	DT
O	NN

tetanic	JJ
O	NN

(	NN
O	NN

50	CD
O	NN

Hz	NN
O	NN

)	NN
O	NN

and	CC
O	NN

train-of-four	JJ
O	NN

(	NN
O	NN

2	CD
O	NN

Hz	NN
O	NN

)	NN
O	NN

or	CC
O	NN

single	JJ
O	NN

twitch	VB
O	NN

responses	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

adductor	NN
O	NN

pollicis	NN
O	NN

muscle	NN
O	NN

in	IN
O	NN

22	CD
O	NN

anaesthetized	VBN
O	NN

patients	NNS
O	NN

Active	JJ
T	NN

forms	NNS
T	NN

of	IN
T	NN

vitamin	NN
T	NN

D3	NN
T	NN

,	,
T	NN

1	CD
T	NN

alpha-hydroxyvitamin	JJ
T	NN

D3	NN
T	NN

and	CC
T	NN

1	CD
T	NN

alpha	NN
T	NN

,	,
T	NN

25-dihydroxyvitamin	NN
T	NN

D3	NN
T	NN

,	,
O	NN

were	VBD
O	NN

administered	VBN
O	NN

in	IN
O	NN

an	DT
O	NN

open-design	JJ
O	NN

study	NN
O	NN

to	TO
O	NN

40	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

psoriasis	NN
D	NN

vulgaris	NN
D	NN

in	IN
O	NN

three	CD
O	NN

ways	NNS
O	NN

:	:
O	NN

to	TO
O	NN

17	CD
O	NN

patients	NNS
O	NN

1	CD
O	NN

alpha-hydroxyvitamin	JJ
O	NN

D3	NN
O	NN

was	VBD
O	NN

given	VBN
O	NN

orally	RB
O	NN

at	IN
O	NN

a	DT
O	NN

dose	NN
O	NN

of	IN
O	NN

1.0	CD
O	NN

micrograms/day	NN
O	NN

for	IN
O	NN

6	CD
O	NN

months	NNS
O	NN

,	,
O	NN

to	TO
O	NN

four	CD
O	NN

patients	NNS
O	NN

1	CD
O	NN

alpha	NN
O	NN

,	,
O	NN

25-dihydroxyvitamin	NN
O	NN

D3	NN
O	NN

was	VBD
O	NN

given	VBN
O	NN

orally	RB
O	NN

at	IN
O	NN

a	DT
O	NN

dose	NN
O	NN

of	IN
O	NN

0.5	CD
O	NN

microgram/day	NNS
O	NN

for	IN
O	NN

6	CD
O	NN

months	NNS
O	NN

,	,
O	NN

and	CC
O	NN

19	CD
O	NN

patients	NNS
O	NN

were	VBD
O	NN

given	VBN
O	NN

1	CD
O	NN

alpha	NN
O	NN

,	,
O	NN

25-dihydroxyvitamin	NN
O	NN

D3	NN
O	NN

applied	VBN
O	NN

topically	RB
O	NN

at	IN
O	NN

concentration	NN
O	NN

of	IN
O	NN

0.5	CD
O	NN

microgram/g	NN
O	NN

of	IN
O	NN

base	NN
O	NN

for	IN
O	NN

8	CD
O	NN

weeks	NNS
O	NN

These	DT
O	NN

data	NNS
O	NN

suggest	VBP
O	NN

that	IN
O	NN

psoriasis	NN
D	NN

may	MD
O	NNP

respond	NN
O	NN

to	TO
O	NN

active	JJ
T	NN

metabolites	NNS
T	NN

of	IN
T	NN

vitamin	NN
T	NN

D3	NN
T	NN

and	CC
O	NN

that	IN
O	NN

abnormalities	NNS
O	NN

in	IN
O	NN

vitamin	NN
O	NN

D	NN
O	NN

metabolism	NN
O	NN

or	CC
O	NN

in	IN
O	NN

responsiveness	NN
O	NN

of	IN
O	NN

the	DT
O	NN

skin	NN
O	NN

cells	NNS
O	VBP

to	TO
O	NN

active	JJ
O	NN

metabolites	NNS
O	VBP

of	IN
O	NN

vitamin	NN
O	NN

D	NN
O	NN

may	MD
O	NNP

be	VB
O	NN

involved	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

pathogenesis	NN
O	NN

of	IN
O	NN

this	DT
O	NN

skin	NN
O	NN

disease	NN
O	NN

Successful	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

psoriasis	NN
D	NN

with	IN
O	NN

topical	JJ
O	NN

application	NN
O	NN

of	IN
O	NN

active	JJ
T	NN

vitamin	NN
T	NN

D3	NN
T	NN

analogue	NN
T	NN

,	,
T	NN

1	CD
T	NN

alpha	NN
T	NN

,	,
T	NN

24-dihydroxycholecalciferol	JJ
T	NN

We	PRP
O	VBP

suggest	VBP
O	NN

that	IN
O	NN

1	CD
T	NN

alpha	NN
T	NN

,	,
T	NN

24	CD
T	NN

(	NN
T	NN

OH	NN
T	NN

)	NN
T	NN

2D3	NN
T	NN

merits	NNS
O	NN

further	RB
O	NN

investigation	NN
O	NN

as	IN
O	NN

a	DT
O	NN

potentially	RB
O	NN

useful	JJ
O	NN

topical	JJ
O	NN

therapy	NN
O	NN

for	IN
O	NN

psoriasis	NN
D	NN

When	WRB
O	NN

indomethacin	NN
T	NN

was	VBD
O	NN

applied	VBN
O	NN

immediately	RB
O	NN

after	IN
O	NN

irradiation	NN
O	NN

,	,
O	NN

UVR	NN
O	NN

(	NN
O	NN

ultraviolet	JJ
O	NN

radiation	NN
O	NN

)	NN
O	NN

dose-dependent	JJ
O	NN

suppression	NN
O	NN

of	IN
O	NN

erythema	NN
D	NN

was	VBD
O	NN

demonstrated	VBD
O	NN

for	IN
O	NN

both	DT
O	NN

wavelengths	NNS
O	NN

until	IN
O	NN

36	CD
O	NN

h	NN
O	NN

after	IN
O	NN

irradiation	NN
O	NN

when	WRB
O	NN

both	DT
O	NN

indomethacin	NN
O	NN

and	CC
O	NN

control	NN
O	NN

gel	NN
O	NN

base-treated	JJ
O	NN

sites	NNS
O	NN

were	VBD
O	NN

equally	RB
O	NN

erythematous	JJ
O	NN

Suppression	NN
O	NN

of	IN
O	NN

erythema	NN
D	NN

also	RB
O	NN

occurred	VBD
O	NN

when	WRB
O	NN

application	NN
O	NN

of	IN
O	NN

indomethacin	NN
T	NN

was	VBD
O	NN

delayed	VBN
O	NN

until	IN
O	NN

24	CD
O	NN

h	NN
O	NN

after	IN
O	NN

irradiation	NN
O	NN

,	,
O	NN

showing	VBG
O	NN

that	IN
O	NN

for	IN
O	NN

both	DT
O	NN

wavelengths	NNS
O	NN

prostaglandin	NN
O	NN

synthesis	NN
O	NN

remains	VBZ
O	NNP

increased	VBN
O	NN

throughout	IN
O	NN

this	DT
O	NN

period	NN
O	NN

There	EX
O	NN

was	VBD
O	NN

one	CD
O	NN

retinal	JJ
O	NN

dialysis	NN
O	NN

,	,
O	NN

and	CC
O	NN

one	CD
O	NN

lens	NN
D	NN

dislocation	NN
D	NN

requiring	VBG
O	NN

extraction	NN
T	NN

Rates	NNP
O	NNP

of	IN
O	NN

superoxide	NN
O	NN

(	NN
O	NN

SA	NNP
O	NNP

)	NN
O	NN

generation	NN
O	NN

by	IN
O	NN

blood	NN
O	NN

monocytes	NNS
O	NN

stimulated	VBN
O	NN

ex	FW
O	FW

vivo	FW
O	FW

were	VBD
O	NN

studied	VBN
O	NN

before	IN
O	NN

and	CC
O	NN

during	IN
O	NN

corticosteroid	NN
T	NN

treatment	NN
O	NN

of	IN
O	NN

rheumatoid	JJ
D	NN

arthritis	NN
D	NN

(	NN
D	NN

RA	NN
D	NN

)	NN
D	NN

patients	NNS
O	NN

,	,
O	NN

in	IN
O	NN

control	NN
O	NN

patients	NNS
O	NN

and	CC
O	NN

in	IN
O	NN

healthy	JJ
O	NN

controls	NNS
O	VBP

Significant	JJ
O	NN

inhibition	NN
O	NN

of	IN
O	NN

monocyte	NN
O	NN

SA	NNP
O	NNP

output	NN
O	NN

stimulated	VBN
O	NN

with	IN
O	NN

IgG-treated	JJ
O	NN

zymosan	NN
O	NN

(	NN
O	NN

ITZ	NN
O	NN

)	NN
O	NN

and	CC
O	NN

fluoride	NN
O	NN

ion	NN
O	NN

(	NN
O	NN

F	NN
O	NN

)	NN
O	NN

,	,
O	NN

but	CC
O	NNP

not	RB
O	NN

serum-treated	JJ
O	NN

zymosan	NN
O	NN

(	NN
O	NN

STZ	NN
O	NN

)	NN
O	NN

was	VBD
O	NN

demonstrated	VBD
O	NN

following	VBG
O	NN

steroid	NN
T	NN

therapy	NN
T	NN

in	IN
O	NN

RA	NN
D	NN

Methotrexate	NNP
T	NN

(	NN
T	NN

MTX	NN
T	NN

)	NN
T	NN

appears	VBZ
O	NN

to	TO
O	NN

be	VB
O	NN

useful	JJ
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

rheumatoid	JJ
D	NN

arthritis	NN
D	NN

(	NN
D	NN

RA	NN
D	NN

)	NN
D	NN

refractory	JJ
O	NN

to	TO
O	NN

other	JJ
O	NN

drugs	NNS
O	NN

but	CC
O	NNP

its	PRP$
O	NN

long-term	JJ
O	NN

toxicity	NN
O	NN

and	CC
O	NN

efficacy	NN
O	NN

are	VBP
O	NN

uncertain	JJ
O	NN

MTX	NN
T	NN

in	IN
O	NN

a	DT
O	NN

low-dose	JJ
O	NN

regimen	NN
O	NN

is	VBZ
O	NN

useful	JJ
O	NN

in	IN
O	NN

refractory	JJ
D	NN

RA	NN
D	NN

and	CC
O	NN

superior	JJ
O	NN

to	TO
O	NN

low-dose	JJ
O	NN

purine	NN
O	NN

analogues	NNS
O	NN

Twelve	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

intractable	JJ
D	NN

rheumatoid	JJ
D	NN

arthritis	NN
D	NN

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

antilymphocyte	JJ
T	NN

globulin	NN
T	NN

(	NN
T	NN

ALG	NN
T	NN

)	NN
T	NN

,	,
T	NN

prednisolone	JJ
T	NN

and	CC
T	NN

a	DT
T	NN

cytotoxic	JJ
T	NN

agent	NN
T	NN

,	,
T	NN

usually	RB
T	NN

azathioprine	NN
T	NN

,	,
O	NN

and	CC
O	NN

were	VBD
O	NN

followed	VBN
O	NN

for	IN
O	NN

1	CD
O	NN

year	NN
O	NN

Rigid	JJ
T	NN

ureteroscopy	JJ
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

ureteric	JJ
D	NN

calculi	NN
D	NN

:	:
O	NN

experience	NN
O	NN

in	IN
O	NN

120	CD
O	NN

cases	NNS
O	NN

Over	IN
O	NN

a	DT
O	NN

1-year	JJ
O	NN

period	NN
O	NN

,	,
O	NN

rigid	JJ
T	NN

ureteroscopy	JJ
T	NN

has	VBZ
O	NN

been	VBN
O	NN

used	VBN
O	NN

to	TO
O	NN

retrieve	VB
O	NN

ureteric	JJ
D	NN

calculi	NN
D	NN

in	IN
O	NN

120	CD
O	NN

patients	NNS
O	NN

Eleven	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

vesicoureteric	JJ
D	NN

reflux	NN
D	NN

secondary	JJ
O	NN

to	TO
O	NN

neuropathic	JJ
O	NN

bladder	NN
O	NN

were	VBD
O	NN

treated	VBN
O	NN

by	IN
O	NN

endoscopic	JJ
T	NN

injection	NN
T	NN

of	IN
T	NN

pyrolised	VBN
T	NN

polytetrafluoroethylene	NN
T	NN

(	NN
T	NN

Polytef	NN
T	NN

)	NN
T	NN

paste	VB
T	NN

Two	CD
O	NN

hundred	CD
O	NN

and	CC
O	NN

seventy-seven	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

prostatic	JJ
D	NN

cancer	NN
D	NN

were	VBD
O	NN

treated	VBN
O	NN

by	IN
O	NN

either	DT
O	NN

orchiectomy	NN
T	NN

or	CC
T	NN

oestrogen	NN
T	NN

Use	NNP
O	NNP

of	IN
O	NN

scarred	VBN
O	NN

flaps	NNS
O	NN

and	CC
O	NN

secondary	JJ
O	NN

flaps	NNS
O	NN

for	IN
O	NN

reconstructive	JJ
T	NN

surgery	NN
T	NN

of	IN
O	NN

extensive	JJ
D	NN

burns	NNS
D	NN

A	DT
O	NN

patient	NN
O	NN

with	IN
O	NN

a	DT
O	NN

vesico-enteric	JJ
D	NN

fistula	NN
D	NN

was	VBD
O	NN

successfully	RB
O	NN

treated	VBN
O	NN

with	IN
O	NN

resection	NN
T	NN

of	IN
T	NN

the	DT
T	NN

small	JJ
T	NN

intestine	NN
T	NN

and	CC
T	NN

dome	NN
T	NN

of	IN
T	NN

the	DT
T	NN

bladder	NN
T	NN

and	CC
T	NN

drainage	NN
T	NN

of	IN
T	NN

the	DT
T	NN

intervening	VBG
T	NN

abscess	NN
T	NN

Supramaximal	JJ
T	NN

horizontal	JJ
T	NN

rectus	NN
T	NN

surgery	NN
T	NN

in	IN
O	NN

the	DT
O	NN

management	NN
O	NN

of	IN
O	NN

third	JJ
D	NN

and	CC
D	NN

sixth	JJ
D	NN

nerve	NN
D	NN

palsy	NN
D	NN

Supramaximal	JJ
T	NN

medial	JJ
T	NN

and	CC
T	NN

lateral	JJ
T	NN

rectus	NN
T	NN

surgery	NN
T	NN

was	VBD
O	NN

performed	VBN
O	NN

to	TO
O	NN

correct	JJ
O	NN

horizontal	JJ
D	NN

deviations	NNS
D	NN

in	IN
D	NN

seven	CD
D	NN

cases	NNS
D	NN

of	IN
D	NN

sixth	JJ
D	NN

nerve	NN
D	NN

palsy	NN
D	NN

and	CC
D	NN

three	CD
D	NN

cases	NNS
D	NN

of	IN
D	NN

third	JJ
D	NN

nerve	NN
D	NN

palsy	NN
D	NN

,	,
O	NN

with	IN
O	NN

satisfactory	JJ
O	NN

results	NNS
O	VBP

in	IN
O	NN

most	JJS
O	NN

cases	NNS
O	NN

Steroid	NN
T	NN

therapy	NN
T	NN

was	VBD
O	NN

also	RB
O	NN

used	VBN
O	NN

in	IN
O	NN

two	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

NSAID-induced	JJ
D	NN

proteinuria	NN
D	NN

Recombinant	JJ
T	NN

leukocyte	NN
T	NN

A	DT
T	NN

interferon	NN
T	NN

(	NN
T	NN

rIFN-alpha	NN
T	NN

A	DT
T	NN

)	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

disseminated	VBN
D	NN

malignant	JJ
D	NN

melanoma	NN
D	NN

Ninety-six	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

disseminated	VBN
D	NN

malignant	JJ
D	NN

melanoma	NN
D	NN

received	VBN
O	NN

thrice	NN
O	NN

weekly	JJ
O	NN

intramuscular	JJ
O	NN

injections	NNS
O	NN

of	IN
O	NN

leukocyte	NN
T	NN

A	DT
T	NN

recombinant	JJ
T	NN

interferon	NN
T	NN

(	NN
T	NN

rIFN-alpha	NN
T	NN

A	DT
T	NN

,	,
T	NN

Roferon-A	NN
T	NN

,	,
T	NN

Hoffmann	NNP
T	NN

La	NNP
T	NN

Roche	NNP
T	NN

)	NN
T	NN

at	IN
O	NN

doses	NNS
O	NN

of	IN
O	NN

12	CD
O	NN

X	NN
O	NN

10	CD
O	NN

(	NN
O	NN

6	CD
O	NN

)	NN
O	NN

U/m2	NN
O	NN

or	CC
O	NN

50	CD
O	NN

X	NN
O	NN

10	CD
O	NN

(	NN
O	NN

6	CD
O	NN

)	NN
O	NN

U/m2	NN
O	NN

with	IN
O	NN

or	CC
O	NN

without	IN
O	NN

cimetidine	NN
O	NN

as	IN
O	NN

an	DT
O	NN

immunorestorative	JJ
O	NN

agent	NN
O	NN

As	IN
O	NN

noted	VBN
O	NN

previously	RB
O	NN

,	,
O	NN

using	VBG
O	NN

chemotherapy	NN
O	NN

,	,
O	NN

a	DT
O	NN

small	JJ
O	NN

proportion	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

malignant	JJ
D	NN

melanoma	NN
D	NN

,	,
O	NN

despite	IN
O	NN

prior	RB
O	NN

therapy	NN
O	NN

,	,
O	NN

may	MD
O	NNP

achieve	VB
O	NN

prolonged	JJ
O	NN

objective	JJ
O	NN

regression	NN
O	NN

with	IN
O	NN

rIFN-alpha	NN
T	NN

A	DT
T	NN

Clinical	JJ
O	NN

course	NN
O	NN

of	IN
O	NN

breast	NN
O	NN

cancer	NN
O	NN

patients	NNS
O	NN

with	IN
O	NN

osseous	JJ
D	NN

metastasis	NN
D	NN

treated	VBN
O	NN

with	IN
O	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

Between	IN
O	NN

July	NNP
O	NNP

1973	CD
O	NN

and	CC
O	NN

December	NNP
O	NN

1979	CD
O	NNP

,	,
O	NN

1171	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

metastatic	JJ
D	NN

breast	NN
D	NN

cancer	NN
D	NN

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

doxorubicin-containing	JJ
T	NN

chemotherapy	NN
T	NN

Two	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

metastatic	JJ
D	NN

dysgerminoma	NN
D	NN

of	IN
D	NN

the	DT
D	NN

ovary	NN
D	NN

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

a	DT
T	NN

combination	NN
T	NN

of	IN
T	NN

etoposide	NN
T	NN

,	,
T	NN

bleomycin	NN
T	NN

,	,
T	NN

and	CC
T	NN

cisplatin	NN
T	NN

at	IN
O	NN

The	DT
O	NN

University	NNP
O	NN

of	IN
O	NN

Texas	NNP
O	NN

M.D	NN
O	NN

Chemotherapy	NN
T	NN

may	MD
O	NNP

be	VB
O	NN

an	DT
O	NN

alternative	JJ
O	NN

to	TO
O	NN

radiotherapy	NN
O	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

metastatic	JJ
D	NN

dysgerminoma	NN
D	NN

and	CC
O	NN

should	MD
O	NNP

also	RB
O	NN

be	VB
O	NN

considered	VBN
O	NN

for	IN
O	NN

selected	VBN
O	NN

patients	NNS
O	NN

with	IN
O	NN

Stage	NN
O	NN

I	PRP
O	VBP

disease	NN
O	NN

Long-term	JJ
O	NN

survival	NN
O	NN

and	CC
O	NN

morbidity	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

metastatic	JJ
D	NN

malignant	JJ
D	NN

germ	NN
D	NN

cell	NN
D	NN

tumors	NNS
D	NN

treated	VBN
O	NN

with	IN
O	NN

cisplatin-based	JJ
T	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

Treatment	NN
O	NN

of	IN
O	NN

advanced	JJ
D	NN

stage	NN
D	NN

mycosis	NN
D	NN

fungoides	NNS
D	NN

with	IN
O	NN

bleomycin	NN
T	NN

,	,
T	NN

doxorubicin	NN
T	NN

,	,
T	NN

and	CC
T	NN

methotrexate	NN
T	NN

with	IN
T	NN

topical	JJ
T	NN

nitrogen	NN
T	NN

mustard	NN
T	NN

(	NN
T	NN

BAM-M	NN
T	NN

)	NN
T	NN

Ten	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

stage	NN
D	NN

(	NN
D	NN

TNM	NN
D	NN

IIB-IVB	NN
D	NN

)	NN
D	NN

mycosis	NN
D	NN

fungoides	NNS
D	NN

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

combination	NN
T	NN

chemotherapy	NN
T	NN

program	NN
T	NN

consisting	VBG
T	NN

of	IN
T	NN

bleomycin	NN
T	NN

and	CC
T	NN

methotrexate	NN
T	NN

weekly	JJ
T	NN

,	,
T	NN

doxorubicin	NN
T	NN

every	DT
T	NN

3	CD
T	NN

weeks	NNS
T	NN

,	,
T	NN

and	CC
T	NN

topical	JJ
T	NN

nitrogen	NN
T	NN

mustard	NN
T	NN

daily	JJ
T	NN

(	NN
T	NN

BAM-M	NN
T	NN

)	NN
T	NN

Three	CD
O	NN

patients	NNS
O	NN

in	IN
O	NN

whom	WP
O	NN

splenomegaly	NN
D	NN

was	VBD
O	NN

detected	VBN
O	NN

during	IN
O	NN

their	PRP$
O	NN

staging	NN
O	NN

evaluation	NN
O	NN

underwent	VBD
O	NN

splenectomy	NN
T	NN

This	DT
O	NN

study	NN
O	NN

indicates	VBZ
O	NN

that	IN
O	NN

BAM-M	NN
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

therapy	NN
O	NN

for	IN
O	NN

advanced	JJ
D	NN

stage	NN
D	NN

mycosis	NN
D	NN

fungoides	NNS
D	NN

and	CC
O	NN

suggests	VBZ
O	NN

that	IN
O	NN

the	DT
O	NN

therapeutic	JJ
O	NN

role	NN
O	NN

of	IN
O	NN

splenectomy	NN
O	NN

should	MD
O	NNP

be	VB
O	NN

evaluated	VBN
O	NN

further	RB
O	NN

Only	RB
O	NN

patients	NNS
O	NN

whose	WP$
O	NN

primary	JJ
D	NN

head	NN
D	NN

and	CC
D	NN

neck	NN
D	NN

tumor	NN
D	NN

shows	NNS
O	VBP

a	DT
O	NN

response	NN
O	NN

to	TO
O	NN

systemic	JJ
O	NN

therapy	NN
O	NN

undergo	VB
O	NN

Ommaya	NNP
T	NN

placement	NN
T	NN

Additional	JJ
O	NN

chemotherapy	NN
T	NN

may	MD
O	NNP

thus	RB
O	NN

have	VB
O	NN

eradicated	VBN
O	NN

these	DT
O	NN

micrometastases	NNS
D	NN

in	IN
O	NN

the	DT
O	NN

older	JJR
O	NN

children	NNS
O	VBP

,	,
O	NN

since	IN
O	NN

the	DT
O	NN

age	NN
O	NN

influence	NN
O	NN

on	IN
O	NN

Stage	NN
O	NN

II	NNP
O	NNP

disease	NN
O	NN

disappeared	VBD
O	NN

when	WRB
O	NN

multimodal	JJ
O	NN

treatment	NN
O	NN

was	VBD
O	NN

given	VBN
O	NN

in	IN
O	NN

this	DT
O	NN

study	NN
O	NN

Traditional	JJ
O	NN

therapy	NN
O	NN

for	IN
O	NN

malignant	JJ
D	NN

pleural	JJ
D	NN

effusions	NNS
D	NN

includes	VBZ
O	NN

thoracentesis	NN
T	NN

or	CC
T	NN

tube	NN
T	NN

drainage	NN
T	NN

with	IN
O	NN

instillation	NN
O	NN

of	IN
O	NN

irritants	NNS
O	VBP

to	TO
O	NN

achieve	VB
O	NN

pleurodesis	NN
O	NN

We	PRP
O	VBP

feel	VB
O	NN

that	IN
O	NN

pleuroperitoneal	NN
T	NN

shunting	VBG
T	NN

is	VBZ
O	NN

a	DT
O	NN

valid	JJ
O	NN

new	JJ
O	NN

method	NN
O	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

malignant	JJ
D	NN

pleural	JJ
D	NN

effusions	NNS
D	NN

which	WDT
O	NN

can	MD
O	NNP

effectively	RB
O	NN

palliate	VB
O	NN

respiratory	JJ
O	NN

symptoms	NNS
O	NN

with	IN
O	NN

low	JJ
O	NN

morbidity	NN
O	NN

When	WRB
O	NN

right	NN
D	NN

ventricular	JJ
D	NN

failure	NN
D	NN

prohibits	VBZ
O	NN

separation	NN
O	NN

from	IN
O	NN

cardiopulmonary	JJ
O	NN

bypass	NN
O	NN

,	,
O	NN

standard	JJ
T	NN

methods	NNS
T	NN

of	IN
T	NN

increasing	VBG
T	NN

pulmonary	JJ
T	NN

blood	NN
T	NN

flow	NN
T	NN

should	MD
O	NNP

be	VB
O	NN

employed	VBN
O	NN

,	,
O	NN

including	VBG
O	NN

correction	NN
O	NN

of	IN
O	NN

hypoxia	NN
O	NN

and	CC
O	NN

acidosis	NN
O	NN

,	,
O	NN

volume	NN
O	NN

loading	VBG
O	NN

,	,
O	NN

and	CC
O	NN

inotropic	JJ
O	NN

support	NN
O	NN

of	IN
O	NN

the	DT
O	NN

right	RB
O	NN

ventricle	NN
O	NN

For	IN
O	NN

refractory	JJ
D	NN

right	NN
D	NN

ventricular	JJ
D	NN

failure	NN
D	NN

following	VBG
O	NN

the	DT
O	NN

surgical	JJ
O	NN

repair	NN
O	NN

of	IN
O	NN

congenital	JJ
O	NN

cardiac	JJ
O	NN

defects	NNS
O	NN

in	IN
O	NN

which	WDT
O	NN

the	DT
O	NN

placement	NN
O	NN

of	IN
O	NN

right	RB
O	NN

atrial	JJ
O	NN

and	CC
O	NN

pulmonary	JJ
O	NN

artery	NN
O	NN

cannulae	FW
O	FW

is	VBZ
O	NN

not	RB
O	NN

technically	RB
O	NN

feasible	JJ
O	NN

,	,
O	NN

use	NN
T	NN

of	IN
T	NN

high-frequency	VB
T	NN

high-volume	JJ
T	NN

ventilation	NN
T	NN

appears	VBZ
O	NN

to	TO
O	NN

be	VB
O	NN

quite	RB
O	NN

promising	JJ
O	NN

Current	JJ
O	NN

results	NNS
O	VBP

suggest	VBP
O	NN

that	IN
O	NN

RHBP	NN
T	NN

remains	VBZ
O	NNP

the	DT
O	NN

gold	NN
O	NN

standard	JJ
O	NN

for	IN
O	NN

severe	JJ
D	NN

RV	NN
D	NN

failure	NN
D	NN

,	,
O	NN

but	CC
O	NNP

further	RB
O	NN

clinical	JJ
O	NN

experience	NN
O	NN

with	IN
O	NN

PABC	NN
O	NN

may	MD
O	NNP

more	RBR
O	NN

clearly	RB
O	NN

define	VB
O	NN

its	PRP$
O	NN

role	NN
O	NN

in	IN
O	NN

the	DT
O	NN

management	NN
O	NN

of	IN
O	NN

RV	NN
O	NN

failure	NN
O	NN

Guiding	VBG
O	NN

surgical	JJ
T	NN

therapy	NN
T	NN

of	IN
O	NN

ventricular	JJ
D	NN

tachycardia	NN
D	NN

by	IN
O	NN

preoperative	JJ
O	NN

endocardial	JJ
O	NN

catheter	NN
O	NN

mapping	VBG
O	NN

necessitates	VBZ
O	NN

improvement	NN
O	NN

of	IN
O	NN

the	DT
O	NN

accuracy	NN
O	NN

of	IN
O	NN

localization	NN
O	NN

of	IN
O	NN

the	DT
O	NN

arrhythmogenic	JJ
O	NN

site	NN
O	NN

However	RB
O	NN

,	,
O	NN

the	DT
O	NN

results	NNS
O	VBP

of	IN
O	NN

this	DT
O	NN

study	NN
O	NN

indicate	VBP
O	NN

that	IN
O	NN

procainamide	NN
T	NN

may	MD
O	NNP

be	VB
O	NN

effective	JJ
O	NN

in	IN
O	NN

suppressing	VBG
O	NN

the	DT
O	NN

induction	NN
O	NN

of	IN
O	NN

sustained	JJ
O	NN

ventricular	JJ
D	NN

tachycardia	NN
D	NN

at	IN
O	NN

a	DT
O	NN

relatively	RB
O	NN

low	JJ
O	NN

plasma	NN
O	NN

concentration	NN
O	NN

,	,
O	NN

but	CC
O	NNP

not	RB
O	NN

at	IN
O	NN

a	DT
O	NN

higher	JJR
O	NN

plasma	NN
O	NN

concentration	NN
O	NN

Coronary	JJ
T	NN

angioplasty	JJ
T	NN

for	IN
O	NN

early	RB
D	NN

postinfarction	NN
D	NN

unstable	JJ
D	NN

angina	NN
D	NN

Coronary	JJ
T	NN

angioplasty	JJ
T	NN

was	VBD
O	NN

performed	VBN
O	NN

in	IN
O	NN

53	CD
O	NN

patients	NNS
O	NN

in	IN
O	NN

whom	WP
O	NN

unstable	JJ
D	NN

angina	NN
D	NN

had	VBD
O	NN

reoccurred	VBD
O	NN

after	IN
O	NN

48	CD
O	NN

hr	NN
O	NN

and	CC
O	NN

within	IN
O	NN

30	CD
O	NN

days	NNS
O	NN

after	IN
O	NN

sustained	JJ
O	NN

myocardial	JJ
O	NN

infarction	NN
O	NN

At	IN
O	NN

6	CD
O	NN

months	NNS
O	NN

follow-up	JJ
O	NN

26	CD
O	NN

%	NN
O	NN

(	NN
O	NN

14/53	CD
O	NN

)	NN
O	NN

of	IN
O	NN

all	DT
O	NN

the	DT
O	NN

patients	NNS
O	NN

who	WP
O	VBP

underwent	VBD
O	NN

angioplasty	JJ
T	NN

had	VBD
O	NN

recurrence	NN
O	NN

of	IN
O	NN

angina	NN
D	NN

,	,
O	NN

which	WDT
O	NN

was	VBD
O	NN

successfully	RB
O	NN

treated	VBN
O	NN

with	IN
O	NN

repeat	NN
T	NN

angioplasty	JJ
T	NN

,	,
T	NN

bypass	NN
T	NN

surgery	NN
T	NN

,	,
T	NN

or	CC
T	NN

medical	JJ
T	NN

therapy	NN
T	NN

Coronary	JJ
D	NN

dissection	NN
D	NN

and	CC
D	NN

total	JJ
D	NN

coronary	JJ
D	NN

occlusion	NN
D	NN

leading	VBG
O	NN

to	TO
O	NN

emergency	NN
T	NN

coronary	JJ
T	NN

surgery	NN
T	NN

are	VBP
O	NN

the	DT
O	NN

most	JJS
O	NN

frequent	JJ
O	NN

complications	NNS
O	NN

of	IN
O	NN

percutaneous	JJ
O	NN

transluminal	JJ
O	NN

coronary	JJ
O	NN

angioplasty	NN
O	NN

(	NN
O	NN

PTCA	NN
O	NN

)	NN
O	NN

and	CC
O	NN

their	PRP$
O	NN

occurrence	NN
O	NN

usually	RB
O	NN

is	VBZ
O	NN

unpredictable	JJ
O	NN

Effect	NN
O	NN

of	IN
O	NN

zanamivir	NN
T	NN

on	IN
O	NN

duration	NN
O	NN

and	CC
O	NN

resolution	NN
O	NN

of	IN
O	NN

influenza	NN
D	NN

symptoms	NNS
O	NN

A	DT
O	NN

comparison	NN
O	NN

of	IN
O	NN

a	DT
O	NN

five-day	JJ
O	NN

regimen	NN
O	NN

of	IN
O	NN

cefdinir	NN
T	NN

with	IN
O	NN

a	DT
O	NN

seven-day	JJ
O	NN

regimen	NN
O	NN

of	IN
O	NN

loracarbef	NN
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

acute	JJ
O	NN

exacerbations	NNS
O	NN

of	IN
O	NN

chronic	JJ
D	NN

bronchitis	NN
D	NN

Initial	JJ
O	NN

empiric	JJ
O	NN

therapy	NN
O	NN

for	IN
O	NN

community-acquired	JJ
O	NN

bacterial	JJ
D	NN

meningitis	NN
D	NN

should	MD
O	NNP

be	VB
O	NN

based	VBN
O	NN

on	IN
O	NN

the	DT
O	NN

possibility	NN
O	NN

that	IN
O	NN

penicillin-resistant	JJ
O	NN

pneumococci	NN
O	NN

may	MD
O	NNP

be	VB
O	NN

the	DT
O	NN

etiologic	JJ
O	NN

organisms	NNS
O	VBP

and	CC
O	NN

,	,
O	NN

hence	RB
O	NN

,	,
O	NN

should	MD
O	NNP

include	VBP
O	NN

a	DT
O	NN

combination	NN
O	NN

of	IN
O	NN

third-generation	JJ
O	NN

cephalosporin	NN
T	NN

(	NN
T	NN

cefotaxime	NN
T	NN

or	CC
T	NN

ceftriaxone	NN
T	NN

)	NN
T	NN

and	CC
T	NN

vancomycin	NN
T	NN

Ampicillin	NNP
T	NN

should	MD
O	NNP

be	VB
O	NN

included	VBN
O	NN

if	IN
O	NN

the	DT
O	NN

patient	NN
O	NN

has	VBZ
O	NN

predisposing	VBG
O	NN

factors	NNS
O	NN

that	IN
O	NN

are	VBP
O	NN

associated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

risk	NN
O	NN

for	IN
O	NN

infection	NN
D	NN

with	IN
D	NN

Listeria	NN
D	NN

monocytogenes	NNS
D	NN

Results	NNS
O	NN

of	IN
O	NN

clinical	JJ
O	NN

trials	NNS
O	NN

and	CC
O	NN

meta-analysis	NN
O	NN

suggest	VBP
O	NN

that	IN
O	NN

dexamethasone	NN
T	NN

therapy	NN
T	NN

improves	VBZ
O	NN

the	DT
O	NN

outcome	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

bacterial	JJ
D	NN

meningitis	NN
D	NN

Placebo-controlled	JJ
O	NN

trials	NNS
O	NN

have	VB
O	NN

shown	VBN
O	NN

that	IN
O	NN

vitamin	NN
T	NN

C	NN
T	NN

supplementation	NN
O	NN

decreases	NNS
O	NN

the	DT
O	NN

duration	NN
O	NN

and	CC
O	NN

severity	NN
O	NN

of	IN
O	NN

common	JJ
D	NN

cold	JJ
D	NN

infections	NNS
D	NN

Since	IN
O	NN

few	JJ
O	NN

trials	NNS
O	NN

have	VB
O	NN

examined	VBN
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

therapeutic	JJ
O	NN

supplementation	NN
O	NN

and	CC
O	NN

their	PRP$
O	NN

results	NNS
O	VBP

have	VB
O	NN

been	VBN
O	NN

variable	JJ
O	NN

,	,
O	NN

further	RB
O	NN

therapeutic	JJ
O	NN

trials	NNS
O	NN

are	VBP
O	NN

required	VBN
O	NN

to	TO
O	NN

examine	VB
O	NN

the	DT
O	NN

role	NN
O	NN

of	IN
O	NN

vitamin	NN
T	NN

C	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

colds	NNS
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Progressive	JJ
D	NN

multifocal	JJ
D	NN

leukoencephalopathy	NN
D	NN

following	VBG
O	NN

oral	JJ
T	NN

fludarabine	NN
T	NN

treatment	NN
O	NN

of	IN
O	NN

chronic	JJ
D	NN

lymphocytic	JJ
D	NN

leukemia	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

PURPOSE	NN
O	NN

:	:
O	NN

To	TO
O	NN

review	NN
O	NN

reported	VBN
O	NN

inflammatory	JJ
D	NN

reactions	NNS
D	NN

occurring	VBG
O	NN

after	IN
O	NN

initiation	NN
O	NN

of	IN
O	NN

highly	RB
O	NN

active	JJ
O	NN

antiretroviral	JJ
T	NN

therapy	NN
T	NN

(	NN
T	NN

HAART	JJ
T	NN

)	NN
T	NN

in	IN
O	NN

persons	NNS
O	VBP

infected	JJ
O	NN

with	IN
O	NN

HIV-1	NN
D	NN

and	CC
O	NN

to	TO
O	NN

explore	VB
O	NN

the	DT
O	NN

mechanisms	NNS
O	VBP

leading	VBG
O	NN

to	TO
O	NN

these	DT
O	NN

reactions	NNS
O	NN

Levofloxacin	NN
T	NN

versus	CC
T	NN

intravenous	JJ
T	NN

ceftriaxone	NN
T	NN

and	CC
T	NN

amoxicillin/clavulanate	JJ
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

community-acquired	JJ
O	NN

pneumonia	NN
D	NN

that	IN
O	NN

require	VB
O	NN

hospitalization	NN
O	NN

Overall	JJ
O	NN

1	CD
O	NN

year	NN
O	NN

survival	NN
O	NN

(	NN
O	NN

operative	JJ
O	NN

deaths	NNS
O	NN

excluded	VBN
O	NN

)	NN
O	NN

was	VBD
O	NN

68	CD
O	NN

%	NN
O	NN

after	IN
O	NN

tumor	NN
D	NN

resection	NN
T	NN

compared	VBN
O	NN

to	TO
O	NN

31	CD
O	NN

%	NN
O	NN

after	IN
O	NN

palliative	JJ
O	NN

surgery	NN
O	NN

(	NN
O	NN

P	NN
O	NN

<	JJR
O	NN

0.001	CD
O	NN

)	NN
O	NN

The	DT
O	NN

results	NNS
O	VBP

of	IN
O	NN

this	DT
O	NN

study	NN
O	NN

show	NN
O	NN

that	IN
O	NN

resection	NN
T	NN

of	IN
O	NN

extrahepatic	JJ
D	NN

bile	NN
D	NN

duct	NN
D	NN

carcinomas	NNS
D	NN

,	,
O	NN

particularly	RB
O	NN

in	IN
O	NN

an	DT
O	NN

upper-third	JJ
O	NN

localization	NN
O	NN

,	,
O	NN

is	VBZ
O	NN

often	RB
O	NN

associated	VBN
O	NN

with	IN
O	NN

worthwhile	JJ
O	NN

long-term	JJ
O	NN

survival	NN
O	NN

Background	NN
O	NN

:	:
O	NN

N-acetylcysteine	NN
T	NN

(	NN
T	NN

NAC	NN
T	NN

)	NN
T	NN

and	CC
T	NN

ambroxol	NN
T	NN

(	NN
T	NN

AMB	NNP
T	NN

)	NN
T	NN

have	VB
O	NN

recently	RB
O	NN

been	VBN
O	NN

proposed	VBN
O	NN

as	IN
O	NN

possible	JJ
O	NN

therapeutic	JJ
O	NN

agents	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

pulmonary	JJ
D	NN

disorders	NNS
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Postoperative	JJ
O	NN

alkaline	NN
D	NN

reflux	NN
D	NN

after	IN
O	NN

total	JJ
T	NN

gastrectomy	NN
T	NN

for	IN
O	NN

stomach	NN
D	NN

cancer	NN
D	NN

Antimicrobial	JJ
T	NN

therapy	NN
T	NN

for	IN
O	NN

respiratory	JJ
D	NN

disease	NN
D	NN

Corticosteroids	NNS
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

croup	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

In	IN
O	NN

the	DT
O	NN

present	JJ
O	NN

study	NN
O	NN

we	PRP
O	VBP

investigated	VBN
O	NN

the	DT
O	NN

efficacy	NN
O	NN

and	CC
O	NN

tolerability	NN
O	NN

of	IN
O	NN

i.m	NN
T	NN

.	.
T	NN

octreotide	NN
T	NN

acetate	NN
T	NN

(	NN
T	NN

octreotide	NN
T	NN

LAR	NN
T	NN

)	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

metastatic	JJ
D	NN

neuroendocrine	NN
D	NN

tumors	NNS
D	NN

(	NN
D	NN

NETs	NNS
D	NN

)	NN
D	NN

previously	RB
O	NN

treated	VBN
O	NN

and	CC
O	NN

failed	VBD
O	NN

on	IN
O	NN

i.m	NN
T	NN

.	.
T	NN

lanreotide	NN
T	NN

The	DT
O	NN

PR	NN
O	NN

was	VBD
O	NN

observed	VBN
O	NN

in	IN
O	NN

one	CD
O	NN

patient	NN
O	NN

with	IN
O	NN

non-functioning	JJ
D	NN

endocrine	NN
D	NN

pancreatic	JJ
D	NN

tumor	NN
D	NN

with	IN
D	NN

progressive	JJ
D	NN

liver	NN
D	NN

and	CC
D	NN

lymph	NN
D	NN

node	NN
D	NN

metastases	NNS
D	NN

after	IN
O	NN

16	CD
O	NN

months	NNS
O	NN

of	IN
O	NN

i.m	NN
T	NN

.	.
T	NN

lanreotide	NN
T	NN

therapy	NN
T	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Octreotide	NN
T	NN

LAR	NN
T	NN

20	CD
O	NN

mg	NN
O	NN

shows	NNS
O	VBP

significant	JJ
O	NN

efficacy	NN
O	NN

in	IN
O	NN

terms	NNS
O	NN

of	IN
O	NN

objective	JJ
O	NN

response	NN
O	NN

rate	NN
O	NN

(	NN
O	NN

PR	NN
O	NN

+	CC
O	NN

SD	NN
O	NN

)	NN
O	NN

,	,
O	NN

biochemical	JJ
O	NN

and	CC
O	NN

symptomatic	JJ
O	NN

control	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

metastatic	JJ
D	NN

NETs	NNS
D	NN

of	IN
O	NN

the	DT
O	NN

GEP	NN
O	NN

system	NN
O	NN

pretreated	JJ
O	NN

and	CC
O	NN

progressing	VBG
O	NN

on	IN
O	NN

slow	JJ
O	NN

release	NN
O	NN

lanreotide	NN
O	NN

Inchinko-to	JJ
T	NN

(	NN
T	NN

TJ-135	NN
T	NN

)	NN
T	NN

is	VBZ
O	NN

a	DT
O	NN

herbal	JJ
O	NN

medicine	NN
O	NN

consisting	VBG
O	NN

of	IN
O	NN

three	CD
O	NN

kinds	NNS
O	NN

of	IN
O	NN

crude	JJ
O	NN

drugs	NNS
O	NN

,	,
O	NN

and	CC
O	NN

in	IN
O	NN

Japan	NNP
O	NNP

it	PRP
O	NN

is	VBZ
O	NN

administered	VBN
O	NN

mainly	RB
O	NN

to	TO
O	NN

patients	NNS
O	NN

with	IN
O	NN

cholestasis	NN
D	NN

The	DT
O	NN

present	JJ
O	NN

study	NN
O	NN

evaluated	VBN
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

TJ-135	NN
T	NN

on	IN
O	NN

concanavalin	NN
D	NN

A	DT
D	NN

(	NN
D	NN

con	NN
D	NN

A	DT
D	NN

)	NN
D	NN

-induced	JJ
D	NN

hepatitis	NN
D	NN

in	IN
O	NN

mice	NNS
O	NN

in	IN
O	NN

vivo	FW
O	FW

and	CC
O	NN

con	RB
O	NN

A-induced	JJ
O	NN

cytokine	NN
O	NN

production	NN
O	NN

in	IN
O	NN

vitro	FW
O	FW

These	DT
O	NN

results	NNS
O	VBP

suggest	VBP
O	NN

that	IN
O	NN

con	NN
D	NN

A-induced	JJ
D	NN

hepatitis	NN
D	NN

was	VBD
O	NN

ameliorated	VBN
O	NN

by	IN
O	NN

pretreatment	NN
O	NN

with	IN
O	NN

TJ-135	NN
T	NN

Therefore	RB
O	NN

administration	NN
O	NN

of	IN
O	NN

TJ-135	NN
T	NN

may	MD
O	NNP

be	VB
O	NN

useful	JJ
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

severe	JJ
O	NN

acute	JJ
O	NN

hepatitis	NN
D	NN

accompanying	VBG
D	NN

cholestasis	NN
D	NN

or	CC
O	NN

in	IN
O	NN

those	DT
O	NNP

with	IN
O	NN

autoimmune	JJ
D	NN

hepatitis	NN
D	NN

Zinc	NN
T	NN

lozenges	NNS
T	NN

--	:
O	NN

a	DT
O	NN

cure	NN
O	NN

for	IN
O	NN

common	JJ
D	NN

colds	NNS
D	NN

?	.
O	NN

T-helper	NN
T	NN

type	NN
T	NN

2	CD
T	NN

cell-directed	JJ
T	NN

therapy	NN
T	NN

for	IN
O	NN

asthma	NN
D	NN

Effects	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

Japanese	JJ
T	NN

herbal	JJ
T	NN

medicine	NN
T	NN

'Inchinko-to	JJ
T	NN

'	''
T	NN

(	NN
T	NN

TJ-135	NN
T	NN

)	NN
T	NN

on	IN
O	NN

concanavalin	NN
D	NN

A-induced	JJ
D	NN

hepatitis	NN
D	NN

in	IN
O	NN

mice	NNS
O	NN

Presumed	VBN
O	NN

cavernomas	NNS
O	NN

have	VB
O	NN

been	VBN
O	NN

documented	VBN
O	NN

following	VBG
O	NN

radiation	NN
T	NN

for	IN
O	NN

malignancy	NN
D	NN

(	NN
O	NN

5-6	CD
O	NN

)	NN
O	NN

,	,
O	NN

and	CC
O	NN

sterotactic	JJ
O	NN

cerebral	JJ
O	NN

biopsy	NN
O	NN

(	NN
O	NN

7	CD
O	NN

)	NN
O	NN

Surgical	NNP
T	NN

management	NN
T	NN

of	IN
O	NN

syringomyelia	NN
D	NN

associated	VBN
D	NN

with	IN
D	NN

spinal	JJ
D	NN

adhesive	JJ
D	NN

arachnoiditis	NN
D	NN

Discontinuation	NN
O	NN

of	IN
O	NN

secondary	JJ
O	NN

prophylaxis	NN
O	NN

for	IN
O	NN

cryptococcal	JJ
D	NN

meningitis	NN
D	NN

in	IN
O	NN

HIV-infected	JJ
O	NN

patients	NNS
O	NN

responding	VBG
O	NN

to	TO
O	NN

highly	RB
O	NN

active	JJ
O	NN

antiretroviral	JJ
T	NN

therapy	NN
T	NN

Hepatectomy	JJ
T	NN

for	IN
O	NN

cholangiocarcinoma	NN
D	NN

complicated	JJ
O	NN

with	IN
O	NN

right	RB
O	NN

umbilical	JJ
O	NN

portion	NN
O	NN

:	:
O	NN

anomalous	JJ
O	NN

configuration	NN
O	NN

of	IN
O	NN

the	DT
O	NN

intrahepatic	JJ
O	NN

biliary	JJ
O	NN

tree	NN
O	NN

Traditionally	RB
O	NN

,	,
O	NN

the	DT
O	NN

therapy	NN
O	NN

of	IN
O	NN

symptomatic	JJ
D	NN

bronchiectasis	NN
D	NN

is	VBZ
O	NN

based	VBN
O	NN

on	IN
O	NN

antibiotics	NNS
T	NN

,	,
T	NN

antibronchoobstructive	JJ
T	NN

medication	NN
T	NN

,	,
T	NN

and	CC
T	NN

chest	NN
T	NN

physical	JJ
T	NN

therapy	NN
T	NN

Bilateral	JJ
T	NN

lung	NN
T	NN

transplantation	NN
T	NN

should	MD
O	NNP

be	VB
O	NN

considered	VBN
O	NN

in	IN
O	NN

younger	JJR
O	NN

patients	NNS
O	NN

with	IN
O	NN

severe	JJ
O	NN

,	,
O	NN

generalized	VBN
O	NN

bronchiectasis	NN
D	NN

and	CC
D	NN

respiratory	JJ
D	NN

failure	NN
D	NN

Prospective	JJ
O	NN

,	,
O	NN

randomized	VBN
O	NN

,	,
O	NN

largescale	JJ
O	NN

trials	NNS
O	NN

supporting	VBG
O	NN

any	DT
O	NN

of	IN
O	NN

the	DT
O	NN

different	JJ
O	NN

treatment	NN
O	NN

strategies	NNS
O	VBP

are	VBP
O	NN

not	RB
O	NN

available	JJ
O	NN

,	,
O	NN

but	CC
O	NNP

antibiotics	NNS
T	NN

and	CC
T	NN

surgery	NN
T	NN

probably	RB
O	NN

have	VB
O	NN

improved	VBN
O	NN

the	DT
O	NN

long-term	JJ
O	NN

outcome	NN
O	NN

of	IN
O	NN

many	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

bronchiectasis	NN
D	NN

OBJECTIVES	NNS
O	VBP

:	:
O	NN

Interest	NN
O	NN

in	IN
O	NN

zinc	NN
T	NN

as	IN
O	NN

a	DT
O	NN

treatment	NN
O	NN

for	IN
O	NN

the	DT
O	NN

common	JJ
D	NN

cold	JJ
D	NN

has	VBZ
O	NN

grown	VBN
O	NN

following	VBG
O	NN

the	DT
O	NN

recent	JJ
O	NN

publication	NN
O	NN

of	IN
O	NN

several	JJ
O	NN

controlled	JJ
O	NN

trials	NNS
O	NN

The	DT
O	NN

objective	JJ
O	NN

of	IN
O	NN

this	DT
O	NN

review	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

assess	VB
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

zinc	NN
T	NN

lozenges	NNS
T	NN

for	IN
O	NN

cold	JJ
D	NN

symptoms	NNS
D	NN

Results	NNS
O	NN

from	IN
O	NN

two	CD
O	NN

trials	NNS
O	NN

(	NN
O	NN

04	NN
O	NN

-	:
O	NN

Mossad	NNP
O	NNP

;	:
O	NN

08	CD
O	NN

-	:
O	NN

Smith	NNP
O	NNP

)	NN
O	NN

suggested	VBN
O	NN

zinc	NN
T	NN

lozenges	NNS
T	NN

reduced	VBN
O	NN

the	DT
O	NN

severity	NN
O	NN

and	CC
O	NN

duration	NN
O	NN

of	IN
O	NN

cold	JJ
D	NN

symptoms	NNS
D	NN

Given	VBN
O	NN

the	DT
O	NN

potential	JJ
O	NN

for	IN
O	NN

treatment	NN
O	NN

to	TO
O	NN

produce	VB
O	NN

side	NN
O	NN

effects	NNS
O	NN

,	,
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

zinc	NN
T	NN

lozenges	NNS
T	NN

to	TO
O	NN

treat	VB
O	NNP

cold	JJ
D	NN

symptoms	NNS
D	NN

deserves	VBZ
O	NN

further	RB
O	NN

study	NN
O	NN

Randomized	VBN
O	NN

trial	NN
O	NN

of	IN
O	NN

interferon-alpha	NN
T	NN

plus	CC
T	NN

ursodeoxycholic	JJ
T	NN

acid	NN
T	NN

versus	CC
O	NN

interferon	NN
T	NN

plus	CC
T	NN

placebo	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

hepatitis	NN
D	NN

C	NN
D	NN

resistant	JJ
D	NN

to	TO
D	NN

interferon	NN
D	NN

We	PRP
O	VBP

describe	VBP
O	NN

a	DT
O	NN

rare	JJ
O	NN

case	NN
O	NN

of	IN
O	NN

spontaneous	JJ
D	NN

rupture	NN
D	NN

of	IN
D	NN

a	DT
D	NN

hepatic	JJ
D	NN

metastasis	NN
D	NN

from	IN
D	NN

renal	JJ
D	NN

cell	NN
D	NN

carcinoma	NN
D	NN

that	IN
O	NN

was	VBD
O	NN

treated	VBN
O	NN

successfully	RB
O	NN

by	IN
O	NN

hepatic	JJ
T	NN

arterial	JJ
T	NN

embolization	NN
T	NN

A	DT
O	NN

65-year-old	JJ
O	NN

woman	NN
O	NN

,	,
O	NN

who	WP
O	VBP

had	VBD
O	NN

been	VBN
O	NN

undergoing	VBG
O	NN

immunotherapy	NN
T	NN

for	IN
O	NN

inoperably	RB
D	NN

disseminated	VBN
D	NN

renal	JJ
D	NN

carcinoma	NN
D	NN

and	CC
D	NN

lung	NN
D	NN

metastases	NNS
D	NN

,	,
O	NN

presented	VBN
O	NN

with	IN
O	NN

severe	JJ
O	NN

abdominal	JJ
O	NN

pain	NN
O	NN

in	IN
O	NN

a	DT
O	NN

state	NN
O	NN

of	IN
O	NN

hypovolemic	JJ
O	NN

shock	NN
O	NN

Although	IN
O	NN

hepatic	JJ
O	NN

rupture	NN
O	NN

due	JJ
O	NN

to	TO
O	NN

metastatic	JJ
O	NN

cancer	NN
O	NN

is	VBZ
O	NN

extremely	RB
O	NN

rare	JJ
O	NN

,	,
O	NN

transcatheter	NN
T	NN

arterial	JJ
T	NN

embolization	NN
T	NN

(	NN
T	NN

TAE	NN
T	NN

)	NN
T	NN

is	VBZ
O	NN

an	DT
O	NN

appropriate	JJ
O	NN

and	CC
O	NN

useful	JJ
O	NN

treatment	NN
O	NN

for	IN
O	NN

massive	JJ
D	NN

hemorrhage	NN
D	NN

caused	VBN
D	NN

by	IN
D	NN

spontaneous	JJ
D	NN

rupture	NN
D	NN

of	IN
D	NN

liver	NN
D	NN

metastasis	NN
D	NN

Patients	NNS
O	NN

with	IN
O	NN

classical	JJ
O	NN

symptoms	NNS
O	NN

such	JJ
O	NN

as	IN
O	NN

heartburn	NN
D	NN

and	CC
D	NN

regurgitation	NN
D	NN

may	MD
O	NNP

be	VB
O	NN

treated	VBN
O	NN

pharmaceutically	RB
T	NN

combined	VBN
T	NN

with	IN
T	NN

life	NN
T	NN

style	NN
T	NN

counselling	VBG
T	NN

Surgical	NNP
T	NN

treatment	NN
T	NN

is	VBZ
O	NN

a	DT
O	NN

good	JJ
O	NN

alternative	JJ
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

persistent	JJ
D	NN

severe	JJ
D	NN

regurgitation	NN
D	NN

during	IN
O	NN

medical	JJ
O	NN

therapy	NN
O	NN

and	CC
O	NN

for	IN
O	NN

young	JJ
O	NN

patients	NNS
O	NN

who	WP
O	VBP

prefer	VBP
O	NN

surgery	NN
O	NN

to	TO
O	NN

lifelong	JJ
O	NN

medication	NN
O	NN

The	DT
O	NN

surgical	JJ
T	NN

treatment	NN
T	NN

of	IN
O	NN

lung	NN
D	NN

lacerations	NNS
D	NN

and	CC
D	NN

major	JJ
D	NN

bronchial	JJ
D	NN

disruptions	NNS
D	NN

caused	VBN
O	NN

by	IN
O	NN

blunt	JJ
O	NN

thoracic	JJ
O	NN

trauma	NN
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

An	DT
O	NN

increasing	VBG
O	NN

number	NN
O	NN

of	IN
O	NN

reports	NNS
O	NN

indicate	VBP
O	NN

symptomatic	JJ
O	NN

relief	NN
O	NN

of	IN
O	NN

biliary	JJ
O	NN

colic	JJ
O	NN

symptoms	NNS
O	NN

after	IN
O	NN

cholecystectomy	NN
T	NN

for	IN
O	NN

biliary	JJ
D	NN

dyskinesia	NN
D	NN

Despite	IN
O	NN

this	DT
O	NN

,	,
O	NN

cholecystectomy	NN
T	NN

as	IN
O	NN

a	DT
O	NN

treatment	NN
O	NN

for	IN
O	NN

biliary	JJ
D	NN

dyskinesia	NN
D	NN

remains	VBZ
O	NNP

controversial	JJ
O	NN

Our	PRP$
O	NN

aim	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

determine	VB
O	NN

efficacy	NN
O	NN

of	IN
O	NN

cholecystectomy	NN
T	NN

in	IN
O	NN

alleviating	VBG
O	NN

biliary	JJ
D	NN

dyskinesia	NN
D	NN

symptoms	NNS
D	NN

and	CC
O	NN

the	DT
O	NN

correlation	NN
O	NN

with	IN
O	NN

histologic	JJ
O	NN

findings	NNS
O	VBP

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Biliary	JJ
D	NN

dyskinesia	NN
D	NN

patients	NNS
O	NN

who	WP
O	VBP

underwent	VBD
O	NN

cholecystectomy	NN
T	NN

had	VBD
O	NN

significantly	RB
O	NN

greater	JJR
O	NN

symptom	NN
O	NN

improvement	NN
O	NN

compared	VBN
O	NN

with	IN
O	NN

nonsurgical	JJ
O	NN

patients	NNS
O	NN

Cholecystectomy	NN
T	NN

should	MD
O	NNP

be	VB
O	NN

a	DT
O	NN

first-line	JJ
O	NN

therapy	NN
O	NN

for	IN
O	NN

biliary	JJ
D	NN

dyskinesia	NN
D	NN

patients	NNS
O	NN

Transbronchial	JJ
O	NN

biopsy	NN
O	NN

revealed	VBD
O	NN

inflammatory	JJ
D	NN

nonspecific	JJ
D	NN

alveolar	JJ
D	NN

lesions	NNS
D	NN

suggestive	JJ
D	NN

of	IN
D	NN

bronchiolitis	NN
D	NN

obliterans	NNS
D	NN

organizing	VBG
D	NN

pneumonia	NN
D	NN

,	,
O	NN

which	WDT
O	NN

responded	VBD
O	NN

well	RB
O	NN

clinically	RB
O	NN

and	CC
O	NN

radiologically	RB
O	NN

to	TO
O	NN

oral	JJ
T	NN

corticosteroids	NNS
T	NN

Novel	JJ
O	NN

treatment	NN
O	NN

strategies	NNS
O	VBP

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

NSCLC	NN
D	NN

may	MD
O	NNP

involve	VB
O	NN

chemotherapy	NN
T	NN

combined	JJ
O	NN

with	IN
O	NN

inhibition	NN
O	NN

of	IN
O	NN

NF-kappaB-dependent	JJ
O	NN

cell-survival	JJ
O	NN

pathways	NNS
O	VBP

Effectiveness	NN
O	NN

of	IN
O	NN

pseudoephedrine	NN
T	NN

plus	CC
T	NN

acetaminophen	NN
T	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

symptoms	NNS
O	NN

attributed	VBN
O	NN

to	TO
O	NN

the	DT
O	NN

paranasal	JJ
O	NN

sinuses	NNS
O	VBP

associated	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

common	JJ
D	NN

cold	JJ
D	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

This	DT
O	NN

retrospective	JJ
O	NN

study	NN
O	NN

was	VBD
O	NN

designed	VBN
O	NN

to	TO
O	NN

confirm	VBP
O	NN

that	IN
O	NN

aggressive	JJ
T	NN

pulmonary	JJ
T	NN

resection	NN
T	NN

can	MD
O	NNP

provide	VB
O	NN

effective	JJ
O	NN

long-term	JJ
O	NN

palliation	NN
O	NN

of	IN
O	NN

disease	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

pulmonary	JJ
D	NN

aspergilloma	NN
D	NN

METHODS	NNS
O	VBP

AND	CC
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

From	IN
O	NN

1959	CD
O	NN

to	TO
O	NN

1998	CD
O	NN

,	,
O	NN

84	CD
O	NN

patients	NNS
O	NN

underwent	VBD
O	NN

a	DT
O	NN

total	JJ
O	NN

of	IN
O	NN

90	CD
O	NN

operations	NNS
T	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

pulmonary	JJ
D	NN

aspergilloma	NN
D	NN

in	IN
O	NN

the	DT
O	NN

Marie-Lannelongue	JJ
O	NN

Hospital	NNP
O	NNP

The	DT
O	NN

lesion	NN
D	NN

was	VBD
O	NN

resected	JJ
O	NN

by	IN
O	NN

video-assisted	JJ
T	NN

thoracoscopic	JJ
T	NN

surgery	NN
T	NN

because	IN
O	NN

it	PRP
O	NN

was	VBD
O	NN

suspected	VBN
O	NN

of	IN
O	NN

being	VBG
O	NN

a	DT
O	NN

lung	NN
O	NN

abscess	NN
O	NN

that	IN
O	NN

had	VBD
O	NN

caused	VBN
O	NN

repeated	VBN
O	NN

episodes	NNS
O	NN

of	IN
O	NN

inflammation	NN
O	NN

In	IN
O	NN

this	DT
O	NN

study	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

investigated	VBN
O	NN

the	DT
O	NN

expression	NN
O	NN

and	CC
O	NN

therapeutic	JJ
O	NN

potential	JJ
O	NN

of	IN
O	NN

TRAIL	NN
T	NN

in	IN
O	NN

cholangiocarcinoma	NN
D	NN

,	,
O	NN

one	CD
O	NN

of	IN
O	NN

the	DT
O	NN

most	JJS
O	NN

devastating	VBG
O	NN

human	JJ
O	NN

hepatic	JJ
O	NN

malignancies	NNS
O	NN

Finally	RB
O	NN

,	,
O	NN

in	IN
O	NN

vivo	FW
O	FW

administration	NN
O	NN

of	IN
O	NN

recombinant	JJ
O	NN

TRAIL	NN
T	NN

substantially	RB
O	NN

inhibited	VBD
O	NN

subcutaneous	JJ
O	NN

tumor	NN
O	NN

growth	NN
O	NN

of	IN
O	NN

human	JJ
O	NN

cholangiocarcinoma	NN
D	NN

cells	NNS
O	VBP

Induction	NN
O	NN

of	IN
O	NN

apoptosis	NN
O	NN

in	IN
O	NN

tumor	NN
O	NN

cells	NNS
O	VBP

is	VBZ
O	NN

possible	JJ
O	NN

with	IN
O	NN

a	DT
O	NN

biologically	RB
O	NN

active	JJ
O	NN

TRAIL	NN
T	NN

,	,
O	NN

and	CC
O	NN

suggests	VBZ
O	NN

that	IN
O	NN

this	DT
O	NN

cytokine	NN
O	NN

is	VBZ
O	NN

a	DT
O	NN

promising	JJ
O	NN

antitumor	JJ
O	NN

agent	NN
O	NN

against	IN
O	NN

human	JJ
D	NN

cholangiocarcinoma	NN
D	NN

Interferon	NN
T	NN

plays	NNS
O	NN

a	DT
O	NN

critical	JJ
O	NN

role	NN
O	NN

in	IN
O	NN

the	DT
O	NN

host	NN
O	NN

's	POS
O	NN

natural	JJ
O	NN

defense	NN
O	NN

against	IN
O	NN

viral	JJ
D	NN

infections	NNS
D	NN

and	CC
O	NN

in	IN
O	NN

their	PRP$
O	NN

treatment	NN
O	NN

This	DT
O	NN

study	NN
O	NN

investigated	VBN
O	NN

whether	IN
O	NN

intensive	JJ
O	NN

chemotherapy	NN
T	NN

might	MD
O	NNP

have	VB
O	NN

a	DT
O	NN

positive	JJ
O	NN

effect	NN
O	NN

on	IN
O	NN

asthma	NN
D	NN

in	IN
O	NN

these	DT
O	NN

special	JJ
O	NN

cases	NNS
O	NN

and	CC
O	NN

whether	IN
O	NN

asthma	NN
O	NN

generally	RB
O	NN

relapses	NNS
O	NN

after	IN
O	NN

completion	NN
O	NN

of	IN
O	NN

chemotherapy	NN
O	NN

The	DT
O	NN

authors	NNS
O	NN

monitored	VBN
O	NN

clinical	JJ
O	NN

outcome	NN
O	NN

and	CC
O	NN

lung	NN
O	NN

function	NN
O	NN

of	IN
O	NN

43	CD
O	NN

children	NNS
O	VBP

with	IN
O	NN

acute	JJ
D	NN

lymphoblastic	JJ
D	NN

leukemia	NN
D	NN

and	CC
D	NN

non-Hodgkin	JJ
D	NN

lymphoma	NN
D	NN

who	WP
O	VBP

received	VBN
O	NN

chemotherapy	NN
T	NN

at	IN
O	NN

the	DT
O	NN

University	NNP
O	NN

Children	NNS
O	VBP

's	POS
O	NN

Hospital	NNP
O	NNP

of	IN
O	NN

Greifswald	NNP
O	NNP

between	IN
O	NN

1993	CD
O	NN

and	CC
O	NN

1998	CD
O	NN

She	PRP
O	VBP

was	VBD
O	NN

diagnosed	VBN
O	NN

as	IN
O	NN

miliary	JJ
D	NN

tuberculosis	NN
D	NN

and	CC
O	NN

treated	VBN
O	NN

with	IN
O	NN

antituberculous	JJ
T	NN

drugs	NNS
T	NN

The	DT
O	NN

hemorrhage	NN
D	NN

was	VBD
O	NN

successfully	RB
O	NN

stopped	VBD
O	NN

by	IN
O	NN

microcoil	NN
T	NN

embolization	NN
T	NN

Immunomodulatory	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

acupuncture	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

allergic	JJ
D	NN

asthma	NN
D	NN

:	:
O	NN

a	DT
O	NN

randomized	VBN
O	NN

controlled	JJ
O	NN

study	NN
O	NN

An	DT
O	NN

open-label	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

lamivudine	NN
T	NN

for	IN
O	NN

chronic	JJ
D	NN

hepatitis	NN
D	NN

B	NN
D	NN

in	IN
O	NN

six	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
O	NN

renal	JJ
O	NN

failure	NN
O	NN

before	IN
O	NN

and	CC
O	NN

after	IN
O	NN

kidney	NN
O	NN

transplantation	NN
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

The	DT
O	NN

WDTA	NN
O	NN

is	VBZ
O	NN

an	DT
O	NN

intrinsically	RB
O	NN

motivating	VBG
O	NN

educational	JJ
O	NN

program	NN
O	NN

that	IN
O	NN

has	VBZ
O	NN

the	DT
O	NN

ability	NN
O	NN

to	TO
O	NN

effect	NN
O	NN

determinants	NNS
O	NN

of	IN
O	NN

asthma	NN
D	NN

self-management	NN
T	NN

behavior	NN
O	NN

in	IN
O	NN

9-	CD
O	NN

to	TO
O	NN

13-year-old	JJ
O	NN

children	NNS
O	VBP

with	IN
O	NN

asthma	NN
O	NN

Usefulness	NN
O	NN

of	IN
O	NN

percutaneous	JJ
T	NN

transhepatic	JJ
T	NN

biliary	JJ
T	NN

drainage	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

surgical	JJ
D	NN

jaundice	NN
D	NN

--	:
O	NN

a	DT
O	NN

prospective	JJ
O	NN

randomised	VBN
O	NN

study	NN
O	NN

Neutralization	NN
O	NN

of	IN
O	NN

hepatitis	NN
D	NN

A	DT
D	NN

virus	NN
D	NN

(	NN
D	NN

HAV	NN
D	NN

)	NN
D	NN

by	IN
O	NN

an	DT
O	NN

immunoadhesin	NN
T	NN

containing	VBG
T	NN

the	DT
T	NN

cysteine-rich	JJ
T	NN

region	NN
T	NN

of	IN
T	NN

HAV	NN
T	NN

cellular	JJ
T	NN

receptor-1	JJ
T	NN

To	TO
O	NN

ascertain	VB
O	NN

the	DT
O	NN

results	NNS
O	VBP

of	IN
O	NN

standard	JJ
T	NN

ABVD	NN
T	NN

chemotherapy	NN
T	NN

(	NN
T	NN

doxorubicin	NN
T	NN

,	,
T	NN

bleomycin	NN
T	NN

,	,
T	NN

vinblastine	NN
T	NN

,	,
T	NN

dacarbazine	NN
T	NN

)	NN
T	NN

in	IN
O	NN

HIV-infected	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

newly	RB
D	NN

diagnosed	VBN
D	NN

Hodgkin	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

(	NN
D	NN

HD	NN
D	NN

)	NN
D	NN

,	,
O	NN

a	DT
O	NN

nonrandomized	JJ
O	NN

,	,
O	NN

prospective	JJ
O	NN

,	,
O	NN

multiinstitutional	JJ
O	NN

clinical	JJ
O	NN

trial	NN
O	NN

was	VBD
O	NN

conducted	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

AIDS	NNP
O	NN

Clinical	JJ
O	NN

Trials	NNS
O	NN

Group	NNP
O	NNP

(	NN
O	NN

ACTG	NN
O	NN

)	NN
O	NN

,	,
O	NN

in	IN
O	NN

HIV-infected	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

Hodgkin	NN
O	NN

's	POS
O	NN

disease	NN
O	NN

The	DT
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

glucocorticoids	NNS
T	NN

in	IN
O	NN

treating	VBG
O	NN

croup	NN
D	NN

:	:
O	NN

meta-analysis	NN
O	NN

(	NN
O	NN

see	VB
O	NNP

comments	NNS
O	NN

)	NN
O	NN

PURPOSE	NN
O	NN

:	:
O	NN

Inhaled	VBN
O	NN

corticosteroids	NNS
T	NN

have	VB
O	NN

beneficial	JJ
O	NN

effects	NNS
O	NN

on	IN
O	NN

pulmonary	JJ
O	NN

function	NN
O	NN

and	CC
O	NN

inflammation	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

asthma	NN
D	NN

,	,
O	NN

but	CC
O	NNP

they	PRP
O	VBP

also	RB
O	NN

cause	NN
O	NN

systemic	JJ
O	NN

adverse	JJ
O	NN

effects	NNS
O	NN

,	,
O	NN

such	JJ
O	NN

as	IN
O	NN

adrenal	JJ
O	NN

suppression	NN
O	NN

Second	JJ
O	NN

,	,
O	NN

children	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

first	RB
O	NN

year	NN
O	NN

of	IN
O	NN

life	NN
O	NN

are	VBP
O	NN

at	IN
O	NN

highest	JJS
O	NN

risk	NN
O	NN

of	IN
O	NN

progression	NN
O	NN

and	CC
O	NN

should	MD
O	NNP

be	VB
O	NN

treated	VBN
O	NN

with	IN
O	NN

trimethoprim-sulfamethoxazole	JJ
T	NN

to	TO
O	NN

prevent	VB
O	NN

Pneumocystis	NN
D	NN

carinii	NN
D	NN

pneumonia	NN
D	NN

,	,
O	NN

and	CC
O	NN

targeted	VBN
O	NN

for	IN
O	NN

receiving	VBG
O	NN

antiretrovirals	NNS
O	NN

Effectiveness	NN
O	NN

of	IN
O	NN

casein	NN
T	NN

hydrolysate	NN
T	NN

feedings	NNS
O	NN

in	IN
O	NN

infants	NNS
O	NN

with	IN
O	NN

colic	JJ
D	NN

(	NN
O	NN

see	VB
O	NNP

comments	NNS
O	NN

)	NN
O	NN

We	PRP
O	VBP

conclude	VBP
O	NN

that	IN
O	NN

antimicrobial/	JJ
T	NN

antituberculous	JJ
T	NN

agents	NNS
T	NN

have	VB
O	NN

only	RB
O	NN

a	DT
O	NN

minor	JJ
O	NN

short-term	JJ
O	NN

effect	NN
O	NN

in	IN
O	NN

long-lasting	JJ
O	NN

CGM	NN
D	NN

of	IN
O	NN

undetermined	JJ
O	NN

cause	NN
O	NN

The	DT
O	NN

patient	NN
O	NN

had	VBD
O	NN

previously	RB
O	NN

been	VBN
O	NN

immunized	VBN
O	NN

with	IN
O	NN

two	CD
O	NN

doses	NNS
O	NN

of	IN
O	NN

Hib	NN
D	NN

conjugate	NN
O	NN

vaccine	NN
T	NN

(	NN
O	NN

PRP-T	NN
O	NN

)	NN
O	NN

Thus	RB
O	NN

,	,
O	NN

s-ECP	NN
O	NN

appears	VBZ
O	NN

to	TO
O	NN

be	VB
O	NN

a	DT
O	NN

useful	JJ
O	NN

marker	NN
O	NN

for	IN
O	NN

determining	VBG
O	NN

when	WRB
O	NN

a	DT
O	NN

step-down	JJ
O	NN

in	IN
O	NN

iBDP	NN
T	NN

therapy	NN
T	NN

is	VBZ
O	NN

indicated	VBD
O	NN

,	,
O	NN

and	CC
O	NN

thus	RB
O	NN

may	MD
O	NNP

contribute	VB
O	NN

to	TO
O	NN

successful	JJ
O	NN

long-term	JJ
O	NN

management	NN
O	NN

of	IN
O	NN

chronic	JJ
D	NN

asthma	NN
D	NN

Twinrix	JJ
T	NN

(	NN
O	NN

SmithKline	NNP
O	NNP

Beecham	NNP
O	NNP

Biologicals	NNS
O	NN

)	NN
O	NN

is	VBZ
O	NN

a	DT
O	NN

combined	JJ
O	NN

hepatitis	NN
D	NN

A	DT
D	NN

and	CC
D	NN

B	NN
D	NN

vaccine	NN
T	NN

licensed	JJ
O	NN

with	IN
O	NN

a	DT
O	NN

three-dose	JJ
O	NN

schedule	NN
O	NN

A	DT
O	NN

two-dose	JJ
O	NN

combined	JJ
O	NN

hepatitis	NN
D	NN

A	DT
D	NN

and	CC
D	NN

B	NN
D	NN

vaccine	NN
T	NN

would	MD
O	NNP

facilitate	VB
O	NN

immunisation	NN
O	NN

programs	NNS
O	NN

Therefore	RB
O	NN

,	,
O	NN

it	PRP
O	NN

can	MD
O	NNP

be	VB
O	NN

concluded	VBD
O	NN

that	IN
O	NN

with	IN
O	NN

two	CD
O	NN

injections	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

high-dose	JJ
O	NN

hepatitis	NN
D	NN

A	DT
D	NN

and	CC
D	NN

B	NN
D	NN

vaccine	NN
T	NN

,	,
O	NN

6	CD
O	NN

months	NNS
O	NN

apart	RB
O	NN

,	,
O	NN

a	DT
O	NN

similar	JJ
O	NN

immune	JJ
O	NN

response	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

obtained	VBN
O	NN

as	IN
O	NN

induced	VBN
O	NN

with	IN
O	NN

three	CD
O	NN

doses	NNS
O	NN

of	IN
O	NN

Twinrix	JJ
T	NN

at	IN
O	NN

months	NNS
O	NN

0	CD
O	NN

,	,
O	NN

1	CD
O	NN

and	CC
O	NN

6	CD
O	NN

AIM	NN
O	NN

:	:
O	NN

To	TO
O	NN

assess	VB
O	NN

the	DT
O	NN

impact	NN
O	NN

on	IN
O	NN

community-based	JJ
O	NN

pediatricians	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

conclusions	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

10th	JJ
O	NN

Conference	NN
O	NN

de	IN
O	NNP

Consensus	NN
O	NN

en	IN
O	NN

Therapeutique	NN
O	NN

Anti-Infectieuse	JJ
O	NN

(	NN
O	NN

CCTAI	NN
O	NN

)	NN
O	NN

on	IN
O	NN

the	DT
O	NN

antibiotic	JJ
T	NN

treatment	NN
T	NN

in	IN
O	NN

acute	JJ
D	NN

nasopharyngitis	NN
D	NN

(	NN
D	NN

ANP	NN
D	NN

)	NN
D	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

These	DT
O	NN

data	NNS
O	NN

,	,
O	NN

the	DT
O	NN

first	RB
O	NN

evidence	NN
O	NN

that	IN
O	NN

chronic	JJ
O	NN

stress	NN
O	NN

can	MD
O	NNP

inhibit	VB
O	NN

the	DT
O	NN

stability	NN
O	NN

of	IN
O	NN

the	DT
O	NN

IgG	NN
O	NN

antibody	NN
O	NN

response	NN
O	NN

to	TO
O	NN

a	DT
O	NN

bacterial	JJ
T	NN

vaccine	NN
T	NN

for	IN
O	NN

pneumonia	NN
D	NN

,	,
O	NN

provide	VB
O	NN

additional	JJ
O	NN

evidence	NN
O	NN

of	IN
O	NN

health	NN
O	NN

risks	NNS
O	VBP

associated	VBN
O	NN

with	IN
O	NN

dementia	NN
O	NN

caregiving	VBG
O	NN

We	PRP
O	VBP

assessed	VBN
O	NN

the	DT
O	NN

prevalence	NN
O	NN

of	IN
O	NN

head	NN
O	NN

louse	NN
O	NN

infestation	NN
O	NN

and	CC
O	NN

the	DT
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

1	CD
T	NN

%	NN
T	NN

permethrin	NN
T	NN

against	IN
O	NN

head	NN
D	NN

lice	NN
D	NN

in	IN
O	NN

Kosovar	JJ
O	NN

refugees	NNS
O	NN

Refugees	NNS
O	NN

with	IN
O	NN

crawling	VBG
D	NN

lice	NN
D	NN

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

pediculicide	NN
T	NN

containing	VBG
T	NN

1	CD
T	NN

%	NN
T	NN

permethrin	NN
T	NN

We	PRP
O	VBP

conclude	VBP
O	NN

that	IN
O	NN

1	CD
T	NN

%	NN
T	NN

permethrin	NN
T	NN

treatment	NN
T	NN

was	VBD
O	NN

effective	JJ
O	NN

in	IN
O	NN

louse	NN
D	NN

control	NN
O	NN

in	IN
O	NN

this	DT
O	NN

refugee	NN
O	NN

population	NN
O	NN

Antibiotics	NNS
T	NN

for	IN
O	NN

Salmonella	FW
D	NN

meningitis	NN
D	NN

in	IN
O	NN

children	NNS
O	VBP

Four	CD
O	NN

patients	NNS
O	NN

developed	VBN
O	NN

mild	JJ
O	NN

pancreatitis	NN
D	NN

,	,
O	NN

one	CD
O	NN

had	VBD
O	NN

moderate	JJ
O	NN

pancreatitis	NN
D	NN

and	CC
O	NN

one	CD
O	NN

had	VBD
O	NN

leak	NN
O	NN

of	IN
O	NN

contrast	NN
O	NN

,	,
O	NN

which	WDT
O	NN

was	VBD
O	NN

treated	VBN
O	NN

by	IN
O	NN

administration	NN
T	NN

of	IN
T	NN

clear	JJ
T	NN

fluids	NNS
T	NN

orally	RB
O	NN

for	IN
O	NN

one	CD
O	NN

day	NN
O	NN

We	PRP
O	VBP

treated	VBN
O	NN

two	CD
O	NN

children	NNS
O	VBP

with	IN
O	NN

influenza-associated	JJ
D	NN

acute	JJ
D	NN

encephalopathy	NN
D	NN

by	IN
O	NN

a	DT
O	NN

combination	NN
T	NN

of	IN
T	NN

mild	JJ
T	NN

hypothermia	NN
T	NN

and	CC
T	NN

steroid	NN
T	NN

pulse	NN
T	NN

therapy	NN
T	NN

Successful	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

anaerobic	JJ
D	NN

pleuropulmonary	JJ
D	NN

infections	NNS
D	NN

requires	VBZ
O	NN

a	DT
O	NN

combination	NN
T	NN

of	IN
T	NN

antibiotic	JJ
T	NN

therapy	NN
T	NN

and	CC
T	NN

surgical	JJ
T	NN

interventions	NNS
T	NN

Treatment	NN
O	NN

of	IN
O	NN

spontaneous	JJ
D	NN

carotid-cavernous	JJ
D	NN

fistula	NN
D	NN

in	IN
D	NN

Ehlers-Danlos	NN
D	NN

syndrome	NN
D	NN

by	IN
O	NN

transvenous	JJ
T	NN

occlusion	NN
T	NN

with	IN
T	NN

Guglielmi	NNP
T	NN

detachable	JJ
T	NN

coils	NNS
T	NN

PURPOSE	NN
O	NN

:	:
O	NN

Macrolide	NN
T	NN

antibiotics	NNS
T	NN

are	VBP
O	NN

frequently	RB
O	NN

prescribed	VBN
O	NN

to	TO
O	NN

patients	NNS
O	NN

with	IN
O	NN

symptoms	NNS
D	NN

of	IN
D	NN

a	DT
D	NN

common	JJ
D	NN

cold	JJ
D	NN

Because	IN
O	NN

the	DT
O	NN

symptoms	NNS
O	NN

of	IN
O	NN

rhinovirus	NN
O	NN

colds	NNS
O	NN

are	VBP
O	NN

attributed	VBN
O	NN

to	TO
O	NN

the	DT
O	NN

inflammatory	JJ
O	NN

response	NN
O	NN

to	TO
O	NN

infection	NN
O	NN

,	,
O	NN

we	PRP
O	VBP

studied	VBN
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

treatment	NN
O	NN

with	IN
O	NN

clarithromycin	NN
T	NN

on	IN
O	NN

the	DT
O	NN

symptomatic	JJ
O	NN

and	CC
O	NN

inflammatory	JJ
O	NN

response	NN
O	NN

to	TO
O	NN

nasal	JJ
O	NN

inoculation	NN
O	NN

with	IN
O	NN

rhinovirus	NN
D	NN

Therapeutic	JJ
T	NN

pneumothorax	NN
T	NN

(	NN
T	NN

TP	NN
T	NN

)	NN
T	NN

proved	VBN
O	NN

its	PRP$
O	NN

efficacy	NN
O	NN

in	IN
O	NN

pre-antibiotic	JJ
O	NN

era	NN
O	NN

,	,
O	NN

so	RB
O	NN

one	CD
O	NN

can	MD
O	NNP

assume	VB
O	NN

that	IN
O	NN

it	PRP
O	NN

can	MD
O	NNP

be	VB
O	NN

applied	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

same	JJ
O	NN

success	NN
O	NN

in	IN
O	NN

multidrug	JJ
D	NN

resistant	JJ
D	NN

TB	NN
D	NN

In	IN
O	NN

conclusion	NN
O	NN

,	,
O	NN

in	IN
O	NN

some	DT
O	NN

cases	NNS
O	NN

of	IN
O	NN

MDR	NN
D	NN

TB	NN
D	NN

,	,
O	NN

the	DT
O	NN

TP	NN
T	NN

(	NN
O	NN

if	IN
O	NN

there	RB
O	NN

are	VBP
O	NN

no	DT
O	NN

pleural	JJ
O	NN

adherences	NNS
O	NN

)	NN
O	NN

may	MD
O	NNP

lead	JJ
O	NN

to	TO
O	NN

good	JJ
O	NN

results	NNS
O	VBP

Acupuncture	NN
T	NN

treatment	NN
O	NN

of	IN
O	NN

common	JJ
D	NN

cold	JJ
D	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

These	DT
O	NN

data	NNS
O	NN

,	,
O	NN

the	DT
O	NN

first	RB
O	NN

evidence	NN
O	NN

that	IN
O	NN

chronic	JJ
O	NN

stress	NN
O	NN

can	MD
O	NNP

inhibit	VB
O	NN

the	DT
O	NN

stability	NN
O	NN

of	IN
O	NN

the	DT
O	NN

IgG	NN
O	NN

antibody	NN
O	NN

response	NN
O	NN

to	TO
O	NN

a	DT
O	NN

bacterial	JJ
T	NN

vaccine	NN
T	NN

for	IN
O	NN

pneumonia	NN
D	NN

,	,
O	NN

provide	VB
O	NN

additional	JJ
O	NN

evidence	NN
O	NN

of	IN
O	NN

health	NN
O	NN

risks	NNS
O	VBP

associated	VBN
O	NN

with	IN
O	NN

dementia	NN
O	NN

caregiving	VBG
O	NN

When	WRB
O	NN

bleeding	NN
D	NN

is	VBZ
O	NN

stopped	VBD
O	NN

via	IN
O	NN

surgical	JJ
T	NN

or	CC
T	NN

radiological	JJ
T	NN

methods	NNS
T	NN

,	,
O	NN

the	DT
O	NN

clinical	JJ
O	NN

course	NN
O	NN

of	IN
O	NN

hemobilia-associated	JJ
O	NN

pancreatitis	NN
O	NN

appears	VBZ
O	NN

to	TO
O	NN

be	VB
O	NN

benign	JJ
O	NN

A	DT
O	NN

case	NN
O	NN

of	IN
O	NN

biliary	JJ
D	NN

stenosis	NN
D	NN

in	IN
O	NN

polycystic	JJ
O	NN

liver	NN
O	NN

improved	VBN
O	NN

by	IN
O	NN

injection	NN
T	NN

of	IN
T	NN

minocycline	NN
T	NN

hydrochloride	NN
T	NN

to	TO
O	NN

a	DT
O	NN

hepatic	JJ
O	NN

cyst	NN
O	NN

The	DT
O	NN

ruptured	VBN
D	NN

horn	NN
D	NN

was	VBD
O	NN

excised	VBN
O	NN

by	IN
O	NN

laparotomy	NN
T	NN

Therapy	NN
O	NN

designed	VBN
O	NN

to	TO
O	NN

control	NN
O	NN

the	DT
O	NN

efferent	NN
D	NN

phase	NN
D	NN

of	IN
D	NN

established	VBN
D	NN

asthma	NN
D	NN

by	IN
O	NN

augmenting	VBG
T	NN

down-regulatory	JJ
T	NN

Th1	NN
T	NN

counterbalancing	VBG
T	NN

mechanisms	NNS
T	NN

should	MD
O	NNP

be	VB
O	NN

effective	JJ
O	NN

All	DT
O	NN

children	NNS
O	VBP

with	IN
O	NN

croup	NN
D	NN

symptoms	NNS
O	NN

who	WP
O	VBP

demonstrate	VB
O	NN

increased	VBN
O	NN

work	NN
O	NN

of	IN
O	NN

breathing	VBG
O	NN

in	IN
O	NN

the	DT
O	NN

clinics	NNS
O	NN

or	CC
O	NN

emergency	NN
O	NN

departments	NNS
O	NN

should	MD
O	NNP

be	VB
O	NN

treated	VBN
O	NN

with	IN
O	NN

glucocorticoids	NNS
T	NN

Increasing	VBG
O	NN

resistance	NN
O	NN

among	IN
O	NN

the	DT
O	NN

common	JJ
D	NN

respiratory	JJ
D	NN

pathogens	NNS
D	NN

has	VBZ
O	NN

encouraged	JJ
O	NN

assessment	NN
O	NN

of	IN
O	NN

alternative	JJ
O	NN

agents	NNS
O	NN

,	,
O	NN

for	IN
O	NN

example	NN
O	NN

,	,
O	NN

levofloxacin	NN
T	NN

Unlike	IN
O	NN

earlier	JJR
O	NN

quinolones	NNS
O	NN

,	,
O	NN

levofloxacin	NN
T	NN

has	VBZ
O	NN

excellent	JJ
O	NN

activity	NN
O	NN

against	IN
O	NN

Streptococcus	NN
D	NN

pneumoniae	FW
D	NN

,	,
O	NN

including	VBG
O	NN

strains	NNS
O	NN

resistant	JJ
O	NN

to	TO
O	NN

penicillin	NN
O	NN

Clinical	JJ
O	NN

trials	NNS
O	NN

show	NN
O	NN

levofloxacin	NN
T	NN

to	TO
O	NN

be	VB
O	NN

as	IN
O	NN

effective	JJ
O	NN

as	IN
O	NN

cephalosporins	NNS
O	NN

in	IN
O	NN

acute	JJ
O	NN

exacerbation	NN
O	NN

of	IN
O	NN

chronic	JJ
D	NN

bronchitis	NN
D	NN

and	CC
O	NN

as	IN
O	NN

effective	JJ
O	NN

as	IN
O	NN

co-amoxiclav	NN
O	NN

,	,
O	NN

cephalosporins	NNS
O	NN

or	CC
O	NN

amoxycillin	NN
O	NN

in	IN
O	NN

community-acquired	JJ
D	NN

pneumonia	NN
D	NN

Additionally	RB
O	NN

,	,
O	NN

epidemiologic	JJ
O	NN

evidence	NN
O	NN

of	IN
O	NN

a	DT
O	NN

marked	JJ
O	NN

decline	NN
O	NN

in	IN
O	NN

new	JJ
O	NN

KS	NN
D	NN

since	IN
O	NN

the	DT
O	NN

widespread	JJ
O	NN

use	NN
O	NN

of	IN
O	NN

highly	RB
T	NN

active	JJ
T	NN

antiretroviral	JJ
T	NN

therapy	NN
T	NN

(	NN
T	NN

HAART	JJ
T	NN

)	NN
T	NN

advocates	NNS
O	VBP

its	PRP$
O	NN

use	NN
O	NN

A	DT
O	NN

field	NN
O	NN

study	NN
O	NN

was	VBD
O	NN

carried	VBD
O	NN

out	IN
O	NN

to	TO
O	NN

evaluate	VB
O	NN

the	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

vaccination	NN
T	NN

against	IN
O	NN

swine	NNS
D	NN

enzootic	JJ
D	NN

pneumonia	NN
D	NN

in	IN
O	NN

different	JJ
O	NN

production	NN
O	NN

systems	NNS
O	NN

(	NN
O	NN

closed	JJ
O	NN

or	CC
O	NN

one-site	JJ
O	NN

,	,
O	NN

and	CC
O	NN

open	JJ
O	NN

,	,
O	NN

two-	CD
O	NN

or	CC
O	NN

three-site	JJ
O	NN

,	,
O	NN

systems	NNS
O	NN

)	NN
O	NN

Humoral	JJ
O	NN

immune	JJ
O	NN

response	NN
O	NN

after	IN
O	NN

vaccination	NN
T	NN

against	IN
O	NN

influenza	NN
D	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

breast	NN
O	NN

cancer	NN
O	NN

Gingyo-san	JJ
T	NN

and	CC
O	NN

its	PRP$
O	NN

components	NNS
O	NN

were	VBD
O	NN

administered	VBN
O	NN

orally	RB
O	NN

to	TO
O	NN

mice	NNS
O	NN

1	CD
O	NN

day	NN
O	NN

before	IN
O	NN

,	,
O	NN

then	RB
O	NN

1	CD
O	NN

and	CC
O	NN

4	CD
O	NN

days	NNS
O	NN

after	IN
O	NN

the	DT
O	NN

inhalation	NN
O	NN

of	IN
O	NN

a	DT
O	NN

mouse-adopted	JJ
D	NN

strain	NN
D	NN

of	IN
D	NN

influenza	NN
D	NN

A2	NN
D	NN

(	NN
D	NN

H2N2	NN
D	NN

)	NN
D	NN

virus	NN
D	NN

From	IN
O	NN

these	DT
O	NN

results	NNS
O	VBP

Gingyo-san	JJ
T	NN

was	VBD
O	NN

shown	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

an	DT
O	NN

antiviral	JJ
O	NN

agent	NN
O	NN

in	IN
O	NN

mice	NNS
O	NN

infected	JJ
O	NN

with	IN
O	NN

a	DT
O	NN

lethal	JJ
O	NN

amount	NN
O	NN

of	IN
O	NN

a	DT
O	NN

mouse-adopted	JJ
D	NN

strain	NN
D	NN

of	IN
D	NN

influenza	NN
D	NN

A2	NN
D	NN

virus	NN
D	NN

The	DT
O	NN

purpose	NN
O	NN

of	IN
O	NN

the	DT
O	NN

present	JJ
O	NN

study	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

analyze	VB
O	NN

the	DT
O	NN

association	NN
O	NN

of	IN
O	NN

recurrent	JJ
O	NN

abdominal	JJ
O	NN

pain	NN
O	NN

and	CC
O	NN

H.	NNP
O	NNP

pylori	NN
O	NN

infection	NN
O	NN

in	IN
O	NN

children	NNS
O	VBP

and	CC
O	NN

to	TO
O	NN

evaluate	VB
O	NN

the	DT
O	NN

efficacy	NN
O	NN

of	IN
O	NN

antimicrobial	JJ
T	NN

treatment	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

evidence	NN
O	NN

of	IN
O	NN

infection	NN
D	NN

Patients	NNS
O	NN

with	IN
O	NN

evidence	NN
O	NN

of	IN
O	NN

infection	NN
D	NN

with	IN
D	NN

H.	NN
D	NN

pylori	NN
D	NN

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

combination	NN
T	NN

of	IN
T	NN

omeprazole	NN
T	NN

,	,
T	NN

amoxicillin	NNP
T	NN

,	,
T	NN

and	CC
T	NN

clarithromycin	NN
T	NN

Treatment	NN
O	NN

with	IN
O	NN

omeprazole	NN
T	NN

,	,
T	NN

amoxicillin	NNP
T	NN

,	,
T	NN

and	CC
T	NN

clarithromycin	NN
T	NN

resulted	VBD
O	NN

in	IN
O	NN

eradication	NN
O	NN

of	IN
O	NN

the	DT
O	NN

infection	NN
D	NN

in	IN
O	NN

all	DT
O	NN

and	CC
O	NN

in	IN
O	NN

resolution	NN
O	NN

of	IN
O	NN

the	DT
O	NN

clinical	JJ
O	NN

symptoms	NNS
O	NN

in	IN
O	NN

15	CD
O	NN

(	NN
O	NN

80	CD
O	NN

%	NN
O	NN

)	NN
O	NN

of	IN
O	NN

19	CD
O	NN

patients	NNS
O	NN

who	WP
O	VBP

had	VBD
O	NN

a	DT
O	NN

follow-up	JJ
O	NN

examination	NN
O	NN

A	DT
O	NN

combined	VBN
T	NN

therapy	NN
T	NN

results	NNS
O	VBP

in	IN
O	NN

eradication	NN
O	NN

of	IN
O	NN

the	DT
O	NN

bacterium	NN
D	NN

and	CC
O	NN

in	IN
O	NN

improvement	NN
O	NN

of	IN
O	NN

the	DT
O	NN

clinical	JJ
O	NN

symptoms	NNS
O	NN

in	IN
O	NN

a	DT
O	NN

significant	JJ
O	NN

majority	NN
O	NN

of	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

In	IN
O	NN

certain	JJ
O	NN

clinical	JJ
O	NN

settings	NNS
O	VBP

,	,
O	NN

interventional	JJ
T	NN

radiologic	JJ
T	NN

procedures	NNS
T	NN

have	VB
O	NN

become	VBN
O	NN

an	DT
O	NN

important	JJ
O	NN

alternative	JJ
O	NN

to	TO
O	NN

surgery	NN
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

gallstones	NNS
D	NN

and	CC
O	NN

their	PRP$
O	NN

complications	NNS
O	NN

;	:
O	NN

techniques	NNS
O	VBP

include	VBP
O	NN

percutaneous	JJ
T	NN

cholecystostomy	NN
T	NN

and	CC
T	NN

gallstone	NN
T	NN

removal	NN
T	NN

BACKGROUND	NN
O	NN

:	:
O	NN

The	DT
O	NN

administration	NN
O	NN

of	IN
O	NN

salbutamol	NN
T	NN

is	VBZ
O	NN

permitted	VBN
O	NN

only	RB
O	NN

by	IN
O	NN

inhalation	NN
O	NN

by	IN
O	NN

the	DT
O	NN

International	NNP
O	NNP

Olympic	NNP
O	NN

Committee	NNP
O	NNP

(	NN
O	NN

IOC	NNP
O	NNP

)	NN
O	NN

for	IN
O	NN

the	DT
O	NN

management	NN
O	NN

of	IN
O	NN

asthma	NN
D	NN

and	CC
D	NN

exercise-induced	JJ
D	NN

asthma	NN
D	NN

in	IN
O	NN

athletes	NNS
O	NN

Urine	NN
O	NN

was	VBD
O	NN

also	RB
O	NN

obtained	VBN
O	NN

from	IN
O	NN

subjects	NNS
O	NN

who	WP
O	VBP

had	VBD
O	NN

received	VBN
O	NN

the	DT
O	NN

maximum	NN
O	NN

dosage	NN
O	NN

of	IN
O	NN

inhaled	VBN
O	NN

salbutamol	NN
T	NN

advisable	JJ
O	NN

for	IN
O	NN

competing	VBG
O	NN

athletes	NNS
O	NN

to	TO
O	NN

provide	VB
O	NN

protection	NN
O	NN

from	IN
O	NN

exercise-induced	JJ
O	NN

asthma	NN
O	NN

and	CC
O	NN

treatment	NN
O	NN

of	IN
O	NN

asthma	NN
D	NN

(	NN
O	NN

1600	CD
O	NN

microg	NN
O	NN

in	IN
O	NN

24	CD
O	NN

h	NN
O	NN

,	,
O	NN

800	CD
O	NN

microg	NN
O	NN

being	VBG
O	NN

in	IN
O	NN

the	DT
O	NN

last	JJ
O	NN

4	CD
O	NN

h	NN
O	NN

)	NN
O	NN

Antimicrobials	NNS
T	NN

were	VBD
O	NN

prescribed	VBN
O	NN

to	TO
O	NN

175	CD
O	NN

(	NN
O	NN

83.73	CD
O	NN

per	IN
O	NN

cent	NN
O	NN

)	NN
O	NN

patients	NNS
O	NN

with	IN
O	NN

common	JJ
D	NN

cold	JJ
D	NN

and	CC
O	NN

78	CD
O	NN

(	NN
O	NN

82.11	CD
O	NN

per	IN
O	NN

cent	NN
O	NN

)	NN
O	NN

patients	NNS
O	NN

with	IN
O	NN

diarrhea	NN
D	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

to	TO
O	NN

evaluate	VB
O	NN

the	DT
O	NN

possible	JJ
O	NN

existence	NN
O	NN

of	IN
O	NN

the	DT
O	NN

so-called	JJ
O	NN

<	JJR
O	NN

Roux-en-Y	NN
O	NN

syndrome	NN
O	NN

>	JJR
O	NN

in	IN
O	NN

a	DT
O	NN

group	NN
O	NN

of	IN
O	NN

21	CD
O	NN

patients	NNS
O	NN

who	WP
O	VBP

underwent	VBD
O	NN

surgery	NN
T	NN

to	TO
O	NN

correct	JJ
O	NN

postoperative	JJ
D	NN

alkaline	NN
D	NN

reflux	NN
D	NN

gastritis	NN
D	NN

All	DT
O	NN

had	VBD
O	NN

undergone	VBN
O	NN

Billroth	JJ
T	NN

II	NNP
T	NN

subtotal	JJ
T	NN

gastrectomy	NN
T	NN

(	NN
O	NN

20	CD
O	NN

for	IN
O	NN

ulcer	NN
D	NN

and	CC
O	NN

1	CD
O	NN

for	IN
O	NN

gastric	JJ
D	NN

cancer	NN
D	NN

)	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

we	PRP
O	VBP

found	VBN
O	NN

no	DT
O	NN

evidence	NN
O	NN

of	IN
O	NN

disturbances	NNS
O	VBP

in	IN
O	NN

gastric	JJ
O	NN

remnant	NN
O	NN

emptying	VBG
O	NN

after	IN
O	NN

Roux-en-Y	JJ
T	NN

gastrojejunostomy	NN
T	NN

to	TO
O	NN

treat	VB
O	NNP

postoperative	JJ
D	NN

alkaline	NN
D	NN

gastric	JJ
D	NN

reflux	NN
D	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Drainage	NN
O	NN

methods	NNS
O	VBP

for	IN
O	NN

the	DT
O	NN

gastric	JJ
O	NN

conduit	NN
O	NN

after	IN
O	NN

esophagectomy	NN
T	NN

for	IN
O	NN

carcinoma	NN
D	NN

have	VB
O	NN

been	VBN
O	NN

controversial	JJ
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

This	DT
O	NN

study	NN
O	NN

indicates	VBZ
O	NN

that	IN
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

a	DT
O	NN

computerized	JJ
O	NN

physician	NN
O	NN

reminder	NN
O	NN

and	CC
O	NN

a	DT
O	NN

mailed	VBN
O	NN

patient	NN
O	NN

reminder	NN
O	NN

had	VBD
O	NN

a	DT
O	NN

positive	JJ
O	NN

impact	NN
O	NN

on	IN
O	NN

influenza	NN
D	NN

immunizations	NNS
T	NN

for	IN
O	NN

older	JJR
O	NN

adults	NNS
O	NN

in	IN
O	NN

a	DT
O	NN

large	JJ
O	NN

family	NN
O	NN

practice	NN
O	NN

office	NN
O	NN

Contemporary	NNP
O	NNP

asthma	NN
O	NN

management	NN
O	NN

guidelines	NNS
O	NN

list	NN
O	NN

inhaled	VBN
T	NN

corticosteroids	NNS
T	NN

as	IN
O	NN

the	DT
O	NN

preferred	VBN
O	NN

controller	NN
O	NN

medication	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

persistent	JJ
D	NN

asthma	NN
D	NN

Fluticasone	NN
T	NN

propionate	NN
T	NN

is	VBZ
O	NN

one	CD
O	NN

of	IN
O	NN

several	JJ
O	NN

inhaled	VBN
O	NN

corticosteroids	NNS
O	NN

used	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

asthma	NN
D	NN

A	DT
O	NN

series	NN
O	NN

of	IN
O	NN

comparative	JJ
O	NN

analyses	NNS
O	VBP

show	NN
O	NN

that	IN
O	NN

inhaled	VBN
T	NN

fluticasone	NN
T	NN

propionate	NN
T	NN

is	VBZ
O	NN

more	RBR
O	NN

cost	NN
O	NN

effective	JJ
O	NN

than	IN
O	NN

oral	JJ
O	NN

zafirlukast	NN
O	NN

and	CC
O	NN

triamcinolone	NN
O	NN

acetonide	NN
O	NN

and	CC
O	NN

slightly	RB
O	NN

more	RBR
O	NN

cost	NN
O	NN

effective	JJ
O	NN

than	IN
O	NN

flunisolide	NN
O	NN

in	IN
O	NN

adult	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

asthma	NN
D	NN

Quality-of-life	JJ
O	NN

assessments	NNS
O	VBP

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

mild	JJ
O	NN

to	TO
O	NN

moderate	JJ
O	NN

disease	NN
O	NN

show	NN
O	NN

that	IN
O	NN

inhaled	VBN
T	NN

fluticasone	NN
T	NN

propionate	NN
T	NN

achieved	VBN
O	NN

improvements	NNS
O	VBP

which	WDT
O	NN

were	VBD
O	NN

deemed	VBD
O	NN

to	TO
O	NN

be	VB
O	NN

clinically	RB
O	NN

meaningful	JJ
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

mild	JJ
O	NN

to	TO
O	NN

moderate	JJ
O	NN

asthma	NN
D	NN

;	:
O	NN

these	DT
O	NN

changes	NNS
O	VBP

were	VBD
O	NN

significantly	RB
O	NN

greater	JJR
O	NN

than	IN
O	NN

those	DT
O	NNP

achieved	VBN
O	NN

with	IN
O	NN

oral	JJ
O	NN

zafirlukast	NN
O	NN

,	,
O	NN

inhaled	VBN
O	NN

triamcinolone	NN
O	NN

acetonide	NN
O	NN

or	CC
O	NN

placebo	NN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

In	IN
O	NN

addition	NN
O	NN

to	TO
O	NN

the	DT
O	NN

considerable	JJ
O	NN

body	NN
O	NN

of	IN
O	NN

clinical	JJ
O	NN

evidence	NN
O	NN

supporting	VBG
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

inhaled	VBN
T	NN

fluticasone	NN
T	NN

propionate	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

asthma	NN
D	NN

,	,
O	NN

accumulating	VBG
O	NN

short	JJ
O	NN

term	NN
O	NN

cost-effectiveness	NN
O	NN

data	NNS
O	NN

also	RB
O	NN

suggest	VBP
O	NN

that	IN
O	NN

this	DT
O	NN

agent	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

administered	VBN
O	NN

for	IN
O	NN

a	DT
O	NN

similar	JJ
O	NN

or	CC
O	NN

lower	JJR
O	NN

cost	NN
O	NN

per	IN
O	NN

outcome	NN
O	NN

than	IN
O	NN

other	JJ
O	NN

inhaled	VBN
O	NN

corticosteroids	NNS
O	NN

or	CC
O	NN

oral	JJ
O	NN

zafirlukast	NN
O	NN

Importantly	RB
O	NN

,	,
O	NN

the	DT
O	NN

clinical	JJ
O	NN

benefits	NNS
O	NN

offered	VBN
O	NN

by	IN
O	NN

fluticasone	NN
T	NN

propionate	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

persistent	JJ
D	NN

asthma	NN
D	NN

are	VBP
O	NN

accompanied	VBN
O	NN

by	IN
O	NN

clinically	RB
O	NN

significant	JJ
O	NN

improvements	NNS
O	VBP

in	IN
O	NN

quality	NN
O	NN

of	IN
O	NN

life	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

describe	VBP
O	NN

the	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

influenza	NN
D	NN

vaccination	NN
T	NN

on	IN
O	NN

long-term	JJ
O	NN

change	NN
O	NN

in	IN
O	NN

CD4	NN
O	NN

count	NN
O	NN

and	CC
O	NN

HIV	NN
O	NN

RNA	NN
O	NN

level	NN
O	NN

,	,
O	NN

and	CC
O	NN

on	IN
O	NN

progression	NN
O	NN

to	TO
O	NN

AIDS	NNP
O	NN

or	CC
O	NN

death	NN
O	NN

Combination	NN
T	NN

therapy	NN
T	NN

with	IN
T	NN

interferon-alpha	NN
T	NN

(	NN
T	NN

IFN	NN
T	NN

alpha	NN
T	NN

)	NN
T	NN

plus	CC
T	NN

Ribavirin	NNP
T	NN

has	VBZ
O	NN

been	VBN
O	NN

shown	VBN
O	NN

to	TO
O	NN

improve	VB
O	NN

the	DT
O	NN

response	NN
O	NN

rate	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

hepatitis	NN
D	NN

C	NN
D	NN

as	IN
O	NN

compared	VBN
O	NN

to	TO
O	NN

IFN	NN
O	NN

alpha	NN
O	NN

alone	RB
O	NN

To	TO
O	NN

prove	VB
O	NN

,	,
O	NN

whether	IN
O	NN

Ribavirin	NNP
T	NN

has	VBZ
O	NN

any	DT
O	NN

additional	JJ
O	NN

effect	NN
O	NN

on	IN
O	NN

the	DT
O	NN

decline	NN
O	NN

of	IN
O	NN

hepatitis	NN
D	NN

C	NN
D	NN

viremia	NN
D	NN

during	IN
O	NN

the	DT
O	NN

first	RB
O	NN

weeks	NNS
O	NN

of	IN
O	NN

treatment	NN
O	NN

patients	NNS
O	NN

with	IN
O	NN

and	CC
O	NN

without	IN
O	NN

combination	NN
O	NN

therapy	NN
O	NN

were	VBD
O	NN

compared	VBN
O	NN

In	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

combination	NN
T	NN

therapy	NN
T	NN

,	,
O	NN

a	DT
O	NN

further	RB
O	NN

reduction	NN
O	NN

of	IN
O	NN

viremia	NN
D	NN

level	NN
O	NN

could	MD
O	NNP

be	VB
O	NN

observed	VBN
O	NN

,	,
O	NN

whereas	IN
O	NN

viremia	NN
O	NN

levels	NNS
O	VBP

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

IFN	NN
O	NN

alpha	NN
O	NN

alone	RB
O	NN

slightly	RB
O	NN

increased	VBN
O	NN

Ribavirin	NNP
T	NN

in	IN
T	NN

combination	NN
T	NN

with	IN
T	NN

IFN	NN
T	NN

alpha	NN
T	NN

exerts	VBZ
O	NN

an	DT
O	NN

additional	JJ
O	NN

anti-viral/immunmodulatory	JJ
O	NN

effect	NN
O	NN

which	WDT
O	NN

manifests	VBZ
O	NN

itself	PRP
O	NN

in	IN
O	NN

phase	NN
O	NN

2	CD
O	NN

of	IN
O	NN

hepatitis	NN
D	NN

C	NN
D	NN

viremia	NN
D	NN

decline	NN
O	NN

Surgical	NNP
T	NN

clearance	NN
T	NN

of	IN
O	NN

CBD	NN
D	NN

stones	NNS
D	NN

was	VBD
O	NN

achieved	VBN
O	NN

in	IN
O	NN

58	CD
O	NN

patients	NNS
O	NN

(	NN
O	NN

93.5	CD
O	NN

%	NN
O	NN

;	:
O	NN

group	NN
O	NN

Ia	NN
O	NN

)	NN
O	NN

Use	NNP
O	NNP

of	IN
O	NN

ES	NN
T	NN

to	TO
O	NN

treat	VB
O	NNP

CBD	NN
D	NN

stones	NNS
D	NN

on	IN
O	NN

a	DT
O	NN

routine	JJ
O	NN

basis	NN
O	NN

was	VBD
O	NN

therefore	RB
O	NN

not	RB
O	NN

found	VBN
O	NN

to	TO
O	NN

be	VB
O	NN

any	DT
O	NN

better	JJR
O	NN

than	IN
O	NN

one-time	JJ
O	NN

surgical	JJ
O	NN

exploration	NN
O	NN

Effect	NN
O	NN

of	IN
O	NN

cholecystectomy	NN
T	NN

on	IN
O	NN

gastroesophageal	NN
D	NN

and	CC
D	NN

duodenogastric	JJ
D	NN

reflux	NN
D	NN

It	PRP
O	NN

is	VBZ
O	NN

suggested	VBN
O	NN

that	IN
O	NN

damaged	VBN
D	NN

mucosal	JJ
D	NN

tissues	NNS
D	NN

with	IN
O	NN

AHF	NN
T	NN

can	MD
O	NNP

be	VB
O	NN

effectively	RB
O	NN

compensated	VBN
O	NN

by	IN
O	NN

enhanced	VBN
O	NN

regeneration	NN
O	NN

response	NN
O	NN

due	JJ
O	NN

to	TO
O	NN

an	DT
O	NN

adequately	RB
O	NN

high	JJ
O	NN

dose	NN
O	NN

intensity	NN
O	NN

,	,
O	NN

suggesting	VBG
O	NN

a	DT
O	NN

possible	JJ
O	NN

tolerability	NN
O	NN

advantage	NN
O	NN

for	IN
O	NN

AHF	NN
O	NN

Minimally	RB
O	NN

invasive	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

abscesses	NNS
D	NN

by	IN
O	NN

CT-controlled	JJ
T	NN

drainage	NN
T	NN

with	IN
T	NN

a	DT
T	NN

basket	NN
T	NN

catheter	NN
T	NN

system	NN
T	NN

PL	NN
T	NN

granule	NN
T	NN

is	VBZ
O	NN

one	CD
O	NN

of	IN
O	NN

the	DT
O	NN

most	JJS
O	NN

common	JJ
O	NN

forms	NNS
O	NN

of	IN
O	NN

composite	JJ
O	NN

medicine	NN
O	NN

for	IN
O	NN

colds	NNS
D	NN

in	IN
O	NN

Japan	NNP
O	NNP

,	,
O	NN

including	VBG
O	NN

acetaminophen	NN
O	NN

A	DT
O	NN

72-year	JJ
O	NN

old	JJ
O	NN

man	NN
O	NN

who	WP
O	VBP

had	VBD
O	NN

been	VBN
O	NN

prescribed	VBN
O	NN

amiodarone	NN
T	NN

for	IN
O	NN

more	RBR
O	NN

than	IN
O	NN

one	CD
O	NN

year	NN
O	NN

before	IN
O	NN

for	IN
O	NN

arrhythmogenic	JJ
D	NN

right	NN
D	NN

ventricular	JJ
D	NN

dystrophy	NN
D	NN

,	,
O	NN

repeatedly	RB
O	NN

took	VBD
O	NN

PL	NN
O	NN

granules	NNS
O	NN

at	IN
O	NN

one-week	JJ
O	NN

intervals	NNS
O	NN

because	IN
O	NN

of	IN
O	NN

sneezing	VBG
O	NN

and	CC
O	NN

fever	NN
O	NN

He	PRP
O	VBP

needed	VBN
O	NN

mechanical	JJ
T	NN

ventilation	NN
T	NN

for	IN
O	NN

severe	JJ
D	NN

hypoxemia	NN
D	NN

,	,
O	NN

but	CC
O	NNP

recovered	VBN
O	NN

with	IN
O	NN

glucocorticoid	NN
T	NN

pulse	NN
T	NN

therapy	NN
T	NN

In	IN
O	NN

a	DT
O	NN

follow-up	JJ
O	NN

study	NN
O	NN

operative	JJ
O	NN

risk	NN
O	NN

,	,
O	NN

postoperative	JJ
O	NN

functional	JJ
O	NN

disorders	NNS
O	NN

and	CC
O	NN

incidence	NN
O	NN

of	IN
O	NN

anastomotic	JJ
O	NN

(	NN
O	NN

recurrent	JJ
O	NN

)	NN
O	NN

ulcer	NN
O	NN

after	IN
O	NN

partial	JJ
T	NN

gastrectomy	NN
T	NN

with	IN
T	NN

Roux-en-Y	JJ
T	NN

gastrojejunostomy	NN
T	NN

for	IN
O	NN

gastroduodenal	NN
D	NN

ulcer	NN
D	NN

were	VBD
O	NN

evaluated	VBN
O	NN

in	IN
O	NN

52	CD
O	NN

patients	NNS
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

With	IN
O	NN

regard	NN
O	NN

to	TO
O	NN

the	DT
O	NN

high	JJ
O	NN

rate	NN
O	NN

of	IN
O	NN

recurrent	JJ
D	NN

ulcer	NN
D	NN

Roux-en-Y	JJ
T	NN

reconstruction	NN
T	NN

after	IN
O	NN

partial	JJ
T	NN

gastrectomy	NN
T	NN

for	IN
O	NN

primary	JJ
D	NN

ulcer	NN
D	NN

surgery	NN
D	NN

should	MD
O	NNP

be	VB
O	NN

avoided	VBN
O	NN

and	CC
O	NN

reconstruction	NN
O	NN

procedures	NNS
O	VBP

preferred	VBN
O	NN

,	,
O	NN

which	WDT
O	NN

guarantee	NN
O	NN

duodenogastric	JJ
O	NN

reflux	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

The	DT
O	NN

aim	NN
O	NN

of	IN
O	NN

these	DT
O	NN

studies	NNS
O	VBP

was	VBD
O	NN

to	TO
O	NN

compare	VB
O	NN

the	DT
O	NN

pharmacokinetics	NNS
O	NN

of	IN
O	NN

inhaled	VBN
T	NN

fluticasone	NN
T	NN

propionate	NN
T	NN

(	NN
T	NN

FP	NN
T	NN

)	NN
T	NN

after	IN
O	NN

repeated	VBN
O	NN

administration	NN
O	NN

via	IN
O	NN

the	DT
O	NN

Diskus	NNP
O	NNP

or	CC
O	NN

Diskhaler	NNP
O	NNP

dry	JJ
O	NN

powder	NN
O	NN

inhalers	NNS
O	NN

(	NN
O	NN

DPIs	NNS
O	NN

)	NN
O	NN

to	TO
O	NN

patients	NNS
O	NN

with	IN
O	NN

mild-to-moderate	JJ
D	NN

asthma	NN
D	NN

CONCLUSION	NN
O	NN

:	:
O	NN

In	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

asthma	NN
D	NN

receiving	VBG
O	NN

repeated	VBN
T	NN

inhaled	VBN
T	NN

doses	NNS
T	NN

of	IN
T	NN

FP	NN
T	NN

,	,
O	NN

the	DT
O	NN

systemic	JJ
O	NN

exposure	NN
O	NN

(	NN
O	NN

AUC	NN
O	NN

)	NN
O	NN

after	IN
O	NN

inhalation	NN
O	NN

from	IN
O	NN

the	DT
O	NN

Diskus	NNP
O	NNP

was	VBD
O	NN

similar	JJ
O	NN

to	TO
O	NN

that	IN
O	NN

from	IN
O	NN

the	DT
O	NN

Diskhaler	NNP
O	NNP

,	,
O	NN

with	IN
O	NN

no	DT
O	NN

difference	NN
O	NN

between	IN
O	NN

the	DT
O	NN

DPIs	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

effects	NNS
O	NN

on	IN
O	NN

cortisol	NN
O	NN

suppression	NN
O	NN

DATA	NNP
O	NNP

SYNTHESIS	NN
O	NN

:	:
O	NN

Recently	RB
O	NN

,	,
O	NN

an	DT
O	NN

expert	NN
O	NN

panel	NN
O	NN

of	IN
O	NN

the	DT
O	NN

Centers	NNPS
O	NNP

for	IN
O	NN

Disease	NN
O	NN

Control	NN
O	NN

and	CC
O	NN

Prevention	NNP
O	NNP

recommended	VBN
O	NN

use	NN
O	NN

of	IN
O	NN

only	RB
O	NN

three	CD
O	NN

of	IN
O	NN

16	CD
O	NN

systemic	JJ
T	NN

antibiotics	NNS
T	NN

approved	VBN
O	NN

by	IN
O	NN

the	DT
O	NN

Food	NNP
O	NNP

and	CC
O	NN

Drug	NN
O	NN

Administration	NNP
O	NNP

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

AOM	NN
D	NN

:	:
O	NN

amoxicillin	NNP
T	NN

,	,
T	NN

cefuroxime	NN
T	NN

axetil	NN
T	NN

,	,
T	NN

and	CC
T	NN

ceftriaxone	NN
T	NN

A	DT
O	NN

three-step	JJ
O	NN

treatment	NN
O	NN

algorithm	NN
O	NN

for	IN
O	NN

refractory	JJ
D	NN

AOM	NN
D	NN

that	IN
O	NN

employs	VBZ
O	NN

amoxicillin	NNP
T	NN

,	,
T	NN

trimethoprim/sulfamethoxazole	NN
T	NN

(	NN
T	NN

TMP/SMX	NN
T	NN

)	NN
T	NN

,	,
T	NN

or	CC
T	NN

high-dose	JJ
T	NN

amoxicillin/clavulanate	JJ
T	NN

(	NN
T	NN

depending	VBG
T	NN

on	IN
T	NN

the	DT
T	NN

prior	RB
T	NN

dose	NN
T	NN

of	IN
T	NN

and	CC
T	NN

adherence	NN
T	NN

to	TO
T	NN

amoxicillin	NNP
T	NN

therapy	NN
T	NN

)	NN
T	NN

,	,
T	NN

and	CC
T	NN

ceftriaxone	NN
T	NN

or	CC
T	NN

tympanocentesis	NN
T	NN

at	IN
O	NN

steps	NNS
O	NN

1	CD
O	NN

,	,
O	NN

2	CD
O	NN

,	,
O	NN

and	CC
O	NN

3	CD
O	NN

,	,
O	NN

respectively	RB
O	NN

,	,
O	NN

appears	VBZ
O	NN

rational	JJ
O	NN

and	CC
O	NN

cost-effective	JJ
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Amoxicillin	NNP
T	NN

remains	VBZ
O	NNP

the	DT
O	NN

antibiotic	JJ
O	NN

of	IN
O	NN

choice	NN
O	NN

for	IN
O	NN

initial	JJ
O	NN

empiric	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

AOM	NN
D	NN

,	,
O	NN

although	IN
O	NN

the	DT
O	NN

traditional	JJ
O	NN

dosage	NN
O	NN

should	MD
O	NNP

be	VB
O	NN

increased	VBN
O	NN

in	IN
O	NN

patients	NNS
O	NN

at	IN
O	NN

risk	NN
O	NN

for	IN
O	NN

drug-resistant	JJ
O	NN

S.	NNP
O	NNP

pneumoniae	FW
O	FW

We	PRP
O	VBP

support	NN
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

conjugate	NN
T	NN

pneumococcal	JJ
T	NN

vaccine	NN
T	NN

per	IN
O	NN

guidelines	NNS
O	NN

for	IN
O	NN

prevention	NN
O	NN

of	IN
O	NN

Raom	NN
D	NN

from	IN
O	NN

the	DT
O	NN

Advisory	NNP
O	NNP

Committee	NNP
O	NNP

on	IN
O	NN

Immunization	NN
O	NN

Practice	NN
O	NN

of	IN
O	NN

the	DT
O	NN

Centers	NNPS
O	NNP

for	IN
O	NN

Disease	NN
O	NN

Control	NN
O	NN

and	CC
O	NN

Prevention	NNP
O	NNP

,	,
O	NN

with	IN
O	NN

consideration	NN
O	NN

given	VBN
O	NN

to	TO
O	NN

influenza	NN
D	NN

vaccine	NN
T	NN

for	IN
O	NN

cases	NNS
O	NN

of	IN
O	NN

rAOM	NN
O	NN

that	IN
O	NN

historically	RB
O	NN

worsen	VB
O	NN

during	IN
O	NN

the	DT
O	NN

flu	NN
O	NN

season	NN
O	NN

This	DT
O	NN

model	NN
O	NN

can	MD
O	NNP

be	VB
O	NN

used	VBN
O	NN

to	TO
O	NN

test	NN
O	NN

the	DT
O	NN

safety	NN
O	NN

and	CC
O	NN

efficacy	NN
O	NN

of	IN
O	NN

liver-assist	JJ
T	NN

devices	NNS
T	NN

aimed	VBN
O	NN

at	IN
O	NN

temporizing	VBG
O	NN

the	DT
O	NN

detoxification	NN
O	NN

functions	NNS
O	VBP

of	IN
O	NN

the	DT
O	NN

failing	VBG
D	NN

liver	NN
D	NN

Recent	JJ
O	NN

major	JJ
O	NN

epidemiologic	JJ
O	NN

trends	NNS
O	VBP

in	IN
O	NN

bacterial	JJ
O	NN

meningitis	NN
O	NN

include	VBP
O	NN

a	DT
O	NN

dramatic	JJ
O	NN

decline	NN
O	NN

in	IN
O	NN

the	DT
O	NN

incidence	NN
O	NN

of	IN
O	NN

Haemophilus	NN
D	NN

influenzae	NN
D	NN

meningitis	NN
D	NN

since	IN
O	NN

the	DT
O	NN

introduction	NN
O	NN

of	IN
O	NN

the	DT
O	NN

protein-conjugated	JJ
T	NN

H.	NNP
T	NN

influenzae	NN
T	NN

vaccines	NNS
T	NN

,	,
O	NN

and	CC
O	NN

a	DT
O	NN

worldwide	JJ
O	NN

increase	NN
O	NN

in	IN
O	NN

infections	NNS
O	NN

with	IN
O	NN

antibiotic-resistant	JJ
O	NN

strains	NNS
O	NN

of	IN
O	NN

bacterial	JJ
O	NN

pathogens	NNS
O	NN

dverse	NN
O	NN

outcomes	NNS
O	VBP

and	CC
O	NN

opioid	JJ
T	NN

analgesic	JJ
T	NN

administration	NN
T	NN

in	IN
O	NN

acute	JJ
D	NN

abdominal	JJ
D	NN

pain	NN
D	NN

We	PRP
O	VBP

examined	VBN
O	NN

the	DT
O	NN

remnant	NN
O	NN

stomach	NN
O	NN

for	IN
O	NN

H.	NNP
O	NNP

pylori	NN
O	NN

infection	NN
O	NN

after	IN
O	NN

gastrectomy	NN
T	NN

for	IN
O	NN

gastric	JJ
D	NN

cancer	NN
D	NN

or	CC
D	NN

peptic	JJ
D	NN

ulcer	NN
D	NN

between	IN
O	NN

October	NNP
O	NN

1992	CD
O	NN

and	CC
O	NN

July	NNP
O	NNP

1997	CD
O	NN

The	DT
O	NN

recent	JJ
O	NN

introduction	NN
O	NN

of	IN
O	NN

ribavirin	NNP
T	NN

,	,
O	NN

given	VBN
O	NN

in	IN
O	NN

combination	NN
O	NN

,	,
O	NN

has	VBZ
O	NN

led	VBD
O	NN

to	TO
O	NN

a	DT
O	NN

re-appraisal	JJ
O	NN

of	IN
O	NN

the	DT
O	NN

management	NN
O	NN

of	IN
O	NN

chronic	JJ
D	NN

hepatitis	NN
D	NN

C	NN
D	NN

The	DT
O	NN

current	JJ
O	NN

report	NN
O	NN

considers	VBZ
O	NN

the	DT
O	NN

additional	JJ
O	NN

benefit	NN
O	NN

of	IN
O	NN

combination	NN
T	NN

therapy	NN
T	NN

(	NN
T	NN

interferon	NN
T	NN

alfa	NN
T	NN

and	CC
T	NN

ribavirin	NNP
T	NN

)	NN
T	NN

compared	VBN
O	NN

with	IN
O	NN

monotherapy	NN
O	NN

(	NN
O	NN

interferon	NN
O	NN

alfa	NN
O	NN

alone	RB
O	NN

)	NN
O	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

hepatitis	NN
D	NN

C	NN
D	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

review	NN
O	NN

the	DT
O	NN

clinical	JJ
O	NN

effectiveness	NN
O	NN

and	CC
O	NN

cost-effectiveness	NN
O	NN

of	IN
O	NN

combination	NN
T	NN

therapy	NN
T	NN

with	IN
T	NN

interferon	NN
T	NN

alfa	NN
T	NN

and	CC
T	NN

ribavirin	NNP
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

hepatitis	NN
D	NN

C	NN
D	NN

Sida	NNP
T	NN

cordifolia	NN
T	NN

L.	NNP
T	NN

(	NN
T	NN

Malvaceae	JJ
T	NN

)	NN
T	NN

is	VBZ
O	NN

used	VBN
O	NN

in	IN
O	NN

folk	NN
O	NN

medicine	NN
O	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

inflammation	NN
D	NN

of	IN
D	NN

the	DT
D	NN

oral	JJ
D	NN

mucosa	NN
D	NN

,	,
D	NN

blenorrhea	NN
D	NN

,	,
D	NN

asthmatic	JJ
D	NN

bronchitis	NN
D	NN

and	CC
D	NN

nasal	JJ
D	NN

congestion	NN
D	NN

Double-blind	JJ
O	NN

placebo-controlled	JJ
O	NN

trial	NN
O	NN

of	IN
O	NN

Mycobacterium	NN
T	NN

vaccae	JJ
T	NN

immunotherapy	NN
T	NN

for	IN
O	NN

tuberculosis	NN
D	NN

in	IN
O	NN

KwaZulu	NNP
O	NNP

,	,
O	NN

South	NNP
O	NNP

Africa	NNP
O	NNP

,	,
O	NN

1991-97	CD
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

evaluate	VB
O	NN

the	DT
O	NN

efficacy	NN
O	NN

of	IN
O	NN

oral	JJ
T	NN

tacrolimus	NN
T	NN

as	IN
O	NN

an	DT
O	NN

induction	NN
O	NN

agent	NN
O	NN

in	IN
O	NN

steroid-refractory	JJ
D	NN

severe	JJ
D	NN

colitis	NN
D	NN

.Study	JJ
O	NN

design	NN
O	NN

:	:
O	NN

Open-label	JJ
O	NN

,	,
O	NN

multicenter	JJ
O	NN

trial	NN
O	NN

of	IN
O	NN

oral	JJ
O	NN

tacrolimus	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

severe	JJ
O	NN

colitis	NN
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

Although	IN
O	NN

tacrolimus	NN
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

induction	NN
O	NN

therapy	NN
O	NN

for	IN
O	NN

severe	JJ
D	NN

ulcerative	JJ
D	NN

or	CC
D	NN

Crohn	NN
D	NN

's	POS
D	NN

colitis	NN
D	NN

,	,
O	NN

fewer	JJR
O	NN

than	IN
O	NN

50	CD
O	NN

%	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

treated	VBN
O	NN

will	MD
O	VB

successfully	RB
O	NN

achieve	VB
O	NN

a	DT
O	NN

long-term	JJ
O	NN

remission	NN
O	NN

Cytomegalovirus	NN
D	NN

(	NN
D	NN

CMV	NN
D	NN

)	NN
D	NN

infection	NN
D	NN

was	VBD
O	NN

one	CD
O	NN

of	IN
O	NN

the	DT
O	NN

most	JJS
O	NN

common	JJ
O	NN

opportunistic	JJ
O	NN

infections	NNS
O	NN

in	IN
O	NN

AIDS	NNP
O	NN

patients	NNS
O	NN

,	,
O	NN

leading	VBG
O	NN

to	TO
O	NN

blindness	NN
O	NN

or	CC
O	NN

life-threatening	JJ
O	NN

disease	NN
O	NN

in	IN
O	NN

about	IN
O	NN

40	CD
O	NN

%	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

later	RB
O	NN

stages	NNS
O	NN

of	IN
O	NN

AIDS	NNP
O	NN

before	IN
O	NN

highly	RB
T	NN

active	JJ
T	NN

antiretroviral	JJ
T	NN

therapy	NN
T	NN

(	NN
T	NN

HAART	JJ
T	NN

)	NN
T	NN

New	JJ
T	NN

vaccines	NNS
T	NN

are	VBP
O	NN

under	IN
O	NN

study	NN
O	NN

to	TO
O	NN

further	RB
O	NN

control	NN
O	NN

bacterial	JJ
D	NN

meningitis	NN
D	NN

The	DT
O	NN

study	NN
O	NN

involved	VBN
O	NN

117	CD
O	NN

infants	NNS
O	NN

(	NN
O	NN

mean	VB
O	NN

age	NN
O	NN

2.6	CD
O	NN

months	NNS
O	NN

)	NN
O	NN

,	,
O	NN

who	WP
O	VBP

needed	VBN
O	NN

hospital	NN
T	NN

treatment	NN
T	NN

because	IN
O	NN

of	IN
O	NN

RSV	NN
D	NN

bronchiolitis	NN
D	NN

According	VBG
O	NN

to	TO
O	NN

the	DT
O	NN

present	JJ
O	NN

study	NN
O	NN

it	PRP
O	NN

seems	VBZ
O	NNP

that	IN
O	NN

inhaled	VBN
T	NN

corticosteroid	NN
T	NN

treatment	NN
T	NN

during	IN
O	NN

and	CC
O	NN

after	IN
O	NN

the	DT
O	NN

acute	JJ
O	NN

phase	NN
O	NN

of	IN
O	NN

infant	NN
D	NN

RSV	NN
D	NN

bronchiolitis	NN
D	NN

may	MD
O	NNP

have	VB
O	NN

a	DT
O	NN

beneficial	JJ
O	NN

effect	NN
O	NN

on	IN
O	NN

subsequent	JJ
O	NN

bronchial	JJ
O	NN

wheezing	VBG
O	NN

tendency	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

This	DT
O	NN

study	NN
O	NN

was	VBD
O	NN

designed	VBN
O	NN

to	TO
O	NN

evaluate	VB
O	NN

the	DT
O	NN

safety	NN
O	NN

and	CC
O	NN

estimate	NN
O	NN

the	DT
O	NN

efficacy	NN
O	NN

of	IN
O	NN

oral	JJ
T	NN

budesonide	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

primary	JJ
D	NN

sclerosing	VBG
D	NN

cholangitis	NN
D	NN

(	NN
D	NN

PSC	NN
D	NN

)	NN
D	NN

Combined	VBN
T	NN

interferon	NN
T	NN

and	CC
T	NN

lamivudine	NN
T	NN

therapy	NN
T	NN

:	:
O	NN

is	VBZ
O	NN

this	DT
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

choice	NN
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

hepatitis	NN
D	NN

B	NN
D	NN

virus	NN
D	NN

infection	NN
D	NN

?	.
O	NN

She	PRP
O	VBP

had	VBD
O	NN

been	VBN
O	NN

taking	VBG
O	NN

amitriptyline	NNP
T	NN

75	CD
O	NN

mg	NN
O	NN

at	IN
O	NN

night	NN
O	NN

for	IN
O	NN

depression	NN
D	NN

for	IN
O	NN

four	CD
O	NN

months	NNS
O	NN

before	IN
O	NN

her	PRP$
O	NN

admission	NN
O	NN

Side	NN
O	NN

effects	NNS
O	NN

from	IN
O	NN

influenza	NN
D	NN

vaccination	NN
T	NN

:	:
O	NN

differences	NNS
O	NN

between	IN
O	NN

returned	VBD
O	NN

and	CC
O	NN

random	JJ
O	NN

surveys	NNS
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

To	TO
O	NN

study	NN
O	NN

the	DT
O	NN

relationship	NN
O	NN

between	IN
O	NN

interleukin-2	NN
O	NN

(	NN
O	NN

IL-2	NN
O	NN

)	NN
O	NN

,	,
O	NN

soluble	JJ
O	NN

interleukin-2	NN
O	NN

receptor	NN
O	NN

(	NN
O	NN

sIL-2R	NN
O	NN

)	NN
O	NN

and	CC
O	NN

the	DT
O	NN

non-and-hypo-responsiveness	JJ
O	NN

to	TO
O	NN

hepatitis	NN
D	NN

B	NN
D	NN

vaccine	NN
T	NN

We	PRP
O	VBP

assessed	VBN
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

early	JJ
T	NN

replacement	NN
T	NN

therapy	NN
T	NN

with	IN
T	NN

protein-C	JJ
T	NN

concentrate	NN
T	NN

together	RB
T	NN

with	IN
T	NN

continuous	JJ
T	NN

veno-venous	JJ
T	NN

haemodiafiltration	NN
T	NN

and	CC
O	NN

conventional	JJ
O	NN

treatment	NN
O	NN

in	IN
O	NN

meningococcaemia	NN
D	NN

The	DT
O	NN

purpose	NN
O	NN

of	IN
O	NN

this	DT
O	NN

study	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

determine	VB
O	NN

if	IN
O	NN

topical	JJ
T	NN

DL-alpha-tocopherol	NN
T	NN

(	NN
T	NN

vitamin	NN
T	NN

E	NN
T	NN

)	NN
T	NN

could	MD
O	NNP

reduce	VB
O	NN

ultraviolet-induced	JJ
D	NN

damage	NN
D	NN

to	TO
D	NN

the	DT
D	NN

epidermis	NN
D	NN

We	PRP
O	VBP

observed	VBN
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

cisapride	NN
T	NN

in	IN
O	NN

the	DT
O	NN

management	NN
O	NN

of	IN
O	NN

idiopathic	JJ
D	NN

constipation	NN
D	NN

in	IN
O	NN

children	NNS
O	VBP

METHODS	NNS
O	VBP

:	:
O	NN

Thirty-seven	CD
O	NN

children	NNS
O	VBP

with	IN
O	NN

a	DT
O	NN

history	NN
O	NN

of	IN
O	NN

constipation	NN
D	NN

(	NN
O	NN

i.e	NN
O	NN

.	.
O	NN

,	,
O	NN

pain	NN
O	NN

and	CC
O	NN

difficulty	NN
O	NN

or	CC
O	NN

delay	NN
O	NN

in	IN
O	NN

defecation	NN
O	NN

for	IN
O	NN

>	JJR
O	NN

3	CD
O	NN

months	NNS
O	NN

)	NN
O	NN

were	VBD
O	NN

recruited	VBN
O	NN

and	CC
O	NN

randomly	RB
O	NN

assigned	VBN
O	NN

to	TO
O	NN

8	CD
O	NN

weeks	NNS
O	NN

of	IN
O	NN

treatment	NN
O	NN

with	IN
O	NN

either	DT
O	NN

cisapride	NN
T	NN

,	,
O	NN

0.2	CD
O	NN

mg/kg	NN
O	NN

three	CD
O	NN

times	NNS
O	NN

daily	RB
O	NN

,	,
O	NN

or	CC
O	NN

matching	VBG
O	NN

placebo	NN
O	NN

after	IN
O	NN

a	DT
O	NN

2-week	JJ
O	NN

run-in	NN
O	NN

period	NN
O	NN

in	IN
O	NN

a	DT
O	NN

double-blind	JJ
O	NN

,	,
O	NN

parallel-group	JJ
O	NN

study	NN
O	NN

design	NN
O	NN

Patient	NN
O	NN

1	CD
O	NN

demonstrated	VBD
O	NN

dramatic	JJ
O	NN

clearing	VBG
O	NN

of	IN
O	NN

his	PRP$
O	NN

MCV	NN
D	NN

lesions	NNS
D	NN

when	WRB
O	NN

intravenous	JJ
T	NN

cidofovir	NN
T	NN

therapy	NN
T	NN

was	VBD
O	NN

started	VBD
O	NN

for	IN
O	NN

his	PRP$
O	NN

treatment-resistant	JJ
D	NN

bilateral	JJ
D	NN

CMV	NN
D	NN

retinitis	NN
D	NN

and	CC
O	NN

because	IN
O	NN

of	IN
O	NN

cidofovir	NN
T	NN

's	POS
T	NN

possible	JJ
O	NN

activity	NN
O	NN

against	IN
O	NN

MCV	NN
D	NN

In	IN
O	NN

case	NN
O	NN

2	CD
O	NN

,	,
O	NN

cidofovir	NN
T	NN

was	VBD
O	NN

compounded	VBN
O	NN

as	IN
O	NN

a	DT
O	NN

3	CD
O	NN

%	NN
O	NN

cream	NN
O	NN

in	IN
O	NN

a	DT
O	NN

combination	NN
O	NN

vehicle	NN
O	NN

(	NN
O	NN

Dermovan	JJ
O	NN

)	NN
O	NN

for	IN
O	NN

extensive	JJ
O	NN

facial	JJ
O	NN

involvement	NN
O	NN

,	,
O	NN

and	CC
O	NN

complete	JJ
O	NN

resolution	NN
O	NN

of	IN
O	NN

MCV	NN
D	NN

was	VBD
O	NN

seen	VBN
O	NN

after	IN
O	NN

1	CD
O	NN

month	NN
O	NN

of	IN
O	NN

therapy	NN
O	NN

In	IN
O	NN

case	NN
O	NN

3	CD
O	NN

,	,
O	NN

intravenous	JJ
T	NN

cidofovir	NN
T	NN

therapy	NN
T	NN

was	VBD
O	NN

started	VBD
O	NN

both	DT
O	NN

for	IN
O	NN

CMV	NN
D	NN

retinitis	NN
D	NN

and	CC
O	NN

in	IN
O	NN

an	DT
O	NN

attempt	NN
O	NN

to	TO
O	NN

clear	JJ
O	NN

90	CD
O	NN

%	NN
O	NN

facial	JJ
O	NN

MCV	NN
D	NN

involvement	NN
O	NN

;	:
O	NN

after	IN
O	NN

1	CD
O	NN

month	NN
O	NN

of	IN
O	NN

treatment	NN
O	NN

,	,
O	NN

all	DT
O	NN

clinical	JJ
O	NN

evidence	NN
O	NN

of	IN
O	NN

MCV	NN
D	NN

had	VBD
O	NN

resolved	VBN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Cidofovir	NNP
T	NN

,	,
O	NN

a	DT
O	NN

nucleotide	NN
O	NN

analog	NN
O	NN

of	IN
O	NN

deoxycytidine	NN
O	NN

monophosphate	NN
O	NN

,	,
O	NN

appears	VBZ
O	NN

to	TO
O	NN

have	VB
O	NN

contributed	VBD
O	NN

to	TO
O	NN

clearing	VBG
O	NN

of	IN
O	NN

advanced	JJ
D	NN

MCV	NN
D	NN

lesions	NNS
D	NN

in	IN
O	NN

these	DT
O	NN

3	CD
O	NN

patients	NNS
O	NN

,	,
O	NN

thus	RB
O	NN

providing	VBG
O	NN

suggestive	JJ
O	NN

evidence	NN
O	NN

of	IN
O	NN

clinical	JJ
O	NN

activity	NN
O	NN

against	IN
O	NN

MCV	NN
D	NN

Controlled	VBN
O	NN

trials	NNS
O	NN

of	IN
O	NN

cidofovir	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

MCV	NN
D	NN

in	IN
O	NN

persons	NNS
O	VBP

infected	JJ
O	NN

with	IN
O	NN

human	JJ
O	NN

immunodeficiency	NN
O	NN

virus	NN
O	NN

are	VBP
O	NN

warranted	VBN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

This	DT
O	NN

study	NN
O	NN

aimed	VBN
O	NN

to	TO
O	NN

determine	VB
O	NN

the	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

external	JJ
T	NN

beam	NN
T	NN

radiation	NN
T	NN

therapy	NN
T	NN

on	IN
O	NN

choroidal	NN
D	NN

neovascularization	NN
D	NN

(	NN
D	NN

CNV	NN
D	NN

)	NN
D	NN

secondary	JJ
O	NN

to	TO
O	NN

age-related	JJ
D	NN

macular	JJ
D	NN

degeneration	NN
D	NN

(	NN
D	NN

AMD	NN
D	NN

)	NN
D	NN

Thrombolytic	JJ
T	NN

therapy	NN
T	NN

has	VBZ
O	NN

been	VBN
O	NN

accepted	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

acute	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

A	DT
O	NN

bolus	NN
O	NN

infusion	NN
O	NN

of	IN
O	NN

tissue	NN
T	NN

plasminogen	NN
T	NN

activator	NN
T	NN

was	VBD
O	NN

administered	VBN
O	NN

during	IN
O	NN

CPR	NNP
T	NN

in	IN
O	NN

refractory	JJ
D	NN

ventricular	JJ
D	NN

fibrillation	NN
D	NN

(	NN
O	NN

two	CD
O	NN

cases	NNS
O	NN

)	NN
O	NN

and	CC
O	NN

pulseless	JJ
D	NN

ventricular	JJ
D	NN

tachycardia	NN
D	NN

(	NN
O	NN

one	CD
O	NN

case	NN
O	NN

)	NN
O	NN

We	PRP
O	VBP

conclude	VBP
O	NN

that	IN
O	NN

bolus	NN
T	NN

thrombolytic	JJ
T	NN

infusions	NNS
T	NN

during	IN
O	NN

CPR	NNP
D	NNP

may	MD
O	NNP

facilitate	VB
O	NN

spontaneous	JJ
O	NN

return	NN
O	NN

of	IN
O	NN

circulation	NN
O	NN

in	IN
O	NN

select	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

confirmed	VBN
D	NN

acute	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

,	,
O	NN

witnessed	VBN
O	NN

cardiac	JJ
D	NN

arrest	NN
D	NN

in	IN
O	NN

the	DT
O	NN

ED	NNP
O	NNP

,	,
O	NN

and	CC
O	NN

refractory	JJ
D	NN

ventricular	JJ
D	NN

fibrillation	NN
D	NN

or	CC
O	NN

tachycardia	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

CASE	NN
O	NN

SUMMARY	NN
O	NN

:	:
O	NN

A	DT
O	NN

92-year	JJ
O	NN

old	JJ
O	NN

white	JJ
O	NN

woman	NN
O	NN

who	WP
O	VBP

was	VBD
O	NN

receiving	VBG
O	NN

venlafaxine	NN
T	NN

for	IN
O	NN

management	NN
O	NN

of	IN
O	NN

depression	NN
D	NN

was	VBD
O	NN

found	VBN
O	NN

to	TO
O	NN

have	VB
O	NN

hyponatremia	NN
O	NN

Touch	VB
O	NN

sensibility	NN
O	NN

was	VBD
O	NN

assessed	VBN
O	NN

with	IN
O	NN

von	NN
O	NN

Frey	NNP
O	NNP

's	POS
O	NN

monofilaments	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

breasts	NNS
O	NN

of	IN
O	NN

10	CD
O	NN

healthy	JJ
O	NN

women	NNS
O	VBP

(	NN
O	NN

controls	NNS
O	VBP

)	NN
O	NN

and	CC
O	NN

of	IN
O	NN

80	CD
O	NN

women	NNS
O	VBP

with	IN
O	NN

breast	NN
D	NN

cancer	NN
D	NN

who	WP
O	VBP

at	IN
O	NN

least	JJS
O	NN

1	CD
O	NN

year	NN
O	NN

previously	RB
O	NN

had	VBD
O	NN

undergone	VBN
O	NN

subcutaneous	JJ
T	NN

mastectomy	NN
T	NN

and	CC
O	NN

immediate	JJ
O	NN

reconstruction	NN
O	NN

with	IN
O	NN

a	DT
O	NN

prosthesis	NN
O	NN

Although	IN
O	NN

improved	VBN
O	NN

glycemic	JJ
T	NN

control	JJ
T	NN

,	,
O	NN

maintenance	NN
O	NN

of	IN
O	NN

normal	JJ
O	NN

blood	NN
O	NN

pressure	NN
O	NN

,	,
O	NN

and	CC
O	NN

use	NN
O	NN

of	IN
O	NN

angiotensin-converting	JJ
T	NN

enzyme	NN
T	NN

inhibitors	NNS
T	NN

are	VBP
O	NN

important	JJ
O	NN

strategies	NNS
O	VBP

to	TO
O	NN

avoid	VB
O	NN

developing	VBG
O	NN

microalbuminuria	NN
D	NN

,	,
O	NN

dietary	JJ
O	NN

macronutrient	JJ
O	NN

intake	NN
O	NN

may	MD
O	NNP

also	RB
O	NN

play	VB
O	NN

a	DT
O	NN

role	NN
O	NN

Local	JJ
O	NN

injection	NN
O	NN

of	IN
O	NN

corticosteroids	NNS
T	NN

into	IN
O	NN

refractory	JJ
O	NN

esophageal	NN
O	NN

strictures	NNS
O	VBP

to	TO
O	NN

decrease	NN
O	NN

the	DT
O	NN

restenosis	NN
D	NN

rate	NN
O	NN

has	VBZ
O	NN

been	VBN
O	NN

reported	VBN
O	NN

We	PRP
O	VBP

systematically	RB
O	NN

reviewed	VBN
O	NN

the	DT
O	NN

evidence	NN
O	NN

concerning	VBG
O	NN

the	DT
O	NN

ability	NN
O	NN

of	IN
O	NN

five	CD
O	NN

systemic	JJ
T	NN

treatments	NNS
T	NN

to	TO
O	NN

induce	VB
O	NN

remission	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

severe	JJ
D	NN

psoriasis	NN
D	NN

:	:
O	NN

ultraviolet	JJ
T	NN

B	NN
T	NN

(	NN
T	NN

UVB	NN
T	NN

)	NN
T	NN

,	,
O	NN

photochemotherapy	JJ
T	NN

(	NN
T	NN

PUVA	NN
T	NN

)	NN
T	NN

,	,
O	NN

methotrexate	NN
T	NN

(	NN
T	NN

MTX	NN
T	NN

)	NN
T	NN

,	,
O	NN

retinoids	NNS
T	NN

(	NN
T	NN

RET	NNP
T	NN

)	NN
T	NN

and	CC
O	NN

cyclosporin	NN
T	NN

A	DT
T	NN

(	NN
T	NN

CYA	NN
T	NN

)	NN
T	NN

Consequently	RB
O	NN

,	,
O	NN

parenteral	JJ
T	NN

nutrition	NN
T	NN

(	NN
T	NN

PN	NN
T	NN

)	NN
T	NN

solutions	NNS
T	NN

used	VBN
O	NN

to	TO
O	NN

treat	VB
O	NNP

malnourished	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

renal	JJ
D	NN

failure	NN
D	NN

usually	RB
O	NN

are	VBP
O	NN

prepared	JJ
O	NN

with	IN
O	NN

little	JJ
O	NN

supplementation	NN
O	NN

of	IN
O	NN

these	DT
O	NN

cations	NNS
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Malnourished	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

renal	JJ
D	NN

failure	NN
D	NN

receiving	VBG
O	NN

PN	NN
T	NN

are	VBP
O	NN

at	IN
O	NN

risk	NN
O	NN

of	IN
O	NN

developing	VBG
O	NN

electrolyte	NN
D	NN

abnormalities	NNS
D	NN

,	,
O	NN

particularly	RB
O	NN

hypophosphatemia	NN
D	NN

PURPOSE	NN
O	NN

:	:
O	NN

We	PRP
O	VBP

report	NN
O	NN

a	DT
O	NN

multicenter	JJ
O	NN

experience	NN
O	NN

using	VBG
O	NN

tubularized	VBN
T	NN

incised	VBN
T	NN

plate	NN
T	NN

urethroplastym	NN
T	NN

for	IN
O	NN

proximal	JJ
D	NN

hypospadias	NN
D	NN

MATERIALS	NNS
O	VBP

AND	CC
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

From	IN
O	NN

August	NNP
O	NN

1993	CD
O	NN

to	TO
O	NN

December	NNP
O	NN

1996	CD
O	NN

tubularized	VBN
T	NN

incised	VBN
T	NN

plate	NN
T	NN

urethroplasty	JJ
T	NN

was	VBD
O	NN

performed	VBN
O	NN

in	IN
O	NN

27	CD
O	NN

boys	NNS
O	NN

6	CD
O	NN

months	NNS
O	NN

to	TO
O	NN

3	CD
O	NN

years	NNS
O	NN

old	JJ
O	NN

with	IN
O	NN

mid	JJ
D	NN

shaft	NN
D	NN

and	CC
D	NN

penoscrotal	JJ
D	NN

hypospadias	NN
D	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Tubularized	VBN
T	NN

incised	VBN
T	NN

plate	NN
T	NN

surgery	NN
T	NN

created	VBN
O	NN

a	DT
O	NN

functional	JJ
O	NN

neourethra	NN
O	NN

even	RB
O	NN

in	IN
O	NN

penoscrotal	JJ
D	NN

hypospadias	NN
D	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

Tubularized	VBN
T	NN

incised	VBN
T	NN

plate	NN
T	NN

urethroplasty	JJ
T	NN

is	VBZ
O	NN

a	DT
O	NN

versatile	JJ
O	NN

operation	NN
O	NN

that	IN
O	NN

corrects	VBZ
O	NN

proximal	JJ
D	NN

hypospadias	NN
D	NN

defects	NNS
D	NN

with	IN
O	NN

few	JJ
O	NN

complications	NNS
O	NN

and	CC
O	NN

superior	JJ
O	NN

cosmetic	JJ
O	NN

results	NNS
O	VBP

Aortocoronary	JJ
T	NN

bypass	NN
T	NN

grafting	VBG
T	NN

is	VBZ
O	NN

an	DT
O	NN

accepted	VBN
O	NN

procedure	NN
O	NN

for	IN
O	NN

ischemic	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

Immunotherapy	NN
T	NN

of	IN
O	NN

mice	NNS
O	NN

with	IN
O	NN

preexisting	VBG
O	NN

cancers	NNS
D	NN

with	IN
O	NN

heat	NN
T	NN

shock	NN
T	NN

protein	NN
T	NN

preparations	NNS
T	NN

derived	VBN
T	NN

from	IN
T	NN

autologous	JJ
T	NN

cancer	NN
T	NN

resulted	VBD
O	NN

in	IN
O	NN

retarded	VBN
O	NN

progression	NN
O	NN

of	IN
O	NN

the	DT
O	NN

primary	JJ
O	NN

cancer	NN
D	NN

,	,
O	NN

a	DT
O	NN

reduced	VBN
O	NN

metastatic	JJ
O	NN

load	NN
O	NN

,	,
O	NN

and	CC
O	NN

prolongation	NN
O	NN

of	IN
O	NN

life-span	JJ
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Intrapleural	JJ
T	NN

injection	NN
T	NN

of	IN
T	NN

irradiated	JJ
T	NN

LLC-IL2	NN
T	NN

cured	VBN
O	NN

pre-existing	JJ
D	NN

lung	NN
D	NN

LLC	NN
D	NN

tumors	NNS
D	NN

and	CC
O	NN

extended	VBN
O	NN

the	DT
O	NN

survival	NN
O	NN

of	IN
O	NN

the	DT
O	NN

mice	NNS
O	NN

but	CC
O	NNP

did	VBD
O	NNP

not	RB
O	NN

affect	VB
O	NN

survival	NN
O	NN

of	IN
O	NN

mice	NNS
O	NN

with	IN
O	NN

pre-existing	JJ
O	NN

peritoneal	NN
D	NN

tumors	NNS
D	NN

nor	CC
O	NN

did	VBD
O	NNP

it	PRP
O	NN

affect	VB
O	NN

the	DT
O	NN

growth	NN
O	NN

of	IN
O	NN

s.c.	NN
D	NN

tumors	NNS
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Intraperitoneal	JJ
T	NN

injection	NN
T	NN

of	IN
T	NN

irradiated	JJ
T	NN

LLC-IL2	NN
T	NN

cured	VBN
O	NN

pre-existing	JJ
D	NN

LLC	NN
D	NN

peritoneal	NN
D	NN

tumors	NNS
D	NN

and	CC
O	NN

extended	VBN
O	NN

the	DT
O	NN

survival	NN
O	NN

of	IN
O	NN

the	DT
O	NN

mice	NNS
O	NN

but	CC
O	NNP

did	VBD
O	NNP

not	RB
O	NN

affect	VB
O	NN

survival	NN
O	NN

of	IN
O	NN

mice	NNS
O	NN

bearing	VBG
O	NN

lung	NN
D	NN

tumors	NNS
D	NN

nor	CC
O	NN

did	VBD
O	NNP

it	PRP
O	NN

affect	VB
O	NN

the	DT
O	NN

growth	NN
O	NN

of	IN
O	NN

s.c.	NN
D	NN

tumors	NNS
D	NN

Subcutaneous	JJ
T	NN

injection	NN
T	NN

of	IN
T	NN

irradiated	JJ
T	NN

LLC-IL2	NN
T	NN

did	VBD
O	NNP

not	RB
O	NN

affect	VB
O	NN

the	DT
O	NN

growth	NN
O	NN

of	IN
O	NN

preexisting	VBG
O	NN

s.c.	NN
D	NN

tumors	NNS
D	NN

and	CC
O	NN

also	RB
O	NN

did	VBD
O	NNP

not	RB
O	NN

improve	VB
O	NN

survival	NN
O	NN

of	IN
O	NN

mice	NNS
O	NN

bearing	VBG
O	NN

the	DT
O	NN

lung	NN
D	NN

or	CC
D	NN

peritoneal	NN
D	NN

tumors	NNS
D	NN

We	PRP
O	VBP

describe	VBP
O	NN

such	JJ
O	NN

an	DT
O	NN

event	NN
O	NN

in	IN
O	NN

a	DT
O	NN

man	NN
O	NN

who	WP
O	VBP

underwent	VBD
O	NN

allogeneic	JJ
T	NN

BMT	NN
T	NN

for	IN
O	NN

APL	NN
D	NN

in	IN
O	NN

second	JJ
O	NN

relapse	NN
O	NN

and	CC
O	NN

4	CD
O	NN

years	NNS
O	NN

later	RB
O	NN

presented	VBN
O	NN

with	IN
O	NN

testicular	JJ
O	NN

relapse	NN
O	NN

Olanzapine	JJ
T	NN

is	VBZ
O	NN

an	DT
O	NN

atypical	JJ
O	NN

antipsychotic	JJ
O	NN

effective	JJ
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

schizophrenic	JJ
D	NN

patients	NNS
D	NN

After	IN
O	NN

a	DT
O	NN

2-	CD
O	NN

to	TO
O	NN

9-day	JJ
O	NN

placebo	NN
O	NN

lead-in	NN
O	NN

,	,
O	NN

79	CD
O	NN

inpatients	NNS
O	NN

with	IN
O	NN

schizophrenia	NN
D	NN

according	VBG
O	NN

to	TO
O	NN

DSM-III-R	NN
O	NN

criteria	NNS
O	NN

were	VBD
O	NN

placed	VBN
O	NN

on	IN
O	NN

an	DT
O	NN

olanzapine	NN
T	NN

dosage	NN
O	NN

of	IN
O	NN

10	CD
O	NN

mg/day	NN
O	NN

or	CC
O	NN

1	CD
O	NN

mg/day	NN
O	NN

for	IN
O	NN

up	RB
O	NN

to	TO
O	NN

6	CD
O	NN

weeks	NNS
O	NN

Fludarabine	NN
T	NN

and	CC
O	NN

ara-C	JJ
T	NN

successfully	RB
O	NN

eradicated	VBN
O	NN

bone	NN
D	NN

marrow	NN
D	NN

disease	NN
D	NN

in	IN
O	NN

16	CD
O	NN

of	IN
O	NN

27	CD
O	NN

patients	NNS
O	NN

(	NN
O	NN

59	CD
O	NN

%	NN
O	NN

)	NN
O	NN

,	,
O	NN

23	CD
O	NN

patients	NNS
O	NN

of	IN
O	NN

which	WDT
O	NN

had	VBD
O	NN

been	VBN
O	NN

treated	VBN
O	NN

previously	RB
O	NN

with	IN
O	NN

high-dose	JJ
O	NN

ara-C	JJ
T	NN

These	DT
O	NN

results	NNS
O	VBP

verified	VBN
O	NN

the	DT
O	NN

synergistic	JJ
O	NN

effect	NN
O	NN

fludarabine	NN
T	NN

exhibited	VBD
O	NN

in	IN
O	NN

augmenting	VBG
O	NN

ara-CTP	JJ
T	NN

concentrations	NNS
O	NN

in	IN
O	NN

patients	NNS
O	NN

'	POS
O	NN

leukemic	JJ
O	NN

blasts	NNS
O	NN

,	,
O	NN

thus	RB
O	NN

improving	VBG
O	NN

the	DT
O	NN

clinical	JJ
O	NN

response	NN
O	NN

in	IN
O	NN

relapsed	VBD
D	NN

pediatric	JJ
D	NN

leukemias	NNS
D	NN

BACKGROUND	NN
O	NN

:	:
O	NN

The	DT
O	NN

growing	VBG
O	NN

use	NN
O	NN

of	IN
O	NN

heparin	NN
T	NN

in	IN
O	NN

acute	JJ
D	NN

thrombotic	JJ
D	NN

disorders	NNS
D	NN

,	,
O	NN

coupled	VBN
O	NN

with	IN
O	NN

the	DT
O	NN

availability	NN
O	NN

of	IN
O	NN

many	JJ
O	NN

new	JJ
O	NN

antithrombotic	JJ
T	NN

agents	NNS
T	NN

,	,
O	NN

emphasizes	VBZ
O	NN

the	DT
O	NN

need	NN
O	NN

for	IN
O	NN

adequate	JJ
O	NN

characterization	NN
O	NN

of	IN
O	NN

the	DT
O	NN

platelet	NN
O	NN

effects	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

various	JJ
O	NN

anticoagulants	NNS
T	NN

METHODS	NNS
O	VBP

AND	CC
O	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Platelet	NN
O	NN

P-selectin	NN
O	NN

(	NN
O	NN

CD62	NN
O	NN

)	NN
O	NN

and	CC
O	NN

activated	VBN
O	NN

GP	NN
O	NN

IIb/IIIa	NN
O	NN

(	NN
O	NN

PAC-1	NN
O	NN

)	NN
O	NN

expression	NN
O	NN

on	IN
O	NN

platelet	NN
O	NN

membrane	NN
O	NN

was	VBD
O	NN

quantified	VBN
O	NN

in	IN
O	NN

whole	JJ
O	NN

blood	NN
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

platelet	NN
O	NN

aggregation	NN
O	NN

in	IN
O	NN

platelet-rich	JJ
O	NN

plasma	NN
O	NN

in	IN
O	NN

43	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

unstable	JJ
D	NN

angina	NN
D	NN

before	IN
O	NN

and	CC
O	NN

during	IN
O	NN

treatment	NN
O	NN

with	IN
O	NN

UFH	NN
T	NN

or	CC
O	NN

enoxaparin	NN
T	NN

PURPOSE	NN
O	NN

:	:
O	NN

We	PRP
O	VBP

review	NN
O	NN

our	PRP$
O	NN

initial	JJ
O	NN

experience	NN
O	NN

with	IN
O	NN

direct	JJ
T	NN

percutaneous	JJ
T	NN

transluminal	JJ
T	NN

angioplasty	JJ
T	NN

(	NN
T	NN

PTA	NNP
T	NN

)	NN
T	NN

as	IN
O	NN

a	DT
O	NN

reperfusion	NN
T	NN

treatment	NN
T	NN

for	IN
O	NN

acute	JJ
D	NN

occlusion	NN
D	NN

of	IN
D	NN

the	DT
D	NN

middle	JJ
D	NN

cerebral	JJ
D	NN

artery	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

Direct	JJ
O	NN

PTA	NNP
O	NNP

may	MD
O	NNP

be	VB
O	NN

performed	VBN
O	NN

safely	RB
O	NN

as	IN
O	NN

an	DT
O	NN

alternative	JJ
O	NN

to	TO
O	NN

thrombolytic	JJ
O	NN

therapy	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

acute	JJ
O	NN

occlusion	NN
O	NN

of	IN
O	NN

the	DT
O	NN

middle	JJ
O	NN

cerebral	JJ
O	NN

artery	NN
O	NN

when	WRB
O	NN

early	RB
O	NN

CT	NN
O	NN

findings	NNS
O	VBP

and/or	CC
O	NN

lenticulostriate	JJ
O	NN

artery	NN
O	NN

involvement	NN
O	NN

are	VBP
O	NN

present	JJ
O	NN

or	CC
O	NN

when	WRB
O	NN

superselective	JJ
O	NN

local	JJ
O	NN

angiography	NN
O	NN

shows	NNS
O	VBP

the	DT
O	NN

presence	NN
O	NN

of	IN
O	NN

a	DT
O	NN

large	JJ
O	NN

embolus	NN
O	NN

or	CC
O	NN

high-grade	JJ
O	NN

stenosis	NN
O	NN

Women	NNS
O	VBP

randomised	VBN
O	NN

to	TO
O	NN

screen-and-treat	NN
O	NN

received	VBN
O	NN

appropriate	JJ
O	NN

antibiotics	NNS
T	NN

only	RB
O	NN

if	IN
O	NN

screening	VBG
O	NN

proved	VBN
O	NN

positive	JJ
O	NN

for	IN
O	NN

one	CD
O	NN

or	CC
O	NN

more	RBR
O	NN

infection	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

A	DT
O	NN

71-year-old	JJ
O	NN

woman	NN
O	NN

with	IN
O	NN

autoimmune	JJ
O	NN

hemolytic	JJ
O	NN

anemia	NN
O	NN

underwent	VBD
O	NN

an	DT
O	NN

emergency	NN
O	NN

endocardial	JJ
T	NN

patch	NN
T	NN

repair	NN
T	NN

for	IN
O	NN

ventricular	JJ
D	NN

septal	JJ
D	NN

perforation	NN
D	NN

after	IN
O	NN

acute	JJ
O	NN

myocardial	JJ
O	NN

infarction	NN
O	NN

Use	NNP
O	NNP

of	IN
O	NN

washed	VBN
T	NN

red	JJ
T	NN

blood	NN
T	NN

cells	NNS
T	NN

was	VBD
O	NN

effective	JJ
O	NN

in	IN
O	NN

averting	VBG
O	NN

hemolytic	JJ
D	NN

crisis	NN
D	NN

throughout	IN
O	NN

perioperative	JJ
O	NN

period	NN
O	NN

Therefore	RB
O	NN

,	,
O	NN

prudent	JJ
O	NN

management	NN
O	NN

and	CC
O	NN

use	NN
O	NN

of	IN
O	NN

washed	VBN
T	NN

red	JJ
T	NN

blood	NN
T	NN

cells	NNS
T	NN

transfusion	NN
T	NN

would	MD
O	NNP

prevent	VB
O	NN

hemolytic	JJ
D	NN

aggravation	NN
D	NN

even	RB
O	NN

in	IN
O	NN

open	JJ
O	NN

heart	NN
O	NN

surgery	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

We	PRP
O	VBP

report	NN
O	NN

a	DT
O	NN

case	NN
O	NN

of	IN
O	NN

a	DT
O	NN

29-year-old	JJ
O	NN

male	JJ
O	NN

chronic	JJ
O	NN

HBV	NN
O	NN

carrier	NN
O	NN

who	WP
O	VBP

developed	VBN
O	NN

fulminant	JJ
D	NN

reactivated	VBN
D	NN

HBV	NN
D	NN

infection	NN
D	NN

following	VBG
O	NN

intensive	JJ
O	NN

chemotherapy	NN
T	NN

for	IN
O	NN

stage	NN
D	NN

IVB	NN
D	NN

large	JJ
D	NN

cell	NN
D	NN

B-cell	NN
D	NN

non-Hodgkin	JJ
D	NN

's	POS
D	NN

lymphoma	NN
D	NN

associated	VBN
O	NN

with	IN
O	NN

extensive	JJ
O	NN

central	JJ
O	NN

nervous	JJ
O	NN

system	NN
O	NN

and	CC
O	NN

bone	NN
O	NN

marrow	NN
O	NN

involvement	NN
O	NN

We	PRP
O	VBP

advise	VB
O	NN

that	IN
O	NN

lamivudine	NN
T	NN

should	MD
O	NNP

be	VB
O	NN

considered	VBN
O	NN

during	IN
O	NN

intensive	JJ
O	NN

chemotherapy	NN
T	NN

treatment	NN
T	NN

of	IN
O	NN

chronic	JJ
O	NN

carriers	NNS
O	VBP

of	IN
O	NN

HBV	NN
D	NN

OBJECTIVES	NNS
O	VBP

:	:
O	NN

The	DT
O	NN

purpose	NN
O	NN

of	IN
O	NN

this	DT
O	NN

analysis	NN
O	NN

was	VBD
O	NN

to	TO
O	NN

determine	VB
O	NN

the	DT
O	NN

influence	NN
O	NN

of	IN
O	NN

an	DT
O	NN

additional	JJ
O	NN

treatment	NN
O	NN

delay	NN
O	NN

inherent	JJ
O	NN

in	IN
O	NN

transfer	NN
O	NN

to	TO
O	NN

an	DT
O	NN

angioplasty	NN
O	NN

center	NN
O	NN

for	IN
O	NN

primary	JJ
T	NN

angioplasty	JJ
T	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

acute	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

who	WP
O	VBP

are	VBP
O	NN

first	RB
O	NN

admitted	VBN
O	NN

to	TO
O	NN

hospitals	NNS
O	NN

without	IN
O	NN

angioplasty	NN
O	NN

facilities	NNS
O	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Several	JJ
O	NN

randomized	VBN
O	NN

trials	NNS
O	NN

have	VB
O	NN

demonstrated	VBD
O	NN

the	DT
O	NN

benefits	NNS
O	NN

of	IN
O	NN

primary	JJ
T	NN

angioplasty	JJ
T	NN

in	IN
O	NN

acute	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

We	PRP
O	VBP

report	NN
O	NN

the	DT
O	NN

first	RB
O	NN

case	NN
O	NN

(	NN
O	NN

to	TO
O	NN

our	PRP$
O	NN

knowledge	NN
O	NN

)	NN
O	NN

of	IN
O	NN

an	DT
O	NN

endoscopic	JJ
T	NN

removal	NN
T	NN

of	IN
O	NN

a	DT
O	NN

forehead	NN
D	NN

soft	JJ
D	NN

tissue	NN
D	NN

mass	NN
D	NN

As	IN
O	NN

the	DT
O	NN

overview	NN
O	NN

shows	NNS
O	VBP

,	,
O	NN

both	DT
O	NN

groups	NNS
O	NN

of	IN
O	NN

substances	NNS
O	NN

are	VBP
O	NN

useful	JJ
O	NN

for	IN
O	NN

individualized	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

benign	JJ
D	NN

prostatic	JJ
D	NN

hyperplasia	NN
D	NN

(	NN
D	NN

BPH	NNP
D	NNP

)	NN
D	NN

,	,
O	NN

provided	VBN
O	NN

that	IN
O	NN

conservative	JJ
O	NN

pharmacological	JJ
T	NN

treatment	NN
T	NN

of	IN
O	NN

BPH	NNP
D	NNP

is	VBZ
O	NN

basically	RB
O	NN

accepted	VBN
O	NN

and	CC
O	NN

that	IN
O	NN

the	DT
O	NN

patients	NNS
O	NN

'	POS
O	NN

quality	NN
O	NN

of	IN
O	NN

life	NN
O	NN

is	VBZ
O	NN

also	RB
O	NN

considered	VBN
O	NN

The	DT
O	NN

results	NNS
O	VBP

of	IN
O	NN

several	JJ
O	NN

clinical	JJ
O	NN

investigations	NNS
O	NN

showed	VBD
O	NN

the	DT
O	NN

efficacy	NN
O	NN

and	CC
O	NN

safety	NN
O	NN

of	IN
O	NN

artichoke	NN
T	NN

extracts	NNS
T	NN

(	NN
T	NN

Cynara	NNP
T	NN

scolymus	NN
T	NN

L.	NNP
T	NN

)	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

hepato-biliary	JJ
D	NN

dysfunction	NN
D	NN

and	CC
D	NN

digestive	JJ
D	NN

complaints	NNS
D	NN

,	,
O	NN

such	JJ
O	NN

as	IN
O	NN

sensation	NN
O	NN

of	IN
O	NN

fullness	NN
O	NN

,	,
O	NN

loss	NN
D	NN

of	IN
D	NN

appetite	NN
D	NN

,	,
O	NN

nausea	NN
D	NN

and	CC
O	NN

abdominal	JJ
D	NN

pain	NN
D	NN

Besides	IN
O	NN

the	DT
O	NN

well-known	JJ
O	NN

nonsteroidal	JJ
T	NN

antiinflammatory	JJ
T	NN

drugs	NNS
T	NN

(	NN
T	NN

NSAID	NN
T	NN

)	NN
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

rheumatic	JJ
D	NN

pain	NN
D	NN

herbal	JJ
T	NN

medicine	NN
T	NN

can	MD
O	NNP

also	RB
O	NN

be	VB
O	NN

applied	VBN
O	NN

successfully	RB
O	NN

Extracts	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

secondary	JJ
O	NN

tubers	NNS
O	NN

of	IN
O	NN

Devil	NNP
T	NN

's	POS
T	NN

Claw	VB
T	NN

(	NN
T	NN

Harpagophytum	NN
T	NN

procumbens	NNS
T	NN

)	NN
T	NN

are	VBP
O	NN

recommended	VBN
O	NN

for	IN
O	NN

the	DT
O	NN

supportive	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

degenerative	JJ
D	NN

painful	JJ
D	NN

rheumatism	NN
D	NN

High-dose	JJ
T	NN

intravenous	JJ
T	NN

immunoglobulin	NN
T	NN

(	NN
T	NN

hdIVIg	NN
T	NN

)	NN
T	NN

is	VBZ
O	NN

increasingly	RB
O	NN

used	VBN
O	NN

to	TO
O	NN

treat	VB
O	NNP

a	DT
O	NN

range	NN
O	NN

of	IN
O	NN

inflammatory	JJ
D	NN

and	CC
D	NN

autoimmune	JJ
D	NN

diseases	NNS
D	NN

The	DT
O	NN

current	JJ
O	NN

dermatological	JJ
O	NN

uses	NNS
O	NN

of	IN
O	NN

hdIVIg	NN
T	NN

include	VBP
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

dermatomyositis	NN
D	NN

and	CC
O	NN

the	DT
O	NN

autoimmune	JJ
D	NN

bullous	JJ
D	NN

disorders	NNS
D	NN

,	,
O	NN

epidermolysis	NN
D	NN

bullosa	NN
D	NN

acquisita	NN
D	NN

,	,
O	NN

pemphigoid	NN
D	NN

,	,
O	NN

and	CC
O	NN

pemphigus	NN
D	NN

Unfortunately	RB
O	NN

,	,
O	NN

current	JJ
O	NN

dermatological	JJ
O	NN

uses	NNS
O	NN

of	IN
O	NN

hdIVIg	NN
O	NN

have	VB
O	NN

been	VBN
O	NN

limited	JJ
O	NN

to	TO
O	NN

either	DT
O	NN

uncontrolled	JJ
O	NN

trials	NNS
O	NN

or	CC
O	NN

anecdotal	JJ
O	NN

case	NN
O	NN

reports	NNS
O	NN

,	,
O	NN

except	IN
O	NN

for	IN
O	NN

a	DT
O	NN

single	JJ
O	NN

controlled	JJ
O	NN

trial	NN
O	NN

of	IN
O	NN

hdIVIg	NN
T	NN

as	IN
O	NN

adjunctive	JJ
O	NN

therapy	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

dermatomyositis	NN
D	NN

,	,
O	NN

which	WDT
O	NN

documented	VBN
O	NN

a	DT
O	NN

significant	JJ
O	NN

benefit	NN
O	NN

We	PRP
O	VBP

describe	VBP
O	NN

a	DT
O	NN

technique	NN
O	NN

that	IN
O	NN

enables	VBZ
O	NN

the	DT
O	NN

autologous	JJ
T	NN

repair	NN
T	NN

of	IN
O	NN

large	JJ
D	NN

midline	NN
D	NN

incisional	JJ
D	NN

hernias	NN
D	NN

by	IN
O	NN

restoring	VBG
O	NN

the	DT
O	NN

functional	JJ
O	NN

musculoaponeurotic	JJ
O	NN

support	NN
O	NN

of	IN
O	NN

the	DT
O	NN

abdominal	JJ
O	NN

wall	NN
O	NN

OBJECTIVE	NN
O	NN

AND	CC
O	NN

IMPORTANCE	NN
O	NN

:	:
O	NN

The	DT
O	NN

use	NN
O	NN

of	IN
O	NN

chronic	JJ
T	NN

intrathecal	JJ
T	NN

morphine	NN
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

intractable	JJ
D	NN

,	,
D	NN

nonmalignant	JJ
D	NN

pain	NN
D	NN

is	VBZ
O	NN

becoming	VBG
O	NN

more	RBR
O	NN

prevalent	JJ
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

During	IN
O	NN

a	DT
O	NN

19-month	JJ
O	NN

period	NN
O	NN

,	,
O	NN

seven	CD
O	NN

children	NNS
O	VBP

with	IN
O	NN

empyema	NN
D	NN

underwent	VBD
O	NN

thoracoscopy	JJ
T	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

We	PRP
O	VBP

describe	VBP
O	NN

a	DT
O	NN

patient	NN
O	NN

with	IN
O	NN

left	RB
D	NN

cardiac	JJ
D	NN

herniation	NN
D	NN

presenting	VBG
O	NN

after	IN
O	NN

intrapericardial	JJ
T	NN

pulmonectomy	JJ
T	NN

for	IN
O	NN

primary	JJ
D	NN

lung	NN
D	NN

cancer	NN
D	NN

The	DT
O	NN

growing	VBG
O	NN

use	NN
O	NN

of	IN
O	NN

automated	VBN
T	NN

night-time	JJ
T	NN

dialysis	NN
T	NN

(	NN
T	NN

APD	NN
T	NN

)	NN
T	NN

in	IN
O	NN

peritoneal	NN
D	NN

dialysis	NN
D	NN

over	IN
O	NN

the	DT
O	NN

last	JJ
O	NN

few	JJ
O	NN

years	NNS
O	NN

shows	NNS
O	VBP

that	IN
O	NN

this	DT
O	NN

method	NN
O	NN

represents	VBZ
O	NN

a	DT
O	NN

valid	JJ
O	NN

alternative	JJ
O	NN

to	TO
O	NN

continuous	JJ
T	NN

ambulatory	JJ
T	NN

peritoneal	JJ
T	NN

dialysis	NN
T	NN

(	NN
T	NN

CAPD	NN
T	NN

)	NN
T	NN

La	NNP
O	NNP

Serna	NNP
O	NNP

et	FW
O	FW

al	NNP
O	NNP

.	.
O	NN

(	NN
O	NN

Lancet	NNP
O	NNP

1987	CD
O	NN

;	:
O	NN

26	CD
O	NN

:	:
O	NN

1517	CD
O	NN

)	NN
O	NN

were	VBD
O	NN

the	DT
O	NN

first	RB
O	NN

to	TO
O	NN

treat	VB
O	NNP

adults	NNS
O	NN

with	IN
O	NN

recurrent	JJ
D	NN

pericarditis	NN
D	NN

with	IN
O	NN

colchicine	NN
T	NN

,	,
O	NN

and	CC
O	NN

were	VBD
O	NN

followed	VBN
O	NN

by	IN
O	NN

other	JJ
O	NN

authors	NNS
O	NN

While	IN
O	NN

these	DT
O	NN

findings	NNS
O	VBP

are	VBP
O	NN

observed	VBN
O	NN

for	IN
O	NN

all	DT
O	NN

classes	NNS
O	NN

of	IN
O	NN

oral	JJ
O	NN

drugs	NNS
O	NN

,	,
O	NN

the	DT
O	NN

issue	NN
O	NN

is	VBZ
O	NN

especially	RB
O	NN

critical	JJ
O	NN

for	IN
O	NN

cancer	NN
D	NN

chemotherapy	NN
T	NN

,	,
O	NN

in	IN
O	NN

which	WDT
O	NN

a	DT
O	NN

narrow	JJ
O	NN

therapeutic	JJ
O	NN

index	NN
O	NN

is	VBZ
O	NN

frequently	RB
O	NN

observed	VBN
O	NN

Treatment	NN
O	NN

for	IN
O	NN

low-grade	JJ
D	NN

NHL	NN
D	NN

during	IN
O	NN

the	DT
O	NN

past	JJ
O	NN

30	CD
O	NN

yr	NN
O	NN

has	VBZ
O	NN

consisted	VBD
O	NN

of	IN
O	NN

high-dose	JJ
T	NN

radiation	NN
T	NN

and	CC
O	NN

cytotoxic	JJ
T	NN

agents	NNS
T	NN

,	,
O	NN

administered	VBN
O	NN

alone	RB
O	NN

or	CC
O	NN

in	IN
O	NN

combination	NN
O	NN

,	,
O	NN

and	CC
O	NN

high-dose	JJ
T	NN

therapy	NN
T	NN

with	IN
T	NN

stem	NN
T	NN

cell	NN
T	NN

transplant	NN
T	NN

However	RB
O	NN

,	,
O	NN

recent	JJ
O	NN

clinical	JJ
O	NN

use	NN
O	NN

of	IN
O	NN

monoclonal	JJ
T	NN

antibodies	NNS
T	NN

(	NN
T	NN

mAbs	NNS
T	NN

)	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

low-grade	JJ
D	NN

or	CC
D	NN

transformed	VBN
D	NN

low-grade	JJ
D	NN

NHL	NN
D	NN

has	VBZ
O	NN

resulted	VBD
O	NN

in	IN
O	NN

less	JJR
O	NN

toxicity	NN
O	NN

than	IN
O	NN

conventional	JJ
O	NN

treatments	NNS
O	VBP

,	,
O	NN

as	IN
O	NN

well	RB
O	NN

as	IN
O	NN

response	NN
O	NN

rates	NNS
O	VBP

that	IN
O	NN

are	VBP
O	NN

comparable	JJ
O	NN

or	CC
O	NN

superior	JJ
O	NN

to	TO
O	NN

those	DT
O	NNP

achieved	VBN
O	NN

with	IN
O	NN

chemotherapy	NN
T	NN

Therefore	RB
O	NN

,	,
O	NN

interest	NN
O	NN

is	VBZ
O	NN

growing	VBG
O	NN

in	IN
O	NN

mAbs	NNS
T	NN

as	IN
O	NN

therapeutic	JJ
O	NN

alternatives	NNS
O	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

low-grade	JJ
D	NN

NHL	NN
D	NN

and	CC
O	NN

those	DT
O	NNP

with	IN
O	NN

transformed	VBN
O	NN

histology	NN
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

The	DT
O	NN

treatment	NN
O	NN

paradigm	NN
O	NN

for	IN
O	NN

NHL	NN
D	NN

is	VBZ
O	NN

expected	VBN
O	NN

to	TO
O	NN

change	NN
O	NN

over	IN
O	NN

the	DT
O	NN

next	JJ
O	NN

few	JJ
O	NN

years	NNS
O	NN

to	TO
O	NN

include	VBP
O	NN

radiolabeled	VBN
T	NN

mAbs	NNS
T	NN

,	,
O	NN

administered	VBN
O	NN

alone	RB
O	NN

or	CC
O	NN

in	IN
O	NN

combination	NN
O	NN

with	IN
O	NN

cytotoxic	JJ
T	NN

agents	NNS
T	NN

RESULTS	NNS
O	VBP

:	:
O	NN

Clinical	JJ
O	NN

trials	NNS
O	NN

of	IN
O	NN

UFT	NNP
T	NN

published	VBN
O	NN

in	IN
O	NN

the	DT
O	NN

Western	JJ
O	NN

world	NN
O	NN

have	VB
O	NN

included	VBN
O	NN

581	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

The	DT
O	NN

activity	NN
O	NN

of	IN
O	NN

oral	JJ
T	NN

UFT	NNP
T	NN

in	IN
O	NN

large-bowel	NN
D	NN

cancer	NN
D	NN

when	WRB
O	NN

administered	VBN
O	NN

with	IN
O	NN

oral	JJ
T	NN

LV	NN
T	NN

(	NN
O	NN

approximately	RB
O	NN

50	CD
O	NN

mg/dose	NN
O	NN

)	NN
O	NN

has	VBZ
O	NN

resulted	VBD
O	NN

in	IN
O	NN

objective	JJ
O	NN

response	NN
O	NN

rates	NNS
O	VBP

of	IN
O	NN

approximately	RB
O	NN

40	CD
O	NN

%	NN
O	NN

CONCLUSION	NN
O	NN

:	:
O	NN

UFT	NNP
T	NN

is	VBZ
O	NN

a	DT
O	NN

fluoropyrimidine	NN
T	NN

active	JJ
O	NN

in	IN
O	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Adrenalectomy	NN
T	NN

is	VBZ
O	NN

the	DT
O	NN

current	JJ
O	NN

treatment	NN
O	NN

for	IN
O	NN

phaeochromocytoma	NN
D	NN

CONCLUSION	NN
O	NN

:	:
O	NN

Adrenal-sparing	JJ
T	NN

surgery	NN
T	NN

is	VBZ
O	NN

safe	JJ
O	NN

and	CC
O	NN

effective	JJ
O	NN

,	,
O	NN

and	CC
O	NN

may	MD
O	NNP

become	VBN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

choice	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

hereditary	JJ
D	NN

phaeochromocytoma	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

PURPOSE	NN
O	NN

:	:
O	NN

The	DT
O	NN

purposes	NNS
O	VBP

of	IN
O	NN

this	DT
O	NN

descriptive	JJ
O	NN

,	,
O	NN

longitudinal	JJ
O	NN

study	NN
O	NN

were	VBD
O	NN

to	TO
O	NN

evaluate	VB
O	NN

the	DT
O	NN

MacDibbs	NNP
O	NNP

Mouth	NN
O	NN

Assessment	NNP
O	NNP

instrument	NN
O	NN

for	IN
O	NN

the	DT
O	NN

assessment	NN
O	NN

of	IN
O	NN

mucositis	NN
O	NN

in	IN
O	NN

the	DT
O	NN

radiation	NN
T	NN

therapy	NN
T	NN

patient	NN
O	NN

being	VBG
O	NN

treated	VBN
O	NN

for	IN
O	NN

head	NN
D	NN

and	CC
D	NN

neck	NN
D	NN

cancer	NN
D	NN

and	CC
O	NN

to	TO
O	NN

describe	VBP
O	NN

the	DT
O	NN

course	NN
O	NN

of	IN
O	NN

radiation-induced	JJ
D	NN

mucositis	NN
D	NN

in	IN
O	NN

these	DT
O	NN

patients	NNS
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

As	IN
O	NN

concomitant	JJ
D	NN

thrombocytosis	NN
D	NN

persisted	VBD
O	NN

despite	IN
O	NN

treatment	NN
O	NN

with	IN
O	NN

hydroxyurea	NN
T	NN

,	,
O	NN

the	DT
O	NN

new	JJ
O	NN

megakaryocyte	NN
T	NN

inhibitor	NN
T	NN

anagrelide	NN
T	NN

(	NN
T	NN

Agrelin	NN
T	NN

)	NN
T	NN

was	VBD
O	NN

administered	VBN
O	NN

and	CC
O	NN

led	VBD
O	NN

to	TO
O	NN

normalization	NN
O	NN

of	IN
O	NN

the	DT
O	NN

platelet	NN
O	NN

count	NN
O	NN

within	IN
O	NN

11	CD
O	NN

days	NNS
O	NN

Background	NN
O	NN

:	:
O	NN

Troglitazone	NN
T	NN

is	VBZ
O	NN

a	DT
O	NN

new	JJ
O	NN

drug	NN
O	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

type	NN
D	NN

2	LS
D	NN

diabetes	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

For	IN
O	NN

a	DT
O	NN

subset	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

Kaposi	NN
D	NN

's	POS
D	NN

sarcoma	NN
D	NN

who	WP
O	VBP

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

recombinant	JJ
T	NN

interferon	NN
T	NN

alfa-2a	JJ
T	NN

,	,
O	NN

the	DT
O	NN

disease	NN
O	NN

is	VBZ
O	NN

in	IN
O	NN

complete	JJ
O	NN

remission	NN
O	NN

,	,
O	NN

without	IN
O	NN

opportunistic	JJ
D	NN

infection	NN
D	NN

,	,
O	NN

and	CC
O	NN

they	PRP
O	VBP

appear	VB
O	NN

to	TO
O	NN

be	VB
O	NN

culture-negative	JJ
O	NN

for	IN
O	NN

the	DT
O	NN

etiologic	JJ
O	NN

retrovirus	NN
O	NN

that	IN
O	NN

causes	NNS
O	VBP

their	PRP$
O	NN

immune	JJ
D	NN

deficiency	NN
D	NN

Interferon	NN
T	NN

alfa-2a	JJ
T	NN

appears	VBZ
O	NN

to	TO
O	NN

have	VB
O	NN

antineoplastic	JJ
O	NN

efficacy	NN
O	NN

,	,
O	NN

(	NN
O	NN

and	CC
O	NN

may	MD
O	NNP

have	VB
O	NN

antiretroviral	JJ
O	NN

efficacy	NN
O	NN

as	IN
O	NN

well	RB
O	NN

)	NN
O	NN

in	IN
O	NN

this	DT
O	NN

epidemic	JJ
O	NN

neoplasm	NN
D	NN

In	IN
O	NN

three	CD
O	NN

consecutive	JJ
O	NN

Phase	NN
O	NN

II	NNP
O	NNP

trials	NNS
O	NN

of	IN
O	NN

recombinant	JJ
T	NN

interferon	NN
T	NN

alfa-2a	JJ
T	NN

(	NN
O	NN

rIFN	NN
O	NN

alfa-2a	JJ
O	NN

;	:
O	NN

Roferon-A	NN
O	NN

Hoffmann-La	NNP
O	NNP

Roche	NNP
O	NNP

,	,
O	NN

Nutley	NNP
O	NNP

,	,
O	NN

NJ	NNP
O	NNP

)	NN
O	NN

involving	VBG
O	NN

96	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

malignant	JJ
D	NN

melanoma	NN
D	NN

,	,
O	NN

an	DT
O	NN

overall	JJ
O	NN

response	NN
O	NN

rate	NN
O	NN

of	IN
O	NN

22	CD
O	NN

%	NN
O	NN

was	VBD
O	NN

observed	VBN
O	NN

As	IN
O	NN

single	JJ
O	NN

agent	NN
O	NN

therapy	NN
O	NN

in	IN
O	NN

malignant	JJ
D	NN

melanoma	NN
D	NN

,	,
O	NN

interferon	NN
T	NN

alfa-2a	JJ
T	NN

was	VBD
O	NN

only	RB
O	NN

marginally	RB
O	NN

useful	JJ
O	NN

in	IN
O	NN

most	JJS
O	NN

patients	NNS
O	NN

Studies	NNS
O	VBP

with	IN
O	NN

various	JJ
O	NN

interferon	NN
T	NN

alpha	NN
T	NN

preparations	NNS
T	NN

,	,
O	NN

including	VBG
O	NN

interferons	NNS
T	NN

induced	VBN
O	NN

in	IN
O	NN

human	JJ
O	NN

leukocytes	NNS
O	NN

,	,
O	NN

interferon	NN
T	NN

alfa-N1	NN
T	NN

,	,
O	NN

interferon	NN
T	NN

alfa-2a	JJ
T	NN

,	,
O	NN

and	CC
O	NN

interferon	NN
T	NN

alfa-2b	JJ
T	NN

,	,
O	NN

have	VB
O	NN

all	DT
O	NN

provided	VBN
O	NN

evidence	NN
O	NN

for	IN
O	NN

modest	JJ
O	NN

but	CC
O	NNP

reproducible	JJ
O	NN

antitumor	JJ
O	NN

activity	NN
O	NN

in	IN
O	NN

advanced	JJ
D	NN

renal	JJ
D	NN

cell	NN
D	NN

carcinoma	NN
D	NN

Preliminary	JJ
O	NN

evidence	NN
O	NN

suggests	VBZ
O	NN

that	IN
O	NN

interferons	NNS
T	NN

beta	NN
T	NN

and	CC
T	NN

gamma	NN
T	NN

may	MD
O	NNP

also	RB
O	NN

induce	VB
O	NN

regression	NN
O	NN

of	IN
O	NN

metastatic	JJ
D	NN

renal	JJ
D	NN

cell	NN
D	NN

carcinoma	NN
D	NN

The	DT
O	NN

rationale	NN
O	NN

for	IN
O	NN

antileukemic	JJ
T	NN

therapy	NN
T	NN

in	IN
O	NN

hairy	JJ
D	NN

cell	NN
D	NN

leukemia	NN
D	NN

is	VBZ
O	NN

to	TO
O	NN

reduce	VB
O	NN

the	DT
O	NN

significant	JJ
O	NN

risk	NN
O	NN

of	IN
O	NN

infection	NN
O	NN

and	CC
O	NN

other	JJ
O	NN

potential	JJ
O	NN

serious	JJ
O	NN

complications	NNS
O	NN

Splenectomy	NN
T	NN

presumably	RB
O	NN

alleviates	VBZ
O	NN

the	DT
O	NN

pancytopenic	JJ
O	NN

effect	NN
O	NN

of	IN
O	NN

hypersplenism	NN
D	NN

by	IN
O	NN

removing	VBG
O	NN

the	DT
O	NN

preferred	VBN
O	NN

site	NN
O	NN

of	IN
O	NN

leukemic	JJ
O	NN

cell	NN
O	NN

proliferation	NN
O	NN

Recombinant	JJ
O	NN

and	CC
O	NN

natural	JJ
O	NN

forms	NNS
O	NN

of	IN
O	NN

interferon	NN
T	NN

alpha	NN
T	NN

have	VB
O	NN

been	VBN
O	NN

shown	VBN
O	NN

to	TO
O	NN

bring	VB
O	NN

about	IN
O	NN

tumor	NN
O	NN

regressions	NNS
O	VBP

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

low-grade	JJ
D	NN

non-Hodgkin	JJ
D	NN

's	POS
D	NN

lymphoma	NN
D	NN

Current	JJ
O	NN

studies	NNS
O	VBP

using	VBG
O	NN

interferon	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

low-grade	JJ
D	NN

non-Hodgkin	JJ
D	NN

's	POS
D	NN

lymphomas	NNS
D	NN

are	VBP
O	NN

evaluating	VBG
O	NN

lower	JJR
O	NN

,	,
O	NN

and	CC
O	NN

perhaps	RB
O	NN

better	JJR
O	NN

tolerated	VBN
O	NN

doses	NNS
O	NN

of	IN
O	NN

interferon	NN
T	NN

This	DT
O	NN

approach	NN
O	NN

is	VBZ
O	NN

being	VBG
O	NN

extended	VBN
O	NN

to	TO
O	NN

the	DT
O	NN

clinic	NN
O	NN

,	,
O	NN

and	CC
O	NN

trials	NNS
O	NN

are	VBP
O	NN

now	RB
O	NN

underway	NN
O	NN

evaluating	VBG
O	NN

combinations	NNS
O	NN

of	IN
O	NN

interferon	NN
T	NN

and	CC
O	NN

various	JJ
O	NN

cytotoxic	JJ
T	NN

drugs	NNS
T	NN

known	JJ
O	NN

from	IN
O	NN

previous	JJ
O	NN

studies	NNS
O	VBP

to	TO
O	NN

be	VB
O	NN

active	JJ
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

low-grade	JJ
D	NN

non-Hodgkin	JJ
D	NN

's	POS
D	NN

lymphomas	NNS
D	NN

While	IN
O	NN

the	DT
O	NN

demonstrated	VBD
O	NN

antiviral	JJ
O	NN

,	,
O	NN

antiproliferative	JJ
O	NN

,	,
O	NN

and	CC
O	NN

immunomodulatory	JJ
O	NN

properties	NNS
O	NN

of	IN
O	NN

interferons	NNS
T	NN

have	VB
O	NN

led	VBD
O	NN

to	TO
O	NN

a	DT
O	NN

number	NN
O	NN

of	IN
O	NN

theories	NNS
O	NN

regarding	VBG
O	NN

their	PRP$
O	NN

potential	JJ
O	NN

use	NN
O	NN

in	IN
O	NN

treating	VBG
O	NN

individuals	NNS
O	VBP

with	IN
O	NN

chronic	JJ
D	NN

myelogenous	JJ
D	NN

leukemia	NN
D	NN

(	NN
D	NN

CML	NN
D	NN

)	NN
D	NN

,	,
O	NN

their	PRP$
O	NN

limited	JJ
O	NN

availability	NN
O	NN

has	VBZ
O	NN

prevented	VBD
O	NN

thorough	JJ
O	NN

clinical	JJ
O	NN

investigation	NN
O	NN

The	DT
O	NN

data	NNS
O	NN

resulting	VBG
O	NN

from	IN
O	NN

these	DT
O	NN

clinical	JJ
O	NN

trials	NNS
O	NN

indicate	VBP
O	NN

that	IN
O	NN

interferon	NN
T	NN

alfa-2a	JJ
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

in	IN
O	NN

inducing	VBG
O	NN

hematologic	JJ
O	NN

remissions	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

majority	NN
O	NN

of	IN
O	NN

minimally	RB
O	NN

treated	VBN
O	NN

,	,
O	NN

benign-phase	NN
D	NN

CML	NN
D	NN

,	,
O	NN

Ph1-positive	JJ
O	NN

patients	NNS
O	NN

More	RBR
O	NN

than	IN
O	NN

1600	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

neoplastic	JJ
D	NN

disorders	NNS
D	NN

have	VB
O	NN

received	VBN
O	NN

recombinant	JJ
T	NN

human	JJ
T	NN

interferon	NN
T	NN

alfa-2a	JJ
T	NN

(	NN
T	NN

Roferon-A	NN
T	NN

,	,
T	NN

Hoffmann-La	NNP
T	NN

Roche	NNP
T	NN

,	,
T	NN

Nutley	NNP
T	NN

,	,
T	NN

NJ	NNP
T	NN

)	NN
T	NN

as	IN
O	NN

part	NN
O	NN

of	IN
O	NN

ongoing	JJ
O	NN

or	CC
O	NN

completed	VBN
O	NN

clinical	JJ
O	NN

trials	NNS
O	NN

PURPOSE	NN
O	NN

:	:
O	NN

A	DT
O	NN

phase	NN
O	NN

I/II	CD
O	NN

trial	NN
O	NN

of	IN
O	NN

docetaxel	NN
T	NN

,	,
O	NN

cisplatin	NN
T	NN

,	,
O	NN

fluorouracil	NN
T	NN

(	NN
T	NN

5-FU	JJ
T	NN

)	NN
T	NN

,	,
O	NN

and	CC
O	NN

leucovorin	NN
T	NN

(	NN
T	NN

TPFL5	NN
T	NN

)	NN
T	NN

induction	NN
T	NN

chemotherapy	NN
T	NN

for	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

locally	RB
D	NN

advanced	JJ
D	NN

squamous	JJ
D	NN

cell	NN
D	NN

carcinoma	NN
D	NN

of	IN
D	NN

the	DT
D	NN

head	NN
D	NN

and	CC
D	NN

neck	NN
D	NN

(	NN
D	NN

SCCHN	NN
D	NN

)	NN
D	NN

PATIENTS	NNS
O	VBP

AND	CC
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

Twenty-three	CD
O	NN

previously	RB
O	NN

untreated	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

stage	NN
D	NN

III	NNP
D	NNP

or	CC
D	NN

IV	CD
D	NN

SCCHN	NN
D	NN

and	CC
O	NN

Eastern	NNP
O	NNP

Cooperative	NNP
O	NNP

Oncology	NNP
O	NNP

Group	NNP
O	NNP

functional	JJ
O	NN

status	NN
O	NN

less	JJR
O	NN

than	IN
O	NN

or	CC
O	NN

equal	JJ
O	NN

to	TO
O	NN

2	CD
O	NN

were	VBD
O	NN

treated	VBN
O	NN

with	IN
O	NN

TPFL5	NN
T	NN

Intrathecal	JJ
T	NN

sufentanil	NN
T	NN

provides	VBZ
O	NN

approximately	RB
O	NN

2	CD
O	NN

h	NN
O	NN

of	IN
O	NN

excellent	JJ
O	NN

labor	NN
D	NN

analgesia	NN
O	NN

with	IN
O	NN

minimal	JJ
O	NN

motor	NN
O	NN

blockade	NN
O	NN

OBJECTIVE	NN
O	NN

:	:
O	NN

We	PRP
O	VBP

report	NN
O	NN

the	DT
O	NN

results	NNS
O	VBP

of	IN
O	NN

a	DT
O	NN

double-blind	JJ
O	NN

,	,
O	NN

double-dummy	JJ
O	NN

,	,
O	NN

active-control	JJ
O	NN

study	NN
O	NN

designed	VBN
O	NN

to	TO
O	NN

evaluate	VB
O	NN

the	DT
O	NN

efficacy	NN
O	NN

and	CC
O	NN

safety	NN
O	NN

of	IN
O	NN

lamotrigine	NN
T	NN

(	NN
T	NN

LTG	NN
T	NN

)	NN
T	NN

administered	VBN
O	NN

as	IN
O	NN

monotherapy	NN
O	NN

to	TO
O	NN

adult	JJ
O	NN

outpatients	NNS
O	NN

with	IN
O	NN

partial	JJ
D	NN

seizures	NNS
D	NN

BACKGROUND	NN
O	NN

:	:
O	NN

The	DT
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

LTG	NN
T	NN

as	IN
O	NN

add-on	JJ
O	NN

therapy	NN
O	NN

for	IN
O	NN

partial	JJ
D	NN

seizures	NNS
D	NN

in	IN
O	NN

adults	NNS
O	NN

has	VBZ
O	NN

previously	RB
O	NN

been	VBN
O	NN

established	VBN
O	NN

CONCLUSIONS	NNS
O	NN

:	:
O	NN

We	PRP
O	VBP

conclude	VBP
O	NN

that	IN
O	NN

LTG	NN
T	NN

is	VBZ
O	NN

effective	JJ
O	NN

and	CC
O	NN

well	RB
O	NN

tolerated	VBN
O	NN

when	WRB
O	NN

administered	VBN
O	NN

as	IN
O	NN

monotherapy	NN
O	NN

in	IN
O	NN

adult	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

partial	JJ
D	NN

seizures	NNS
D	NN

BACKGROUND	NN
O	NN

:	:
O	NN

Omega3	NN
O	NN

fatty	JJ
O	NN

acids	NNS
O	NN

may	MD
O	NNP

inhibit	VB
O	NN

neuronal	JJ
O	NN

signal	NN
O	NN

transduction	NN
O	NN

pathways	NNS
O	VBP

in	IN
O	NN

a	DT
O	NN

manner	NN
O	NN

similar	JJ
O	NN

to	TO
O	NN

that	IN
O	NN

of	IN
O	NN

lithium	NN
T	NN

carbonate	NN
T	NN

and	CC
O	NN

valproate	NN
T	NN

,	,
O	NN

2	CD
O	NN

effective	JJ
O	NN

treatments	NNS
O	VBP

for	IN
O	NN

bipolar	JJ
D	NN

disorder	NN
D	NN

The	DT
O	NN

present	JJ
O	NN

study	NN
O	NN

was	VBD
O	NN

performed	VBN
O	NN

to	TO
O	NN

examine	VB
O	NN

whether	IN
O	NN

omega3	NN
T	NN

fatty	JJ
T	NN

acids	NNS
T	NN

also	RB
O	NN

exhibit	NN
O	NN

mood-stabilizing	JJ
O	NN

properties	NNS
O	NN

in	IN
O	NN

bipolar	JJ
D	NN

disorder	NN
D	NN

CONCLUSION	NN
O	NN

:	:
O	NN

Omega3	NN
T	NN

fatty	JJ
T	NN

acids	NNS
T	NN

were	VBD
O	NN

well	RB
O	NN

tolerated	VBN
O	NN

and	CC
O	NN

improved	VBN
O	NN

the	DT
O	NN

short-term	JJ
O	NN

course	NN
O	NN

of	IN
O	NN

illness	NN
O	NN

in	IN
O	NN

this	DT
O	NN

preliminary	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

bipolar	JJ
D	NN

disorder	NN
D	NN

Several	JJ
O	NN

large-scale	JJ
O	NN

trials	NNS
O	NN

have	VB
O	NN

firmly	RB
O	NN

established	VBN
O	NN

the	DT
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

thrombolytic	JJ
T	NN

therapy	NN
T	NN

,	,
O	NN

beta	NN
T	NN

blockers	NNS
T	NN

,	,
O	NN

and	CC
O	NN

aspirin	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

AMI	NNP
D	NNP

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

While	IN
O	NN

diastolic	JJ
D	NN

left	RB
D	NN

ventricular	JJ
D	NN

(	NN
D	NN

LV	NN
D	NN

)	NN
D	NN

dysfunction	NN
D	NN

is	VBZ
O	NN

frequent	JJ
O	NN

and	CC
O	NN

associated	VBN
O	NN

with	IN
O	NN

cardiovascular	JJ
D	NN

complications	NNS
D	NN

in	IN
O	NN

end-stage	NN
D	NN

renal	JJ
D	NN

disease	NN
D	NN

treated	VBN
O	NN

with	IN
O	NN

dialysis	NN
T	NN

,	,
O	NN

controversial	JJ
O	NN

information	NN
O	NN

exists	VBZ
O	NN

on	IN
O	NN

diastolic	JJ
O	NN

LV	NN
O	NN

function	NN
O	NN

after	IN
O	NN

renal	JJ
O	NN

transplantation	NN
O	NN

METHODS	NNS
O	VBP

:	:
O	NN

Fluvastatin	NN
T	NN

40	CD
O	NN

mg	NN
O	NN

daily	RB
O	NN

was	VBD
O	NN

administered	VBN
O	NN

to	TO
O	NN

25	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

hypercholesterolaemia	NN
D	NN

for	IN
O	NN

up	RB
O	NN

to	TO
O	NN

24	CD
O	NN

weeks	NNS
O	NN

The	DT
O	NN

inhibitory	JJ
O	NN

effect	NN
O	NN

of	IN
O	NN

n-3	JJ
T	NN

polyunsaturated	JJ
T	NN

fatty	JJ
T	NN

acids	NNS
T	NN

on	IN
O	NN

human	JJ
D	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

has	VBZ
O	NN

been	VBN
O	NN

speculated	VBD
O	NN

on	IN
O	NN

from	IN
O	NN

epidemiological	JJ
O	NN

data	NNS
O	NN

and	CC
O	NN

animal	NN
O	NN

studies	NNS
O	VBP

We	PRP
O	VBP

conducted	VBN
O	NN

a	DT
O	NN

long-term	JJ
O	NN

trial	NN
O	NN

of	IN
O	NN

docosahexanoic	JJ
T	NN

acid	NN
T	NN

(	NN
T	NN

DHA	NN
T	NN

)	NN
T	NN

-concentrated	JJ
T	NN

fish	NN
T	NN

oil	NN
T	NN

capsules	NNS
T	NN

for	IN
O	NN

patients	NNS
O	NN

in	IN
O	NN

a	DT
O	NN

high-risk	JJ
O	NN

group	NN
O	NN

for	IN
O	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

Three	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

FAP	NN
D	NN

and	CC
O	NN

two	CD
O	NN

patients	NNS
O	NN

with	IN
O	NN

multiple	JJ
O	NN

(	NN
O	NN

more	RBR
O	NN

than	IN
O	NN

30	CD
O	NN

)	NN
O	NN

colorectal	JJ
D	NN

polyps	NNS
D	NN

were	VBD
O	NN

administered	VBN
O	NN

DHA-concentrated	JJ
T	NN

fish	NN
T	NN

oil	NN
T	NN

capsules_Hlk427554600	NN
T	NN

(	NN
T	NN

2.2	CD
T	NN

g	NN
T	NN

of	IN
T	NN

DHA	NN
T	NN

and	CC
T	NN

0.6	CD
T	NN

g	NN
T	NN

of	IN
T	NN

eicosapentanoic	JJ
T	NN

acid	NN
T	NN

(	NN
T	NN

EPA	NNP
T	NN

)	NN
T	NN

per	IN
T	NN

day	NN
T	NN

)	NN
T	NN

for	IN
O	NN

one	CD
O	NN

or	CC
O	NN

two	CD
O	NN

years	NNS
O	NN

This	DT
O	NN

article	NN
O	NN

reviews	NNS
O	VBP

current	JJ
O	NN

trends	NNS
O	VBP

in	IN
O	NN

management	NN
O	NN

of	IN
O	NN

esophageal	NN
D	NN

achalasia	NN
D	NN

,	,
O	NN

highlighting	VBG
O	NN

short-term	JJ
O	NN

outcome	NN
O	NN

and	CC
O	NN

cost	NN
O	NN

comparisons	NNS
O	NN

of	IN
O	NN

three	CD
O	NN

treatments	NNS
O	VBP

:	:
O	NN

botulinum	NN
T	NN

toxin	NN
T	NN

injection	NN
T	NN

,	,
O	NN

pneumatic	JJ
T	NN

dilation	NN
T	NN

,	,
O	NN

and	CC
O	NN

laparoscopic	JJ
T	NN

myotomy	JJ
T	NN

The	DT
O	NN

clinical	JJ
O	NN

application	NN
O	NN

of	IN
O	NN

therapeutic	JJ
T	NN

hysteroscopy	NN
T	NN

,	,
O	NN

mainly	RB
O	NN

in	IN
O	NN

the	DT
O	NN

field	NN
O	NN

of	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

abnormal	JJ
D	NN

uterine	NN
D	NN

bleeding	NN
D	NN

,	,
O	NN

started	VBD
O	NN

in	IN
O	NN

the	DT
O	NN

1980s	NNS
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

In	IN
O	NN

this	DT
O	NN

article	NN
O	NN

,	,
O	NN

evidence	NN
O	NN

of	IN
O	NN

effectiveness	NN
O	NN

and	CC
O	NN

cost-effectiveness	NN
O	NN

of	IN
O	NN

the	DT
O	NN

following	VBG
O	NN

procedures	NNS
O	VBP

is	VBZ
O	NN

reviewed	VBN
O	NN

:	:
O	NN

(	NN
O	NN

1	CD
O	NN

)	NN
O	NN

laser	NN
T	NN

treatment	NN
T	NN

of	IN
O	NN

bladder	NN
D	NN

tumors	NNS
D	NN

;	:
O	NN

(	NN
O	NN

2	CD
O	NN

)	NN
O	NN

extracorporeal	JJ
O	NN

shock-wave	NN
O	NN

lithotripsy	NN
O	NN

and	CC
O	NN

percutaneous	JJ
O	NN

nephrolithotomy	NN
O	NN

;	:
O	NN

(	NN
O	NN

3	CD
O	NN

)	NN
O	NN

laparoscopic	JJ
T	NN

treatment	NN
T	NN

of	IN
O	NN

endometriosis	NN
D	NN

;	:
O	NN

(	NN
O	NN

4	CD
O	NN

)	NN
O	NN

laparoscopic	JJ
T	NN

removal	NN
T	NN

of	IN
O	NN

ovarian	JJ
D	NN

cysts	NNS
D	NN

;	:
O	NN

(	NN
O	NN

5	CD
O	NN

)	NN
O	NN

laparoscopic	JJ
O	NN

cholecystectomy	NN
O	NN

;	:
O	NN

(	NN
O	NN

6	CD
O	NN

)	NN
O	NN

laparoscopic	JJ
O	NN

appendectomy	NN
O	NN

;	:
O	NN

(	NN
O	NN

7	CD
O	NN

)	NN
O	NN

catheter	NN
T	NN

treatment	NN
T	NN

of	IN
O	NN

coronary	JJ
D	NN

artery	NN
D	NN

disease	NN
D	NN

;	:
O	NN

(	NN
O	NN

8	CD
O	NN

)	NN
O	NN

palliation	NN
O	NN

of	IN
O	NN

colon	NN
O	NN

cancer	NN
O	NN

by	IN
O	NN

endoscopic	JJ
O	NN

intervention	NN
O	NN

;	:
O	NN

(	NN
O	NN

9	CD
O	NN

)	NN
O	NN

treatment	NN
O	NN

of	IN
O	NN

upper	JJ
D	NN

gastrointestinal	JJ
D	NN

(	NN
D	NN

UGI	NNP
D	NNP

)	NN
D	NN

bleeding	NN
D	NN

by	IN
O	NN

endoscopic	JJ
T	NN

intervention	NN
T	NN

;	:
O	NN

and	CC
O	NN

(	NN
O	NN

10	CD
O	NN

)	NN
O	NN

arthroscopic	JJ
O	NN

knee	NN
O	NN

surgery	NN
O	NN

Gene	NNP
T	NN

therapy	NN
T	NN

of	IN
O	NN

malignant	JJ
D	NN

brain	NN
D	NN

tumors	NNS
D	NN

Treatment	NN
O	NN

of	IN
O	NN

irritable	JJ
D	NN

bowel	NN
D	NN

syndrome	NN
D	NN

with	IN
O	NN

Chinese	JJ
T	NN

herbal	JJ
T	NN

medicine	NN
T	NN

:	:
O	NN

a	DT
O	NN

randomized	VBN
O	NN

controlled	JJ
O	NN

trial	NN
O	NN

Randomised	VBN
O	NN

trial	NN
O	NN

of	IN
O	NN

interferon	NN
T	NN

alpha2b	NN
T	NN

plus	CC
T	NN

ribavirin	NNP
T	NN

for	IN
O	NN

48	CD
O	NN

weeks	NNS
O	NN

or	CC
O	NN

for	IN
O	NN

24	CD
O	NN

weeks	NNS
O	NN

versus	CC
O	NN

interferon	NN
T	NN

alpha2b	NN
T	NN

plus	CC
T	NN

placebo	NN
T	NN

for	IN
O	NN

48	CD
O	NN

weeks	NNS
O	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

chronic	JJ
D	NN

infection	NN
D	NN

with	IN
D	NN

hepatitis	NN
D	NN

C	NN
D	NN

virus	NN
D	NN

Low-molecular-weight	JJ
T	NN

heparin	NN
T	NN

for	IN
O	NN

immediate	JJ
O	NN

management	NN
O	NN

of	IN
O	NN

thromboembolic	NN
D	NN

disease	NN
D	NN

in	IN
O	NN

pregnancy	NN
O	NN

Tubularized	VBN
T	NN

incised	VBN
T	NN

plate	NN
T	NN

hypospadias	NN
T	NN

repair	NN
T	NN

for	IN
O	NN

proximal	JJ
D	NN

hypospadias	NN
D	NN

Comparison	NN
O	NN

of	IN
O	NN

radical	JJ
T	NN

prostatectomy	NN
T	NN

and	CC
O	NN

iodine	NN
T	NN

125	CD
T	NN

interstitial	JJ
T	NN

radiotherapy	NN
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

clinically	RB
D	NN

localized	JJ
D	NN

prostate	NN
D	NN

cancer	NN
D	NN

:	:
O	NN

a	DT
O	NN

7-year	JJ
O	NN

biochemical	JJ
O	NN

(	NN
O	NN

PSA	NN
O	NN

)	NN
O	NN

progression	NN
O	NN

analysis	NN
O	NN

The	DT
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

acupuncture	NN
T	NN

in	IN
O	NN

treating	VBG
O	NN

acute	JJ
D	NN

dental	JJ
D	NN

pain	NN
D	NN

:	:
O	NN

a	DT
O	NN

systematic	JJ
O	NN

review	NN
O	NN

Correction	NN
O	NN

of	IN
O	NN

cardiac	JJ
D	NN

defects	NNS
D	NN

through	IN
O	NN

a	DT
O	NN

right	JJ
T	NN

thoracotomy	NN
T	NN

in	IN
O	NN

children	NNS
O	VBP

New	NNP
O	NNP

technique	NN
O	NN

for	IN
O	NN

mesh	NN
T	NN

repair	NN
T	NN

of	IN
O	NN

paracolostomy	NN
D	NN

hernias	NN
D	NN

Immunotherapy	NN
T	NN

of	IN
O	NN

tumors	NNS
D	NN

with	IN
O	NN

autologous	JJ
T	NN

tumor-derived	JJ
T	NN

heat	NN
T	NN

shock	NN
T	NN

protein	NN
T	NN

preparations	NNS
T	NN

Comprehensive	JJ
T	NN

modified	VBN
T	NN

diet	NN
T	NN

simplifies	VBZ
O	NN

nutrition	NN
T	NN

management	NN
T	NN

of	IN
O	NN

adults	NNS
O	NN

with	IN
O	NN

short-bowel	NN
D	NN

syndrome	NN
D	NN

Extended	VBN
O	NN

use	NN
O	NN

of	IN
O	NN

glatiramer	NN
T	NN

acetate	NN
T	NN

(	NN
T	NN

Copaxone	NN
T	NN

)	NN
T	NN

is	VBZ
O	NN

well	RB
O	NN

tolerated	VBN
O	NN

and	CC
O	NN

maintains	VBZ
O	NN

its	PRP$
O	NN

clinical	JJ
O	NN

effect	NN
O	NN

on	IN
O	NN

multiple	JJ
D	NN

sclerosis	NN
D	NN

relapse	NN
O	NN

rate	NN
O	NN

and	CC
O	NN

degree	NN
O	NN

of	IN
O	NN

disability	NN
O	NN

European	JJ
O	NN

register	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

sickle	NN
D	NN

cell	NN
D	NN

disease	NN
D	NN

treated	VBN
O	NN

with	IN
O	NN

hydroxyurea	NN
T	NN

is	VBZ
O	NN

being	VBG
O	NN

set	VBN
O	NN

up	RB
O	NN

Understanding	VBG
O	NN

the	DT
O	NN

culture	NN
O	NN

of	IN
O	NN

prescribing	VBG
O	NN

:	:
O	NN

qualitative	JJ
O	NN

study	NN
O	NN

of	IN
O	NN

general	JJ
O	NN

practitioners	NNS
O	VBP

'	POS
O	NN

and	CC
O	NN

patients	NNS
O	NN

'	POS
O	NN

perceptions	NNS
O	NN

of	IN
O	NN

antibiotics	NNS
T	NN

for	IN
O	NN

sore	JJ
D	NN

throats	NNS
D	NN

Steroid	NN
T	NN

delivery	NN
T	NN

in	IN
O	NN

croup	NN
D	NN

Haematoma	NN
T	NN

block	NN
T	NN

versus	CC
O	NN

intravenous	JJ
T	NN

regional	JJ
T	NN

anaesthesia	NN
T	NN

in	IN
O	NN

Colles	NNP
D	NNP

'	POS
D	NN

fractures	NNS
D	NN

Direct	JJ
T	NN

percutaneous	JJ
T	NN

transluminal	JJ
T	NN

angioplasty	JJ
T	NN

for	IN
O	NN

acute	JJ
D	NN

middle	JJ
D	NN

cerebral	JJ
D	NN

artery	NN
D	NN

occlusion	NN
D	NN

Magnesium	NN
T	NN

sulphate	NN
T	NN

for	IN
O	NN

the	DT
O	NN

control	NN
O	NN

of	IN
O	NN

spasms	NNS
D	NN

in	IN
D	NN

severe	JJ
D	NN

tetanus	NN
D	NN

Protective	JJ
O	NN

effect	NN
O	NN

of	IN
O	NN

pralidoxime	NN
T	NN

on	IN
O	NN

muscle	NN
D	NN

fiber	NN
D	NN

necrosis	NN
D	NN

induced	VBN
O	NN

by	IN
O	NN

organophosphate	NN
O	NN

compounds	NNS
O	NN

Assessment	NNP
O	NNP

of	IN
O	NN

atrioventricular	JJ
T	NN

junction	NN
T	NN

ablation	NN
T	NN

and	CC
T	NN

VVIR	NN
T	NN

pacemaker	NN
T	NN

versus	CC
O	NN

pharmacological	JJ
T	NN

treatment	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

heart	NN
D	NN

failure	NN
D	NN

and	CC
D	NN

chronic	JJ
D	NN

atrial	NN
D	NN

fibrillation	NN
D	NN

:	:
O	NN

a	DT
O	NN

randomized	VBN
O	NN

,	,
O	NN

controlled	JJ
O	NN

study	NN
O	NN

Statins	NNS
T	NN

for	IN
O	NN

prevention	NN
O	NN

of	IN
O	NN

stroke	NN
D	NN

Repair	JJ
O	NN

of	IN
O	NN

ventral	JJ
D	NN

hernias	NN
D	NN

with	IN
O	NN

expanded	VBN
T	NN

polytetrafluoroethylene	NN
T	NN

patch	NN
T	NN

Spinal	JJ
T	NN

manipulation	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

episodic	JJ
D	NN

tension-type	JJ
D	NN

headache	NN
D	NN

:	:
O	NN

a	DT
O	NN

randomized	VBN
O	NN

controlled	JJ
O	NN

trial	NN
O	NN

Successful	JJ
O	NN

treatment	NN
O	NN

with	IN
O	NN

lamivudine	NN
T	NN

for	IN
O	NN

fulminant	JJ
D	NN

reactivated	VBN
D	NN

hepatitis	NN
D	NN

B	NN
D	NN

infectioN	NN
D	NN

following	VBG
O	NN

intensive	JJ
T	NN

therapy	NN
T	NN

for	IN
O	NN

high-grade	JJ
D	NN

non-Hodgkin	JJ
D	NN

's	POS
D	NN

lymphoma	NN
D	NN

Influence	NN
O	NN

of	IN
O	NN

treatment	NN
O	NN

delay	NN
O	NN

on	IN
O	NN

infarct	NN
O	NN

size	NN
O	NN

and	CC
O	NN

clinical	JJ
O	NN

outcome	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

acute	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

treated	VBN
O	NN

with	IN
O	NN

primary	JJ
T	NN

angioplasty	JJ
T	NN

Should	MD
O	NNP

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

sarcomas	NNS
D	NN

be	VB
O	NN

treated	VBN
O	NN

with	IN
O	NN

chemotherapy	NN
T	NN

?	.
O	NN

Plasma	NN
T	NN

exchange	NN
T	NN

and	CC
T	NN

tacrolimus-mycophenolate	JJ
T	NN

rescue	NN
T	NN

for	IN
O	NN

acute	JJ
D	NN

humoral	JJ
D	NN

rejection	NN
D	NN

in	IN
O	NN

kidney	NN
O	NN

transplantation	NN
O	NN

Hyperbaric	JJ
T	NN

oxygen	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

children	NNS
O	VBP

with	IN
O	NN

cerebral	JJ
D	NN

palsy	NN
D	NN

Endoscopic	JJ
T	NN

excision	NN
T	NN

of	IN
O	NN

a	DT
D	NN

forehead	NN
D	NN

mass	NN
D	NN

Effect	NN
O	NN

of	IN
O	NN

photodynamic	JJ
T	NN

therapy	NN
T	NN

in	IN
T	NN

combination	NN
T	NN

with	IN
T	NN

mitomycin	NN
T	NN

C	NN
T	NN

on	IN
O	NN

a	DT
O	NN

mitomycin-resistant	JJ
D	NN

bladder	NN
D	NN

cancer	NN
D	NN

cell	NN
O	NN

line	NN
O	NN

Is	VBZ
O	NN

conservative	JJ
T	NN

surgery	NN
T	NN

for	IN
O	NN

tubal	JJ
D	NN

pregnancy	NN
D	NN

preferable	JJ
O	NN

to	TO
O	NN

salpingectomy	NN
T	NN

?	.
O	NN

An	DT
O	NN

economic	JJ
O	NN

analysis	NN
O	NN

Laparoscopic	JJ
T	NN

cornuostomy	JJ
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

interstitial	JJ
D	NN

pregnancy	NN
D	NN

with	IN
O	NN

subsequent	JJ
O	NN

hysterosalpingography	NN
O	NN

Experimental	JJ
O	NN

evaluation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

recombinant	JJ
T	NN

prourokinase	NN
T	NN

and	CC
O	NN

its	PRP$
O	NN

immobilized	VBN
O	NN

forms	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

postoperative	JJ
D	NN

fibrinoid	NN
D	NN

syndrome	NN
D	NN

in	IN
O	NN

ophthalmology	NN
O	NN

In	IN
O	NN

vitro	FW
O	FW

and	CC
O	NN

in	IN
O	NN

vivo	FW
O	FW

comparison	NN
O	NN

between	IN
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

treatment	NN
O	NN

with	IN
O	NN

adenosine	NN
T	NN

triphosphate	NN
T	NN

and	CC
O	NN

treatment	NN
O	NN

with	IN
O	NN

buthionine	NN
T	NN

sulfoximine	NN
T	NN

on	IN
O	NN

chemosensitization	NN
O	NN

and	CC
O	NN

tumour	NN
O	NN

growth	NN
O	NN

of	IN
O	NN

B16	NN
D	NN

melanoma	NN
D	NN

Effects	NNS
O	NN

of	IN
O	NN

transpupillary	JJ
T	NN

thermotherapy	JJ
T	NN

on	IN
O	NN

immunological	JJ
O	NN

parameters	NNS
O	VBP

and	CC
O	NN

apoptosis	NN
O	NN

in	IN
O	NN

a	DT
O	NN

case	NN
O	NN

of	IN
O	NN

primary	JJ
D	NN

uveal	NN
D	NN

melanoma	NN
D	NN

Is	VBZ
O	NN

there	RB
O	NN

a	DT
O	NN

rational	JJ
O	NN

therapy	NN
O	NN

for	IN
O	NN

symptomatic	JJ
O	NN

treatment	NN
O	NN

of	IN
O	NN

benign	JJ
D	NN

prostatic	JJ
D	NN

hyperplasia	NN
D	NN

with	IN
O	NN

phytogenic	JJ
T	NN

drugs	NNS
T	NN

?	.
O	NN

Illustrated	NNP
O	NNP

with	IN
O	NN

the	DT
O	NN

example	NN
O	NN

of	IN
O	NN

the	DT
O	NN

prostate	NN
O	NN

agent	NN
O	NN

from	IN
O	NN

Serenoa	NN
O	NN

repens	NNS
O	NN

(	NN
O	NN

Sabal	NNP
O	NNP

fructus	NN
O	NN

)	NN
O	NN

Pharmacological	JJ
O	NN

and	CC
O	NN

clinical	JJ
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

a	DT
O	NN

fixed	VBN
T	NN

phytogenic	JJ
T	NN

combination	NN
T	NN

trembling	VBG
T	NN

poplar	JJ
T	NN

(	NN
T	NN

Populus	JJ
T	NN

tremula	NN
T	NN

)	NN
T	NN

,	,
T	NN

true	JJ
T	NN

goldenrod	NN
T	NN

(	NN
T	NN

Solidago	NNP
T	NN

virgaurea	NN
T	NN

)	NN
T	NN

and	CC
T	NN

ash	JJ
T	NN

(	NN
T	NN

Fraxinus	NN
T	NN

excelsior	NN
T	NN

)	NN
T	NN

in	IN
O	NN

mild	JJ
D	NN

to	TO
D	NN

moderate	JJ
D	NN

rheumatic	JJ
D	NN

complaints	NNS
D	NN

Therapy	NN
O	NN

of	IN
O	NN

degenerative	JJ
D	NN

diseases	NNS
D	NN

of	IN
D	NN

the	DT
D	NN

musculoskeletal	JJ
D	NN

system	NN
D	NN

with	IN
O	NN

South	NNP
T	NN

African	JJ
T	NN

devil	NNP
T	NN

's	POS
T	NN

claw	VB
T	NN

(	NN
T	NN

Harpagophytum	NN
T	NN

procumbens	NNS
T	NN

DC	NN
T	NN

)	NN
T	NN

Treatment	NN
O	NN

strategy	NN
O	NN

for	IN
O	NN

mucin-producing	JJ
D	NN

intrahepatic	JJ
D	NN

cholangiocarcinoma	NN
D	NN

:	:
O	NN

value	NN
O	NN

of	IN
O	NN

percutaneous	JJ
T	NN

transhepatic	JJ
T	NN

biliary	JJ
T	NN

drainage	NN
T	NN

and	CC
O	NN

cholangioscopy	JJ
T	NN

Strategy	NN
O	NN

for	IN
O	NN

surgical	JJ
T	NN

management	NN
T	NN

of	IN
O	NN

ileocolonic	JJ
D	NN

anastomotic	JJ
D	NN

recurrence	NN
D	NN

in	IN
D	NN

Crohn	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

Nerve-sparing	JJ
T	NN

surgery	NN
T	NN

for	IN
O	NN

advanced	JJ
D	NN

rectal	JJ
D	NN

cancer	NN
D	NN

patients	NNS
O	NN

:	:
O	NN

special	JJ
O	NN

reference	NN
O	NN

to	TO
O	NN

Dukes	NNP
O	NNP

C	NN
O	NN

patients	NNS
O	NN

Prognostic	JJ
O	NN

factors	NNS
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

locally	RB
O	NN

advanced	JJ
O	NN

rectal	JJ
D	NN

adenocarcinoma	NN
D	NN

treated	VBN
O	NN

with	IN
O	NN

preoperative	JJ
T	NN

radiotherapy	NN
T	NN

and	CC
O	NN

surgery	NN
T	NN

Current	JJ
O	NN

surgical	JJ
T	NN

therapy	NN
T	NN

for	IN
O	NN

bronchiectasis	NN
D	NN

Thoracic	JJ
T	NN

surgery	NN
T	NN

for	IN
O	NN

hydatid	NN
D	NN

disease	NN
D	NN

Surgical	NNP
T	NN

treatment	NN
T	NN

of	IN
O	NN

postpneumonic	JJ
D	NN

empyema	NN
D	NN

Thoracoscopic	JJ
T	NN

surgery	NN
T	NN

for	IN
O	NN

pulmonary	JJ
D	NN

tuberculosis	NN
D	NN

Thoracoscopic	JJ
T	NN

surgery	NN
T	NN

for	IN
O	NN

spontaneous	JJ
D	NN

pneumothorax	NN
D	NN

Surgery	NN
T	NN

for	IN
O	NN

chronic	JJ
D	NN

thromboembolic	NN
D	NN

pulmonary	JJ
D	NN

hypertension	NN
D	NN

Transabdominal	JJ
T	NN

extensive	JJ
T	NN

esophagogastric	JJ
T	NN

devascularization	NN
T	NN

with	IN
T	NN

gastroesophageal	NN
T	NN

stapling	VBG
T	NN

for	IN
O	NN

management	NN
O	NN

of	IN
O	NN

noncirrhotic	JJ
D	NN

portal	NN
D	NN

hypertension	NN
D	NN

:	:
O	NN

long-term	JJ
O	NN

results	NNS
O	VBP

Surgical	NNP
T	NN

treatment	NN
T	NN

for	IN
O	NN

lung	NN
D	NN

hydatid	NN
D	NN

disease	NN
D	NN

Sliding	VBG
T	NN

door	NN
T	NN

technique	NN
T	NN

for	IN
O	NN

the	DT
O	NN

repair	NN
O	NN

of	IN
O	NN

midline	NN
D	NN

incisional	JJ
D	NN

hernias	NN
D	NN

One-lung	JJ
T	NN

ventilation	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

difficult	JJ
D	NN

airways	NNS
D	NN

Thoracoscopy	JJ
T	NN

for	IN
O	NN

empyema	NN
D	NN

in	IN
O	NN

children	NNS
O	VBP

Sex	NN
O	NN

differences	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

asthma	NN
D	NN

drugs	NNS
T	NN

:	:
O	NN

cross	JJ
O	NN

sectional	JJ
O	NN

study	NN
O	NN

Conventional	JJ
T	NN

treatments	NNS
T	NN

for	IN
O	NN

non-Hodgkin	JJ
D	NN

's	POS
D	NN

lymphoma	NN
D	NN

:	:
O	NN

the	DT
O	NN

need	NN
O	NN

for	IN
O	NN

new	JJ
O	NN

therapies	NNS
O	NN

Adrenal-sparing	JJ
T	NN

surgery	NN
T	NN

for	IN
O	NN

phaeochromocytoma	NN
D	NN

Antiplatelet	JJ
T	NN

therapy	NN
T	NN

in	IN
O	NN

acute	JJ
D	NN

cerebral	JJ
D	NN

ischemia	NN
D	NN

Laugier-Hunziker	NN
D	NN

syndrome	NN
D	NN

:	:
O	NN

case	NN
O	NN

report	NN
O	NN

and	CC
O	NN

treatment	NN
O	NN

with	IN
O	NN

the	DT
O	NN

Q-switched	JJ
T	NN

Nd-Yag	NN
T	NN

laser	NN
T	NN

Thoracoscopic	JJ
T	NN

operation	NN
T	NN

for	IN
O	NN

secondary	JJ
D	NN

pneumothorax	NN
D	NN

under	IN
O	NN

local	JJ
O	NN

and	CC
O	NN

epidural	JJ
O	NN

anesthesia	NN
O	NN

in	IN
O	NN

high-risk	JJ
O	NN

patients	NNS
O	NN

Troglitazone-induced	JJ
D	NN

hepatic	JJ
D	NN

failure	NN
D	NN

leading	VBG
O	NN

to	TO
O	NN

liver	NN
T	NN

transplantation	NN
T	NN

A	DT
O	NN

modified	VBN
O	NN

technique	NN
O	NN

of	IN
O	NN

tubeless	JJ
O	NN

anaesthesia	NN
O	NN

for	IN
O	NN

microlaryngoscopy	JJ
T	NN

and	CC
T	NN

bronchoscopy	NN
T	NN

in	IN
O	NN

young	JJ
O	NN

children	NNS
O	VBP

with	IN
O	NN

stridor	NN
D	NN

A	DT
O	NN

randomized	VBN
O	NN

trial	NN
O	NN

of	IN
O	NN

Lactobacillus	NN
T	NN

acidophilus	NN
T	NN

BG2FO4	NN
T	NN

to	TO
O	NN

treat	VB
O	NNP

lactose	NN
D	NN

intolerance	NN
D	NN

Treatment	NN
O	NN

of	IN
O	NN

idiopathic	JJ
D	NN

thrombopenic	JJ
D	NN

purpura	NN
D	NN

in	IN
O	NN

adolescents	NNS
O	NN

by	IN
O	NN

intravenous	JJ
T	NN

immunoglobulin	NN
T	NN

Azithromycin	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

scrub	NN
D	NN

typhus	NN
D	NN

during	IN
O	NN

pregnancy	NN
O	NN

Excimer	NNP
T	NN

laser	NN
T	NN

assisted	VBN
T	NN

in	IN
T	NN

situ	FW
T	NN

keratomileusis	NN
T	NN

for	IN
O	NN

hyperopia	NN
D	NN

Three	CD
O	NN

consecutive	JJ
O	NN

phase	NN
O	NN

II	NNP
O	NNP

studies	NNS
O	VBP

of	IN
O	NN

recombinant	JJ
T	NN

interferon	NN
T	NN

alfa-2a	JJ
T	NN

in	IN
O	NN

advanced	JJ
D	NN

malignant	JJ
D	NN

melanoma	NN
D	NN

Interferon	NN
T	NN

treatment	NN
T	NN

of	IN
O	NN

renal	JJ
D	NN

cell	NN
D	NN

carcinoma	NN
D	NN

Current	JJ
O	NN

and	CC
O	NN

future	JJ
O	NN

uses	NNS
O	NN

of	IN
O	NN

recombinant	JJ
T	NN

interferon	NN
T	NN

alpha	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

low-grade	JJ
D	NN

non-Hodgkin	JJ
D	NN

's	POS
D	NN

lymphoma	NN
D	NN

Antimicrobial	JJ
T	NN

treatment	NN
T	NN

options	NNS
O	NN

in	IN
O	NN

the	DT
O	NN

management	NN
O	NN

of	IN
O	NN

odontogenic	JJ
D	NN

infections	NNS
D	NN

Recombinant	JJ
T	NN

glycoprotein	NN
T	NN

vaccine	NN
T	NN

for	IN
O	NN

the	DT
O	NN

prevention	NN
O	NN

of	IN
O	NN

genital	JJ
D	NN

HSV-2	NN
D	NN

infection	NN
D	NN

:	:
O	NN

two	CD
O	NN

randomized	VBN
O	NN

controlled	JJ
O	NN

trials	NNS
O	NN

Induction	NN
T	NN

chemotherapy	NN
T	NN

with	IN
T	NN

docetaxel	NN
T	NN

,	,
T	NN

cisplatin	NN
T	NN

,	,
T	NN

fluorouracil	NN
T	NN

,	,
T	NN

and	CC
T	NN

leucovorin	NN
T	NN

for	IN
O	NN

squamous	JJ
D	NN

cell	NN
D	NN

carcinoma	NN
D	NN

of	IN
O	NN

the	DT
O	NN

head	NN
O	NN

and	CC
O	NN

neck	NN
O	NN

:	:
O	NN

a	DT
O	NN

phase	NN
O	NN

I/II	CD
O	NN

trial	NN
O	NN

Low-dose	JJ
T	NN

steroids	NNS
T	NN

reduce	VB
O	NN

flu-like	JJ
D	NN

symptoms	NNS
D	NN

at	IN
O	NN

the	DT
O	NN

initiation	NN
O	NN

of	IN
O	NN

IFNbeta-1b	NN
O	NN

in	IN
O	NN

relapsing-remitting	JJ
O	NN

MS	NN
O	NN

Study	NNP
O	NNP

of	IN
O	NN

three	CD
O	NN

different	JJ
O	NN

doses	NNS
O	NN

of	IN
O	NN

epidural	JJ
T	NN

neostigmine	NN
T	NN

coadministered	VBN
T	NN

with	IN
T	NN

lidocaine	NN
T	NN

for	IN
O	NN

postoperative	JJ
D	NN

analgesia	NN
D	NN

An	DT
O	NN

active-control	JJ
O	NN

trial	NN
O	NN

of	IN
O	NN

lamotrigine	NN
T	NN

monotherapy	JJ
T	NN

for	IN
O	NN

partial	JJ
D	NN

seizures	NNS
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Safety	NN
O	NN

of	IN
O	NN

intrathecal	JJ
T	NN

sodium	NN
T	NN

nitroprusside	JJ
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

and	CC
O	NN

prevention	NN
O	NN

of	IN
O	NN

refractory	JJ
D	NN

cerebral	JJ
D	NN

vasospasm	NN
D	NN

and	CC
D	NN

ischemia	NN
D	NN

in	IN
O	NN

humans	NNS
O	NN

The	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

heliox	JJ
T	NN

in	IN
O	NN

acute	JJ
D	NN

severe	JJ
D	NN

asthma	NN
D	NN

:	:
O	NN

a	DT
O	NN

randomized	VBN
O	NN

controlled	JJ
O	NN

trial	NN
O	NN

.	.
O	NN

Long-term	JJ
O	NN

survival	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

unresectable	JJ
D	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

liver	NN
D	NN

metastases	NNS
D	NN

following	VBG
O	NN

infusional	JJ
T	NN

chemotherapy	NN
T	NN

with	IN
T	NN

5-fluorouracil	NN
T	NN

,	,
T	NN

leucovorin	NN
T	NN

,	,
T	NN

oxaliplatin	NN
T	NN

and	CC
T	NN

surgery	NN
T	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Fatal	JJ
D	NN

acute	JJ
D	NN

haemolysis	NN
D	NN

in	IN
O	NN

an	DT
O	NN

AIDS	NN
D	NN

patient	NN
O	NN

treated	VBN
O	NN

with	IN
O	NN

lindinavir	NN
T	NN

A	DT
O	NN

simplified	VBN
O	NN

laparoscopic	JJ
T	NN

technique	NN
T	NN

for	IN
T	NN

mesh	NN
T	NN

placement	NN
T	NN

in	IN
O	NN

ventral	JJ
D	NN

hernia	NN
D	NN

repair	NN
O	NN

Pharmacological	JJ
T	NN

management	NN
T	NN

of	IN
O	NN

acute	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

Mesenteric	JJ
D	NN

venous	JJ
D	NN

thrombosis	NN
D	NN

:	:
O	NN

successful	JJ
O	NN

treatment	NN
O	NN

by	IN
O	NN

intraarterial	JJ
T	NN

lytic	JJ
T	NN

therapy	NN
T	NN

Gene	NNP
T	NN

therapy	NN
T	NN

for	IN
O	NN

myocardial	JJ
D	NN

angiogenesis	NN
D	NN

Dipyridamole	NNP
T	NN

plus	CC
T	NN

aspirin	NN
T	NN

in	IN
O	NN

cerebrovascular	JJ
D	NN

disease	NN
D	NN

What	WDT
O	NN

is	VBZ
O	NN

the	DT
O	NN

real	JJ
O	NN

role	NN
O	NN

of	IN
O	NN

CD40	NN
O	NN

in	IN
O	NN

cancer	NN
D	NN

immunotherapy	NN
T	NN

?	.
O	NN

The	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

oral	JJ
T	NN

liarozole	NN
T	NN

on	IN
O	NN

epidermal	JJ
O	NN

proliferation	NN
O	NN

and	CC
O	NN

differentiation	NN
O	NN

in	IN
O	NN

severe	JJ
D	NN

plaque	NN
D	NN

psoriasis	NN
D	NN

are	VBP
O	NN

comparable	JJ
O	NN

with	IN
O	NN

those	DT
O	NNP

of	IN
O	NN

acitretin	NN
T	NN

.	.
O	NN

Safety	NN
O	NN

and	CC
O	NN

potential	JJ
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

daunorubicin-containing	JJ
T	NN

liposomes	NNS
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

advanced	JJ
D	NN

recurrent	JJ
D	NN

malignant	JJ
D	NN

CNS	NN
D	NN

tumors	NNS
D	NN

An	DT
O	NN

experimental	JJ
O	NN

application	NN
O	NN

of	IN
O	NN

gene	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

human	JJ
D	NN

retinoblastoma	NN
D	NN

Acid	NN
T	NN

suppression	NN
T	NN

therapy	NN
T	NN

in	IN
O	NN

Barrett	NNP
D	NNP

's	POS
D	NN

esophagus	NN
D	NN

:	:
O	NN

the	DT
O	NN

importance	NN
O	NN

of	IN
O	NN

pH	NN
O	NN

monitoring	VBG
O	NN

Surgical	NNP
T	NN

approaches	NNS
T	NN

to	TO
O	NN

pediatric	JJ
D	NN

defecatory	JJ
D	NN

disorders	NNS
D	NN

Lutein	NN
T	NN

improves	VBZ
O	NN

visual	JJ
O	NN

function	NN
O	NN

in	IN
O	NN

some	DT
O	NN

patients	NNS
O	NN

with	IN
O	NN

retinal	JJ
D	NN

degeneration	NN
D	NN

:	:
O	NN

a	DT
O	NN

pilot	NN
O	NN

study	NN
O	NN

via	IN
O	NN

the	DT
O	NN

Internet	NN
O	NN

Drug	NN
O	NN

information	NN
O	NN

questions	NNS
O	NN

and	CC
O	NN

answers	NNS
O	NN

:	:
O	NN

new	JJ
O	NN

for	IN
O	NN

psoriasis	NN
D	NN

:	:
O	NN

colchicine	NN
T	NN

IPPB	NN
T	NN

in	IN
O	NN

severe	JJ
D	NN

pulmonary	JJ
D	NN

emphysema	NN
D	NN

:	:
O	NN

limited	JJ
O	NN

applications	NNS
O	NN

Long-term	JJ
O	NN

mortality	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

after	IN
O	NN

a	DT
O	NN

British	JJ
O	NN

trial	NN
O	NN

of	IN
O	NN

anticoagulants	NNS
T	NN

in	IN
O	NN

acute	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

Our	PRP$
O	NN

results	NNS
O	VBP

in	IN
O	NN

the	DT
O	NN

surgical	JJ
T	NN

treatment	NN
T	NN

of	IN
O	NN

habitual	JJ
D	NN

shoulder	NN
D	NN

dislocation	NN
D	NN

with	IN
O	NN

special	JJ
O	NN

reference	NN
O	NN

to	TO
O	NN

occupational	JJ
O	NN

disability	NN
O	NN

Alkaline	NN
O	NN

phosphatase	NN
O	NN

in	IN
O	NN

neutrophil	NN
O	NN

leukocytes	NNS
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

infectious	JJ
D	NN

mononucleosis	NN
D	NN

and	CC
O	NN

the	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

corticosteroid	NN
T	NN

therapy	NN
T	NN

Surgical	NNP
T	NN

treatment	NN
T	NN

of	IN
O	NN

uterine	NN
D	NN

cervix	NN
D	NN

insufficiency	NN
D	NN

during	IN
O	NN

the	DT
O	NN

2d	JJ
O	NN

trimester	NN
O	NN

of	IN
O	NN

pregnancy	NN
O	NN

Physiologic	JJ
T	NN

treatment	NN
T	NN

of	IN
O	NN

depressive	JJ
D	NN

reactions	NNS
D	NN

:	:
O	NN

a	DT
O	NN

pilot	NN
O	NN

study	NN
O	NN

The	DT
O	NN

use	NN
O	NN

of	IN
O	NN

quinidine	NN
T	NN

sulphate	NN
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

atrial	NN
D	NN

fibrillation	NN
D	NN

in	IN
O	NN

twelve	CD
O	NN

horses	NNS
O	NN

Synergism	NN
O	NN

in	IN
O	NN

the	DT
O	NN

chemotherapy	NN
T	NN

of	IN
O	NN

Eimeria	NN
D	NN

infections	NNS
D	NN

of	IN
O	NN

chicks	NNS
O	NN

Treatment	NN
O	NN

of	IN
O	NN

hydrocele	NN
D	NN

and	CC
D	NN

cysts	NNS
D	NN

of	IN
D	NN

the	DT
D	NN

epididymis	NN
D	NN

with	IN
O	NN

sclerosing	VBG
T	NN

injections	NNS
T	NN

of	IN
T	NN

quinine	NN
T	NN

and	CC
T	NN

urea	NN
T	NN

chlorhydrolactate	NN
T	NN

in	IN
O	NN

a	DT
O	NN

30	CD
O	NN

per	IN
O	NN

cent	NN
O	NN

solution	NN
O	NN

The	DT
O	NN

single-place	JJ
T	NN

caisson	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

decompression	NN
D	NN

accidents	NNS
D	NN

Blood	NN
O	NN

volume	NN
O	NN

measurements	NNS
O	NN

in	IN
O	NN

burn	VB
D	NN

therapy	NN
T	NN

Phenylbutazone	NN
T	NN

and	CC
O	NN

acute	JJ
D	NN

leukemia	NN
D	NN

.	.
O	NN

The	DT
O	NN

place	NN
O	NN

of	IN
O	NN

surgery	NN
T	NN

in	IN
O	NN

hypertrophic	NN
D	NN

obstructive	JJ
D	NN

cardiomyopathy	NN
D	NN

(	NN
D	NN

idiopathic	JJ
D	NN

hypertrophic	NN
D	NN

subaortic	JJ
D	NN

stenosis	NN
D	NN

)	NN
D	NN

The	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

autoimmune	JJ
D	NN

hemolytic	JJ
D	NN

anemia	NN
D	NN

with	IN
O	NN

heparin	NN
T	NN

Effects	NNS
O	NN

of	IN
O	NN

clomiphene	NN
T	NN

citrate	NN
T	NN

on	IN
O	NN

endometrial	JJ
D	NN

hyperplasia	NN
D	NN

in	IN
O	NN

the	DT
O	NN

premenopausal	JJ
O	NN

female	JJ
O	NN

Prolonged	JJ
O	NN

use	NN
O	NN

of	IN
O	NN

methyldopa	NN
T	NN

in	IN
O	NN

severe	JJ
D	NN

hypertension	NN
D	NN

in	IN
O	NN

pregnancy	NN
O	NN

The	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

social	JJ
O	NN

class	NN
O	NN

and	CC
O	NN

friends	NNS
O	NN

'	POS
O	NN

expectations	NNS
O	IN

on	IN
O	NN

oral	JJ
O	NN

polio	NNP
D	NNP

vaccination	NN
T	NN

participation	NN
O	NN

Glutathione	NN
O	NN

S-transferase	NN
O	NN

activity	NN
O	NN

in	IN
O	NN

epithelial	JJ
D	NN

ovarian	JJ
D	NN

cancer	NN
D	NN

:	:
O	NN

association	NN
O	NN

with	IN
O	NN

response	NN
O	NN

to	TO
O	NN

chemotherapy	NN
T	NN

and	CC
O	NN

disease	NN
O	NN

outcome	NN
O	NN

Interferon-alpha-2b	JJ
T	NN

in	IN
O	NN

the	DT
O	NN

management	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

relapsed	VBD
O	NN

and/or	CC
O	NN

refractory	JJ
O	NN

Hodgkin	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Frontal	JJ
D	NN

dysfunction	NN
D	NN

blocks	NNS
O	NN

the	DT
O	NN

therapeutic	JJ
O	NN

effect	NN
O	NN

of	IN
O	NN

THA	NN
T	NN

on	IN
O	NN

attention	NN
O	NN

in	IN
O	NN

Alzheimer	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

Effects	NNS
O	NN

of	IN
O	NN

clomipramine	NN
T	NN

on	IN
O	NN

plasma	NN
O	NN

amino	NN
O	NN

acids	NNS
O	NN

and	CC
O	NN

serotonergic	JJ
O	NN

parameters	NNS
O	VBP

in	IN
O	NN

panic	NN
D	NN

disorder	NN
D	NN

and	CC
D	NN

depression	NN
D	NN

.	.
O	NN

Thalidomide	NNP
T	NN

for	IN
O	NN

aphthous	JJ
D	NN

ulcers	NNS
D	NN

in	IN
O	NN

HIV	NN
D	NN

infection	NN
D	NN

Aspirin	NN
T	NN

therapy	NN
T	NN

in	IN
O	NN

diabetes	NN
D	NN

mellitus	NN
D	NN

Combined	VBN
T	NN

pancreas-/kidney	JJ
T	NN

transplantation	NN
T	NN

as	IN
O	NN

a	DT
O	NN

standard	JJ
O	NN

procedure	NN
O	NN

in	IN
O	NN

therapy	NN
O	NN

of	IN
O	NN

kidney	NN
D	NN

failure	NN
D	NN

in	IN
D	NN

type	NN
D	NN

I	PRP
D	NN

diabetic	JJ
D	NN

patients	NNS
D	NN

Corticosteroid	NN
T	NN

injections	NNS
T	NN

for	IN
O	NN

sciatica	NN
D	NN

Flutamide	NN
T	NN

plus	CC
T	NN

castration	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

previously	RB
O	NN

untreated	JJ
O	NN

prostate	NN
D	NN

cancer	NN
D	NN

The	DT
O	NN

immediate	JJ
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

electrical	JJ
T	NN

nerve	NN
T	NN

stimulation	NN
T	NN

and	CC
O	NN

electrical	JJ
T	NN

muscle	NN
T	NN

stimulation	NN
T	NN

on	IN
O	NN

myofascial	JJ
D	NN

trigger	NN
D	NN

points	NNS
D	NN

In	IN
O	NN

vitro	FW
O	FW

radiation-induced	JJ
O	NN

apoptosis	NN
O	NN

and	CC
O	NN

tumour	NN
O	NN

response	NN
O	NN

to	TO
O	NN

radiotherapy	NN
T	NN

:	:
O	NN

a	DT
O	NN

prospective	JJ
O	NN

study	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

non-Hodgkin	JJ
D	NN

lymphomas	NNS
D	NN

treated	VBN
O	NN

by	IN
O	NN

low-dose	JJ
T	NN

irradiation	NN
T	NN

Drug	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

coronary	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

:	:
O	NN

the	DT
O	NN

Sheffield	NNP
O	NNP

table	NN
O	NN

Percutaneous	JJ
T	NN

drainage	NN
T	NN

of	IN
O	NN

hydatid	NN
D	NN

cysts	NNS
D	NN

Surgery	NN
T	NN

for	IN
O	NN

ectopia	NN
D	NN

lentis	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Antiplatelet	JJ
T	NN

therapy	NN
T	NN

to	TO
O	NN

prevent	VB
O	NN

stroke	NN
D	NN

:	:
O	NN

risk	NN
O	NN

of	IN
O	NN

brain	NN
D	NN

hemorrhage	NN
D	NN

and	CC
O	NN

efficacy	NN
O	NN

in	IN
O	NN

atrial	JJ
T	NN

fibrillation	NN
T	NN

High-dose	JJ
T	NN

chemotherapy	NN
T	NN

with	IN
T	NN

autologous	JJ
T	NN

hematopoietic	JJ
T	NN

stem-cell	NN
T	NN

support	NN
T	NN

for	IN
O	NN

breast	NN
D	NN

cancer	NN
D	NN

in	IN
O	NN

North	NNP
O	NNP

America	NNP
O	NNP

Is	VBZ
O	NN

concomitant	JJ
T	NN

radiotherapy	NN
T	NN

and	CC
T	NN

chemotherapy	NN
T	NN

superior	JJ
O	NN

to	TO
O	NN

optimal	JJ
O	NN

radiotherapy	NN
T	NN

alone	RB
O	NN

in	IN
O	NN

anal	JJ
D	NN

cancer	NN
D	NN

?	.
O	NN

Standard	JJ
T	NN

versus	CC
T	NN

high-dose	JJ
T	NN

therapy	NN
T	NN

in	IN
O	NN

10+	CD
O	NN

breast	NN
D	NN

cancer	NN
D	NN

Anal	JJ
O	NN

continence	NN
O	NN

after	IN
O	NN

surgery	NN
T	NN

for	IN
O	NN

rectal	JJ
D	NN

prolapse	NN
D	NN

Aspirin	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

cardiovascular	JJ
D	NN

disease	NN
D	NN

Dosing	NN
O	NN

of	IN
O	NN

amoxicillin/clavulanate	JJ
T	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

lower	JJR
D	NN

respiratory	JJ
D	NN

tract	NN
D	NN

infection	NN
D	NN

Pharmacoeconomic	JJ
O	NN

analysis	NN
O	NN

of	IN
O	NN

ampicillin-sulbactam	JJ
T	NN

versus	CC
O	NN

cefoxitin	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

intraabdominal	JJ
D	NN

infections	NNS
D	NN

New	JJ
T	NN

therapies	NNS
T	NN

for	IN
O	NN

severe	JJ
D	NN

meningococcal	JJ
D	NN

disease	NN
D	NN

Another	DT
O	NN

potential	JJ
O	NN

use	NN
O	NN

of	IN
O	NN

troglitazone	NN
T	NN

in	IN
O	NN

noninsulin-dependent	JJ
D	NN

diabetes	NN
D	NN

mellitus	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Jaw	NN
D	NN

clenching	VBG
D	NN

following	VBG
O	NN

Gamma	NN
T	NN

Knife	NNP
T	NN

treatment	NN
T	NN

for	IN
O	NN

trigeminal	JJ
D	NN

neuralgia	NN
D	NN

The	DT
O	NN

protective	JJ
O	NN

effect	NN
O	NN

of	IN
O	NN

condoms	NNS
T	NN

and	CC
O	NN

nonoxynol-9	JJ
T	NN

against	IN
O	NN

HIV	NN
D	NN

infection	NN
D	NN

Evaluation	NN
O	NN

of	IN
O	NN

adjuvant	JJ
T	NN

psychological	JJ
T	NN

therapy	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

testicular	JJ
D	NN

cancer	NN
D	NN

:	:
O	NN

randomised	VBN
O	NN

controlled	JJ
O	NN

trial	NN
O	NN

The	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

an	DT
O	NN

endothelin-receptor	JJ
T	NN

antagonist	NN
T	NN

,	,
T	NN

bosentan	NN
T	NN

,	,
O	NN

on	IN
O	NN

blood	NN
O	NN

pressure	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

essential	JJ
D	NN

hypertension	NN
D	NN

.	.
O	NN

Guidelines	NNS
O	NN

for	IN
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

antiretroviral	JJ
T	NN

agents	NNS
T	NN

in	IN
O	NN

HIV	NN
D	NN

-infected	JJ
O	NN

adults	NNS
O	NN

and	CC
O	NN

adolescents	NNS
O	NN

Long-term	JJ
O	NN

therapy	NN
O	NN

with	IN
O	NN

long-acting	JJ
T	NN

octreotide	NN
T	NN

(	NN
T	NN

Sandostatin-LAR	JJ
T	NN

)	NN
T	NN

for	IN
O	NN

the	DT
O	NN

management	NN
O	NN

of	IN
O	NN

acromegaly	NN
D	NN

Are	VBP
O	NN

ABVD	NN
T	NN

and	CC
O	NN

MOPP/ABV	NN
T	NN

truly	RB
O	NN

equivalent	JJ
O	NN

for	IN
O	NN

treating	VBG
O	NN

Hodgkin	NN
D	NN

's	POS
D	NN

disease	NN
D	NN

at	IN
O	NN

advanced	JJ
O	NN

stages	NNS
O	NN

?	.
O	NN

Paclitaxel	NN
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

lymphoma	NN
D	NN

Montelukast	JJ
T	NN

,	,
T	NN

a	DT
T	NN

leukotriene-receptor	NN
T	NN

antagonist	NN
T	NN

,	,
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

mild	JJ
D	NN

asthma	NN
D	NN

and	CC
D	NN

exercise-induced	JJ
D	NN

bronchoconstriction	NN
D	NN

Atypical	JJ
O	NN

antipsychotic	JJ
T	NN

agents	NNS
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

Schizophrenia	NN
D	NN

and	CC
D	NN

other	JJ
D	NN

psychiatric	JJ
D	NN

disorders	NNS
D	NN

Percutaneous	JJ
T	NN

transluminal	JJ
T	NN

angioplasty	JJ
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

renovascular	JJ
D	NN

hypertension	NN
D	NN

:	:
O	NN

sequential	JJ
O	NN

prospective	JJ
O	NN

study	NN
O	NN

Esophageal	JJ
T	NN

intubation	NN
T	NN

for	IN
O	NN

palliative	JJ
O	NN

treatment	NN
O	NN

in	IN
O	NN

advanced	JJ
D	NN

carcinoma	NN
D	NN

of	IN
D	NN

the	DT
D	NN

esophagus	NN
D	NN

and	CC
D	NN

cardia	NN
D	NN

Pathological	JJ
O	NN

staging	NN
O	NN

and	CC
O	NN

biochemical	JJ
O	NN

recurrence	NN
O	NN

after	IN
O	NN

neoadjuvant	JJ
T	NN

androgen	NN
T	NN

deprivation	NN
T	NN

therapy	NN
T	NN

in	IN
O	NN

combination	NN
O	NN

with	IN
O	NN

radical	JJ
T	NN

prostatectomy	NN
T	NN

in	IN
O	NN

clinically	RB
O	NN

localized	JJ
O	NN

prostate	NN
D	NN

cancer	NN
D	NN

How	WRB
O	NN

often	RB
O	NN

does	VBZ
O	NNP

surgery	NN
T	NN

for	IN
O	NN

peptic	JJ
D	NN

ulceration	NN
D	NN

eradicate	VB
O	NN

Helicobacter	NNP
O	NNP

pylori	NN
O	NN

?	.
O	NN

Systematic	JJ
O	NN

review	NN
O	NN

of	IN
O	NN

36	CD
O	NN

studies	NNS
O	VBP

A	DT
O	NN

comparison	NN
O	NN

of	IN
O	NN

noninvasive	JJ
T	NN

positive-pressure	JJ
T	NN

ventilation	NN
T	NN

and	CC
O	NN

conventional	JJ
T	NN

mechanical	JJ
T	NN

ventilation	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

acute	JJ
D	NN

respiratory	JJ
D	NN

failure	NN
D	NN

Long-term	JJ
O	NN

safety	NN
O	NN

and	CC
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

iron-chelation	JJ
T	NN

therapy	NN
T	NN

with	IN
T	NN

deferiprone	NN
T	NN

for	IN
O	NN

thalassemia	NN
D	NN

major	JJ
D	NN

Positron	NNP
O	NNP

emission	NN
O	NN

tomography	NN
O	NN

in	IN
O	NN

assessing	VBG
O	NN

response	NN
O	NN

to	TO
O	NN

neoadjuvant	JJ
T	NN

chemotherapy	NN
T	NN

for	IN
O	NN

non-small-cell	JJ
D	NN

lung	NN
D	NN

cancer	NN
D	NN

Reconstruction	NN
O	NN

of	IN
O	NN

thoracic	JJ
O	NN

wall	NN
O	NN

defects	NNS
O	NN

after	IN
O	NN

tumor	NN
D	NN

resection	NN
T	NN

using	VBG
O	NN

a	DT
O	NN

polytetrafluoroethylene	NN
O	NN

soft	JJ
O	NN

tissue	NN
O	NN

(	NN
O	NN

Gore-Tex	NNP
O	NNP

)	NN
O	NN

patch	NN
O	NN

A	DT
O	NN

comparison	NN
O	NN

of	IN
O	NN

rectal	JJ
T	NN

diazepam	NN
T	NN

gel	NN
T	NN

and	CC
O	NN

placebo	NN
O	NN

for	IN
O	NN

acute	JJ
D	NN

repetitive	JJ
D	NN

seizures	NNS
D	NN

Effect	NN
O	NN

of	IN
O	NN

long-term	JJ
O	NN

salmeterol	NN
T	NN

treatment	NN
T	NN

on	IN
O	NN

exercise-induced	JJ
D	NN

asthma	NN
D	NN

Randomized	VBN
O	NN

trial	NN
O	NN

of	IN
O	NN

intensive	JJ
T	NN

cyclophosphamide	NN
T	NN

,	,
T	NN

epirubicin	NN
T	NN

,	,
T	NN

and	CC
T	NN

fluorouracil	NN
T	NN

chemotherapy	NN
T	NN

compared	VBN
O	NN

with	IN
O	NN

cyclophosphamide	NN
T	NN

,	,
T	NN

methotrexate	NN
T	NN

,	,
T	NN

and	CC
T	NN

fluorouracil	NN
T	NN

in	IN
O	NN

premenopausal	JJ
O	NN

women	NNS
O	VBP

with	IN
O	NN

node-positive	JJ
D	NN

breast	NN
D	NN

cancer	NN
D	NN

Acute	JJ
O	NN

effect	NN
O	NN

of	IN
O	NN

lorazepam	NN
T	NN

on	IN
O	NN

respiratory	JJ
O	NN

muscles	NNS
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

obstructive	JJ
D	NN

pulmonary	JJ
D	NN

disease	NN
D	NN

Low-molecular-weight	JJ
T	NN

heparins	NNS
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

venous	JJ
D	NN

thromboembolism	NN
D	NN

5-year	JJ
O	NN

outcome	NN
O	NN

of	IN
O	NN

surgical	JJ
T	NN

resection	NN
T	NN

and	CC
O	NN

watchful	JJ
O	NN

waiting	VBG
O	NN

for	IN
O	NN

men	NNS
O	NN

with	IN
O	NN

moderately	RB
O	NN

symptomatic	JJ
O	NN

benign	JJ
D	NN

prostatic	JJ
D	NN

hyperplasia	NN
D	NN

:	:
O	NN

a	DT
O	NN

Department	NNP
O	NN

of	IN
O	NN

Veterans	NNP
O	NNP

Affairs	NNP
O	NNP

cooperative	JJ
O	NN

study	NN
O	NN

For	IN
O	NN

how	WRB
O	NN

long	RB
O	NN

should	MD
O	NNP

antipsychotic	JJ
T	NN

medication	NN
T	NN

be	VB
O	NN

continued	VBN
O	NN

after	IN
O	NN

the	DT
O	NN

first	RB
O	NN

psychotic	JJ
D	NN

episode	NN
D	NN

in	IN
D	NN

schizophrenics	NNS
D	NN

?	.
O	NN

IDA-FLAG	NN
T	NN

(	NN
T	NN

idarubicin	NN
T	NN

,	,
T	NN

fludarabine	NN
T	NN

,	,
T	NN

cytarabine	NN
T	NN

,	,
T	NN

G-CSF	NN
T	NN

)	NN
T	NN

,	,
O	NN

an	DT
O	NN

effective	JJ
O	NN

remission-induction	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

poor-prognosis	NN
D	NN

AML	NN
D	NN

of	IN
D	NN

childhood	NN
D	NN

prior	RB
O	NN

to	TO
O	NN

allogeneic	JJ
O	NN

or	CC
O	NN

autologous	JJ
O	NN

bone	NN
O	NN

marrow	NN
O	NN

transplantation	NN
O	NN

:	:
O	NN

experiences	NNS
O	NN

of	IN
O	NN

a	DT
O	NN

phase	NN
O	NN

II	NNP
O	NNP

trial	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Effects	NNS
O	NN

of	IN
O	NN

anal	JJ
T	NN

invasive	JJ
T	NN

treatment	NN
T	NN

and	CC
O	NN

incontinence	NN
D	NN

on	IN
O	NN

mental	JJ
O	NN

health	NN
O	NN

and	CC
O	NN

psychosocial	JJ
O	NN

functioning	VBG
O	NN

of	IN
O	NN

adolescents	NNS
O	NN

with	IN
O	NN

Hirshsprung	VBG
D	NN

's	POS
D	NN

disease	NN
D	NN

and	CC
O	NN

low	JJ
O	NN

anorectal	JJ
D	NN

anomalies	NNS
D	NN

Single	JJ
O	NN

or	CC
O	NN

double	JJ
O	NN

lung	NN
T	NN

transplantation	NN
T	NN

for	IN
O	NN

pulmonary	JJ
D	NN

hypertension	NN
D	NN

Interferon	NN
T	NN

beta	NN
T	NN

treatment	NN
T	NN

for	IN
O	NN

multiple	JJ
D	NN

sclerosis	NN
D	NN

Ten-year	JJ
O	NN

disease	NN
O	NN

free	JJ
O	NN

survival	NN
O	NN

after	IN
O	NN

transperineal	JJ
T	NN

sonography-guided	JJ
T	NN

iodine-125	NN
T	NN

brachytherapy	NN
T	NN

with	IN
O	NN

or	CC
O	NN

without	IN
O	NN

45-Gray	JJ
T	NN

external	JJ
T	NN

beam	NN
T	NN

irradiation	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

clinically	RB
O	NN

localized	JJ
O	NN

,	,
O	NN

low	JJ
O	NN

to	TO
O	NN

high	JJ
O	NN

Gleason	NN
D	NN

grade	NN
D	NN

prostate	NN
D	NN

carcinoma	NN
D	NN

Partial	JJ
O	NN

or	CC
O	NN

near	IN
O	NN

total	JJ
O	NN

pancreatectomy	NN
T	NN

for	IN
O	NN

persistent	JJ
D	NN

neonatal	JJ
D	NN

hyperinsulinaemic	JJ
D	NN

hypoglycaemia	NN
D	NN

:	:
O	NN

the	DT
O	NN

pathologist	NN
O	NN

's	POS
O	NN

role	NN
O	NN

Radical	NNP
T	NN

prostatectomy	NN
T	NN

for	IN
O	NN

prostate	NN
D	NN

cancer	NN
D	NN

:	:
O	NN

the	DT
O	NN

perineal	NN
O	NN

approach	NN
O	NN

increases	NNS
O	NN

the	DT
O	NN

risk	NN
O	NN

of	IN
O	NN

surgically	RB
O	NN

induced	VBN
O	NN

positive	JJ
O	NN

margins	NNS
O	NN

and	CC
O	NN

capsular	JJ
O	NN

incisions	NNS
O	NN

Open	VB
T	NN

capsulorrhaphy	NN
T	NN

with	IN
T	NN

suture	NN
T	NN

anchors	NNS
T	NN

for	IN
O	NN

recurrent	JJ
D	NN

anterior	JJ
D	NN

dislocation	NN
D	NN

of	IN
D	NN

the	DT
D	NN

shoulder	NN
D	NN

Intravenous	JJ
T	NN

immunoglobulin	NN
T	NN

treatment	NN
T	NN

in	IN
O	NN

multiple	JJ
D	NN

sclerosis	NN
D	NN

Randomised	VBN
O	NN

trial	NN
O	NN

of	IN
O	NN

irinotecan	JJ
T	NN

versus	CC
O	NN

fluorouracil	NN
T	NN

by	IN
O	NN

continuous	JJ
O	NN

infusion	NN
O	NN

after	IN
O	NN

fluorouracil	NN
O	NN

failure	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

metastatic	JJ
D	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

The	DT
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

intraocular	JJ
T	NN

pressure	NN
T	NN

reduction	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

normal-tension	NN
D	NN

glaucoma	NN
D	NN

Perceived	VBN
O	NN

contraindications	NNS
O	NN

to	TO
O	NN

thrombolytic	JJ
T	NN

treatment	NN
T	NN

in	IN
O	NN

acute	JJ
D	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

Lignocaine	JJ
T	NN

or	CC
O	NN

bupivacaine	NN
T	NN

for	IN
O	NN

digital	JJ
D	NN

ring	NN
D	NN

block	NN
D	NN

Steroids	NNS
T	NN

in	IN
O	NN

lateral	JJ
D	NN

epicondylitis	NN
D	NN

Steroids	NNS
T	NN

in	IN
O	NN

De	NNP
D	NNP

Quervain	NN
D	NN

's	POS
D	NN

tenosynovitis	NN
D	NN

Antibiotics	NNS
T	NN

after	IN
O	NN

dog	NN
D	NN

bite	NN
D	NN

Immobilisation	NN
T	NN

after	IN
O	NN

first	RB
O	NN

anterior	JJ
O	NN

shoulder	NN
D	NN

dislocation	NN
D	NN

Stereotactic	JJ
T	NN

radiosurgery	NN
T	NN

for	IN
O	NN

acoustic	JJ
D	NN

neuroma	NN
D	NN

:	:
O	NN

a	DT
O	NN

Canadian	JJ
O	NN

perspective	NN
O	NN

Anticytokine	JJ
T	NN

therapy	NN
T	NN

--	:
O	NN

a	DT
O	NN

new	JJ
O	NN

era	NN
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

rheumatoid	JJ
D	NN

arthritis	NN
D	NN

?	.
O	NN

Control	NN
O	NN

of	IN
O	NN

the	DT
O	NN

malignant	JJ
D	NN

hyperpyrexic	NN
D	NN

syndrome	NN
D	NN

in	IN
O	NN

MHS	NN
O	NN

swine	NNS
O	NN

by	IN
O	NN

dantrolene	JJ
T	NN

sodium	NN
T	NN

Hematopoietic	JJ
T	NN

stem-cell	NN
T	NN

transplantation	NN
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

severe	JJ
D	NN

combined	VBN
D	NN

immunodeficiency	NN
D	NN

Low-dose	JJ
T	NN

clozapine	NN
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

drug-induced	JJ
D	NN

psychosis	NN
D	NN

in	IN
D	NN

Parkinson	NNP
D	NNP

's	POS
D	NN

disease	NN
D	NN

Comparing	VBG
O	NN

the	DT
O	NN

efficacy	NN
O	NN

and	CC
O	NN

safety	NN
O	NN

of	IN
O	NN

fluoxetine	NN
T	NN

and	CC
O	NN

venlafaxine	NN
T	NN

in	IN
O	NN

outpatient	NN
D	NN

depression	NN
D	NN

Cost-effectiveness	NN
O	NN

of	IN
O	NN

interferon	NN
T	NN

treatment	NN
T	NN

for	IN
O	NN

hepatitis	NN
D	NN

C	NN
D	NN

Hyperbaric	JJ
T	NN

oxygen	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

children	NNS
O	VBP

with	IN
O	NN

cerebral	JJ
D	NN

palsy	NN
D	NN

Peripheral	JJ
T	NN

retinal	JJ
T	NN

cryotherapy	NN
T	NN

for	IN
O	NN

postvitrectomy	NN
D	NN

diabetic	JJ
D	NN

vitreous	JJ
D	NN

hemorrhage	NN
D	NN

in	IN
O	NN

phakic	JJ
O	NN

patients	NNS
O	NN

Hyperbaric	JJ
T	NN

or	CC
T	NN

normobaric	JJ
T	NN

oxygen	NN
T	NN

for	IN
O	NN

acute	JJ
D	NN

carbon	NN
D	NN

monoxide	NN
D	NN

poisoning	NN
D	NN

:	:
O	NN

a	DT
O	NN

randomised	VBN
O	NN

controlled	JJ
O	NN

clinical	JJ
O	NN

trial	NN
O	NN

Multicentre	JJ
O	NN

clinical	JJ
O	NN

evaluation	NN
O	NN

of	IN
O	NN

vigabatrin	NN
T	NN

(	NN
T	NN

Sabril	JJ
T	NN

)	NN
T	NN

in	IN
O	NN

mild	JJ
D	NN

to	TO
D	NN

moderate	JJ
D	NN

partial	JJ
D	NN

epilepsies	NNS
D	NN

Matrix	NNP
T	NN

metalloproteinase	NN
T	NN

inhibitors	NNS
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

cancer	NN
D	NN

High	JJ
O	NN

dose	NN
O	NN

cyclophosphamide	NN
T	NN

with	IN
O	NN

carboplatin	NN
T	NN

:	:
O	NN

a	DT
O	NN

tolerable	JJ
O	NN

regimen	NN
O	NN

suitable	JJ
O	NN

for	IN
O	NN

dose	NN
O	NN

intensification	NN
O	NN

in	IN
O	NN

children	NNS
O	VBP

with	IN
O	NN

solid	JJ
D	NN

tumors	NNS
D	NN

Microsurgical	JJ
T	NN

treatment	NN
T	NN

of	IN
O	NN

supratentorial	JJ
D	NN

cavernous	JJ
D	NN

malformations	NNS
D	NN

Microsurgical	JJ
T	NN

treatment	NN
T	NN

of	IN
O	NN

infratentorial	NN
D	NN

malformations	NNS
D	NN

Stereotactic	JJ
T	NN

radiosurgery	NN
T	NN

for	IN
O	NN

management	NN
O	NN

of	IN
O	NN

deep	JJ
D	NN

brain	NN
D	NN

cavernous	JJ
D	NN

malformations	NNS
D	NN

Interferon-antibodies	JJ
T	NN

and	CC
O	NN

the	DT
O	NN

breakthrough	NN
O	NN

phenomenon	NN
O	NN

during	IN
O	NN

ribavirin/interferon-alpha	NN
T	NN

combination	NN
T	NN

therapy	NN
T	NN

and	CC
O	NN

interferon-alpha	NN
T	NN

monotherapy	JJ
T	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

chronic	JJ
D	NN

hepatitis	NN
D	NN

C	NN
D	NN

Treatment	NN
O	NN

of	IN
O	NN

Barrett	NNP
D	NNP

esophagus	NN
D	NN

with	IN
O	NN

argon	NNP
T	NN

plasma	NN
T	NN

coagulation	NN
T	NN

with	IN
T	NN

acid	NN
T	NN

suppression	NN
T	NN

--	:
O	NN

a	DT
O	NN

prospective	JJ
O	NN

study	NN
O	NN

Meta-analysis	NN
O	NN

of	IN
O	NN

typhoid	NN
D	NN

vaccine	NN
T	NN

efficacy	NN
O	NN

trials	NNS
O	NN

showed	VBD
O	NN

that	IN
O	NN

whole	JJ
O	NN

cell	NN
O	NN

vaccines	NNS
O	NN

are	VBP
O	NN

more	RBR
O	NN

effective	JJ
O	NN

than	IN
O	NN

either	DT
O	NN

the	DT
O	NN

oral	JJ
O	NN

,	,
O	NN

attenuated	VBN
O	NN

vaccine	NN
O	NN

or	CC
O	NN

the	DT
O	NN

Vi	NNP
O	NNP

polysaccharide	NN
O	NN

vaccine	NN
O	NN

Experimental	JJ
O	NN

vaccination	NN
T	NN

against	IN
O	NN

Mycoplasma	NN
D	NN

agalactiae	NN
D	NN

using	VBG
O	NN

different	JJ
O	NN

inactivated	VBN
O	NN

vaccines	NNS
O	NN

A	DT
O	NN

randomized	VBN
O	NN

,	,
O	NN

controlled	JJ
O	NN

study	NN
O	NN

in	IN
O	NN

adults	NNS
O	NN

of	IN
O	NN

the	DT
O	NN

immunogenicity	NN
O	NN

of	IN
O	NN

a	DT
O	NN

novel	JJ
O	NN

hepatitis	NN
D	NN

B	NN
D	NN

vaccine	NN
T	NN

containing	VBG
O	NN

MF59	NN
O	NN

adjuvant	JJ
O	NN

Immunogenicity	NN
O	NN

of	IN
O	NN

three	CD
O	NN

Haemophilus	NN
D	NN

influenzae	NN
D	NN

type	NN
D	NN

b	NN
D	NN

protein	NN
O	NN

conjugate	NN
O	NN

vaccines	NNS
T	NN

in	IN
O	NN

HIV	NN
O	NN

seropositive	JJ
O	NN

adults	NNS
O	NN

and	CC
O	NN

analysis	NN
O	NN

of	IN
O	NN

predictors	NNS
O	NN

of	IN
O	NN

vaccine	NN
O	NN

response	NN
O	NN

Vaccination	NN
T	NN

against	IN
O	NN

Schistosoma	NN
D	NN

mansoni	NN
D	NN

infection	NN
D	NN

using	VBG
O	NN

74	CD
O	NN

kDa	NN
O	NN

Schistosoma	NN
O	NN

protein	NN
O	NN

antigen	NN
O	NN

Phase	NN
O	NN

1	CD
O	NN

safety	NN
O	NN

and	CC
O	NN

immune	JJ
O	NN

response	NN
O	NN

studies	NNS
O	VBP

of	IN
O	NN

a	DT
O	NN

DNA	NN
T	NN

vaccine	NN
T	NN

encoding	VBG
O	NN

hepatitis	NN
D	NN

B	NN
D	NN

surface	NN
O	NN

antigen	NN
O	NN

delivered	VBN
O	NN

by	IN
O	NN

a	DT
O	NN

gene	NN
O	NN

delivery	NN
O	NN

device	NN
O	NN

Protection	NNP
O	NNP

of	IN
O	NN

swine	NNS
O	NN

from	IN
O	NN

foot-and-mouth	NN
D	NN

disease	NN
D	NN

with	IN
O	NN

one	CD
O	NN

dose	NN
O	NN

of	IN
O	NN

an	DT
O	NN

all-D	JJ
T	NN

retro	NN
T	NN

peptide	NN
T	NN

Intranasal	JJ
T	NN

immunization	NN
T	NN

with	IN
O	NN

Chlamydia	NN
D	NN

trachomatis	NN
D	NN

,	,
D	NN

serovar	NN
D	NN

E	NN
D	NN

,	,
O	NN

protects	VBZ
O	NN

from	IN
O	NN

a	DT
O	NN

subsequent	JJ
O	NN

vaginal	JJ
O	NN

challenge	NN
O	NN

with	IN
O	NN

the	DT
O	NN

homologous	JJ
O	NN

serovar	NN
O	NN

Mutants	NNS
O	NN

of	IN
O	NN

cholera	NN
O	NN

toxin	NN
O	NN

as	IN
O	NN

an	DT
O	NN

effective	JJ
O	NN

and	CC
O	NN

safe	JJ
O	NN

adjuvant	JJ
O	NN

for	IN
O	NN

nasal	JJ
D	NN

influenza	NN
D	NN

vaccine	NN
T	NN

Field	NN
O	NN

evaluation	NN
O	NN

of	IN
O	NN

the	DT
O	NN

clinical	JJ
O	NN

effectiveness	NN
O	NN

of	IN
O	NN

vaccines	NNS
T	NN

against	IN
O	NN

pertussis	NN
D	NN

,	,
D	NN

measles	NNS
D	NN

,	,
D	NN

rubella	NN
D	NN

and	CC
D	NN

mumps	NNS
D	NN

:	:
O	NN

comments	NNS
O	NN

Transmural	JJ
T	NN

drainage	NN
T	NN

of	IN
O	NN

pancreatic	JJ
D	NN

fluid	NN
D	NN

collections	NNS
D	NN

without	IN
O	NN

electrocautery	NN
O	NN

using	VBG
O	NN

the	DT
O	NN

Seldinger	NN
O	NN

technique	NN
O	NN

Echocardiography-guided	JJ
T	NN

ethanol	NN
T	NN

septal	JJ
T	NN

reduction	NN
T	NN

for	IN
O	NN

hypertrophic	NN
D	NN

obstructive	JJ
D	NN

cardiomyopathy	NN
D	NN

Alterations	NNS
O	VBP

of	IN
O	NN

monocyte	NN
O	NN

function	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

growth	NN
D	NN

hormone	NN
D	NN

(	NN
D	NN

GH	NN
D	NN

)	NN
D	NN

deficiency	NN
D	NN

:	:
O	NN

effect	NN
O	NN

of	IN
O	NN

substitutive	JJ
O	NN

GH	NN
T	NN

therapy	NN
T	NN

Comparison	NN
O	NN

of	IN
O	NN

the	DT
O	NN

effects	NNS
O	NN

of	IN
O	NN

salmeterol	NN
T	NN

and	CC
O	NN

ipratropium	NN
T	NN

bromide	NN
T	NN

on	IN
O	NN

exercise	NN
O	NN

performance	NN
O	NN

and	CC
O	NN

breathlessness	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

stable	JJ
D	NN

chronic	JJ
D	NN

obstructive	JJ
D	NN

pulmonary	JJ
D	NN

disease	NN
D	NN

.	.
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Safety	NN
O	NN

trial	NN
O	NN

with	IN
O	NN

the	DT
O	NN

5HT1B/1D	NN
T	NN

agonist	NN
T	NN

avitriptan	NN
T	NN

(	NN
O	NN

BMS-180048	NN
O	NN

)	NN
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

migraine	NN
D	NN

who	WP
O	VBP

have	VB
O	NN

experienced	JJ
O	NN

pressure	NN
D	NN

,	,
D	NN

tightness	NN
D	NN

,	,
D	NN

and/or	CC
D	NN

pain	NN
D	NN

in	IN
O	NN

the	DT
O	NN

chest	NN
O	NN

,	,
O	NN

neck	NN
O	NN

,	,
O	NN

and/or	CC
O	NN

throat	NN
O	NN

following	VBG
O	NN

sumatriptan	NN
T	NN

Double	JJ
O	NN

blind	JJ
O	NN

,	,
O	NN

cluster	NN
O	NN

randomised	VBN
O	NN

trial	NN
O	NN

of	IN
O	NN

low	JJ
O	NN

dose	NN
O	NN

supplementation	NN
O	NN

with	IN
O	NN

vitamin	NN
T	NN

A	DT
T	NN

or	CC
O	NN

beta	NN
T	NN

carotene	NN
T	NN

on	IN
O	NN

mortality	NN
D	NN

related	JJ
D	NN

to	TO
D	NN

pregnancy	NN
D	NN

in	IN
O	NN

Nepal	NNP
O	NNP

.	.
O	NN

Medical	JJ
T	NN

treatments	NNS
T	NN

for	IN
O	NN

balding	NN
D	NN

in	IN
O	NN

men	NNS
O	NN

Carbon	NNP
D	NNP

monoxide	NN
D	NN

poisoning	NN
D	NN

treated	VBN
O	NN

with	IN
O	NN

hyperbaric	JJ
T	NN

oxygen	NN
T	NN

:	:
O	NN

metabolic	JJ
O	NN

acidosis	NN
O	NN

as	IN
O	NN

a	DT
O	NN

predictor	NN
O	NN

of	IN
O	NN

treatment	NN
O	NN

requirements	NNS
O	VBP

Medication	NN
T	NN

received	VBN
O	NN

by	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

depression	NN
D	NN

following	VBG
O	NN

the	DT
O	NN

acute	JJ
O	NN

episode	NN
O	NN

:	:
O	NN

adequacy	NN
O	NN

and	CC
O	NN

relation	NN
O	NN

to	TO
O	NN

outcome	NN
O	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Reduced	VBN
D	NN

bone	NN
D	NN

density	NN
D	NN

at	IN
O	NN

completion	NN
O	NN

of	IN
O	NN

chemotherapy	NN
T	NN

for	IN
O	NN

a	DT
O	NN

malignancy	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Surgical-site	NN
D	NN

complications	NNS
D	NN

associated	VBN
O	NN

with	IN
O	NN

a	DT
O	NN

morphine	NN
T	NN

nerve	NN
T	NN

paste	VB
T	NN

used	VBN
O	NN

for	IN
O	NN

postoperative	JJ
D	NN

pain	NN
D	NN

control	NN
D	NN

after	IN
D	NN

laminectomy	NN
D	NN

Splenectomy	NN
T	NN

during	IN
O	NN

pregnancy	NN
O	NN

:	:
O	NN

an	DT
O	NN

option	NN
O	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

autoimmune	JJ
D	NN

thrombocytopenic	JJ
D	NN

purpura	NN
D	NN

Melatonin	NN
T	NN

treatment	NN
T	NN

of	IN
O	NN

sleep-wake	NN
D	NN

cycle	NN
D	NN

disorders	NNS
D	NN

in	IN
O	NN

children	NNS
O	VBP

and	CC
O	NN

adolescents	NNS
O	NN

Randomized	VBN
O	NN

phase	NN
O	NN

II	NNP
O	NNP

study	NN
O	NN

of	IN
O	NN

the	DT
O	NN

neurokinin	NN
T	NN

1	CD
T	NN

receptor	NN
T	NN

antagonist	NN
T	NN

CJ-11	NN
T	NN

,	,
T	NN

974	CD
T	NN

in	IN
O	NN

the	DT
O	NN

control	NN
O	NN

of	IN
O	NN

cisplatin-induced	JJ
D	NN

emesis	NN
D	NN

Cataract	NN
D	NN

surgery	NN
T	NN

and	CC
O	NN

its	PRP$
O	NN

effect	NN
O	NN

on	IN
O	NN

intraocular	JJ
O	NN

pressure	NN
O	NN

The	DT
O	NN

outcome	NN
O	NN

of	IN
O	NN

arthroscopic	JJ
T	NN

treatment	NN
T	NN

of	IN
O	NN

temporomandibular	JJ
D	NN

joint	JJ
D	NN

arthropathy	NN
D	NN

Neostigmine	NN
T	NN

for	IN
O	NN

acute	JJ
D	NN

colonic	JJ
D	NN

pseudo-obstruction	NN
D	NN

New	NNP
O	NNP

vaccine	NN
T	NN

targets	NNS
O	VBP

childhood	NN
D	NN

pneumonia	NN
D	NN

A	DT
O	NN

comparison	NN
O	NN

of	IN
O	NN

botulinum	NN
T	NN

toxin	NN
T	NN

and	CC
O	NN

nitroglycerin	NN
T	NN

ointment	NN
T	NN

for	IN
O	NN

chronic	JJ
D	NN

anal	JJ
D	NN

fissure	NN
D	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

The	DT
O	NN

effect	NN
O	NN

of	IN
O	NN

bisoprolol	NN
T	NN

on	IN
O	NN

perioperative	NN
D	NN

mortality	NN
D	NN

and	CC
O	NN

myocardial	JJ
D	NN

infarction	NN
D	NN

in	IN
O	NN

high-risk	JJ
O	NN

patients	NNS
O	NN

undergoing	VBG
O	NN

vascular	JJ
T	NN

surgery	NN
T	NN

Surgical	NNP
T	NN

management	NN
T	NN

of	IN
O	NN

severe	JJ
D	NN

secondary	JJ
D	NN

peritonitis	NN
D	NN

Early	JJ
T	NN

surgical	JJ
T	NN

treatment	NN
T	NN

for	IN
O	NN

supratentorial	JJ
D	NN

intracerebral	JJ
D	NN

hemorrhage	NN
D	NN

:	:
O	NN

a	DT
O	NN

randomized	VBN
O	NN

feasibility	NN
O	NN

study	NN
O	NN

Evaluation	NN
O	NN

of	IN
O	NN

clomipramine	NN
T	NN

as	IN
O	NN

an	DT
O	NN

adjunct	NN
O	NN

to	TO
O	NN

behavioural	JJ
T	NN

therapy	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

separation-related	JJ
D	NN

problems	NNS
D	NN

in	IN
O	NN

dogs	NNS
O	NN

NICE	JJ
O	NN

to	TO
O	NN

rule	NN
O	NN

on	IN
O	NN

influenza	NN
D	NN

flu	NN
D	NN

drug	NN
O	NN

zanamivir	NN
T	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Longitudinal	JJ
D	NN

melanonychia	NN
D	NN

associated	VBN
O	NN

with	IN
O	NN

hydroxyurea	NN
T	NN

therapy	NN
T	NN

in	IN
O	NN

a	DT
O	NN

patient	NN
O	NN

with	IN
O	NN

essential	JJ
D	NN

thrombocytosis	NN
D	NN

Biologic	JJ
O	NN

markers	NNS
O	VBP

as	IN
O	NN

predictors	NNS
O	NN

of	IN
O	NN

clinical	JJ
O	NN

outcome	NN
O	NN

from	IN
O	NN

systemic	JJ
T	NN

therapy	NN
T	NN

for	IN
O	NN

primary	JJ
O	NN

operable	JJ
O	NN

breast	NN
D	NN

cancer	NN
D	NN

Treatment	NN
O	NN

of	IN
O	NN

hypertension	NN
D	NN

with	IN
O	NN

ascorbic	JJ
T	NN

acid	NN
T	NN

Postoperative	JJ
D	NN

peritonitis	NN
D	NN

originating	VBG
O	NN

from	IN
O	NN

the	DT
O	NN

duodenum	NN
O	NN

:	:
O	NN

operative	JJ
O	NN

management	NN
O	NN

by	IN
O	NN

intubation	NN
T	NN

and	CC
T	NN

continuous	JJ
T	NN

intraluminal	JJ
T	NN

irrigation	NN
T	NN

Efficacy	NN
O	NN

of	IN
O	NN

open-bite	NN
D	NN

treatment	NN
O	NN

with	IN
O	NN

the	DT
O	NN

Thera-spoon	JJ
T	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Pompholyx	NN
D	NN

(	NN
D	NN

vesicular	JJ
D	NN

eczema	NN
D	NN

)	NN
D	NN

after	IN
O	NN

i.v	NN
T	NN

.	.
T	NN

immunoglobulin	NN
T	NN

therapy	NN
T	NN

for	IN
O	NN

neurologic	JJ
D	NN

disease	NN
D	NN

Mitomycin	NN
T	NN

,	,
T	NN

ifosfamide	NN
T	NN

,	,
T	NN

and	CC
T	NN

cisplatin	NN
T	NN

in	IN
O	NN

unresectable	JJ
D	NN

non-small-cell	JJ
D	NN

lung	NN
D	NN

cancer	NN
D	NN

:	:
O	NN

effects	NNS
O	NN

on	IN
O	NN

survival	NN
O	NN

and	CC
O	NN

quality	NN
O	NN

of	IN
O	NN

life	NN
O	NN

.	.
O	NN

Hepatic	JJ
O	NN

arterial	JJ
O	NN

infusion	NN
O	NN

of	IN
O	NN

chemotherapy	NN
T	NN

after	IN
O	NN

resection	NN
T	NN

of	IN
O	NN

hepatic	JJ
D	NN

metastases	NNS
D	NN

from	IN
O	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

Waiting	VBG
O	NN

for	IN
O	NN

the	DT
O	NN

definitive	JJ
O	NN

trial	NN
O	NN

of	IN
O	NN

hepatic	JJ
T	NN

arterial	JJ
T	NN

chemotherapy	NN
T	NN

for	IN
O	NN

colorectal	JJ
D	NN

cancer	NN
D	NN

Phase	NN
O	NN

III	NNP
O	NN

randomized	VBN
O	NN

study	NN
O	NN

of	IN
O	NN

cisplatin	NN
T	NN

versus	CC
O	NN

paclitaxel	NN
T	NN

versus	CC
O	NN

cisplatin	NN
T	NN

and	CC
T	NN

paclitaxel	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

suboptimal	JJ
O	NN

stage	NN
O	NN

III	NNP
O	NN

or	CC
O	NN

IV	CD
O	NN

ovarian	JJ
D	NN

cancer	NN
D	NN

:	:
O	NN

a	DT
O	NN

gynecologic	JJ
O	NN

oncology	NN
O	NN

group	NN
O	NN

study	NN
O	NN

Evidence	NN
O	NN

for	IN
O	NN

double	JJ
O	NN

resistance	NN
O	NN

to	TO
O	NN

permethrin	NN
T	NN

and	CC
T	NN

malathion	NN
T	NN

in	IN
O	NN

head	NN
D	NN

lice	NN
D	NN

Urgent	JJ
O	NN

colonoscopy	NN
T	NN

for	IN
O	NN

the	DT
O	NN

diagnosis	NN
O	NN

and	CC
O	NN

treatment	NN
O	NN

of	IN
O	NN

severe	JJ
D	NN

diverticular	JJ
D	NN

hemorrhage	NN
D	NN

Treatment	NN
O	NN

of	IN
O	NN

Parkinson	NNP
D	NNP

's	POS
D	NN

disease	NN
D	NN

should	MD
O	NNP

begin	VB
O	NN

with	IN
O	NN

a	DT
O	NN

dopamine	NN
T	NN

agonist	NN
T	NN

<	JJR
O	NN

TO_SEE	NN
O	NN

>	JJR
O	NN

Ulceration	NN
D	NN

in	IN
O	NN

an	DT
O	NN

ileocolic	JJ
D	NN

anastomosis	NN
D	NN

treated	VBN
O	NN

with	IN
O	NN

ranitidin	NN
T	NN

Low-molecular-weight	JJ
T	NN

heparin	NN
T	NN

vs	CC
O	NN

heparin	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

pulmonary	JJ
D	NN

embolism	NN
D	NN

Radiotherapy	NN
T	NN

in	IN
O	NN

breast-conserving	JJ
T	NN

treatment	NN
T	NN

for	IN
O	NN

ductal	JJ
D	NN

carcinoma	NN
D	NN

in	IN
O	NN

situ	FW
O	FW

:	:
O	NN

first	RB
O	NN

results	NNS
O	VBP

of	IN
O	NN

the	DT
O	NN

EORTC	NN
O	NN

randomised	VBN
O	NN

phase	NN
O	NN

III	NNP
O	NN

trial	NN
O	NN

10853	CD
O	NN

Methadone	NNP
T	NN

maintenance	NN
T	NN

vs	CC
O	NN

180-day	JJ
O	NN

psychosocially	RB
O	NN

enriched	JJ
O	NN

detoxification	NN
T	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

opioid	NN
D	NN

dependence	NN
D	NN

:	:
O	NN

a	DT
O	NN

randomized	VBN
O	NN

controlled	JJ
O	NN

trial	NN
O	NN

Cryogen	NN
O	NN

spray	NN
O	NN

cooling	VBG
O	NN

during	IN
O	NN

Nd	NN
T	NN

:	:
T	NN

YAG	NN
T	NN

laser	NN
T	NN

treatment	NN
T	NN

of	IN
O	NN

hemangiomas	NN
D	NN

Effects	NNS
O	NN

of	IN
O	NN

tolcapone	NN
T	NN

,	,
T	NN

a	DT
T	NN

catechol-O-methyltransferase	NN
T	NN

inhibitor	NN
T	NN

,	,
O	NN

on	IN
O	NN

motor	NN
O	NN

symptoms	NNS
O	NN

and	CC
O	NN

pharmacokinetics	NNS
O	NN

of	IN
O	NN

levodopa	NN
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

Parkinson	NNP
D	NNP

's	POS
D	NN

disease	NN
D	NN

.	.
O	NN

Gene	NNP
T	NN

therapy	NN
T	NN

for	IN
O	NN

cancer	NN
D	NN

Therapeutic	JJ
O	NN

effects	NNS
O	NN

of	IN
O	NN

LDL	NN
T	NN

apheresis	NN
T	NN

in	IN
O	NN

the	DT
O	NN

prevention	NN
O	NN

of	IN
O	NN

atherosclerosis	NN
D	NN

Dry	NNP
T	NN

powdered	JJ
T	NN

formoterol	NN
T	NN

,	,
O	NN

twice	RB
O	NN

a	DT
O	NN

day	NN
O	NN

versus	CC
O	NN

aerosolized	VBN
T	NN

salbutamol	NN
T	NN

,	,
O	NN

four	CD
O	NN

times	NNS
O	NN

a	DT
O	NN

day	NN
O	NN

,	,
O	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

stable	JJ
D	NN

asthma	NN
D	NN

Cell-based	JJ
T	NN

vaccination	NN
T	NN

against	IN
O	NN

melanoma	NN
D	NN

--	:
O	NN

background	NN
O	NN

,	,
O	NN

preliminary	JJ
O	NN

results	NNS
O	VBP

,	,
O	NN

and	CC
O	NN

perspective	NN
O	NN

Celecoxib	NNP
T	NN

for	IN
O	NN

arthritis	NN
D	NN

Poliomyelitis	NN
D	NN

prevention	NN
O	NN

:	:
O	NN

revised	VBN
O	NN

recommendations	NNS
O	NN

for	IN
O	NN

use	NN
O	NN

of	IN
O	NN

inactivated	VBN
O	NN

and	CC
O	NN

live	JJ
O	NN

oral	JJ
O	NN

poliovirus	NN
D	NN

vaccines	NNS
T	NN

Mesh	NN
O	NN

plug	NN
O	NN

repair	NN
O	NN

and	CC
O	NN

groin	NN
D	NN

hernia	NN
D	NN

surgery	NN
T	NN

Brimonidine	NN
T	NN

tartrate	JJ
T	NN

0.2	CD
O	NN

%	NN
O	NN

twice	RB
O	NN

daily	RB
O	NN

vs	CC
O	NN

timolol	NN
T	NN

0.5	CD
O	NN

%	NN
O	NN

twice	RB
O	NN

daily	RB
O	NN

:	:
O	NN

1-year	JJ
O	NN

results	NNS
O	VBP

in	IN
O	NN

glaucoma	NN
D	NN

patients	NNS
O	NN

Ticarcillin/clavulanate	JJ
T	NN

versus	CC
O	NN

imipenem/cilistatin	NN
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

infections	NNS
D	NN

associated	VBN
D	NN

with	IN
D	NN

gangrenous	JJ
D	NN

and	CC
D	NN

perforated	JJ
D	NN

appendicitis	NN
D	NN

Is	VBZ
O	NN

zero	CD
O	NN

dose	NN
O	NN

oral	JJ
O	NN

polio	NNP
D	NNP

vaccine	NN
T	NN

effective	JJ
O	NN

in	IN
O	NN

preterm	NN
O	NN

babies	NNS
O	NN

?	.
O	NN

An	DT
O	NN

economic	JJ
O	NN

analysis	NN
O	NN

of	IN
O	NN

different	JJ
O	NN

strategies	NNS
O	VBP

of	IN
O	NN

immunization	NN
T	NN

against	IN
O	NN

hepatitis	NN
D	NN

A	DT
D	NN

virus	NN
D	NN

in	IN
O	NN

developed	VBN
O	NN

countries	NNS
O	NN

Issues	NNS
O	VBP

and	CC
O	NN

challenges	NNS
O	IN

with	IN
O	NN

antithrombotic	JJ
T	NN

therapy	NN
T	NN

in	IN
O	NN

diabetic	JJ
O	NN

patients	NNS
O	NN

with	IN
O	NN

acute	JJ
D	NN

coronary	JJ
D	NN

syndromes	NNS
D	NN

Global	JJ
O	NN

risk	NN
O	NN

assessment	NN
O	NN

for	IN
O	NN

lipid	NN
T	NN

therapy	NN
T	NN

to	TO
O	NN

prevent	VB
O	NN

coronary	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

The	DT
O	NN

role	NN
O	NN

of	IN
O	NN

fibric	JJ
T	NN

acid	NN
T	NN

derivatives	NNS
T	NN

in	IN
O	NN

the	DT
O	NN

secondary	JJ
O	NN

prevention	NN
O	NN

of	IN
O	NN

coronary	JJ
D	NN

heart	NN
D	NN

disease	NN
D	NN

Epoetin	NN
T	NN

:	:
O	NN

a	DT
O	NN

pharmacoeconomic	JJ
O	NN

review	NN
O	NN

of	IN
O	NN

its	PRP$
O	NN

use	NN
O	NN

in	IN
O	NN

chronic	JJ
D	NN

renal	JJ
D	NN

failure	NN
D	NN

and	CC
O	NN

its	PRP$
O	NN

effects	NNS
O	NN

on	IN
O	NN

quality	NN
O	NN

of	IN
O	NN

life	NN
O	NN

Rationale	NN
O	NN

for	IN
O	NN

the	DT
O	NN

use	NN
O	NN

of	IN
O	NN

antiplatelet	JJ
T	NN

drugs	NNS
T	NN

in	IN
O	NN

patients	NNS
O	NN

with	IN
O	NN

peripheral	JJ
D	NN

vascular	JJ
D	NN

disease	NN
D	NN

The	DT
O	NN

fluoroquinolones	NNS
T	NN

for	IN
O	NN

urinary	JJ
D	NN

tract	NN
D	NN

infections	NNS
D	NN

:	:
O	NN

a	DT
O	NN

review	NN
O	NN

Reduction	NN
O	NN

of	IN
O	NN

vasoreactivity	NN
D	NN

and	CC
O	NN

thrombogenicity	NN
D	NN

with	IN
O	NN

laser-thermal	JJ
T	NN

angioplasty	JJ
T	NN

:	:
O	NN

comparison	NN
O	NN

with	IN
O	NN

balloon	NN
T	NN

angioplasty	JJ
T	NN

Effects	NNS
O	NN

of	IN
O	NN

ultrasound	NN
T	NN

energy	NN
T	NN

on	IN
O	NN

total	JJ
D	NN

peripheral	JJ
D	NN

artery	NN
D	NN

occlusions	NNS
D	NN

:	:
O	NN

initial	JJ
O	NN

angiographic	JJ
O	NN

and	CC
O	NN

angioscopic	JJ
O	NN

results	NNS
O	VBP

.	.
O	NN

High-dose	JJ
T	NN

chemotherapy	NN
T	NN

with	IN
T	NN

autologous	JJ
T	NN

stem-cell	NN
T	NN

support	NN
T	NN

for	IN
O	NN

epithelial	JJ
D	NN

ovarian	JJ
D	NN

cancer	NN
D	NN

Pelvic	JJ
T	NN

floor	NN
T	NN

stimulation	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

adult	JJ
D	NN

urinary	JJ
D	NN

incontinence	NN
D	NN

Chronic	JJ
T	NN

vagus	NN
T	NN

nerve	NN
T	NN

stimulation	NN
T	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

seizures	NNS
D	NN

``	``
T	NN

Tandem	JJ
T	NN

''	''
T	NN

high-dose	JJ
T	NN

chemoradiotherapy	JJ
T	NN

with	IN
T	NN

autologous	JJ
T	NN

stem-cell	NN
T	NN

support	NN
T	NN

in	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

newly	RB
O	NN

diagnosed	VBN
O	NN

or	CC
O	NN

responsive	JJ
O	NN

multiple	JJ
D	NN

myeloma	NN
D	NN

Special	JJ
O	NN

report	NN
O	NN

:	:
O	NN

comparative	JJ
O	NN

efficacy	NN
O	NN

of	IN
O	NN

different	JJ
O	NN

types	NNS
O	NN

of	IN
O	NN

pneumatic	JJ
T	NN

compression	NN
T	NN

pumps	NNS
T	NN

for	IN
O	NN

the	DT
O	NN

treatment	NN
O	NN

of	IN
O	NN

lymphedema	NN
D	NN

Special	JJ
O	NN

report	NN
O	NN

:	:
O	NN

pressure-reducing	JJ
T	NN

support	NN
T	NN

surfaces	NNS
T	NN

in	IN
O	NN

the	DT
O	NN

prevention	NN
O	NN

and	CC
O	NN

treatment	NN
O	NN

of	IN
O	NN

pressure	NN
D	NN

ulcers	NNS
D	NN

:	:
O	NN

group	NN
O	NN

1	CD
O	NN

technologies	NNS
O	NN

Intravenous	JJ
T	NN

immune	JJ
T	NN

globulin	NN
T	NN

for	IN
O	NN

recurrent	JJ
D	NN

spontaneous	JJ
D	NN

abortion	NN
D	NN

External	JJ
T	NN

counterpulsation	NN
T	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

chronic	JJ
D	NN

stable	JJ
D	NN

angina	NN
D	NN

pectoris	NN
D	NN

Intra-articular	JJ
T	NN

hyaluronan	NN
T	NN

injections	NNS
T	NN

for	IN
O	NN

treatment	NN
O	NN

of	IN
O	NN

osteoarthritis	NN
D	NN

of	IN
O	NN

the	DT
O	NN

knee	NN
O	NN

Pneumococcal	JJ
D	NN

vaccine	NN
T	NN

:	:
O	NN

a	DT
O	NN

second	JJ
O	NN

look	NN
O	NN

